Abstract
Background
We performed a systematic review, a standard meta‐analysis and network meta‐analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease‐modifying anti‐rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD‐experienced).
Objectives
To assess the benefits and harms of biologic monotherapy (includes anti‐tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non‐TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD‐experienced.
Methods
We searched for randomized controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2015, Issue 6, June), MEDLINE (via OVID 1946 to June 2015), and Embase (via OVID 1947 to June 2015). Article selection, data extraction and risk of bias and GRADE assessments were done in duplicate. We calculated direct estimates with 95% confidence intervals (CI) using standard meta‐analysis. We used a Bayesian mixed treatment comparisons (MTC) approach for NMA estimates with 95% credible intervals (CrI). We converted odds ratios (OR) to risk ratios (RR) for ease of understanding. We calculated absolute measures as risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB).
Main results
This update includes 40 new RCTs for a total of 46 RCTs, of which 41 studies with 14,049 participants provided data. The comparator was placebo in 16 RCTs (4,532 patients), MTX or other DMARD in 13 RCTs (5,602 patients), and another biologic in 12 RCTs (3,915 patients).
Monotherapy versus placebo
Based on moderate‐quality direct evidence, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in American College of Rheumatology score (ACR50) and physical function, as measured by the Health Assessment Questionnaire (HAQ) versus placebo. RR was 4.68 for ACR50 (95% CI, 2.93 to 7.48); absolute benefit RD 23% (95% CI, 18% to 29%); and NNTB = 5 (95% CI, 3 to 8). The mean difference (MD) was ‐0.32 for HAQ (95% CI, ‐0.42 to ‐0.23; a negative sign represents greater HAQ improvement); absolute benefit of ‐10.7% (95% CI, ‐14% to ‐7.7%); and NNTB = 4 (95% CI, 3 to 5). Direct and NMA estimates for TNF biologic, non‐TNF biologic or tofacitinib monotherapy showed similar results for ACR50 , downgraded to moderate‐quality evidence. Direct and NMA estimates for TNF biologic, anakinra or tofacitinib monotherapy showed a similar results for HAQ versus placebo with mostly moderate quality evidence.
Based on moderate‐quality direct evidence, biologic monotherapy was associated with a clinically meaningful and statistically significant greater proportion of disease remission versus placebo with RR 1.12 (95% CI 1.03 to 1.22); absolute benefit 10% (95% CI, 3% to 17%; NNTB = 10 (95% CI, 8 to 21)).
Based on low‐quality direct evidence, results for biologic monotherapy for withdrawals due to adverse events and serious adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase. The direct estimate for TNF monotherapy for withdrawals due to adverse events showed a clinically meaningful and statistically significant result with RR 2.02 (95% CI, 1.08 to 3.78), absolute benefit RD 3% (95% CI,1% to 4%), based on moderate‐quality evidence. The NMA estimates for TNF biologic, non‐TNF biologic, anakinra, or tofacitinib monotherapy for withdrawals due to adverse events and for serious adverse events were all inconclusive and downgraded to low‐quality evidence.
Monotherapy versus active comparator (MTX/other DMARDs)
Based on direct evidence of moderate quality, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in ACR50 and HAQ scores versus MTX/other DMARDs with a RR of 1.54 (95% CI, 1.14 to 2.08); absolute benefit 13% (95% CI, 2% to 23%), NNTB = 7 (95% CI, 4 to 26) and a mean difference in HAQ of ‐0.27 (95% CI, ‐0.40 to ‐0.14); absolute benefit of ‐9% (95% CI, ‐13.3% to ‐4.7%), NNTB = 2 (95% CI, 2 to 4). Direct and NMA estimates for TNF monotherapy and NMA estimate for non‐TNF biologic monotherapy for ACR50 showed similar results, based on moderate‐quality evidence. Direct and NMA estimates for non‐TNF biologic monotherapy, but not TNF monotherapy, showed similar HAQ improvements , based on mostly moderate‐quality evidence.
There were no statistically significant or clinically meaningful differences for direct estimates of biologic monotherapy versus active comparator for RA disease remission. NMA estimates showed a statistically significant and clinically meaningful difference versus active comparator for TNF monotherapy (absolute improvement 7% (95% CI, 2% to 14%)) and non‐TNF monotherapy (absolute improvement 19% (95% CrI, 7% to 36%)), both downgraded to moderate quality.
Based on moderate‐quality direct evidence from a single study, radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologic monotherapy versus active comparator, MD ‐4.34 (95% CI, ‐7.56 to ‐1.12), though the absolute reduction was small, ‐0.97% (95% CI, ‐1.69% to ‐0.25%). We are not sure of the clinical relevance of this reduction.
Direct and NMA evidence (downgraded to low quality), showed inconclusive results for withdrawals due to adverse events, serious adverse events and cancer, with wide confidence intervals encompassing the null effect and evidence of an important increase.
Authors' conclusions
Based mostly on RCTs of six to 12‐month duration in people with RA who had previously experienced and failed treatment with MTX/other DMARDs, biologic monotherapy improved ACR50, function and RA remission rates compared to placebo or MTX/other DMARDs.
Radiographic progression was reduced versus active comparator, although the clinical significance was unclear.
Results were inconclusive for whether biologic monotherapy was associated with an increased risk of withdrawals due to adverse events, serious adverse events or cancer, versus placebo (no data on cancer) or MTX/other DMARDs.
Plain language summary
Biologics or tofacitinib alone for people with rheumatoid arthritis who had not improved with traditional disease‐modifying anti‐rheumatic drugs
In people with rheumatoid arthritis (RA), the immune system, which normally fights infection, attacks the joint lining making joints inflamed, swollen, stiff and painful. We looked for trials of biologics (large molecules administered by injection) or tofacitinib (small molecules given by mouth) in people with RA.
The review shows that in people with RA compared to salt water (placebo) or traditional drugs such as MTX/other DMARDs, biologic monotherapy (without MTX/other DMARDs) improves or probably improves signs and symptoms of RA (tender or swollen joints), function and chances of RA remission (disappearance of symptoms). Compared to salt water (placebo) or MTX/other DMARDs, biologic monotherapy may increase slightly or make no difference to the number of serious adverse events and withdrawals due to adverse events. In the short‐term evidence summarised here, biologic monotherapy does not increase the risk of cancer compared to MTX/other DMARDs.
Best estimate of what happens to people with RA taking biologic monotherapy
Monotherapy versus placebo
RA Symptoms
29 people out of 100 on biologic monotherapy experienced improvement compared to 6 people out of 100 who were on placebo, that is 23 more people out of 100 (23% absolute improvement).
Function improvement by Health Assessment Questionnaire
People who took biologic monotherapy rated that their function improved by 0.46 points on a scale of 0 to 3 compared to 0.14 points by people who took placebo, that is 0.32 points more (11% absolute improvement).
Remission
95 people out of 100 had disappearance of all symptoms of their RA compared to 85 people out of 100 who were on placebo, that is 10 more people out of 100 (10% absolute improvement).
Progression of disease damage as measured on X‐rays (on a scale of 0 to 448)
No studies provided data on this comparison.
Withdrawal from study due to adverse events
52 people out of 1000 who took biologic monotherapy withdrew from the study compared to 32 people out of 1000 who were on placebo, that is 20 more people out of 1000 (2% more withdrawals).
Serious Adverse Events
92 people out of 1000 who took biologic monotherapy had serious adverse events (most commonly infections) compared to 72 people out of 1000 who were on placebo, that is 20 more people out of 1000 (2% more withdrawals).
Cancer
No studies provided data on this comparison.
Monotherapy versus other traditional drugs (MTX/other DMARDs)
RA Symptoms
42 people out of 100 who were on biologic monotherapy experienced improvement compared to 29 people out of 100 who were on MTX/other DMARDs, that is 13 more people out of 100 (13% absolute improvement).
Function improvement by Health Assessment Questionnaire
People who took biologic monotherapy rated that their function improved by 0.43 points compared to people who took MTX/other DMARDs, whose function improved by 0.16 points on a scale of 0 to 3, that is 0.27 points (9% absolute improvement).
Remission
21 people out of 100 had disappearance of all symptoms of their RA compared to 15 people out of 100 who were on MTX/other DMARDs, that is 6 more people out of 100 (6% absolute improvement).
Progression of disease damage as measured on X‐rays (on a scale of 0 to 448)
The damage to joints of people on biologic monotherapy was 1.6 points compared to 5.9 points for people who took MTX/other DMARDs, that is 4.3 points lower (‐0.97% absolute improvement).
Withdrawal from study due to adverse events
80 people out of 1000 who took biologic monotherapy withdrew from the study compared to 70 people out of 1000 who were on MTX/other DMARDs, that is 10 more people out of 1000 (1% more withdrawals).
Serious Adverse Events
79 people out of 1000 who took biologic monotherapy had serious adverse events compared to 49 people out of 1000 who were on MTX/other DMARDs, that is 30 more people out of 1000 (3% more withdrawals).
Cancer
The same number of people (1 out of 1000) who took biologic monotherapy compared to those on MTX/other DMARDs had cancer. However, we are cautious about this estimate as there were few events of cancer.
Background
Description of the condition
Rheumatoid arthritis (RA), the most common form of autoimmune arthritis, affects 0.5% to 1.0% of the general population (Kvien 2004). RA is a characterized by inflammation of the synovial lining of the joints, tendons and periarticular structures (Lee 2001). The impact of RA on health‐related quality of life (HRQoL) is significant (Kvien 2005; Lubeck 2004). Long‐standing RA can lead to disability characterized by severe functional limitation (Odegard 2005; Yelin 2007).
In addition to the non‐steroidal anti‐inflammatory drugs (NSAIDs) that provide symptomatic relief, many disease‐modifying anti‐rheumatic drugs (DMARDs) are available for the treatment of RA. These include glucocorticoids, traditional DMARDs such as methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine etc. (referred to as DMARDs from here on), biologic DMARDs (referred to as biologics from here on) or oral synthetic molecules such as tofacitinib. The use of DMARDs leads to an improvement in pain and functioning for people with RA as well as more long‐term outcomes such as reduced radiographic progression (Finckh 2006; Pincus 2002) and disability (Cash 1994; Strand 2008).
Traditional DMARDs, including methotrexate (MTX), are usually the first choice treatment for people with RA (Smolen 2014a; Singh 2012). When traditional DMARDs (including MTX) have failed either due to being ineffective (i.e. inadequate responders (DMARD‐IR/MTX‐IR); primary or secondary efficacy failure usually) (Tugwell 2000) or because of associated side/adverse effects, treatment options include other traditional DMARDs, biologics or tofacitinib (Smolen 2014a; Singh 2012). This patient population is the focus of this review and will be referred to as MTX/other DMARD‐experienced, indicating that treatment with MTX, or one or more traditional DMARDs (including but not limited to sulfasalazine, hydroxychloroquine, leflunomide etc.), was unsuccessful.
Description of the interventions
There are two types of therapy, biologics and small molecules.
Biologics
Use of biologics leads to improvements in pain and function in people not responding to, or intolerant to traditional DMARDs including MTX. While biologics appear to have fewer side effects and greater success in slowing structural joint destruction than MTX, higher cost and concern for longer‐term harms are important considerations. Biologics include the following.
Tumor necrosis factor (TNF) inhibitors (Scott 2006): infliximab (Remicade, approved 1998 in the USA) (FDA 1999), etanercept (Enbrel, approved 1998) (FDA 1998), adalimumab (Humira, approved 2002) (FDA 2002), certolizumab pegol (Cimzia, approved 2008) (FDA 2008d), golimumab (Simponi, approved 2009) (FDA 2008a).
Anti‐CD28 therapy: abatacept (Orencia, approved 2005) (FDA 2005; FDA 2008b).
Anti‐IL1 therapy: anakinra (Kineret, approved 2001) (FDA 2001).
Anti‐B‐cell therapy: rituximab (Rituxan/MabThera, approved 1997 for lymphoma and 2006 for RA) (Drugs 2006).
Anti‐IL 6 therapy: tocilizumab (Actemra, approved 2010) (FDA 2010).
Small molecule synthetic drug, tofacitinib
Tofacitinib (Xeljanz) (FDA 2012), has also been approved in the USA. The indications for use of biologics and tofacitinib differ slightly between countries.
How the intervention might work
The mechanism of action of the biologics is summarized in the individual Cochrane systematic reviews. In brief, the systemic and joint inflammation in RA is mediated by activation of T‐cells (Cope 2008), B‐cells, macrophages (Szekanecz 2007) and other immune cells (Woolley 2003). These interactions lead to expression of chemokines, metalloproteinases and inflammatory cytokines such as tumor necrosis factor‐alpha (TNF‐alpha) and various interleukins (IL) (Brennan 2008; Choy 2001). Interaction of lymphocytes and inflammatory cytokines with host cells such as fibroblasts, osteoclasts and chondrocytes leads to bone and cartilage destruction, a hallmark of RA (Brennan 2008; Connell 2006). It is possible that, due to different contributions of these cytokines and processes to the disease expression, the use of therapy targeting one cytokine may be more efficacious or safer than therapy targeting other mechanisms. As briefly mentioned in Description of the interventions, the mechanism of action differs between the biologics (TNF‐alpha versus interleukin‐1 versus interleukin‐6 versus B‐cells versus T‐cell co‐stimulatory molecule).
Small molecule synthetic drug tofacitinib works by a targeted inhibition of several Janus Kinase (JAK) protein isoforms, especially JAK3 and JAK1; JAK proteins integrate signals from many cytokines (Ghoreschi 2009). JAKs phosphorylate the signal transducers and activators of transcription (STATs) to modulate gene expression (O’Sullivan 2007). The use of tofacitinib is associated with reduced synovial mRNA expression of matrix metalloproteinase (MMP) ‐1 and MMP‐3 and chemokines CCL2, CXCL10 and CXCL13, which have been associated with joint inflammation (Boyle 2015).
Why it is important to do this overview
Treatment guidelines published recently (Saag 2008; Singh 2012; Singh 2016a; Smolen 2014a) as well as consensus statements (Furst 2008; Furst 2010; Furst 2012) have summarized guidance based on previous systematic reviews. Several new trials have been published since the publication of these guidelines. Our previous overview of biologics for RA was performed in 2009 and is ready for an update. The previous overview did not include an NMA, and included all patients with RA, regardless of previous experience of MTX/other DMARDs or biologic/s . Due to clinical relevance and feasibility of presenting all information together, we made an a priori decision to examine the use of biologics or tofacitinib in four separate RA populations, namely:
MTX/other DMARD‐naive;
MTX/other DMARD‐experienced (biologics or tofacitinib used concomitantly with MTX/other DMARD) (Singh 2016);
MTX/other DMARD‐experienced (biologics or tofacitinib used as monotherapy); and
Biologic‐experienced.
The other RA populations will be reported in separate Cochrane Reviews. This review will focus on people with RA whose treatment with MTX/other DMARDs (subset of the second category) had failed, and who were switched to biologic or tofacitinib monotherapy (without MTX/other DMARDs).
The Cochrane Systematic Reviews for biologics and tofacitinib in RA have been published in The Cochrane Library, and show that these medications are associated with improved outcomes in RA, compared to placebo/MTX/other DMARDs (Blumenauer 2002; Lethaby 2013; Lopez‐Olivo 2013; Lopez‐Olivo 2015; Maxwell 2009; Mertens 2009; Navarro‐Sarabia 2005; Ruiz Garcia 2014; Singh 2010a; Singh 2010b). Each existing Cochrane systematic review assessed one biologic at a time. Patients, clinicians and policy‐makers need to know if there are any important differences between biologics in terms of important benefits and harms. Such data can be provided by head‐to‐head comparison studies of biologics; however, such studies are few to date (Gabay 2013a; Schiff 2008; Weinblatt 2013a). In the absence of a large evidence base from head‐to‐head biologic comparator studies, indirect comparisons can best demonstrate any differences between biologics (Kristensen 2007; Kristensen 2011). There is guidance for using a common comparator to make an indirect comparison (Song 2003).
Our network meta‐analysis (NMA) and review differs from the usual review, such that it is not intended to examine only one intervention for RA but aims to systematically review and simultaneously compare the existing randomized trials of biologics or small molecule tofacitinib for RA (Becker 2011; Puhan 2014). Our NMA uses both direct and indirect evidence for making these comparisons.
Objectives
To determine the comparative benefits and harms of biologic monotherapy or tofacitinib (oral small molecule drug) monotherapy in adults with RA previously treated unsuccessfully with MTX/other DMARDs (MTX/other DMARD‐experienced).
Monotherapy indicates that biologic or tofacitinib was used without MTX and other traditional DMARDs. These people with RA are often using glucocorticoids or non‐steroidal anti‐inflammatory drugs (NSAIDs), or both, and other non‐pharmacologic treatments (occupational therapy, physical therapy, yoga, exercise, Tai Chi etc.), and therefore biologic monotherapy does not exclude the use of these adjunctive therapies.
Methods
Criteria for considering reviews for inclusion
Randomized controlled trials (RCTs) of biologics or tofacitinib for people with RA previously treated unsuccessfully with MTX/other DMARDs (MTX/other DMARD‐experienced).
Search methods for identification of reviews
For the 2015 update, we searched for individual RCTs rather than for systematic reviews as was done in the original review. A Cochrane Information Specialist (TR) conducted a search to identify the individual studies in the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2015, Issue 6), MEDLINE (via OVID 1946 to June 2015), and Embase (via OVID 1947 to June 2015). We considered the 31 studies included in the 2009 version for this review that included people with RA who were incomplete responders to MTX/other DMARDs.
Types of studies
For the 2015 update, we included all nine biologics and the oral small molecule tofacitinib approved for the treatment of RA. We included studies with any dose of biologic or tofacitinib, expanded from studies with only standard‐dose biologic considered in the original 2009 review. RCTs were included in this review, if they had clinically relevant outcomes and included people whose treatment with MTX/other DMARDs had failed.
Although all doses were considered, we defined the standard doses of biologics as for the 2009 version, and included definitions for the newer biologics and tofacitinib, as follows.
Abatacept intravenous: every four weeks intravenously at 500 mg dose in people weighing under 60 kg, 750 mg in people 60 kg to 100 kg, and 1000 mg in people weighing over 100 kg, after the initial dosing regimen of baseline, two‐ and four‐week infusions.
Abatacept subcutaneous: 125 mg subcutaneous weekly.
Adalimumab: 40 mg subcutaneous every two weeks.
Anakinra: 100 mg subcutaneous every day.
Certolizumab pegol: 400 mg initially and at weeks 2 and 4, followed by 200 mg every other week (for maintenance dosing, 400 mg every four weeks could be considered).
Etanercept: 25 mg subcutaneous twice weekly or 50 mg subcutaneous once weekly.
Golimumab: 50 mg administered by subcutaneous injection once a month.
Infliximab: 3 mg/kg intravenous every eight weeks after initial dosing at 0, 2 and 6 weeks.
Rituximab: two 1000 mg intravenous doses two weeks apart.
Tocilizumab intravenous: starting dose is 4 mg per kg every four weeks followed by an increase to 8 mg per kg every four weeks based on clinical response.
Tocilizumab subcutaneous: 162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response for people weighing less than 100 kg and 162 mg administered subcutaneously every week for people weighing 100 kg or over.
Tofacitinib: 5 mg orally twice a day.
Types of participants
Adults, 18 years or older, with RA meeting the 1987 American College of Rheumatology (ACR) classification criteria for RA (Arnett 1988) or the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA (Aletaha 2010), who were MTX/other DMARD‐experienced, i.e., whose treatment with MTX/other DMARDs had failed due to any reason including incomplete response, intolerance or adverse events to MTX/other DMARDs.
Types of interventions
Biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) or tofacitinib used alone that is, monotherapy (used without MTX and other traditional DMARDs), compared to placebo plus traditional DMARDs (including methotrexate (MTX)) or combinations of DMARDs or placebo alone or to biologics.
Types of outcome measures
Primary/major outcomes
American College of Rheumatology score (ACR50) defined as 50% improvement in both tender and swollen joint counts and 50% improvement in at least three of the following five variables: patient global assessment, physician global assessment, pain score, disability as measured by validated measures such as Health Assessment Questionnaire (HAQ) score, and acute phase reactant (Erythrocyte Sedimentation Rate (ESR) or C‐Reactive Protein (CRP) (Chung 2006; Felson 1995). ACR50 was chosen, as clinical and statistical evidence supports this as one of the preferred endpoints for contemporary RA clinical trials (Ghogomu 2014).
RA disease remission defined as Disease Activity Score (DAS) less than 1.6 or DAS28 less than 2.6 (Fransen 2005; Prevoo 1996).
Function measured by HAQ score or modified HAQ calculated as score changes (Fries 1980; Pincus 1983) and the proportion achieving minimal clinically important difference on HAQ ≤ 0.22 (Wells 1993).
Radiographic progression, as measured by Larsen/Sharp/modified Sharp scores (Larsen 1977; Sharp 1971; Van der Heijde 1989).
Withdrawals due to adverse events (Ioannidis 2004)
Serious adverse events (SAEs) (Ioannidis 2004)
Cancer
Since RCTs are limited in their ability to assess long‐term safety, as rare or delayed effects will not be detected, we also searched the US Food and Drug Administration (FDA) web site for labels and warnings. We also searched other regulatory agencies' web sites from Canada (Health Canada) and Europe (European Medicines Agency, EMA) to summarize warnings related to included medications under study.
Data collection and analysis
Selection of reviews
For the 2015 update, we only included RCTs, not systematic reviews. We conducted a search of the databases from inception to June 2015 (one update to February 2014 and a second one to June 2015). We had previously included all completed/updated/available Cochrane systematic reviews of biologics for RA for the 2009 version (that included all studies to 2009), if they had been completed and submitted for review or updated by 30 May 2009, or both.
As noted earlier, for reasons of clinical relevance and feasibility, we separated the original 2009 review according to three patient populations for this 2015 update, based on the previous drug exposure/experience:
MTX/other DMARD‐naive;
MTX/other DMARD‐experienced (biologics or tofacitinib used concomitantly with MTX/other DMARD) (Singh 2016);
MTX/other DMARD‐experienced (biologics or tofacitinib used as monotherapy); and
Biologic‐experienced/failed.
NMAs and systematic reviews focusing on MTX/other DMARD‐naive and biologic‐experienced (i.e. biologic‐failure) patient populations will be published shortly. For MTX/other DMARD‐experienced, we carried out analyses separately for biologic + MTX/other DMARDs and for biologic monotherapy. This review focuses on findings for biologic monotherapy, that is, no concomitant MTX/other DMARDs, in people who were MTX/other DMARD‐ experienced.
Two authors (JS/GW and SN/TC) reviewed the results of the search (titles and abstracts), and obtained the full text of articles identified as relevant for this update. The PRISMA flow chart for study selection is provided in Figure 1 (Liberati 2009).
1.
PRISMA study flow diagram
Data extraction and management
For this systematic review and NMA, we abstracted only studies including people with RA who were MTX‐experienced or DMARD‐experienced and were treated with biologic or tofacitinib monotherapy. Two review authors (JS and GW for the original review; SN and TC for the update) independently extracted data from the reviews into a Microsoft Excel® spreadsheet for the 2015 update. Two abstractors independently abstracted additional data for all doses of biologics (SN, JS) for RCTs abstracted for the 2009 original overview, since the original review only included standard doses of biologics. TC double‐checked data for accuracy. Disagreements were resolved by discussion with JS (or GW, as appropriate). We contacted/emailed authors of RCTs where data were missing or methods were unclear, followed by reminder emails.
Assessment of methodological quality of included reviews
Two review authors in three teams (SN/JS; TC/JS; JS/NS) independently evaluated the methodological quality of the included studies, as well as overall quality of evidence for each of the seven outcomes using GRADE, as summarized below.
Risk of Bias of included trials: Study quality
We assessed the study quality using the Cochrane risk of bias tool (TC/JS/NS/SN) and two abstractors independently assessed the following risk of bias criteria for each included trial: random sequence generation, allocation concealment, presence of blinding (participants, personnel, and outcome assessors) in the studies, incomplete outcome data, and selective outcome reporting (Higgins 2011). The risk of bias was assessed as recommended: low risk, high risk, or unclear risk (i.e. either lack of information or uncertainty over the potential for bias). Disagreements were resolved by discussion between the review authors.
Quality of evidence
Two review authors (AM and JS) independently assessed the overall quality of the evidence for each outcome using the GRADE approach for both direct and NMA estimates (Guyatt 2008; Puhan 2014). The GRADE approach improves reliability in comparison to intuitive judgments about the certainty of a body of evidence (Mustafa 2013). The GRADE system specifies four levels of quality of evidence:
high quality for randomized trials; or double‐upgraded observational studies;
moderate quality for downgraded randomized trials; or upgraded observational studies;
low quality for double‐downgraded randomized trials; or observational studies; and
very low quality for triple‐downgraded randomized trials; or downgraded observational studies; or case series/case reports.
Randomized trial evidence could be downgraded by one or two levels depending on the presence of five factors:
serious (‐1) or very serious (‐2) limitation to study quality;
important inconsistency (‐1);
some (‐1) or major (‐2) uncertainty about directness;
imprecise or sparse data (‐1);
high probability of reporting bias (‐1).
Data synthesis
Statistical analyses
We performed the main analyses considering factors including the route of biologic (intravenous versus subcutaneous) and dose (low dose (LD), standard dose (SD) and high dose (HD)) as important variables/characteristics that could potentially impact benefits and harms of the medications. We also performed pre‐specified analyses for several subgroups to assess the impact of RA type on outcomes (early versus established versus late) and trial duration (less than six months versus six months or more).
We analyzed MTX‐ and other DMARD‐experienced patients together for this systematic review and NMA, since these are usually defined as a single category in most trials and MTX is a DMARD. We compared biologic and tofacitinib monotherapy to placebo; and biologic and tofacitinib monotherapy to MTX/DMARD.
Network meta‐analysis methods (includes direct and indirect estimates)
We conducted NMAs using a Bayesian mixed treatment comparison (MTC) approach to determine the comparative effectiveness of treatments. WinBUGS statistical software for Bayesian analysis (Spiegelhalter 2003), was used for effecting the NMAs. We assessed the model fit based on deviance information criterion (DIC) and the comparison of residual deviance (Spiegelhalter 2003) and assessed model convergence based on trace plots and the Brooks‐Gelman‐Rubin statistic (Spiegelhalter 2003). We used the continuity correction approach for zero event cells to make non‐zero cells where needed. We calculated the corresponding 95% credible intervals (CrI) using Markov Chain Monte Carlo (MCMC) simulation approach with at least 20,000 or more iterations, as needed. We used informative priors for the variance parameters (Turner 2012), and vague priors for the basic parameters. We compared deviance and DIC statistics in fitted consistency and inconsistency models, and examined inconsistency plots to evaluate inconsistency (i.e. a conflict between direct and indirect evidence) (Dias 2011). We chose between the random‐effects model and the fixed‐effects model for each comparison based on the assessment of the DIC statistics and comparison of residual deviance to number of unconstrained data points; in each case we chose and presented the model with the better fit. We used the continuity correction approach for handling zero event cells. We evaluated heterogeneity for the indirect comparison analyses using τ2, which quantifies heterogeneity based on the variance resulting from the interaction between study and treatment (Deeks 2011).
For dichotomous outcomes (i.e. the number of participants achieving more than 50% symptomatic improvement (ACR50) and withdrawal due to adverse events), we performed the meta‐analysis by combining trials of various drugs versus placebo to obtain mutually independent estimates using odds ratios (OR) as effect measures. For data on serious adverse events or cancer, we anticipated that events would be rare (Bradburn 2007; Sweeting 2004). In order to handle these expected sparse data, we applied an empirical Bayes (treatment arm‐based) approach (Salanti 2008).
Traditional meta‐analysis methods
We also considered traditional meta‐analyses for assessing the comparative effectiveness of treatments. We used Review Manager 5 (RevMan) (Revman 2014) to conduct the NMA and traditional meta‐analysis respectively. Heterogeneity, a common issue encountered while performing meta‐analysis (Higgins 2002; Thompson 1999) was quantified using the I2 statistic (Higgins 2003). In all the forest plots presenting effect measure data per treatment for direct comparisons, we applied the random‐effects model as the conservative default option (DerSimonian 2007).
Overall
We considered P values less than 0.05 and 95% CIs or 95% CrIs that did not include 1 to be statistically significant.
We estimated the number needed to treat for an additional beneficial or harmful outcome, with 95% CIs, by using the derived OR comparing treatment to control, and considering the overall event rate in the comparator group as a proxy for the community baseline event rate. This method enabled direct translation into clinical practice (Osiri 2003), using Visual Rx with the overall (pooled) number of responders within the available studies as proxy for the expected rate of responders in a given RA population (Cates 2009).
Since clinicians may find it easier to interpret relative risks (RR) compared to odds ratios (OR), we converted the OR obtained from the NMA into RR for the 'Summary of findings' table, the Abstract and the Plain language summary (PLS). The NMA produces OR, which are presented in most of the tables and the text of the results section.
AK and AH performed data analyses under the supervision of GW.
Sub‐group analyses/planned comparisons
Our main analysis focused on comparing the biologics versus comparator (placebo; active comparator) and tofacitinib versus comparator with regard to benefits and harms. In addition, we specified a priori that we would calculate overall OR for the following.
Overall biologic versus placebo, and overall biologic versus active comparator (MTX/other DMARDs)
Type of medication (by mechanism): TNF inhibitors (etanercept (ETN), adalimumab (ADA), certolizumab pegol (CERT), golimumab (GOLI), infliximab (INF)) versus nonTNF‐inhibitors (abatacept (ABA), rituximab (RITUX), tocilizumab (TOCI), ) versus anakinra (ANA) versus tofacitinib (TOFA): We decided a priori to separate anakinra and tofacitinib and keep the other three non‐TNF biologics together due to a low prevalence of use of anakinra in RA (Saag 2008; Zhang 2016), a different mechanism of action and route for tofacitinib versus biologics (oral versus parenteral), a similar categorization of these agents in widely‐used treatment guidelines from the ACR (Singh 2012; Singh 2016a), and to keep this review consistent with other recently published Cochrane Reviews, meta‐analyses and NMAs (Singh 2016).
Type of biologic (antibody versus receptor): medications targeting TNF receptor (etanercept (ETN)) versus monoclonal antibodies against TNF (adalimumab, certolizumab, golimumab, infliximab) versus non‐TNF (abatacept, rituximab, tocilizumab) versus anakinra versus tofacitinib
Dose: high‐dose (HD) versus standard‐dose (SD) versus low‐dose (LD) biologic
We also pre‐specified and performed the following subgroup analyses.
Trial duration: short duration (six months or less), intermediate duration (six to 12 months) or long duration (longer than 12 months).
RA disease duration: early RA (mean/median duration of less than two years) (Boers 2001), established RA (mean/median duration two to 10 years) or late RA (mean/median duration more than 10 years) (Barlow 1999).
Results
The number of included studies increased dramatically for this 2015 update due to advances in the treatment for RA in the last six years with the availability of new biologic drugs, and the accompanying trials. Our update encompassed the original 31 RCTs from the 2009 review that included people with prior MTX/other DMARD‐failure, as well as all eligible new RCTs published since 2009. An example of an evidence network diagram is provided in Figure 2 for cancer. Our analyses were much more detailed than the original 2009 review, given the advances in analytic methods allowing us to interpret the data.
2.
Network diagram for cancer: biologic monotherapy
We described only the updated results in this review, rather than pointing out similarities and differences between the 2015 and 2009 versions, preferring the ease of readability over comprehensiveness (which would have lengthened this review). As described earlier, we divided the 2015 update into four reviews, based on prior drug experience, due to clinical relevance and feasibility. Results are easier to follow, interpret and discuss when presented by patient populations based on the prior drug experience.
Description of included reviews
Note: this update uses individual studies, not reviews, as the basis of all analyses.
The overall study selection process for this 2015 update is shown in Figure 1. For the 2015 update, we identified a total of 46 studies from 8,771 titles (including six of the 31 RCTs from the seven Cochrane Reviews in the original 2009 version), which had monotherapy arms for people with RA whose treatment with MTX or DMARDs had failed. Five studies (MacIsaac 2014; Moreland 2012; Ohta 2014; Pavelka 2009; Van Riel 2008) did not provide data. Reasons for exclusion of studies that we reviewed as full text are provided in Table 1. Of the 41 RCTs providing usable data (Table 2), 66% (27/41) were less than six months in duration, 19% (8/41) lasted between six months and 12 months, and 15% (6/41) were longer than 12 months. The comparator was placebo in 16 RCTs (4,532 patients), MTX or other DMARD in 13 RCTs (5,602 patients), and another biologic in 12 RCTs (3,915 patients).
1. Characteristics of excluded studies.
| Study | Reason for exclusion |
| Abe 2006 | Wrong drug exposure |
| Axelsen 2015 | Duplicate of Horslev 2014 |
| Bae 2013 | Wrong drug exposure |
| Bathon 2000 | Duplicate of Genovese 2002 |
| Bejarano 2008 | Wrong drug exposure |
| Bingham 2015 | Wrong drug exposure |
| Bonafede 2015 | Not a RCT |
| Breedveld 2006 | Wrong drug exposure |
| Burmester 2013 | Comparing two routes of administration of a biologic |
| Burmester 2015 | Wrong drug exposure |
| Chen 2009 | Wrong drug exposure |
| Cheng 2014 | Conference abstract |
| Choy 2012 | Wrong drug exposure |
| Cohen 2002 | Wrong drug exposure |
| Cohen 2003 | Wrong drug exposure |
| Cohen 2004 | Wrong drug exposure |
| Cohen 2006 | Wrong drug exposure |
| Combe 2006 | Wrong drug exposure |
| Conaghan 2013 | Wrong drug exposure |
| Conaghan 2014 | Sub‐study of Huizinga 2015 |
| Detert 2013 | Wrong drug exposure |
| Dougados 2014 | Duplicate of Huizinga 2015 |
| Durez 2004 | Wrong drug exposure |
| Durez 2007 | Wrong drug exposure |
| Emery 2006 | Wrong drug exposure |
| Emery 2008 | Wrong drug exposure |
| Emery 2010 | Wrong drug exposure |
| Emery 2014a | Duplicate |
| Emery 2014b | Conference abstract |
| Eriksson 2015 | Follow‐up at two years of Vollenhoven 2012 NCT00764725 |
| Fleischmann 2003 | Wrong drug exposure |
| Fleischmann 2009 | Wrong drug exposure |
| Fleischmann 2013 | Wrong drug exposure |
| Fleischmann 2014 | Conference abstract |
| Furst 2003 | Wrong drug exposure |
| Furst 2007 | Wrong drug exposure |
| Furst 2015 | Open label study |
| Gashi 2014 | Comparing two doses of a biologic |
| Genovese 2004 | Wrong drug exposure |
| Genovese 2005 | Wrong drug exposure |
| Genovese 2008 | Wrong drug exposure |
| Genovese 2011 | Wrong drug exposure |
| Genovese 2014 | Wrong drug exposure |
| Gherge 2014 | Conference abstract |
| Goekoop‐Ruiterman 2007 | Wrong drug exposure |
| Haraoui 2014 | Duplicate of Pope 2014 |
| Heimans 2014 | Wrong drug exposure |
| Hørslev‐Petersen 2014 | Open label study |
| Iannone 2014 | Open label study |
| Kaine 2011 | Wrong drug exposure |
| Kameda 2011 | Wrong drug exposure |
| Kavanaugh 2013 | Wrong drug exposure |
| Kavanaugh 2014 | Conference abstract |
| Kay 2008 | Wrong drug exposure |
| Kennedy 2014 | Wrong drug exposure |
| Keystone 2004a | Wrong drug exposure |
| Keystone 2004b | Wrong drug exposure |
| Keystone 2008 | Wrong drug exposure |
| Keystone 2014 | Conference abstract |
| Kim 2007 | Wrong drug exposure |
| Kim 2012 | Wrong drug exposure |
| Kim 2013 | Wrong drug exposure |
| Kivitz 2014 | Vaccine response study |
| Koroleva 2014a | Conference abstract |
| Koroleva 2014b | Conference abstract |
| Kremer 2003 | Wrong drug exposure |
| Kremer 2005 | Wrong drug exposure |
| Kremer 2006 | Wrong drug exposure |
| Kremer 2011 | Wrong drug exposure |
| Kremer 2012 | Wrong drug exposure |
| Kremer 2015 | Cross over study design |
| Lan 2004 | Wrong drug exposure |
| Landewé 2015 | Conference abstract |
| Lipsky 2000 | Wrong drug exposure |
| Lisbona 2008 | Wrong drug exposure |
| Lisbona 2010 | Wrong drug exposure |
| Machado 2014 | Wrong drug exposure |
| Maini 1999 | Wrong drug exposure |
| Manders 2015 | Participants switched therapy within one year/before completion of study period |
| Mathias 2000a | Wrong drug exposure |
| McInnes 2015 | Compared lipid levels in those randomized to CZP or PL, in MTX‐IR patients |
| Moreland 2002 | Wrong drug exposure |
| Nam 2014a | Wrong drug exposure |
| Nam 2014b | Wrong drug exposure |
| Navarro 2014 | Conference abstract |
| Nishimoto 2009 | Wrong drug exposure |
| O'Dell 2013 | Wrong drug exposure |
| Oakley 2014 | Conference abstract |
| Pavelka 2013 | Sub‐group analysis of Smolen 2013 NCT00565409 |
| Quinn 2005 | Wrong drug exposure |
| Rantalaiho 2014 | Wrong drug exposure |
| Rau 2004 | Wrong drug exposure |
| Rigby 2011 | Duplicate of Tak 2011 |
| Rubbert‐Roth 2010 | Wrong drug exposure |
| Schiff 2004 | Wrong drug exposure |
| Schiff 2008 | Wrong drug exposure Not in excluded study refs |
| Smolen 2013b | Wrong drug exposure |
| Smolen 2008 | Wrong drug exposure |
| Smolen 2009 | Wrong drug exposure |
| Smolen 2013a | Wrong drug exposure |
| Smolen 2014a | Participants in the control group also received the intervention |
| Smolen 2015 | Wrong drug exposure |
| Smolen 2014b | Open label study |
| Soubrier 2009 | Wrong drug exposure |
| St Clair 2004 | Wrong drug exposure |
| Strand 2012 | Wrong drug exposure |
| Tak 2011 | Wrong drug exposure |
| Tak 2012 | Wrong drug exposure |
| Takeuchi 2014 | Wrong drug exposure |
| Tam 2012 | Wrong drug exposure |
| Tanaka 2011 | Wrong drug exposure |
| Tanaka 2012 | Wrong drug exposure |
| Taylor 2004 | Wrong drug exposure |
| Taylor 2006 | Wrong drug exposure |
| Van der Heidje 2013 | Wrong drug exposure |
| Van der Kooij 2009 | Wrong drug exposure |
| Van Vollenhoven 2009 | Wrong drug exposure |
| Van Vollenhoven 2012a | Duplicate of Van Vollenhoven 2009 |
| Van Vollenhoven 2012b | Wrong drug exposure |
| Vital 2015 | B cell depletion study |
| Weinblatt 1999 | Wrong drug exposure |
| Weinblatt 2003 | Wrong drug exposure |
| Weinblatt 2006 | Wrong drug exposure |
| Weinblatt 2007 | Wrong drug exposure |
| Weinblatt 2008 | Wrong drug exposure |
| Weinblatt 2012 | Wrong drug exposure |
| Weinblatt 2013a | Wrong drug exposure |
| Weinblatt 2013b | Wrong drug exposure |
| Weinblatt 2014 | Results at 1 year of Weinblatt 2013b GO‐FURTHER trial, NCT00973479 |
| Weisman 2003 | Wrong drug exposure |
| Weisman 2007 | Wrong drug exposure |
| Westhovens 2006 | Wrong drug exposure |
| Westhovens 2009 | Wrong drug exposure |
| Westhovens 2014 | Conference abstract |
| Yamamoto 2014b | Wrong drug exposure |
| Yamanaka 2014 | Post hoc analysis of Takeuchi 2014 |
| Yazici 2012 | Wrong drug exposure |
| Zhang 2006 | Wrong drug exposure |
2. Characteristics of 41 studies of biologic monotherapy with usable data.
| Study name | Year | Biologic(s) | Biologic dose(s) | Number of study arms | Non‐biologic comparator | Trial duration | RA duration* | Biologic‐naive |
Total number of participants |
| Boyle 2015 | 2015 | Tofacitinib | HD | 2 | PL | 1 month | Late | Yes | 27 |
| Bresnihan 1998 | 1998 | Anakinra | SD, LD, HD | 4 | PL | 6 months | Established | Yes | 468 |
| Burmester 2014 | 2014 | Tocilizumab (SC v IV) | SD | 2 | None | 6 months | Established | No | 1262 |
| Combe 2009 | 2009 | Etanercept | SD | 3 | DMARD | 24 months | Established | No | 254 |
| Coombs 2010 | 2009 | Tofacitinib | SD, HD | 3 | PL | 2 months | Established | No | 195 |
| Dougados 2013 | 2013 | Tocilizumab (+/‐ MTX) | HD | 2 | None | 6 months | Established | No | 556 |
| Doyle 2013 | 2013 | Golimumab (SC v. IV) | SD | 2 | None | 6 months | N/A | N/A | 49 |
| Edwards 2004 | 2004 | Rituximab | SD, LD | 4 | MTX + PL | 12 months | Late | Yes | 161 |
| Fleischmann 2012a | 2012 | Tofacitinib | SD, HD | 3 | PL | 6 months | Established | No | 610 |
| Fleischmann 2012b | 2012 | Adalimumab, Tofacitinib | SD, HD | 4 | None | 6 months | Established | No | 226 |
| Gabay 2013b | 2013 | Adalimumab, Tocilizumab | SD | 2 | None | 6 months | Established | Yes | 326 |
| Genovese 2002 (ERA 2yr) | 2002 | Etanercept | SD, LD | 3 | MTX + PL | 24 months | Late | No | 632 |
| Hobbs 2015 | 2015 | Etanercept | SD | 2 | PL | 3 months | Established | No | 210 |
| Huizinga 2015 | 2015 | Tocilizumab (+/‐ MTX) | HD | 2 | None | 24 months | Established | Yes | 553 |
| Jobanputra 2012 | 2013 | Adalimumab, Etanercept | SD | 2 | None | 12 months | Established | No | 125 |
| Johnsen 2006 | 2006 | Etanercept | SD, HD | 2 | None | 6 months | Late | No | 77 |
| Jones 2010 | 2010 | Tocilizumab | HD | 2 | MTX | 6 months | Established | Yes | 572 |
| Kameda 2010 (JESMR) | 2010 | Etanercept (+/‐ MTX) | SD | 2 | None | 6 months | Established | Yes | 151 |
| Keystone 2009 (GO‐FORWARD) | 2009 | Golimumab | SD, HD | 4 | MTX + PL | 12 months | Established | No | 444 |
| Kremer 2009 | 2009 | Tofacitinib | SD, HD | 3 | PL | 3 months | Established | No | 195 |
| Kremer 2010 | 2010 | Golimumab | SD, LD | 5 | MTX + PL | 11 months | Established | No | 643 |
| Kremer 2013 | 2013 | Tofacitinib | SD, HD | 3 | PL | 12 months | Established | No | 792 |
| Maini 2006 (CHARISMA) | 2006 | Tocilizumab | SD, LD, HD | 7 | MTX + PL | 5 months | Established | No | 359 |
| Mathias 2000 | 2000 | Etanercept | SD | 2 | DMARD | 6 months | Established | No | 156 |
| Miyasaka 2008 (CHANGE) | 2008 | Adalimumab | SD, LD, HD | 4 | PL | 6 months | Established | Yes | 352 |
| Moreland 1999 | 1999 | Etanercept | SD, LD | 3 | PL | 6 months | Late | Yes | 234 |
| Nishimoto 2004 | 2004 | Tocilizumab | SD, HD | 3 | PL | 3 months | Established | No | 162 |
| Nishimoto 2007 (SAMURAI) | 2007 | Tocilizumab | HD | 2 | DMARD | 12 months | Established | No | 306 |
| Østergaard 2015 | 2015 | Certolizumab | SD | 2 | PL | 4 months | Established | No | 40 |
| Pope 2014 (CAMEO) | 2014 | Etanercept (+/‐ MTX) | SD | 2 | None | 6 months | Established | Yes | 205 |
| Strand 2006 | 2006 | Rituximab | SD | 4 | MTX + PL | 24 months | Late | N/A | 161 |
| Tada 2012 (PRECEPT) | 2012 | Etanercept | SD, LD | 2 | None | 12 months | Established | No | 70 |
| Takeuchi 2013a | 2013 | Etanercept | SD, LD | 3 | MTX + PL | 12 months | Established | No | 550 |
| Takeuchi 2013b | 2013 | Abatacept | SD, HD | 3 | PL | 6 months | Established | Yes | 194 |
| Takeuchi 2013c | 2013 | Golimumab | SD, HD | 3 | PL | 4 months | Established | N/A | 316 |
| Van de Putte 2003 | 2003 | Adalimumab | SD, LD, HD | 4 | PL | 3 months | Established | No | 284 |
| Van de Putte 2004 | 2004 | Adalimumab | SD | 2 | PL | 6 months | Late | Yes | 223 |
| Van der Heidje 2006 (TEMPO) | 2006 | Etanercept | SD | 3 | MTX | 24 months | Established | Yes | 682 |
| Van der Heijde 2007 (TEMPO) | 2007 | Etanercept | SD | 3 | MTX | 36 months | Established | Yes | 682 |
| Van Riel 2006 (ADORE) | 2006 | Etanercept (+/‐ MTX) | SD | 2 | None | 4 months | Established | Yes | 315 |
| Yamamoto 2014a | 2014b | Certolizumab | SD | 2 | PL | 6 months | Established | Yes | 230 |
*RA Duration: early = 2 years or less; established = > 2‐10 years; late = > 10 years HD ‐ high dose IV ‐ intravenous LD ‐ low dose SC ‐ subcutaneous SD ‐ standard dose
Methodological quality of included reviews
Note: this update uses individual studies, not reviews, as the basis of all analyses. Two reviewers abstracted study characteristics from the published reports of the individual trials for the 2015 update.
Risk of bias of included trials
Detailed risk of bias assessment for each of the 46 trials, including the reasons for each judgment, are available at the Cochrane Musculoskeletal Group web site (Risk of Bias Assessment A and Risk of Bias Assessment B).
Allocation sequence generation and concealment (selection bias)
All trials were described as randomized, however only 17 (37%) reported adequate sequence generation and were assessed as low risk while 29 (63%) did not describe the method used and were assessed as unclear risk.
Allocation concealment was assessed as low risk in 17 (37%) trials, and unclear in 29 (63%) trials.
Blinding (performance and detection bias)
A total of 19 (41%) trials were judged at low risk of performance bias and 18 (39%) at unclear risk of bias. In nine trials (20%), participants were not blinded and these trials were at high risk of performance bias.
We assessed low risk of detection bias in 17 (37%) trials, high risk of detection bias in nine (20%) and unclear risk in 20 (43%) trials.
Incomplete outcome data (attrition bias)
Most trials (22 trials; 48%) were judged at high risk of attrition bias because more than 20% of participants dropped out. Twenty (43%) trials had low risk of attrition bias and 4 (9%) trials were unclear risk.
Selective reporting (reporting bias)
Four trials (9%) had a protocol and were judged as low risk of selective reporting. One trial (2%) was at high risk of selective reporting and 41 trials (89%) were judged as unclear risk since the study protocols were not available and we did not have enough information in the study report to assess selective reporting.
Other potential sources of bias
We assessed studies for major baseline imbalance; 39 (85%) trials had low risk of bias, five (11%) had high risk of bias and two (4%) trials had unclear risk of bias.
Study characteristics are provided in Table 2 for the 41 included studies with 14,049 participants with usable data available for analysis.
Quality of evidence
The overall quality of the evidence for each outcome using the GRADE approach for both direct and NMA estimates was assessed, which is detailed for each outcome in the Summary of Findings tables (Table 3; Table 4) and in the section below (Summary of findings' tables under the section, Effects of interventions).
3. Summary of findings table for biologics vs placebo in MTX/DMARD‐experienced people (MTX/DMARD inadequate‐responders): only Placebo as a comparator.
| Comparison | Direct evidence | Network meta‐analysis | |||||
| Absolute risk difference, NNTB | Quality of Evidence (GRADE) | Absolute risk difference, NNTB | Quality of evidence (GRADE) | ||||
| Outcome: ACR50 | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 4.68 (2.93 to 7.48) | 23% (18% to 29%), NNTB = 5 (3 to 8) | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)1 | n/a | ||
| TNF biologic | vs comparator | 4.13 (2.51 to 6.80) | 21% (16% to 26%), NNTB = 5 (3 to 9) | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)2 | 4.40 [3.02,6.68] | 21% (13% to 30%), NNTB = 5 (3 to 8) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)4 |
| NonTNF biologic** | vs comparator | 8.23 (3.44 to 19.65) | 33% (26% to 40%), NNTB = 4 (2 to 8) | ⊕⊕⊕⊖ moderate (downgraded for imprecision)3 | 8.20 [4.06,14.89] | 44% (20% to 70%), NNTB = 3 (2 to 7) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)4 |
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | 4.09 [1.94, 8.61] | 29% (18% to 40%), NNTB = 4 (2 to 9) | ⊕⊕⊕⊖ moderate [downgraded for imprecision]3 | 4.63 [2.60,8.83] | 22% (10% to 42%), NNTB = 4 (2 to 7) | ⊕⊕⊕O moderate [downgraded for indirectness]4 |
| Outcome: Health Assessment Questionnaire (HAQ) score, 0‐3 (higher = worse): A measure of function | MD (95% CI) | MD (95% CrI) | |||||
| All biologics | vs comparator | ‐0.32 (‐0.42 to ‐0.23) | ‐10.7% (‐14% to ‐7.7%), NNTB = 4 (3 to 5) | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)5 | n/a | ||
| TNF biologic | vs comparator | ‐0.34 (‐0.44 to ‐0.23) | ‐11.3% (‐14.7% to ‐7.7%), NNTB = 4 (3 to 5) | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)6 | ‐0.33[‐0.48,‐0.17] | ‐11% (‐16% to ‐5.7%), NNTB = 7 (5 to 13) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)4 |
| Non‐TNF biologic | vs comparator | no data | |||||
| Anakinra | vs comparator | ‐0.23 (‐0.33 to ‐0.14) | ‐7.7% (‐11% to ‐4.7%), NNTB = 5 (4 to 9) | ⊕⊕⊕⊖ moderate (downgraded for imprecision)7 | ‐0.23[‐0.61,0.14] | ‐7.7% (‐20.3% to 4.7%), NNTB = n/a | ⊕⊕⊖⊖ low (downgraded for indirectness and imprecision)4,9 |
| Tofacitinib | vs comparator | ‐0.38 [‐0.52, ‐0.25] | ‐12.7% (‐8.3% to ‐17.3%), NNTB = 4 (3 to 8) | ⊕⊕⊕O moderate (downgraded for inconsistency) 8 | ‐0.38[‐0.65,‐0.12] | ‐12.7% (‐21.7% to ‐4%), NNTB = 6 (4 to 18) | ⊕⊕⊕O moderate [downgraded for indirectness]4 |
| Outcome: Remission (defined as DAS < 1.6 or DAS28 < 2.6) | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 1.12 (1.03 to 1.22) | 10% (3% to 17%), NNTB = 10 (8 to 21) | ⊕⊕⊕⊖ moderate (downgraded for imprecision)3,7 | n/a | ||
| TNF biologic | vs comparator | 1.12 (1.03 to 1.22) | 10% (3% to 17%), NNTB = 10 (8 to 21) | ⊕⊕⊕⊖ moderate (downgraded for imprecision)3,7 | |||
| Non‐TNF biologic | vs comparator | no data | |||||
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | no data | |||||
| Outcome: Withdrawals due to adverse events | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 1.65 (0.97 to 2.79) | 2% (1% to 4%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)10 | n/a | ||
| TNF biologic | vs comparator | 2.02 (1.08 to 3.78) | 3% (1% to 4%), NNTH = 40 (16 to 476) | ⊕⊕⊕O moderate [downgraded for imprecision]3 | 2.09 [1.14,4.04] | 3% (0% to 6%), NNTH = 39 (15 to 306) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)4 |
| Non‐TNF biologic | vs comparator | 0.24 (0.05 to 1.29) | ‐6% (‐13% to 2%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)10 | 0.22 [0.03,1.29] | ‐2% (‐3% to 1%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for indirectness and imprecision)4,9 |
| Anakinra | vs comparator | 1.53 (0.65 to 3.63) | 3% (‐2% to 8%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)10 | 1.59 [0.59,4.73] | 1% (‐1% to 9%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for indirectness and imprecision)4,9 |
| Tofacitinib | vs. comparator | 1.17 [0.31, 4.36] | 1% (‐5% to 6%), NNTH = n/a | ⊕⊕OO low [downgraded for serious imprecision]10 | 1.19 [0.31,4.96] | 0% (‐2% to 8%), NNTH = n/a | ⊕⊕OO low [downgraded for indirectness and imprecision]4,9 |
| Outcome: Serious adverse events | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 1.21 (0.71 to 2.07) | 2% (‐2% to 5%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)10 | n/a | ||
| TNF biologic | vs comparator | 1.21 (0.71 to 2.07) | 2% (‐2% to 5%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)10 | 1.25 [0.76,2.19] | 1% (‐1% to 5%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for indirectness and imprecision)4,9 |
| Non‐TNF biologic | vs comparator | no data | |||||
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | 0.44 [0.16, 1.23] | 0% (‐2% to 3%), NNTH = n/a | ⊕⊕OO low [downgraded for serious imprecision]10 | 0.48 [0.20,1.17] | ‐2% (‐4% to 1%), NNTH = n/a | ⊕⊕OO low [downgraded for indirectness and imprecision]4,9 |
* No studies for radiographic progression or cancer
** Non‐TNF biologic includes abatacept, rituximab, tocilizumab; i.e. all except anakinra, which was considered separately, as specified a priori.
High quality (⊕⊕⊕⊕) ‐ We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality (⊕⊕⊕⊖) ‐ We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality (⊕⊕⊖⊖) ‐ Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low quality (⊕⊖⊖⊖) ‐ We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
n/a = not available
DAS = Disease Activity Score; DMARD = disease‐modifying anti‐rheumatic drug; MTX = methotrexate; TNF = tumor necrosis factor
Comparator = placebo
The following control event rates were used in NMA calculations: ACR50 = 6.3%, withdrawals = 3.1%
- I2 = 56% ‐ downgraded for inconsistency
- I2 = 58% ‐ downgraded for inconsistency
- Downgraded for imprecision ‐ few events (< 300)
- Downgraded for indirectness/intransitivity due to differing patient characteristics (established vs late RA; types of failures); differing biologic doses and co‐interventions; and differing comparators
- I2 = 70% ‐ downgraded for inconsistency
- I2 = 67% ‐ downgraded for inconsistency
- Only one study provided data
- I2 = 77% ‐ downgraded for inconsistency
- Downgraded for imprecision ‐ 95% CI estimate includes both null effect and appreciable benefit or harm
- Downgraded twice for serious imprecision ‐ few events (< 300) and 95% CI estimate includes both null effect and appreciable benefit or harm
4. Summary of findings table for biologics vs MTX/DMARD (active comparator) in MTX/DMARD‐experienced people.
| Comparison | Direct evidence | Network meta‐analysis | |||||
| Absolute risk difference, NNTB | Quality of evidence | Absolute risk difference, NNTB | Quality of evidence | ||||
| Outcome: ACR50 | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 1.54 (1.14 to 2.08) | 13% (2% to 23%) to NNTB = 7 (4 to 26) | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)1 | n/a | ||
| TNF biologic | vs comparator | 1.43 (1.06 to 1.93) | 12% (2% to 22%), NNTB = 8 (4 to 44) | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)2 | 1.75 (1.30 to 2.31) | 9% (4% to 16%), NNTB = 7 (5 to 15) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)5 |
| Non‐TNF biologic | vs comparator | 1.57 (0.67 to 3.68) | 14% (‐11% to 39%), NNTB = n/a | ⊕⊕⊖⊖ low(downgraded for inconsistency and imprecision)3,4 | 2.24 (1.55 to 3.10) | 15% (7% to 25%), NNTB = 5 (3 to 10) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)5 |
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | no data | |||||
| Outcome: Health Assessment Questionnaire (HAQ) score, 0‐3 (higher = worse): a measure of function | MD (95% CI) | MD (95% CrI) | |||||
| All biologics | vs comparator | ‐0.27 (‐0.40 to ‐0.14) | ‐9% (‐13.3% to ‐4.7%), NNTB = 2 (2 to 4) | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)6 | n/a | ||
| TNF biologic | vs comparator | ‐0.21 (‐0.44 to 0.02) | ‐7% (‐14.7% to 0.7%), NNTB = n/a | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)7 | ‐0.18(‐0.41 to 0.06) | ‐3% (‐13.7 to 2%), NNTB = n/a | ⊕⊕⊖⊖ low (downgraded for indirectness and imprecision)4,5 |
| Non‐TNF biologic | vs comparator | ‐0.33 (‐0.51 to ‐0.16) | ‐11% (‐17% to ‐5.3%), NNTB = 4 (3 to 10) | ⊕⊕⊕⊖ moderate (downgraded for inconsistency)8 | ‐0.32(‐0.61 to ‐0.03) | ‐10.7% (‐20.3.7 to ‐1%), NNTB = 7 (4 to 73) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)5 |
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | no data | |||||
| Outcome: remission (defined as DAS < 1.6 or DAS28 < 2.6) | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 1.55 (0.94 to 2.53) | 6% (2% to 9%), NNTB = n/a | ⊕⊕⊖⊖ low (downgraded for imprecision and inconsistency)4,9 | n/a | ||
| TNF biologic | vs comparator | 1.50 (0.84 to 2.68) | 6% (2% to 9%), NNTB = n/a | ⊕⊕⊖⊖ low (downgraded for imprecision and inconsistency)4,10 | 1.96 (1.27 to 3.04) | 7% (2% to 14%), NNTB = 6 (4 to 19) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)5 |
| Non‐TNF biologic | vs comparator | 2.12 (0.70 to 6.44) | 9% (‐4% to 22%), NNTB = n/a | ⊕⊕⊖⊖ low (downgraded for imprecision and inconsistency)4,11 | 3.66 (1.93 to 6.36) | 19% (7% to 36%), NNTB = 3 (2 to 7) | ⊕⊕⊕⊖ moderate (downgraded for indirectness)5 |
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | no data | |||||
| Outcome: radiographic progression on Sharp/Van Der Heijde modification (0‐448 points) | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | ‐4.34 (‐7.56 to ‐1.12) | ‐0.97% (‐1.69% to ‐0.25%), NNTB = 9 (5 to 35) | ⊕⊕⊕⊖ moderate12 | n/a | ||
| TNF biologic | vs comparator | ‐4.34 (‐7.56 to ‐1.12) | ‐0.97% (‐1.69% to ‐0.25%), NNTB = 9 (5 to 35) | ⊕⊕⊕⊖ moderate12 | ‐2.35 (‐9.12 to 3.49) | ‐0.52% (‐2.04% to 0.78%), NNTB = n/a | ⊕⊕⊖⊖ low (downgraded for indirectness and imprecision)4,5 |
| Non‐TNF biologic | vs comparator | no data | |||||
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | no data | |||||
| Outcome: withdrawals due to adverse events | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 1.08 (0.69 to 1.69) | 1% (‐3% to 4%), NNTH = n/a | ⊕⊕⊖⊖ low(downgraded for imprecision and inconsistency)4,13 | n/a | ||
| TNF biologic | vs comparator | 0.96 (0.54 to 1.69) | 0% (‐5% to 5%), NNTH = n/a | ⊕⊕⊖⊖ low(downgraded for imprecision and inconsistency)4,14 | 1.14 (0.79 to 1.67) | 0% (‐1% to 2%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for imprecision and indirectness)4,5 |
| Non‐TNF biologic | vs comparator | 1.35 (0.63 to 2.92) | 2% (‐3% to 7%), NNTH = n/a | ⊕⊕⊕⊖ moderate (downgraded for imprecision)4 | 1.23 (0.75 to 2.02) | 1% (‐1% to 3%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for imprecision and indirectness)4,5 |
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | no data | |||||
| Outcome: serious adverse events | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 1.45 (0.94 to 2.22) | 3% (‐1% to 6%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)4,11 | n/a | ||
| TNF | vs comparator | 1.99 (0.78 to 5.09) | 4% (‐1% to 10%), NNTH = n/a | ⊕⊖⊖⊖ very low (downgraded for serious imprecision and inconsistency)4,11,15 | 1.21 (0.86 to 1.67) | 1% (‐1% to 4%), NNTH =n/a | ⊕⊖⊖⊖ very low (downgraded for serious imprecision and inconsistency)4,5,11 |
| Non‐TNF | vs comparator | 1.31 (0.84 to 2.05) | 1% (‐1% to 4%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)4,11 | 1.20 (0.83 to 1.72) | 1% (‐1% to 4%), NNTH = n/a | ⊕⊖⊖⊖ very low (downgraded for serious imprecision and inconsistency)4,5,11 |
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | no data | |||||
| Outcome: cancer (note: Peto OR used but can interpret as RR due to low event rate) | RR (95% CI) | RR (95% CrI) | |||||
| All biologics | vs comparator | 1.40 (0.67 to 2.93) | 0% (0% to 1%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)4,11 | n/a | ||
| TNF | vs comparator | 1.44 (0.61 to 3.38) | 0% (‐1% to 2%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for serious imprecision)4,11 | 1.31 (0.63 to 2.98) | 0% (0% to 1%), NNTH = n/a | |
| Non‐TNF | vs comparator | 1.29 (0.29 to 5.68) | 0% (‐1% to 1%), NNTH = n/a | ⊕⊕⊖⊖ low (downgraded for inconsistency and imprecision)4,16 | 1.25 (0.36 to 4.92) | 0% (‐1% to 3%), NNTH = n/a | |
| Anakinra | vs comparator | no data | |||||
| Tofacitinib | vs comparator | no data | |||||
High quality (⊕⊕⊕⊕) ‐ We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality (⊕⊕⊕⊖) ‐ We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality (⊕⊕⊖⊖) ‐ Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low quality (⊕⊖⊖⊖) ‐ We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
n/a = not available
DAS = Disease Activity Score; DMARD = disease‐modifying anti‐rheumatic drug; MTX = methotrexate; TNF = tumor necrosis factor
- I2 = 87% ‐ downgraded for inconsistency
- I2 = 81% ‐ downgraded for inconsistency
- I2 = 92% ‐ downgraded for inconsistency
- Downgraded for imprecision ‐ 95% CI estimate includes both null effect and appreciable benefit or harm
- Downgraded for indirectness/intransitivity due to differing patient characteristics (established vs late RA; types of failures); differing biologic doses and co‐interventions; and differing comparators
- I2 = 91% ‐ downgraded for inconsistency
- I2 = 95% ‐ downgraded for inconsistency
- I2 = 77% ‐ downgraded for inconsistency
- I2 = 50% ‐ downgraded for inconsistency
- I2 = 61% ‐ downgraded for inconsistency
- Downgraded for imprecision ‐ few events (< 300)
- Only one study provided data
- I2 = 62% ‐ downgraded for inconsistency
- I2 = 69% ‐ downgraded for inconsistency
- I2 = 58% ‐ downgraded for inconsistency
- I2 = 73% ‐ downgraded for inconsistency
Effect of interventions
We extracted all relevant RCT data for the seven pre‐specified outcomes, ACR50, HAQ, RA disease remission, radiographic progression, withdrawals due to adverse events, serious adverse events (SAEs) and cancer. We carried out analyses and comparisons when possible.
In comparison to the original 2009 version, the 2015 update has several new key aspects.
Instead of six biologics, we included all nine biologics and the oral small molecule, tofacitinib in this review.
We included cancer and serious adverse events as outcomes, which were limited to seven outcomes, as per CMSG guidance.
We included all doses of biologics and the oral small molecule, tofacitinib and analyzed by dose.
We analyzed outcomes by whether MTX/other DMARDs were used concomitantly or not. The current review focuses on biologic monotherapy and a separate published review focuses on biologic with MTX/other DMARDs in people whose treatment with MTX/other DMARDs has failed (Singh 2016).
We used a Bayesian approach rather than a frequentist approach for analyses and reported odds ratios (ORs) and 95% credible intervals (CrI).
We examined the main results for prior MTX/other DMARD/biologic‐experienced participants divided into three categories and each was considered in a separate review (MTX‐naïve, MTX/other DMARD‐experienced, biologic‐experienced). The current review is focused on examining the benefits and harms of biologic monotherapy in a RA patient population for whom treatment with MTX or other DMARDs has failed.
We combined TNF‐biologics and non‐TNF biologics for comprehensiveness in the 'Summary of findings' table, Abstract and the beginning of each outcome, but we have presented the results separately for each TNF‐ and non‐TNF biologic, by dose and route, in the main comparisons in the results section, so that readers can evaluate these comparisons.
How to navigate this Review
This 2015 update presents several pre‐specified estimates and comparisons. We followed the following principles while describing results to keep this review as clear and comprehensive as possible.
Firstly we have presented the overall OR for the entire group of biologics from direct comparison of biologic versus placebo followed by biologic versus active comparator.
This was followed by pre‐specified three sets of comparisons (e.g. TNF versus non‐TNF versus anakinra versus tofacitinib), based on the NMA.
In the three sets of comparative analyses (type of biologic; type of medication; biologic dose), only the last set of ORs compared the biologic by dose; other analyses prior to the dose analysis, included all doses and provided comparison by a different characteristic of interest, (e.g. the type of biologic).
This section was followed by the main analyses, where we have presented NMA results, for each individual biologic, in every dose, compared to other biologics or itself in a different dose regimen. We carried out these main analyses separately for three groups, MTX‐naïve, MTX/other DMARD‐experienced, biologic‐experienced. This review only discusses the monotherapy portion of the MTX/other DMARD‐experienced.
This was followed by two pre‐specified subgroup analyses by NMA, based on the trial duration and RA disease duration, to assess whether the results varied by these two pre‐specified characteristics.
When not specified, the biologic or tofacitinib was used in standard doses (details under "Types of studies" section above). We specified high‐dose (HD) and low‐dose (LD) in every instance that a dose other than standard dose was used. For biologics that are approved for only one route of administration (i.e. intravenous or subcutaneous), we did not specify the route when discussing results. When we mention a drug without specifying the route, it implies that we considered only the approved route for the drug, namely: subcutaneous route for adalimumab, anakinra, certolizumab pegol, etanercept and golimumab; intravenous route for infliximab and rituximab; and oral for small molecule, tofacitinib. There were two exceptions to this. Firstly, since only two biologics are approved for both subcutaneous and intravenous use (tocilizumab and abatacept), we specified one of these two routes when describing results for these two medications; and secondly, some data exist on different, non‐approved routes for some of the other biologics that were initially tested, but not approved by the regulatory agencies, and we have presented these data. The remaining seven biologics were only approved for one route of administration.
Due to our attempt to keep the narrative short, we have summarized the clinically meaningful and/or statistically significant results in the text; and we have commented on the clinical significance of these results. We have provided the entire comparison in the appendices for interested readers. The full network was previously published in the Cochrane Review on Biologic + MTX/other DMARDs in patients who previously failed MTX/other DMARDs (Singh 2016). This network included both biologic + MTX/other DMARDs and biologic monotherapy treatment arms. Therefore, the appendices presented in this review are the same as those presented as appendices in the companion NMA on the MTX/other DMARD‐experienced population that assessed biologic + MTX/other DMARDs (Singh 2016). They are presented here again to make it easier for the reader to find the data on biologic monotherapy within this systematic review. This review discusses the biologic monotherapy comparisons, and the previous review focused on biologic +MTX/other DMARDs combination therapy comparisons (Singh 2016).
'Summary of findings' tables
The first 'Summary of findings' table (Table 3) presents both the estimates from direct comparison of biologic monotherapy versus placebo and the NMA estimates, alongside the quality of evidence, in people whose previous treatment with MTX/other DMARDs failed. We provide absolute risk difference as well as relative difference (converted from OR in the NMA to relative risk for ease of interpretation for clinicians) for each estimate. Since cancer is a rare outcome, Peto's odds ratio is the most appropriate statistic, and can be viewed as relative risk (RR). We noted that direct estimates were consistent with NMA estimates for all seven outcomes. The second 'Summary of findings' table (Table 4) presents the results for biologic monotherapy versus active comparator (MTX/other DMARDs). Monotherapy refers to the use of biologic or tofacitinib without MTX/other DMARDs; participants may be using NSAIDs, corticosteroids and other non‐pharmacological interventions).
Monotherapy versus placebo
Compared to placebo, biologic monotherapy was associated with clinically meaningful and statistically significant improvement in ACR50, function as measured by the Health Assessment Questionnaire (HAQ) score and RA disease remission, all with moderate quality evidence (Table 3). Results for withdrawals due to adverse events and serious adverse events were mostly inconclusive, with wide CIs that included the null effect and an important increase, based on low‐quality evidence for direct and NMA estimates. Results for the TNF biologic, non‐TNF biologic, anakinra, and tofacitinib monotherapy were similar to that of the main groups for all outcomes versus placebo (with the exception of the TNF monotherapy subgroup for withdrawals due to adverse events, which showed a clinically meaningful and statistically significant difference), with similar quality of evidence ratings. No studies were included in the placebo‐only analysis for radiographic progression and cancer outcomes.
Monotherapy versus active comparator
Our findings were similar when we compared biologic monotherapy to active comparators (MTX/other DMARDs) (Table 4) although RRs for biologic monotherapy versus these comparators for ACR50 were somewhat lower, and the effect on RA disease remission was no longer significant. Data on radiographic progression (scale 0 to 448) versus active comparator showed a significant, but small, absolute reduction (0.97%) and therefore we were not sure of the clinical relevance of this reduction. There were inconclusive results for the risk of withdrawals due to adverse events, serious adverse events, and cancer with biologics, with wide CIs that included the null effect and an important increase, based on low‐quality evidence. The results for the TNF and the non‐TNF biologic subgroups were similar and the quality of evidence for all outcomes versus active comparator was moderate to low. There were no anakinra or tofacitinib studies.
Number needed to treat for an additional beneficial (NNTB) or harmful (NNTH) outcome
We derived the NNTB and NNTH values by comparing biologic monotherapy to comparator. The comparator was MTX or another DMARD for most of the studies. Only 39% (16 of the 41 studies), used placebo (PL) as the comparator: 39% (11 of the 28 studies) for ACR50; 45% (nine of the 20 studies) for HAQ; 10% (one of the 10 studies) for remission; 0% for radiographic progression; 41% (nine of the 22 studies) for serious adverse events; 41% (11 of the 27 studies) for withdrawals due to adverse events; and 0% for cancer. We derived the control event rates used from the control/comparator arms.
Monotherapy versus placebo
Based on direct estimates, the NNTB for biologic monotherapy versus placebo (Table 3) was 5 (95% CI, 3 to 8) for ACR50, 4 (95% CI, 3 to 5) for a meaningful improvement in HAQ score, and 10 (95% CI, 8 to 21) for RA remission. The harms outcomes that were included in the placebo‐only analysis (withdrawals and SAEs) were not significant and therefore we did not calculate NNTH.
Monotherapy versus active comparator
When compared to MTX/other DMARDs (Table 4), NNTBs for ACR50 were slightly higher at 7 (95% CI, 4 to 26) and were lower for HAQ at 2 (95% CI, 2 to 4). Radiographic progression showed a significant result and an NNTB of 9 (95% CI, 5 to 35) based on one study. Estimates for remission and the safety outcomes (withdrawals due to adverse events, SAEs, and cancer) were not significant and therefore we did not calculate any NNTBs or NNTHs.
Primary/major benefit outcome: ACR50
The network presented for all 7 outcomes included both biologic monotherapy (current review and NMA) and biologic used concomitantly with MTX/DMARDs, recently published (Singh 2016). Seventy‐nine studies with 30,229 participants, who did not previously respond to treatment with MTX/other DMARDs, reported data on ACR50. Of these, 60 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and 25 studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).
A list of all abbreviations used in tables/appendices is provided in Appendix 1.
Monotherapy versus placebo
Biologic monotherapy was associated with clinically meaningful and statistically significantly higher ACR50 rate versus placebo with over a six‐fold increase in the odds of improved ACR50, OR 6.39 (95% CI, 3.76 to 10.85), and with I2 of 58% denoting moderate heterogeneity in standard meta‐analyses (nine studies; Figure 3).
3.
ACR50: biologic monotherapy vs placebo
The overall OR (95% CrI) of ACR50 by the type of medication, type of biologic (including mechanism of TNF antibody versus receptor) and the dose using the NMA were as follows.
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib
In placebo comparator analysis, compared to TNF biologic monotherapy, the odds (95% CrI) of achieving ACR50, were not clinically meaningfully or statistically significantly different for non‐TNF biologic monotherapy, OR 2.73 (95% CrI, 0.81 to 10.56) or tofacitinib monotherapy, OR 1.08 (95% CrI, 0.44 to 3.02) (Table 5).
-
Type of biologic: monoclonal TNF antibody versus TNF receptor versus non‐TNF versus anakinra versus tofacitinib
In placebo comparator analysis, compared to monoclonal TNF antibody monotherapy, etanercept monotherapy, OR 0.54 (95% CrI, 0.19 to 1.58), non‐TNF monotherapy OR, 2.25 (95% CrI, 0.65 to 9.25) or tofacitinib monotherapy, OR 0.88 (95% CrI, 0.35 to 2.56), were not clinically meaningfully or statistically significantly different (Table 6).
-
By dose: SD versus HD versus LD
In placebo comparator analysis, compared to SD biologic monotherapy, LD and HD biologic monotherapy were not associated with differences in odds of ACR50, with OR 0.74 (95% CrI, 0.39 to 1.51) and 1.36 (95% CrI, 0.80 to 2.38) respectively (Table 7).
5. ACR50 analysis 2 for the type of medication (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| TNF Inhibitors | Placebo | 5.66(3.54,9.68) | 4.40(3.02,6.68) | 0.21(0.13,0.30) |
| TOFA | 6.07(2.93,15.51) | 4.63(2.60,8.83) | 0.22(0.10,0.42) | |
| non‐TNF | 15.53(5.23,55.72) | 8.20(4.06,14.89) | 0.44(0.20,0.70) | |
| TOFA | TNF Inhibitors | 1.08(0.44,3.02) | 1.05(0.54,2.10) | 0.01(‐0.15,0.24) |
| non‐TNF | 2.73(0.81,10.56) | 1.85(0.86,3.50) | 0.23(‐0.04,0.52) | |
| non‐TNF | TOFA | 2.55(0.60,10.69) | 1.76(0.72,3.78) | 0.21(‐0.11,0.52) |
| Random‐effects model | Residual deviance | 18.42 vs 9 data‐points | ||
| Deviance information criteria | 110.799 | |||
| Fixed‐effect model | Residual deviance | 26.5 vs 9 data‐points | ||
| Deviance information criteria | 114.009 | |||
| Total participants | 2205 | |||
| Total studies | 9 | |||
| 2‐arm | 9 | |||
See Appendix 25 for the list of abbreviations
6. ACR50 analysis 3 for the type of biologic (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| Monoclonal antibodies against TNF: | Placebo | 6.85(3.92,12.88) | 5.05(3.28,8.04) | 0.24(0.14,0.37) |
| TOFA | 6.01(2.93,15.13) | 4.61(2.60,8.72) | 0.22(0.10,0.41) | |
| non‐TNF | 15.34(5.31,56.88) | 8.18(4.12,15.11) | 0.44(0.20,0.70) | |
| Medications targeting TNF receptor: etanercept | 3.73(1.61,9.36) | 3.20(1.55,6.43) | 0.13(0.03,0.30) | |
| TOFA | Monoclonal antibodies against TNF | 0.88(0.35,2.56) | 0.91(0.46,1.87) | ‐0.03(‐0.21,0.20) |
| non‐TNF | 2.25(0.65,9.25) | 1.62(0.75,3.17) | 0.19(‐0.09,0.50) | |
| Medications targeting TNF receptor: etanercept | 0.54(0.19,1.58) | 0.63(0.27,1.38) | ‐0.11(‐0.28,0.09) | |
| non‐TNF | TOFA | 2.55(0.63,11.08) | 1.77(0.74,3.83) | 0.21(‐0.10,0.53) |
| Medications targeting TNF receptor: etanercept | 0.62(0.18,1.94) | 0.69(0.27,1.63) | ‐0.08(‐0.31,0.12) | |
| Medications targeting TNF receptor: etanercept | non‐TNF | 0.24(0.05,0.99) | 0.39(0.15,0.99) | ‐0.30(‐0.60,0.00) |
| Random‐effects model | Residual deviance | 26.21 vs 24 data points | ||
| Deviance information criteria | 146.132 | |||
| Fixed‐effect model | Residual deviance | 32.92 vs 24 data points | ||
| Deviance information criteria | 149.36 | |||
| Total participants | 3,037 | |||
| Total studies | 12 | |||
| 2‐arm | 12 | |||
See Appendix 25 for the list of abbreviations
7. ACR50 analysis 4 by dose (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD | Placebo | 6.64 (4.22, 11.40) | 5.03 (3.46, 7.76) | 0.23 (0.16, 0.32) |
| HD | 9.02 (5.14, 17.70) | 6.19 (4.02, 10.05) | 0.29 (0.19, 0.43) | |
| LD | 4.94 (2.50, 11.12) | 4.04 (2.28, 7.50) | 0.17 (0.08, 0.32) | |
| HD | SD | 1.36 (0.80, 2.38) | 1.23 (0.86, 1.77) | 0.07 (‐0.05, 0.19) |
| LD | 0.74 (0.39, 1.51) | 0.80 (0.48, 1.33) | ‐0.06 (‐0.17, 0.09) | |
| LD | HD | 0.55 (0.26, 1.16) | 0.65 (0.38, 1.11) | ‐0.12 (‐0.26, 0.03) |
| Random‐effects model | Residual deviance | 27.6 vs 26 data‐points | ||
| Deviance information criteria | 155.135 | |||
| Fixed‐effect model | Residual deviance | 39.15 vs 26 data‐points | ||
| Deviance information criteria | 159.022 | |||
| Total participants | 2205 | |||
| Total studies | 9 | |||
| 2‐arm | 3 | |||
| 3‐arm | 4 | |||
| 4‐arm | 2 | |||
See Appendix 25 for the list of abbreviations
Direct estimates for ACR50 by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to placebo (Figure 4).
4.
ACR50: biologic monotherapy vs placebo by drug group
Monotherapy versus active comparator
Biologic monotherapy was associated with clinically meaningful and statistically significant improvement in ACR50 versus MTX/other DMARDs, nearly a two‐fold increase in the odds of improved ACR50 (OR 1.94; 95% CI, 1.20 to 3.15), and with I2 of 88% denoting considerable heterogeneity in standard meta‐analyses (ten studies; Figure 5).
5.
ACR50: biologic monotherapy vs MTX/DMARD
The overall OR (95% CrI) of ACR50 by the type of medication, type of biologic (including mechanism of TNF antibody versus receptor) and the dose, using the NMA, were as follows.
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib
In active comparator analysis, compared to TNF biologic monotherapy, the odds (95% CrI) of achieving ACR50, were not clinically meaningfully or statistically significantly different for non‐TNF biologic monotherapy, OR 1.39 (95% CrI, 0.79 to 2.41) (Table 8).
-
Type of biologic: monoclonal TNF antibody versus TNF receptor versus non‐TNF versus anakinra versus tofacitinib
In active comparator analysis, compared to monoclonal TNF antibody monotherapy, etanercept monotherapy, OR 1.27 (95% CrI, 0.60 to 2.74) and non‐TNF monotherapy 1.59 (95% CrI, 0.81 to 3.13) were not clinically meaningfully or statistically significantly different (Table 9).
-
By dose: SD versus HD versus LD
In active comparator analysis, compared to SD biologic monotherapy, HD biologic monotherapy was not associated with a statistically significant difference in odds of ACR50 with OR 1.35 (95% CrI, 0.93 to 1.96), but LD biologic monotherapy showed statistically significantly lower odds of ACR50 with OR 0.52 (95% CrI, 0.31 to 0.85). LD biologic monotherapy also showed statistically significantly lower odds of ACR50when compared to HD biologic monotherapy with OR 0.39 (95% CrI, 0.22 to 0.66) (Table 10).
8. ACR50 analysis 2 for the type of medication (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| ACR50 Analysis 2: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% CrI) |
| TNF inhibitors | Comparator: MTX/other DMARD | 1.95 (1.36, 2.80) | 1.75 (1.30, 2.31) | 0.09 (0.04, 0.16) |
| Non‐TNF | 2.71 (1.67, 4.33) | 2.24 (1.55, 3.10) | 0.15 (0.07, 0.25) | |
| TOFA | 7.31 (3.46, 15.92) | 4.15 (2.66, 5.77) | 0.38 (0.20, 0.56) | |
| (MTX or DMARD) + TNF inhibitors | 4.13 (3.37, 5.11) | 3.00 (2.60, 3.47) | 0.24 (0.20, 0.29) | |
| (MTX or DMARD) + non‐TNF | 3.73 (2.77, 5.02) | 2.81 (2.28, 3.41) | 0.22 (0.16, 0.29) | |
| (MTX or DMARD) + TOFA | 5.58 (2.94, 10.76) | 3.60 (2.38, 5.01) | 0.31 (0.17, 0.47) | |
| (MTX or DMARD) + ANA | 2.82 (1.10, 7.61) | 2.31 (1.08, 4.27) | 0.16 (0.01, 0.39) | |
| non‐TNF | TNF inhibitors | 1.39 (0.79, 2.41) | 1.28 (0.84, 1.92) | 0.06 (‐0.04, 0.17) |
| TOFA | 3.76 (1.72, 8.38) | 2.37 (1.47, 3.56) | 0.29 (0.11, 0.47) | |
| (MTX or DMARD) + TNF inhibitors | 2.12 (1.48, 3.06) | 1.72 (1.31, 2.29) | 0.15 (0.08, 0.21) | |
| (MTX or DMARD) + non‐TNF | 1.92 (1.22, 3.01) | 1.61 (1.15, 2.25) | 0.13 (0.04, 0.21) | |
| (MTX or DMARD) + TOFA | 2.87 (1.37, 6.02) | 2.06 (1.26, 3.18) | 0.22 (0.06, 0.39) | |
| (MTX or DMARD) + ANA | 1.45 (0.52, 4.17) | 1.33 (0.59, 2.62) | 0.07 (‐0.10, 0.30) | |
| TOFA | non‐TNF | 2.70 (1.13, 6.69) | 1.84 (1.08, 3.02) | 0.23 (0.03, 0.43) |
| (MTX or DMARD) + TNF inhibitors | 1.53 (0.93, 2.56) | 1.34 (0.95, 1.98) | 0.09 (‐0.02, 0.19) | |
| (MTX or DMARD) + non‐TNF | 1.38 (0.84, 2.28) | 1.25 (0.89, 1.82) | 0.07 (‐0.04, 0.16) | |
| (MTX or DMARD) + TOFA | 2.06 (0.94, 4.63) | 1.60 (0.96, 2.62) | 0.16 (‐0.01, 0.34) | |
| (MTX or DMARD) + ANA | 1.05 (0.36, 3.15) | 1.03 (0.45, 2.12) | 0.01 (‐0.17, 0.25) | |
| (MTX or DMARD) + TNF inhibitors | TOFA | 0.57 (0.26, 1.23) | 0.72 (0.51, 1.14) | ‐0.14 (‐0.33, 0.05) |
| (MTX or DMARD) + non‐TNF | 0.51 (0.22, 1.14) | 0.68 (0.46, 1.09) | ‐0.16 (‐0.36, 0.03) | |
| (MTX or DMARD) + TOFA | 0.76 (0.28, 2.07) | 0.87 (0.51, 1.50) | ‐0.07 (‐0.30, 0.18) | |
| (MTX or DMARD) + ANA | 0.39 (0.11, 1.33) | 0.56 (0.25, 1.18) | ‐0.22 (‐0.46, 0.07) | |
| (MTX or DMARD) + non‐TNF | (MTX or DMARD) + TNF inhibitors | 0.90 (0.64, 1.27) | 0.94 (0.74, 1.16) | ‐0.02 (‐0.10, 0.05) |
| (MTX or DMARD) + TOFA | 1.35 (0.69, 2.68) | 1.20 (0.78, 1.70) | 0.07 (‐0.08, 0.24) | |
| (MTX or DMARD) + ANA | 0.68 (0.26, 1.87) | 0.77 (0.36, 1.44) | ‐0.08 (‐0.24, 0.15) | |
| (MTX or DMARD) + TOFA | (MTX or DMARD) + non‐TNF | 1.50 (0.74, 3.08) | 1.28 (0.82, 1.88) | 0.09 (‐0.07, 0.27) |
| (MTX or DMARD) + ANA | 0.76 (0.28, 2.13) | 0.82 (0.38, 1.57) | ‐0.06 (‐0.23, 0.18) | |
| (MTX or DMARD) + ANA | (MTX or DMARD) + TOFA | 0.51 (0.16, 1.64) | 0.65 (0.28, 1.34) | ‐0.15 (‐0.38, 0.12) |
| Random‐effects model | Residual deviance | 136.3 vs. 9 data‐points | ||
| Deviance information criteria | 916.003 | |||
| Fixed‐effect model | Residual deviance | 322 vs. 9 data‐points | ||
| Deviance information criteria | 1058.74 | |||
| Note: | ||||
| Total participants | 25,861 | |||
| Total studies | 65 | |||
| 2‐arm | 58 | |||
| 3‐arm | 7 | |||
See Appendix 25 for the list of abbreviations
9. ACR50 analysis 3 for the type of biologic (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| ACR50 analysis 3: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% CrI) |
| Monoclonal antibodies against TNF | Comparator: MTX/other DMARD | 1.65 (0.91, 2.96) | 1.53 (0.92, 2.40) | 0.06 (‐0.01, 0.17) |
| Medication targeting TNF receptor: etanercept | 2.10 (1.31, 3.44) | 1.85 (1.26, 2.67) | 0.10 (0.03, 0.20) | |
| Non‐TNF | 2.62 (1.60, 4.26) | 2.20 (1.49, 3.08) | 0.14 (0.06, 0.25) | |
| TOFA | 6.94 (3.21, 15.43) | 4.05 (2.53, 5.71) | 0.37 (0.18, 0.56) | |
| (MTX or DMARD) + Monoclonal antibodies against TNF | 4.23 (3.30, 5.46) | 3.05 (2.57, 3.61) | 0.25 (0.19, 0.30) | |
| (MTX or DMARD) + non‐TNF | 3.73 (2.76, 5.06) | 2.81 (2.27, 3.43) | 0.22 (0.15, 0.29) | |
| (MTX or DMARD) + Medication targeting TNF receptor: etanercept | 3.95 (2.69, 5.95) | 2.92 (2.23, 3.76) | 0.23 (0.15, 0.33) | |
| (MTX or DMARD) + TOFA | 5.60 (2.95, 10.92) | 3.61 (2.38, 5.04) | 0.31 (0.17, 0.48) | |
| (MTX or DMARD) + ANA | 2.82 (1.07, 7.72) | 2.31 (1.06, 4.30) | 0.16 (0.01, 0.39) | |
| Medication targeting TNF receptor: etanercept | Monoclonal antibodies against TNF | 1.27 (0.60, 2.74) | 1.21 (0.67, 2.25) | 0.04 (‐0.09, 0.16) |
| Non‐TNF | 1.59 (0.81, 3.13) | 1.43 (0.85, 2.46) | 0.08 (‐0.04, 0.19) | |
| TOFA | 4.22 (1.81, 10.15) | 2.62 (1.51, 4.55) | 0.30 (0.12, 0.49) | |
| (MTX or DMARD) + Monoclonal antibodies against TNF | 2.57 (1.41, 4.71) | 1.99 (1.27, 3.30) | 0.18 (0.07, 0.27) | |
| (MTX or DMARD) + non‐TNF | 2.27 (1.19, 4.32) | 1.84 (1.13, 3.11) | 0.15 (0.04, 0.25) | |
| (MTX or DMARD) + Medication targeting TNF receptor: etanercept | 2.40 (1.20, 4.93) | 1.91 (1.14, 3.35) | 0.17 (0.04, 0.29) | |
| (MTX or DMARD) + TOFA | 3.39 (1.42, 8.29) | 2.35 (1.28, 4.32) | 0.25 (0.07, 0.43) | |
| (MTX or DMARD) + ANA | 1.71 (0.55, 5.49) | 1.51 (0.62, 3.38) | 0.09 (‐0.09, 0.34) | |
| Non‐TNF | Medication targeting TNF receptor: etanercept | 1.25 (0.62, 2.45) | 1.18 (0.70, 1.97) | 0.04 (‐0.09, 0.17) |
| TOFA | 3.31 (1.33, 8.33) | 2.17 (1.22, 3.65) | 0.26 (0.06, 0.47) | |
| (MTX or DMARD) + Monoclonal antibodies against TNF | 2.02 (1.16, 3.46) | 1.64 (1.11, 2.49) | 0.14 (0.03, 0.24) | |
| (MTX or DMARD) + non‐TNF | 1.78 (1.00, 3.12) | 1.51 (1.00, 2.33) | 0.11 (0.00, 0.22) | |
| (MTX or DMARD) + Medication targeting TNF receptor: etanercept | 1.88 (1.17, 3.05) | 1.57 (1.11, 2.26) | 0.13 (0.03, 0.22) | |
| (MTX or DMARD) + TOFA | 2.66 (1.18, 6.02) | 1.94 (1.12, 3.24) | 0.21 (0.03, 0.39) | |
| (MTX or DMARD) + ANA | 1.35 (0.45, 4.07) | 1.25 (0.53, 2.59) | 0.05 (‐0.13, 0.30) | |
| TOFA | non‐TNF | 2.65 (1.09, 6.67) | 1.84 (1.06, 3.06) | 0.22 (0.02, 0.43) |
| (MTX or DMARD) + Monoclonal antibodies against TNF | 1.61 (0.95, 2.79) | 1.39 (0.97, 2.09) | 0.10 (‐0.01, 0.20) | |
| (MTX or DMARD) + non‐TNF | 1.42 (0.86, 2.39) | 1.28 (0.90, 1.89) | 0.07 (‐0.03, 0.17) | |
| (MTX or DMARD) + Medication targeting TNF receptor: etanercept | 1.51 (0.82, 2.89) | 1.33 (0.87, 2.12) | 0.09 (‐0.04, 0.22) | |
| (MTX or DMARD) + TOFA | 2.14 (0.96, 4.90) | 1.64 (0.97, 2.74) | 0.17 (‐0.01, 0.35) | |
| (MTX or DMARD) + ANA | 1.08 (0.37, 3.34) | 1.06 (0.46, 2.20) | 0.01 (‐0.17, 0.26) | |
| (MTX or DMARD) + Monoclonal antibodies against TNF | TOFA | 0.61 (0.27, 1.36) | 0.75 (0.52, 1.22) | ‐0.12 (‐0.32, 0.07) |
| (MTX or DMARD) + non‐TNF | 0.54 (0.23, 1.23) | 0.70 (0.47, 1.15) | ‐0.15 (‐0.35, 0.05) | |
| (MTX or DMARD) + Medication targeting TNF receptor: etanercept | 0.57 (0.24, 1.36) | 0.72 (0.47, 1.22) | ‐0.13 (‐0.34, 0.07) | |
| (MTX or DMARD) + TOFA | 0.81 (0.29, 2.24) | 0.89 (0.52, 1.57) | ‐0.05 (‐0.30, 0.19) | |
| (MTX or DMARD) + ANA | 0.41 (0.12, 1.44) | 0.58 (0.24, 1.24) | ‐0.20 (‐0.46, 0.09) | |
| (MTX or DMARD) + non‐TNF | (MTX or DMARD) + Monoclonal antibodies against TNF | 0.88 (0.61, 1.28) | 0.92 (0.72, 1.17) | ‐0.03 (‐0.11, 0.06) |
| (MTX or DMARD) + Medication targeting TNF receptor: etanercept | 0.94 (0.59, 1.50) | 0.96 (0.70, 1.29) | ‐0.02 (‐0.12, 0.10) | |
| (MTX or DMARD) + TOFA | 1.32 (0.66, 2.69) | 1.18 (0.76, 1.70) | 0.07 (‐0.09, 0.24) | |
| (MTX or DMARD) + ANA | 0.67 (0.24, 1.89) | 0.76 (0.34, 1.44) | ‐0.09 (‐0.25, 0.15) | |
| (MTX or DMARD) + Medication targeting TNF receptor: etanercept | (MTX or DMARD) + non‐TNF | 1.06 (0.65, 1.76) | 1.04 (0.75, 1.44) | 0.01 (‐0.09, 0.13) |
| (MTX or DMARD) + TOFA | 1.50 (0.74, 3.11) | 1.28 (0.81, 1.89) | 0.10 (‐0.07, 0.27) | |
| (MTX or DMARD) + ANA | 0.76 (0.27, 2.17) | 0.82 (0.37, 1.58) | ‐0.06 (‐0.23, 0.18) | |
| (MTX or DMARD) + TOFA | (MTX or DMARD) + Medication targeting TNF receptor: etanercept | 1.42 (0.66, 3.04) | 1.23 (0.77, 1.88) | 0.08 (‐0.09, 0.27) |
| (MTX or DMARD) + ANA | 0.71 (0.25, 2.08) | 0.79 (0.35, 1.55) | ‐0.07 (‐0.26, 0.17) | |
| (MTX or DMARD) + ANA | (MTX or DMARD) + TOFA | 0.50 (0.16, 1.66) | 0.65 (0.28, 1.35) | ‐0.15 (‐0.38, 0.12) |
| Random‐effects model | Residual deviance | 136.2 vs 137 data‐points | ||
| Deviance information criteria | 916.929 | |||
| Fixed‐effect model | Residual deviance | 319.8 vs 137 data‐points | ||
| Deviance information criteria | 1058.59 | |||
| Note: | ||||
| Total participants | 25,861 | |||
| Total studies | 65 | |||
| 2‐arm | 58 | |||
| 3‐arm | 7 | |||
See Appendix 25 for the list of abbreviations
10. ACR50 analysis 4 by dose (MTX/DMARD active comparator): odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| ACR50 analysis 4: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% CrI) |
| SD biologic | Comparator: MTX/other DMARD | 2.30 (1.73, 3.11) | 1.99 (1.58, 2.48) | 0.12 (0.07, 0.18) |
| HD biologic | 3.12 (2.23, 4.37) | 2.48 (1.94, 3.11) | 0.18 (0.12, 0.26) | |
| LD biologic | 1.20 (0.74, 1.94) | 1.17 (0.77, 1.75) | 0.02 (‐0.03, 0.09) | |
| MTXSD biologic | 3.97 (3.37, 4.70) | 2.91 (2.59, 3.28) | 0.23 (0.20, 0.27) | |
| MTXHD biologic | 4.97 (3.89, 6.40) | 3.34 (2.85, 3.91) | 0.29 (0.23, 0.35) | |
| MTXLD biologic | 2.88 (2.20, 3.79) | 2.34 (1.91, 2.85) | 0.16 (0.11, 0.22) | |
| HD biologic | SD biologic | 1.35 (0.93, 1.96) | 1.25 (0.95, 1.62) | 0.06 (‐0.01, 0.14) |
| LD biologic | 0.52 (0.31, 0.85) | 0.59 (0.38, 0.88) | ‐0.10 (‐0.17, ‐0.03) | |
| MTXSD biologic | 1.72 (1.28, 2.32) | 1.46 (1.18, 1.83) | 0.11 (0.05, 0.17) | |
| MTXHD biologic | 2.16 (1.51, 3.08) | 1.68 (1.32, 2.16) | 0.17 (0.09, 0.24) | |
| MTXLD biologic | 1.25 (0.86, 1.81) | 1.18 (0.90, 1.55) | 0.04 (‐0.03, 0.11) | |
| LD biologic | HD biologic | 0.39 (0.22, 0.66) | 0.48 (0.30, 0.73) | ‐0.16 (‐0.24, ‐0.07) |
| MTXSD biologic | 1.27 (0.90, 1.81) | 1.18 (0.93, 1.51) | 0.05 (‐0.02, 0.12) | |
| MTXHD biologic | 1.59 (1.10, 2.33) | 1.35 (1.06, 1.75) | 0.11 (0.02, 0.19) | |
| MTXLD biologic | 0.92 (0.61, 1.40) | 0.95 (0.71, 1.27) | ‐0.02 (‐0.10, 0.07) | |
| MTXSD biologic | LD biologic | 3.30 (2.04, 5.40) | 2.48 (1.67, 3.81) | 0.21 (0.14, 0.27) |
| MTXHD biologic | 4.13 (2.47, 7.01) | 2.84 (1.89, 4.43) | 0.26 (0.18, 0.34) | |
| MTXLD biologic | 2.40 (1.42, 4.08) | 1.99 (1.31, 3.13) | 0.14 (0.06, 0.22) | |
| MTXHD biologic | MTXSD biologic | 1.25 (0.97, 1.62) | 1.15 (0.98, 1.34) | 0.05 (‐0.01, 0.11) |
| MTXLD biologic | 0.73 (0.55, 0.95) | 0.81 (0.66, 0.97) | ‐0.07 (‐0.12, ‐0.01) | |
| MTXLD biologic | MTXHD biologic | 0.58 (0.41, 0.81) | 0.70 (0.56, 0.87) | ‐0.12 (‐0.20, ‐0.05) |
| Random‐effects model | Residual deviance | 163.8 vs 158 data‐points | ||
| Deviance information criteria | 1027.23 | |||
| Fixed‐effect model | Residual deviance | 335.4 vs 158 data‐points | ||
| Deviance information criteria | 1144.83 | |||
| Note: | ||||
| Total participants | 23,526 | |||
| Total studies | 61 | |||
| 2‐arm | 35 | |||
| 3‐arm | 20 | |||
| 4‐arm | 4 | |||
| 5‐arm | 1 | |||
| 7‐arm | 1 | |||
See Appendix 25 for the list of abbreviations
Direct estimates for ACR50 by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to MTX/DMARD (Figure 6).
6.
ACR50: biologic monotherapy vs MTX/DMARD by drug group
Main analyses for MTX/other DMARD‐experienced participants using the NMA
Seventy‐nine RCTs (38 two‐arm, 33 three‐arm, 6 four‐arm, 1 five‐arm and 1 seven‐arm trials) with 30,229 participants provided data for all dose analyses (Appendix 2), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.
Monotherapy versus placebo
All nine biologics, in LD, SD or HD, were superior to placebo in achieving ACR50; exceptions were SD rituximab intravenous alone and LD tocilizumab intravenous alone.
Monotherapy versus active comparator
Compared to MTX, we noted the following:
only SD etanercept was superior, with OR 1.91, but others were similar;
only LD tocilizumab intravenous was inferior, with OR 0.18, but others were similar;
most HD biologic monotherapy regimens were superior.
Compared to DMARDs, we noted the following:
most SD biologic monotherapy regimens were superior, with ORs 2.6 to 10.2;
most LD biologic monotherapy regimens were superior, with ORs ranging from 3.5 to 4.0; and
all HD biologic monotherapy regimens were superior, with ORs ranging from 4.9 to 14.6.
We found several other clinically and statistically significant differences (Appendix 2), namely that:
high doses of most biologic monotherapy regimens were often more effective in achieving ACR50 compared to standard doses of that biologic as well as standard doses of other biologics;
low doses of most biologic monotherapy regimens were often less effective in achieving ACR50 compared to standard dose of biologics (same or other biologic) and compared to SD tofacitinib monotherapy.
Subgroup analyses by early versus established versus late RA using the NMA
Early RA (RA disease duration less than two years)
There were not enough data to perform NMA.
Established RA (disease duration two to 10 years)
Compared to placebo, all biologic and tofacitinib monotherapy comparators in SD and HD, were associated with higher OR of ACR50, ranging from 3.77 to 14.79. In general, HD biologic monotherapy was associated with higher OR of ACR50 compared to SD (24,984 participants, 60 trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 3).
Late RA (disease duration more than 10 years)
Compared to LD biologic monotherapy, LD biologic + MTX was associated with higher OR of ACR50, ranging from 4.5 to 7.9 (3481 participants, 12 trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 4).
Subgroup analyses by trial duration using the NMA
Trial duration, less than six months
Compared to MTX, most (but not all) biologic monotherapy (LD, SD or HD) was associated with similar odds of ACR50; exceptions included SD etanercept, SD and HD golimumab and HD abatacept, associated with ORs ranging from 2.67 to 5.45 (24,122 participants, 66 trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 5).
Trial duration, six to 12 months
Compared to MTX, most (but not all) biologic monotherapy (LD, SD, or HD) was associated with similar odds of ACR50 (3209 participants, six trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 6).
Trial duration, more than 12 months
There were not enough data to perform NMA.
Primary/major efficacy outcome: HAQ
Forty‐eight studies with 16,355 participants whose treatment with MTX/other DMARDs had failed previously, reported data on HAQ scores. Of these, 35 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and 16 studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).
Monotherapy versus placebo
The use of biologic monotherapy was associated with clinically meaningful and statistically significant improvement in HAQ scores versus placebo, with a mean difference (MD) of ‐0.32 (95% CI, ‐0.42 to ‐0.23) based on results with considerable heterogeneity, with an I2 of 70% in standard meta‐analyses (seven studies; Figure 7).
7.
HAQ: biologic monotherapy vs placebo
The HAQ improvements by the type of medication, type of biologic and the biologic dose were as follows using the NMA.
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib
In placebo comparator analysis, compared to TNF biologic monotherapy, the HAQ scores were not clinically meaningfully or statistically significantly different for tofacitinib monotherapy, MD ‐0.05 (95% CrI, ‐0.38 to 0.24) or anakinra monotherapy, 0.09 (95% CrI, ‐0.32 to 0.49) (Table 11).
-
Type of biologic: monoclonal TNF antibody versus TNF receptor versus non‐TNF versus anakinra versus tofacitinib
In placebo comparator analysis, compared to TNF biologic monotherapy, HAQ scores were not clinically meaningfully or statistically significantly different for etanercept monotherapy, MD 0.18 (95% CI, ‐0.24 to 0.55), anakinra monotherapy, MD 0.14 (95% CrI, ‐0.30 to 0.53) or tofacitinib monotherapy, MD ‐0.01 (95% CrI, ‐0.35 to 0.28) (Table 12).
-
By dose: SD versus HD versus LD
In placebo comparator analysis, compared to SD biologic monotherapy, LD and HD biologic monotherapy were not associated with statistically significant differences in HAQ scores, MD was ‐0.10 (95% CrI, ‐0.25 to 0.04) and 0.01 (95% CrI, ‐0.14 to 0.15) (Table 13)
11. HAQ analysis 2 (only placebo comparator trials) for the type of medication: mean difference (MD) for all treatment comparisons ‐ random‐effects model.
| HAQ analysis 2: mean difference (MD) for all treatment comparisons ‐ random‐effects model | ||
| Treatment | Reference | MD (95% CrI) |
| TNF Inhibitors | PL | ‐0.33(‐0.48,‐0.17) |
| TOFA | ‐0.38(‐0.65,‐0.12) | |
| ANA | ‐0.23(‐0.61,0.14) | |
| TOFA | TNF Inhibitors | ‐0.05(‐0.38,0.24) |
| ANA | 0.09(‐0.32,0.49) | |
| ANA | TOFA | 0.15(‐0.31,0.61) |
| Random‐Effect Model | Total Residual Deviance | 18.47 vs 18 data points |
| Deviance Information Criteria | ‐30.822 | |
| Fixed‐Effect Model | Total Residual Deviance | 26.58 vs 18 data points |
| Deviance Information Criteria | ‐26.861 | |
| Note: | ||
| Total Patients | 1855 | |
| Total Studies | 9 | |
| 2‐arm | 9 | |
12. HAQ analysis 3 (only placebo comparator trials) for the type of biologic: mean difference (MD) for all treatment comparisons ‐ random‐effects model.
| Table. HAQ Analysis 3: Mean Difference (MD) for All Treatment Comparisons‐Random Effects Model | ||
| Treatment | Reference | MD (95% CrI) |
| Monoclonal antibodies against TNF | Placebo | ‐0.37(‐0.52,‐0.18) |
| TOFA | ‐0.38(‐0.65,‐0.13) | |
| ANA | ‐0.23(‐0.61,0.14) | |
| Medications targeting TNF receptor: etanercept | ‐0.19(‐0.54,0.16) | |
| TOFA | Monoclonal antibodies against TNF | ‐0.01(‐0.35,0.28) |
| ANA | 0.14(‐0.30,0.53) | |
| Medications targeting TNF receptor: etanercept | 0.18(‐0.24,0.55) | |
| ANA | TOFA | 0.14(‐0.30,0.61) |
| Medications targeting TNF receptor: etanercept | 0.19(‐0.24,0.64) | |
| Medications targeting TNF receptor: etanercept | ANA | 0.04(‐0.47,0.56) |
| Random‐Effect Model | Total Residual Deviance | 18.54 vs 18 data points |
| Deviance Information Criteria | ‐30.977 | |
| Fixed‐Effect Model | Total Residual Deviance | 21.34 vs 18 data points |
| Deviance Information Criteria | ‐31.106 | |
| Note: | ||
| Total Patients | 1855 | |
| Total Studies | 9 | |
| 2‐arm | 9 | |
13. HAQ analysis 4 by dose (only placebo): mean difference (MD) for all treatment comparisons ‐ random‐effects model.
| THAQ Analysis 4: mean difference (MD) for all treatment comparisons ‐ random‐effects model | |||
| Treatment | Reference | MD (95% CrI) | |
| SD biologic | Comparator: placebo | ‐0.31 (‐0.41, ‐0.20) | |
| HD biologic | ‐0.30 (‐0.44, ‐0.16) | ||
| LD biologic | ‐0.41 (‐0.55, ‐0.26) | ||
| HD biologic | SD biologic | 0.01 (‐0.14, 0.15) | |
| LD biologic | ‐0.10 (‐0.25, 0.04) | ||
| LD biologic | HD biologic | ‐0.11 (‐0.26, 0.04) | |
| Random‐effects model | Total residual deviance | 20.68 vs 20 data‐points | |
| Deviance information criteria | ‐41.312 | ||
| Fixed‐effect model | Total residual deviance | 33.27 vs 20 data‐points | |
| Deviance information criteria | ‐35.067 | ||
| Note | |||
| Total studies | 7 | ||
| 2‐arm | 4 | ||
| 4‐arm | 3 | ||
Direct estimates for HAQ by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to placebo (Figure 8).
8.
HAQ: biologic monotherapy vs placebo by drug group
Monotherapy versus active comparator
The use of biologic monotherapy was associated with clinically meaningful and statistically significant improvement in HAQ scores versus MTX/other DMARDs, with a MD of ‐0.27 (95% CI, ‐0.40 to ‐0.14) based on results with considerable heterogeneity, with I2 of 91% in standard meta‐analyses (six studies; Figure 9).
9.
HAQ: biologic monotherapy vs MTX/DMARD
The HAQ improvements by the type of medication, type of biologic and the biologic dose were as follows using the NMA.
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib
In active comparator analysis, compared to TNF biologic monotherapy, the HAQ scores were not clinically meaningfully or statistically significantly different for non‐TNF biologic monotherapy, MD ‐0.14 (95% CrI, ‐0.52 to 0.23) (Table 14).
-
Type of biologic, monoclonal TNF antibody versus TNF receptor versus non‐TNF versus anakinra versus tofacitinib
In active comparator analysis, compared to TNF biologic receptor monotherapy (etanercept) and monoclonal TNF antibody therapy, the HAQ scores were not statistically significantly different for non‐TNF biologic monotherapy, MD of MD ‐0.01 (95% CrI, ‐0.39 to 0.38) and ‐0.23 (95% CrI, ‐0.78 to 0.32), respectively (Table 15).
-
By dose, SD versus HD versus LD:
In active comparator analysis, compared to SD biologic monotherapy, HD biologic monotherapy was not associated with statistically significant differences in HAQ scores, MD ‐0.03 (95% CrI, ‐0.34 to 0.28) (Table 16).
14. HAQ analysis 2 (MTX/other DMARD active comparator) for the type of medication: mean difference (MD) for all treatment comparisons ‐ random‐effects model.
| HAQ analysis 2: mean difference (MD) for all treatment comparisons ‐ random‐effects model | ||
| Treatment | Reference | MD (95% CrI) |
| TNF inhibitors | MTX/other DMARD | ‐0.18 (‐0.41, 0.06) |
| Non‐TNF | ‐0.32 (‐0.61, ‐0.03) | |
| TOFA | ‐0.55 (‐1.25, 0.14) | |
| (MTX or DMARD) + TNF inhibitors | ‐0.29 (‐0.42, ‐0.16) | |
| (MTX or DMARD) + non‐TNF | ‐0.22 (‐0.43, 0.00) | |
| (MTX or DMARD) + TOFA | ‐0.44 (‐0.98, 0.11) | |
| non‐TNF | TNF inhibitors | ‐0.14 (‐0.52, 0.23) |
| TOFA | ‐0.37 (‐1.03, 0.28) | |
| (MTX or DMARD) + TNF inhibitors | ‐0.12 (‐0.34, 0.11) | |
| (MTX or DMARD) + non‐TNF | ‐0.04 (‐0.36, 0.28) | |
| (MTX or DMARD) + TOFA | ‐0.26 (‐0.86, 0.34) | |
| TOFA | non‐TNF | ‐0.23 (‐0.98, 0.52) |
| (MTX or DMARD) + TNF inhibitors | 0.03 (‐0.29, 0.34) | |
| (MTX or DMARD) + non‐TNF | 0.10 (‐0.21, 0.41) | |
| (MTX or DMARD) + TOFA | ‐0.12 (‐0.73, 0.50) | |
| (MTX or DMARD) + TNF inhibitors | TOFA | 0.26 (‐0.43, 0.95) |
| (MTX or DMARD) + non‐TNF | 0.33 (‐0.39, 1.06) | |
| (MTX or DMARD) + TOFA | 0.11 (‐0.77, 1.01) | |
| (MTX or DMARD) + non‐TNF | (MTX or DMARD) + TNF inhibitors | 0.08 (‐0.17, 0.32) |
| (MTX or DMARD) + TOFA | ‐0.14 (‐0.70, 0.42) | |
| (MTX or DMARD) + TOFA | (MTX or DMARD) + non‐TNF | ‐0.22 (‐0.81, 0.37) |
| Random‐effects model | Total residual deviance | 76.95 vs 79 data‐points |
| Deviance information criteria | ‐172.458 | |
| Fixed‐effect model | Total residual deviance | 533.2 vs 79 data‐points |
| Deviance information criteria | 253.917 | |
| Note: | ||
| Total participants | 13,017 | |
| Total studies | 38 | |
| 2‐arm | 35 | |
| 3‐arm | 3 | |
15. HAQ analysis 3 (MTX/other DMARD active comparator) for the type of biologic: mean difference (MD) for all treatment comparisons ‐ random‐effects model.
| HAQ analysis 3: mean difference (MD) for all treatment comparisons ‐ random‐effects model | ||
| Treatment | Reference | MD (95% CrI) |
| Monoclonal antibodies against TNF | MTX/other DMARD | ‐0.09 (‐0.57, 0.39) |
| Medications targeting TNF receptor: etanercept | ‐0.31 (‐0.58, ‐0.04) | |
| non‐TNF: tocilizumab, rituximab, abatacept | ‐0.32 (‐0.59, ‐0.05) | |
| TOFA | ‐0.47 (‐1.26, 0.33) | |
| (MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab | ‐0.19 (‐0.34, ‐0.03) | |
| (MTX or DMARD) + medication targeting TNF receptor: etanercept | ‐0.48 (‐0.68, ‐0.28) | |
| (MTX or DMARD) + non‐TNF | ‐0.22 (‐0.42, ‐0.01) | |
| (MTX or DMARD) + TOFA | ‐0.44 (‐0.95, 0.09) | |
| Medication targeting TNF receptor: etanercept | Monoclonal antibodies against TNF | ‐0.22 (‐0.77, 0.33) |
| Non‐TNF: tocilizumab, rituximab, abatacept | ‐0.23 (‐0.78, 0.32) | |
| TOFA | ‐0.37 (‐1.00, 0.26) | |
| (MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab | ‐0.09 (‐0.57, 0.38) | |
| (MTX or DMARD) + medications targeting TNF receptor: etanercept | ‐0.38 (‐0.90, 0.13) | |
| (MTX or DMARD) + non‐TNF | ‐0.12 (‐0.64, 0.39) | |
| (MTX or DMARD) + TOFA | ‐0.34 (‐1.05, 0.36) | |
| Non‐TNF: tocilizumab, rituximab, abatacept | Medication targeting TNF receptor: etanercept | ‐0.01 (‐0.39, 0.38) |
| TOFA | ‐0.16 (‐0.99, 0.69) | |
| (MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab | 0.13 (‐0.19, 0.44) | |
| (MTX or DMARD) + medication targeting TNF receptor: etanercept | ‐0.17 (‐0.41, 0.08) | |
| (MTX or DMARD) + non‐TNF | 0.09 (‐0.24, 0.43) | |
| (MTX or DMARD) + TOFA | ‐0.13 (‐0.71, 0.46) | |
| TOFA | non‐TNF: tocilizumab, rituximab, abatacept | ‐0.15 (‐0.98, 0.69) |
| (MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab | 0.13 (‐0.18, 0.45) | |
| (MTX or DMARD) + medication targeting TNF receptor: etanercept | ‐0.16 (‐0.50, 0.18) | |
| (MTX or DMARD) + non‐TNF | 0.10 (‐0.19, 0.40) | |
| (MTX or DMARD) + TOFA | ‐0.12 (‐0.70, 0.47) | |
| (MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab | TOFA | 0.28 (‐0.52, 1.07) |
| (MTX or DMARD) + medication targeting TNF receptor: etanercept | ‐0.01 (‐0.83,0.81) | |
| (MTX or DMARD) + non‐TNF | 0.25 (‐0.57,1.07) | |
| (MTX or DMARD) + TOFA | 0.03 (‐0.91, 0.98) | |
| (MTX or DMARD) + medication targeting TNF receptor: etanercept | (MTX or DMARD) + monoclonal antibodies against TNF: adalimumab, certolizumab pegol, golimumab, infliximab | ‐0.29 (‐0.54, ‐0.04) |
| (MTX or DMARD) + non‐TNF | ‐0.03 (‐0.28, 0.22) | |
| (MTX or DMARD) + TOFA | ‐0.25 (‐0.79, 0.29) | |
| (MTX or DMARD) + non‐TNF | (MTX or DMARD) + medication targeting TNF receptor: etanercept | 0.26 (‐0.02, 0.55) |
| (MTX or DMARD) + TOFA | 0.04 (‐0.51, 0.60) | |
| (MTX or DMARD) + TOFA | (MTX or DMARD) + non‐TNF | ‐0.22 (‐0.77, 0.34) |
| Random‐effects model | Total residual deviance | 77.27 vs 79 data‐points |
| Deviance information criteria | ‐172.331 | |
| Fixed‐effect model | Total residual deviance | 414.4 vs 79 data‐points |
| Deviance Information Criteria | 137.144 | |
| Note | ||
| Total studies | 38 | |
| 2‐arm | 35 | |
| 3‐arm | 3 | |
16. HAQ analysis 4 by dose (MTX/other DMARD active comparator): mean difference (MD) for all treatment comparisons ‐ random‐effects model.
| HAQ Analysis 4: standardized mean difference (SMD) for all treatment comparisons ‐ random‐effects model | ||
| Treatment | Reference | MD (95% CrI) |
| SD biologic | Comparator: MTX/other DMARD | ‐0.23 (‐0.43, ‐0.02) |
| HD biologic | ‐0.25 (‐0.49, ‐0.01) | |
| MTX SD biologic | ‐0.28 (‐0.38, ‐0.18) | |
| MTX HD biologic | ‐0.28 (‐0.43, ‐0.13) | |
| MTX LD biologic | ‐0.20 (‐0.36, ‐0.04) | |
| HD biologic | SD biologic | ‐0.03 (‐0.34, 0.28) |
| MTX SD biologic | ‐0.05 (‐0.25, 0.14) | |
| MTX HD biologic | ‐0.06 (‐0.30, 0.19) | |
| MTX LD biologic | 0.03 (‐0.22, 0.27) | |
| MTX SD biologic | HD biologic | ‐0.03 (‐0.27, 0.22) |
| MTX HD biologic | ‐0.03 (‐0.28, 0.23) | |
| MTX LD biologic | 0.06 (‐0.23, 0.34) | |
| MTX HD biologic | MTX SD biologic | 0.00 (‐0.16, 0.15) |
| MTX LD biologic | 0.08 (‐0.08, 0.25) | |
| MTX LD biologic | MTX HD biologic | 0.08 (‐0.12, 0.28) |
| Random‐effects model | Total residual deviance | 87.32 vs 88 data‐points |
| Deviance information criteria | ‐223.589 | |
| Fixed‐effect model | Total residual deviance | 1368 vs 88 data‐points |
| Deviance information criteria | 1014.69 | |
| Note | ||
| Total participants | ||
| Total studies | 35 | |
| 2‐arm | 21 | |
| 3‐arm | 10 | |
| 4‐arm | 4 | |
Direct estimates for HAQ by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to MTX/DMARD (Figure 10).
10.
HAQ: biologic monotherapy vs MTX/DMARD by drug group
Main analyses using the NMA
Forty‐eight studies (25 two‐arm, 15 three‐arm and 8 four‐arm trials), with 16,355 participants provided HAQ data in DMARD‐experienced participants (Appendix 7), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.
Monotherapy versus placebo
Compared to placebo, the following treatments were associated with statistically significantly and clinically meaningfully better HAQ scores (reduction) with the following MDs: SD adalimumab , ‐0.29; SD tofacitinib, ‐0.40; LD adalimumab, ‐0.32; HD tofacitinib, ‐0.52; and HD adalimumab ‐0.43.
Monotherapy versus active comparator
Compared to MTX, HD biologic monotherapy was associated with statistically significantly and clinically meaningfully better HAQ scores (reduction), and key examples were HD tocilizumab, MD ‐0.32 and HD tofacitinib, MD ‐0.56. Compared to MTX, SD biologic monotherapy regimens were not associated with any significant difference in HAQ improvement, except SD etanercept, MD ‐0.38. LD biologic monotherapy did not differ from MTX significantly.
Compared to DMARDs, SD etanercept, MD ‐0.38 and HD tofacitinib, MD ‐0.56 were associated with statistically significantly and clinically meaningfully greater improvements in HAQ scores. LD biologic did not differ statistically significantly from DMARDs.
Subgroup analyses by early versus established versus late RA using the NMA
Early RA (RA disease duration less than two years)
There were not enough data to perform NMA.
Established RA (disease duration two to 10 years)
Compared to MTX or DMARD, only SD etanercept monotherapy was associated with statistically significantly and clinically meaningfully more significant improvements of HAQ scores with a MD of ‐0.38 (95% CI, ‐0.69 to ‐0.07) and MD ‐0.38 (95% CI, ‐0.74 to ‐0.01), respectively. All other biologic monotherapy regimens had no significant differences in HAQ improvements compared to MTX. None of the biologic monotherapy regimens were superior to MTX + DMARD regimens (39 trials (22 two‐arm, 11 three‐arm and 6 four‐arm trials), 14,018 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 8).
Late RA (disease duration more than 10 years)
Compared to MTX, SD rituximab was associated with more significant improvements of HAQ scores: MD ‐0.44 (95% CI, ‐0.70 to ‐0.18), and this was the only monotherapy comparison to MTX available (seven trials (1 two‐arm, 4 three‐arm and 2 four‐arm trials), with 2084 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 9).
Subgroup analyses by trial duration using the NMA
Trial duration, less than six months
Compared to placebo, the following were associated with statistically significantly and clinically meaningfully greater improvements in HAQ scores with the following MDS: SD etanercept, ‐0.31; SD tofacitinib, ‐0.39; SD certolizumab, ‐0.36; LD adalimumab, ‐0.32; HD tofacitinib, ‐0.51; and HD adalimumab, ‐0.44 (42 trials (23 two‐arm, 11 three‐arm and 8 four‐arm trials), with 13,213 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 10).
Trial duration, six to 12 months
There were not enough data to perform NMA.
Trial duration, more than 12 months
There were not enough data to perform NMA.
Primary/major efficacy outcome: remission
Thirty studies with 14,125 participants, whose treatment with MTX/other DMARDs had failed, reported data on RA disease remission. Of these, 28 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often the comparator was MTX; published as a separate review) and six studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).
Monotherapy versus placebo
Participants receiving biologic monotherapy had higher OR of remission versus placebo at 3.73 (95% CI, 1.59 to 8.74, no I2; based on one study) in standard meta‐analyses (Figure 11). This was both clinically meaningful and statistically significant, but was based on only one study.
11.
Remission: biologic monotherapy vs placebo
Since there was only one study comparing biologic monotherapy versus placebo, no analyses could be performed for the type of biologic.
Monotherapy versus active comparator
Participants receiving biologic monotherapy had higher OR of remission versus MTX/other DMARDs, but this result was not statistically significant with OR of 1.65 (95% CI, 0.98 to 2.80, I2= 42% showing moderate heterogeneity) in standard meta‐analyses (four studies; Figure 12).
12.
Remission: biologic monotherapy vs MTX/DMARD
The overall odds (95% CrI) of RA disease remission by the type of medication, type of biologic and the dose using the NMA were as follows. We performed these analyses only for studies of biologic monotherapy versus MTX/DMARD.
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib (Table 17)
Compared to TNF biologic, non‐TNF biologic was not associated with any statistically significant differences in RA remission, OR 2.17 (95% CrI, 0.94 to 4.93).
-
Type of biologic: monoclonal TNF antibody versus TNF receptor versus non‐TNF versus anakinra versus tofacitinib (Table 18)
Compared to monoclonal TNF antibody biologic, etanercept was not associated with any statistically significant differences in remission rates, OR 2.21 (95% CrI, 0.87 to 5.47), but non‐TNF biologic was associated with a statistically significantly higher rate of remission OR 2.12 (95% CrI, 1.02 to 4.43). Compared to etanercept, non‐TNF biologic was not associated with any statistically significant differences in remission rates, OR 2.23 (95% CrI, 0.86 to 5.92).
-
By dose: SD versus HD versus LD (Table 19)
Compared to SD, HD biologic monotherapy was associated with statistically significantly higher OR of remission, 2.17 (95% CrI, 1.12 to 4.19); LD biologic monotherapy was not clinically meaningfully or statistically significantly different than SD biologic monotherapy, OR 1.46 (95% CrI, 0.52 to 4.11) or HD biologic monotherapy, OR 0.67 (95% CrI, 0.22 to 2.10).
17. Remission analysis 2 (MTX/DMARD active comparator) for the type of medication: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| TNF | MTX/other DMARD | 2.11 (1.29, 3.54) | 1.96 (1.27, 3.04) | 0.07 (0.02, 0.14) |
| Non‐TNF | 4.59 (2.08, 10.27) | 3.66 (1.93, 6.36) | 0.19 (0.07, 0.36) | |
| MTX + TNF | 4.09 (2.91, 5.93) | 3.36 (2.54, 4.50) | 0.17 (0.11, 0.23) | |
| MTX + non‐TNF | 4.71 (3.02, 7.60) | 3.73 (2.62, 5.32) | 0.19 (0.12, 0.28) | |
| MTX + TOFA | 8.15 (1.66, 49.85) | 5.40 (1.58, 11.79) | 0.31 (0.04, 0.71) | |
| Non‐TNF | TNF | 2.17 (0.94, 4.93) | 1.87 (0.95, 3.38) | 0.12 (‐0.01, 0.28) |
| MTX + TNF | 1.93 (1.22, 3.09) | 1.71 (1.17, 2.56) | 0.10 (0.03, 0.16) | |
| MTX + non‐TNF | 2.23 (1.20, 4.17) | 1.90 (1.16, 3.17) | 0.12 (0.03, 0.23) | |
| MTX + TOFA | 3.85 (0.72, 25.04) | 2.74 (0.76, 6.70) | 0.24 (‐0.04, 0.65) | |
| MTX + TNF | Non‐TNF | 0.89 (0.40, 2.05) | 0.92 (0.53, 1.78) | ‐0.02 (‐0.20, 0.11) |
| MTX + non‐TNF | 1.02 (0.48, 2.23) | 1.02 (0.61, 1.88) | 0.00 (‐0.16, 0.13) | |
| MTX + TOFA | 1.78 (0.30, 12.74) | 1.47 (0.39, 4.02) | 0.12 (‐0.21, 0.55) | |
| MTX + non‐TNF | MTX + TNF | 1.15 (0.69, 1.93) | 1.11 (0.75, 1.62) | 0.03 (‐0.07, 0.13) |
| MTX + TOFA | 1.99 (0.39, 12.55) | 1.61 (0.46, 3.60) | 0.14 (‐0.14, 0.56) | |
| MTX + TOFA | MTX + non‐TNF | 1.73 (0.33, 11.10) | 1.45 (0.41, 3.34) | 0.12 (‐0.17, 0.53) |
| Random‐effects model | Residual deviance | 64.66 vs 63 data‐points | ||
| Deviance information criteria | 409.045 | |||
| Fixed‐Effect Model | Residual deviance | 134.2 vs 63 data‐points | ||
| Deviance information criteria | 459.699 | |||
| Note | ||||
| Total participants | 12668 | |||
| Total studies | 29 | |||
| 2‐arm | 24 | |||
| 3‐arm | 5 |
18. Remission: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| Mono | MTX/other DMARD | 2.00 (0.87, 4.70) | 1.96 (1.05, 3.56) | 0.07 (0.00, 0.17) |
| Medication targeting TNF receptor: etanercept | 4.64 (1.98, 11.03) | 1.87 (0.87, 3.76) | 0.06 (‐0.01, 0.19) | |
| Non‐TNF | 4.46 (2.86, 7.27) | 3.70 (1.85, 6.65) | 0.19 (0.06, 0.37) | |
| MTX + Monoclonal antibodies against TNF | 4.83 (3.02, 8.00) | 3.60 (2.51, 5.22) | 0.18 (0.11, 0.27) | |
| MTX + non‐TNF | 3.64 (1.93, 7.01) | 3.82 (2.63, 5.54) | 0.19 (0.12, 0.29) | |
| MTX + Medication targeting TNF receptor: etanercept | 7.78 (1.53, 50.47) | 3.08 (1.81, 5.01) | 0.14 (0.06, 0.27) | |
| MTX + TOFA | 0.95 (0.31, 2.85) | 5.29 (1.47, 11.93) | 0.30 (0.03, 0.71) | |
| Medication targeting TNF receptor: etanercept | Monoclonal antibodies against TNF | 2.21 (0.87, 5.47) | 0.96 (0.36, 2.43) | ‐0.01 (‐0.13, 0.14) |
| Non‐TNF | 2.12 (1.02, 4.43) | 1.89 (0.89, 3.80) | 0.12 (‐0.02, 0.29) | |
| MTX + Monoclonal antibodies against TNF | 2.30 (1.05, 5.07) | 1.84 (1.02, 3.48) | 0.11 (0.00, 0.21) | |
| MTX + non‐TNF | 1.73 (0.66, 4.49) | 1.95 (1.04, 3.81) | 0.13 (0.01, 0.24) | |
| MTX + Medication targeting TNF receptor: etanercept | 3.72 (0.61, 26.89) | 1.57 (0.71, 3.45) | 0.08 (‐0.06, 0.22) | |
| MTX + TOFA | 2.32 (0.69, 7.63) | 2.68 (0.66, 7.56) | 0.23 (‐0.06, 0.65) | |
| Non‐TNF | Medication targeting TNF receptor: etanercept | 2.23 (0.86, 5.92) | 1.97 (0.74, 5.14) | 0.12 (‐0.06, 0.33) |
| MTX + Monoclonal antibodies against TNF | 2.41 (0.92, 6.44) | 1.92 (0.89, 4.52) | 0.12 (‐0.03, 0.23) | |
| MTX + non‐TNF | 1.82 (0.94, 3.52) | 2.03 (0.94, 4.75) | 0.13 (‐0.01, 0.26) | |
| MTX + Medication targeting TNF receptor: etanercept | 3.90 (0.62, 29.66) | 1.64 (0.95, 2.95) | 0.08 (‐0.01, 0.17) | |
| MTX + TOFA | 0.96 (0.39, 2.43) | 2.79 (0.67, 8.70) | 0.23 (‐0.06, 0.66) | |
| MTX + Monoclonal antibodies against TNF | Non‐TNF | 1.04 (0.46, 2.40) | 0.97 (0.53, 2.02) | ‐0.01 (‐0.20, 0.14) |
| MTX + non‐TNF | 0.79 (0.27, 2.31) | 1.03 (0.59, 2.00) | 0.01 (‐0.17, 0.14) | |
| MTX + Medication targeting TNF receptor: etanercept | 1.69 (0.26, 12.95) | 0.83 (0.38, 1.93) | ‐0.04 (‐0.25, 0.14) | |
| MTX + TOFA | 1.08 (0.60, 1.93) | 1.42 (0.35, 4.18) | 0.11 (‐0.22, 0.55) | |
| MTX + non‐TNF | MTX + Monoclonal antibodies against TNF | 0.82 (0.36, 1.79) | 1.06 (0.69, 1.62) | 0.02 (‐0.10, 0.13) |
| MTX + Medication targeting TNF receptor: etanercept | 1.75 (0.32, 11.67) | 0.86 (0.45, 1.54) | ‐0.04 (‐0.17, 0.11) | |
| MTX + TOFA | 0.75 (0.33, 1.68) | 1.47 (0.39, 3.48) | 0.12 (‐0.17, 0.54) | |
| MTX + Medication targeting TNF receptor: etanercept | MTX + non‐TNF | 1.61 (0.29, 10.92) | 0.81 (0.42, 1.46) | ‐0.05 (‐0.19, 0.10) |
| MTX + TOFA | 2.14 (0.37, 15.21) | 1.39 (0.37, 3.32) | 0.10 (‐0.19, 0.53) | |
| MTX + TOFA | MTX + Medication targeting TNF receptor: etanercept | 1.71 (0.44, 4.56) | 0.15 (‐0.15, 0.58) | |
| Random‐effects model | Residual deviance | 64.03 vs 63 data‐points | ||
| Deviance information criteria | 409.476 | |||
| Fixed‐effect model | Residual deviance | 135.9 vs 63 data‐points | ||
| Deviance information criteria | 463.334 | |||
| Note | ||||
| Total participants | 12,668 | |||
| Total studies | 29 | |||
| 2‐arm | 24 | |||
| 3‐arm | 5 |
19. Remission: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD | MTX/other DMARD | 1.90 (1.18, 3.15) | 1.78 (1.16, 2.73) | 0.06 (0.01, 0.12) |
| HD | 4.14 (2.25, 7.68) | 3.34 (2.05, 5.22) | 0.18 (0.08, 0.30) | |
| LD | 2.79 (1.02, 7.63) | 2.45 (1.02, 5.15) | 0.11 (0.00, 0.30) | |
| MTX SD | 4.15 (3.10, 5.68) | 3.35 (2.64, 4.31) | 0.18 (0.13, 0.23) | |
| MTX HD | 5.82 (3.57, 9.92) | 4.27 (2.96, 6.14) | 0.25 (0.15, 0.36) | |
| MTX LD | 2.26 (1.30, 3.95) | 2.07 (1.27, 3.26) | 0.08 (0.02, 0.16) | |
| HD | SD | 2.17 (1.12, 4.19) | 1.87 (1.10, 3.12) | 0.12 (0.02, 0.24) |
| LD | 1.46 (0.52, 4.11) | 1.38 (0.56, 3.02) | 0.05 (‐0.07, 0.24) | |
| MTX SD | 2.17 (1.38, 3.45) | 1.88 (1.29, 2.81) | 0.12 (0.05, 0.18) | |
| MTX HD | 3.06 (1.65, 5.82) | 2.39 (1.47, 3.95) | 0.19 (0.08, 0.30) | |
| MTX LD | 1.19 (0.60, 2.30) | 1.16 (0.65, 2.02) | 0.02 (‐0.06, 0.11) | |
| LD | HD | 0.67 (0.22, 2.10) | 0.73 (0.28, 1.72) | ‐0.07 (‐0.23, 0.14) |
| MTX SD | 1.00 (0.54, 1.85) | 1.00 (0.65, 1.63) | 0.00 (‐0.13, 0.10) | |
| MTX HD | 1.41 (0.78, 2.62) | 1.27 (0.84, 2.03) | 0.07 (‐0.05, 0.19) | |
| MTX LD | 0.55 (0.25, 1.20) | 0.62 (0.33, 1.16) | ‐0.10 (‐0.23, 0.03) | |
| MTX SD | LD | 1.49 (0.56, 4.06) | 1.36 (0.67, 3.27) | 0.07 (‐0.12, 0.18) |
| MTX HD | 2.09 (0.71, 6.32) | 1.74 (0.79, 4.39) | 0.13 (‐0.07, 0.29) | |
| MTX LD | 0.81 (0.28, 2.33) | 0.84 (0.38, 2.09) | ‐0.03 (‐0.22, 0.10) | |
| MTX HD | MTX SD | 1.40 (0.86, 2.35) | 1.27 (0.89, 1.79) | 0.07 (‐0.03, 0.18) |
| MTX LD | 0.55 (0.31, 0.93) | 0.62 (0.38, 0.95) | ‐0.10 (‐0.17, ‐0.01) | |
| MTX LD | MTX HD | 0.39 (0.19, 0.78) | 0.48 (0.27, 0.83) | ‐0.16 (‐0.29, ‐0.04) |
| Random‐effects model | Residual deviance | 68.24 vs 68 data‐points | ||
| Deviance information criteria | 427.568 | |||
| Fixed‐effect model | Residual deviance | 137.3 vs 68 data‐points | ||
| Deviance information criteria | 475.55 | |||
| Note | ||||
| Total participants | 11,225 | |||
| Total studies | 27 | |||
| 2‐arm | 16 | |||
| 3‐arm | 9 | |||
| 4‐arm | 1 | |||
| 5‐arm | 1 |
Direct estimates for remission by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra or tofacitinib, or both, are shown in Figure 13.
13.
Remission: biologic monotherapy vs MTX/DMARD by drug group
Main analyses using the NMA
Thirty studies (17 two‐arm, 11 three‐arm, 1 four‐arm and 1 five‐arm trials), with 14,125 participants provided data for MTX/other DMARD‐experienced participants for remission (Appendix 11), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.
Monotherapy versus active comparator
Compared to MTX/other DMARDs, HD biologic monotherapy regimens (tocilizumab, golimumab) were associated with two to three times the OR of remission, which was statistically significant. Compared to MTX, the ORs of remission were similar for most SD and LD biologic monotherapy regimens.
High‐dose biologic (higher remission) versus standard‐ or LD biologic
In general, compared to SD or LD biologic monotherapy, most HD biologic monotherapy was associated with higher rates of remission. Compared to SD adalimumab, HD tocilizumab intravenous was associated with statistically significantly higher OR of RA disease remission: 5.81 (95% CrI, 1.78 to 19.48).
Subgroup analyses by early versus established versus late RA using the NMA
Early RA (RA disease duration less than two years)
There were not enough data to perform NMA.
Established RA (disease duration two to 10 years)
Compared to MTX, most HD biologic monotherapy (tocilizumab, golimumab) was associated with two times higher OR of remission, which was statistically significant. Compared to MTX + DMARD, HD biologic monotherapy was associated with 7 to 10 times higher OR of remission (statistically significant), but SD or LD biologic monotherapy were associated with similar OR (13,479 participants, 29 trials including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 12).
Late RA (disease duration more than 10 years)
There were not enough data to perform NMA.
Subgroup analyses by trial duration using the NMA
Trial duration, less than six months
We created two networks, one with 9626 participants and 20 trials (Appendix 13) and the other with 1392 participants and five trials (Appendix 14).
Compared to SD adalimumab subcutaneous, HD tocilizumab IV was associated with 5.9 times odds of remission, which was statistically significant. We observed a higher OR with HD tocilizumab or golimumab, as described above.
Trial duration, six to 12 months
There were not enough data to perform NMA.
Trial duration, more than 12 months
There were not enough data to perform NMA.
Primary/major efficacy outcome: radiographic progression
Eight studies with 3267 participants, whose treatment with MTX/other DMARDS had failed, reported data on radiographic progression. Of these, all eight studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and only one study had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).
Monotherapy versus placebo
There were no data available for biologic monotherapy versus placebo.
Monotherapy versus active comparator
The one included study showed that the use of SD etanercept monotherapy (one of the TNF biologics) was statistically significantly associated with less radiographic progression compared to MTX with a MD of ‐4.34 (95% CI, ‐7.56 to ‐1.12) modified Sharp units in standard meta‐analyses (Figure 14); whether this difference is clinically meaningful or not is unclear.
14.
Radiographic progression: biologic monotherapy vs MTX/DMARD
Since there was only one study available, no estimates could be derived by the type of medication, type of biologic and biologic dose.
Subgroup analyses by early versus established versus late RA using the NMA
Early RA (RA disease duration less than two years)
There were not enough data to perform NMA.
Established RA (disease duration two to 10 years)
There were not enough data to perform NMA.
Late RA (disease duration longer than 10 years)
There were not enough data to perform NMA.
Subgroup analyses by trial duration using the NMA
Trial duration, less than six months
There were not enough data to perform NMA.
Trial duration, six to 12 months
There were not enough data to perform NMA.
Trial duration, more than 12 months
There were not enough data to perform NMA.
Primary/major safety outcome: Withdrawals due to adverse events (WdAE)
Seventy studies with 29,062 participants reported withdrawals due to AEs. Of these, 52 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and 23 studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).
Monotherapy versus placebo
The use of biologic monotherapy was associated with no statistically significant increase in the likelihood of withdrawals due to AEs versus placebo, with an OR of 1.70 (95% CI, 0.98 to 2.95) and with I2 of 15%, denoting low heterogeneity in standard meta‐analyses (nine studies; Figure 15).
15.
Withdrawals due to Adverse Events: biologic monotherapy vs placebo
The overall odds (95% CrI) of withdrawals due to AEs by the type of medication, type of biologic and the dose using the NMA were as follows.
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib
In placebo comparator analysis, compared to TNF biologic monotherapy, non‐TNF biologic monotherapy was associated with statistically significantly and clinically meaningfully lower OR of withdrawals due to AEs, OR 0.10 (95% CrI, 0.01 to 0.67), but anakinra monotherapy, OR 0.75 (95% CrI, 0.22 to 2.76) or tofacitinib monotherapy were not, 0.55 (95% CrI, 0.12 to 2.89) (Table 20).
-
Type of biologic: monoclonal TNF antibody versus TNF receptor versus non‐TNF biologic versus anakinra versus tofacitinib
In placebo comparator analysis, compared to monoclonal TNF antibody monotherapy, there were no significant differences in the OR of withdrawals due to AEs with etanercept monotherapy, OR 0.71 (95% CrI, 0.17 to 3.51), tofacitinib monotherapy, OR 0.48 (95% CrI, 0.10 to 2.78) or anakinra monotherapy, OR 0.69 (95% CrI, 0.18 to 2.78). Non‐TNF biologic monotherapy, OR 0.09 (95% CrI, 0.01 to 0.63), was associated with statistically significantly lower odds compared to monoclonal TNF antibody monotherapy (Table 21).
-
By dose: SD versus HD versus LD
In placebo comparator analysis, compared to SD biologic monotherapy, LD or HD biologic monotherapy were not associated with a difference in OR of withdrawals due to AEs, OR 0.62 (95% CrI, 0.22 to 1.63) and 0.84 (95% CrI, 0.31 to 2.19), respectively (Table 22)
20. Withdrawals due to adverse events: analysis 2 (only placebo comparator trials) for the type of medication: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| TNF Inhibitors | Placebo | 2.14(1.14,4.27) | 2.09(1.14,4.04) | 0.03(0.00,0.06) |
| TOFA | 1.20(0.30,5.40) | 1.19(0.31,4.96) | 0.00(‐0.02,0.08) | |
| non‐TNF | 0.21(0.03,1.30) | 0.22(0.03,1.29) | ‐0.02(‐0.03,0.01) | |
| ANA | 1.61(0.59,5.16) | 1.59(0.59,4.73) | 0.01(‐0.01,0.09) | |
| TOFA | TNF inhibitors | 0.55(0.12,2.89) | 0.57(0.13,2.69) | ‐0.02(‐0.06,0.06) |
| non‐TNF | 0.10(0.01,0.67) | 0.10(0.01,0.68) | ‐0.04(‐0.08,‐0.01) | |
| ANA | 0.75(0.22,2.76) | 0.76(0.23,2.58) | ‐0.01(‐0.05,0.07) | |
| non‐TNF | TOFA | 0.17(0.01,1.74) | 0.18(0.02,1.72) | ‐0.02(‐0.10,0.01) |
| ANA | 1.37(0.22,8.13) | 1.35(0.23,7.53) | 0.01(‐0.07,0.09) | |
| ANA | non‐TNF | 7.67(0.99,82.01) | 7.38(0.99,76.17) | 0.03(0.00,0.11) |
| Random‐effects model | Residual deviance | 17.25 vs 22 data points | ||
| Deviance information criteria | 97.681 | |||
| Fixed‐effect model | Residual deviance | 17.32 vs 22 data points | ||
| Deviance information criteria | 97.409 | |||
| Note | ||||
| Total Patients | 2747 | |||
| Total Studies | 11 | |||
| 2‐arm | 11 | |||
21. Withdrawals due to adverse events: analysis 3 (only placebo comparator trials) for the type of biologic: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| Monoclonal antibodies against TNF | Placebo | 2.38(1.14,5.45) | 2.30(1.14,5.05) | 0.03(0.00,0.08) |
| Medications targeting TNF receptor: etanercept | 1.71(0.50,6.98) | 1.68(0.51,6.23) | 0.02(‐0.01,0.11) | |
| TOFA | 1.16(0.30,5.47) | 1.16(0.31,5.03) | 0.00(‐0.02,0.08) | |
| non‐TNF | 0.21(0.02,1.32) | 0.21(0.02,1.31) | ‐0.02(‐0.03,0.01) | |
| ANA | 1.64(0.58,5.40) | 1.62(0.59,4.93) | 0.01(‐0.01,0.09) | |
| Medications targeting TNF receptor: etanercept | Monoclonal antibodies against TNF | 0.71(0.17,3.51) | 0.72(0.18,3.19) | ‐0.01(‐0.07,0.09) |
| TOFA | 0.48(0.10,2.78) | 0.50(0.11,2.61) | ‐0.03(‐0.08,0.06) | |
| non‐TNF | 0.09(0.01,0.63) | 0.09(0.01,0.64) | ‐0.05(‐0.10,‐0.01) | |
| ANA | 0.69(0.18,2.78) | 0.70(0.19,2.60) | ‐0.02(‐0.07,0.07) | |
| TOFA | Medications targeting TNF receptor: etanercept | 0.67(0.10,4.91) | 0.68(0.10,4.56) | ‐0.01(‐0.11,0.07) |
| non‐TNF | 0.12(0.01,1.15) | 0.12(0.01,1.15) | ‐0.03(‐0.13,0.00) | |
| ANA | 0.96(0.16,5.17) | 0.96(0.18,4.79) | 0.00(‐0.10,0.08) | |
| non‐TNF | TOFA | 0.18(0.01,1.74) | 0.18(0.01,1.72) | ‐0.02(‐0.10,0.01) |
| ANA | 1.42(0.22,8.73) | 1.41(0.24,8.04) | 0.01(‐0.07,0.09) | |
| ANA | non‐TNF | 8.08(0.95,91.00) | 7.78(0.95,84.53) | 0.03(0.00,0.11) |
| Random‐effects model | Residual deviance | 17.99 vs 22 data points | ||
| Deviance information criteria | 99.313 | |||
| Fixed‐effect model | Residual deviance | 18.09 vs 22 data points | ||
| Deviance information criteria | 99.128 | |||
| Note | ||||
| Total Patients | 2747 | |||
| Total Studies | 11 | |||
| 2‐arm | 11 |
22. Withdrawals due to adverse events: analysis 4 (only placebo comparator trials) by dose: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD biologic | Comparator: placebo | 1.81 (0.83, 3.87) | 1.77 (0.84, 3.69) | 0.02 (0.00, 0.05) |
| LD biologic | 1.13 (0.39, 2.99) | 1.12 (0.40, 2.88) | 0.00 (‐0.02, 0.04) | |
| HD biologic | 1.53 (0.54, 4.00) | 1.51 (0.55, 3.79) | 0.01 (‐0.01, 0.06) | |
| LD biologic | SD biologic | 0.62 (0.22, 1.63) | 0.63 (0.23, 1.60) | ‐0.01 (‐0.05, 0.02) |
| HD biologic | 0.84 (0.31, 2.19) | 0.85 (0.32, 2.11) | ‐0.01 (‐0.04, 0.04) | |
| HD biologic | LD biologic | 1.35 (0.44, 4.16) | 1.34 (0.46, 3.97) | 0.01 (‐0.03, 0.05) |
| Random‐effects model | Residual deviance | 26.76 vs 26 data‐points | ||
| Deviance information criteria | 119.734 | |||
| Fixed‐effect model | Residual deviance | 33.61 vs 26 data‐points | ||
| Deviance information criteria | 120.824 | |||
| Note | ||||
| Total studies | 9 | |||
| 2‐arm | 4 | |||
| 3‐arm | 2 | |||
| 4‐arm | 3 | |||
Direct estimates for withdrawals due to AEs by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra or tofacitinib, or both, are shown for comparison to placebo (Figure 16).
16.
Withdrawals due to Adverse Events: biologic monotherapy vs placebo by drug group
Monotherapy versus active comparator
Biologic monotherapy was associated with no statistically significant increase in the likelihood of withdrawals due to AEs versus MTX/other DMARDs with an OR of 1.09 (95% CI, 0.67 to 1.79; nine studies) and with I2 of 62%, denoting moderate heterogeneity in standard meta‐analyses (Figure 17).
17.
Withdrawals due to Adverse Events: biologic monotherapy vs MTX/DMARD
The overall odds (95% CrI) of withdrawals due to AEs by the type of medication, type of biologic and the dose using the NMA were as follows.
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib
In active comparator analysis, compared to TNF biologic monotherapy, non‐TNF biologic monotherapy was not associated with any statistically significant differences in the odds of withdrawals due to AEs: OR 1.08 (95% CrI, 0.60 to 1.94) (Table 23).
-
Type of biologic: monoclonal TNF antibody versus TNF receptor versus non‐TNF versus anakinra versus tofacitinib
In active comparator analysis, compared to monoclonal TNF antibody monotherapy, there was no statistically significant difference in odds of withdrawals due to AEs with etanercept monotherapy, OR 0.88 (95% CrI, 0.38 to 1.96). When compared to etanercept monotherapy, non‐TNF monotherapy was not associated with a statistically significant difference in odds, OR 1.42 (95% CrI, 0.66 to 3.13) (Table 24).
-
By dose: SD versus HD versus LD
In active comparator analysis, compared to SD biologic monotherapy, LD or HD biologic monotherapy were not associated with a statistically significant difference in odds of withdrawals due to AEs, OR 0.74 (95% CrI, 0.44 to 1.25) and 1.00 (95% CrI, 0.55 to 1.79), respectively. Likewise, when compared to HD biologic monotherapy, LD biologic monotherapy showed no statistically significant difference, OR 0.74 (95% CrI, 0.37 to 1.51) (Table 25).
23. Withdrawals due to adverse events: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% CrI) |
| TNF | MTX/other DMARD | 1.14 (0.79, 1.70) | 1.14 (0.79, 1.67) | 0.00 (‐0.01, 0.02) |
| Non‐TNF | 1.23 (0.75, 2.07) | 1.23 (0.75, 2.02) | 0.01 (‐0.01, 0.03) | |
| (MTX or DMARD) + TNF | 1.20 (0.94, 1.54) | 1.19 (0.94, 1.52) | 0.00 (0.00, 0.01) | |
| (MTX or DMARD) + non‐TNF | 1.21 (0.87, 1.72) | 1.21 (0.87, 1.69) | 0.00 (0.00, 0.02) | |
| (MTX or DMARD) + TOFA | 1.56 (0.83, 3.01) | 1.54 (0.83, 2.87) | 0.01 (0.00, 0.05) | |
| Non‐TNF | TNF | 1.08 (0.60, 1.94) | 1.08 (0.61, 1.90) | 0.00 (‐0.02, 0.02) |
| (MTX or DMARD) + TNF | 1.05 (0.71, 1.53) | 1.05 (0.72, 1.51) | 0.00 (‐0.01, 0.01) | |
| (MTX or DMARD) + non‐TNF | 1.07 (0.65, 1.73) | 1.06 (0.66, 1.70) | 0.00 (‐0.01, 0.02) | |
| (MTX or DMARD) + TOFA | 1.37 (0.65, 2.86) | 1.36 (0.66, 2.73) | 0.01 (‐0.01, 0.05) | |
| (MTX or DMARD) + TNF | non‐TNF | 0.97 (0.55, 1.69) | 0.97 (0.57, 1.67) | 0.00 (‐0.02, 0.01) |
| (MTX or DMARD) + non‐TNF | 0.99 (0.57, 1.68) | 0.99 (0.58, 1.65) | 0.00 (‐0.02, 0.02) | |
| (MTX or DMARD) + TOFA | 1.27 (0.56, 2.87) | 1.26 (0.57, 2.75) | 0.01 (‐0.02, 0.05) | |
| (MTX or DMARD) + non‐TNF | (MTX or DMARD) + TNF | 1.01 (0.69, 1.51) | 1.01 (0.69, 1.49) | 0.00 (‐0.01, 0.01) |
| (MTX or DMARD) + TOFA | 1.30 (0.67, 2.55) | 1.29 (0.68, 2.44) | 0.01 (‐0.01, 0.04) | |
| (MTX or DMARD) + TOFA | (MTX or DMARD) + non‐TNF | 1.28 (0.62, 2.69) | 1.27 (0.63, 2.57) | 0.01 (‐0.01, 0.05) |
| Random‐effects model | Residual deviance | 115.4 vs 117 data‐points | ||
| Deviance information criteria | 612.815 | |||
| Fixed‐effect model | Residual deviance | 148.7 vs 117 data‐points | ||
| Deviance Information Criteria | 628.564 | |||
| Note | ||||
| Total participants | 23,310 | |||
| Total Studies | 55 | |||
| 2‐arm | 48 | |||
| 3‐arm | 7 | |||
24. Withdrawals due to adverse events: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% CrI) |
| Monoclonal antibodies against TNF | MTX/other DMARD | 0.93(0.63,1.43) | 0.93(0.64,1.41) | 0.00(‐0.01,0.01) |
| Medication targeting TNF receptor: etanercept | 0.82(0.38,1.71) | 0.82(0.39,1.68) | 0.00(‐0.02,0.02) | |
| Non‐TNF | 1.16(0.71,1.90) | 1.15(0.72,1.86) | 0.00(‐0.01,0.02) | |
| MTX + Monoclonal antibodies against TNF | 1.53(1.16,2.02) | 1.51(1.16,1.97) | 0.01(0.00,0.03) | |
| MTX + non‐TNF | 1.24(0.91,1.70) | 1.23(0.91,1.67) | 0.01(0.00,0.02) | |
| MTX + TNF | 0.73(0.50,1.07) | 0.74(0.51,1.07) | ‐0.01(‐0.02,0.00) | |
| MTX + TOFA | 1.66(0.93,3.00) | 1.63(0.93,2.87) | 0.01(0.00,0.05) | |
| TNF | Monoclonal antibodies against TNF | 0.88(0.38,1.96) | 0.88(0.39,1.92) | 0.00(‐0.02,0.02) |
| Non‐TNF | 1.25(0.66,2.33) | 1.24(0.66,2.28) | 0.00(‐0.01,0.03) | |
| MTX + Monoclonal antibodies against TNF | 1.65(0.99,2.66) | 1.62(0.99,2.58) | 0.01(0.00,0.03) | |
| MTX + non‐TNF | 1.33(0.79,2.17) | 1.32(0.79,2.13) | 0.01(‐0.01,0.02) | |
| MTX + Medication targeting TNF receptor: etanercept | 0.79(0.50,1.20) | 0.79(0.51,1.19) | 0.00(‐0.02,0.00) | |
| MTX + TOFA | 1.78(0.87,3.59) | 1.75(0.87,3.42) | 0.02(0.00,0.05) | |
| Non‐TNF | Medication targeting TNF receptor: etanercept | 1.42(0.66,3.13) | 1.41(0.67,3.05) | 0.01(‐0.01,0.03) |
| MTX + Monoclonal antibodies against TNF | 1.87(0.86,4.15) | 1.84(0.86,4.02) | 0.02(0.00,0.04) | |
| MTX + non‐TNF | 1.52(0.70,3.40) | 1.50(0.70,3.32) | 0.01(‐0.01,0.03) | |
| MTX + Medication targeting TNF receptor: etanercept | 0.90(0.42,1.94) | 0.90(0.43,1.91) | 0.00(‐0.02,0.01) | |
| MTX + TOFA | 2.04(0.80,5.39) | 2.00(0.80,5.14) | 0.02(‐0.01,0.06) | |
| MTX + Monoclonal antibodies against TNF | Non‐TNF | 1.33(0.76,2.28) | 1.32(0.77,2.23) | 0.01(‐0.01,0.03) |
| MTX + non‐TNF | 1.07(0.64,1.78) | 1.07(0.65,1.76) | 0.00(‐0.02,0.02) | |
| MTX + Medication targeting TNF receptor: etanercept | 0.63(0.34,1.15) | 0.64(0.35,1.14) | ‐0.01(‐0.03,0.00) | |
| MTX + TOFA | 1.44(0.67,3.09) | 1.42(0.67,2.95) | 0.01(‐0.01,0.05) | |
| MTX + non‐TNF | MTX + Monoclonal antibodies against TNF | 0.81(0.55,1.19) | 0.81(0.56,1.19) | ‐0.01(‐0.02,0.01) |
| MTX + Medication targeting TNF receptor: etanercept | 0.48(0.30,0.76) | 0.49(0.31,0.77) | ‐0.02(‐0.04,‐0.01) | |
| MTX + TOFA | 1.08(0.60,2.02) | 1.08(0.61,1.95) | 0.00(‐0.02,0.04) | |
| MTX + Medication targeting TNF receptor: etanercept | MTX + non‐TNF | 0.59(0.36,0.96) | 0.60(0.37,0.96) | ‐0.01(‐0.03,0.00) |
| MTX + TOFA | 1.34(0.69,2.62) | 1.33(0.70,2.51) | 0.01(‐0.01,0.04) | |
| MTX + TOFA | MTX + Medication targeting TNF receptor: etanercept | 2.28(1.14,4.60) | 2.22(1.14,4.37) | 0.02(0.00,0.06) |
| Random‐effects model | Residual deviance | 116.4 vs 117 data‐points | ||
| Deviance information criteria | 610.745 | |||
| Fixed‐effect model | Residual deviance | 135 vs 117 data‐points | ||
| Deviance information criteria | 616.812 | |||
| Note | ||||
| Total participants | 23,309 | |||
| Total studies | 55 | |||
| 2‐arm | 48 | |||
| 3‐arm | 7 | |||
25. Withdrawals due to adverse events: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% CrI) |
| SD biologic | Comparator: MTX/other DMARD | 1.16 (0.84, 1.67) | 1.16 (0.84, 1.64) | 0.00 (0.00, 0.02) |
| HD biologic | 1.17 (0.71, 1.91) | 1.17 (0.72, 1.87) | 0.00 (‐0.01, 0.02) | |
| LD biologic | 0.87 (0.52, 1.49) | 0.87 (0.52, 1.47) | 0.00 (‐0.01, 0.01) | |
| MTX SD biologic | 1.15 (0.95, 1.41) | 1.15 (0.95, 1.39) | 0.00 (0.00, 0.01) | |
| MTX HD biologic | 1.46 (1.07, 1.99) | 1.44 (1.06, 1.95) | 0.01 (0.00, 0.03) | |
| MTX LD biologic | 1.12 (0.68, 1.79) | 1.12 (0.69, 1.76) | 0.00 (‐0.01, 0.02) | |
| HD biologic | SD biologic | 1.00 (0.55, 1.79) | 1.00 (0.56, 1.75) | 0.00 (‐0.02, 0.02) |
| LD biologic | 0.74 (0.44, 1.25) | 0.75 (0.45, 1.24) | ‐0.01 (‐0.02, 0.01) | |
| MTX SD biologic | 0.99 (0.69, 1.37) | 0.99 (0.70, 1.36) | 0.00 (‐0.01, 0.01) | |
| MTX HD biologic | 1.25 (0.80, 1.92) | 1.24 (0.80, 1.88) | 0.01 (‐0.01, 0.02) | |
| MTX LD biologic | 0.96 (0.54, 1.64) | 0.96 (0.55, 1.62) | 0.00 (‐0.02, 0.02) | |
| LD biologic | HD biologic | 0.74 (0.37, 1.51) | 0.75 (0.38, 1.49) | ‐0.01 (‐0.03, 0.01) |
| MTX SD biologic | 0.98 (0.59, 1.66) | 0.98 (0.60, 1.64) | 0.00 (‐0.02, 0.01) | |
| MTX HD biologic | 1.25 (0.74, 2.14) | 1.24 (0.75, 2.10) | 0.01 (‐0.01, 0.02) | |
| MTX LD biologic | 0.95 (0.50, 1.86) | 0.95 (0.51, 1.83) | 0.00 (‐0.02, 0.02) | |
| MTX SD biologic | LD biologic | 1.33 (0.77, 2.26) | 1.32 (0.77, 2.22) | 0.01 (‐0.01, 0.02) |
| MTX HD biologic | 1.69 (0.92, 3.01) | 1.66 (0.92, 2.92) | 0.01 (0.00, 0.03) | |
| MTX LD biologic | 1.29 (0.64, 2.52) | 1.28 (0.65, 2.46) | 0.01 (‐0.01, 0.03) | |
| MTX HD biologic | MTX SD biologic | 1.27 (0.91, 1.76) | 1.26 (0.91, 1.72) | 0.01 (0.00, 0.02) |
| MTX LD biologic | 0.97 (0.59, 1.55) | 0.97 (0.60, 1.53) | 0.00 (‐0.01, 0.02) | |
| MTX LD biologic | MTX HD biologic | 0.77 (0.44, 1.31) | 0.77 (0.45, 1.30) | ‐0.01 (‐0.03, 0.01) |
| Random‐effects model | Residual deviance | 127.5 vs 130 data‐points | ||
| Deviance information criteria | 640.011 | |||
| Fixed‐effect model | Residual deviance | 143.8 vs 130 data‐points | ||
| Deviance information criteria | 644.025 | |||
| Note | ||||
| Total participants | 21,395 | |||
| Total studies | 52 | |||
| 2‐arm | 33 | |||
| 3‐arm | 15 | |||
| 4‐arm | 3 | |||
| 7‐arm | 1 | |||
WHERE IS ANALYSIS 2 (PBO), SAE?
Direct estimates for withdrawals due to AEs by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra or tofacitinib, or both are shown for comparison to MTX/other DMARDs and were similar to the results above (Figure 18).
18.
Withdrawals due to Adverse Events: biologic monotherapy vs MTX/DMARD by drug group
Main analyses using the NMA
Seventy studies (42 two‐arm, 20 three‐arm, 7 four‐arm and 1 seven‐arm trials), with 29,062 participants provided data for all dose analyses (Appendix 15), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.
Monotherapy versus active comparator
We noted no significant increase in the odds of withdrawals due to AEs with biologic monotherapy in any dose, compared to MTX or DMARDs.
Adalimumab and infliximab comparisons
Compared to SD adalimumab + MTX or SD infliximab + MTX, LD adalimumab and HD adalimumab monotherapy showed statistically significantly lower OR of withdrawals ranging from 0.12 to 0.40. Compared to LD adalimumab monotherapy, most HD biologics + MTX as well as tofacitinib + MTX were associated with statistically significantly higher OR of withdrawals, 4.59 to 7.41. Compared to HD adalimumab monotherapy, most HD biologics + MTX as well as tofacitinib + MTX were associated with statistically significantly higher OR of withdrawals due to AEs, OR 4.33 to 7.26.
Compared to SD certolizumab + MTX, we found that LD adalimumab and HD adalimumab monotherapy were associated with statistically significantly lower odds of withdrawals due to AEs, OR 0.17.
Compared to SD tofacitinib + MTX, LD etanercept, LD adalimumab and HD adalimumab monotherapy were associated with statistically significantly lower OR of withdrawals due to AEs, 0.12 to 0.40.
Compared to SD abatacept + MTX, we found that HD tofacitinib monotherapy was associated with statistically significantly higher OR of withdrawals due to AEs, 2.82 to 3.86.
Subgroup analyses by early versus established versus late RA using the NMA
Early RA (RA disease duration less than two years)
There were not enough data to perform NMA.
Established RA (disease duration two to 10 years)
Compared to placebo, most SD, LD, and HD biologics were not associated with any differences in the odds of withdrawals due to AEs, except SD and LD etanercept monotherapy, which were associated with statistically significantly higher OR ranging from 4.38 to 4.75. Compared to DMARDs alone, we noted no statistically significant increase in the OR of withdrawals due to AEs with biologic monotherapy (any dose), with minor exceptions (48 trials (30 two‐arm, 13 three‐arm, and 5 four‐arm trials), with 20,301 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 16).
Compared to SD biologic monotherapy, SD or HD biologics + MTX, were associated with statistically significantly higher OR of withdrawals due to AEs, ranging from 4.10 to 16.2. Compared to HD biologic monotherapy, HD biologics + MTX were associated with statistically significantly higher OR of withdrawals due to AEs, ranging from 4.35 to 18.0.
Late RA (disease duration more than 10 years)
Compared to SD etanercept, SD rituximab and SD rituximab + MTX were each associated with statistically significantly higher OR of withdrawals due to AEs of 26.6 and 7.4, respectively (nine trials (4 two‐arm, 4 three‐arm and 1 four‐arm trials), with 3276 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 17).
Subgroup analyses by trial duration using the NMA
Trial duration, less than six months
Compared to SD adalimumab subcutaneous monotherapy, LD adalimumab subcutaneous monotherapy was associated with statistically significantly lower OR of 0.34 (52 trials, 20,850 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 18).
Trial duration, six to 12 months
We noted no significant differences between treatments (seven trials, 3279 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 19).
Trial duration, more than 12 months
There were not enough data to perform NMA.
Primary/major safety outcome: serious adverse events (SAEs)
Sixty‐one studies with 28,661 participants reported serious adverse events (SAEs). Of these, 46 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and 19 studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).
Monotherapy versus placebo
The use of biologic monotherapy was not associated with statistically significantly higher OR of SAEs versus placebo, 1.25 (95% CI, 0.70 to 2.25; six studies), and with I2 of 45%, denoting moderate heterogeneity in standard meta‐analyses (Figure 19).
19.
Serious Adverse Events: biologic monotherapy vs placebo
The overall odds (95% CrI) of SAEs differed by the type of biologic and the dose as follows:
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib
In placebo comparator analysis, compared to TNF biologic, the OR of SAEs were not clinically meaningfully or statistically significantly different with tofacitinib monotherapy at 0.37 (95% CrI, 0.13 to 1.06) (Table 26).
-
Type of biologic: monoclonal TNF antibody versus TNF receptor versus non‐TNF versus anakinra versus tofacitinib
In placebo comparator analysis, compared to monoclonal antibody monotherapy, the OR of SAEs were not clinically meaningfully or statistically significantly different with etanercept monotherapy at 1.25 (95% CrI, 0.14 to 12.92) or tofacitinib monotherapy at 0.38 (95% CrI, 0.12 to 1.11) (Table 27).
-
By dose: SD versus HD versus LD
In placebo comparator analysis, compared to SD biologic monotherapy, the odds of SAEs were not clinically meaningfully or statistically significantly different with HD or LD biologic monotherapy, OR 0.48 (95% CrI, 0.15 to 1.44) and 0.80 (95% CrI, 0.28 to 2.36), respectively (Table 28).
26. Serious Adverse Events analysis 2 for the type of medication (only placebo comparator trials): odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% Crl) |
| TNF Inhibitors | Placebo | 1.27(0.75,2.29) | 1.252(0.7623,2.19) | 0.01(‐0.01,0.05) |
| TOFA | 0.47(0.19,1.18) | 0.4828(0.2015,1.172) | ‐0.02(‐0.04,0.01) | |
| TOFA | TNF Inhibitors | 0.37(0.13,1.06) | 0.3863(0.134,1.055) | ‐0.03(‐0.07,0.00) |
| Random‐Effect Model | Residual Deviance | 18.55 vs 18 data points | ||
| Deviance Information Criteria | 92.72 | |||
| Fixed‐Effect Model | Residual Deviance | 21.64 vs 18 data points | ||
| Deviance Information Criteria | 93.944 | |||
| Total Patients | 3092 | |||
| Total Studies | 9 | |||
| 2‐arm | 9 | |||
27. Serious adverse events: analysis 3 (only placebo comparator trials) for the type of biologic: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| Monoclonal antibodies against TNF | Placebo | 1.25(0.72,2.38) | 1.24(0.73,2.27) | 0.01(‐0.01,0.05) |
| TOFA | 0.47(0.19,1.21) | 0.48(0.20,1.20) | ‐0.02(‐0.04,0.01) | |
| Medication targeting TNF receptor: etanercept | 1.57(0.20,15.45) | 1.54(0.20,10.09) | 0.02(‐0.04,0.33) | |
| TOFA | Monoclonal antibodies against TNF | 0.38(0.12,1.11) | 0.39(0.13,1.10) | ‐0.03(‐0.08,0.00) |
| Medication targeting TNF receptor: etanercept | 1.25(0.14,12.92) | 1.23(0.15,8.61) | 0.01(‐0.06,0.33) | |
| Medication targeting TNF receptor: etanercept | TOFA | 3.32(0.34,37.78) | 3.15(0.35,24.97) | 0.04(‐0.02,0.35) |
| Random‐effects model | Residual deviance | 19.27 vs 18 data points | ||
| Deviance information criteria | 94.334 | |||
| Fixed‐Effect Model | Residual deviance | 22.69 vs 18 data points | ||
| Deviance information criteria | 95.962 | |||
| Note | ||||
| Total participants | 3092 | |||
| Total studies | 9 | |||
| 2‐arm | 9 | |||
28. Serious adverse events analysis 4 (only placebo trials) by dose: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD | Placebo | 1.46 (0.71, 3.13) | 1.43 (0.73, 2.91) | 0.02 (‐0.02, 0.07) |
| HD | 0.71 (0.22, 2.15) | 0.72 (0.23, 2.05) | ‐0.01 (‐0.04, 0.04) | |
| LD | 1.18 (0.41, 3.53) | 1.17 (0.43, 3.21) | 0.01 (‐0.03, 0.09) | |
| HD | SD | 0.48 (0.15, 1.44) | 0.50 (0.16, 1.40) | ‐0.03 (‐0.08, 0.02) |
| LD | 0.80 (0.28, 2.36) | 0.81 (0.30, 2.19) | ‐0.01 (‐0.07, 0.07) | |
| LD | HD | 1.66 (0.51, 5.99) | 1.62 (0.53, 5.52) | 0.02 (‐0.03, 0.10) |
| Random‐effects model | Residual deviance | 15.97 vs 16 data‐points | ||
| Deviance information criteria | 83.893 | |||
| Fixed‐effect model | Residual deviance | 23.26 vs 16 data‐points | ||
| Deviance information criteria | 87.741 | |||
| Note | ||||
| Total participants | 1660 | |||
| Total studies | 6 | |||
| 2‐arm | 4 | |||
| 4‐arm | 2 | |||
Inconsistency was noted for several of these analyses.
Direct estimates for SAEs by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra and/or tofacitinib, are shown for comparison to placebo (Figure 20).
20.
Serious Adverse Events: biologic monotherapy vs placebo by drug group
Monotherapy versus active comparator
The use of biologic monotherapy was not associated with statistically significantly higher OR of SAEs versus MTX/other DMARDs, 1.54 (95% CI, 0.94 to 2.51; seven studies), and with I2 of 30%, denoting moderate heterogeneity in standard meta‐analyses (Figure 21).
21.
Serious Adverse Events: biologic monotherapy vs MTX/DMARD
The overall odds (95% CrI) of SAEs differed by the type of biologic and the biologic dose as follows, based on NMA.
-
Type of medication: TNF biologic versus non‐TNF biologic versus anakinra versus tofacitinib
In active comparator analysis, compared to TNF monotherapy, non‐TNF monotherapy showed no statistically significant difference in odds of SAEs, OR 1.00 (95% CrI, 0.63 to 1.57) (Table 29).
-
Type of biologic: monoclonal TNF antibody versus TNF receptor versus non‐TNF versus anakinra versus tofacitinib
In active comparator analysis, compared to etanercept monotherapy, the OR of SAEs were not clinically meaningfully or statistically significantly different for TNF monoclonal antibody monotherapy, 1.42 (95% CrI, 0.70 to 2.97), or non‐TNF monotherapy, 0.77 (95% CrI, 0.38 to 1.46) (Table 30).
-
By dose: SD versus HD versus LD
In active comparator analysis, compared to SD biologic monotherapy, the odds of SAEs were not statistically significantly different with HD or LD biologic monotherapy, OR 1.00 (95% CrI, 0.55 to 1.79) and 0.74 (95% CrI, 0.44 to 1.25), respectively. Compared to HD monotherapy, LD monotherapy also did not show any statistically significant difference, OR 0.74 (95% CrI, 0.37 to 1.51) (Table 31).
29. Serious adverse events: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% CrI) |
| TNF | MTX/other DMARD | 1.23 (0.86, 1.74) | 1.21 (0.86, 1.67) | 0.01 (‐0.01, 0.04) |
| Non‐TNF | 1.21 (0.82, 1.80) | 1.20 (0.83, 1.72) | 0.01 (‐0.01, 0.04) | |
| MTX + TNF | 1.19 (0.98, 1.44) | 1.18 (0.98, 1.41) | 0.01 (0.00, 0.02) | |
| MTX + non‐TNF | 1.11 (0.92, 1.35) | 1.10 (0.92, 1.33) | 0.01 (0.00, 0.02) | |
| MTX + TOFA | 1.69 (0.88, 3.34) | 1.63 (0.89, 2.98) | 0.03 (‐0.01, 0.10) | |
| MTX + ANA | 1.06 (0.65, 1.80) | 1.05 (0.66, 1.73) | 0.00 (‐0.02, 0.04) | |
| Non‐TNF | TNF | 1.00 (0.63, 1.57) | 1.00 (0.65, 1.52) | 0.00 (‐0.03, 0.03) |
| MTX + TNF | 0.97 (0.68, 1.40) | 0.97 (0.70, 1.37) | 0.00 (‐0.03, 0.02) | |
| MTX + TNF | 0.91 (0.62, 1.32) | 0.91 (0.64, 1.30) | ‐0.01 (‐0.03, 0.01) | |
| MTX + TOFA | 1.39 (0.66, 2.95) | 1.35 (0.68, 2.66) | 0.02 (‐0.03, 0.09) | |
| MTX + ANA | 0.86 (0.47, 1.65) | 0.87 (0.49, 1.60) | ‐0.01 (‐0.04, 0.03) | |
| MTX + TNF | Non‐TNF | 0.97 (0.64, 1.49) | 0.98 (0.67, 1.46) | 0.00 (‐0.03, 0.02) |
| MTX + TNF | 0.91 (0.61, 1.37) | 0.91 (0.63, 1.35) | ‐0.01 (‐0.03, 0.02) | |
| MTX + TOFA | 1.40 (0.64, 3.02) | 1.36 (0.66, 2.73) | 0.02 (‐0.03, 0.09) | |
| MTX + ANA | 0.87 (0.46, 1.69) | 0.88 (0.49, 1.63) | ‐0.01 (‐0.04, 0.03) | |
| MTX + TNF | MTX + TNF | 0.93 (0.73, 1.20) | 0.94 (0.74, 1.18) | 0.00 (‐0.02, 0.01) |
| MTX + TOFA | 1.43 (0.73, 2.84) | 1.39 (0.74, 2.56) | 0.02 (‐0.02, 0.09) | |
| MTX + ANA | 0.89 (0.52, 1.57) | 0.90 (0.54, 1.52) | ‐0.01 (‐0.03, 0.03) | |
| MTX + TOFA | MTX + non‐TNF | 1.53 (0.77, 3.06) | 1.48 (0.78, 2.75) | 0.03 (‐0.01, 0.10) |
| MTX + ANA | 0.96 (0.56, 1.67) | 0.96 (0.58, 1.61) | 0.00 (‐0.03, 0.03) | |
| MTX + ANA | MTX + TOFA | 0.63 (0.27, 1.46) | 0.65 (0.30, 1.42) | ‐0.03 (‐0.10, 0.02) |
| Random‐effecst model | Residual deviance | 110.1 vs 104 data‐points | ||
| Deviance information criteria | 587.613 | |||
| Fixed‐effect model | Residual deviance | 136.3 vs 104 data‐points | ||
| Deviance information criteria | 587.457 | |||
| Note | ||||
| Total participants | 22,780 | |||
| Total studies | 49 | |||
| 2‐arm | 43 | |||
| 3‐arm | 6 | |||
30. Serious adverse events: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD (95% CrI) |
| Monoclonal antibodies against TNF | MTX/other DMARD | 1.08 (0.65, 1.79) | 1.07 (0.66, 1.72) | 0.00 (‐0.02, 0.04) |
| Medication targeting TNF receptor: etanercept | 1.53 (0.90, 2.63) | 1.49 (0.91, 2.42) | 0.03 (‐0.01, 0.07) | |
| Non‐TNF | 1.17 (0.77, 1.74) | 1.16 (0.78, 1.68) | 0.01 (‐0.01, 0.04) | |
| MTX + Monoclonal antibodies against TNF | 1.18 (0.95, 1.46) | 1.16 (0.95, 1.43) | 0.01 (0.00, 0.02) | |
| MTX + non‐TNF | 1.07 (0.88, 1.30) | 1.06 (0.88, 1.28) | 0.00 (‐0.01, 0.01) | |
| MTX + Medication targeting TNF receptor: etanercept | 1.32 (0.90, 1.98) | 1.30 (0.91, 1.89) | 0.02 (‐0.01, 0.05) | |
| MTX + TOFA | 2.02 (1.00, 4.31) | 1.92 (1.00, 3.68) | 0.05 (0.00, 0.14) | |
| MTX + ANA | 1.06 (0.63, 1.83) | 1.06 (0.65, 1.75) | 0.00 (‐0.02, 0.04) | |
| Medication targeting TNF receptor: etanercept | Monoclonal antibodies against TNF | 1.42 (0.70, 2.97) | 1.38 (0.71, 2.74) | 0.02 (‐0.02, 0.08) |
| Non‐TNF | 1.09 (0.63, 1.83) | 1.08 (0.65, 1.77) | 0.00 (‐0.03, 0.03) | |
| MTX + Monoclonal antibodies against TNF | 1.09 (0.66, 1.85) | 1.08 (0.68, 1.79) | 0.00 (‐0.03, 0.03) | |
| MTX + non‐TNF | 0.99 (0.59, 1.69) | 0.99 (0.61, 1.65) | 0.00 (‐0.03, 0.02) | |
| MTX + Medication targeting TNF receptor: etanercept | 1.23 (0.68, 2.27) | 1.22 (0.70, 2.16) | 0.01 (‐0.03, 0.05) | |
| MTX + TOFA | 1.89 (0.80, 4.66) | 1.80 (0.81, 4.02) | 0.05 (‐0.01, 0.14) | |
| MTX + ANA | 0.99 (0.48, 2.06) | 0.99 (0.50, 1.97) | 0.00 (‐0.04, 0.04) | |
| Non‐TNF | Medication targeting TNF receptor: etanercept | 0.77 (0.38, 1.46) | 0.78 (0.41, 1.42) | ‐0.02 (‐0.07, 0.02) |
| MTX + Monoclonal antibodies against TNF | 0.77 (0.44, 1.35) | 0.78 (0.47, 1.33) | ‐0.02 (‐0.07, 0.02) | |
| MTX + non‐TNF | 0.70 (0.39, 1.22) | 0.72 (0.43, 1.21) | ‐0.02 (‐0.07, 0.01) | |
| MTX + Medication targeting TNF receptor: etanercept | 0.87 (0.52, 1.44) | 0.88 (0.55, 1.40) | ‐0.01 (‐0.05, 0.02) | |
| MTX + TOFA | 1.34 (0.55, 3.26) | 1.30 (0.58, 2.86) | 0.02 (‐0.05, 0.12) | |
| MTX + ANA | 0.70 (0.33, 1.47) | 0.72 (0.36, 1.43) | ‐0.02 (‐0.08, 0.02) | |
| MTX + Monoclonal antibodies against TNF | Non‐TNF | 1.00 (0.65, 1.59) | 1.00 (0.67, 1.55) | 0.00 (‐0.03, 0.02) |
| MTX + non‐TNF | 0.91 (0.60, 1.41) | 0.92 (0.62, 1.38) | ‐0.01 (‐0.03, 0.02) | |
| MTX + Medication targeting TNF receptor: etanercept | 1.13 (0.66, 2.01) | 1.12 (0.68, 1.92) | 0.01 (‐0.03, 0.04) | |
| MTX + TOFA | 1.74 (0.78, 4.07) | 1.66 (0.79, 3.51) | 0.04 (‐0.02, 0.13) | |
| MTX + ANA | 0.91 (0.48, 1.79) | 0.92 (0.50, 1.72) | ‐0.01 (‐0.04, 0.04) | |
| MTX + non‐TNF | MTX + Monoclonal antibodies against TNF | 0.91 (0.69, 1.18) | 0.91 (0.71, 1.17) | ‐0.01 (‐0.02, 0.01) |
| MTX + Medication targeting TNF receptor: etanercept | 1.13 (0.73, 1.78) | 1.12 (0.74, 1.70) | 0.01 (‐0.02, 0.04) | |
| MTX + TOFA | 1.73 (0.85, 3.71) | 1.65 (0.86, 3.19) | 0.04 (‐0.01, 0.13) | |
| MTX + ANA | 0.91 (0.51, 1.63) | 0.91 (0.53, 1.57) | ‐0.01 (‐0.03, 0.03) | |
| MTX + Medication targeting TNF receptor: etanercept | MTX + non‐TNF | 1.24 (0.81, 1.95) | 1.23 (0.82, 1.86) | 0.01 (‐0.01, 0.04) |
| MTX + TOFA | 1.90 (0.92, 4.13) | 1.81 (0.92, 3.54) | 0.05 (0.00, 0.14) | |
| MTX + ANA | 1.00 (0.58, 1.78) | 1.00 (0.59, 1.70) | 0.00 (‐0.03, 0.04) | |
| MTX + TOFA | MTX + Medication targeting TNF receptor: etanercept | 1.53 (0.69, 3.54) | 1.47 (0.70, 3.08) | 0.03 (‐0.03, 0.13) |
| MTX + ANA | 0.80 (0.42, 1.53) | 0.82 (0.44, 1.49) | ‐0.01 (‐0.05, 0.03) | |
| MTX + ANA | MTX + TOFA | 0.52 (0.21, 1.28) | 0.55 (0.24, 1.26) | ‐0.05 (‐0.14, 0.02) |
| Random‐effects model | Residual deviance | 109.4 vs 104 data‐points | ||
| Deviance information criteria | 588.641 | |||
| Fixed‐effect model | Residual deviance | 115.5 vs 104 data‐points | ||
| Deviance information criteria | 588.677 | |||
| Note | ||||
| Total participants | 22,781 | |||
| Total studies | 49 | |||
| 2‐arm | 43 | |||
| 3‐arm | 6 | |||
31. Serious adverse events analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD biologic | Comparator: MTX/other DMARD | 1.16 (0.84, 1.67) | 1.19 (0.8102, 1.736) | 0.01 (‐0.01, 0.04) |
| HD biologic | 1.17 (0.71, 1.91) | 1.219 (0.825, 1.785) | 0.01 (‐0.01, 0.04) | |
| LD biologic | 0.87 (0.52, 1.49) | 1.268 (0.6808, 2.274) | 0.01 (‐0.02, 0.07) | |
| MTX SD biologic | 1.15 (0.95, 1.41) | 1.094 (0.9497, 1.264) | 0.01 (0.00, 0.01) | |
| MTX LD biologic | 1.46 (1.07, 1.99) | 1.079 (0.8211, 1.426) | 0.00 (‐0.01, 0.02) | |
| MTX HD biologic | 1.12 (0.68, 1.79) | 1.302 (1.014, 1.665) | 0.02 (0.00, 0.04) | |
| HD biologic | SD biologic | 1.00 (0.55, 1.79) | 1.024 (0.596, 1.757) | 0.00 (‐0.03, 0.04) |
| LD biologic | 0.74 (0.44, 1.25) | 1.064 (0.5752, 1.936) | 0.00 (‐0.03, 0.06) | |
| MTX SD biologic | 0.99 (0.69, 1.37) | 0.9206 (0.6377, 1.342) | ‐0.01 (‐0.03, 0.02) | |
| MTX LD biologic | 1.25 (0.80, 1.92) | 0.9079 (0.5811, 1.437) | ‐0.01 (‐0.04, 0.02) | |
| MTX HD biologic | 0.96 (0.54, 1.64) | 1.095 (0.7013, 1.711) | 0.01 (‐0.03, 0.03) | |
| LD biologic | HD biologic | 0.74 (0.37, 1.51) | 1.036 (0.5036, 2.125) | 0.00 (‐0.04, 0.06) |
| MTX SD biologic | 0.98 (0.59, 1.66) | 0.8979 (0.6064, 1.346) | ‐0.01 (‐0.04, 0.02) | |
| MTX LD biologic | 1.25 (0.74, 2.14) | 0.8826 (0.5705, 1.421) | ‐0.01 (‐0.04, 0.02) | |
| MTX HD biologic | 0.95 (0.50, 1.86) | 1.068 (0.706, 1.638) | 0.00 (‐0.03, 0.03) | |
| MTX SD biologic | LD biologic | 1.33 (0.77, 2.26) | 0.8627 (0.482, 1.6) | ‐0.01 (‐0.06, 0.02) |
| MTX LD biologic | 1.69 (0.92, 3.01) | 0.849 (0.4534, 1.658) | ‐0.01 (‐0.07, 0.03) | |
| MTX HD biologic | 1.29 (0.64, 2.52) | 1.026 (0.5434, 2.002) | 0.00 (‐0.06, 0.04) | |
| MTX LD biologic | MTX SD biologic | 1.27 (0.91, 1.76) | 0.9871 (0.7486, 1.299) | 0.00 (‐0.02, 0.02) |
| MTX HD biologic | 0.97 (0.59, 1.55) | 1.191 (0.9129, 1.539) | 0.01 (‐0.01, 0.03) | |
| MTX HD biologic | MTX LD biologic | 0.77 (0.44, 1.31) | 1.206 (0.8417, 1.73) | 0.01 (‐0.01, 0.04) |
| Random‐effects model | Residual deviance | 116.9 vs 115 data‐points | ||
| Deviance information criteria | 609.119 | |||
| Fixed‐effect model | Residual deviance | 120.9 vs. 115 data‐points | ||
| Deviance information criteria | 608.065 | |||
| Note | ||||
| Total participants | 20,677 | |||
| Total studies | 47 | |||
| 2‐arm | 31 | |||
| 3‐arm | 12 | |||
| 4‐arm | 3 | |||
| 5‐arm | 1 | |||
Inconsistency was noted for several of these analyses.
Direct estimates for SAEs by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra and/or tofacitinib, are shown for comparison to MTX/other DMARDs (Figure 22).
22.
Serious Adverse Events: biologic monotherapy vs MTX/DMARD by drug group
Main analyses using the NMA
Sixty‐one RCTs (38 two‐arm, 16 three‐arm, 6 four‐arm, and one 5‐arm trials), with 28,661 participants provided data for all dose analyses for SAEs (Appendix 20), including biologic + MTX/other DMARD combinations or biologic monotherapy arms. Main findings are summarized in the section below.
Monotherapy versus placebo
None of the treatments were significantly different from placebo, except SD certolizumab and LD golimumab intravenous monotherapy, which were associated with 4.67 times and 6.90 times odds of SAEs (Appendix 20). In general, golimumab and certolizumab monotherapy were associated with higher OR and abatacept and adalimumab monotherapy with lower odds of SAEs compared to other biologic or tofacitinib monotherapy.
Monotherapy versus active comparator
MTX/other DMARD comparisons (lower odds)
Compared to MTX, none of the comparators were clinically or statistically significant different. Compared to DMARDs, some SD biologic monotherapy treatments were associated with statistically significantly higher OR of SAEs, two‐times and higher. Compared to MTX + DMARD combination, we found that LD golimumab intravenous monotherapy was associated with statistically significantly higher OR of SAEs, 8.93.
Tofacitinib comparisons
Compared to SD tofacitinib monotherapy, several biologic + MTX as well as tofacitinib + MTX combinations were associated with statistically significantly higher OR of SAEs, ranging from 5.42 to 11.17.
Golimumab comparisons (higher odds)
LD golimumab intravenous monotherapy was associated with statistically significantly higher OR of SAEs compared to several treatments:
SD adalimumab monotherapy, 6.29;
SD tofacitinib monotherapy, 18.17;
SD golimumab intravenous monotherapy, 4.58 times;
SD rituximab monotherapy, 12.36 times;
SD infliximab + MTX, 5.64;
SD adalimumab subcutaneous + MTX, 5.68;
SD abatacept + MTX, 6.30;
SD abatacept intravenous + DMARD, 10.09;
SD adalimumab subcutaneous + DMARD, 16.15
SD anakinra +DMARD, 11.02;
SD certolizumab + DMARD, 16.49;
LD adalimumab monotherapy, 10.84; and
LD etanercept monotherapy, 6.83.
Several treatments were associated with statistically significantly lower odds of SAEs compared to LD golimumab intravenous monotherapy: HD tofacitinib monotherapy, OR 0.08 and HD adalimumab monotherapy, 0.14. HD golimumab subcutaneous + MTX was associated with higher OR of SAEs compared to HD tofacitinib monotherapy, 7.54.
Certolizumab comparisons (higher odds)
HD certolizumab subcutaneous + MTX was associated with statistically significantly higher OR of SAEs compared to LD etanercept monotherapy, 3.95. Several treatments were associated with statistically significantly lower OR of SAEs compared to SD certolizumab subcutaneous monotherapy including: LD adalimumab monotherapy, OR 0.14; and HD tofacitinib monotherapy, OR 0.11.
Subgroup analyses by early versus established versus late RA using the NMA
Early RA (RA disease duration less than two years)
There were not enough data to perform NMA.
Established RA (disease duration two to 10 years)
Compared to DMARD + placebo, most biologics in SD monotherapy regimens were not associated with any statistically significant differences in the OR of SAEs, except SD certolizumab pegol, which was associated with a three‐fold higher OR of SAEs (statistically significant). Compared to SD tofacitinib, several biologics + MTX combinations were associated with statistically significantly higher OR of SAEs, ranging from 5.7 to 24.1, as well as tofacitinib + MTX, OR 12.3, with wide confidence intervals (50 trials, 22,022 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 21).
Late RA (disease duration more than 10 years)
There were no statistically significant differences (four trials (1 two‐arm, 2 three‐arm and 1 four‐arm trials), with 1390 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 22).
Subgroup analyses by trial duration using the NMA
Trial duration, less than six months
We created two networks, one with 23 studies and 11,146 participants (Appendix 23) and the other with 26 trials and 12,263 participants (Appendix 24). In the first network, compared to SD and HD biologic monotherapy, MTX + DMARD or biologic combination therapy were not associated with statistically significantly lower OR of SAEs with minor exceptions.
Compared to SD and HD biologic monotherapy, MTX alone/biologic combination therapy was not associated with statistically significantly lower OR of SAEs with minor exceptions.
Trial duration, six to 12 months
We noted no statistically significant differences between biologic monotherapy and other comparators (six trials (1 two‐arm and 5 three‐arm trials), with 2277 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 25).
Trial duration, more than 12 months
There were not enough data to perform NMA.
Primary/major safety outcome: cancer
Twenty‐four studies with 10,843 participants reported data on cancer. Of these, 19 studies included at least one arm with participants on a biologic with concomitant MTX/other DMARDs (most often MTX; published as a separate review) and seven studies had at least one arm with biologic monotherapy (no concomitant MTX/other DMARD therapy; current review).
Monotherapy versus placebo
There were no data available for the comparison of biologic monotherapy to placebo.
Monotherapy versus active comparator
The use of biologic monotherapy was associated with no statistically and clinically significant increase in the odds of cancer, versus MTX/DMARD in participants with RA (six studies), Peto's OR 1.40 (95% CI, 0.67 to 2.93), and with I2 of 18% in standard meta‐analyses (Figure 23), denoting little heterogeneity.
23.
Cancer: biologic monotherapy vs MTX/DMARD
The overall odds (95% CrI) of cancer by the type of medication, type of biologic and the dose for biologic versus MTX/DMARD, based on NMA, were as follows.
-
Type of medication (Table 32)
Compared to TNF inhibitors, the OR of cancer with non‐TNF biologic were not clinically meaningfully or statistically significantly different at 0.95 (95% CrI, 0.22 to 4.35).
-
Type of biologic: receptor versus antibody (Table 33)
Compared to etanercept monotherapy, neither monoclonal TNF antibody monotherapy nor non‐TNF biologic monotherapy, were associated with any significant differences in the odds of cancer, OR 0.91 (95% CrI, 0.06 to 13.28) and 0.91 (95% CrI, 0.17 to 5.40), respectively.
-
By dose (Table 34):
Compared to SD biologic, the odds of cancer were not clinically meaningfully or statistically significantly different with HD biologic, OR 0.97 (95% CrI, 0.22 to 4.53) and LD biologic, OR 0.46 (95% CrI, 0.10 to 1.68). Compared to HD biologic, LD biologic was not associated with statistically significant differences in the odds of cancer, OR 0.47 (95% CrI, 0.06 to 3.15).
32. Cancer: analysis 2 (MTX/other DMARD active comparator trials) for the type of medication: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| TNF | MTX/other DMARD | 1.32 (0.63,3.02) | 1.31 (0.63,2.98) | 0.00 (0.00,0.01) |
| Non‐TNF | 1.25 (0.36,5.05) | 1.25 (0.36,4.92) | 0.00 (‐0.01,0.03) | |
| MTX + TNF | 1.21 (0.63,2.40) | 1.21 (0.63,2.38) | 0.00 (0.00,0.01) | |
| MTX + non‐TNF | 0.99 (0.58,1.79) | 0.99 (0.58,1.78) | 0.00 (0.00,0.01) | |
| Non‐TNF | TNF | 0.95 (0.22,4.35) | 0.95 (0.23,4.25) | 0.00 (‐0.01,0.03) |
| MTX + TNF | 0.91 (0.39,2.16) | 0.91 (0.40,2.15) | 0.00 (‐0.01,0.01) | |
| MTX + non‐TNF | 0.75 (0.29,1.84) | 0.75 (0.30,1.83) | 0.00 (‐0.01,0.01) | |
| MTX + TNF | Non‐TNF | 0.97 (0.21,3.77) | 0.97 (0.22,3.73) | 0.00 (‐0.03,0.01) |
| MTX + non‐TNF | 0.79 (0.18,3.07) | 0.79 (0.18,3.05) | 0.00 (‐0.03,0.01) | |
| MTX + non‐TNF | MTX + TNF | 0.83 (0.38,1.71) | 0.83 (0.39,1.70) | 0.00 (‐0.01,0.00) |
| Random‐effects model | Residual deviance | 38.11 vs 49 datapoints | ||
| Deviance information criteria | 180.758 | |||
| Fixed‐effect model | Residual deviance | 38.09 vs 49 datapoints | ||
| Deviance information criteria | 179.805 | |||
| Note | ||||
| Total participants | 9386 | |||
| Total studies | 23 | |||
| 2‐arm | 20 | |||
| 3‐arm | 3 |
33. Cancer: analysis 3 (MTX/other DMARD active comparator trials) for the type of biologic: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| Medication targeting TNF receptor: etanercept | MTX/other DMARD | 1.43 (0.62, 3.54) | 1.43 (0.62, 3.48) | 0.00 (0.00, 0.02) |
| Non‐TNF | 1.31 (0.31, 5.92) | 1.30 (0.32, 5.72) | 0.00 (‐0.01, 0.04) | |
| Monoclonal antibodies against TNF | 1.31 (0.10, 17.94) | 1.31 (0.10, 15.86) | 0.00 (‐0.01, 0.11) | |
| MTX + non‐TNF | 0.92 (0.52, 1.70) | 0.92 (0.52, 1.69) | 0.00 (0.00, 0.00) | |
| MTX + Medication targeting TNF receptor: etanercept | 1.42 (0.62, 3.52) | 1.42 (0.62, 3.46) | 0.00 (0.00, 0.02) | |
| MTX + Monoclonal antibodies against TNF | 0.93 (0.33, 2.55) | 0.93 (0.33, 2.53) | 0.00 (‐0.01, 0.01) | |
| Non‐TNF | Medication targeting TNF receptor: etanercept | 0.91 (0.17, 5.40) | 0.91 (0.17, 5.22) | 0.00 (‐0.02, 0.03) |
| Monoclonal antibodies against TNF | 0.91 (0.06, 13.28) | 0.91 (0.07, 11.82) | 0.00 (‐0.02, 0.11) | |
| MTX + non‐TNF | 0.64 (0.22, 1.80) | 0.64 (0.22, 1.79) | 0.00 (‐0.02, 0.00) | |
| MTX + Medication targeting TNF receptor: etanercept | 0.99 (0.39, 2.62) | 0.99 (0.39, 2.59) | 0.00 (‐0.01, 0.01) | |
| MTX + Monoclonal antibodies against TNF | 0.65 (0.16, 2.33) | 0.65 (0.16, 2.31) | 0.00 (‐0.02, 0.01) | |
| Monoclonal antibodies against TNF | Non‐TNF | 0.97 (0.09, 12.11) | 0.97 (0.09, 11.11) | 0.00 (‐0.03, 0.10) |
| MTX + non‐TNF | 0.71 (0.14, 3.14) | 0.71 (0.15, 3.13) | 0.00 (‐0.04, 0.01) | |
| MTX + Medication targeting TNF receptor: etanercept | 1.09 (0.20, 5.80) | 1.09 (0.21, 5.70) | 0.00 (‐0.03, 0.02) | |
| MTX + Monoclonal antibodies against TNF | 0.71 (0.11, 4.09) | 0.71 (0.12, 4.05) | 0.00 (‐0.04, 0.01) | |
| MTX + non‐TNF | Monoclonal antibodies against TNF | 0.70 (0.05, 9.51) | 0.71 (0.05, 9.44) | 0.00 (‐0.12, 0.01) |
| MTX + Medication targeting TNF receptor: etanercept | 1.07 (0.09, 14.19) | 1.07 (0.10, 14.03) | 0.00 (‐0.11, 0.02) | |
| MTX + Monoclonal antibodies against TNF | 0.71 (0.04, 11.12) | 0.72 (0.05, 11.01) | 0.00 (‐0.12, 0.01) | |
| MTX + Medication targeting TNF receptor: etanercept | MTX + non‐TNF | 1.54 (0.56, 4.51) | 1.54 (0.56, 4.43) | 0.00 (0.00, 0.02) |
| MTX + Monoclonal antibodies against TNF | 1.00 (0.38, 2.62) | 1.00 (0.38, 2.60) | 0.00 (‐0.01, 0.01) | |
| MTX + Monoclonal antibodies against TNF | MTX + Medication targeting TNF receptor: etanercept | 0.65 (0.16, 2.42) | 0.65 (0.16, 2.40) | 0.00 (‐0.02, 0.01) |
| Random‐effects model | Residual deviance | 39.55 vs 49 datapoints | ||
| Deviance information criteria | 184.079 | |||
| Fixed‐effect model | Residual deviance | 39.64 vs 49 datapoints | ||
| Deviance information criteria | 183.351 | |||
| Note | ||||
| Total participants | 9386 | |||
| Total studies | 23 | |||
| 2‐arm | 20 | |||
| 3‐arm | 3 |
34. Cancer: analysis 4 (MTX/other DMARD active comparator trials) by dose: odds ratio for all treatment comparisons ‐ random‐effects model.
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD | MTX/other DMARD | 1.40 (0.63, 3.00) | 1.40 (0.63, 2.96) | 0.00 (0.00, 0.01) |
| HD | 1.35 (0.35, 5.77) | 1.35 (0.35, 5.58) | 0.00 (‐0.01, 0.03) | |
| LD | 0.64 (0.13, 2.33) | 0.64 (0.13, 2.31) | 0.00 (‐0.01, 0.01) | |
| MTX SD | 1.05 (0.65, 1.71) | 1.05 (0.65, 1.70) | 0.00 (0.00, 0.00) | |
| MTX LD | 1.37 (0.42, 4.05) | 1.36 (0.43, 3.97) | 0.00 (‐0.01, 0.02) | |
| HD | SD | 0.97 (0.22, 4.53) | 0.97 (0.23, 4.40) | 0.00 (‐0.01, 0.03) |
| LD | 0.46 (0.10, 1.68) | 0.46 (0.10, 1.67) | ‐0.01 (‐0.02, 0.01) | |
| MTX SD | 0.75 (0.34, 1.69) | 0.75 (0.35, 1.68) | 0.00 (‐0.01, 0.00) | |
| MTX LD | 0.98 (0.25, 3.60) | 0.98 (0.26, 3.53) | 0.00 (‐0.01, 0.02) | |
| LD | HD | 0.47 (0.06, 3.15) | 0.47 (0.06, 3.11) | ‐0.01 (‐0.04, 0.01) |
| MTX SD | 0.79 (0.17, 3.14) | 0.79 (0.18, 3.12) | 0.00 (‐0.03, 0.01) | |
| MTX LD | 1.02 (0.17, 5.56) | 1.02 (0.17, 5.45) | 0.00 (‐0.03, 0.02) | |
| MTX SD | LD | 1.63 (0.42, 8.73) | 1.63 (0.43, 8.65) | 0.00 (‐0.01, 0.01) |
| MTX LD | 2.13 (0.39, 14.46) | 2.11 (0.39, 14.17) | 0.01 (‐0.01, 0.03) | |
| MTX LD | MTX SD | 1.31 (0.40, 3.77) | 1.30 (0.40, 3.69) | 0.00 (‐0.01, 0.02) |
| Random‐effects model | Residual deviance | 39.23 vs 51 datapoints | ||
| Deviance information criteria | 181.671 | |||
| Fixed‐effect model | Residual deviance | 39.27 vs 51 datapoints | ||
| Deviance information criteria | 180.863 | |||
| Note | ||||
| Total participants | 8740 | |||
| Total studies | 22 | |||
| 2‐arm | 15 | |||
| 3‐arm | 7 |
Direct estimates for cancer by the type of biologic, that is, TNF biologic versus non‐TNF biologic versus anakinra or tofacitinib, or both are shown in Figure 24.
24.
Cancer: biologic monotherapy vs MTX/DMARD by drug group
Main analyses using the NMA
24 RCTs (16 two‐arm and 8 three‐arm trials), with 10,843 participants provided data for all dose analyses (Appendix 26), including biologic + MTX/other DMARD combinations or biologic monotherapy arms.
Monotherapy versus active comparator
Compared to DMARD, SD etanercept was associated with 13.86‐times higher OR of cancer. Compared to SD etanercept, SD etanercept + DMARD and SD abatacept IV + DMARD were associated with lower OR of cancer, odds of 0.06 and 0.07 respectively.
Subgroup analyses by early versus established versus late RA using the NMA
Early RA (RA disease duration less than two years)
There were not enough data to perform NMA
Established RA (disease duration two to 10 years)
No statistically significant differences in cancer rates were noted between treatments (13 trials, 5853 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 27).
Late RA (disease duration more than 10 years)
There were not enough data to perform NMA.
Subgroup analyses by trial duration using the NMA
Trial duration, less than six months
No statistically significant differences in cancer rates were noted between treatments (eight trials, 3895 participants, including biologic + MTX/other DMARD combinations or biologic monotherapy arms) (Appendix 28).
Trial duration, six to 12 months
There were not enough data to perform NMA.
Trial duration, more than 12 months
There were not enough data to perform NMA.
Summary of safety warnings from regulatory agencies
Evidence from RCTs is limited in informing participants and physicians regarding uncommon or rare adverse events. In the section below, we summarize warnings related to biologics from the FDA, EMA and Health Canada, the regulatory agencies in the USA, Europe and Canada, respectively. This section is similar to the warnings section in the companion review for biologic +MTX/other DMARDs (Singh 2016).
Abatacept
No recent warnings have been issued with regard to abatacept. On the product label of abatacept, the FDA warns against known safety implications reporting, "In controlled clinical trials, participants receiving concomitant abatacept and TNF antagonist therapy experienced more infections (63%) and serious infections (4.4%) compared to participants treated with only TNF antagonists (43% and 0.8%, respectively). Concurrent administration of a TNF antagonist with abatacept has been associated with an increased risk of serious infections and no statistically significant additional benefit over use of the TNF antagonists alone" (FDA 2007). Furthermore, the FDA reports that, "rare occurrences of anaphylaxis or anaphylactoid reactions have been observed in two of 2,688 participants treated with abatacept in clinical trials" (FDA 2007). Trials have also shown that, "COPD participants treated with abatacept developed adverse events more frequently than those treated with placebo, including COPD exacerbations, cough, rhonchi, and dyspnea" (FDA 2007).
The effects of abatacept on pregnant women, children, and the development of malignancies is "not yet fully understood" (FDA 2007). The European Medicines Agency (EMA) reports adverse reactions in people treated with abatacept, ranking the occurrences of such reactions as very common (≤ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); and very rare (< 1/10,000). EMA 2009a reports that increase in blood pressure, abnormal liver function test (transaminases increased) and headaches are very common adverse reactions. Dizziness, cough, rash including dermatitis, diarrhea, nausea, dyspepsia, abdominal pain, lower respiratory tract infection (including bronchitis), urinary tract infection, herpes simplex, upper respiratory tract infection, hypertension, flushing, fatigue and asthenia are common (EMA 2009a). Overall, "the most commonly reported adverse events (occurring in 10% or more of patients) were headaches, upper respiratory tract infection, nasopharyngitis, and nausea. The adverse events most commonly resulting in clinical intervention were due to infection" (FDA 2007).
Adalimumab
The updated 2008 FDA label for adalimumab reports, "Serious infections, sepsis, tuberculosis and cases of opportunistic infections, including fatalities, have been reported with the use of TNF blocking agents including Humira® (adalimumab)" (FDA 2008a). "Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and septicaemia. Hospitalization or fatal outcomes associated with infections have been reported" (EMA 2009b). Furthermore, hepatitis B reactivation has been shown to be associated with adalimumab treatment (Health Canada 2006). The FDA reports, "As observed with other TNF blocking agents, tuberculosis associated with the administration of Humira® in clinical trials has been reported" (FDA 2008a).
In rare instances, adalimumab has been associated with, "new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease including multiple sclerosis" (EMA 2009b). Furthermore, "In the controlled portions of clinical trials of some TNF‐blocking agents, including Humira, more cases of malignancies have been observed among patients receiving those TNF blockers compared to control patients" (FDA 2008a).
"Some of these hepatosplenic T‐cell lymphomas have occurred in young adult patients on concomitant treatment with azathioprine or 6‐mercaptopurine used for Crohn’s disease". Thus, the risk of the development of hepatosplenic T‐cell lymphoma cannot be excluded for patients treated with adalimumab (EMA 2009b). Though the causal relationship of hematological reactions and the use of adalimumab remain unclear as of 2008, the FDA label states, "Rare reports of pancytopenia including aplastic anemia have been reported with TNF blocking agents". Furthermore, the FDA reports "Treatment with Humira® (adalimumab) may result in the formation of autoantibodies and rarely in the development of a lupus‐like syndrome" (FDA 2008a).
Anakinra
Anakinra leads to an increased rate of infections (2%) versus placebo (less than 1%). Following the EMA standard of classification of frequency of the occurrence of "undesirable effects" mentioned above, neutropenia and serious infection requiring hospitalizations were common (between 1/10 and 1/100) and headaches and injection site reactions were very common occurring in 1/10 or more patients treated with anakinra (EMA 2004). "A… clinical trial sponsored by Amgen Inc. showed a higher incidence of serious infection and of neutropenia in anakinra and etanercept combination group than patients receiving Enbrel (etanercept) alone and higher than observed in previous trials where Kineret (anakinra) was used alone (EMA 2003), therefore, the use of etanercept and anakinra is not recommended as it leads to safety complications)". Furthermore, the FDA reports in its most recent report on anakinra that "Hypersensitivity reactions associated with Kineret (anakinra) administration are rare" (FDA 2001). Moreover, the FDA reports the effects of anakinra on the hematologic conditions of patients stating that, "In placebo‐controlled studies with Kineret® (anakinra), treatment was associated with small reductions in the mean values for total white blood count, platelets, and absolute neutrophil count (ANC), and a small increase in the mean eosinophil differential percentage" (FDA 2001). With regard to the development of malignancies for people treated with anakinra, trials show that, "among 5300 RA patients treated with Kineret (anakinra) clinical trials for a mean of 15 months (approximately 6400 patient years of treatment), lymphomas were observed for a rate of 0.12 cases per 100 patient years. This is 3.6 fold higher than the rate of lymphomas expected in the general population, based on the National Cancer Institutes Surveillance Epidemiology and End Results (SEER) database" (FDA 2001).
Etanercept
In the post‐marketing reports of etanercept, "Infections, including serious infections leading to hospitalization or death, have been observed in patients treated with Enbrel® (etanercept)" (FDA 2008c). Furthermore, "Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel® than with TNF‐blocking monoclonal antibodies. Nonetheless, post‐marketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel® (etanercept). Patients receiving Enbrel® should be monitored closely for signs and symptoms of active tuberculosis. The possibility of tuberculosis should be considered, especially in patients who have travelled to countries with a high prevalence of tuberculosis or had close contact with a person with active tuberculosis. All patients treated with Enbrel® should have a thorough history taken prior to initiating therapy" (FDA 2008c). This finding is also stated in an important health warning issued by Health Canada in 2006 (Health Canada 2006).
Furthemore, etanercept has been associated with the risk of histoplasmosis and other invasive fungal infections. Health Canada 2009 states, "...although no histoplasmosis infections were reported among 17,696 patients from the United States and Canada who were treated with Enbrel®, in 38 clinical trials and four cohort studies involving all authorized indications, post marketing cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel®." The FDA also outlines the risk of nervous system complications stating, "nervous system complications such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes have occurred in rare cases" (FDA 2008c).
Infections, including serious infections leading to hospitalization or death, have been observed in patients treated with Enbrel® (etanercept) (FDA 2008c). The FDA reports on the risk of malignancies for patients on etanercept treatment, stating "Patients have been observed in clinical trials with Enbrel® for over five years. Among 4462 rheumatoid arthritis patients treated with Enbrel® in clinical trials for a mean of 27 months (approximately 10,000 patient‐years of therapy), lymphomas were observed for a rate of 0.09 cases per 100 patient‐years. This is 3‐fold higher than the rate of lymphomas expected in the general population based on the Surveillance, Epidemiology, and End Results Database. Rare reports of pancytopenia including aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel®" (FDA 2008c). The FDA also reports, "Treatment with Enbrel® may result in the formation of autoantibodies and, rarely, in the development of a lupus‐like syndrome or autoimmune hepatitis which may resolve following withdrawal of Enbrel®" (FDA 2008c).
The use of etanercept has also been associated with the relapse of hepatitis B (Health Canada 2006).
Infliximab
In its recent revised report on infliximab, the EMA reports on the risk of infusion reactions and hypersensitivity, stating, "An infusion‐related reaction was defined in clinical studies as any adverse event occurring during an infusion or within 1 to 2 hours after an infusion. In clinical studies, approximately 20% of infliximab‐treated patients compared with approximately 10% of placebo‐treated patients experienced an infusion‐related effect. Approximately 3% of patients discontinued treatment due to infusions reactions" (EMA 2009a). Infliximab is also associated with the relapse of hepatitis B as reported by Health Canada in 2006 (Health Canada 2006). "Opportunistic infections have been reported in patients treated with infliximab, suggesting that host defence against infection is compromised. It should be noted that suppression of TNF‐alpha may also mask symptoms of infection such as fever." There is also a possible association between infliximab and heptosplenix T‐Cell lymphoma in pediatric and young adult patients with Crohn’s disease (Health Canada 2006b).
"In a study designed to evaluate Remicade® (infliximab) in congestive heart failure (CHF), 150 patients with moderate to severe (NYHA class II‐intravenous) CHF were treated with three infusions of Remicade 5 mg/ kg, or placebo over six weeks. Higher incidences of mortality and hospitalization for worsening heart failure were seen in those patients treated with Remicade®, especially have treated with the higher dose of 10 mg/kg. At present 7 out of 101 patients treated with Remicade® have died compared to no deaths among 49 patients on placebo" (EMA 2001). In a May 2009 revision of the Remicade label, the FDA warns, "Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving TNF‐ blocking agents. Among opportunistic infections, tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis were the most commonly reported. Patients have frequently presented with disseminated rather than localized disease, and are often taking concomitant immunosuppressants such as methotrexate or corticosteroids with Remicade®" (FDA 2009). In an investigation of neurological events, EMA reports "Infliximab and other agents that inhibit TNF‐alpha have been associated in rare cases with optic neuritis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis, and peripheral demyelinating disorders, including Guillain‐Barré syndrome" (EMA 2009a).
The increased risk of developing lymphoma is also reported. An FDA archived report from October 2004 on infliximab safety alerts notifies that
"During the controlled portions of REMICADE trials in patients with moderately to severely active rheumatoid arthritis and Crohn's disease, 1 patient developed lymphoma among 1389 REMICADE‐treated patients versus 0 among 483 control patients (median duration of follow‐up 1.1 years).” “ In the controlled and open‐label portions of these clinical trials of REMICADE, 3 patients developed lymphomas (1 patient with rheumatoid arthritis and 2 patients with Crohn’s disease) among 2410 patients (median duration of follow‐up 1.1 years).” “As a result of this evaluation, a warning concerning malignancy has been added to the labelling for all therapeutic agents that block TNF.”(FDA 2004).
Another evidence of infliximab associated with lymphoma states that "In the controlled portions of clinical trials of all the TNF‐blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared with control patients… In the combined clinical trial population for rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and plaque psoriasis, lymphomas were observed for a rate of 0.10 cases per 100 patient‐years of follow‐up, which is approximately 4‐fold higher than expected in the general population. Patients with Crohn's disease, rheumatoid arthritis or plaque psoriasis, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF‐blocking therapy" (EMA 2009a).
TNF‐blockers as a group
In 2008, the FDA issued a safety alert regarding anti‐TNF biologics, which stated that the risk of pulmonary and disseminated histoplasmosis, coccidioidomycosis, blastomycosis and other opportunistic infections were not consistently recognized in patients taking tumor necrosis factor‐alpha blockers (TNF blockers including etanercept, adalimumab, infliximab or certolizumab), which resulted in the delay of proper antifungal treatment and at times led to death (FDA 2008b). The FDA reviewed 240 reports of histoplasmosis, an infection caused by the fungus Histoplasma capsulatum, in patients being treated with Enbrel, Humira, or Remicade. The majority of the reports involved people in the Ohio River and Mississippi River valleys (the fungus is commonly found in those areas). In at least 21 of the reports, histoplasmosis was initially not recognized by healthcare professionals, and antifungal treatment was delayed. Twelve of those patients died. The FDA recommended that for patients at risk of histoplasmosis and other invasive fungal infections, clinicians should consider empiric antifungal treatment until the pathogen(s) are identified.
Rituximab
While no reviews exist for rituximab in the EMA web site and Health Canada’s reviews are outdated, the FDA provides its most recent safety information for Rituxan® (rituximab) from 2009. Rituxan was found to be associated with progressive multifocal leukoencephalopathy. FDA and Genetech notified, "A third case of progressive multifocal leukoencephalopathy (PML) has been reported in a patient with rheumatoid arthritis treated with Rituxan.” In view of this event, Genetech has advised physicians to have high index of suspicion for PML stated as “Physicians should consider PML in any patient being treated with Rituxan who presents with new onset neurologic manifestations. Consultation with a neurologist, brain MRI, and lumbar puncture should be considered as clinically indicated. In patients who develop PML, Rituxan should be discontinued.” (FDA 2009a). Another event associated with Rituxan was notified in a FDA label from 2008. In this label, the possible safety complications of Rituxan® use included "tumor lysis syndrome which necessitates clinicians to administer prophylaxis and monitor patients renal function, hepatitis B reactivation with fulminant hepatitis, which can sometimes [be] fatal and the risk of progressive multifocal leukoencephalopathy" (Drugs 2006).
FDA and Genentech informed healthcare professionals of important emerging safety information about Rituxan®. "Two patients died after being treated with Rituxan® for systemic lupus erythematosus (SLE). Rituxan® is approved for the above indication and is prescribed off‐label for other serious diseases and conditions such as SLE. The cause of death was progressive multifocal leukoencephalopathy, a viral infection of the brain (that is caused by reactivated JC virus which is present in about 80% of adults" (FDA 2006). Further risks include "cardiac arrhythmias and angina", which can be life threatening, and "bowel obstruction and perforation" (FDA 2008c). Health Canada 2006 also provided warnings of bowel obstruction and perforation, "Reports of abdominal pain, bowel obstruction, and perforation, in some cases leading to death, have been observed in patients receiving Rituxan®. The majority of reports, including all deaths, have occurred in patients receiving Rituxan in combination with chemotherapy for NHL ((non‐Hodgkin’s Lymphoma)) indication. A causal relationship has not been established".
Tofacitinib
The FDA issued a Risk Evaluation and Mitigation Strategy (REMS) document, a modification in February 2015 to the original 11/2012 document, highlighting the known concerns with tofacitinib, instructing the pharmaceutical company to send information to physicians and pharmacists regarding the risk of serious infections, malignancies, decreases in peripheral lymphocyte counts, neutrophil counts, hemoglobin, and increases in lipid parameters in peripheral blood with XELJANZ (tofacitinib) (FDA 2015).
Discussion
Summary of main results
Monotherapy versus placebo
ACR50
Biologic monotherapy was associated with a clinically meaningful and statistically significant improvement in ACR50 versus placebo, RR 4.68 (95% CI, 2.93 to 7.48); absolute benefit 23% (95% CI, 18% to 29%), NNTB = 5 (95% CI, 3 to 8), based on direct evidence of moderate quality (downgraded for inconsistency).
NMA estimates for TNF biologic monotherapy and non‐TNF biologic monotherapy groups showed similar results to the direct estimates for active comparators and placebo comparisons with slightly wider confidence intervals, and all were downgraded to moderate‐quality evidence for indirectness. Specifically, in direct comparisons, TNF and non‐TNF monotherapy were associated with RR of 4.13 (95% CI, 2.51 to 6.80) and 8.23 (95% CI, 3.44 to 19.65) of ACR50 versus placebo; respective RRs from NMA were 4.40 (95% CrI, 3.02 to 6.68) and 8.20 (95% CrI, 4.06 to 14.89), all based on moderate‐quality evidence. In direct comparison with moderate‐quality evidence downgraded for imprecision, tofacitinib monotherapy showed clinically meaningful and statistically significant improvement in ACR50 versus placebo with RR of 4.09 (95% CI, 1.94 to 8.61) and similar NMA estimate of 4.63 (95% CrI, 2.60 to 8.83) with moderate‐quality evidence, downgraded for indirectness.
Most HD biologic monotherapy regimens were often more effective in achieving ACR50 compared to SD biologic monotherapy (same or other biologics).
With respect to the type of biologics, TNF biologics did not differ from non‐TNF biologics or tofacitinib in the ACR50 rates.
Function assessed by Health Assessment Questionnaire (HAQ)
Biologic monotherapy was associated with clinically meaningful and statistically significant improvement in function as measured by HAQ (0 to 3 scale, higher = worse function) score improvement versus placebo, with a MD of ‐0.32 (95% CI, ‐0.42 to ‐0.23); absolute benefit of ‐10.7% (95% CI, ‐14% to ‐7.7%), NNTB = 4 (95% CI, 3 to 5), based on moderate‐quality direct evidence (downgraded for inconsistency).
Direct and NMA estimates for TNF biologic monotherapy and tofacitinib monotherapy showed a clinically meaningful and similar statistically significant MD versus placebo, based on moderate‐quality evidence. Anakinra monotherapy showed clinically meaningful and statistically significant improvement in direct comparison (MD ‐0.23 (95% CI, ‐0.33 to ‐0.14)) , based on moderate‐quality evidence, but this effect was not significant in NMA based on low‐quality evidence.
Remission
Biologic monotherapy was associated with a clinically meaningful and statistically significant greater proportion of participants achieving remission in RA versus placebo ((disease activity score (DAS) < 1.6 or DAS28 < 2.6) with RR 1.12 (95% CI, 1.03 to 1.22); absolute benefit 10% (95% CI, 3% to 17%); NNTB = 10 (95% CI, 8 to 21), based on moderate‐quality direct evidence (downgraded for imprecision).
We did not perform NMA analysis versus placebo since there was only one study with a placebo comparator.
Radiographic Progression
No data were available for radiographic progression for monotherapy vs. placebo.
Withdrawals due to adverse events (WdAE)
Results for withdrawals due to AE were inconclusive when compared to placebo, with wide confidence intervals encompassing the null effect and evidence of an important increase, based on low‐quality direct evidence (downgraded for imprecision and inconsistency).
Direct and NMA estimates for TNF biologic monotherapy versus placebo showed a clinically meaningful and statistically significant result, with RR 2.02 (95% CI, 1.08 to 3.78) for direct comparison and RR 2.09 (95% CrI, 1.14 to 4.04) for NMA, both with an absolute difference of 3%. Non‐TNF biologic monotherapy (versus placebo), anakinra monotherapy (versus placebo), and tofacitinib monotherapy (versus placebo) comparisons were inconclusive and downgraded to low quality for both imprecision and indirectness.
Serious adverse events (SAE)
Results for SAE were inconclusive, with wide confidence intervals that included the null effect and the evidence of an important increase when compared to placebo, based on low‐quality direct evidence (downgraded for serious imprecision).
The NMA estimates for TNF biologic monotherapy (versus placebo) and tofacitinib monotherapy (versus placebo) also included the null effect and the evidence of an important increase, downgraded to low quality, for concerns about imprecision and indirectness.
Cancer
No data were available for cancer for monotherapy vs. placebo.
Monotherapy versus active comparator (MTX/other DMARDs)
ACR50
Biologic monotherapy was associated with a clinically meaningful and statistically significant improvement in ACR50 when compared to active comparator (MTX/other DMARDs), RR 1.54 (95% CI, 1.14 to 2.08); absolute benefit 13% (95% CI, 2% to 23%), NNTB = 7 (95% CI, 4 to 26).
In direct comparisons, TNF biologic monotherapy showed a statistically significant improvement with RR of 1.43 (95% CI, 1.06 to1.93) versus MTX/other DMARDs; but non‐TNF monotherapy was not significant (RR: 1.57 (95% CI, 0.67 to 3.68)). Both respective RRs from NMA did showed a clinically meaningful and statistically significant result; 1.75 (95% CrI, 1.30 to 2.31) for TNF biologic monotherapy and 2.24 (95% CrI 1.55 to 3.10) for non‐TNF biologic monotherapy, all based on moderate‐quality evidence.
Function assessed by HAQ
Biologic monotherapy was associated with clinically meaningful and statistically significant improvement in function as measured by HAQ (0 to 3 scale, higher = worse function) score improvement versus active comparator (MTX/other DMARDs) with a MD of ‐0.27 (95% CI, ‐0.40 to ‐0.14); absolute benefit of ‐9% (95% CI, ‐13.3% to ‐4.7%), NNTB = 2 (95% CI, 2 to 4), based on moderate‐quality evidence.
Non‐TNF biologic monotherapy showed a clinically meaningful and statistically significant MD for direct and NMA estimates versus the active comparator group (MTX/other DMARDs), where as TNF biologic monotherapy did not show a clinically meaningful and statistically significant MD for direct and NMA estimates versus the active comparator. All group analyses were downgraded to moderate‐ or low‐quality evidence.
We noted no differences in HAQ scores by the type of biologic (TNF versus non‐TNF biologics) or receptor versus antibody TNF‐biologic.
Remission
There were no clinically meaningful and statistically significant direct estimates for biologic monotherapy versus the active comparator group.
NMA estimates showed a significant difference versus active comparator for TNF biologic monotherapy, absolute improvement 7% (95% CI, 2% to 14%) and non‐TNF biologic monotherapy, absolute improvement 19% (95% CrI, 7% to 36%). These were downgraded to moderate‐quality for concerns about indirectness.
Radiographic Progression
Based on moderate‐quality direct evidence (downgraded for inconsistency) from a single study, radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologic monotherapy versus active comparator, MD ‐4.34 (95% CI, ‐7.56 to ‐1.12), though the absolute reduction was small, ‐0.97% (95% CI ‐1.69% to ‐0.25%). We are not sure of the clinical relevance of this reduction.
Withdrawals due to adverse events
Results for withdrawals due to AEs were inconclusive when compared to the active comparator, with wide confidence intervals encompassing the null effect and evidence of an important increase, based on low‐quality direct evidence (downgraded to low level for imprecision and inconsistency).
The NMA estimates for TNF biologic monotherapy (versus active comparator) and non‐TNF biologic monotherapy (versus active comparator) also included null effect and the evidence of an important increase, both downgraded to low quality for both imprecision and indirectness.
Serious adverse events
Results for SAEs were inconclusive, with wide confidence intervals that included the null effect and the evidence of an important increase when compared to the active comparator, based on low‐quality direct evidence (downgraded for serious imprecision).
The NMA estimates for TNF biologic monotherapy (versus active comparator) and non‐TNF biologic monotherapy (versus active comparator) also included null effect and the evidence of an important increase, downgraded to low and very low quality respectively, for concerns about imprecision and indirectness.
Cancer
Based on low‐quality direct evidence (downgraded for serious imprecision), results for all cancer comparisons were inconclusive, with wide confidence intervals.
With respect to the type of biologics, TNF biologics did not differ from non‐TNF biologics in the risk of cancer. Also, the odds of cancer did not differ between SD, HD and LD biologic monotherapy.
Overall completeness and applicability of evidence
This review is up to date to 2015. In addition to the traditional meta‐analysis showing direct comparisons of biologic versus placebo and biologic versus active comparator, our review provides NMA estimates for various categories and doses of biologics compared to each other. The NMA comparisons incorporate both direct and indirect comparisons of biologics/tofacitinib to each other and to MTX/other traditional DMARDs. Since trials with direct comparisons of biologics to each other are few, this study provides evidence comparing biologic monotherapy to placebo and to MTX/other traditional DMARDs.
Quality of the evidence
For this update, the quality of included trials was reasonably good. We noted poor reporting of the conduct of the included trials, with only 37% of included trials reporting adequate sequence generation and 37% of trials judged to be at low risk for allocation concealment. Selective reporting bias could not be assessed since for several (89%) trials, as we could not find published protocols.
The overall quality of the evidence for most outcomes was assessed using GRADE as per the recommendation from Cochrane (Schünemann 2011) and was downgraded to moderate due to limitations in the study designs of the included studies, inconsistency of effect or indirectness, with few head‐to‐head comparisons. In some cases, such as withdrawals due to adverse events and cancer, the level of evidence was low (very low in one instance). For serious adverse events, the level of evidence was moderate for direct comparison and low for NMA. The quality of evidence reflects the extent to which we are confident that an estimate of the effect is correct. The outcomes for this review were selected following the recommendations of the Outcome Measures in Rheumatology (OMERACT) group, as being relevant to people with RA.
Potential biases in the overview process
Our review has several limitations, as noted below.
Lack of reporting of many important outcomes from RCTs (cancer) and the lack of measurement for some outcome (radiographic scores, etc.) limited our ability to analyze them in detail.
Our NMA combines the available direct and indirect evidence, including the few head‐to‐head comparisons of benefit and harms (e.g. Gabay 2013a; Schiff 2008; Weinblatt 2013a etc.) of various biologic monotherapy regimens or tofacitinib monotherapy in people with RA. In the absence of direct comparisons, our approach using NMA provides useful information and comparisons. However, most interpretations are likely based on indirect comparisons.
RCTs included in this review and NMA differed in socio‐demographic characteristics, prior failed therapy, concomitant use of DMARDs, biologic dose, mean RA disease duration, and trial duration. To address this limitation, we analyzed data by previous DMARD/biologic history (MTX‐naive, MTX/other DMARD‐experienced, and biologic‐experienced), in four separate reviews‐ this current review focused on the benefits and harms of biologic monotherapy in MTX/other DMARD‐experienced population. We also carefully considered and analyzed data by dose (SD, HD, LD) and the type of biologic and also specified a priori and performed subgroup analyses by the duration of RA (early, established, late; might indicate disease severity/impact over time) and by trial duration (less than six months, six to 12 months and more than 12 months), a surrogate of the duration of biologic exposure.
Subgroup analyses presented in this study are subject to type II error, that is, we likely missed some significant results, by chance, due to lower number of studies and patients. Therefore, these results must be interpreted with caution.
Some studies presented data on safety for all doses of the biologic together, not just the recommended dose and in some cases presented data for the entire study duration, including the open‐label phase. This limited our ability to get the data for the randomized phase or by dose, and we were unable to use these data.
Some studies allowed continuation of DMARDs such as methotrexate in a proportion of the participants, but not all. As an example, 78% of patients in an abatacept study continued on methotrexate (Weinblatt 2006). Such studies make the placebo group heterogeneous compared to other studies, where participants are usually randomized to biologic versus placebo or biologic + placebo versus methotrexate + placebo .
There is also a possibility of type I error, due to multiple comparisons. Up to five differences per 100 comparisons may be due to chance. Due to limited data for most outcomes, short trial duration and rarity of harms outcomes, our main concern with most of these analyses is Type‐II error, that is, missing an important difference due to small number of events, not Type‐I error. In the main analyses, we likely missed some significant differences due to short trial duration and/or rarity of outcome leading to type II error. More trial data and data from observational studies would allow meaningful comparisons and increase our confidence in these findings.
Some odds ratios and relative risks may look slightly different from each other numerically, but not statistically. These can be challenging to interpret. One must be careful in interpreting these results and should focus on the 95% confidence interval to make a judgement of whether the result indicates a clinically meaningful increase in benefits or harms.
Agreements and disagreements with other studies or reviews
We performed a comprehensive NMA and systematic review, accounting for potential factors that differ between trials and trial arms such as prior DMARD/biologic exposure and concomitant MTX/other DMARD use. Therefore, direct comparison of results to most published NMAs is not possible, particularly those that have not stratified participants by these important characteristics. The use of Bayesian methods and the inclusion of several more studies than included in the previous reviews/overviews, explain some differences when compared to earlier studies, as expected. Additionally, our review includes nine biologics and tofacitinib, while most previous reviews have focused on anti‐TNF biologics.
In a systematic review for European League Against Rheumatism (EULAR) guidelines for RA in 2010, biologic monotherapy was as effective as traditional DMARD therapy and was inferior to biologic + DMARD combination for both patient‐reported outcomes and radiographic progression (Nam 2010). The systematic review included 51 full papers and 57 abstracts. One of these observations was confirmed in our systematic review, namely that biologic monotherapy was inferior to biologic + MTX/DMARD. In contrast to the previous systematic review, our findings for biologic monotherapy were different for ACR50 and HAQ. We found that biologic monotherapy was associated with significantly higher ACR50 and improvement in function, but no difference in RA disease remission versus MTX/other DMARDs. Our study advances knowledge compared to this previous systematic review, by performing an NMA and providing additional analyses by dose and trial duration.
In a meta‐analysis of 14 eligible studies of licensed‐dose etanercept, adalimumab, and tocilizumab monotherapy, biologics were significantly better than placebo in improving ACR 20/50/70 outcomes, and biologic combination therapy was better than biologic monotherapy (Orme 2012). Similarly we found that biologic monotherapy was better than placebo for ACR50, functional improvement on HAQ and RA disease remission. Our study also adds to the current knowledge by showing that withdrawals due to adverse events and serious adverse events were not clinically meaningfully or statistically significantly different between biologics and placebo.
In a meta‐analysis of RCTs of anti‐TNF biologics for RA (Alonso‐Ruiz 2008), compared to control treatment, the relative risk of achieving ACR50 for biologic monotherapy versus MTX was 1.3 (95% CI 1.1 to 1.5). We found that biologic monotherapy was more effective versus active comparator (MTX/other DMARDs) with RR of 1.54 (95% CI 1.14 to 2.08) and versus placebo, RR 4.68 (95% CI 2.93 to 7.48) ; however, as described above, when compared to MTX, biologic monotherapy in standard doses was similar in efficacy for ACR50 and HAQ improvement, but high‐dose biologic was superior to MTX for both ACR50 and HAQ improvement.
In a systematic review of four biologics for RA, TNF‐inhibitors were similar to each other in benefit, and seemed to be better than anakinra for ACR20, but not ACR50 (Gartlehner 2006), when all biologic arms were combined regardless of monotherapy or combination with DMARDs/MTX. Our study shows that for several outcomes, TNF inhibitor monotherapy was similar to non‐TNF monotherapy regimens, thus extending the observation to a larger group of non‐TNF biologics, now with far more data available.
Kristensen 2007 examined ACR50 in people with established RA after one year of therapy. Based on three trials, one each for etanercept, infliximab and adalimumab, they estimated the NNTB to be 8 (5 to 38) people for infliximab, 4 (3 to 6) for etanercept and 4 (3 to 6) for adalimumab. Our NNTB estimates for achieving ACR50 were very similar to this previous study ranging from 5 to 8.
In a meta‐analysis of serious adverse events that combined all patient populations (MTX/DMARD‐naïve, MTX/DMARD‐failure) and biologic use (monotherapy and use with concomitant MTX/other DMARDs), biologics at recommended doses were not associated with any increase in the risk of serious adverse events (Leombruno 2008). Fewer trials were available previously as compared to our study. In our study, we had a similar finding for both comparison of biologic to placebo and biologic to MTX/other DMARDs, based on evidence that was low quality due to imprecision and indirectness or due to serious imprecision.
Several meta‐analyses could not be compared to our study since they focused on biologic combination therapy with MTX/other DMARDs or discontinuation rates (Desai 2012), but not biologic monotherapy; or included only early RA trials with no prior failure of MTX/other DMARDs (Thompson 2011). Other systematic reviews and meta‐analyses addressed patient populations different than those in the current review, namely: Lee 2008 focused on comparison of biologic + MTX versus MTX; monotherapy was not analyzed separately than biologic + DMARD/MTX (Bongartz 2006; Bongartz 2009; Nixon 2007). For example, Nixon 2007 performed indirect comparisons of TNF‐inhibitors and anakinra for RA including RCTs with both standard approved doses as well as RCTs with non‐standardized doses. Similar to our study, they found that ACR50 was similar between various TNF‐biologics, with odds ratios (95% CI) as follows: infliximab/etanercept, 0.98 (0.45 to 1.93); adalimumab/etanercept, 0.94 (0.51 to 1.62); and adalimumab/infliximab, 0.96 (0.48 to 1.90). However, this previous study (Nixon 2007) did not distinguish between biologic monotherapy and biologic + MTX/other DMARD arms.
Donahue 2008 performed a qualitative synthesis (and where meta‐analyses provided quantitative analysis) of RCTs, observational studies and meta‐analyses of traditional and biologics for RA. They reported that TNFi biologic monotherapy was better than MTX for radiographic improvement, but did not differ in ACR50 rates. We confirmed the finding related to greater statistically significantly better improvement in radiographic progression with biologic monotherapy versus MTX/other DMARDs, but are not sure whether this is clinically meaningful or not. In addition, only one study provided these data. We also found that biologic monotherapy improved ACR50 and HAQ scores in a clinically meaningful and statistically significant way. However, we only included all RCTs to date, not observational data.
An NMA, Lopez‐Olivo 2012, concluded that biologics were not associated with a higher risk of cancer compared to DMARDs or placebo. Our findings are similar to this earlier analysis. However, we caution that data in both the previous publication and our systematic review and NMA are based on few short‐term RCTs. A much longer follow‐up and larger evidence base is needed to make such conclusions, which could be achieved with large post‐marketing surveillance studies or registry data, or both.
Authors' conclusions
Implications for practice.
Biologic monotherapy improved RA signs and symptoms (ACR50), physical function and disease remission compared to placebo. There were no data on radiographic progression. We noted inconclusive results for withdrawals due to adverse events, serious adverse events and cancer with biologic monotherapy versus placebo, with wide confidence intervals.
Biologic monotherapy improved RA signs and symptoms (ACR50), physical function and radiographic progression compared to active comparator (MTX/other DMARDs). There were no significant differences in RA remission. We noted inconclusive results for withdrawals due to adverse events, serious adverse events and cancer with biologic monotherapy versus active comparator, with wide confidence intervals.
We provided both direct and NMA comparisons (includes indirect and direct comparison data) of data for biologic or tofacitinib monotherapy versus placebo or versus comparator (MTX/other DMARDs) in people with RA previously unsuccessfully treated with MTX/other DMARDs. We realize that our NMA relies a lot on indirect evidence, since direct comparator trials are few. The finding of a great concordance between direct and NMA estimates, as shown in the SOF tables, confirms the validity of the approach using NMA for performing these analyses and their robustness. In the relative absence of direct head‐to‐head comparator trials of biologics in people with RA, patients and healthcare providers face a dilemma when selecting biologics or tofacitinib, for people whose treatment with traditional MTX or other DMARDs has failed. Our NMA now provides these comparisons and estimates for biologic or tofacitinib monotherapy in such people. Our NMA also advances evidence‐based medicine by making several observations comparing biologic monotherapy in various doses (standard, low and high) to each other, as well to comparators, and by comparing various groups of drugs, namely TNF versus non‐TNF versus tofacitinib versus anakinra. More comparative effectiveness data are needed to better understand comparative benefits and harms of biologic or tofacitinib monotherapy.
Implications for research.
More RCTs of direct head‐to‐head comparisons of biologics and head‐to‐head comparisons of biologics and tofacitinib in people with RA are needed, which can add new knowledge regarding their comparative benefits and harms. There are several clinical situations where we need these data, including various disease stages (early, established and late RA), functional limitation levels (mild, moderate and severe limitation) and prior treatments (traditional DMARD‐failure versus MTX‐failure versus both). Observational studies and registry data can provide additional invaluable insights into harms/side effects of biologics that are uncommon or rare and usually require large sample sizes and longer follow‐up, such as cancer, neurological adverse events and others. Although such studies provide real world data, one much carefully consider channeling bias, confounding bias and other study design limitations in data interpretation from observational studies.
What's new
| Date | Event | Description |
|---|---|---|
| 22 June 2015 | New search has been performed | New citation: conclusions changed, description: Original review of biologics in RA split into four by the patient populations
This review presents comparisons of comparisons of biologic monotherapy (without concurrent methotrexate) versus a) placebo and b) head‐to‐head studies against other traditional DMARDs in a RA patient population with MTX/other DMARD failure (number 3 above). |
| 22 June 2015 | New citation required and conclusions have changed | Updated, description: new search with 40 new studies included |
History
Review first published: Issue 11, 2016
| Date | Event | Description |
|---|---|---|
| 1 March 2010 | Amended | Odds ratios have been used in the network meta‐analyses. Relative risks presented in the abstract, SoF table and PLS for ease of understanding. See 'Published notes' for details. |
| 25 February 2010 | Amended | CMSG ID: C187‐R |
Notes
This original 2009 version was co‐published in the Canadian Medical Association Journal (CMAJ 2009 DOI:10.1503/cmaj.091391) and because of separate review processes, both versions were substantively different ‐ risk ratios were used in the network meta‐analyses in the Cochrane version and odds ratios in the CMAJ version. Since the indirect comparisons approach used requires odds ratios, we have now harmonized the network meta‐analyses using odds ratios in this Cochrane review while describing results as well using risk ratios in the 'Summary of findings' tables, as well as Abstract and Plain language summary.
Acknowledgements
We acknowledge the valuable contributions of Dr. Buchbinder from the Monash University, Malvern, Australia and Dr. Suarez‐Almazor and Ms. Lopez‐Olivo from the MD Anderson cancer center, Houston, Texas, USA for their contributions to the original 2009 version of this review. We thank Shahrzad Noorbaloochi and Tyler Cullis (SN, TC) at the Boston University for contributing to abstract/title review and data abstraction; Tamara Rader of University of Ottawa for performing the searches.
Appendices
Appendix 1. List of all abbreviations used in appendices and figures
| [Insert text] | [Insert text] |
| TNF | TNF biologic including etanercept, infliximab, certolizumab pegol, golimumab, adalimumab |
| non‐TNF | Non‐TNF biologic including abatacept, rituximab or tocilizumab |
| DMARD | Disease‐modifying anti‐rheumatic drug |
| MTX | Methotrexate |
| PL | Placebo |
| NMA | Network Meta‐Analysis |
| CI | confidence interval |
| CrI | Credible interval |
| OR | Odds ratio |
| RR | Relative risk |
| SD | Standard dose |
| LD | Low dose |
| HD | High dose |
| IV | Intravenous (given via a needle into the vein) |
| SQ or SC | Subcutaneous (given/injected below the skin) |
| ABA | Abatacept |
| ADA | Adalimumab |
| ANA | Anakinra |
| CERTO | Certolizumab pegol |
| ETN | Etanercept |
| GOLI | Golimumab |
| INF | Infliximab |
| TOFA | Tofacitinib |
| TOCI | Tocilizumab |
| RITUX | Rituximab |
| Mono | Monoclonal antibody TNF biologic‐ includes Adalimumab, certolizumab pegol, infliximab and golimumab |
| TNF receptor | TNF receptor biologic = etanercept |
| TNF inhibitors | Includes 5 biologics that target TNF: Adalimumab, certolizumab pegol, infliximab, golimumab and etanercept |
| non‐TNF | Includes 5 biologics that target cells/molecules other than TNF: Abatacept, tocilizumab and rituximab |
| Oral synthetic drug (oral small molecule) | Includes new janus kinase inhibitor oral drug, tofacitinib |
Appendix 2. ACR50: main analysis
| ACR50 combined: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| PL + MTX/MTX | PL | 3.66(1.69,6.81) | 3.15(1.62,5.14) | 0.13(0.04,0.24) |
| DMARD/DMARD + PL | 0.98(0.37,2.38) | 0.98(0.38,2.20) | 0.00(‐0.04,0.07) | |
| MTX + DMARD | 5.57(2.31,13.66) | 4.36(2.11,8.02) | 0.20(0.07,0.39) | |
| SD ETN SC | 6.94(3.38,13.10) | 5.09(2.90,7.94) | 0.25(0.13,0.38) | |
| SD ADA SC | 3.69(2.13,6.72) | 3.16(1.98,5.13) | 0.13(0.07,0.23) | |
| SD TOFA PO | 6.44(3.31,13.07) | 4.82(2.87,7.77) | 0.23(0.12,0.39) | |
| SD GOLI SC | 8.10(3.04,22.03) | 5.65(2.70,10.08) | 0.28(0.11,0.52) | |
| SD GOLI IV | 6.49(2.15,18.77) | 4.85(2.00,9.34) | 0.23(0.06,0.48) | |
| SD TOCI IV | 5.43(2.12,13.52) | 4.26(1.97,8.06) | 0.20(0.06,0.39) | |
| SD RITUX IV | 2.52(0.29,13.36) | 2.30(0.30,7.87) | 0.08(‐0.04,0.39) | |
| SD ABA SC | 9.95(2.69,46.12) | 6.40(2.43,13.14) | 0.33(0.09,0.68) | |
| SD CERTO SC | 9.56(3.04,34.80) | 6.26(2.70,11.93) | 0.32(0.10,0.63) | |
| SD ETN SC + MTX | 14.81(6.84,31.08) | 8.01(4.78,12.05) | 0.43(0.26,0.59) | |
| SD INF IV + MTX | 11.26(4.80,24.64) | 6.94(3.82,10.64) | 0.36(0.19,0.54) | |
| SD ABA IV + MTX | 14.62(6.12,33.05) | 7.97(4.48,12.16) | 0.43(0.23,0.61) | |
| SD ADA SC + MTX | 23.24(9.03,57.59) | 9.75(5.74,14.38) | 0.54(0.32,0.72) | |
| SD CERTO SC + MTX/CERTO+MTX | 21.19(8.18,46.26) | 9.46(5.51,13.45) | 0.52(0.30,0.69) | |
| SD RITUX IV + MTX | 9.14(3.91,21.04) | 6.08(3.26,9.92) | 0.31(0.14,0.51) | |
| SD TOFA PO + MTX | 23.26(9.75,57.30) | 9.82(6.11,14.14) | 0.54(0.34,0.72) | |
| SD GOLI SC + MTX | 23.12(8.75,58.38) | 9.79(5.68,14.19) | 0.54(0.32,0.72) | |
| SD ABA SC + MTX | 18.02(6.44,49.02) | 8.78(4.70,13.72) | 0.48(0.25,0.68) | |
| SD GOLI IV + MTX | 8.64(3.20,22.14) | 5.88(2.79,10.06) | 0.30(0.12,0.52) | |
| SD ANA SC + MTX | 10.68(3.49,30.43) | 6.67(3.01,11.55) | 0.35(0.13,0.59) | |
| SD TOCI IV + MTX | 7.50(2.32,22.43) | 5.36(2.13,10.30) | 0.27(0.08,0.52) | |
| SD CERTO SC + DMARD | 5.17(1.87,14.27) | 4.12(1.77,8.03) | 0.19(0.05,0.41) | |
| SD ADA SC + DMARD | 3.09(0.76,11.16) | 2.74(0.78,6.94) | 0.11(‐0.01,0.35) | |
| SD ETN SC + DMARD | 12.68(4.15,38.46) | 7.36(3.45,12.62) | 0.39(0.16,0.65) | |
| SD TOCI SC + DMARD | 4.91(1.24,18.43) | 3.95(1.22,9.00) | 0.18(0.01,0.48) | |
| LD ADA SC | 3.33(1.59,7.53) | 2.92(1.53,5.52) | 0.12(0.03,0.26) | |
| LD ETN SC | 3.51(1.56,7.76) | 3.04(1.50,5.60) | 0.12(0.03,0.27) | |
| LD GOLI IV | 3.85(1.15,12.60) | 3.27(1.14,7.53) | 0.14(0.01,0.38) | |
| LD TOCI IV | 0.65(0.11,2.67) | 0.67(0.12,2.43) | ‐0.02(‐0.06,0.08) | |
| LD ADA SC + MTX | 16.49(6.28,46.62) | 8.42(4.58,13.41) | 0.46(0.24,0.68) | |
| LD RITUX IV + MTX | 8.07(3.19,18.75) | 5.62(2.79,9.50) | 0.28(0.12,0.48) | |
| LD ADA IV + MTX | 14.69(2.25,82.04) | 7.93(2.08,15.00) | 0.43(0.07,0.78) | |
| LD ABA IV + MTX | 7.85(2.93,21.08) | 5.52(2.62,9.82) | 0.28(0.10,0.50) | |
| LD ANA SC + MTX | 7.33(1.54,32.97) | 5.26(1.49,11.70) | 0.26(0.03,0.61) | |
| LD CERTO SC + MTX | 14.70(4.41,47.72) | 7.99(3.58,13.38) | 0.43(0.17,0.69) | |
| LD ETN SC + MTX | 12.99(4.49,37.72) | 7.49(3.65,12.44) | 0.40(0.18,0.64) | |
| LD GOLI IV + MTX | 7.58(2.45,24.09) | 5.38(2.22,10.42) | 0.27(0.08,0.54) | |
| LD TOCI IV + MTX | 6.08(1.95,18.19) | 4.64(1.83,9.22) | 0.22(0.05,0.46) | |
| LD TOFA PO + MTX | 12.84(2.98,48.04) | 7.40(2.66,13.00) | 0.39(0.11,0.70) | |
| HD TOCI IV | 9.85(4.54,19.49) | 6.40(3.64,9.73) | 0.33(0.18,0.48) | |
| HD TOFA PO | 10.26(5.02,20.82) | 6.53(3.97,9.90) | 0.34(0.19,0.50) | |
| HD ADA SC | 4.69(2.28,10.74) | 3.82(2.09,7.00) | 0.17(0.07,0.34) | |
| HD ETN SC | 7.12(2.81,17.55) | 5.19(2.49,9.25) | 0.25(0.10,0.47) | |
| HD GOLI SC | 9.57(3.90,21.77) | 6.26(3.25,10.12) | 0.32(0.15,0.52) | |
| HD ABA SC | 14.48(3.81,62.31) | 7.86(3.20,14.09) | 0.42(0.14,0.74) | |
| HD INF IV + MTX | 18.36(7.49,43.86) | 8.92(5.14,13.22) | 0.48(0.28,0.67) | |
| HD TOCI IV + MTX | 17.54(7.25,37.88) | 8.70(5.10,12.70) | 0.47(0.27,0.64) | |
| HD TOFA PO + MTX | 18.47(7.83,45.79) | 8.90(5.26,13.32) | 0.49(0.29,0.68) | |
| HD GOLI SC + MTX | 17.77(6.82,47.15) | 8.77(4.86,13.44) | 0.48(0.26,0.68) | |
| HD CERTO SC + MTX | 24.79(10.00,59.86) | 10.08(6.17,14.60) | 0.56(0.35,0.73) | |
| HD ADA SC + MTX | 20.68(6.34,70.20) | 9.33(4.67,14.68) | 0.51(0.24,0.75) | |
| HD TOCI IV + DMARD | 3.61(1.09,11.27) | 3.11(1.08,7.06) | 0.13(0.01,0.35) | |
| SD ANA SC + SD ETN SC + MTX | 9.29(2.84,33.61) | 6.10(2.51,11.95) | 0.32(0.10,0.62) | |
| SD ANA SC + LD ETN SC + MTX | 14.26(4.13,48.43) | 7.82(3.39,13.56) | 0.42(0.16,0.69) | |
| DMARD/DMARD + PL | PL + MTX/MTX | 0.27(0.12,0.63) | 0.31(0.15,0.68) | ‐0.13(‐0.23,‐0.05) |
| MTX + DMARD | 1.57(0.88,2.82) | 1.41(0.90,2.15) | 0.08(‐0.02,0.21) | |
| SD ETN SC | 1.91(1.28,2.89) | 1.63(1.19,2.29) | 0.12(0.04,0.20) | |
| SD ADA SC | 1.03(0.50,2.31) | 1.03(0.58,2.00) | 0.00(‐0.11,0.13) | |
| SD TOFA PO | 1.80(0.72,4.69) | 1.56(0.78,3.18) | 0.11(‐0.06,0.29) | |
| SD GOLI SC | 2.27(0.89,6.00) | 1.82(0.91,3.47) | 0.15(‐0.02,0.37) | |
| SD GOLI IV | 1.81(0.74,4.28) | 1.57(0.78,2.76) | 0.10(‐0.05,0.31) | |
| SD TOCI IV | 1.52(0.69,3.30) | 1.38(0.74,2.45) | 0.07(‐0.06,0.23) | |
| SD RITUX IV | 0.71(0.10,3.42) | 0.75(0.12,2.35) | ‐0.05(‐0.19,0.24) | |
| SD ABA SC | 2.80(0.61,14.74) | 2.05(0.67,5.45) | 0.20(‐0.08,0.57) | |
| SD CERTO SC | 2.61(0.70,13.42) | 1.99(0.75,5.34) | 0.19(‐0.06,0.53) | |
| SD ETN SC + MTX | 4.16(2.76,6.35) | 2.56(1.93,3.64) | 0.30(0.19,0.40) | |
| SD INF IV + MTX | 3.11(2.05,4.77) | 2.19(1.68,2.99) | 0.23(0.12,0.34) | |
| SD ABA IV + MTX | 4.07(2.66,6.22) | 2.53(1.93,3.43) | 0.29(0.17,0.41) | |
| SD ADA SC + MTX | 6.35(3.76,11.26) | 3.10(2.31,4.37) | 0.40(0.26,0.54) | |
| SD CERTO SC + MTX/CERTO+MTX | 5.80(3.65,9.41) | 2.99(2.25,4.21) | 0.38(0.24,0.50) | |
| SD RITUX IV + MTX | 2.54(1.53,4.27) | 1.95(1.37,2.78) | 0.18(0.07,0.31) | |
| SD TOFA PO + MTX | 6.49(3.80,11.61) | 3.11(2.28,4.56) | 0.41(0.26,0.54) | |
| SD GOLI SC + MTX | 6.39(3.32,12.48) | 3.10(2.14,4.71) | 0.40(0.24,0.54) | |
| SD ABA SC + MTX | 5.06(2.49,10.03) | 2.81(1.88,4.20) | 0.35(0.17,0.51) | |
| SD GOLI IV + MTX | 2.37(1.22,4.82) | 1.87(1.16,2.88) | 0.17(0.03,0.34) | |
| SD ANA SC + MTX | 2.99(1.27,6.77) | 2.14(1.21,3.49) | 0.22(0.04,0.42) | |
| SD TOCI IV + MTX | 2.10(0.78,5.43) | 1.74(0.81,3.13) | 0.14(‐0.04,0.36) | |
| SD CERTO SC + DMARD | 1.45(0.47,4.57) | 1.34(0.55,3.01) | 0.06(‐0.12,0.30) | |
| SD ADA SC + DMARD | 0.87(0.26,3.00) | 0.89(0.30,2.27) | ‐0.02(‐0.16,0.21) | |
| SD ETN SC + DMARD | 3.56(1.36,9.54) | 2.37(1.25,4.09) | 0.26(0.05,0.49) | |
| SD TOCI SC + DMARD | 1.37(0.41,4.84) | 1.28(0.47,2.92) | 0.05(‐0.12,0.33) | |
| LD ADA SC | 0.95(0.37,2.61) | 0.96(0.44,2.15) | ‐0.01(‐0.14,0.15) | |
| LD ETN SC | 0.98(0.50,1.88) | 0.98(0.57,1.64) | 0.00(‐0.10,0.11) | |
| LD GOLI IV | 1.08(0.37,2.92) | 1.06(0.43,2.13) | 0.01(‐0.12,0.21) | |
| LD TOCI IV | 0.18(0.03,0.66) | 0.22(0.04,0.71) | ‐0.14(‐0.25,‐0.04) | |
| LD ADA SC + MTX | 4.55(2.36,9.09) | 2.67(1.83,3.95) | 0.32(0.16,0.49) | |
| LD RITUX IV + MTX | 2.22(1.29,3.78) | 1.78(1.22,2.57) | 0.15(0.04,0.29) | |
| LD ADA IV + MTX | 4.07(0.70,20.43) | 2.52(0.75,4.91) | 0.29(‐0.05,0.63) | |
| LD ABA IV + MTX | 2.19(1.15,4.20) | 1.78(1.11,2.65) | 0.15(0.02,0.31) | |
| LD ANA SC + MTX | 2.01(0.54,8.21) | 1.67(0.59,3.74) | 0.13(‐0.07,0.46) | |
| LD CERTO SC + MTX | 4.12(1.67,10.42) | 2.54(1.49,4.24) | 0.30(0.08,0.52) | |
| LD ETN SC + MTX | 3.66(1.61,8.16) | 2.40(1.43,3.82) | 0.27(0.08,0.47) | |
| LD GOLI IV + MTX | 2.13(0.83,5.69) | 1.75(0.85,3.06) | 0.14(‐0.03,0.38) | |
| LD TOCI IV + MTX | 1.71(0.63,4.45) | 1.50(0.68,2.88) | 0.09(‐0.07,0.30) | |
| LD TOFA PO + MTX | 3.54(1.05,10.97) | 2.35(1.05,4.11) | 0.26(0.01,0.53) | |
| HD TOCI IV | 2.69(1.64,4.53) | 2.02(1.42,3.00) | 0.19(0.09,0.30) | |
| HD TOFA PO | 2.91(1.13,6.96) | 2.11(1.09,3.99) | 0.21(0.02,0.39) | |
| HD ADA SC | 1.31(0.53,3.66) | 1.23(0.61,2.74) | 0.04(‐0.10,0.23) | |
| HD ETN SC | 2.00(0.98,4.13) | 1.68(0.98,2.69) | 0.13(0.00,0.30) | |
| HD GOLI SC | 2.66(1.32,5.56) | 2.01(1.22,3.29) | 0.19(0.05,0.36) | |
| HD ABA SC | 3.98(0.87,21.43) | 2.48(0.90,6.26) | 0.29(‐0.02,0.63) | |
| HD INF IV + MTX | 5.06(2.95,8.88) | 2.80(2.04,4.07) | 0.35(0.20,0.48) | |
| HD TOCI IV + MTX | 4.85(2.84,8.32) | 2.77(1.98,4.06) | 0.34(0.20,0.46) | |
| HD TOFA PO + MTX | 5.23(2.96,9.43) | 2.84(2.08,4.16) | 0.35(0.20,0.50) | |
| HD GOLI SC + MTX | 4.96(2.55,10.15) | 2.78(1.90,4.24) | 0.34(0.17,0.51) | |
| HD CERTO SC + MTX | 6.96(4.03,12.34) | 3.21(2.38,4.77) | 0.42(0.28,0.55) | |
| HD ADA SC + MTX | 5.77(2.26,15.13) | 2.96(1.80,4.72) | 0.38(0.15,0.58) | |
| HD TOCI IV + DMARD | 0.99(0.37,2.99) | 1.00(0.43,2.21) | 0.00(‐0.13,0.21) | |
| SD ANA SC + SD ETN SC + MTX | 2.65(0.91,7.95) | 1.99(0.92,3.62) | 0.19(‐0.01,0.45) | |
| SD ANA SC + LD ETN SC + MTX | 3.92(1.35,11.55) | 2.48(1.27,4.39) | 0.28(0.05,0.53) | |
| MTX + DMARD | DMARD/DMARD + PL | 5.73(2.15,15.44) | 4.44(1.92,10.18) | 0.20(0.08,0.38) |
| SD ETN SC | 7.00(3.18,16.12) | 5.12(2.54,10.99) | 0.24(0.15,0.37) | |
| SD ADA SC | 3.82(1.49,10.43) | 3.24(1.41,8.32) | 0.13(0.04,0.23) | |
| SD TOFA PO | 6.69(2.23,20.71) | 4.95(1.94,13.32) | 0.23(0.10,0.39) | |
| SD GOLI SC | 8.45(2.52,28.38) | 5.74(2.18,14.79) | 0.28(0.11,0.51) | |
| SD GOLI IV | 6.69(2.03,21.73) | 4.90(1.84,12.38) | 0.23(0.07,0.47) | |
| SD TOCI IV | 5.54(1.99,15.19) | 4.30(1.81,10.25) | 0.20(0.07,0.38) | |
| SD RITUX IV | 2.62(0.35,14.24) | 2.37(0.36,9.12) | 0.08(‐0.04,0.38) | |
| SD ABA SC | 10.22(1.96,67.26) | 6.42(1.78,21.42) | 0.33(0.07,0.68) | |
| SD CERTO SC | 9.52(2.41,55.12) | 6.21(2.11,20.67) | 0.32(0.09,0.64) | |
| SD ETN SC + MTX | 15.43(6.09,36.84) | 8.16(3.82,17.50) | 0.43(0.27,0.58) | |
| SD INF IV + MTX | 11.55(4.44,28.43) | 6.97(3.19,15.12) | 0.36(0.20,0.53) | |
| SD ABA IV + MTX | 14.98(5.67,38.74) | 8.01(3.80,17.66) | 0.42(0.25,0.60) | |
| SD ADA SC + MTX | 23.75(8.83,64.04) | 9.87(4.67,22.02) | 0.54(0.33,0.71) | |
| SD CERTO SC + MTX/CERTO+MTX | 21.40(8.90,54.77) | 9.45(4.58,21.00) | 0.51(0.32,0.67) | |
| SD RITUX IV + MTX | 9.36(3.71,24.79) | 6.17(2.85,13.68) | 0.31(0.16,0.49) | |
| SD TOFA PO + MTX | 24.16(8.45,63.98) | 9.85(4.53,22.14) | 0.54(0.35,0.71) | |
| SD GOLI SC + MTX | 23.37(8.62,68.20) | 9.78(4.66,22.22) | 0.53(0.34,0.72) | |
| SD ABA SC + MTX | 18.79(6.14,55.73) | 8.88(3.96,20.29) | 0.48(0.26,0.68) | |
| SD GOLI IV + MTX | 8.82(3.13,25.00) | 5.96(2.52,13.35) | 0.29(0.13,0.51) | |
| SD ANA SC + MTX | 10.76(3.51,34.96) | 6.68(2.78,15.97) | 0.35(0.14,0.58) | |
| SD TOCI IV + MTX | 7.72(2.37,24.38) | 5.42(2.08,13.15) | 0.26(0.09,0.50) | |
| SD CERTO SC + DMARD | 5.29(2.04,14.40) | 4.16(1.83,9.28) | 0.19(0.06,0.40) | |
| SD ADA SC + DMARD | 3.17(1.27,7.97) | 2.78(1.24,5.67) | 0.11(0.01,0.32) | |
| SD ETN SC + DMARD | 13.15(4.43,40.09) | 7.44(3.25,16.84) | 0.39(0.18,0.63) | |
| SD TOCI SC + DMARD | 5.09(2.05,12.60) | 3.99(1.93,7.58) | 0.18(0.04,0.43) | |
| LD ADA SC | 3.51(1.11,11.39) | 3.02(1.10,8.87) | 0.12(0.01,0.26) | |
| LD ETN SC | 3.57(1.35,9.68) | 3.07(1.30,7.43) | 0.12(0.03,0.26) | |
| LD GOLI IV | 3.95(1.07,14.06) | 3.33(1.06,9.32) | 0.14(0.01,0.36) | |
| LD TOCI IV | 0.66(0.12,3.03) | 0.67(0.13,2.77) | ‐0.02(‐0.09,0.08) | |
| LD ADA SC + MTX | 17.11(5.62,50.08) | 8.52(3.75,19.41) | 0.45(0.25,0.66) | |
| LD RITUX IV + MTX | 8.19(3.22,20.68) | 5.65(2.63,12.55) | 0.28(0.13,0.47) | |
| LD ADA IV + MTX | 14.37(2.12,93.58) | 7.65(1.97,22.26) | 0.42(0.06,0.78) | |
| LD ABA IV + MTX | 8.07(2.70,22.51) | 5.62(2.32,12.95) | 0.27(0.11,0.48) | |
| LD ANA SC + MTX | 7.55(1.67,34.99) | 5.28(1.59,14.89) | 0.26(0.04,0.60) | |
| LD CERTO SC + MTX | 15.23(4.36,51.01) | 8.03(3.36,18.78) | 0.43(0.18,0.68) | |
| LD ETN SC + MTX | 13.60(4.08,41.18) | 7.57(3.08,17.26) | 0.40(0.18,0.63) | |
| LD GOLI IV + MTX | 7.88(2.31,27.60) | 5.58(2.03,13.62) | 0.27(0.09,0.53) | |
| LD TOCI IV + MTX | 6.21(2.01,20.21) | 4.64(1.83,11.75) | 0.22(0.06,0.46) | |
| LD TOFA PO + MTX | 13.09(3.10,53.35) | 7.35(2.61,18.10) | 0.39(0.11,0.68) | |
| HD TOCI IV | 10.02(4.58,21.22) | 6.44(3.23,13.55) | 0.32(0.20,0.45) | |
| HD TOFA PO | 10.64(3.51,31.38) | 6.67(2.69,17.25) | 0.34(0.17,0.50) | |
| HD ADA SC | 4.92(1.56,16.41) | 3.95(1.46,11.38) | 0.17(0.05,0.34) | |
| HD ETN SC | 7.30(2.73,21.44) | 5.23(2.30,12.42) | 0.25(0.10,0.47) | |
| HD GOLI SC | 9.78(3.41,28.72) | 6.38(2.68,15.33) | 0.32(0.16,0.52) | |
| HD ABA SC | 14.60(3.02,89.72) | 7.82(2.52,24.97) | 0.42(0.13,0.74) | |
| HD INF IV + MTX | 18.86(7.03,48.19) | 8.96(4.12,19.83) | 0.48(0.29,0.65) | |
| HD TOCI IV + MTX | 17.95(7.14,42.71) | 8.77(4.14,18.85) | 0.47(0.30,0.63) | |
| HD TOFA PO + MTX | 19.49(6.68,52.18) | 9.08(4.03,20.32) | 0.48(0.29,0.67) | |
| HD GOLI SC + MTX | 18.31(6.35,54.48) | 8.80(3.96,20.53) | 0.47(0.27,0.67) | |
| HD CERTO SC + MTX | 25.75(9.86,68.31) | 10.24(4.85,22.45) | 0.56(0.37,0.72) | |
| HD ADA SC + MTX | 21.47(6.23,78.69) | 9.39(4.00,22.26) | 0.51(0.25,0.75) | |
| HD TOCI IV + DMARD | 3.74(1.94,6.85) | 3.16(1.83,5.11) | 0.13(0.04,0.30) | |
| SD ANA SC + SD ETN SC + MTX | 9.84(2.56,36.96) | 6.33(2.21,15.71) | 0.32(0.10,0.60) | |
| SD ANA SC + LD ETN SC + MTX | 14.70(3.90,54.42) | 7.81(2.97,19.10) | 0.42(0.16,0.68) | |
| SD ETN SC | MTX + DMARD | 1.23(0.66,2.37) | 1.16(0.76,1.91) | 0.04(‐0.09,0.16) |
| SD ADA SC | 0.67(0.28,1.68) | 0.74(0.39,1.50) | ‐0.07(‐0.26,0.08) | |
| SD TOFA PO | 1.16(0.39,3.34) | 1.11(0.52,2.43) | 0.03(‐0.19,0.23) | |
| SD GOLI SC | 1.46(0.48,4.22) | 1.29(0.59,2.64) | 0.08(‐0.15,0.32) | |
| SD GOLI IV | 1.15(0.38,3.37) | 1.10(0.48,2.27) | 0.03(‐0.19,0.26) | |
| SD TOCI IV | 0.97(0.38,2.54) | 0.98(0.47,1.95) | ‐0.01(‐0.19,0.18) | |
| SD RITUX IV | 0.45(0.06,2.33) | 0.54(0.08,1.75) | ‐0.12(‐0.33,0.17) | |
| SD ABA SC | 1.81(0.36,10.65) | 1.48(0.47,4.03) | 0.13(‐0.19,0.51) | |
| SD CERTO SC | 1.71(0.39,8.34) | 1.43(0.51,3.69) | 0.11(‐0.18,0.46) | |
| SD ETN SC + MTX | 2.67(1.63,4.24) | 1.83(1.30,2.72) | 0.22(0.11,0.32) | |
| SD INF IV + MTX | 2.00(1.05,3.70) | 1.56(1.03,2.49) | 0.15(0.01,0.28) | |
| SD ABA IV + MTX | 2.61(1.28,5.27) | 1.80(1.15,2.99) | 0.21(0.06,0.37) | |
| SD ADA SC + MTX | 4.11(1.87,9.46) | 2.22(1.38,3.82) | 0.32(0.14,0.50) | |
| SD CERTO SC + MTX/CERTO+MTX | 3.71(1.76,7.84) | 2.13(1.36,3.57) | 0.30(0.13,0.46) | |
| SD RITUX IV + MTX | 1.62(0.75,3.65) | 1.39(0.81,2.43) | 0.10(‐0.06,0.28) | |
| SD TOFA PO + MTX | 4.17(1.85,9.68) | 2.22(1.39,3.87) | 0.33(0.14,0.50) | |
| SD GOLI SC + MTX | 4.13(1.65,9.80) | 2.22(1.31,3.91) | 0.32(0.12,0.50) | |
| SD ABA SC + MTX | 3.24(1.27,8.10) | 2.00(1.16,3.54) | 0.26(0.05,0.46) | |
| SD GOLI IV + MTX | 1.51(0.63,3.81) | 1.32(0.73,2.48) | 0.08(‐0.09,0.29) | |
| SD ANA SC + MTX | 1.92(0.67,5.09) | 1.53(0.75,2.85) | 0.14(‐0.08,0.36) | |
| SD TOCI IV + MTX | 1.35(0.45,4.09) | 1.23(0.55,2.57) | 0.06(‐0.15,0.30) | |
| SD CERTO SC + DMARD | 0.94(0.27,3.22) | 0.96(0.37,2.30) | ‐0.01(‐0.25,0.24) | |
| SD ADA SC + DMARD | 0.56(0.15,2.14) | 0.63(0.20,1.73) | ‐0.09(‐0.30,0.14) | |
| SD ETN SC + DMARD | 2.27(0.78,6.68) | 1.67(0.85,3.24) | 0.18(‐0.05,0.43) | |
| SD TOCI SC + DMARD | 0.88(0.23,3.44) | 0.91(0.31,2.25) | ‐0.02(‐0.25,0.27) | |
| LD ADA SC | 0.61(0.21,1.83) | 0.68(0.30,1.61) | ‐0.08(‐0.29,0.11) | |
| LD ETN SC | 0.62(0.28,1.46) | 0.70(0.37,1.36) | ‐0.08(‐0.24,0.06) | |
| LD GOLI IV | 0.69(0.21,2.31) | 0.75(0.28,1.80) | ‐0.06(‐0.26,0.17) | |
| LD TOCI IV | 0.12(0.02,0.51) | 0.15(0.03,0.56) | ‐0.22(‐0.40,‐0.08) | |
| LD ADA SC + MTX | 2.88(1.20,7.42) | 1.90(1.13,3.38) | 0.24(0.04,0.45) | |
| LD RITUX IV + MTX | 1.42(0.65,3.15) | 1.27(0.74,2.21) | 0.07(‐0.09,0.24) | |
| LD ADA IV + MTX | 2.62(0.40,15.12) | 1.79(0.48,4.13) | 0.21(‐0.15,0.58) | |
| LD ABA IV + MTX | 1.40(0.56,3.39) | 1.26(0.67,2.30) | 0.07(‐0.12,0.26) | |
| LD ANA SC + MTX | 1.30(0.30,5.78) | 1.20(0.38,2.85) | 0.05(‐0.19,0.39) | |
| LD CERTO SC + MTX | 2.63(0.91,8.27) | 1.80(0.94,3.44) | 0.22(‐0.02,0.47) | |
| LD ETN SC + MTX | 2.36(0.92,5.64) | 1.70(0.95,2.92) | 0.19(‐0.02,0.39) | |
| LD GOLI IV + MTX | 1.37(0.45,4.14) | 1.24(0.54,2.52) | 0.06(‐0.15,0.30) | |
| LD TOCI IV + MTX | 1.09(0.34,3.27) | 1.06(0.45,2.25) | 0.02(‐0.20,0.25) | |
| LD TOFA PO + MTX | 2.25(0.57,8.33) | 1.66(0.67,3.40) | 0.18(‐0.10,0.47) | |
| HD TOCI IV | 1.74(0.81,3.70) | 1.45(0.88,2.56) | 0.12(‐0.05,0.27) | |
| HD TOFA PO | 1.85(0.61,5.04) | 1.51(0.73,3.04) | 0.13(‐0.11,0.34) | |
| HD ADA SC | 0.85(0.28,2.57) | 0.89(0.40,2.03) | ‐0.03(‐0.24,0.18) | |
| HD ETN SC | 1.27(0.53,3.13) | 1.18(0.65,2.24) | 0.05(‐0.13,0.24) | |
| HD GOLI SC | 1.70(0.67,4.28) | 1.42(0.77,2.71) | 0.11(‐0.09,0.31) | |
| HD ABA SC | 2.57(0.53,14.69) | 1.79(0.65,4.51) | 0.21(‐0.13,0.57) | |
| HD INF IV + MTX | 3.24(1.55,7.05) | 2.01(1.28,3.40) | 0.27(0.10,0.43) | |
| HD TOCI IV + MTX | 3.12(1.42,6.58) | 1.97(1.22,3.35) | 0.26(0.08,0.42) | |
| HD TOFA PO + MTX | 3.35(1.44,7.78) | 2.04(1.23,3.57) | 0.27(0.09,0.46) | |
| HD GOLI SC + MTX | 3.20(1.30,7.77) | 1.99(1.17,3.54) | 0.26(0.06,0.45) | |
| HD CERTO SC + MTX | 4.47(1.96,10.26) | 2.28(1.43,4.03) | 0.34(0.15,0.51) | |
| HD ADA SC + MTX | 3.73(1.27,11.82) | 2.11(1.15,3.91) | 0.30(0.05,0.54) | |
| HD TOCI IV + DMARD | 0.65(0.20,2.05) | 0.72(0.28,1.69) | ‐0.07(‐0.26,0.15) | |
| SD ANA SC + SD ETN SC + MTX | 1.69(0.56,5.21) | 1.41(0.65,2.74) | 0.11(‐0.11,0.38) | |
| SD ANA SC + LD ETN SC + MTX | 2.53(0.87,7.62) | 1.76(0.91,3.26) | 0.20(‐0.03,0.45) | |
| SD ADA SC | SD ETN SC | 0.54(0.26,1.21) | 0.63(0.37,1.15) | ‐0.11(‐0.26,0.03) |
| SD TOFA PO | 0.94(0.39,2.37) | 0.96(0.51,1.81) | ‐0.01(‐0.20,0.18) | |
| SD GOLI SC | 1.19(0.45,3.22) | 1.13(0.57,2.06) | 0.04(‐0.16,0.27) | |
| SD GOLI IV | 0.94(0.35,2.46) | 0.96(0.44,1.73) | ‐0.01(‐0.19,0.21) | |
| SD TOCI IV | 0.80(0.33,1.87) | 0.85(0.42,1.50) | ‐0.04(‐0.21,0.14) | |
| SD RITUX IV | 0.37(0.05,1.82) | 0.46(0.07,1.45) | ‐0.16(‐0.33,0.14) | |
| SD ABA SC | 1.47(0.32,7.50) | 1.28(0.44,3.01) | 0.09(‐0.21,0.46) | |
| SD CERTO SC | 1.39(0.37,6.41) | 1.24(0.48,2.90) | 0.07(‐0.20,0.42) | |
| SD ETN SC + MTX | 2.17(1.40,3.36) | 1.58(1.23,2.08) | 0.18(0.08,0.29) | |
| SD INF IV + MTX | 1.64(0.92,2.82) | 1.36(0.95,1.89) | 0.11(‐0.02,0.24) | |
| SD ABA IV + MTX | 2.12(1.15,3.75) | 1.56(1.10,2.16) | 0.17(0.03,0.31) | |
| SD ADA SC + MTX | 3.31(1.70,6.75) | 1.91(1.35,2.69) | 0.28(0.12,0.44) | |
| SD CERTO SC + MTX/CERTO+MTX | 3.04(1.63,5.70) | 1.84(1.34,2.61) | 0.26(0.11,0.41) | |
| SD RITUX IV + MTX | 1.32(0.71,2.58) | 1.20(0.78,1.80) | 0.06(‐0.07,0.22) | |
| SD TOFA PO + MTX | 3.40(1.68,7.11) | 1.93(1.35,2.80) | 0.29(0.12,0.45) | |
| SD GOLI SC + MTX | 3.32(1.58,7.24) | 1.91(1.31,2.84) | 0.28(0.10,0.45) | |
| SD ABA SC + MTX | 2.64(1.14,5.82) | 1.73(1.08,2.55) | 0.23(0.03,0.41) | |
| SD GOLI IV + MTX | 1.25(0.57,2.80) | 1.15(0.67,1.88) | 0.05(‐0.11,0.24) | |
| SD ANA SC + MTX | 1.57(0.61,3.87) | 1.34(0.69,2.14) | 0.10(‐0.10,0.31) | |
| SD TOCI IV + MTX | 1.11(0.38,2.98) | 1.07(0.48,1.95) | 0.02(‐0.18,0.25) | |
| SD CERTO SC + DMARD | 0.76(0.25,2.22) | 0.82(0.35,1.67) | ‐0.05(‐0.25,0.18) | |
| SD ADA SC + DMARD | 0.45(0.13,1.55) | 0.54(0.19,1.34) | ‐0.14(‐0.30,0.09) | |
| SD ETN SC + DMARD | 1.85(0.75,4.62) | 1.45(0.83,2.34) | 0.14(‐0.06,0.36) | |
| SD TOCI SC + DMARD | 0.72(0.21,2.47) | 0.79(0.29,1.73) | ‐0.06(‐0.25,0.21) | |
| LD ADA SC | 0.49(0.19,1.33) | 0.59(0.28,1.23) | ‐0.13(‐0.29,0.05) | |
| LD ETN SC | 0.51(0.27,0.93) | 0.61(0.37,0.95) | ‐0.12(‐0.23,‐0.01) | |
| LD GOLI IV | 0.57(0.18,1.64) | 0.66(0.26,1.38) | ‐0.10(‐0.26,0.10) | |
| LD TOCI IV | 0.09(0.02,0.36) | 0.13(0.03,0.45) | ‐0.26(‐0.39,‐0.14) | |
| LD ADA SC + MTX | 2.39(1.11,5.53) | 1.65(1.07,2.47) | 0.20(0.02,0.40) | |
| LD RITUX IV + MTX | 1.17(0.58,2.22) | 1.11(0.68,1.66) | 0.03(‐0.11,0.18) | |
| LD ADA IV + MTX | 2.15(0.35,11.91) | 1.57(0.44,3.05) | 0.18(‐0.17,0.53) | |
| LD ABA IV + MTX | 1.13(0.52,2.52) | 1.09(0.62,1.74) | 0.03(‐0.12,0.21) | |
| LD ANA SC + MTX | 1.07(0.27,4.40) | 1.05(0.34,2.22) | 0.01(‐0.22,0.35) | |
| LD CERTO SC + MTX | 2.15(0.78,5.93) | 1.57(0.84,2.51) | 0.18(‐0.05,0.41) | |
| LD ETN SC + MTX | 1.92(0.79,4.40) | 1.48(0.85,2.26) | 0.15(‐0.05,0.35) | |
| LD GOLI IV + MTX | 1.11(0.40,3.11) | 1.07(0.50,1.95) | 0.02(‐0.17,0.27) | |
| LD TOCI IV + MTX | 0.88(0.31,2.38) | 0.92(0.40,1.72) | ‐0.03(‐0.21,0.20) | |
| LD TOFA PO + MTX | 1.87(0.52,6.29) | 1.46(0.61,2.61) | 0.14(‐0.12,0.42) | |
| HD TOCI IV | 1.41(0.79,2.48) | 1.25(0.86,1.82) | 0.08(‐0.05,0.21) | |
| HD TOFA PO | 1.52(0.60,3.60) | 1.31(0.71,2.27) | 0.09(‐0.11,0.29) | |
| HD ADA SC | 0.69(0.28,1.87) | 0.76(0.40,1.56) | ‐0.07(‐0.25,0.13) | |
| HD ETN SC | 1.04(0.53,2.06) | 1.03(0.63,1.57) | 0.01(‐0.12,0.17) | |
| HD GOLI SC | 1.38(0.63,3.12) | 1.23(0.72,2.01) | 0.07(‐0.10,0.26) | |
| HD ABA SC | 2.11(0.46,10.73) | 1.56(0.58,3.37) | 0.17(‐0.16,0.52) | |
| HD INF IV + MTX | 2.66(1.38,5.23) | 1.74(1.21,2.50) | 0.23(0.07,0.38) | |
| HD TOCI IV + MTX | 2.51(1.36,4.86) | 1.70(1.20,2.49) | 0.22(0.07,0.36) | |
| HD TOFA PO + MTX | 2.73(1.35,5.74) | 1.76(1.21,2.59) | 0.23(0.07,0.40) | |
| HD GOLI SC + MTX | 2.60(1.22,5.76) | 1.72(1.14,2.58) | 0.22(0.04,0.41) | |
| HD CERTO SC + MTX | 3.63(1.87,7.36) | 1.98(1.42,2.86) | 0.31(0.14,0.45) | |
| HD ADA SC + MTX | 3.03(1.06,8.85) | 1.84(1.03,2.87) | 0.26(0.01,0.48) | |
| HD TOCI IV + DMARD | 0.52(0.19,1.50) | 0.62(0.26,1.31) | ‐0.11(‐0.27,0.09) | |
| SD ANA SC + SD ETN SC + MTX | 1.36(0.47,4.22) | 1.22(0.57,2.16) | 0.07(‐0.14,0.34) | |
| SD ANA SC + LD ETN SC + MTX | 2.05(0.69,5.80) | 1.53(0.77,2.52) | 0.17(‐0.07,0.40) | |
| SD TOFA PO | SD ADA SC | 1.73(0.80,3.81) | 1.51(0.85,2.66) | 0.10(‐0.04,0.26) |
| SD GOLI SC | 2.16(0.74,6.48) | 1.75(0.78,3.50) | 0.15(‐0.05,0.39) | |
| SD GOLI IV | 1.73(0.54,5.57) | 1.51(0.61,3.22) | 0.10(‐0.09,0.35) | |
| SD TOCI IV | 1.46(0.57,3.69) | 1.34(0.63,2.60) | 0.07(‐0.09,0.26) | |
| SD RITUX IV | 0.67(0.08,3.59) | 0.72(0.09,2.47) | ‐0.05(‐0.20,0.26) | |
| SD ABA SC | 2.74(0.62,13.53) | 2.03(0.68,4.74) | 0.20(‐0.07,0.55) | |
| SD CERTO SC | 2.59(0.71,10.10) | 1.98(0.76,4.10) | 0.19(‐0.06,0.50) | |
| SD ETN SC + MTX | 3.97(1.77,8.94) | 2.49(1.47,4.16) | 0.29(0.12,0.47) | |
| SD INF IV + MTX | 3.00(1.21,7.15) | 2.13(1.16,3.72) | 0.22(0.04,0.42) | |
| SD ABA IV + MTX | 3.88(1.60,9.17) | 2.46(1.40,4.19) | 0.29(0.09,0.47) | |
| SD ADA SC + MTX | 6.24(2.30,15.44) | 3.04(1.70,4.99) | 0.41(0.17,0.58) | |
| SD CERTO SC + MTX/CERTO+MTX | 5.69(2.20,14.03) | 2.92(1.70,4.87) | 0.38(0.16,0.56) | |
| SD RITUX IV + MTX | 2.46(0.94,5.83) | 1.91(0.95,3.29) | 0.18(‐0.01,0.37) | |
| SD TOFA PO + MTX | 6.34(2.41,15.58) | 3.06(1.76,4.98) | 0.41(0.19,0.59) | |
| SD GOLI SC + MTX | 6.17(2.25,17.16) | 3.03(1.73,5.10) | 0.40(0.17,0.60) | |
| SD ABA SC + MTX | 4.84(1.63,13.02) | 2.74(1.41,4.62) | 0.34(0.10,0.55) | |
| SD GOLI IV + MTX | 2.29(0.81,6.37) | 1.82(0.85,3.44) | 0.16(‐0.03,0.39) | |
| SD ANA SC + MTX | 2.90(0.91,8.36) | 2.10(0.93,3.88) | 0.22(‐0.02,0.46) | |
| SD TOCI IV + MTX | 2.01(0.67,6.11) | 1.67(0.72,3.44) | 0.13(‐0.06,0.39) | |
| SD CERTO SC + DMARD | 1.37(0.47,4.26) | 1.27(0.53,2.75) | 0.05(‐0.11,0.29) | |
| SD ADA SC + DMARD | 0.83(0.20,3.18) | 0.86(0.24,2.33) | ‐0.03(‐0.18,0.22) | |
| SD ETN SC + DMARD | 3.42(1.09,10.90) | 2.31(1.06,4.23) | 0.26(0.01,0.51) | |
| SD TOCI SC + DMARD | 1.32(0.33,5.23) | 1.25(0.39,3.03) | 0.05(‐0.14,0.35) | |
| LD ADA SC | 0.91(0.44,1.87) | 0.92(0.50,1.63) | ‐0.01(‐0.11,0.11) | |
| LD ETN SC | 0.94(0.37,2.19) | 0.95(0.44,1.85) | ‐0.01(‐0.14,0.14) | |
| LD GOLI IV | 1.03(0.29,3.53) | 1.03(0.35,2.47) | 0.01(‐0.15,0.25) | |
| LD TOCI IV | 0.18(0.03,0.73) | 0.21(0.04,0.76) | ‐0.15(‐0.25,‐0.04) | |
| LD ADA SC + MTX | 4.38(1.60,12.11) | 2.63(1.40,4.53) | 0.32(0.10,0.54) | |
| LD RITUX IV + MTX | 2.15(0.81,5.17) | 1.74(0.85,3.15) | 0.15(‐0.04,0.34) | |
| LD ADA IV + MTX | 3.98(0.57,20.80) | 2.50(0.63,4.94) | 0.29(‐0.08,0.63) | |
| LD ABA IV + MTX | 2.09(0.73,5.57) | 1.72(0.78,3.24) | 0.14(‐0.05,0.36) | |
| LD ANA SC + MTX | 1.93(0.41,8.78) | 1.63(0.47,3.77) | 0.12(‐0.11,0.47) | |
| LD CERTO SC + MTX | 3.97(1.19,13.41) | 2.50(1.13,4.56) | 0.29(0.03,0.56) | |
| LD ETN SC + MTX | 3.49(1.19,10.53) | 2.34(1.14,4.20) | 0.26(0.03,0.52) | |
| LD GOLI IV + MTX | 2.02(0.65,6.88) | 1.67(0.71,3.59) | 0.13(‐0.06,0.41) | |
| LD TOCI IV + MTX | 1.63(0.51,4.73) | 1.45(0.57,3.02) | 0.09(‐0.10,0.32) | |
| LD TOFA PO + MTX | 3.39(0.77,13.20) | 2.30(0.81,4.47) | 0.26(‐0.04,0.56) | |
| HD TOCI IV | 2.61(1.25,5.23) | 1.98(1.18,3.19) | 0.19(0.04,0.34) | |
| HD TOFA PO | 2.75(1.23,5.94) | 2.05(1.17,3.40) | 0.20(0.04,0.37) | |
| HD ADA SC | 1.28(0.63,2.69) | 1.21(0.69,2.09) | 0.04(‐0.07,0.19) | |
| HD ETN SC | 1.93(0.72,5.18) | 1.63(0.77,3.17) | 0.12(‐0.05,0.34) | |
| HD GOLI SC | 2.56(0.98,6.77) | 1.94(0.98,3.62) | 0.19(0.00,0.40) | |
| HD ABA SC | 3.84(0.91,19.43) | 2.44(0.94,5.29) | 0.28(‐0.02,0.62) | |
| HD INF IV + MTX | 4.86(1.92,12.96) | 2.74(1.57,4.72) | 0.34(0.13,0.55) | |
| HD TOCI IV + MTX | 4.65(1.91,10.77) | 2.70(1.56,4.51) | 0.33(0.13,0.51) | |
| HD TOFA PO + MTX | 5.09(1.99,12.40) | 2.81(1.58,4.58) | 0.35(0.14,0.54) | |
| HD GOLI SC + MTX | 4.81(1.72,13.21) | 2.73(1.46,4.72) | 0.34(0.11,0.55) | |
| HD CERTO SC + MTX | 6.80(2.61,16.93) | 3.14(1.85,5.20) | 0.42(0.20,0.60) | |
| HD ADA SC + MTX | 5.60(1.70,19.32) | 2.92(1.47,5.02) | 0.38(0.10,0.62) | |
| HD TOCI IV + DMARD | 0.97(0.30,3.08) | 0.98(0.36,2.26) | 0.00(‐0.15,0.22) | |
| SD ANA SC + SD ETN SC + MTX | 2.57(0.75,9.10) | 1.94(0.80,3.91) | 0.19(‐0.05,0.47) | |
| SD ANA SC + LD ETN SC + MTX | 3.84(1.10,12.87) | 2.46(1.08,4.53) | 0.28(0.02,0.55) | |
| SD GOLI SC | SD TOFA PO | 1.28(0.39,3.96) | 1.18(0.51,2.41) | 0.05(‐0.19,0.31) |
| SD GOLI IV | 1.00(0.28,3.34) | 1.00(0.38,2.20) | 0.00(‐0.23,0.27) | |
| SD TOCI IV | 0.83(0.26,2.48) | 0.88(0.37,1.86) | ‐0.04(‐0.25,0.19) | |
| SD RITUX IV | 0.39(0.04,2.29) | 0.48(0.06,1.74) | ‐0.15(‐0.36,0.17) | |
| SD ABA SC | 1.58(0.33,8.35) | 1.34(0.44,3.11) | 0.10(‐0.21,0.48) | |
| SD CERTO SC | 1.51(0.38,6.32) | 1.31(0.50,2.84) | 0.09(‐0.19,0.42) | |
| SD ETN SC + MTX | 2.31(0.88,6.26) | 1.66(0.93,3.01) | 0.19(‐0.03,0.41) | |
| SD INF IV + MTX | 1.72(0.62,4.76) | 1.41(0.73,2.69) | 0.12(‐0.11,0.35) | |
| SD ABA IV + MTX | 2.24(0.80,6.24) | 1.63(0.86,3.03) | 0.19(‐0.05,0.41) | |
| SD ADA SC + MTX | 3.55(1.17,10.48) | 2.01(1.10,3.61) | 0.30(0.04,0.52) | |
| SD CERTO SC + MTX/CERTO+MTX | 3.21(1.12,9.16) | 1.92(1.07,3.46) | 0.28(0.03,0.50) | |
| SD RITUX IV + MTX | 1.42(0.46,3.90) | 1.26(0.59,2.42) | 0.08(‐0.16,0.30) | |
| SD TOFA PO + MTX | 3.60(1.19,10.34) | 2.02(1.11,3.62) | 0.30(0.04,0.52) | |
| SD GOLI SC + MTX | 3.58(1.17,10.70) | 2.01(1.09,3.64) | 0.30(0.04,0.52) | |
| SD ABA SC + MTX | 2.78(0.88,8.76) | 1.81(0.92,3.33) | 0.24(‐0.03,0.49) | |
| SD GOLI IV + MTX | 1.31(0.42,4.18) | 1.19(0.54,2.50) | 0.06(‐0.18,0.32) | |
| SD ANA SC + MTX | 1.64(0.51,5.60) | 1.36(0.62,2.80) | 0.11(‐0.14,0.39) | |
| SD TOCI IV + MTX | 1.17(0.33,4.14) | 1.11(0.44,2.43) | 0.03(‐0.21,0.32) | |
| SD CERTO SC + DMARD | 0.79(0.24,2.75) | 0.85(0.35,1.98) | ‐0.04(‐0.26,0.22) | |
| SD ADA SC + DMARD | 0.47(0.11,2.03) | 0.56(0.16,1.63) | ‐0.13(‐0.33,0.15) | |
| SD ETN SC + DMARD | 1.95(0.56,7.17) | 1.52(0.68,3.07) | 0.15(‐0.13,0.44) | |
| SD TOCI SC + DMARD | 0.77(0.18,3.11) | 0.83(0.25,2.09) | ‐0.05(‐0.28,0.25) | |
| LD ADA SC | 0.52(0.20,1.40) | 0.61(0.29,1.29) | ‐0.11(‐0.29,0.06) | |
| LD ETN SC | 0.54(0.19,1.54) | 0.63(0.28,1.37) | ‐0.11(‐0.29,0.08) | |
| LD GOLI IV | 0.59(0.15,2.28) | 0.68(0.22,1.74) | ‐0.09(‐0.31,0.17) | |
| LD TOCI IV | 0.10(0.01,0.46) | 0.14(0.02,0.53) | ‐0.25(‐0.41,‐0.10) | |
| LD ADA SC + MTX | 2.57(0.85,8.46) | 1.74(0.90,3.31) | 0.22(‐0.04,0.48) | |
| LD RITUX IV + MTX | 1.24(0.40,3.55) | 1.16(0.52,2.31) | 0.05(‐0.18,0.28) | |
| LD ADA IV + MTX | 2.27(0.32,14.64) | 1.64(0.43,3.55) | 0.19(‐0.20,0.57) | |
| LD ABA IV + MTX | 1.21(0.37,3.79) | 1.14(0.50,2.34) | 0.04(‐0.19,0.30) | |
| LD ANA SC + MTX | 1.12(0.22,5.62) | 1.08(0.31,2.73) | 0.02(‐0.25,0.40) | |
| LD CERTO SC + MTX | 2.25(0.63,9.29) | 1.62(0.73,3.32) | 0.19(‐0.10,0.50) | |
| LD ETN SC + MTX | 2.03(0.62,7.04) | 1.55(0.72,3.06) | 0.16(‐0.10,0.44) | |
| LD GOLI IV + MTX | 1.17(0.32,4.45) | 1.11(0.43,2.48) | 0.03(‐0.21,0.33) | |
| LD TOCI IV + MTX | 0.94(0.26,3.11) | 0.96(0.36,2.11) | ‐0.01(‐0.24,0.25) | |
| LD TOFA PO + MTX | 1.95(0.43,8.36) | 1.52(0.52,3.23) | 0.15(‐0.16,0.48) | |
| HD TOCI IV | 1.49(0.60,3.77) | 1.30(0.71,2.41) | 0.09(‐0.12,0.29) | |
| HD TOFA PO | 1.59(0.88,2.79) | 1.35(0.92,1.97) | 0.10(‐0.03,0.23) | |
| HD ADA SC | 0.74(0.27,2.01) | 0.80(0.38,1.65) | ‐0.06(‐0.25,0.14) | |
| HD ETN SC | 1.09(0.37,3.48) | 1.06(0.49,2.27) | 0.02(‐0.19,0.27) | |
| HD GOLI SC | 1.49(0.49,4.16) | 1.30(0.61,2.50) | 0.09(‐0.15,0.32) | |
| HD ABA SC | 2.25(0.47,11.73) | 1.63(0.60,3.46) | 0.19(‐0.15,0.54) | |
| HD INF IV + MTX | 2.79(0.94,8.38) | 1.80(0.96,3.31) | 0.24(‐0.01,0.48) | |
| HD TOCI IV + MTX | 2.70(1.00,7.10) | 1.77(1.00,3.19) | 0.23(0.00,0.44) | |
| HD TOFA PO + MTX | 2.92(1.00,8.04) | 1.84(1.00,3.29) | 0.25(0.00,0.47) | |
| HD GOLI SC + MTX | 2.76(0.89,8.24) | 1.80(0.93,3.29) | 0.24(‐0.03,0.47) | |
| HD CERTO SC + MTX | 3.88(1.33,11.44) | 2.07(1.18,3.68) | 0.32(0.07,0.54) | |
| HD ADA SC + MTX | 3.20(0.82,13.02) | 1.91(0.88,3.63) | 0.27(‐0.05,0.56) | |
| HD TOCI IV + DMARD | 0.56(0.15,2.04) | 0.65(0.22,1.67) | ‐0.10(‐0.31,0.15) | |
| SD ANA SC + SD ETN SC + MTX | 1.47(0.37,6.12) | 1.29(0.49,2.85) | 0.09(‐0.19,0.41) | |
| SD ANA SC + LD ETN SC + MTX | 2.15(0.57,8.30) | 1.59(0.67,3.30) | 0.18(‐0.12,0.48) | |
| SD GOLI IV | SD GOLI SC | 0.79(0.27,2.32) | 0.86(0.40,1.74) | ‐0.05(‐0.27,0.18) |
| SD TOCI IV | 0.66(0.21,2.27) | 0.75(0.34,1.81) | ‐0.09(‐0.34,0.16) | |
| SD RITUX IV | 0.31(0.04,1.82) | 0.41(0.06,1.50) | ‐0.19(‐0.45,0.12) | |
| SD ABA SC | 1.23(0.23,7.46) | 1.14(0.37,3.15) | 0.05(‐0.31,0.46) | |
| SD CERTO SC | 1.17(0.27,5.93) | 1.11(0.42,2.89) | 0.04(‐0.29,0.40) | |
| SD ETN SC + MTX | 1.83(0.66,5.08) | 1.42(0.80,2.76) | 0.14(‐0.10,0.36) | |
| SD INF IV + MTX | 1.38(0.48,3.74) | 1.21(0.65,2.39) | 0.07(‐0.17,0.29) | |
| SD ABA IV + MTX | 1.81(0.63,4.85) | 1.40(0.78,2.69) | 0.14(‐0.11,0.36) | |
| SD ADA SC + MTX | 2.82(0.93,8.79) | 1.71(0.96,3.35) | 0.24(‐0.02,0.49) | |
| SD CERTO SC + MTX/CERTO+MTX | 2.60(0.90,7.38) | 1.65(0.95,3.25) | 0.22(‐0.03,0.45) | |
| SD RITUX IV + MTX | 1.12(0.38,3.30) | 1.07(0.55,2.20) | 0.02(‐0.22,0.26) | |
| SD TOFA PO + MTX | 2.85(0.96,8.93) | 1.72(0.98,3.43) | 0.25(‐0.01,0.49) | |
| SD GOLI SC + MTX | 2.81(1.00,8.35) | 1.71(1.00,3.33) | 0.24(0.00,0.48) | |
| SD ABA SC + MTX | 2.22(0.68,7.31) | 1.55(0.81,3.11) | 0.19(‐0.09,0.45) | |
| SD GOLI IV + MTX | 1.05(0.36,3.21) | 1.03(0.51,2.15) | 0.01(‐0.23,0.25) | |
| SD ANA SC + MTX | 1.31(0.35,4.50) | 1.18(0.52,2.57) | 0.06(‐0.23,0.34) | |
| SD TOCI IV + MTX | 0.93(0.24,3.45) | 0.96(0.37,2.25) | ‐0.02(‐0.31,0.28) | |
| SD CERTO SC + DMARD | 0.64(0.17,2.49) | 0.74(0.29,1.85) | ‐0.09(‐0.37,0.19) | |
| SD ADA SC + DMARD | 0.37(0.08,1.82) | 0.48(0.14,1.52) | ‐0.17(‐0.43,0.12) | |
| SD ETN SC + DMARD | 1.57(0.42,6.01) | 1.30(0.58,2.82) | 0.10(‐0.20,0.41) | |
| SD TOCI SC + DMARD | 0.61(0.13,2.73) | 0.71(0.22,1.87) | ‐0.10(‐0.37,0.21) | |
| LD ADA SC | 0.41(0.13,1.46) | 0.52(0.23,1.33) | ‐0.16(‐0.42,0.06) | |
| LD ETN SC | 0.43(0.14,1.26) | 0.54(0.26,1.19) | ‐0.16(‐0.39,0.04) | |
| LD GOLI IV | 0.48(0.13,1.70) | 0.59(0.22,1.45) | ‐0.14(‐0.38,0.11) | |
| LD TOCI IV | 0.08(0.01,0.41) | 0.12(0.02,0.49) | ‐0.30(‐0.53,‐0.11) | |
| LD ADA SC + MTX | 2.00(0.62,6.80) | 1.47(0.77,3.04) | 0.16(‐0.11,0.43) | |
| LD RITUX IV + MTX | 0.99(0.32,2.88) | 0.99(0.49,2.06) | 0.00(‐0.26,0.23) | |
| LD ADA IV + MTX | 1.79(0.24,12.52) | 1.39(0.34,3.44) | 0.13(‐0.27,0.55) | |
| LD ABA IV + MTX | 0.97(0.31,2.94) | 0.98(0.46,2.08) | ‐0.01(‐0.27,0.24) | |
| LD ANA SC + MTX | 0.91(0.17,4.98) | 0.94(0.27,2.51) | ‐0.02(‐0.34,0.36) | |
| LD CERTO SC + MTX | 1.81(0.47,7.41) | 1.40(0.63,3.14) | 0.14(‐0.17,0.45) | |
| LD ETN SC + MTX | 1.61(0.48,5.33) | 1.32(0.64,2.73) | 0.11(‐0.17,0.38) | |
| LD GOLI IV + MTX | 0.94(0.29,3.21) | 0.96(0.42,2.09) | ‐0.01(‐0.26,0.27) | |
| LD TOCI IV + MTX | 0.74(0.20,2.81) | 0.81(0.32,2.03) | ‐0.06(‐0.33,0.22) | |
| LD TOFA PO + MTX | 1.58(0.33,6.53) | 1.30(0.48,2.88) | 0.10(‐0.23,0.43) | |
| HD TOCI IV | 1.20(0.41,3.21) | 1.12(0.60,2.24) | 0.04(‐0.21,0.25) | |
| HD TOFA PO | 1.26(0.41,4.19) | 1.15(0.59,2.63) | 0.05(‐0.22,0.30) | |
| HD ADA SC | 0.58(0.18,2.03) | 0.69(0.31,1.68) | ‐0.11(‐0.37,0.14) | |
| HD ETN SC | 0.87(0.28,2.82) | 0.91(0.44,2.00) | ‐0.03(‐0.28,0.23) | |
| HD GOLI SC | 1.18(0.48,2.78) | 1.10(0.64,1.98) | 0.04(‐0.17,0.22) | |
| HD ABA SC | 1.76(0.34,10.96) | 1.38(0.50,3.52) | 0.13(‐0.25,0.52) | |
| HD INF IV + MTX | 2.25(0.72,6.53) | 1.56(0.84,3.12) | 0.19(‐0.08,0.42) | |
| HD TOCI IV + MTX | 2.13(0.73,6.30) | 1.52(0.85,3.04) | 0.18(‐0.08,0.41) | |
| HD TOFA PO + MTX | 2.28(0.77,7.15) | 1.57(0.87,3.11) | 0.20(‐0.06,0.44) | |
| HD GOLI SC + MTX | 2.16(0.72,6.83) | 1.52(0.84,3.02) | 0.18(‐0.08,0.44) | |
| HD CERTO SC + MTX | 3.09(1.03,9.34) | 1.78(1.01,3.48) | 0.27(0.01,0.49) | |
| HD ADA SC + MTX | 2.52(0.70,9.68) | 1.63(0.81,3.35) | 0.22(‐0.09,0.51) | |
| HD TOCI IV + DMARD | 0.44(0.11,1.76) | 0.55(0.20,1.47) | ‐0.15(‐0.41,0.11) | |
| SD ANA SC + SD ETN SC + MTX | 1.16(0.27,4.95) | 1.10(0.42,2.57) | 0.03(‐0.28,0.36) | |
| SD ANA SC + LD ETN SC + MTX | 1.79(0.40,7.49) | 1.38(0.56,3.08) | 0.13(‐0.20,0.45) | |
| SD TOCI IV | SD GOLI IV | 0.83(0.26,2.80) | 0.87(0.39,2.13) | ‐0.04(‐0.29,0.19) |
| SD RITUX IV | 0.39(0.05,2.29) | 0.48(0.07,1.73) | ‐0.14(‐0.40,0.16) | |
| SD ABA SC | 1.63(0.26,9.41) | 1.37(0.40,3.98) | 0.10(‐0.27,0.49) | |
| SD CERTO SC | 1.48(0.32,8.09) | 1.29(0.46,3.71) | 0.09(‐0.24,0.44) | |
| SD ETN SC + MTX | 2.28(0.88,6.42) | 1.64(0.94,3.63) | 0.19(‐0.03,0.39) | |
| SD INF IV + MTX | 1.70(0.67,4.67) | 1.40(0.79,2.89) | 0.12(‐0.10,0.33) | |
| SD ABA IV + MTX | 2.24(0.87,6.17) | 1.63(0.93,3.39) | 0.18(‐0.03,0.39) | |
| SD ADA SC + MTX | 3.55(1.26,10.41) | 1.99(1.12,4.15) | 0.29(0.06,0.51) | |
| SD CERTO SC + MTX/CERTO+MTX | 3.21(1.20,8.69) | 1.92(1.09,4.00) | 0.27(0.04,0.47) | |
| SD RITUX IV + MTX | 1.41(0.50,4.00) | 1.26(0.65,2.66) | 0.07(‐0.16,0.28) | |
| SD TOFA PO + MTX | 3.55(1.29,10.77) | 2.00(1.12,4.38) | 0.29(0.06,0.51) | |
| SD GOLI SC + MTX | 3.56(1.23,10.36) | 1.99(1.11,4.27) | 0.29(0.05,0.51) | |
| SD ABA SC + MTX | 2.72(0.91,9.50) | 1.79(0.94,3.99) | 0.23(‐0.02,0.49) | |
| SD GOLI IV + MTX | 1.31(0.54,3.34) | 1.19(0.68,2.33) | 0.06(‐0.13,0.25) | |
| SD ANA SC + MTX | 1.67(0.49,5.35) | 1.37(0.64,3.00) | 0.11(‐0.16,0.36) | |
| SD TOCI IV + MTX | 1.19(0.31,4.64) | 1.12(0.44,2.77) | 0.03(‐0.24,0.32) | |
| SD CERTO SC + DMARD | 0.79(0.20,3.39) | 0.85(0.32,2.40) | ‐0.04(‐0.33,0.24) | |
| SD ADA SC + DMARD | 0.48(0.11,2.21) | 0.58(0.17,1.78) | ‐0.12(‐0.39,0.15) | |
| SD ETN SC + DMARD | 1.96(0.55,7.94) | 1.51(0.68,3.70) | 0.15(‐0.13,0.44) | |
| SD TOCI SC + DMARD | 0.79(0.17,3.47) | 0.84(0.25,2.36) | ‐0.04(‐0.33,0.26) | |
| LD ADA SC | 0.52(0.14,1.85) | 0.61(0.25,1.66) | ‐0.11(‐0.38,0.10) | |
| LD ETN SC | 0.54(0.19,1.60) | 0.63(0.30,1.47) | ‐0.11(‐0.33,0.07) | |
| LD GOLI IV | 0.59(0.21,1.72) | 0.68(0.29,1.48) | ‐0.09(‐0.29,0.10) | |
| LD TOCI IV | 0.10(0.02,0.49) | 0.14(0.03,0.56) | ‐0.25(‐0.49,‐0.07) | |
| LD ADA SC + MTX | 2.49(0.83,7.83) | 1.72(0.90,3.79) | 0.21(‐0.04,0.45) | |
| LD RITUX IV + MTX | 1.24(0.43,3.66) | 1.16(0.59,2.45) | 0.04(‐0.19,0.26) | |
| LD ADA IV + MTX | 2.30(0.30,14.83) | 1.62(0.41,4.17) | 0.18(‐0.23,0.57) | |
| LD ABA IV + MTX | 1.21(0.41,3.57) | 1.13(0.56,2.47) | 0.04(‐0.19,0.26) | |
| LD ANA SC + MTX | 1.12(0.23,5.89) | 1.07(0.34,2.99) | 0.02(‐0.27,0.39) | |
| LD CERTO SC + MTX | 2.26(0.63,8.62) | 1.62(0.75,3.71) | 0.18(‐0.10,0.47) | |
| LD ETN SC + MTX | 2.03(0.63,7.01) | 1.53(0.76,3.42) | 0.16(‐0.10,0.41) | |
| LD GOLI IV + MTX | 1.18(0.46,3.15) | 1.12(0.57,2.25) | 0.03(‐0.16,0.25) | |
| LD TOCI IV + MTX | 0.94(0.26,3.34) | 0.96(0.38,2.39) | ‐0.01(‐0.27,0.25) | |
| LD TOFA PO + MTX | 2.02(0.44,8.07) | 1.51(0.56,3.52) | 0.15(‐0.17,0.46) | |
| HD TOCI IV | 1.50(0.54,4.28) | 1.30(0.71,2.87) | 0.09(‐0.14,0.29) | |
| HD TOFA PO | 1.60(0.48,5.54) | 1.36(0.65,3.33) | 0.10(‐0.17,0.34) | |
| HD ADA SC | 0.73(0.21,2.66) | 0.80(0.34,2.12) | ‐0.06(‐0.33,0.17) | |
| HD ETN SC | 1.09(0.37,3.65) | 1.06(0.52,2.44) | 0.02(‐0.22,0.26) | |
| HD GOLI SC | 1.47(0.51,4.28) | 1.29(0.67,2.79) | 0.08(‐0.15,0.30) | |
| HD ABA SC | 2.28(0.36,13.60) | 1.62(0.52,4.64) | 0.18(‐0.22,0.56) | |
| HD INF IV + MTX | 2.77(1.02,8.60) | 1.80(1.01,3.88) | 0.23(0.01,0.46) | |
| HD TOCI IV + MTX | 2.69(0.97,7.55) | 1.78(0.99,3.80) | 0.23(‐0.01,0.44) | |
| HD TOFA PO + MTX | 2.88(1.00,8.48) | 1.83(1.00,3.88) | 0.24(0.00,0.47) | |
| HD GOLI SC + MTX | 2.74(0.95,8.32) | 1.78(0.97,3.84) | 0.23(‐0.01,0.47) | |
| HD CERTO SC + MTX | 3.91(1.39,11.12) | 2.06(1.18,4.46) | 0.31(0.08,0.52) | |
| HD ADA SC + MTX | 3.20(0.89,12.30) | 1.90(0.93,4.33) | 0.26(‐0.03,0.54) | |
| HD TOCI IV + DMARD | 0.55(0.14,2.36) | 0.64(0.23,1.86) | ‐0.10(‐0.36,0.15) | |
| SD ANA SC + SD ETN SC + MTX | 1.46(0.38,6.28) | 1.28(0.50,3.21) | 0.08(‐0.21,0.40) | |
| SD ANA SC + LD ETN SC + MTX | 2.17(0.55,8.79) | 1.59(0.66,3.83) | 0.18(‐0.13,0.47) | |
| SD RITUX IV | SD TOCI IV | 0.45(0.06,2.62) | 0.54(0.08,1.98) | ‐0.12(‐0.33,0.20) |
| SD ABA SC | 1.83(0.36,11.86) | 1.48(0.46,4.33) | 0.13(‐0.20,0.53) | |
| SD CERTO SC | 1.75(0.41,9.08) | 1.45(0.52,3.98) | 0.12(‐0.18,0.47) | |
| SD ETN SC + MTX | 2.71(1.13,6.78) | 1.86(1.08,3.65) | 0.22(0.03,0.40) | |
| SD INF IV + MTX | 2.07(0.83,5.17) | 1.60(0.89,3.10) | 0.16(‐0.04,0.34) | |
| SD ABA IV + MTX | 2.66(1.08,6.74) | 1.83(1.05,3.55) | 0.22(0.02,0.41) | |
| SD ADA SC + MTX | 4.19(1.58,11.07) | 2.25(1.29,4.30) | 0.32(0.11,0.53) | |
| SD CERTO SC + MTX/CERTO+MTX | 3.84(1.57,9.46) | 2.17(1.27,4.19) | 0.31(0.10,0.49) | |
| SD RITUX IV + MTX | 1.67(0.63,4.23) | 1.42(0.73,2.79) | 0.11(‐0.09,0.30) | |
| SD TOFA PO + MTX | 4.31(1.65,11.31) | 2.27(1.30,4.39) | 0.33(0.12,0.52) | |
| SD GOLI SC + MTX | 4.24(1.56,11.54) | 2.27(1.29,4.37) | 0.33(0.10,0.53) | |
| SD ABA SC + MTX | 3.33(1.10,9.34) | 2.05(1.06,3.99) | 0.27(0.02,0.49) | |
| SD GOLI IV + MTX | 1.58(0.54,4.50) | 1.36(0.65,2.81) | 0.09(‐0.13,0.32) | |
| SD ANA SC + MTX | 1.98(0.63,5.86) | 1.56(0.72,3.19) | 0.14(‐0.10,0.39) | |
| SD TOCI IV + MTX | 1.40(0.50,3.81) | 1.25(0.60,2.54) | 0.07(‐0.14,0.29) | |
| SD CERTO SC + DMARD | 0.95(0.28,3.40) | 0.96(0.39,2.42) | ‐0.01(‐0.24,0.24) | |
| SD ADA SC + DMARD | 0.56(0.14,2.34) | 0.64(0.20,1.82) | ‐0.09(‐0.30,0.16) | |
| SD ETN SC + DMARD | 2.36(0.67,8.14) | 1.72(0.76,3.69) | 0.19(‐0.08,0.46) | |
| SD TOCI SC + DMARD | 0.90(0.23,3.50) | 0.92(0.31,2.34) | ‐0.02(‐0.24,0.26) | |
| LD ADA SC | 0.62(0.21,2.00) | 0.69(0.30,1.73) | ‐0.08(‐0.28,0.11) | |
| LD ETN SC | 0.65(0.24,1.74) | 0.71(0.35,1.55) | ‐0.07(‐0.26,0.09) | |
| LD GOLI IV | 0.71(0.18,2.55) | 0.77(0.25,1.98) | ‐0.06(‐0.27,0.18) | |
| LD TOCI IV | 0.12(0.02,0.49) | 0.16(0.03,0.56) | ‐0.21(‐0.39,‐0.08) | |
| LD ADA SC + MTX | 3.01(1.09,8.51) | 1.94(1.06,3.83) | 0.25(0.02,0.46) | |
| LD RITUX IV + MTX | 1.46(0.56,3.80) | 1.29(0.67,2.59) | 0.08(‐0.12,0.27) | |
| LD ADA IV + MTX | 2.72(0.38,15.97) | 1.84(0.47,4.52) | 0.22(‐0.16,0.59) | |
| LD ABA IV + MTX | 1.44(0.51,3.84) | 1.28(0.61,2.59) | 0.07(‐0.14,0.29) | |
| LD ANA SC + MTX | 1.33(0.29,6.67) | 1.21(0.39,3.19) | 0.06(‐0.21,0.42) | |
| LD CERTO SC + MTX | 2.71(0.81,8.99) | 1.85(0.86,3.92) | 0.22(‐0.05,0.48) | |
| LD ETN SC + MTX | 2.42(0.75,7.25) | 1.74(0.82,3.62) | 0.19(‐0.06,0.43) | |
| LD GOLI IV + MTX | 1.40(0.40,4.77) | 1.27(0.52,2.90) | 0.07(‐0.18,0.34) | |
| LD TOCI IV + MTX | 1.12(0.39,3.10) | 1.08(0.49,2.23) | 0.02(‐0.17,0.24) | |
| LD TOFA PO + MTX | 2.34(0.53,9.11) | 1.71(0.64,3.72) | 0.19(‐0.12,0.49) | |
| HD TOCI IV | 1.79(0.85,3.71) | 1.48(0.91,2.63) | 0.12(‐0.04,0.26) | |
| HD TOFA PO | 1.91(0.63,5.76) | 1.53(0.75,3.39) | 0.14(‐0.10,0.35) | |
| HD ADA SC | 0.88(0.29,2.73) | 0.91(0.40,2.16) | ‐0.02(‐0.24,0.18) | |
| HD ETN SC | 1.29(0.46,4.11) | 1.20(0.57,2.74) | 0.05(‐0.16,0.29) | |
| HD GOLI SC | 1.75(0.59,4.93) | 1.46(0.71,3.02) | 0.12(‐0.11,0.33) | |
| HD ABA SC | 2.61(0.48,16.78) | 1.80(0.61,5.00) | 0.21(‐0.15,0.59) | |
| HD INF IV + MTX | 3.35(1.30,8.69) | 2.04(1.17,3.95) | 0.27(0.06,0.47) | |
| HD TOCI IV + MTX | 3.21(1.43,7.28) | 2.00(1.23,3.67) | 0.26(0.09,0.43) | |
| HD TOFA PO + MTX | 3.44(1.27,9.02) | 2.07(1.15,4.09) | 0.28(0.06,0.48) | |
| HD GOLI SC + MTX | 3.33(1.18,9.47) | 2.03(1.10,4.00) | 0.27(0.04,0.49) | |
| HD CERTO SC + MTX | 4.62(1.78,11.81) | 2.33(1.35,4.50) | 0.35(0.14,0.54) | |
| HD ADA SC + MTX | 3.85(1.10,12.74) | 2.16(1.06,4.37) | 0.30(0.02,0.55) | |
| HD TOCI IV + DMARD | 0.66(0.21,2.26) | 0.72(0.28,1.82) | ‐0.07(‐0.27,0.16) | |
| SD ANA SC + SD ETN SC + MTX | 1.74(0.48,6.36) | 1.46(0.59,3.25) | 0.12(‐0.14,0.41) | |
| SD ANA SC + LD ETN SC + MTX | 2.63(0.69,9.59) | 1.82(0.77,3.86) | 0.21(‐0.08,0.48) | |
| SD ABA SC | SD RITUX IV | 4.21(0.44,42.54) | 2.76(0.56,19.85) | 0.25(‐0.16,0.61) |
| SD CERTO SC | 3.74(0.53,50.05) | 2.65(0.64,23.72) | 0.23(‐0.13,0.57) | |
| SD ETN SC + MTX | 5.89(1.18,42.29) | 3.44(1.09,22.67) | 0.34(0.04,0.53) | |
| SD INF IV + MTX | 4.43(0.91,31.70) | 2.94(0.95,18.79) | 0.26(‐0.02,0.47) | |
| SD ABA IV + MTX | 5.80(1.18,40.44) | 3.41(1.10,21.64) | 0.33(0.04,0.55) | |
| SD ADA SC + MTX | 8.90(1.82,65.79) | 4.09(1.35,26.12) | 0.43(0.14,0.66) | |
| SD CERTO SC + MTX/CERTO+MTX | 8.30(1.68,59.65) | 4.00(1.29,26.59) | 0.42(0.12,0.62) | |
| SD RITUX IV + MTX | 3.56(0.84,23.14) | 2.57(0.90,15.84) | 0.22(‐0.04,0.42) | |
| SD TOFA PO + MTX | 9.40(1.74,68.15) | 4.19(1.31,28.09) | 0.44(0.13,0.65) | |
| SD GOLI SC + MTX | 9.13(1.73,70.86) | 4.15(1.30,28.21) | 0.44(0.13,0.66) | |
| SD ABA SC + MTX | 7.12(1.31,53.91) | 3.73(1.18,24.59) | 0.37(0.06,0.62) | |
| SD GOLI IV + MTX | 3.47(0.62,25.53) | 2.49(0.73,16.35) | 0.21(‐0.10,0.45) | |
| SD ANA SC + MTX | 4.30(0.69,35.24) | 2.88(0.81,19.26) | 0.26(‐0.08,0.51) | |
| SD TOCI IV + MTX | 3.03(0.48,24.29) | 2.31(0.60,15.65) | 0.18(‐0.15,0.46) | |
| SD CERTO SC + DMARD | 2.06(0.34,19.39) | 1.77(0.45,13.85) | 0.11(‐0.22,0.35) | |
| SD ADA SC + DMARD | 1.26(0.18,10.65) | 1.21(0.25,8.40) | 0.03(‐0.28,0.27) | |
| SD ETN SC + DMARD | 5.13(0.82,40.39) | 3.16(0.90,22.15) | 0.29(‐0.04,0.58) | |
| SD TOCI SC + DMARD | 1.96(0.28,17.69) | 1.69(0.38,11.57) | 0.09(‐0.22,0.40) | |
| LD ADA SC | 1.34(0.23,11.47) | 1.27(0.33,9.14) | 0.04(‐0.28,0.22) | |
| LD ETN SC | 1.39(0.26,10.49) | 1.31(0.38,8.58) | 0.04(‐0.26,0.21) | |
| LD GOLI IV | 1.55(0.24,12.86) | 1.43(0.34,9.67) | 0.06(‐0.25,0.30) | |
| LD TOCI IV | 0.26(0.03,2.85) | 0.30(0.04,2.65) | ‐0.09(‐0.40,0.05) | |
| LD ADA SC + MTX | 6.43(1.26,49.13) | 3.54(1.14,24.27) | 0.36(0.05,0.61) | |
| LD RITUX IV + MTX | 3.16(0.66,21.59) | 2.40(0.77,15.27) | 0.19(‐0.09,0.39) | |
| LD ADA IV + MTX | 5.98(0.47,90.52) | 3.31(0.58,25.83) | 0.33(‐0.13,0.73) | |
| LD ABA IV + MTX | 3.14(0.60,22.91) | 2.37(0.71,15.40) | 0.19(‐0.11,0.42) | |
| LD ANA SC + MTX | 2.97(0.35,27.99) | 2.24(0.47,15.55) | 0.17(‐0.18,0.53) | |
| LD CERTO SC + MTX | 6.02(0.94,48.13) | 3.42(0.97,23.32) | 0.33(‐0.01,0.61) | |
| LD ETN SC + MTX | 5.25(0.87,42.64) | 3.19(0.92,22.59) | 0.30(‐0.03,0.56) | |
| LD GOLI IV + MTX | 3.07(0.50,25.30) | 2.31(0.62,16.01) | 0.18(‐0.14,0.46) | |
| LD TOCI IV + MTX | 2.37(0.42,19.76) | 1.96(0.53,13.70) | 0.13(‐0.17,0.41) | |
| LD TOFA PO + MTX | 5.16(0.70,44.64) | 3.14(0.79,21.06) | 0.29(‐0.07,0.61) | |
| HD TOCI IV | 3.77(0.81,28.69) | 2.71(0.88,17.89) | 0.23(‐0.05,0.42) | |
| HD TOFA PO | 4.12(0.70,39.19) | 2.85(0.81,21.72) | 0.25(‐0.08,0.47) | |
| HD ADA SC | 1.90(0.32,18.13) | 1.67(0.46,13.74) | 0.09(‐0.22,0.30) | |
| HD ETN SC | 2.85(0.49,21.62) | 2.25(0.63,14.83) | 0.17(‐0.15,0.39) | |
| HD GOLI SC | 3.77(0.70,28.57) | 2.68(0.81,18.53) | 0.23(‐0.08,0.45) | |
| HD ABA SC | 6.03(0.63,63.43) | 3.37(0.73,24.85) | 0.33(‐0.10,0.67) | |
| HD INF IV + MTX | 7.28(1.39,51.14) | 3.77(1.19,23.86) | 0.39(0.07,0.60) | |
| HD TOCI IV + MTX | 6.83(1.35,52.63) | 3.68(1.17,25.31) | 0.37(0.07,0.58) | |
| HD TOFA PO + MTX | 7.46(1.37,56.14) | 3.85(1.18,26.06) | 0.39(0.07,0.61) | |
| HD GOLI SC + MTX | 7.03(1.24,55.18) | 3.72(1.12,25.45) | 0.38(0.05,0.62) | |
| HD CERTO SC + MTX | 10.00(1.95,75.46) | 4.32(1.39,30.12) | 0.46(0.16,0.67) | |
| HD ADA SC + MTX | 8.21(1.51,71.89) | 3.95(1.21,26.17) | 0.41(0.09,0.69) | |
| HD TOCI IV + DMARD | 1.42(0.23,11.64) | 1.33(0.32,9.34) | 0.05(‐0.27,0.27) | |
| SD ANA SC + SD ETN SC + MTX | 3.78(0.55,31.04) | 2.64(0.68,18.20) | 0.22(‐0.11,0.54) | |
| SD ANA SC + LD ETN SC + MTX | 5.70(0.81,44.18) | 3.32(0.88,21.37) | 0.32(‐0.05,0.62) | |
| SD CERTO SC | SD ABA SC | 0.95(0.15,6.00) | 0.97(0.34,3.23) | ‐0.01(‐0.43,0.39) |
| SD ETN SC + MTX | 1.47(0.27,6.88) | 1.23(0.55,3.54) | 0.09(‐0.31,0.42) | |
| SD INF IV + MTX | 1.12(0.19,5.26) | 1.07(0.45,3.10) | 0.03(‐0.38,0.35) | |
| SD ABA IV + MTX | 1.44(0.26,7.18) | 1.22(0.52,3.63) | 0.09(‐0.32,0.42) | |
| SD ADA SC + MTX | 2.31(0.39,11.64) | 1.50(0.68,4.33) | 0.20(‐0.22,0.54) | |
| SD CERTO SC + MTX/CERTO+MTX | 2.07(0.36,10.29) | 1.45(0.64,4.08) | 0.18(‐0.24,0.51) | |
| SD RITUX IV + MTX | 0.90(0.16,4.50) | 0.94(0.37,2.87) | ‐0.02(‐0.42,0.31) | |
| SD TOFA PO + MTX | 2.36(0.39,12.22) | 1.52(0.68,4.38) | 0.20(‐0.21,0.54) | |
| SD GOLI SC + MTX | 2.32(0.39,11.59) | 1.49(0.67,4.31) | 0.20(‐0.22,0.53) | |
| SD ABA SC + MTX | 1.80(0.30,9.81) | 1.35(0.58,3.94) | 0.14(‐0.29,0.50) | |
| SD GOLI IV + MTX | 0.86(0.14,4.71) | 0.91(0.33,2.85) | ‐0.03(‐0.44,0.32) | |
| SD ANA SC + MTX | 1.05(0.16,6.47) | 1.03(0.37,3.30) | 0.01(‐0.42,0.39) | |
| SD TOCI IV + MTX | 0.75(0.11,4.27) | 0.83(0.28,2.71) | ‐0.06(‐0.48,0.31) | |
| SD CERTO SC + DMARD | 0.52(0.08,2.85) | 0.64(0.22,2.10) | ‐0.14(‐0.53,0.20) | |
| SD ADA SC + DMARD | 0.30(0.04,2.06) | 0.43(0.09,1.69) | ‐0.22(‐0.59,0.14) | |
| SD ETN SC + DMARD | 1.27(0.19,7.51) | 1.14(0.42,3.60) | 0.06(‐0.37,0.44) | |
| SD TOCI SC + DMARD | 0.49(0.06,3.27) | 0.62(0.16,2.25) | ‐0.14(‐0.56,0.25) | |
| LD ADA SC | 0.34(0.06,1.56) | 0.46(0.18,1.42) | ‐0.21(‐0.57,0.07) | |
| LD ETN SC | 0.35(0.06,1.72) | 0.48(0.18,1.52) | ‐0.20(‐0.57,0.09) | |
| LD GOLI IV | 0.38(0.05,2.21) | 0.51(0.14,1.80) | ‐0.19(‐0.59,0.15) | |
| LD TOCI IV | 0.06(0.01,0.47) | 0.10(0.02,0.54) | ‐0.35(‐0.69,‐0.08) | |
| LD ADA SC + MTX | 1.60(0.27,8.88) | 1.29(0.55,3.76) | 0.11(‐0.31,0.47) | |
| LD RITUX IV + MTX | 0.81(0.14,4.00) | 0.87(0.33,2.63) | ‐0.05(‐0.44,0.28) | |
| LD ADA IV + MTX | 1.49(0.12,14.01) | 1.23(0.26,4.12) | 0.09(‐0.45,0.56) | |
| LD ABA IV + MTX | 0.79(0.12,4.23) | 0.86(0.30,2.68) | ‐0.05(‐0.46,0.31) | |
| LD ANA SC + MTX | 0.72(0.09,6.25) | 0.82(0.19,3.03) | ‐0.07(‐0.52,0.40) | |
| LD CERTO SC + MTX | 1.44(0.22,9.13) | 1.21(0.44,3.75) | 0.09(‐0.35,0.48) | |
| LD ETN SC + MTX | 1.30(0.21,7.28) | 1.15(0.45,3.50) | 0.06(‐0.36,0.42) | |
| LD GOLI IV + MTX | 0.75(0.11,4.54) | 0.84(0.28,2.79) | ‐0.06(‐0.47,0.32) | |
| LD TOCI IV + MTX | 0.60(0.09,3.57) | 0.72(0.23,2.38) | ‐0.11(‐0.52,0.26) | |
| LD TOFA PO + MTX | 1.25(0.16,9.65) | 1.13(0.34,3.72) | 0.05(‐0.42,0.48) | |
| HD TOCI IV | 0.96(0.17,4.48) | 0.98(0.41,2.89) | ‐0.01(‐0.41,0.30) | |
| HD TOFA PO | 1.02(0.20,4.82) | 1.01(0.45,2.95) | 0.00(‐0.37,0.32) | |
| HD ADA SC | 0.47(0.09,2.27) | 0.59(0.24,1.83) | ‐0.16(‐0.53,0.15) | |
| HD ETN SC | 0.69(0.12,3.76) | 0.79(0.30,2.55) | ‐0.08(‐0.46,0.27) | |
| HD GOLI SC | 0.96(0.16,4.86) | 0.97(0.38,2.96) | ‐0.01(‐0.42,0.33) | |
| HD ABA SC | 1.41(0.50,4.38) | 1.19(0.67,2.49) | 0.08(‐0.16,0.33) | |
| HD INF IV + MTX | 1.83(0.31,9.05) | 1.36(0.59,3.92) | 0.14(‐0.28,0.48) | |
| HD TOCI IV + MTX | 1.75(0.29,8.75) | 1.34(0.57,3.87) | 0.13(‐0.29,0.46) | |
| HD TOFA PO + MTX | 1.86(0.31,9.51) | 1.38(0.60,3.99) | 0.15(‐0.28,0.49) | |
| HD GOLI SC + MTX | 1.78(0.29,9.95) | 1.35(0.57,4.08) | 0.14(‐0.29,0.48) | |
| HD CERTO SC + MTX | 2.46(0.44,13.05) | 1.55(0.72,4.43) | 0.22(‐0.19,0.55) | |
| HD ADA SC + MTX | 2.07(0.31,11.93) | 1.43(0.57,4.07) | 0.17(‐0.27,0.54) | |
| HD TOCI IV + DMARD | 0.36(0.05,2.15) | 0.49(0.13,1.73) | ‐0.19(‐0.59,0.15) | |
| SD ANA SC + SD ETN SC + MTX | 0.95(0.14,5.66) | 0.97(0.32,2.91) | ‐0.01(‐0.43,0.38) | |
| SD ANA SC + LD ETN SC + MTX | 1.40(0.21,8.53) | 1.20(0.43,3.59) | 0.08(‐0.36,0.47) | |
| SD ETN SC + MTX | SD CERTO SC | 1.55(0.35,6.31) | 1.28(0.58,3.21) | 0.10(‐0.26,0.41) |
| SD INF IV + MTX | 1.18(0.23,4.70) | 1.10(0.45,2.78) | 0.04(‐0.35,0.33) | |
| SD ABA IV + MTX | 1.55(0.28,6.56) | 1.28(0.53,3.25) | 0.10(‐0.30,0.41) | |
| SD ADA SC + MTX | 2.43(0.44,10.13) | 1.55(0.69,3.86) | 0.21(‐0.20,0.51) | |
| SD CERTO SC + MTX/CERTO+MTX | 2.25(0.41,9.25) | 1.51(0.67,3.78) | 0.19(‐0.21,0.49) | |
| SD RITUX IV + MTX | 0.95(0.19,3.97) | 0.97(0.39,2.56) | ‐0.01(‐0.38,0.29) | |
| SD TOFA PO + MTX | 2.46(0.45,10.50) | 1.56(0.71,3.83) | 0.22(‐0.19,0.52) | |
| SD GOLI SC + MTX | 2.43(0.47,10.61) | 1.56(0.72,3.91) | 0.21(‐0.18,0.51) | |
| SD ABA SC + MTX | 1.90(0.35,8.57) | 1.40(0.59,3.58) | 0.15(‐0.25,0.47) | |
| SD GOLI IV + MTX | 0.91(0.17,3.93) | 0.94(0.35,2.50) | ‐0.02(‐0.41,0.29) | |
| SD ANA SC + MTX | 1.13(0.19,5.17) | 1.07(0.38,2.87) | 0.03(‐0.38,0.36) | |
| SD TOCI IV + MTX | 0.79(0.14,4.01) | 0.86(0.29,2.49) | ‐0.05(‐0.44,0.31) | |
| SD CERTO SC + DMARD | 0.54(0.11,2.40) | 0.66(0.24,1.83) | ‐0.13(‐0.48,0.18) | |
| SD ADA SC + DMARD | 0.33(0.04,1.71) | 0.45(0.10,1.48) | ‐0.20(‐0.56,0.10) | |
| SD ETN SC + DMARD | 1.34(0.22,6.51) | 1.18(0.45,3.07) | 0.07(‐0.34,0.41) | |
| SD TOCI SC + DMARD | 0.54(0.07,2.78) | 0.65(0.17,1.93) | ‐0.13(‐0.52,0.21) | |
| LD ADA SC | 0.35(0.08,1.39) | 0.47(0.20,1.29) | ‐0.20(‐0.52,0.06) | |
| LD ETN SC | 0.37(0.08,1.51) | 0.49(0.18,1.36) | ‐0.19(‐0.52,0.07) | |
| LD GOLI IV | 0.40(0.07,2.05) | 0.54(0.16,1.66) | ‐0.18(‐0.52,0.15) | |
| LD TOCI IV | 0.07(0.01,0.43) | 0.11(0.02,0.51) | ‐0.34(‐0.64,‐0.10) | |
| LD ADA SC + MTX | 1.71(0.30,7.31) | 1.34(0.56,3.27) | 0.13(‐0.28,0.44) | |
| LD RITUX IV + MTX | 0.85(0.15,3.42) | 0.90(0.34,2.34) | ‐0.04(‐0.42,0.26) | |
| LD ADA IV + MTX | 1.55(0.14,13.76) | 1.26(0.27,3.74) | 0.10(‐0.42,0.56) | |
| LD ABA IV + MTX | 0.83(0.15,3.60) | 0.89(0.31,2.39) | ‐0.04(‐0.43,0.27) | |
| LD ANA SC + MTX | 0.79(0.09,5.35) | 0.86(0.20,2.60) | ‐0.05(‐0.47,0.37) | |
| LD CERTO SC + MTX | 1.57(0.25,7.88) | 1.28(0.47,3.40) | 0.11(‐0.32,0.46) | |
| LD ETN SC + MTX | 1.37(0.24,6.67) | 1.20(0.45,3.19) | 0.07(‐0.33,0.42) | |
| LD GOLI IV + MTX | 0.79(0.13,3.92) | 0.87(0.29,2.49) | ‐0.05(‐0.44,0.30) | |
| LD TOCI IV + MTX | 0.65(0.11,3.09) | 0.75(0.24,2.14) | ‐0.09(‐0.47,0.24) | |
| LD TOFA PO + MTX | 1.38(0.18,7.25) | 1.19(0.37,3.12) | 0.07(‐0.38,0.44) | |
| HD TOCI IV | 1.03(0.22,3.76) | 1.02(0.45,2.52) | 0.01(‐0.36,0.27) | |
| HD TOFA PO | 1.06(0.26,4.30) | 1.04(0.50,2.66) | 0.01(‐0.32,0.30) | |
| HD ADA SC | 0.49(0.12,2.09) | 0.62(0.27,1.69) | ‐0.15(‐0.46,0.14) | |
| HD ETN SC | 0.75(0.14,3.26) | 0.83(0.31,2.31) | ‐0.06(‐0.44,0.24) | |
| HD GOLI SC | 1.01(0.20,4.04) | 1.01(0.41,2.60) | 0.00(‐0.37,0.30) | |
| HD ABA SC | 1.49(0.25,9.40) | 1.25(0.44,3.33) | 0.09(‐0.31,0.50) | |
| HD INF IV + MTX | 1.89(0.38,7.69) | 1.40(0.63,3.47) | 0.15(‐0.24,0.45) | |
| HD TOCI IV + MTX | 1.79(0.38,7.48) | 1.37(0.63,3.45) | 0.14(‐0.23,0.44) | |
| HD TOFA PO + MTX | 1.95(0.38,8.22) | 1.42(0.63,3.60) | 0.16(‐0.23,0.47) | |
| HD GOLI SC + MTX | 1.87(0.33,8.17) | 1.39(0.58,3.65) | 0.15(‐0.26,0.46) | |
| HD CERTO SC + MTX | 2.68(0.51,11.20) | 1.61(0.75,4.02) | 0.24(‐0.15,0.53) | |
| HD ADA SC + MTX | 2.17(0.38,11.15) | 1.48(0.61,3.82) | 0.18(‐0.23,0.52) | |
| HD TOCI IV + DMARD | 0.38(0.06,1.85) | 0.51(0.15,1.56) | ‐0.18(‐0.55,0.12) | |
| SD ANA SC + SD ETN SC + MTX | 1.01(0.16,5.44) | 1.01(0.34,2.81) | 0.00(‐0.40,0.38) | |
| SD ANA SC + LD ETN SC + MTX | 1.49(0.24,7.93) | 1.25(0.44,3.35) | 0.09(‐0.33,0.47) | |
| SD INF IV + MTX | SD ETN SC + MTX | 0.76(0.43,1.28) | 0.86(0.60,1.14) | ‐0.07(‐0.20,0.06) |
| SD ABA IV + MTX | 0.98(0.54,1.79) | 0.99(0.71,1.33) | 0.00(‐0.15,0.14) | |
| SD ADA SC + MTX | 1.52(0.78,3.23) | 1.21(0.88,1.65) | 0.10(‐0.06,0.27) | |
| SD CERTO SC + MTX/CERTO+MTX | 1.39(0.76,2.70) | 1.16(0.88,1.59) | 0.08(‐0.07,0.24) | |
| SD RITUX IV + MTX | 0.61(0.31,1.21) | 0.76(0.49,1.11) | ‐0.12(‐0.27,0.05) | |
| SD TOFA PO + MTX | 1.57(0.77,3.31) | 1.22(0.89,1.69) | 0.11(‐0.06,0.28) | |
| SD GOLI SC + MTX | 1.55(0.70,3.44) | 1.21(0.83,1.73) | 0.10(‐0.09,0.28) | |
| SD ABA SC + MTX | 1.21(0.53,2.65) | 1.10(0.70,1.54) | 0.05(‐0.15,0.23) | |
| SD GOLI IV + MTX | 0.57(0.26,1.31) | 0.73(0.43,1.15) | ‐0.13(‐0.30,0.07) | |
| SD ANA SC + MTX | 0.72(0.26,1.81) | 0.84(0.44,1.33) | ‐0.08(‐0.30,0.14) | |
| SD TOCI IV + MTX | 0.51(0.18,1.39) | 0.68(0.32,1.19) | ‐0.16(‐0.38,0.08) | |
| SD CERTO SC + DMARD | 0.35(0.11,1.14) | 0.52(0.22,1.08) | ‐0.23(‐0.47,0.03) | |
| SD ADA SC + DMARD | 0.21(0.06,0.76) | 0.34(0.11,0.85) | ‐0.31(‐0.51,‐0.06) | |
| SD ETN SC + DMARD | 0.86(0.33,2.27) | 0.93(0.50,1.47) | ‐0.04(‐0.26,0.20) | |
| SD TOCI SC + DMARD | 0.33(0.10,1.24) | 0.50(0.18,1.12) | ‐0.24(‐0.45,0.05) | |
| LD ADA SC | 0.23(0.08,0.64) | 0.37(0.18,0.74) | ‐0.31(‐0.50,‐0.10) | |
| LD ETN SC | 0.23(0.12,0.48) | 0.38(0.23,0.63) | ‐0.30(‐0.45,‐0.15) | |
| LD GOLI IV | 0.26(0.08,0.80) | 0.41(0.16,0.88) | ‐0.28(‐0.47,‐0.05) | |
| LD TOCI IV | 0.04(0.01,0.17) | 0.08(0.02,0.28) | ‐0.44(‐0.60,‐0.28) | |
| LD ADA SC + MTX | 1.10(0.50,2.53) | 1.05(0.68,1.51) | 0.02(‐0.16,0.22) | |
| LD RITUX IV + MTX | 0.54(0.27,1.04) | 0.70(0.44,1.02) | ‐0.14(‐0.30,0.01) | |
| LD ADA IV + MTX | 0.98(0.16,5.36) | 0.99(0.28,1.89) | 0.00(‐0.36,0.36) | |
| LD ABA IV + MTX | 0.52(0.24,1.15) | 0.69(0.40,1.08) | ‐0.15(‐0.32,0.04) | |
| LD ANA SC + MTX | 0.49(0.12,2.12) | 0.66(0.21,1.38) | ‐0.16(‐0.41,0.18) | |
| LD CERTO SC + MTX | 1.00(0.36,2.80) | 1.00(0.53,1.57) | 0.00(‐0.23,0.24) | |
| LD ETN SC + MTX | 0.88(0.40,1.93) | 0.93(0.57,1.33) | ‐0.03(‐0.22,0.15) | |
| LD GOLI IV + MTX | 0.52(0.18,1.45) | 0.68(0.32,1.19) | ‐0.15(‐0.36,0.09) | |
| LD TOCI IV + MTX | 0.41(0.14,1.14) | 0.59(0.25,1.08) | ‐0.20(‐0.42,0.03) | |
| LD TOFA PO + MTX | 0.85(0.24,2.97) | 0.92(0.38,1.60) | ‐0.04(‐0.30,0.25) | |
| HD TOCI IV | 0.65(0.36,1.23) | 0.79(0.56,1.12) | ‐0.10(‐0.25,0.05) | |
| HD TOFA PO | 0.70(0.26,1.68) | 0.82(0.47,1.34) | ‐0.09(‐0.32,0.13) | |
| HD ADA SC | 0.32(0.12,0.92) | 0.48(0.25,0.95) | ‐0.25(‐0.46,‐0.02) | |
| HD ETN SC | 0.48(0.22,1.04) | 0.65(0.38,1.02) | ‐0.17(‐0.34,0.01) | |
| HD GOLI SC | 0.64(0.28,1.48) | 0.78(0.47,1.24) | ‐0.11(‐0.29,0.09) | |
| HD ABA SC | 0.96(0.21,5.15) | 0.98(0.37,2.00) | ‐0.01(‐0.35,0.37) | |
| HD INF IV + MTX | 1.23(0.63,2.38) | 1.10(0.78,1.51) | 0.05(‐0.11,0.21) | |
| HD TOCI IV + MTX | 1.17(0.59,2.28) | 1.08(0.76,1.49) | 0.04(‐0.13,0.20) | |
| HD TOFA PO + MTX | 1.26(0.62,2.64) | 1.11(0.78,1.55) | 0.06(‐0.12,0.23) | |
| HD GOLI SC + MTX | 1.20(0.54,2.74) | 1.09(0.71,1.57) | 0.04(‐0.15,0.23) | |
| HD CERTO SC + MTX | 1.69(0.83,3.46) | 1.25(0.91,1.73) | 0.12(‐0.05,0.29) | |
| HD ADA SC + MTX | 1.39(0.51,3.97) | 1.16(0.68,1.75) | 0.08(‐0.16,0.31) | |
| HD TOCI IV + DMARD | 0.24(0.09,0.77) | 0.39(0.16,0.86) | ‐0.29(‐0.48,‐0.06) | |
| SD ANA SC + SD ETN SC + MTX | 0.63(0.24,1.71) | 0.78(0.38,1.26) | ‐0.11(‐0.31,0.13) | |
| SD ANA SC + LD ETN SC + MTX | 0.95(0.37,2.58) | 0.97(0.52,1.47) | ‐0.01(‐0.22,0.22) | |
| SD ABA IV + MTX | SD INF IV + MTX | 1.30(0.75,2.23) | 1.15(0.85,1.58) | 0.06(‐0.07,0.19) |
| SD ADA SC + MTX | 2.06(1.02,4.14) | 1.41(1.01,2.07) | 0.17(0.00,0.33) | |
| SD CERTO SC + MTX/CERTO+MTX | 1.85(1.00,3.55) | 1.35(1.00,1.92) | 0.15(0.00,0.30) | |
| SD RITUX IV + MTX | 0.82(0.42,1.59) | 0.89(0.58,1.31) | ‐0.04(‐0.20,0.11) | |
| SD TOFA PO + MTX | 2.08(1.04,4.31) | 1.42(1.02,2.10) | 0.18(0.01,0.34) | |
| SD GOLI SC + MTX | 2.04(0.93,4.39) | 1.42(0.96,2.10) | 0.17(‐0.02,0.35) | |
| SD ABA SC + MTX | 1.63(0.72,3.47) | 1.28(0.83,1.89) | 0.12(‐0.08,0.29) | |
| SD GOLI IV + MTX | 0.77(0.34,1.71) | 0.86(0.50,1.36) | ‐0.06(‐0.24,0.13) | |
| SD ANA SC + MTX | 0.96(0.36,2.42) | 0.97(0.52,1.62) | ‐0.01(‐0.22,0.21) | |
| SD TOCI IV + MTX | 0.68(0.23,1.82) | 0.79(0.37,1.41) | ‐0.09(‐0.30,0.15) | |
| SD CERTO SC + DMARD | 0.46(0.14,1.58) | 0.60(0.26,1.34) | ‐0.16(‐0.40,0.10) | |
| SD ADA SC + DMARD | 0.28(0.08,1.04) | 0.40(0.14,1.02) | ‐0.24(‐0.44,0.01) | |
| SD ETN SC + DMARD | 1.14(0.39,3.45) | 1.08(0.56,1.87) | 0.03(‐0.21,0.29) | |
| SD TOCI SC + DMARD | 0.44(0.12,1.72) | 0.58(0.20,1.34) | ‐0.17(‐0.40,0.13) | |
| LD ADA SC | 0.30(0.11,0.91) | 0.43(0.21,0.94) | ‐0.24(‐0.44,‐0.02) | |
| LD ETN SC | 0.31(0.15,0.68) | 0.44(0.25,0.76) | ‐0.23(‐0.39,‐0.08) | |
| LD GOLI IV | 0.35(0.11,1.01) | 0.48(0.19,1.01) | ‐0.21(‐0.41,0.00) | |
| LD TOCI IV | 0.06(0.01,0.23) | 0.10(0.02,0.33) | ‐0.37(‐0.56,‐0.21) | |
| LD ADA SC + MTX | 1.46(0.70,3.34) | 1.21(0.81,1.83) | 0.09(‐0.09,0.28) | |
| LD RITUX IV + MTX | 0.71(0.36,1.41) | 0.82(0.51,1.23) | ‐0.08(‐0.23,0.08) | |
| LD ADA IV + MTX | 1.30(0.21,7.03) | 1.15(0.32,2.23) | 0.06(‐0.29,0.42) | |
| LD ABA IV + MTX | 0.70(0.33,1.51) | 0.81(0.47,1.27) | ‐0.08(‐0.25,0.10) | |
| LD ANA SC + MTX | 0.65(0.16,2.68) | 0.77(0.25,1.63) | ‐0.09(‐0.34,0.23) | |
| LD CERTO SC + MTX | 1.32(0.49,3.72) | 1.16(0.64,1.91) | 0.07(‐0.16,0.31) | |
| LD ETN SC + MTX | 1.18(0.48,2.76) | 1.09(0.64,1.72) | 0.04(‐0.17,0.24) | |
| LD GOLI IV + MTX | 0.68(0.24,1.89) | 0.80(0.38,1.43) | ‐0.08(‐0.29,0.15) | |
| LD TOCI IV + MTX | 0.55(0.18,1.51) | 0.68(0.30,1.28) | ‐0.13(‐0.35,0.10) | |
| LD TOFA PO + MTX | 1.14(0.33,3.94) | 1.07(0.46,1.90) | 0.03(‐0.24,0.32) | |
| HD TOCI IV | 0.87(0.46,1.66) | 0.92(0.65,1.38) | ‐0.03(‐0.19,0.12) | |
| HD TOFA PO | 0.94(0.33,2.50) | 0.96(0.52,1.73) | ‐0.02(‐0.26,0.21) | |
| HD ADA SC | 0.43(0.15,1.27) | 0.56(0.28,1.17) | ‐0.18(‐0.40,0.05) | |
| HD ETN SC | 0.65(0.28,1.51) | 0.76(0.43,1.27) | ‐0.10(‐0.28,0.10) | |
| HD GOLI SC | 0.85(0.38,2.01) | 0.91(0.54,1.52) | ‐0.04(‐0.23,0.17) | |
| HD ABA SC | 1.28(0.27,7.19) | 1.14(0.44,2.59) | 0.06(‐0.29,0.45) | |
| HD INF IV + MTX | 1.63(0.96,2.74) | 1.28(0.98,1.73) | 0.12(‐0.01,0.24) | |
| HD TOCI IV + MTX | 1.56(0.79,3.03) | 1.26(0.88,1.85) | 0.11(‐0.05,0.26) | |
| HD TOFA PO + MTX | 1.67(0.82,3.47) | 1.29(0.90,1.91) | 0.12(‐0.05,0.30) | |
| HD GOLI SC + MTX | 1.60(0.73,3.62) | 1.27(0.84,1.94) | 0.11(‐0.08,0.31) | |
| HD CERTO SC + MTX | 2.24(1.11,4.53) | 1.46(1.06,2.13) | 0.19(0.03,0.35) | |
| HD ADA SC + MTX | 1.85(0.66,5.21) | 1.35(0.79,2.16) | 0.15(‐0.10,0.37) | |
| HD TOCI IV + DMARD | 0.32(0.11,1.03) | 0.45(0.19,1.02) | ‐0.22(‐0.42,0.01) | |
| SD ANA SC + SD ETN SC + MTX | 0.84(0.28,2.68) | 0.91(0.41,1.67) | ‐0.04(‐0.27,0.23) | |
| SD ANA SC + LD ETN SC + MTX | 1.28(0.42,3.77) | 1.14(0.56,1.93) | 0.06(‐0.19,0.31) | |
| SD ADA SC + MTX | SD ABA IV + MTX | 1.57(0.80,3.04) | 1.22(0.91,1.67) | 0.11(‐0.06,0.26) |
| SD CERTO SC + MTX/CERTO+MTX | 1.42(0.77,2.72) | 1.17(0.88,1.65) | 0.08(‐0.06,0.24) | |
| SD RITUX IV + MTX | 0.63(0.32,1.21) | 0.77(0.50,1.11) | ‐0.11(‐0.26,0.05) | |
| SD TOFA PO + MTX | 1.62(0.79,3.31) | 1.23(0.89,1.78) | 0.12(‐0.06,0.28) | |
| SD GOLI SC + MTX | 1.58(0.71,3.44) | 1.22(0.86,1.80) | 0.11(‐0.08,0.29) | |
| SD ABA SC + MTX | 1.25(0.62,2.46) | 1.11(0.77,1.49) | 0.05(‐0.11,0.21) | |
| SD GOLI IV + MTX | 0.59(0.27,1.35) | 0.74(0.43,1.17) | ‐0.12(‐0.30,0.07) | |
| SD ANA SC + MTX | 0.73(0.28,1.97) | 0.85(0.45,1.40) | ‐0.08(‐0.29,0.16) | |
| SD TOCI IV + MTX | 0.52(0.18,1.42) | 0.68(0.32,1.21) | ‐0.15(‐0.37,0.08) | |
| SD CERTO SC + DMARD | 0.36(0.11,1.20) | 0.52(0.22,1.12) | ‐0.22(‐0.47,0.04) | |
| SD ADA SC + DMARD | 0.21(0.06,0.81) | 0.35(0.12,0.88) | ‐0.31(‐0.52,‐0.05) | |
| SD ETN SC + DMARD | 0.88(0.30,2.58) | 0.93(0.49,1.59) | ‐0.03(‐0.28,0.22) | |
| SD TOCI SC + DMARD | 0.34(0.09,1.33) | 0.51(0.18,1.16) | ‐0.24(‐0.46,0.07) | |
| LD ADA SC | 0.23(0.08,0.73) | 0.38(0.18,0.81) | ‐0.30(‐0.51,‐0.07) | |
| LD ETN SC | 0.24(0.11,0.53) | 0.39(0.22,0.65) | ‐0.30(‐0.46,‐0.13) | |
| LD GOLI IV | 0.27(0.09,0.77) | 0.42(0.16,0.86) | ‐0.27(‐0.47,‐0.06) | |
| LD TOCI IV | 0.05(0.01,0.17) | 0.09(0.02,0.28) | ‐0.44(‐0.62,‐0.25) | |
| LD ADA SC + MTX | 1.13(0.52,2.45) | 1.06(0.69,1.52) | 0.03(‐0.16,0.21) | |
| LD RITUX IV + MTX | 0.55(0.27,1.09) | 0.71(0.45,1.05) | ‐0.14(‐0.30,0.02) | |
| LD ADA IV + MTX | 1.02(0.16,5.57) | 1.01(0.27,1.87) | 0.01(‐0.36,0.36) | |
| LD ABA IV + MTX | 0.54(0.28,1.03) | 0.70(0.44,1.01) | ‐0.14(‐0.28,0.01) | |
| LD ANA SC + MTX | 0.49(0.12,2.19) | 0.66(0.21,1.45) | ‐0.16(‐0.40,0.19) | |
| LD CERTO SC + MTX | 1.01(0.37,2.97) | 1.01(0.55,1.63) | 0.00(‐0.23,0.25) | |
| LD ETN SC + MTX | 0.92(0.34,2.19) | 0.95(0.54,1.46) | ‐0.02(‐0.24,0.19) | |
| LD GOLI IV + MTX | 0.53(0.19,1.50) | 0.69(0.33,1.22) | ‐0.15(‐0.36,0.09) | |
| LD TOCI IV + MTX | 0.41(0.14,1.18) | 0.59(0.27,1.10) | ‐0.20(‐0.41,0.04) | |
| LD TOFA PO + MTX | 0.86(0.25,3.13) | 0.93(0.40,1.64) | ‐0.04(‐0.29,0.26) | |
| HD TOCI IV | 0.67(0.34,1.33) | 0.80(0.57,1.18) | ‐0.10(‐0.26,0.07) | |
| HD TOFA PO | 0.72(0.25,1.95) | 0.84(0.46,1.49) | ‐0.08(‐0.32,0.16) | |
| HD ADA SC | 0.32(0.12,0.96) | 0.49(0.25,0.97) | ‐0.25(‐0.46,‐0.01) | |
| HD ETN SC | 0.49(0.22,1.16) | 0.66(0.38,1.08) | ‐0.16(‐0.34,0.03) | |
| HD GOLI SC | 0.65(0.29,1.57) | 0.78(0.47,1.28) | ‐0.10(‐0.30,0.11) | |
| HD ABA SC | 0.98(0.20,5.58) | 0.99(0.37,2.16) | ‐0.01(‐0.36,0.39) | |
| HD INF IV + MTX | 1.26(0.64,2.52) | 1.11(0.80,1.58) | 0.06(‐0.11,0.22) | |
| HD TOCI IV + MTX | 1.20(0.60,2.35) | 1.09(0.78,1.57) | 0.04(‐0.12,0.20) | |
| HD TOFA PO + MTX | 1.29(0.63,2.67) | 1.13(0.79,1.61) | 0.06(‐0.11,0.23) | |
| HD GOLI SC + MTX | 1.23(0.54,2.75) | 1.10(0.72,1.65) | 0.05(‐0.15,0.24) | |
| HD CERTO SC + MTX | 1.73(0.85,3.54) | 1.26(0.93,1.85) | 0.13(‐0.04,0.30) | |
| HD ADA SC + MTX | 1.43(0.51,3.93) | 1.18(0.69,1.77) | 0.09(‐0.16,0.31) | |
| HD TOCI IV + DMARD | 0.25(0.08,0.80) | 0.39(0.16,0.88) | ‐0.29(‐0.49,‐0.05) | |
| SD ANA SC + SD ETN SC + MTX | 0.65(0.20,2.08) | 0.79(0.36,1.45) | ‐0.10(‐0.34,0.18) | |
| SD ANA SC + LD ETN SC + MTX | 0.97(0.31,3.09) | 0.99(0.49,1.63) | ‐0.01(‐0.26,0.26) | |
| SD CERTO SC + MTX/CERTO+MTX | SD ADA SC + MTX | 0.91(0.44,1.81) | 0.96(0.72,1.32) | ‐0.02(‐0.19,0.14) |
| SD RITUX IV + MTX | 0.40(0.19,0.83) | 0.63(0.41,0.91) | ‐0.22(‐0.39,‐0.05) | |
| SD TOFA PO + MTX | 1.03(0.46,2.14) | 1.01(0.73,1.40) | 0.01(‐0.18,0.17) | |
| SD GOLI SC + MTX | 0.99(0.43,2.34) | 1.00(0.71,1.43) | 0.00(‐0.19,0.20) | |
| SD ABA SC + MTX | 0.79(0.39,1.57) | 0.91(0.63,1.20) | ‐0.06(‐0.22,0.10) | |
| SD GOLI IV + MTX | 0.38(0.16,0.89) | 0.61(0.36,0.94) | ‐0.23(‐0.42,‐0.03) | |
| SD ANA SC + MTX | 0.47(0.17,1.27) | 0.70(0.36,1.10) | ‐0.18(‐0.41,0.05) | |
| SD TOCI IV + MTX | 0.33(0.11,1.02) | 0.56(0.26,1.01) | ‐0.26(‐0.49,0.00) | |
| SD CERTO SC + DMARD | 0.23(0.06,0.84) | 0.43(0.19,0.91) | ‐0.34(‐0.59,‐0.04) | |
| SD ADA SC + DMARD | 0.13(0.04,0.52) | 0.29(0.09,0.70) | ‐0.42(‐0.63,‐0.15) | |
| SD ETN SC + DMARD | 0.56(0.19,1.62) | 0.77(0.41,1.24) | ‐0.14(‐0.38,0.11) | |
| SD TOCI SC + DMARD | 0.21(0.05,0.85) | 0.41(0.15,0.92) | ‐0.34(‐0.58,‐0.04) | |
| LD ADA SC | 0.15(0.05,0.48) | 0.31(0.15,0.62) | ‐0.41(‐0.62,‐0.16) | |
| LD ETN SC | 0.15(0.06,0.36) | 0.32(0.18,0.54) | ‐0.40(‐0.58,‐0.22) | |
| LD GOLI IV | 0.17(0.05,0.51) | 0.34(0.13,0.70) | ‐0.38(‐0.58,‐0.16) | |
| LD TOCI IV | 0.03(0.00,0.13) | 0.07(0.01,0.24) | ‐0.55(‐0.73,‐0.34) | |
| LD ADA SC + MTX | 0.71(0.38,1.36) | 0.87(0.62,1.14) | ‐0.08(‐0.22,0.07) | |
| LD RITUX IV + MTX | 0.35(0.16,0.74) | 0.58(0.36,0.85) | ‐0.25(‐0.42,‐0.07) | |
| LD ADA IV + MTX | 0.65(0.10,3.48) | 0.82(0.23,1.52) | ‐0.10(‐0.47,0.26) | |
| LD ABA IV + MTX | 0.34(0.15,0.77) | 0.58(0.33,0.88) | ‐0.25(‐0.43,‐0.06) | |
| LD ANA SC + MTX | 0.32(0.07,1.39) | 0.54(0.18,1.15) | ‐0.26(‐0.53,0.08) | |
| LD CERTO SC + MTX | 0.65(0.22,1.91) | 0.83(0.44,1.29) | ‐0.10(‐0.35,0.14) | |
| LD ETN SC + MTX | 0.57(0.21,1.54) | 0.78(0.44,1.20) | ‐0.13(‐0.36,0.10) | |
| LD GOLI IV + MTX | 0.34(0.11,0.99) | 0.56(0.27,1.00) | ‐0.26(‐0.48,0.00) | |
| LD TOCI IV + MTX | 0.27(0.08,0.78) | 0.48(0.22,0.88) | ‐0.30(‐0.53,‐0.06) | |
| LD TOFA PO + MTX | 0.56(0.14,1.95) | 0.77(0.31,1.31) | ‐0.14(‐0.42,0.16) | |
| HD TOCI IV | 0.42(0.20,0.90) | 0.65(0.46,0.94) | ‐0.21(‐0.37,‐0.03) | |
| HD TOFA PO | 0.45(0.15,1.33) | 0.68(0.39,1.16) | ‐0.19(‐0.43,0.07) | |
| HD ADA SC | 0.21(0.07,0.65) | 0.40(0.21,0.77) | ‐0.36(‐0.57,‐0.10) | |
| HD ETN SC | 0.32(0.12,0.80) | 0.54(0.30,0.89) | ‐0.27(‐0.47,‐0.05) | |
| HD GOLI SC | 0.42(0.16,1.06) | 0.65(0.38,1.04) | ‐0.21(‐0.42,0.01) | |
| HD ABA SC | 0.62(0.12,3.54) | 0.81(0.32,1.66) | ‐0.11(‐0.47,0.28) | |
| HD INF IV + MTX | 0.80(0.36,1.74) | 0.91(0.64,1.28) | ‐0.05(‐0.24,0.13) | |
| HD TOCI IV + MTX | 0.76(0.36,1.61) | 0.89(0.63,1.25) | ‐0.06(‐0.24,0.11) | |
| HD TOFA PO + MTX | 0.83(0.38,1.77) | 0.92(0.64,1.28) | ‐0.04(‐0.23,0.13) | |
| HD GOLI SC + MTX | 0.78(0.33,1.82) | 0.90(0.60,1.31) | ‐0.06(‐0.25,0.14) | |
| HD CERTO SC + MTX | 1.11(0.49,2.40) | 1.04(0.75,1.45) | 0.02(‐0.17,0.20) | |
| HD ADA SC + MTX | 0.92(0.37,2.26) | 0.96(0.61,1.33) | ‐0.02(‐0.23,0.17) | |
| HD TOCI IV + DMARD | 0.16(0.05,0.54) | 0.32(0.13,0.71) | ‐0.39(‐0.60,‐0.15) | |
| SD ANA SC + SD ETN SC + MTX | 0.42(0.12,1.41) | 0.65(0.30,1.16) | ‐0.21(‐0.46,0.08) | |
| SD ANA SC + LD ETN SC + MTX | 0.62(0.19,2.04) | 0.81(0.40,1.33) | ‐0.11(‐0.38,0.16) | |
| SD RITUX IV + MTX | SD CERTO SC + MTX/CERTO+MTX | 0.44(0.21,0.90) | 0.66(0.42,0.94) | ‐0.20(‐0.36,‐0.03) |
| SD TOFA PO + MTX | 1.12(0.55,2.38) | 1.05(0.76,1.42) | 0.03(‐0.14,0.19) | |
| SD GOLI SC + MTX | 1.10(0.50,2.45) | 1.04(0.74,1.45) | 0.02(‐0.16,0.20) | |
| SD ABA SC + MTX | 0.87(0.37,1.95) | 0.94(0.60,1.33) | ‐0.03(‐0.24,0.15) | |
| SD GOLI IV + MTX | 0.42(0.18,0.93) | 0.63(0.36,0.97) | ‐0.21(‐0.39,‐0.02) | |
| SD ANA SC + MTX | 0.51(0.20,1.29) | 0.72(0.38,1.13) | ‐0.16(‐0.37,0.06) | |
| SD TOCI IV + MTX | 0.36(0.12,1.04) | 0.58(0.27,1.02) | ‐0.24(‐0.46,0.01) | |
| SD CERTO SC + DMARD | 0.25(0.07,0.83) | 0.44(0.19,0.90) | ‐0.31(‐0.55,‐0.05) | |
| SD ADA SC + DMARD | 0.15(0.04,0.54) | 0.29(0.10,0.72) | ‐0.39(‐0.59,‐0.14) | |
| SD ETN SC + DMARD | 0.61(0.21,1.83) | 0.79(0.42,1.29) | ‐0.12(‐0.37,0.14) | |
| SD TOCI SC + DMARD | 0.23(0.07,0.87) | 0.43(0.15,0.93) | ‐0.32(‐0.55,‐0.03) | |
| LD ADA SC | 0.16(0.06,0.51) | 0.32(0.16,0.65) | ‐0.40(‐0.59,‐0.15) | |
| LD ETN SC | 0.17(0.08,0.37) | 0.33(0.19,0.55) | ‐0.38(‐0.54,‐0.21) | |
| LD GOLI IV | 0.19(0.06,0.55) | 0.35(0.14,0.73) | ‐0.36(‐0.56,‐0.14) | |
| LD TOCI IV | 0.03(0.01,0.13) | 0.07(0.01,0.24) | ‐0.53(‐0.69,‐0.33) | |
| LD ADA SC + MTX | 0.78(0.37,1.77) | 0.90(0.59,1.28) | ‐0.06(‐0.24,0.13) | |
| LD RITUX IV + MTX | 0.39(0.18,0.77) | 0.60(0.37,0.88) | ‐0.23(‐0.39,‐0.06) | |
| LD ADA IV + MTX | 0.69(0.12,3.87) | 0.85(0.23,1.58) | ‐0.09(‐0.44,0.28) | |
| LD ABA IV + MTX | 0.37(0.17,0.81) | 0.59(0.34,0.90) | ‐0.23(‐0.41,‐0.05) | |
| LD ANA SC + MTX | 0.35(0.09,1.48) | 0.56(0.18,1.18) | ‐0.24(‐0.49,0.09) | |
| LD CERTO SC + MTX | 0.70(0.29,1.84) | 0.85(0.49,1.27) | ‐0.08(‐0.28,0.14) | |
| LD ETN SC + MTX | 0.63(0.24,1.55) | 0.81(0.46,1.21) | ‐0.11(‐0.33,0.10) | |
| LD GOLI IV + MTX | 0.37(0.13,1.04) | 0.58(0.27,1.02) | ‐0.23(‐0.45,0.01) | |
| LD TOCI IV + MTX | 0.29(0.10,0.83) | 0.50(0.22,0.91) | ‐0.28(‐0.50,‐0.04) | |
| LD TOFA PO + MTX | 0.60(0.18,2.09) | 0.79(0.34,1.34) | ‐0.12(‐0.38,0.17) | |
| HD TOCI IV | 0.47(0.24,0.90) | 0.68(0.48,0.94) | ‐0.18(‐0.34,‐0.03) | |
| HD TOFA PO | 0.50(0.17,1.37) | 0.71(0.41,1.19) | ‐0.17(‐0.40,0.08) | |
| HD ADA SC | 0.22(0.08,0.72) | 0.41(0.22,0.82) | ‐0.34(‐0.54,‐0.07) | |
| HD ETN SC | 0.34(0.15,0.83) | 0.56(0.32,0.91) | ‐0.25(‐0.43,‐0.05) | |
| HD GOLI SC | 0.46(0.19,1.06) | 0.67(0.41,1.03) | ‐0.19(‐0.38,0.01) | |
| HD ABA SC | 0.69(0.14,4.04) | 0.84(0.33,1.75) | ‐0.09(‐0.45,0.31) | |
| HD INF IV + MTX | 0.88(0.43,1.77) | 0.94(0.68,1.29) | ‐0.03(‐0.20,0.13) | |
| HD TOCI IV + MTX | 0.84(0.41,1.64) | 0.93(0.67,1.25) | ‐0.04(‐0.21,0.12) | |
| HD TOFA PO + MTX | 0.89(0.43,1.90) | 0.95(0.66,1.33) | ‐0.03(‐0.20,0.15) | |
| HD GOLI SC + MTX | 0.85(0.38,1.96) | 0.93(0.62,1.32) | ‐0.04(‐0.23,0.16) | |
| HD CERTO SC + MTX | 1.20(0.71,1.99) | 1.07(0.86,1.35) | 0.04(‐0.08,0.16) | |
| HD ADA SC + MTX | 1.00(0.33,2.94) | 1.00(0.58,1.50) | 0.00(‐0.26,0.23) | |
| HD TOCI IV + DMARD | 0.17(0.06,0.51) | 0.34(0.13,0.70) | ‐0.37(‐0.56,‐0.16) | |
| SD ANA SC + SD ETN SC + MTX | 0.46(0.14,1.41) | 0.67(0.31,1.16) | ‐0.19(‐0.43,0.08) | |
| SD ANA SC + LD ETN SC + MTX | 0.68(0.21,2.11) | 0.84(0.41,1.34) | ‐0.09(‐0.36,0.17) | |
| SD TOFA PO + MTX | SD RITUX IV + MTX | 2.55(1.21,5.49) | 1.60(1.10,2.49) | 0.22(0.05,0.40) |
| SD GOLI SC + MTX | 2.52(1.10,5.87) | 1.59(1.05,2.58) | 0.22(0.02,0.41) | |
| SD ABA SC + MTX | 1.99(0.85,4.70) | 1.44(0.91,2.34) | 0.16(‐0.04,0.36) | |
| SD GOLI IV + MTX | 0.93(0.39,2.25) | 0.96(0.54,1.63) | ‐0.01(‐0.20,0.19) | |
| SD ANA SC + MTX | 1.18(0.43,3.10) | 1.10(0.58,1.90) | 0.04(‐0.18,0.27) | |
| SD TOCI IV + MTX | 0.83(0.27,2.38) | 0.89(0.41,1.67) | ‐0.04(‐0.27,0.20) | |
| SD CERTO SC + DMARD | 0.58(0.17,1.88) | 0.69(0.28,1.51) | ‐0.11(‐0.36,0.14) | |
| SD ADA SC + DMARD | 0.34(0.09,1.22) | 0.46(0.15,1.14) | ‐0.19(‐0.40,0.04) | |
| SD ETN SC + DMARD | 1.41(0.45,4.13) | 1.21(0.61,2.20) | 0.08(‐0.18,0.33) | |
| SD TOCI SC + DMARD | 0.54(0.14,2.01) | 0.66(0.23,1.53) | ‐0.12(‐0.36,0.16) | |
| LD ADA SC | 0.37(0.13,1.14) | 0.49(0.23,1.10) | ‐0.19(‐0.41,0.03) | |
| LD ETN SC | 0.39(0.17,0.86) | 0.51(0.27,0.90) | ‐0.18(‐0.36,‐0.02) | |
| LD GOLI IV | 0.42(0.13,1.28) | 0.55(0.21,1.17) | ‐0.16(‐0.37,0.05) | |
| LD TOCI IV | 0.07(0.01,0.29) | 0.11(0.02,0.39) | ‐0.32(‐0.52,‐0.16) | |
| LD ADA SC + MTX | 1.80(0.79,4.27) | 1.37(0.86,2.21) | 0.14(‐0.06,0.34) | |
| LD RITUX IV + MTX | 0.88(0.51,1.51) | 0.92(0.63,1.31) | ‐0.03(‐0.15,0.09) | |
| LD ADA IV + MTX | 1.62(0.24,9.49) | 1.30(0.35,2.76) | 0.11(‐0.27,0.49) | |
| LD ABA IV + MTX | 0.85(0.37,1.95) | 0.90(0.52,1.50) | ‐0.04(‐0.21,0.16) | |
| LD ANA SC + MTX | 0.80(0.18,3.55) | 0.87(0.28,1.94) | ‐0.05(‐0.30,0.30) | |
| LD CERTO SC + MTX | 1.61(0.57,4.78) | 1.30(0.70,2.29) | 0.11(‐0.12,0.36) | |
| LD ETN SC + MTX | 1.44(0.56,3.77) | 1.23(0.70,2.10) | 0.08(‐0.13,0.31) | |
| LD GOLI IV + MTX | 0.84(0.29,2.50) | 0.89(0.41,1.69) | ‐0.04(‐0.26,0.22) | |
| LD TOCI IV + MTX | 0.67(0.22,1.89) | 0.77(0.33,1.52) | ‐0.08(‐0.30,0.15) | |
| LD TOFA PO + MTX | 1.39(0.38,5.07) | 1.20(0.51,2.24) | 0.08(‐0.20,0.37) | |
| HD TOCI IV | 1.05(0.53,2.18) | 1.03(0.69,1.66) | 0.01(‐0.15,0.17) | |
| HD TOFA PO | 1.13(0.40,3.21) | 1.07(0.57,2.12) | 0.03(‐0.21,0.26) | |
| HD ADA SC | 0.53(0.18,1.60) | 0.64(0.31,1.40) | ‐0.13(‐0.36,0.09) | |
| HD ETN SC | 0.79(0.34,1.90) | 0.86(0.48,1.50) | ‐0.05(‐0.24,0.15) | |
| HD GOLI SC | 1.05(0.42,2.59) | 1.03(0.59,1.82) | 0.01(‐0.20,0.21) | |
| HD ABA SC | 1.58(0.32,8.91) | 1.29(0.47,3.02) | 0.11(‐0.25,0.49) | |
| HD INF IV + MTX | 2.00(0.96,4.27) | 1.45(0.98,2.27) | 0.16(‐0.01,0.33) | |
| HD TOCI IV + MTX | 1.91(0.92,3.98) | 1.42(0.96,2.24) | 0.15(‐0.02,0.32) | |
| HD TOFA PO + MTX | 2.08(0.94,4.43) | 1.47(0.97,2.29) | 0.17(‐0.01,0.35) | |
| HD GOLI SC + MTX | 1.95(0.83,4.69) | 1.42(0.90,2.35) | 0.16(‐0.04,0.36) | |
| HD CERTO SC + MTX | 2.74(1.30,5.90) | 1.64(1.13,2.61) | 0.24(0.06,0.41) | |
| HD ADA SC + MTX | 2.29(0.79,6.68) | 1.52(0.87,2.54) | 0.20(‐0.05,0.43) | |
| HD TOCI IV + DMARD | 0.39(0.13,1.27) | 0.51(0.21,1.16) | ‐0.18(‐0.37,0.05) | |
| SD ANA SC + SD ETN SC + MTX | 1.03(0.34,3.46) | 1.02(0.46,1.94) | 0.01(‐0.23,0.30) | |
| SD ANA SC + LD ETN SC + MTX | 1.55(0.49,5.05) | 1.27(0.62,2.33) | 0.10(‐0.16,0.37) | |
| SD GOLI SC + MTX | SD TOFA PO + MTX | 0.97(0.41,2.39) | 0.99(0.69,1.43) | ‐0.01(‐0.21,0.20) |
| SD ABA SC + MTX | 0.78(0.31,1.85) | 0.90(0.57,1.29) | ‐0.06(‐0.27,0.14) | |
| SD GOLI IV + MTX | 0.37(0.14,0.93) | 0.60(0.34,0.96) | ‐0.24(‐0.44,‐0.02) | |
| SD ANA SC + MTX | 0.46(0.16,1.29) | 0.69(0.35,1.12) | ‐0.18(‐0.42,0.06) | |
| SD TOCI IV + MTX | 0.32(0.10,0.97) | 0.55(0.25,0.99) | ‐0.27(‐0.49,‐0.01) | |
| SD CERTO SC + DMARD | 0.22(0.06,0.78) | 0.42(0.19,0.87) | ‐0.34(‐0.59,‐0.06) | |
| SD ADA SC + DMARD | 0.13(0.03,0.53) | 0.28(0.09,0.70) | ‐0.42(‐0.63,‐0.15) | |
| SD ETN SC + DMARD | 0.55(0.17,1.73) | 0.76(0.40,1.26) | ‐0.14(‐0.41,0.13) | |
| SD TOCI SC + DMARD | 0.21(0.06,0.84) | 0.41(0.14,0.92) | ‐0.35(‐0.58,‐0.04) | |
| LD ADA SC | 0.14(0.05,0.44) | 0.30(0.15,0.60) | ‐0.42(‐0.61,‐0.18) | |
| LD ETN SC | 0.15(0.06,0.36) | 0.31(0.18,0.54) | ‐0.41(‐0.59,‐0.22) | |
| LD GOLI IV | 0.17(0.05,0.53) | 0.34(0.13,0.73) | ‐0.39(‐0.60,‐0.15) | |
| LD TOCI IV | 0.03(0.00,0.12) | 0.07(0.01,0.24) | ‐0.55(‐0.73,‐0.35) | |
| LD ADA SC + MTX | 0.70(0.30,1.72) | 0.86(0.56,1.26) | ‐0.08(‐0.28,0.13) | |
| LD RITUX IV + MTX | 0.34(0.16,0.74) | 0.57(0.35,0.86) | ‐0.25(‐0.42,‐0.07) | |
| LD ADA IV + MTX | 0.63(0.10,3.41) | 0.81(0.22,1.47) | ‐0.11(‐0.47,0.25) | |
| LD ABA IV + MTX | 0.33(0.14,0.79) | 0.57(0.33,0.90) | ‐0.26(‐0.44,‐0.06) | |
| LD ANA SC + MTX | 0.31(0.07,1.42) | 0.54(0.17,1.16) | ‐0.27(‐0.53,0.08) | |
| LD CERTO SC + MTX | 0.63(0.22,1.81) | 0.82(0.43,1.27) | ‐0.11(‐0.35,0.13) | |
| LD ETN SC + MTX | 0.56(0.20,1.50) | 0.77(0.44,1.19) | ‐0.14(‐0.37,0.09) | |
| LD GOLI IV + MTX | 0.33(0.10,1.07) | 0.55(0.26,1.03) | ‐0.26(‐0.49,0.02) | |
| LD TOCI IV + MTX | 0.26(0.08,0.77) | 0.48(0.21,0.88) | ‐0.31(‐0.52,‐0.06) | |
| LD TOFA PO + MTX | 0.55(0.17,1.67) | 0.76(0.34,1.20) | ‐0.14(‐0.39,0.11) | |
| HD TOCI IV | 0.41(0.20,0.91) | 0.65(0.45,0.95) | ‐0.21(‐0.37,‐0.02) | |
| HD TOFA PO | 0.44(0.15,1.23) | 0.67(0.39,1.12) | ‐0.20(‐0.43,0.05) | |
| HD ADA SC | 0.20(0.07,0.63) | 0.40(0.21,0.76) | ‐0.36(‐0.57,‐0.10) | |
| HD ETN SC | 0.31(0.12,0.76) | 0.53(0.30,0.87) | ‐0.28(‐0.47,‐0.06) | |
| HD GOLI SC | 0.41(0.16,1.05) | 0.64(0.39,1.02) | ‐0.21(‐0.42,0.01) | |
| HD ABA SC | 0.61(0.12,3.64) | 0.81(0.31,1.63) | ‐0.12(‐0.48,0.29) | |
| HD INF IV + MTX | 0.79(0.36,1.73) | 0.91(0.63,1.26) | ‐0.06(‐0.24,0.13) | |
| HD TOCI IV + MTX | 0.74(0.34,1.59) | 0.88(0.62,1.24) | ‐0.07(‐0.25,0.11) | |
| HD TOFA PO + MTX | 0.80(0.48,1.30) | 0.92(0.72,1.12) | ‐0.05(‐0.17,0.06) | |
| HD GOLI SC + MTX | 0.76(0.32,1.91) | 0.90(0.58,1.30) | ‐0.06(‐0.27,0.15) | |
| HD CERTO SC + MTX | 1.07(0.50,2.42) | 1.03(0.75,1.45) | 0.02(‐0.16,0.20) | |
| HD ADA SC + MTX | 0.88(0.32,2.70) | 0.95(0.55,1.43) | ‐0.03(‐0.27,0.22) | |
| HD TOCI IV + DMARD | 0.15(0.05,0.52) | 0.32(0.13,0.71) | ‐0.40(‐0.60,‐0.15) | |
| SD ANA SC + SD ETN SC + MTX | 0.40(0.12,1.45) | 0.64(0.28,1.17) | ‐0.21(‐0.48,0.09) | |
| SD ANA SC + LD ETN SC + MTX | 0.60(0.18,2.12) | 0.80(0.38,1.33) | ‐0.12(‐0.39,0.17) | |
| SD ABA SC + MTX | SD GOLI SC + MTX | 0.79(0.30,1.98) | 0.91(0.56,1.35) | ‐0.06(‐0.28,0.16) |
| SD GOLI IV + MTX | 0.37(0.14,0.96) | 0.60(0.34,0.98) | ‐0.23(‐0.44,‐0.01) | |
| SD ANA SC + MTX | 0.47(0.16,1.31) | 0.69(0.36,1.12) | ‐0.18(‐0.42,0.06) | |
| SD TOCI IV + MTX | 0.33(0.10,1.03) | 0.56(0.25,1.02) | ‐0.26(‐0.51,0.01) | |
| SD CERTO SC + DMARD | 0.23(0.06,0.79) | 0.43(0.19,0.89) | ‐0.33(‐0.59,‐0.05) | |
| SD ADA SC + DMARD | 0.14(0.03,0.53) | 0.28(0.09,0.71) | ‐0.42(‐0.64,‐0.14) | |
| SD ETN SC + DMARD | 0.56(0.17,1.79) | 0.77(0.38,1.28) | ‐0.14(‐0.41,0.14) | |
| SD TOCI SC + DMARD | 0.21(0.06,0.83) | 0.41(0.14,0.91) | ‐0.34(‐0.58,‐0.05) | |
| LD ADA SC | 0.15(0.05,0.49) | 0.30(0.15,0.63) | ‐0.41(‐0.63,‐0.16) | |
| LD ETN SC | 0.15(0.06,0.37) | 0.32(0.18,0.54) | ‐0.40(‐0.59,‐0.21) | |
| LD GOLI IV | 0.17(0.05,0.55) | 0.34(0.13,0.73) | ‐0.38(‐0.59,‐0.14) | |
| LD TOCI IV | 0.03(0.00,0.13) | 0.07(0.01,0.25) | ‐0.55(‐0.74,‐0.33) | |
| LD ADA SC + MTX | 0.73(0.29,1.78) | 0.87(0.54,1.27) | ‐0.08(‐0.29,0.13) | |
| LD RITUX IV + MTX | 0.34(0.15,0.82) | 0.58(0.35,0.91) | ‐0.25(‐0.43,‐0.05) | |
| LD ADA IV + MTX | 0.64(0.10,3.52) | 0.82(0.22,1.51) | ‐0.10(‐0.48,0.26) | |
| LD ABA IV + MTX | 0.34(0.14,0.86) | 0.57(0.32,0.93) | ‐0.25(‐0.44,‐0.04) | |
| LD ANA SC + MTX | 0.32(0.07,1.48) | 0.55(0.17,1.17) | ‐0.26(‐0.55,0.09) | |
| LD CERTO SC + MTX | 0.65(0.21,2.08) | 0.83(0.43,1.35) | ‐0.10(‐0.36,0.17) | |
| LD ETN SC + MTX | 0.57(0.19,1.66) | 0.78(0.42,1.24) | ‐0.13(‐0.38,0.12) | |
| LD GOLI IV + MTX | 0.33(0.11,1.06) | 0.57(0.25,1.03) | ‐0.26(‐0.49,0.01) | |
| LD TOCI IV + MTX | 0.27(0.08,0.84) | 0.48(0.22,0.92) | ‐0.30(‐0.53,‐0.04) | |
| LD TOFA PO + MTX | 0.56(0.14,2.01) | 0.76(0.31,1.35) | ‐0.14(‐0.43,0.16) | |
| HD TOCI IV | 0.43(0.18,0.92) | 0.66(0.44,0.96) | ‐0.20(‐0.39,‐0.02) | |
| HD TOFA PO | 0.45(0.15,1.37) | 0.68(0.39,1.18) | ‐0.19(‐0.43,0.08) | |
| HD ADA SC | 0.21(0.06,0.69) | 0.40(0.21,0.80) | ‐0.36(‐0.59,‐0.08) | |
| HD ETN SC | 0.31(0.12,0.81) | 0.53(0.30,0.90) | ‐0.27(‐0.48,‐0.05) | |
| HD GOLI SC | 0.42(0.18,0.96) | 0.65(0.41,0.98) | ‐0.21(‐0.39,‐0.01) | |
| HD ABA SC | 0.63(0.12,3.59) | 0.81(0.32,1.67) | ‐0.11(‐0.47,0.28) | |
| HD INF IV + MTX | 0.80(0.34,1.90) | 0.91(0.62,1.34) | ‐0.05(‐0.25,0.15) | |
| HD TOCI IV + MTX | 0.76(0.32,1.72) | 0.89(0.62,1.30) | ‐0.07(‐0.26,0.13) | |
| HD TOFA PO + MTX | 0.82(0.34,1.98) | 0.92(0.62,1.35) | ‐0.05(‐0.25,0.16) | |
| HD GOLI SC + MTX | 0.78(0.42,1.45) | 0.90(0.66,1.16) | ‐0.06(‐0.20,0.09) | |
| HD CERTO SC + MTX | 1.11(0.45,2.57) | 1.04(0.74,1.48) | 0.02(‐0.18,0.22) | |
| HD ADA SC + MTX | 0.91(0.28,2.80) | 0.96(0.53,1.48) | ‐0.02(‐0.30,0.23) | |
| HD TOCI IV + DMARD | 0.16(0.05,0.53) | 0.32(0.13,0.70) | ‐0.39(‐0.61,‐0.15) | |
| SD ANA SC + SD ETN SC + MTX | 0.41(0.12,1.56) | 0.65(0.28,1.23) | ‐0.21(‐0.48,0.10) | |
| SD ANA SC + LD ETN SC + MTX | 0.62(0.17,2.19) | 0.81(0.38,1.38) | ‐0.11(‐0.41,0.18) | |
| SD GOLI IV + MTX | SD ABA SC + MTX | 0.47(0.18,1.28) | 0.67(0.38,1.13) | ‐0.18(‐0.39,0.06) |
| SD ANA SC + MTX | 0.58(0.20,1.86) | 0.76(0.39,1.39) | ‐0.13(‐0.37,0.15) | |
| SD TOCI IV + MTX | 0.41(0.13,1.36) | 0.61(0.28,1.18) | ‐0.21(‐0.45,0.07) | |
| SD CERTO SC + DMARD | 0.29(0.08,1.13) | 0.48(0.20,1.07) | ‐0.28(‐0.55,0.03) | |
| SD ADA SC + DMARD | 0.17(0.04,0.76) | 0.32(0.10,0.84) | ‐0.36(‐0.59,‐0.06) | |
| SD ETN SC + DMARD | 0.71(0.21,2.38) | 0.84(0.43,1.51) | ‐0.08(‐0.37,0.21) | |
| SD TOCI SC + DMARD | 0.28(0.07,1.15) | 0.47(0.16,1.08) | ‐0.28(‐0.54,0.03) | |
| LD ADA SC | 0.19(0.06,0.64) | 0.34(0.17,0.75) | ‐0.35(‐0.58,‐0.09) | |
| LD ETN SC | 0.19(0.07,0.49) | 0.35(0.19,0.63) | ‐0.35(‐0.55,‐0.14) | |
| LD GOLI IV | 0.21(0.06,0.70) | 0.38(0.15,0.82) | ‐0.33(‐0.56,‐0.08) | |
| LD TOCI IV | 0.04(0.01,0.17) | 0.08(0.01,0.27) | ‐0.49(‐0.69,‐0.26) | |
| LD ADA SC + MTX | 0.91(0.39,2.24) | 0.96(0.63,1.44) | ‐0.02(‐0.22,0.19) | |
| LD RITUX IV + MTX | 0.44(0.19,1.08) | 0.64(0.38,1.04) | ‐0.19(‐0.39,0.02) | |
| LD ADA IV + MTX | 0.82(0.13,4.51) | 0.92(0.25,1.83) | ‐0.05(‐0.42,0.33) | |
| LD ABA IV + MTX | 0.43(0.18,1.07) | 0.63(0.36,1.04) | ‐0.20(‐0.40,0.02) | |
| LD ANA SC + MTX | 0.40(0.09,1.99) | 0.60(0.19,1.37) | ‐0.21(‐0.49,0.16) | |
| LD CERTO SC + MTX | 0.81(0.27,2.63) | 0.91(0.48,1.61) | ‐0.05(‐0.30,0.23) | |
| LD ETN SC + MTX | 0.72(0.25,2.12) | 0.86(0.47,1.45) | ‐0.08(‐0.32,0.18) | |
| LD GOLI IV + MTX | 0.42(0.14,1.37) | 0.62(0.29,1.18) | ‐0.20(‐0.44,0.08) | |
| LD TOCI IV + MTX | 0.33(0.10,1.12) | 0.53(0.24,1.06) | ‐0.25(‐0.49,0.03) | |
| LD TOFA PO + MTX | 0.70(0.18,2.71) | 0.84(0.34,1.58) | ‐0.09(‐0.38,0.23) | |
| HD TOCI IV | 0.54(0.23,1.29) | 0.72(0.48,1.16) | ‐0.15(‐0.35,0.06) | |
| HD TOFA PO | 0.58(0.19,1.81) | 0.75(0.42,1.40) | ‐0.13(‐0.39,0.14) | |
| HD ADA SC | 0.26(0.08,0.88) | 0.44(0.23,0.92) | ‐0.30(‐0.53,‐0.03) | |
| HD ETN SC | 0.39(0.15,1.05) | 0.60(0.33,1.03) | ‐0.22(‐0.43,0.01) | |
| HD GOLI SC | 0.54(0.19,1.44) | 0.72(0.41,1.23) | ‐0.15(‐0.39,0.08) | |
| HD ABA SC | 0.80(0.15,4.83) | 0.90(0.34,2.00) | ‐0.05(‐0.43,0.35) | |
| HD INF IV + MTX | 1.01(0.42,2.46) | 1.01(0.68,1.58) | 0.00(‐0.20,0.21) | |
| HD TOCI IV + MTX | 0.96(0.41,2.31) | 0.98(0.67,1.56) | ‐0.01(‐0.21,0.20) | |
| HD TOFA PO + MTX | 1.02(0.42,2.59) | 1.01(0.68,1.61) | 0.01(‐0.20,0.23) | |
| HD GOLI SC + MTX | 0.98(0.38,2.69) | 0.99(0.64,1.61) | 0.00(‐0.23,0.23) | |
| HD CERTO SC + MTX | 1.37(0.59,3.51) | 1.14(0.81,1.83) | 0.07(‐0.12,0.29) | |
| HD ADA SC + MTX | 1.15(0.40,3.40) | 1.07(0.63,1.69) | 0.03(‐0.22,0.27) | |
| HD TOCI IV + DMARD | 0.20(0.06,0.73) | 0.36(0.14,0.83) | ‐0.34(‐0.57,‐0.07) | |
| SD ANA SC + SD ETN SC + MTX | 0.52(0.15,1.89) | 0.71(0.32,1.35) | ‐0.15(‐0.42,0.15) | |
| SD ANA SC + LD ETN SC + MTX | 0.78(0.24,2.91) | 0.89(0.44,1.60) | ‐0.06(‐0.32,0.25) | |
| SD ANA SC + MTX | SD GOLI IV + MTX | 1.25(0.43,3.50) | 1.14(0.58,2.11) | 0.05(‐0.19,0.29) |
| SD TOCI IV + MTX | 0.88(0.28,2.81) | 0.92(0.41,1.93) | ‐0.03(‐0.28,0.24) | |
| SD CERTO SC + DMARD | 0.60(0.17,2.29) | 0.71(0.29,1.72) | ‐0.10(‐0.36,0.19) | |
| SD ADA SC + DMARD | 0.36(0.09,1.41) | 0.48(0.15,1.26) | ‐0.18(‐0.43,0.07) | |
| SD ETN SC + DMARD | 1.48(0.46,4.78) | 1.26(0.63,2.44) | 0.09(‐0.17,0.36) | |
| SD TOCI SC + DMARD | 0.58(0.14,2.34) | 0.68(0.23,1.72) | ‐0.11(‐0.36,0.20) | |
| LD ADA SC | 0.39(0.12,1.34) | 0.51(0.22,1.23) | ‐0.18(‐0.42,0.06) | |
| LD ETN SC | 0.41(0.16,1.00) | 0.52(0.27,1.00) | ‐0.17(‐0.38,0.00) | |
| LD GOLI IV | 0.45(0.17,1.17) | 0.57(0.24,1.11) | ‐0.15(‐0.34,0.03) | |
| LD TOCI IV | 0.08(0.01,0.34) | 0.12(0.02,0.42) | ‐0.31(‐0.53,‐0.13) | |
| LD ADA SC + MTX | 1.90(0.74,5.11) | 1.43(0.85,2.58) | 0.15(‐0.07,0.37) | |
| LD RITUX IV + MTX | 0.94(0.39,2.24) | 0.96(0.55,1.70) | ‐0.01(‐0.22,0.17) | |
| LD ADA IV + MTX | 1.76(0.23,10.18) | 1.36(0.35,3.06) | 0.13(‐0.27,0.50) | |
| LD ABA IV + MTX | 0.92(0.35,2.27) | 0.95(0.52,1.66) | ‐0.02(‐0.23,0.18) | |
| LD ANA SC + MTX | 0.84(0.19,4.05) | 0.90(0.30,2.20) | ‐0.04(‐0.31,0.32) | |
| LD CERTO SC + MTX | 1.73(0.55,5.37) | 1.35(0.69,2.63) | 0.13(‐0.14,0.38) | |
| LD ETN SC + MTX | 1.52(0.52,4.45) | 1.27(0.68,2.43) | 0.10(‐0.15,0.34) | |
| LD GOLI IV + MTX | 0.89(0.36,2.24) | 0.93(0.49,1.66) | ‐0.02(‐0.22,0.19) | |
| LD TOCI IV + MTX | 0.72(0.21,2.28) | 0.80(0.34,1.75) | ‐0.07(‐0.33,0.18) | |
| LD TOFA PO + MTX | 1.50(0.37,5.83) | 1.26(0.51,2.57) | 0.09(‐0.21,0.40) | |
| HD TOCI IV | 1.13(0.47,2.63) | 1.08(0.66,1.95) | 0.03(‐0.18,0.21) | |
| HD TOFA PO | 1.22(0.38,3.66) | 1.13(0.56,2.37) | 0.05(‐0.23,0.28) | |
| HD ADA SC | 0.55(0.18,1.87) | 0.66(0.31,1.57) | ‐0.12(‐0.36,0.12) | |
| HD ETN SC | 0.84(0.31,2.23) | 0.89(0.46,1.71) | ‐0.04(‐0.26,0.18) | |
| HD GOLI SC | 1.12(0.42,2.87) | 1.07(0.59,1.99) | 0.02(‐0.20,0.23) | |
| HD ABA SC | 1.69(0.31,10.13) | 1.34(0.46,3.48) | 0.12(‐0.26,0.51) | |
| HD INF IV + MTX | 2.13(0.87,5.23) | 1.51(0.92,2.69) | 0.18(‐0.03,0.37) | |
| HD TOCI IV + MTX | 2.05(0.82,4.82) | 1.48(0.91,2.61) | 0.17(‐0.05,0.36) | |
| HD TOFA PO + MTX | 2.19(0.87,5.57) | 1.53(0.93,2.69) | 0.18(‐0.03,0.39) | |
| HD GOLI SC + MTX | 2.07(0.80,5.42) | 1.48(0.89,2.70) | 0.17(‐0.05,0.39) | |
| HD CERTO SC + MTX | 2.92(1.21,7.21) | 1.70(1.08,3.06) | 0.25(0.05,0.45) | |
| HD ADA SC + MTX | 2.44(0.73,7.73) | 1.59(0.85,3.00) | 0.21(‐0.07,0.46) | |
| HD TOCI IV + DMARD | 0.41(0.12,1.43) | 0.53(0.21,1.28) | ‐0.16(‐0.41,0.07) | |
| SD ANA SC + SD ETN SC + MTX | 1.10(0.30,3.93) | 1.06(0.45,2.20) | 0.02(‐0.25,0.31) | |
| SD ANA SC + LD ETN SC + MTX | 1.66(0.45,5.64) | 1.33(0.61,2.64) | 0.12(‐0.17,0.40) | |
| SD TOCI IV + MTX | SD ANA SC + MTX | 0.70(0.20,2.50) | 0.80(0.36,1.77) | ‐0.08(‐0.35,0.20) |
| SD CERTO SC + DMARD | 0.50(0.12,1.96) | 0.63(0.24,1.59) | ‐0.15(‐0.44,0.14) | |
| SD ADA SC + DMARD | 0.29(0.07,1.32) | 0.42(0.13,1.20) | ‐0.23(‐0.49,0.06) | |
| SD ETN SC + DMARD | 1.19(0.34,4.17) | 1.10(0.54,2.30) | 0.04(‐0.25,0.33) | |
| SD TOCI SC + DMARD | 0.46(0.11,1.92) | 0.60(0.20,1.48) | ‐0.16(‐0.44,0.14) | |
| LD ADA SC | 0.31(0.09,1.15) | 0.44(0.20,1.11) | ‐0.23(‐0.49,0.02) | |
| LD ETN SC | 0.33(0.11,0.96) | 0.46(0.23,0.96) | ‐0.22(‐0.46,‐0.01) | |
| LD GOLI IV | 0.36(0.10,1.24) | 0.50(0.19,1.16) | ‐0.20(‐0.45,0.04) | |
| LD TOCI IV | 0.06(0.01,0.30) | 0.10(0.02,0.38) | ‐0.36(‐0.60,‐0.14) | |
| LD ADA SC + MTX | 1.53(0.54,4.58) | 1.25(0.73,2.43) | 0.10(‐0.15,0.35) | |
| LD RITUX IV + MTX | 0.74(0.28,2.00) | 0.83(0.47,1.62) | ‐0.07(‐0.29,0.15) | |
| LD ADA IV + MTX | 1.40(0.18,9.16) | 1.19(0.30,2.80) | 0.08(‐0.33,0.48) | |
| LD ABA IV + MTX | 0.73(0.24,2.19) | 0.83(0.41,1.67) | ‐0.07(‐0.32,0.17) | |
| LD ANA SC + MTX | 0.68(0.18,2.54) | 0.80(0.29,1.65) | ‐0.08(‐0.33,0.22) | |
| LD CERTO SC + MTX | 1.38(0.42,4.91) | 1.19(0.60,2.37) | 0.08(‐0.21,0.36) | |
| LD ETN SC + MTX | 1.23(0.38,4.08) | 1.12(0.59,2.30) | 0.05(‐0.22,0.32) | |
| LD GOLI IV + MTX | 0.71(0.22,2.47) | 0.82(0.37,1.72) | ‐0.08(‐0.34,0.21) | |
| LD TOCI IV + MTX | 0.57(0.16,2.01) | 0.70(0.30,1.59) | ‐0.12(‐0.39,0.16) | |
| LD TOFA PO + MTX | 1.18(0.26,4.90) | 1.10(0.42,2.37) | 0.04(‐0.29,0.36) | |
| HD TOCI IV | 0.90(0.35,2.35) | 0.94(0.57,1.81) | ‐0.02(‐0.25,0.19) | |
| HD TOFA PO | 0.98(0.29,3.14) | 0.99(0.50,2.13) | ‐0.01(‐0.29,0.25) | |
| HD ADA SC | 0.44(0.13,1.65) | 0.58(0.27,1.45) | ‐0.17(‐0.44,0.10) | |
| HD ETN SC | 0.66(0.22,2.12) | 0.77(0.40,1.62) | ‐0.09(‐0.34,0.16) | |
| HD GOLI SC | 0.89(0.31,2.72) | 0.94(0.51,1.90) | ‐0.03(‐0.27,0.22) | |
| HD ABA SC | 1.34(0.24,8.97) | 1.17(0.41,3.20) | 0.07(‐0.33,0.49) | |
| HD INF IV + MTX | 1.69(0.62,4.76) | 1.31(0.80,2.53) | 0.13(‐0.11,0.36) | |
| HD TOCI IV + MTX | 1.61(0.61,4.65) | 1.28(0.79,2.51) | 0.11(‐0.12,0.35) | |
| HD TOFA PO + MTX | 1.73(0.63,5.21) | 1.32(0.79,2.67) | 0.13(‐0.11,0.38) | |
| HD GOLI SC + MTX | 1.65(0.58,5.18) | 1.28(0.76,2.51) | 0.12(‐0.13,0.37) | |
| HD CERTO SC + MTX | 2.34(0.90,6.51) | 1.49(0.96,2.81) | 0.20(‐0.02,0.42) | |
| HD ADA SC + MTX | 1.94(0.57,7.07) | 1.37(0.74,2.82) | 0.16(‐0.13,0.44) | |
| HD TOCI IV + DMARD | 0.34(0.10,1.28) | 0.47(0.18,1.18) | ‐0.21(‐0.47,0.05) | |
| SD ANA SC + SD ETN SC + MTX | 0.89(0.25,3.60) | 0.93(0.40,2.08) | ‐0.03(‐0.32,0.30) | |
| SD ANA SC + LD ETN SC + MTX | 1.31(0.35,5.32) | 1.16(0.53,2.44) | 0.06(‐0.24,0.38) | |
| SD CERTO SC + DMARD | SD TOCI IV + MTX | 0.69(0.17,2.87) | 0.77(0.30,2.15) | ‐0.07(‐0.36,0.20) |
| SD ADA SC + DMARD | 0.40(0.09,1.87) | 0.51(0.15,1.58) | ‐0.16(‐0.42,0.12) | |
| SD ETN SC + DMARD | 1.72(0.44,6.77) | 1.38(0.61,3.23) | 0.12(‐0.19,0.42) | |
| SD TOCI SC + DMARD | 0.65(0.15,2.82) | 0.74(0.25,2.02) | ‐0.08(‐0.36,0.22) | |
| LD ADA SC | 0.45(0.13,1.65) | 0.56(0.24,1.49) | ‐0.14(‐0.41,0.08) | |
| LD ETN SC | 0.46(0.16,1.50) | 0.57(0.27,1.37) | ‐0.14(‐0.38,0.07) | |
| LD GOLI IV | 0.51(0.13,2.07) | 0.62(0.21,1.70) | ‐0.12(‐0.39,0.14) | |
| LD TOCI IV | 0.09(0.01,0.40) | 0.13(0.02,0.46) | ‐0.28(‐0.51,‐0.10) | |
| LD ADA SC + MTX | 2.17(0.70,7.11) | 1.55(0.83,3.37) | 0.18(‐0.08,0.43) | |
| LD RITUX IV + MTX | 1.06(0.37,3.23) | 1.04(0.53,2.28) | 0.01(‐0.22,0.24) | |
| LD ADA IV + MTX | 1.98(0.23,13.19) | 1.46(0.34,3.71) | 0.16(‐0.26,0.54) | |
| LD ABA IV + MTX | 1.03(0.33,3.27) | 1.02(0.48,2.30) | 0.01(‐0.25,0.25) | |
| LD ANA SC + MTX | 0.95(0.19,5.03) | 0.97(0.29,2.74) | ‐0.01(‐0.31,0.36) | |
| LD CERTO SC + MTX | 1.96(0.52,7.60) | 1.47(0.68,3.41) | 0.15(‐0.15,0.45) | |
| LD ETN SC + MTX | 1.74(0.48,6.39) | 1.39(0.65,3.29) | 0.13(‐0.17,0.40) | |
| LD GOLI IV + MTX | 1.02(0.25,3.92) | 1.01(0.39,2.49) | 0.00(‐0.29,0.29) | |
| LD TOCI IV + MTX | 0.81(0.26,2.44) | 0.86(0.39,1.85) | ‐0.04(‐0.28,0.18) | |
| LD TOFA PO + MTX | 1.69(0.34,7.74) | 1.36(0.50,3.23) | 0.12(‐0.23,0.45) | |
| HD TOCI IV | 1.29(0.51,3.31) | 1.17(0.69,2.40) | 0.06(‐0.16,0.24) | |
| HD TOFA PO | 1.38(0.37,4.61) | 1.22(0.56,2.95) | 0.07(‐0.23,0.32) | |
| HD ADA SC | 0.64(0.18,2.34) | 0.73(0.33,1.88) | ‐0.09(‐0.36,0.15) | |
| HD ETN SC | 0.94(0.29,3.21) | 0.96(0.46,2.27) | ‐0.01(‐0.27,0.24) | |
| HD GOLI SC | 1.26(0.39,4.32) | 1.16(0.57,2.76) | 0.05(‐0.22,0.31) | |
| HD ABA SC | 1.90(0.35,11.83) | 1.45(0.51,4.05) | 0.14(‐0.23,0.54) | |
| HD INF IV + MTX | 2.42(0.81,7.42) | 1.63(0.90,3.53) | 0.21(‐0.05,0.44) | |
| HD TOCI IV + MTX | 2.33(0.88,6.34) | 1.61(0.94,3.39) | 0.20(‐0.03,0.40) | |
| HD TOFA PO + MTX | 2.51(0.77,8.00) | 1.65(0.88,3.62) | 0.21(‐0.06,0.45) | |
| HD GOLI SC + MTX | 2.34(0.71,8.13) | 1.60(0.83,3.76) | 0.20(‐0.08,0.46) | |
| HD CERTO SC + MTX | 3.34(1.08,10.66) | 1.87(1.03,4.06) | 0.28(0.02,0.51) | |
| HD ADA SC + MTX | 2.76(0.73,10.83) | 1.71(0.84,3.87) | 0.24(‐0.07,0.52) | |
| HD TOCI IV + DMARD | 0.48(0.13,1.88) | 0.58(0.22,1.57) | ‐0.13(‐0.39,0.12) | |
| SD ANA SC + SD ETN SC + MTX | 1.27(0.32,5.18) | 1.16(0.47,2.80) | 0.05(‐0.25,0.36) | |
| SD ANA SC + LD ETN SC + MTX | 1.89(0.47,7.69) | 1.44(0.63,3.35) | 0.14(‐0.17,0.45) | |
| SD ADA SC + DMARD | SD CERTO SC + DMARD | 0.60(0.16,2.21) | 0.67(0.22,1.78) | ‐0.08(‐0.30,0.15) |
| SD ETN SC + DMARD | 2.43(0.66,9.99) | 1.75(0.76,4.25) | 0.19(‐0.09,0.50) | |
| SD TOCI SC + DMARD | 0.96(0.24,3.63) | 0.97(0.33,2.46) | ‐0.01(‐0.25,0.27) | |
| LD ADA SC | 0.65(0.18,2.32) | 0.72(0.28,1.93) | ‐0.07(‐0.32,0.13) | |
| LD ETN SC | 0.68(0.21,2.24) | 0.74(0.32,1.86) | ‐0.06(‐0.30,0.13) | |
| LD GOLI IV | 0.75(0.16,3.15) | 0.80(0.24,2.39) | ‐0.05(‐0.32,0.22) | |
| LD TOCI IV | 0.12(0.02,0.64) | 0.16(0.03,0.68) | ‐0.20(‐0.43,‐0.05) | |
| LD ADA SC + MTX | 3.14(0.82,12.22) | 2.02(0.89,4.88) | 0.25(‐0.05,0.52) | |
| LD RITUX IV + MTX | 1.52(0.46,5.28) | 1.34(0.59,3.28) | 0.08(‐0.17,0.33) | |
| LD ADA IV + MTX | 2.77(0.33,19.55) | 1.85(0.43,5.19) | 0.22(‐0.17,0.62) | |
| LD ABA IV + MTX | 1.50(0.41,5.47) | 1.32(0.54,3.32) | 0.08(‐0.18,0.35) | |
| LD ANA SC + MTX | 1.39(0.25,7.96) | 1.26(0.35,3.73) | 0.06(‐0.24,0.44) | |
| LD CERTO SC + MTX | 2.84(0.67,12.21) | 1.90(0.77,4.65) | 0.23(‐0.08,0.54) | |
| LD ETN SC + MTX | 2.54(0.64,9.87) | 1.80(0.76,4.44) | 0.20(‐0.09,0.49) | |
| LD GOLI IV + MTX | 1.50(0.35,6.23) | 1.32(0.46,3.53) | 0.08(‐0.21,0.38) | |
| LD TOCI IV + MTX | 1.15(0.30,4.82) | 1.10(0.41,3.01) | 0.03(‐0.23,0.31) | |
| LD TOFA PO + MTX | 2.41(0.44,12.35) | 1.76(0.56,4.60) | 0.19(‐0.16,0.53) | |
| HD TOCI IV | 1.87(0.64,5.60) | 1.53(0.75,3.52) | 0.13(‐0.10,0.33) | |
| HD TOFA PO | 1.98(0.59,6.42) | 1.58(0.72,3.76) | 0.15(‐0.12,0.37) | |
| HD ADA SC | 0.92(0.26,3.13) | 0.94(0.38,2.46) | ‐0.01(‐0.26,0.20) | |
| HD ETN SC | 1.36(0.40,4.99) | 1.25(0.53,3.13) | 0.06(‐0.19,0.32) | |
| HD GOLI SC | 1.83(0.50,6.69) | 1.51(0.65,3.81) | 0.13(‐0.15,0.38) | |
| HD ABA SC | 2.77(0.51,16.05) | 1.90(0.64,5.14) | 0.22(‐0.14,0.58) | |
| HD INF IV + MTX | 3.49(1.03,12.10) | 2.11(1.02,4.80) | 0.28(0.01,0.53) | |
| HD TOCI IV + MTX | 3.33(1.03,11.15) | 2.08(1.02,4.74) | 0.27(0.01,0.50) | |
| HD TOFA PO + MTX | 3.59(1.01,12.56) | 2.14(1.01,4.94) | 0.29(0.00,0.54) | |
| HD GOLI SC + MTX | 3.41(1.00,13.70) | 2.08(1.00,5.04) | 0.27(0.00,0.55) | |
| HD CERTO SC + MTX | 4.76(1.39,17.80) | 2.42(1.20,5.58) | 0.35(0.08,0.60) | |
| HD ADA SC + MTX | 3.98(0.87,18.35) | 2.22(0.92,5.31) | 0.31(‐0.03,0.61) | |
| HD TOCI IV + DMARD | 0.69(0.22,2.34) | 0.75(0.30,1.91) | ‐0.06(‐0.27,0.16) | |
| SD ANA SC + SD ETN SC + MTX | 1.83(0.40,8.62) | 1.50(0.52,4.00) | 0.13(‐0.19,0.45) | |
| SD ANA SC + LD ETN SC + MTX | 2.73(0.58,12.40) | 1.86(0.70,4.57) | 0.22(‐0.11,0.54) | |
| SD ETN SC + DMARD | SD ADA SC + DMARD | 4.19(1.03,16.78) | 2.67(1.02,7.96) | 0.27(0.01,0.53) |
| SD TOCI SC + DMARD | 1.61(0.45,5.68) | 1.44(0.53,3.88) | 0.07(‐0.13,0.31) | |
| LD ADA SC | 1.10(0.25,5.16) | 1.08(0.34,4.15) | 0.01(‐0.25,0.19) | |
| LD ETN SC | 1.12(0.30,4.34) | 1.10(0.40,3.61) | 0.02(‐0.22,0.19) | |
| LD GOLI IV | 1.26(0.25,6.03) | 1.21(0.34,4.43) | 0.03(‐0.23,0.28) | |
| LD TOCI IV | 0.21(0.03,1.31) | 0.25(0.04,1.28) | ‐0.12(‐0.36,0.02) | |
| LD ADA SC + MTX | 5.32(1.22,21.84) | 3.02(1.15,9.46) | 0.34(0.04,0.57) | |
| LD RITUX IV + MTX | 2.61(0.71,9.79) | 2.03(0.79,6.26) | 0.17(‐0.07,0.37) | |
| LD ADA IV + MTX | 4.64(0.55,36.88) | 2.76(0.64,9.90) | 0.30(‐0.09,0.69) | |
| LD ABA IV + MTX | 2.57(0.61,9.99) | 2.01(0.71,6.28) | 0.16(‐0.10,0.39) | |
| LD ANA SC + MTX | 2.33(0.39,15.09) | 1.86(0.49,6.95) | 0.15(‐0.15,0.52) | |
| LD CERTO SC + MTX | 4.80(1.03,20.93) | 2.84(1.02,8.79) | 0.31(0.00,0.58) | |
| LD ETN SC + MTX | 4.24(0.92,18.33) | 2.70(0.95,8.61) | 0.28(‐0.02,0.54) | |
| LD GOLI IV + MTX | 2.50(0.53,11.38) | 1.98(0.63,6.55) | 0.15(‐0.11,0.44) | |
| LD TOCI IV + MTX | 1.96(0.44,8.68) | 1.69(0.55,5.53) | 0.11(‐0.15,0.37) | |
| LD TOFA PO + MTX | 4.02(0.75,22.03) | 2.58(0.82,8.69) | 0.27(‐0.05,0.59) | |
| HD TOCI IV | 3.12(0.93,10.30) | 2.29(0.95,6.72) | 0.21(‐0.02,0.37) | |
| HD TOFA PO | 3.34(0.77,14.33) | 2.38(0.84,8.27) | 0.23(‐0.06,0.44) | |
| HD ADA SC | 1.53(0.37,7.20) | 1.41(0.48,5.23) | 0.07(‐0.20,0.27) | |
| HD ETN SC | 2.29(0.55,9.79) | 1.86(0.67,5.97) | 0.14(‐0.12,0.38) | |
| HD GOLI SC | 3.15(0.75,12.83) | 2.30(0.82,7.36) | 0.21(‐0.06,0.44) | |
| HD ABA SC | 4.68(0.73,35.39) | 2.80(0.79,11.14) | 0.30(‐0.07,0.66) | |
| HD INF IV + MTX | 5.90(1.53,22.18) | 3.21(1.28,9.75) | 0.36(0.10,0.58) | |
| HD TOCI IV + MTX | 5.62(1.49,20.38) | 3.15(1.26,9.32) | 0.35(0.09,0.55) | |
| HD TOFA PO + MTX | 6.10(1.44,22.51) | 3.25(1.25,9.98) | 0.37(0.09,0.59) | |
| HD GOLI SC + MTX | 5.85(1.36,23.34) | 3.15(1.20,10.00) | 0.36(0.07,0.59) | |
| HD CERTO SC + MTX | 8.25(2.16,30.92) | 3.66(1.48,11.08) | 0.44(0.17,0.65) | |
| HD ADA SC + MTX | 6.84(1.41,32.79) | 3.36(1.23,10.84) | 0.39(0.07,0.67) | |
| HD TOCI IV + DMARD | 1.17(0.38,3.50) | 1.14(0.47,2.90) | 0.02(‐0.16,0.19) | |
| SD ANA SC + SD ETN SC + MTX | 3.13(0.63,15.56) | 2.26(0.72,7.46) | 0.20(‐0.09,0.50) | |
| SD ANA SC + LD ETN SC + MTX | 4.64(0.94,21.72) | 2.83(0.96,8.93) | 0.30(‐0.01,0.59) | |
| SD TOCI SC + DMARD | SD ETN SC + DMARD | 0.39(0.09,1.50) | 0.55(0.19,1.27) | ‐0.20(‐0.48,0.09) |
| LD ADA SC | 0.26(0.07,1.01) | 0.40(0.18,1.01) | ‐0.27(‐0.54,0.00) | |
| LD ETN SC | 0.27(0.09,0.82) | 0.42(0.21,0.87) | ‐0.26(‐0.51,‐0.04) | |
| LD GOLI IV | 0.30(0.07,1.17) | 0.45(0.16,1.11) | ‐0.24(‐0.51,0.04) | |
| LD TOCI IV | 0.05(0.01,0.26) | 0.09(0.02,0.36) | ‐0.40(‐0.66,‐0.17) | |
| LD ADA SC + MTX | 1.29(0.41,4.09) | 1.13(0.64,2.23) | 0.06(‐0.21,0.33) | |
| LD RITUX IV + MTX | 0.62(0.21,1.88) | 0.76(0.40,1.50) | ‐0.11(‐0.37,0.14) | |
| LD ADA IV + MTX | 1.16(0.15,7.23) | 1.08(0.28,2.45) | 0.03(‐0.38,0.44) | |
| LD ABA IV + MTX | 0.61(0.18,1.97) | 0.75(0.36,1.54) | ‐0.11(‐0.39,0.16) | |
| LD ANA SC + MTX | 0.56(0.10,3.09) | 0.71(0.21,1.89) | ‐0.13(‐0.45,0.27) | |
| LD CERTO SC + MTX | 1.17(0.29,4.63) | 1.08(0.51,2.27) | 0.04(‐0.29,0.35) | |
| LD ETN SC + MTX | 1.03(0.29,3.59) | 1.02(0.51,2.04) | 0.01(‐0.29,0.30) | |
| LD GOLI IV + MTX | 0.61(0.16,2.30) | 0.74(0.31,1.61) | ‐0.11(‐0.41,0.18) | |
| LD TOCI IV + MTX | 0.48(0.12,1.70) | 0.64(0.25,1.41) | ‐0.16(‐0.45,0.12) | |
| LD TOFA PO + MTX | 1.00(0.19,4.51) | 1.00(0.37,2.17) | 0.00(‐0.36,0.35) | |
| HD TOCI IV | 0.77(0.27,2.14) | 0.86(0.51,1.63) | ‐0.06(‐0.31,0.17) | |
| HD TOFA PO | 0.82(0.22,2.74) | 0.89(0.46,1.91) | ‐0.05(‐0.35,0.23) | |
| HD ADA SC | 0.37(0.10,1.42) | 0.52(0.25,1.27) | ‐0.21(‐0.49,0.07) | |
| HD ETN SC | 0.56(0.18,1.70) | 0.71(0.36,1.41) | ‐0.13(‐0.39,0.11) | |
| HD GOLI SC | 0.75(0.23,2.38) | 0.85(0.45,1.72) | ‐0.07(‐0.34,0.19) | |
| HD ABA SC | 1.14(0.20,7.19) | 1.07(0.40,2.73) | 0.03(‐0.37,0.44) | |
| HD INF IV + MTX | 1.43(0.45,4.68) | 1.19(0.70,2.32) | 0.09(‐0.19,0.36) | |
| HD TOCI IV + MTX | 1.35(0.48,4.16) | 1.16(0.71,2.26) | 0.07(‐0.17,0.33) | |
| HD TOFA PO + MTX | 1.46(0.46,4.62) | 1.21(0.70,2.29) | 0.09(‐0.19,0.35) | |
| HD GOLI SC + MTX | 1.38(0.43,4.58) | 1.17(0.67,2.32) | 0.08(‐0.20,0.36) | |
| HD CERTO SC + MTX | 1.98(0.65,5.90) | 1.36(0.84,2.66) | 0.16(‐0.10,0.41) | |
| HD ADA SC + MTX | 1.63(0.45,6.67) | 1.25(0.65,2.55) | 0.12(‐0.19,0.43) | |
| HD TOCI IV + DMARD | 0.28(0.08,1.02) | 0.43(0.17,1.02) | ‐0.25(‐0.51,0.01) | |
| SD ANA SC + SD ETN SC + MTX | 0.73(0.18,3.07) | 0.84(0.35,1.87) | ‐0.07(‐0.38,0.26) | |
| SD ANA SC + LD ETN SC + MTX | 1.10(0.27,4.41) | 1.05(0.47,2.23) | 0.02(‐0.30,0.34) | |
| LD ADA SC | SD TOCI SC + DMARD | 0.69(0.15,2.89) | 0.75(0.26,2.49) | ‐0.06(‐0.37,0.15) |
| LD ETN SC | 0.72(0.18,2.77) | 0.77(0.30,2.35) | ‐0.05(‐0.34,0.14) | |
| LD GOLI IV | 0.77(0.15,3.70) | 0.82(0.24,2.77) | ‐0.04(‐0.35,0.22) | |
| LD TOCI IV | 0.13(0.02,0.74) | 0.17(0.03,0.76) | ‐0.19(‐0.49,‐0.03) | |
| LD ADA SC + MTX | 3.34(0.82,13.39) | 2.09(0.89,6.26) | 0.26(‐0.05,0.52) | |
| LD RITUX IV + MTX | 1.60(0.43,6.16) | 1.39(0.59,4.04) | 0.09(‐0.19,0.32) | |
| LD ADA IV + MTX | 2.88(0.34,24.83) | 1.91(0.45,6.86) | 0.23(‐0.19,0.65) | |
| LD ABA IV + MTX | 1.59(0.38,6.12) | 1.39(0.54,3.95) | 0.09(‐0.22,0.34) | |
| LD ANA SC + MTX | 1.47(0.28,8.57) | 1.30(0.38,4.59) | 0.07(‐0.25,0.44) | |
| LD CERTO SC + MTX | 3.02(0.67,13.54) | 1.98(0.78,5.72) | 0.23(‐0.09,0.53) | |
| LD ETN SC + MTX | 2.65(0.56,11.24) | 1.85(0.71,5.70) | 0.21(‐0.13,0.48) | |
| LD GOLI IV + MTX | 1.53(0.32,7.64) | 1.35(0.46,4.40) | 0.08(‐0.24,0.40) | |
| LD TOCI IV + MTX | 1.23(0.28,5.39) | 1.16(0.42,3.63) | 0.04(‐0.25,0.31) | |
| LD TOFA PO + MTX | 2.59(0.47,14.40) | 1.82(0.61,5.73) | 0.20(‐0.16,0.54) | |
| HD TOCI IV | 1.97(0.59,6.57) | 1.59(0.73,4.24) | 0.14(‐0.13,0.33) | |
| HD TOFA PO | 2.09(0.50,8.90) | 1.64(0.67,5.08) | 0.16(‐0.16,0.39) | |
| HD ADA SC | 0.98(0.22,4.20) | 0.98(0.36,3.28) | 0.00(‐0.32,0.22) | |
| HD ETN SC | 1.47(0.36,6.01) | 1.31(0.52,3.96) | 0.07(‐0.22,0.32) | |
| HD GOLI SC | 1.94(0.48,7.88) | 1.57(0.64,4.74) | 0.13(‐0.17,0.38) | |
| HD ABA SC | 2.90(0.46,23.04) | 1.94(0.61,7.28) | 0.23(‐0.17,0.62) | |
| HD INF IV + MTX | 3.70(0.92,14.22) | 2.19(0.95,6.30) | 0.29(‐0.02,0.52) | |
| HD TOCI IV + MTX | 3.55(0.95,12.45) | 2.18(0.97,6.02) | 0.28(‐0.01,0.50) | |
| HD TOFA PO + MTX | 3.81(0.95,14.85) | 2.24(0.97,6.42) | 0.29(‐0.01,0.54) | |
| HD GOLI SC + MTX | 3.63(0.90,14.77) | 2.18(0.94,6.34) | 0.28(‐0.03,0.54) | |
| HD CERTO SC + MTX | 5.07(1.33,19.89) | 2.51(1.15,7.28) | 0.36(0.07,0.60) | |
| HD ADA SC + MTX | 4.25(0.84,20.80) | 2.32(0.91,6.75) | 0.31(‐0.04,0.62) | |
| HD TOCI IV + DMARD | 0.72(0.24,2.22) | 0.78(0.35,1.87) | ‐0.05(‐0.26,0.13) | |
| SD ANA SC + SD ETN SC + MTX | 1.97(0.38,9.73) | 1.57(0.52,4.79) | 0.13(‐0.20,0.45) | |
| SD ANA SC + LD ETN SC + MTX | 3.01(0.56,12.97) | 1.96(0.69,5.90) | 0.23(‐0.13,0.52) | |
| LD ETN SC | LD ADA SC | 1.04(0.35,2.94) | 1.03(0.42,2.40) | 0.01(‐0.16,0.16) |
| LD GOLI IV | 1.15(0.29,4.45) | 1.12(0.34,3.09) | 0.02(‐0.18,0.27) | |
| LD TOCI IV | 0.19(0.03,0.90) | 0.23(0.04,0.91) | ‐0.13(‐0.28,‐0.01) | |
| LD ADA SC + MTX | 4.87(1.49,15.92) | 2.83(1.31,5.92) | 0.33(0.08,0.56) | |
| LD RITUX IV + MTX | 2.36(0.80,6.85) | 1.89(0.85,4.11) | 0.16(‐0.04,0.37) | |
| LD ADA IV + MTX | 4.39(0.62,26.94) | 2.69(0.67,6.30) | 0.30(‐0.07,0.66) | |
| LD ABA IV + MTX | 2.31(0.66,7.47) | 1.86(0.74,4.26) | 0.15(‐0.07,0.39) | |
| LD ANA SC + MTX | 2.16(0.39,11.29) | 1.77(0.46,4.90) | 0.14(‐0.13,0.51) | |
| LD CERTO SC + MTX | 4.38(1.11,17.68) | 2.71(1.08,5.91) | 0.30(0.02,0.59) | |
| LD ETN SC + MTX | 3.89(1.08,13.39) | 2.52(1.06,5.44) | 0.27(0.02,0.54) | |
| LD GOLI IV + MTX | 2.28(0.59,8.60) | 1.83(0.66,4.47) | 0.15(‐0.09,0.44) | |
| LD TOCI IV + MTX | 1.81(0.49,5.91) | 1.57(0.57,3.64) | 0.10(‐0.11,0.35) | |
| LD TOFA PO + MTX | 3.79(0.74,15.77) | 2.50(0.79,5.64) | 0.27(‐0.05,0.57) | |
| HD TOCI IV | 2.90(1.06,7.27) | 2.15(1.05,4.29) | 0.21(0.01,0.38) | |
| HD TOFA PO | 3.08(1.11,8.05) | 2.22(1.08,4.53) | 0.22(0.02,0.40) | |
| HD ADA SC | 1.41(0.67,2.96) | 1.31(0.73,2.36) | 0.05(‐0.07,0.19) | |
| HD ETN SC | 2.12(0.63,6.81) | 1.76(0.69,4.07) | 0.13(‐0.08,0.37) | |
| HD GOLI SC | 2.88(0.90,8.57) | 2.12(0.92,4.70) | 0.20(‐0.02,0.42) | |
| HD ABA SC | 4.27(0.90,22.60) | 2.65(0.93,6.40) | 0.30(‐0.02,0.63) | |
| HD INF IV + MTX | 5.40(1.69,16.10) | 2.99(1.40,6.04) | 0.36(0.11,0.57) | |
| HD TOCI IV + MTX | 5.22(1.74,14.19) | 2.94(1.43,5.80) | 0.35(0.12,0.54) | |
| HD TOFA PO + MTX | 5.51(1.82,16.31) | 2.99(1.48,6.04) | 0.36(0.13,0.57) | |
| HD GOLI SC + MTX | 5.32(1.53,16.94) | 2.96(1.34,6.13) | 0.35(0.09,0.58) | |
| HD CERTO SC + MTX | 7.41(2.25,23.01) | 3.40(1.66,6.78) | 0.44(0.18,0.64) | |
| HD ADA SC + MTX | 6.10(1.57,24.34) | 3.11(1.37,6.65) | 0.39(0.09,0.65) | |
| HD TOCI IV + DMARD | 1.07(0.28,3.93) | 1.05(0.34,2.76) | 0.01(‐0.16,0.24) | |
| SD ANA SC + SD ETN SC + MTX | 2.81(0.67,11.10) | 2.09(0.73,4.98) | 0.20(‐0.07,0.50) | |
| SD ANA SC + LD ETN SC + MTX | 4.24(0.97,16.58) | 2.64(0.98,5.85) | 0.30(‐0.01,0.58) | |
| LD GOLI IV | LD ETN SC | 1.11(0.33,3.54) | 1.09(0.39,2.59) | 0.02(‐0.15,0.24) |
| LD TOCI IV | 0.18(0.03,0.79) | 0.22(0.04,0.81) | ‐0.14(‐0.28,‐0.02) | |
| LD ADA SC + MTX | 4.67(1.86,12.20) | 2.73(1.50,5.07) | 0.32(0.13,0.54) | |
| LD RITUX IV + MTX | 2.26(0.97,5.21) | 1.82(0.98,3.37) | 0.15(0.00,0.34) | |
| LD ADA IV + MTX | 4.10(0.66,25.89) | 2.54(0.71,5.84) | 0.30(‐0.06,0.66) | |
| LD ABA IV + MTX | 2.21(0.89,5.52) | 1.80(0.92,3.38) | 0.14(‐0.02,0.35) | |
| LD ANA SC + MTX | 2.08(0.48,9.29) | 1.72(0.54,4.08) | 0.13(‐0.10,0.47) | |
| LD CERTO SC + MTX | 4.18(1.39,13.73) | 2.59(1.27,5.14) | 0.30(0.06,0.55) | |
| LD ETN SC + MTX | 3.74(1.36,10.23) | 2.44(1.24,4.59) | 0.27(0.06,0.49) | |
| LD GOLI IV + MTX | 2.14(0.71,6.86) | 1.76(0.76,3.82) | 0.14(‐0.06,0.40) | |
| LD TOCI IV + MTX | 1.75(0.54,5.07) | 1.53(0.61,3.27) | 0.10(‐0.10,0.33) | |
| LD TOFA PO + MTX | 3.63(0.92,13.79) | 2.37(0.93,5.09) | 0.26(‐0.01,0.55) | |
| HD TOCI IV | 2.75(1.33,5.89) | 2.06(1.22,3.69) | 0.20(0.06,0.35) | |
| HD TOFA PO | 2.95(1.04,7.65) | 2.15(1.03,4.40) | 0.21(0.01,0.40) | |
| HD ADA SC | 1.35(0.49,4.07) | 1.27(0.57,3.00) | 0.05(‐0.12,0.24) | |
| HD ETN SC | 2.03(0.82,4.99) | 1.69(0.85,3.23) | 0.13(‐0.03,0.32) | |
| HD GOLI SC | 2.72(1.08,7.03) | 2.06(1.06,3.99) | 0.19(0.01,0.39) | |
| HD ABA SC | 4.14(0.85,22.78) | 2.53(0.88,6.31) | 0.30(‐0.03,0.63) | |
| HD INF IV + MTX | 5.17(2.25,12.14) | 2.87(1.68,5.13) | 0.35(0.17,0.53) | |
| HD TOCI IV + MTX | 4.98(2.21,11.49) | 2.83(1.64,5.15) | 0.34(0.17,0.51) | |
| HD TOFA PO + MTX | 5.30(2.31,12.72) | 2.91(1.67,5.28) | 0.35(0.17,0.54) | |
| HD GOLI SC + MTX | 5.08(2.05,12.85) | 2.85(1.59,5.23) | 0.34(0.15,0.54) | |
| HD CERTO SC + MTX | 7.09(3.03,16.65) | 3.29(1.95,5.89) | 0.43(0.23,0.59) | |
| HD ADA SC + MTX | 5.98(1.81,19.47) | 3.02(1.51,5.84) | 0.38(0.11,0.62) | |
| HD TOCI IV + DMARD | 1.02(0.32,3.40) | 1.02(0.39,2.53) | 0.00(‐0.16,0.23) | |
| SD ANA SC + SD ETN SC + MTX | 2.69(0.82,9.62) | 2.02(0.86,4.34) | 0.19(‐0.03,0.48) | |
| SD ANA SC + LD ETN SC + MTX | 4.01(1.27,13.05) | 2.54(1.19,5.03) | 0.29(0.04,0.55) | |
| LD TOCI IV | LD GOLI IV | 0.17(0.03,0.91) | 0.20(0.04,0.92) | ‐0.15(‐0.39,‐0.01) |
| LD ADA SC + MTX | 4.25(1.31,14.65) | 2.52(1.19,6.45) | 0.30(0.06,0.53) | |
| LD RITUX IV + MTX | 2.07(0.67,6.74) | 1.70(0.77,4.45) | 0.13(‐0.09,0.34) | |
| LD ADA IV + MTX | 3.84(0.48,26.26) | 2.35(0.55,7.55) | 0.27(‐0.12,0.66) | |
| LD ABA IV + MTX | 2.02(0.62,7.01) | 1.67(0.72,4.41) | 0.13(‐0.10,0.35) | |
| LD ANA SC + MTX | 1.89(0.36,10.40) | 1.59(0.45,5.05) | 0.11(‐0.17,0.48) | |
| LD CERTO SC + MTX | 3.84(1.04,16.07) | 2.38(1.03,6.81) | 0.28(0.01,0.56) | |
| LD ETN SC + MTX | 3.42(0.94,12.61) | 2.26(0.96,6.13) | 0.25(‐0.01,0.50) | |
| LD GOLI IV + MTX | 1.99(0.74,5.68) | 1.63(0.81,3.78) | 0.12(‐0.06,0.35) | |
| LD TOCI IV + MTX | 1.61(0.39,6.55) | 1.42(0.50,4.14) | 0.08(‐0.18,0.33) | |
| LD TOFA PO + MTX | 3.29(0.72,15.29) | 2.19(0.80,6.39) | 0.24(‐0.06,0.55) | |
| HD TOCI IV | 2.51(0.84,7.85) | 1.93(0.91,5.00) | 0.18(‐0.04,0.36) | |
| HD TOFA PO | 2.67(0.72,9.88) | 1.99(0.81,5.75) | 0.20(‐0.08,0.41) | |
| HD ADA SC | 1.24(0.32,5.01) | 1.17(0.44,3.65) | 0.03(‐0.22,0.25) | |
| HD ETN SC | 1.83(0.54,6.74) | 1.57(0.65,4.33) | 0.11(‐0.13,0.34) | |
| HD GOLI SC | 2.47(0.75,8.14) | 1.90(0.83,5.01) | 0.17(‐0.06,0.39) | |
| HD ABA SC | 3.74(0.60,27.98) | 2.34(0.71,8.23) | 0.27(‐0.10,0.65) | |
| HD INF IV + MTX | 4.69(1.60,15.36) | 2.65(1.30,6.97) | 0.33(0.11,0.53) | |
| HD TOCI IV + MTX | 4.56(1.52,13.83) | 2.62(1.27,6.60) | 0.32(0.09,0.51) | |
| HD TOFA PO + MTX | 4.81(1.46,16.33) | 2.67(1.23,7.00) | 0.33(0.09,0.56) | |
| HD GOLI SC + MTX | 4.62(1.46,15.62) | 2.64(1.23,6.90) | 0.32(0.08,0.55) | |
| HD CERTO SC + MTX | 6.52(2.12,21.71) | 3.02(1.47,8.12) | 0.41(0.18,0.60) | |
| HD ADA SC + MTX | 5.35(1.40,22.28) | 2.80(1.21,7.36) | 0.36(0.07,0.62) | |
| HD TOCI IV + DMARD | 0.93(0.23,3.99) | 0.94(0.32,3.16) | ‐0.01(‐0.26,0.22) | |
| SD ANA SC + SD ETN SC + MTX | 2.41(0.61,11.84) | 1.87(0.69,5.82) | 0.17(‐0.10,0.48) | |
| SD ANA SC + LD ETN SC + MTX | 3.65(0.85,16.59) | 2.31(0.90,6.80) | 0.26(‐0.03,0.55) | |
| LD ADA SC + MTX | LD TOCI IV | 25.53(5.70,150.60) | 12.46(3.50,66.43) | 0.46(0.25,0.68) |
| LD RITUX IV + MTX | 12.12(3.02,67.88) | 8.24(2.38,43.65) | 0.29(0.14,0.48) | |
| LD ADA IV + MTX | 23.04(2.12,238.20) | 11.12(1.92,70.61) | 0.44(0.07,0.80) | |
| LD ABA IV + MTX | 11.85(2.79,70.60) | 8.06(2.28,45.31) | 0.29(0.12,0.50) | |
| LD ANA SC + MTX | 11.47(1.62,90.12) | 7.71(1.51,42.95) | 0.27(0.04,0.62) | |
| LD CERTO SC + MTX | 22.25(4.67,152.50) | 11.39(3.16,62.75) | 0.44(0.19,0.70) | |
| LD ETN SC + MTX | 20.54(4.45,112.80) | 10.99(3.07,57.41) | 0.41(0.19,0.64) | |
| LD GOLI IV + MTX | 11.71(2.39,76.13) | 8.05(2.04,42.32) | 0.28(0.09,0.55) | |
| LD TOCI IV + MTX | 9.40(2.06,49.65) | 6.78(1.84,32.50) | 0.23(0.07,0.47) | |
| LD TOFA PO + MTX | 19.86(3.10,146.10) | 10.62(2.49,64.70) | 0.40(0.12,0.70) | |
| HD TOCI IV | 14.93(3.90,75.23) | 9.42(2.87,47.66) | 0.34(0.20,0.48) | |
| HD TOFA PO | 15.66(3.47,102.30) | 9.71(2.62,55.93) | 0.35(0.18,0.53) | |
| HD ADA SC | 7.35(1.51,48.47) | 5.80(1.44,33.74) | 0.19(0.05,0.36) | |
| HD ETN SC | 11.19(2.44,60.78) | 7.80(2.04,39.32) | 0.27(0.10,0.49) | |
| HD GOLI SC | 14.83(3.29,82.73) | 9.44(2.55,47.97) | 0.33(0.15,0.53) | |
| HD ABA SC | 22.78(3.05,200.40) | 11.47(2.48,66.75) | 0.43(0.14,0.75) | |
| HD INF IV + MTX | 28.18(6.73,162.10) | 13.13(3.77,69.26) | 0.49(0.30,0.68) | |
| HD TOCI IV + MTX | 26.62(6.91,137.90) | 12.86(3.88,65.61) | 0.48(0.30,0.65) | |
| HD TOFA PO + MTX | 28.74(6.44,171.10) | 13.26(3.78,73.25) | 0.50(0.29,0.69) | |
| HD GOLI SC + MTX | 27.56(5.96,166.40) | 12.94(3.59,69.76) | 0.49(0.27,0.69) | |
| HD CERTO SC + MTX | 38.93(9.22,211.20) | 15.06(4.51,77.16) | 0.57(0.37,0.74) | |
| HD ADA SC + MTX | 32.21(6.08,214.40) | 13.87(3.73,74.13) | 0.52(0.26,0.76) | |
| HD TOCI IV + DMARD | 5.61(1.03,35.62) | 4.66(1.03,26.81) | 0.14(0.00,0.37) | |
| SD ANA SC + SD ETN SC + MTX | 15.09(2.41,97.04) | 9.22(2.04,48.43) | 0.33(0.10,0.62) | |
| SD ANA SC + LD ETN SC + MTX | 22.49(3.81,146.20) | 11.54(2.87,63.49) | 0.44(0.16,0.70) | |
| LD RITUX IV + MTX | LD ADA SC + MTX | 0.49(0.20,1.16) | 0.67(0.41,1.09) | ‐0.17(‐0.37,0.04) |
| LD ADA IV + MTX | 0.90(0.15,4.77) | 0.95(0.27,1.84) | ‐0.02(‐0.38,0.34) | |
| LD ABA IV + MTX | 0.47(0.19,1.20) | 0.66(0.37,1.11) | ‐0.17(‐0.37,0.04) | |
| LD ANA SC + MTX | 0.44(0.10,2.00) | 0.63(0.21,1.39) | ‐0.18(‐0.47,0.16) | |
| LD CERTO SC + MTX | 0.90(0.28,3.03) | 0.95(0.50,1.70) | ‐0.02(‐0.29,0.25) | |
| LD ETN SC + MTX | 0.80(0.26,2.32) | 0.90(0.50,1.53) | ‐0.05(‐0.31,0.20) | |
| LD GOLI IV + MTX | 0.46(0.15,1.53) | 0.64(0.30,1.24) | ‐0.18(‐0.43,0.10) | |
| LD TOCI IV + MTX | 0.37(0.11,1.16) | 0.56(0.24,1.10) | ‐0.22(‐0.47,0.04) | |
| LD TOFA PO + MTX | 0.76(0.19,2.96) | 0.88(0.36,1.62) | ‐0.06(‐0.36,0.25) | |
| HD TOCI IV | 0.59(0.26,1.36) | 0.75(0.50,1.21) | ‐0.13(‐0.32,0.07) | |
| HD TOFA PO | 0.64(0.20,1.86) | 0.79(0.43,1.44) | ‐0.11(‐0.37,0.15) | |
| HD ADA SC | 0.29(0.09,0.98) | 0.46(0.23,0.98) | ‐0.27(‐0.52,‐0.01) | |
| HD ETN SC | 0.44(0.17,1.15) | 0.62(0.34,1.09) | ‐0.19(‐0.41,0.03) | |
| HD GOLI SC | 0.58(0.21,1.64) | 0.75(0.44,1.31) | ‐0.13(‐0.36,0.12) | |
| HD ABA SC | 0.89(0.16,4.91) | 0.95(0.36,2.08) | ‐0.03(‐0.41,0.37) | |
| HD INF IV + MTX | 1.11(0.47,2.56) | 1.05(0.71,1.63) | 0.03(‐0.18,0.23) | |
| HD TOCI IV + MTX | 1.05(0.45,2.46) | 1.02(0.70,1.62) | 0.01(‐0.18,0.22) | |
| HD TOFA PO + MTX | 1.15(0.48,2.67) | 1.06(0.72,1.65) | 0.03(‐0.18,0.23) | |
| HD GOLI SC + MTX | 1.07(0.45,2.77) | 1.03(0.68,1.67) | 0.02(‐0.19,0.24) | |
| HD CERTO SC + MTX | 1.55(0.62,3.71) | 1.20(0.83,1.87) | 0.10(‐0.11,0.30) | |
| HD ADA SC + MTX | 1.26(0.50,3.32) | 1.10(0.70,1.67) | 0.05(‐0.16,0.27) | |
| HD TOCI IV + DMARD | 0.22(0.06,0.79) | 0.37(0.15,0.87) | ‐0.32(‐0.55,‐0.05) | |
| SD ANA SC + SD ETN SC + MTX | 0.57(0.17,2.15) | 0.74(0.34,1.46) | ‐0.13(‐0.40,0.18) | |
| SD ANA SC + LD ETN SC + MTX | 0.86(0.25,2.99) | 0.93(0.46,1.64) | ‐0.04(‐0.32,0.26) | |
| LD ADA IV + MTX | LD RITUX IV + MTX | 1.85(0.28,10.98) | 1.41(0.40,3.03) | 0.14(‐0.22,0.52) |
| LD ABA IV + MTX | 0.98(0.43,2.26) | 0.99(0.56,1.67) | 0.00(‐0.18,0.18) | |
| LD ANA SC + MTX | 0.91(0.22,4.20) | 0.94(0.30,2.19) | ‐0.02(‐0.27,0.33) | |
| LD CERTO SC + MTX | 1.86(0.65,5.46) | 1.42(0.75,2.53) | 0.15(‐0.10,0.39) | |
| LD ETN SC + MTX | 1.62(0.65,4.27) | 1.33(0.76,2.35) | 0.11(‐0.10,0.33) | |
| LD GOLI IV + MTX | 0.96(0.32,2.91) | 0.97(0.44,1.87) | ‐0.01(‐0.23,0.25) | |
| LD TOCI IV + MTX | 0.77(0.26,2.21) | 0.84(0.37,1.70) | ‐0.05(‐0.27,0.17) | |
| LD TOFA PO + MTX | 1.58(0.46,5.37) | 1.31(0.59,2.45) | 0.11(‐0.16,0.39) | |
| HD TOCI IV | 1.21(0.60,2.57) | 1.12(0.74,1.88) | 0.04(‐0.12,0.21) | |
| HD TOFA PO | 1.30(0.45,3.67) | 1.17(0.62,2.39) | 0.06(‐0.19,0.28) | |
| HD ADA SC | 0.60(0.21,1.86) | 0.70(0.33,1.58) | ‐0.10(‐0.32,0.12) | |
| HD ETN SC | 0.91(0.36,2.17) | 0.94(0.51,1.66) | ‐0.02(‐0.22,0.17) | |
| HD GOLI SC | 1.19(0.47,3.01) | 1.12(0.63,2.04) | 0.04(‐0.17,0.25) | |
| HD ABA SC | 1.83(0.37,10.53) | 1.41(0.52,3.31) | 0.14(‐0.21,0.52) | |
| HD INF IV + MTX | 2.29(1.04,5.06) | 1.57(1.02,2.56) | 0.19(0.01,0.37) | |
| HD TOCI IV + MTX | 2.19(1.06,4.52) | 1.55(1.03,2.50) | 0.18(0.01,0.35) | |
| HD TOFA PO + MTX | 2.36(1.10,5.07) | 1.59(1.05,2.61) | 0.20(0.02,0.37) | |
| HD GOLI SC + MTX | 2.24(0.93,5.53) | 1.56(0.96,2.66) | 0.19(‐0.02,0.39) | |
| HD CERTO SC + MTX | 3.14(1.49,6.76) | 1.77(1.23,2.94) | 0.27(0.10,0.44) | |
| HD ADA SC + MTX | 2.59(0.92,8.01) | 1.65(0.95,2.92) | 0.22(‐0.02,0.47) | |
| HD TOCI IV + DMARD | 0.45(0.15,1.41) | 0.56(0.22,1.26) | ‐0.14(‐0.34,0.07) | |
| SD ANA SC + SD ETN SC + MTX | 1.19(0.38,4.01) | 1.11(0.50,2.21) | 0.04(‐0.20,0.33) | |
| SD ANA SC + LD ETN SC + MTX | 1.78(0.54,5.67) | 1.40(0.66,2.56) | 0.13(‐0.13,0.40) | |
| LD ABA IV + MTX | LD ADA IV + MTX | 0.53(0.09,3.69) | 0.70(0.32,2.65) | ‐0.15(‐0.52,0.24) |
| LD ANA SC + MTX | 0.50(0.06,4.61) | 0.68(0.19,2.88) | ‐0.15(‐0.59,0.29) | |
| LD CERTO SC + MTX | 1.01(0.15,7.25) | 1.00(0.43,3.59) | 0.00(‐0.42,0.41) | |
| LD ETN SC + MTX | 0.91(0.13,6.17) | 0.95(0.41,3.56) | ‐0.02(‐0.43,0.37) | |
| LD GOLI IV + MTX | 0.53(0.08,4.13) | 0.69(0.26,2.63) | ‐0.14(‐0.55,0.27) | |
| LD TOCI IV + MTX | 0.42(0.07,3.01) | 0.60(0.23,2.37) | ‐0.19(‐0.57,0.20) | |
| LD TOFA PO + MTX | 0.86(0.12,7.05) | 0.93(0.32,3.49) | ‐0.04(‐0.46,0.40) | |
| HD TOCI IV | 0.67(0.12,4.36) | 0.80(0.42,2.94) | ‐0.10(‐0.46,0.26) | |
| HD TOFA PO | 0.70(0.11,5.26) | 0.83(0.39,3.27) | ‐0.09(‐0.47,0.32) | |
| HD ADA SC | 0.32(0.05,2.46) | 0.49(0.22,2.01) | ‐0.25(‐0.61,0.15) | |
| HD ETN SC | 0.50(0.08,3.29) | 0.67(0.29,2.46) | ‐0.16(‐0.53,0.21) | |
| HD GOLI SC | 0.66(0.11,4.61) | 0.80(0.37,2.91) | ‐0.10(‐0.48,0.28) | |
| HD ABA SC | 0.97(0.11,12.73) | 0.98(0.34,4.67) | ‐0.01(‐0.49,0.52) | |
| HD INF IV + MTX | 1.25(0.21,8.23) | 1.11(0.59,4.10) | 0.05(‐0.33,0.42) | |
| HD TOCI IV + MTX | 1.18(0.22,7.94) | 1.08(0.59,4.02) | 0.04(‐0.32,0.42) | |
| HD TOFA PO + MTX | 1.29(0.24,7.85) | 1.12(0.61,3.92) | 0.06(‐0.30,0.42) | |
| HD GOLI SC + MTX | 1.21(0.22,8.24) | 1.09(0.58,4.04) | 0.05(‐0.32,0.42) | |
| HD CERTO SC + MTX | 1.73(0.31,10.93) | 1.27(0.68,4.58) | 0.13(‐0.24,0.49) | |
| HD ADA SC + MTX | 1.40(0.23,12.60) | 1.16(0.55,4.66) | 0.08(‐0.33,0.50) | |
| HD TOCI IV + DMARD | 0.26(0.03,2.01) | 0.41(0.13,1.71) | ‐0.28(‐0.67,0.11) | |
| SD ANA SC + SD ETN SC + MTX | 0.67(0.09,5.59) | 0.80(0.30,3.00) | ‐0.09(‐0.52,0.34) | |
| SD ANA SC + LD ETN SC + MTX | 0.99(0.13,7.58) | 1.00(0.39,3.57) | 0.00(‐0.44,0.42) | |
| LD ANA SC + MTX | LD ABA IV + MTX | 0.91(0.20,4.66) | 0.94(0.29,2.52) | ‐0.02(‐0.29,0.34) |
| LD CERTO SC + MTX | 1.91(0.63,6.04) | 1.45(0.74,2.79) | 0.15(‐0.10,0.41) | |
| LD ETN SC + MTX | 1.70(0.57,4.75) | 1.36(0.71,2.52) | 0.12(‐0.13,0.36) | |
| LD GOLI IV + MTX | 0.97(0.32,2.95) | 0.98(0.45,1.98) | ‐0.01(‐0.24,0.24) | |
| LD TOCI IV + MTX | 0.78(0.24,2.42) | 0.84(0.35,1.81) | ‐0.05(‐0.29,0.19) | |
| LD TOFA PO + MTX | 1.61(0.43,6.11) | 1.32(0.56,2.75) | 0.11(‐0.17,0.41) | |
| HD TOCI IV | 1.23(0.55,2.86) | 1.14(0.71,2.11) | 0.05(‐0.14,0.22) | |
| HD TOFA PO | 1.32(0.42,3.99) | 1.19(0.60,2.58) | 0.06(‐0.20,0.30) | |
| HD ADA SC | 0.61(0.20,2.00) | 0.70(0.33,1.66) | ‐0.10(‐0.34,0.14) | |
| HD ETN SC | 0.91(0.35,2.36) | 0.94(0.49,1.82) | ‐0.02(‐0.24,0.18) | |
| HD GOLI SC | 1.22(0.46,3.29) | 1.14(0.62,2.17) | 0.04(‐0.18,0.26) | |
| HD ABA SC | 1.78(0.34,11.27) | 1.40(0.49,3.73) | 0.13(‐0.24,0.53) | |
| HD INF IV + MTX | 2.33(0.99,5.52) | 1.59(1.00,2.82) | 0.20(0.00,0.39) | |
| HD TOCI IV + MTX | 2.21(0.98,5.30) | 1.56(0.99,2.86) | 0.19(0.00,0.37) | |
| HD TOFA PO + MTX | 2.39(1.03,5.58) | 1.61(1.01,2.78) | 0.20(0.01,0.39) | |
| HD GOLI SC + MTX | 2.27(0.91,5.99) | 1.56(0.95,2.89) | 0.19(‐0.02,0.40) | |
| HD CERTO SC + MTX | 3.21(1.37,7.60) | 1.81(1.17,3.32) | 0.27(0.08,0.46) | |
| HD ADA SC + MTX | 2.67(0.86,8.46) | 1.67(0.92,3.16) | 0.23(‐0.03,0.48) | |
| HD TOCI IV + DMARD | 0.45(0.14,1.69) | 0.57(0.22,1.43) | ‐0.14(‐0.36,0.11) | |
| SD ANA SC + SD ETN SC + MTX | 1.20(0.34,4.46) | 1.12(0.47,2.44) | 0.04(‐0.23,0.34) | |
| SD ANA SC + LD ETN SC + MTX | 1.79(0.53,6.53) | 1.40(0.67,2.80) | 0.13(‐0.14,0.42) | |
| LD CERTO SC + MTX | LD ANA SC + MTX | 2.06(0.40,9.99) | 1.51(0.63,4.88) | 0.16(‐0.21,0.47) |
| LD ETN SC + MTX | 1.78(0.36,8.78) | 1.41(0.60,4.58) | 0.13(‐0.24,0.43) | |
| LD GOLI IV + MTX | 1.04(0.21,5.34) | 1.03(0.39,3.31) | 0.01(‐0.35,0.33) | |
| LD TOCI IV + MTX | 0.84(0.16,4.23) | 0.89(0.31,2.97) | ‐0.04(‐0.40,0.26) | |
| LD TOFA PO + MTX | 1.72(0.27,11.39) | 1.37(0.46,5.08) | 0.12(‐0.28,0.49) | |
| HD TOCI IV | 1.33(0.33,5.28) | 1.20(0.57,3.73) | 0.07(‐0.26,0.30) | |
| HD TOFA PO | 1.41(0.29,6.98) | 1.24(0.52,4.38) | 0.08(‐0.29,0.36) | |
| HD ADA SC | 0.65(0.13,3.66) | 0.74(0.28,2.91) | ‐0.08(‐0.45,0.20) | |
| HD ETN SC | 0.98(0.21,4.57) | 0.99(0.40,3.28) | 0.00(‐0.35,0.28) | |
| HD GOLI SC | 1.30(0.28,6.49) | 1.18(0.52,3.96) | 0.06(‐0.30,0.35) | |
| HD ABA SC | 2.01(0.23,17.30) | 1.49(0.43,5.94) | 0.15(‐0.34,0.59) | |
| HD INF IV + MTX | 2.52(0.57,10.48) | 1.68(0.78,5.22) | 0.21(‐0.14,0.48) | |
| HD TOCI IV + MTX | 2.39(0.53,10.14) | 1.64(0.76,5.12) | 0.20(‐0.15,0.46) | |
| HD TOFA PO + MTX | 2.56(0.57,11.78) | 1.68(0.78,5.35) | 0.22(‐0.13,0.50) | |
| HD GOLI SC + MTX | 2.46(0.52,11.41) | 1.66(0.73,5.36) | 0.21(‐0.16,0.50) | |
| HD CERTO SC + MTX | 3.48(0.80,14.93) | 1.93(0.93,5.96) | 0.29(‐0.05,0.55) | |
| HD ADA SC + MTX | 2.87(0.57,14.52) | 1.73(0.77,5.56) | 0.24(‐0.14,0.55) | |
| HD TOCI IV + DMARD | 0.50(0.09,2.44) | 0.60(0.19,2.03) | ‐0.12(‐0.48,0.14) | |
| SD ANA SC + SD ETN SC + MTX | 1.34(0.24,7.63) | 1.19(0.43,4.02) | 0.06(‐0.32,0.40) | |
| SD ANA SC + LD ETN SC + MTX | 1.96(0.34,11.07) | 1.46(0.55,4.94) | 0.15(‐0.25,0.49) | |
| LD ETN SC + MTX | LD CERTO SC + MTX | 0.87(0.25,2.86) | 0.93(0.50,1.83) | ‐0.03(‐0.32,0.24) |
| LD GOLI IV + MTX | 0.52(0.14,1.99) | 0.69(0.30,1.49) | ‐0.15(‐0.43,0.16) | |
| LD TOCI IV + MTX | 0.41(0.10,1.53) | 0.59(0.24,1.31) | ‐0.20(‐0.49,0.09) | |
| LD TOFA PO + MTX | 0.86(0.19,3.62) | 0.92(0.37,1.95) | ‐0.04(‐0.36,0.29) | |
| HD TOCI IV | 0.66(0.22,1.84) | 0.80(0.48,1.51) | ‐0.10(‐0.35,0.13) | |
| HD TOFA PO | 0.70(0.17,2.49) | 0.83(0.42,1.81) | ‐0.09(‐0.41,0.20) | |
| HD ADA SC | 0.32(0.08,1.30) | 0.48(0.23,1.19) | ‐0.25(‐0.54,0.05) | |
| HD ETN SC | 0.48(0.16,1.57) | 0.66(0.34,1.35) | ‐0.16(‐0.42,0.10) | |
| HD GOLI SC | 0.64(0.19,2.11) | 0.79(0.43,1.60) | ‐0.11(‐0.39,0.17) | |
| HD ABA SC | 0.98(0.16,6.38) | 0.99(0.36,2.50) | 0.00(‐0.41,0.42) | |
| HD INF IV + MTX | 1.22(0.42,3.54) | 1.10(0.69,2.09) | 0.05(‐0.20,0.29) | |
| HD TOCI IV + MTX | 1.18(0.41,3.38) | 1.09(0.68,2.04) | 0.04(‐0.21,0.28) | |
| HD TOFA PO + MTX | 1.27(0.43,3.74) | 1.12(0.70,2.08) | 0.06(‐0.20,0.30) | |
| HD GOLI SC + MTX | 1.20(0.39,3.86) | 1.09(0.65,2.10) | 0.04(‐0.22,0.32) | |
| HD CERTO SC + MTX | 1.70(0.68,4.09) | 1.26(0.86,2.19) | 0.13(‐0.09,0.33) | |
| HD ADA SC + MTX | 1.42(0.37,5.40) | 1.16(0.62,2.27) | 0.08(‐0.23,0.38) | |
| HD TOCI IV + DMARD | 0.24(0.06,0.97) | 0.40(0.15,0.97) | ‐0.29(‐0.57,‐0.01) | |
| SD ANA SC + SD ETN SC + MTX | 0.64(0.15,2.60) | 0.79(0.33,1.71) | ‐0.10(‐0.42,0.22) | |
| SD ANA SC + LD ETN SC + MTX | 0.97(0.22,3.75) | 0.98(0.45,1.98) | ‐0.01(‐0.34,0.31) | |
| LD GOLI IV + MTX | LD ETN SC + MTX | 0.58(0.17,2.03) | 0.73(0.33,1.52) | ‐0.12(‐0.38,0.17) |
| LD TOCI IV + MTX | 0.46(0.13,1.54) | 0.63(0.26,1.33) | ‐0.17(‐0.43,0.10) | |
| LD TOFA PO + MTX | 0.98(0.24,4.00) | 0.99(0.39,2.06) | 0.00(‐0.32,0.32) | |
| HD TOCI IV | 0.74(0.30,1.94) | 0.84(0.53,1.54) | ‐0.07(‐0.29,0.15) | |
| HD TOFA PO | 0.79(0.21,2.56) | 0.88(0.45,1.77) | ‐0.06(‐0.36,0.22) | |
| HD ADA SC | 0.36(0.10,1.25) | 0.52(0.25,1.17) | ‐0.22(‐0.49,0.05) | |
| HD ETN SC | 0.54(0.19,1.60) | 0.69(0.38,1.35) | ‐0.14(‐0.37,0.10) | |
| HD GOLI SC | 0.73(0.25,2.18) | 0.84(0.47,1.61) | ‐0.07(‐0.31,0.18) | |
| HD ABA SC | 1.11(0.20,6.49) | 1.06(0.38,2.51) | 0.03(‐0.37,0.42) | |
| HD INF IV + MTX | 1.40(0.54,3.72) | 1.18(0.75,2.06) | 0.08(‐0.15,0.31) | |
| HD TOCI IV + MTX | 1.33(0.50,3.47) | 1.15(0.73,2.07) | 0.07(‐0.16,0.29) | |
| HD TOFA PO + MTX | 1.44(0.52,3.90) | 1.19(0.73,2.14) | 0.09(‐0.16,0.32) | |
| HD GOLI SC + MTX | 1.37(0.48,4.04) | 1.16(0.71,2.10) | 0.08(‐0.17,0.33) | |
| HD CERTO SC + MTX | 1.92(0.74,5.30) | 1.34(0.88,2.42) | 0.16(‐0.07,0.38) | |
| HD ADA SC + MTX | 1.58(0.46,5.79) | 1.23(0.68,2.37) | 0.11(‐0.18,0.39) | |
| HD TOCI IV + DMARD | 0.27(0.08,1.05) | 0.42(0.16,1.04) | ‐0.26(‐0.51,0.01) | |
| SD ANA SC + SD ETN SC + MTX | 0.73(0.21,2.58) | 0.83(0.37,1.70) | ‐0.07(‐0.34,0.23) | |
| SD ANA SC + LD ETN SC + MTX | 1.08(0.33,3.87) | 1.04(0.52,2.01) | 0.02(‐0.26,0.31) | |
| LD TOCI IV + MTX | LD GOLI IV + MTX | 0.79(0.20,3.00) | 0.85(0.33,2.15) | ‐0.05(‐0.33,0.22) |
| LD TOFA PO + MTX | 1.68(0.34,7.25) | 1.36(0.50,3.21) | 0.12(‐0.23,0.44) | |
| HD TOCI IV | 1.27(0.42,3.58) | 1.17(0.62,2.48) | 0.05(‐0.21,0.26) | |
| HD TOFA PO | 1.35(0.36,4.50) | 1.20(0.57,2.84) | 0.07(‐0.24,0.31) | |
| HD ADA SC | 0.62(0.16,2.42) | 0.72(0.30,1.92) | ‐0.09(‐0.39,0.16) | |
| HD ETN SC | 0.93(0.28,3.25) | 0.95(0.46,2.26) | ‐0.02(‐0.29,0.23) | |
| HD GOLI SC | 1.24(0.41,3.80) | 1.15(0.59,2.48) | 0.05(‐0.21,0.28) | |
| HD ABA SC | 1.89(0.32,12.68) | 1.44(0.49,4.06) | 0.15(‐0.25,0.54) | |
| HD INF IV + MTX | 2.35(0.82,7.16) | 1.62(0.90,3.50) | 0.20(‐0.05,0.43) | |
| HD TOCI IV + MTX | 2.28(0.77,6.69) | 1.59(0.88,3.39) | 0.19(‐0.06,0.41) | |
| HD TOFA PO + MTX | 2.46(0.75,7.74) | 1.63(0.87,3.64) | 0.21(‐0.07,0.44) | |
| HD GOLI SC + MTX | 2.32(0.75,7.19) | 1.59(0.87,3.49) | 0.20(‐0.07,0.44) | |
| HD CERTO SC + MTX | 3.29(1.08,10.01) | 1.84(1.03,4.04) | 0.28(0.02,0.50) | |
| HD ADA SC + MTX | 2.72(0.72,9.55) | 1.70(0.84,3.75) | 0.23(‐0.08,0.50) | |
| HD TOCI IV + DMARD | 0.46(0.12,1.91) | 0.57(0.21,1.61) | ‐0.13(‐0.41,0.12) | |
| SD ANA SC + SD ETN SC + MTX | 1.25(0.29,5.44) | 1.15(0.45,2.89) | 0.05(‐0.26,0.38) | |
| SD ANA SC + LD ETN SC + MTX | 1.83(0.46,7.74) | 1.41(0.62,3.45) | 0.14(‐0.18,0.44) | |
| LD TOFA PO + MTX | LD TOCI IV + MTX | 2.10(0.44,9.63) | 1.57(0.56,3.92) | 0.16(‐0.16,0.49) |
| HD TOCI IV | 1.60(0.63,4.23) | 1.36(0.77,2.90) | 0.10(‐0.11,0.28) | |
| HD TOFA PO | 1.70(0.51,5.90) | 1.41(0.66,3.53) | 0.12(‐0.16,0.35) | |
| HD ADA SC | 0.77(0.23,2.91) | 0.83(0.35,2.29) | ‐0.05(‐0.30,0.19) | |
| HD ETN SC | 1.17(0.38,4.05) | 1.12(0.52,2.73) | 0.03(‐0.22,0.29) | |
| HD GOLI SC | 1.55(0.49,5.07) | 1.33(0.63,3.18) | 0.09(‐0.16,0.34) | |
| HD ABA SC | 2.40(0.42,15.15) | 1.68(0.56,5.08) | 0.19(‐0.19,0.57) | |
| HD INF IV + MTX | 2.99(1.08,9.45) | 1.88(1.04,4.25) | 0.25(0.02,0.49) | |
| HD TOCI IV + MTX | 2.87(1.08,7.82) | 1.87(1.04,3.99) | 0.24(0.02,0.43) | |
| HD TOFA PO + MTX | 3.07(1.00,9.38) | 1.90(1.00,4.35) | 0.26(0.00,0.48) | |
| HD GOLI SC + MTX | 2.87(0.89,10.00) | 1.85(0.94,4.31) | 0.24(‐0.03,0.49) | |
| HD CERTO SC + MTX | 4.16(1.36,12.90) | 2.16(1.15,4.86) | 0.33(0.07,0.55) | |
| HD ADA SC + MTX | 3.39(0.89,13.77) | 1.98(0.93,4.69) | 0.28(‐0.03,0.56) | |
| HD TOCI IV + DMARD | 0.60(0.16,2.30) | 0.68(0.25,1.86) | ‐0.09(‐0.34,0.16) | |
| SD ANA SC + SD ETN SC + MTX | 1.57(0.41,6.71) | 1.33(0.55,3.50) | 0.09(‐0.19,0.42) | |
| SD ANA SC + LD ETN SC + MTX | 2.37(0.60,10.10) | 1.67(0.71,4.07) | 0.19(‐0.11,0.50) | |
| HD TOCI IV | LD TOFA PO + MTX | 0.76(0.22,2.84) | 0.85(0.49,2.18) | ‐0.07(‐0.35,0.21) |
| HD TOFA PO | 0.81(0.19,3.83) | 0.89(0.44,2.52) | ‐0.05(‐0.38,0.27) | |
| HD ADA SC | 0.37(0.09,1.85) | 0.53(0.23,1.57) | ‐0.21(‐0.52,0.11) | |
| HD ETN SC | 0.57(0.15,2.26) | 0.71(0.35,1.77) | ‐0.13(‐0.43,0.17) | |
| HD GOLI SC | 0.74(0.20,3.12) | 0.85(0.44,2.15) | ‐0.07(‐0.37,0.23) | |
| HD ABA SC | 1.16(0.16,8.45) | 1.08(0.38,3.27) | 0.03(‐0.41,0.47) | |
| HD INF IV + MTX | 1.45(0.39,5.44) | 1.20(0.68,2.88) | 0.09(‐0.21,0.37) | |
| HD TOCI IV + MTX | 1.35(0.40,5.29) | 1.16(0.68,2.88) | 0.07(‐0.21,0.36) | |
| HD TOFA PO + MTX | 1.48(0.49,4.58) | 1.20(0.75,2.60) | 0.09(‐0.16,0.33) | |
| HD GOLI SC + MTX | 1.40(0.39,5.69) | 1.18(0.66,2.85) | 0.08(‐0.22,0.39) | |
| HD CERTO SC + MTX | 2.01(0.56,7.16) | 1.37(0.81,3.39) | 0.17(‐0.13,0.43) | |
| HD ADA SC + MTX | 1.64(0.37,7.93) | 1.25(0.64,3.23) | 0.11(‐0.23,0.45) | |
| HD TOCI IV + DMARD | 0.28(0.06,1.35) | 0.43(0.15,1.24) | ‐0.25(‐0.57,0.05) | |
| SD ANA SC + SD ETN SC + MTX | 0.75(0.15,3.85) | 0.85(0.33,2.27) | ‐0.07(‐0.41,0.30) | |
| SD ANA SC + LD ETN SC + MTX | 1.14(0.22,5.38) | 1.07(0.45,2.75) | 0.03(‐0.34,0.37) | |
| HD TOFA PO | HD TOCI IV | 1.08(0.41,2.57) | 1.05(0.57,1.78) | 0.02(‐0.21,0.22) |
| HD ADA SC | 0.48(0.20,1.28) | 0.61(0.32,1.18) | ‐0.15(‐0.33,0.05) | |
| HD ETN SC | 0.74(0.31,1.78) | 0.82(0.46,1.39) | ‐0.07(‐0.24,0.13) | |
| HD GOLI SC | 0.98(0.42,2.30) | 0.99(0.57,1.63) | ‐0.01(‐0.19,0.20) | |
| HD ABA SC | 1.45(0.34,7.89) | 1.22(0.48,2.68) | 0.09(‐0.24,0.46) | |
| HD INF IV + MTX | 1.88(0.93,3.87) | 1.40(0.96,2.00) | 0.15(‐0.02,0.32) | |
| HD TOCI IV + MTX | 1.79(1.03,3.11) | 1.37(1.02,1.82) | 0.14(0.01,0.27) | |
| HD TOFA PO + MTX | 1.94(0.87,4.04) | 1.41(0.92,2.06) | 0.16(‐0.03,0.33) | |
| HD GOLI SC + MTX | 1.84(0.81,4.44) | 1.37(0.88,2.08) | 0.15(‐0.05,0.35) | |
| HD CERTO SC + MTX | 2.57(1.29,5.38) | 1.59(1.14,2.27) | 0.23(0.06,0.39) | |
| HD ADA SC + MTX | 2.17(0.71,6.31) | 1.48(0.82,2.29) | 0.19(‐0.08,0.41) | |
| HD TOCI IV + DMARD | 0.37(0.14,1.05) | 0.49(0.21,1.03) | ‐0.19(‐0.35,0.01) | |
| SD ANA SC + SD ETN SC + MTX | 0.98(0.31,3.04) | 0.99(0.44,1.80) | 0.00(‐0.24,0.27) | |
| SD ANA SC + LD ETN SC + MTX | 1.46(0.45,4.56) | 1.24(0.60,2.09) | 0.09(‐0.17,0.35) | |
| HD ADA SC | HD TOFA PO | 0.46(0.17,1.32) | 0.59(0.29,1.21) | ‐0.16(‐0.36,0.06) |
| HD ETN SC | 0.68(0.23,2.29) | 0.78(0.37,1.64) | ‐0.09(‐0.30,0.19) | |
| HD GOLI SC | 0.93(0.33,2.63) | 0.96(0.50,1.81) | ‐0.02(‐0.25,0.23) | |
| HD ABA SC | 1.42(0.31,7.05) | 1.20(0.47,2.49) | 0.09(‐0.26,0.44) | |
| HD INF IV + MTX | 1.75(0.64,5.29) | 1.34(0.78,2.41) | 0.14(‐0.11,0.39) | |
| HD TOCI IV + MTX | 1.69(0.62,4.72) | 1.31(0.77,2.28) | 0.13(‐0.11,0.36) | |
| HD TOFA PO + MTX | 1.82(0.65,5.22) | 1.36(0.79,2.36) | 0.15(‐0.10,0.38) | |
| HD GOLI SC + MTX | 1.73(0.57,5.23) | 1.33(0.72,2.37) | 0.13(‐0.14,0.39) | |
| HD CERTO SC + MTX | 2.44(0.87,7.25) | 1.53(0.93,2.65) | 0.22(‐0.03,0.45) | |
| HD ADA SC + MTX | 2.00(0.55,7.96) | 1.42(0.70,2.61) | 0.17(‐0.14,0.46) | |
| HD TOCI IV + DMARD | 0.35(0.09,1.29) | 0.48(0.17,1.17) | ‐0.21(‐0.41,0.05) | |
| SD ANA SC + SD ETN SC + MTX | 0.91(0.24,3.71) | 0.95(0.38,1.96) | ‐0.02(‐0.30,0.31) | |
| SD ANA SC + LD ETN SC + MTX | 1.36(0.35,5.27) | 1.18(0.51,2.29) | 0.07(‐0.23,0.39) | |
| HD ETN SC | HD ADA SC | 1.54(0.43,4.77) | 1.36(0.54,2.89) | 0.08(‐0.16,0.32) |
| HD GOLI SC | 2.03(0.61,6.02) | 1.63(0.71,3.38) | 0.15(‐0.10,0.38) | |
| HD ABA SC | 3.03(0.62,15.42) | 2.02(0.72,4.66) | 0.24(‐0.09,0.58) | |
| HD INF IV + MTX | 3.85(1.22,11.95) | 2.29(1.13,4.47) | 0.30(0.04,0.53) | |
| HD TOCI IV + MTX | 3.68(1.26,10.12) | 2.24(1.15,4.29) | 0.29(0.05,0.49) | |
| HD TOFA PO + MTX | 3.93(1.33,11.68) | 2.30(1.19,4.49) | 0.31(0.07,0.53) | |
| HD GOLI SC + MTX | 3.78(1.11,11.88) | 2.26(1.07,4.47) | 0.30(0.02,0.54) | |
| HD CERTO SC + MTX | 5.31(1.67,15.81) | 2.61(1.36,4.92) | 0.38(0.12,0.59) | |
| HD ADA SC + MTX | 4.34(1.09,16.97) | 2.39(1.06,4.78) | 0.33(0.02,0.60) | |
| HD TOCI IV + DMARD | 0.75(0.21,2.89) | 0.80(0.28,2.17) | ‐0.05(‐0.24,0.21) | |
| SD ANA SC + SD ETN SC + MTX | 2.00(0.46,7.90) | 1.60(0.56,3.66) | 0.14(‐0.14,0.46) | |
| SD ANA SC + LD ETN SC + MTX | 3.04(0.69,11.57) | 2.01(0.77,4.17) | 0.24(‐0.07,0.54) | |
| HD GOLI SC | HD ETN SC | 1.34(0.49,3.53) | 1.21(0.63,2.32) | 0.06(‐0.16,0.29) |
| HD ABA SC | 2.05(0.39,11.60) | 1.52(0.54,3.72) | 0.16(‐0.21,0.53) | |
| HD INF IV + MTX | 2.55(1.06,6.32) | 1.68(1.03,3.03) | 0.22(0.01,0.41) | |
| HD TOCI IV + MTX | 2.44(0.96,5.82) | 1.66(0.98,3.02) | 0.21(‐0.01,0.39) | |
| HD TOFA PO + MTX | 2.62(1.03,6.51) | 1.72(1.01,3.00) | 0.22(0.01,0.43) | |
| HD GOLI SC + MTX | 2.51(0.93,6.81) | 1.68(0.96,3.12) | 0.21(‐0.02,0.43) | |
| HD CERTO SC + MTX | 3.52(1.39,8.85) | 1.93(1.19,3.43) | 0.29(0.08,0.49) | |
| HD ADA SC + MTX | 2.91(0.85,9.56) | 1.78(0.91,3.37) | 0.24(‐0.04,0.50) | |
| HD TOCI IV + DMARD | 0.51(0.15,1.74) | 0.61(0.23,1.48) | ‐0.12(‐0.36,0.11) | |
| SD ANA SC + SD ETN SC + MTX | 1.31(0.37,4.89) | 1.19(0.50,2.49) | 0.06(‐0.20,0.35) | |
| SD ANA SC + LD ETN SC + MTX | 1.98(0.56,6.95) | 1.49(0.69,2.97) | 0.15(‐0.13,0.44) | |
| HD ABA SC | HD GOLI SC | 1.53(0.30,8.55) | 1.26(0.47,2.95) | 0.10(‐0.27,0.48) |
| HD INF IV + MTX | 1.93(0.76,4.66) | 1.41(0.87,2.35) | 0.16(‐0.06,0.36) | |
| HD TOCI IV + MTX | 1.83(0.77,4.34) | 1.38(0.86,2.35) | 0.14(‐0.06,0.34) | |
| HD TOFA PO + MTX | 1.97(0.74,4.83) | 1.43(0.85,2.41) | 0.16(‐0.07,0.37) | |
| HD GOLI SC + MTX | 1.88(0.78,4.38) | 1.39(0.88,2.23) | 0.15(‐0.06,0.35) | |
| HD CERTO SC + MTX | 2.63(1.05,6.51) | 1.60(1.02,2.68) | 0.23(0.01,0.43) | |
| HD ADA SC + MTX | 2.19(0.68,7.50) | 1.48(0.80,2.66) | 0.19(‐0.09,0.45) | |
| HD TOCI IV + DMARD | 0.38(0.11,1.36) | 0.50(0.20,1.23) | ‐0.19(‐0.42,0.07) | |
| SD ANA SC + SD ETN SC + MTX | 0.98(0.28,3.66) | 0.99(0.42,2.02) | 0.00(‐0.27,0.31) | |
| SD ANA SC + LD ETN SC + MTX | 1.50(0.41,5.27) | 1.25(0.58,2.36) | 0.10(‐0.20,0.38) | |
| HD INF IV + MTX | HD ABA SC | 1.28(0.24,6.28) | 1.12(0.54,2.82) | 0.06(‐0.33,0.41) |
| HD TOCI IV + MTX | 1.22(0.21,5.94) | 1.10(0.51,2.87) | 0.05(‐0.36,0.40) | |
| HD TOFA PO + MTX | 1.30(0.24,6.77) | 1.13(0.55,2.99) | 0.06(‐0.33,0.43) | |
| HD GOLI SC + MTX | 1.26(0.22,6.45) | 1.11(0.50,2.97) | 0.06(‐0.35,0.42) | |
| HD CERTO SC + MTX | 1.73(0.30,8.54) | 1.27(0.65,3.26) | 0.13(‐0.26,0.48) | |
| HD ADA SC + MTX | 1.43(0.22,8.63) | 1.17(0.52,3.08) | 0.08(‐0.34,0.48) | |
| HD TOCI IV + DMARD | 0.25(0.04,1.54) | 0.40(0.12,1.32) | ‐0.28(‐0.65,0.09) | |
| SD ANA SC + SD ETN SC + MTX | 0.66(0.09,3.85) | 0.80(0.28,2.18) | ‐0.10(‐0.52,0.31) | |
| SD ANA SC + LD ETN SC + MTX | 1.00(0.14,5.90) | 1.00(0.38,2.72) | 0.00(‐0.44,0.40) | |
| HD TOCI IV + MTX | HD INF IV + MTX | 0.95(0.45,2.05) | 0.98(0.69,1.41) | ‐0.01(‐0.19,0.17) |
| HD TOFA PO + MTX | 1.04(0.45,2.32) | 1.02(0.69,1.49) | 0.01(‐0.19,0.20) | |
| HD GOLI SC + MTX | 0.97(0.40,2.34) | 0.99(0.64,1.48) | ‐0.01(‐0.22,0.20) | |
| HD CERTO SC + MTX | 1.38(0.63,2.98) | 1.14(0.82,1.62) | 0.08(‐0.11,0.25) | |
| HD ADA SC + MTX | 1.14(0.38,3.46) | 1.06(0.61,1.65) | 0.03(‐0.23,0.28) | |
| HD TOCI IV + DMARD | 0.19(0.06,0.65) | 0.35(0.14,0.79) | ‐0.34(‐0.55,‐0.10) | |
| SD ANA SC + SD ETN SC + MTX | 0.51(0.16,1.69) | 0.71(0.32,1.29) | ‐0.16(‐0.40,0.12) | |
| SD ANA SC + LD ETN SC + MTX | 0.78(0.26,2.44) | 0.89(0.44,1.47) | ‐0.06(‐0.31,0.21) | |
| HD TOFA PO + MTX | HD TOCI IV + MTX | 1.08(0.50,2.43) | 1.04(0.70,1.49) | 0.02(‐0.17,0.21) |
| HD GOLI SC + MTX | 1.03(0.44,2.50) | 1.01(0.66,1.50) | 0.01(‐0.20,0.22) | |
| HD CERTO SC + MTX | 1.43(0.67,3.18) | 1.16(0.84,1.65) | 0.09(‐0.10,0.27) | |
| HD ADA SC + MTX | 1.19(0.41,3.65) | 1.08(0.62,1.65) | 0.04(‐0.21,0.28) | |
| HD TOCI IV + DMARD | 0.21(0.07,0.66) | 0.36(0.15,0.79) | ‐0.33(‐0.52,‐0.10) | |
| SD ANA SC + SD ETN SC + MTX | 0.55(0.18,1.81) | 0.73(0.33,1.31) | ‐0.14(‐0.38,0.15) | |
| SD ANA SC + LD ETN SC + MTX | 0.81(0.25,2.63) | 0.91(0.43,1.54) | ‐0.05(‐0.32,0.23) | |
| HD GOLI SC + MTX | HD TOFA PO + MTX | 0.95(0.37,2.42) | 0.98(0.62,1.49) | ‐0.01(‐0.23,0.21) |
| HD CERTO SC + MTX | 1.34(0.62,2.99) | 1.12(0.81,1.63) | 0.07(‐0.12,0.25) | |
| HD ADA SC + MTX | 1.09(0.39,3.55) | 1.04(0.61,1.63) | 0.02(‐0.22,0.28) | |
| HD TOCI IV + DMARD | 0.19(0.06,0.68) | 0.35(0.14,0.80) | ‐0.35(‐0.56,‐0.09) | |
| SD ANA SC + SD ETN SC + MTX | 0.51(0.15,1.83) | 0.70(0.31,1.31) | ‐0.16(‐0.43,0.14) | |
| SD ANA SC + LD ETN SC + MTX | 0.76(0.21,2.54) | 0.88(0.42,1.51) | ‐0.07(‐0.35,0.22) | |
| HD CERTO SC + MTX | HD GOLI SC + MTX | 1.42(0.58,3.45) | 1.15(0.80,1.76) | 0.08(‐0.13,0.29) |
| HD ADA SC + MTX | 1.17(0.37,3.71) | 1.07(0.59,1.75) | 0.04(‐0.24,0.29) | |
| HD TOCI IV + DMARD | 0.20(0.06,0.71) | 0.36(0.14,0.82) | ‐0.33(‐0.57,‐0.08) | |
| SD ANA SC + SD ETN SC + MTX | 0.53(0.15,1.94) | 0.72(0.31,1.39) | ‐0.15(‐0.42,0.15) | |
| SD ANA SC + LD ETN SC + MTX | 0.80(0.23,2.79) | 0.90(0.42,1.57) | ‐0.05(‐0.34,0.23) | |
| HD ADA SC + MTX | HD CERTO SC + MTX | 0.82(0.28,2.59) | 0.93(0.54,1.40) | ‐0.05(‐0.30,0.20) |
| HD TOCI IV + DMARD | 0.14(0.05,0.46) | 0.31(0.13,0.67) | ‐0.42(‐0.61,‐0.18) | |
| SD ANA SC + SD ETN SC + MTX | 0.38(0.11,1.26) | 0.62(0.28,1.11) | ‐0.23(‐0.49,0.05) | |
| SD ANA SC + LD ETN SC + MTX | 0.56(0.17,1.96) | 0.78(0.38,1.28) | ‐0.14(‐0.41,0.15) | |
| HD TOCI IV + DMARD | HD ADA SC + MTX | 0.17(0.04,0.77) | 0.34(0.13,0.85) | ‐0.37(‐0.63,‐0.06) |
| SD ANA SC + SD ETN SC + MTX | 0.46(0.11,1.88) | 0.67(0.30,1.39) | ‐0.18(‐0.48,0.15) | |
| SD ANA SC + LD ETN SC + MTX | 0.69(0.17,2.78) | 0.84(0.40,1.62) | ‐0.08(‐0.40,0.24) | |
| SD ANA SC + SD ETN SC + MTX | HD TOCI IV + DMARD | 2.66(0.61,11.12) | 1.99(0.70,5.51) | 0.18(‐0.10,0.48) |
| SD ANA SC + LD ETN SC + MTX | 3.96(0.90,15.38) | 2.47(0.94,6.49) | 0.28(‐0.02,0.56) | |
| SD ANA SC + LD ETN SC + MTX | SD ANA SC + SD ETN SC + MTX | 1.49(0.55,4.14) | 1.24(0.72,2.35) | 0.09(‐0.13,0.32) |
| Random‐effects model | Residual deviance | 212.5 vs 213 data points | ||
| Deviance information criteria | 1368.54 | |||
| Fixed‐effect model | Residual deviance | 333.4 vs 213 data points | ||
| Deviance information criteria | 1449.97 | |||
| Note | ||||
| Total participants | 30,229 | |||
| Total studies | 79 | |||
| 2‐arm | 38 | |||
| 3‐arm | 33 | |||
| 4‐arm | 6 | |||
| 5‐arm | 1 | |||
| 7‐arm | 1 | |||
Appendix 3. ACR50: subgroup ‐ established RA (2‐10 years)
| ACR50 established: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX | PL | 3.01(1.47,6.08) | 2.68(1.43,4.76) | 0.10(0.03,0.21) |
| DMARD | 0.84(0.34,2.09) | 0.85(0.36,1.97) | ‐0.01(‐0.04,0.05) | |
| MTX + DMARD | 4.04(1.64,9.92) | 3.40(1.57,6.61) | 0.14(0.04,0.32) | |
| SD ETN SC | 5.37(2.65,11.01) | 4.25(2.40,7.11) | 0.20(0.09,0.34) | |
| SD ADA SC | 3.77(1.96,7.47) | 3.23(1.84,5.56) | 0.13(0.05,0.25) | |
| SD TOFA PO | 6.61(3.30,13.96) | 4.94(2.87,8.12) | 0.24(0.12,0.40) | |
| SD TOCI IV | 4.76(1.89,11.98) | 3.88(1.78,7.41) | 0.17(0.05,0.37) | |
| SD GOLI SC | 7.48(2.54,22.98) | 5.37(2.31,10.43) | 0.26(0.08,0.53) | |
| SD GOLI IV | 5.61(1.70,18.79) | 4.37(1.63,9.29) | 0.20(0.04,0.48) | |
| SD ABA SC | 10.25(2.56,47.10) | 6.54(2.33,13.59) | 0.34(0.08,0.68) | |
| SD CERTO SC | 9.70(3.03,32.66) | 6.33(2.69,11.66) | 0.32(0.10,0.61) | |
| SD ETN SC + MTX | 10.23(4.69,22.42) | 6.55(3.78,10.40) | 0.34(0.17,0.52) | |
| SD INF IV + MTX | 9.01(3.97,20.72) | 6.07(3.35,10.05) | 0.31(0.15,0.50) | |
| SD ABA IV + MTX | 11.51(4.85,26.93) | 7.02(3.90,11.23) | 0.36(0.18,0.56) | |
| SD CERTO SC + MTX | 17.37(7.32,41.58) | 8.68(5.19,13.11) | 0.47(0.26,0.66) | |
| SD TOFA PO + MTX | 18.69(7.47,51.23) | 9.00(5.23,13.94) | 0.48(0.26,0.70) | |
| SD GOLI SC + MTX | 20.69(8.35,53.21) | 9.39(5.61,13.89) | 0.51(0.29,0.70) | |
| SD ADA SC + MTX | 12.42(3.61,44.27) | 7.34(3.09,13.11) | 0.38(0.13,0.67) | |
| SD RITUX IV + MTX | 6.43(2.42,18.59) | 4.85(2.22,9.41) | 0.23(0.07,0.47) | |
| SD GOLI IV + MTX | 7.23(2.75,19.67) | 5.24(2.47,9.63) | 0.26(0.09,0.49) | |
| SD ABA SC + MTX | 12.38(3.67,41.58) | 7.30(3.14,12.96) | 0.38(0.13,0.66) | |
| SD ANA SC + MTX | 15.95(2.40,129.30) | 8.35(2.22,16.03) | 0.44(0.07,0.83) | |
| SD TOCI IV + MTX | 6.45(1.99,20.90) | 4.85(1.87,9.96) | 0.23(0.05,0.50) | |
| SD CERTO SC + DMARD | 4.83(1.75,13.91) | 3.92(1.67,8.05) | 0.18(0.04,0.40) | |
| SD ADA SC + DMARD | 2.67(0.74,10.00) | 2.42(0.75,6.62) | 0.09(‐0.02,0.32) | |
| SD ETN SC + DMARD | 10.60(3.43,34.78) | 6.67(2.98,12.03) | 0.34(0.12,0.62) | |
| LD ADA SC | 3.47(1.47,8.34) | 3.02(1.43,5.94) | 0.12(0.03,0.28) | |
| LD GOLI IV | 3.32(0.95,11.16) | 2.90(0.96,7.10) | 0.11(0.00,0.35) | |
| LD TOCI IV | 0.59(0.10,2.51) | 0.61(0.11,2.31) | ‐0.02(‐0.06,0.08) | |
| LD RITUX IV + MTX | 5.34(2.00,15.20) | 4.23(1.89,8.52) | 0.19(0.06,0.42) | |
| LD ABA IV + MTX | 6.29(2.28,17.23) | 4.75(2.12,9.10) | 0.23(0.07,0.45) | |
| LD ANA SC + MTX | 9.03(1.29,76.76) | 6.06(1.27,14.67) | 0.31(0.02,0.77) | |
| LD CERTO SC + MTX | 12.43(3.91,40.48) | 7.33(3.29,12.79) | 0.38(0.14,0.66) | |
| LD ETN SC + MTX | 9.76(3.29,29.06) | 6.36(2.88,11.44) | 0.32(0.12,0.59) | |
| LD GOLI IV + MTX | 6.41(1.98,21.30) | 4.83(1.87,10.01) | 0.23(0.05,0.51) | |
| LD TOCI IV + MTX | 5.41(1.69,17.11) | 4.26(1.62,9.01) | 0.20(0.04,0.45) | |
| LD TOFA PO + MTX | 9.58(2.42,38.84) | 6.30(2.24,12.60) | 0.32(0.08,0.65) | |
| HD TOCI IV | 8.54(4.39,17.47) | 5.86(3.58,9.35) | 0.29(0.17,0.45) | |
| HD TOFA PO | 10.58(5.28,22.12) | 6.69(4.12,10.32) | 0.34(0.20,0.52) | |
| HD ADA SC | 4.95(2.16,11.79) | 3.99(2.01,7.44) | 0.18(0.06,0.36) | |
| HD GOLI SC | 8.87(3.71,21.75) | 6.00(3.15,10.14) | 0.30(0.13,0.51) | |
| HD ETN SC | 5.94(2.15,17.26) | 4.57(2.00,9.00) | 0.22(0.06,0.46) | |
| HD ABA SC | 14.79(3.72,67.13) | 8.02(3.17,14.87) | 0.43(0.14,0.74) | |
| HD TOCI IV + MTX | 14.79(6.72,33.84) | 8.03(4.89,12.34) | 0.43(0.25,0.61) | |
| HD TOFA PO + MTX | 15.00(5.88,40.02) | 8.08(4.48,12.84) | 0.43(0.22,0.65) | |
| HD GOLI SC + MTX | 15.89(6.41,40.49) | 8.33(4.74,12.87) | 0.44(0.24,0.65) | |
| HD CERTO SC + MTX | 20.66(8.33,52.67) | 9.39(5.62,14.01) | 0.51(0.29,0.70) | |
| HD INF IV + MTX | 12.70(4.73,34.29) | 7.42(3.82,12.28) | 0.39(0.18,0.62) | |
| HD TOCI IV + DMARD | 3.13(1.03,9.52) | 2.78(1.03,6.40) | 0.11(0.00,0.31) | |
| DMARD | MTX | 0.28(0.12,0.65) | 0.32(0.14,0.68) | ‐0.11(‐0.20,‐0.04) |
| MTX + DMARD | 1.35(0.70,2.54) | 1.28(0.74,2.06) | 0.04(‐0.05,0.17) | |
| SD ETN SC | 1.80(1.09,2.94) | 1.59(1.07,2.36) | 0.09(0.01,0.19) | |
| SD ADA SC | 1.26(0.56,2.91) | 1.21(0.62,2.42) | 0.03(‐0.09,0.16) | |
| SD TOFA PO | 2.21(0.85,5.98) | 1.85(0.88,3.90) | 0.14(‐0.03,0.32) | |
| SD TOCI IV | 1.59(0.70,3.60) | 1.45(0.74,2.67) | 0.07(‐0.05,0.24) | |
| SD GOLI SC | 2.54(0.79,8.01) | 2.02(0.82,4.35) | 0.16(‐0.03,0.42) | |
| SD GOLI IV | 1.87(0.69,5.16) | 1.63(0.72,3.14) | 0.10(‐0.04,0.34) | |
| SD ABA SC | 3.42(0.71,18.44) | 2.43(0.76,6.30) | 0.23(‐0.05,0.59) | |
| SD CERTO SC | 3.22(0.82,13.12) | 2.35(0.85,5.65) | 0.22(‐0.03,0.52) | |
| SD ETN SC + MTX | 3.43(2.12,5.48) | 2.44(1.72,3.44) | 0.23(0.12,0.36) | |
| SD INF IV + MTX | 3.02(1.88,4.88) | 2.25(1.61,3.18) | 0.20(0.09,0.33) | |
| SD ABA IV + MTX | 3.83(2.35,6.31) | 2.60(1.86,3.66) | 0.26(0.13,0.40) | |
| SD CERTO SC + MTX | 5.79(3.56,9.50) | 3.22(2.33,4.53) | 0.36(0.21,0.49) | |
| SD TOFA PO + MTX | 6.29(3.50,11.75) | 3.33(2.32,4.86) | 0.38(0.22,0.53) | |
| SD GOLI SC + MTX | 6.87(3.42,14.35) | 3.47(2.27,5.52) | 0.40(0.23,0.56) | |
| SD ADA SC + MTX | 4.16(1.46,11.69) | 2.69(1.35,4.71) | 0.28(0.05,0.53) | |
| SD RITUX IV + MTX | 2.16(1.06,4.48) | 1.81(1.05,2.94) | 0.13(0.01,0.31) | |
| SD GOLI IV + MTX | 2.42(1.19,5.00) | 1.95(1.15,3.11) | 0.15(0.02,0.33) | |
| SD ABA SC + MTX | 4.14(1.52,11.20) | 2.69(1.40,4.63) | 0.28(0.06,0.52) | |
| SD ANA SC + MTX | 5.32(0.89,36.66) | 3.05(0.91,6.36) | 0.34(‐0.01,0.71) | |
| SD TOCI IV + MTX | 2.14(0.77,6.09) | 1.79(0.81,3.51) | 0.13(‐0.03,0.37) | |
| SD CERTO SC + DMARD | 1.60(0.53,5.10) | 1.46(0.59,3.42) | 0.07(‐0.09,0.30) | |
| SD ADA SC + DMARD | 0.90(0.24,3.18) | 0.92(0.28,2.41) | ‐0.01(‐0.15,0.21) | |
| SD ETN SC + DMARD | 3.56(1.26,10.16) | 2.48(1.20,4.62) | 0.24(0.03,0.49) | |
| LD ADA SC | 1.15(0.42,3.28) | 1.13(0.48,2.61) | 0.02(‐0.12,0.19) | |
| LD GOLI IV | 1.10(0.39,3.08) | 1.08(0.43,2.31) | 0.01(‐0.10,0.21) | |
| LD TOCI IV | 0.20(0.04,0.77) | 0.23(0.04,0.79) | ‐0.12(‐0.22,‐0.03) | |
| LD RITUX IV + MTX | 1.79(0.88,3.78) | 1.58(0.90,2.65) | 0.09(‐0.02,0.27) | |
| LD ABA IV + MTX | 2.10(1.02,4.29) | 1.77(1.02,2.86) | 0.12(0.00,0.30) | |
| LD ANA SC + MTX | 3.05(0.49,21.80) | 2.25(0.54,5.41) | 0.20(‐0.08,0.64) | |
| LD CERTO SC + MTX | 4.17(1.63,10.69) | 2.71(1.47,4.51) | 0.28(0.07,0.51) | |
| LD ETN SC + MTX | 3.28(1.37,7.76) | 2.37(1.29,3.99) | 0.22(0.05,0.44) | |
| LD GOLI IV + MTX | 2.16(0.81,5.70) | 1.81(0.83,3.36) | 0.13(‐0.03,0.36) | |
| LD TOCI IV + MTX | 1.80(0.65,5.01) | 1.59(0.70,3.19) | 0.09(‐0.05,0.32) | |
| LD TOFA PO + MTX | 3.23(0.98,10.73) | 2.34(0.99,4.42) | 0.22(0.00,0.51) | |
| HD TOCI IV | 2.85(1.69,4.96) | 2.18(1.47,3.40) | 0.19(0.09,0.31) | |
| HD TOFA PO | 3.53(1.37,9.55) | 2.49(1.26,5.07) | 0.24(0.06,0.43) | |
| HD ADA SC | 1.66(0.60,4.70) | 1.50(0.66,3.33) | 0.08(‐0.08,0.27) | |
| HD GOLI SC | 2.98(1.30,6.71) | 2.23(1.22,3.97) | 0.20(0.04,0.38) | |
| HD ETN SC | 1.99(0.85,4.71) | 1.71(0.87,3.06) | 0.11(‐0.02,0.31) | |
| HD ABA SC | 4.88(1.08,25.35) | 2.95(1.06,7.04) | 0.32(0.01,0.65) | |
| HD TOCI IV + MTX | 4.95(2.86,8.78) | 2.98(2.04,4.57) | 0.32(0.19,0.46) | |
| HD TOFA PO + MTX | 5.01(2.74,9.20) | 2.99(2.07,4.36) | 0.33(0.17,0.48) | |
| HD GOLI SC + MTX | 5.27(2.59,10.98) | 3.07(1.96,4.88) | 0.34(0.17,0.51) | |
| HD CERTO SC + MTX | 6.93(3.84,12.54) | 3.48(2.44,5.13) | 0.40(0.24,0.55) | |
| HD INF IV + MTX | 4.22(2.12,8.71) | 2.74(1.76,4.23) | 0.28(0.12,0.46) | |
| HD TOCI IV + DMARD | 1.06(0.35,3.00) | 1.05(0.41,2.33) | 0.01(‐0.12,0.19) | |
| MTX + DMARD | DMARD | 4.75(1.78,13.41) | 3.95(1.66,9.80) | 0.15(0.05,0.32) |
| SD ETN SC | 6.38(2.80,14.83) | 4.94(2.40,10.72) | 0.20(0.10,0.34) | |
| SD ADA SC | 4.48(1.67,12.12) | 3.78(1.56,9.27) | 0.14(0.05,0.26) | |
| SD TOFA PO | 7.87(2.58,23.95) | 5.77(2.21,14.80) | 0.24(0.11,0.41) | |
| SD TOCI IV | 5.63(1.99,16.22) | 4.50(1.81,11.05) | 0.18(0.06,0.36) | |
| SD GOLI SC | 8.98(2.33,33.68) | 6.24(2.07,17.07) | 0.27(0.08,0.53) | |
| SD GOLI IV | 6.59(1.85,25.43) | 5.06(1.74,14.10) | 0.21(0.05,0.48) | |
| SD ABA SC | 12.25(2.29,68.23) | 7.60(2.05,23.30) | 0.34(0.08,0.69) | |
| SD CERTO SC | 11.38(2.59,51.27) | 7.28(2.25,21.19) | 0.33(0.10,0.62) | |
| SD ETN SC + MTX | 12.11(4.99,31.14) | 7.57(3.60,17.11) | 0.34(0.19,0.51) | |
| SD INF IV + MTX | 10.67(4.20,28.91) | 7.00(3.23,16.24) | 0.31(0.16,0.50) | |
| SD ABA IV + MTX | 13.55(5.12,36.64) | 8.10(3.71,18.61) | 0.37(0.19,0.56) | |
| SD CERTO SC + MTX | 20.42(7.69,56.02) | 10.05(4.70,22.73) | 0.47(0.28,0.66) | |
| SD TOFA PO + MTX | 22.07(8.24,65.85) | 10.39(4.94,23.55) | 0.49(0.28,0.69) | |
| SD GOLI SC + MTX | 24.47(8.47,73.59) | 10.85(4.87,25.08) | 0.51(0.30,0.70) | |
| SD ADA SC + MTX | 14.51(3.93,56.13) | 8.29(3.16,21.02) | 0.39(0.14,0.67) | |
| SD RITUX IV + MTX | 7.60(2.57,24.73) | 5.60(2.25,14.24) | 0.24(0.09,0.47) | |
| SD GOLI IV + MTX | 8.57(2.81,26.42) | 6.07(2.41,14.87) | 0.26(0.10,0.49) | |
| SD ABA SC + MTX | 14.58(4.01,54.98) | 8.33(3.18,20.84) | 0.39(0.14,0.66) | |
| SD ANA SC + MTX | 19.11(2.64,157.80) | 9.44(2.33,25.66) | 0.45(0.08,0.83) | |
| SD TOCI IV + MTX | 7.57(2.21,27.29) | 5.55(2.01,14.63) | 0.24(0.06,0.50) | |
| SD CERTO SC + DMARD | 5.76(2.02,16.38) | 4.55(1.85,10.85) | 0.18(0.06,0.39) | |
| SD ADA SC + DMARD | 3.16(1.20,8.26) | 2.82(1.19,6.08) | 0.09(0.01,0.30) | |
| SD ETN SC + DMARD | 12.48(4.39,38.15) | 7.64(3.46,17.10) | 0.35(0.14,0.61) | |
| LD ADA SC | 4.09(1.30,13.57) | 3.51(1.27,10.05) | 0.13(0.02,0.28) | |
| LD GOLI IV | 3.91(0.99,15.51) | 3.36(1.00,10.37) | 0.12(0.00,0.35) | |
| LD TOCI IV | 0.69(0.11,3.24) | 0.70(0.12,2.99) | ‐0.01(‐0.08,0.08) | |
| LD RITUX IV + MTX | 6.35(2.10,20.24) | 4.91(1.92,12.60) | 0.20(0.06,0.42) | |
| LD ABA IV + MTX | 7.37(2.47,22.77) | 5.47(2.20,13.79) | 0.23(0.08,0.45) | |
| LD ANA SC + MTX | 10.91(1.38,88.88) | 7.03(1.34,21.59) | 0.31(0.02,0.77) | |
| LD CERTO SC + MTX | 14.73(4.21,52.91) | 8.40(3.32,20.38) | 0.39(0.15,0.65) | |
| LD ETN SC + MTX | 11.52(3.62,38.11) | 7.30(2.95,17.91) | 0.33(0.13,0.58) | |
| LD GOLI IV + MTX | 7.63(2.08,28.74) | 5.60(1.91,15.06) | 0.24(0.06,0.51) | |
| LD TOCI IV + MTX | 6.40(1.89,22.37) | 4.91(1.77,13.04) | 0.20(0.05,0.45) | |
| LD TOFA PO + MTX | 11.42(2.71,50.51) | 7.23(2.39,19.59) | 0.32(0.09,0.64) | |
| HD TOCI IV | 10.13(4.65,22.67) | 6.81(3.42,14.40) | 0.30(0.18,0.44) | |
| HD TOFA PO | 12.63(4.20,38.26) | 7.87(3.14,19.74) | 0.35(0.19,0.53) | |
| HD ADA SC | 5.90(1.89,19.18) | 4.66(1.74,12.78) | 0.19(0.06,0.36) | |
| HD GOLI SC | 10.52(3.45,32.32) | 6.98(2.79,17.25) | 0.31(0.14,0.51) | |
| HD ETN SC | 7.02(2.25,22.38) | 5.27(2.04,13.34) | 0.22(0.07,0.45) | |
| HD ABA SC | 17.57(3.38,98.73) | 9.21(2.78,26.24) | 0.43(0.14,0.75) | |
| HD TOCI IV + MTX | 17.47(7.19,45.59) | 9.31(4.54,20.47) | 0.43(0.27,0.61) | |
| HD TOFA PO + MTX | 17.73(6.48,51.47) | 9.30(4.28,21.36) | 0.43(0.23,0.64) | |
| HD GOLI SC + MTX | 18.65(6.40,57.05) | 9.60(4.21,22.52) | 0.45(0.25,0.65) | |
| HD CERTO SC + MTX | 24.36(8.95,70.21) | 10.84(5.07,24.65) | 0.51(0.31,0.70) | |
| HD INF IV + MTX | 14.98(5.23,46.24) | 8.53(3.75,20.19) | 0.39(0.19,0.61) | |
| HD TOCI IV + DMARD | 3.72(1.91,7.08) | 3.23(1.81,5.45) | 0.11(0.03,0.27) | |
| SD ETN SC | MTX + DMARD | 1.34(0.67,2.67) | 1.25(0.75,2.21) | 0.05(‐0.08,0.16) |
| SD ADA SC | 0.94(0.35,2.57) | 0.96(0.45,2.18) | ‐0.01(‐0.19,0.14) | |
| SD TOFA PO | 1.66(0.54,5.08) | 1.46(0.64,3.48) | 0.09(‐0.12,0.29) | |
| SD TOCI IV | 1.18(0.42,3.28) | 1.14(0.51,2.52) | 0.03(‐0.15,0.21) | |
| SD GOLI SC | 1.89(0.50,6.85) | 1.58(0.59,3.85) | 0.12(‐0.12,0.39) | |
| SD GOLI IV | 1.39(0.43,4.63) | 1.28(0.51,2.98) | 0.06(‐0.13,0.31) | |
| SD ABA SC | 2.53(0.48,15.15) | 1.90(0.58,5.57) | 0.18(‐0.13,0.56) | |
| SD CERTO SC | 2.42(0.52,11.13) | 1.86(0.62,4.92) | 0.17(‐0.12,0.49) | |
| SD ETN SC + MTX | 2.55(1.52,4.28) | 1.92(1.30,3.00) | 0.18(0.08,0.29) | |
| SD INF IV + MTX | 2.24(1.16,4.47) | 1.77(1.10,3.04) | 0.16(0.03,0.30) | |
| SD ABA IV + MTX | 2.85(1.30,6.33) | 2.05(1.19,3.73) | 0.21(0.05,0.38) | |
| SD CERTO SC + MTX | 4.31(1.89,9.70) | 2.53(1.47,4.66) | 0.31(0.14,0.48) | |
| SD TOFA PO + MTX | 4.70(1.97,11.52) | 2.62(1.50,4.93) | 0.33(0.14,0.52) | |
| SD GOLI SC + MTX | 5.12(1.98,13.25) | 2.74(1.51,5.40) | 0.35(0.15,0.54) | |
| SD ADA SC + MTX | 3.08(0.90,10.40) | 2.11(0.93,4.47) | 0.23(‐0.02,0.50) | |
| SD RITUX IV + MTX | 1.61(0.62,4.25) | 1.43(0.70,2.91) | 0.08(‐0.08,0.29) | |
| SD GOLI IV + MTX | 1.80(0.67,4.70) | 1.54(0.75,3.04) | 0.11(‐0.07,0.31) | |
| SD ABA SC + MTX | 3.07(0.94,9.88) | 2.11(0.96,4.40) | 0.23(‐0.01,0.49) | |
| SD ANA SC + MTX | 3.97(0.61,31.66) | 2.38(0.67,5.81) | 0.29(‐0.07,0.67) | |
| SD TOCI IV + MTX | 1.59(0.48,5.31) | 1.41(0.56,3.27) | 0.08(‐0.11,0.34) | |
| SD CERTO SC + DMARD | 1.20(0.34,4.28) | 1.15(0.43,3.01) | 0.03(‐0.18,0.27) | |
| SD ADA SC + DMARD | 0.67(0.16,2.64) | 0.72(0.21,2.11) | ‐0.05(‐0.24,0.17) | |
| SD ETN SC + DMARD | 2.66(0.82,8.47) | 1.95(0.87,4.19) | 0.19(‐0.04,0.45) | |
| LD ADA SC | 0.86(0.27,2.82) | 0.89(0.35,2.29) | ‐0.02(‐0.22,0.16) | |
| LD GOLI IV | 0.82(0.24,2.79) | 0.86(0.30,2.17) | ‐0.03(‐0.20,0.18) | |
| LD TOCI IV | 0.14(0.02,0.66) | 0.18(0.03,0.69) | ‐0.16(‐0.34,‐0.04) | |
| LD RITUX IV + MTX | 1.34(0.52,3.60) | 1.25(0.60,2.59) | 0.05(‐0.11,0.24) | |
| LD ABA IV + MTX | 1.56(0.62,4.03) | 1.39(0.69,2.81) | 0.08(‐0.09,0.27) | |
| LD ANA SC + MTX | 2.28(0.32,17.50) | 1.77(0.40,4.90) | 0.16(‐0.15,0.60) | |
| LD CERTO SC + MTX | 3.11(1.00,9.77) | 2.13(1.00,4.41) | 0.23(0.00,0.49) | |
| LD ETN SC + MTX | 2.44(0.92,6.48) | 1.86(0.94,3.60) | 0.17(‐0.02,0.40) | |
| LD GOLI IV + MTX | 1.61(0.50,5.06) | 1.42(0.58,3.17) | 0.08(‐0.11,0.34) | |
| LD TOCI IV + MTX | 1.34(0.40,4.50) | 1.25(0.49,2.99) | 0.05(‐0.14,0.29) | |
| LD TOFA PO + MTX | 2.42(0.62,9.38) | 1.84(0.69,4.16) | 0.17(‐0.08,0.48) | |
| HD TOCI IV | 2.13(0.95,4.91) | 1.72(0.97,3.35) | 0.14(‐0.01,0.29) | |
| HD TOFA PO | 2.64(0.85,8.04) | 1.96(0.89,4.50) | 0.20(‐0.04,0.41) | |
| HD ADA SC | 1.25(0.38,3.93) | 1.19(0.48,2.92) | 0.04(‐0.17,0.24) | |
| HD GOLI SC | 2.22(0.78,6.08) | 1.76(0.84,3.68) | 0.15(‐0.05,0.36) | |
| HD ETN SC | 1.49(0.54,4.17) | 1.35(0.62,2.84) | 0.07(‐0.10,0.28) | |
| HD ABA SC | 3.63(0.73,21.55) | 2.32(0.79,6.27) | 0.27(‐0.06,0.63) | |
| HD TOCI IV + MTX | 3.69(1.61,8.66) | 2.35(1.35,4.50) | 0.27(0.11,0.44) | |
| HD TOFA PO + MTX | 3.73(1.59,9.16) | 2.35(1.34,4.45) | 0.28(0.09,0.47) | |
| HD GOLI SC + MTX | 3.92(1.53,10.33) | 2.41(1.31,4.76) | 0.29(0.09,0.49) | |
| HD CERTO SC + MTX | 5.14(2.18,12.37) | 2.74(1.57,5.11) | 0.36(0.17,0.53) | |
| HD INF IV + MTX | 3.15(1.31,7.82) | 2.15(1.20,4.07) | 0.23(0.05,0.44) | |
| HD TOCI IV + DMARD | 0.78(0.23,2.59) | 0.82(0.30,2.09) | ‐0.04(‐0.21,0.16) | |
| SD ADA SC | SD ETN SC | 0.71(0.30,1.64) | 0.77(0.40,1.47) | ‐0.06(‐0.22,0.08) |
| SD TOFA PO | 1.23(0.46,3.30) | 1.16(0.57,2.33) | 0.04(‐0.16,0.24) | |
| SD TOCI IV | 0.89(0.35,2.17) | 0.91(0.44,1.75) | ‐0.02(‐0.18,0.16) | |
| SD GOLI SC | 1.41(0.41,4.61) | 1.27(0.51,2.69) | 0.07(‐0.16,0.34) | |
| SD GOLI IV | 1.04(0.35,3.24) | 1.03(0.43,2.14) | 0.01(‐0.17,0.26) | |
| SD ABA SC | 1.90(0.39,10.18) | 1.53(0.50,3.77) | 0.14(‐0.16,0.51) | |
| SD CERTO SC | 1.80(0.44,7.39) | 1.48(0.54,3.40) | 0.12(‐0.15,0.44) | |
| SD ETN SC + MTX | 1.90(1.17,3.13) | 1.53(1.11,2.15) | 0.14(0.03,0.26) | |
| SD INF IV + MTX | 1.68(0.88,3.25) | 1.42(0.91,2.20) | 0.11(‐0.03,0.26) | |
| SD ABA IV + MTX | 2.13(1.07,4.27) | 1.64(1.04,2.55) | 0.16(0.01,0.33) | |
| SD CERTO SC + MTX | 3.22(1.60,6.62) | 2.03(1.33,3.13) | 0.26(0.10,0.43) | |
| SD TOFA PO + MTX | 3.48(1.61,7.86) | 2.10(1.36,3.31) | 0.28(0.10,0.46) | |
| SD GOLI SC + MTX | 3.84(1.64,9.05) | 2.19(1.35,3.59) | 0.31(0.11,0.49) | |
| SD ADA SC + MTX | 2.29(0.73,7.27) | 1.70(0.79,3.12) | 0.18(‐0.06,0.45) | |
| SD RITUX IV + MTX | 1.20(0.51,2.93) | 1.14(0.60,2.05) | 0.03(‐0.12,0.24) | |
| SD GOLI IV + MTX | 1.35(0.57,3.21) | 1.23(0.65,2.16) | 0.06(‐0.10,0.26) | |
| SD ABA SC + MTX | 2.29(0.76,7.00) | 1.70(0.81,3.09) | 0.18(‐0.05,0.44) | |
| SD ANA SC + MTX | 2.94(0.47,22.26) | 1.93(0.55,4.06) | 0.24(‐0.12,0.62) | |
| SD TOCI IV + MTX | 1.19(0.40,3.67) | 1.13(0.48,2.31) | 0.03(‐0.16,0.29) | |
| SD CERTO SC + DMARD | 0.89(0.29,2.84) | 0.92(0.38,2.08) | ‐0.02(‐0.21,0.21) | |
| SD ADA SC + DMARD | 0.50(0.14,1.78) | 0.57(0.19,1.50) | ‐0.10(‐0.26,0.11) | |
| SD ETN SC + DMARD | 1.99(0.76,5.22) | 1.57(0.82,2.68) | 0.15(‐0.05,0.38) | |
| LD ADA SC | 0.65(0.23,1.85) | 0.71(0.31,1.59) | ‐0.07(‐0.25,0.11) | |
| LD GOLI IV | 0.61(0.20,1.89) | 0.68(0.25,1.57) | ‐0.08(‐0.24,0.13) | |
| LD TOCI IV | 0.11(0.02,0.46) | 0.14(0.03,0.52) | ‐0.21(‐0.36,‐0.09) | |
| LD RITUX IV + MTX | 1.00(0.42,2.44) | 1.00(0.50,1.83) | 0.00(‐0.15,0.19) | |
| LD ABA IV + MTX | 1.16(0.49,2.80) | 1.11(0.57,2.01) | 0.03(‐0.12,0.22) | |
| LD ANA SC + MTX | 1.69(0.26,12.73) | 1.42(0.33,3.49) | 0.11(‐0.19,0.55) | |
| LD CERTO SC + MTX | 2.33(0.81,6.73) | 1.72(0.85,3.04) | 0.18(‐0.04,0.43) | |
| LD ETN SC + MTX | 1.82(0.73,4.61) | 1.49(0.79,2.58) | 0.12(‐0.06,0.35) | |
| LD GOLI IV + MTX | 1.19(0.40,3.71) | 1.14(0.48,2.29) | 0.03(‐0.15,0.29) | |
| LD TOCI IV + MTX | 1.00(0.34,3.02) | 1.00(0.42,2.10) | 0.00(‐0.18,0.24) | |
| LD TOFA PO + MTX | 1.80(0.50,6.60) | 1.48(0.59,2.94) | 0.12(‐0.12,0.42) | |
| HD TOCI IV | 1.58(0.84,3.16) | 1.37(0.88,2.22) | 0.09(‐0.04,0.24) | |
| HD TOFA PO | 1.97(0.73,5.20) | 1.57(0.81,3.04) | 0.15(‐0.07,0.35) | |
| HD ADA SC | 0.92(0.33,2.65) | 0.94(0.42,2.05) | ‐0.01(‐0.20,0.19) | |
| HD GOLI SC | 1.66(0.65,4.05) | 1.41(0.73,2.55) | 0.10(‐0.09,0.31) | |
| HD ETN SC | 1.11(0.48,2.65) | 1.08(0.56,1.89) | 0.02(‐0.12,0.21) | |
| HD ABA SC | 2.74(0.60,14.42) | 1.87(0.69,4.21) | 0.23(‐0.10,0.57) | |
| HD TOCI IV + MTX | 2.75(1.37,5.68) | 1.88(1.22,3.00) | 0.23(0.07,0.39) | |
| HD TOFA PO + MTX | 2.78(1.31,6.13) | 1.89(1.20,3.01) | 0.23(0.06,0.41) | |
| HD GOLI SC + MTX | 2.95(1.25,7.06) | 1.94(1.16,3.24) | 0.24(0.05,0.44) | |
| HD CERTO SC + MTX | 3.81(1.78,8.36) | 2.19(1.42,3.46) | 0.31(0.13,0.48) | |
| HD INF IV + MTX | 2.34(1.03,5.59) | 1.72(1.02,2.86) | 0.19(0.01,0.39) | |
| HD TOCI IV + DMARD | 0.59(0.20,1.66) | 0.66(0.26,1.44) | ‐0.09(‐0.24,0.10) | |
| SD TOFA PO | SD ADA SC | 1.74(0.76,4.14) | 1.52(0.82,2.83) | 0.10(‐0.05,0.27) |
| SD TOCI IV | 1.26(0.45,3.46) | 1.20(0.53,2.52) | 0.04(‐0.12,0.23) | |
| SD GOLI SC | 2.00(0.55,6.90) | 1.66(0.63,3.70) | 0.13(‐0.09,0.40) | |
| SD GOLI IV | 1.48(0.41,5.41) | 1.34(0.48,3.20) | 0.07(‐0.12,0.35) | |
| SD ABA SC | 2.70(0.59,14.14) | 2.02(0.66,4.83) | 0.20(‐0.08,0.56) | |
| SD CERTO SC | 2.55(0.64,10.19) | 1.95(0.71,4.42) | 0.18(‐0.07,0.49) | |
| SD ETN SC + MTX | 2.70(1.11,6.73) | 2.02(1.08,3.72) | 0.20(0.02,0.39) | |
| SD INF IV + MTX | 2.38(0.94,6.12) | 1.86(0.95,3.52) | 0.17(‐0.01,0.37) | |
| SD ABA IV + MTX | 3.04(1.15,7.85) | 2.15(1.11,4.00) | 0.22(0.02,0.43) | |
| SD CERTO SC + MTX | 4.60(1.74,11.84) | 2.67(1.45,4.75) | 0.33(0.11,0.53) | |
| SD TOFA PO + MTX | 4.95(1.80,13.82) | 2.76(1.48,4.99) | 0.35(0.12,0.56) | |
| SD GOLI SC + MTX | 5.47(1.97,15.38) | 2.88(1.57,5.19) | 0.37(0.14,0.58) | |
| SD ADA SC + MTX | 3.27(0.87,12.49) | 2.23(0.90,4.61) | 0.24(‐0.02,0.54) | |
| SD RITUX IV + MTX | 1.71(0.58,5.26) | 1.50(0.65,3.18) | 0.10(‐0.09,0.34) | |
| SD GOLI IV + MTX | 1.92(0.64,5.65) | 1.62(0.70,3.34) | 0.12(‐0.07,0.36) | |
| SD ABA SC + MTX | 3.27(0.87,11.74) | 2.24(0.90,4.53) | 0.24(‐0.02,0.53) | |
| SD ANA SC + MTX | 4.23(0.60,35.03) | 2.55(0.66,5.57) | 0.30(‐0.07,0.70) | |
| SD TOCI IV + MTX | 1.71(0.49,5.80) | 1.50(0.56,3.31) | 0.10(‐0.11,0.36) | |
| SD CERTO SC + DMARD | 1.27(0.40,4.21) | 1.20(0.47,2.86) | 0.04(‐0.14,0.28) | |
| SD ADA SC + DMARD | 0.71(0.18,2.78) | 0.75(0.22,2.15) | ‐0.05(‐0.20,0.19) | |
| SD ETN SC + DMARD | 2.82(0.84,9.66) | 2.06(0.87,4.20) | 0.21(‐0.03,0.49) | |
| LD ADA SC | 0.92(0.42,1.98) | 0.93(0.49,1.70) | ‐0.01(‐0.12,0.12) | |
| LD GOLI IV | 0.87(0.23,3.20) | 0.89(0.28,2.36) | ‐0.02(‐0.18,0.22) | |
| LD TOCI IV | 0.15(0.03,0.70) | 0.19(0.04,0.74) | ‐0.15(‐0.27,‐0.04) | |
| LD RITUX IV + MTX | 1.42(0.48,4.34) | 1.31(0.55,2.87) | 0.06(‐0.11,0.29) | |
| LD ABA IV + MTX | 1.65(0.55,4.88) | 1.46(0.62,3.08) | 0.09(‐0.09,0.32) | |
| LD ANA SC + MTX | 2.39(0.32,20.29) | 1.86(0.39,4.88) | 0.17(‐0.14,0.63) | |
| LD CERTO SC + MTX | 3.31(0.95,11.76) | 2.26(0.96,4.52) | 0.25(‐0.01,0.53) | |
| LD ETN SC + MTX | 2.58(0.81,8.33) | 1.96(0.84,3.93) | 0.19(‐0.04,0.45) | |
| LD GOLI IV + MTX | 1.71(0.48,6.04) | 1.49(0.55,3.40) | 0.10(‐0.11,0.37) | |
| LD TOCI IV + MTX | 1.43(0.43,4.62) | 1.32(0.50,2.95) | 0.06(‐0.12,0.31) | |
| LD TOFA PO + MTX | 2.54(0.60,10.95) | 1.94(0.67,4.29) | 0.18(‐0.08,0.51) | |
| HD TOCI IV | 2.26(1.07,4.69) | 1.81(1.05,3.07) | 0.16(0.01,0.31) | |
| HD TOFA PO | 2.80(1.21,6.50) | 2.06(1.14,3.67) | 0.21(0.04,0.39) | |
| HD ADA SC | 1.32(0.62,2.79) | 1.24(0.68,2.15) | 0.05(‐0.07,0.19) | |
| HD GOLI SC | 2.34(0.84,6.67) | 1.84(0.87,3.71) | 0.17(‐0.03,0.39) | |
| HD ETN SC | 1.58(0.50,4.94) | 1.41(0.57,3.07) | 0.08(‐0.11,0.32) | |
| HD ABA SC | 3.89(0.85,20.41) | 2.46(0.89,5.43) | 0.29(‐0.03,0.63) | |
| HD TOCI IV + MTX | 3.92(1.62,9.54) | 2.47(1.38,4.38) | 0.29(0.10,0.48) | |
| HD TOFA PO + MTX | 3.95(1.45,11.00) | 2.48(1.30,4.54) | 0.29(0.07,0.51) | |
| HD GOLI SC + MTX | 4.17(1.48,12.15) | 2.55(1.32,4.76) | 0.31(0.08,0.53) | |
| HD CERTO SC + MTX | 5.46(1.94,15.08) | 2.87(1.55,5.11) | 0.37(0.14,0.58) | |
| HD INF IV + MTX | 3.36(1.12,9.87) | 2.28(1.09,4.36) | 0.25(0.02,0.49) | |
| HD TOCI IV + DMARD | 0.83(0.25,2.67) | 0.86(0.30,2.11) | ‐0.03(‐0.18,0.18) | |
| SD TOCI IV | SD TOFA PO | 0.72(0.23,2.22) | 0.78(0.33,1.76) | ‐0.06(‐0.27,0.16) |
| SD GOLI SC | 1.13(0.30,4.41) | 1.09(0.42,2.50) | 0.03(‐0.23,0.33) | |
| SD GOLI IV | 0.86(0.21,3.25) | 0.90(0.30,2.11) | ‐0.03(‐0.27,0.26) | |
| SD ABA SC | 1.53(0.32,8.07) | 1.32(0.43,3.11) | 0.09(‐0.21,0.47) | |
| SD CERTO SC | 1.45(0.36,5.84) | 1.28(0.48,2.83) | 0.08(‐0.20,0.40) | |
| SD ETN SC + MTX | 1.54(0.55,4.24) | 1.32(0.67,2.58) | 0.10(‐0.13,0.32) | |
| SD INF IV + MTX | 1.36(0.46,3.95) | 1.22(0.59,2.42) | 0.07(‐0.16,0.30) | |
| SD ABA IV + MTX | 1.74(0.58,5.05) | 1.42(0.69,2.74) | 0.12(‐0.12,0.36) | |
| SD CERTO SC + MTX | 2.63(0.85,7.68) | 1.76(0.91,3.24) | 0.23(‐0.04,0.46) | |
| SD TOFA PO + MTX | 2.83(0.89,9.18) | 1.81(0.93,3.40) | 0.24(‐0.03,0.50) | |
| SD GOLI SC + MTX | 3.13(0.99,9.62) | 1.90(0.99,3.49) | 0.27(0.00,0.50) | |
| SD ADA SC + MTX | 1.87(0.44,7.68) | 1.47(0.56,3.11) | 0.14(‐0.17,0.46) | |
| SD RITUX IV + MTX | 0.98(0.29,3.30) | 0.98(0.40,2.19) | 0.00(‐0.24,0.26) | |
| SD GOLI IV + MTX | 1.10(0.33,3.54) | 1.06(0.45,2.25) | 0.02(‐0.22,0.28) | |
| SD ABA SC + MTX | 1.88(0.45,7.52) | 1.48(0.57,3.09) | 0.14(‐0.16,0.46) | |
| SD ANA SC + MTX | 2.42(0.31,21.34) | 1.68(0.41,3.78) | 0.21(‐0.21,0.62) | |
| SD TOCI IV + MTX | 0.97(0.25,3.75) | 0.98(0.35,2.31) | ‐0.01(‐0.25,0.30) | |
| SD CERTO SC + DMARD | 0.72(0.21,2.59) | 0.79(0.31,1.91) | ‐0.06(‐0.28,0.20) | |
| SD ADA SC + DMARD | 0.40(0.09,1.78) | 0.49(0.14,1.50) | ‐0.15(‐0.35,0.12) | |
| SD ETN SC + DMARD | 1.61(0.44,6.20) | 1.35(0.56,2.86) | 0.10(‐0.17,0.41) | |
| LD ADA SC | 0.53(0.18,1.51) | 0.61(0.27,1.36) | ‐0.11(‐0.30,0.08) | |
| LD GOLI IV | 0.50(0.12,1.92) | 0.59(0.18,1.58) | ‐0.12(‐0.33,0.14) | |
| LD TOCI IV | 0.09(0.01,0.42) | 0.12(0.02,0.49) | ‐0.25(‐0.43,‐0.11) | |
| LD RITUX IV + MTX | 0.82(0.24,2.76) | 0.87(0.34,1.97) | ‐0.04(‐0.26,0.22) | |
| LD ABA IV + MTX | 0.95(0.28,3.09) | 0.96(0.39,2.12) | ‐0.01(‐0.24,0.25) | |
| LD ANA SC + MTX | 1.37(0.17,12.35) | 1.23(0.25,3.38) | 0.07(‐0.28,0.55) | |
| LD CERTO SC + MTX | 1.90(0.48,7.42) | 1.49(0.60,3.09) | 0.14(‐0.15,0.45) | |
| LD ETN SC + MTX | 1.47(0.41,5.25) | 1.29(0.53,2.71) | 0.08(‐0.18,0.37) | |
| LD GOLI IV + MTX | 0.98(0.25,3.70) | 0.99(0.35,2.27) | 0.00(‐0.25,0.29) | |
| LD TOCI IV + MTX | 0.82(0.21,3.06) | 0.87(0.31,2.07) | ‐0.04(‐0.27,0.25) | |
| LD TOFA PO + MTX | 1.44(0.31,6.91) | 1.27(0.41,2.98) | 0.08(‐0.22,0.44) | |
| HD TOCI IV | 1.30(0.50,3.33) | 1.19(0.64,2.27) | 0.06(‐0.15,0.26) | |
| HD TOFA PO | 1.60(0.88,2.96) | 1.35(0.92,2.05) | 0.10(‐0.03,0.24) | |
| HD ADA SC | 0.75(0.27,2.15) | 0.81(0.38,1.71) | ‐0.05(‐0.25,0.16) | |
| HD GOLI SC | 1.34(0.42,4.06) | 1.22(0.55,2.47) | 0.06(‐0.18,0.31) | |
| HD ETN SC | 0.90(0.26,3.17) | 0.93(0.37,2.13) | ‐0.02(‐0.25,0.25) | |
| HD ABA SC | 2.21(0.46,11.37) | 1.61(0.58,3.50) | 0.18(‐0.16,0.53) | |
| HD TOCI IV + MTX | 2.24(0.79,6.42) | 1.63(0.87,3.05) | 0.19(‐0.05,0.42) | |
| HD TOFA PO + MTX | 2.24(0.70,7.22) | 1.63(0.79,3.12) | 0.19(‐0.08,0.45) | |
| HD GOLI SC + MTX | 2.38(0.74,7.39) | 1.67(0.83,3.19) | 0.20(‐0.07,0.45) | |
| HD CERTO SC + MTX | 3.15(0.98,9.47) | 1.91(0.99,3.46) | 0.27(‐0.01,0.50) | |
| HD INF IV + MTX | 1.92(0.56,6.18) | 1.50(0.68,2.93) | 0.15(‐0.12,0.41) | |
| HD TOCI IV + DMARD | 0.47(0.13,1.67) | 0.56(0.19,1.45) | ‐0.13(‐0.33,0.10) | |
| SD GOLI SC | SD TOCI IV | 1.58(0.41,6.09) | 1.38(0.51,3.54) | 0.09(‐0.17,0.37) |
| SD GOLI IV | 1.18(0.32,4.30) | 1.13(0.41,2.74) | 0.03(‐0.19,0.30) | |
| SD ABA SC | 2.18(0.40,12.62) | 1.68(0.50,4.73) | 0.16(‐0.17,0.54) | |
| SD CERTO SC | 2.05(0.43,9.44) | 1.63(0.55,4.26) | 0.15(‐0.16,0.47) | |
| SD ETN SC + MTX | 2.13(0.85,5.52) | 1.67(0.90,3.42) | 0.16(‐0.03,0.34) | |
| SD INF IV + MTX | 1.90(0.75,4.83) | 1.56(0.82,3.13) | 0.13(‐0.06,0.32) | |
| SD ABA IV + MTX | 2.42(0.93,6.29) | 1.79(0.95,3.60) | 0.19(‐0.02,0.38) | |
| SD CERTO SC + MTX | 3.63(1.44,9.57) | 2.22(1.24,4.41) | 0.28(0.08,0.48) | |
| SD TOFA PO + MTX | 3.95(1.45,11.20) | 2.29(1.25,4.69) | 0.30(0.08,0.51) | |
| SD GOLI SC + MTX | 4.34(1.52,12.39) | 2.40(1.28,4.92) | 0.33(0.10,0.53) | |
| SD ADA SC + MTX | 2.62(0.68,9.67) | 1.87(0.76,4.13) | 0.20(‐0.07,0.49) | |
| SD RITUX IV + MTX | 1.36(0.46,4.08) | 1.25(0.56,2.77) | 0.06(‐0.15,0.29) | |
| SD GOLI IV + MTX | 1.53(0.51,4.48) | 1.35(0.61,2.92) | 0.08(‐0.13,0.30) | |
| SD ABA SC + MTX | 2.60(0.71,9.32) | 1.86(0.78,4.17) | 0.20(‐0.07,0.48) | |
| SD ANA SC + MTX | 3.39(0.46,28.16) | 2.10(0.56,5.23) | 0.26(‐0.12,0.66) | |
| SD TOCI IV + MTX | 1.35(0.46,4.03) | 1.24(0.54,2.65) | 0.06(‐0.14,0.29) | |
| SD CERTO SC + DMARD | 1.01(0.27,3.77) | 1.01(0.37,2.68) | 0.00(‐0.22,0.25) | |
| SD ADA SC + DMARD | 0.56(0.14,2.28) | 0.63(0.19,1.89) | ‐0.08(‐0.29,0.15) | |
| SD ETN SC + DMARD | 2.22(0.64,8.05) | 1.71(0.72,3.94) | 0.16(‐0.09,0.44) | |
| LD ADA SC | 0.73(0.22,2.48) | 0.78(0.31,2.06) | ‐0.05(‐0.26,0.15) | |
| LD GOLI IV | 0.69(0.18,2.61) | 0.75(0.25,2.04) | ‐0.06(‐0.26,0.18) | |
| LD TOCI IV | 0.12(0.02,0.52) | 0.16(0.03,0.57) | ‐0.19(‐0.37,‐0.07) | |
| LD RITUX IV + MTX | 1.13(0.37,3.40) | 1.10(0.47,2.45) | 0.02(‐0.17,0.24) | |
| LD ABA IV + MTX | 1.32(0.44,3.93) | 1.22(0.54,2.70) | 0.05(‐0.16,0.27) | |
| LD ANA SC + MTX | 1.90(0.25,16.32) | 1.55(0.33,4.45) | 0.13(‐0.20,0.58) | |
| LD CERTO SC + MTX | 2.63(0.76,9.00) | 1.87(0.83,4.07) | 0.20(‐0.05,0.48) | |
| LD ETN SC + MTX | 2.03(0.63,6.68) | 1.62(0.72,3.59) | 0.14(‐0.09,0.40) | |
| LD GOLI IV + MTX | 1.36(0.38,4.95) | 1.25(0.47,3.02) | 0.06(‐0.17,0.33) | |
| LD TOCI IV + MTX | 1.13(0.38,3.33) | 1.10(0.46,2.37) | 0.02(‐0.17,0.24) | |
| LD TOFA PO + MTX | 2.01(0.49,8.77) | 1.61(0.58,3.97) | 0.14(‐0.13,0.47) | |
| HD TOCI IV | 1.80(0.84,3.86) | 1.51(0.90,2.80) | 0.12(‐0.04,0.26) | |
| HD TOFA PO | 2.23(0.72,6.85) | 1.72(0.81,3.95) | 0.17(‐0.07,0.38) | |
| HD ADA SC | 1.05(0.31,3.42) | 1.04(0.41,2.58) | 0.01(‐0.22,0.22) | |
| HD GOLI SC | 1.87(0.61,5.68) | 1.54(0.71,3.46) | 0.12(‐0.10,0.35) | |
| HD ETN SC | 1.25(0.39,4.10) | 1.18(0.49,2.75) | 0.04(‐0.17,0.28) | |
| HD ABA SC | 3.14(0.60,18.06) | 2.05(0.69,5.37) | 0.25(‐0.10,0.61) | |
| HD TOCI IV + MTX | 3.11(1.37,7.40) | 2.06(1.21,3.96) | 0.25(0.07,0.42) | |
| HD TOFA PO + MTX | 3.14(1.15,8.96) | 2.06(1.10,4.26) | 0.25(0.03,0.47) | |
| HD GOLI SC + MTX | 3.30(1.14,9.73) | 2.11(1.08,4.46) | 0.26(0.03,0.48) | |
| HD CERTO SC + MTX | 4.34(1.62,12.05) | 2.39(1.32,4.83) | 0.33(0.11,0.53) | |
| HD INF IV + MTX | 2.66(0.94,7.79) | 1.88(0.96,3.94) | 0.21(‐0.01,0.43) | |
| HD TOCI IV + DMARD | 0.66(0.19,2.27) | 0.72(0.26,1.88) | ‐0.06(‐0.26,0.14) | |
| SD GOLI IV | SD GOLI SC | 0.74(0.16,3.46) | 0.81(0.27,2.34) | ‐0.06(‐0.36,0.26) |
| SD ABA SC | 1.35(0.22,9.27) | 1.21(0.36,3.71) | 0.07(‐0.31,0.48) | |
| SD CERTO SC | 1.30(0.24,6.31) | 1.18(0.39,3.22) | 0.06(‐0.31,0.40) | |
| SD ETN SC + MTX | 1.36(0.40,4.70) | 1.21(0.59,2.91) | 0.07(‐0.21,0.32) | |
| SD INF IV + MTX | 1.20(0.34,4.27) | 1.12(0.53,2.72) | 0.04(‐0.24,0.30) | |
| SD ABA IV + MTX | 1.52(0.44,5.38) | 1.29(0.62,3.11) | 0.10(‐0.19,0.36) | |
| SD CERTO SC + MTX | 2.27(0.66,8.08) | 1.59(0.81,3.75) | 0.19(‐0.10,0.45) | |
| SD TOFA PO + MTX | 2.48(0.67,9.64) | 1.65(0.81,3.93) | 0.21(‐0.10,0.49) | |
| SD GOLI SC + MTX | 2.73(0.81,9.24) | 1.73(0.90,3.88) | 0.23(‐0.05,0.48) | |
| SD ADA SC + MTX | 1.63(0.36,7.86) | 1.34(0.51,3.51) | 0.11(‐0.22,0.45) | |
| SD RITUX IV + MTX | 0.86(0.22,3.33) | 0.90(0.36,2.32) | ‐0.03(‐0.32,0.25) | |
| SD GOLI IV + MTX | 0.95(0.25,3.77) | 0.97(0.39,2.50) | ‐0.01(‐0.30,0.28) | |
| SD ABA SC + MTX | 1.63(0.35,7.65) | 1.34(0.52,3.42) | 0.11(‐0.23,0.44) | |
| SD ANA SC + MTX | 2.10(0.26,20.11) | 1.51(0.38,4.26) | 0.17(‐0.27,0.61) | |
| SD TOCI IV + MTX | 0.86(0.19,3.78) | 0.90(0.32,2.46) | ‐0.03(‐0.34,0.28) | |
| SD CERTO SC + DMARD | 0.64(0.14,2.84) | 0.73(0.26,2.10) | ‐0.09(‐0.39,0.20) | |
| SD ADA SC + DMARD | 0.35(0.07,1.89) | 0.45(0.12,1.61) | ‐0.17(‐0.45,0.12) | |
| SD ETN SC + DMARD | 1.41(0.32,6.53) | 1.24(0.49,3.31) | 0.08(‐0.25,0.41) | |
| LD ADA SC | 0.46(0.12,1.84) | 0.56(0.22,1.60) | ‐0.14(‐0.43,0.10) | |
| LD GOLI IV | 0.44(0.09,2.02) | 0.54(0.16,1.68) | ‐0.14(‐0.43,0.13) | |
| LD TOCI IV | 0.08(0.01,0.44) | 0.11(0.02,0.51) | ‐0.28(‐0.55,‐0.09) | |
| LD RITUX IV + MTX | 0.71(0.18,2.83) | 0.79(0.31,2.08) | ‐0.07(‐0.35,0.21) | |
| LD ABA IV + MTX | 0.82(0.21,3.22) | 0.88(0.35,2.29) | ‐0.04(‐0.32,0.24) | |
| LD ANA SC + MTX | 1.20(0.14,11.81) | 1.12(0.23,3.63) | 0.04(‐0.35,0.53) | |
| LD CERTO SC + MTX | 1.65(0.38,7.43) | 1.35(0.54,3.42) | 0.11(‐0.21,0.44) | |
| LD ETN SC + MTX | 1.29(0.31,5.46) | 1.17(0.48,2.98) | 0.06(‐0.26,0.36) | |
| LD GOLI IV + MTX | 0.85(0.19,3.97) | 0.89(0.31,2.52) | ‐0.03(‐0.33,0.29) | |
| LD TOCI IV + MTX | 0.72(0.16,3.22) | 0.79(0.27,2.23) | ‐0.07(‐0.36,0.24) | |
| LD TOFA PO + MTX | 1.28(0.25,6.87) | 1.16(0.39,3.21) | 0.05(‐0.29,0.42) | |
| HD TOCI IV | 1.13(0.35,3.78) | 1.09(0.54,2.60) | 0.03(‐0.25,0.26) | |
| HD TOFA PO | 1.40(0.38,5.44) | 1.24(0.58,3.18) | 0.08(‐0.23,0.35) | |
| HD ADA SC | 0.66(0.17,2.65) | 0.75(0.30,2.07) | ‐0.08(‐0.37,0.18) | |
| HD GOLI SC | 1.17(0.44,3.25) | 1.10(0.60,2.31) | 0.03(‐0.19,0.25) | |
| HD ETN SC | 0.79(0.19,3.21) | 0.85(0.32,2.30) | ‐0.05(‐0.34,0.24) | |
| HD ABA SC | 1.92(0.33,13.06) | 1.46(0.50,4.21) | 0.15(‐0.24,0.55) | |
| HD TOCI IV + MTX | 1.97(0.58,7.18) | 1.48(0.75,3.55) | 0.16(‐0.13,0.42) | |
| HD TOFA PO + MTX | 1.96(0.53,7.70) | 1.48(0.70,3.59) | 0.16(‐0.15,0.44) | |
| HD GOLI SC + MTX | 2.07(0.63,7.23) | 1.52(0.78,3.53) | 0.17(‐0.11,0.43) | |
| HD CERTO SC + MTX | 2.74(0.77,9.95) | 1.73(0.88,4.05) | 0.24(‐0.06,0.50) | |
| HD INF IV + MTX | 1.69(0.45,6.56) | 1.36(0.62,3.34) | 0.12(‐0.19,0.41) | |
| HD TOCI IV + DMARD | 0.42(0.10,1.83) | 0.52(0.17,1.57) | ‐0.15(‐0.44,0.11) | |
| SD ABA SC | SD GOLI IV | 1.83(0.28,12.96) | 1.48(0.42,5.16) | 0.13(‐0.26,0.53) |
| SD CERTO SC | 1.72(0.32,9.36) | 1.43(0.47,4.59) | 0.11(‐0.24,0.46) | |
| SD ETN SC + MTX | 1.83(0.59,5.58) | 1.49(0.74,3.61) | 0.13(‐0.12,0.33) | |
| SD INF IV + MTX | 1.61(0.53,4.83) | 1.38(0.68,3.31) | 0.10(‐0.15,0.30) | |
| SD ABA IV + MTX | 2.05(0.68,6.20) | 1.59(0.80,3.84) | 0.15(‐0.09,0.36) | |
| SD CERTO SC + MTX | 3.09(1.01,9.42) | 1.97(1.00,4.70) | 0.25(0.00,0.46) | |
| SD TOFA PO + MTX | 3.36(1.09,10.84) | 2.04(1.05,4.86) | 0.27(0.02,0.50) | |
| SD GOLI SC + MTX | 3.67(1.06,12.65) | 2.12(1.03,5.34) | 0.29(0.01,0.52) | |
| SD ADA SC + MTX | 2.23(0.53,8.94) | 1.65(0.66,4.26) | 0.17(‐0.14,0.47) | |
| SD RITUX IV + MTX | 1.16(0.35,4.00) | 1.11(0.49,2.81) | 0.03(‐0.22,0.26) | |
| SD GOLI IV + MTX | 1.29(0.49,3.47) | 1.19(0.63,2.56) | 0.05(‐0.15,0.24) | |
| SD ABA SC + MTX | 2.20(0.55,9.17) | 1.64(0.68,4.41) | 0.17(‐0.13,0.46) | |
| SD ANA SC + MTX | 2.86(0.37,25.79) | 1.85(0.49,5.45) | 0.23(‐0.19,0.65) | |
| SD TOCI IV + MTX | 1.15(0.27,4.96) | 1.11(0.40,3.17) | 0.03(‐0.27,0.31) | |
| SD CERTO SC + DMARD | 0.87(0.19,3.86) | 0.90(0.31,2.80) | ‐0.03(‐0.33,0.24) | |
| SD ADA SC + DMARD | 0.48(0.10,2.36) | 0.56(0.15,1.90) | ‐0.11(‐0.40,0.15) | |
| SD ETN SC + DMARD | 1.91(0.44,8.10) | 1.52(0.58,4.19) | 0.13(‐0.18,0.43) | |
| LD ADA SC | 0.62(0.15,2.60) | 0.70(0.25,2.16) | ‐0.08(‐0.37,0.15) | |
| LD GOLI IV | 0.59(0.20,1.75) | 0.67(0.28,1.54) | ‐0.08(‐0.29,0.10) | |
| LD TOCI IV | 0.11(0.01,0.56) | 0.14(0.02,0.61) | ‐0.22(‐0.49,‐0.05) | |
| LD RITUX IV + MTX | 0.96(0.28,3.30) | 0.97(0.41,2.47) | ‐0.01(‐0.26,0.22) | |
| LD ABA IV + MTX | 1.12(0.32,3.89) | 1.08(0.46,2.80) | 0.02(‐0.24,0.25) | |
| LD ANA SC + MTX | 1.63(0.20,14.91) | 1.38(0.29,4.58) | 0.10(‐0.27,0.57) | |
| LD CERTO SC + MTX | 2.23(0.55,8.94) | 1.66(0.69,4.28) | 0.17(‐0.13,0.46) | |
| LD ETN SC + MTX | 1.74(0.46,6.35) | 1.44(0.62,3.66) | 0.11(‐0.17,0.38) | |
| LD GOLI IV + MTX | 1.15(0.41,3.30) | 1.10(0.53,2.41) | 0.03(‐0.18,0.24) | |
| LD TOCI IV + MTX | 0.97(0.23,3.94) | 0.97(0.35,2.76) | ‐0.01(‐0.28,0.26) | |
| LD TOFA PO + MTX | 1.74(0.38,8.13) | 1.43(0.51,3.92) | 0.11(‐0.20,0.44) | |
| HD TOCI IV | 1.53(0.49,4.82) | 1.34(0.66,3.34) | 0.09(‐0.17,0.28) | |
| HD TOFA PO | 1.88(0.49,7.57) | 1.51(0.67,4.29) | 0.14(‐0.17,0.39) | |
| HD ADA SC | 0.90(0.21,3.79) | 0.93(0.34,2.80) | ‐0.02(‐0.33,0.22) | |
| HD GOLI SC | 1.59(0.44,5.81) | 1.36(0.60,3.66) | 0.09(‐0.19,0.34) | |
| HD ETN SC | 1.06(0.29,3.92) | 1.04(0.43,2.77) | 0.01(‐0.26,0.26) | |
| HD ABA SC | 2.64(0.42,18.45) | 1.81(0.57,5.79) | 0.21(‐0.19,0.60) | |
| HD TOCI IV + MTX | 2.65(0.83,8.23) | 1.83(0.91,4.49) | 0.21(‐0.04,0.43) | |
| HD TOFA PO + MTX | 2.68(0.86,8.46) | 1.83(0.92,4.35) | 0.21(‐0.04,0.44) | |
| HD GOLI SC + MTX | 2.81(0.81,9.90) | 1.88(0.90,4.77) | 0.23(‐0.05,0.47) | |
| HD CERTO SC + MTX | 3.70(1.18,11.73) | 2.13(1.08,5.12) | 0.29(0.04,0.51) | |
| HD INF IV + MTX | 2.26(0.65,7.75) | 1.67(0.78,4.19) | 0.17(‐0.10,0.42) | |
| HD TOCI IV + DMARD | 0.56(0.13,2.32) | 0.64(0.21,1.96) | ‐0.09(‐0.38,0.13) | |
| SD CERTO SC | SD ABA SC | 0.94(0.13,5.99) | 0.96(0.32,3.09) | ‐0.02(‐0.44,0.39) |
| SD ETN SC + MTX | 1.01(0.18,4.82) | 1.01(0.42,2.96) | 0.00(‐0.39,0.33) | |
| SD INF IV + MTX | 0.88(0.16,4.45) | 0.93(0.37,2.84) | ‐0.03(‐0.42,0.30) | |
| SD ABA IV + MTX | 1.13(0.19,5.78) | 1.07(0.44,3.23) | 0.03(‐0.38,0.37) | |
| SD CERTO SC + MTX | 1.70(0.29,8.79) | 1.33(0.57,3.95) | 0.13(‐0.29,0.46) | |
| SD TOFA PO + MTX | 1.84(0.29,10.11) | 1.37(0.57,4.11) | 0.15(‐0.29,0.50) | |
| SD GOLI SC + MTX | 2.00(0.34,11.30) | 1.42(0.63,4.22) | 0.17(‐0.25,0.52) | |
| SD ADA SC + MTX | 1.20(0.17,7.97) | 1.11(0.37,3.53) | 0.04(‐0.40,0.45) | |
| SD RITUX IV + MTX | 0.63(0.10,3.75) | 0.74(0.26,2.54) | ‐0.10(‐0.49,0.26) | |
| SD GOLI IV + MTX | 0.71(0.12,3.96) | 0.80(0.28,2.60) | ‐0.08(‐0.48,0.28) | |
| SD ABA SC + MTX | 1.21(0.16,7.70) | 1.11(0.37,3.47) | 0.04(‐0.41,0.44) | |
| SD ANA SC + MTX | 1.55(0.13,19.67) | 1.25(0.29,4.21) | 0.10(‐0.43,0.60) | |
| SD TOCI IV + MTX | 0.63(0.09,3.71) | 0.75(0.23,2.50) | ‐0.10(‐0.51,0.28) | |
| SD CERTO SC + DMARD | 0.47(0.08,2.70) | 0.60(0.21,2.06) | ‐0.15(‐0.54,0.19) | |
| SD ADA SC + DMARD | 0.26(0.04,1.81) | 0.38(0.09,1.55) | ‐0.24(‐0.62,0.11) | |
| SD ETN SC + DMARD | 1.02(0.16,6.39) | 1.01(0.36,3.22) | 0.00(‐0.41,0.41) | |
| LD ADA SC | 0.34(0.06,1.80) | 0.46(0.17,1.57) | ‐0.21(‐0.59,0.10) | |
| LD GOLI IV | 0.32(0.04,2.08) | 0.45(0.12,1.71) | ‐0.21(‐0.60,0.14) | |
| LD TOCI IV | 0.06(0.01,0.45) | 0.09(0.01,0.51) | ‐0.35(‐0.70,‐0.08) | |
| LD RITUX IV + MTX | 0.52(0.09,3.10) | 0.65(0.22,2.26) | ‐0.14(‐0.52,0.22) | |
| LD ABA IV + MTX | 0.61(0.10,3.44) | 0.73(0.25,2.41) | ‐0.10(‐0.50,0.24) | |
| LD ANA SC + MTX | 0.88(0.07,11.24) | 0.93(0.16,3.56) | ‐0.03(‐0.51,0.52) | |
| LD CERTO SC + MTX | 1.23(0.18,7.57) | 1.12(0.40,3.51) | 0.05(‐0.39,0.44) | |
| LD ETN SC + MTX | 0.95(0.15,5.58) | 0.97(0.34,3.10) | ‐0.01(‐0.43,0.37) | |
| LD GOLI IV + MTX | 0.63(0.09,3.98) | 0.75(0.23,2.54) | ‐0.10(‐0.51,0.29) | |
| LD TOCI IV + MTX | 0.52(0.08,3.21) | 0.65(0.20,2.27) | ‐0.13(‐0.53,0.24) | |
| LD TOFA PO + MTX | 0.95(0.12,6.83) | 0.97(0.27,3.23) | ‐0.01(‐0.45,0.42) | |
| HD TOCI IV | 0.83(0.16,4.00) | 0.89(0.39,2.68) | ‐0.04(‐0.42,0.27) | |
| HD TOFA PO | 1.04(0.20,4.89) | 1.03(0.46,3.00) | 0.01(‐0.37,0.33) | |
| HD ADA SC | 0.48(0.09,2.52) | 0.61(0.23,2.00) | ‐0.15(‐0.53,0.17) | |
| HD GOLI SC | 0.87(0.15,4.66) | 0.92(0.36,2.90) | ‐0.03(‐0.44,0.31) | |
| HD ETN SC | 0.58(0.09,3.39) | 0.70(0.24,2.36) | ‐0.12(‐0.51,0.24) | |
| HD ABA SC | 1.44(0.48,4.29) | 1.20(0.65,2.44) | 0.08(‐0.17,0.33) | |
| HD TOCI IV + MTX | 1.45(0.26,7.48) | 1.22(0.54,3.66) | 0.09(‐0.31,0.42) | |
| HD TOFA PO + MTX | 1.47(0.24,8.02) | 1.23(0.50,3.68) | 0.09(‐0.33,0.45) | |
| HD GOLI SC + MTX | 1.55(0.25,8.58) | 1.26(0.52,3.83) | 0.10(‐0.32,0.46) | |
| HD CERTO SC + MTX | 2.03(0.34,10.70) | 1.43(0.64,4.20) | 0.17(‐0.25,0.51) | |
| HD INF IV + MTX | 1.24(0.20,6.94) | 1.13(0.44,3.45) | 0.05(‐0.37,0.42) | |
| HD TOCI IV + DMARD | 0.30(0.05,1.86) | 0.43(0.13,1.60) | ‐0.22(‐0.60,0.11) | |
| SD ETN SC + MTX | SD CERTO SC | 1.06(0.25,4.54) | 1.03(0.47,2.76) | 0.01(‐0.32,0.32) |
| SD INF IV + MTX | 0.93(0.21,4.09) | 0.96(0.42,2.58) | ‐0.02(‐0.36,0.29) | |
| SD ABA IV + MTX | 1.19(0.27,5.16) | 1.11(0.49,2.90) | 0.04(‐0.31,0.35) | |
| SD CERTO SC + MTX | 1.80(0.40,7.80) | 1.37(0.63,3.49) | 0.14(‐0.22,0.45) | |
| SD TOFA PO + MTX | 1.95(0.42,9.15) | 1.42(0.65,3.65) | 0.16(‐0.21,0.48) | |
| SD GOLI SC + MTX | 2.12(0.48,9.77) | 1.47(0.71,3.77) | 0.18(‐0.17,0.49) | |
| SD ADA SC + MTX | 1.27(0.23,7.50) | 1.15(0.41,3.19) | 0.06(‐0.33,0.45) | |
| SD RITUX IV + MTX | 0.67(0.14,3.26) | 0.77(0.29,2.24) | ‐0.09(‐0.43,0.25) | |
| SD GOLI IV + MTX | 0.75(0.16,3.52) | 0.83(0.32,2.32) | ‐0.06(‐0.40,0.26) | |
| SD ABA SC + MTX | 1.27(0.23,7.04) | 1.15(0.41,3.12) | 0.06(‐0.33,0.43) | |
| SD ANA SC + MTX | 1.64(0.18,18.45) | 1.29(0.32,3.87) | 0.11(‐0.36,0.59) | |
| SD TOCI IV + MTX | 0.66(0.12,3.66) | 0.77(0.26,2.35) | ‐0.09(‐0.44,0.28) | |
| SD CERTO SC + DMARD | 0.50(0.10,2.51) | 0.62(0.22,1.90) | ‐0.14(‐0.47,0.18) | |
| SD ADA SC + DMARD | 0.28(0.05,1.65) | 0.39(0.10,1.42) | ‐0.22(‐0.55,0.10) | |
| SD ETN SC + DMARD | 1.10(0.21,5.81) | 1.06(0.39,3.00) | 0.02(‐0.36,0.39) | |
| LD ADA SC | 0.36(0.08,1.59) | 0.48(0.18,1.42) | ‐0.20(‐0.51,0.08) | |
| LD GOLI IV | 0.34(0.06,1.86) | 0.46(0.13,1.57) | ‐0.20(‐0.52,0.12) | |
| LD TOCI IV | 0.06(0.01,0.42) | 0.10(0.02,0.49) | ‐0.34(‐0.64,‐0.09) | |
| LD RITUX IV + MTX | 0.56(0.11,2.76) | 0.68(0.24,2.04) | ‐0.12(‐0.46,0.20) | |
| LD ABA IV + MTX | 0.64(0.13,3.13) | 0.75(0.28,2.21) | ‐0.09(‐0.44,0.24) | |
| LD ANA SC + MTX | 0.93(0.10,10.84) | 0.96(0.19,3.34) | ‐0.01(‐0.44,0.51) | |
| LD CERTO SC + MTX | 1.30(0.24,6.79) | 1.16(0.43,3.15) | 0.06(‐0.32,0.43) | |
| LD ETN SC + MTX | 1.01(0.20,5.38) | 1.00(0.38,2.87) | 0.00(‐0.36,0.37) | |
| LD GOLI IV + MTX | 0.67(0.13,3.52) | 0.77(0.26,2.31) | ‐0.09(‐0.43,0.27) | |
| LD TOCI IV + MTX | 0.56(0.11,2.98) | 0.68(0.22,2.08) | ‐0.12(‐0.46,0.23) | |
| LD TOFA PO + MTX | 1.00(0.16,6.21) | 1.00(0.30,3.00) | 0.00(‐0.39,0.41) | |
| HD TOCI IV | 0.89(0.22,3.58) | 0.93(0.43,2.46) | ‐0.03(‐0.35,0.26) | |
| HD TOFA PO | 1.09(0.27,4.37) | 1.06(0.50,2.71) | 0.02(‐0.31,0.31) | |
| HD ADA SC | 0.52(0.12,2.29) | 0.64(0.26,1.83) | ‐0.14(‐0.46,0.16) | |
| HD GOLI SC | 0.92(0.21,4.03) | 0.95(0.41,2.57) | ‐0.02(‐0.36,0.30) | |
| HD ETN SC | 0.62(0.13,3.05) | 0.73(0.26,2.17) | ‐0.10(‐0.44,0.23) | |
| HD ABA SC | 1.53(0.24,10.61) | 1.26(0.43,3.62) | 0.10(‐0.32,0.51) | |
| HD TOCI IV + MTX | 1.55(0.36,6.66) | 1.27(0.60,3.26) | 0.10(‐0.25,0.41) | |
| HD TOFA PO + MTX | 1.55(0.33,7.27) | 1.28(0.56,3.34) | 0.10(‐0.26,0.43) | |
| HD GOLI SC + MTX | 1.63(0.37,7.55) | 1.31(0.59,3.41) | 0.11(‐0.24,0.44) | |
| HD CERTO SC + MTX | 2.15(0.47,9.77) | 1.48(0.69,3.75) | 0.18(‐0.18,0.50) | |
| HD INF IV + MTX | 1.31(0.28,6.39) | 1.17(0.49,3.18) | 0.06(‐0.30,0.40) | |
| HD TOCI IV + DMARD | 0.32(0.06,1.61) | 0.44(0.14,1.43) | ‐0.21(‐0.53,0.09) | |
| SD INF IV + MTX | SD ETN SC + MTX | 0.88(0.49,1.63) | 0.93(0.63,1.35) | ‐0.03(‐0.16,0.11) |
| SD ABA IV + MTX | 1.12(0.57,2.21) | 1.07(0.71,1.58) | 0.03(‐0.13,0.19) | |
| SD CERTO SC + MTX | 1.69(0.85,3.36) | 1.32(0.92,1.92) | 0.13(‐0.04,0.29) | |
| SD TOFA PO + MTX | 1.82(0.87,4.08) | 1.36(0.92,2.06) | 0.14(‐0.03,0.33) | |
| SD GOLI SC + MTX | 2.01(0.87,4.73) | 1.42(0.93,2.23) | 0.17(‐0.04,0.36) | |
| SD ADA SC + MTX | 1.21(0.39,3.85) | 1.11(0.52,1.95) | 0.04(‐0.20,0.32) | |
| SD RITUX IV + MTX | 0.63(0.27,1.51) | 0.74(0.40,1.28) | ‐0.10(‐0.27,0.10) | |
| SD GOLI IV + MTX | 0.71(0.30,1.68) | 0.80(0.43,1.36) | ‐0.08(‐0.26,0.12) | |
| SD ABA SC + MTX | 1.20(0.40,3.63) | 1.11(0.54,1.92) | 0.04(‐0.19,0.30) | |
| SD ANA SC + MTX | 1.55(0.25,11.52) | 1.26(0.37,2.55) | 0.10(‐0.26,0.49) | |
| SD TOCI IV + MTX | 0.63(0.21,1.91) | 0.74(0.31,1.47) | ‐0.10(‐0.31,0.15) | |
| SD CERTO SC + DMARD | 0.47(0.15,1.57) | 0.60(0.25,1.34) | ‐0.16(‐0.38,0.10) | |
| SD ADA SC + DMARD | 0.26(0.07,0.98) | 0.38(0.12,0.98) | ‐0.24(‐0.43,‐0.01) | |
| SD ETN SC + DMARD | 1.04(0.36,3.03) | 1.02(0.51,1.78) | 0.01(‐0.22,0.26) | |
| LD ADA SC | 0.34(0.11,1.02) | 0.46(0.21,1.01) | ‐0.21(‐0.42,0.00) | |
| LD GOLI IV | 0.32(0.10,0.99) | 0.45(0.16,1.00) | ‐0.21(‐0.40,0.00) | |
| LD TOCI IV | 0.06(0.01,0.24) | 0.09(0.02,0.34) | ‐0.35(‐0.53,‐0.19) | |
| LD RITUX IV + MTX | 0.52(0.22,1.26) | 0.65(0.34,1.15) | ‐0.13(‐0.30,0.05) | |
| LD ABA IV + MTX | 0.61(0.26,1.46) | 0.73(0.38,1.25) | ‐0.10(‐0.28,0.09) | |
| LD ANA SC + MTX | 0.88(0.14,6.69) | 0.93(0.22,2.20) | ‐0.03(‐0.34,0.42) | |
| LD CERTO SC + MTX | 1.22(0.42,3.50) | 1.12(0.56,1.90) | 0.05(‐0.19,0.29) | |
| LD ETN SC + MTX | 0.96(0.41,2.27) | 0.97(0.54,1.55) | ‐0.01(‐0.19,0.20) | |
| LD GOLI IV + MTX | 0.63(0.21,1.86) | 0.74(0.32,1.41) | ‐0.10(‐0.31,0.14) | |
| LD TOCI IV + MTX | 0.53(0.18,1.61) | 0.65(0.28,1.34) | ‐0.13(‐0.34,0.11) | |
| LD TOFA PO + MTX | 0.94(0.26,3.45) | 0.96(0.38,1.84) | ‐0.01(‐0.27,0.29) | |
| HD TOCI IV | 0.83(0.43,1.70) | 0.89(0.60,1.41) | ‐0.04(‐0.20,0.12) | |
| HD TOFA PO | 1.04(0.37,2.90) | 1.02(0.56,1.91) | 0.01(‐0.23,0.25) | |
| HD ADA SC | 0.49(0.16,1.46) | 0.62(0.29,1.29) | ‐0.15(‐0.37,0.08) | |
| HD GOLI SC | 0.87(0.34,2.20) | 0.92(0.50,1.60) | ‐0.03(‐0.24,0.18) | |
| HD ETN SC | 0.58(0.24,1.46) | 0.70(0.35,1.25) | ‐0.12(‐0.29,0.09) | |
| HD ABA SC | 1.42(0.30,7.84) | 1.21(0.46,2.66) | 0.08(‐0.26,0.46) | |
| HD TOCI IV + MTX | 1.45(0.72,3.01) | 1.22(0.83,1.87) | 0.09(‐0.08,0.26) | |
| HD TOFA PO + MTX | 1.46(0.69,3.19) | 1.23(0.80,1.86) | 0.09(‐0.09,0.27) | |
| HD GOLI SC + MTX | 1.53(0.66,3.67) | 1.26(0.79,2.01) | 0.10(‐0.10,0.31) | |
| HD CERTO SC + MTX | 2.02(0.96,4.29) | 1.43(0.98,2.12) | 0.17(‐0.01,0.34) | |
| HD INF IV + MTX | 1.23(0.54,2.85) | 1.13(0.68,1.77) | 0.05(‐0.14,0.25) | |
| HD TOCI IV + DMARD | 0.31(0.10,0.91) | 0.43(0.17,0.94) | ‐0.22(‐0.41,‐0.02) | |
| SD ABA IV + MTX | SD INF IV + MTX | 1.27(0.68,2.35) | 1.15(0.79,1.68) | 0.05(‐0.09,0.20) |
| SD CERTO SC + MTX | 1.92(0.97,3.79) | 1.42(0.99,2.14) | 0.15(‐0.01,0.31) | |
| SD TOFA PO + MTX | 2.08(0.98,4.52) | 1.47(0.99,2.28) | 0.17(0.00,0.35) | |
| SD GOLI SC + MTX | 2.28(0.98,5.44) | 1.54(0.99,2.51) | 0.20(0.00,0.39) | |
| SD ADA SC + MTX | 1.37(0.44,4.24) | 1.20(0.57,2.14) | 0.07(‐0.18,0.34) | |
| SD RITUX IV + MTX | 0.72(0.30,1.70) | 0.80(0.43,1.39) | ‐0.07(‐0.25,0.12) | |
| SD GOLI IV + MTX | 0.80(0.33,1.94) | 0.87(0.47,1.51) | ‐0.05(‐0.23,0.15) | |
| SD ABA SC + MTX | 1.37(0.47,3.92) | 1.20(0.60,2.08) | 0.07(‐0.16,0.32) | |
| SD ANA SC + MTX | 1.78(0.28,12.80) | 1.37(0.39,2.84) | 0.14(‐0.24,0.52) | |
| SD TOCI IV + MTX | 0.71(0.23,2.23) | 0.80(0.34,1.63) | ‐0.07(‐0.29,0.19) | |
| SD CERTO SC + DMARD | 0.54(0.16,1.80) | 0.65(0.26,1.47) | ‐0.13(‐0.36,0.13) | |
| SD ADA SC + DMARD | 0.30(0.07,1.13) | 0.41(0.12,1.08) | ‐0.21(‐0.42,0.03) | |
| SD ETN SC + DMARD | 1.18(0.38,3.66) | 1.10(0.53,2.07) | 0.04(‐0.20,0.30) | |
| LD ADA SC | 0.38(0.12,1.19) | 0.50(0.22,1.13) | ‐0.18(‐0.40,0.03) | |
| LD GOLI IV | 0.36(0.12,1.15) | 0.48(0.18,1.09) | ‐0.18(‐0.37,0.03) | |
| LD TOCI IV | 0.07(0.01,0.28) | 0.10(0.02,0.37) | ‐0.32(‐0.51,‐0.16) | |
| LD RITUX IV + MTX | 0.60(0.25,1.43) | 0.71(0.37,1.25) | ‐0.10(‐0.28,0.08) | |
| LD ABA IV + MTX | 0.69(0.30,1.60) | 0.79(0.42,1.34) | ‐0.08(‐0.25,0.10) | |
| LD ANA SC + MTX | 1.00(0.15,7.64) | 1.00(0.23,2.46) | 0.00(‐0.32,0.44) | |
| LD CERTO SC + MTX | 1.38(0.48,3.98) | 1.21(0.61,2.10) | 0.07(‐0.16,0.32) | |
| LD ETN SC + MTX | 1.08(0.42,2.77) | 1.05(0.55,1.81) | 0.02(‐0.18,0.24) | |
| LD GOLI IV + MTX | 0.71(0.24,2.12) | 0.80(0.35,1.56) | ‐0.07(‐0.28,0.18) | |
| LD TOCI IV + MTX | 0.60(0.20,1.81) | 0.71(0.29,1.47) | ‐0.10(‐0.31,0.13) | |
| LD TOFA PO + MTX | 1.07(0.31,3.79) | 1.04(0.42,2.04) | 0.02(‐0.24,0.31) | |
| HD TOCI IV | 0.95(0.47,1.93) | 0.97(0.63,1.56) | ‐0.01(‐0.18,0.14) | |
| HD TOFA PO | 1.18(0.41,3.43) | 1.10(0.59,2.17) | 0.04(‐0.21,0.28) | |
| HD ADA SC | 0.55(0.18,1.69) | 0.66(0.30,1.44) | ‐0.12(‐0.35,0.11) | |
| HD GOLI SC | 0.99(0.39,2.52) | 0.99(0.54,1.78) | 0.00(‐0.21,0.21) | |
| HD ETN SC | 0.66(0.25,1.70) | 0.76(0.37,1.40) | ‐0.09(‐0.28,0.12) | |
| HD ABA SC | 1.61(0.34,8.89) | 1.31(0.49,2.99) | 0.11(‐0.23,0.49) | |
| HD TOCI IV + MTX | 1.64(0.81,3.46) | 1.32(0.89,2.11) | 0.12(‐0.05,0.29) | |
| HD TOFA PO + MTX | 1.66(0.77,3.60) | 1.33(0.86,2.07) | 0.12(‐0.06,0.30) | |
| HD GOLI SC + MTX | 1.74(0.75,4.15) | 1.36(0.85,2.25) | 0.13(‐0.07,0.33) | |
| HD CERTO SC + MTX | 2.29(1.09,4.91) | 1.54(1.04,2.37) | 0.20(0.02,0.37) | |
| HD INF IV + MTX | 1.40(0.72,2.77) | 1.22(0.81,1.78) | 0.08(‐0.07,0.24) | |
| HD TOCI IV + DMARD | 0.35(0.11,1.07) | 0.46(0.18,1.05) | ‐0.19(‐0.40,0.01) | |
| SD CERTO SC + MTX | SD ABA IV + MTX | 1.51(0.75,3.04) | 1.24(0.86,1.84) | 0.10(‐0.07,0.26) |
| SD TOFA PO + MTX | 1.63(0.77,3.60) | 1.28(0.87,1.95) | 0.12(‐0.06,0.30) | |
| SD GOLI SC + MTX | 1.80(0.77,4.27) | 1.33(0.88,2.12) | 0.14(‐0.06,0.34) | |
| SD ADA SC + MTX | 1.08(0.34,3.37) | 1.04(0.49,1.85) | 0.02(‐0.23,0.29) | |
| SD RITUX IV + MTX | 0.56(0.24,1.37) | 0.70(0.37,1.21) | ‐0.13(‐0.31,0.07) | |
| SD GOLI IV + MTX | 0.63(0.26,1.49) | 0.76(0.41,1.27) | ‐0.10(‐0.29,0.09) | |
| SD ABA SC + MTX | 1.07(0.45,2.58) | 1.04(0.58,1.59) | 0.02(‐0.17,0.22) | |
| SD ANA SC + MTX | 1.40(0.22,10.19) | 1.19(0.34,2.43) | 0.08(‐0.31,0.47) | |
| SD TOCI IV + MTX | 0.56(0.18,1.75) | 0.69(0.30,1.39) | ‐0.13(‐0.35,0.13) | |
| SD CERTO SC + DMARD | 0.42(0.12,1.47) | 0.56(0.23,1.28) | ‐0.18(‐0.42,0.09) | |
| SD ADA SC + DMARD | 0.24(0.06,0.91) | 0.35(0.11,0.94) | ‐0.26(‐0.48,‐0.02) | |
| SD ETN SC + DMARD | 0.92(0.30,3.02) | 0.95(0.46,1.78) | ‐0.02(‐0.26,0.26) | |
| LD ADA SC | 0.30(0.10,0.95) | 0.43(0.19,0.96) | ‐0.24(‐0.46,‐0.01) | |
| LD GOLI IV | 0.29(0.09,0.89) | 0.42(0.15,0.93) | ‐0.24(‐0.43,‐0.03) | |
| LD TOCI IV | 0.05(0.01,0.23) | 0.09(0.02,0.32) | ‐0.38(‐0.58,‐0.19) | |
| LD RITUX IV + MTX | 0.47(0.19,1.13) | 0.61(0.31,1.08) | ‐0.16(‐0.34,0.03) | |
| LD ABA IV + MTX | 0.55(0.27,1.07) | 0.68(0.40,1.04) | ‐0.13(‐0.28,0.02) | |
| LD ANA SC + MTX | 0.79(0.12,5.87) | 0.87(0.20,2.05) | ‐0.05(‐0.38,0.38) | |
| LD CERTO SC + MTX | 1.09(0.38,3.14) | 1.05(0.53,1.78) | 0.02(‐0.22,0.27) | |
| LD ETN SC + MTX | 0.85(0.32,2.23) | 0.91(0.48,1.54) | ‐0.04(‐0.25,0.19) | |
| LD GOLI IV + MTX | 0.56(0.19,1.68) | 0.69(0.31,1.35) | ‐0.12(‐0.34,0.12) | |
| LD TOCI IV + MTX | 0.47(0.15,1.47) | 0.61(0.25,1.26) | ‐0.16(‐0.37,0.09) | |
| LD TOFA PO + MTX | 0.85(0.24,3.02) | 0.91(0.37,1.74) | ‐0.04(‐0.30,0.26) | |
| HD TOCI IV | 0.75(0.36,1.56) | 0.84(0.56,1.34) | ‐0.07(‐0.24,0.10) | |
| HD TOFA PO | 0.92(0.32,2.80) | 0.95(0.53,1.87) | ‐0.02(‐0.27,0.24) | |
| HD ADA SC | 0.43(0.14,1.33) | 0.58(0.27,1.21) | ‐0.18(‐0.42,0.06) | |
| HD GOLI SC | 0.77(0.30,2.00) | 0.86(0.47,1.51) | ‐0.06(‐0.28,0.16) | |
| HD ETN SC | 0.52(0.19,1.38) | 0.66(0.32,1.21) | ‐0.14(‐0.34,0.07) | |
| HD ABA SC | 1.28(0.26,7.22) | 1.14(0.43,2.53) | 0.06(‐0.30,0.44) | |
| HD TOCI IV + MTX | 1.29(0.62,2.77) | 1.14(0.78,1.81) | 0.06(‐0.11,0.24) | |
| HD TOFA PO + MTX | 1.30(0.61,2.88) | 1.15(0.75,1.75) | 0.06(‐0.12,0.25) | |
| HD GOLI SC + MTX | 1.37(0.59,3.31) | 1.18(0.75,1.89) | 0.08(‐0.13,0.28) | |
| HD CERTO SC + MTX | 1.80(0.86,3.88) | 1.33(0.92,2.04) | 0.14(‐0.04,0.32) | |
| HD INF IV + MTX | 1.10(0.49,2.51) | 1.05(0.65,1.65) | 0.02(‐0.16,0.22) | |
| HD TOCI IV + DMARD | 0.27(0.08,0.87) | 0.40(0.15,0.92) | ‐0.25(‐0.46,‐0.03) | |
| SD TOFA PO + MTX | SD CERTO SC + MTX | 1.09(0.51,2.36) | 1.04(0.72,1.49) | 0.02(‐0.16,0.20) |
| SD GOLI SC + MTX | 1.19(0.51,2.86) | 1.08(0.72,1.61) | 0.04(‐0.16,0.24) | |
| SD ADA SC + MTX | 0.71(0.23,2.24) | 0.84(0.40,1.42) | ‐0.08(‐0.33,0.19) | |
| SD RITUX IV + MTX | 0.37(0.16,0.90) | 0.56(0.30,0.95) | ‐0.22(‐0.41,‐0.02) | |
| SD GOLI IV + MTX | 0.42(0.17,0.99) | 0.61(0.33,0.99) | ‐0.20(‐0.38,0.00) | |
| SD ABA SC + MTX | 0.72(0.24,2.13) | 0.85(0.41,1.40) | ‐0.08(‐0.33,0.18) | |
| SD ANA SC + MTX | 0.92(0.15,6.65) | 0.96(0.27,1.86) | ‐0.02(‐0.39,0.37) | |
| SD TOCI IV + MTX | 0.37(0.12,1.18) | 0.56(0.24,1.09) | ‐0.23(‐0.45,0.04) | |
| SD CERTO SC + DMARD | 0.28(0.08,0.98) | 0.45(0.19,0.99) | ‐0.28(‐0.52,0.00) | |
| SD ADA SC + DMARD | 0.15(0.04,0.62) | 0.28(0.09,0.75) | ‐0.37(‐0.58,‐0.11) | |
| SD ETN SC + DMARD | 0.61(0.19,1.95) | 0.78(0.37,1.37) | ‐0.12(‐0.37,0.16) | |
| LD ADA SC | 0.20(0.07,0.63) | 0.35(0.16,0.74) | ‐0.34(‐0.55,‐0.10) | |
| LD GOLI IV | 0.19(0.06,0.59) | 0.34(0.13,0.74) | ‐0.34(‐0.53,‐0.12) | |
| LD TOCI IV | 0.03(0.01,0.15) | 0.07(0.01,0.25) | ‐0.48(‐0.67,‐0.28) | |
| LD RITUX IV + MTX | 0.31(0.13,0.76) | 0.49(0.26,0.86) | ‐0.26(‐0.44,‐0.06) | |
| LD ABA IV + MTX | 0.36(0.15,0.86) | 0.55(0.28,0.92) | ‐0.23(‐0.42,‐0.04) | |
| LD ANA SC + MTX | 0.52(0.08,4.01) | 0.70(0.16,1.64) | ‐0.15(‐0.48,0.29) | |
| LD CERTO SC + MTX | 0.72(0.29,1.80) | 0.85(0.47,1.29) | ‐0.08(‐0.28,0.14) | |
| LD ETN SC + MTX | 0.57(0.21,1.52) | 0.74(0.39,1.22) | ‐0.13(‐0.36,0.10) | |
| LD GOLI IV + MTX | 0.38(0.13,1.13) | 0.56(0.25,1.06) | ‐0.22(‐0.44,0.03) | |
| LD TOCI IV + MTX | 0.31(0.10,0.96) | 0.49(0.21,0.98) | ‐0.26(‐0.47,‐0.01) | |
| LD TOFA PO + MTX | 0.56(0.16,2.02) | 0.73(0.30,1.35) | ‐0.14(‐0.40,0.16) | |
| HD TOCI IV | 0.49(0.24,1.02) | 0.68(0.46,1.01) | ‐0.17(‐0.34,0.00) | |
| HD TOFA PO | 0.61(0.21,1.86) | 0.77(0.45,1.41) | ‐0.12(‐0.37,0.15) | |
| HD ADA SC | 0.29(0.09,0.93) | 0.46(0.22,0.96) | ‐0.28(‐0.51,‐0.02) | |
| HD GOLI SC | 0.51(0.20,1.30) | 0.70(0.39,1.16) | ‐0.16(‐0.37,0.06) | |
| HD ETN SC | 0.34(0.13,0.93) | 0.53(0.26,0.96) | ‐0.24(‐0.44,‐0.02) | |
| HD ABA SC | 0.85(0.17,4.69) | 0.92(0.35,1.92) | ‐0.04(‐0.40,0.35) | |
| HD TOCI IV + MTX | 0.86(0.40,1.79) | 0.93(0.64,1.35) | ‐0.04(‐0.22,0.14) | |
| HD TOFA PO + MTX | 0.87(0.40,1.85) | 0.93(0.62,1.34) | ‐0.03(‐0.22,0.14) | |
| HD GOLI SC + MTX | 0.91(0.39,2.20) | 0.96(0.61,1.46) | ‐0.02(‐0.23,0.19) | |
| HD CERTO SC + MTX | 1.20(0.70,2.03) | 1.08(0.85,1.38) | 0.04(‐0.08,0.16) | |
| HD INF IV + MTX | 0.73(0.31,1.70) | 0.85(0.52,1.29) | ‐0.08(‐0.27,0.13) | |
| HD TOCI IV + DMARD | 0.18(0.05,0.58) | 0.32(0.13,0.72) | ‐0.35(‐0.56,‐0.12) | |
| SD GOLI SC + MTX | SD TOFA PO + MTX | 1.10(0.43,2.84) | 1.04(0.69,1.61) | 0.02(‐0.20,0.24) |
| SD ADA SC + MTX | 0.66(0.19,2.18) | 0.82(0.38,1.42) | ‐0.10(‐0.37,0.18) | |
| SD RITUX IV + MTX | 0.34(0.14,0.89) | 0.55(0.29,0.94) | ‐0.24(‐0.44,‐0.03) | |
| SD GOLI IV + MTX | 0.39(0.15,0.97) | 0.59(0.31,0.98) | ‐0.22(‐0.42,‐0.01) | |
| SD ABA SC + MTX | 0.66(0.21,2.09) | 0.82(0.39,1.39) | ‐0.10(‐0.36,0.17) | |
| SD ANA SC + MTX | 0.85(0.13,6.50) | 0.93(0.27,1.83) | ‐0.04(‐0.43,0.36) | |
| SD TOCI IV + MTX | 0.34(0.10,1.14) | 0.54(0.23,1.07) | ‐0.24(‐0.48,0.03) | |
| SD CERTO SC + DMARD | 0.26(0.07,0.94) | 0.44(0.18,0.97) | ‐0.30(‐0.56,‐0.01) | |
| SD ADA SC + DMARD | 0.14(0.03,0.57) | 0.28(0.09,0.72) | ‐0.38(‐0.62,‐0.13) | |
| SD ETN SC + DMARD | 0.57(0.17,1.86) | 0.75(0.35,1.35) | ‐0.13(‐0.41,0.15) | |
| LD ADA SC | 0.19(0.05,0.61) | 0.34(0.15,0.72) | ‐0.36(‐0.59,‐0.10) | |
| LD GOLI IV | 0.18(0.05,0.58) | 0.33(0.12,0.73) | ‐0.36(‐0.57,‐0.12) | |
| LD TOCI IV | 0.03(0.01,0.14) | 0.07(0.01,0.24) | ‐0.50(‐0.71,‐0.29) | |
| LD RITUX IV + MTX | 0.29(0.11,0.75) | 0.48(0.24,0.85) | ‐0.28(‐0.48,‐0.07) | |
| LD ABA IV + MTX | 0.33(0.13,0.84) | 0.53(0.28,0.91) | ‐0.25(‐0.45,‐0.04) | |
| LD ANA SC + MTX | 0.48(0.07,3.81) | 0.68(0.16,1.59) | ‐0.17(‐0.51,0.28) | |
| LD CERTO SC + MTX | 0.67(0.22,2.03) | 0.82(0.41,1.38) | ‐0.10(‐0.35,0.17) | |
| LD ETN SC + MTX | 0.52(0.18,1.47) | 0.71(0.37,1.21) | ‐0.15(‐0.39,0.09) | |
| LD GOLI IV + MTX | 0.35(0.11,1.07) | 0.55(0.24,1.03) | ‐0.24(‐0.47,0.01) | |
| LD TOCI IV + MTX | 0.29(0.09,0.94) | 0.48(0.20,0.96) | ‐0.28(‐0.51,‐0.02) | |
| LD TOFA PO + MTX | 0.52(0.16,1.63) | 0.71(0.30,1.23) | ‐0.15(‐0.40,0.11) | |
| HD TOCI IV | 0.46(0.20,1.01) | 0.65(0.44,1.01) | ‐0.19(‐0.37,0.00) | |
| HD TOFA PO | 0.57(0.17,1.77) | 0.75(0.42,1.37) | ‐0.14(‐0.41,0.13) | |
| HD ADA SC | 0.26(0.08,0.89) | 0.45(0.21,0.93) | ‐0.30(‐0.55,‐0.03) | |
| HD GOLI SC | 0.47(0.16,1.31) | 0.67(0.36,1.16) | ‐0.18(‐0.41,0.06) | |
| HD ETN SC | 0.32(0.11,0.89) | 0.51(0.25,0.94) | ‐0.26(‐0.48,‐0.03) | |
| HD ABA SC | 0.78(0.15,4.72) | 0.89(0.34,1.94) | ‐0.06(‐0.43,0.35) | |
| HD TOCI IV + MTX | 0.79(0.34,1.79) | 0.90(0.61,1.36) | ‐0.06(‐0.25,0.14) | |
| HD TOFA PO + MTX | 0.80(0.47,1.33) | 0.90(0.68,1.15) | ‐0.05(‐0.18,0.07) | |
| HD GOLI SC + MTX | 0.84(0.33,2.18) | 0.93(0.58,1.45) | ‐0.04(‐0.26,0.18) | |
| HD CERTO SC + MTX | 1.10(0.47,2.52) | 1.04(0.72,1.54) | 0.02(‐0.17,0.22) | |
| HD INF IV + MTX | 0.67(0.26,1.70) | 0.83(0.48,1.30) | ‐0.09(‐0.31,0.13) | |
| HD TOCI IV + DMARD | 0.17(0.05,0.55) | 0.31(0.12,0.69) | ‐0.37(‐0.59,‐0.13) | |
| SD ADA SC + MTX | SD GOLI SC + MTX | 0.60(0.17,2.09) | 0.78(0.36,1.36) | ‐0.12(‐0.40,0.17) |
| SD RITUX IV + MTX | 0.31(0.11,0.87) | 0.52(0.26,0.93) | ‐0.27(‐0.48,‐0.03) | |
| SD GOLI IV + MTX | 0.35(0.13,0.95) | 0.57(0.29,0.97) | ‐0.24(‐0.46,‐0.01) | |
| SD ABA SC + MTX | 0.60(0.17,2.00) | 0.78(0.36,1.35) | ‐0.12(‐0.39,0.16) | |
| SD ANA SC + MTX | 0.77(0.12,6.30) | 0.89(0.25,1.77) | ‐0.06(‐0.46,0.35) | |
| SD TOCI IV + MTX | 0.31(0.09,1.07) | 0.52(0.21,1.03) | ‐0.27(‐0.51,0.02) | |
| SD CERTO SC + DMARD | 0.23(0.06,0.87) | 0.42(0.17,0.93) | ‐0.32(‐0.57,‐0.03) | |
| SD ADA SC + DMARD | 0.13(0.03,0.53) | 0.26(0.08,0.70) | ‐0.41(‐0.63,‐0.14) | |
| SD ETN SC + DMARD | 0.51(0.15,1.84) | 0.72(0.33,1.33) | ‐0.16(‐0.43,0.14) | |
| LD ADA SC | 0.17(0.05,0.57) | 0.33(0.15,0.70) | ‐0.38(‐0.60,‐0.12) | |
| LD GOLI IV | 0.16(0.05,0.55) | 0.31(0.11,0.72) | ‐0.38(‐0.59,‐0.14) | |
| LD TOCI IV | 0.03(0.00,0.13) | 0.07(0.01,0.24) | ‐0.52(‐0.72,‐0.31) | |
| LD RITUX IV + MTX | 0.26(0.10,0.71) | 0.46(0.22,0.84) | ‐0.30(‐0.51,‐0.08) | |
| LD ABA IV + MTX | 0.30(0.11,0.83) | 0.51(0.25,0.91) | ‐0.27(‐0.49,‐0.04) | |
| LD ANA SC + MTX | 0.44(0.06,3.62) | 0.65(0.15,1.55) | ‐0.19(‐0.54,0.26) | |
| LD CERTO SC + MTX | 0.60(0.19,1.96) | 0.79(0.39,1.35) | ‐0.12(‐0.38,0.16) | |
| LD ETN SC + MTX | 0.48(0.15,1.41) | 0.69(0.34,1.18) | ‐0.18(‐0.42,0.08) | |
| LD GOLI IV + MTX | 0.31(0.09,1.04) | 0.52(0.22,1.02) | ‐0.27(‐0.50,0.01) | |
| LD TOCI IV + MTX | 0.26(0.08,0.91) | 0.46(0.19,0.95) | ‐0.30(‐0.53,‐0.02) | |
| LD TOFA PO + MTX | 0.47(0.12,1.86) | 0.68(0.26,1.30) | ‐0.18(‐0.46,0.14) | |
| HD TOCI IV | 0.42(0.18,0.97) | 0.63(0.41,0.98) | ‐0.21(‐0.40,‐0.01) | |
| HD TOFA PO | 0.51(0.17,1.62) | 0.71(0.41,1.30) | ‐0.16(‐0.41,0.12) | |
| HD ADA SC | 0.24(0.07,0.80) | 0.43(0.20,0.87) | ‐0.32(‐0.56,‐0.05) | |
| HD GOLI SC | 0.43(0.18,1.00) | 0.64(0.38,1.00) | ‐0.20(‐0.39,0.00) | |
| HD ETN SC | 0.29(0.10,0.89) | 0.49(0.23,0.94) | ‐0.28(‐0.50,‐0.03) | |
| HD ABA SC | 0.71(0.13,3.99) | 0.86(0.32,1.77) | ‐0.08(‐0.45,0.31) | |
| HD TOCI IV + MTX | 0.73(0.30,1.75) | 0.86(0.57,1.32) | ‐0.08(‐0.28,0.13) | |
| HD TOFA PO + MTX | 0.72(0.29,1.85) | 0.86(0.54,1.33) | ‐0.08(‐0.29,0.14) | |
| HD GOLI SC + MTX | 0.77(0.40,1.45) | 0.89(0.63,1.19) | ‐0.06(‐0.22,0.09) | |
| HD CERTO SC + MTX | 1.00(0.41,2.52) | 1.00(0.67,1.50) | 0.00(‐0.21,0.21) | |
| HD INF IV + MTX | 0.61(0.22,1.67) | 0.79(0.45,1.26) | ‐0.12(‐0.35,0.12) | |
| HD TOCI IV + DMARD | 0.15(0.04,0.52) | 0.30(0.12,0.68) | ‐0.39(‐0.61,‐0.14) | |
| SD RITUX IV + MTX | SD ADA SC + MTX | 0.52(0.15,1.93) | 0.67(0.32,1.56) | ‐0.14(‐0.42,0.14) |
| SD GOLI IV + MTX | 0.59(0.16,2.07) | 0.73(0.34,1.63) | ‐0.12(‐0.41,0.15) | |
| SD ABA SC + MTX | 1.00(0.24,4.20) | 1.00(0.44,2.30) | 0.00(‐0.33,0.32) | |
| SD ANA SC + MTX | 1.29(0.17,12.03) | 1.13(0.31,3.02) | 0.06(‐0.38,0.51) | |
| SD TOCI IV + MTX | 0.52(0.12,2.23) | 0.67(0.27,1.68) | ‐0.14(‐0.45,0.17) | |
| SD CERTO SC + DMARD | 0.39(0.08,1.77) | 0.54(0.21,1.49) | ‐0.20(‐0.52,0.11) | |
| SD ADA SC + DMARD | 0.22(0.04,1.13) | 0.34(0.10,1.09) | ‐0.28(‐0.59,0.02) | |
| SD ETN SC + DMARD | 0.86(0.19,3.76) | 0.92(0.40,2.20) | ‐0.03(‐0.38,0.30) | |
| LD ADA SC | 0.28(0.06,1.19) | 0.42(0.17,1.14) | ‐0.25(‐0.56,0.03) | |
| LD GOLI IV | 0.27(0.06,1.20) | 0.41(0.14,1.14) | ‐0.25(‐0.55,0.03) | |
| LD TOCI IV | 0.05(0.01,0.27) | 0.09(0.02,0.35) | ‐0.40(‐0.69,‐0.14) | |
| LD RITUX IV + MTX | 0.44(0.12,1.53) | 0.59(0.27,1.34) | ‐0.18(‐0.46,0.09) | |
| LD ABA IV + MTX | 0.51(0.14,1.82) | 0.66(0.30,1.50) | ‐0.15(‐0.43,0.12) | |
| LD ANA SC + MTX | 0.74(0.09,6.89) | 0.84(0.18,2.55) | ‐0.07(‐0.47,0.42) | |
| LD CERTO SC + MTX | 1.01(0.26,4.08) | 1.01(0.47,2.30) | 0.00(‐0.32,0.32) | |
| LD ETN SC + MTX | 0.79(0.20,3.05) | 0.88(0.41,1.99) | ‐0.05(‐0.36,0.25) | |
| LD GOLI IV + MTX | 0.52(0.12,2.20) | 0.67(0.27,1.66) | ‐0.14(‐0.45,0.17) | |
| LD TOCI IV + MTX | 0.44(0.10,1.90) | 0.59(0.23,1.52) | ‐0.18(‐0.48,0.14) | |
| LD TOFA PO + MTX | 0.78(0.16,3.86) | 0.87(0.32,2.17) | ‐0.06(‐0.40,0.31) | |
| HD TOCI IV | 0.69(0.21,2.27) | 0.80(0.46,1.79) | ‐0.09(‐0.36,0.17) | |
| HD TOFA PO | 0.85(0.21,3.69) | 0.91(0.46,2.34) | ‐0.04(‐0.36,0.28) | |
| HD ADA SC | 0.41(0.09,1.76) | 0.56(0.23,1.51) | ‐0.19(‐0.51,0.11) | |
| HD GOLI SC | 0.72(0.19,2.75) | 0.83(0.40,1.97) | ‐0.08(‐0.39,0.22) | |
| HD ETN SC | 0.48(0.12,1.85) | 0.64(0.28,1.50) | ‐0.16(‐0.46,0.13) | |
| HD ABA SC | 1.20(0.18,8.04) | 1.10(0.39,3.07) | 0.04(‐0.39,0.46) | |
| HD TOCI IV + MTX | 1.19(0.38,3.99) | 1.09(0.65,2.39) | 0.04(‐0.23,0.31) | |
| HD TOFA PO + MTX | 1.20(0.36,3.99) | 1.10(0.62,2.36) | 0.04(‐0.24,0.31) | |
| HD GOLI SC + MTX | 1.28(0.36,4.50) | 1.13(0.62,2.52) | 0.06(‐0.24,0.34) | |
| HD CERTO SC + MTX | 1.67(0.51,5.47) | 1.28(0.76,2.72) | 0.12(‐0.15,0.39) | |
| HD INF IV + MTX | 1.02(0.29,3.62) | 1.01(0.53,2.23) | 0.00(‐0.29,0.29) | |
| HD TOCI IV + DMARD | 0.25(0.06,1.09) | 0.39(0.14,1.07) | ‐0.26(‐0.56,0.02) | |
| SD GOLI IV + MTX | SD RITUX IV + MTX | 1.12(0.40,3.04) | 1.08(0.54,2.17) | 0.02(‐0.19,0.23) |
| SD ABA SC + MTX | 1.92(0.55,6.31) | 1.49(0.67,3.11) | 0.14(‐0.13,0.41) | |
| SD ANA SC + MTX | 2.42(0.37,19.71) | 1.67(0.47,4.05) | 0.20(‐0.17,0.60) | |
| SD TOCI IV + MTX | 0.99(0.28,3.48) | 1.00(0.39,2.34) | 0.00(‐0.25,0.27) | |
| SD CERTO SC + DMARD | 0.74(0.20,2.86) | 0.81(0.30,2.12) | ‐0.06(‐0.32,0.21) | |
| SD ADA SC + DMARD | 0.42(0.09,1.81) | 0.51(0.14,1.55) | ‐0.14(‐0.39,0.11) | |
| SD ETN SC + DMARD | 1.64(0.45,5.84) | 1.37(0.59,3.04) | 0.11(‐0.17,0.39) | |
| LD ADA SC | 0.54(0.15,1.88) | 0.62(0.25,1.63) | ‐0.11(‐0.36,0.11) | |
| LD GOLI IV | 0.51(0.14,1.74) | 0.60(0.21,1.50) | ‐0.11(‐0.34,0.11) | |
| LD TOCI IV | 0.09(0.01,0.41) | 0.13(0.02,0.48) | ‐0.25(‐0.48,‐0.09) | |
| LD RITUX IV + MTX | 0.83(0.41,1.69) | 0.88(0.52,1.45) | ‐0.03(‐0.18,0.10) | |
| LD ABA IV + MTX | 0.97(0.35,2.67) | 0.98(0.47,2.00) | ‐0.01(‐0.22,0.20) | |
| LD ANA SC + MTX | 1.38(0.20,11.43) | 1.23(0.28,3.45) | 0.07(‐0.26,0.52) | |
| LD CERTO SC + MTX | 1.93(0.59,6.27) | 1.50(0.71,3.09) | 0.14(‐0.11,0.41) | |
| LD ETN SC + MTX | 1.52(0.48,4.60) | 1.31(0.61,2.72) | 0.09(‐0.15,0.33) | |
| LD GOLI IV + MTX | 1.00(0.29,3.25) | 1.00(0.41,2.20) | 0.00(‐0.24,0.25) | |
| LD TOCI IV + MTX | 0.83(0.24,2.91) | 0.88(0.35,2.11) | ‐0.03(‐0.28,0.22) | |
| LD TOFA PO + MTX | 1.49(0.37,5.95) | 1.30(0.49,2.95) | 0.08(‐0.20,0.39) | |
| HD TOCI IV | 1.33(0.53,3.25) | 1.21(0.69,2.38) | 0.06(‐0.15,0.23) | |
| HD TOFA PO | 1.65(0.48,5.44) | 1.38(0.65,3.21) | 0.11(‐0.17,0.35) | |
| HD ADA SC | 0.77(0.22,2.73) | 0.83(0.35,2.12) | ‐0.05(‐0.31,0.19) | |
| HD GOLI SC | 1.38(0.46,4.05) | 1.24(0.60,2.63) | 0.07(‐0.18,0.29) | |
| HD ETN SC | 0.92(0.30,2.83) | 0.94(0.42,2.05) | ‐0.02(‐0.25,0.22) | |
| HD ABA SC | 2.28(0.40,13.35) | 1.63(0.55,4.36) | 0.19(‐0.19,0.56) | |
| HD TOCI IV + MTX | 2.30(0.89,5.73) | 1.65(0.94,3.19) | 0.19(‐0.03,0.38) | |
| HD TOFA PO + MTX | 2.32(0.89,5.86) | 1.65(0.93,3.13) | 0.19(‐0.03,0.39) | |
| HD GOLI SC + MTX | 2.44(0.88,6.86) | 1.70(0.93,3.36) | 0.20(‐0.03,0.42) | |
| HD CERTO SC + MTX | 3.21(1.26,8.19) | 1.91(1.12,3.64) | 0.27(0.05,0.46) | |
| HD INF IV + MTX | 1.95(0.71,5.37) | 1.51(0.82,2.92) | 0.15(‐0.08,0.37) | |
| HD TOCI IV + DMARD | 0.49(0.13,1.74) | 0.58(0.20,1.51) | ‐0.12(‐0.36,0.10) | |
| SD ABA SC + MTX | SD GOLI IV + MTX | 1.70(0.50,5.91) | 1.37(0.63,2.89) | 0.12(‐0.15,0.40) |
| SD ANA SC + MTX | 2.19(0.32,18.87) | 1.57(0.44,3.79) | 0.18(‐0.22,0.59) | |
| SD TOCI IV + MTX | 0.89(0.26,3.23) | 0.92(0.37,2.18) | ‐0.02(‐0.27,0.25) | |
| SD CERTO SC + DMARD | 0.66(0.18,2.55) | 0.74(0.29,1.95) | ‐0.08(‐0.34,0.19) | |
| SD ADA SC + DMARD | 0.37(0.09,1.65) | 0.47(0.14,1.43) | ‐0.16(‐0.41,0.09) | |
| SD ETN SC + DMARD | 1.47(0.41,5.27) | 1.27(0.56,2.80) | 0.08(‐0.19,0.37) | |
| LD ADA SC | 0.48(0.14,1.71) | 0.58(0.24,1.51) | ‐0.13(‐0.38,0.09) | |
| LD GOLI IV | 0.46(0.16,1.26) | 0.56(0.24,1.17) | ‐0.13(‐0.32,0.04) | |
| LD TOCI IV | 0.08(0.01,0.38) | 0.12(0.02,0.45) | ‐0.27(‐0.50,‐0.10) | |
| LD RITUX IV + MTX | 0.74(0.27,2.10) | 0.81(0.40,1.68) | ‐0.06(‐0.27,0.15) | |
| LD ABA IV + MTX | 0.87(0.31,2.39) | 0.91(0.44,1.82) | ‐0.03(‐0.24,0.18) | |
| LD ANA SC + MTX | 1.25(0.18,10.77) | 1.15(0.26,3.19) | 0.05(‐0.30,0.50) | |
| LD CERTO SC + MTX | 1.73(0.53,5.55) | 1.39(0.66,2.81) | 0.12(‐0.14,0.39) | |
| LD ETN SC + MTX | 1.35(0.45,4.08) | 1.21(0.59,2.47) | 0.07(‐0.17,0.31) | |
| LD GOLI IV + MTX | 0.89(0.34,2.35) | 0.92(0.46,1.77) | ‐0.02(‐0.21,0.19) | |
| LD TOCI IV + MTX | 0.75(0.22,2.65) | 0.82(0.32,1.94) | ‐0.06(‐0.30,0.20) | |
| LD TOFA PO + MTX | 1.34(0.34,5.31) | 1.20(0.46,2.62) | 0.06(‐0.21,0.37) | |
| HD TOCI IV | 1.18(0.48,2.91) | 1.12(0.65,2.18) | 0.04(‐0.17,0.21) | |
| HD TOFA PO | 1.45(0.45,4.82) | 1.27(0.62,2.94) | 0.08(‐0.19,0.33) | |
| HD ADA SC | 0.69(0.19,2.43) | 0.77(0.32,1.91) | ‐0.07(‐0.34,0.17) | |
| HD GOLI SC | 1.24(0.41,3.64) | 1.15(0.57,2.41) | 0.05(‐0.20,0.27) | |
| HD ETN SC | 0.82(0.28,2.54) | 0.87(0.40,1.89) | ‐0.04(‐0.26,0.20) | |
| HD ABA SC | 2.03(0.38,12.21) | 1.51(0.53,3.94) | 0.16(‐0.21,0.54) | |
| HD TOCI IV + MTX | 2.05(0.82,5.14) | 1.53(0.90,2.94) | 0.16(‐0.05,0.36) | |
| HD TOFA PO + MTX | 2.07(0.81,5.27) | 1.53(0.89,2.84) | 0.17(‐0.05,0.37) | |
| HD GOLI SC + MTX | 2.19(0.81,6.05) | 1.57(0.89,3.11) | 0.18(‐0.05,0.40) | |
| HD CERTO SC + MTX | 2.85(1.15,7.15) | 1.77(1.08,3.32) | 0.24(0.03,0.44) | |
| HD INF IV + MTX | 1.74(0.63,4.86) | 1.40(0.76,2.74) | 0.12(‐0.11,0.35) | |
| HD TOCI IV + DMARD | 0.43(0.12,1.55) | 0.53(0.19,1.38) | ‐0.14(‐0.38,0.08) | |
| SD ANA SC + MTX | SD ABA SC + MTX | 1.30(0.17,11.09) | 1.14(0.31,2.89) | 0.06(‐0.37,0.49) |
| SD TOCI IV + MTX | 0.52(0.12,2.16) | 0.68(0.26,1.63) | ‐0.14(‐0.44,0.17) | |
| SD CERTO SC + DMARD | 0.39(0.09,1.75) | 0.54(0.20,1.47) | ‐0.20(‐0.52,0.11) | |
| SD ADA SC + DMARD | 0.22(0.04,1.10) | 0.34(0.10,1.07) | ‐0.28(‐0.58,0.02) | |
| SD ETN SC + DMARD | 0.86(0.21,3.58) | 0.92(0.40,2.13) | ‐0.04(‐0.35,0.29) | |
| LD ADA SC | 0.28(0.07,1.19) | 0.42(0.17,1.14) | ‐0.25(‐0.55,0.03) | |
| LD GOLI IV | 0.27(0.06,1.10) | 0.41(0.14,1.07) | ‐0.25(‐0.54,0.02) | |
| LD TOCI IV | 0.05(0.01,0.26) | 0.09(0.02,0.34) | ‐0.40(‐0.67,‐0.15) | |
| LD RITUX IV + MTX | 0.43(0.13,1.54) | 0.59(0.27,1.34) | ‐0.18(‐0.45,0.09) | |
| LD ABA IV + MTX | 0.51(0.17,1.57) | 0.66(0.33,1.34) | ‐0.15(‐0.40,0.09) | |
| LD ANA SC + MTX | 0.73(0.10,6.66) | 0.84(0.19,2.41) | ‐0.07(‐0.46,0.41) | |
| LD CERTO SC + MTX | 1.02(0.26,4.03) | 1.01(0.46,2.22) | 0.00(‐0.31,0.32) | |
| LD ETN SC + MTX | 0.79(0.21,2.91) | 0.88(0.41,1.94) | ‐0.05(‐0.35,0.24) | |
| LD GOLI IV + MTX | 0.52(0.13,2.09) | 0.67(0.27,1.59) | ‐0.14(‐0.44,0.16) | |
| LD TOCI IV + MTX | 0.44(0.11,1.82) | 0.60(0.23,1.47) | ‐0.18(‐0.47,0.13) | |
| LD TOFA PO + MTX | 0.78(0.16,3.79) | 0.87(0.32,2.09) | ‐0.06(‐0.39,0.30) | |
| HD TOCI IV | 0.69(0.23,2.20) | 0.80(0.47,1.75) | ‐0.09(‐0.35,0.16) | |
| HD TOFA PO | 0.86(0.22,3.47) | 0.91(0.47,2.27) | ‐0.04(‐0.36,0.27) | |
| HD ADA SC | 0.40(0.10,1.69) | 0.55(0.24,1.46) | ‐0.20(‐0.50,0.10) | |
| HD GOLI SC | 0.72(0.20,2.62) | 0.83(0.41,1.90) | ‐0.08(‐0.37,0.21) | |
| HD ETN SC | 0.48(0.13,1.80) | 0.64(0.28,1.48) | ‐0.16(‐0.44,0.12) | |
| HD ABA SC | 1.18(0.20,8.27) | 1.09(0.40,3.03) | 0.04(‐0.37,0.47) | |
| HD TOCI IV + MTX | 1.21(0.39,3.85) | 1.10(0.65,2.32) | 0.05(‐0.22,0.30) | |
| HD TOFA PO + MTX | 1.21(0.38,3.92) | 1.10(0.63,2.31) | 0.05(‐0.23,0.31) | |
| HD GOLI SC + MTX | 1.27(0.38,4.38) | 1.13(0.63,2.42) | 0.06(‐0.23,0.34) | |
| HD CERTO SC + MTX | 1.68(0.54,5.38) | 1.28(0.76,2.69) | 0.12(‐0.15,0.38) | |
| HD INF IV + MTX | 1.02(0.32,3.46) | 1.01(0.55,2.13) | 0.01(‐0.27,0.28) | |
| HD TOCI IV + DMARD | 0.26(0.06,1.10) | 0.39(0.14,1.07) | ‐0.26(‐0.56,0.02) | |
| SD TOCI IV + MTX | SD ANA SC + MTX | 0.40(0.04,3.21) | 0.60(0.21,2.32) | ‐0.20(‐0.63,0.22) |
| SD CERTO SC + DMARD | 0.30(0.03,2.48) | 0.48(0.16,1.99) | ‐0.26(‐0.69,0.16) | |
| SD ADA SC + DMARD | 0.17(0.02,1.51) | 0.31(0.08,1.37) | ‐0.34(‐0.75,0.06) | |
| SD ETN SC + DMARD | 0.66(0.07,5.14) | 0.81(0.32,2.99) | ‐0.10(‐0.53,0.33) | |
| LD ADA SC | 0.22(0.02,1.72) | 0.37(0.14,1.54) | ‐0.32(‐0.71,0.08) | |
| LD GOLI IV | 0.21(0.02,1.64) | 0.36(0.11,1.44) | ‐0.31(‐0.72,0.08) | |
| LD TOCI IV | 0.04(0.00,0.37) | 0.08(0.01,0.43) | ‐0.46(‐0.85,‐0.09) | |
| LD RITUX IV + MTX | 0.34(0.04,2.28) | 0.53(0.21,1.86) | ‐0.24(‐0.63,0.14) | |
| LD ABA IV + MTX | 0.39(0.05,2.76) | 0.58(0.23,2.13) | ‐0.21(‐0.61,0.18) | |
| LD ANA SC + MTX | 0.56(0.13,2.39) | 0.76(0.26,1.64) | ‐0.11(‐0.42,0.18) | |
| LD CERTO SC + MTX | 0.78(0.09,5.84) | 0.89(0.35,3.12) | ‐0.06(‐0.49,0.37) | |
| LD ETN SC + MTX | 0.61(0.07,4.38) | 0.77(0.31,2.75) | ‐0.11(‐0.53,0.30) | |
| LD GOLI IV + MTX | 0.41(0.04,3.03) | 0.60(0.21,2.20) | ‐0.20(‐0.63,0.21) | |
| LD TOCI IV + MTX | 0.34(0.04,2.62) | 0.53(0.18,2.04) | ‐0.24(‐0.65,0.17) | |
| LD TOFA PO + MTX | 0.61(0.06,5.07) | 0.78(0.25,2.87) | ‐0.11(‐0.56,0.34) | |
| HD TOCI IV | 0.54(0.07,3.36) | 0.71(0.36,2.51) | ‐0.15(‐0.53,0.22) | |
| HD TOFA PO | 0.66(0.08,5.13) | 0.80(0.38,3.16) | ‐0.10(‐0.52,0.32) | |
| HD ADA SC | 0.31(0.03,2.47) | 0.49(0.20,2.01) | ‐0.26(‐0.66,0.15) | |
| HD GOLI SC | 0.56(0.07,3.89) | 0.73(0.32,2.67) | ‐0.14(‐0.55,0.25) | |
| HD ETN SC | 0.37(0.04,2.62) | 0.56(0.22,2.04) | ‐0.22(‐0.63,0.18) | |
| HD ABA SC | 0.94(0.08,10.52) | 0.97(0.32,3.99) | ‐0.01(‐0.53,0.50) | |
| HD TOCI IV + MTX | 0.92(0.12,5.90) | 0.96(0.50,3.40) | ‐0.02(‐0.41,0.36) | |
| HD TOFA PO + MTX | 0.94(0.12,5.88) | 0.97(0.47,3.32) | ‐0.01(‐0.42,0.37) | |
| HD GOLI SC + MTX | 0.98(0.13,6.73) | 0.99(0.48,3.61) | 0.00(‐0.41,0.39) | |
| HD CERTO SC + MTX | 1.30(0.17,8.36) | 1.12(0.58,4.03) | 0.06(‐0.33,0.45) | |
| HD INF IV + MTX | 0.80(0.10,5.40) | 0.89(0.41,3.15) | ‐0.05(‐0.46,0.35) | |
| HD TOCI IV + DMARD | 0.20(0.02,1.55) | 0.35(0.11,1.42) | ‐0.33(‐0.73,0.07) | |
| SD CERTO SC + DMARD | SD TOCI IV + MTX | 0.75(0.17,3.29) | 0.82(0.29,2.45) | ‐0.05(‐0.35,0.22) |
| SD ADA SC + DMARD | 0.42(0.09,2.00) | 0.51(0.14,1.70) | ‐0.13(‐0.42,0.12) | |
| SD ETN SC + DMARD | 1.65(0.39,7.10) | 1.38(0.55,3.61) | 0.11(‐0.21,0.41) | |
| LD ADA SC | 0.54(0.13,2.21) | 0.63(0.24,1.88) | ‐0.11(‐0.39,0.12) | |
| LD GOLI IV | 0.51(0.12,2.20) | 0.61(0.19,1.81) | ‐0.11(‐0.39,0.14) | |
| LD TOCI IV | 0.09(0.02,0.41) | 0.13(0.03,0.48) | ‐0.25(‐0.50,‐0.08) | |
| LD RITUX IV + MTX | 0.84(0.23,3.02) | 0.88(0.36,2.27) | ‐0.03(‐0.30,0.21) | |
| LD ABA IV + MTX | 0.97(0.28,3.42) | 0.98(0.42,2.44) | ‐0.01(‐0.27,0.24) | |
| LD ANA SC + MTX | 1.41(0.17,13.53) | 1.25(0.26,4.02) | 0.07(‐0.31,0.55) | |
| LD CERTO SC + MTX | 1.95(0.48,7.98) | 1.51(0.63,3.78) | 0.15(‐0.16,0.45) | |
| LD ETN SC + MTX | 1.53(0.40,5.83) | 1.31(0.56,3.28) | 0.09(‐0.20,0.37) | |
| LD GOLI IV + MTX | 0.99(0.24,4.22) | 1.00(0.36,2.72) | 0.00(‐0.29,0.29) | |
| LD TOCI IV + MTX | 0.85(0.25,2.73) | 0.89(0.37,2.06) | ‐0.03(‐0.28,0.20) | |
| LD TOFA PO + MTX | 1.49(0.31,7.21) | 1.29(0.45,3.49) | 0.08(‐0.23,0.43) | |
| HD TOCI IV | 1.33(0.49,3.66) | 1.21(0.66,2.67) | 0.06(‐0.17,0.24) | |
| HD TOFA PO | 1.65(0.44,6.31) | 1.38(0.62,3.73) | 0.11(‐0.20,0.36) | |
| HD ADA SC | 0.77(0.19,3.23) | 0.83(0.33,2.46) | ‐0.05(‐0.34,0.21) | |
| HD GOLI SC | 1.37(0.39,4.94) | 1.23(0.55,3.15) | 0.07(‐0.22,0.32) | |
| HD ETN SC | 0.93(0.24,3.53) | 0.95(0.38,2.54) | ‐0.01(‐0.29,0.24) | |
| HD ABA SC | 2.27(0.39,15.04) | 1.63(0.55,4.95) | 0.18(‐0.21,0.57) | |
| HD TOCI IV + MTX | 2.29(0.83,6.50) | 1.65(0.91,3.72) | 0.19(‐0.05,0.39) | |
| HD TOFA PO + MTX | 2.33(0.70,7.71) | 1.65(0.82,3.92) | 0.19(‐0.08,0.43) | |
| HD GOLI SC + MTX | 2.45(0.70,8.76) | 1.70(0.82,4.17) | 0.20(‐0.08,0.46) | |
| HD CERTO SC + MTX | 3.22(0.99,10.62) | 1.92(1.00,4.50) | 0.27(0.00,0.50) | |
| HD INF IV + MTX | 1.98(0.57,6.85) | 1.52(0.71,3.69) | 0.15(‐0.13,0.40) | |
| HD TOCI IV + DMARD | 0.49(0.12,1.95) | 0.58(0.20,1.70) | ‐0.12(‐0.40,0.11) | |
| SD ADA SC + DMARD | SD CERTO SC + DMARD | 0.55(0.13,2.34) | 0.62(0.19,1.90) | ‐0.08(‐0.31,0.15) |
| SD ETN SC + DMARD | 2.20(0.56,8.91) | 1.69(0.67,4.39) | 0.16(‐0.12,0.46) | |
| LD ADA SC | 0.73(0.19,2.64) | 0.78(0.28,2.19) | ‐0.05(‐0.30,0.15) | |
| LD GOLI IV | 0.69(0.14,3.18) | 0.74(0.21,2.43) | ‐0.06(‐0.31,0.20) | |
| LD TOCI IV | 0.12(0.02,0.67) | 0.15(0.03,0.71) | ‐0.19(‐0.42,‐0.04) | |
| LD RITUX IV + MTX | 1.12(0.28,4.31) | 1.09(0.39,2.95) | 0.02(‐0.24,0.28) | |
| LD ABA IV + MTX | 1.30(0.34,5.01) | 1.21(0.45,3.27) | 0.05(‐0.21,0.31) | |
| LD ANA SC + MTX | 1.85(0.22,19.38) | 1.52(0.29,5.21) | 0.12(‐0.23,0.61) | |
| LD CERTO SC + MTX | 2.59(0.58,11.10) | 1.86(0.69,4.83) | 0.20(‐0.11,0.50) | |
| LD ETN SC + MTX | 2.03(0.50,8.17) | 1.62(0.61,4.22) | 0.14(‐0.14,0.43) | |
| LD GOLI IV + MTX | 1.34(0.30,6.07) | 1.24(0.41,3.55) | 0.05(‐0.22,0.36) | |
| LD TOCI IV + MTX | 1.12(0.26,4.84) | 1.09(0.36,3.17) | 0.02(‐0.24,0.30) | |
| LD TOFA PO + MTX | 2.01(0.38,10.64) | 1.60(0.50,4.60) | 0.14(‐0.18,0.49) | |
| HD TOCI IV | 1.78(0.58,5.38) | 1.50(0.70,3.58) | 0.12(‐0.12,0.31) | |
| HD TOFA PO | 2.21(0.63,7.63) | 1.71(0.74,4.28) | 0.17(‐0.10,0.39) | |
| HD ADA SC | 1.04(0.27,3.82) | 1.03(0.39,2.84) | 0.01(‐0.26,0.23) | |
| HD GOLI SC | 1.85(0.50,6.84) | 1.53(0.63,3.97) | 0.12(‐0.15,0.38) | |
| HD ETN SC | 1.24(0.31,4.88) | 1.17(0.42,3.22) | 0.04(‐0.23,0.30) | |
| HD ABA SC | 3.07(0.54,18.58) | 2.03(0.66,5.61) | 0.24(‐0.13,0.61) | |
| HD TOCI IV + MTX | 3.08(0.93,10.53) | 2.05(0.96,4.92) | 0.24(‐0.02,0.47) | |
| HD TOFA PO + MTX | 3.11(0.82,11.54) | 2.05(0.89,5.04) | 0.25(‐0.04,0.51) | |
| HD GOLI SC + MTX | 3.28(0.87,12.37) | 2.11(0.92,5.18) | 0.26(‐0.03,0.52) | |
| HD CERTO SC + MTX | 4.31(1.19,15.33) | 2.39(1.10,5.66) | 0.33(0.04,0.56) | |
| HD INF IV + MTX | 2.63(0.70,10.14) | 1.88(0.79,4.71) | 0.21(‐0.08,0.48) | |
| HD TOCI IV + DMARD | 0.65(0.19,2.23) | 0.71(0.26,1.86) | ‐0.07(‐0.28,0.14) | |
| SD ETN SC + DMARD | SD ADA SC + DMARD | 3.96(0.96,16.87) | 2.69(0.97,8.53) | 0.24(‐0.01,0.51) |
| LD ADA SC | 1.29(0.28,6.03) | 1.23(0.38,4.70) | 0.03(‐0.22,0.22) | |
| LD GOLI IV | 1.23(0.23,6.37) | 1.18(0.30,4.70) | 0.02(‐0.22,0.27) | |
| LD TOCI IV | 0.22(0.03,1.35) | 0.25(0.04,1.30) | ‐0.10(‐0.34,0.02) | |
| LD RITUX IV + MTX | 2.00(0.45,9.24) | 1.72(0.55,6.23) | 0.10(‐0.14,0.34) | |
| LD ABA IV + MTX | 2.31(0.55,10.35) | 1.92(0.64,6.71) | 0.13(‐0.11,0.37) | |
| LD ANA SC + MTX | 3.43(0.37,35.91) | 2.44(0.44,10.08) | 0.21(‐0.14,0.68) | |
| LD CERTO SC + MTX | 4.66(0.94,23.07) | 2.95(0.96,9.82) | 0.28(‐0.01,0.57) | |
| LD ETN SC + MTX | 3.61(0.83,17.21) | 2.57(0.88,8.68) | 0.23(‐0.04,0.50) | |
| LD GOLI IV + MTX | 2.40(0.49,12.55) | 1.96(0.58,7.12) | 0.14(‐0.12,0.42) | |
| LD TOCI IV + MTX | 2.01(0.42,9.41) | 1.74(0.51,6.04) | 0.10(‐0.15,0.37) | |
| LD TOFA PO + MTX | 3.59(0.66,21.36) | 2.52(0.73,9.55) | 0.22(‐0.07,0.56) | |
| HD TOCI IV | 3.20(0.91,11.22) | 2.40(0.94,7.30) | 0.20(‐0.02,0.37) | |
| HD TOFA PO | 3.97(0.88,17.13) | 2.75(0.92,9.37) | 0.25(‐0.03,0.46) | |
| HD ADA SC | 1.86(0.42,8.53) | 1.64(0.52,5.97) | 0.09(‐0.16,0.30) | |
| HD GOLI SC | 3.32(0.76,14.84) | 2.44(0.83,8.40) | 0.21(‐0.06,0.44) | |
| HD ETN SC | 2.24(0.51,9.86) | 1.87(0.61,6.43) | 0.12(‐0.12,0.37) | |
| HD ABA SC | 5.51(0.79,39.89) | 3.24(0.85,12.27) | 0.32(‐0.05,0.68) | |
| HD TOCI IV + MTX | 5.51(1.52,21.29) | 3.29(1.27,10.27) | 0.33(0.09,0.53) | |
| HD TOFA PO + MTX | 5.58(1.39,23.39) | 3.26(1.23,10.64) | 0.33(0.07,0.57) | |
| HD GOLI SC + MTX | 5.90(1.41,25.44) | 3.38(1.24,10.98) | 0.34(0.07,0.58) | |
| HD CERTO SC + MTX | 7.71(1.89,32.25) | 3.80(1.43,12.17) | 0.41(0.15,0.63) | |
| HD INF IV + MTX | 4.74(1.13,21.25) | 3.00(1.08,9.94) | 0.29(0.02,0.54) | |
| HD TOCI IV + DMARD | 1.17(0.36,3.79) | 1.13(0.45,3.11) | 0.02(‐0.17,0.18) | |
| LD ADA SC | SD ETN SC + DMARD | 0.33(0.08,1.31) | 0.46(0.19,1.23) | ‐0.22(‐0.51,0.05) |
| LD GOLI IV | 0.31(0.07,1.40) | 0.44(0.14,1.27) | ‐0.22(‐0.51,0.06) | |
| LD TOCI IV | 0.05(0.01,0.30) | 0.09(0.02,0.38) | ‐0.36(‐0.64,‐0.14) | |
| LD RITUX IV + MTX | 0.51(0.14,1.86) | 0.64(0.28,1.52) | ‐0.14(‐0.42,0.12) | |
| LD ABA IV + MTX | 0.59(0.16,2.07) | 0.71(0.32,1.63) | ‐0.11(‐0.40,0.15) | |
| LD ANA SC + MTX | 0.85(0.11,8.09) | 0.91(0.20,2.70) | ‐0.04(‐0.42,0.45) | |
| LD CERTO SC + MTX | 1.18(0.28,4.75) | 1.10(0.47,2.45) | 0.04(‐0.29,0.36) | |
| LD ETN SC + MTX | 0.92(0.24,3.46) | 0.95(0.42,2.15) | ‐0.02(‐0.33,0.28) | |
| LD GOLI IV + MTX | 0.61(0.14,2.65) | 0.73(0.27,1.86) | ‐0.11(‐0.42,0.22) | |
| LD TOCI IV + MTX | 0.51(0.12,2.09) | 0.64(0.24,1.64) | ‐0.14(‐0.43,0.16) | |
| LD TOFA PO + MTX | 0.91(0.19,4.62) | 0.95(0.34,2.38) | ‐0.02(‐0.36,0.34) | |
| HD TOCI IV | 0.81(0.27,2.37) | 0.88(0.50,1.82) | ‐0.05(‐0.31,0.18) | |
| HD TOFA PO | 1.01(0.27,3.63) | 1.00(0.50,2.36) | 0.00(‐0.31,0.28) | |
| HD ADA SC | 0.47(0.12,1.82) | 0.60(0.26,1.55) | ‐0.16(‐0.46,0.12) | |
| HD GOLI SC | 0.84(0.22,2.98) | 0.90(0.42,2.05) | ‐0.04(‐0.35,0.24) | |
| HD ETN SC | 0.56(0.16,1.95) | 0.69(0.30,1.57) | ‐0.12(‐0.40,0.14) | |
| HD ABA SC | 1.40(0.23,8.73) | 1.20(0.41,3.14) | 0.08(‐0.34,0.48) | |
| HD TOCI IV + MTX | 1.39(0.45,4.42) | 1.19(0.68,2.54) | 0.08(‐0.19,0.33) | |
| HD TOFA PO + MTX | 1.41(0.42,4.83) | 1.20(0.65,2.56) | 0.08(‐0.20,0.36) | |
| HD GOLI SC + MTX | 1.49(0.41,5.36) | 1.23(0.64,2.73) | 0.09(‐0.21,0.38) | |
| HD CERTO SC + MTX | 1.94(0.58,6.49) | 1.39(0.78,2.92) | 0.16(‐0.13,0.42) | |
| HD INF IV + MTX | 1.19(0.34,4.18) | 1.10(0.56,2.40) | 0.04(‐0.25,0.32) | |
| HD TOCI IV + DMARD | 0.30(0.08,1.01) | 0.42(0.16,1.01) | ‐0.23(‐0.49,0.00) | |
| LD GOLI IV | LD ADA SC | 0.95(0.22,4.00) | 0.96(0.27,2.93) | ‐0.01(‐0.20,0.24) |
| LD TOCI IV | 0.17(0.03,0.88) | 0.20(0.03,0.89) | ‐0.14(‐0.30,‐0.01) | |
| LD RITUX IV + MTX | 1.55(0.45,5.33) | 1.40(0.52,3.56) | 0.07(‐0.13,0.31) | |
| LD ABA IV + MTX | 1.80(0.52,6.25) | 1.56(0.59,3.88) | 0.10(‐0.11,0.34) | |
| LD ANA SC + MTX | 2.64(0.32,23.26) | 2.01(0.38,6.04) | 0.18(‐0.15,0.64) | |
| LD CERTO SC + MTX | 3.61(0.88,14.55) | 2.40(0.91,5.72) | 0.26(‐0.02,0.55) | |
| LD ETN SC + MTX | 2.80(0.75,10.53) | 2.09(0.80,5.03) | 0.20(‐0.05,0.47) | |
| LD GOLI IV + MTX | 1.85(0.46,7.54) | 1.59(0.53,4.25) | 0.11(‐0.12,0.40) | |
| LD TOCI IV + MTX | 1.57(0.39,6.08) | 1.42(0.47,3.80) | 0.07(‐0.14,0.34) | |
| LD TOFA PO + MTX | 2.77(0.57,13.40) | 2.06(0.65,5.41) | 0.19(‐0.09,0.54) | |
| HD TOCI IV | 2.46(0.93,6.55) | 1.93(0.95,4.17) | 0.17(‐0.02,0.34) | |
| HD TOFA PO | 3.07(1.07,8.74) | 2.21(1.05,4.83) | 0.22(0.01,0.42) | |
| HD ADA SC | 1.44(0.65,3.13) | 1.33(0.72,2.46) | 0.06(‐0.07,0.20) | |
| HD GOLI SC | 2.56(0.77,8.42) | 1.97(0.82,4.71) | 0.18(‐0.05,0.41) | |
| HD ETN SC | 1.72(0.47,6.28) | 1.51(0.56,3.89) | 0.09(‐0.12,0.34) | |
| HD ABA SC | 4.23(0.79,23.84) | 2.62(0.84,6.72) | 0.30(‐0.04,0.64) | |
| HD TOCI IV + MTX | 4.25(1.43,12.74) | 2.64(1.27,5.75) | 0.30(0.08,0.51) | |
| HD TOFA PO + MTX | 4.32(1.32,14.45) | 2.65(1.20,5.93) | 0.30(0.06,0.54) | |
| HD GOLI SC + MTX | 4.57(1.34,15.22) | 2.74(1.23,6.09) | 0.32(0.06,0.55) | |
| HD CERTO SC + MTX | 5.97(1.79,19.51) | 3.08(1.46,6.70) | 0.38(0.12,0.60) | |
| HD INF IV + MTX | 3.69(1.04,12.57) | 2.44(1.02,5.61) | 0.26(0.01,0.51) | |
| HD TOCI IV + DMARD | 0.91(0.23,3.37) | 0.92(0.28,2.63) | ‐0.01(‐0.20,0.20) | |
| LD TOCI IV | LD GOLI IV | 0.18(0.03,0.97) | 0.21(0.03,0.97) | ‐0.13(‐0.36,0.00) |
| LD RITUX IV + MTX | 1.61(0.48,5.91) | 1.45(0.58,4.17) | 0.08(‐0.14,0.29) | |
| LD ABA IV + MTX | 1.91(0.54,6.97) | 1.63(0.64,4.72) | 0.11(‐0.11,0.32) | |
| LD ANA SC + MTX | 2.71(0.34,26.19) | 2.04(0.42,7.72) | 0.18(‐0.16,0.64) | |
| LD CERTO SC + MTX | 3.83(0.97,14.94) | 2.49(0.97,7.05) | 0.26(‐0.01,0.53) | |
| LD ETN SC + MTX | 2.95(0.79,11.52) | 2.15(0.85,6.29) | 0.20(‐0.05,0.46) | |
| LD GOLI IV + MTX | 1.96(0.66,5.88) | 1.65(0.73,4.02) | 0.11(‐0.07,0.32) | |
| LD TOCI IV + MTX | 1.63(0.39,7.02) | 1.46(0.49,4.61) | 0.08(‐0.16,0.33) | |
| LD TOFA PO + MTX | 2.93(0.62,13.99) | 2.13(0.70,6.55) | 0.20(‐0.08,0.52) | |
| HD TOCI IV | 2.61(0.81,8.59) | 2.01(0.88,5.73) | 0.17(‐0.05,0.34) | |
| HD TOFA PO | 3.19(0.82,13.52) | 2.28(0.88,7.41) | 0.22(‐0.04,0.45) | |
| HD ADA SC | 1.51(0.35,6.45) | 1.38(0.46,4.69) | 0.06(‐0.20,0.28) | |
| HD GOLI SC | 2.70(0.72,10.22) | 2.06(0.80,6.15) | 0.18(‐0.07,0.40) | |
| HD ETN SC | 1.81(0.50,6.93) | 1.58(0.59,4.66) | 0.09(‐0.13,0.33) | |
| HD ABA SC | 4.45(0.70,31.35) | 2.69(0.78,9.79) | 0.30(‐0.07,0.66) | |
| HD TOCI IV + MTX | 4.50(1.38,15.12) | 2.74(1.20,7.77) | 0.30(0.07,0.50) | |
| HD TOFA PO + MTX | 4.55(1.41,14.70) | 2.75(1.22,7.36) | 0.30(0.07,0.51) | |
| HD GOLI SC + MTX | 4.78(1.38,17.07) | 2.83(1.22,7.96) | 0.31(0.07,0.54) | |
| HD CERTO SC + MTX | 6.28(1.96,20.63) | 3.22(1.45,8.65) | 0.38(0.15,0.58) | |
| HD INF IV + MTX | 3.86(1.13,13.52) | 2.52(1.08,6.99) | 0.26(0.03,0.49) | |
| HD TOCI IV + DMARD | 0.96(0.21,4.24) | 0.96(0.29,3.35) | ‐0.01(‐0.25,0.20) | |
| LD RITUX IV + MTX | LD TOCI IV | 9.16(1.99,56.51) | 6.92(1.78,37.78) | 0.21(0.07,0.43) |
| LD ABA IV + MTX | 10.70(2.29,67.10) | 7.72(2.00,42.78) | 0.24(0.08,0.46) | |
| LD ANA SC + MTX | 16.16(1.40,200.30) | 9.73(1.35,63.50) | 0.32(0.02,0.78) | |
| LD CERTO SC + MTX | 21.02(4.03,140.00) | 11.70(2.99,63.85) | 0.40(0.16,0.67) | |
| LD ETN SC + MTX | 16.69(3.41,106.30) | 10.26(2.67,55.69) | 0.34(0.13,0.59) | |
| LD GOLI IV + MTX | 10.97(2.10,75.57) | 7.77(1.86,44.20) | 0.25(0.07,0.52) | |
| LD TOCI IV + MTX | 9.20(2.07,51.29) | 6.87(1.86,34.95) | 0.21(0.06,0.45) | |
| LD TOFA PO + MTX | 16.80(2.68,125.80) | 10.19(2.27,58.61) | 0.34(0.09,0.66) | |
| HD TOCI IV | 14.50(3.83,77.33) | 9.64(2.83,48.60) | 0.31(0.19,0.46) | |
| HD TOFA PO | 18.08(3.77,117.20) | 11.04(2.79,61.95) | 0.36(0.20,0.54) | |
| HD ADA SC | 8.56(1.64,53.20) | 6.66(1.53,37.47) | 0.20(0.05,0.38) | |
| HD GOLI SC | 15.01(3.19,95.36) | 9.76(2.49,54.89) | 0.32(0.14,0.53) | |
| HD ETN SC | 10.17(2.02,66.08) | 7.45(1.81,42.46) | 0.23(0.07,0.47) | |
| HD ABA SC | 25.35(3.24,254.00) | 12.86(2.59,78.02) | 0.44(0.14,0.77) | |
| HD TOCI IV + MTX | 25.26(6.42,138.30) | 13.18(3.84,67.50) | 0.44(0.27,0.62) | |
| HD TOFA PO + MTX | 25.35(5.76,155.60) | 13.11(3.65,69.81) | 0.44(0.23,0.66) | |
| HD GOLI SC + MTX | 26.90(5.82,164.10) | 13.57(3.64,74.17) | 0.46(0.25,0.67) | |
| HD CERTO SC + MTX | 35.15(7.94,203.30) | 15.25(4.27,79.07) | 0.52(0.31,0.72) | |
| HD INF IV + MTX | 21.32(4.76,131.90) | 11.92(3.27,63.50) | 0.40(0.19,0.63) | |
| HD TOCI IV + DMARD | 5.33(1.01,36.04) | 4.55(1.01,27.50) | 0.12(0.00,0.33) | |
| LD ABA IV + MTX | LD RITUX IV + MTX | 1.16(0.41,3.22) | 1.11(0.53,2.34) | 0.03(‐0.17,0.23) |
| LD ANA SC + MTX | 1.67(0.25,13.36) | 1.41(0.33,3.97) | 0.10(‐0.22,0.55) | |
| LD CERTO SC + MTX | 2.31(0.71,7.65) | 1.70(0.79,3.69) | 0.18(‐0.07,0.44) | |
| LD ETN SC + MTX | 1.82(0.58,5.63) | 1.49(0.69,3.17) | 0.12(‐0.11,0.37) | |
| LD GOLI IV + MTX | 1.21(0.36,3.94) | 1.14(0.47,2.60) | 0.04(‐0.19,0.29) | |
| LD TOCI IV + MTX | 1.00(0.28,3.51) | 1.00(0.38,2.47) | 0.00(‐0.23,0.25) | |
| LD TOFA PO + MTX | 1.80(0.44,7.19) | 1.48(0.55,3.42) | 0.12(‐0.16,0.43) | |
| HD TOCI IV | 1.60(0.64,3.99) | 1.38(0.76,2.81) | 0.09(‐0.10,0.26) | |
| HD TOFA PO | 1.97(0.59,6.65) | 1.57(0.72,3.82) | 0.14(‐0.12,0.38) | |
| HD ADA SC | 0.92(0.27,3.29) | 0.94(0.38,2.48) | ‐0.02(‐0.26,0.21) | |
| HD GOLI SC | 1.65(0.55,5.02) | 1.40(0.67,3.10) | 0.10(‐0.13,0.33) | |
| HD ETN SC | 1.11(0.37,3.39) | 1.08(0.48,2.41) | 0.02(‐0.20,0.25) | |
| HD ABA SC | 2.76(0.49,16.52) | 1.88(0.62,5.18) | 0.22(‐0.15,0.59) | |
| HD TOCI IV + MTX | 2.76(1.08,6.96) | 1.88(1.04,3.82) | 0.22(0.02,0.41) | |
| HD TOFA PO + MTX | 2.77(1.07,7.21) | 1.88(1.04,3.72) | 0.22(0.01,0.42) | |
| HD GOLI SC + MTX | 2.92(1.07,8.13) | 1.94(1.04,3.96) | 0.24(0.01,0.45) | |
| HD CERTO SC + MTX | 3.87(1.50,9.95) | 2.19(1.24,4.33) | 0.30(0.09,0.49) | |
| HD INF IV + MTX | 2.35(0.86,6.55) | 1.73(0.91,3.53) | 0.18(‐0.03,0.40) | |
| HD TOCI IV + DMARD | 0.59(0.15,2.10) | 0.66(0.22,1.76) | ‐0.08(‐0.32,0.13) | |
| LD ANA SC + MTX | LD ABA IV + MTX | 1.46(0.20,11.51) | 1.27(0.28,3.57) | 0.08(‐0.26,0.52) |
| LD CERTO SC + MTX | 1.98(0.60,6.52) | 1.53(0.72,3.21) | 0.15(‐0.10,0.41) | |
| LD ETN SC + MTX | 1.56(0.51,4.80) | 1.33(0.64,2.77) | 0.09(‐0.14,0.34) | |
| LD GOLI IV + MTX | 1.03(0.31,3.49) | 1.02(0.42,2.33) | 0.01(‐0.23,0.27) | |
| LD TOCI IV + MTX | 0.87(0.25,3.01) | 0.90(0.36,2.16) | ‐0.03(‐0.26,0.22) | |
| LD TOFA PO + MTX | 1.55(0.38,6.29) | 1.33(0.50,3.09) | 0.09(‐0.19,0.40) | |
| HD TOCI IV | 1.37(0.56,3.39) | 1.23(0.71,2.48) | 0.07(‐0.13,0.24) | |
| HD TOFA PO | 1.68(0.50,5.83) | 1.40(0.66,3.41) | 0.11(‐0.16,0.36) | |
| HD ADA SC | 0.80(0.23,2.82) | 0.85(0.35,2.19) | ‐0.04(‐0.30,0.19) | |
| HD GOLI SC | 1.41(0.47,4.22) | 1.26(0.62,2.72) | 0.07(‐0.16,0.30) | |
| HD ETN SC | 0.95(0.31,2.89) | 0.97(0.43,2.08) | ‐0.01(‐0.23,0.22) | |
| HD ABA SC | 2.33(0.45,14.25) | 1.65(0.58,4.56) | 0.19(‐0.17,0.57) | |
| HD TOCI IV + MTX | 2.37(0.97,5.94) | 1.68(0.98,3.34) | 0.19(‐0.01,0.38) | |
| HD TOFA PO + MTX | 2.38(0.94,6.08) | 1.68(0.97,3.26) | 0.19(‐0.01,0.40) | |
| HD GOLI SC + MTX | 2.49(0.93,7.08) | 1.73(0.96,3.53) | 0.21(‐0.02,0.43) | |
| HD CERTO SC + MTX | 3.30(1.31,8.53) | 1.96(1.16,3.85) | 0.27(0.06,0.47) | |
| HD INF IV + MTX | 2.01(0.75,5.50) | 1.54(0.84,3.05) | 0.15(‐0.06,0.37) | |
| HD TOCI IV + DMARD | 0.50(0.14,1.77) | 0.59(0.21,1.54) | ‐0.11(‐0.34,0.10) | |
| LD CERTO SC + MTX | LD ANA SC + MTX | 1.40(0.15,10.56) | 1.20(0.42,5.41) | 0.07(‐0.40,0.45) |
| LD ETN SC + MTX | 1.08(0.12,8.16) | 1.05(0.37,4.81) | 0.02(‐0.46,0.39) | |
| LD GOLI IV + MTX | 0.72(0.08,5.62) | 0.81(0.25,3.72) | ‐0.07(‐0.55,0.30) | |
| LD TOCI IV + MTX | 0.60(0.06,4.73) | 0.71(0.21,3.39) | ‐0.10(‐0.58,0.26) | |
| LD TOFA PO + MTX | 1.06(0.12,9.47) | 1.04(0.32,4.93) | 0.01(‐0.46,0.43) | |
| HD TOCI IV | 0.95(0.13,6.37) | 0.97(0.41,4.32) | ‐0.01(‐0.45,0.30) | |
| HD TOFA PO | 1.17(0.13,9.01) | 1.10(0.42,5.38) | 0.04(‐0.44,0.39) | |
| HD ADA SC | 0.55(0.06,4.26) | 0.66(0.23,3.31) | ‐0.12(‐0.59,0.22) | |
| HD GOLI SC | 0.97(0.12,7.08) | 0.98(0.37,4.51) | ‐0.01(‐0.47,0.34) | |
| HD ETN SC | 0.66(0.08,4.83) | 0.77(0.25,3.45) | ‐0.08(‐0.55,0.26) | |
| HD ABA SC | 1.65(0.13,20.12) | 1.31(0.38,7.09) | 0.11(‐0.44,0.58) | |
| HD TOCI IV + MTX | 1.63(0.22,11.26) | 1.31(0.57,5.77) | 0.11(‐0.33,0.44) | |
| HD TOFA PO + MTX | 1.67(0.21,11.09) | 1.33(0.56,5.73) | 0.12(‐0.33,0.45) | |
| HD GOLI SC + MTX | 1.76(0.21,12.43) | 1.37(0.56,6.10) | 0.13(‐0.33,0.48) | |
| HD CERTO SC + MTX | 2.28(0.29,15.46) | 1.53(0.65,6.73) | 0.19(‐0.26,0.53) | |
| HD INF IV + MTX | 1.40(0.17,9.75) | 1.21(0.48,5.32) | 0.08(‐0.38,0.43) | |
| HD TOCI IV + DMARD | 0.34(0.04,2.90) | 0.47(0.14,2.42) | ‐0.19(‐0.66,0.15) | |
| LD ETN SC + MTX | LD CERTO SC + MTX | 0.78(0.22,2.80) | 0.87(0.41,1.85) | ‐0.06(‐0.35,0.23) |
| LD GOLI IV + MTX | 0.52(0.13,1.98) | 0.67(0.27,1.54) | ‐0.14(‐0.43,0.15) | |
| LD TOCI IV + MTX | 0.43(0.11,1.68) | 0.59(0.24,1.40) | ‐0.18(‐0.47,0.11) | |
| LD TOFA PO + MTX | 0.77(0.17,3.40) | 0.87(0.33,2.00) | ‐0.06(‐0.38,0.28) | |
| HD TOCI IV | 0.68(0.23,2.04) | 0.80(0.47,1.64) | ‐0.09(‐0.34,0.15) | |
| HD TOFA PO | 0.85(0.22,3.34) | 0.91(0.47,2.17) | ‐0.04(‐0.35,0.27) | |
| HD ADA SC | 0.40(0.10,1.61) | 0.55(0.24,1.40) | ‐0.20(‐0.50,0.10) | |
| HD GOLI SC | 0.71(0.20,2.44) | 0.82(0.41,1.79) | ‐0.08(‐0.37,0.20) | |
| HD ETN SC | 0.48(0.13,1.73) | 0.63(0.28,1.42) | ‐0.16(‐0.44,0.12) | |
| HD ABA SC | 1.17(0.20,7.79) | 1.08(0.39,2.89) | 0.04(‐0.37,0.46) | |
| HD TOCI IV + MTX | 1.19(0.40,3.58) | 1.09(0.65,2.21) | 0.04(‐0.22,0.29) | |
| HD TOFA PO + MTX | 1.20(0.40,3.68) | 1.10(0.64,2.20) | 0.04(‐0.22,0.30) | |
| HD GOLI SC + MTX | 1.26(0.39,4.12) | 1.13(0.64,2.31) | 0.06(‐0.22,0.33) | |
| HD CERTO SC + MTX | 1.65(0.64,4.28) | 1.27(0.83,2.38) | 0.12(‐0.10,0.33) | |
| HD INF IV + MTX | 1.02(0.31,3.28) | 1.01(0.54,2.05) | 0.00(‐0.27,0.27) | |
| HD TOCI IV + DMARD | 0.25(0.06,1.02) | 0.38(0.14,1.01) | ‐0.27(‐0.55,0.00) | |
| LD GOLI IV + MTX | LD ETN SC + MTX | 0.66(0.18,2.42) | 0.77(0.31,1.74) | ‐0.09(‐0.36,0.19) |
| LD TOCI IV + MTX | 0.55(0.15,2.10) | 0.67(0.26,1.66) | ‐0.12(‐0.39,0.16) | |
| LD TOFA PO + MTX | 0.99(0.22,4.31) | 0.99(0.37,2.32) | 0.00(‐0.32,0.33) | |
| HD TOCI IV | 0.88(0.32,2.37) | 0.92(0.54,1.85) | ‐0.03(‐0.27,0.18) | |
| HD TOFA PO | 1.08(0.31,3.96) | 1.05(0.53,2.49) | 0.02(‐0.28,0.29) | |
| HD ADA SC | 0.51(0.14,1.90) | 0.63(0.27,1.59) | ‐0.14(‐0.42,0.13) | |
| HD GOLI SC | 0.91(0.28,2.99) | 0.94(0.47,2.05) | ‐0.02(‐0.29,0.24) | |
| HD ETN SC | 0.61(0.19,2.02) | 0.72(0.32,1.60) | ‐0.10(‐0.36,0.15) | |
| HD ABA SC | 1.50(0.27,9.56) | 1.24(0.45,3.31) | 0.09(‐0.30,0.49) | |
| HD TOCI IV + MTX | 1.52(0.56,4.18) | 1.26(0.74,2.50) | 0.10(‐0.14,0.31) | |
| HD TOFA PO + MTX | 1.53(0.54,4.46) | 1.27(0.73,2.49) | 0.10(‐0.14,0.33) | |
| HD GOLI SC + MTX | 1.61(0.53,5.02) | 1.30(0.72,2.64) | 0.11(‐0.15,0.36) | |
| HD CERTO SC + MTX | 2.11(0.76,6.02) | 1.46(0.88,2.88) | 0.18(‐0.07,0.41) | |
| HD INF IV + MTX | 1.30(0.44,3.92) | 1.16(0.63,2.31) | 0.06(‐0.19,0.31) | |
| HD TOCI IV + DMARD | 0.32(0.08,1.21) | 0.44(0.16,1.15) | ‐0.21(‐0.47,0.04) | |
| LD TOCI IV + MTX | LD GOLI IV + MTX | 0.84(0.20,3.41) | 0.88(0.32,2.42) | ‐0.03(‐0.31,0.24) |
| LD TOFA PO + MTX | 1.49(0.33,6.96) | 1.29(0.47,3.45) | 0.08(‐0.23,0.42) | |
| HD TOCI IV | 1.33(0.43,4.09) | 1.21(0.62,2.88) | 0.06(‐0.20,0.26) | |
| HD TOFA PO | 1.63(0.44,6.47) | 1.38(0.63,3.84) | 0.11(‐0.19,0.37) | |
| HD ADA SC | 0.78(0.19,3.21) | 0.84(0.32,2.43) | ‐0.05(‐0.35,0.20) | |
| HD GOLI SC | 1.37(0.39,4.95) | 1.23(0.55,3.20) | 0.07(‐0.22,0.32) | |
| HD ETN SC | 0.92(0.26,3.33) | 0.95(0.40,2.44) | ‐0.01(‐0.29,0.23) | |
| HD ABA SC | 2.28(0.36,15.71) | 1.63(0.53,5.06) | 0.18(‐0.23,0.58) | |
| HD TOCI IV + MTX | 2.29(0.74,7.20) | 1.65(0.86,3.92) | 0.19(‐0.07,0.41) | |
| HD TOFA PO + MTX | 2.31(0.75,7.41) | 1.64(0.85,3.78) | 0.19(‐0.07,0.43) | |
| HD GOLI SC + MTX | 2.44(0.73,8.26) | 1.69(0.85,4.07) | 0.20(‐0.08,0.44) | |
| HD CERTO SC + MTX | 3.19(1.02,10.06) | 1.92(1.01,4.44) | 0.27(0.01,0.49) | |
| HD INF IV + MTX | 1.97(0.58,6.61) | 1.52(0.72,3.61) | 0.15(‐0.13,0.40) | |
| HD TOCI IV + DMARD | 0.49(0.11,2.04) | 0.58(0.19,1.74) | ‐0.12(‐0.41,0.12) | |
| LD TOFA PO + MTX | LD TOCI IV + MTX | 1.78(0.37,8.74) | 1.46(0.50,4.09) | 0.12(‐0.19,0.46) |
| HD TOCI IV | 1.58(0.60,4.37) | 1.37(0.73,3.10) | 0.09(‐0.12,0.26) | |
| HD TOFA PO | 1.98(0.53,7.29) | 1.57(0.68,4.29) | 0.15(‐0.15,0.38) | |
| HD ADA SC | 0.92(0.24,3.59) | 0.94(0.36,2.71) | ‐0.02(‐0.29,0.22) | |
| HD GOLI SC | 1.64(0.46,6.05) | 1.40(0.61,3.68) | 0.10(‐0.17,0.35) | |
| HD ETN SC | 1.10(0.30,4.06) | 1.07(0.43,2.87) | 0.02(‐0.24,0.27) | |
| HD ABA SC | 2.73(0.45,17.79) | 1.85(0.60,5.61) | 0.22(‐0.17,0.59) | |
| HD TOCI IV + MTX | 2.76(1.01,7.82) | 1.87(1.01,4.30) | 0.22(0.00,0.42) | |
| HD TOFA PO + MTX | 2.78(0.85,9.12) | 1.88(0.91,4.54) | 0.22(‐0.04,0.46) | |
| HD GOLI SC + MTX | 2.92(0.88,10.05) | 1.93(0.93,4.81) | 0.24(‐0.03,0.48) | |
| HD CERTO SC + MTX | 3.83(1.20,12.17) | 2.19(1.10,5.23) | 0.30(0.04,0.52) | |
| HD INF IV + MTX | 2.36(0.68,7.90) | 1.72(0.79,4.23) | 0.18(‐0.09,0.43) | |
| HD TOCI IV + DMARD | 0.58(0.14,2.26) | 0.66(0.22,1.93) | ‐0.08(‐0.34,0.14) | |
| HD TOCI IV | LD TOFA PO + MTX | 0.89(0.24,3.27) | 0.93(0.48,2.43) | ‐0.03(‐0.34,0.22) |
| HD TOFA PO | 1.12(0.23,5.17) | 1.07(0.48,3.16) | 0.03(‐0.34,0.33) | |
| HD ADA SC | 0.52(0.11,2.57) | 0.64(0.25,2.04) | ‐0.14(‐0.49,0.17) | |
| HD GOLI SC | 0.92(0.21,3.85) | 0.95(0.43,2.59) | ‐0.02(‐0.36,0.27) | |
| HD ETN SC | 0.61(0.14,2.71) | 0.73(0.30,2.05) | ‐0.10(‐0.43,0.19) | |
| HD ABA SC | 1.52(0.22,11.95) | 1.26(0.42,4.11) | 0.10(‐0.35,0.53) | |
| HD TOCI IV + MTX | 1.54(0.41,5.65) | 1.27(0.67,3.22) | 0.10(‐0.20,0.36) | |
| HD TOFA PO + MTX | 1.55(0.49,4.96) | 1.27(0.72,2.95) | 0.10(‐0.17,0.34) | |
| HD GOLI SC + MTX | 1.64(0.41,6.37) | 1.31(0.66,3.36) | 0.12(‐0.21,0.40) | |
| HD CERTO SC + MTX | 2.15(0.57,8.03) | 1.48(0.79,3.70) | 0.18(‐0.13,0.45) | |
| HD INF IV + MTX | 1.32(0.33,5.21) | 1.17(0.57,3.00) | 0.06(‐0.26,0.35) | |
| HD TOCI IV + DMARD | 0.33(0.07,1.59) | 0.45(0.15,1.42) | ‐0.21(‐0.53,0.08) | |
| HD TOFA PO | HD TOCI IV | 1.24(0.49,3.16) | 1.14(0.64,2.02) | 0.05(‐0.17,0.27) |
| HD ADA SC | 0.59(0.22,1.55) | 0.69(0.33,1.34) | ‐0.11(‐0.30,0.09) | |
| HD GOLI SC | 1.03(0.41,2.58) | 1.02(0.55,1.77) | 0.01(‐0.19,0.22) | |
| HD ETN SC | 0.70(0.26,1.86) | 0.78(0.37,1.45) | ‐0.08(‐0.26,0.15) | |
| HD ABA SC | 1.71(0.38,8.82) | 1.37(0.51,2.83) | 0.13(‐0.21,0.49) | |
| HD TOCI IV + MTX | 1.73(0.98,3.14) | 1.37(0.99,1.90) | 0.13(‐0.01,0.27) | |
| HD TOFA PO + MTX | 1.75(0.77,3.95) | 1.37(0.85,2.08) | 0.13(‐0.06,0.32) | |
| HD GOLI SC + MTX | 1.85(0.78,4.44) | 1.41(0.86,2.22) | 0.15(‐0.06,0.35) | |
| HD CERTO SC + MTX | 2.41(1.09,5.50) | 1.59(1.05,2.36) | 0.21(0.02,0.39) | |
| HD INF IV + MTX | 1.48(0.61,3.53) | 1.26(0.72,1.97) | 0.09(‐0.11,0.30) | |
| HD TOCI IV + DMARD | 0.37(0.13,1.02) | 0.48(0.19,1.01) | ‐0.18(‐0.34,0.00) | |
| HD ADA SC | HD TOFA PO | 0.47(0.17,1.31) | 0.60(0.29,1.20) | ‐0.16(‐0.36,0.06) |
| HD GOLI SC | 0.84(0.27,2.54) | 0.90(0.43,1.73) | ‐0.04(‐0.29,0.22) | |
| HD ETN SC | 0.57(0.16,1.98) | 0.69(0.28,1.51) | ‐0.12(‐0.37,0.16) | |
| HD ABA SC | 1.39(0.30,7.02) | 1.20(0.45,2.42) | 0.08(‐0.27,0.44) | |
| HD TOCI IV + MTX | 1.40(0.50,4.03) | 1.20(0.67,2.13) | 0.08(‐0.17,0.33) | |
| HD TOFA PO + MTX | 1.40(0.44,4.57) | 1.20(0.62,2.20) | 0.08(‐0.19,0.36) | |
| HD GOLI SC + MTX | 1.49(0.47,4.61) | 1.24(0.65,2.22) | 0.10(‐0.18,0.36) | |
| HD CERTO SC + MTX | 1.96(0.61,5.87) | 1.41(0.77,2.41) | 0.16(‐0.12,0.41) | |
| HD INF IV + MTX | 1.20(0.36,3.87) | 1.11(0.53,2.05) | 0.04(‐0.23,0.32) | |
| HD TOCI IV + DMARD | 0.29(0.08,1.06) | 0.41(0.15,1.04) | ‐0.23(‐0.44,0.01) | |
| HD GOLI SC | HD ADA SC | 1.77(0.55,5.82) | 1.49(0.66,3.38) | 0.12(‐0.12,0.36) |
| HD ETN SC | 1.20(0.33,4.34) | 1.14(0.43,2.81) | 0.03(‐0.20,0.30) | |
| HD ABA SC | 2.95(0.58,16.90) | 1.97(0.69,4.88) | 0.24(‐0.11,0.60) | |
| HD TOCI IV + MTX | 3.00(1.00,9.18) | 2.00(1.00,4.20) | 0.24(0.00,0.47) | |
| HD TOFA PO + MTX | 3.04(0.89,9.90) | 2.01(0.93,4.27) | 0.24(‐0.02,0.49) | |
| HD GOLI SC + MTX | 3.17(0.96,10.70) | 2.06(0.97,4.46) | 0.26(‐0.01,0.51) | |
| HD CERTO SC + MTX | 4.17(1.23,13.41) | 2.33(1.13,4.81) | 0.32(0.05,0.55) | |
| HD INF IV + MTX | 2.55(0.74,8.89) | 1.84(0.81,4.06) | 0.20(‐0.07,0.47) | |
| HD TOCI IV + DMARD | 0.63(0.16,2.29) | 0.70(0.23,1.88) | ‐0.07(‐0.28,0.15) | |
| HD ETN SC | HD GOLI SC | 0.67(0.21,2.21) | 0.77(0.33,1.67) | ‐0.08(‐0.32,0.17) |
| HD ABA SC | 1.66(0.32,9.56) | 1.33(0.48,3.10) | 0.12(‐0.25,0.50) | |
| HD TOCI IV + MTX | 1.68(0.65,4.45) | 1.34(0.79,2.46) | 0.12(‐0.10,0.34) | |
| HD TOFA PO + MTX | 1.68(0.61,4.95) | 1.34(0.75,2.48) | 0.12(‐0.12,0.36) | |
| HD GOLI SC + MTX | 1.77(0.76,4.30) | 1.37(0.86,2.34) | 0.13(‐0.06,0.33) | |
| HD CERTO SC + MTX | 2.34(0.87,6.39) | 1.55(0.93,2.81) | 0.20(‐0.03,0.42) | |
| HD INF IV + MTX | 1.43(0.50,4.21) | 1.23(0.65,2.32) | 0.08(‐0.16,0.33) | |
| HD TOCI IV + DMARD | 0.35(0.10,1.27) | 0.47(0.17,1.18) | ‐0.19(‐0.42,0.05) | |
| HD ABA SC | HD ETN SC | 2.47(0.45,15.55) | 1.72(0.59,4.88) | 0.20(‐0.17,0.58) |
| HD TOCI IV + MTX | 2.50(0.91,6.90) | 1.75(0.95,3.70) | 0.20(‐0.02,0.41) | |
| HD TOFA PO + MTX | 2.52(0.89,7.07) | 1.75(0.93,3.64) | 0.21(‐0.03,0.42) | |
| HD GOLI SC + MTX | 2.64(0.87,8.00) | 1.79(0.93,3.91) | 0.22(‐0.03,0.45) | |
| HD CERTO SC + MTX | 3.47(1.23,9.81) | 2.03(1.11,4.22) | 0.28(0.05,0.49) | |
| HD INF IV + MTX | 2.11(0.72,6.50) | 1.60(0.82,3.44) | 0.16(‐0.08,0.40) | |
| HD TOCI IV + DMARD | 0.52(0.14,1.92) | 0.61(0.22,1.66) | ‐0.10(‐0.34,0.11) | |
| HD TOCI IV + MTX | HD ABA SC | 1.01(0.18,4.85) | 1.01(0.49,2.61) | 0.00(‐0.38,0.35) |
| HD TOFA PO + MTX | 1.03(0.17,5.35) | 1.02(0.45,2.69) | 0.01(‐0.40,0.38) | |
| HD GOLI SC + MTX | 1.07(0.18,5.66) | 1.03(0.47,2.79) | 0.02(‐0.38,0.39) | |
| HD CERTO SC + MTX | 1.41(0.24,7.32) | 1.17(0.57,3.04) | 0.08(‐0.31,0.44) | |
| HD INF IV + MTX | 0.86(0.14,4.62) | 0.92(0.40,2.50) | ‐0.04(‐0.43,0.35) | |
| HD TOCI IV + DMARD | 0.21(0.03,1.24) | 0.35(0.11,1.17) | ‐0.31(‐0.66,0.04) | |
| HD TOFA PO + MTX | HD TOCI IV + MTX | 1.01(0.44,2.30) | 1.00(0.64,1.50) | 0.00(‐0.19,0.20) |
| HD GOLI SC + MTX | 1.06(0.44,2.61) | 1.03(0.64,1.61) | 0.01(‐0.20,0.23) | |
| HD CERTO SC + MTX | 1.39(0.62,3.13) | 1.16(0.79,1.71) | 0.08(‐0.11,0.27) | |
| HD INF IV + MTX | 0.85(0.35,2.08) | 0.92(0.54,1.44) | ‐0.04(‐0.25,0.17) | |
| HD TOCI IV + DMARD | 0.21(0.07,0.64) | 0.35(0.14,0.75) | ‐0.31(‐0.51,‐0.10) | |
| HD GOLI SC + MTX | HD TOFA PO + MTX | 1.05(0.41,2.66) | 1.03(0.64,1.67) | 0.01(‐0.21,0.23) |
| HD CERTO SC + MTX | 1.38(0.60,3.13) | 1.16(0.79,1.78) | 0.08(‐0.12,0.27) | |
| HD INF IV + MTX | 0.84(0.33,2.16) | 0.92(0.54,1.50) | ‐0.04(‐0.26,0.18) | |
| HD TOCI IV + DMARD | 0.21(0.06,0.70) | 0.35(0.13,0.80) | ‐0.31(‐0.54,‐0.07) | |
| HD CERTO SC + MTX | HD GOLI SC + MTX | 1.31(0.53,3.32) | 1.13(0.74,1.79) | 0.06(‐0.15,0.28) |
| HD INF IV + MTX | 0.80(0.30,2.17) | 0.89(0.51,1.50) | ‐0.05(‐0.29,0.19) | |
| HD TOCI IV + DMARD | 0.20(0.06,0.69) | 0.34(0.13,0.79) | ‐0.33(‐0.56,‐0.08) | |
| HD INF IV + MTX | HD CERTO SC + MTX | 0.61(0.25,1.53) | 0.79(0.47,1.22) | ‐0.12(‐0.33,0.10) |
| HD TOCI IV + DMARD | 0.15(0.04,0.51) | 0.30(0.12,0.67) | ‐0.39(‐0.61,‐0.15) | |
| HD TOCI IV + DMARD | HD INF IV + MTX | 0.25(0.07,0.84) | 0.38(0.14,0.89) | ‐0.27(‐0.52,‐0.03) |
| Random‐effects model | Residual deviance | 165.2 vs 163 data points | ||
| Deviance information criteria | 1084.66 | |||
| Fixed‐effect model | Residual deviance | vs data points | ||
| Deviance information criteria | ||||
| Note | ||||
| Total participants | 24,984 | |||
| Total studies | 60 | |||
| 2‐arm | 28 | |||
| 3‐arm | 25 | |||
| 4‐arm | 5 | |||
| 5‐arm | 1 | |||
| 7‐arm | 1 | |||
Appendix 4. ACR50: subgroup ‐ late RA (> 10 years)
| ACR50 late RA: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| PL + MTX | PL | 9.03(2.77,32.14) | 5.98(2.40,14.46) | 0.31(0.11,0.55) |
| SD ETN SC | 12.36(4.09,40.45) | 7.19(3.20,16.25) | 0.38(0.18,0.60) | |
| SD ADA SC | 3.25(1.25,9.09) | 2.84(1.22,6.57) | 0.11(0.02,0.28) | |
| SD RITUX IV | 7.61(1.05,48.91) | 5.31(1.05,15.48) | 0.27(0.00,0.67) | |
| SD ADA SC + MTX | 78.18(21.30,316.50) | 13.37(7.38,25.96) | 0.77(0.56,0.89) | |
| SD RITUX IV + MTX | 29.22(7.62,123.90) | 10.42(4.86,21.99) | 0.59(0.30,0.81) | |
| SD INF IV + MTX | 28.50(5.64,150.40) | 10.32(4.06,21.95) | 0.59(0.24,0.84) | |
| SD ANA SC + MTX | 21.62(5.29,100.60) | 9.34(3.88,20.73) | 0.52(0.22,0.78) | |
| LD ETN SC | 6.53(2.15,21.87) | 4.84(1.95,12.08) | 0.24(0.08,0.45) | |
| LD ADA SC + MTX | 52.44(14.07,203.40) | 12.33(6.47,24.47) | 0.71(0.45,0.86) | |
| LD ADA IV + MTX | 37.02(4.69,310.40) | 11.04(3.64,24.02) | 0.64(0.19,0.89) | |
| LD RITUX IV + MTX | 29.07(7.11,128.80) | 10.41(4.65,22.13) | 0.59(0.29,0.81) | |
| HD ETN SC | 11.74(2.36,61.75) | 6.95(2.11,17.43) | 0.37(0.08,0.71) | |
| HD INF IV + MTX | 70.87(14.10,366.00) | 13.00(6.55,25.50) | 0.76(0.46,0.90) | |
| HD ADA SC + MTX | 64.44(15.62,288.90) | 12.83(6.77,25.34) | 0.74(0.47,0.88) | |
| SD ETN SC | PL + MTX | 1.38(0.76,2.56) | 1.20(0.86,1.84) | 0.07(‐0.06,0.21) |
| SD ADA SC | 0.36(0.07,1.79) | 0.48(0.15,1.54) | ‐0.19(‐0.49,0.11) | |
| SD RITUX IV | 0.85(0.16,3.46) | 0.91(0.23,1.91) | ‐0.03(‐0.30,0.29) | |
| SD ADA SC + MTX | 8.66(4.91,16.96) | 2.24(1.53,3.76) | 0.45(0.31,0.57) | |
| SD RITUX IV + MTX | 3.25(1.67,6.41) | 1.74(1.27,2.63) | 0.27(0.11,0.41) | |
| SD INF IV + MTX | 3.14(1.10,10.16) | 1.70(1.05,2.87) | 0.26(0.02,0.48) | |
| SD ANA SC + MTX | 2.43(1.15,5.27) | 1.55(1.08,2.37) | 0.21(0.03,0.37) | |
| LD ETN SC | 0.73(0.40,1.35) | 0.82(0.55,1.23) | ‐0.07(‐0.21,0.06) | |
| LD ADA SC + MTX | 5.81(3.23,10.66) | 2.06(1.46,3.26) | 0.39(0.25,0.50) | |
| LD ADA IV + MTX | 4.10(0.76,22.94) | 1.81(0.83,3.35) | 0.32(‐0.06,0.58) | |
| LD RITUX IV + MTX | 3.25(1.52,6.96) | 1.73(1.23,2.67) | 0.27(0.09,0.42) | |
| HD ETN SC | 1.30(0.38,4.74) | 1.16(0.51,2.26) | 0.06(‐0.20,0.35) | |
| HD INF IV + MTX | 7.73(2.84,23.51) | 2.15(1.46,3.72) | 0.43(0.23,0.60) | |
| HD ADA SC + MTX | 7.10(3.18,16.90) | 2.14(1.47,3.57) | 0.42(0.25,0.56) | |
| SD ADA SC | SD ETN SC | 0.26(0.05,1.24) | 0.40(0.13,1.16) | ‐0.27(‐0.55,0.04) |
| SD RITUX IV | 0.62(0.10,2.82) | 0.75(0.18,1.61) | ‐0.11(‐0.40,0.24) | |
| SD ADA SC + MTX | 6.29(2.78,15.30) | 1.84(1.36,2.85) | 0.37(0.22,0.53) | |
| SD RITUX IV + MTX | 2.38(0.95,5.71) | 1.44(0.97,2.17) | 0.20(‐0.01,0.38) | |
| SD INF IV + MTX | 2.30(0.68,8.47) | 1.42(0.81,2.29) | 0.19(‐0.09,0.43) | |
| SD ANA SC + MTX | 1.77(0.66,4.65) | 1.30(0.79,1.97) | 0.14(‐0.09,0.34) | |
| LD ETN SC | 0.53(0.32,0.88) | 0.68(0.46,0.93) | ‐0.14(‐0.26,‐0.03) | |
| LD ADA SC + MTX | 4.22(1.81,9.69) | 1.70(1.25,2.56) | 0.31(0.14,0.47) | |
| LD ADA IV + MTX | 2.98(0.48,17.74) | 1.53(0.64,2.60) | 0.24(‐0.16,0.52) | |
| LD RITUX IV + MTX | 2.37(0.88,6.08) | 1.44(0.93,2.18) | 0.20(‐0.03,0.39) | |
| HD ETN SC | 0.95(0.32,2.95) | 0.97(0.45,1.61) | ‐0.01(‐0.24,0.24) | |
| HD INF IV + MTX | 5.61(1.73,19.73) | 1.79(1.24,2.83) | 0.35(0.13,0.54) | |
| HD ADA SC + MTX | 5.18(1.90,14.64) | 1.77(1.27,2.74) | 0.34(0.15,0.51) | |
| SD RITUX IV | SD ADA SC | 2.31(0.26,19.14) | 1.86(0.32,6.88) | 0.15(‐0.19,0.59) |
| SD ADA SC + MTX | 24.02(4.41,138.70) | 4.70(2.08,11.58) | 0.65(0.35,0.84) | |
| SD RITUX IV + MTX | 8.97(1.62,51.78) | 3.68(1.35,9.85) | 0.47(0.11,0.74) | |
| SD INF IV + MTX | 8.70(1.25,61.66) | 3.61(1.16,9.86) | 0.47(0.05,0.76) | |
| SD ANA SC + MTX | 6.65(1.16,40.42) | 3.29(1.11,9.28) | 0.40(0.03,0.71) | |
| LD ETN SC | 2.02(0.43,9.84) | 1.71(0.53,5.65) | 0.12(‐0.15,0.40) | |
| LD ADA SC + MTX | 15.95(2.91,90.03) | 4.33(1.79,10.94) | 0.59(0.25,0.80) | |
| LD ADA IV + MTX | 11.47(1.14,117.00) | 3.86(1.09,10.54) | 0.52(0.03,0.82) | |
| LD RITUX IV + MTX | 8.91(1.55,53.22) | 3.67(1.32,9.84) | 0.47(0.09,0.75) | |
| HD ETN SC | 3.59(0.53,25.06) | 2.43(0.62,7.85) | 0.25(‐0.11,0.63) | |
| HD INF IV + MTX | 21.42(3.13,149.10) | 4.57(1.86,11.37) | 0.63(0.26,0.84) | |
| HD ADA SC + MTX | 19.49(3.30,119.80) | 4.51(1.91,11.25) | 0.62(0.28,0.83) | |
| SD ADA SC + MTX | SD RITUX IV | 10.16(2.23,60.86) | 2.46(1.20,10.85) | 0.48(0.14,0.75) |
| SD RITUX IV + MTX | 3.78(0.98,19.16) | 1.91(1.00,7.58) | 0.30(0.00,0.57) | |
| SD INF IV + MTX | 3.74(0.63,27.40) | 1.88(0.81,8.12) | 0.29(‐0.11,0.64) | |
| SD ANA SC + MTX | 2.86(0.57,17.81) | 1.71(0.78,7.20) | 0.23(‐0.13,0.56) | |
| LD ETN SC | 0.86(0.19,5.08) | 0.90(0.40,3.77) | ‐0.03(‐0.38,0.24) | |
| LD ADA SC + MTX | 6.77(1.49,39.92) | 2.26(1.11,9.79) | 0.42(0.08,0.70) | |
| LD ADA IV + MTX | 4.91(0.54,48.35) | 1.98(0.72,9.04) | 0.33(‐0.14,0.72) | |
| LD RITUX IV + MTX | 3.77(0.86,21.06) | 1.90(0.95,7.79) | 0.30(‐0.03,0.59) | |
| HD ETN SC | 1.54(0.23,13.15) | 1.28(0.43,6.03) | 0.09(‐0.32,0.49) | |
| HD INF IV + MTX | 9.21(1.56,66.83) | 2.38(1.13,10.47) | 0.46(0.09,0.76) | |
| HD ADA SC + MTX | 8.35(1.68,54.98) | 2.35(1.15,10.26) | 0.45(0.10,0.74) | |
| SD RITUX IV + MTX | SD ADA SC + MTX | 0.37(0.15,0.90) | 0.79(0.51,0.98) | ‐0.17(‐0.38,‐0.02) |
| SD INF IV + MTX | 0.36(0.10,1.31) | 0.79(0.41,1.05) | ‐0.18(‐0.46,0.04) | |
| SD ANA SC + MTX | 0.28(0.10,0.73) | 0.71(0.41,0.94) | ‐0.24(‐0.46,‐0.05) | |
| LD ETN SC | 0.08(0.03,0.19) | 0.36(0.21,0.56) | ‐0.52(‐0.65,‐0.36) | |
| LD ADA SC + MTX | 0.67(0.38,1.07) | 0.93(0.77,1.01) | ‐0.06(‐0.17,0.01) | |
| LD ADA IV + MTX | 0.47(0.08,2.60) | 0.85(0.35,1.15) | ‐0.12(‐0.52,0.11) | |
| LD RITUX IV + MTX | 0.38(0.13,0.94) | 0.79(0.49,0.99) | ‐0.17(‐0.40,‐0.01) | |
| HD ETN SC | 0.15(0.04,0.60) | 0.53(0.21,0.89) | ‐0.39(‐0.65,‐0.09) | |
| HD INF IV + MTX | 0.89(0.26,3.07) | 0.98(0.70,1.21) | ‐0.02(‐0.24,0.14) | |
| HD ADA SC + MTX | 0.82(0.38,1.70) | 0.97(0.77,1.10) | ‐0.03(‐0.17,0.07) | |
| SD INF IV + MTX | SD RITUX IV + MTX | 0.96(0.28,3.76) | 0.99(0.56,1.53) | ‐0.01(‐0.28,0.26) |
| SD ANA SC + MTX | 0.74(0.27,2.13) | 0.90(0.56,1.33) | ‐0.06(‐0.29,0.16) | |
| LD ETN SC | 0.22(0.09,0.55) | 0.47(0.28,0.73) | ‐0.34(‐0.52,‐0.13) | |
| LD ADA SC + MTX | 1.79(0.74,4.31) | 1.17(0.92,1.72) | 0.11(‐0.06,0.30) | |
| LD ADA IV + MTX | 1.26(0.21,7.77) | 1.07(0.45,1.76) | 0.05(‐0.35,0.35) | |
| LD RITUX IV + MTX | 0.99(0.51,1.98) | 1.00(0.75,1.29) | 0.00(‐0.15,0.14) | |
| HD ETN SC | 0.40(0.10,1.73) | 0.67(0.28,1.24) | ‐0.21(‐0.50,0.12) | |
| HD INF IV + MTX | 2.36(0.72,8.88) | 1.23(0.91,1.91) | 0.15(‐0.06,0.38) | |
| HD ADA SC + MTX | 2.19(0.76,6.44) | 1.21(0.93,1.86) | 0.14(‐0.05,0.36) | |
| SD ANA SC + MTX | SD INF IV + MTX | 0.77(0.19,2.90) | 0.92(0.53,1.63) | ‐0.05(‐0.34,0.24) |
| LD ETN SC | 0.23(0.06,0.77) | 0.48(0.27,0.86) | ‐0.34(‐0.57,‐0.05) | |
| LD ADA SC + MTX | 1.85(0.50,6.31) | 1.18(0.86,2.17) | 0.12(‐0.11,0.39) | |
| LD ADA IV + MTX | 1.30(0.17,9.16) | 1.07(0.44,2.07) | 0.05(‐0.39,0.41) | |
| LD RITUX IV + MTX | 1.03(0.25,3.75) | 1.01(0.63,1.79) | 0.01(‐0.27,0.29) | |
| HD ETN SC | 0.41(0.07,2.16) | 0.69(0.27,1.42) | ‐0.20(‐0.54,0.17) | |
| HD INF IV + MTX | 2.46(1.05,5.75) | 1.24(1.01,2.01) | 0.16(0.01,0.36) | |
| HD ADA SC + MTX | 2.25(0.55,8.92) | 1.22(0.87,2.31) | 0.15(‐0.10,0.44) | |
| LD ETN SC | SD ANA SC + MTX | 0.30(0.11,0.78) | 0.53(0.31,0.86) | ‐0.28(‐0.48,‐0.05) |
| LD ADA SC + MTX | 2.38(0.91,6.30) | 1.30(0.98,2.18) | 0.17(‐0.02,0.39) | |
| LD ADA IV + MTX | 1.67(0.27,10.90) | 1.17(0.50,2.16) | 0.10(‐0.30,0.43) | |
| LD RITUX IV + MTX | 1.34(0.44,3.87) | 1.11(0.72,1.80) | 0.06(‐0.18,0.29) | |
| HD ETN SC | 0.54(0.13,2.43) | 0.75(0.31,1.49) | ‐0.14(‐0.45,0.20) | |
| HD INF IV + MTX | 3.16(0.88,12.20) | 1.36(0.96,2.41) | 0.21(‐0.02,0.47) | |
| HD ADA SC + MTX | 2.92(0.96,9.18) | 1.35(0.99,2.34) | 0.21(‐0.01,0.44) | |
| LD ADA SC + MTX | LD ETN SC | 7.94(3.42,18.41) | 2.52(1.67,4.23) | 0.46(0.28,0.60) |
| LD ADA IV + MTX | 5.61(0.90,33.83) | 2.23(0.93,4.23) | 0.39(‐0.02,0.65) | |
| LD RITUX IV + MTX | 4.46(1.67,11.67) | 2.12(1.33,3.56) | 0.34(0.11,0.53) | |
| HD ETN SC | 1.79(0.53,6.27) | 1.42(0.63,2.73) | 0.13(‐0.12,0.41) | |
| HD INF IV + MTX | 10.54(3.32,37.56) | 2.65(1.67,4.71) | 0.50(0.27,0.67) | |
| HD ADA SC + MTX | 9.76(3.59,27.53) | 2.62(1.70,4.54) | 0.49(0.29,0.64) | |
| LD ADA IV + MTX | LD ADA SC + MTX | 0.70(0.13,3.73) | 0.92(0.38,1.27) | ‐0.06(‐0.44,0.18) |
| LD RITUX IV + MTX | 0.56(0.21,1.44) | 0.86(0.55,1.10) | ‐0.11(‐0.32,0.07) | |
| HD ETN SC | 0.22(0.06,0.93) | 0.57(0.23,0.98) | ‐0.32(‐0.59,‐0.01) | |
| HD INF IV + MTX | 1.32(0.40,4.66) | 1.05(0.77,1.40) | 0.04(‐0.17,0.24) | |
| HD ADA SC + MTX | 1.22(0.58,2.64) | 1.04(0.86,1.27) | 0.03(‐0.10,0.16) | |
| LD RITUX IV + MTX | LD ADA IV + MTX | 0.79(0.12,5.12) | 0.94(0.55,2.21) | ‐0.05(‐0.36,0.36) |
| HD ETN SC | 0.32(0.04,2.57) | 0.65(0.25,1.65) | ‐0.24(‐0.61,0.21) | |
| HD INF IV + MTX | 1.92(0.27,14.27) | 1.14(0.77,2.87) | 0.10(‐0.19,0.52) | |
| HD ADA SC + MTX | 1.75(0.28,10.64) | 1.13(0.79,2.77) | 0.09(‐0.18,0.49) | |
| HD ETN SC | LD RITUX IV + MTX | 0.40(0.10,1.79) | 0.68(0.28,1.27) | ‐0.21(‐0.50,0.13) |
| HD INF IV + MTX | 2.36(0.69,9.30) | 1.23(0.90,2.00) | 0.15(‐0.07,0.40) | |
| HD ADA SC + MTX | 2.19(0.72,6.90) | 1.21(0.92,1.95) | 0.14(‐0.06,0.37) | |
| HD INF IV + MTX | HD ETN SC | 5.95(1.14,31.00) | 1.83(1.04,4.69) | 0.36(0.03,0.66) |
| HD ADA SC + MTX | 5.45(1.21,24.49) | 1.82(1.05,4.56) | 0.35(0.04,0.63) | |
| HD ADA SC + MTX | HD INF IV + MTX | 0.92(0.23,3.55) | 0.99(0.73,1.38) | ‐0.01(‐0.22,0.22) |
| Random‐effects model | Residual deviance | 31.33 vs 33 data points | ||
| Deviance information criteria | 198.481 | |||
| Fixed‐effect model | Residual deviance | 32.58 vs 33 data points | ||
| Deviance information criteria | 198.437 | |||
| Note | ||||
| Total participants | 3481 | |||
| Total Studies | 12 | |||
| 2‐arm | 4 | |||
| 3‐arm | 7 | |||
| 4‐arm | 1 | |||
Appendix 5. ACR50: subgroup ‐ trial duration (<= 6 months)
| ACR50 short: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX | PL | 2.55(1.22,5.33) | 2.33(1.21,4.30) | 0.08(0.01,0.19) |
| DMARD + PL | 2.23(0.35,15.88) | 2.07(0.37,8.76) | 0.07(‐0.04,0.43) | |
| MTX + DMARD | 4.87(1.89,13.63) | 3.93(1.80,7.95) | 0.18(0.05,0.40) | |
| SD ETN SC | 7.47(3.69,15.72) | 5.33(3.13,8.70) | 0.27(0.13,0.43) | |
| SD ADA SC | 3.51(2.03,6.27) | 3.04(1.90,4.88) | 0.13(0.06,0.22) | |
| SD TOFA PO | 6.49(3.24,13.34) | 4.84(2.82,7.90) | 0.24(0.12,0.40) | |
| SD GOLI SC | 6.87(2.62,18.68) | 5.04(2.37,9.33) | 0.25(0.09,0.48) | |
| SD GOLI IV | 4.85(1.73,13.91) | 3.92(1.65,7.98) | 0.18(0.04,0.41) | |
| SD TOCI IV | 4.06(1.65,10.59) | 3.42(1.58,6.88) | 0.15(0.04,0.33) | |
| SD ABA SC | 9.70(2.55,42.23) | 6.30(2.33,12.94) | 0.33(0.08,0.66) | |
| SD CERTO SC | 9.56(3.10,31.95) | 6.25(2.73,11.67) | 0.32(0.11,0.61) | |
| SD ETN SC + MTX | 13.71(6.17,32.64) | 7.65(4.60,12.03) | 0.41(0.23,0.61) | |
| SD ABA IV + MTX | 9.91(4.17,23.64) | 6.38(3.46,10.53) | 0.33(0.16,0.54) | |
| SD CERTO SC + MTX | 14.70(6.35,35.45) | 7.94(4.70,12.27) | 0.43(0.24,0.63) | |
| SD INF IV + MTX | 8.50(3.54,20.49) | 5.80(3.03,9.91) | 0.30(0.13,0.50) | |
| SD ADA SC + MTX | 18.53(6.63,55.31) | 8.89(4.84,13.93) | 0.48(0.25,0.71) | |
| SD TOFA PO + MTX | 17.33(6.20,45.92) | 8.60(4.64,13.30) | 0.47(0.23,0.68) | |
| SD GOLI SC + MTX | 17.44(6.73,46.14) | 8.63(4.89,13.52) | 0.47(0.25,0.68) | |
| SD RITUX IV + MTX | 9.11(3.28,25.67) | 6.05(2.84,10.82) | 0.31(0.12,0.55) | |
| SD GOLI IV + MTX | 6.25(2.39,16.37) | 4.72(2.18,8.78) | 0.23(0.07,0.44) | |
| SD ANA SC + MTX | 7.55(2.54,21.72) | 5.37(2.32,10.03) | 0.27(0.08,0.51) | |
| SD ABA SC + MTX | 10.68(3.19,35.56) | 6.67(2.80,12.04) | 0.35(0.11,0.63) | |
| SD TOCI IV + MTX | 5.36(1.74,17.50) | 4.23(1.66,9.07) | 0.20(0.04,0.46) | |
| SD CERTO SC + DMARD | 8.22(2.18,37.10) | 5.67(2.02,12.39) | 0.29(0.07,0.63) | |
| SD ADA SC + DMARD | 7.12(0.90,64.70) | 5.16(0.91,14.25) | 0.26(‐0.01,0.74) | |
| SD TOCI SC + DMARD | 11.64(1.44,99.75) | 6.98(1.40,15.58) | 0.37(0.03,0.80) | |
| LD ADA SC | 3.30(1.50,7.54) | 2.89(1.45,5.55) | 0.12(0.03,0.26) | |
| LD ETN SC | 4.15(1.36,12.15) | 3.49(1.33,7.44) | 0.15(0.02,0.38) | |
| LD GOLI IV | 2.89(0.87,9.18) | 2.59(0.87,6.21) | 0.10(‐0.01,0.31) | |
| LD TOCI IV | 0.51(0.08,2.31) | 0.52(0.09,2.15) | ‐0.03(‐0.06,0.07) | |
| LD ADA SC + MTX | 10.23(3.07,34.66) | 6.52(2.71,12.01) | 0.34(0.11,0.62) | |
| LD RITUX IV + MTX | 8.96(3.27,25.59) | 6.00(2.83,10.74) | 0.31(0.12,0.55) | |
| LD ADA IV + MTX | 9.05(1.24,57.71) | 6.05(1.23,13.65) | 0.31(0.01,0.72) | |
| LD ABA IV + MTX | 5.37(2.01,14.58) | 4.21(1.89,8.23) | 0.20(0.06,0.41) | |
| LD ANA SC + MTX | 5.03(0.99,23.55) | 4.03(0.99,10.23) | 0.19(0.00,0.54) | |
| LD CERTO SC + MTX | 10.48(3.40,34.48) | 6.62(2.93,12.00) | 0.35(0.12,0.63) | |
| LD GOLI IV + MTX | 5.57(1.76,17.07) | 4.33(1.67,8.93) | 0.20(0.04,0.46) | |
| LD TOCI IV + MTX | 4.58(1.48,14.58) | 3.74(1.44,8.24) | 0.17(0.03,0.41) | |
| LD TOFA PO + MTX | 7.70(1.88,30.51) | 5.44(1.78,11.31) | 0.27(0.05,0.60) | |
| HD TOCI IV | 7.18(3.51,15.04) | 5.19(3.00,8.55) | 0.26(0.13,0.42) | |
| HD TOFA PO | 10.26(5.29,21.10) | 6.53(4.10,9.99) | 0.34(0.20,0.51) | |
| HD ADA SC | 4.74(2.21,10.66) | 3.85(2.05,6.91) | 0.17(0.07,0.34) | |
| HD GOLI SC | 7.91(3.29,18.94) | 5.53(2.85,9.48) | 0.28(0.12,0.48) | |
| HD ETN SC | 7.29(1.60,31.99) | 5.25(1.54,11.43) | 0.26(0.03,0.61) | |
| HD ABA SC | 13.97(3.81,59.84) | 7.75(3.21,14.13) | 0.42(0.14,0.73) | |
| HD TOCI IV + MTX | 12.46(5.56,29.67) | 7.28(4.26,11.67) | 0.39(0.21,0.58) | |
| HD INF IV + MTX | 11.45(4.40,31.21) | 6.95(3.60,11.69) | 0.37(0.17,0.60) | |
| HD TOFA PO + MTX | 9.77(3.55,25.79) | 6.33(3.05,10.91) | 0.33(0.13,0.56) | |
| HD GOLI SC + MTX | 13.39(5.17,35.25) | 7.57(4.09,12.40) | 0.40(0.19,0.63) | |
| HD CERTO SC + MTX | 17.57(7.13,44.53) | 8.69(5.06,13.19) | 0.47(0.26,0.68) | |
| HD ADA SC + MTX | 14.67(4.28,54.00) | 7.94(3.51,13.68) | 0.43(0.16,0.71) | |
| HD TOCI IV + DMARD | 8.38(1.22,68.40) | 5.74(1.20,14.29) | 0.29(0.01,0.75) | |
| SD ANA SC + SD ETN SC + MTX | 8.79(2.43,33.12) | 5.93(2.23,11.66) | 0.30(0.08,0.62) | |
| SD ANA SC + LD ETN SC + MTX | 12.92(3.62,49.50) | 7.40(3.12,13.21) | 0.39(0.13,0.70) | |
| DMARD + PL | MTX | 0.89(0.13,6.94) | 0.91(0.15,4.20) | ‐0.01(‐0.17,0.36) |
| MTX + DMARD | 1.90(0.80,4.89) | 1.67(0.82,3.39) | 0.10(‐0.03,0.29) | |
| SD ETN SC | 2.90(1.34,6.71) | 2.26(1.25,4.32) | 0.18(0.05,0.34) | |
| SD ADA SC | 1.36(0.65,3.06) | 1.30(0.70,2.60) | 0.04(‐0.07,0.15) | |
| SD TOFA PO | 2.51(0.96,6.87) | 2.05(0.97,4.54) | 0.15(‐0.01,0.32) | |
| SD GOLI SC | 2.67(1.03,6.99) | 2.14(1.03,4.20) | 0.16(0.00,0.37) | |
| SD GOLI IV | 1.90(0.80,4.49) | 1.68(0.83,3.13) | 0.09(‐0.03,0.29) | |
| SD TOCI IV | 1.59(0.71,3.59) | 1.47(0.75,2.75) | 0.06(‐0.04,0.22) | |
| SD ABA SC | 3.84(0.84,19.22) | 2.70(0.86,6.84) | 0.24(‐0.03,0.59) | |
| SD CERTO SC | 3.76(0.93,15.37) | 2.67(0.95,6.49) | 0.24(‐0.01,0.54) | |
| SD ETN SC + MTX | 5.35(2.71,11.94) | 3.24(2.05,5.68) | 0.32(0.17,0.50) | |
| SD ABA IV + MTX | 3.88(2.45,6.23) | 2.71(1.97,3.80) | 0.25(0.13,0.38) | |
| SD CERTO SC + MTX | 5.77(3.65,9.24) | 3.37(2.45,4.79) | 0.34(0.21,0.48) | |
| SD INF IV + MTX | 3.32(2.03,5.43) | 2.46(1.73,3.49) | 0.21(0.10,0.35) | |
| SD ADA SC + MTX | 7.23(3.37,16.26) | 3.72(2.39,6.02) | 0.40(0.20,0.58) | |
| SD TOFA PO + MTX | 6.75(3.33,13.51) | 3.62(2.36,5.62) | 0.38(0.19,0.55) | |
| SD GOLI SC + MTX | 6.80(3.52,13.59) | 3.65(2.41,5.68) | 0.39(0.21,0.55) | |
| SD RITUX IV + MTX | 3.55(1.76,7.28) | 2.56(1.57,4.06) | 0.23(0.07,0.42) | |
| SD GOLI IV + MTX | 2.43(1.24,4.79) | 2.00(1.20,3.22) | 0.14(0.03,0.31) | |
| SD ANA SC + MTX | 2.90(1.32,6.64) | 2.25(1.26,3.85) | 0.18(0.03,0.39) | |
| SD ABA SC + MTX | 4.14(1.60,10.51) | 2.81(1.46,4.80) | 0.26(0.06,0.50) | |
| SD TOCI IV + MTX | 2.12(0.79,5.62) | 1.81(0.82,3.51) | 0.11(‐0.03,0.34) | |
| SD CERTO SC + DMARD | 3.26(0.72,17.46) | 2.43(0.76,6.58) | 0.20(‐0.04,0.56) | |
| SD ADA SC + DMARD | 2.78(0.33,28.96) | 2.19(0.37,7.38) | 0.17(‐0.11,0.67) | |
| SD TOCI SC + DMARD | 4.59(0.50,43.80) | 2.96(0.56,8.33) | 0.29(‐0.07,0.73) | |
| LD ADA SC | 1.29(0.47,3.56) | 1.24(0.53,2.86) | 0.03(‐0.10,0.19) | |
| LD ETN SC | 1.62(0.48,5.30) | 1.49(0.53,3.67) | 0.07(‐0.09,0.29) | |
| LD GOLI IV | 1.13(0.42,2.93) | 1.11(0.46,2.31) | 0.01(‐0.09,0.18) | |
| LD TOCI IV | 0.20(0.04,0.78) | 0.23(0.04,0.80) | ‐0.11(‐0.20,‐0.03) | |
| LD ADA SC + MTX | 3.94(1.54,11.17) | 2.72(1.42,4.93) | 0.25(0.06,0.50) | |
| LD RITUX IV + MTX | 3.50(1.73,7.27) | 2.53(1.55,3.99) | 0.22(0.07,0.42) | |
| LD ADA IV + MTX | 3.51(0.58,20.32) | 2.53(0.62,6.00) | 0.22(‐0.05,0.62) | |
| LD ABA IV + MTX | 2.09(1.08,4.13) | 1.79(1.06,2.91) | 0.11(0.01,0.28) | |
| LD ANA SC + MTX | 1.95(0.46,7.82) | 1.70(0.50,4.07) | 0.10(‐0.07,0.42) | |
| LD CERTO SC + MTX | 4.09(1.68,10.25) | 2.79(1.52,4.80) | 0.26(0.07,0.49) | |
| LD GOLI IV + MTX | 2.17(0.85,5.42) | 1.84(0.88,3.45) | 0.12(‐0.02,0.33) | |
| LD TOCI IV + MTX | 1.79(0.69,4.69) | 1.60(0.73,3.17) | 0.09(‐0.04,0.29) | |
| LD TOFA PO + MTX | 2.99(0.90,9.84) | 2.30(0.91,4.62) | 0.19(‐0.01,0.48) | |
| HD TOCI IV | 2.79(1.68,4.85) | 2.21(1.48,3.48) | 0.17(0.08,0.29) | |
| HD TOFA PO | 4.00(1.56,10.84) | 2.77(1.39,5.90) | 0.26(0.08,0.44) | |
| HD ADA SC | 1.85(0.69,5.13) | 1.65(0.73,3.71) | 0.09(‐0.06,0.27) | |
| HD GOLI SC | 3.07(1.46,6.49) | 2.34(1.35,4.05) | 0.19(0.06,0.36) | |
| HD ETN SC | 2.86(0.63,12.73) | 2.22(0.68,5.46) | 0.18(‐0.05,0.52) | |
| HD ABA SC | 5.45(1.22,27.20) | 3.29(1.16,7.69) | 0.33(0.03,0.66) | |
| HD TOCI IV + MTX | 4.87(2.87,8.65) | 3.08(2.13,4.75) | 0.30(0.17,0.45) | |
| HD INF IV + MTX | 4.46(2.35,8.54) | 2.92(1.93,4.47) | 0.28(0.13,0.45) | |
| HD TOFA PO + MTX | 3.81(1.87,7.74) | 2.67(1.64,4.23) | 0.24(0.09,0.43) | |
| HD GOLI SC + MTX | 5.23(2.66,10.42) | 3.19(2.07,5.05) | 0.32(0.15,0.50) | |
| HD CERTO SC + MTX | 6.85(3.97,12.00) | 3.66(2.58,5.37) | 0.39(0.23,0.53) | |
| HD ADA SC + MTX | 5.71(2.09,16.60) | 3.32(1.79,5.83) | 0.34(0.11,0.59) | |
| HD TOCI IV + DMARD | 3.33(0.43,29.84) | 2.47(0.49,7.72) | 0.21(‐0.09,0.67) | |
| SD ANA SC + SD ETN SC + MTX | 3.39(1.00,12.78) | 2.49(1.00,5.38) | 0.22(0.00,0.52) | |
| SD ANA SC + LD ETN SC + MTX | 5.03(1.51,18.48) | 3.12(1.38,6.26) | 0.31(0.06,0.60) | |
| MTX + DMARD | DMARD + PL | 2.13(0.26,17.12) | 1.84(0.39,11.46) | 0.10(‐0.27,0.36) |
| SD ETN SC | 3.28(0.42,22.89) | 2.51(0.57,14.53) | 0.19(‐0.20,0.40) | |
| SD ADA SC | 1.54(0.21,10.73) | 1.44(0.34,8.66) | 0.05(‐0.31,0.21) | |
| SD TOFA PO | 2.84(0.38,20.69) | 2.29(0.53,13.86) | 0.16(‐0.21,0.38) | |
| SD GOLI SC | 3.00(0.36,23.68) | 2.35(0.50,14.38) | 0.17(‐0.22,0.44) | |
| SD GOLI IV | 2.13(0.24,17.08) | 1.84(0.36,11.35) | 0.10(‐0.28,0.36) | |
| SD TOCI IV | 1.78(0.21,13.15) | 1.61(0.33,9.66) | 0.07(‐0.30,0.30) | |
| SD ABA SC | 4.23(0.45,41.99) | 2.89(0.58,18.44) | 0.24(‐0.16,0.61) | |
| SD CERTO SC | 4.23(0.46,37.08) | 2.93(0.61,18.40) | 0.24(‐0.16,0.57) | |
| SD ETN SC + MTX | 6.03(0.81,44.15) | 3.61(0.88,20.24) | 0.33(‐0.05,0.58) | |
| SD ABA IV + MTX | 4.31(0.52,33.57) | 2.98(0.67,17.79) | 0.25(‐0.14,0.51) | |
| SD CERTO SC + MTX | 6.38(0.78,49.00) | 3.72(0.87,21.82) | 0.35(‐0.06,0.60) | |
| SD INF IV + MTX | 3.73(0.47,27.63) | 2.72(0.62,15.81) | 0.22(‐0.17,0.47) | |
| SD ADA SC + MTX | 8.00(0.89,72.65) | 4.14(0.94,25.18) | 0.39(‐0.03,0.69) | |
| SD TOFA PO + MTX | 7.62(0.84,60.65) | 4.01(0.90,23.12) | 0.38(‐0.04,0.65) | |
| SD GOLI SC + MTX | 7.62(0.87,62.09) | 4.02(0.93,23.87) | 0.39(‐0.03,0.65) | |
| SD RITUX IV + MTX | 4.04(0.43,31.73) | 2.86(0.58,16.82) | 0.23(‐0.18,0.51) | |
| SD GOLI IV + MTX | 2.72(0.32,21.26) | 2.21(0.47,13.52) | 0.15(‐0.23,0.41) | |
| SD ANA SC + MTX | 3.24(0.36,26.83) | 2.47(0.50,15.15) | 0.18(‐0.21,0.48) | |
| SD ABA SC + MTX | 4.59(0.48,41.94) | 3.06(0.63,19.18) | 0.26(‐0.15,0.59) | |
| SD TOCI IV + MTX | 2.37(0.25,20.03) | 2.00(0.37,12.81) | 0.12(‐0.27,0.41) | |
| SD CERTO SC + DMARD | 3.61(1.08,13.20) | 2.60(1.04,8.93) | 0.20(0.01,0.42) | |
| SD ADA SC + DMARD | 3.16(1.27,8.05) | 2.30(1.21,4.97) | 0.18(0.02,0.43) | |
| SD TOCI SC + DMARD | 5.09(2.01,12.61) | 3.06(1.52,6.63) | 0.28(0.05,0.52) | |
| LD ADA SC | 1.43(0.19,11.26) | 1.36(0.30,8.78) | 0.04(‐0.32,0.24) | |
| LD ETN SC | 1.79(0.20,15.67) | 1.61(0.31,10.96) | 0.07(‐0.30,0.34) | |
| LD GOLI IV | 1.26(0.13,10.61) | 1.22(0.21,8.05) | 0.03(‐0.34,0.27) | |
| LD TOCI IV | 0.22(0.02,2.29) | 0.25(0.03,2.19) | ‐0.09(‐0.46,0.05) | |
| LD ADA SC + MTX | 4.42(0.47,43.81) | 2.98(0.62,19.68) | 0.25(‐0.16,0.58) | |
| LD RITUX IV + MTX | 3.96(0.44,31.31) | 2.81(0.59,16.79) | 0.23(‐0.18,0.51) | |
| LD ADA IV + MTX | 3.88(0.28,53.46) | 2.70(0.38,19.90) | 0.21(‐0.22,0.68) | |
| LD ABA IV + MTX | 2.30(0.27,18.75) | 1.95(0.40,12.17) | 0.12(‐0.27,0.38) | |
| LD ANA SC + MTX | 2.17(0.18,24.21) | 1.85(0.27,13.25) | 0.10(‐0.29,0.49) | |
| LD CERTO SC + MTX | 4.55(0.52,41.05) | 3.04(0.66,19.40) | 0.26(‐0.14,0.58) | |
| LD GOLI IV + MTX | 2.45(0.27,20.29) | 2.03(0.39,12.75) | 0.13(‐0.26,0.42) | |
| LD TOCI IV + MTX | 2.00(0.22,16.94) | 1.76(0.33,11.51) | 0.09(‐0.29,0.37) | |
| LD TOFA PO + MTX | 3.32(0.29,32.80) | 2.49(0.42,16.29) | 0.19(‐0.24,0.55) | |
| HD TOCI IV | 3.16(0.40,23.05) | 2.45(0.56,14.82) | 0.18(‐0.20,0.39) | |
| HD TOFA PO | 4.62(0.60,33.78) | 3.11(0.73,18.54) | 0.26(‐0.12,0.48) | |
| HD ADA SC | 2.07(0.27,15.63) | 1.80(0.41,11.40) | 0.10(‐0.27,0.32) | |
| HD GOLI SC | 3.49(0.40,25.46) | 2.62(0.56,15.44) | 0.20(‐0.20,0.45) | |
| HD ETN SC | 3.18(0.27,31.90) | 2.43(0.39,15.19) | 0.17(‐0.24,0.56) | |
| HD ABA SC | 6.06(0.64,63.98) | 3.54(0.76,22.23) | 0.32(‐0.10,0.68) | |
| HD TOCI IV + MTX | 5.44(0.69,41.42) | 3.41(0.80,19.88) | 0.31(‐0.09,0.56) | |
| HD INF IV + MTX | 5.01(0.60,39.15) | 3.23(0.73,18.73) | 0.28(‐0.12,0.56) | |
| HD TOFA PO + MTX | 4.32(0.49,35.01) | 2.97(0.63,17.59) | 0.25(‐0.16,0.52) | |
| HD GOLI SC + MTX | 5.91(0.68,48.66) | 3.54(0.80,21.87) | 0.32(‐0.09,0.60) | |
| HD CERTO SC + MTX | 7.64(0.93,59.67) | 4.05(0.96,23.39) | 0.39(‐0.02,0.65) | |
| HD ADA SC + MTX | 6.24(0.67,64.15) | 3.63(0.77,23.11) | 0.33(‐0.09,0.68) | |
| HD TOCI IV + DMARD | 3.73(1.99,7.03) | 2.60(1.49,4.71) | 0.22(0.05,0.41) | |
| SD ANA SC + SD ETN SC + MTX | 3.76(0.41,35.98) | 2.69(0.54,16.75) | 0.21(‐0.18,0.58) | |
| SD ANA SC + LD ETN SC + MTX | 5.60(0.62,54.38) | 3.38(0.75,20.57) | 0.31(‐0.10,0.65) | |
| SD ETN SC | MTX + DMARD | 1.54(0.64,3.39) | 1.36(0.75,2.52) | 0.08(‐0.10,0.23) |
| SD ADA SC | 0.72(0.24,2.02) | 0.77(0.36,1.79) | ‐0.05(‐0.28,0.10) | |
| SD TOFA PO | 1.33(0.40,4.19) | 1.23(0.53,2.97) | 0.05(‐0.19,0.26) | |
| SD GOLI SC | 1.40(0.40,4.68) | 1.27(0.52,3.04) | 0.07(‐0.18,0.31) | |
| SD GOLI IV | 1.00(0.28,3.27) | 1.00(0.37,2.43) | 0.00(‐0.23,0.23) | |
| SD TOCI IV | 0.83(0.25,2.62) | 0.87(0.35,2.11) | ‐0.03(‐0.25,0.17) | |
| SD ABA SC | 1.99(0.38,11.67) | 1.59(0.49,4.61) | 0.14(‐0.19,0.52) | |
| SD CERTO SC | 1.96(0.42,9.09) | 1.57(0.53,4.20) | 0.14(‐0.18,0.46) | |
| SD ETN SC + MTX | 2.82(1.66,4.83) | 1.94(1.31,3.11) | 0.22(0.11,0.34) | |
| SD ABA IV + MTX | 2.04(0.72,5.40) | 1.62(0.81,3.34) | 0.15(‐0.07,0.35) | |
| SD CERTO SC + MTX | 3.04(1.08,8.19) | 2.01(1.05,4.16) | 0.24(0.02,0.44) | |
| SD INF IV + MTX | 1.75(0.62,4.68) | 1.47(0.72,3.08) | 0.11(‐0.11,0.31) | |
| SD ADA SC + MTX | 3.82(1.14,12.55) | 2.23(1.08,4.82) | 0.30(0.03,0.54) | |
| SD TOFA PO + MTX | 3.55(1.10,10.34) | 2.15(1.06,4.52) | 0.28(0.02,0.50) | |
| SD GOLI SC + MTX | 3.59(1.14,10.56) | 2.17(1.08,4.56) | 0.28(0.03,0.51) | |
| SD RITUX IV + MTX | 1.87(0.58,5.74) | 1.53(0.68,3.32) | 0.13(‐0.11,0.37) | |
| SD GOLI IV + MTX | 1.29(0.39,3.85) | 1.20(0.51,2.69) | 0.05(‐0.19,0.26) | |
| SD ANA SC + MTX | 1.53(0.43,5.13) | 1.35(0.54,3.16) | 0.08(‐0.16,0.33) | |
| SD ABA SC + MTX | 2.18(0.58,7.72) | 1.67(0.68,3.80) | 0.16(‐0.11,0.44) | |
| SD TOCI IV + MTX | 1.11(0.29,4.07) | 1.08(0.39,2.74) | 0.02(‐0.22,0.28) | |
| SD CERTO SC + DMARD | 1.68(0.32,9.50) | 1.44(0.43,4.18) | 0.10(‐0.21,0.48) | |
| SD ADA SC + DMARD | 1.46(0.15,14.94) | 1.31(0.22,4.59) | 0.07(‐0.28,0.57) | |
| SD TOCI SC + DMARD | 2.40(0.23,23.89) | 1.76(0.32,5.23) | 0.18(‐0.23,0.65) | |
| LD ADA SC | 0.67(0.20,2.36) | 0.73(0.29,2.01) | ‐0.06(‐0.30,0.14) | |
| LD ETN SC | 0.85(0.23,2.95) | 0.88(0.31,2.26) | ‐0.03(‐0.26,0.20) | |
| LD GOLI IV | 0.59(0.15,2.15) | 0.66(0.21,1.80) | ‐0.08(‐0.30,0.13) | |
| LD TOCI IV | 0.10(0.02,0.51) | 0.13(0.02,0.57) | ‐0.20(‐0.42,‐0.06) | |
| LD ADA SC + MTX | 2.08(0.56,7.92) | 1.63(0.67,3.84) | 0.15(‐0.11,0.44) | |
| LD RITUX IV + MTX | 1.83(0.57,5.64) | 1.51(0.68,3.33) | 0.12(‐0.11,0.36) | |
| LD ADA IV + MTX | 1.83(0.24,12.73) | 1.50(0.31,4.34) | 0.12(‐0.22,0.54) | |
| LD ABA IV + MTX | 1.10(0.35,3.33) | 1.07(0.46,2.42) | 0.02(‐0.20,0.23) | |
| LD ANA SC + MTX | 1.02(0.17,5.31) | 1.02(0.24,3.09) | 0.00(‐0.27,0.36) | |
| LD CERTO SC + MTX | 2.14(0.60,7.60) | 1.66(0.70,3.79) | 0.16(‐0.10,0.43) | |
| LD GOLI IV + MTX | 1.15(0.29,3.90) | 1.11(0.39,2.69) | 0.02(‐0.22,0.27) | |
| LD TOCI IV + MTX | 0.93(0.24,3.37) | 0.95(0.33,2.44) | ‐0.01(‐0.25,0.23) | |
| LD TOFA PO + MTX | 1.57(0.33,6.88) | 1.36(0.43,3.49) | 0.09(‐0.19,0.42) | |
| HD TOCI IV | 1.48(0.54,3.99) | 1.32(0.66,2.87) | 0.08(‐0.13,0.25) | |
| HD TOFA PO | 2.12(0.64,6.62) | 1.66(0.75,3.86) | 0.16(‐0.10,0.38) | |
| HD ADA SC | 0.96(0.28,3.27) | 0.97(0.40,2.51) | ‐0.01(‐0.25,0.21) | |
| HD GOLI SC | 1.62(0.51,4.77) | 1.40(0.63,3.11) | 0.10(‐0.14,0.31) | |
| HD ETN SC | 1.49(0.31,6.49) | 1.32(0.39,3.28) | 0.08(‐0.19,0.41) | |
| HD ABA SC | 2.87(0.53,16.08) | 1.94(0.65,5.25) | 0.23(‐0.13,0.58) | |
| HD TOCI IV + MTX | 2.56(0.88,7.15) | 1.84(0.93,3.90) | 0.20(‐0.03,0.41) | |
| HD INF IV + MTX | 2.35(0.76,7.02) | 1.75(0.84,3.79) | 0.18(‐0.06,0.41) | |
| HD TOFA PO + MTX | 2.00(0.62,6.01) | 1.60(0.72,3.48) | 0.14(‐0.10,0.37) | |
| HD GOLI SC + MTX | 2.76(0.86,8.32) | 1.92(0.91,4.03) | 0.22(‐0.03,0.45) | |
| HD CERTO SC + MTX | 3.60(1.23,10.18) | 2.17(1.13,4.55) | 0.28(0.05,0.49) | |
| HD ADA SC + MTX | 3.03(0.76,11.72) | 2.00(0.82,4.54) | 0.24(‐0.06,0.53) | |
| HD TOCI IV + DMARD | 1.76(0.20,15.95) | 1.47(0.28,4.71) | 0.11(‐0.25,0.58) | |
| SD ANA SC + SD ETN SC + MTX | 1.79(0.56,5.67) | 1.48(0.64,3.06) | 0.11(‐0.10,0.39) | |
| SD ANA SC + LD ETN SC + MTX | 2.65(0.86,8.33) | 1.85(0.90,3.65) | 0.21(‐0.03,0.46) | |
| SD ADA SC | SD ETN SC | 0.47(0.19,1.12) | 0.57(0.31,1.09) | ‐0.14(‐0.32,0.02) |
| SD TOFA PO | 0.87(0.31,2.38) | 0.91(0.45,1.82) | ‐0.03(‐0.25,0.18) | |
| SD GOLI SC | 0.92(0.30,2.85) | 0.95(0.42,1.95) | ‐0.02(‐0.25,0.23) | |
| SD GOLI IV | 0.65(0.21,2.02) | 0.74(0.30,1.59) | ‐0.08(‐0.29,0.15) | |
| SD TOCI IV | 0.55(0.19,1.60) | 0.64(0.29,1.39) | ‐0.12(‐0.31,0.09) | |
| SD ABA SC | 1.31(0.29,6.76) | 1.18(0.41,2.80) | 0.06(‐0.25,0.44) | |
| SD CERTO SC | 1.29(0.33,5.22) | 1.17(0.46,2.57) | 0.06(‐0.22,0.38) | |
| SD ETN SC + MTX | 1.85(1.00,3.56) | 1.43(1.00,2.12) | 0.14(0.00,0.30) | |
| SD ABA IV + MTX | 1.33(0.52,3.31) | 1.20(0.65,2.11) | 0.06(‐0.14,0.27) | |
| SD CERTO SC + MTX | 1.99(0.77,4.98) | 1.49(0.85,2.55) | 0.16(‐0.06,0.37) | |
| SD INF IV + MTX | 1.15(0.43,2.84) | 1.09(0.57,1.93) | 0.03(‐0.18,0.24) | |
| SD ADA SC + MTX | 2.50(0.82,7.64) | 1.65(0.89,2.96) | 0.22(‐0.05,0.46) | |
| SD TOFA PO + MTX | 2.34(0.78,6.42) | 1.61(0.86,2.83) | 0.20(‐0.06,0.43) | |
| SD GOLI SC + MTX | 2.34(0.85,6.53) | 1.61(0.91,2.83) | 0.20(‐0.04,0.43) | |
| SD RITUX IV + MTX | 1.21(0.42,3.54) | 1.13(0.54,2.15) | 0.04(‐0.18,0.29) | |
| SD GOLI IV + MTX | 0.84(0.29,2.25) | 0.89(0.40,1.70) | ‐0.04(‐0.25,0.18) | |
| SD ANA SC + MTX | 1.00(0.31,3.17) | 1.00(0.43,2.06) | 0.00(‐0.23,0.26) | |
| SD ABA SC + MTX | 1.42(0.41,4.78) | 1.25(0.53,2.42) | 0.08(‐0.18,0.36) | |
| SD TOCI IV + MTX | 0.72(0.21,2.46) | 0.80(0.31,1.77) | ‐0.07(‐0.29,0.20) | |
| SD CERTO SC + DMARD | 1.09(0.25,5.83) | 1.06(0.36,2.67) | 0.02(‐0.26,0.40) | |
| SD ADA SC + DMARD | 0.95(0.11,9.39) | 0.97(0.17,2.97) | ‐0.01(‐0.33,0.49) | |
| SD TOCI SC + DMARD | 1.58(0.17,14.63) | 1.32(0.25,3.31) | 0.10(‐0.29,0.56) | |
| LD ADA SC | 0.44(0.15,1.29) | 0.54(0.24,1.21) | ‐0.15(‐0.34,0.05) | |
| LD ETN SC | 0.55(0.20,1.50) | 0.65(0.28,1.31) | ‐0.11(‐0.28,0.09) | |
| LD GOLI IV | 0.38(0.11,1.32) | 0.49(0.16,1.21) | ‐0.16(‐0.35,0.06) | |
| LD TOCI IV | 0.07(0.01,0.31) | 0.10(0.02,0.39) | ‐0.29(‐0.46,‐0.14) | |
| LD ADA SC + MTX | 1.35(0.39,4.98) | 1.20(0.52,2.49) | 0.07(‐0.19,0.37) | |
| LD RITUX IV + MTX | 1.20(0.40,3.48) | 1.12(0.53,2.12) | 0.04(‐0.19,0.29) | |
| LD ADA IV + MTX | 1.19(0.16,8.17) | 1.12(0.24,2.83) | 0.04(‐0.29,0.47) | |
| LD ABA IV + MTX | 0.72(0.25,2.02) | 0.80(0.36,1.59) | ‐0.06(‐0.27,0.15) | |
| LD ANA SC + MTX | 0.67(0.12,3.35) | 0.75(0.18,2.06) | ‐0.08(‐0.33,0.28) | |
| LD CERTO SC + MTX | 1.41(0.42,4.72) | 1.24(0.55,2.41) | 0.08(‐0.18,0.36) | |
| LD GOLI IV + MTX | 0.75(0.21,2.45) | 0.82(0.31,1.77) | ‐0.06(‐0.28,0.20) | |
| LD TOCI IV + MTX | 0.61(0.18,2.03) | 0.70(0.27,1.61) | ‐0.09(‐0.31,0.15) | |
| LD TOFA PO + MTX | 1.02(0.24,4.31) | 1.01(0.34,2.29) | 0.00(‐0.25,0.34) | |
| HD TOCI IV | 0.97(0.39,2.30) | 0.98(0.54,1.75) | ‐0.01(‐0.20,0.18) | |
| HD TOFA PO | 1.38(0.50,3.78) | 1.22(0.65,2.34) | 0.07(‐0.16,0.30) | |
| HD ADA SC | 0.63(0.23,1.84) | 0.72(0.34,1.55) | ‐0.09(‐0.30,0.13) | |
| HD GOLI SC | 1.06(0.39,2.86) | 1.04(0.52,1.97) | 0.01(‐0.20,0.24) | |
| HD ETN SC | 0.97(0.27,3.52) | 0.98(0.35,1.97) | ‐0.01(‐0.22,0.29) | |
| HD ABA SC | 1.86(0.41,9.56) | 1.44(0.54,3.12) | 0.15(‐0.19,0.50) | |
| HD TOCI IV + MTX | 1.69(0.64,4.20) | 1.37(0.76,2.40) | 0.12(‐0.10,0.33) | |
| HD INF IV + MTX | 1.54(0.53,4.27) | 1.30(0.67,2.34) | 0.10(‐0.14,0.33) | |
| HD TOFA PO + MTX | 1.31(0.44,3.69) | 1.18(0.57,2.20) | 0.06(‐0.17,0.30) | |
| HD GOLI SC + MTX | 1.80(0.65,5.05) | 1.42(0.75,2.55) | 0.14(‐0.10,0.37) | |
| HD CERTO SC + MTX | 2.36(0.89,6.34) | 1.62(0.93,2.81) | 0.20(‐0.03,0.42) | |
| HD ADA SC + MTX | 1.96(0.53,7.54) | 1.48(0.65,2.85) | 0.16(‐0.13,0.46) | |
| HD TOCI IV + DMARD | 1.15(0.15,9.90) | 1.09(0.22,3.02) | 0.03(‐0.31,0.51) | |
| SD ANA SC + SD ETN SC + MTX | 1.17(0.37,3.97) | 1.10(0.47,2.14) | 0.03(‐0.19,0.32) | |
| SD ANA SC + LD ETN SC + MTX | 1.71(0.54,5.87) | 1.37(0.65,2.47) | 0.12(‐0.12,0.41) | |
| SD TOFA PO | SD ADA SC | 1.83(0.84,4.08) | 1.58(0.87,2.81) | 0.11(‐0.03,0.27) |
| SD GOLI SC | 1.95(0.68,5.74) | 1.66(0.73,3.35) | 0.12(‐0.06,0.36) | |
| SD GOLI IV | 1.38(0.45,4.18) | 1.29(0.51,2.78) | 0.05(‐0.11,0.28) | |
| SD TOCI IV | 1.16(0.44,3.05) | 1.13(0.51,2.32) | 0.02(‐0.11,0.21) | |
| SD ABA SC | 2.76(0.64,13.71) | 2.07(0.70,4.84) | 0.20(‐0.07,0.55) | |
| SD CERTO SC | 2.75(0.76,10.23) | 2.07(0.80,4.32) | 0.20(‐0.05,0.50) | |
| SD ETN SC + MTX | 3.92(1.59,10.02) | 2.51(1.40,4.41) | 0.28(0.09,0.49) | |
| SD ABA IV + MTX | 2.86(1.13,6.78) | 2.11(1.10,3.65) | 0.21(0.02,0.41) | |
| SD CERTO SC + MTX | 4.23(1.71,10.34) | 2.61(1.46,4.38) | 0.30(0.10,0.50) | |
| SD INF IV + MTX | 2.43(0.95,6.12) | 1.91(0.96,3.45) | 0.17(‐0.01,0.38) | |
| SD ADA SC + MTX | 5.24(1.82,15.68) | 2.90(1.53,4.96) | 0.36(0.12,0.59) | |
| SD TOFA PO + MTX | 4.92(1.66,13.45) | 2.81(1.44,4.83) | 0.34(0.10,0.56) | |
| SD GOLI SC + MTX | 4.98(1.79,13.53) | 2.82(1.51,4.81) | 0.34(0.11,0.56) | |
| SD RITUX IV + MTX | 2.61(0.87,7.53) | 1.99(0.89,3.76) | 0.19(‐0.02,0.43) | |
| SD GOLI IV + MTX | 1.79(0.63,4.89) | 1.55(0.69,3.06) | 0.10(‐0.07,0.32) | |
| SD ANA SC + MTX | 2.14(0.70,6.29) | 1.76(0.75,3.46) | 0.14(‐0.05,0.39) | |
| SD ABA SC + MTX | 3.04(0.88,9.99) | 2.18(0.90,4.19) | 0.22(‐0.02,0.50) | |
| SD TOCI IV + MTX | 1.53(0.48,4.91) | 1.39(0.54,3.00) | 0.07(‐0.10,0.33) | |
| SD CERTO SC + DMARD | 2.35(0.54,11.30) | 1.87(0.61,4.51) | 0.16(‐0.09,0.52) | |
| SD ADA SC + DMARD | 2.04(0.23,19.03) | 1.71(0.28,5.02) | 0.13(‐0.16,0.62) | |
| SD TOCI SC + DMARD | 3.33(0.37,30.29) | 2.30(0.43,5.62) | 0.24(‐0.12,0.68) | |
| LD ADA SC | 0.94(0.45,1.99) | 0.95(0.51,1.71) | ‐0.01(‐0.11,0.12) | |
| LD ETN SC | 1.18(0.35,3.85) | 1.14(0.41,2.67) | 0.03(‐0.14,0.26) | |
| LD GOLI IV | 0.82(0.23,2.66) | 0.85(0.28,2.10) | ‐0.03(‐0.16,0.18) | |
| LD TOCI IV | 0.14(0.02,0.64) | 0.17(0.03,0.69) | ‐0.15(‐0.24,‐0.05) | |
| LD ADA SC + MTX | 2.92(0.86,9.85) | 2.12(0.88,4.13) | 0.21(‐0.02,0.49) | |
| LD RITUX IV + MTX | 2.56(0.88,7.45) | 1.97(0.90,3.74) | 0.18(‐0.02,0.42) | |
| LD ADA IV + MTX | 2.56(0.36,16.19) | 1.97(0.41,4.74) | 0.18(‐0.12,0.59) | |
| LD ABA IV + MTX | 1.55(0.54,4.17) | 1.40(0.60,2.78) | 0.07(‐0.09,0.29) | |
| LD ANA SC + MTX | 1.43(0.27,6.74) | 1.32(0.32,3.43) | 0.06(‐0.14,0.41) | |
| LD CERTO SC + MTX | 2.98(0.93,9.80) | 2.16(0.94,4.12) | 0.22(‐0.01,0.49) | |
| LD GOLI IV + MTX | 1.58(0.48,5.13) | 1.42(0.55,3.14) | 0.08(‐0.10,0.33) | |
| LD TOCI IV + MTX | 1.31(0.41,4.03) | 1.24(0.47,2.68) | 0.04(‐0.12,0.28) | |
| LD TOFA PO + MTX | 2.18(0.50,8.90) | 1.78(0.56,3.90) | 0.14(‐0.09,0.47) | |
| HD TOCI IV | 2.05(1.00,4.19) | 1.71(1.00,2.83) | 0.13(0.00,0.28) | |
| HD TOFA PO | 2.92(1.38,6.40) | 2.14(1.26,3.61) | 0.21(0.06,0.39) | |
| HD ADA SC | 1.35(0.65,2.83) | 1.26(0.70,2.18) | 0.05(‐0.06,0.20) | |
| HD GOLI SC | 2.25(0.87,5.69) | 1.81(0.90,3.39) | 0.15(‐0.02,0.36) | |
| HD ETN SC | 2.09(0.41,9.89) | 1.73(0.47,4.11) | 0.14(‐0.11,0.49) | |
| HD ABA SC | 3.97(0.94,19.17) | 2.52(0.95,5.29) | 0.29(‐0.01,0.62) | |
| HD TOCI IV + MTX | 3.55(1.54,8.35) | 2.39(1.37,4.02) | 0.26(0.08,0.45) | |
| HD INF IV + MTX | 3.27(1.17,8.74) | 2.28(1.13,4.07) | 0.24(0.03,0.47) | |
| HD TOFA PO + MTX | 2.80(0.96,7.65) | 2.08(0.97,3.80) | 0.20(‐0.01,0.43) | |
| HD GOLI SC + MTX | 3.86(1.36,10.41) | 2.50(1.26,4.36) | 0.28(0.06,0.50) | |
| HD CERTO SC + MTX | 5.04(1.93,13.17) | 2.83(1.59,4.73) | 0.34(0.13,0.55) | |
| HD ADA SC + MTX | 4.17(1.17,15.23) | 2.59(1.12,4.81) | 0.30(0.03,0.58) | |
| HD TOCI IV + DMARD | 2.44(0.31,20.12) | 1.92(0.37,5.12) | 0.17(‐0.14,0.63) | |
| SD ANA SC + SD ETN SC + MTX | 2.50(0.65,10.02) | 1.94(0.70,4.17) | 0.18(‐0.06,0.49) | |
| SD ANA SC + LD ETN SC + MTX | 3.70(0.95,14.48) | 2.43(0.96,4.71) | 0.27(‐0.01,0.57) | |
| SD GOLI SC | SD TOFA PO | 1.07(0.33,3.41) | 1.05(0.44,2.23) | 0.01(‐0.22,0.27) |
| SD GOLI IV | 0.76(0.21,2.49) | 0.82(0.31,1.88) | ‐0.05(‐0.27,0.19) | |
| SD TOCI IV | 0.63(0.21,1.98) | 0.71(0.30,1.64) | ‐0.09(‐0.28,0.14) | |
| SD ABA SC | 1.50(0.33,7.50) | 1.30(0.44,3.08) | 0.09(‐0.21,0.45) | |
| SD CERTO SC | 1.47(0.40,6.07) | 1.29(0.52,2.88) | 0.08(‐0.18,0.41) | |
| SD ETN SC + MTX | 2.13(0.75,6.41) | 1.59(0.83,3.04) | 0.17(‐0.06,0.42) | |
| SD ABA IV + MTX | 1.56(0.50,4.36) | 1.33(0.62,2.54) | 0.10(‐0.15,0.33) | |
| SD CERTO SC + MTX | 2.29(0.77,6.57) | 1.65(0.85,3.06) | 0.19(‐0.06,0.42) | |
| SD INF IV + MTX | 1.34(0.43,3.79) | 1.21(0.55,2.39) | 0.06(‐0.17,0.30) | |
| SD ADA SC + MTX | 2.88(0.84,9.69) | 1.84(0.90,3.43) | 0.25(‐0.04,0.51) | |
| SD TOFA PO + MTX | 2.68(0.78,8.94) | 1.78(0.85,3.37) | 0.23(‐0.05,0.49) | |
| SD GOLI SC + MTX | 2.72(0.83,8.49) | 1.78(0.90,3.34) | 0.23(‐0.04,0.48) | |
| SD RITUX IV + MTX | 1.41(0.41,4.66) | 1.25(0.53,2.59) | 0.08(‐0.18,0.35) | |
| SD GOLI IV + MTX | 0.97(0.29,3.00) | 0.98(0.40,2.10) | ‐0.01(‐0.23,0.24) | |
| SD ANA SC + MTX | 1.17(0.33,3.85) | 1.11(0.44,2.36) | 0.03(‐0.21,0.30) | |
| SD ABA SC + MTX | 1.66(0.41,6.23) | 1.38(0.53,2.88) | 0.11(‐0.18,0.42) | |
| SD TOCI IV + MTX | 0.83(0.23,3.18) | 0.88(0.32,2.12) | ‐0.04(‐0.26,0.25) | |
| SD CERTO SC + DMARD | 1.28(0.28,6.58) | 1.18(0.38,2.94) | 0.05(‐0.24,0.43) | |
| SD ADA SC + DMARD | 1.12(0.12,10.72) | 1.08(0.17,3.24) | 0.02(‐0.31,0.52) | |
| SD TOCI SC + DMARD | 1.81(0.19,16.82) | 1.45(0.27,3.63) | 0.13(‐0.26,0.59) | |
| LD ADA SC | 0.51(0.18,1.45) | 0.60(0.27,1.32) | ‐0.12(‐0.30,0.07) | |
| LD ETN SC | 0.64(0.17,2.38) | 0.72(0.25,1.81) | ‐0.08(‐0.30,0.18) | |
| LD GOLI IV | 0.45(0.11,1.63) | 0.54(0.16,1.42) | ‐0.13(‐0.33,0.10) | |
| LD TOCI IV | 0.08(0.01,0.41) | 0.11(0.02,0.48) | ‐0.26(‐0.42,‐0.11) | |
| LD ADA SC + MTX | 1.58(0.41,5.85) | 1.34(0.52,2.78) | 0.10(‐0.18,0.40) | |
| LD RITUX IV + MTX | 1.38(0.42,4.49) | 1.24(0.54,2.57) | 0.07(‐0.18,0.34) | |
| LD ADA IV + MTX | 1.39(0.19,9.58) | 1.24(0.27,3.23) | 0.07(‐0.26,0.50) | |
| LD ABA IV + MTX | 0.83(0.25,2.63) | 0.88(0.35,1.92) | ‐0.04(‐0.26,0.21) | |
| LD ANA SC + MTX | 0.78(0.13,3.89) | 0.84(0.19,2.28) | ‐0.05(‐0.30,0.31) | |
| LD CERTO SC + MTX | 1.62(0.44,6.17) | 1.36(0.55,2.88) | 0.11(‐0.17,0.41) | |
| LD GOLI IV + MTX | 0.86(0.22,3.03) | 0.90(0.32,2.10) | ‐0.03(‐0.26,0.24) | |
| LD TOCI IV + MTX | 0.70(0.19,2.61) | 0.77(0.28,1.90) | ‐0.07(‐0.28,0.21) | |
| LD TOFA PO + MTX | 1.20(0.25,5.45) | 1.13(0.34,2.69) | 0.04(‐0.24,0.39) | |
| HD TOCI IV | 1.11(0.43,2.87) | 1.08(0.56,2.10) | 0.02(‐0.18,0.22) | |
| HD TOFA PO | 1.60(0.90,2.88) | 1.35(0.93,2.00) | 0.10(‐0.02,0.23) | |
| HD ADA SC | 0.73(0.27,1.99) | 0.80(0.39,1.63) | ‐0.06(‐0.25,0.14) | |
| HD GOLI SC | 1.23(0.40,3.50) | 1.15(0.53,2.29) | 0.04(‐0.19,0.27) | |
| HD ETN SC | 1.13(0.20,5.55) | 1.09(0.29,2.72) | 0.03(‐0.27,0.39) | |
| HD ABA SC | 2.16(0.48,10.85) | 1.59(0.61,3.46) | 0.18(‐0.15,0.53) | |
| HD TOCI IV + MTX | 1.93(0.68,5.49) | 1.50(0.77,2.88) | 0.15(‐0.09,0.38) | |
| HD INF IV + MTX | 1.78(0.55,5.55) | 1.44(0.66,2.83) | 0.13(‐0.13,0.38) | |
| HD TOFA PO + MTX | 1.52(0.45,4.85) | 1.31(0.58,2.68) | 0.09(‐0.16,0.35) | |
| HD GOLI SC + MTX | 2.08(0.64,6.48) | 1.56(0.75,3.02) | 0.17(‐0.10,0.42) | |
| HD CERTO SC + MTX | 2.74(0.88,8.31) | 1.79(0.92,3.32) | 0.23(‐0.03,0.48) | |
| HD ADA SC + MTX | 2.28(0.55,9.15) | 1.64(0.66,3.26) | 0.19(‐0.12,0.50) | |
| HD TOCI IV + DMARD | 1.32(0.16,11.50) | 1.20(0.23,3.30) | 0.06(‐0.28,0.53) | |
| SD ANA SC + SD ETN SC + MTX | 1.37(0.31,5.84) | 1.23(0.42,2.78) | 0.07(‐0.21,0.40) | |
| SD ANA SC + LD ETN SC + MTX | 2.02(0.47,8.79) | 1.53(0.59,3.25) | 0.16(‐0.15,0.49) | |
| SD GOLI IV | SD GOLI SC | 0.71(0.25,2.07) | 0.78(0.35,1.67) | ‐0.07(‐0.27,0.15) |
| SD TOCI IV | 0.59(0.18,1.91) | 0.68(0.29,1.62) | ‐0.10(‐0.33,0.12) | |
| SD ABA SC | 1.43(0.28,7.98) | 1.25(0.41,3.36) | 0.08(‐0.26,0.46) | |
| SD CERTO SC | 1.40(0.31,6.48) | 1.24(0.45,3.20) | 0.07(‐0.24,0.41) | |
| SD ETN SC + MTX | 2.01(0.66,6.45) | 1.52(0.79,3.27) | 0.16(‐0.10,0.41) | |
| SD ABA IV + MTX | 1.44(0.51,4.14) | 1.26(0.66,2.63) | 0.08(‐0.15,0.30) | |
| SD CERTO SC + MTX | 2.15(0.75,6.13) | 1.57(0.85,3.21) | 0.18(‐0.07,0.40) | |
| SD INF IV + MTX | 1.24(0.42,3.63) | 1.15(0.58,2.41) | 0.05(‐0.19,0.27) | |
| SD ADA SC + MTX | 2.73(0.80,9.04) | 1.75(0.87,3.59) | 0.23(‐0.05,0.49) | |
| SD TOFA PO + MTX | 2.52(0.77,8.08) | 1.69(0.86,3.57) | 0.21(‐0.06,0.46) | |
| SD GOLI SC + MTX | 2.54(0.87,7.55) | 1.70(0.92,3.41) | 0.22(‐0.03,0.45) | |
| SD RITUX IV + MTX | 1.33(0.40,4.33) | 1.20(0.54,2.60) | 0.06(‐0.20,0.32) | |
| SD GOLI IV + MTX | 0.91(0.30,2.76) | 0.93(0.43,2.03) | ‐0.02(‐0.25,0.21) | |
| SD ANA SC + MTX | 1.09(0.31,3.82) | 1.05(0.45,2.47) | 0.02(‐0.24,0.29) | |
| SD ABA SC + MTX | 1.54(0.40,5.88) | 1.31(0.54,2.99) | 0.10(‐0.19,0.39) | |
| SD TOCI IV + MTX | 0.79(0.21,3.01) | 0.85(0.32,2.10) | ‐0.05(‐0.30,0.23) | |
| SD CERTO SC + DMARD | 1.21(0.23,6.88) | 1.14(0.35,3.20) | 0.04(‐0.28,0.42) | |
| SD ADA SC + DMARD | 1.05(0.11,11.51) | 1.03(0.18,3.58) | 0.01(‐0.35,0.53) | |
| SD TOCI SC + DMARD | 1.72(0.17,17.02) | 1.39(0.26,4.00) | 0.12(‐0.30,0.59) | |
| LD ADA SC | 0.48(0.14,1.64) | 0.58(0.24,1.46) | ‐0.13(‐0.38,0.08) | |
| LD ETN SC | 0.60(0.15,2.48) | 0.69(0.24,1.93) | ‐0.09(‐0.36,0.18) | |
| LD GOLI IV | 0.42(0.12,1.50) | 0.51(0.18,1.35) | ‐0.14(‐0.37,0.07) | |
| LD TOCI IV | 0.07(0.01,0.39) | 0.10(0.02,0.45) | ‐0.27(‐0.50,‐0.10) | |
| LD ADA SC + MTX | 1.47(0.39,5.82) | 1.28(0.53,2.93) | 0.08(‐0.20,0.39) | |
| LD RITUX IV + MTX | 1.31(0.40,4.29) | 1.19(0.55,2.59) | 0.06(‐0.20,0.32) | |
| LD ADA IV + MTX | 1.32(0.17,9.67) | 1.19(0.25,3.34) | 0.06(‐0.30,0.50) | |
| LD ABA IV + MTX | 0.78(0.25,2.51) | 0.84(0.37,1.93) | ‐0.05(‐0.28,0.18) | |
| LD ANA SC + MTX | 0.73(0.13,3.79) | 0.80(0.20,2.33) | ‐0.06(‐0.34,0.30) | |
| LD CERTO SC + MTX | 1.53(0.42,5.72) | 1.30(0.56,2.95) | 0.09(‐0.19,0.39) | |
| LD GOLI IV + MTX | 0.81(0.24,2.74) | 0.86(0.34,2.01) | ‐0.04(‐0.28,0.21) | |
| LD TOCI IV + MTX | 0.66(0.18,2.47) | 0.74(0.28,1.88) | ‐0.08(‐0.32,0.19) | |
| LD TOFA PO + MTX | 1.10(0.25,5.05) | 1.07(0.36,2.69) | 0.02(‐0.26,0.36) | |
| HD TOCI IV | 1.04(0.38,2.96) | 1.03(0.54,2.19) | 0.01(‐0.22,0.21) | |
| HD TOFA PO | 1.50(0.48,4.82) | 1.29(0.65,2.92) | 0.09(‐0.18,0.33) | |
| HD ADA SC | 0.69(0.20,2.33) | 0.76(0.33,1.86) | ‐0.07(‐0.33,0.16) | |
| HD GOLI SC | 1.15(0.48,2.78) | 1.10(0.61,2.05) | 0.03(‐0.16,0.21) | |
| HD ETN SC | 1.06(0.19,5.99) | 1.04(0.29,2.93) | 0.01(‐0.30,0.40) | |
| HD ABA SC | 2.04(0.39,11.51) | 1.52(0.54,3.83) | 0.16(‐0.20,0.53) | |
| HD TOCI IV + MTX | 1.82(0.61,5.33) | 1.44(0.75,3.01) | 0.13(‐0.12,0.37) | |
| HD INF IV + MTX | 1.67(0.54,5.22) | 1.37(0.67,2.88) | 0.11(‐0.14,0.36) | |
| HD TOFA PO + MTX | 1.42(0.44,4.60) | 1.25(0.59,2.72) | 0.08(‐0.18,0.33) | |
| HD GOLI SC + MTX | 1.96(0.68,5.76) | 1.50(0.79,3.02) | 0.15(‐0.09,0.39) | |
| HD CERTO SC + MTX | 2.55(0.85,7.57) | 1.70(0.92,3.50) | 0.22(‐0.04,0.45) | |
| HD ADA SC + MTX | 2.14(0.53,8.76) | 1.56(0.67,3.49) | 0.17(‐0.14,0.48) | |
| HD TOCI IV + DMARD | 1.25(0.15,11.99) | 1.16(0.22,3.70) | 0.05(‐0.32,0.53) | |
| SD ANA SC + SD ETN SC + MTX | 1.28(0.28,6.10) | 1.17(0.41,3.04) | 0.05(‐0.25,0.40) | |
| SD ANA SC + LD ETN SC + MTX | 1.89(0.42,8.64) | 1.46(0.56,3.47) | 0.14(‐0.18,0.48) | |
| SD TOCI IV | SD GOLI IV | 0.84(0.27,2.73) | 0.88(0.37,2.20) | ‐0.03(‐0.25,0.17) |
| SD ABA SC | 2.03(0.37,12.03) | 1.60(0.49,4.81) | 0.14(‐0.20,0.52) | |
| SD CERTO SC | 1.97(0.40,9.85) | 1.59(0.53,4.59) | 0.14(‐0.19,0.47) | |
| SD ETN SC + MTX | 2.83(0.95,9.18) | 1.94(0.97,4.54) | 0.22(‐0.01,0.45) | |
| SD ABA IV + MTX | 2.04(0.77,5.57) | 1.62(0.85,3.49) | 0.15(‐0.06,0.34) | |
| SD CERTO SC + MTX | 3.04(1.14,8.11) | 2.01(1.08,4.30) | 0.24(0.03,0.44) | |
| SD INF IV + MTX | 1.74(0.65,4.76) | 1.47(0.75,3.13) | 0.11(‐0.09,0.31) | |
| SD ADA SC + MTX | 3.83(1.20,12.87) | 2.23(1.11,5.08) | 0.29(0.04,0.53) | |
| SD TOFA PO + MTX | 3.54(1.17,10.64) | 2.16(1.09,4.73) | 0.28(0.03,0.50) | |
| SD GOLI SC + MTX | 3.61(1.25,10.53) | 2.17(1.13,4.72) | 0.28(0.05,0.50) | |
| SD RITUX IV + MTX | 1.87(0.61,5.77) | 1.53(0.71,3.45) | 0.13(‐0.10,0.36) | |
| SD GOLI IV + MTX | 1.29(0.53,3.09) | 1.20(0.63,2.34) | 0.05(‐0.13,0.22) | |
| SD ANA SC + MTX | 1.53(0.48,5.04) | 1.35(0.60,3.13) | 0.08(‐0.14,0.33) | |
| SD ABA SC + MTX | 2.19(0.62,7.85) | 1.68(0.72,3.95) | 0.16(‐0.10,0.44) | |
| SD TOCI IV + MTX | 1.11(0.31,4.10) | 1.08(0.41,2.78) | 0.02(‐0.22,0.27) | |
| SD CERTO SC + DMARD | 1.70(0.32,10.48) | 1.44(0.42,4.61) | 0.11(‐0.22,0.49) | |
| SD ADA SC + DMARD | 1.48(0.15,17.24) | 1.32(0.22,5.01) | 0.07(‐0.28,0.59) | |
| SD TOCI SC + DMARD | 2.42(0.24,26.07) | 1.76(0.32,5.68) | 0.19(‐0.23,0.66) | |
| LD ADA SC | 0.68(0.19,2.42) | 0.74(0.29,2.04) | ‐0.06(‐0.30,0.13) | |
| LD ETN SC | 0.86(0.20,3.51) | 0.89(0.29,2.61) | ‐0.03(‐0.29,0.23) | |
| LD GOLI IV | 0.59(0.21,1.63) | 0.66(0.28,1.45) | ‐0.08(‐0.26,0.08) | |
| LD TOCI IV | 0.10(0.02,0.54) | 0.14(0.02,0.58) | ‐0.20(‐0.42,‐0.05) | |
| LD ADA SC + MTX | 2.07(0.58,8.04) | 1.62(0.68,4.06) | 0.15(‐0.11,0.44) | |
| LD RITUX IV + MTX | 1.85(0.60,5.61) | 1.51(0.71,3.42) | 0.12(‐0.10,0.35) | |
| LD ADA IV + MTX | 1.85(0.25,12.96) | 1.51(0.32,4.48) | 0.12(‐0.21,0.55) | |
| LD ABA IV + MTX | 1.10(0.37,3.37) | 1.07(0.48,2.50) | 0.02(‐0.19,0.23) | |
| LD ANA SC + MTX | 1.03(0.20,5.24) | 1.02(0.26,3.06) | 0.00(‐0.26,0.35) | |
| LD CERTO SC + MTX | 2.18(0.63,7.71) | 1.66(0.73,3.93) | 0.16(‐0.10,0.43) | |
| LD GOLI IV + MTX | 1.15(0.42,2.99) | 1.11(0.53,2.24) | 0.02(‐0.16,0.22) | |
| LD TOCI IV + MTX | 0.94(0.26,3.46) | 0.96(0.36,2.54) | ‐0.01(‐0.25,0.24) | |
| LD TOFA PO + MTX | 1.57(0.36,6.71) | 1.37(0.46,3.51) | 0.09(‐0.18,0.41) | |
| HD TOCI IV | 1.48(0.55,4.06) | 1.32(0.67,2.96) | 0.07(‐0.13,0.25) | |
| HD TOFA PO | 2.12(0.65,7.37) | 1.66(0.76,4.24) | 0.16(‐0.10,0.39) | |
| HD ADA SC | 0.97(0.28,3.50) | 0.98(0.39,2.69) | ‐0.01(‐0.25,0.21) | |
| HD GOLI SC | 1.63(0.57,4.63) | 1.41(0.69,3.14) | 0.09(‐0.12,0.30) | |
| HD ETN SC | 1.49(0.28,8.50) | 1.32(0.36,4.08) | 0.08(‐0.22,0.45) | |
| HD ABA SC | 2.92(0.52,16.92) | 1.96(0.64,5.56) | 0.23(‐0.14,0.58) | |
| HD TOCI IV + MTX | 2.56(0.94,7.24) | 1.84(0.96,4.08) | 0.20(‐0.01,0.41) | |
| HD INF IV + MTX | 2.34(0.81,6.94) | 1.75(0.87,3.85) | 0.18(‐0.05,0.40) | |
| HD TOFA PO + MTX | 2.01(0.67,6.03) | 1.60(0.76,3.56) | 0.14(‐0.09,0.37) | |
| HD GOLI SC + MTX | 2.76(0.95,8.09) | 1.91(0.97,4.20) | 0.22(‐0.01,0.44) | |
| HD CERTO SC + MTX | 3.63(1.30,10.32) | 2.18(1.15,4.70) | 0.28(0.06,0.49) | |
| HD ADA SC + MTX | 3.02(0.81,12.32) | 1.99(0.87,4.80) | 0.24(‐0.04,0.53) | |
| HD TOCI IV + DMARD | 1.77(0.20,17.84) | 1.47(0.28,5.19) | 0.11(‐0.25,0.60) | |
| SD ANA SC + SD ETN SC + MTX | 1.79(0.41,8.73) | 1.48(0.52,4.18) | 0.11(‐0.17,0.45) | |
| SD ANA SC + LD ETN SC + MTX | 2.65(0.61,12.84) | 1.86(0.71,4.88) | 0.21(‐0.10,0.53) | |
| SD ABA SC | SD TOCI IV | 2.40(0.47,13.22) | 1.82(0.56,5.15) | 0.17(‐0.14,0.54) |
| SD CERTO SC | 2.36(0.52,10.79) | 1.81(0.62,4.78) | 0.17(‐0.12,0.49) | |
| SD ETN SC + MTX | 3.37(1.19,9.90) | 2.22(1.12,4.82) | 0.26(0.04,0.47) | |
| SD ABA IV + MTX | 2.44(0.96,6.12) | 1.85(0.97,3.66) | 0.18(‐0.01,0.37) | |
| SD CERTO SC + MTX | 3.62(1.42,9.19) | 2.31(1.25,4.58) | 0.27(0.08,0.46) | |
| SD INF IV + MTX | 2.08(0.81,5.33) | 1.68(0.86,3.40) | 0.14(‐0.04,0.34) | |
| SD ADA SC + MTX | 4.53(1.51,13.99) | 2.55(1.30,5.20) | 0.33(0.09,0.56) | |
| SD TOFA PO + MTX | 4.24(1.43,12.16) | 2.47(1.25,4.99) | 0.31(0.08,0.53) | |
| SD GOLI SC + MTX | 4.29(1.51,11.84) | 2.50(1.29,5.09) | 0.31(0.09,0.52) | |
| SD RITUX IV + MTX | 2.24(0.76,6.40) | 1.76(0.82,3.72) | 0.16(‐0.05,0.38) | |
| SD GOLI IV + MTX | 1.52(0.53,4.29) | 1.36(0.62,2.96) | 0.08(‐0.12,0.28) | |
| SD ANA SC + MTX | 1.83(0.58,5.72) | 1.55(0.67,3.41) | 0.11(‐0.10,0.35) | |
| SD ABA SC + MTX | 2.61(0.73,8.75) | 1.93(0.80,4.20) | 0.19(‐0.06,0.46) | |
| SD TOCI IV + MTX | 1.32(0.45,3.81) | 1.23(0.53,2.64) | 0.05(‐0.13,0.27) | |
| SD CERTO SC + DMARD | 2.01(0.41,11.52) | 1.64(0.50,4.75) | 0.13(‐0.15,0.51) | |
| SD ADA SC + DMARD | 1.76(0.19,18.97) | 1.50(0.25,5.34) | 0.10(‐0.22,0.61) | |
| SD TOCI SC + DMARD | 2.91(0.31,29.40) | 2.02(0.38,6.03) | 0.22(‐0.17,0.68) | |
| LD ADA SC | 0.81(0.25,2.57) | 0.84(0.34,2.17) | ‐0.03(‐0.23,0.15) | |
| LD ETN SC | 1.02(0.25,3.87) | 1.02(0.32,2.81) | 0.00(‐0.22,0.24) | |
| LD GOLI IV | 0.70(0.20,2.49) | 0.75(0.26,2.01) | ‐0.05(‐0.23,0.15) | |
| LD TOCI IV | 0.12(0.02,0.51) | 0.15(0.03,0.57) | ‐0.17(‐0.34,‐0.06) | |
| LD ADA SC + MTX | 2.48(0.73,8.79) | 1.86(0.79,4.18) | 0.18(‐0.06,0.46) | |
| LD RITUX IV + MTX | 2.19(0.74,6.47) | 1.73(0.81,3.71) | 0.15(‐0.06,0.38) | |
| LD ADA IV + MTX | 2.21(0.31,14.42) | 1.73(0.38,4.79) | 0.15(‐0.16,0.57) | |
| LD ABA IV + MTX | 1.32(0.46,3.75) | 1.23(0.56,2.70) | 0.05(‐0.14,0.25) | |
| LD ANA SC + MTX | 1.23(0.23,6.10) | 1.17(0.29,3.36) | 0.03(‐0.20,0.38) | |
| LD CERTO SC + MTX | 2.57(0.76,8.78) | 1.91(0.82,4.19) | 0.19(‐0.05,0.46) | |
| LD GOLI IV + MTX | 1.36(0.40,4.50) | 1.26(0.49,3.02) | 0.05(‐0.15,0.30) | |
| LD TOCI IV + MTX | 1.12(0.39,3.15) | 1.09(0.46,2.36) | 0.02(‐0.15,0.22) | |
| LD TOFA PO + MTX | 1.87(0.43,7.90) | 1.57(0.51,3.91) | 0.12(‐0.13,0.43) | |
| HD TOCI IV | 1.75(0.85,3.68) | 1.51(0.90,2.75) | 0.10(‐0.03,0.24) | |
| HD TOFA PO | 2.52(0.81,7.62) | 1.91(0.87,4.35) | 0.19(‐0.05,0.40) | |
| HD ADA SC | 1.16(0.37,3.74) | 1.12(0.48,2.76) | 0.03(‐0.18,0.22) | |
| HD GOLI SC | 1.93(0.68,5.43) | 1.60(0.76,3.48) | 0.13(‐0.08,0.33) | |
| HD ETN SC | 1.77(0.33,9.17) | 1.51(0.41,4.25) | 0.11(‐0.17,0.46) | |
| HD ABA SC | 3.44(0.68,19.23) | 2.23(0.75,5.82) | 0.26(‐0.07,0.61) | |
| HD TOCI IV + MTX | 3.05(1.36,6.97) | 2.10(1.22,3.98) | 0.23(0.07,0.40) | |
| HD INF IV + MTX | 2.79(1.00,7.89) | 2.01(1.00,4.14) | 0.21(0.00,0.43) | |
| HD TOFA PO + MTX | 2.38(0.80,7.01) | 1.83(0.85,3.90) | 0.17(‐0.04,0.40) | |
| HD GOLI SC + MTX | 3.29(1.17,9.41) | 2.19(1.11,4.52) | 0.25(0.03,0.47) | |
| HD CERTO SC + MTX | 4.31(1.60,11.61) | 2.50(1.34,5.06) | 0.32(0.10,0.51) | |
| HD ADA SC + MTX | 3.59(1.00,13.30) | 2.27(1.00,4.96) | 0.27(0.00,0.55) | |
| HD TOCI IV + DMARD | 2.11(0.26,19.54) | 1.69(0.33,5.43) | 0.14(‐0.20,0.62) | |
| SD ANA SC + SD ETN SC + MTX | 2.14(0.52,9.37) | 1.70(0.60,4.34) | 0.15(‐0.12,0.47) | |
| SD ANA SC + LD ETN SC + MTX | 3.18(0.72,13.73) | 2.13(0.79,5.13) | 0.24(‐0.06,0.55) | |
| SD CERTO SC | SD ABA SC | 0.98(0.16,5.86) | 0.99(0.35,3.01) | 0.00(‐0.41,0.38) |
| SD ETN SC + MTX | 1.42(0.27,7.03) | 1.21(0.53,3.52) | 0.08(‐0.31,0.42) | |
| SD ABA IV + MTX | 1.01(0.19,5.06) | 1.01(0.42,3.03) | 0.00(‐0.38,0.34) | |
| SD CERTO SC + MTX | 1.52(0.27,7.46) | 1.25(0.55,3.56) | 0.10(‐0.30,0.43) | |
| SD INF IV + MTX | 0.86(0.16,4.39) | 0.91(0.37,2.72) | ‐0.03(‐0.42,0.31) | |
| SD ADA SC + MTX | 1.91(0.32,10.24) | 1.39(0.59,3.94) | 0.15(‐0.26,0.51) | |
| SD TOFA PO + MTX | 1.76(0.31,9.04) | 1.34(0.57,3.86) | 0.13(‐0.27,0.48) | |
| SD GOLI SC + MTX | 1.80(0.31,9.37) | 1.36(0.59,3.88) | 0.14(‐0.27,0.48) | |
| SD RITUX IV + MTX | 0.93(0.16,5.22) | 0.96(0.36,2.96) | ‐0.02(‐0.41,0.35) | |
| SD GOLI IV + MTX | 0.64(0.11,3.26) | 0.75(0.27,2.32) | ‐0.10(‐0.48,0.24) | |
| SD ANA SC + MTX | 0.76(0.12,4.18) | 0.85(0.29,2.61) | ‐0.06(‐0.46,0.30) | |
| SD ABA SC + MTX | 1.09(0.17,6.86) | 1.05(0.36,3.28) | 0.02(‐0.40,0.41) | |
| SD TOCI IV + MTX | 0.55(0.09,3.27) | 0.67(0.21,2.32) | ‐0.12(‐0.51,0.24) | |
| SD CERTO SC + DMARD | 0.86(0.12,5.57) | 0.91(0.27,2.92) | ‐0.03(‐0.45,0.38) | |
| SD ADA SC + DMARD | 0.74(0.06,8.62) | 0.83(0.14,3.14) | ‐0.06(‐0.51,0.47) | |
| SD TOCI SC + DMARD | 1.19(0.10,13.54) | 1.10(0.20,3.70) | 0.04(‐0.45,0.54) | |
| LD ADA SC | 0.34(0.06,1.60) | 0.47(0.17,1.45) | ‐0.21(‐0.56,0.08) | |
| LD ETN SC | 0.42(0.07,2.39) | 0.55(0.18,1.87) | ‐0.17(‐0.55,0.16) | |
| LD GOLI IV | 0.29(0.05,1.74) | 0.41(0.12,1.51) | ‐0.22(‐0.58,0.10) | |
| LD TOCI IV | 0.05(0.01,0.39) | 0.08(0.01,0.45) | ‐0.35(‐0.69,‐0.09) | |
| LD ADA SC + MTX | 1.04(0.17,6.22) | 1.02(0.35,3.17) | 0.01(‐0.40,0.39) | |
| LD RITUX IV + MTX | 0.91(0.16,5.00) | 0.95(0.36,2.91) | ‐0.02(‐0.41,0.34) | |
| LD ADA IV + MTX | 0.91(0.09,9.57) | 0.95(0.18,3.49) | ‐0.02(‐0.47,0.49) | |
| LD ABA IV + MTX | 0.55(0.10,2.93) | 0.67(0.24,2.19) | ‐0.13(‐0.50,0.22) | |
| LD ANA SC + MTX | 0.51(0.06,3.92) | 0.64(0.14,2.39) | ‐0.13(‐0.54,0.29) | |
| LD CERTO SC + MTX | 1.07(0.18,6.44) | 1.04(0.38,3.25) | 0.01(‐0.39,0.41) | |
| LD GOLI IV + MTX | 0.57(0.09,3.17) | 0.69(0.22,2.22) | ‐0.12(‐0.50,0.24) | |
| LD TOCI IV + MTX | 0.47(0.07,2.80) | 0.60(0.18,2.10) | ‐0.15(‐0.53,0.20) | |
| LD TOFA PO + MTX | 0.78(0.11,5.52) | 0.86(0.24,2.90) | ‐0.05(‐0.47,0.37) | |
| HD TOCI IV | 0.74(0.14,3.42) | 0.82(0.35,2.46) | ‐0.07(‐0.44,0.24) | |
| HD TOFA PO | 1.06(0.21,4.79) | 1.04(0.47,2.96) | 0.01(‐0.36,0.32) | |
| HD ADA SC | 0.49(0.09,2.32) | 0.61(0.24,1.88) | ‐0.15(‐0.51,0.15) | |
| HD GOLI SC | 0.80(0.15,3.94) | 0.87(0.35,2.62) | ‐0.05(‐0.43,0.28) | |
| HD ETN SC | 0.75(0.09,5.41) | 0.84(0.21,2.92) | ‐0.06(‐0.49,0.36) | |
| HD ABA SC | 1.43(0.49,4.28) | 1.20(0.66,2.42) | 0.08(‐0.16,0.32) | |
| HD TOCI IV + MTX | 1.28(0.24,6.31) | 1.15(0.51,3.38) | 0.06(‐0.33,0.39) | |
| HD INF IV + MTX | 1.16(0.20,6.26) | 1.09(0.44,3.30) | 0.03(‐0.37,0.40) | |
| HD TOFA PO + MTX | 0.99(0.18,5.18) | 0.99(0.38,3.01) | 0.00(‐0.39,0.35) | |
| HD GOLI SC + MTX | 1.39(0.23,7.24) | 1.20(0.48,3.49) | 0.08(‐0.34,0.43) | |
| HD CERTO SC + MTX | 1.79(0.32,9.60) | 1.36(0.59,3.90) | 0.14(‐0.27,0.49) | |
| HD ADA SC + MTX | 1.51(0.24,9.19) | 1.25(0.45,3.67) | 0.10(‐0.33,0.48) | |
| HD TOCI IV + DMARD | 0.88(0.08,9.11) | 0.93(0.17,3.28) | ‐0.03(‐0.48,0.48) | |
| SD ANA SC + SD ETN SC + MTX | 0.89(0.12,6.25) | 0.94(0.28,3.11) | ‐0.02(‐0.45,0.40) | |
| SD ANA SC + LD ETN SC + MTX | 1.34(0.19,9.17) | 1.18(0.39,3.69) | 0.07(‐0.38,0.48) | |
| SD ETN SC + MTX | SD CERTO SC | 1.44(0.35,6.09) | 1.23(0.58,3.08) | 0.09(‐0.25,0.39) |
| SD ABA IV + MTX | 1.03(0.24,4.46) | 1.02(0.44,2.67) | 0.01(‐0.33,0.33) | |
| SD CERTO SC + MTX | 1.53(0.35,6.74) | 1.27(0.59,3.20) | 0.10(‐0.25,0.42) | |
| SD INF IV + MTX | 0.89(0.20,3.86) | 0.93(0.39,2.47) | ‐0.03(‐0.37,0.29) | |
| SD ADA SC + MTX | 1.93(0.39,9.53) | 1.41(0.62,3.56) | 0.16(‐0.22,0.50) | |
| SD TOFA PO + MTX | 1.79(0.36,8.51) | 1.36(0.60,3.41) | 0.14(‐0.24,0.47) | |
| SD GOLI SC + MTX | 1.83(0.40,8.16) | 1.38(0.62,3.47) | 0.14(‐0.22,0.46) | |
| SD RITUX IV + MTX | 0.94(0.20,4.53) | 0.97(0.37,2.62) | ‐0.01(‐0.37,0.33) | |
| SD GOLI IV + MTX | 0.64(0.14,3.00) | 0.75(0.29,2.11) | ‐0.09(‐0.43,0.23) | |
| SD ANA SC + MTX | 0.77(0.16,3.87) | 0.85(0.31,2.42) | ‐0.06(‐0.40,0.29) | |
| SD ABA SC + MTX | 1.10(0.20,6.15) | 1.06(0.37,2.97) | 0.02(‐0.35,0.41) | |
| SD TOCI IV + MTX | 0.56(0.11,2.83) | 0.68(0.23,2.06) | ‐0.12(‐0.45,0.22) | |
| SD CERTO SC + DMARD | 0.86(0.14,5.67) | 0.91(0.27,2.78) | ‐0.03(‐0.41,0.39) | |
| SD ADA SC + DMARD | 0.76(0.07,8.49) | 0.84(0.14,2.99) | ‐0.06(‐0.48,0.47) | |
| SD TOCI SC + DMARD | 1.22(0.11,13.82) | 1.12(0.21,3.48) | 0.05(‐0.41,0.55) | |
| LD ADA SC | 0.34(0.08,1.43) | 0.46(0.19,1.31) | ‐0.20(‐0.51,0.06) | |
| LD ETN SC | 0.44(0.08,2.08) | 0.56(0.18,1.68) | ‐0.16(‐0.50,0.14) | |
| LD GOLI IV | 0.30(0.05,1.55) | 0.42(0.12,1.38) | ‐0.22(‐0.54,0.08) | |
| LD TOCI IV | 0.05(0.01,0.35) | 0.09(0.01,0.42) | ‐0.35(‐0.64,‐0.11) | |
| LD ADA SC + MTX | 1.05(0.20,5.69) | 1.03(0.37,2.84) | 0.01(‐0.37,0.39) | |
| LD RITUX IV + MTX | 0.93(0.19,4.42) | 0.95(0.37,2.61) | ‐0.02(‐0.37,0.32) | |
| LD ADA IV + MTX | 0.94(0.10,8.31) | 0.97(0.19,3.04) | ‐0.01(‐0.44,0.47) | |
| LD ABA IV + MTX | 0.56(0.12,2.65) | 0.68(0.25,1.99) | ‐0.12(‐0.45,0.20) | |
| LD ANA SC + MTX | 0.52(0.07,3.42) | 0.64(0.14,2.16) | ‐0.13(‐0.49,0.27) | |
| LD CERTO SC + MTX | 1.09(0.21,5.81) | 1.05(0.40,2.90) | 0.02(‐0.35,0.39) | |
| LD GOLI IV + MTX | 0.58(0.11,3.15) | 0.70(0.23,2.15) | ‐0.12(‐0.46,0.24) | |
| LD TOCI IV + MTX | 0.48(0.09,2.36) | 0.61(0.20,1.82) | ‐0.15(‐0.49,0.18) | |
| LD TOFA PO + MTX | 0.80(0.13,4.89) | 0.87(0.25,2.65) | ‐0.05(‐0.43,0.35) | |
| HD TOCI IV | 0.74(0.19,3.03) | 0.83(0.38,2.18) | ‐0.07(‐0.39,0.22) | |
| HD TOFA PO | 1.07(0.28,4.04) | 1.04(0.50,2.55) | 0.02(‐0.31,0.30) | |
| HD ADA SC | 0.49(0.12,2.01) | 0.61(0.26,1.69) | ‐0.15(‐0.46,0.13) | |
| HD GOLI SC | 0.82(0.19,3.48) | 0.88(0.37,2.37) | ‐0.05(‐0.38,0.26) | |
| HD ETN SC | 0.76(0.11,5.00) | 0.85(0.21,2.60) | ‐0.06(‐0.44,0.36) | |
| HD ABA SC | 1.44(0.25,9.00) | 1.22(0.44,3.30) | 0.09(‐0.32,0.48) | |
| HD TOCI IV + MTX | 1.30(0.30,5.51) | 1.16(0.54,2.94) | 0.06(‐0.28,0.37) | |
| HD INF IV + MTX | 1.18(0.26,5.48) | 1.10(0.47,2.90) | 0.04(‐0.31,0.38) | |
| HD TOFA PO + MTX | 1.02(0.20,4.79) | 1.01(0.39,2.71) | 0.00(‐0.36,0.34) | |
| HD GOLI SC + MTX | 1.40(0.30,6.39) | 1.21(0.53,3.13) | 0.08(‐0.28,0.41) | |
| HD CERTO SC + MTX | 1.82(0.40,8.22) | 1.37(0.64,3.42) | 0.14(‐0.21,0.47) | |
| HD ADA SC + MTX | 1.55(0.27,8.61) | 1.27(0.47,3.34) | 0.10(‐0.30,0.48) | |
| HD TOCI IV + DMARD | 0.89(0.09,9.32) | 0.93(0.17,3.13) | ‐0.03(‐0.45,0.49) | |
| SD ANA SC + SD ETN SC + MTX | 0.91(0.15,5.45) | 0.95(0.30,2.76) | ‐0.02(‐0.40,0.38) | |
| SD ANA SC + LD ETN SC + MTX | 1.35(0.23,8.14) | 1.19(0.42,3.20) | 0.07(‐0.33,0.46) | |
| SD ABA IV + MTX | SD ETN SC + MTX | 0.72(0.29,1.63) | 0.84(0.48,1.32) | ‐0.08(‐0.29,0.12) |
| SD CERTO SC + MTX | 1.08(0.44,2.50) | 1.04(0.64,1.62) | 0.02(‐0.20,0.22) | |
| SD INF IV + MTX | 0.62(0.24,1.44) | 0.76(0.43,1.23) | ‐0.11(‐0.32,0.09) | |
| SD ADA SC + MTX | 1.35(0.45,3.90) | 1.15(0.65,1.89) | 0.07(‐0.19,0.31) | |
| SD TOFA PO + MTX | 1.26(0.44,3.27) | 1.12(0.64,1.79) | 0.05(‐0.20,0.28) | |
| SD GOLI SC + MTX | 1.27(0.46,3.32) | 1.12(0.67,1.79) | 0.06(‐0.19,0.29) | |
| SD RITUX IV + MTX | 0.66(0.23,1.80) | 0.79(0.40,1.38) | ‐0.10(‐0.33,0.14) | |
| SD GOLI IV + MTX | 0.46(0.15,1.19) | 0.62(0.29,1.11) | ‐0.18(‐0.40,0.04) | |
| SD ANA SC + MTX | 0.54(0.17,1.61) | 0.70(0.32,1.30) | ‐0.14(‐0.38,0.11) | |
| SD ABA SC + MTX | 0.78(0.22,2.46) | 0.87(0.39,1.55) | ‐0.06(‐0.33,0.21) | |
| SD TOCI IV + MTX | 0.39(0.11,1.31) | 0.56(0.23,1.17) | ‐0.21(‐0.44,0.06) | |
| SD CERTO SC + DMARD | 0.60(0.12,3.11) | 0.74(0.25,1.75) | ‐0.12(‐0.43,0.27) | |
| SD ADA SC + DMARD | 0.52(0.06,4.99) | 0.67(0.12,1.95) | ‐0.15(‐0.50,0.36) | |
| SD TOCI SC + DMARD | 0.86(0.09,7.91) | 0.92(0.18,2.18) | ‐0.04(‐0.45,0.43) | |
| LD ADA SC | 0.24(0.08,0.74) | 0.38(0.18,0.82) | ‐0.29(‐0.52,‐0.06) | |
| LD ETN SC | 0.30(0.09,0.95) | 0.45(0.18,0.97) | ‐0.25(‐0.47,‐0.01) | |
| LD GOLI IV | 0.21(0.06,0.67) | 0.34(0.12,0.78) | ‐0.30(‐0.52,‐0.09) | |
| LD TOCI IV | 0.04(0.01,0.17) | 0.07(0.01,0.27) | ‐0.43(‐0.63,‐0.25) | |
| LD ADA SC + MTX | 0.74(0.21,2.46) | 0.84(0.38,1.57) | ‐0.07(‐0.34,0.21) | |
| LD RITUX IV + MTX | 0.65(0.23,1.80) | 0.78(0.39,1.37) | ‐0.10(‐0.34,0.14) | |
| LD ADA IV + MTX | 0.65(0.09,4.15) | 0.78(0.17,1.82) | ‐0.10(‐0.44,0.32) | |
| LD ABA IV + MTX | 0.39(0.14,1.05) | 0.55(0.26,1.03) | ‐0.21(‐0.41,0.01) | |
| LD ANA SC + MTX | 0.36(0.07,1.78) | 0.52(0.13,1.34) | ‐0.22(‐0.49,0.14) | |
| LD CERTO SC + MTX | 0.76(0.23,2.42) | 0.86(0.40,1.55) | ‐0.07(‐0.32,0.21) | |
| LD GOLI IV + MTX | 0.41(0.12,1.24) | 0.57(0.23,1.13) | ‐0.20(‐0.43,0.05) | |
| LD TOCI IV + MTX | 0.33(0.09,1.08) | 0.49(0.19,1.05) | ‐0.24(‐0.47,0.02) | |
| LD TOFA PO + MTX | 0.55(0.13,2.27) | 0.71(0.24,1.50) | ‐0.14(‐0.41,0.20) | |
| HD TOCI IV | 0.52(0.22,1.20) | 0.68(0.40,1.12) | ‐0.15(‐0.35,0.04) | |
| HD TOFA PO | 0.75(0.26,2.11) | 0.85(0.48,1.55) | ‐0.07(‐0.32,0.18) | |
| HD ADA SC | 0.34(0.11,1.07) | 0.50(0.24,1.04) | ‐0.24(‐0.47,0.01) | |
| HD GOLI SC | 0.57(0.20,1.49) | 0.72(0.38,1.27) | ‐0.13(‐0.36,0.10) | |
| HD ETN SC | 0.52(0.12,2.08) | 0.68(0.22,1.43) | ‐0.15(‐0.41,0.18) | |
| HD ABA SC | 1.01(0.21,5.24) | 1.01(0.39,2.09) | 0.00(‐0.35,0.37) | |
| HD TOCI IV + MTX | 0.91(0.36,2.18) | 0.95(0.57,1.53) | ‐0.02(‐0.24,0.19) | |
| HD INF IV + MTX | 0.83(0.30,2.14) | 0.91(0.50,1.50) | ‐0.04(‐0.28,0.18) | |
| HD TOFA PO + MTX | 0.71(0.25,1.87) | 0.83(0.42,1.41) | ‐0.08(‐0.31,0.15) | |
| HD GOLI SC + MTX | 0.97(0.35,2.58) | 0.99(0.55,1.63) | ‐0.01(‐0.25,0.23) | |
| HD CERTO SC + MTX | 1.28(0.49,3.17) | 1.13(0.69,1.77) | 0.06(‐0.17,0.27) | |
| HD ADA SC + MTX | 1.07(0.30,3.72) | 1.03(0.48,1.81) | 0.02(‐0.28,0.30) | |
| HD TOCI IV + DMARD | 0.62(0.08,5.30) | 0.76(0.16,1.99) | ‐0.11(‐0.47,0.37) | |
| SD ANA SC + SD ETN SC + MTX | 0.63(0.23,1.77) | 0.77(0.35,1.30) | ‐0.11(‐0.31,0.14) | |
| SD ANA SC + LD ETN SC + MTX | 0.93(0.35,2.55) | 0.96(0.49,1.49) | ‐0.02(‐0.24,0.21) | |
| SD CERTO SC + MTX | SD ABA IV + MTX | 1.48(0.77,2.87) | 1.24(0.87,1.84) | 0.09(‐0.06,0.25) |
| SD INF IV + MTX | 0.85(0.46,1.58) | 0.91(0.61,1.33) | ‐0.04(‐0.18,0.10) | |
| SD ADA SC + MTX | 1.87(0.76,4.62) | 1.37(0.85,2.22) | 0.15(‐0.07,0.36) | |
| SD TOFA PO + MTX | 1.73(0.74,3.98) | 1.33(0.84,2.08) | 0.13(‐0.07,0.32) | |
| SD GOLI SC + MTX | 1.75(0.77,4.07) | 1.34(0.87,2.17) | 0.13(‐0.06,0.33) | |
| SD RITUX IV + MTX | 0.91(0.39,2.12) | 0.95(0.54,1.55) | ‐0.02(‐0.20,0.18) | |
| SD GOLI IV + MTX | 0.62(0.28,1.41) | 0.74(0.41,1.24) | ‐0.10(‐0.27,0.08) | |
| SD ANA SC + MTX | 0.75(0.29,1.92) | 0.83(0.42,1.47) | ‐0.06(‐0.26,0.15) | |
| SD ABA SC + MTX | 1.07(0.47,2.38) | 1.04(0.60,1.58) | 0.02(‐0.16,0.20) | |
| SD TOCI IV + MTX | 0.54(0.19,1.59) | 0.67(0.29,1.33) | ‐0.13(‐0.34,0.11) | |
| SD CERTO SC + DMARD | 0.84(0.17,4.57) | 0.90(0.29,2.25) | ‐0.04(‐0.36,0.36) | |
| SD ADA SC + DMARD | 0.72(0.08,7.90) | 0.81(0.14,2.56) | ‐0.07(‐0.43,0.46) | |
| SD TOCI SC + DMARD | 1.18(0.12,11.75) | 1.10(0.21,2.85) | 0.04(‐0.38,0.52) | |
| LD ADA SC | 0.33(0.11,1.00) | 0.45(0.21,1.00) | ‐0.21(‐0.43,0.00) | |
| LD ETN SC | 0.42(0.11,1.47) | 0.55(0.20,1.30) | ‐0.17(‐0.41,0.08) | |
| LD GOLI IV | 0.29(0.09,0.82) | 0.41(0.16,0.88) | ‐0.23(‐0.41,‐0.04) | |
| LD TOCI IV | 0.05(0.01,0.22) | 0.08(0.02,0.31) | ‐0.35(‐0.55,‐0.18) | |
| LD ADA SC + MTX | 1.02(0.35,3.10) | 1.01(0.49,1.84) | 0.00(‐0.22,0.26) | |
| LD RITUX IV + MTX | 0.90(0.39,2.11) | 0.94(0.54,1.54) | ‐0.02(‐0.21,0.18) | |
| LD ADA IV + MTX | 0.90(0.14,5.40) | 0.94(0.22,2.18) | ‐0.02(‐0.34,0.38) | |
| LD ABA IV + MTX | 0.54(0.28,1.04) | 0.67(0.40,1.02) | ‐0.13(‐0.26,0.01) | |
| LD ANA SC + MTX | 0.50(0.11,2.13) | 0.63(0.18,1.53) | ‐0.14(‐0.37,0.18) | |
| LD CERTO SC + MTX | 1.06(0.40,2.92) | 1.03(0.54,1.80) | 0.01(‐0.20,0.25) | |
| LD GOLI IV + MTX | 0.56(0.19,1.54) | 0.68(0.30,1.30) | ‐0.12(‐0.32,0.10) | |
| LD TOCI IV + MTX | 0.46(0.16,1.33) | 0.59(0.26,1.20) | ‐0.16(‐0.36,0.06) | |
| LD TOFA PO + MTX | 0.77(0.21,2.79) | 0.85(0.32,1.73) | ‐0.06(‐0.30,0.24) | |
| HD TOCI IV | 0.72(0.36,1.49) | 0.81(0.53,1.31) | ‐0.07(‐0.24,0.08) | |
| HD TOFA PO | 1.03(0.37,3.13) | 1.02(0.56,2.06) | 0.01(‐0.24,0.26) | |
| HD ADA SC | 0.47(0.16,1.49) | 0.60(0.29,1.32) | ‐0.16(‐0.38,0.08) | |
| HD GOLI SC | 0.79(0.33,1.92) | 0.86(0.49,1.51) | ‐0.05(‐0.25,0.14) | |
| HD ETN SC | 0.73(0.15,3.56) | 0.82(0.25,1.99) | ‐0.07(‐0.35,0.30) | |
| HD ABA SC | 1.41(0.28,7.27) | 1.21(0.45,2.68) | 0.08(‐0.28,0.45) | |
| HD TOCI IV + MTX | 1.26(0.62,2.64) | 1.14(0.76,1.78) | 0.05(‐0.12,0.23) | |
| HD INF IV + MTX | 1.15(0.53,2.49) | 1.08(0.67,1.68) | 0.03(‐0.14,0.21) | |
| HD TOFA PO + MTX | 0.98(0.42,2.28) | 0.99(0.57,1.61) | 0.00(‐0.20,0.20) | |
| HD GOLI SC + MTX | 1.35(0.59,3.12) | 1.18(0.73,1.92) | 0.07(‐0.12,0.27) | |
| HD CERTO SC + MTX | 1.77(0.87,3.66) | 1.34(0.92,2.05) | 0.14(‐0.03,0.30) | |
| HD ADA SC + MTX | 1.48(0.47,4.65) | 1.24(0.62,2.18) | 0.09(‐0.16,0.35) | |
| HD TOCI IV + DMARD | 0.86(0.10,8.16) | 0.91(0.18,2.62) | ‐0.04(‐0.40,0.46) | |
| SD ANA SC + SD ETN SC + MTX | 0.88(0.24,3.53) | 0.92(0.37,1.97) | ‐0.03(‐0.29,0.29) | |
| SD ANA SC + LD ETN SC + MTX | 1.30(0.36,4.98) | 1.15(0.50,2.24) | 0.06(‐0.22,0.37) | |
| SD INF IV + MTX | SD CERTO SC + MTX | 0.58(0.29,1.14) | 0.73(0.47,1.07) | ‐0.13(‐0.29,0.03) |
| SD ADA SC + MTX | 1.26(0.51,3.23) | 1.11(0.70,1.71) | 0.05(‐0.16,0.27) | |
| SD TOFA PO + MTX | 1.17(0.49,2.73) | 1.08(0.69,1.62) | 0.04(‐0.17,0.24) | |
| SD GOLI SC + MTX | 1.19(0.52,2.71) | 1.08(0.71,1.62) | 0.04(‐0.15,0.24) | |
| SD RITUX IV + MTX | 0.62(0.26,1.44) | 0.76(0.43,1.21) | ‐0.11(‐0.30,0.09) | |
| SD GOLI IV + MTX | 0.42(0.19,0.95) | 0.60(0.33,0.97) | ‐0.19(‐0.37,‐0.01) | |
| SD ANA SC + MTX | 0.50(0.20,1.32) | 0.67(0.35,1.15) | ‐0.16(‐0.35,0.07) | |
| SD ABA SC + MTX | 0.72(0.25,2.00) | 0.84(0.41,1.39) | ‐0.08(‐0.31,0.17) | |
| SD TOCI IV + MTX | 0.37(0.12,1.09) | 0.54(0.23,1.05) | ‐0.22(‐0.43,0.02) | |
| SD CERTO SC + DMARD | 0.56(0.11,3.11) | 0.72(0.24,1.74) | ‐0.14(‐0.46,0.27) | |
| SD ADA SC + DMARD | 0.49(0.05,5.17) | 0.66(0.12,1.93) | ‐0.16(‐0.52,0.36) | |
| SD TOCI SC + DMARD | 0.80(0.08,7.86) | 0.89(0.17,2.15) | ‐0.05(‐0.48,0.43) | |
| LD ADA SC | 0.22(0.07,0.68) | 0.37(0.17,0.77) | ‐0.31(‐0.53,‐0.08) | |
| LD ETN SC | 0.28(0.08,1.00) | 0.44(0.17,1.00) | ‐0.27(‐0.51,0.00) | |
| LD GOLI IV | 0.20(0.06,0.56) | 0.33(0.13,0.70) | ‐0.32(‐0.51,‐0.13) | |
| LD TOCI IV | 0.03(0.01,0.14) | 0.07(0.01,0.24) | ‐0.45(‐0.64,‐0.27) | |
| LD ADA SC + MTX | 0.68(0.24,2.10) | 0.82(0.40,1.42) | ‐0.09(‐0.32,0.18) | |
| LD RITUX IV + MTX | 0.60(0.26,1.43) | 0.76(0.43,1.21) | ‐0.12(‐0.30,0.09) | |
| LD ADA IV + MTX | 0.60(0.09,3.69) | 0.76(0.17,1.69) | ‐0.12(‐0.44,0.29) | |
| LD ABA IV + MTX | 0.36(0.16,0.83) | 0.53(0.29,0.90) | ‐0.22(‐0.39,‐0.04) | |
| LD ANA SC + MTX | 0.34(0.07,1.47) | 0.51(0.14,1.21) | ‐0.23(‐0.48,0.09) | |
| LD CERTO SC + MTX | 0.71(0.30,1.75) | 0.83(0.46,1.30) | ‐0.08(‐0.27,0.13) | |
| LD GOLI IV + MTX | 0.38(0.13,1.04) | 0.55(0.24,1.02) | ‐0.22(‐0.42,0.01) | |
| LD TOCI IV + MTX | 0.31(0.10,0.89) | 0.47(0.20,0.94) | ‐0.25(‐0.46,‐0.03) | |
| LD TOFA PO + MTX | 0.52(0.14,1.87) | 0.68(0.26,1.34) | ‐0.15(‐0.40,0.15) | |
| HD TOCI IV | 0.49(0.25,0.99) | 0.66(0.43,0.99) | ‐0.17(‐0.33,0.00) | |
| HD TOFA PO | 0.70(0.24,2.03) | 0.82(0.47,1.52) | ‐0.09(‐0.33,0.17) | |
| HD ADA SC | 0.32(0.11,0.98) | 0.48(0.24,0.99) | ‐0.25(‐0.48,0.00) | |
| HD GOLI SC | 0.53(0.22,1.29) | 0.70(0.40,1.15) | ‐0.15(‐0.34,0.06) | |
| HD ETN SC | 0.50(0.10,2.34) | 0.67(0.20,1.52) | ‐0.16(‐0.46,0.20) | |
| HD ABA SC | 0.94(0.20,5.03) | 0.97(0.38,2.04) | ‐0.01(‐0.37,0.36) | |
| HD TOCI IV + MTX | 0.85(0.42,1.78) | 0.92(0.62,1.37) | ‐0.04(‐0.21,0.14) | |
| HD INF IV + MTX | 0.78(0.35,1.72) | 0.88(0.54,1.32) | ‐0.06(‐0.24,0.13) | |
| HD TOFA PO + MTX | 0.66(0.28,1.53) | 0.80(0.46,1.25) | ‐0.10(‐0.29,0.10) | |
| HD GOLI SC + MTX | 0.91(0.40,2.14) | 0.95(0.60,1.46) | ‐0.02(‐0.22,0.18) | |
| HD CERTO SC + MTX | 1.19(0.73,1.95) | 1.09(0.85,1.39) | 0.04(‐0.08,0.16) | |
| HD ADA SC + MTX | 0.99(0.33,3.20) | 1.00(0.51,1.66) | 0.00(‐0.25,0.27) | |
| HD TOCI IV + DMARD | 0.58(0.07,5.40) | 0.74(0.15,2.00) | ‐0.13(‐0.50,0.38) | |
| SD ANA SC + SD ETN SC + MTX | 0.59(0.16,2.30) | 0.75(0.30,1.49) | ‐0.12(‐0.39,0.20) | |
| SD ANA SC + LD ETN SC + MTX | 0.88(0.24,3.37) | 0.93(0.41,1.72) | ‐0.03(‐0.32,0.28) | |
| SD ADA SC + MTX | SD INF IV + MTX | 2.18(0.86,5.75) | 1.51(0.92,2.57) | 0.18(‐0.04,0.40) |
| SD TOFA PO + MTX | 2.03(0.85,4.87) | 1.46(0.91,2.42) | 0.17(‐0.04,0.37) | |
| SD GOLI SC + MTX | 2.06(0.89,4.80) | 1.48(0.94,2.44) | 0.17(‐0.03,0.36) | |
| SD RITUX IV + MTX | 1.06(0.45,2.52) | 1.04(0.59,1.76) | 0.01(‐0.17,0.21) | |
| SD GOLI IV + MTX | 0.73(0.31,1.69) | 0.81(0.44,1.41) | ‐0.07(‐0.24,0.11) | |
| SD ANA SC + MTX | 0.87(0.34,2.30) | 0.91(0.47,1.67) | ‐0.03(‐0.22,0.19) | |
| SD ABA SC + MTX | 1.25(0.44,3.44) | 1.14(0.57,2.02) | 0.05(‐0.17,0.29) | |
| SD TOCI IV + MTX | 0.63(0.22,1.93) | 0.73(0.32,1.52) | ‐0.09(‐0.30,0.15) | |
| SD CERTO SC + DMARD | 0.97(0.20,5.33) | 0.98(0.32,2.58) | ‐0.01(‐0.32,0.39) | |
| SD ADA SC + DMARD | 0.84(0.10,8.93) | 0.90(0.16,2.89) | ‐0.04(‐0.39,0.48) | |
| SD TOCI SC + DMARD | 1.37(0.15,14.07) | 1.20(0.23,3.21) | 0.07(‐0.34,0.55) | |
| LD ADA SC | 0.39(0.13,1.20) | 0.50(0.22,1.15) | ‐0.17(‐0.40,0.03) | |
| LD ETN SC | 0.48(0.13,1.78) | 0.60(0.22,1.48) | ‐0.14(‐0.38,0.12) | |
| LD GOLI IV | 0.34(0.11,0.99) | 0.45(0.17,0.99) | ‐0.19(‐0.38,0.00) | |
| LD TOCI IV | 0.06(0.01,0.25) | 0.09(0.02,0.34) | ‐0.32(‐0.51,‐0.16) | |
| LD ADA SC + MTX | 1.18(0.40,3.77) | 1.10(0.53,2.12) | 0.04(‐0.19,0.31) | |
| LD RITUX IV + MTX | 1.05(0.45,2.50) | 1.03(0.58,1.74) | 0.01(‐0.17,0.21) | |
| LD ADA IV + MTX | 1.04(0.17,6.64) | 1.03(0.24,2.47) | 0.01(‐0.30,0.43) | |
| LD ABA IV + MTX | 0.63(0.28,1.45) | 0.73(0.40,1.27) | ‐0.09(‐0.26,0.08) | |
| LD ANA SC + MTX | 0.59(0.13,2.58) | 0.70(0.19,1.72) | ‐0.10(‐0.34,0.22) | |
| LD CERTO SC + MTX | 1.24(0.45,3.54) | 1.13(0.58,2.06) | 0.05(‐0.17,0.29) | |
| LD GOLI IV + MTX | 0.66(0.23,1.87) | 0.75(0.34,1.49) | ‐0.09(‐0.29,0.14) | |
| LD TOCI IV + MTX | 0.54(0.18,1.62) | 0.65(0.28,1.36) | ‐0.12(‐0.32,0.10) | |
| LD TOFA PO + MTX | 0.90(0.24,3.31) | 0.94(0.35,1.96) | ‐0.02(‐0.27,0.28) | |
| HD TOCI IV | 0.85(0.41,1.80) | 0.90(0.57,1.51) | ‐0.04(‐0.21,0.12) | |
| HD TOFA PO | 1.20(0.41,3.71) | 1.12(0.60,2.35) | 0.04(‐0.21,0.29) | |
| HD ADA SC | 0.55(0.18,1.77) | 0.66(0.31,1.51) | ‐0.12(‐0.36,0.12) | |
| HD GOLI SC | 0.93(0.38,2.26) | 0.96(0.53,1.70) | ‐0.02(‐0.22,0.18) | |
| HD ETN SC | 0.86(0.18,4.11) | 0.90(0.27,2.21) | ‐0.03(‐0.32,0.33) | |
| HD ABA SC | 1.66(0.34,8.63) | 1.33(0.50,3.05) | 0.12(‐0.24,0.48) | |
| HD TOCI IV + MTX | 1.47(0.70,3.18) | 1.25(0.81,2.06) | 0.09(‐0.08,0.27) | |
| HD INF IV + MTX | 1.34(0.72,2.58) | 1.19(0.81,1.76) | 0.07(‐0.07,0.22) | |
| HD TOFA PO + MTX | 1.14(0.49,2.74) | 1.09(0.63,1.85) | 0.03(‐0.16,0.23) | |
| HD GOLI SC + MTX | 1.58(0.68,3.68) | 1.30(0.79,2.17) | 0.11(‐0.09,0.30) | |
| HD CERTO SC + MTX | 2.07(0.98,4.36) | 1.48(0.99,2.34) | 0.17(0.00,0.34) | |
| HD ADA SC + MTX | 1.72(0.56,5.49) | 1.36(0.68,2.48) | 0.13(‐0.13,0.39) | |
| HD TOCI IV + DMARD | 1.00(0.12,9.28) | 1.00(0.20,2.94) | 0.00(‐0.37,0.49) | |
| SD ANA SC + SD ETN SC + MTX | 1.03(0.28,4.10) | 1.02(0.40,2.22) | 0.01(‐0.26,0.33) | |
| SD ANA SC + LD ETN SC + MTX | 1.51(0.41,5.90) | 1.27(0.55,2.56) | 0.10(‐0.19,0.41) | |
| SD TOFA PO + MTX | SD ADA SC + MTX | 0.93(0.32,2.60) | 0.97(0.58,1.61) | ‐0.02(‐0.26,0.23) |
| SD GOLI SC + MTX | 0.94(0.33,2.66) | 0.97(0.60,1.63) | ‐0.01(‐0.26,0.23) | |
| SD RITUX IV + MTX | 0.49(0.16,1.39) | 0.69(0.36,1.20) | ‐0.17(‐0.41,0.08) | |
| SD GOLI IV + MTX | 0.33(0.11,0.94) | 0.54(0.28,0.96) | ‐0.25(‐0.48,‐0.02) | |
| SD ANA SC + MTX | 0.40(0.13,1.26) | 0.61(0.29,1.13) | ‐0.21(‐0.45,0.05) | |
| SD ABA SC + MTX | 0.57(0.17,1.94) | 0.76(0.35,1.38) | ‐0.13(‐0.40,0.16) | |
| SD TOCI IV + MTX | 0.29(0.08,1.00) | 0.49(0.20,1.00) | ‐0.27(‐0.53,0.00) | |
| SD CERTO SC + DMARD | 0.45(0.08,2.71) | 0.65(0.22,1.63) | ‐0.19(‐0.54,0.23) | |
| SD ADA SC + DMARD | 0.39(0.04,4.54) | 0.59(0.10,1.81) | ‐0.22(‐0.61,0.33) | |
| SD TOCI SC + DMARD | 0.63(0.06,6.86) | 0.80(0.15,2.04) | ‐0.11(‐0.57,0.40) | |
| LD ADA SC | 0.18(0.05,0.62) | 0.33(0.15,0.72) | ‐0.36(‐0.61,‐0.10) | |
| LD ETN SC | 0.22(0.05,0.91) | 0.40(0.15,0.94) | ‐0.32(‐0.60,‐0.02) | |
| LD GOLI IV | 0.15(0.04,0.52) | 0.30(0.11,0.67) | ‐0.38(‐0.61,‐0.13) | |
| LD TOCI IV | 0.03(0.00,0.13) | 0.06(0.01,0.23) | ‐0.51(‐0.73,‐0.27) | |
| LD ADA SC + MTX | 0.54(0.21,1.44) | 0.74(0.39,1.19) | ‐0.14(‐0.35,0.09) | |
| LD RITUX IV + MTX | 0.48(0.16,1.38) | 0.68(0.35,1.19) | ‐0.17(‐0.42,0.08) | |
| LD ADA IV + MTX | 0.48(0.07,3.13) | 0.69(0.16,1.58) | ‐0.17(‐0.51,0.26) | |
| LD ABA IV + MTX | 0.29(0.10,0.81) | 0.48(0.24,0.89) | ‐0.28(‐0.50,‐0.05) | |
| LD ANA SC + MTX | 0.27(0.05,1.29) | 0.46(0.12,1.14) | ‐0.28(‐0.57,0.06) | |
| LD CERTO SC + MTX | 0.57(0.17,1.85) | 0.75(0.37,1.36) | ‐0.13(‐0.40,0.14) | |
| LD GOLI IV + MTX | 0.30(0.09,0.98) | 0.50(0.21,0.99) | ‐0.27(‐0.51,‐0.01) | |
| LD TOCI IV + MTX | 0.25(0.07,0.83) | 0.43(0.18,0.90) | ‐0.30(‐0.55,‐0.04) | |
| LD TOFA PO + MTX | 0.41(0.09,1.73) | 0.62(0.22,1.30) | ‐0.20(‐0.50,0.13) | |
| HD TOCI IV | 0.39(0.15,0.98) | 0.59(0.37,0.99) | ‐0.22(‐0.44,‐0.01) | |
| HD TOFA PO | 0.55(0.16,1.84) | 0.74(0.42,1.44) | ‐0.14(‐0.42,0.14) | |
| HD ADA SC | 0.26(0.07,0.90) | 0.44(0.21,0.94) | ‐0.30(‐0.56,‐0.02) | |
| HD GOLI SC | 0.42(0.14,1.25) | 0.63(0.34,1.14) | ‐0.20(‐0.44,0.05) | |
| HD ETN SC | 0.39(0.07,2.09) | 0.60(0.18,1.44) | ‐0.21(‐0.54,0.18) | |
| HD ABA SC | 0.75(0.14,4.22) | 0.87(0.34,1.90) | ‐0.07(‐0.44,0.33) | |
| HD TOCI IV + MTX | 0.67(0.25,1.75) | 0.83(0.52,1.36) | ‐0.10(‐0.32,0.13) | |
| HD INF IV + MTX | 0.62(0.22,1.72) | 0.79(0.45,1.33) | ‐0.12(‐0.35,0.13) | |
| HD TOFA PO + MTX | 0.53(0.18,1.46) | 0.72(0.39,1.24) | ‐0.15(‐0.39,0.09) | |
| HD GOLI SC + MTX | 0.72(0.25,2.04) | 0.86(0.50,1.44) | ‐0.08(‐0.32,0.17) | |
| HD CERTO SC + MTX | 0.94(0.36,2.41) | 0.97(0.63,1.58) | ‐0.01(‐0.24,0.21) | |
| HD ADA SC + MTX | 0.79(0.30,2.09) | 0.90(0.50,1.38) | ‐0.05(‐0.28,0.17) | |
| HD TOCI IV + DMARD | 0.47(0.05,4.71) | 0.67(0.13,1.86) | ‐0.18(‐0.58,0.34) | |
| SD ANA SC + SD ETN SC + MTX | 0.47(0.11,2.11) | 0.67(0.26,1.44) | ‐0.18(‐0.48,0.18) | |
| SD ANA SC + LD ETN SC + MTX | 0.69(0.16,3.13) | 0.84(0.36,1.67) | ‐0.09(‐0.41,0.26) | |
| SD GOLI SC + MTX | SD TOFA PO + MTX | 1.02(0.39,2.62) | 1.01(0.64,1.63) | 0.00(‐0.22,0.23) |
| SD RITUX IV + MTX | 0.53(0.19,1.44) | 0.71(0.38,1.21) | ‐0.15(‐0.38,0.09) | |
| SD GOLI IV + MTX | 0.36(0.14,0.97) | 0.56(0.29,0.98) | ‐0.23(‐0.44,‐0.01) | |
| SD ANA SC + MTX | 0.43(0.15,1.31) | 0.62(0.31,1.16) | ‐0.20(‐0.42,0.06) | |
| SD ABA SC + MTX | 0.62(0.19,2.01) | 0.78(0.37,1.41) | ‐0.11(‐0.37,0.17) | |
| SD TOCI IV + MTX | 0.31(0.09,1.05) | 0.50(0.21,1.03) | ‐0.26(‐0.49,0.01) | |
| SD CERTO SC + DMARD | 0.48(0.09,2.99) | 0.67(0.22,1.70) | ‐0.17(‐0.51,0.26) | |
| SD ADA SC + DMARD | 0.41(0.04,4.67) | 0.60(0.10,1.92) | ‐0.21(‐0.58,0.34) | |
| SD TOCI SC + DMARD | 0.68(0.07,7.40) | 0.82(0.16,2.18) | ‐0.09(‐0.53,0.42) | |
| LD ADA SC | 0.19(0.06,0.67) | 0.34(0.16,0.76) | ‐0.35(‐0.58,‐0.08) | |
| LD ETN SC | 0.24(0.06,0.99) | 0.41(0.15,1.00) | ‐0.31(‐0.56,0.00) | |
| LD GOLI IV | 0.17(0.05,0.54) | 0.31(0.11,0.69) | ‐0.36(‐0.58,‐0.12) | |
| LD TOCI IV | 0.03(0.00,0.14) | 0.06(0.01,0.24) | ‐0.49(‐0.70,‐0.26) | |
| LD ADA SC + MTX | 0.59(0.18,2.01) | 0.76(0.36,1.39) | ‐0.13(‐0.38,0.16) | |
| LD RITUX IV + MTX | 0.52(0.19,1.41) | 0.71(0.38,1.20) | ‐0.15(‐0.38,0.08) | |
| LD ADA IV + MTX | 0.53(0.08,3.36) | 0.71(0.16,1.66) | ‐0.15(‐0.49,0.27) | |
| LD ABA IV + MTX | 0.31(0.12,0.83) | 0.50(0.26,0.90) | ‐0.26(‐0.47,‐0.04) | |
| LD ANA SC + MTX | 0.29(0.06,1.38) | 0.47(0.13,1.18) | ‐0.27(‐0.54,0.08) | |
| LD CERTO SC + MTX | 0.61(0.20,1.91) | 0.78(0.38,1.39) | ‐0.12(‐0.37,0.15) | |
| LD GOLI IV + MTX | 0.32(0.10,1.01) | 0.51(0.22,1.00) | ‐0.25(‐0.48,0.00) | |
| LD TOCI IV + MTX | 0.26(0.08,0.90) | 0.44(0.18,0.94) | ‐0.29(‐0.52,‐0.02) | |
| LD TOFA PO + MTX | 0.45(0.14,1.41) | 0.64(0.26,1.17) | ‐0.18(‐0.42,0.08) | |
| HD TOCI IV | 0.42(0.18,1.04) | 0.61(0.38,1.02) | ‐0.21(‐0.40,0.01) | |
| HD TOFA PO | 0.60(0.18,1.99) | 0.76(0.42,1.50) | ‐0.13(‐0.40,0.16) | |
| HD ADA SC | 0.27(0.08,0.97) | 0.45(0.22,0.98) | ‐0.29(‐0.54,‐0.01) | |
| HD GOLI SC | 0.46(0.17,1.26) | 0.65(0.36,1.14) | ‐0.18(‐0.41,0.05) | |
| HD ETN SC | 0.42(0.08,2.30) | 0.62(0.18,1.51) | ‐0.20(‐0.50,0.20) | |
| HD ABA SC | 0.82(0.16,4.55) | 0.91(0.35,1.97) | ‐0.05(‐0.42,0.34) | |
| HD TOCI IV + MTX | 0.73(0.30,1.84) | 0.85(0.55,1.41) | ‐0.08(‐0.28,0.14) | |
| HD INF IV + MTX | 0.66(0.26,1.74) | 0.81(0.48,1.34) | ‐0.10(‐0.31,0.13) | |
| HD TOFA PO + MTX | 0.57(0.31,1.05) | 0.74(0.50,1.03) | ‐0.13(‐0.28,0.01) | |
| HD GOLI SC + MTX | 0.78(0.30,2.06) | 0.89(0.53,1.46) | ‐0.06(‐0.28,0.17) | |
| HD CERTO SC + MTX | 1.02(0.42,2.56) | 1.01(0.67,1.61) | 0.01(‐0.20,0.22) | |
| HD ADA SC + MTX | 0.86(0.24,3.07) | 0.93(0.45,1.67) | ‐0.04(‐0.32,0.26) | |
| HD TOCI IV + DMARD | 0.50(0.06,4.95) | 0.68(0.14,1.96) | ‐0.16(‐0.55,0.35) | |
| SD ANA SC + SD ETN SC + MTX | 0.51(0.12,2.21) | 0.70(0.27,1.46) | ‐0.16(‐0.45,0.19) | |
| SD ANA SC + LD ETN SC + MTX | 0.75(0.19,3.18) | 0.87(0.37,1.70) | ‐0.07(‐0.38,0.27) | |
| SD RITUX IV + MTX | SD GOLI SC + MTX | 0.52(0.19,1.41) | 0.71(0.38,1.19) | ‐0.15(‐0.38,0.08) |
| SD GOLI IV + MTX | 0.36(0.14,0.92) | 0.55(0.29,0.95) | ‐0.23(‐0.44,‐0.02) | |
| SD ANA SC + MTX | 0.43(0.15,1.22) | 0.62(0.30,1.11) | ‐0.20(‐0.42,0.05) | |
| SD ABA SC + MTX | 0.61(0.19,1.90) | 0.78(0.37,1.36) | ‐0.12(‐0.37,0.15) | |
| SD TOCI IV + MTX | 0.31(0.09,1.02) | 0.49(0.21,1.01) | ‐0.26(‐0.50,0.00) | |
| SD CERTO SC + DMARD | 0.47(0.09,2.81) | 0.66(0.22,1.66) | ‐0.18(‐0.50,0.25) | |
| SD ADA SC + DMARD | 0.41(0.04,4.63) | 0.60(0.10,1.87) | ‐0.21(‐0.57,0.34) | |
| SD TOCI SC + DMARD | 0.67(0.07,6.90) | 0.82(0.16,2.04) | ‐0.10(‐0.52,0.40) | |
| LD ADA SC | 0.19(0.06,0.64) | 0.34(0.16,0.74) | ‐0.35(‐0.58,‐0.09) | |
| LD ETN SC | 0.24(0.06,0.89) | 0.41(0.15,0.93) | ‐0.31(‐0.57,‐0.03) | |
| LD GOLI IV | 0.16(0.05,0.52) | 0.30(0.11,0.67) | ‐0.36(‐0.57,‐0.14) | |
| LD TOCI IV | 0.03(0.00,0.14) | 0.06(0.01,0.24) | ‐0.49(‐0.70,‐0.27) | |
| LD ADA SC + MTX | 0.58(0.18,1.98) | 0.75(0.35,1.40) | ‐0.13(‐0.39,0.16) | |
| LD RITUX IV + MTX | 0.51(0.19,1.37) | 0.70(0.37,1.19) | ‐0.16(‐0.38,0.08) | |
| LD ADA IV + MTX | 0.51(0.07,3.30) | 0.70(0.16,1.65) | ‐0.15(‐0.50,0.27) | |
| LD ABA IV + MTX | 0.31(0.12,0.80) | 0.49(0.25,0.88) | ‐0.26(‐0.46,‐0.05) | |
| LD ANA SC + MTX | 0.28(0.06,1.32) | 0.47(0.13,1.15) | ‐0.27(‐0.53,0.07) | |
| LD CERTO SC + MTX | 0.61(0.20,1.83) | 0.77(0.38,1.34) | ‐0.12(‐0.37,0.14) | |
| LD GOLI IV + MTX | 0.32(0.10,0.97) | 0.51(0.22,0.99) | ‐0.26(‐0.49,‐0.01) | |
| LD TOCI IV + MTX | 0.26(0.08,0.86) | 0.44(0.19,0.92) | ‐0.29(‐0.52,‐0.03) | |
| LD TOFA PO + MTX | 0.44(0.11,1.66) | 0.64(0.23,1.27) | ‐0.19(‐0.45,0.12) | |
| HD TOCI IV | 0.41(0.18,0.97) | 0.61(0.38,0.98) | ‐0.21(‐0.40,‐0.01) | |
| HD TOFA PO | 0.58(0.19,1.91) | 0.75(0.43,1.46) | ‐0.13(‐0.39,0.15) | |
| HD ADA SC | 0.27(0.08,0.90) | 0.45(0.22,0.94) | ‐0.29(‐0.53,‐0.02) | |
| HD GOLI SC | 0.45(0.20,1.02) | 0.65(0.39,1.02) | ‐0.19(‐0.37,0.01) | |
| HD ETN SC | 0.41(0.08,2.13) | 0.61(0.18,1.44) | ‐0.20(‐0.51,0.18) | |
| HD ABA SC | 0.80(0.16,4.44) | 0.90(0.35,1.94) | ‐0.05(‐0.42,0.34) | |
| HD TOCI IV + MTX | 0.71(0.30,1.73) | 0.85(0.54,1.35) | ‐0.08(‐0.28,0.13) | |
| HD INF IV + MTX | 0.66(0.26,1.65) | 0.81(0.47,1.29) | ‐0.10(‐0.32,0.12) | |
| HD TOFA PO + MTX | 0.56(0.21,1.46) | 0.74(0.41,1.21) | ‐0.14(‐0.36,0.09) | |
| HD GOLI SC + MTX | 0.77(0.41,1.44) | 0.88(0.62,1.20) | ‐0.06(‐0.21,0.09) | |
| HD CERTO SC + MTX | 1.01(0.42,2.41) | 1.00(0.66,1.54) | 0.00(‐0.21,0.21) | |
| HD ADA SC + MTX | 0.84(0.24,2.97) | 0.92(0.44,1.62) | ‐0.04(‐0.33,0.25) | |
| HD TOCI IV + DMARD | 0.49(0.05,4.87) | 0.68(0.14,1.91) | ‐0.17(‐0.55,0.35) | |
| SD ANA SC + SD ETN SC + MTX | 0.50(0.12,2.19) | 0.69(0.26,1.45) | ‐0.16(‐0.45,0.18) | |
| SD ANA SC + LD ETN SC + MTX | 0.74(0.18,3.07) | 0.86(0.37,1.65) | ‐0.07(‐0.38,0.26) | |
| SD GOLI IV + MTX | SD RITUX IV + MTX | 0.69(0.25,1.77) | 0.79(0.40,1.48) | ‐0.08(‐0.30,0.12) |
| SD ANA SC + MTX | 0.82(0.28,2.52) | 0.88(0.42,1.80) | ‐0.04(‐0.28,0.20) | |
| SD ABA SC + MTX | 1.17(0.36,3.75) | 1.10(0.51,2.18) | 0.04(‐0.22,0.30) | |
| SD TOCI IV + MTX | 0.59(0.18,1.97) | 0.71(0.29,1.56) | ‐0.11(‐0.35,0.15) | |
| SD CERTO SC + DMARD | 0.90(0.17,5.65) | 0.94(0.30,2.70) | ‐0.02(‐0.36,0.39) | |
| SD ADA SC + DMARD | 0.78(0.08,9.40) | 0.86(0.15,3.09) | ‐0.05(‐0.43,0.49) | |
| SD TOCI SC + DMARD | 1.27(0.13,14.09) | 1.15(0.22,3.44) | 0.06(‐0.37,0.56) | |
| LD ADA SC | 0.36(0.11,1.28) | 0.48(0.21,1.21) | ‐0.19(‐0.45,0.04) | |
| LD ETN SC | 0.46(0.11,1.83) | 0.58(0.21,1.50) | ‐0.15(‐0.43,0.12) | |
| LD GOLI IV | 0.32(0.09,1.04) | 0.43(0.16,1.03) | ‐0.20(‐0.43,0.01) | |
| LD TOCI IV | 0.06(0.01,0.26) | 0.09(0.02,0.34) | ‐0.33(‐0.57,‐0.14) | |
| LD ADA SC + MTX | 1.11(0.34,3.88) | 1.06(0.49,2.22) | 0.02(‐0.24,0.31) | |
| LD RITUX IV + MTX | 0.99(0.51,1.88) | 0.99(0.65,1.51) | 0.00(‐0.15,0.14) | |
| LD ADA IV + MTX | 1.00(0.14,6.65) | 1.00(0.23,2.57) | 0.00(‐0.35,0.43) | |
| LD ABA IV + MTX | 0.59(0.22,1.57) | 0.70(0.36,1.36) | ‐0.11(‐0.32,0.10) | |
| LD ANA SC + MTX | 0.54(0.11,2.68) | 0.66(0.18,1.80) | ‐0.12(‐0.39,0.23) | |
| LD CERTO SC + MTX | 1.15(0.37,3.69) | 1.09(0.53,2.17) | 0.03(‐0.22,0.30) | |
| LD GOLI IV + MTX | 0.61(0.19,1.96) | 0.72(0.31,1.55) | ‐0.10(‐0.34,0.14) | |
| LD TOCI IV + MTX | 0.50(0.15,1.65) | 0.62(0.26,1.41) | ‐0.14(‐0.37,0.11) | |
| LD TOFA PO + MTX | 0.84(0.21,3.37) | 0.90(0.33,2.03) | ‐0.04(‐0.31,0.28) | |
| HD TOCI IV | 0.79(0.33,1.93) | 0.86(0.51,1.59) | ‐0.05(‐0.26,0.13) | |
| HD TOFA PO | 1.12(0.34,3.93) | 1.07(0.54,2.48) | 0.03(‐0.25,0.30) | |
| HD ADA SC | 0.52(0.15,1.84) | 0.64(0.29,1.58) | ‐0.13(‐0.40,0.12) | |
| HD GOLI SC | 0.87(0.31,2.43) | 0.91(0.48,1.82) | ‐0.03(‐0.26,0.19) | |
| HD ETN SC | 0.80(0.15,4.28) | 0.87(0.26,2.31) | ‐0.05(‐0.37,0.33) | |
| HD ABA SC | 1.53(0.28,9.04) | 1.27(0.46,3.25) | 0.10(‐0.28,0.49) | |
| HD TOCI IV + MTX | 1.38(0.56,3.47) | 1.20(0.73,2.24) | 0.07(‐0.14,0.28) | |
| HD INF IV + MTX | 1.27(0.48,3.24) | 1.14(0.64,2.10) | 0.05(‐0.17,0.27) | |
| HD TOFA PO + MTX | 1.07(0.39,2.89) | 1.04(0.55,1.96) | 0.01(‐0.21,0.24) | |
| HD GOLI SC + MTX | 1.48(0.54,3.96) | 1.25(0.71,2.34) | 0.09(‐0.14,0.32) | |
| HD CERTO SC + MTX | 1.94(0.79,4.73) | 1.42(0.89,2.54) | 0.16(‐0.06,0.36) | |
| HD ADA SC + MTX | 1.62(0.47,5.96) | 1.30(0.62,2.63) | 0.11(‐0.17,0.40) | |
| HD TOCI IV + DMARD | 0.92(0.11,9.66) | 0.95(0.19,3.11) | ‐0.02(‐0.40,0.49) | |
| SD ANA SC + SD ETN SC + MTX | 0.96(0.23,4.34) | 0.97(0.37,2.35) | ‐0.01(‐0.31,0.34) | |
| SD ANA SC + LD ETN SC + MTX | 1.41(0.34,6.29) | 1.21(0.51,2.72) | 0.08(‐0.23,0.41) | |
| SD ANA SC + MTX | SD GOLI IV + MTX | 1.19(0.42,3.49) | 1.13(0.54,2.32) | 0.04(‐0.17,0.27) |
| SD ABA SC + MTX | 1.71(0.53,5.26) | 1.41(0.65,2.84) | 0.12(‐0.13,0.37) | |
| SD TOCI IV + MTX | 0.86(0.27,2.91) | 0.90(0.37,2.08) | ‐0.03(‐0.25,0.22) | |
| SD CERTO SC + DMARD | 1.33(0.25,7.66) | 1.21(0.36,3.53) | 0.06(‐0.26,0.44) | |
| SD ADA SC + DMARD | 1.16(0.12,13.18) | 1.11(0.18,3.92) | 0.03(‐0.33,0.56) | |
| SD TOCI SC + DMARD | 1.89(0.19,19.88) | 1.48(0.28,4.42) | 0.14(‐0.27,0.62) | |
| LD ADA SC | 0.53(0.16,1.75) | 0.62(0.26,1.55) | ‐0.11(‐0.34,0.09) | |
| LD ETN SC | 0.66(0.17,2.67) | 0.74(0.26,2.06) | ‐0.07(‐0.32,0.19) | |
| LD GOLI IV | 0.46(0.17,1.20) | 0.55(0.24,1.14) | ‐0.12(‐0.30,0.03) | |
| LD TOCI IV | 0.08(0.01,0.38) | 0.11(0.02,0.44) | ‐0.25(‐0.46,‐0.10) | |
| LD ADA SC + MTX | 1.62(0.51,5.62) | 1.36(0.62,2.92) | 0.10(‐0.14,0.38) | |
| LD RITUX IV + MTX | 1.43(0.55,3.95) | 1.26(0.66,2.51) | 0.07(‐0.13,0.30) | |
| LD ADA IV + MTX | 1.44(0.21,9.33) | 1.27(0.28,3.37) | 0.08(‐0.25,0.49) | |
| LD ABA IV + MTX | 0.87(0.33,2.24) | 0.90(0.45,1.79) | ‐0.03(‐0.22,0.16) | |
| LD ANA SC + MTX | 0.80(0.16,3.82) | 0.86(0.22,2.32) | ‐0.04(‐0.30,0.30) | |
| LD CERTO SC + MTX | 1.68(0.56,5.33) | 1.39(0.67,2.85) | 0.11(‐0.12,0.37) | |
| LD GOLI IV + MTX | 0.89(0.35,2.22) | 0.92(0.45,1.73) | ‐0.02(‐0.20,0.17) | |
| LD TOCI IV + MTX | 0.74(0.23,2.42) | 0.80(0.32,1.86) | ‐0.06(‐0.27,0.18) | |
| LD TOFA PO + MTX | 1.22(0.31,4.94) | 1.15(0.41,2.68) | 0.04(‐0.21,0.36) | |
| HD TOCI IV | 1.15(0.49,2.78) | 1.10(0.64,2.14) | 0.03(‐0.16,0.20) | |
| HD TOFA PO | 1.64(0.53,5.48) | 1.38(0.68,3.27) | 0.11(‐0.15,0.35) | |
| HD ADA SC | 0.76(0.23,2.52) | 0.82(0.35,2.04) | ‐0.05(‐0.30,0.17) | |
| HD GOLI SC | 1.26(0.48,3.39) | 1.17(0.61,2.36) | 0.05(‐0.16,0.25) | |
| HD ETN SC | 1.17(0.22,6.09) | 1.11(0.31,3.07) | 0.03(‐0.26,0.40) | |
| HD ABA SC | 2.26(0.44,12.43) | 1.63(0.58,4.10) | 0.18(‐0.18,0.55) | |
| HD TOCI IV + MTX | 1.99(0.85,4.98) | 1.54(0.91,2.96) | 0.15(‐0.04,0.35) | |
| HD INF IV + MTX | 1.83(0.73,4.68) | 1.46(0.82,2.74) | 0.13(‐0.07,0.34) | |
| HD TOFA PO + MTX | 1.57(0.57,4.17) | 1.34(0.70,2.57) | 0.10(‐0.12,0.31) | |
| HD GOLI SC + MTX | 2.16(0.84,5.68) | 1.59(0.89,3.06) | 0.17(‐0.04,0.38) | |
| HD CERTO SC + MTX | 2.82(1.16,6.73) | 1.82(1.09,3.42) | 0.24(0.03,0.42) | |
| HD ADA SC + MTX | 2.36(0.70,8.41) | 1.66(0.79,3.45) | 0.19(‐0.08,0.47) | |
| HD TOCI IV + DMARD | 1.38(0.16,13.49) | 1.23(0.23,3.99) | 0.07(‐0.30,0.56) | |
| SD ANA SC + SD ETN SC + MTX | 1.39(0.33,6.30) | 1.24(0.45,3.12) | 0.07(‐0.21,0.41) | |
| SD ANA SC + LD ETN SC + MTX | 2.05(0.51,8.91) | 1.55(0.63,3.58) | 0.16(‐0.14,0.48) | |
| SD ABA SC + MTX | SD ANA SC + MTX | 1.43(0.41,4.94) | 1.24(0.56,2.72) | 0.08(‐0.19,0.35) |
| SD TOCI IV + MTX | 0.72(0.20,2.57) | 0.80(0.31,1.92) | ‐0.06(‐0.32,0.19) | |
| SD CERTO SC + DMARD | 1.11(0.20,7.12) | 1.07(0.33,3.31) | 0.02(‐0.32,0.43) | |
| SD ADA SC + DMARD | 0.97(0.10,10.92) | 0.98(0.16,3.54) | ‐0.01(‐0.39,0.52) | |
| SD TOCI SC + DMARD | 1.57(0.15,16.87) | 1.31(0.25,4.05) | 0.10(‐0.34,0.59) | |
| LD ADA SC | 0.45(0.12,1.63) | 0.55(0.23,1.47) | ‐0.15(‐0.41,0.08) | |
| LD ETN SC | 0.55(0.13,2.41) | 0.66(0.22,1.90) | ‐0.11(‐0.39,0.17) | |
| LD GOLI IV | 0.39(0.11,1.34) | 0.49(0.18,1.25) | ‐0.16(‐0.40,0.05) | |
| LD TOCI IV | 0.07(0.01,0.34) | 0.10(0.02,0.41) | ‐0.29(‐0.53,‐0.11) | |
| LD ADA SC + MTX | 1.36(0.39,4.97) | 1.20(0.54,2.71) | 0.07(‐0.20,0.36) | |
| LD RITUX IV + MTX | 1.20(0.40,3.62) | 1.12(0.56,2.37) | 0.04(‐0.20,0.27) | |
| LD ADA IV + MTX | 1.21(0.17,8.02) | 1.12(0.26,3.10) | 0.04(‐0.30,0.46) | |
| LD ABA IV + MTX | 0.72(0.25,2.06) | 0.80(0.38,1.66) | ‐0.06(‐0.29,0.14) | |
| LD ANA SC + MTX | 0.67(0.17,2.39) | 0.76(0.24,1.71) | ‐0.07(‐0.30,0.20) | |
| LD CERTO SC + MTX | 1.42(0.41,4.80) | 1.24(0.57,2.68) | 0.08(‐0.19,0.34) | |
| LD GOLI IV + MTX | 0.75(0.21,2.52) | 0.82(0.33,1.87) | ‐0.06(‐0.32,0.19) | |
| LD TOCI IV + MTX | 0.61(0.18,2.13) | 0.71(0.28,1.70) | ‐0.09(‐0.34,0.15) | |
| LD TOFA PO + MTX | 1.03(0.24,4.37) | 1.02(0.35,2.48) | 0.01(‐0.29,0.33) | |
| HD TOCI IV | 0.97(0.37,2.52) | 0.98(0.54,1.98) | ‐0.01(‐0.23,0.18) | |
| HD TOFA PO | 1.39(0.41,4.89) | 1.23(0.59,2.98) | 0.07(‐0.21,0.32) | |
| HD ADA SC | 0.63(0.18,2.29) | 0.72(0.32,1.88) | ‐0.09(‐0.36,0.15) | |
| HD GOLI SC | 1.05(0.35,3.16) | 1.03(0.52,2.28) | 0.01(‐0.23,0.24) | |
| HD ETN SC | 0.98(0.17,5.43) | 0.99(0.27,2.84) | 0.00(‐0.34,0.37) | |
| HD ABA SC | 1.86(0.35,11.26) | 1.43(0.50,3.92) | 0.14(‐0.23,0.52) | |
| HD TOCI IV + MTX | 1.66(0.64,4.52) | 1.36(0.78,2.77) | 0.12(‐0.11,0.32) | |
| HD INF IV + MTX | 1.55(0.54,4.27) | 1.30(0.70,2.60) | 0.10(‐0.14,0.32) | |
| HD TOFA PO + MTX | 1.32(0.43,3.77) | 1.19(0.59,2.41) | 0.06(‐0.18,0.29) | |
| HD GOLI SC + MTX | 1.80(0.62,5.18) | 1.41(0.76,2.92) | 0.13(‐0.11,0.36) | |
| HD CERTO SC + MTX | 2.38(0.87,6.21) | 1.62(0.93,3.17) | 0.20(‐0.03,0.41) | |
| HD ADA SC + MTX | 1.98(0.52,7.37) | 1.48(0.66,3.27) | 0.16(‐0.15,0.45) | |
| HD TOCI IV + DMARD | 1.15(0.13,11.61) | 1.09(0.21,3.69) | 0.03(‐0.36,0.53) | |
| SD ANA SC + SD ETN SC + MTX | 1.17(0.26,5.61) | 1.11(0.40,2.91) | 0.03(‐0.27,0.38) | |
| SD ANA SC + LD ETN SC + MTX | 1.74(0.39,7.94) | 1.39(0.55,3.36) | 0.13(‐0.21,0.46) | |
| SD TOCI IV + MTX | SD ABA SC + MTX | 0.50(0.14,1.98) | 0.64(0.27,1.59) | ‐0.14(‐0.42,0.14) |
| SD CERTO SC + DMARD | 0.79(0.13,5.14) | 0.86(0.27,2.58) | ‐0.05(‐0.43,0.37) | |
| SD ADA SC + DMARD | 0.68(0.06,8.08) | 0.79(0.13,2.79) | ‐0.08(‐0.50,0.46) | |
| SD TOCI SC + DMARD | 1.11(0.10,12.55) | 1.06(0.19,3.28) | 0.02(‐0.45,0.53) | |
| LD ADA SC | 0.31(0.08,1.27) | 0.44(0.19,1.20) | ‐0.23(‐0.52,0.04) | |
| LD ETN SC | 0.39(0.08,1.79) | 0.53(0.18,1.53) | ‐0.19(‐0.50,0.11) | |
| LD GOLI IV | 0.27(0.07,1.04) | 0.40(0.14,1.03) | ‐0.24(‐0.51,0.01) | |
| LD TOCI IV | 0.05(0.01,0.25) | 0.08(0.01,0.33) | ‐0.37(‐0.64,‐0.14) | |
| LD ADA SC + MTX | 0.95(0.25,3.82) | 0.97(0.43,2.22) | ‐0.01(‐0.31,0.30) | |
| LD RITUX IV + MTX | 0.83(0.26,2.73) | 0.90(0.46,1.93) | ‐0.04(‐0.30,0.22) | |
| LD ADA IV + MTX | 0.85(0.11,6.07) | 0.91(0.21,2.60) | ‐0.04(‐0.41,0.41) | |
| LD ABA IV + MTX | 0.50(0.18,1.48) | 0.64(0.33,1.31) | ‐0.14(‐0.38,0.08) | |
| LD ANA SC + MTX | 0.47(0.09,2.56) | 0.61(0.16,1.79) | ‐0.15(‐0.47,0.21) | |
| LD CERTO SC + MTX | 0.98(0.28,3.71) | 0.99(0.47,2.22) | 0.00(‐0.29,0.29) | |
| LD GOLI IV + MTX | 0.52(0.14,1.92) | 0.66(0.28,1.53) | ‐0.14(‐0.41,0.14) | |
| LD TOCI IV + MTX | 0.42(0.11,1.69) | 0.57(0.23,1.42) | ‐0.17(‐0.45,0.11) | |
| LD TOFA PO + MTX | 0.72(0.16,3.37) | 0.82(0.28,2.06) | ‐0.07(‐0.39,0.27) | |
| HD TOCI IV | 0.67(0.23,2.06) | 0.78(0.45,1.68) | ‐0.09(‐0.34,0.14) | |
| HD TOFA PO | 0.97(0.26,3.87) | 0.98(0.50,2.46) | ‐0.01(‐0.32,0.29) | |
| HD ADA SC | 0.44(0.12,1.81) | 0.58(0.26,1.55) | ‐0.17(‐0.47,0.11) | |
| HD GOLI SC | 0.74(0.22,2.50) | 0.83(0.42,1.89) | ‐0.07(‐0.34,0.19) | |
| HD ETN SC | 0.69(0.12,4.05) | 0.80(0.23,2.30) | ‐0.08(‐0.43,0.32) | |
| HD ABA SC | 1.33(0.22,8.53) | 1.16(0.41,3.13) | 0.07(‐0.34,0.47) | |
| HD TOCI IV + MTX | 1.16(0.41,3.64) | 1.09(0.64,2.33) | 0.04(‐0.21,0.28) | |
| HD INF IV + MTX | 1.08(0.36,3.38) | 1.04(0.57,2.21) | 0.02(‐0.24,0.27) | |
| HD TOFA PO + MTX | 0.93(0.28,2.97) | 0.96(0.48,2.02) | ‐0.02(‐0.30,0.24) | |
| HD GOLI SC + MTX | 1.26(0.41,4.13) | 1.13(0.62,2.42) | 0.05(‐0.21,0.32) | |
| HD CERTO SC + MTX | 1.66(0.56,5.01) | 1.30(0.76,2.69) | 0.12(‐0.14,0.36) | |
| HD ADA SC + MTX | 1.39(0.35,5.75) | 1.19(0.55,2.67) | 0.08(‐0.24,0.39) | |
| HD TOCI IV + DMARD | 0.81(0.08,8.56) | 0.88(0.17,2.85) | ‐0.05(‐0.47,0.47) | |
| SD ANA SC + SD ETN SC + MTX | 0.82(0.18,4.16) | 0.89(0.32,2.30) | ‐0.04(‐0.38,0.32) | |
| SD ANA SC + LD ETN SC + MTX | 1.21(0.26,5.77) | 1.11(0.45,2.70) | 0.04(‐0.30,0.40) | |
| SD CERTO SC + DMARD | SD TOCI IV + MTX | 1.53(0.27,10.01) | 1.33(0.39,4.46) | 0.08(‐0.26,0.48) |
| SD ADA SC + DMARD | 1.32(0.13,16.60) | 1.21(0.19,4.93) | 0.05(‐0.32,0.58) | |
| SD TOCI SC + DMARD | 2.13(0.20,24.44) | 1.61(0.30,5.56) | 0.16(‐0.27,0.65) | |
| LD ADA SC | 0.61(0.17,2.33) | 0.68(0.27,1.99) | ‐0.08(‐0.35,0.13) | |
| LD ETN SC | 0.77(0.16,3.43) | 0.82(0.25,2.57) | ‐0.05(‐0.33,0.22) | |
| LD GOLI IV | 0.53(0.13,2.12) | 0.61(0.20,1.79) | ‐0.10(‐0.35,0.12) | |
| LD TOCI IV | 0.09(0.02,0.42) | 0.13(0.02,0.48) | ‐0.22(‐0.47,‐0.07) | |
| LD ADA SC + MTX | 1.90(0.47,7.47) | 1.51(0.60,3.92) | 0.13(‐0.16,0.42) | |
| LD RITUX IV + MTX | 1.67(0.50,5.51) | 1.41(0.63,3.34) | 0.10(‐0.15,0.35) | |
| LD ADA IV + MTX | 1.67(0.21,12.25) | 1.40(0.29,4.38) | 0.10(‐0.27,0.54) | |
| LD ABA IV + MTX | 0.99(0.30,3.28) | 0.99(0.43,2.44) | 0.00(‐0.24,0.22) | |
| LD ANA SC + MTX | 0.93(0.16,4.97) | 0.95(0.23,2.98) | ‐0.01(‐0.30,0.34) | |
| LD CERTO SC + MTX | 1.93(0.53,7.53) | 1.53(0.65,3.92) | 0.14(‐0.14,0.42) | |
| LD GOLI IV + MTX | 1.03(0.27,4.02) | 1.02(0.38,2.79) | 0.00(‐0.25,0.27) | |
| LD TOCI IV + MTX | 0.85(0.27,2.64) | 0.89(0.37,2.07) | ‐0.03(‐0.25,0.18) | |
| LD TOFA PO + MTX | 1.41(0.30,6.84) | 1.26(0.40,3.66) | 0.07(‐0.22,0.40) | |
| HD TOCI IV | 1.33(0.52,3.52) | 1.22(0.67,2.70) | 0.06(‐0.15,0.22) | |
| HD TOFA PO | 1.92(0.50,7.06) | 1.54(0.66,4.14) | 0.14(‐0.16,0.38) | |
| HD ADA SC | 0.88(0.24,3.41) | 0.91(0.37,2.61) | ‐0.02(‐0.30,0.20) | |
| HD GOLI SC | 1.46(0.44,4.96) | 1.30(0.58,3.30) | 0.08(‐0.18,0.30) | |
| HD ETN SC | 1.36(0.23,7.82) | 1.23(0.34,3.79) | 0.06(‐0.27,0.43) | |
| HD ABA SC | 2.60(0.44,16.75) | 1.81(0.58,5.41) | 0.21(‐0.17,0.59) | |
| HD TOCI IV + MTX | 2.30(0.87,6.38) | 1.70(0.93,3.76) | 0.18(‐0.03,0.37) | |
| HD INF IV + MTX | 2.13(0.64,6.85) | 1.62(0.76,3.81) | 0.16(‐0.10,0.40) | |
| HD TOFA PO + MTX | 1.81(0.55,6.06) | 1.48(0.69,3.56) | 0.12(‐0.13,0.37) | |
| HD GOLI SC + MTX | 2.50(0.77,8.24) | 1.77(0.85,4.23) | 0.20(‐0.06,0.44) | |
| HD CERTO SC + MTX | 3.24(1.07,10.27) | 2.02(1.04,4.72) | 0.26(0.02,0.48) | |
| HD ADA SC + MTX | 2.73(0.65,11.85) | 1.85(0.76,4.70) | 0.22(‐0.09,0.52) | |
| HD TOCI IV + DMARD | 1.57(0.17,17.11) | 1.35(0.25,5.05) | 0.09(‐0.30,0.59) | |
| SD ANA SC + SD ETN SC + MTX | 1.62(0.35,8.40) | 1.38(0.47,4.07) | 0.10(‐0.21,0.45) | |
| SD ANA SC + LD ETN SC + MTX | 2.41(0.52,11.85) | 1.73(0.64,4.70) | 0.19(‐0.14,0.52) | |
| SD ADA SC + DMARD | SD CERTO SC + DMARD | 0.88(0.19,4.18) | 0.92(0.26,2.10) | ‐0.03(‐0.29,0.31) |
| SD TOCI SC + DMARD | 1.42(0.28,6.67) | 1.20(0.39,2.61) | 0.07(‐0.22,0.41) | |
| LD ADA SC | 0.40(0.08,1.98) | 0.51(0.19,1.72) | ‐0.17(‐0.52,0.11) | |
| LD ETN SC | 0.50(0.08,2.87) | 0.61(0.18,2.17) | ‐0.13(‐0.51,0.19) | |
| LD GOLI IV | 0.35(0.05,2.01) | 0.46(0.12,1.71) | ‐0.19(‐0.56,0.12) | |
| LD TOCI IV | 0.06(0.01,0.46) | 0.09(0.01,0.52) | ‐0.31(‐0.66,‐0.07) | |
| LD ADA SC + MTX | 1.22(0.19,7.88) | 1.13(0.38,3.77) | 0.04(‐0.37,0.43) | |
| LD RITUX IV + MTX | 1.09(0.18,5.74) | 1.05(0.37,3.35) | 0.02(‐0.39,0.36) | |
| LD ADA IV + MTX | 1.08(0.10,11.13) | 1.05(0.20,3.96) | 0.02(‐0.44,0.51) | |
| LD ABA IV + MTX | 0.64(0.11,3.53) | 0.74(0.25,2.54) | ‐0.09(‐0.48,0.24) | |
| LD ANA SC + MTX | 0.60(0.06,4.51) | 0.71(0.14,2.76) | ‐0.10(‐0.51,0.32) | |
| LD CERTO SC + MTX | 1.26(0.20,7.79) | 1.15(0.40,3.74) | 0.05(‐0.36,0.43) | |
| LD GOLI IV + MTX | 0.67(0.10,3.90) | 0.76(0.23,2.61) | ‐0.08(‐0.47,0.27) | |
| LD TOCI IV + MTX | 0.56(0.08,3.18) | 0.67(0.19,2.32) | ‐0.11(‐0.50,0.21) | |
| LD TOFA PO + MTX | 0.93(0.11,6.43) | 0.96(0.24,3.33) | ‐0.01(‐0.45,0.40) | |
| HD TOCI IV | 0.87(0.17,4.07) | 0.91(0.37,2.81) | ‐0.03(‐0.41,0.26) | |
| HD TOFA PO | 1.25(0.24,5.67) | 1.15(0.48,3.41) | 0.05(‐0.34,0.35) | |
| HD ADA SC | 0.57(0.11,2.97) | 0.67(0.26,2.30) | ‐0.11(‐0.47,0.18) | |
| HD GOLI SC | 0.96(0.16,4.71) | 0.98(0.35,3.07) | ‐0.01(‐0.41,0.30) | |
| HD ETN SC | 0.88(0.11,6.45) | 0.92(0.22,3.38) | ‐0.03(‐0.46,0.40) | |
| HD ABA SC | 1.67(0.25,11.35) | 1.33(0.45,4.24) | 0.12(‐0.31,0.52) | |
| HD TOCI IV + MTX | 1.52(0.28,7.23) | 1.28(0.53,3.83) | 0.10(‐0.30,0.41) | |
| HD INF IV + MTX | 1.39(0.23,7.23) | 1.22(0.45,3.76) | 0.07(‐0.34,0.41) | |
| HD TOFA PO + MTX | 1.19(0.19,6.29) | 1.11(0.39,3.47) | 0.04(‐0.37,0.38) | |
| HD GOLI SC + MTX | 1.64(0.27,8.62) | 1.33(0.51,4.00) | 0.11(‐0.31,0.45) | |
| HD CERTO SC + MTX | 2.11(0.38,10.95) | 1.50(0.63,4.48) | 0.18(‐0.23,0.51) | |
| HD ADA SC + MTX | 1.76(0.26,12.19) | 1.37(0.48,4.45) | 0.13(‐0.30,0.53) | |
| HD TOCI IV + DMARD | 1.04(0.25,4.07) | 1.02(0.34,2.14) | 0.01(‐0.25,0.31) | |
| SD ANA SC + SD ETN SC + MTX | 1.05(0.15,6.85) | 1.03(0.31,3.45) | 0.01(‐0.41,0.41) | |
| SD ANA SC + LD ETN SC + MTX | 1.55(0.23,9.96) | 1.29(0.43,4.04) | 0.10(‐0.33,0.49) | |
| SD TOCI SC + DMARD | SD ADA SC + DMARD | 1.61(0.43,5.86) | 1.29(0.59,3.28) | 0.09(‐0.17,0.38) |
| LD ADA SC | 0.46(0.05,4.29) | 0.56(0.17,3.50) | ‐0.14(‐0.63,0.17) | |
| LD ETN SC | 0.58(0.05,5.95) | 0.68(0.17,4.35) | ‐0.10(‐0.60,0.25) | |
| LD GOLI IV | 0.40(0.03,3.89) | 0.51(0.11,3.14) | ‐0.15(‐0.66,0.18) | |
| LD TOCI IV | 0.07(0.00,0.86) | 0.10(0.01,0.88) | ‐0.28(‐0.77,‐0.01) | |
| LD ADA SC + MTX | 1.41(0.11,16.29) | 1.24(0.34,7.81) | 0.07(‐0.47,0.50) | |
| LD RITUX IV + MTX | 1.25(0.11,12.11) | 1.15(0.33,6.71) | 0.05(‐0.49,0.43) | |
| LD ADA IV + MTX | 1.22(0.07,19.91) | 1.13(0.18,7.95) | 0.04(‐0.53,0.57) | |
| LD ABA IV + MTX | 0.75(0.07,7.20) | 0.82(0.22,4.96) | ‐0.06(‐0.58,0.30) | |
| LD ANA SC + MTX | 0.69(0.04,9.40) | 0.77(0.14,5.34) | ‐0.07(‐0.60,0.39) | |
| LD CERTO SC + MTX | 1.46(0.13,15.84) | 1.27(0.36,7.79) | 0.08(‐0.45,0.49) | |
| LD GOLI IV + MTX | 0.79(0.06,7.74) | 0.85(0.21,5.10) | ‐0.05(‐0.58,0.33) | |
| LD TOCI IV + MTX | 0.63(0.05,6.70) | 0.72(0.18,4.74) | ‐0.09(‐0.60,0.28) | |
| LD TOFA PO + MTX | 1.07(0.07,12.79) | 1.04(0.22,6.72) | 0.01(‐0.54,0.46) | |
| HD TOCI IV | 1.00(0.10,8.74) | 1.00(0.33,5.87) | 0.00(‐0.51,0.32) | |
| HD TOFA PO | 1.44(0.14,12.73) | 1.26(0.43,7.38) | 0.08(‐0.43,0.41) | |
| HD ADA SC | 0.66(0.07,6.25) | 0.74(0.23,4.65) | ‐0.08(‐0.58,0.24) | |
| HD GOLI SC | 1.12(0.10,9.87) | 1.08(0.32,6.18) | 0.02(‐0.51,0.36) | |
| HD ETN SC | 1.03(0.07,11.56) | 1.02(0.21,6.08) | 0.01(‐0.54,0.45) | |
| HD ABA SC | 1.94(0.17,22.89) | 1.47(0.42,8.94) | 0.14(‐0.39,0.58) | |
| HD TOCI IV + MTX | 1.73(0.17,15.76) | 1.40(0.47,8.02) | 0.12(‐0.39,0.48) | |
| HD INF IV + MTX | 1.59(0.14,14.67) | 1.33(0.41,7.52) | 0.10(‐0.43,0.47) | |
| HD TOFA PO + MTX | 1.39(0.12,13.06) | 1.23(0.35,7.17) | 0.07(‐0.47,0.44) | |
| HD GOLI SC + MTX | 1.87(0.16,18.51) | 1.45(0.46,8.73) | 0.14(‐0.40,0.51) | |
| HD CERTO SC + MTX | 2.45(0.23,22.88) | 1.66(0.56,9.49) | 0.21(‐0.32,0.57) | |
| HD ADA SC + MTX | 2.00(0.16,24.85) | 1.49(0.43,9.38) | 0.15(‐0.41,0.59) | |
| HD TOCI IV + DMARD | 1.19(0.39,3.59) | 1.10(0.54,2.53) | 0.03(‐0.20,0.26) | |
| SD ANA SC + SD ETN SC + MTX | 1.22(0.10,13.91) | 1.13(0.29,7.02) | 0.04(‐0.49,0.47) | |
| SD ANA SC + LD ETN SC + MTX | 1.79(0.16,20.19) | 1.40(0.40,8.29) | 0.13(‐0.41,0.56) | |
| LD ADA SC | SD TOCI SC + DMARD | 0.28(0.03,2.70) | 0.42(0.15,2.32) | ‐0.25(‐0.70,0.13) |
| LD ETN SC | 0.35(0.03,3.77) | 0.51(0.14,2.86) | ‐0.21(‐0.67,0.21) | |
| LD GOLI IV | 0.25(0.02,2.59) | 0.38(0.09,2.18) | ‐0.27(‐0.72,0.14) | |
| LD TOCI IV | 0.04(0.00,0.55) | 0.08(0.01,0.60) | ‐0.39(‐0.83,‐0.04) | |
| LD ADA SC + MTX | 0.87(0.08,10.35) | 0.93(0.30,5.27) | ‐0.03(‐0.53,0.44) | |
| LD RITUX IV + MTX | 0.77(0.07,7.57) | 0.86(0.29,4.52) | ‐0.06(‐0.56,0.37) | |
| LD ADA IV + MTX | 0.76(0.05,13.19) | 0.87(0.16,5.25) | ‐0.06(‐0.60,0.51) | |
| LD ABA IV + MTX | 0.46(0.04,4.68) | 0.61(0.20,3.34) | ‐0.17(‐0.64,0.25) | |
| LD ANA SC + MTX | 0.42(0.03,5.99) | 0.59(0.11,3.69) | ‐0.17(‐0.67,0.32) | |
| LD CERTO SC + MTX | 0.89(0.08,10.27) | 0.94(0.31,5.11) | ‐0.03(‐0.53,0.44) | |
| LD GOLI IV + MTX | 0.47(0.04,5.09) | 0.63(0.18,3.50) | ‐0.16(‐0.64,0.27) | |
| LD TOCI IV + MTX | 0.38(0.03,4.05) | 0.54(0.16,2.98) | ‐0.20(‐0.67,0.23) | |
| LD TOFA PO + MTX | 0.65(0.05,7.86) | 0.78(0.19,4.34) | ‐0.09(‐0.62,0.39) | |
| HD TOCI IV | 0.61(0.07,5.69) | 0.74(0.30,3.93) | ‐0.11(‐0.57,0.28) | |
| HD TOFA PO | 0.89(0.10,8.27) | 0.94(0.39,4.87) | ‐0.03(‐0.49,0.37) | |
| HD ADA SC | 0.40(0.04,3.86) | 0.55(0.21,3.03) | ‐0.19(‐0.64,0.20) | |
| HD GOLI SC | 0.68(0.07,6.33) | 0.79(0.29,4.15) | ‐0.09(‐0.57,0.31) | |
| HD ETN SC | 0.62(0.05,7.80) | 0.76(0.18,4.17) | ‐0.10(‐0.62,0.40) | |
| HD ABA SC | 1.19(0.10,14.94) | 1.09(0.35,5.83) | 0.04(‐0.48,0.53) | |
| HD TOCI IV + MTX | 1.07(0.11,10.15) | 1.03(0.42,5.29) | 0.01(‐0.46,0.43) | |
| HD INF IV + MTX | 0.98(0.09,9.35) | 0.99(0.37,5.08) | 0.00(‐0.50,0.42) | |
| HD TOFA PO + MTX | 0.85(0.08,8.39) | 0.91(0.31,4.83) | ‐0.04(‐0.54,0.39) | |
| HD GOLI SC + MTX | 1.15(0.11,11.85) | 1.07(0.41,5.66) | 0.03(‐0.47,0.47) | |
| HD CERTO SC + MTX | 1.48(0.15,15.21) | 1.22(0.51,6.46) | 0.09(‐0.39,0.52) | |
| HD ADA SC + MTX | 1.22(0.11,15.19) | 1.11(0.38,6.22) | 0.05(‐0.47,0.53) | |
| HD TOCI IV + DMARD | 0.74(0.24,2.21) | 0.86(0.41,1.71) | ‐0.06(‐0.31,0.16) | |
| SD ANA SC + SD ETN SC + MTX | 0.73(0.07,8.86) | 0.84(0.25,4.60) | ‐0.07(‐0.56,0.42) | |
| SD ANA SC + LD ETN SC + MTX | 1.08(0.10,13.00) | 1.04(0.35,5.48) | 0.02(‐0.48,0.51) | |
| LD ETN SC | LD ADA SC | 1.27(0.31,4.68) | 1.20(0.38,3.26) | 0.04(‐0.16,0.27) |
| LD GOLI IV | 0.87(0.21,3.40) | 0.89(0.26,2.61) | ‐0.02(‐0.19,0.20) | |
| LD TOCI IV | 0.15(0.02,0.78) | 0.18(0.03,0.81) | ‐0.14(‐0.29,‐0.02) | |
| LD ADA SC + MTX | 3.08(0.77,12.14) | 2.22(0.82,5.23) | 0.22(‐0.04,0.52) | |
| LD RITUX IV + MTX | 2.71(0.76,9.32) | 2.06(0.81,4.76) | 0.19(‐0.05,0.45) | |
| LD ADA IV + MTX | 2.73(0.34,19.06) | 2.06(0.40,5.83) | 0.19(‐0.13,0.61) | |
| LD ABA IV + MTX | 1.63(0.47,5.45) | 1.46(0.55,3.58) | 0.08(‐0.12,0.31) | |
| LD ANA SC + MTX | 1.51(0.26,8.30) | 1.38(0.31,4.20) | 0.07(‐0.17,0.43) | |
| LD CERTO SC + MTX | 3.18(0.83,12.39) | 2.27(0.86,5.26) | 0.22(‐0.03,0.52) | |
| LD GOLI IV + MTX | 1.68(0.44,6.31) | 1.49(0.51,3.85) | 0.09(‐0.13,0.35) | |
| LD TOCI IV + MTX | 1.39(0.38,4.91) | 1.29(0.45,3.30) | 0.05(‐0.14,0.30) | |
| LD TOFA PO + MTX | 2.33(0.47,10.82) | 1.86(0.54,4.86) | 0.15(‐0.11,0.49) | |
| HD TOCI IV | 2.17(0.81,5.72) | 1.79(0.86,3.80) | 0.14(‐0.04,0.31) | |
| HD TOFA PO | 3.11(1.16,8.68) | 2.25(1.11,4.86) | 0.22(0.03,0.41) | |
| HD ADA SC | 1.43(0.67,3.15) | 1.32(0.72,2.50) | 0.06(‐0.07,0.19) | |
| HD GOLI SC | 2.37(0.77,7.38) | 1.90(0.82,4.35) | 0.16(‐0.05,0.38) | |
| HD ETN SC | 2.21(0.39,11.68) | 1.80(0.46,5.05) | 0.14(‐0.13,0.50) | |
| HD ABA SC | 4.24(0.90,21.81) | 2.63(0.92,6.43) | 0.29(‐0.02,0.63) | |
| HD TOCI IV + MTX | 3.79(1.30,10.94) | 2.51(1.20,5.31) | 0.27(0.05,0.48) | |
| HD INF IV + MTX | 3.45(1.06,11.42) | 2.37(1.04,5.27) | 0.24(0.01,0.50) | |
| HD TOFA PO + MTX | 2.97(0.84,9.82) | 2.19(0.88,4.93) | 0.21(‐0.03,0.46) | |
| HD GOLI SC + MTX | 4.08(1.21,13.31) | 2.61(1.14,5.69) | 0.28(0.04,0.52) | |
| HD CERTO SC + MTX | 5.32(1.70,17.15) | 2.98(1.42,6.31) | 0.35(0.11,0.58) | |
| HD ADA SC + MTX | 4.45(1.08,19.08) | 2.70(1.06,6.24) | 0.31(0.01,0.61) | |
| HD TOCI IV + DMARD | 2.62(0.31,22.55) | 2.01(0.38,5.95) | 0.18(‐0.15,0.64) | |
| SD ANA SC + SD ETN SC + MTX | 2.64(0.59,12.25) | 2.02(0.66,5.25) | 0.18(‐0.08,0.51) | |
| SD ANA SC + LD ETN SC + MTX | 3.89(0.88,17.58) | 2.53(0.91,5.94) | 0.27(‐0.02,0.59) | |
| LD GOLI IV | LD ETN SC | 0.70(0.15,3.24) | 0.75(0.21,2.56) | ‐0.05(‐0.29,0.18) |
| LD TOCI IV | 0.12(0.02,0.76) | 0.15(0.02,0.78) | ‐0.17(‐0.40,‐0.03) | |
| LD ADA SC + MTX | 2.45(0.54,12.34) | 1.84(0.64,5.60) | 0.18(‐0.12,0.50) | |
| LD RITUX IV + MTX | 2.15(0.54,8.88) | 1.71(0.65,4.89) | 0.15(‐0.12,0.42) | |
| LD ADA IV + MTX | 2.16(0.25,18.72) | 1.70(0.33,5.98) | 0.15(‐0.21,0.60) | |
| LD ABA IV + MTX | 1.29(0.32,5.11) | 1.21(0.43,3.54) | 0.04(‐0.21,0.29) | |
| LD ANA SC + MTX | 1.21(0.18,7.76) | 1.15(0.25,4.17) | 0.03(‐0.26,0.41) | |
| LD CERTO SC + MTX | 2.55(0.57,11.64) | 1.89(0.67,5.41) | 0.19(‐0.11,0.50) | |
| LD GOLI IV + MTX | 1.35(0.30,6.06) | 1.25(0.40,3.89) | 0.05(‐0.22,0.33) | |
| LD TOCI IV + MTX | 1.10(0.25,5.00) | 1.08(0.34,3.40) | 0.02(‐0.24,0.28) | |
| LD TOFA PO + MTX | 1.86(0.34,10.20) | 1.55(0.44,4.90) | 0.11(‐0.19,0.47) | |
| HD TOCI IV | 1.73(0.52,6.13) | 1.49(0.65,4.15) | 0.10(‐0.14,0.31) | |
| HD TOFA PO | 2.49(0.68,9.22) | 1.88(0.78,5.19) | 0.19(‐0.09,0.41) | |
| HD ADA SC | 1.14(0.31,4.44) | 1.11(0.43,3.31) | 0.02(‐0.22,0.24) | |
| HD GOLI SC | 1.89(0.51,7.31) | 1.58(0.63,4.45) | 0.12(‐0.14,0.37) | |
| HD ETN SC | 1.77(0.32,8.88) | 1.50(0.42,4.43) | 0.11(‐0.18,0.45) | |
| HD ABA SC | 3.37(0.59,21.05) | 2.20(0.69,6.73) | 0.25(‐0.11,0.62) | |
| HD TOCI IV + MTX | 3.00(0.85,11.33) | 2.09(0.90,5.62) | 0.23(‐0.04,0.47) | |
| HD INF IV + MTX | 2.76(0.71,10.86) | 1.98(0.79,5.37) | 0.21(‐0.07,0.47) | |
| HD TOFA PO + MTX | 2.37(0.58,9.39) | 1.81(0.69,5.02) | 0.17(‐0.11,0.43) | |
| HD GOLI SC + MTX | 3.23(0.86,12.76) | 2.16(0.91,5.85) | 0.24(‐0.03,0.51) | |
| HD CERTO SC + MTX | 4.24(1.15,16.26) | 2.47(1.09,6.51) | 0.31(0.03,0.56) | |
| HD ADA SC + MTX | 3.54(0.75,18.25) | 2.24(0.82,6.48) | 0.27(‐0.06,0.59) | |
| HD TOCI IV + DMARD | 2.08(0.22,20.49) | 1.67(0.29,6.32) | 0.14(‐0.23,0.61) | |
| SD ANA SC + SD ETN SC + MTX | 2.10(0.45,10.90) | 1.67(0.55,5.09) | 0.14(‐0.15,0.48) | |
| SD ANA SC + LD ETN SC + MTX | 3.12(0.68,15.79) | 2.10(0.76,5.94) | 0.23(‐0.08,0.56) | |
| LD TOCI IV | LD GOLI IV | 0.17(0.03,0.96) | 0.20(0.03,0.96) | ‐0.12(‐0.32,0.00) |
| LD ADA SC + MTX | 3.49(0.94,15.36) | 2.44(0.96,7.07) | 0.23(‐0.01,0.51) | |
| LD RITUX IV + MTX | 3.11(0.95,10.65) | 2.29(0.97,6.20) | 0.20(‐0.01,0.43) | |
| LD ADA IV + MTX | 3.15(0.43,23.07) | 2.26(0.49,8.01) | 0.20(‐0.12,0.62) | |
| LD ABA IV + MTX | 1.86(0.59,6.26) | 1.63(0.67,4.52) | 0.09(‐0.09,0.30) | |
| LD ANA SC + MTX | 1.75(0.31,9.20) | 1.54(0.37,5.29) | 0.08(‐0.16,0.42) | |
| LD CERTO SC + MTX | 3.64(0.99,14.23) | 2.51(1.00,7.11) | 0.24(0.00,0.51) | |
| LD GOLI IV + MTX | 1.93(0.69,5.50) | 1.66(0.75,3.95) | 0.10(‐0.06,0.30) | |
| LD TOCI IV + MTX | 1.60(0.41,6.53) | 1.45(0.49,4.54) | 0.07(‐0.14,0.31) | |
| LD TOFA PO + MTX | 2.65(0.56,12.60) | 2.06(0.63,6.39) | 0.16(‐0.09,0.49) | |
| HD TOCI IV | 2.49(0.85,7.87) | 2.00(0.89,5.42) | 0.16(‐0.03,0.32) | |
| HD TOFA PO | 3.52(0.97,14.43) | 2.49(0.98,8.02) | 0.24(‐0.01,0.45) | |
| HD ADA SC | 1.66(0.43,6.78) | 1.49(0.53,4.98) | 0.08(‐0.16,0.27) | |
| HD GOLI SC | 2.74(0.85,9.01) | 2.12(0.89,5.90) | 0.17(‐0.03,0.37) | |
| HD ETN SC | 2.53(0.42,15.64) | 1.98(0.50,7.37) | 0.16(‐0.13,0.52) | |
| HD ABA SC | 4.84(0.84,30.92) | 2.94(0.88,9.98) | 0.31(‐0.03,0.65) | |
| HD TOCI IV + MTX | 4.33(1.46,14.12) | 2.79(1.26,7.54) | 0.28(0.08,0.48) | |
| HD INF IV + MTX | 3.98(1.27,12.76) | 2.65(1.17,6.91) | 0.26(0.05,0.47) | |
| HD TOFA PO + MTX | 3.36(1.05,11.84) | 2.40(1.03,6.55) | 0.22(0.01,0.45) | |
| HD GOLI SC + MTX | 4.66(1.46,15.43) | 2.89(1.28,7.75) | 0.30(0.08,0.51) | |
| HD CERTO SC + MTX | 6.13(2.02,18.97) | 3.31(1.52,8.79) | 0.36(0.15,0.56) | |
| HD ADA SC + MTX | 5.09(1.28,22.23) | 2.99(1.18,8.64) | 0.32(0.04,0.60) | |
| HD TOCI IV + DMARD | 2.96(0.32,33.53) | 2.21(0.39,9.52) | 0.19(‐0.16,0.67) | |
| SD ANA SC + SD ETN SC + MTX | 3.02(0.64,15.66) | 2.25(0.71,7.45) | 0.19(‐0.07,0.52) | |
| SD ANA SC + LD ETN SC + MTX | 4.48(0.95,23.21) | 2.81(0.96,8.96) | 0.29(‐0.01,0.61) | |
| LD ADA SC + MTX | LD TOCI IV | 20.08(3.82,137.60) | 11.95(2.95,69.30) | 0.36(0.14,0.64) |
| LD RITUX IV + MTX | 17.68(3.85,106.00) | 11.21(2.94,60.92) | 0.33(0.14,0.57) | |
| LD ADA IV + MTX | 17.82(2.04,187.20) | 10.83(1.87,68.75) | 0.33(0.04,0.74) | |
| LD ABA IV + MTX | 10.78(2.31,63.96) | 8.05(2.01,44.35) | 0.22(0.08,0.43) | |
| LD ANA SC + MTX | 9.99(1.34,82.22) | 7.51(1.30,46.80) | 0.21(0.02,0.55) | |
| LD CERTO SC + MTX | 20.67(4.15,138.30) | 12.32(3.09,70.88) | 0.37(0.15,0.64) | |
| LD GOLI IV + MTX | 11.13(2.03,73.87) | 8.17(1.83,48.35) | 0.23(0.06,0.47) | |
| LD TOCI IV + MTX | 9.08(2.05,51.80) | 7.03(1.86,37.56) | 0.19(0.06,0.41) | |
| LD TOFA PO + MTX | 15.36(2.43,118.40) | 9.98(2.11,61.52) | 0.29(0.07,0.62) | |
| HD TOCI IV | 14.03(3.83,77.39) | 9.78(2.87,53.02) | 0.28(0.16,0.42) | |
| HD TOFA PO | 20.22(3.95,139.10) | 12.31(2.91,74.78) | 0.36(0.20,0.54) | |
| HD ADA SC | 9.39(1.85,62.71) | 7.31(1.68,45.24) | 0.20(0.07,0.36) | |
| HD GOLI SC | 15.76(3.27,98.50) | 10.45(2.61,59.14) | 0.30(0.14,0.49) | |
| HD ETN SC | 14.52(1.92,131.90) | 9.72(1.76,65.53) | 0.28(0.05,0.63) | |
| HD ABA SC | 28.65(3.64,268.10) | 14.57(2.89,92.29) | 0.44(0.15,0.76) | |
| HD TOCI IV + MTX | 24.32(6.37,137.50) | 13.61(3.92,74.19) | 0.41(0.24,0.59) | |
| HD INF IV + MTX | 22.63(5.08,140.80) | 13.02(3.43,74.04) | 0.39(0.19,0.61) | |
| HD TOFA PO + MTX | 19.19(4.16,119.50) | 11.85(3.09,65.92) | 0.35(0.15,0.57) | |
| HD GOLI SC + MTX | 26.64(5.66,168.80) | 14.22(3.68,81.14) | 0.43(0.22,0.64) | |
| HD CERTO SC + MTX | 34.59(7.89,207.90) | 16.15(4.32,89.67) | 0.49(0.29,0.69) | |
| HD ADA SC + MTX | 29.29(5.38,202.30) | 14.69(3.71,86.02) | 0.45(0.18,0.72) | |
| HD TOCI IV + DMARD | 17.18(1.46,248.40) | 10.89(1.41,81.13) | 0.32(0.03,0.77) | |
| SD ANA SC + SD ETN SC + MTX | 17.47(2.81,138.90) | 11.06(2.35,67.58) | 0.33(0.09,0.64) | |
| SD ANA SC + LD ETN SC + MTX | 25.95(4.22,209.40) | 13.76(3.14,85.61) | 0.42(0.15,0.72) | |
| LD RITUX IV + MTX | LD ADA SC + MTX | 0.89(0.25,2.93) | 0.93(0.44,2.01) | ‐0.03(‐0.32,0.23) |
| LD ADA IV + MTX | 0.89(0.14,5.17) | 0.94(0.23,2.28) | ‐0.03(‐0.37,0.37) | |
| LD ABA IV + MTX | 0.53(0.16,1.77) | 0.66(0.30,1.49) | ‐0.13(‐0.41,0.11) | |
| LD ANA SC + MTX | 0.49(0.08,2.68) | 0.63(0.16,1.83) | ‐0.14(‐0.47,0.21) | |
| LD CERTO SC + MTX | 1.04(0.28,3.88) | 1.02(0.47,2.33) | 0.01(‐0.29,0.31) | |
| LD GOLI IV + MTX | 0.55(0.14,2.09) | 0.68(0.27,1.63) | ‐0.12(‐0.42,0.15) | |
| LD TOCI IV + MTX | 0.45(0.11,1.74) | 0.59(0.23,1.45) | ‐0.16(‐0.45,0.11) | |
| LD TOFA PO + MTX | 0.76(0.15,3.48) | 0.85(0.28,2.11) | ‐0.06(‐0.39,0.28) | |
| HD TOCI IV | 0.71(0.23,2.08) | 0.81(0.45,1.70) | ‐0.08(‐0.34,0.15) | |
| HD TOFA PO | 1.01(0.27,3.89) | 1.00(0.50,2.52) | 0.00(‐0.31,0.29) | |
| HD ADA SC | 0.46(0.12,1.87) | 0.60(0.27,1.59) | ‐0.16(‐0.47,0.12) | |
| HD GOLI SC | 0.78(0.23,2.58) | 0.86(0.42,1.95) | ‐0.06(‐0.34,0.19) | |
| HD ETN SC | 0.72(0.11,4.33) | 0.82(0.22,2.34) | ‐0.07(‐0.44,0.33) | |
| HD ABA SC | 1.39(0.24,8.22) | 1.19(0.43,3.25) | 0.08(‐0.33,0.47) | |
| HD TOCI IV + MTX | 1.23(0.40,3.65) | 1.13(0.63,2.34) | 0.05(‐0.22,0.29) | |
| HD INF IV + MTX | 1.13(0.34,3.64) | 1.07(0.55,2.28) | 0.03(‐0.25,0.29) | |
| HD TOFA PO + MTX | 0.96(0.28,3.11) | 0.98(0.48,2.11) | ‐0.01(‐0.29,0.25) | |
| HD GOLI SC + MTX | 1.33(0.38,4.31) | 1.17(0.60,2.52) | 0.07(‐0.23,0.32) | |
| HD CERTO SC + MTX | 1.74(0.55,5.24) | 1.33(0.76,2.75) | 0.13(‐0.14,0.37) | |
| HD ADA SC + MTX | 1.44(0.53,4.02) | 1.21(0.69,2.28) | 0.08(‐0.15,0.32) | |
| HD TOCI IV + DMARD | 0.85(0.08,8.81) | 0.90(0.16,3.01) | ‐0.04(‐0.47,0.48) | |
| SD ANA SC + SD ETN SC + MTX | 0.86(0.18,4.25) | 0.91(0.33,2.40) | ‐0.03(‐0.37,0.32) | |
| SD ANA SC + LD ETN SC + MTX | 1.28(0.27,6.13) | 1.14(0.46,2.84) | 0.06(‐0.30,0.41) | |
| LD ADA IV + MTX | LD RITUX IV + MTX | 1.01(0.14,6.86) | 1.01(0.23,2.59) | 0.00(‐0.35,0.43) |
| LD ABA IV + MTX | 0.60(0.22,1.60) | 0.71(0.36,1.36) | ‐0.10(‐0.32,0.10) | |
| LD ANA SC + MTX | 0.56(0.11,2.75) | 0.67(0.18,1.81) | ‐0.12(‐0.39,0.23) | |
| LD CERTO SC + MTX | 1.17(0.37,3.73) | 1.10(0.53,2.17) | 0.04(‐0.22,0.30) | |
| LD GOLI IV + MTX | 0.62(0.19,2.01) | 0.73(0.31,1.58) | ‐0.10(‐0.34,0.15) | |
| LD TOCI IV + MTX | 0.51(0.16,1.69) | 0.63(0.26,1.43) | ‐0.13(‐0.37,0.11) | |
| LD TOFA PO + MTX | 0.86(0.21,3.45) | 0.91(0.33,2.05) | ‐0.03(‐0.31,0.28) | |
| HD TOCI IV | 0.80(0.33,1.98) | 0.87(0.52,1.63) | ‐0.05(‐0.26,0.14) | |
| HD TOFA PO | 1.15(0.35,3.87) | 1.09(0.55,2.45) | 0.03(‐0.25,0.29) | |
| HD ADA SC | 0.53(0.16,1.87) | 0.64(0.29,1.57) | ‐0.13(‐0.40,0.12) | |
| HD GOLI SC | 0.88(0.31,2.45) | 0.92(0.49,1.84) | ‐0.03(‐0.26,0.19) | |
| HD ETN SC | 0.82(0.16,4.34) | 0.88(0.26,2.35) | ‐0.04(‐0.36,0.33) | |
| HD ABA SC | 1.57(0.30,9.12) | 1.29(0.46,3.23) | 0.11(‐0.27,0.49) | |
| HD TOCI IV + MTX | 1.39(0.57,3.48) | 1.21(0.74,2.23) | 0.08(‐0.13,0.28) | |
| HD INF IV + MTX | 1.28(0.49,3.35) | 1.15(0.65,2.14) | 0.06(‐0.17,0.27) | |
| HD TOFA PO + MTX | 1.09(0.39,2.93) | 1.05(0.56,1.98) | 0.02(‐0.21,0.24) | |
| HD GOLI SC + MTX | 1.51(0.56,4.04) | 1.26(0.71,2.35) | 0.09(‐0.14,0.32) | |
| HD CERTO SC + MTX | 1.97(0.79,4.81) | 1.44(0.89,2.57) | 0.16(‐0.06,0.36) | |
| HD ADA SC + MTX | 1.64(0.49,6.07) | 1.31(0.64,2.73) | 0.11(‐0.16,0.41) | |
| HD TOCI IV + DMARD | 0.95(0.11,9.48) | 0.97(0.19,3.12) | ‐0.01(‐0.40,0.49) | |
| SD ANA SC + SD ETN SC + MTX | 0.98(0.23,4.32) | 0.99(0.37,2.35) | 0.00(‐0.30,0.34) | |
| SD ANA SC + LD ETN SC + MTX | 1.45(0.35,6.17) | 1.23(0.51,2.71) | 0.08(‐0.23,0.41) | |
| LD ABA IV + MTX | LD ADA IV + MTX | 0.59(0.09,4.02) | 0.71(0.26,3.09) | ‐0.11(‐0.52,0.21) |
| LD ANA SC + MTX | 0.55(0.06,5.19) | 0.68(0.15,3.39) | ‐0.11(‐0.56,0.30) | |
| LD CERTO SC + MTX | 1.19(0.16,8.73) | 1.11(0.40,4.77) | 0.04(‐0.41,0.40) | |
| LD GOLI IV + MTX | 0.61(0.08,4.62) | 0.73(0.24,3.36) | ‐0.10(‐0.53,0.24) | |
| LD TOCI IV + MTX | 0.51(0.07,3.85) | 0.63(0.20,2.98) | ‐0.13(‐0.56,0.21) | |
| LD TOFA PO + MTX | 0.85(0.10,7.52) | 0.91(0.26,4.28) | ‐0.03(‐0.49,0.38) | |
| HD TOCI IV | 0.80(0.14,5.08) | 0.86(0.38,3.73) | ‐0.05(‐0.45,0.25) | |
| HD TOFA PO | 1.14(0.17,8.32) | 1.08(0.45,5.10) | 0.03(‐0.40,0.37) | |
| HD ADA SC | 0.52(0.08,4.11) | 0.64(0.24,3.18) | ‐0.13(‐0.56,0.20) | |
| HD GOLI SC | 0.88(0.13,6.38) | 0.92(0.36,4.23) | ‐0.03(‐0.45,0.31) | |
| HD ETN SC | 0.81(0.08,8.04) | 0.88(0.21,4.52) | ‐0.04(‐0.53,0.40) | |
| HD ABA SC | 1.55(0.16,16.31) | 1.27(0.39,6.59) | 0.10(‐0.41,0.54) | |
| HD TOCI IV + MTX | 1.39(0.23,9.45) | 1.21(0.53,5.39) | 0.08(‐0.33,0.40) | |
| HD INF IV + MTX | 1.28(0.20,8.57) | 1.15(0.48,5.05) | 0.06(‐0.37,0.39) | |
| HD TOFA PO + MTX | 1.08(0.17,7.33) | 1.05(0.41,4.55) | 0.02(‐0.41,0.36) | |
| HD GOLI SC + MTX | 1.49(0.22,10.58) | 1.25(0.52,5.58) | 0.09(‐0.34,0.43) | |
| HD CERTO SC + MTX | 1.96(0.32,13.10) | 1.44(0.63,6.28) | 0.16(‐0.26,0.49) | |
| HD ADA SC + MTX | 1.63(0.23,11.76) | 1.29(0.51,5.67) | 0.11(‐0.33,0.48) | |
| HD TOCI IV + DMARD | 0.98(0.06,14.45) | 0.99(0.17,5.63) | 0.00(‐0.55,0.54) | |
| SD ANA SC + SD ETN SC + MTX | 0.98(0.12,8.38) | 0.99(0.30,4.75) | ‐0.01(‐0.46,0.41) | |
| SD ANA SC + LD ETN SC + MTX | 1.44(0.19,12.99) | 1.22(0.41,5.84) | 0.08(‐0.38,0.50) | |
| LD ANA SC + MTX | LD ABA IV + MTX | 0.92(0.19,4.30) | 0.94(0.26,2.59) | ‐0.01(‐0.25,0.32) |
| LD CERTO SC + MTX | 1.95(0.64,6.17) | 1.54(0.74,3.25) | 0.14(‐0.09,0.40) | |
| LD GOLI IV + MTX | 1.04(0.32,3.17) | 1.03(0.42,2.29) | 0.01(‐0.21,0.23) | |
| LD TOCI IV + MTX | 0.85(0.27,2.78) | 0.89(0.36,2.11) | ‐0.03(‐0.24,0.20) | |
| LD TOFA PO + MTX | 1.43(0.36,5.59) | 1.28(0.46,3.01) | 0.07(‐0.18,0.38) | |
| HD TOCI IV | 1.34(0.58,3.23) | 1.23(0.70,2.45) | 0.06(‐0.12,0.22) | |
| HD TOFA PO | 1.92(0.61,6.50) | 1.54(0.74,3.75) | 0.14(‐0.11,0.37) | |
| HD ADA SC | 0.88(0.27,3.11) | 0.91(0.38,2.39) | ‐0.02(‐0.26,0.20) | |
| HD GOLI SC | 1.46(0.54,3.92) | 1.30(0.66,2.69) | 0.08(‐0.13,0.27) | |
| HD ETN SC | 1.35(0.25,7.07) | 1.23(0.35,3.50) | 0.06(‐0.24,0.42) | |
| HD ABA SC | 2.62(0.50,14.41) | 1.82(0.61,4.86) | 0.21(‐0.15,0.57) | |
| HD TOCI IV + MTX | 2.33(0.98,5.70) | 1.71(0.99,3.36) | 0.18(0.00,0.37) | |
| HD INF IV + MTX | 2.13(0.85,5.36) | 1.62(0.90,3.11) | 0.16(‐0.04,0.36) | |
| HD TOFA PO + MTX | 1.81(0.67,4.71) | 1.48(0.77,2.89) | 0.12(‐0.08,0.33) | |
| HD GOLI SC + MTX | 2.50(0.96,6.54) | 1.78(0.98,3.51) | 0.20(‐0.01,0.40) | |
| HD CERTO SC + MTX | 3.27(1.36,7.90) | 2.03(1.19,3.83) | 0.26(0.07,0.45) | |
| HD ADA SC + MTX | 2.75(0.78,9.46) | 1.85(0.85,3.88) | 0.22(‐0.05,0.49) | |
| HD TOCI IV + DMARD | 1.60(0.18,16.02) | 1.37(0.27,4.57) | 0.10(‐0.27,0.59) | |
| SD ANA SC + SD ETN SC + MTX | 1.61(0.39,7.05) | 1.38(0.50,3.44) | 0.10(‐0.18,0.42) | |
| SD ANA SC + LD ETN SC + MTX | 2.39(0.60,10.16) | 1.73(0.70,4.03) | 0.19(‐0.10,0.50) | |
| LD CERTO SC + MTX | LD ANA SC + MTX | 2.12(0.39,11.79) | 1.63(0.57,6.33) | 0.15(‐0.21,0.46) |
| LD GOLI IV + MTX | 1.12(0.20,6.14) | 1.08(0.34,4.18) | 0.02(‐0.33,0.30) | |
| LD TOCI IV + MTX | 0.92(0.17,5.10) | 0.94(0.29,3.72) | ‐0.01(‐0.36,0.26) | |
| LD TOFA PO + MTX | 1.52(0.24,9.73) | 1.34(0.38,5.44) | 0.08(‐0.29,0.44) | |
| HD TOCI IV | 1.44(0.33,6.72) | 1.29(0.53,4.77) | 0.07(‐0.26,0.29) | |
| HD TOFA PO | 2.04(0.40,11.78) | 1.61(0.61,6.93) | 0.15(‐0.22,0.41) | |
| HD ADA SC | 0.95(0.18,5.59) | 0.96(0.32,4.19) | ‐0.01(‐0.37,0.24) | |
| HD GOLI SC | 1.57(0.33,7.96) | 1.36(0.52,5.22) | 0.09(‐0.25,0.34) | |
| HD ETN SC | 1.48(0.18,11.79) | 1.30(0.29,6.00) | 0.07(‐0.34,0.47) | |
| HD ABA SC | 2.79(0.38,24.14) | 1.89(0.55,8.66) | 0.22(‐0.22,0.61) | |
| HD TOCI IV + MTX | 2.50(0.56,11.77) | 1.80(0.74,6.80) | 0.20(‐0.14,0.44) | |
| HD INF IV + MTX | 2.28(0.51,11.10) | 1.71(0.68,6.33) | 0.17(‐0.16,0.44) | |
| HD TOFA PO + MTX | 1.95(0.42,9.75) | 1.56(0.59,5.83) | 0.13(‐0.21,0.40) | |
| HD GOLI SC + MTX | 2.69(0.58,13.19) | 1.87(0.76,6.95) | 0.21(‐0.13,0.47) | |
| HD CERTO SC + MTX | 3.52(0.80,16.77) | 2.14(0.90,7.86) | 0.27(‐0.05,0.53) | |
| HD ADA SC + MTX | 2.97(0.52,17.42) | 1.94(0.68,7.53) | 0.23(‐0.15,0.55) | |
| HD TOCI IV + DMARD | 1.72(0.14,23.13) | 1.44(0.24,7.80) | 0.11(‐0.35,0.61) | |
| SD ANA SC + SD ETN SC + MTX | 1.74(0.28,12.85) | 1.45(0.43,6.32) | 0.11(‐0.28,0.48) | |
| SD ANA SC + LD ETN SC + MTX | 2.59(0.40,18.65) | 1.82(0.57,7.71) | 0.20(‐0.20,0.56) | |
| LD GOLI IV + MTX | LD CERTO SC + MTX | 0.53(0.14,1.88) | 0.66(0.28,1.51) | ‐0.13(‐0.41,0.13) |
| LD TOCI IV + MTX | 0.43(0.12,1.63) | 0.57(0.22,1.39) | ‐0.17(‐0.45,0.10) | |
| LD TOFA PO + MTX | 0.73(0.16,3.21) | 0.83(0.29,1.96) | ‐0.07(‐0.38,0.26) | |
| HD TOCI IV | 0.68(0.24,1.95) | 0.79(0.45,1.62) | ‐0.08(‐0.33,0.13) | |
| HD TOFA PO | 0.99(0.26,3.66) | 0.99(0.50,2.37) | 0.00(‐0.32,0.28) | |
| HD ADA SC | 0.45(0.12,1.75) | 0.58(0.26,1.49) | ‐0.17(‐0.46,0.10) | |
| HD GOLI SC | 0.74(0.23,2.43) | 0.83(0.43,1.82) | ‐0.07(‐0.33,0.19) | |
| HD ETN SC | 0.70(0.12,3.91) | 0.80(0.22,2.18) | ‐0.08(‐0.43,0.31) | |
| HD ABA SC | 1.34(0.23,8.00) | 1.17(0.42,2.99) | 0.07(‐0.34,0.46) | |
| HD TOCI IV + MTX | 1.19(0.42,3.47) | 1.10(0.64,2.21) | 0.04(‐0.21,0.27) | |
| HD INF IV + MTX | 1.09(0.36,3.29) | 1.05(0.57,2.10) | 0.02(‐0.24,0.26) | |
| HD TOFA PO + MTX | 0.93(0.30,2.82) | 0.96(0.50,1.95) | ‐0.02(‐0.28,0.23) | |
| HD GOLI SC + MTX | 1.28(0.42,3.90) | 1.14(0.63,2.33) | 0.06(‐0.21,0.31) | |
| HD CERTO SC + MTX | 1.66(0.68,4.11) | 1.30(0.84,2.39) | 0.12(‐0.09,0.32) | |
| HD ADA SC + MTX | 1.40(0.36,5.68) | 1.19(0.55,2.57) | 0.08(‐0.24,0.39) | |
| HD TOCI IV + DMARD | 0.82(0.08,8.19) | 0.89(0.17,2.87) | ‐0.04(‐0.47,0.46) | |
| SD ANA SC + SD ETN SC + MTX | 0.83(0.18,4.14) | 0.90(0.33,2.29) | ‐0.04(‐0.37,0.32) | |
| SD ANA SC + LD ETN SC + MTX | 1.23(0.26,5.77) | 1.12(0.45,2.65) | 0.05(‐0.30,0.40) | |
| LD TOCI IV + MTX | LD GOLI IV + MTX | 0.83(0.22,3.17) | 0.87(0.32,2.38) | ‐0.03(‐0.29,0.21) |
| LD TOFA PO + MTX | 1.37(0.31,6.19) | 1.24(0.42,3.38) | 0.06(‐0.22,0.39) | |
| HD TOCI IV | 1.30(0.45,3.78) | 1.20(0.61,2.82) | 0.05(‐0.18,0.24) | |
| HD TOFA PO | 1.85(0.52,7.01) | 1.50(0.68,4.10) | 0.13(‐0.15,0.37) | |
| HD ADA SC | 0.86(0.23,3.36) | 0.89(0.36,2.56) | ‐0.03(‐0.30,0.20) | |
| HD GOLI SC | 1.41(0.46,4.48) | 1.26(0.60,3.05) | 0.07(‐0.17,0.29) | |
| HD ETN SC | 1.31(0.23,7.51) | 1.20(0.33,3.81) | 0.05(‐0.27,0.42) | |
| HD ABA SC | 2.52(0.44,15.71) | 1.76(0.59,5.29) | 0.20(‐0.18,0.57) | |
| HD TOCI IV + MTX | 2.25(0.76,6.73) | 1.67(0.85,3.87) | 0.18(‐0.06,0.39) | |
| HD INF IV + MTX | 2.04(0.67,6.49) | 1.58(0.78,3.68) | 0.15(‐0.09,0.38) | |
| HD TOFA PO + MTX | 1.75(0.56,5.82) | 1.44(0.69,3.51) | 0.12(‐0.13,0.36) | |
| HD GOLI SC + MTX | 2.42(0.80,7.62) | 1.73(0.88,4.09) | 0.19(‐0.05,0.42) | |
| HD CERTO SC + MTX | 3.17(1.10,9.53) | 1.98(1.05,4.53) | 0.26(0.02,0.47) | |
| HD ADA SC + MTX | 2.63(0.67,10.67) | 1.80(0.78,4.36) | 0.21(‐0.09,0.51) | |
| HD TOCI IV + DMARD | 1.52(0.17,15.87) | 1.33(0.25,4.95) | 0.08(‐0.30,0.58) | |
| SD ANA SC + SD ETN SC + MTX | 1.56(0.34,7.82) | 1.34(0.47,3.96) | 0.09(‐0.21,0.43) | |
| SD ANA SC + LD ETN SC + MTX | 2.33(0.51,11.57) | 1.68(0.64,4.61) | 0.18(‐0.14,0.52) | |
| LD TOFA PO + MTX | LD TOCI IV + MTX | 1.67(0.35,7.78) | 1.43(0.44,4.13) | 0.10(‐0.19,0.42) |
| HD TOCI IV | 1.57(0.62,4.10) | 1.38(0.74,3.08) | 0.09(‐0.11,0.24) | |
| HD TOFA PO | 2.27(0.62,8.42) | 1.75(0.74,4.80) | 0.17(‐0.11,0.40) | |
| HD ADA SC | 1.02(0.29,3.86) | 1.02(0.42,2.94) | 0.00(‐0.24,0.22) | |
| HD GOLI SC | 1.71(0.53,5.66) | 1.46(0.65,3.65) | 0.10(‐0.14,0.32) | |
| HD ETN SC | 1.58(0.27,9.48) | 1.38(0.36,4.47) | 0.09(‐0.23,0.46) | |
| HD ABA SC | 3.03(0.53,19.91) | 2.03(0.66,6.26) | 0.24(‐0.13,0.61) | |
| HD TOCI IV + MTX | 2.71(1.04,7.39) | 1.93(1.03,4.31) | 0.21(0.01,0.40) | |
| HD INF IV + MTX | 2.49(0.79,8.16) | 1.83(0.87,4.40) | 0.19(‐0.05,0.42) | |
| HD TOFA PO + MTX | 2.14(0.63,7.21) | 1.67(0.74,4.12) | 0.15(‐0.10,0.39) | |
| HD GOLI SC + MTX | 2.95(0.90,9.54) | 2.01(0.94,4.76) | 0.23(‐0.02,0.46) | |
| HD CERTO SC + MTX | 3.84(1.30,11.94) | 2.29(1.16,5.34) | 0.29(0.06,0.51) | |
| HD ADA SC + MTX | 3.24(0.79,13.56) | 2.08(0.86,5.38) | 0.25(‐0.05,0.54) | |
| HD TOCI IV + DMARD | 1.87(0.20,19.42) | 1.54(0.28,5.80) | 0.12(‐0.25,0.60) | |
| SD ANA SC + SD ETN SC + MTX | 1.90(0.40,9.49) | 1.56(0.51,4.50) | 0.12(‐0.18,0.46) | |
| SD ANA SC + LD ETN SC + MTX | 2.82(0.60,13.84) | 1.95(0.71,5.41) | 0.22(‐0.10,0.55) | |
| HD TOCI IV | LD TOFA PO + MTX | 0.94(0.26,3.62) | 0.96(0.47,2.72) | ‐0.01(‐0.32,0.22) |
| HD TOFA PO | 1.34(0.29,6.55) | 1.20(0.53,3.89) | 0.07(‐0.29,0.36) | |
| HD ADA SC | 0.62(0.13,3.05) | 0.71(0.28,2.41) | ‐0.10(‐0.44,0.18) | |
| HD GOLI SC | 1.03(0.25,4.19) | 1.02(0.46,2.93) | 0.01(‐0.32,0.27) | |
| HD ETN SC | 0.95(0.14,6.80) | 0.97(0.25,3.62) | ‐0.01(‐0.41,0.39) | |
| HD ABA SC | 1.84(0.27,13.28) | 1.42(0.46,4.82) | 0.14(‐0.30,0.54) | |
| HD TOCI IV + MTX | 1.63(0.44,6.31) | 1.34(0.67,3.81) | 0.11(‐0.19,0.37) | |
| HD INF IV + MTX | 1.51(0.38,5.94) | 1.28(0.60,3.53) | 0.09(‐0.23,0.36) | |
| HD TOFA PO + MTX | 1.27(0.40,4.13) | 1.16(0.61,2.80) | 0.05(‐0.21,0.28) | |
| HD GOLI SC + MTX | 1.75(0.46,7.03) | 1.39(0.67,3.87) | 0.13(‐0.18,0.40) | |
| HD CERTO SC + MTX | 2.30(0.62,8.73) | 1.59(0.81,4.38) | 0.19(‐0.11,0.45) | |
| HD ADA SC + MTX | 1.93(0.39,10.08) | 1.45(0.58,4.30) | 0.15(‐0.22,0.49) | |
| HD TOCI IV + DMARD | 1.14(0.11,14.27) | 1.09(0.20,4.67) | 0.03(‐0.42,0.55) | |
| SD ANA SC + SD ETN SC + MTX | 1.16(0.20,6.79) | 1.09(0.36,3.57) | 0.03(‐0.35,0.39) | |
| SD ANA SC + LD ETN SC + MTX | 1.71(0.30,9.81) | 1.36(0.49,4.22) | 0.12(‐0.27,0.48) | |
| HD TOFA PO | HD TOCI IV | 1.43(0.56,3.74) | 1.25(0.69,2.33) | 0.08(‐0.13,0.29) |
| HD ADA SC | 0.66(0.26,1.74) | 0.74(0.37,1.48) | ‐0.08(‐0.26,0.12) | |
| HD GOLI SC | 1.10(0.46,2.61) | 1.06(0.58,1.85) | 0.02(‐0.16,0.22) | |
| HD ETN SC | 1.01(0.21,4.71) | 1.01(0.29,2.40) | 0.00(‐0.26,0.36) | |
| HD ABA SC | 1.96(0.43,9.65) | 1.49(0.56,3.17) | 0.16(‐0.17,0.50) | |
| HD TOCI IV + MTX | 1.75(0.99,3.08) | 1.40(0.99,1.98) | 0.13(0.00,0.26) | |
| HD INF IV + MTX | 1.59(0.69,3.67) | 1.33(0.78,2.15) | 0.10(‐0.08,0.30) | |
| HD TOFA PO + MTX | 1.36(0.55,3.21) | 1.21(0.66,2.01) | 0.07(‐0.12,0.27) | |
| HD GOLI SC + MTX | 1.88(0.79,4.42) | 1.45(0.86,2.33) | 0.15(‐0.05,0.35) | |
| HD CERTO SC + MTX | 2.45(1.15,5.21) | 1.66(1.09,2.53) | 0.21(0.03,0.38) | |
| HD ADA SC + MTX | 2.04(0.66,6.69) | 1.51(0.75,2.66) | 0.17(‐0.09,0.43) | |
| HD TOCI IV + DMARD | 1.20(0.15,10.25) | 1.12(0.22,3.10) | 0.04(‐0.30,0.52) | |
| SD ANA SC + SD ETN SC + MTX | 1.21(0.33,4.84) | 1.13(0.43,2.40) | 0.04(‐0.21,0.36) | |
| SD ANA SC + LD ETN SC + MTX | 1.79(0.48,6.85) | 1.42(0.59,2.73) | 0.13(‐0.15,0.44) | |
| HD ADA SC | HD TOFA PO | 0.46(0.17,1.22) | 0.59(0.29,1.14) | ‐0.16(‐0.36,0.04) |
| HD GOLI SC | 0.77(0.25,2.21) | 0.85(0.40,1.61) | ‐0.06(‐0.30,0.19) | |
| HD ETN SC | 0.70(0.13,3.58) | 0.80(0.22,1.95) | ‐0.08(‐0.38,0.30) | |
| HD ABA SC | 1.35(0.30,6.83) | 1.18(0.46,2.40) | 0.07(‐0.26,0.43) | |
| HD TOCI IV + MTX | 1.21(0.43,3.48) | 1.12(0.60,1.99) | 0.05(‐0.20,0.29) | |
| HD INF IV + MTX | 1.12(0.34,3.46) | 1.07(0.51,1.99) | 0.03(‐0.25,0.29) | |
| HD TOFA PO + MTX | 0.95(0.28,3.08) | 0.97(0.44,1.87) | ‐0.01(‐0.28,0.27) | |
| HD GOLI SC + MTX | 1.30(0.40,4.07) | 1.16(0.57,2.11) | 0.06(‐0.21,0.33) | |
| HD CERTO SC + MTX | 1.71(0.55,5.12) | 1.33(0.71,2.31) | 0.13(‐0.14,0.38) | |
| HD ADA SC + MTX | 1.44(0.35,5.74) | 1.22(0.51,2.30) | 0.09(‐0.23,0.40) | |
| HD TOCI IV + DMARD | 0.82(0.10,7.14) | 0.88(0.17,2.34) | ‐0.05(‐0.40,0.43) | |
| SD ANA SC + SD ETN SC + MTX | 0.85(0.20,3.81) | 0.91(0.33,1.97) | ‐0.04(‐0.33,0.31) | |
| SD ANA SC + LD ETN SC + MTX | 1.26(0.30,5.48) | 1.14(0.45,2.26) | 0.06(‐0.26,0.39) | |
| HD GOLI SC | HD ADA SC | 1.66(0.53,5.13) | 1.43(0.63,3.11) | 0.10(‐0.12,0.33) |
| HD ETN SC | 1.54(0.27,7.84) | 1.36(0.35,3.57) | 0.08(‐0.20,0.45) | |
| HD ABA SC | 2.95(0.62,15.08) | 1.99(0.71,4.63) | 0.23(‐0.09,0.58) | |
| HD TOCI IV + MTX | 2.63(0.90,7.64) | 1.88(0.93,3.82) | 0.21(‐0.02,0.43) | |
| HD INF IV + MTX | 2.43(0.72,7.91) | 1.81(0.80,3.81) | 0.19(‐0.07,0.44) | |
| HD TOFA PO + MTX | 2.06(0.60,6.84) | 1.63(0.69,3.58) | 0.15(‐0.10,0.41) | |
| HD GOLI SC + MTX | 2.86(0.85,9.26) | 1.96(0.89,4.07) | 0.23(‐0.03,0.48) | |
| HD CERTO SC + MTX | 3.72(1.17,11.58) | 2.24(1.11,4.50) | 0.29(0.04,0.53) | |
| HD ADA SC + MTX | 3.11(0.74,13.00) | 2.05(0.81,4.44) | 0.25(‐0.06,0.55) | |
| HD TOCI IV + DMARD | 1.81(0.21,15.25) | 1.51(0.28,4.33) | 0.12(‐0.22,0.58) | |
| SD ANA SC + SD ETN SC + MTX | 1.85(0.42,8.59) | 1.53(0.52,3.79) | 0.12(‐0.15,0.47) | |
| SD ANA SC + LD ETN SC + MTX | 2.74(0.60,12.43) | 1.93(0.70,4.38) | 0.22(‐0.10,0.54) | |
| HD ETN SC | HD GOLI SC | 0.92(0.18,4.68) | 0.95(0.28,2.45) | ‐0.02(‐0.31,0.35) |
| HD ABA SC | 1.78(0.36,9.35) | 1.39(0.51,3.24) | 0.13(‐0.22,0.50) | |
| HD TOCI IV + MTX | 1.59(0.64,3.95) | 1.31(0.77,2.36) | 0.11(‐0.10,0.31) | |
| HD INF IV + MTX | 1.45(0.55,3.90) | 1.25(0.69,2.30) | 0.09(‐0.13,0.31) | |
| HD TOFA PO + MTX | 1.24(0.45,3.40) | 1.14(0.59,2.14) | 0.05(‐0.17,0.28) | |
| HD GOLI SC + MTX | 1.70(0.74,3.87) | 1.36(0.84,2.25) | 0.12(‐0.07,0.31) | |
| HD CERTO SC + MTX | 2.25(0.87,5.71) | 1.56(0.93,2.76) | 0.19(‐0.03,0.40) | |
| HD ADA SC + MTX | 1.87(0.53,6.68) | 1.42(0.66,2.80) | 0.14(‐0.14,0.43) | |
| HD TOCI IV + DMARD | 1.08(0.13,10.71) | 1.05(0.21,3.23) | 0.02(‐0.34,0.52) | |
| SD ANA SC + SD ETN SC + MTX | 1.11(0.27,4.84) | 1.07(0.39,2.47) | 0.02(‐0.26,0.36) | |
| SD ANA SC + LD ETN SC + MTX | 1.65(0.40,6.88) | 1.34(0.54,2.83) | 0.11(‐0.19,0.44) | |
| HD ABA SC | HD ETN SC | 1.92(0.27,15.51) | 1.46(0.46,5.62) | 0.15(‐0.30,0.56) |
| HD TOCI IV + MTX | 1.73(0.36,8.34) | 1.39(0.59,4.64) | 0.12(‐0.24,0.41) | |
| HD INF IV + MTX | 1.57(0.31,8.12) | 1.31(0.53,4.47) | 0.10(‐0.28,0.41) | |
| HD TOFA PO + MTX | 1.36(0.24,6.81) | 1.21(0.45,4.06) | 0.07(‐0.32,0.38) | |
| HD GOLI SC + MTX | 1.85(0.36,9.57) | 1.43(0.60,4.86) | 0.14(‐0.24,0.45) | |
| HD CERTO SC + MTX | 2.42(0.49,12.49) | 1.63(0.72,5.55) | 0.20(‐0.17,0.51) | |
| HD ADA SC + MTX | 2.05(0.33,12.63) | 1.50(0.54,5.25) | 0.16(‐0.25,0.52) | |
| HD TOCI IV + DMARD | 1.16(0.11,14.39) | 1.10(0.20,5.07) | 0.03(‐0.43,0.55) | |
| SD ANA SC + SD ETN SC + MTX | 1.21(0.21,7.35) | 1.13(0.37,3.89) | 0.04(‐0.35,0.41) | |
| SD ANA SC + LD ETN SC + MTX | 1.79(0.32,10.19) | 1.40(0.52,4.57) | 0.13(‐0.26,0.48) | |
| HD TOCI IV + MTX | HD ABA SC | 0.89(0.17,4.27) | 0.94(0.45,2.44) | ‐0.03(‐0.40,0.32) |
| HD INF IV + MTX | 0.81(0.15,4.30) | 0.89(0.39,2.42) | ‐0.05(‐0.43,0.33) | |
| HD TOFA PO + MTX | 0.69(0.13,3.64) | 0.82(0.34,2.24) | ‐0.09(‐0.46,0.29) | |
| HD GOLI SC + MTX | 0.96(0.17,4.95) | 0.98(0.43,2.59) | ‐0.01(‐0.40,0.36) | |
| HD CERTO SC + MTX | 1.26(0.23,6.53) | 1.12(0.53,2.89) | 0.06(‐0.33,0.42) | |
| HD ADA SC + MTX | 1.04(0.17,6.26) | 1.02(0.40,2.76) | 0.01(‐0.40,0.42) | |
| HD TOCI IV + DMARD | 0.62(0.05,6.51) | 0.77(0.14,2.50) | ‐0.11(‐0.56,0.42) | |
| SD ANA SC + SD ETN SC + MTX | 0.63(0.09,4.31) | 0.77(0.25,2.32) | ‐0.11(‐0.52,0.33) | |
| SD ANA SC + LD ETN SC + MTX | 0.91(0.14,6.39) | 0.96(0.34,2.73) | ‐0.02(‐0.44,0.42) | |
| HD INF IV + MTX | HD TOCI IV + MTX | 0.92(0.38,2.17) | 0.96(0.56,1.51) | ‐0.02(‐0.22,0.19) |
| HD TOFA PO + MTX | 0.78(0.31,1.89) | 0.87(0.48,1.42) | ‐0.06(‐0.26,0.15) | |
| HD GOLI SC + MTX | 1.08(0.44,2.58) | 1.04(0.62,1.64) | 0.02(‐0.19,0.22) | |
| HD CERTO SC + MTX | 1.41(0.64,3.07) | 1.18(0.79,1.78) | 0.08(‐0.11,0.27) | |
| HD ADA SC + MTX | 1.17(0.38,3.85) | 1.08(0.54,1.85) | 0.04(‐0.22,0.31) | |
| HD TOCI IV + DMARD | 0.69(0.09,6.07) | 0.80(0.17,2.20) | ‐0.09(‐0.45,0.40) | |
| SD ANA SC + SD ETN SC + MTX | 0.70(0.19,2.89) | 0.81(0.32,1.69) | ‐0.08(‐0.35,0.25) | |
| SD ANA SC + LD ETN SC + MTX | 1.03(0.28,4.07) | 1.02(0.44,1.95) | 0.01(‐0.28,0.32) | |
| HD TOFA PO + MTX | HD INF IV + MTX | 0.86(0.32,2.19) | 0.92(0.50,1.58) | ‐0.04(‐0.26,0.18) |
| HD GOLI SC + MTX | 1.18(0.46,2.98) | 1.09(0.65,1.86) | 0.04(‐0.18,0.25) | |
| HD CERTO SC + MTX | 1.53(0.66,3.63) | 1.24(0.81,2.05) | 0.10(‐0.10,0.30) | |
| HD ADA SC + MTX | 1.29(0.38,4.39) | 1.14(0.56,2.10) | 0.06(‐0.22,0.34) | |
| HD TOCI IV + DMARD | 0.75(0.09,6.98) | 0.84(0.17,2.50) | ‐0.06(‐0.45,0.44) | |
| SD ANA SC + SD ETN SC + MTX | 0.77(0.19,3.21) | 0.85(0.33,1.85) | ‐0.06(‐0.35,0.27) | |
| SD ANA SC + LD ETN SC + MTX | 1.13(0.29,4.59) | 1.07(0.45,2.18) | 0.03(‐0.28,0.35) | |
| HD GOLI SC + MTX | HD TOFA PO + MTX | 1.38(0.52,3.67) | 1.19(0.69,2.19) | 0.07(‐0.15,0.30) |
| HD CERTO SC + MTX | 1.80(0.75,4.53) | 1.36(0.86,2.41) | 0.14(‐0.07,0.35) | |
| HD ADA SC + MTX | 1.51(0.43,5.51) | 1.25(0.60,2.48) | 0.10(‐0.19,0.39) | |
| HD TOCI IV + DMARD | 0.87(0.10,8.84) | 0.92(0.18,2.89) | ‐0.03(‐0.41,0.48) | |
| SD ANA SC + SD ETN SC + MTX | 0.90(0.22,3.87) | 0.94(0.36,2.18) | ‐0.02(‐0.32,0.31) | |
| SD ANA SC + LD ETN SC + MTX | 1.33(0.33,5.74) | 1.17(0.49,2.54) | 0.07(‐0.24,0.39) | |
| HD CERTO SC + MTX | HD GOLI SC + MTX | 1.32(0.53,3.14) | 1.14(0.74,1.85) | 0.07(‐0.15,0.27) |
| HD ADA SC + MTX | 1.09(0.32,3.87) | 1.04(0.51,1.94) | 0.02(‐0.26,0.31) | |
| HD TOCI IV + DMARD | 0.63(0.07,6.39) | 0.77(0.15,2.23) | ‐0.11(‐0.50,0.41) | |
| SD ANA SC + SD ETN SC + MTX | 0.65(0.16,2.81) | 0.79(0.30,1.70) | ‐0.10(‐0.39,0.24) | |
| SD ANA SC + LD ETN SC + MTX | 0.96(0.24,4.08) | 0.98(0.42,1.97) | ‐0.01(‐0.32,0.32) | |
| HD ADA SC + MTX | HD CERTO SC + MTX | 0.84(0.26,2.74) | 0.92(0.46,1.54) | ‐0.04(‐0.31,0.23) |
| HD TOCI IV + DMARD | 0.49(0.06,4.58) | 0.68(0.14,1.83) | ‐0.17(‐0.55,0.34) | |
| SD ANA SC + SD ETN SC + MTX | 0.49(0.13,2.04) | 0.69(0.27,1.39) | ‐0.17(‐0.44,0.17) | |
| SD ANA SC + LD ETN SC + MTX | 0.74(0.19,2.97) | 0.86(0.37,1.59) | ‐0.07(‐0.37,0.25) | |
| HD TOCI IV + DMARD | HD ADA SC + MTX | 0.61(0.05,6.65) | 0.76(0.14,2.40) | ‐0.11(‐0.56,0.41) |
| SD ANA SC + SD ETN SC + MTX | 0.59(0.12,3.12) | 0.75(0.28,1.88) | ‐0.12(‐0.46,0.26) | |
| SD ANA SC + LD ETN SC + MTX | 0.87(0.18,4.53) | 0.93(0.38,2.19) | ‐0.03(‐0.39,0.34) | |
| SD ANA SC + SD ETN SC + MTX | HD TOCI IV + DMARD | 1.01(0.10,10.84) | 1.00(0.28,5.37) | 0.00(‐0.50,0.45) |
| SD ANA SC + LD ETN SC + MTX | 1.49(0.15,15.67) | 1.25(0.38,6.50) | 0.09(‐0.42,0.53) | |
| SD ANA SC + LD ETN SC + MTX | SD ANA SC + SD ETN SC + MTX | 1.47(0.54,4.10) | 1.24(0.69,2.45) | 0.08(‐0.14,0.31) |
| Random‐effects model | Residual deviance | 180 vs 175 data points | ||
| Deviance information criteria | 1121.54 | |||
| Fixed‐effect model | Residual deviance | 251.8 vs 175 data points | ||
| Deviance information criteria | 1166.12 | |||
| Note | ||||
| Total participants | 24,122 | |||
| Total studies | 66 | |||
| 2‐arm | 35 | |||
| 3‐arm | 23 | |||
| 4‐arm | 6 | |||
| 5‐arm | 1 | |||
| 7‐arm | 1 | |||
Appendix 6. ACR50: subgroup ‐ trial duration (> 6‐12 months)
| ACR50 intermediate: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD ETN SC | PL + MTX | 2.81(1.01,7.87) | 2.13(1.01,3.59) | 0.20(0.00,0.45) |
| SD ETN SC + MTX | 4.74(1.71,13.91) | 2.85(1.52,4.32) | 0.33(0.09,0.57) | |
| SD INF IV + MTX | 3.14(0.90,13.36) | 2.28(0.92,4.49) | 0.23(‐0.01,0.56) | |
| SD ADA SC + MTX | 6.83(2.41,20.66) | 3.35(1.92,4.83) | 0.42(0.17,0.64) | |
| SD RITUX IV + MTX | 1.42(0.50,4.08) | 1.32(0.55,2.65) | 0.06(‐0.08,0.29) | |
| SD TOFA PO + MTX | 5.57(1.78,16.57) | 3.08(1.56,4.66) | 0.37(0.10,0.60) | |
| LD ADA SC + MTX | 5.79(2.05,17.54) | 3.13(1.72,4.65) | 0.38(0.13,0.61) | |
| LD RITUX IV + MTX | 0.98(0.35,2.82) | 0.99(0.39,2.13) | 0.00(‐0.11,0.20) | |
| LD ETN SC + MTX | 3.84(1.43,11.41) | 2.56(1.33,4.10) | 0.27(0.06,0.53) | |
| HD ETN SC | 2.51(0.91,6.89) | 1.98(0.92,3.39) | 0.17(‐0.01,0.42) | |
| HD INF IV + MTX | 7.84(2.21,31.05) | 3.54(1.80,5.41) | 0.45(0.15,0.69) | |
| HD TOFA PO + MTX | 8.98(2.97,27.44) | 3.72(2.17,5.17) | 0.48(0.22,0.68) | |
| SD ETN SC + MTX | SD ETN SC | 1.68(0.41,7.67) | 1.33(0.62,3.05) | 0.12(‐0.20,0.44) |
| SD INF IV + MTX | 1.12(0.22,6.35) | 1.07(0.39,2.80) | 0.03(‐0.32,0.41) | |
| SD ADA SC + MTX | 2.43(0.58,10.48) | 1.57(0.77,3.45) | 0.21(‐0.12,0.50) | |
| SD RITUX IV + MTX | 0.50(0.12,2.21) | 0.62(0.23,1.70) | ‐0.14(‐0.42,0.16) | |
| SD TOFA PO + MTX | 1.99(0.41,8.74) | 1.44(0.62,3.22) | 0.17(‐0.20,0.47) | |
| LD ADA SC + MTX | 2.06(0.49,9.44) | 1.47(0.69,3.30) | 0.17(‐0.16,0.47) | |
| LD RITUX IV + MTX | 0.35(0.08,1.47) | 0.47(0.16,1.31) | ‐0.20(‐0.46,0.07) | |
| LD ETN SC + MTX | 1.36(0.33,6.05) | 1.20(0.54,2.82) | 0.07(‐0.24,0.38) | |
| HD ETN SC | 0.89(0.32,2.50) | 0.93(0.49,1.75) | ‐0.03(‐0.23,0.19) | |
| HD INF IV + MTX | 2.80(0.54,15.37) | 1.66(0.73,3.72) | 0.25(‐0.14,0.57) | |
| HD TOFA PO + MTX | 3.22(0.69,14.41) | 1.74(0.85,3.75) | 0.28(‐0.08,0.56) | |
| SD INF IV + MTX | SD ETN SC + MTX | 0.66(0.13,3.80) | 0.80(0.30,1.88) | ‐0.10(‐0.44,0.30) |
| SD ADA SC + MTX | 1.45(0.32,6.48) | 1.18(0.60,2.34) | 0.09(‐0.25,0.40) | |
| SD RITUX IV + MTX | 0.30(0.07,1.29) | 0.47(0.18,1.17) | ‐0.26(‐0.54,0.05) | |
| SD TOFA PO + MTX | 1.18(0.23,5.09) | 1.08(0.50,2.19) | 0.04(‐0.32,0.36) | |
| LD ADA SC + MTX | 1.23(0.27,5.46) | 1.10(0.55,2.22) | 0.05(‐0.28,0.37) | |
| LD RITUX IV + MTX | 0.21(0.05,0.88) | 0.35(0.13,0.93) | ‐0.32(‐0.58,‐0.02) | |
| LD ETN SC + MTX | 0.81(0.29,2.29) | 0.90(0.53,1.52) | ‐0.05(‐0.27,0.18) | |
| HD ETN SC | 0.53(0.12,2.17) | 0.70(0.30,1.53) | ‐0.15(‐0.45,0.17) | |
| HD INF IV + MTX | 1.66(0.31,8.96) | 1.24(0.60,2.49) | 0.12(‐0.26,0.46) | |
| HD TOFA PO + MTX | 1.90(0.39,8.32) | 1.30(0.69,2.50) | 0.15(‐0.20,0.45) | |
| SD ADA SC + MTX | SD INF IV + MTX | 2.17(0.37,11.79) | 1.46(0.65,3.74) | 0.19(‐0.22,0.53) |
| SD RITUX IV + MTX | 0.45(0.08,2.40) | 0.58(0.20,1.82) | ‐0.17(‐0.51,0.17) | |
| SD TOFA PO + MTX | 1.78(0.28,9.05) | 1.35(0.55,3.48) | 0.14(‐0.29,0.48) | |
| LD ADA SC + MTX | 1.82(0.31,10.15) | 1.36(0.58,3.53) | 0.14(‐0.27,0.50) | |
| LD RITUX IV + MTX | 0.31(0.05,1.62) | 0.44(0.14,1.42) | ‐0.22(‐0.57,0.08) | |
| LD ETN SC + MTX | 1.23(0.22,6.52) | 1.12(0.46,3.05) | 0.05(‐0.34,0.40) | |
| HD ETN SC | 0.80(0.14,3.96) | 0.87(0.33,2.41) | ‐0.05(‐0.42,0.29) | |
| HD INF IV + MTX | 2.47(0.77,7.67) | 1.52(0.90,3.03) | 0.21(‐0.05,0.44) | |
| HD TOFA PO + MTX | 2.85(0.46,14.83) | 1.62(0.73,4.00) | 0.25(‐0.17,0.56) | |
| SD RITUX IV + MTX | SD ADA SC + MTX | 0.21(0.05,0.92) | 0.40(0.16,0.95) | ‐0.35(‐0.61,‐0.02) |
| SD TOFA PO + MTX | 0.82(0.16,3.58) | 0.92(0.44,1.72) | ‐0.05(‐0.39,0.28) | |
| LD ADA SC + MTX | 0.85(0.31,2.31) | 0.94(0.60,1.41) | ‐0.04(‐0.25,0.18) | |
| LD RITUX IV + MTX | 0.14(0.03,0.64) | 0.30(0.11,0.77) | ‐0.41(‐0.66,‐0.09) | |
| LD ETN SC + MTX | 0.56(0.13,2.51) | 0.76(0.38,1.53) | ‐0.14(‐0.44,0.21) | |
| HD ETN SC | 0.37(0.08,1.57) | 0.59(0.26,1.25) | ‐0.24(‐0.53,0.10) | |
| HD INF IV + MTX | 1.15(0.20,6.47) | 1.05(0.51,2.00) | 0.03(‐0.35,0.39) | |
| HD TOFA PO + MTX | 1.33(0.27,5.83) | 1.11(0.61,1.99) | 0.07(‐0.28,0.37) | |
| SD TOFA PO + MTX | SD RITUX IV + MTX | 3.95(0.82,17.29) | 2.32(0.89,5.80) | 0.31(‐0.04,0.57) |
| LD ADA SC + MTX | 4.06(0.91,18.89) | 2.34(0.95,5.90) | 0.31(‐0.02,0.58) | |
| LD RITUX IV + MTX | 0.69(0.24,1.98) | 0.75(0.33,1.68) | ‐0.06(‐0.24,0.11) | |
| LD ETN SC + MTX | 2.70(0.63,11.96) | 1.92(0.76,4.98) | 0.21(‐0.09,0.49) | |
| HD ETN SC | 1.77(0.41,7.58) | 1.49(0.55,4.07) | 0.11(‐0.17,0.39) | |
| HD INF IV + MTX | 5.54(1.05,30.12) | 2.65(1.03,6.75) | 0.39(0.01,0.67) | |
| HD TOFA PO + MTX | 6.36(1.35,28.09) | 2.80(1.17,6.76) | 0.42(0.06,0.66) | |
| LD ADA SC + MTX | SD TOFA PO + MTX | 1.03(0.24,5.17) | 1.01(0.52,2.14) | 0.01(‐0.32,0.36) |
| LD RITUX IV + MTX | 0.17(0.04,0.81) | 0.32(0.12,0.88) | ‐0.36(‐0.61,‐0.04) | |
| LD ETN SC + MTX | 0.69(0.16,3.41) | 0.83(0.40,1.84) | ‐0.09(‐0.40,0.27) | |
| HD ETN SC | 0.45(0.10,2.11) | 0.64(0.28,1.50) | ‐0.19(‐0.49,0.17) | |
| HD INF IV + MTX | 1.40(0.26,8.53) | 1.15(0.56,2.40) | 0.08(‐0.30,0.45) | |
| HD TOFA PO + MTX | 1.61(0.61,4.39) | 1.20(0.83,1.93) | 0.11(‐0.10,0.31) | |
| LD RITUX IV + MTX | LD ADA SC + MTX | 0.17(0.04,0.75) | 0.32(0.12,0.84) | ‐0.37(‐0.63,‐0.05) |
| LD ETN SC + MTX | 0.66(0.15,2.95) | 0.82(0.39,1.68) | ‐0.10(‐0.41,0.24) | |
| HD ETN SC | 0.43(0.10,1.87) | 0.63(0.28,1.38) | ‐0.20(‐0.49,0.14) | |
| HD INF IV + MTX | 1.36(0.24,7.78) | 1.13(0.53,2.23) | 0.07(‐0.32,0.43) | |
| HD TOFA PO + MTX | 1.56(0.31,6.82) | 1.19(0.64,2.23) | 0.10(‐0.25,0.41) | |
| LD ETN SC + MTX | LD RITUX IV + MTX | 3.91(0.95,17.62) | 2.58(0.97,7.05) | 0.27(‐0.01,0.54) |
| HD ETN SC | 2.55(0.60,11.03) | 2.00(0.69,5.81) | 0.17(‐0.09,0.43) | |
| HD INF IV + MTX | 7.97(1.55,44.08) | 3.54(1.29,9.51) | 0.45(0.09,0.71) | |
| HD TOFA PO + MTX | 9.20(2.02,39.56) | 3.75(1.48,9.45) | 0.48(0.14,0.70) | |
| HD ETN SC | LD ETN SC + MTX | 0.65(0.15,2.65) | 0.78(0.33,1.75) | ‐0.10(‐0.41,0.21) |
| HD INF IV + MTX | 2.04(0.40,10.79) | 1.38(0.64,2.88) | 0.17(‐0.21,0.50) | |
| HD TOFA PO + MTX | 2.33(0.49,10.00) | 1.45(0.74,2.89) | 0.20(‐0.16,0.49) | |
| HD INF IV + MTX | HD ETN SC | 3.13(0.60,16.97) | 1.77(0.77,4.04) | 0.27(‐0.11,0.58) |
| HD TOFA PO + MTX | 3.60(0.77,15.84) | 1.88(0.89,4.11) | 0.30(‐0.06,0.57) | |
| HD TOFA PO + MTX | HD INF IV + MTX | 1.15(0.20,6.02) | 1.05(0.57,2.07) | 0.03(‐0.33,0.38) |
| Random‐effects model | Residual deviance | 18.31 vs 18 data points | ||
| Deviance information criteria | 132.003 | |||
| Fixed‐effect model | Residual deviance | 18.03 vs data points | ||
| Deviance information criteria | 131.437 | |||
| Note | ||||
| Total participants | 3209 | |||
| Total studies | 6 | |||
| 3‐arm | 6 | |||
Appendix 7. HAQ: main analysis
| HAQ: mean difference for all treatments | ||
| Treatment | Reference | MD (95% CrI) |
| MTX | PL | 0.04(‐0.39,0.50) |
| DMARD | 0.04(‐0.37,0.45) | |
| MTX + DMARD | ‐0.30(‐0.83,0.23) | |
| SD ETN SC | ‐0.34(‐0.70,0.03) | |
| SD ADA SC | ‐0.29(‐0.51,‐0.06) | |
| SD TOFA PO | ‐0.40(‐0.68,‐0.13) | |
| SD CERTO | ‐0.33(‐0.66,0.01) | |
| SD ANA | ‐0.20(‐0.63,0.23) | |
| SD RITUX IV | ‐0.33(‐0.93,0.29) | |
| SD ETN SC + MTX | ‐0.58(‐0.99,‐0.16) | |
| SD CERTO SC + MTX | ‐0.24(‐0.72,0.24) | |
| SD RITUX IV + MTX | ‐0.14(‐0.64,0.39) | |
| SD ADA SC + MTX | ‐0.27(‐0.77,0.25) | |
| SD GOLI SC + MTX | 0.04(‐0.49,0.59) | |
| SD TOFA PO + MTX | ‐0.39(‐0.99,0.22) | |
| SD TOCI IV + MTX | ‐0.16(‐0.67,0.37) | |
| SD ABA SC + MTX | ‐0.18(‐0.83,0.49) | |
| SD GOLI IV + MTX | 0.35(‐0.25,0.97) | |
| SD ETN SC + DMARD | ‐0.28(‐0.81,0.27) | |
| SD CERTO + DMARD | ‐0.33(‐0.71,0.04) | |
| LD ADA SC | ‐0.32(‐0.61,‐0.03) | |
| LD ANA | ‐0.20(‐0.62,0.22) | |
| LD ADA SC + MTX | ‐0.23(‐0.74,0.30) | |
| LD RITUX IV + MTX | ‐0.08(‐0.58,0.45) | |
| LD ADA IV + MTX | ‐0.25(‐0.88,0.38) | |
| LD CERTO SC + MTX | ‐0.16(‐0.75,0.44) | |
| LD ETN SC + MTX | ‐0.32(‐0.87,0.23) | |
| LD TOFA PO + MTX | ‐0.31(‐0.92,0.30) | |
| HD TOCI IV | ‐0.28(‐0.74,0.20) | |
| HD TOFA PO | ‐0.52(‐0.79,‐0.25) | |
| HD ADA SC | ‐0.43(‐0.72,‐0.14) | |
| HD ANA | ‐0.30(‐0.73,0.13) | |
| HD GOLI SC | 0.09(‐0.49,0.69) | |
| HD TOCI IV + MTX | ‐0.26(‐0.73,0.23) | |
| HD CERTO SC + MTX | ‐0.29(‐0.78,0.22) | |
| HD TOFA PO + MTX | ‐0.47(‐1.07,0.14) | |
| HD GOLI SC + MTX | 0.08(‐0.46,0.62) | |
| HD ADA SC + MTX | ‐0.27(‐0.85,0.33) | |
| DMARD | MTX | ‐0.01(‐0.36,0.34) |
| MTX + DMARD | ‐0.35(‐0.75,0.05) | |
| SD ETN SC | ‐0.38(‐0.65,‐0.11) | |
| SD ADA SC | ‐0.33(‐0.83,0.16) | |
| SD TOFA PO | ‐0.45(‐0.97,0.07) | |
| SD CERTO | ‐0.37(‐0.93,0.19) | |
| SD ANA | ‐0.25(‐0.87,0.36) | |
| SD RITUX IV | ‐0.37(‐0.79,0.05) | |
| SD ETN SC + MTX | ‐0.62(‐0.86,‐0.39) | |
| SD CERTO SC + MTX | ‐0.29(‐0.48,‐0.10) | |
| SD RITUX IV + MTX | ‐0.18(‐0.44,0.07) | |
| SD ADA SC + MTX | ‐0.32(‐0.56,‐0.07) | |
| SD GOLI SC + MTX | 0.00(‐0.31,0.31) | |
| SD TOFA PO + MTX | ‐0.44(‐0.85,‐0.03) | |
| SD TOCI IV + MTX | ‐0.20(‐0.48,0.08) | |
| SD ABA SC + MTX | ‐0.22(‐0.70,0.27) | |
| SD GOLI IV + MTX | 0.31(‐0.11,0.73) | |
| SD ETN SC + DMARD | ‐0.32(‐0.81,0.17) | |
| SD CERTO + DMARD | ‐0.37(‐0.83,0.08) | |
| LD ADA SC | ‐0.36(‐0.90,0.16) | |
| LD ANA | ‐0.25(‐0.87,0.36) | |
| LD ADA SC + MTX | ‐0.27(‐0.53,‐0.01) | |
| LD RITUX IV + MTX | ‐0.12(‐0.38,0.14) | |
| LD ADA IV + MTX | ‐0.29(‐0.74,0.15) | |
| LD CERTO SC + MTX | ‐0.20(‐0.60,0.20) | |
| LD ETN SC + MTX | ‐0.36(‐0.75,0.02) | |
| LD TOFA PO + MTX | ‐0.36(‐0.77,0.05) | |
| HD TOCI IV | ‐0.32(‐0.60,‐0.04) | |
| HD TOFA PO | ‐0.56(‐1.09,‐0.05) | |
| HD ADA SC | ‐0.47(‐1.02,0.05) | |
| HD ANA | ‐0.35(‐0.97,0.27) | |
| HD GOLI SC | 0.05(‐0.34,0.44) | |
| HD TOCI IV + MTX | ‐0.30(‐0.53,‐0.08) | |
| HD CERTO SC + MTX | ‐0.33(‐0.56,‐0.09) | |
| HD TOFA PO + MTX | ‐0.51(‐0.93,‐0.11) | |
| HD GOLI SC + MTX | 0.03(‐0.27,0.34) | |
| HD ADA SC + MTX | ‐0.31(‐0.70,0.08) | |
| MTX + DMARD | DMARD | ‐0.34(‐0.81,0.14) |
| SD ETN SC | ‐0.38(‐0.68,‐0.06) | |
| SD ADA SC | ‐0.33(‐0.80,0.14) | |
| SD TOFA PO | ‐0.44(‐0.94,0.05) | |
| SD CERTO | ‐0.37(‐0.89,0.17) | |
| SD ANA | ‐0.24(‐0.83,0.35) | |
| SD RITUX IV | ‐0.36(‐0.91,0.18) | |
| SD ETN SC + MTX | ‐0.62(‐0.97,‐0.27) | |
| SD CERTO SC + MTX | ‐0.28(‐0.68,0.12) | |
| SD RITUX IV + MTX | ‐0.17(‐0.61,0.27) | |
| SD ADA SC + MTX | ‐0.31(‐0.74,0.13) | |
| SD GOLI SC + MTX | 0.01(‐0.46,0.48) | |
| SD TOFA PO + MTX | ‐0.43(‐0.97,0.11) | |
| SD TOCI IV + MTX | ‐0.20(‐0.63,0.24) | |
| SD ABA SC + MTX | ‐0.21(‐0.81,0.39) | |
| SD GOLI IV + MTX | 0.32(‐0.23,0.86) | |
| SD ETN SC + DMARD | ‐0.32(‐0.66,0.04) | |
| SD CERTO + DMARD | ‐0.37(‐0.74,0.00) | |
| LD ADA SC | ‐0.36(‐0.86,0.15) | |
| LD ANA | ‐0.24(‐0.83,0.35) | |
| LD ADA SC + MTX | ‐0.27(‐0.71,0.18) | |
| LD RITUX IV + MTX | ‐0.11(‐0.55,0.33) | |
| LD ADA IV + MTX | ‐0.29(‐0.85,0.28) | |
| LD CERTO SC + MTX | ‐0.20(‐0.73,0.34) | |
| LD ETN SC + MTX | ‐0.36(‐0.85,0.13) | |
| LD TOFA PO + MTX | ‐0.35(‐0.89,0.19) | |
| HD TOCI IV | ‐0.31(‐0.65,0.03) | |
| HD TOFA PO | ‐0.56(‐1.05,‐0.07) | |
| HD ADA SC | ‐0.47(‐0.98,0.04) | |
| HD ANA | ‐0.34(‐0.93,0.25) | |
| HD GOLI SC | 0.05(‐0.47,0.58) | |
| HD TOCI IV + MTX | ‐0.30(‐0.68,0.09) | |
| HD CERTO SC + MTX | ‐0.32(‐0.74,0.10) | |
| HD TOFA PO + MTX | ‐0.51(‐1.05,0.03) | |
| HD GOLI SC + MTX | 0.04(‐0.42,0.51) | |
| HD ADA SC + MTX | ‐0.31(‐0.82,0.22) | |
| SD ETN SC | MTX + DMARD | ‐0.03(‐0.42,0.36) |
| SD ADA SC | 0.02(‐0.56,0.59) | |
| SD TOFA PO | ‐0.10(‐0.70,0.49) | |
| SD CERTO | ‐0.03(‐0.65,0.61) | |
| SD ANA | 0.10(‐0.58,0.78) | |
| SD RITUX IV | ‐0.02(‐0.61,0.56) | |
| SD ETN SC + MTX | ‐0.28(‐0.60,0.05) | |
| SD CERTO SC + MTX | 0.06(‐0.38,0.50) | |
| SD RITUX IV + MTX | 0.17(‐0.30,0.64) | |
| SD ADA SC + MTX | 0.03(‐0.44,0.50) | |
| SD GOLI SC + MTX | 0.35(‐0.16,0.85) | |
| SD TOFA PO + MTX | ‐0.09(‐0.66,0.48) | |
| SD TOCI IV + MTX | 0.15(‐0.34,0.63) | |
| SD ABA SC + MTX | 0.13(‐0.50,0.76) | |
| SD GOLI IV + MTX | 0.66(0.08,1.24) | |
| SD ETN SC + DMARD | 0.02(‐0.56,0.61) | |
| SD CERTO + DMARD | ‐0.03(‐0.58,0.52) | |
| LD ADA SC | ‐0.01(‐0.62,0.59) | |
| LD ANA | 0.10(‐0.58,0.77) | |
| LD ADA SC + MTX | 0.07(‐0.40,0.55) | |
| LD RITUX IV + MTX | 0.23(‐0.25,0.71) | |
| LD ADA IV + MTX | 0.05(‐0.54,0.65) | |
| LD CERTO SC + MTX | 0.14(‐0.42,0.71) | |
| LD ETN SC + MTX | ‐0.02(‐0.52,0.48) | |
| LD TOFA PO + MTX | ‐0.01(‐0.58,0.57) | |
| HD TOCI IV | 0.03(‐0.44,0.49) | |
| HD TOFA PO | ‐0.21(‐0.82,0.38) | |
| HD ADA SC | ‐0.13(‐0.74,0.48) | |
| HD ANA | 0.00(‐0.68,0.68) | |
| HD GOLI SC | 0.40(‐0.17,0.95) | |
| HD TOCI IV + MTX | 0.04(‐0.40,0.50) | |
| HD CERTO SC + MTX | 0.02(‐0.45,0.48) | |
| HD TOFA PO + MTX | ‐0.17(‐0.74,0.40) | |
| HD GOLI SC + MTX | 0.38(‐0.12,0.88) | |
| HD ADA SC + MTX | 0.04(‐0.52,0.60) | |
| SD ADA SC | SD ETN SC | 0.05(‐0.39,0.48) |
| SD TOFA PO | ‐0.07(‐0.53,0.39) | |
| SD CERTO | 0.01(‐0.49,0.51) | |
| SD ANA | 0.14(‐0.43,0.70) | |
| SD RITUX IV | 0.01(‐0.49,0.52) | |
| SD ETN SC + MTX | ‐0.24(‐0.45,‐0.03) | |
| SD CERTO SC + MTX | 0.09(‐0.23,0.43) | |
| SD RITUX IV + MTX | 0.20(‐0.17,0.58) | |
| SD ADA SC + MTX | 0.06(‐0.30,0.44) | |
| SD GOLI SC + MTX | 0.38(‐0.03,0.79) | |
| SD TOFA PO + MTX | ‐0.06(‐0.54,0.43) | |
| SD TOCI IV + MTX | 0.18(‐0.20,0.56) | |
| SD ABA SC + MTX | 0.16(‐0.39,0.72) | |
| SD GOLI IV + MTX | 0.69(0.20,1.19) | |
| SD ETN SC + DMARD | 0.06(‐0.41,0.53) | |
| SD CERTO + DMARD | 0.01(‐0.40,0.42) | |
| LD ADA SC | 0.02(‐0.45,0.49) | |
| LD ANA | 0.13(‐0.43,0.69) | |
| LD ADA SC + MTX | 0.11(‐0.26,0.49) | |
| LD RITUX IV + MTX | 0.26(‐0.11,0.64) | |
| LD ADA IV + MTX | 0.09(‐0.43,0.61) | |
| LD CERTO SC + MTX | 0.18(‐0.30,0.66) | |
| LD ETN SC + MTX | 0.02(‐0.40,0.44) | |
| LD TOFA PO + MTX | 0.02(‐0.47,0.52) | |
| HD TOCI IV | 0.06(‐0.28,0.41) | |
| HD TOFA PO | ‐0.18(‐0.64,0.27) | |
| HD ADA SC | ‐0.10(‐0.57,0.38) | |
| HD ANA | 0.03(‐0.53,0.60) | |
| HD GOLI SC | 0.43(‐0.04,0.91) | |
| HD TOCI IV + MTX | 0.08(‐0.26,0.42) | |
| HD CERTO SC + MTX | 0.05(‐0.30,0.41) | |
| HD TOFA PO + MTX | ‐0.13(‐0.62,0.36) | |
| HD GOLI SC + MTX | 0.41(0.01,0.82) | |
| HD ADA SC + MTX | 0.07(‐0.40,0.55) | |
| SD TOFA PO | SD ADA SC | ‐0.12(‐0.43,0.19) |
| SD CERTO | ‐0.04(‐0.45,0.37) | |
| SD ANA | 0.09(‐0.40,0.57) | |
| SD RITUX IV | ‐0.04(‐0.69,0.62) | |
| SD ETN SC + MTX | ‐0.29(‐0.77,0.18) | |
| SD CERTO SC + MTX | 0.04(‐0.49,0.58) | |
| SD RITUX IV + MTX | 0.15(‐0.41,0.72) | |
| SD ADA SC + MTX | 0.01(‐0.54,0.57) | |
| SD GOLI SC + MTX | 0.33(‐0.25,0.92) | |
| SD TOFA PO + MTX | ‐0.11(‐0.75,0.54) | |
| SD TOCI IV + MTX | 0.13(‐0.43,0.70) | |
| SD ABA SC + MTX | 0.11(‐0.58,0.82) | |
| SD GOLI IV + MTX | 0.64(‐0.01,1.30) | |
| SD ETN SC + DMARD | 0.01(‐0.57,0.60) | |
| SD CERTO + DMARD | ‐0.04(‐0.48,0.39) | |
| LD ADA SC | ‐0.03(‐0.32,0.26) | |
| LD ANA | 0.08(‐0.40,0.56) | |
| LD ADA SC + MTX | 0.06(‐0.50,0.62) | |
| LD RITUX IV + MTX | 0.21(‐0.35,0.78) | |
| LD ADA IV + MTX | 0.04(‐0.63,0.70) | |
| LD CERTO SC + MTX | 0.13(‐0.51,0.77) | |
| LD ETN SC + MTX | ‐0.03(‐0.63,0.56) | |
| LD TOFA PO + MTX | ‐0.03(‐0.67,0.63) | |
| HD TOCI IV | 0.01(‐0.51,0.54) | |
| HD TOFA PO | ‐0.23(‐0.54,0.08) | |
| HD ADA SC | ‐0.15(‐0.44,0.15) | |
| HD ANA | ‐0.02(‐0.51,0.47) | |
| HD GOLI SC | 0.38(‐0.25,1.02) | |
| HD TOCI IV + MTX | 0.03(‐0.50,0.56) | |
| HD CERTO SC + MTX | 0.00(‐0.55,0.56) | |
| HD TOFA PO + MTX | ‐0.18(‐0.83,0.47) | |
| HD GOLI SC + MTX | 0.36(‐0.22,0.95) | |
| HD ADA SC + MTX | 0.02(‐0.61,0.65) | |
| SD CERTO | SD TOFA PO | 0.07(‐0.36,0.52) |
| SD ANA | 0.20(‐0.31,0.72) | |
| SD RITUX IV | 0.08(‐0.59,0.75) | |
| SD ETN SC + MTX | ‐0.18(‐0.67,0.32) | |
| SD CERTO SC + MTX | 0.16(‐0.39,0.72) | |
| SD RITUX IV + MTX | 0.27(‐0.31,0.86) | |
| SD ADA SC + MTX | 0.13(‐0.44,0.71) | |
| SD GOLI SC + MTX | 0.44(‐0.16,1.06) | |
| SD TOFA PO + MTX | 0.01(‐0.65,0.68) | |
| SD TOCI IV + MTX | 0.25(‐0.33,0.84) | |
| SD ABA SC + MTX | 0.23(‐0.48,0.95) | |
| SD GOLI IV + MTX | 0.76(0.09,1.44) | |
| SD ETN SC + DMARD | 0.12(‐0.47,0.74) | |
| SD CERTO + DMARD | 0.07(‐0.39,0.53) | |
| LD ADA SC | 0.09(‐0.29,0.47) | |
| LD ANA | 0.20(‐0.30,0.71) | |
| LD ADA SC + MTX | 0.17(‐0.40,0.76) | |
| LD RITUX IV + MTX | 0.33(‐0.25,0.92) | |
| LD ADA IV + MTX | 0.15(‐0.53,0.84) | |
| LD CERTO SC + MTX | 0.24(‐0.41,0.90) | |
| LD ETN SC + MTX | 0.08(‐0.53,0.70) | |
| LD TOFA PO + MTX | 0.09(‐0.57,0.77) | |
| HD TOCI IV | 0.13(‐0.42,0.68) | |
| HD TOFA PO | ‐0.11(‐0.37,0.15) | |
| HD ADA SC | ‐0.03(‐0.41,0.36) | |
| HD ANA | 0.10(‐0.41,0.61) | |
| HD GOLI SC | 0.50(‐0.15,1.15) | |
| HD TOCI IV + MTX | 0.15(‐0.40,0.70) | |
| HD CERTO SC + MTX | 0.12(‐0.45,0.69) | |
| HD TOFA PO + MTX | ‐0.07(‐0.73,0.61) | |
| HD GOLI SC + MTX | 0.48(‐0.12,1.09) | |
| HD ADA SC + MTX | 0.14(‐0.50,0.79) | |
| SD ANA | SD CERTO | 0.13(‐0.43,0.67) |
| SD RITUX IV | 0.00(‐0.70,0.70) | |
| SD ETN SC + MTX | ‐0.25(‐0.80,0.28) | |
| SD CERTO SC + MTX | 0.09(‐0.51,0.67) | |
| SD RITUX IV + MTX | 0.19(‐0.42,0.81) | |
| SD ADA SC + MTX | 0.06(‐0.55,0.67) | |
| SD GOLI SC + MTX | 0.37(‐0.27,1.01) | |
| SD TOFA PO + MTX | ‐0.06(‐0.75,0.63) | |
| SD TOCI IV + MTX | 0.17(‐0.45,0.79) | |
| SD ABA SC + MTX | 0.15(‐0.58,0.90) | |
| SD GOLI IV + MTX | 0.68(‐0.02,1.38) | |
| SD ETN SC + DMARD | 0.05(‐0.59,0.68) | |
| SD CERTO + DMARD | 0.00(‐0.51,0.50) | |
| LD ADA SC | 0.01(‐0.44,0.45) | |
| LD ANA | 0.13(‐0.42,0.66) | |
| LD ADA SC + MTX | 0.10(‐0.51,0.72) | |
| LD RITUX IV + MTX | 0.25(‐0.36,0.87) | |
| LD ADA IV + MTX | 0.08(‐0.63,0.79) | |
| LD CERTO SC + MTX | 0.17(‐0.51,0.86) | |
| LD ETN SC + MTX | 0.01(‐0.64,0.65) | |
| LD TOFA PO + MTX | 0.02(‐0.68,0.72) | |
| HD TOCI IV | 0.06(‐0.53,0.64) | |
| HD TOFA PO | ‐0.19(‐0.63,0.24) | |
| HD ADA SC | ‐0.10(‐0.56,0.35) | |
| HD ANA | 0.03(‐0.53,0.57) | |
| HD GOLI SC | 0.42(‐0.26,1.11) | |
| HD TOCI IV + MTX | 0.07(‐0.52,0.66) | |
| HD CERTO SC + MTX | 0.04(‐0.57,0.65) | |
| HD TOFA PO + MTX | ‐0.14(‐0.84,0.56) | |
| HD GOLI SC + MTX | 0.41(‐0.23,1.04) | |
| HD ADA SC + MTX | 0.07(‐0.62,0.74) | |
| SD RITUX IV | SD ANA | ‐0.12(‐0.86,0.63) |
| SD ETN SC + MTX | ‐0.38(‐0.97,0.22) | |
| SD CERTO SC + MTX | ‐0.04(‐0.68,0.60) | |
| SD RITUX IV + MTX | 0.07(‐0.59,0.74) | |
| SD ADA SC + MTX | ‐0.07(‐0.73,0.60) | |
| SD GOLI SC + MTX | 0.25(‐0.43,0.94) | |
| SD TOFA PO + MTX | ‐0.19(‐0.92,0.55) | |
| SD TOCI IV + MTX | 0.05(‐0.62,0.72) | |
| SD ABA SC + MTX | 0.03(‐0.76,0.82) | |
| SD GOLI IV + MTX | 0.56(‐0.19,1.31) | |
| SD ETN SC + DMARD | ‐0.07(‐0.75,0.61) | |
| SD CERTO + DMARD | ‐0.13(‐0.70,0.43) | |
| LD ADA SC | ‐0.12(‐0.63,0.40) | |
| LD ANA | 0.00(‐0.43,0.43) | |
| LD ADA SC + MTX | ‐0.03(‐0.69,0.65) | |
| LD RITUX IV + MTX | 0.13(‐0.53,0.81) | |
| LD ADA IV + MTX | ‐0.05(‐0.80,0.71) | |
| LD CERTO SC + MTX | 0.04(‐0.68,0.78) | |
| LD ETN SC + MTX | ‐0.12(‐0.81,0.58) | |
| LD TOFA PO + MTX | ‐0.11(‐0.85,0.64) | |
| HD TOCI IV | ‐0.07(‐0.70,0.56) | |
| HD TOFA PO | ‐0.31(‐0.83,0.19) | |
| HD ADA SC | ‐0.23(‐0.75,0.29) | |
| HD ANA | ‐0.10(‐0.54,0.33) | |
| HD GOLI SC | 0.29(‐0.43,1.02) | |
| HD TOCI IV + MTX | ‐0.06(‐0.69,0.59) | |
| HD CERTO SC + MTX | ‐0.08(‐0.74,0.58) | |
| HD TOFA PO + MTX | ‐0.27(‐0.99,0.48) | |
| HD GOLI SC + MTX | 0.28(‐0.40,0.97) | |
| HD ADA SC + MTX | ‐0.07(‐0.78,0.66) | |
| SD ETN SC + MTX | SD RITUX IV | ‐0.25(‐0.74,0.23) |
| SD CERTO SC + MTX | 0.08(‐0.38,0.54) | |
| SD RITUX IV + MTX | 0.19(‐0.23,0.61) | |
| SD ADA SC + MTX | 0.06(‐0.43,0.55) | |
| SD GOLI SC + MTX | 0.37(‐0.15,0.89) | |
| SD TOFA PO + MTX | ‐0.07(‐0.65,0.52) | |
| SD TOCI IV + MTX | 0.17(‐0.33,0.67) | |
| SD ABA SC + MTX | 0.15(‐0.49,0.80) | |
| SD GOLI IV + MTX | 0.68(0.08,1.27) | |
| SD ETN SC + DMARD | 0.05(‐0.60,0.71) | |
| SD CERTO + DMARD | ‐0.01(‐0.63,0.61) | |
| LD ADA SC | 0.01(‐0.68,0.68) | |
| LD ANA | 0.13(‐0.64,0.86) | |
| LD ADA SC + MTX | 0.10(‐0.39,0.60) | |
| LD RITUX IV + MTX | 0.25(‐0.17,0.68) | |
| LD ADA IV + MTX | 0.08(‐0.53,0.69) | |
| LD CERTO SC + MTX | 0.17(‐0.41,0.74) | |
| LD ETN SC + MTX | 0.01(‐0.57,0.57) | |
| LD TOFA PO + MTX | 0.01(‐0.57,0.60) | |
| HD TOCI IV | 0.05(‐0.45,0.56) | |
| HD TOFA PO | ‐0.19(‐0.86,0.47) | |
| HD ADA SC | ‐0.10(‐0.80,0.57) | |
| HD ANA | 0.02(‐0.73,0.77) | |
| HD GOLI SC | 0.42(‐0.15,0.99) | |
| HD TOCI IV + MTX | 0.07(‐0.41,0.54) | |
| HD CERTO SC + MTX | 0.04(‐0.43,0.52) | |
| HD TOFA PO + MTX | ‐0.14(‐0.73,0.44) | |
| HD GOLI SC + MTX | 0.40(‐0.11,0.92) | |
| HD ADA SC + MTX | 0.06(‐0.51,0.63) | |
| SD CERTO SC + MTX | SD ETN SC + MTX | 0.34(0.03,0.64) |
| SD RITUX IV + MTX | 0.44(0.10,0.80) | |
| SD ADA SC + MTX | 0.31(‐0.03,0.65) | |
| SD GOLI SC + MTX | 0.62(0.24,1.01) | |
| SD TOFA PO + MTX | 0.19(‐0.28,0.66) | |
| SD TOCI IV + MTX | 0.42(0.06,0.79) | |
| SD ABA SC + MTX | 0.41(‐0.14,0.95) | |
| SD GOLI IV + MTX | 0.93(0.45,1.42) | |
| SD ETN SC + DMARD | 0.30(‐0.19,0.80) | |
| SD CERTO + DMARD | 0.25(‐0.20,0.70) | |
| LD ADA SC | 0.26(‐0.25,0.77) | |
| LD ANA | 0.38(‐0.22,0.97) | |
| LD ADA SC + MTX | 0.35(0.00,0.71) | |
| LD RITUX IV + MTX | 0.50(0.16,0.86) | |
| LD ADA IV + MTX | 0.33(‐0.17,0.83) | |
| LD CERTO SC + MTX | 0.42(‐0.03,0.89) | |
| LD ETN SC + MTX | 0.26(‐0.12,0.64) | |
| LD TOFA PO + MTX | 0.27(‐0.21,0.74) | |
| HD TOCI IV | 0.30(‐0.03,0.64) | |
| HD TOFA PO | 0.06(‐0.43,0.55) | |
| HD ADA SC | 0.15(‐0.37,0.66) | |
| HD ANA | 0.28(‐0.32,0.88) | |
| HD GOLI SC | 0.67(0.22,1.13) | |
| HD TOCI IV + MTX | 0.32(0.01,0.64) | |
| HD CERTO SC + MTX | 0.30(‐0.03,0.63) | |
| HD TOFA PO + MTX | 0.11(‐0.36,0.59) | |
| HD GOLI SC + MTX | 0.66(0.28,1.04) | |
| HD ADA SC + MTX | 0.31(‐0.13,0.77) | |
| SD RITUX IV + MTX | SD CERTO SC + MTX | 0.11(‐0.21,0.43) |
| SD ADA SC + MTX | ‐0.03(‐0.34,0.29) | |
| SD GOLI SC + MTX | 0.29(‐0.07,0.65) | |
| SD TOFA PO + MTX | ‐0.15(‐0.60,0.30) | |
| SD TOCI IV + MTX | 0.09(‐0.26,0.43) | |
| SD ABA SC + MTX | 0.07(‐0.45,0.59) | |
| SD GOLI IV + MTX | 0.60(0.14,1.06) | |
| SD ETN SC + DMARD | ‐0.03(‐0.56,0.50) | |
| SD CERTO + DMARD | ‐0.09(‐0.59,0.41) | |
| LD ADA SC | ‐0.07(‐0.64,0.48) | |
| LD ANA | 0.04(‐0.61,0.68) | |
| LD ADA SC + MTX | 0.02(‐0.31,0.35) | |
| LD RITUX IV + MTX | 0.17(‐0.15,0.49) | |
| LD ADA IV + MTX | ‐0.01(‐0.49,0.48) | |
| LD CERTO SC + MTX | 0.09(‐0.31,0.48) | |
| LD ETN SC + MTX | ‐0.08(‐0.51,0.36) | |
| LD TOFA PO + MTX | ‐0.07(‐0.52,0.38) | |
| HD TOCI IV | ‐0.03(‐0.37,0.31) | |
| HD TOFA PO | ‐0.27(‐0.83,0.27) | |
| HD ADA SC | ‐0.19(‐0.76,0.38) | |
| HD ANA | ‐0.06(‐0.71,0.59) | |
| HD GOLI SC | 0.34(‐0.10,0.77) | |
| HD TOCI IV + MTX | ‐0.01(‐0.31,0.28) | |
| HD CERTO SC + MTX | ‐0.04(‐0.27,0.19) | |
| HD TOFA PO + MTX | ‐0.23(‐0.68,0.23) | |
| HD GOLI SC + MTX | 0.32(‐0.04,0.68) | |
| HD ADA SC + MTX | ‐0.02(‐0.45,0.42) | |
| SD ADA SC + MTX | SD RITUX IV + MTX | ‐0.14(‐0.49,0.22) |
| SD GOLI SC + MTX | 0.18(‐0.22,0.58) | |
| SD TOFA PO + MTX | ‐0.26(‐0.74,0.22) | |
| SD TOCI IV + MTX | ‐0.02(‐0.40,0.36) | |
| SD ABA SC + MTX | ‐0.04(‐0.59,0.52) | |
| SD GOLI IV + MTX | 0.49(‐0.01,0.98) | |
| SD ETN SC + DMARD | ‐0.14(‐0.70,0.42) | |
| SD CERTO + DMARD | ‐0.20(‐0.72,0.33) | |
| LD ADA SC | ‐0.18(‐0.78,0.40) | |
| LD ANA | ‐0.07(‐0.74,0.59) | |
| LD ADA SC + MTX | ‐0.09(‐0.46,0.28) | |
| LD RITUX IV + MTX | 0.06(‐0.20,0.32) | |
| LD ADA IV + MTX | ‐0.12(‐0.62,0.40) | |
| LD CERTO SC + MTX | ‐0.02(‐0.50,0.45) | |
| LD ETN SC + MTX | ‐0.19(‐0.65,0.28) | |
| LD TOFA PO + MTX | ‐0.18(‐0.67,0.31) | |
| HD TOCI IV | ‐0.14(‐0.52,0.24) | |
| HD TOFA PO | ‐0.38(‐0.97,0.19) | |
| HD ADA SC | ‐0.30(‐0.89,0.29) | |
| HD ANA | ‐0.17(‐0.85,0.49) | |
| HD GOLI SC | 0.23(‐0.24,0.70) | |
| HD TOCI IV + MTX | ‐0.12(‐0.46,0.22) | |
| HD CERTO SC + MTX | ‐0.15(‐0.49,0.20) | |
| HD TOFA PO + MTX | ‐0.34(‐0.82,0.15) | |
| HD GOLI SC + MTX | 0.21(‐0.19,0.61) | |
| HD ADA SC + MTX | ‐0.13(‐0.59,0.34) | |
| SD GOLI SC + MTX | SD ADA SC + MTX | 0.32(‐0.09,0.71) |
| SD TOFA PO + MTX | ‐0.12(‐0.60,0.36) | |
| SD TOCI IV + MTX | 0.11(‐0.26,0.49) | |
| SD ABA SC + MTX | 0.10(‐0.45,0.65) | |
| SD GOLI IV + MTX | 0.62(0.13,1.11) | |
| SD ETN SC + DMARD | ‐0.01(‐0.56,0.55) | |
| SD CERTO + DMARD | ‐0.06(‐0.58,0.45) | |
| LD ADA SC | ‐0.05(‐0.64,0.54) | |
| LD ANA | 0.07(‐0.60,0.72) | |
| LD ADA SC + MTX | 0.04(‐0.24,0.33) | |
| LD RITUX IV + MTX | 0.20(‐0.17,0.55) | |
| LD ADA IV + MTX | 0.02(‐0.46,0.51) | |
| LD CERTO SC + MTX | 0.11(‐0.36,0.58) | |
| LD ETN SC + MTX | ‐0.05(‐0.51,0.41) | |
| LD TOFA PO + MTX | ‐0.04(‐0.53,0.44) | |
| HD TOCI IV | 0.00(‐0.39,0.37) | |
| HD TOFA PO | ‐0.25(‐0.82,0.33) | |
| HD ADA SC | ‐0.16(‐0.75,0.42) | |
| HD ANA | ‐0.03(‐0.70,0.63) | |
| HD GOLI SC | 0.37(‐0.10,0.83) | |
| HD TOCI IV + MTX | 0.01(‐0.33,0.35) | |
| HD CERTO SC + MTX | ‐0.01(‐0.36,0.33) | |
| HD TOFA PO + MTX | ‐0.20(‐0.68,0.28) | |
| HD GOLI SC + MTX | 0.35(‐0.05,0.74) | |
| HD ADA SC + MTX | 0.00(‐0.39,0.40) | |
| SD TOFA PO + MTX | SD GOLI SC + MTX | ‐0.44(‐0.95,0.07) |
| SD TOCI IV + MTX | ‐0.20(‐0.61,0.22) | |
| SD ABA SC + MTX | ‐0.22(‐0.79,0.36) | |
| SD GOLI IV + MTX | 0.31(‐0.21,0.83) | |
| SD ETN SC + DMARD | ‐0.32(‐0.90,0.27) | |
| SD CERTO + DMARD | ‐0.38(‐0.93,0.18) | |
| LD ADA SC | ‐0.36(‐0.98,0.25) | |
| LD ANA | ‐0.25(‐0.93,0.44) | |
| LD ADA SC + MTX | ‐0.27(‐0.67,0.14) | |
| LD RITUX IV + MTX | ‐0.12(‐0.52,0.28) | |
| LD ADA IV + MTX | ‐0.29(‐0.83,0.25) | |
| LD CERTO SC + MTX | ‐0.20(‐0.70,0.30) | |
| LD ETN SC + MTX | ‐0.36(‐0.86,0.13) | |
| LD TOFA PO + MTX | ‐0.36(‐0.87,0.16) | |
| HD TOCI IV | ‐0.32(‐0.74,0.09) | |
| HD TOFA PO | ‐0.56(‐1.17,0.04) | |
| HD ADA SC | ‐0.48(‐1.10,0.13) | |
| HD ANA | ‐0.35(‐1.04,0.34) | |
| HD GOLI SC | 0.05(‐0.35,0.45) | |
| HD TOCI IV + MTX | ‐0.30(‐0.68,0.08) | |
| HD CERTO SC + MTX | ‐0.33(‐0.71,0.05) | |
| HD TOFA PO + MTX | ‐0.51(‐1.03,‐0.01) | |
| HD GOLI SC + MTX | 0.03(‐0.28,0.34) | |
| HD ADA SC + MTX | ‐0.31(‐0.80,0.19) | |
| SD TOCI IV + MTX | SD TOFA PO + MTX | 0.24(‐0.26,0.73) |
| SD ABA SC + MTX | 0.22(‐0.42,0.85) | |
| SD GOLI IV + MTX | 0.75(0.16,1.34) | |
| SD ETN SC + DMARD | 0.11(‐0.52,0.76) | |
| SD CERTO + DMARD | 0.06(‐0.55,0.67) | |
| LD ADA SC | 0.08(‐0.60,0.74) | |
| LD ANA | 0.19(‐0.55,0.92) | |
| LD ADA SC + MTX | 0.17(‐0.32,0.66) | |
| LD RITUX IV + MTX | 0.32(‐0.16,0.80) | |
| LD ADA IV + MTX | 0.14(‐0.46,0.75) | |
| LD CERTO SC + MTX | 0.23(‐0.33,0.80) | |
| LD ETN SC + MTX | 0.07(‐0.49,0.63) | |
| LD TOFA PO + MTX | 0.08(‐0.33,0.49) | |
| HD TOCI IV | 0.12(‐0.38,0.61) | |
| HD TOFA PO | ‐0.12(‐0.79,0.53) | |
| HD ADA SC | ‐0.04(‐0.72,0.63) | |
| HD ANA | 0.09(‐0.65,0.82) | |
| HD GOLI SC | 0.49(‐0.08,1.05) | |
| HD TOCI IV + MTX | 0.13(‐0.33,0.60) | |
| HD CERTO SC + MTX | 0.11(‐0.36,0.58) | |
| HD TOFA PO + MTX | ‐0.08(‐0.48,0.33) | |
| HD GOLI SC + MTX | 0.47(‐0.04,0.98) | |
| HD ADA SC + MTX | 0.12(‐0.43,0.69) | |
| SD ABA SC + MTX | SD TOCI IV + MTX | ‐0.02(‐0.58,0.55) |
| SD GOLI IV + MTX | 0.51(0.00,1.02) | |
| SD ETN SC + DMARD | ‐0.12(‐0.67,0.44) | |
| SD CERTO + DMARD | ‐0.17(‐0.71,0.35) | |
| LD ADA SC | ‐0.16(‐0.75,0.43) | |
| LD ANA | ‐0.05(‐0.72,0.62) | |
| LD ADA SC + MTX | ‐0.07(‐0.45,0.32) | |
| LD RITUX IV + MTX | 0.08(‐0.30,0.46) | |
| LD ADA IV + MTX | ‐0.09(‐0.62,0.44) | |
| LD CERTO SC + MTX | 0.00(‐0.49,0.49) | |
| LD ETN SC + MTX | ‐0.16(‐0.64,0.31) | |
| LD TOFA PO + MTX | ‐0.16(‐0.66,0.34) | |
| HD TOCI IV | ‐0.12(‐0.49,0.26) | |
| HD TOFA PO | ‐0.36(‐0.94,0.21) | |
| HD ADA SC | ‐0.28(‐0.87,0.31) | |
| HD ANA | ‐0.15(‐0.82,0.52) | |
| HD GOLI SC | 0.25(‐0.23,0.73) | |
| HD TOCI IV + MTX | ‐0.10(‐0.38,0.18) | |
| HD CERTO SC + MTX | ‐0.13(‐0.49,0.24) | |
| HD TOFA PO + MTX | ‐0.31(‐0.81,0.18) | |
| HD GOLI SC + MTX | 0.23(‐0.18,0.64) | |
| HD ADA SC + MTX | ‐0.11(‐0.59,0.37) | |
| SD GOLI IV + MTX | SD ABA SC + MTX | 0.53(‐0.12,1.18) |
| SD ETN SC + DMARD | ‐0.10(‐0.79,0.59) | |
| SD CERTO + DMARD | ‐0.16(‐0.83,0.51) | |
| LD ADA SC | ‐0.14(‐0.87,0.57) | |
| LD ANA | ‐0.03(‐0.82,0.75) | |
| LD ADA SC + MTX | ‐0.05(‐0.61,0.51) | |
| LD RITUX IV + MTX | 0.10(‐0.45,0.65) | |
| LD ADA IV + MTX | ‐0.08(‐0.73,0.59) | |
| LD CERTO SC + MTX | 0.02(‐0.61,0.65) | |
| LD ETN SC + MTX | ‐0.14(‐0.76,0.48) | |
| LD TOFA PO + MTX | ‐0.14(‐0.78,0.50) | |
| HD TOCI IV | ‐0.10(‐0.67,0.46) | |
| HD TOFA PO | ‐0.34(‐1.06,0.37) | |
| HD ADA SC | ‐0.25(‐0.99,0.46) | |
| HD ANA | ‐0.13(‐0.92,0.65) | |
| HD GOLI SC | 0.27(‐0.35,0.89) | |
| HD TOCI IV + MTX | ‐0.08(‐0.62,0.45) | |
| HD CERTO SC + MTX | ‐0.11(‐0.65,0.43) | |
| HD TOFA PO + MTX | ‐0.30(‐0.93,0.34) | |
| HD GOLI SC + MTX | 0.25(‐0.32,0.82) | |
| HD ADA SC + MTX | ‐0.09(‐0.72,0.54) | |
| SD ETN SC + DMARD | SD GOLI IV + MTX | ‐0.63(‐1.28,0.02) |
| SD CERTO + DMARD | ‐0.69(‐1.31,‐0.07) | |
| LD ADA SC | ‐0.67(‐1.35,0.00) | |
| LD ANA | ‐0.56(‐1.30,0.19) | |
| LD ADA SC + MTX | ‐0.58(‐1.07,‐0.08) | |
| LD RITUX IV + MTX | ‐0.43(‐0.92,0.06) | |
| LD ADA IV + MTX | ‐0.61(‐1.21,0.01) | |
| LD CERTO SC + MTX | ‐0.51(‐1.09,0.06) | |
| LD ETN SC + MTX | ‐0.68(‐1.24,‐0.11) | |
| LD TOFA PO + MTX | ‐0.67(‐1.26,‐0.07) | |
| HD TOCI IV | ‐0.63(‐1.14,‐0.12) | |
| HD TOFA PO | ‐0.87(‐1.55,‐0.20) | |
| HD ADA SC | ‐0.78(‐1.47,‐0.11) | |
| HD ANA | ‐0.66(‐1.41,0.09) | |
| HD GOLI SC | ‐0.26(‐0.83,0.32) | |
| HD TOCI IV + MTX | ‐0.61(‐1.09,‐0.13) | |
| HD CERTO SC + MTX | ‐0.64(‐1.12,‐0.16) | |
| HD TOFA PO + MTX | ‐0.82(‐1.42,‐0.24) | |
| HD GOLI SC + MTX | ‐0.28(‐0.79,0.25) | |
| HD ADA SC + MTX | ‐0.62(‐1.19,‐0.04) | |
| SD CERTO + DMARD | SD ETN SC + DMARD | ‐0.05(‐0.56,0.45) |
| LD ADA SC | ‐0.04(‐0.66,0.57) | |
| LD ANA | 0.08(‐0.61,0.75) | |
| LD ADA SC + MTX | 0.05(‐0.52,0.61) | |
| LD RITUX IV + MTX | 0.20(‐0.36,0.76) | |
| LD ADA IV + MTX | 0.03(‐0.64,0.69) | |
| LD CERTO SC + MTX | 0.12(‐0.52,0.75) | |
| LD ETN SC + MTX | ‐0.04(‐0.64,0.55) | |
| LD TOFA PO + MTX | ‐0.04(‐0.69,0.60) | |
| HD TOCI IV | 0.00(‐0.49,0.48) | |
| HD TOFA PO | ‐0.24(‐0.85,0.35) | |
| HD ADA SC | ‐0.16(‐0.78,0.46) | |
| HD ANA | ‐0.03(‐0.72,0.65) | |
| HD GOLI SC | 0.37(‐0.26,1.00) | |
| HD TOCI IV + MTX | 0.02(‐0.50,0.54) | |
| HD CERTO SC + MTX | ‐0.01(‐0.56,0.54) | |
| HD TOFA PO + MTX | ‐0.19(‐0.84,0.44) | |
| HD GOLI SC + MTX | 0.35(‐0.23,0.93) | |
| HD ADA SC + MTX | 0.01(‐0.62,0.64) | |
| LD ADA SC | SD CERTO + DMARD | 0.01(‐0.46,0.49) |
| LD ANA | 0.13(‐0.43,0.69) | |
| LD ADA SC + MTX | 0.10(‐0.42,0.63) | |
| LD RITUX IV + MTX | 0.25(‐0.26,0.78) | |
| LD ADA IV + MTX | 0.08(‐0.56,0.72) | |
| LD CERTO SC + MTX | 0.17(‐0.43,0.78) | |
| LD ETN SC + MTX | 0.01(‐0.56,0.58) | |
| LD TOFA PO + MTX | 0.02(‐0.60,0.64) | |
| HD TOCI IV | 0.06(‐0.41,0.52) | |
| HD TOFA PO | ‐0.19(‐0.64,0.27) | |
| HD ADA SC | ‐0.10(‐0.57,0.37) | |
| HD ANA | 0.03(‐0.54,0.60) | |
| HD GOLI SC | 0.42(‐0.17,1.03) | |
| HD TOCI IV + MTX | 0.07(‐0.41,0.57) | |
| HD CERTO SC + MTX | 0.05(‐0.46,0.57) | |
| HD TOFA PO + MTX | ‐0.14(‐0.75,0.48) | |
| HD GOLI SC + MTX | 0.41(‐0.14,0.96) | |
| HD ADA SC + MTX | 0.07(‐0.53,0.67) | |
| LD ANA | LD ADA SC | 0.11(‐0.40,0.63) |
| LD ADA SC + MTX | 0.09(‐0.50,0.69) | |
| LD RITUX IV + MTX | 0.24(‐0.35,0.84) | |
| LD ADA IV + MTX | 0.07(‐0.62,0.76) | |
| LD CERTO SC + MTX | 0.16(‐0.50,0.82) | |
| LD ETN SC + MTX | 0.00(‐0.62,0.62) | |
| LD TOFA PO + MTX | 0.00(‐0.67,0.69) | |
| HD TOCI IV | 0.04(‐0.51,0.60) | |
| HD TOFA PO | ‐0.20(‐0.58,0.18) | |
| HD ADA SC | ‐0.12(‐0.43,0.20) | |
| HD ANA | 0.01(‐0.51,0.53) | |
| HD GOLI SC | 0.41(‐0.25,1.08) | |
| HD TOCI IV + MTX | 0.06(‐0.50,0.62) | |
| HD CERTO SC + MTX | 0.03(‐0.54,0.62) | |
| HD TOFA PO + MTX | ‐0.15(‐0.82,0.53) | |
| HD GOLI SC + MTX | 0.39(‐0.21,1.01) | |
| HD ADA SC + MTX | 0.05(‐0.60,0.71) | |
| LD ADA SC + MTX | LD ANA | ‐0.02(‐0.68,0.65) |
| LD RITUX IV + MTX | 0.12(‐0.53,0.80) | |
| LD ADA IV + MTX | ‐0.05(‐0.80,0.72) | |
| LD CERTO SC + MTX | 0.04(‐0.68,0.78) | |
| LD ETN SC + MTX | ‐0.12(‐0.81,0.57) | |
| LD TOFA PO + MTX | ‐0.11(‐0.85,0.64) | |
| HD TOCI IV | ‐0.07(‐0.70,0.56) | |
| HD TOFA PO | ‐0.31(‐0.82,0.19) | |
| HD ADA SC | ‐0.23(‐0.74,0.29) | |
| HD ANA | ‐0.10(‐0.53,0.33) | |
| HD GOLI SC | 0.30(‐0.42,1.02) | |
| HD TOCI IV + MTX | ‐0.05(‐0.69,0.59) | |
| HD CERTO SC + MTX | ‐0.08(‐0.73,0.58) | |
| HD TOFA PO + MTX | ‐0.27(‐1.00,0.48) | |
| HD GOLI SC + MTX | 0.28(‐0.40,0.97) | |
| HD ADA SC + MTX | ‐0.06(‐0.78,0.67) | |
| LD RITUX IV + MTX | LD ADA SC + MTX | 0.15(‐0.22,0.52) |
| LD ADA IV + MTX | ‐0.02(‐0.49,0.44) | |
| LD CERTO SC + MTX | 0.07(‐0.41,0.54) | |
| LD ETN SC + MTX | ‐0.09(‐0.56,0.37) | |
| LD TOFA PO + MTX | ‐0.09(‐0.58,0.40) | |
| HD TOCI IV | ‐0.05(‐0.44,0.34) | |
| HD TOFA PO | ‐0.29(‐0.88,0.28) | |
| HD ADA SC | ‐0.20(‐0.81,0.38) | |
| HD ANA | ‐0.08(‐0.75,0.59) | |
| HD GOLI SC | 0.32(‐0.16,0.79) | |
| HD TOCI IV + MTX | ‐0.03(‐0.38,0.32) | |
| HD CERTO SC + MTX | ‐0.06(‐0.42,0.30) | |
| HD TOFA PO + MTX | ‐0.24(‐0.73,0.24) | |
| HD GOLI SC + MTX | 0.30(‐0.10,0.71) | |
| HD ADA SC + MTX | ‐0.04(‐0.44,0.36) | |
| LD ADA IV + MTX | LD RITUX IV + MTX | ‐0.17(‐0.68,0.34) |
| LD CERTO SC + MTX | ‐0.08(‐0.55,0.39) | |
| LD ETN SC + MTX | ‐0.25(‐0.71,0.22) | |
| LD TOFA PO + MTX | ‐0.24(‐0.72,0.25) | |
| HD TOCI IV | ‐0.20(‐0.59,0.18) | |
| HD TOFA PO | ‐0.44(‐1.03,0.14) | |
| HD ADA SC | ‐0.36(‐0.96,0.23) | |
| HD ANA | ‐0.23(‐0.91,0.44) | |
| HD GOLI SC | 0.17(‐0.30,0.64) | |
| HD TOCI IV + MTX | ‐0.18(‐0.52,0.16) | |
| HD CERTO SC + MTX | ‐0.21(‐0.56,0.14) | |
| HD TOFA PO + MTX | ‐0.39(‐0.88,0.09) | |
| HD GOLI SC + MTX | 0.15(‐0.24,0.55) | |
| HD ADA SC + MTX | ‐0.19(‐0.66,0.28) | |
| LD CERTO SC + MTX | LD ADA IV + MTX | 0.09(‐0.51,0.69) |
| LD ETN SC + MTX | ‐0.07(‐0.66,0.51) | |
| LD TOFA PO + MTX | ‐0.06(‐0.68,0.54) | |
| HD TOCI IV | ‐0.03(‐0.55,0.50) | |
| HD TOFA PO | ‐0.27(‐0.95,0.41) | |
| HD ADA SC | ‐0.18(‐0.88,0.51) | |
| HD ANA | ‐0.06(‐0.82,0.70) | |
| HD GOLI SC | 0.34(‐0.25,0.93) | |
| HD TOCI IV + MTX | ‐0.01(‐0.51,0.49) | |
| HD CERTO SC + MTX | ‐0.04(‐0.54,0.47) | |
| HD TOFA PO + MTX | ‐0.22(‐0.83,0.38) | |
| HD GOLI SC + MTX | 0.33(‐0.21,0.86) | |
| HD ADA SC + MTX | ‐0.02(‐0.59,0.55) | |
| LD ETN SC + MTX | LD CERTO SC + MTX | ‐0.16(‐0.71,0.39) |
| LD TOFA PO + MTX | ‐0.16(‐0.73,0.42) | |
| HD TOCI IV | ‐0.11(‐0.61,0.37) | |
| HD TOFA PO | ‐0.36(‐1.01,0.29) | |
| HD ADA SC | ‐0.27(‐0.94,0.39) | |
| HD ANA | ‐0.14(‐0.88,0.59) | |
| HD GOLI SC | 0.25(‐0.30,0.81) | |
| HD TOCI IV + MTX | ‐0.10(‐0.56,0.36) | |
| HD CERTO SC + MTX | ‐0.13(‐0.53,0.28) | |
| HD TOFA PO + MTX | ‐0.31(‐0.88,0.26) | |
| HD GOLI SC + MTX | 0.23(‐0.26,0.74) | |
| HD ADA SC + MTX | ‐0.11(‐0.66,0.45) | |
| LD TOFA PO + MTX | LD ETN SC + MTX | 0.00(‐0.55,0.57) |
| HD TOCI IV | 0.05(‐0.42,0.51) | |
| HD TOFA PO | ‐0.20(‐0.81,0.42) | |
| HD ADA SC | ‐0.11(‐0.73,0.51) | |
| HD ANA | 0.02(‐0.69,0.71) | |
| HD GOLI SC | 0.41(‐0.13,0.96) | |
| HD TOCI IV + MTX | 0.06(‐0.38,0.50) | |
| HD CERTO SC + MTX | 0.04(‐0.42,0.49) | |
| HD TOFA PO + MTX | ‐0.15(‐0.71,0.41) | |
| HD GOLI SC + MTX | 0.40(‐0.09,0.89) | |
| HD ADA SC + MTX | 0.05(‐0.49,0.60) | |
| HD TOCI IV | LD TOFA PO + MTX | 0.04(‐0.46,0.53) |
| HD TOFA PO | ‐0.20(‐0.88,0.46) | |
| HD ADA SC | ‐0.12(‐0.80,0.55) | |
| HD ANA | 0.01(‐0.74,0.75) | |
| HD GOLI SC | 0.41(‐0.16,0.98) | |
| HD TOCI IV + MTX | 0.06(‐0.41,0.53) | |
| HD CERTO SC + MTX | 0.03(‐0.45,0.50) | |
| HD TOFA PO + MTX | ‐0.16(‐0.57,0.26) | |
| HD GOLI SC + MTX | 0.39(‐0.12,0.91) | |
| HD ADA SC + MTX | 0.05(‐0.52,0.61) | |
| HD TOFA PO | HD TOCI IV | ‐0.24(‐0.79,0.30) |
| HD ADA SC | ‐0.16(‐0.72,0.40) | |
| HD ANA | ‐0.03(‐0.67,0.61) | |
| HD GOLI SC | 0.37(‐0.12,0.86) | |
| HD TOCI IV + MTX | 0.02(‐0.28,0.32) | |
| HD CERTO SC + MTX | ‐0.01(‐0.38,0.36) | |
| HD TOFA PO + MTX | ‐0.20(‐0.69,0.30) | |
| HD GOLI SC + MTX | 0.35(‐0.06,0.77) | |
| HD ADA SC + MTX | 0.01(‐0.47,0.49) | |
| HD ADA SC | HD TOFA PO | 0.09(‐0.30,0.47) |
| HD ANA | 0.21(‐0.30,0.73) | |
| HD GOLI SC | 0.61(‐0.03,1.26) | |
| HD TOCI IV + MTX | 0.26(‐0.28,0.81) | |
| HD CERTO SC + MTX | 0.23(‐0.33,0.81) | |
| HD TOFA PO + MTX | 0.05(‐0.62,0.72) | |
| HD GOLI SC + MTX | 0.59(0.00,1.20) | |
| HD ADA SC + MTX | 0.25(‐0.39,0.90) | |
| HD ANA | HD ADA SC | 0.13(‐0.39,0.65) |
| HD GOLI SC | 0.53(‐0.13,1.19) | |
| HD TOCI IV + MTX | 0.17(‐0.38,0.74) | |
| HD CERTO SC + MTX | 0.15(‐0.43,0.73) | |
| HD TOFA PO + MTX | ‐0.04(‐0.71,0.64) | |
| HD GOLI SC + MTX | 0.51(‐0.10,1.13) | |
| HD ADA SC + MTX | 0.17(‐0.48,0.82) | |
| HD GOLI SC | HD ANA | 0.40(‐0.32,1.13) |
| HD TOCI IV + MTX | 0.05(‐0.59,0.69) | |
| HD CERTO SC + MTX | 0.02(‐0.64,0.68) | |
| HD TOFA PO + MTX | ‐0.17(‐0.91,0.58) | |
| HD GOLI SC + MTX | 0.38(‐0.31,1.08) | |
| HD ADA SC + MTX | 0.04(‐0.68,0.78) | |
| HD TOCI IV + MTX | HD GOLI SC | ‐0.35(‐0.80,0.10) |
| HD CERTO SC + MTX | ‐0.38(‐0.83,0.08) | |
| HD TOFA PO + MTX | ‐0.56(‐1.13,0.00) | |
| HD GOLI SC + MTX | ‐0.02(‐0.41,0.38) | |
| HD ADA SC + MTX | ‐0.36(‐0.91,0.19) | |
| HD CERTO SC + MTX | HD TOCI IV + MTX | ‐0.03(‐0.35,0.30) |
| HD TOFA PO + MTX | ‐0.21(‐0.68,0.26) | |
| HD GOLI SC + MTX | 0.33(‐0.04,0.71) | |
| HD ADA SC + MTX | ‐0.01(‐0.46,0.45) | |
| HD TOFA PO + MTX | HD CERTO SC + MTX | ‐0.18(‐0.66,0.29) |
| HD GOLI SC + MTX | 0.36(‐0.02,0.74) | |
| HD ADA SC + MTX | 0.02(‐0.43,0.48) | |
| HD GOLI SC + MTX | HD TOFA PO + MTX | 0.55(0.04,1.06) |
| HD ADA SC + MTX | 0.21(‐0.36,0.77) | |
| HD ADA SC + MTX | HD GOLI SC + MTX | ‐0.34(‐0.84,0.15) |
| Random‐effects model | Total residual deviance | 125.3 vs 127 data points |
| Deviance information criteria | ‐289.413 | |
| Note | ||
| Total participants | 16,355 | |
| Total studies | 48 | |
| 2‐arm | 25 | |
| 3‐arm | 15 | |
| 4‐arm | 8 | |
Appendix 8. HAQ: subgroup ‐ established RA (2‐10 years)
| HAQ established: mean difference (MD) for all treatment comparisons ‐ random‐effects model | ||
| Treatment | Reference | MD (95% CrI) |
| MTX | PL | 0.04(‐0.46,0.56) |
| DMARD | 0.04(‐0.44,0.52) | |
| MTX + DMARD | ‐0.31(‐0.92,0.31) | |
| SD ETN SC | ‐0.34(‐0.76,0.09) | |
| SD ADA SC | ‐0.27(‐0.58,0.04) | |
| SD TOFA PO | ‐0.40(‐0.72,‐0.09) | |
| SD CERTO SC | ‐0.32(‐0.70,0.07) | |
| SD ANA | ‐0.20(‐0.70,0.31) | |
| SD ETN SC + MTX | ‐0.59(‐1.07,‐0.09) | |
| SD CERTO SC + MTX | ‐0.25(‐0.80,0.32) | |
| SD GOLI SC + MTX | 0.04(‐0.58,0.66) | |
| SD TOFA PO + MTX | ‐0.39(‐1.09,0.31) | |
| SD RITUX IV + MTX | 0.04(‐0.66,0.77) | |
| SD ADA SC + MTX | ‐0.26(‐0.97,0.48) | |
| SD TOCI IV + MTX | ‐0.12(‐0.78,0.56) | |
| SD ABA SC + MTX | ‐0.18(‐0.92,0.57) | |
| SD GOLI IV + MTX | 0.35(‐0.35,1.07) | |
| SD CERTO SC + DMARD | ‐0.33(‐0.77,0.11) | |
| SD ETN SC + DMARD | ‐0.46(‐1.17,0.24) | |
| LD ADA SC | ‐0.31(‐0.66,0.04) | |
| LD ANA | ‐0.20(‐0.69,0.30) | |
| LD RITUX IV + MTX | 0.14(‐0.56,0.87) | |
| LD CERTO SC + MTX | ‐0.16(‐0.84,0.53) | |
| LD ETN SC + MTX | ‐0.32(‐0.96,0.33) | |
| LD TOFA PO + MTX | ‐0.31(‐1.01,0.39) | |
| HD TOCI IV | ‐0.27(‐0.82,0.28) | |
| HD TOFA PO | ‐0.52(‐0.84,‐0.20) | |
| HD ADA SC | ‐0.42(‐0.77,‐0.07) | |
| HD ANA | ‐0.30(‐0.81,0.21) | |
| HD GOLI SC | 0.09(‐0.58,0.78) | |
| HD TOCI IV + MTX | ‐0.24(‐0.81,0.34) | |
| HD CERTO SC + MTX | ‐0.29(‐0.86,0.30) | |
| HD TOFA PO + MTX | ‐0.47(‐1.16,0.23) | |
| HD GOLI SC + MTX | 0.07(‐0.54,0.70) | |
| DMARD | MTX | ‐0.01(‐0.41,0.40) |
| MTX + DMARD | ‐0.35(‐0.81,0.12) | |
| SD ETN SC | ‐0.38(‐0.69,‐0.07) | |
| SD ADA SC | ‐0.31(‐0.91,0.27) | |
| SD TOFA PO | ‐0.45(‐1.06,0.14) | |
| SD CERTO SC | ‐0.36(‐1.00,0.28) | |
| SD ANA | ‐0.24(‐0.96,0.46) | |
| SD ETN SC + MTX | ‐0.63(‐0.90,‐0.36) | |
| SD CERTO SC + MTX | ‐0.29(‐0.51,‐0.07) | |
| SD GOLI SC + MTX | 0.00(‐0.36,0.35) | |
| SD TOFA PO + MTX | ‐0.43(‐0.91,0.05) | |
| SD RITUX IV + MTX | 0.00(‐0.50,0.51) | |
| SD ADA SC + MTX | ‐0.30(‐0.82,0.22) | |
| SD TOCI IV + MTX | ‐0.16(‐0.61,0.29) | |
| SD ABA SC + MTX | ‐0.22(‐0.78,0.33) | |
| SD GOLI IV + MTX | 0.31(‐0.18,0.81) | |
| SD CERTO SC + DMARD | ‐0.37(‐0.91,0.15) | |
| SD ETN SC + DMARD | ‐0.51(‐1.17,0.16) | |
| LD ADA SC | ‐0.35(‐0.98,0.26) | |
| LD ANA | ‐0.24(‐0.96,0.47) | |
| LD RITUX IV + MTX | 0.10(‐0.41,0.61) | |
| LD CERTO SC + MTX | ‐0.20(‐0.66,0.26) | |
| LD ETN SC + MTX | ‐0.36(‐0.82,0.09) | |
| LD TOFA PO + MTX | ‐0.35(‐0.84,0.13) | |
| HD TOCI IV | ‐0.31(‐0.66,0.03) | |
| HD TOFA PO | ‐0.56(‐1.17,0.03) | |
| HD ADA SC | ‐0.47(‐1.09,0.14) | |
| HD ANA | ‐0.34(‐1.06,0.36) | |
| HD GOLI SC | 0.05(‐0.40,0.51) | |
| HD TOCI IV + MTX | ‐0.29(‐0.59,0.02) | |
| HD CERTO SC + MTX | ‐0.33(‐0.60,‐0.06) | |
| HD TOFA PO + MTX | ‐0.51(‐0.98,‐0.03) | |
| HD GOLI SC + MTX | 0.03(‐0.32,0.39) | |
| MTX + DMARD | DMARD | ‐0.34(‐0.90,0.22) |
| SD ETN SC | ‐0.38(‐0.74,‐0.01) | |
| SD ADA SC | ‐0.31(‐0.89,0.26) | |
| SD TOFA PO | ‐0.44(‐1.02,0.13) | |
| SD CERTO SC | ‐0.35(‐0.97,0.27) | |
| SD ANA | ‐0.23(‐0.93,0.46) | |
| SD ETN SC + MTX | ‐0.62(‐1.03,‐0.21) | |
| SD CERTO SC + MTX | ‐0.28(‐0.75,0.19) | |
| SD GOLI SC + MTX | 0.00(‐0.54,0.55) | |
| SD TOFA PO + MTX | ‐0.43(‐1.06,0.20) | |
| SD RITUX IV + MTX | 0.00(‐0.64,0.66) | |
| SD ADA SC + MTX | ‐0.29(‐0.95,0.36) | |
| SD TOCI IV + MTX | ‐0.15(‐0.74,0.44) | |
| SD ABA SC + MTX | ‐0.22(‐0.90,0.47) | |
| SD GOLI IV + MTX | 0.32(‐0.32,0.95) | |
| SD CERTO SC + DMARD | ‐0.37(‐0.80,0.06) | |
| SD ETN SC + DMARD | ‐0.50(‐1.01,0.02) | |
| LD ADA SC | ‐0.35(‐0.94,0.24) | |
| LD ANA | ‐0.23(‐0.93,0.46) | |
| LD RITUX IV + MTX | 0.10(‐0.55,0.76) | |
| LD CERTO SC + MTX | ‐0.20(‐0.81,0.42) | |
| LD ETN SC + MTX | ‐0.36(‐0.93,0.22) | |
| LD TOFA PO + MTX | ‐0.35(‐0.98,0.28) | |
| HD TOCI IV | ‐0.31(‐0.70,0.09) | |
| HD TOFA PO | ‐0.55(‐1.13,0.02) | |
| HD ADA SC | ‐0.46(‐1.06,0.13) | |
| HD ANA | ‐0.34(‐1.03,0.36) | |
| HD GOLI SC | 0.06(‐0.55,0.67) | |
| HD TOCI IV + MTX | ‐0.28(‐0.75,0.19) | |
| HD CERTO SC + MTX | ‐0.33(‐0.81,0.16) | |
| HD TOFA PO + MTX | ‐0.51(‐1.13,0.12) | |
| HD GOLI SC + MTX | 0.04(‐0.50,0.57) | |
| SD ETN SC | MTX + DMARD | ‐0.04(‐0.48,0.41) |
| SD ADA SC | 0.03(‐0.66,0.72) | |
| SD TOFA PO | ‐0.10(‐0.80,0.59) | |
| SD CERTO SC | ‐0.01(‐0.74,0.71) | |
| SD ANA | 0.11(‐0.69,0.90) | |
| SD ETN SC + MTX | ‐0.28(‐0.66,0.10) | |
| SD CERTO SC + MTX | 0.06(‐0.46,0.57) | |
| SD GOLI SC + MTX | 0.34(‐0.24,0.93) | |
| SD TOFA PO + MTX | ‐0.09(‐0.75,0.58) | |
| SD RITUX IV + MTX | 0.35(‐0.33,1.03) | |
| SD ADA SC + MTX | 0.05(‐0.65,0.74) | |
| SD TOCI IV + MTX | 0.19(‐0.44,0.83) | |
| SD ABA SC + MTX | 0.13(‐0.60,0.84) | |
| SD GOLI IV + MTX | 0.66(‐0.01,1.34) | |
| SD CERTO SC + DMARD | ‐0.03(‐0.67,0.61) | |
| SD ETN SC + DMARD | ‐0.16(‐0.92,0.60) | |
| LD ADA SC | 0.00(‐0.72,0.70) | |
| LD ANA | 0.11(‐0.68,0.90) | |
| LD RITUX IV + MTX | 0.45(‐0.24,1.13) | |
| LD CERTO SC + MTX | 0.14(‐0.51,0.80) | |
| LD ETN SC + MTX | ‐0.02(‐0.61,0.57) | |
| LD TOFA PO + MTX | ‐0.01(‐0.68,0.67) | |
| HD TOCI IV | 0.03(‐0.51,0.59) | |
| HD TOFA PO | ‐0.21(‐0.91,0.47) | |
| HD ADA SC | ‐0.12(‐0.83,0.59) | |
| HD ANA | 0.01(‐0.79,0.80) | |
| HD GOLI SC | 0.40(‐0.25,1.05) | |
| HD TOCI IV + MTX | 0.06(‐0.48,0.61) | |
| HD CERTO SC + MTX | 0.01(‐0.52,0.55) | |
| HD TOFA PO + MTX | ‐0.16(‐0.83,0.50) | |
| HD GOLI SC + MTX | 0.38(‐0.20,0.96) | |
| SD ADA SC | SD ETN SC | 0.07(‐0.46,0.59) |
| SD TOFA PO | ‐0.06(‐0.60,0.46) | |
| SD CERTO SC | 0.02(‐0.55,0.61) | |
| SD ANA | 0.14(‐0.52,0.80) | |
| SD ETN SC + MTX | ‐0.25(‐0.49,0.00) | |
| SD CERTO SC + MTX | 0.09(‐0.29,0.48) | |
| SD GOLI SC + MTX | 0.38(‐0.09,0.85) | |
| SD TOFA PO + MTX | ‐0.05(‐0.62,0.52) | |
| SD RITUX IV + MTX | 0.38(‐0.21,0.98) | |
| SD ADA SC + MTX | 0.08(‐0.52,0.69) | |
| SD TOCI IV + MTX | 0.22(‐0.31,0.77) | |
| SD ABA SC + MTX | 0.16(‐0.48,0.80) | |
| SD GOLI IV + MTX | 0.69(0.11,1.28) | |
| SD CERTO SC + DMARD | 0.01(‐0.47,0.48) | |
| SD ETN SC + DMARD | ‐0.12(‐0.76,0.51) | |
| LD ADA SC | 0.03(‐0.53,0.58) | |
| LD ANA | 0.14(‐0.52,0.80) | |
| LD RITUX IV + MTX | 0.48(‐0.11,1.08) | |
| LD CERTO SC + MTX | 0.18(‐0.37,0.74) | |
| LD ETN SC + MTX | 0.02(‐0.47,0.51) | |
| LD TOFA PO + MTX | 0.03(‐0.55,0.60) | |
| HD TOCI IV | 0.07(‐0.33,0.47) | |
| HD TOFA PO | ‐0.18(‐0.71,0.35) | |
| HD ADA SC | ‐0.08(‐0.64,0.47) | |
| HD ANA | 0.04(‐0.62,0.70) | |
| HD GOLI SC | 0.43(‐0.11,0.98) | |
| HD TOCI IV + MTX | 0.10(‐0.32,0.52) | |
| HD CERTO SC + MTX | 0.05(‐0.36,0.46) | |
| HD TOFA PO + MTX | ‐0.13(‐0.69,0.44) | |
| HD GOLI SC + MTX | 0.41(‐0.06,0.89) | |
| SD TOFA PO | SD ADA SC | ‐0.13(‐0.51,0.24) |
| SD CERTO SC | ‐0.04(‐0.54,0.45) | |
| SD ANA | 0.07(‐0.51,0.66) | |
| SD ETN SC + MTX | ‐0.31(‐0.88,0.26) | |
| SD CERTO SC + MTX | 0.02(‐0.61,0.66) | |
| SD GOLI SC + MTX | 0.31(‐0.37,1.01) | |
| SD TOFA PO + MTX | ‐0.12(‐0.88,0.65) | |
| SD RITUX IV + MTX | 0.31(‐0.45,1.10) | |
| SD ADA SC + MTX | 0.01(‐0.77,0.81) | |
| SD TOCI IV + MTX | 0.16(‐0.57,0.90) | |
| SD ABA SC + MTX | 0.09(‐0.72,0.90) | |
| SD GOLI IV + MTX | 0.62(‐0.13,1.40) | |
| SD CERTO SC + DMARD | ‐0.06(‐0.59,0.47) | |
| SD ETN SC + DMARD | ‐0.19(‐0.96,0.58) | |
| LD ADA SC | ‐0.04(‐0.39,0.31) | |
| LD ANA | 0.07(‐0.51,0.66) | |
| LD RITUX IV + MTX | 0.41(‐0.36,1.20) | |
| LD CERTO SC + MTX | 0.11(‐0.64,0.87) | |
| LD ETN SC + MTX | ‐0.05(‐0.75,0.66) | |
| LD TOFA PO + MTX | ‐0.04(‐0.81,0.73) | |
| HD TOCI IV | 0.00(‐0.62,0.63) | |
| HD TOFA PO | ‐0.24(‐0.62,0.12) | |
| HD ADA SC | ‐0.15(‐0.50,0.20) | |
| HD ANA | ‐0.03(‐0.62,0.56) | |
| HD GOLI SC | 0.36(‐0.37,1.12) | |
| HD TOCI IV + MTX | 0.03(‐0.61,0.69) | |
| HD CERTO SC + MTX | ‐0.02(‐0.67,0.64) | |
| HD TOFA PO + MTX | ‐0.20(‐0.95,0.57) | |
| HD GOLI SC + MTX | 0.35(‐0.34,1.04) | |
| SD CERTO SC | SD TOFA PO | 0.09(‐0.41,0.59) |
| SD ANA | 0.21(‐0.38,0.81) | |
| SD ETN SC + MTX | ‐0.18(‐0.75,0.41) | |
| SD CERTO SC + MTX | 0.16(‐0.48,0.81) | |
| SD GOLI SC + MTX | 0.44(‐0.25,1.15) | |
| SD TOFA PO + MTX | 0.01(‐0.75,0.78) | |
| SD RITUX IV + MTX | 0.44(‐0.32,1.24) | |
| SD ADA SC + MTX | 0.15(‐0.64,0.95) | |
| SD TOCI IV + MTX | 0.29(‐0.44,1.04) | |
| SD ABA SC + MTX | 0.22(‐0.59,1.04) | |
| SD GOLI IV + MTX | 0.76(‐0.01,1.54) | |
| SD CERTO SC + DMARD | 0.07(‐0.47,0.61) | |
| SD ETN SC + DMARD | ‐0.06(‐0.83,0.72) | |
| LD ADA SC | 0.09(‐0.35,0.54) | |
| LD ANA | 0.21(‐0.39,0.80) | |
| LD RITUX IV + MTX | 0.54(‐0.23,1.33) | |
| LD CERTO SC + MTX | 0.24(‐0.51,1.01) | |
| LD ETN SC + MTX | 0.08(‐0.62,0.80) | |
| LD TOFA PO + MTX | 0.09(‐0.67,0.87) | |
| HD TOCI IV | 0.13(‐0.50,0.77) | |
| HD TOFA PO | ‐0.11(‐0.42,0.19) | |
| HD ADA SC | ‐0.02(‐0.46,0.43) | |
| HD ANA | 0.11(‐0.49,0.70) | |
| HD GOLI SC | 0.50(‐0.24,1.26) | |
| HD TOCI IV + MTX | 0.16(‐0.49,0.82) | |
| HD CERTO SC + MTX | 0.11(‐0.54,0.78) | |
| HD TOFA PO + MTX | ‐0.06(‐0.82,0.70) | |
| HD GOLI SC + MTX | 0.48(‐0.21,1.18) | |
| SD ANA | SD CERTO SC | 0.12(‐0.52,0.75) |
| SD ETN SC + MTX | ‐0.27(‐0.89,0.35) | |
| SD CERTO SC + MTX | 0.07(‐0.61,0.75) | |
| SD GOLI SC + MTX | 0.36(‐0.38,1.08) | |
| SD TOFA PO + MTX | ‐0.07(‐0.87,0.73) | |
| SD RITUX IV + MTX | 0.36(‐0.45,1.17) | |
| SD ADA SC + MTX | 0.06(‐0.76,0.88) | |
| SD TOCI IV + MTX | 0.20(‐0.57,0.98) | |
| SD ABA SC + MTX | 0.14(‐0.71,0.98) | |
| SD GOLI IV + MTX | 0.67(‐0.14,1.48) | |
| SD CERTO SC + DMARD | ‐0.02(‐0.60,0.56) | |
| SD ETN SC + DMARD | ‐0.15(‐0.97,0.66) | |
| LD ADA SC | 0.01(‐0.51,0.53) | |
| LD ANA | 0.12(‐0.52,0.75) | |
| LD RITUX IV + MTX | 0.46(‐0.35,1.27) | |
| LD CERTO SC + MTX | 0.16(‐0.63,0.94) | |
| LD ETN SC + MTX | ‐0.01(‐0.76,0.75) | |
| LD TOFA PO + MTX | 0.00(‐0.80,0.81) | |
| HD TOCI IV | 0.05(‐0.63,0.72) | |
| HD TOFA PO | ‐0.20(‐0.71,0.30) | |
| HD ADA SC | ‐0.11(‐0.63,0.41) | |
| HD ANA | 0.02(‐0.62,0.65) | |
| HD GOLI SC | 0.41(‐0.37,1.20) | |
| HD TOCI IV + MTX | 0.07(‐0.62,0.77) | |
| HD CERTO SC + MTX | 0.03(‐0.67,0.72) | |
| HD TOFA PO + MTX | ‐0.15(‐0.94,0.64) | |
| HD GOLI SC + MTX | 0.39(‐0.34,1.12) | |
| SD ETN SC + MTX | SD ANA | ‐0.39(‐1.09,0.31) |
| SD CERTO SC + MTX | ‐0.05(‐0.79,0.70) | |
| SD GOLI SC + MTX | 0.24(‐0.56,1.04) | |
| SD TOFA PO + MTX | ‐0.19(‐1.05,0.66) | |
| SD RITUX IV + MTX | 0.24(‐0.62,1.12) | |
| SD ADA SC + MTX | ‐0.06(‐0.93,0.83) | |
| SD TOCI IV + MTX | 0.08(‐0.75,0.93) | |
| SD ABA SC + MTX | 0.02(‐0.89,0.93) | |
| SD GOLI IV + MTX | 0.55(‐0.31,1.43) | |
| SD CERTO SC + DMARD | ‐0.13(‐0.81,0.53) | |
| SD ETN SC + DMARD | ‐0.27(‐1.13,0.60) | |
| LD ADA SC | ‐0.11(‐0.72,0.50) | |
| LD ANA | 0.00(‐0.50,0.50) | |
| LD RITUX IV + MTX | 0.34(‐0.53,1.22) | |
| LD CERTO SC + MTX | 0.04(‐0.80,0.89) | |
| LD ETN SC + MTX | ‐0.13(‐0.94,0.70) | |
| LD TOFA PO + MTX | ‐0.11(‐0.98,0.75) | |
| HD TOCI IV | ‐0.07(‐0.81,0.67) | |
| HD TOFA PO | ‐0.32(‐0.91,0.27) | |
| HD ADA SC | ‐0.23(‐0.84,0.39) | |
| HD ANA | ‐0.10(‐0.61,0.41) | |
| HD GOLI SC | 0.29(‐0.55,1.15) | |
| HD TOCI IV + MTX | ‐0.05(‐0.81,0.72) | |
| HD CERTO SC + MTX | ‐0.09(‐0.86,0.68) | |
| HD TOFA PO + MTX | ‐0.27(‐1.13,0.60) | |
| HD GOLI SC + MTX | 0.27(‐0.52,1.08) | |
| SD CERTO SC + MTX | SD ETN SC + MTX | 0.34(‐0.01,0.69) |
| SD GOLI SC + MTX | 0.62(0.18,1.07) | |
| SD TOFA PO + MTX | 0.20(‐0.35,0.75) | |
| SD RITUX IV + MTX | 0.63(0.06,1.20) | |
| SD ADA SC + MTX | 0.33(‐0.26,0.91) | |
| SD TOCI IV + MTX | 0.47(‐0.05,0.99) | |
| SD ABA SC + MTX | 0.41(‐0.21,1.02) | |
| SD GOLI IV + MTX | 0.94(0.38,1.50) | |
| SD CERTO SC + DMARD | 0.25(‐0.27,0.77) | |
| SD ETN SC + DMARD | 0.12(‐0.54,0.78) | |
| LD ADA SC | 0.28(‐0.33,0.87) | |
| LD ANA | 0.39(‐0.31,1.08) | |
| LD RITUX IV + MTX | 0.73(0.15,1.30) | |
| LD CERTO SC + MTX | 0.43(‐0.10,0.96) | |
| LD ETN SC + MTX | 0.26(‐0.19,0.72) | |
| LD TOFA PO + MTX | 0.27(‐0.28,0.83) | |
| HD TOCI IV | 0.31(‐0.08,0.72) | |
| HD TOFA PO | 0.07(‐0.52,0.64) | |
| HD ADA SC | 0.16(‐0.43,0.75) | |
| HD ANA | 0.29(‐0.42,0.98) | |
| HD GOLI SC | 0.68(0.16,1.21) | |
| HD TOCI IV + MTX | 0.34(‐0.06,0.74) | |
| HD CERTO SC + MTX | 0.30(‐0.09,0.68) | |
| HD TOFA PO + MTX | 0.12(‐0.43,0.67) | |
| HD GOLI SC + MTX | 0.66(0.22,1.11) | |
| SD GOLI SC + MTX | SD CERTO SC + MTX | 0.29(‐0.13,0.70) |
| SD TOFA PO + MTX | ‐0.14(‐0.67,0.39) | |
| SD RITUX IV + MTX | 0.29(‐0.26,0.84) | |
| SD ADA SC + MTX | ‐0.01(‐0.57,0.56) | |
| SD TOCI IV + MTX | 0.13(‐0.37,0.64) | |
| SD ABA SC + MTX | 0.07(‐0.53,0.66) | |
| SD GOLI IV + MTX | 0.60(0.06,1.15) | |
| SD CERTO SC + DMARD | ‐0.08(‐0.67,0.49) | |
| SD ETN SC + DMARD | ‐0.22(‐0.91,0.48) | |
| LD ADA SC | ‐0.06(‐0.73,0.59) | |
| LD ANA | 0.05(‐0.70,0.79) | |
| LD RITUX IV + MTX | 0.39(‐0.17,0.94) | |
| LD CERTO SC + MTX | 0.09(‐0.37,0.55) | |
| LD ETN SC + MTX | ‐0.07(‐0.59,0.43) | |
| LD TOFA PO + MTX | ‐0.06(‐0.60,0.47) | |
| HD TOCI IV | ‐0.02(‐0.43,0.39) | |
| HD TOFA PO | ‐0.27(‐0.92,0.36) | |
| HD ADA SC | ‐0.18(‐0.84,0.47) | |
| HD ANA | ‐0.05(‐0.80,0.69) | |
| HD GOLI SC | 0.34(‐0.16,0.85) | |
| HD TOCI IV + MTX | 0.00(‐0.38,0.39) | |
| HD CERTO SC + MTX | ‐0.04(‐0.32,0.23) | |
| HD TOFA PO + MTX | ‐0.22(‐0.75,0.30) | |
| HD GOLI SC + MTX | 0.32(‐0.10,0.74) | |
| SD TOFA PO + MTX | SD GOLI SC + MTX | ‐0.43(‐1.03,0.17) |
| SD RITUX IV + MTX | 0.00(‐0.62,0.63) | |
| SD ADA SC + MTX | ‐0.30(‐0.92,0.33) | |
| SD TOCI IV + MTX | ‐0.15(‐0.73,0.42) | |
| SD ABA SC + MTX | ‐0.22(‐0.88,0.44) | |
| SD GOLI IV + MTX | 0.31(‐0.30,0.92) | |
| SD CERTO SC + DMARD | ‐0.37(‐1.01,0.26) | |
| SD ETN SC + DMARD | ‐0.50(‐1.26,0.25) | |
| LD ADA SC | ‐0.35(‐1.06,0.36) | |
| LD ANA | ‐0.24(‐1.04,0.55) | |
| LD RITUX IV + MTX | 0.10(‐0.52,0.73) | |
| LD CERTO SC + MTX | ‐0.20(‐0.78,0.38) | |
| LD ETN SC + MTX | ‐0.36(‐0.93,0.21) | |
| LD TOFA PO + MTX | ‐0.35(‐0.95,0.25) | |
| HD TOCI IV | ‐0.31(‐0.80,0.18) | |
| HD TOFA PO | ‐0.56(‐1.26,0.13) | |
| HD ADA SC | ‐0.46(‐1.18,0.24) | |
| HD ANA | ‐0.34(‐1.14,0.45) | |
| HD GOLI SC | 0.05(‐0.40,0.52) | |
| HD TOCI IV + MTX | ‐0.28(‐0.75,0.19) | |
| HD CERTO SC + MTX | ‐0.33(‐0.78,0.12) | |
| HD TOFA PO + MTX | ‐0.51(‐1.10,0.09) | |
| HD GOLI SC + MTX | 0.03(‐0.32,0.40) | |
| SD RITUX IV + MTX | SD TOFA PO + MTX | 0.43(‐0.27,1.12) |
| SD ADA SC + MTX | 0.13(‐0.57,0.84) | |
| SD TOCI IV + MTX | 0.27(‐0.38,0.93) | |
| SD ABA SC + MTX | 0.21(‐0.52,0.94) | |
| SD GOLI IV + MTX | 0.74(0.05,1.43) | |
| SD CERTO SC + DMARD | 0.06(‐0.66,0.77) | |
| SD ETN SC + DMARD | ‐0.07(‐0.89,0.74) | |
| LD ADA SC | 0.08(‐0.71,0.86) | |
| LD ANA | 0.19(‐0.67,1.05) | |
| LD RITUX IV + MTX | 0.53(‐0.17,1.24) | |
| LD CERTO SC + MTX | 0.23(‐0.44,0.89) | |
| LD ETN SC + MTX | 0.07(‐0.59,0.73) | |
| LD TOFA PO + MTX | 0.08(‐0.41,0.56) | |
| HD TOCI IV | 0.12(‐0.47,0.71) | |
| HD TOFA PO | ‐0.13(‐0.90,0.64) | |
| HD ADA SC | ‐0.03(‐0.82,0.75) | |
| HD ANA | 0.09(‐0.77,0.95) | |
| HD GOLI SC | 0.48(‐0.17,1.15) | |
| HD TOCI IV + MTX | 0.15(‐0.43,0.72) | |
| HD CERTO SC + MTX | 0.10(‐0.44,0.65) | |
| HD TOFA PO + MTX | ‐0.08(‐0.55,0.41) | |
| HD GOLI SC + MTX | 0.46(‐0.13,1.06) | |
| SD ADA SC + MTX | SD RITUX IV + MTX | ‐0.30(‐1.02,0.42) |
| SD TOCI IV + MTX | ‐0.16(‐0.83,0.52) | |
| SD ABA SC + MTX | ‐0.22(‐0.97,0.53) | |
| SD GOLI IV + MTX | 0.31(‐0.39,1.02) | |
| SD CERTO SC + DMARD | ‐0.37(‐1.11,0.36) | |
| SD ETN SC + DMARD | ‐0.51(‐1.34,0.33) | |
| LD ADA SC | ‐0.35(‐1.16,0.44) | |
| LD ANA | ‐0.24(‐1.12,0.61) | |
| LD RITUX IV + MTX | 0.10(‐0.41,0.61) | |
| LD CERTO SC + MTX | ‐0.20(‐0.89,0.49) | |
| LD ETN SC + MTX | ‐0.36(‐1.04,0.32) | |
| LD TOFA PO + MTX | ‐0.35(‐1.05,0.35) | |
| HD TOCI IV | ‐0.31(‐0.92,0.29) | |
| HD TOFA PO | ‐0.56(‐1.35,0.21) | |
| HD ADA SC | ‐0.46(‐1.26,0.32) | |
| HD ANA | ‐0.34(‐1.23,0.52) | |
| HD GOLI SC | 0.05(‐0.64,0.73) | |
| HD TOCI IV + MTX | ‐0.29(‐0.88,0.30) | |
| HD CERTO SC + MTX | ‐0.33(‐0.91,0.25) | |
| HD TOFA PO + MTX | ‐0.51(‐1.20,0.19) | |
| HD GOLI SC + MTX | 0.03(‐0.59,0.65) | |
| SD TOCI IV + MTX | SD ADA SC + MTX | 0.14(‐0.54,0.82) |
| SD ABA SC + MTX | 0.08(‐0.68,0.83) | |
| SD GOLI IV + MTX | 0.61(‐0.10,1.33) | |
| SD CERTO SC + DMARD | ‐0.07(‐0.82,0.66) | |
| SD ETN SC + DMARD | ‐0.21(‐1.05,0.63) | |
| LD ADA SC | ‐0.05(‐0.87,0.75) | |
| LD ANA | 0.06(‐0.83,0.93) | |
| LD RITUX IV + MTX | 0.40(‐0.32,1.13) | |
| LD CERTO SC + MTX | 0.10(‐0.59,0.79) | |
| LD ETN SC + MTX | ‐0.06(‐0.75,0.62) | |
| LD TOFA PO + MTX | ‐0.05(‐0.76,0.65) | |
| HD TOCI IV | ‐0.01(‐0.64,0.60) | |
| HD TOFA PO | ‐0.26(‐1.06,0.53) | |
| HD ADA SC | ‐0.17(‐0.99,0.64) | |
| HD ANA | ‐0.04(‐0.93,0.83) | |
| HD GOLI SC | 0.35(‐0.34,1.04) | |
| HD TOCI IV + MTX | 0.01(‐0.59,0.62) | |
| HD CERTO SC + MTX | ‐0.03(‐0.62,0.55) | |
| HD TOFA PO + MTX | ‐0.21(‐0.91,0.49) | |
| HD GOLI SC + MTX | 0.33(‐0.30,0.96) | |
| SD ABA SC + MTX | SD TOCI IV + MTX | ‐0.06(‐0.78,0.65) |
| SD GOLI IV + MTX | 0.47(‐0.20,1.14) | |
| SD CERTO SC + DMARD | ‐0.22(‐0.90,0.47) | |
| SD ETN SC + DMARD | ‐0.35(‐1.13,0.43) | |
| LD ADA SC | ‐0.19(‐0.96,0.55) | |
| LD ANA | ‐0.08(‐0.92,0.75) | |
| LD RITUX IV + MTX | 0.26(‐0.42,0.94) | |
| LD CERTO SC + MTX | ‐0.04(‐0.68,0.60) | |
| LD ETN SC + MTX | ‐0.21(‐0.85,0.43) | |
| LD TOFA PO + MTX | ‐0.20(‐0.86,0.46) | |
| HD TOCI IV | ‐0.16(‐0.68,0.38) | |
| HD TOFA PO | ‐0.40(‐1.15,0.33) | |
| HD ADA SC | ‐0.31(‐1.07,0.44) | |
| HD ANA | ‐0.18(‐1.03,0.65) | |
| HD GOLI SC | 0.21(‐0.43,0.85) | |
| HD TOCI IV + MTX | ‐0.13(‐0.58,0.32) | |
| HD CERTO SC + MTX | ‐0.17(‐0.70,0.35) | |
| HD TOFA PO + MTX | ‐0.35(‐1.00,0.30) | |
| HD GOLI SC + MTX | 0.19(‐0.38,0.76) | |
| SD GOLI IV + MTX | SD ABA SC + MTX | 0.53(‐0.21,1.28) |
| SD CERTO SC + DMARD | ‐0.15(‐0.92,0.61) | |
| SD ETN SC + DMARD | ‐0.29(‐1.15,0.58) | |
| LD ADA SC | ‐0.13(‐0.95,0.70) | |
| LD ANA | ‐0.02(‐0.92,0.88) | |
| LD RITUX IV + MTX | 0.32(‐0.43,1.07) | |
| LD CERTO SC + MTX | 0.02(‐0.70,0.75) | |
| LD ETN SC + MTX | ‐0.14(‐0.86,0.58) | |
| LD TOFA PO + MTX | ‐0.13(‐0.87,0.60) | |
| HD TOCI IV | ‐0.09(‐0.74,0.56) | |
| HD TOFA PO | ‐0.34(‐1.16,0.47) | |
| HD ADA SC | ‐0.24(‐1.07,0.58) | |
| HD ANA | ‐0.12(‐1.03,0.78) | |
| HD GOLI SC | 0.27(‐0.45,1.00) | |
| HD TOCI IV + MTX | ‐0.07(‐0.69,0.58) | |
| HD CERTO SC + MTX | ‐0.11(‐0.73,0.52) | |
| HD TOFA PO + MTX | ‐0.29(‐1.02,0.45) | |
| HD GOLI SC + MTX | 0.25(‐0.40,0.91) | |
| SD CERTO SC + DMARD | SD GOLI IV + MTX | ‐0.68(‐1.41,0.03) |
| SD ETN SC + DMARD | ‐0.82(‐1.63,0.01) | |
| LD ADA SC | ‐0.66(‐1.46,0.12) | |
| LD ANA | ‐0.55(‐1.43,0.30) | |
| LD RITUX IV + MTX | ‐0.21(‐0.92,0.50) | |
| LD CERTO SC + MTX | ‐0.51(‐1.19,0.17) | |
| LD ETN SC + MTX | ‐0.68(‐1.34,0.00) | |
| LD TOFA PO + MTX | ‐0.66(‐1.36,0.03) | |
| HD TOCI IV | ‐0.62(‐1.22,‐0.03) | |
| HD TOFA PO | ‐0.87(‐1.65,‐0.11) | |
| HD ADA SC | ‐0.78(‐1.57,0.01) | |
| HD ANA | ‐0.65(‐1.52,0.21) | |
| HD GOLI SC | ‐0.26(‐0.93,0.41) | |
| HD TOCI IV + MTX | ‐0.60(‐1.18,‐0.02) | |
| HD CERTO SC + MTX | ‐0.64(‐1.21,‐0.08) | |
| HD TOFA PO + MTX | ‐0.82(‐1.50,‐0.13) | |
| HD GOLI SC + MTX | ‐0.28(‐0.89,0.33) | |
| SD ETN SC + DMARD | SD CERTO SC + DMARD | ‐0.13(‐0.81,0.55) |
| LD ADA SC | 0.02(‐0.53,0.58) | |
| LD ANA | 0.13(‐0.53,0.80) | |
| LD RITUX IV + MTX | 0.47(‐0.26,1.21) | |
| LD CERTO SC + MTX | 0.17(‐0.52,0.88) | |
| LD ETN SC + MTX | 0.01(‐0.66,0.67) | |
| LD TOFA PO + MTX | 0.02(‐0.69,0.74) | |
| HD TOCI IV | 0.06(‐0.49,0.61) | |
| HD TOFA PO | ‐0.18(‐0.72,0.35) | |
| HD ADA SC | ‐0.09(‐0.65,0.47) | |
| HD ANA | 0.03(‐0.64,0.70) | |
| HD GOLI SC | 0.42(‐0.27,1.13) | |
| HD TOCI IV + MTX | 0.09(‐0.50,0.68) | |
| HD CERTO SC + MTX | 0.04(‐0.55,0.65) | |
| HD TOFA PO + MTX | ‐0.14(‐0.85,0.57) | |
| HD GOLI SC + MTX | 0.41(‐0.23,1.05) | |
| LD ADA SC | SD ETN SC + DMARD | 0.16(‐0.64,0.94) |
| LD ANA | 0.27(‐0.61,1.14) | |
| LD RITUX IV + MTX | 0.61(‐0.23,1.45) | |
| LD CERTO SC + MTX | 0.30(‐0.50,1.11) | |
| LD ETN SC + MTX | 0.14(‐0.64,0.92) | |
| LD TOFA PO + MTX | 0.15(‐0.66,0.97) | |
| HD TOCI IV | 0.19(‐0.46,0.85) | |
| HD TOFA PO | ‐0.05(‐0.83,0.72) | |
| HD ADA SC | 0.04(‐0.75,0.83) | |
| HD ANA | 0.17(‐0.71,1.03) | |
| HD GOLI SC | 0.56(‐0.24,1.36) | |
| HD TOCI IV + MTX | 0.22(‐0.48,0.92) | |
| HD CERTO SC + MTX | 0.17(‐0.54,0.90) | |
| HD TOFA PO + MTX | 0.00(‐0.81,0.81) | |
| HD GOLI SC + MTX | 0.54(‐0.21,1.29) | |
| LD ANA | LD ADA SC | 0.11(‐0.50,0.72) |
| LD RITUX IV + MTX | 0.45(‐0.34,1.25) | |
| LD CERTO SC + MTX | 0.15(‐0.62,0.92) | |
| LD ETN SC + MTX | ‐0.01(‐0.74,0.73) | |
| LD TOFA PO + MTX | 0.00(‐0.79,0.79) | |
| HD TOCI IV | 0.04(‐0.61,0.69) | |
| HD TOFA PO | ‐0.21(‐0.65,0.23) | |
| HD ADA SC | ‐0.11(‐0.48,0.24) | |
| HD ANA | 0.01(‐0.61,0.62) | |
| HD GOLI SC | 0.40(‐0.36,1.18) | |
| HD TOCI IV + MTX | 0.06(‐0.60,0.75) | |
| HD CERTO SC + MTX | 0.02(‐0.65,0.71) | |
| HD TOFA PO + MTX | ‐0.16(‐0.93,0.62) | |
| HD GOLI SC + MTX | 0.38(‐0.32,1.10) | |
| LD RITUX IV + MTX | LD ANA | 0.34(‐0.52,1.22) |
| LD CERTO SC + MTX | 0.04(‐0.81,0.89) | |
| LD ETN SC + MTX | ‐0.12(‐0.92,0.69) | |
| LD TOFA PO + MTX | ‐0.11(‐0.97,0.75) | |
| HD TOCI IV | ‐0.07(‐0.81,0.67) | |
| HD TOFA PO | ‐0.32(‐0.91,0.27) | |
| HD ADA SC | ‐0.23(‐0.83,0.39) | |
| HD ANA | ‐0.10(‐0.60,0.40) | |
| HD GOLI SC | 0.29(‐0.55,1.14) | |
| HD TOCI IV + MTX | ‐0.05(‐0.80,0.72) | |
| HD CERTO SC + MTX | ‐0.09(‐0.85,0.68) | |
| HD TOFA PO + MTX | ‐0.27(‐1.12,0.59) | |
| HD GOLI SC + MTX | 0.27(‐0.52,1.07) | |
| LD CERTO SC + MTX | LD RITUX IV + MTX | ‐0.30(‐0.99,0.38) |
| LD ETN SC + MTX | ‐0.46(‐1.14,0.21) | |
| LD TOFA PO + MTX | ‐0.45(‐1.15,0.25) | |
| HD TOCI IV | ‐0.41(‐1.03,0.19) | |
| HD TOFA PO | ‐0.66(‐1.45,0.12) | |
| HD ADA SC | ‐0.56(‐1.37,0.23) | |
| HD ANA | ‐0.44(‐1.32,0.43) | |
| HD GOLI SC | ‐0.05(‐0.73,0.63) | |
| HD TOCI IV + MTX | ‐0.39(‐0.98,0.21) | |
| HD CERTO SC + MTX | ‐0.43(‐1.01,0.15) | |
| HD TOFA PO + MTX | ‐0.61(‐1.30,0.09) | |
| HD GOLI SC + MTX | ‐0.07(‐0.69,0.56) | |
| LD ETN SC + MTX | LD CERTO SC + MTX | ‐0.16(‐0.81,0.48) |
| LD TOFA PO + MTX | ‐0.15(‐0.82,0.52) | |
| HD TOCI IV | ‐0.11(‐0.68,0.46) | |
| HD TOFA PO | ‐0.36(‐1.11,0.39) | |
| HD ADA SC | ‐0.26(‐1.03,0.50) | |
| HD ANA | ‐0.14(‐1.00,0.71) | |
| HD GOLI SC | 0.25(‐0.39,0.90) | |
| HD TOCI IV + MTX | ‐0.08(‐0.64,0.47) | |
| HD CERTO SC + MTX | ‐0.13(‐0.60,0.33) | |
| HD TOFA PO + MTX | ‐0.31(‐0.97,0.36) | |
| HD GOLI SC + MTX | 0.23(‐0.35,0.82) | |
| LD TOFA PO + MTX | LD ETN SC + MTX | 0.01(‐0.65,0.67) |
| HD TOCI IV | 0.05(‐0.50,0.61) | |
| HD TOFA PO | ‐0.19(‐0.92,0.51) | |
| HD ADA SC | ‐0.10(‐0.83,0.62) | |
| HD ANA | 0.02(‐0.80,0.83) | |
| HD GOLI SC | 0.41(‐0.23,1.06) | |
| HD TOCI IV + MTX | 0.08(‐0.46,0.63) | |
| HD CERTO SC + MTX | 0.03(‐0.49,0.56) | |
| HD TOFA PO + MTX | ‐0.15(‐0.80,0.51) | |
| HD GOLI SC + MTX | 0.40(‐0.18,0.97) | |
| HD TOCI IV | LD TOFA PO + MTX | 0.04(‐0.55,0.64) |
| HD TOFA PO | ‐0.20(‐0.98,0.56) | |
| HD ADA SC | ‐0.11(‐0.90,0.68) | |
| HD ANA | 0.01(‐0.86,0.88) | |
| HD GOLI SC | 0.40(‐0.26,1.07) | |
| HD TOCI IV + MTX | 0.07(‐0.50,0.65) | |
| HD CERTO SC + MTX | 0.02(‐0.54,0.58) | |
| HD TOFA PO + MTX | ‐0.16(‐0.64,0.33) | |
| HD GOLI SC + MTX | 0.39(‐0.22,0.98) | |
| HD TOFA PO | HD TOCI IV | ‐0.25(‐0.88,0.38) |
| HD ADA SC | ‐0.15(‐0.81,0.50) | |
| HD ANA | ‐0.03(‐0.78,0.71) | |
| HD GOLI SC | 0.36(‐0.20,0.94) | |
| HD TOCI IV + MTX | 0.03(‐0.34,0.40) | |
| HD CERTO SC + MTX | ‐0.02(‐0.46,0.42) | |
| HD TOFA PO + MTX | ‐0.20(‐0.78,0.39) | |
| HD GOLI SC + MTX | 0.35(‐0.15,0.83) | |
| HD ADA SC | HD TOFA PO | 0.09(‐0.35,0.54) |
| HD ANA | 0.22(‐0.37,0.82) | |
| HD GOLI SC | 0.61(‐0.13,1.37) | |
| HD TOCI IV + MTX | 0.27(‐0.38,0.94) | |
| HD CERTO SC + MTX | 0.23(‐0.42,0.89) | |
| HD TOFA PO + MTX | 0.05(‐0.71,0.82) | |
| HD GOLI SC + MTX | 0.59(‐0.09,1.29) | |
| HD ANA | HD ADA SC | 0.12(‐0.49,0.74) |
| HD GOLI SC | 0.52(‐0.24,1.28) | |
| HD TOCI IV + MTX | 0.18(‐0.48,0.85) | |
| HD CERTO SC + MTX | 0.13(‐0.54,0.81) | |
| HD TOFA PO + MTX | ‐0.05(‐0.82,0.74) | |
| HD GOLI SC + MTX | 0.50(‐0.20,1.21) | |
| HD GOLI SC | HD ANA | 0.39(‐0.45,1.24) |
| HD TOCI IV + MTX | 0.05(‐0.71,0.83) | |
| HD CERTO SC + MTX | 0.01(‐0.75,0.78) | |
| HD TOFA PO + MTX | ‐0.17(‐1.03,0.69) | |
| HD GOLI SC + MTX | 0.37(‐0.42,1.17) | |
| HD TOCI IV + MTX | HD GOLI SC | ‐0.34(‐0.89,0.21) |
| HD CERTO SC + MTX | ‐0.38(‐0.91,0.15) | |
| HD TOFA PO + MTX | ‐0.56(‐1.22,0.10) | |
| HD GOLI SC + MTX | ‐0.02(‐0.49,0.44) | |
| HD CERTO SC + MTX | HD TOCI IV + MTX | ‐0.05(‐0.46,0.36) |
| HD TOFA PO + MTX | ‐0.22(‐0.79,0.34) | |
| HD GOLI SC + MTX | 0.32(‐0.16,0.79) | |
| HD TOFA PO + MTX | HD CERTO SC + MTX | ‐0.18(‐0.72,0.37) |
| HD GOLI SC + MTX | 0.36(‐0.08,0.81) | |
| HD GOLI SC + MTX | HD TOFA PO + MTX | 0.54(‐0.05,1.14) |
| Random‐effects model | Total residual deviance | 99.73 |
| Deviance information criteria | ‐252.066 | |
| Fixed‐effect model | Total residual deviance | 322.3 |
| Deviance information criteria | ‐52.613 | |
| Note | ||
| Total participants | 14,018 | |
| Total studies | 39 | |
| 2‐arm | 22 | |
| 3‐arm | 11 | |
| 4‐arm | 6 | |
Appendix 9. HAQ: subgroup ‐ late RA (> 10 years)
| HAQ late: mean difference (MD) for all treatment comparisons ‐ random‐effects model | ||
| Treatment | Reference | MD (95% CrI) |
| SD RITUX IV | MTX + PL | ‐0.44(‐0.70,‐0.18) |
| SD RITUX IV + MTX | ‐0.30(‐0.45,‐0.11) | |
| SD ADA SC + MTX | ‐0.33(‐0.49,‐0.17) | |
| SD TOCI IV + MTX | ‐0.26(‐0.48,‐0.04) | |
| LD ADA SC + MTX | ‐0.31(‐0.46,‐0.15) | |
| LD RITUX IV + MTX | ‐0.25(‐0.42,‐0.07) | |
| LD ADA IV + MTX | ‐0.32(‐0.67,0.03) | |
| HD TOCI IV + MTX | ‐0.34(‐0.56,‐0.12) | |
| HD ADA SC + MTX | ‐0.33(‐0.55,‐0.11) | |
| SD RITUX IV + MTX | SD RITUX IV | 0.14(‐0.12,0.42) |
| SD ADA SC + MTX | 0.11(‐0.20,0.42) | |
| SD TOCI IV + MTX | 0.18(‐0.17,0.52) | |
| LD ADA SC + MTX | 0.13(‐0.17,0.44) | |
| LD RITUX IV + MTX | 0.19(‐0.08,0.47) | |
| LD ADA IV + MTX | 0.12(‐0.32,0.55) | |
| HD TOCI IV + MTX | 0.10(‐0.24,0.45) | |
| HD ADA SC + MTX | 0.11(‐0.24,0.47) | |
| SD ADA SC + MTX | SD RITUX IV + MTX | ‐0.04(‐0.28,0.19) |
| SD TOCI IV + MTX | 0.04(‐0.25,0.30) | |
| LD ADA SC + MTX | ‐0.02(‐0.24,0.21) | |
| LD RITUX IV + MTX | 0.05(‐0.14,0.22) | |
| LD ADA IV + MTX | ‐0.03(‐0.42,0.36) | |
| HD TOCI IV + MTX | ‐0.04(‐0.34,0.22) | |
| HD ADA SC + MTX | ‐0.04(‐0.33,0.24) | |
| SD TOCI IV + MTX | SD ADA SC + MTX | 0.07(‐0.20,0.35) |
| LD ADA SC + MTX | 0.02(‐0.13,0.19) | |
| LD RITUX IV + MTX | 0.08(‐0.15,0.33) | |
| LD ADA IV + MTX | 0.01(‐0.36,0.38) | |
| HD TOCI IV + MTX | ‐0.01(‐0.28,0.27) | |
| HD ADA SC + MTX | 0.00(‐0.23,0.23) | |
| LD ADA SC + MTX | SD TOCI IV + MTX | ‐0.05(‐0.31,0.23) |
| LD RITUX IV + MTX | 0.01(‐0.27,0.30) | |
| LD ADA IV + MTX | ‐0.06(‐0.48,0.35) | |
| HD TOCI IV + MTX | ‐0.08(‐0.30,0.14) | |
| HD ADA SC + MTX | ‐0.07(‐0.38,0.24) | |
| LD RITUX IV + MTX | LD ADA SC + MTX | 0.06(‐0.17,0.29) |
| LD ADA IV + MTX | ‐0.01(‐0.38,0.35) | |
| HD TOCI IV + MTX | ‐0.03(‐0.30,0.23) | |
| HD ADA SC + MTX | ‐0.02(‐0.25,0.20) | |
| LD ADA IV + MTX | LD RITUX IV + MTX | ‐0.07(‐0.47,0.31) |
| HD TOCI IV + MTX | ‐0.09(‐0.38,0.18) | |
| HD ADA SC + MTX | ‐0.08(‐0.37,0.20) | |
| HD TOCI IV + MTX | LD ADA IV + MTX | ‐0.02(‐0.42,0.40) |
| HD ADA SC + MTX | ‐0.01(‐0.41,0.40) | |
| HD ADA SC + MTX | HD TOCI IV + MTX | 0.01(‐0.31,0.32) |
| Random‐effects model | Total residual deviance | 19.24 vs 22 data point |
| Deviance information criteria | ‐35.801 | |
| Fixed‐effect model | Total residual deviance | 19.04 vs 22 data point |
| Deviance information criteria | ‐37.435 | |
| Note | ||
| Total participants | 2084 | |
| Total studies | 7 | |
| 2‐arm | 1 | |
| 3‐arm | 4 | |
| 4‐arm | 2 | |
Appendix 10. HAQ: subgroup ‐ trial duration (<= 6 months)
| HAQ short duration: mean difference (MD) for all treatment comparisons ‐ random‐effects model | ||
| Treatment | Reference | MD (95% CrI) |
| MTX + PL | PL | 1.08(0.60,1.58) |
| DMARD + PL | ‐0.01(‐0.30,0.29) | |
| MTX + DMARD | ‐0.15(‐0.56,0.25) | |
| SD ETN SC | ‐0.31(‐0.57,‐0.05) | |
| SD ADA SC + PL | ‐0.30(‐0.45,‐0.14) | |
| SD TOFA PO | ‐0.39(‐0.59,‐0.20) | |
| SD CERTO SC | ‐0.36(‐0.60,‐0.11) | |
| SD ANA | ‐0.20(‐0.49,0.09) | |
| SD RITUX IV | 0.65(0.08,1.23) | |
| SD ETN SC + MTX | ‐0.42(‐0.74,‐0.09) | |
| SD CERTO SC + MTX | 0.80(0.30,1.31) | |
| SD RITUX IV + MTX | 0.80(0.28,1.34) | |
| SD ADA SC + MTX | 0.77(0.24,1.31) | |
| SD GOLI SC + MTX | 1.08(0.56,1.62) | |
| SD TOFA PO + MTX | 0.65(0.10,1.22) | |
| SD TOCI IV + MTX | 0.88(0.37,1.41) | |
| SD ABA SC + MTX | 0.86(0.25,1.47) | |
| SD GOLI IV + MTX | 1.40(0.84,1.96) | |
| SD ETN SC + DMARD | ‐0.36(‐0.75,0.04) | |
| SD CERTO SC + DMARD | ‐0.35(‐0.61,‐0.09) | |
| LD ADA SC | ‐0.32(‐0.52,‐0.12) | |
| LD ANA | ‐0.20(‐0.48,0.08) | |
| LD ADA SC + MTX | 0.86(0.33,1.42) | |
| LD RITUX IV + MTX | 0.84(0.31,1.38) | |
| LD ADA IV + MTX | 0.80(0.19,1.42) | |
| LD CERTO SC + MTX | 0.89(0.33,1.46) | |
| LD TOFA PO + MTX | 0.73(0.18,1.29) | |
| HD TOFA PO | ‐0.51(‐0.70,‐0.32) | |
| HD ADA SC | ‐0.44(‐0.64,‐0.23) | |
| HD TOCI IV | 0.88(0.33,1.45) | |
| HD ANA | ‐0.30(‐0.59,0.00) | |
| HD GOLI SC | 1.12(0.58,1.68) | |
| HD TOCI IV + MTX | 0.77(0.27,1.29) | |
| HD CERTO SC + MTX | 0.76(0.26,1.28) | |
| HD TOFA PO + MTX | 0.57(0.02,1.14) | |
| HD GOLI SC + MTX | 1.11(0.59,1.65) | |
| HD ADA SC + MTX | 0.79(0.23,1.37) | |
| DMARD + PL | MTX + PL | ‐1.09(‐1.56,‐0.63) |
| MTX + DMARD | ‐1.24(‐1.66,‐0.82) | |
| SD ETN SC | ‐1.39(‐1.79,‐1.01) | |
| SD ADA SC + PL | ‐1.38(‐1.89,‐0.88) | |
| SD TOFA PO | ‐1.48(‐2.01,‐0.96) | |
| SD CERTO SC | ‐1.45(‐1.99,‐0.91) | |
| SD ANA | ‐1.28(‐1.85,‐0.73) | |
| SD RITUX IV | ‐0.44(‐0.76,‐0.11) | |
| SD ETN SC + MTX | ‐1.50(‐1.84,‐1.17) | |
| SD CERTO SC + MTX | ‐0.28(‐0.41,‐0.16) | |
| SD RITUX IV + MTX | ‐0.28(‐0.50,‐0.06) | |
| SD ADA SC + MTX | ‐0.31(‐0.54,‐0.09) | |
| SD GOLI SC + MTX | 0.00(‐0.21,0.20) | |
| SD TOFA PO + MTX | ‐0.44(‐0.70,‐0.17) | |
| SD TOCI IV + MTX | ‐0.20(‐0.39,‐0.01) | |
| SD ABA SC + MTX | ‐0.22(‐0.59,0.15) | |
| SD GOLI IV + MTX | 0.31(0.03,0.59) | |
| SD ETN SC + DMARD | ‐1.44(‐1.97,‐0.91) | |
| SD CERTO SC + DMARD | ‐1.43(‐1.94,‐0.94) | |
| LD ADA SC | ‐1.41(‐1.93,‐0.89) | |
| LD ANA | ‐1.28(‐1.84,‐0.73) | |
| LD ADA SC + MTX | ‐0.22(‐0.49,0.04) | |
| LD RITUX IV + MTX | ‐0.24(‐0.47,‐0.01) | |
| LD ADA IV + MTX | ‐0.29(‐0.69,0.11) | |
| LD CERTO SC + MTX | ‐0.20(‐0.49,0.09) | |
| LD TOFA PO + MTX | ‐0.36(‐0.62,‐0.09) | |
| HD TOFA PO | ‐1.59(‐2.12,‐1.08) | |
| HD ADA SC | ‐1.52(‐2.05,‐1.00) | |
| HD TOCI IV | ‐0.20(‐0.48,0.09) | |
| HD ANA | ‐1.38(‐1.95,‐0.82) | |
| HD GOLI SC | 0.04(‐0.23,0.30) | |
| HD TOCI IV + MTX | ‐0.31(‐0.47,‐0.14) | |
| HD CERTO SC + MTX | ‐0.32(‐0.48,‐0.17) | |
| HD TOFA PO + MTX | ‐0.52(‐0.78,‐0.25) | |
| HD GOLI SC + MTX | 0.03(‐0.18,0.23) | |
| HD ADA SC + MTX | ‐0.29(‐0.59,0.00) | |
| MTX + DMARD | DMARD + PL | ‐0.15(‐0.53,0.24) |
| SD ETN SC | ‐0.30(‐0.54,‐0.06) | |
| SD ADA SC + PL | ‐0.29(‐0.62,0.05) | |
| SD TOFA PO | ‐0.39(‐0.74,‐0.04) | |
| SD CERTO SC | ‐0.36(‐0.73,0.03) | |
| SD ANA | ‐0.19(‐0.60,0.23) | |
| SD RITUX IV | 0.65(0.09,1.23) | |
| SD ETN SC + MTX | ‐0.41(‐0.71,‐0.11) | |
| SD CERTO SC + MTX | 0.81(0.34,1.30) | |
| SD RITUX IV + MTX | 0.81(0.30,1.34) | |
| SD ADA SC + MTX | 0.78(0.26,1.30) | |
| SD GOLI SC + MTX | 1.09(0.59,1.60) | |
| SD TOFA PO + MTX | 0.65(0.13,1.21) | |
| SD TOCI IV + MTX | 0.89(0.40,1.40) | |
| SD ABA SC + MTX | 0.87(0.28,1.46) | |
| SD GOLI IV + MTX | 1.40(0.87,1.95) | |
| SD ETN SC + DMARD | ‐0.35(‐0.61,‐0.08) | |
| SD CERTO SC + DMARD | ‐0.34(‐0.60,‐0.09) | |
| LD ADA SC | ‐0.32(‐0.67,0.04) | |
| LD ANA | ‐0.19(‐0.60,0.22) | |
| LD ADA SC + MTX | 0.87(0.34,1.41) | |
| LD RITUX IV + MTX | 0.85(0.34,1.38) | |
| LD ADA IV + MTX | 0.80(0.21,1.42) | |
| LD CERTO SC + MTX | 0.89(0.35,1.45) | |
| LD TOFA PO + MTX | 0.73(0.20,1.28) | |
| HD TOFA PO | ‐0.50(‐0.85,‐0.15) | |
| HD ADA SC | ‐0.43(‐0.78,‐0.07) | |
| HD TOCI IV | 0.89(0.36,1.44) | |
| HD ANA | ‐0.29(‐0.71,0.13) | |
| HD GOLI SC | 1.13(0.60,1.67) | |
| HD TOCI IV + MTX | 0.78(0.29,1.28) | |
| HD CERTO SC + MTX | 0.77(0.28,1.27) | |
| HD TOFA PO + MTX | 0.57(0.05,1.12) | |
| HD GOLI SC + MTX | 1.12(0.62,1.63) | |
| HD ADA SC + MTX | 0.80(0.25,1.36) | |
| SD ETN SC | MTX + DMARD | ‐0.16(‐0.46,0.14) |
| SD ADA SC + PL | ‐0.14(‐0.58,0.29) | |
| SD TOFA PO | ‐0.24(‐0.69,0.20) | |
| SD CERTO SC | ‐0.21(‐0.68,0.26) | |
| SD ANA | ‐0.04(‐0.55,0.45) | |
| SD RITUX IV | 0.80(0.27,1.33) | |
| SD ETN SC + MTX | ‐0.27(‐0.51,‐0.03) | |
| SD CERTO SC + MTX | 0.95(0.52,1.39) | |
| SD RITUX IV + MTX | 0.96(0.49,1.43) | |
| SD ADA SC + MTX | 0.92(0.44,1.40) | |
| SD GOLI SC + MTX | 1.23(0.77,1.70) | |
| SD TOFA PO + MTX | 0.80(0.31,1.30) | |
| SD TOCI IV + MTX | 1.04(0.58,1.50) | |
| SD ABA SC + MTX | 1.02(0.46,1.57) | |
| SD GOLI IV + MTX | 1.55(1.05,2.05) | |
| SD ETN SC + DMARD | ‐0.20(‐0.67,0.26) | |
| SD CERTO SC + DMARD | ‐0.20(‐0.62,0.22) | |
| LD ADA SC | ‐0.17(‐0.62,0.28) | |
| LD ANA | ‐0.04(‐0.54,0.44) | |
| LD ADA SC + MTX | 1.02(0.52,1.51) | |
| LD RITUX IV + MTX | 1.00(0.52,1.47) | |
| LD ADA IV + MTX | 0.95(0.38,1.52) | |
| LD CERTO SC + MTX | 1.04(0.53,1.55) | |
| LD TOFA PO + MTX | 0.88(0.38,1.38) | |
| HD TOFA PO | ‐0.35(‐0.80,0.09) | |
| HD ADA SC | ‐0.28(‐0.73,0.17) | |
| HD TOCI IV | 1.04(0.54,1.54) | |
| HD ANA | ‐0.14(‐0.65,0.35) | |
| HD GOLI SC | 1.27(0.78,1.77) | |
| HD TOCI IV + MTX | 0.93(0.48,1.38) | |
| HD CERTO SC + MTX | 0.91(0.47,1.36) | |
| HD TOFA PO + MTX | 0.72(0.23,1.22) | |
| HD GOLI SC + MTX | 1.27(0.81,1.74) | |
| HD ADA SC + MTX | 0.95(0.43,1.46) | |
| SD ADA SC + PL | SD ETN SC | 0.01(‐0.29,0.31) |
| SD TOFA PO | ‐0.08(‐0.41,0.23) | |
| SD CERTO SC | ‐0.05(‐0.40,0.31) | |
| SD ANA | 0.11(‐0.28,0.50) | |
| SD RITUX IV | 0.96(0.45,1.47) | |
| SD ETN SC + MTX | ‐0.11(‐0.30,0.08) | |
| SD CERTO SC + MTX | 1.11(0.70,1.53) | |
| SD RITUX IV + MTX | 1.11(0.67,1.57) | |
| SD ADA SC + MTX | 1.08(0.62,1.53) | |
| SD GOLI SC + MTX | 1.39(0.95,1.84) | |
| SD TOFA PO + MTX | 0.96(0.49,1.44) | |
| SD TOCI IV + MTX | 1.19(0.76,1.63) | |
| SD ABA SC + MTX | 1.17(0.63,1.71) | |
| SD GOLI IV + MTX | 1.70(1.22,2.19) | |
| SD ETN SC + DMARD | ‐0.05(‐0.40,0.31) | |
| SD CERTO SC + DMARD | ‐0.04(‐0.33,0.25) | |
| LD ADA SC | ‐0.01(‐0.34,0.31) | |
| LD ANA | 0.11(‐0.27,0.49) | |
| LD ADA SC + MTX | 1.17(0.70,1.65) | |
| LD RITUX IV + MTX | 1.15(0.70,1.61) | |
| LD ADA IV + MTX | 1.11(0.56,1.66) | |
| LD CERTO SC + MTX | 1.20(0.71,1.69) | |
| LD TOFA PO + MTX | 1.04(0.56,1.52) | |
| HD TOFA PO | ‐0.20(‐0.52,0.12) | |
| HD ADA SC | ‐0.13(‐0.46,0.20) | |
| HD TOCI IV | 1.19(0.71,1.68) | |
| HD ANA | 0.01(‐0.38,0.40) | |
| HD GOLI SC | 1.43(0.96,1.91) | |
| HD TOCI IV + MTX | 1.08(0.66,1.51) | |
| HD CERTO SC + MTX | 1.07(0.65,1.50) | |
| HD TOFA PO + MTX | 0.88(0.41,1.36) | |
| HD GOLI SC + MTX | 1.42(0.98,1.87) | |
| HD ADA SC + MTX | 1.10(0.61,1.60) | |
| SD TOFA PO | SD ADA SC + PL | ‐0.10(‐0.33,0.13) |
| SD CERTO SC | ‐0.07(‐0.36,0.23) | |
| SD ANA | 0.10(‐0.24,0.43) | |
| SD RITUX IV | 0.94(0.35,1.55) | |
| SD ETN SC + MTX | ‐0.12(‐0.48,0.24) | |
| SD CERTO SC + MTX | 1.10(0.58,1.62) | |
| SD RITUX IV + MTX | 1.10(0.55,1.66) | |
| SD ADA SC + MTX | 1.07(0.51,1.63) | |
| SD GOLI SC + MTX | 1.38(0.83,1.93) | |
| SD TOFA PO + MTX | 0.94(0.37,1.54) | |
| SD TOCI IV + MTX | 1.18(0.65,1.73) | |
| SD ABA SC + MTX | 1.16(0.53,1.79) | |
| SD GOLI IV + MTX | 1.69(1.11,2.28) | |
| SD ETN SC + DMARD | ‐0.06(‐0.48,0.37) | |
| SD CERTO SC + DMARD | ‐0.05(‐0.36,0.25) | |
| LD ADA SC | ‐0.03(‐0.23,0.17) | |
| LD ANA | 0.10(‐0.22,0.42) | |
| LD ADA SC + MTX | 1.16(0.60,1.74) | |
| LD RITUX IV + MTX | 1.14(0.59,1.70) | |
| LD ADA IV + MTX | 1.09(0.47,1.74) | |
| LD CERTO SC + MTX | 1.18(0.60,1.78) | |
| LD TOFA PO + MTX | 1.02(0.45,1.61) | |
| HD TOFA PO | ‐0.21(‐0.44,0.01) | |
| HD ADA SC | ‐0.14(‐0.34,0.06) | |
| HD TOCI IV | 1.18(0.61,1.77) | |
| HD ANA | 0.00(‐0.34,0.34) | |
| HD GOLI SC | 1.42(0.86,2.00) | |
| HD TOCI IV + MTX | 1.07(0.54,1.61) | |
| HD CERTO SC + MTX | 1.06(0.53,1.60) | |
| HD TOFA PO + MTX | 0.86(0.30,1.46) | |
| HD GOLI SC + MTX | 1.41(0.87,1.96) | |
| HD ADA SC + MTX | 1.09(0.51,1.68) | |
| SD CERTO SC | SD TOFA PO | 0.03(‐0.28,0.35) |
| SD ANA | 0.19(‐0.16,0.55) | |
| SD RITUX IV | 1.04(0.43,1.66) | |
| SD ETN SC + MTX | ‐0.03(‐0.40,0.36) | |
| SD CERTO SC + MTX | 1.19(0.66,1.74) | |
| SD RITUX IV + MTX | 1.20(0.64,1.77) | |
| SD ADA SC + MTX | 1.16(0.60,1.74) | |
| SD GOLI SC + MTX | 1.47(0.92,2.05) | |
| SD TOFA PO + MTX | 1.04(0.47,1.65) | |
| SD TOCI IV + MTX | 1.27(0.73,1.84) | |
| SD ABA SC + MTX | 1.26(0.62,1.90) | |
| SD GOLI IV + MTX | 1.79(1.20,2.39) | |
| SD ETN SC + DMARD | 0.04(‐0.39,0.48) | |
| SD CERTO SC + DMARD | 0.04(‐0.28,0.37) | |
| LD ADA SC | 0.07(‐0.19,0.34) | |
| LD ANA | 0.19(‐0.14,0.54) | |
| LD ADA SC + MTX | 1.26(0.69,1.85) | |
| LD RITUX IV + MTX | 1.24(0.68,1.81) | |
| LD ADA IV + MTX | 1.19(0.55,1.85) | |
| LD CERTO SC + MTX | 1.28(0.69,1.89) | |
| LD TOFA PO + MTX | 1.12(0.54,1.72) | |
| HD TOFA PO | ‐0.11(‐0.30,0.07) | |
| HD ADA SC | ‐0.04(‐0.31,0.23) | |
| HD TOCI IV | 1.28(0.69,1.88) | |
| HD ANA | 0.10(‐0.26,0.46) | |
| HD GOLI SC | 1.51(0.95,2.11) | |
| HD TOCI IV + MTX | 1.17(0.63,1.73) | |
| HD CERTO SC + MTX | 1.15(0.62,1.71) | |
| HD TOFA PO + MTX | 0.96(0.39,1.57) | |
| HD GOLI SC + MTX | 1.50(0.96,2.08) | |
| HD ADA SC + MTX | 1.18(0.60,1.79) | |
| SD ANA | SD CERTO SC | 0.16(‐0.23,0.54) |
| SD RITUX IV | 1.01(0.38,1.64) | |
| SD ETN SC + MTX | ‐0.06(‐0.47,0.35) | |
| SD CERTO SC + MTX | 1.16(0.61,1.72) | |
| SD RITUX IV + MTX | 1.17(0.58,1.75) | |
| SD ADA SC + MTX | 1.13(0.55,1.71) | |
| SD GOLI SC + MTX | 1.44(0.86,2.02) | |
| SD TOFA PO + MTX | 1.01(0.41,1.62) | |
| SD TOCI IV + MTX | 1.25(0.68,1.82) | |
| SD ABA SC + MTX | 1.23(0.57,1.88) | |
| SD GOLI IV + MTX | 1.76(1.15,2.37) | |
| SD ETN SC + DMARD | 0.01(‐0.46,0.47) | |
| SD CERTO SC + DMARD | 0.01(‐0.35,0.37) | |
| LD ADA SC | 0.04(‐0.28,0.35) | |
| LD ANA | 0.16(‐0.22,0.53) | |
| LD ADA SC + MTX | 1.23(0.63,1.83) | |
| LD RITUX IV + MTX | 1.21(0.62,1.79) | |
| LD ADA IV + MTX | 1.16(0.49,1.83) | |
| LD CERTO SC + MTX | 1.25(0.63,1.87) | |
| LD TOFA PO + MTX | 1.09(0.49,1.70) | |
| HD TOFA PO | ‐0.14(‐0.46,0.17) | |
| HD ADA SC | ‐0.07(‐0.39,0.24) | |
| HD TOCI IV | 1.25(0.64,1.86) | |
| HD ANA | 0.07(‐0.32,0.44) | |
| HD GOLI SC | 1.48(0.89,2.08) | |
| HD TOCI IV + MTX | 1.14(0.57,1.70) | |
| HD CERTO SC + MTX | 1.12(0.56,1.69) | |
| HD TOFA PO + MTX | 0.93(0.33,1.54) | |
| HD GOLI SC + MTX | 1.48(0.90,2.06) | |
| HD ADA SC + MTX | 1.16(0.54,1.77) | |
| SD RITUX IV | SD ANA | 0.85(0.20,1.50) |
| SD ETN SC + MTX | ‐0.22(‐0.66,0.22) | |
| SD CERTO SC + MTX | 1.00(0.43,1.58) | |
| SD RITUX IV + MTX | 1.00(0.40,1.61) | |
| SD ADA SC + MTX | 0.97(0.37,1.59) | |
| SD GOLI SC + MTX | 1.28(0.68,1.89) | |
| SD TOFA PO + MTX | 0.85(0.23,1.48) | |
| SD TOCI IV + MTX | 1.08(0.50,1.68) | |
| SD ABA SC + MTX | 1.06(0.39,1.74) | |
| SD GOLI IV + MTX | 1.59(0.97,2.23) | |
| SD ETN SC + DMARD | ‐0.16(‐0.65,0.34) | |
| SD CERTO SC + DMARD | ‐0.15(‐0.55,0.24) | |
| LD ADA SC | ‐0.12(‐0.48,0.23) | |
| LD ANA | 0.00(‐0.29,0.29) | |
| LD ADA SC + MTX | 1.06(0.45,1.69) | |
| LD RITUX IV + MTX | 1.04(0.44,1.65) | |
| LD ADA IV + MTX | 1.00(0.32,1.69) | |
| LD CERTO SC + MTX | 1.09(0.45,1.72) | |
| LD TOFA PO + MTX | 0.93(0.31,1.56) | |
| HD TOFA PO | ‐0.31(‐0.66,0.04) | |
| HD ADA SC | ‐0.24(‐0.59,0.12) | |
| HD TOCI IV | 1.08(0.46,1.72) | |
| HD ANA | ‐0.10(‐0.40,0.20) | |
| HD GOLI SC | 1.32(0.71,1.95) | |
| HD TOCI IV + MTX | 0.97(0.40,1.57) | |
| HD CERTO SC + MTX | 0.96(0.38,1.55) | |
| HD TOFA PO + MTX | 0.77(0.15,1.41) | |
| HD GOLI SC + MTX | 1.31(0.71,1.92) | |
| HD ADA SC + MTX | 0.99(0.36,1.63) | |
| SD ETN SC + MTX | SD RITUX IV | ‐1.07(‐1.54,‐0.60) |
| SD CERTO SC + MTX | 0.15(‐0.20,0.51) | |
| SD RITUX IV + MTX | 0.16(‐0.17,0.49) | |
| SD ADA SC + MTX | 0.12(‐0.27,0.52) | |
| SD GOLI SC + MTX | 0.43(0.05,0.82) | |
| SD TOFA PO + MTX | 0.00(‐0.42,0.42) | |
| SD TOCI IV + MTX | 0.23(‐0.14,0.61) | |
| SD ABA SC + MTX | 0.22(‐0.27,0.71) | |
| SD GOLI IV + MTX | 0.75(0.32,1.18) | |
| SD ETN SC + DMARD | ‐1.00(‐1.63,‐0.37) | |
| SD CERTO SC + DMARD | ‐1.00(‐1.60,‐0.40) | |
| LD ADA SC | ‐0.97(‐1.59,‐0.36) | |
| LD ANA | ‐0.85(‐1.49,‐0.21) | |
| LD ADA SC + MTX | 0.22(‐0.20,0.63) | |
| LD RITUX IV + MTX | 0.20(‐0.14,0.53) | |
| LD ADA IV + MTX | 0.15(‐0.37,0.67) | |
| LD CERTO SC + MTX | 0.24(‐0.20,0.68) | |
| LD TOFA PO + MTX | 0.08(‐0.34,0.50) | |
| HD TOFA PO | ‐1.15(‐1.77,‐0.55) | |
| HD ADA SC | ‐1.08(‐1.70,‐0.48) | |
| HD TOCI IV | 0.24(‐0.19,0.67) | |
| HD ANA | ‐0.94(‐1.60,‐0.30) | |
| HD GOLI SC | 0.47(0.06,0.90) | |
| HD TOCI IV + MTX | 0.13(‐0.24,0.49) | |
| HD CERTO SC + MTX | 0.11(‐0.25,0.47) | |
| HD TOFA PO + MTX | ‐0.08(‐0.50,0.34) | |
| HD GOLI SC + MTX | 0.46(0.08,0.85) | |
| HD ADA SC + MTX | 0.14(‐0.30,0.58) | |
| SD CERTO SC + MTX | SD ETN SC + MTX | 1.22(0.86,1.58) |
| SD RITUX IV + MTX | 1.22(0.82,1.63) | |
| SD ADA SC + MTX | 1.19(0.78,1.60) | |
| SD GOLI SC + MTX | 1.50(1.11,1.90) | |
| SD TOFA PO + MTX | 1.07(0.64,1.51) | |
| SD TOCI IV + MTX | 1.30(0.92,1.69) | |
| SD ABA SC + MTX | 1.28(0.78,1.78) | |
| SD GOLI IV + MTX | 1.81(1.38,2.25) | |
| SD ETN SC + DMARD | 0.06(‐0.34,0.47) | |
| SD CERTO SC + DMARD | 0.07(‐0.28,0.42) | |
| LD ADA SC | 0.10(‐0.28,0.48) | |
| LD ANA | 0.22(‐0.21,0.65) | |
| LD ADA SC + MTX | 1.28(0.85,1.71) | |
| LD RITUX IV + MTX | 1.26(0.86,1.67) | |
| LD ADA IV + MTX | 1.22(0.70,1.74) | |
| LD CERTO SC + MTX | 1.31(0.86,1.76) | |
| LD TOFA PO + MTX | 1.15(0.72,1.58) | |
| HD TOFA PO | ‐0.09(‐0.47,0.29) | |
| HD ADA SC | ‐0.02(‐0.40,0.37) | |
| HD TOCI IV | 1.31(0.87,1.75) | |
| HD ANA | 0.12(‐0.32,0.56) | |
| HD GOLI SC | 1.54(1.12,1.98) | |
| HD TOCI IV + MTX | 1.19(0.82,1.57) | |
| HD CERTO SC + MTX | 1.18(0.81,1.55) | |
| HD TOFA PO + MTX | 0.99(0.56,1.42) | |
| HD GOLI SC + MTX | 1.53(1.14,1.93) | |
| HD ADA SC + MTX | 1.21(0.76,1.66) | |
| SD RITUX IV + MTX | SD CERTO SC + MTX | 0.00(‐0.25,0.26) |
| SD ADA SC + MTX | ‐0.03(‐0.29,0.23) | |
| SD GOLI SC + MTX | 0.28(0.03,0.52) | |
| SD TOFA PO + MTX | ‐0.15(‐0.45,0.15) | |
| SD TOCI IV + MTX | 0.08(‐0.15,0.31) | |
| SD ABA SC + MTX | 0.06(‐0.33,0.45) | |
| SD GOLI IV + MTX | 0.59(0.29,0.90) | |
| SD ETN SC + DMARD | ‐1.16(‐1.71,‐0.61) | |
| SD CERTO SC + DMARD | ‐1.15(‐1.67,‐0.64) | |
| LD ADA SC | ‐1.12(‐1.66,‐0.59) | |
| LD ANA | ‐1.00(‐1.58,‐0.43) | |
| LD ADA SC + MTX | 0.06(‐0.24,0.36) | |
| LD RITUX IV + MTX | 0.04(‐0.22,0.31) | |
| LD ADA IV + MTX | 0.00(‐0.42,0.42) | |
| LD CERTO SC + MTX | 0.09(‐0.21,0.38) | |
| LD TOFA PO + MTX | ‐0.07(‐0.37,0.22) | |
| HD TOFA PO | ‐1.31(‐1.85,‐0.77) | |
| HD ADA SC | ‐1.24(‐1.78,‐0.70) | |
| HD TOCI IV | 0.08(‐0.23,0.40) | |
| HD ANA | ‐1.10(‐1.68,‐0.52) | |
| HD GOLI SC | 0.32(0.03,0.62) | |
| HD TOCI IV + MTX | ‐0.03(‐0.23,0.19) | |
| HD CERTO SC + MTX | ‐0.04(‐0.19,0.11) | |
| HD TOFA PO + MTX | ‐0.23(‐0.53,0.07) | |
| HD GOLI SC + MTX | 0.31(0.07,0.56) | |
| HD ADA SC + MTX | ‐0.01(‐0.33,0.31) | |
| SD ADA SC + MTX | SD RITUX IV + MTX | ‐0.03(‐0.35,0.28) |
| SD GOLI SC + MTX | 0.28(‐0.03,0.58) | |
| SD TOFA PO + MTX | ‐0.16(‐0.50,0.19) | |
| SD TOCI IV + MTX | 0.08(‐0.21,0.37) | |
| SD ABA SC + MTX | 0.06(‐0.37,0.49) | |
| SD GOLI IV + MTX | 0.59(0.23,0.95) | |
| SD ETN SC + DMARD | ‐1.16(‐1.74,‐0.58) | |
| SD CERTO SC + DMARD | ‐1.15(‐1.71,‐0.61) | |
| LD ADA SC | ‐1.13(‐1.70,‐0.56) | |
| LD ANA | ‐1.00(‐1.60,‐0.41) | |
| LD ADA SC + MTX | 0.06(‐0.29,0.40) | |
| LD RITUX IV + MTX | 0.04(‐0.20,0.27) | |
| LD ADA IV + MTX | ‐0.01(‐0.46,0.45) | |
| LD CERTO SC + MTX | 0.08(‐0.29,0.45) | |
| LD TOFA PO + MTX | ‐0.08(‐0.42,0.27) | |
| HD TOFA PO | ‐1.31(‐1.89,‐0.75) | |
| HD ADA SC | ‐1.24(‐1.82,‐0.68) | |
| HD TOCI IV | 0.08(‐0.28,0.44) | |
| HD ANA | ‐1.10(‐1.71,‐0.50) | |
| HD GOLI SC | 0.32(‐0.03,0.66) | |
| HD TOCI IV + MTX | ‐0.03(‐0.31,0.25) | |
| HD CERTO SC + MTX | ‐0.04(‐0.32,0.23) | |
| HD TOFA PO + MTX | ‐0.24(‐0.58,0.11) | |
| HD GOLI SC + MTX | 0.31(0.00,0.61) | |
| HD ADA SC + MTX | ‐0.01(‐0.38,0.35) | |
| SD GOLI SC + MTX | SD ADA SC + MTX | 0.31(0.00,0.62) |
| SD TOFA PO + MTX | ‐0.12(‐0.47,0.23) | |
| SD TOCI IV + MTX | 0.11(‐0.18,0.41) | |
| SD ABA SC + MTX | 0.09(‐0.34,0.53) | |
| SD GOLI IV + MTX | 0.62(0.26,0.98) | |
| SD ETN SC + DMARD | ‐1.13(‐1.71,‐0.55) | |
| SD CERTO SC + DMARD | ‐1.12(‐1.67,‐0.57) | |
| LD ADA SC | ‐1.09(‐1.67,‐0.53) | |
| LD ANA | ‐0.97(‐1.58,‐0.37) | |
| LD ADA SC + MTX | 0.09(‐0.20,0.38) | |
| LD RITUX IV + MTX | 0.07(‐0.25,0.39) | |
| LD ADA IV + MTX | 0.03(‐0.42,0.47) | |
| LD CERTO SC + MTX | 0.12(‐0.25,0.48) | |
| LD TOFA PO + MTX | ‐0.04(‐0.40,0.31) | |
| HD TOFA PO | ‐1.28(‐1.86,‐0.72) | |
| HD ADA SC | ‐1.21(‐1.78,‐0.64) | |
| HD TOCI IV | 0.11(‐0.25,0.48) | |
| HD ANA | ‐1.07(‐1.68,‐0.46) | |
| HD GOLI SC | 0.35(0.00,0.70) | |
| HD TOCI IV + MTX | 0.00(‐0.28,0.29) | |
| HD CERTO SC + MTX | ‐0.01(‐0.29,0.26) | |
| HD TOFA PO + MTX | ‐0.20(‐0.55,0.15) | |
| HD GOLI SC + MTX | 0.34(0.03,0.65) | |
| HD ADA SC + MTX | 0.02(‐0.28,0.32) | |
| SD TOFA PO + MTX | SD GOLI SC + MTX | ‐0.43(‐0.77,‐0.09) |
| SD TOCI IV + MTX | ‐0.20(‐0.48,0.08) | |
| SD ABA SC + MTX | ‐0.22(‐0.64,0.21) | |
| SD GOLI IV + MTX | 0.32(‐0.03,0.66) | |
| SD ETN SC + DMARD | ‐1.43(‐2.01,‐0.87) | |
| SD CERTO SC + DMARD | ‐1.43(‐1.98,‐0.89) | |
| LD ADA SC | ‐1.40(‐1.97,‐0.85) | |
| LD ANA | ‐1.28(‐1.88,‐0.69) | |
| LD ADA SC + MTX | ‐0.22(‐0.56,0.12) | |
| LD RITUX IV + MTX | ‐0.24(‐0.55,0.07) | |
| LD ADA IV + MTX | ‐0.28(‐0.73,0.17) | |
| LD CERTO SC + MTX | ‐0.19(‐0.55,0.16) | |
| LD TOFA PO + MTX | ‐0.35(‐0.69,‐0.01) | |
| HD TOFA PO | ‐1.58(‐2.16,‐1.03) | |
| HD ADA SC | ‐1.52(‐2.09,‐0.96) | |
| HD TOCI IV | ‐0.19(‐0.55,0.16) | |
| HD ANA | ‐1.38(‐1.99,‐0.78) | |
| HD GOLI SC | 0.04(‐0.23,0.32) | |
| HD TOCI IV + MTX | ‐0.31(‐0.57,‐0.04) | |
| HD CERTO SC + MTX | ‐0.32(‐0.58,‐0.06) | |
| HD TOFA PO + MTX | ‐0.51(‐0.85,‐0.17) | |
| HD GOLI SC + MTX | 0.03(‐0.18,0.25) | |
| HD ADA SC + MTX | ‐0.29(‐0.65,0.07) | |
| SD TOCI IV + MTX | SD TOFA PO + MTX | 0.23(‐0.09,0.56) |
| SD ABA SC + MTX | 0.22(‐0.24,0.67) | |
| SD GOLI IV + MTX | 0.75(0.36,1.13) | |
| SD ETN SC + DMARD | ‐1.00(‐1.61,‐0.41) | |
| SD CERTO SC + DMARD | ‐1.00(‐1.58,‐0.44) | |
| LD ADA SC | ‐0.97(‐1.57,‐0.39) | |
| LD ANA | ‐0.85(‐1.48,‐0.24) | |
| LD ADA SC + MTX | 0.22(‐0.16,0.58) | |
| LD RITUX IV + MTX | 0.20(‐0.16,0.55) | |
| LD ADA IV + MTX | 0.15(‐0.33,0.63) | |
| LD CERTO SC + MTX | 0.24(‐0.15,0.63) | |
| LD TOFA PO + MTX | 0.08(‐0.19,0.34) | |
| HD TOFA PO | ‐1.15(‐1.76,‐0.58) | |
| HD ADA SC | ‐1.08(‐1.69,‐0.50) | |
| HD TOCI IV | 0.24(‐0.15,0.62) | |
| HD ANA | ‐0.94(‐1.59,‐0.33) | |
| HD GOLI SC | 0.47(0.10,0.85) | |
| HD TOCI IV + MTX | 0.13(‐0.19,0.44) | |
| HD CERTO SC + MTX | 0.11(‐0.20,0.42) | |
| HD TOFA PO + MTX | ‐0.08(‐0.34,0.19) | |
| HD GOLI SC + MTX | 0.46(0.12,0.80) | |
| HD ADA SC + MTX | 0.14(‐0.25,0.54) | |
| SD ABA SC + MTX | SD TOCI IV + MTX | ‐0.02(‐0.44,0.39) |
| SD GOLI IV + MTX | 0.51(0.17,0.85) | |
| SD ETN SC + DMARD | ‐1.24(‐1.81,‐0.68) | |
| SD CERTO SC + DMARD | ‐1.23(‐1.78,‐0.71) | |
| LD ADA SC | ‐1.20(‐1.76,‐0.66) | |
| LD ANA | ‐1.08(‐1.67,‐0.50) | |
| LD ADA SC + MTX | ‐0.02(‐0.35,0.30) | |
| LD RITUX IV + MTX | ‐0.04(‐0.34,0.26) | |
| LD ADA IV + MTX | ‐0.09(‐0.53,0.36) | |
| LD CERTO SC + MTX | 0.00(‐0.34,0.35) | |
| LD TOFA PO + MTX | ‐0.16(‐0.48,0.17) | |
| HD TOFA PO | ‐1.39(‐1.95,‐0.84) | |
| HD ADA SC | ‐1.32(‐1.88,‐0.77) | |
| HD TOCI IV | 0.00(‐0.34,0.34) | |
| HD ANA | ‐1.18(‐1.78,‐0.59) | |
| HD GOLI SC | 0.24(‐0.09,0.57) | |
| HD TOCI IV + MTX | ‐0.11(‐0.30,0.08) | |
| HD CERTO SC + MTX | ‐0.12(‐0.37,0.12) | |
| HD TOFA PO + MTX | ‐0.31(‐0.64,0.01) | |
| HD GOLI SC + MTX | 0.23(‐0.05,0.51) | |
| HD ADA SC + MTX | ‐0.09(‐0.44,0.25) | |
| SD GOLI IV + MTX | SD ABA SC + MTX | 0.53(0.07,0.99) |
| SD ETN SC + DMARD | ‐1.22(‐1.86,‐0.57) | |
| SD CERTO SC + DMARD | ‐1.21(‐1.84,‐0.59) | |
| LD ADA SC | ‐1.18(‐1.82,‐0.54) | |
| LD ANA | ‐1.06(‐1.73,‐0.39) | |
| LD ADA SC + MTX | 0.00(‐0.46,0.46) | |
| LD RITUX IV + MTX | ‐0.02(‐0.45,0.42) | |
| LD ADA IV + MTX | ‐0.07(‐0.61,0.48) | |
| LD CERTO SC + MTX | 0.02(‐0.45,0.50) | |
| LD TOFA PO + MTX | ‐0.14(‐0.59,0.32) | |
| HD TOFA PO | ‐1.37(‐2.01,‐0.73) | |
| HD ADA SC | ‐1.30(‐1.94,‐0.66) | |
| HD TOCI IV | 0.02(‐0.44,0.49) | |
| HD ANA | ‐1.16(‐1.84,‐0.48) | |
| HD GOLI SC | 0.26(‐0.19,0.72) | |
| HD TOCI IV + MTX | ‐0.09(‐0.49,0.32) | |
| HD CERTO SC + MTX | ‐0.10(‐0.51,0.30) | |
| HD TOFA PO + MTX | ‐0.29(‐0.75,0.16) | |
| HD GOLI SC + MTX | 0.25(‐0.18,0.68) | |
| HD ADA SC + MTX | ‐0.07(‐0.54,0.40) | |
| SD ETN SC + DMARD | SD GOLI IV + MTX | ‐1.75(‐2.35,‐1.15) |
| SD CERTO SC + DMARD | ‐1.74(‐2.32,‐1.18) | |
| LD ADA SC | ‐1.72(‐2.31,‐1.13) | |
| LD ANA | ‐1.59(‐2.22,‐0.98) | |
| LD ADA SC + MTX | ‐0.53(‐0.92,‐0.14) | |
| LD RITUX IV + MTX | ‐0.55(‐0.91,‐0.19) | |
| LD ADA IV + MTX | ‐0.60(‐1.09,‐0.11) | |
| LD CERTO SC + MTX | ‐0.51(‐0.91,‐0.11) | |
| LD TOFA PO + MTX | ‐0.67(‐1.05,‐0.28) | |
| HD TOFA PO | ‐1.90(‐2.50,‐1.31) | |
| HD ADA SC | ‐1.83(‐2.43,‐1.24) | |
| HD TOCI IV | ‐0.51(‐0.91,‐0.11) | |
| HD ANA | ‐1.69(‐2.32,‐1.07) | |
| HD GOLI SC | ‐0.27(‐0.65,0.12) | |
| HD TOCI IV + MTX | ‐0.62(‐0.95,‐0.29) | |
| HD CERTO SC + MTX | ‐0.63(‐0.95,‐0.31) | |
| HD TOFA PO + MTX | ‐0.83(‐1.21,‐0.44) | |
| HD GOLI SC + MTX | ‐0.28(‐0.63,0.06) | |
| HD ADA SC + MTX | ‐0.60(‐1.01,‐0.20) | |
| SD CERTO SC + DMARD | SD ETN SC + DMARD | 0.01(‐0.36,0.37) |
| LD ADA SC | 0.03(‐0.41,0.47) | |
| LD ANA | 0.16(‐0.33,0.64) | |
| LD ADA SC + MTX | 1.22(0.63,1.82) | |
| LD RITUX IV + MTX | 1.20(0.62,1.78) | |
| LD ADA IV + MTX | 1.15(0.50,1.82) | |
| LD CERTO SC + MTX | 1.24(0.63,1.86) | |
| LD TOFA PO + MTX | 1.08(0.49,1.69) | |
| HD TOFA PO | ‐0.15(‐0.60,0.28) | |
| HD ADA SC | ‐0.08(‐0.53,0.36) | |
| HD TOCI IV | 1.24(0.64,1.84) | |
| HD ANA | 0.06(‐0.44,0.55) | |
| HD GOLI SC | 1.48(0.89,2.07) | |
| HD TOCI IV + MTX | 1.13(0.58,1.69) | |
| HD CERTO SC + MTX | 1.12(0.56,1.67) | |
| HD TOFA PO + MTX | 0.92(0.33,1.52) | |
| HD GOLI SC + MTX | 1.47(0.90,2.04) | |
| HD ADA SC + MTX | 1.15(0.54,1.76) | |
| LD ADA SC | SD CERTO SC + DMARD | 0.03(‐0.30,0.36) |
| LD ANA | 0.15(‐0.24,0.54) | |
| LD ADA SC + MTX | 1.21(0.65,1.79) | |
| LD RITUX IV + MTX | 1.19(0.65,1.75) | |
| LD ADA IV + MTX | 1.15(0.52,1.79) | |
| LD CERTO SC + MTX | 1.24(0.66,1.83) | |
| LD TOFA PO + MTX | 1.08(0.51,1.66) | |
| HD TOFA PO | ‐0.16(‐0.48,0.17) | |
| HD ADA SC | ‐0.09(‐0.42,0.25) | |
| HD TOCI IV | 1.23(0.67,1.82) | |
| HD ANA | 0.05(‐0.34,0.45) | |
| HD GOLI SC | 1.47(0.91,2.05) | |
| HD TOCI IV + MTX | 1.12(0.60,1.66) | |
| HD CERTO SC + MTX | 1.11(0.59,1.65) | |
| HD TOFA PO + MTX | 0.92(0.35,1.50) | |
| HD GOLI SC + MTX | 1.46(0.92,2.01) | |
| HD ADA SC + MTX | 1.14(0.57,1.73) | |
| LD ANA | LD ADA SC | 0.12(‐0.22,0.47) |
| LD ADA SC + MTX | 1.18(0.61,1.78) | |
| LD RITUX IV + MTX | 1.16(0.60,1.74) | |
| LD ADA IV + MTX | 1.12(0.48,1.78) | |
| LD CERTO SC + MTX | 1.21(0.61,1.82) | |
| LD TOFA PO + MTX | 1.05(0.47,1.65) | |
| HD TOFA PO | ‐0.18(‐0.45,0.08) | |
| HD ADA SC | ‐0.11(‐0.33,0.10) | |
| HD TOCI IV | 1.21(0.62,1.81) | |
| HD ANA | 0.02(‐0.33,0.38) | |
| HD GOLI SC | 1.44(0.87,2.04) | |
| HD TOCI IV + MTX | 1.10(0.56,1.65) | |
| HD CERTO SC + MTX | 1.08(0.55,1.63) | |
| HD TOFA PO + MTX | 0.89(0.31,1.49) | |
| HD GOLI SC + MTX | 1.43(0.88,2.00) | |
| HD ADA SC + MTX | 1.11(0.52,1.71) | |
| LD ADA SC + MTX | LD ANA | 1.06(0.46,1.68) |
| LD RITUX IV + MTX | 1.04(0.45,1.65) | |
| LD ADA IV + MTX | 1.00(0.32,1.69) | |
| LD CERTO SC + MTX | 1.09(0.45,1.72) | |
| LD TOFA PO + MTX | 0.93(0.31,1.56) | |
| HD TOFA PO | ‐0.31(‐0.65,0.03) | |
| HD ADA SC | ‐0.24(‐0.59,0.11) | |
| HD TOCI IV | 1.08(0.47,1.72) | |
| HD ANA | ‐0.10(‐0.40,0.20) | |
| HD GOLI SC | 1.32(0.71,1.94) | |
| HD TOCI IV + MTX | 0.97(0.40,1.56) | |
| HD CERTO SC + MTX | 0.96(0.39,1.54) | |
| HD TOFA PO + MTX | 0.77(0.15,1.40) | |
| HD GOLI SC + MTX | 1.31(0.72,1.92) | |
| HD ADA SC + MTX | 0.99(0.36,1.63) | |
| LD RITUX IV + MTX | LD ADA SC + MTX | ‐0.02(‐0.37,0.33) |
| LD ADA IV + MTX | ‐0.07(‐0.49,0.36) | |
| LD CERTO SC + MTX | 0.02(‐0.37,0.42) | |
| LD TOFA PO + MTX | ‐0.14(‐0.51,0.24) | |
| HD TOFA PO | ‐1.37(‐1.97,‐0.80) | |
| HD ADA SC | ‐1.30(‐1.90,‐0.73) | |
| HD TOCI IV | 0.02(‐0.36,0.41) | |
| HD ANA | ‐1.16(‐1.79,‐0.54) | |
| HD GOLI SC | 0.26(‐0.12,0.64) | |
| HD TOCI IV + MTX | ‐0.09(‐0.40,0.23) | |
| HD CERTO SC + MTX | ‐0.10(‐0.41,0.21) | |
| HD TOFA PO + MTX | ‐0.29(‐0.67,0.08) | |
| HD GOLI SC + MTX | 0.25(‐0.09,0.59) | |
| HD ADA SC + MTX | ‐0.07(‐0.38,0.24) | |
| LD ADA IV + MTX | LD RITUX IV + MTX | ‐0.05(‐0.50,0.42) |
| LD CERTO SC + MTX | 0.04(‐0.33,0.42) | |
| LD TOFA PO + MTX | ‐0.12(‐0.47,0.24) | |
| HD TOFA PO | ‐1.35(‐1.92,‐0.79) | |
| HD ADA SC | ‐1.28(‐1.86,‐0.72) | |
| HD TOCI IV | 0.04(‐0.32,0.41) | |
| HD ANA | ‐1.14(‐1.76,‐0.53) | |
| HD GOLI SC | 0.28(‐0.07,0.63) | |
| HD TOCI IV + MTX | ‐0.07(‐0.35,0.22) | |
| HD CERTO SC + MTX | ‐0.08(‐0.36,0.19) | |
| HD TOFA PO + MTX | ‐0.27(‐0.63,0.08) | |
| HD GOLI SC + MTX | 0.27(‐0.04,0.58) | |
| HD ADA SC + MTX | ‐0.05(‐0.42,0.32) | |
| LD CERTO SC + MTX | LD ADA IV + MTX | 0.09(‐0.41,0.58) |
| LD TOFA PO + MTX | ‐0.07(‐0.55,0.41) | |
| HD TOFA PO | ‐1.30(‐1.96,‐0.66) | |
| HD ADA SC | ‐1.23(‐1.90,‐0.59) | |
| HD TOCI IV | 0.09(‐0.40,0.57) | |
| HD ANA | ‐1.09(‐1.79,‐0.41) | |
| HD GOLI SC | 0.32(‐0.15,0.81) | |
| HD TOCI IV + MTX | ‐0.02(‐0.46,0.41) | |
| HD CERTO SC + MTX | ‐0.04(‐0.46,0.39) | |
| HD TOFA PO + MTX | ‐0.23(‐0.71,0.25) | |
| HD GOLI SC + MTX | 0.31(‐0.13,0.76) | |
| HD ADA SC + MTX | ‐0.01(‐0.47,0.47) | |
| LD TOFA PO + MTX | LD CERTO SC + MTX | ‐0.16(‐0.55,0.24) |
| HD TOFA PO | ‐1.39(‐2.00,‐0.80) | |
| HD ADA SC | ‐1.32(‐1.93,‐0.73) | |
| HD TOCI IV | 0.00(‐0.41,0.41) | |
| HD ANA | ‐1.18(‐1.83,‐0.54) | |
| HD GOLI SC | 0.23(‐0.16,0.63) | |
| HD TOCI IV + MTX | ‐0.11(‐0.44,0.23) | |
| HD CERTO SC + MTX | ‐0.13(‐0.42,0.17) | |
| HD TOFA PO + MTX | ‐0.32(‐0.71,0.08) | |
| HD GOLI SC + MTX | 0.23(‐0.13,0.58) | |
| HD ADA SC + MTX | ‐0.09(‐0.50,0.32) | |
| HD TOFA PO | LD TOFA PO + MTX | ‐1.23(‐1.83,‐0.65) |
| HD ADA SC | ‐1.16(‐1.76,‐0.58) | |
| HD TOCI IV | 0.16(‐0.23,0.54) | |
| HD ANA | ‐1.02(‐1.66,‐0.40) | |
| HD GOLI SC | 0.39(0.02,0.77) | |
| HD TOCI IV + MTX | 0.05(‐0.27,0.37) | |
| HD CERTO SC + MTX | 0.03(‐0.28,0.34) | |
| HD TOFA PO + MTX | ‐0.16(‐0.42,0.11) | |
| HD GOLI SC + MTX | 0.39(0.05,0.72) | |
| HD ADA SC + MTX | 0.07(‐0.33,0.46) | |
| HD ADA SC | HD TOFA PO | 0.07(‐0.20,0.34) |
| HD TOCI IV | 1.39(0.81,1.99) | |
| HD ANA | 0.21(‐0.14,0.57) | |
| HD GOLI SC | 1.63(1.06,2.22) | |
| HD TOCI IV + MTX | 1.28(0.74,1.84) | |
| HD CERTO SC + MTX | 1.27(0.73,1.82) | |
| HD TOFA PO + MTX | 1.07(0.50,1.68) | |
| HD GOLI SC + MTX | 1.62(1.07,2.19) | |
| HD ADA SC + MTX | 1.30(0.71,1.91) | |
| HD TOCI IV | HD ADA SC | 1.32(0.73,1.93) |
| HD ANA | 0.14(‐0.22,0.50) | |
| HD GOLI SC | 1.56(0.98,2.15) | |
| HD TOCI IV + MTX | 1.21(0.67,1.77) | |
| HD CERTO SC + MTX | 1.20(0.65,1.75) | |
| HD TOFA PO + MTX | 1.01(0.43,1.61) | |
| HD GOLI SC + MTX | 1.55(0.99,2.12) | |
| HD ADA SC + MTX | 1.23(0.64,1.83) | |
| HD ANA | HD TOCI IV | ‐1.18(‐1.82,‐0.56) |
| HD GOLI SC | 0.24(‐0.15,0.63) | |
| HD TOCI IV + MTX | ‐0.11(‐0.44,0.22) | |
| HD CERTO SC + MTX | ‐0.12(‐0.45,0.20) | |
| HD TOFA PO + MTX | ‐0.32(‐0.71,0.07) | |
| HD GOLI SC + MTX | 0.23(‐0.12,0.58) | |
| HD ADA SC + MTX | ‐0.09(‐0.50,0.31) | |
| HD GOLI SC | HD ANA | 1.42(0.81,2.05) |
| HD TOCI IV + MTX | 1.07(0.49,1.67) | |
| HD CERTO SC + MTX | 1.06(0.48,1.65) | |
| HD TOFA PO + MTX | 0.87(0.24,1.50) | |
| HD GOLI SC + MTX | 1.41(0.81,2.02) | |
| HD ADA SC + MTX | 1.09(0.46,1.73) | |
| HD TOCI IV + MTX | HD GOLI SC | ‐0.35(‐0.66,‐0.03) |
| HD CERTO SC + MTX | ‐0.36(‐0.67,‐0.05) | |
| HD TOFA PO + MTX | ‐0.55(‐0.93,‐0.18) | |
| HD GOLI SC + MTX | ‐0.01(‐0.28,0.26) | |
| HD ADA SC + MTX | ‐0.33(‐0.72,0.07) | |
| HD CERTO SC + MTX | HD TOCI IV + MTX | ‐0.01(‐0.24,0.21) |
| HD TOFA PO + MTX | ‐0.21(‐0.52,0.11) | |
| HD GOLI SC + MTX | 0.34(0.07,0.60) | |
| HD ADA SC + MTX | 0.02(‐0.32,0.35) | |
| HD TOFA PO + MTX | HD CERTO SC + MTX | ‐0.19(‐0.50,0.12) |
| HD GOLI SC + MTX | 0.35(0.09,0.61) | |
| HD ADA SC + MTX | 0.03(‐0.30,0.37) | |
| HD GOLI SC + MTX | HD TOFA PO + MTX | 0.54(0.21,0.88) |
| HD ADA SC + MTX | 0.22(‐0.17,0.62) | |
| HD ADA SC + MTX | HD GOLI SC + MTX | ‐0.32(‐0.68,0.04) |
| Random‐effects model | Total residual deviance | 108.9 |
| Deviance information criteria | ‐253.47 | |
| Fixed‐Effect Model | Total residual deviance | 443.8 |
| Deviance information criteria | 188.147 | |
| Note | ||
| Total participants | 13,213 | |
| Total studies | 42 | |
| 2‐arm | 23 | |
| 3‐arm | 11 | |
| 4‐arm | 8 | |
Appendix 11. Remission: main analysis
| Remission combined: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX + DMARD | MTX + PL | 0.70(0.21,2.15) | 0.71(0.22,2.05) | ‐0.01(‐0.04,0.05) |
| PL | 0.98(0.11,8.09) | 0.98(0.11,6.26) | 0.00(‐0.04,0.22) | |
| SD ETN SC | 1.80(0.77,4.19) | 1.74(0.77,3.68) | 0.03(‐0.01,0.12) | |
| SD ADA SC | 1.19(0.19,7.38) | 1.18(0.20,5.85) | 0.01(‐0.04,0.20) | |
| SD GOLI IV | 1.45(0.42,4.98) | 1.42(0.44,4.26) | 0.02(‐0.03,0.14) | |
| SD GOLI SC | 3.40(0.34,33.10) | 3.07(0.35,14.16) | 0.09(‐0.03,0.55) | |
| SD ETN SC + MTX | 3.19(1.51,6.77) | 2.91(1.48,5.42) | 0.08(0.02,0.19) | |
| SD ABA IV + MTX | 4.86(2.53,9.91) | 4.15(2.36,7.26) | 0.14(0.06,0.26) | |
| SD ABA SC + MTX | 3.81(1.63,9.06) | 3.39(1.59,6.76) | 0.11(0.03,0.24) | |
| SD GOLI SC + MTX | 10.48(3.72,31.95) | 7.37(3.29,14.41) | 0.28(0.11,0.53) | |
| SD ADA SC + MTX | 4.68(1.54,16.01) | 4.02(1.50,9.94) | 0.13(0.02,0.37) | |
| SD INF IV + MTX | 3.97(1.79,9.33) | 3.51(1.73,6.90) | 0.11(0.03,0.25) | |
| SD RITUX IV + MTX | 2.26(0.90,5.87) | 2.14(0.90,4.87) | 0.05(0.00,0.17) | |
| SD GOLI IV + MTX | 3.75(1.42,10.74) | 3.34(1.39,7.59) | 0.10(0.02,0.28) | |
| SD CERTO + MTX | 3.18(1.25,8.54) | 2.90(1.24,6.48) | 0.08(0.01,0.23) | |
| SD TOFA PO + MTX | 4.43(0.95,27.56) | 3.84(0.96,13.18) | 0.13(0.00,0.50) | |
| LD GOLI IV | 2.24(0.69,7.63) | 2.13(0.70,5.97) | 0.05(‐0.01,0.21) | |
| LD RITUX IV + MTX | 1.50(0.58,3.98) | 1.47(0.59,3.53) | 0.02(‐0.02,0.11) | |
| LD ETN SC + MTX | 2.99(1.04,8.23) | 2.74(1.04,6.27) | 0.08(0.00,0.23) | |
| LD GOLI IV + MTX | 1.35(0.38,4.84) | 1.33(0.39,4.15) | 0.01(‐0.03,0.14) | |
| HD TOCI IV | 6.93(1.80,28.87) | 5.48(1.73,13.53) | 0.20(0.03,0.51) | |
| HD GOLI SC | 4.59(1.15,19.15) | 3.96(1.14,11.02) | 0.13(0.01,0.41) | |
| HD TOCI IV + MTX | 12.77(3.97,47.17) | 8.35(3.48,16.66) | 0.33(0.11,0.63) | |
| HD GOLI SC + MTX | 9.28(3.29,27.72) | 6.78(2.97,13.56) | 0.26(0.09,0.50) | |
| HD INF IV + MTX | 3.52(1.27,9.89) | 3.16(1.26,7.17) | 0.10(0.01,0.27) | |
| HD TOFA PO + MTX | 11.09(2.48,65.57) | 7.66(2.32,18.02) | 0.29(0.06,0.70) | |
| PL | MTX + DMARD | 1.39(0.12,16.02) | 1.37(0.13,12.69) | 0.01(‐0.06,0.23) |
| SD ETN SC | 2.59(0.92,7.87) | 2.46(0.93,7.20) | 0.04(0.00,0.12) | |
| SD ADA SC | 1.72(0.21,15.45) | 1.68(0.22,12.35) | 0.02(‐0.05,0.21) | |
| SD GOLI IV | 2.08(0.40,11.51) | 2.01(0.42,9.93) | 0.03(‐0.04,0.15) | |
| SD GOLI SC | 4.89(0.38,66.45) | 4.29(0.39,31.89) | 0.10(‐0.03,0.56) | |
| SD ETN SC + MTX | 4.59(1.94,11.53) | 4.10(1.82,10.14) | 0.09(0.04,0.18) | |
| SD ABA IV + MTX | 6.98(1.93,28.27) | 5.85(1.79,21.70) | 0.15(0.06,0.27) | |
| SD ABA SC + MTX | 5.43(1.36,24.12) | 4.74(1.33,18.88) | 0.12(0.02,0.26) | |
| SD GOLI SC + MTX | 15.18(3.36,75.90) | 10.34(2.82,39.73) | 0.29(0.11,0.54) | |
| SD ADA SC + MTX | 6.74(1.41,37.63) | 5.66(1.37,25.28) | 0.14(0.02,0.38) | |
| SD INF IV + MTX | 5.68(1.47,25.34) | 4.92(1.42,19.65) | 0.12(0.03,0.27) | |
| SD RITUX IV + MTX | 3.26(0.77,14.95) | 3.03(0.78,12.66) | 0.06(‐0.02,0.18) | |
| SD GOLI IV + MTX | 5.39(1.22,26.74) | 4.71(1.20,20.16) | 0.11(0.01,0.29) | |
| SD CERTO + MTX | 4.58(1.05,22.26) | 4.09(1.05,17.58) | 0.09(0.00,0.25) | |
| SD TOFA PO + MTX | 6.41(0.92,54.71) | 5.41(0.93,29.41) | 0.13(0.00,0.51) | |
| LD GOLI IV | 3.21(0.63,18.15) | 2.99(0.65,14.50) | 0.06(‐0.02,0.22) | |
| LD RITUX IV + MTX | 2.16(0.49,10.31) | 2.08(0.51,9.23) | 0.03(‐0.04,0.12) | |
| LD ETN SC + MTX | 4.26(1.13,17.46) | 3.83(1.12,14.05) | 0.09(0.01,0.23) | |
| LD GOLI IV + MTX | 1.94(0.36,11.09) | 1.88(0.38,9.70) | 0.03(‐0.04,0.15) | |
| HD TOCI IV | 9.98(1.77,63.04) | 7.64(1.67,33.66) | 0.21(0.04,0.52) | |
| HD GOLI SC | 6.58(1.13,43.05) | 5.55(1.12,27.21) | 0.14(0.01,0.42) | |
| HD TOCI IV + MTX | 18.27(3.69,107.80) | 11.57(3.07,46.42) | 0.34(0.12,0.64) | |
| HD GOLI SC + MTX | 13.37(2.93,69.16) | 9.54(2.54,37.77) | 0.27(0.10,0.51) | |
| HD INF IV + MTX | 5.02(1.13,25.11) | 4.43(1.12,18.99) | 0.11(0.01,0.28) | |
| HD TOFA PO + MTX | 16.14(2.38,133.20) | 10.64(2.17,46.84) | 0.30(0.06,0.71) | |
| SD ETN SC | PL | 1.86(0.19,18.82) | 1.79(0.23,16.93) | 0.03(‐0.19,0.13) |
| SD ADA SC | 1.22(0.07,22.02) | 1.21(0.09,18.28) | 0.01(‐0.21,0.20) | |
| SD GOLI IV | 1.48(0.13,18.96) | 1.45(0.16,16.73) | 0.02(‐0.20,0.15) | |
| SD GOLI SC | 3.51(0.84,16.83) | 3.00(0.85,11.73) | 0.08(‐0.01,0.43) | |
| SD ETN SC + MTX | 3.30(0.36,33.04) | 2.99(0.43,27.70) | 0.08(‐0.14,0.20) | |
| SD ABA IV + MTX | 5.01(0.56,49.45) | 4.24(0.64,39.07) | 0.13(‐0.09,0.27) | |
| SD ABA SC + MTX | 3.97(0.40,40.40) | 3.48(0.48,32.69) | 0.10(‐0.12,0.25) | |
| SD GOLI SC + MTX | 10.92(1.52,87.02) | 7.47(1.35,56.90) | 0.27(0.06,0.50) | |
| SD ADA SC + MTX | 4.95(0.45,57.22) | 4.16(0.52,41.03) | 0.13(‐0.11,0.37) | |
| SD INF IV + MTX | 4.14(0.44,42.18) | 3.62(0.51,33.82) | 0.10(‐0.11,0.26) | |
| SD RITUX IV + MTX | 2.34(0.23,25.19) | 2.20(0.28,21.68) | 0.05(‐0.17,0.17) | |
| SD GOLI IV + MTX | 3.84(0.39,43.24) | 3.39(0.45,34.05) | 0.10(‐0.12,0.28) | |
| SD CERTO + MTX | 3.27(0.32,37.80) | 2.95(0.38,30.52) | 0.08(‐0.14,0.24) | |
| SD TOFA PO + MTX | 4.66(0.34,72.48) | 3.94(0.40,43.94) | 0.12(‐0.12,0.49) | |
| LD GOLI IV | 2.30(0.21,29.17) | 2.16(0.25,24.49) | 0.04(‐0.17,0.21) | |
| LD RITUX IV + MTX | 1.56(0.15,16.84) | 1.52(0.19,15.35) | 0.02(‐0.20,0.12) | |
| LD ETN SC + MTX | 3.07(0.29,33.96) | 2.79(0.35,27.74) | 0.07(‐0.15,0.24) | |
| LD GOLI IV + MTX | 1.36(0.12,17.67) | 1.33(0.15,15.69) | 0.01(‐0.20,0.14) | |
| HD TOCI IV | 7.14(0.55,98.72) | 5.54(0.61,59.26) | 0.19(‐0.08,0.51) | |
| HD GOLI SC | 4.68(1.02,25.32) | 3.94(1.01,20.87) | 0.12(0.00,0.32) | |
| HD TOCI IV + MTX | 13.18(1.15,172.20) | 8.41(1.11,84.04) | 0.31(0.02,0.63) | |
| HD GOLI SC + MTX | 9.64(1.37,75.71) | 6.86(1.26,51.02) | 0.24(0.05,0.47) | |
| HD INF IV + MTX | 3.64(0.36,40.20) | 3.23(0.42,31.55) | 0.09(‐0.13,0.27) | |
| HD TOFA PO + MTX | 11.77(0.84,177.10) | 7.66(0.88,76.14) | 0.28(‐0.02,0.69) | |
| SD ADA SC | SD ETN SC | 0.66(0.09,4.94) | 0.68(0.10,4.05) | ‐0.02(‐0.12,0.17) |
| SD GOLI IV | 0.80(0.18,3.60) | 0.81(0.20,3.20) | ‐0.01(‐0.11,0.11) | |
| SD GOLI SC | 1.90(0.16,21.31) | 1.77(0.18,10.21) | 0.06(‐0.09,0.52) | |
| SD ETN SC + MTX | 1.78(0.99,3.19) | 1.67(0.99,2.87) | 0.05(0.00,0.12) | |
| SD ABA IV + MTX | 2.71(0.95,8.10) | 2.39(0.96,6.32) | 0.10(‐0.01,0.23) | |
| SD ABA SC + MTX | 2.11(0.66,7.05) | 1.94(0.69,5.63) | 0.07(‐0.04,0.22) | |
| SD GOLI SC + MTX | 5.87(1.55,23.32) | 4.22(1.44,11.94) | 0.25(0.05,0.50) | |
| SD ADA SC + MTX | 2.61(0.67,11.36) | 2.31(0.70,7.67) | 0.10(‐0.04,0.34) | |
| SD INF IV + MTX | 2.21(0.71,7.37) | 2.02(0.74,5.77) | 0.08(‐0.03,0.22) | |
| SD RITUX IV + MTX | 1.26(0.35,4.51) | 1.23(0.39,3.90) | 0.02(‐0.08,0.14) | |
| SD GOLI IV + MTX | 2.08(0.57,8.23) | 1.91(0.61,6.20) | 0.07(‐0.05,0.25) | |
| SD CERTO + MTX | 1.77(0.51,6.51) | 1.67(0.55,5.26) | 0.05(‐0.06,0.21) | |
| SD TOFA PO + MTX | 2.45(0.43,18.19) | 2.19(0.46,9.57) | 0.09(‐0.06,0.47) | |
| LD GOLI IV | 1.25(0.29,5.60) | 1.23(0.32,4.59) | 0.02(‐0.09,0.18) | |
| LD RITUX IV + MTX | 0.84(0.23,3.05) | 0.85(0.26,2.80) | ‐0.01(‐0.11,0.09) | |
| LD ETN SC + MTX | 1.66(0.52,5.22) | 1.57(0.55,4.27) | 0.04(‐0.05,0.19) | |
| LD GOLI IV + MTX | 0.75(0.16,3.46) | 0.76(0.18,3.07) | ‐0.02(‐0.11,0.11) | |
| HD TOCI IV | 3.87(0.80,19.79) | 3.14(0.82,10.47) | 0.16(‐0.02,0.48) | |
| HD GOLI SC | 2.55(0.51,13.26) | 2.26(0.55,8.27) | 0.10(‐0.06,0.38) | |
| HD TOCI IV + MTX | 7.08(1.71,33.40) | 4.75(1.56,13.93) | 0.29(0.06,0.60) | |
| HD GOLI SC + MTX | 5.19(1.38,20.64) | 3.89(1.32,11.33) | 0.22(0.04,0.47) | |
| HD INF IV + MTX | 1.95(0.53,7.41) | 1.81(0.56,5.71) | 0.06(‐0.05,0.24) | |
| HD TOFA PO + MTX | 6.18(1.09,43.57) | 4.34(1.08,14.33) | 0.26(0.01,0.66) | |
| SD GOLI IV | SD ADA SC | 1.21(0.13,10.80) | 1.20(0.16,9.59) | 0.01(‐0.19,0.14) |
| SD GOLI SC | 2.89(0.15,53.58) | 2.56(0.17,28.63) | 0.08(‐0.15,0.53) | |
| SD ETN SC + MTX | 2.67(0.37,19.12) | 2.45(0.43,15.83) | 0.07(‐0.13,0.20) | |
| SD ABA IV + MTX | 4.09(0.60,29.39) | 3.50(0.66,22.83) | 0.13(‐0.08,0.26) | |
| SD ABA SC + MTX | 3.18(0.43,24.47) | 2.84(0.49,19.34) | 0.09(‐0.11,0.24) | |
| SD GOLI SC + MTX | 8.85(1.06,76.90) | 6.18(1.04,42.23) | 0.26(0.01,0.53) | |
| SD ADA SC + MTX | 3.94(0.47,35.70) | 3.37(0.53,24.92) | 0.12(‐0.10,0.36) | |
| SD INF IV + MTX | 3.35(0.47,25.34) | 2.96(0.53,19.92) | 0.10(‐0.10,0.25) | |
| SD RITUX IV + MTX | 1.89(0.24,14.91) | 1.81(0.29,12.88) | 0.04(‐0.16,0.17) | |
| SD GOLI IV + MTX | 3.20(0.38,25.90) | 2.85(0.44,19.93) | 0.09(‐0.12,0.27) | |
| SD CERTO + MTX | 2.67(0.35,21.18) | 2.45(0.41,17.27) | 0.07(‐0.13,0.23) | |
| SD TOFA PO + MTX | 3.73(0.35,48.40) | 3.19(0.40,28.58) | 0.11(‐0.11,0.49) | |
| LD GOLI IV | 1.90(0.21,16.63) | 1.80(0.25,13.84) | 0.04(‐0.16,0.21) | |
| LD RITUX IV + MTX | 1.26(0.16,10.02) | 1.24(0.20,9.04) | 0.01(‐0.18,0.11) | |
| LD ETN SC + MTX | 2.50(0.30,20.34) | 2.30(0.36,16.43) | 0.06(‐0.14,0.23) | |
| LD GOLI IV + MTX | 1.13(0.12,10.41) | 1.12(0.15,9.19) | 0.01(‐0.19,0.14) | |
| HD TOCI IV | 5.81(1.78,19.48) | 4.50(1.54,15.03) | 0.18(0.05,0.40) | |
| HD GOLI SC | 3.86(0.38,38.51) | 3.30(0.44,25.76) | 0.11(‐0.11,0.40) | |
| HD TOCI IV + MTX | 10.69(2.61,48.07) | 6.85(1.93,30.17) | 0.30(0.12,0.54) | |
| HD GOLI SC + MTX | 7.83(0.97,65.92) | 5.66(0.98,38.74) | 0.24(‐0.01,0.49) | |
| HD INF IV + MTX | 2.95(0.37,24.65) | 2.66(0.43,19.04) | 0.08(‐0.12,0.27) | |
| HD TOFA PO + MTX | 9.32(0.87,117.10) | 6.23(0.90,46.60) | 0.27(‐0.02,0.69) | |
| SD GOLI SC | SD GOLI IV | 2.40(0.17,30.12) | 2.18(0.19,15.31) | 0.07(‐0.11,0.53) |
| SD ETN SC + MTX | 2.22(0.52,9.29) | 2.06(0.56,7.76) | 0.06(‐0.07,0.18) | |
| SD ABA IV + MTX | 3.39(0.84,14.08) | 2.93(0.86,10.93) | 0.12(‐0.02,0.25) | |
| SD ABA SC + MTX | 2.64(0.60,11.90) | 2.38(0.64,9.48) | 0.08(‐0.06,0.23) | |
| SD GOLI SC + MTX | 7.34(1.40,36.77) | 5.19(1.31,19.86) | 0.26(0.04,0.52) | |
| SD ADA SC + MTX | 3.25(0.63,18.48) | 2.83(0.67,12.57) | 0.11(‐0.05,0.35) | |
| SD INF IV + MTX | 2.76(0.64,12.20) | 2.47(0.68,9.65) | 0.09(‐0.05,0.24) | |
| SD RITUX IV + MTX | 1.57(0.34,7.38) | 1.51(0.37,6.31) | 0.03(‐0.10,0.15) | |
| SD GOLI IV + MTX | 2.60(0.82,8.89) | 2.35(0.84,7.13) | 0.08(‐0.02,0.23) | |
| SD CERTO + MTX | 2.21(0.47,10.55) | 2.05(0.51,8.45) | 0.06(‐0.08,0.22) | |
| SD TOFA PO + MTX | 3.09(0.43,26.32) | 2.70(0.47,14.75) | 0.10(‐0.07,0.48) | |
| LD GOLI IV | 1.55(0.46,5.56) | 1.49(0.49,4.77) | 0.03(‐0.06,0.16) | |
| LD RITUX IV + MTX | 1.05(0.22,4.98) | 1.04(0.25,4.51) | 0.00(‐0.12,0.10) | |
| LD ETN SC + MTX | 2.06(0.41,10.12) | 1.93(0.45,8.15) | 0.06(‐0.08,0.22) | |
| LD GOLI IV + MTX | 0.93(0.26,3.38) | 0.93(0.28,3.10) | 0.00(‐0.10,0.09) | |
| HD TOCI IV | 4.85(0.77,30.70) | 3.85(0.80,16.78) | 0.17(‐0.03,0.49) | |
| HD GOLI SC | 3.23(0.49,20.08) | 2.81(0.53,13.04) | 0.11(‐0.07,0.39) | |
| HD TOCI IV + MTX | 8.85(1.63,52.81) | 5.80(1.47,22.87) | 0.30(0.06,0.61) | |
| HD GOLI SC + MTX | 6.52(1.24,33.35) | 4.79(1.20,18.81) | 0.23(0.03,0.48) | |
| HD INF IV + MTX | 2.44(0.49,11.97) | 2.23(0.53,9.24) | 0.07(‐0.07,0.25) | |
| HD TOFA PO + MTX | 7.74(1.11,64.66) | 5.28(1.09,23.09) | 0.27(0.01,0.68) | |
| SD ETN SC + MTX | SD GOLI SC | 0.93(0.09,10.54) | 0.94(0.18,8.90) | ‐0.01(‐0.47,0.16) |
| SD ABA IV + MTX | 1.44(0.14,15.64) | 1.35(0.27,12.31) | 0.05(‐0.41,0.23) | |
| SD ABA SC + MTX | 1.12(0.10,12.39) | 1.11(0.20,10.17) | 0.01(‐0.45,0.20) | |
| SD GOLI SC + MTX | 3.11(0.37,27.05) | 2.37(0.55,17.83) | 0.17(‐0.23,0.42) | |
| SD ADA SC + MTX | 1.39(0.11,17.51) | 1.31(0.21,13.03) | 0.04(‐0.43,0.31) | |
| SD INF IV + MTX | 1.18(0.11,13.44) | 1.15(0.21,10.99) | 0.02(‐0.44,0.21) | |
| SD RITUX IV + MTX | 0.67(0.06,8.08) | 0.70(0.12,7.10) | ‐0.04(‐0.50,0.13) | |
| SD GOLI IV + MTX | 1.09(0.10,14.45) | 1.08(0.19,11.23) | 0.01(‐0.45,0.24) | |
| SD CERTO + MTX | 0.93(0.08,11.91) | 0.94(0.16,9.80) | ‐0.01(‐0.47,0.20) | |
| SD TOFA PO + MTX | 1.33(0.08,22.74) | 1.26(0.16,14.42) | 0.03(‐0.44,0.42) | |
| LD GOLI IV | 0.64(0.05,9.43) | 0.68(0.10,7.97) | ‐0.04(‐0.50,0.17) | |
| LD RITUX IV + MTX | 0.44(0.04,5.28) | 0.48(0.08,4.85) | ‐0.07(‐0.53,0.08) | |
| LD ETN SC + MTX | 0.87(0.07,10.81) | 0.89(0.15,8.85) | ‐0.01(‐0.48,0.19) | |
| LD GOLI IV + MTX | 0.39(0.03,5.66) | 0.43(0.06,5.13) | ‐0.07(‐0.53,0.10) | |
| HD TOCI IV | 2.03(0.14,30.73) | 1.75(0.26,18.67) | 0.09(‐0.38,0.45) | |
| HD GOLI SC | 1.33(0.23,8.13) | 1.26(0.37,6.82) | 0.03(‐0.29,0.22) | |
| HD TOCI IV + MTX | 3.74(0.29,53.12) | 2.66(0.47,26.15) | 0.22(‐0.27,0.57) | |
| HD GOLI SC + MTX | 2.75(0.32,23.94) | 2.18(0.51,16.38) | 0.15(‐0.25,0.39) | |
| HD INF IV + MTX | 1.04(0.09,12.54) | 1.03(0.17,10.17) | 0.00(‐0.46,0.22) | |
| HD TOFA PO + MTX | 3.32(0.21,55.39) | 2.43(0.36,24.14) | 0.18(‐0.32,0.63) | |
| SD ABA IV + MTX | SD ETN SC + MTX | 1.52(0.58,4.26) | 1.42(0.63,3.42) | 0.05(‐0.08,0.19) |
| SD ABA SC + MTX | 1.19(0.39,3.74) | 1.16(0.45,3.07) | 0.02(‐0.11,0.17) | |
| SD GOLI SC + MTX | 3.31(0.92,12.29) | 2.53(0.93,6.45) | 0.19(‐0.01,0.46) | |
| SD ADA SC + MTX | 1.46(0.40,6.15) | 1.37(0.45,4.25) | 0.05(‐0.11,0.29) | |
| SD INF IV + MTX | 1.24(0.42,3.88) | 1.20(0.48,3.16) | 0.03(‐0.11,0.18) | |
| SD RITUX IV + MTX | 0.71(0.21,2.35) | 0.74(0.25,2.11) | ‐0.03(‐0.16,0.10) | |
| SD GOLI IV + MTX | 1.18(0.34,4.34) | 1.15(0.39,3.38) | 0.02(‐0.12,0.21) | |
| SD CERTO + MTX | 1.00(0.30,3.51) | 1.00(0.35,2.90) | 0.00(‐0.13,0.16) | |
| SD TOFA PO + MTX | 1.39(0.24,9.76) | 1.32(0.28,5.30) | 0.04(‐0.13,0.42) | |
| LD GOLI IV | 0.70(0.17,3.03) | 0.73(0.20,2.55) | ‐0.03(‐0.16,0.14) | |
| LD RITUX IV + MTX | 0.47(0.14,1.62) | 0.51(0.17,1.54) | ‐0.06(‐0.18,0.04) | |
| LD ETN SC + MTX | 0.93(0.33,2.61) | 0.94(0.37,2.22) | ‐0.01(‐0.11,0.13) | |
| LD GOLI IV + MTX | 0.42(0.10,1.85) | 0.45(0.12,1.71) | ‐0.07(‐0.19,0.06) | |
| HD TOCI IV | 2.18(0.47,10.79) | 1.88(0.53,5.79) | 0.11(‐0.09,0.43) | |
| HD GOLI SC | 1.43(0.30,7.10) | 1.35(0.35,4.57) | 0.04(‐0.12,0.33) | |
| HD TOCI IV + MTX | 3.98(1.00,18.03) | 2.85(1.00,7.54) | 0.24(0.00,0.55) | |
| HD GOLI SC + MTX | 2.93(0.83,10.84) | 2.33(0.86,6.07) | 0.17(‐0.03,0.43) | |
| HD INF IV + MTX | 1.10(0.31,3.96) | 1.09(0.36,3.14) | 0.01(‐0.13,0.19) | |
| HD TOFA PO + MTX | 3.46(0.64,23.59) | 2.59(0.69,7.83) | 0.21(‐0.05,0.62) | |
| SD ABA SC + MTX | SD ABA IV + MTX | 0.79(0.33,1.78) | 0.82(0.39,1.59) | ‐0.03(‐0.15,0.09) |
| SD GOLI SC + MTX | 2.15(0.60,7.78) | 1.77(0.67,4.16) | 0.14(‐0.08,0.41) | |
| SD ADA SC + MTX | 0.97(0.29,3.26) | 0.97(0.35,2.42) | 0.00(‐0.16,0.22) | |
| SD INF IV + MTX | 0.82(0.33,2.05) | 0.85(0.39,1.78) | ‐0.03(‐0.15,0.11) | |
| SD RITUX IV + MTX | 0.46(0.14,1.45) | 0.52(0.18,1.37) | ‐0.09(‐0.22,0.05) | |
| SD GOLI IV + MTX | 0.77(0.23,2.64) | 0.81(0.29,2.13) | ‐0.03(‐0.19,0.16) | |
| SD CERTO + MTX | 0.66(0.20,2.12) | 0.70(0.25,1.84) | ‐0.05(‐0.20,0.12) | |
| SD TOFA PO + MTX | 0.92(0.17,6.21) | 0.93(0.21,3.47) | ‐0.01(‐0.20,0.37) | |
| LD GOLI IV | 0.46(0.12,1.82) | 0.51(0.15,1.62) | ‐0.09(‐0.23,0.09) | |
| LD RITUX IV + MTX | 0.31(0.09,0.99) | 0.35(0.12,0.99) | ‐0.12(‐0.25,0.00) | |
| LD ETN SC + MTX | 0.61(0.17,2.00) | 0.66(0.22,1.75) | ‐0.06(‐0.21,0.11) | |
| LD GOLI IV + MTX | 0.28(0.07,1.15) | 0.32(0.08,1.12) | ‐0.12(‐0.25,0.02) | |
| HD TOCI IV | 1.43(0.31,6.62) | 1.32(0.37,3.72) | 0.06(‐0.15,0.38) | |
| HD GOLI SC | 0.94(0.20,4.47) | 0.95(0.25,2.98) | ‐0.01(‐0.19,0.28) | |
| HD TOCI IV + MTX | 2.63(0.66,11.24) | 2.00(0.72,4.81) | 0.18(‐0.07,0.50) | |
| HD GOLI SC + MTX | 1.92(0.54,6.83) | 1.64(0.61,3.91) | 0.12(‐0.10,0.38) | |
| HD INF IV + MTX | 0.73(0.22,2.27) | 0.77(0.28,1.91) | ‐0.04(‐0.19,0.13) | |
| HD TOFA PO + MTX | 2.28(0.43,14.91) | 1.83(0.50,5.03) | 0.15(‐0.12,0.57) | |
| SD GOLI SC + MTX | SD ABA SC + MTX | 2.75(0.71,11.09) | 2.17(0.76,5.88) | 0.17(‐0.06,0.45) |
| SD ADA SC + MTX | 1.23(0.48,3.41) | 1.19(0.53,2.58) | 0.03(‐0.09,0.22) | |
| SD INF IV + MTX | 1.04(0.35,3.29) | 1.03(0.42,2.72) | 0.00(‐0.15,0.16) | |
| SD RITUX IV + MTX | 0.59(0.17,2.13) | 0.63(0.21,1.93) | ‐0.05(‐0.20,0.09) | |
| SD GOLI IV + MTX | 0.99(0.27,3.78) | 0.99(0.32,2.98) | 0.00(‐0.17,0.19) | |
| SD CERTO + MTX | 0.84(0.23,3.09) | 0.86(0.28,2.57) | ‐0.02(‐0.18,0.15) | |
| SD TOFA PO + MTX | 1.17(0.20,8.65) | 1.14(0.24,4.72) | 0.02(‐0.17,0.41) | |
| LD GOLI IV | 0.59(0.14,2.59) | 0.63(0.17,2.23) | ‐0.05(‐0.21,0.12) | |
| LD RITUX IV + MTX | 0.39(0.11,1.42) | 0.44(0.14,1.36) | ‐0.08(‐0.23,0.03) | |
| LD ETN SC + MTX | 0.78(0.20,2.92) | 0.81(0.25,2.47) | ‐0.03(‐0.18,0.14) | |
| LD GOLI IV + MTX | 0.35(0.08,1.63) | 0.39(0.10,1.53) | ‐0.09(‐0.24,0.05) | |
| HD TOCI IV | 1.83(0.37,9.29) | 1.61(0.43,5.14) | 0.09(‐0.13,0.42) | |
| HD GOLI SC | 1.20(0.24,6.15) | 1.16(0.29,4.09) | 0.02(‐0.17,0.31) | |
| HD TOCI IV + MTX | 3.35(0.77,15.81) | 2.45(0.82,6.72) | 0.22(‐0.04,0.54) | |
| HD GOLI SC + MTX | 2.45(0.63,9.73) | 1.99(0.70,5.52) | 0.15(‐0.07,0.41) | |
| HD INF IV + MTX | 0.92(0.25,3.42) | 0.93(0.31,2.78) | ‐0.01(‐0.17,0.18) | |
| HD TOFA PO + MTX | 2.91(0.51,21.10) | 2.23(0.58,7.09) | 0.18(‐0.09,0.60) | |
| SD ADA SC + MTX | SD GOLI SC + MTX | 0.45(0.09,2.18) | 0.55(0.17,1.76) | ‐0.14(‐0.43,0.15) |
| SD INF IV + MTX | 0.38(0.10,1.46) | 0.48(0.18,1.34) | ‐0.17(‐0.44,0.06) | |
| SD RITUX IV + MTX | 0.21(0.05,0.91) | 0.29(0.10,0.92) | ‐0.23(‐0.49,‐0.01) | |
| SD GOLI IV + MTX | 0.36(0.08,1.58) | 0.46(0.15,1.42) | ‐0.17(‐0.45,0.08) | |
| SD CERTO + MTX | 0.30(0.07,1.30) | 0.40(0.13,1.23) | ‐0.19(‐0.47,0.04) | |
| SD TOFA PO + MTX | 0.42(0.06,3.35) | 0.53(0.11,2.17) | ‐0.15(‐0.45,0.26) | |
| LD GOLI IV | 0.21(0.04,1.08) | 0.29(0.08,1.06) | ‐0.23(‐0.49,0.01) | |
| LD RITUX IV + MTX | 0.14(0.03,0.60) | 0.20(0.06,0.65) | ‐0.26(‐0.51,‐0.06) | |
| LD ETN SC + MTX | 0.28(0.06,1.23) | 0.37(0.12,1.18) | ‐0.20(‐0.47,0.03) | |
| LD GOLI IV + MTX | 0.13(0.02,0.67) | 0.18(0.04,0.72) | ‐0.26(‐0.52,‐0.05) | |
| HD TOCI IV | 0.66(0.12,3.78) | 0.75(0.20,2.41) | ‐0.08(‐0.40,0.28) | |
| HD GOLI SC | 0.43(0.13,1.45) | 0.54(0.19,1.29) | ‐0.14(‐0.35,0.07) | |
| HD TOCI IV + MTX | 1.22(0.24,6.35) | 1.13(0.39,3.15) | 0.04(‐0.30,0.41) | |
| HD GOLI SC + MTX | 0.89(0.41,1.95) | 0.92(0.54,1.58) | ‐0.02(‐0.19,0.14) | |
| HD INF IV + MTX | 0.33(0.07,1.45) | 0.43(0.14,1.33) | ‐0.18(‐0.45,0.06) | |
| HD TOFA PO + MTX | 1.06(0.16,8.20) | 1.04(0.27,3.31) | 0.01(‐0.35,0.47) | |
| SD INF IV + MTX | SD ADA SC + MTX | 0.85(0.20,3.33) | 0.87(0.29,2.78) | ‐0.02(‐0.27,0.16) |
| SD RITUX IV + MTX | 0.48(0.10,2.03) | 0.53(0.15,1.85) | ‐0.08(‐0.32,0.08) | |
| SD GOLI IV + MTX | 0.80(0.17,3.67) | 0.83(0.24,2.95) | ‐0.03(‐0.28,0.18) | |
| SD CERTO + MTX | 0.68(0.14,2.98) | 0.73(0.21,2.54) | ‐0.05(‐0.30,0.14) | |
| SD TOFA PO + MTX | 0.95(0.13,7.48) | 0.96(0.18,4.42) | ‐0.01(‐0.28,0.38) | |
| LD GOLI IV | 0.48(0.09,2.45) | 0.53(0.12,2.14) | ‐0.08(‐0.33,0.11) | |
| LD RITUX IV + MTX | 0.32(0.07,1.35) | 0.37(0.10,1.31) | ‐0.11(‐0.35,0.03) | |
| LD ETN SC + MTX | 0.63(0.13,2.83) | 0.68(0.18,2.42) | ‐0.05(‐0.30,0.13) | |
| LD GOLI IV + MTX | 0.29(0.05,1.56) | 0.33(0.07,1.48) | ‐0.11(‐0.35,0.04) | |
| HD TOCI IV | 1.47(0.24,8.64) | 1.35(0.32,4.96) | 0.06(‐0.23,0.40) | |
| HD GOLI SC | 0.97(0.16,5.74) | 0.97(0.22,3.94) | 0.00(‐0.27,0.30) | |
| HD TOCI IV + MTX | 2.71(0.49,14.90) | 2.05(0.60,6.77) | 0.19(‐0.13,0.52) | |
| HD GOLI SC + MTX | 1.98(0.41,9.38) | 1.68(0.52,5.54) | 0.12(‐0.17,0.40) | |
| HD INF IV + MTX | 0.75(0.16,3.37) | 0.79(0.22,2.74) | ‐0.04(‐0.29,0.17) | |
| HD TOFA PO + MTX | 2.38(0.34,18.69) | 1.88(0.43,6.82) | 0.15(‐0.18,0.58) | |
| SD RITUX IV + MTX | SD INF IV + MTX | 0.57(0.16,1.95) | 0.61(0.21,1.78) | ‐0.06(‐0.21,0.08) |
| SD GOLI IV + MTX | 0.94(0.26,3.51) | 0.95(0.31,2.80) | ‐0.01(‐0.18,0.19) | |
| SD CERTO + MTX | 0.80(0.22,2.85) | 0.83(0.28,2.40) | ‐0.03(‐0.19,0.14) | |
| SD TOFA PO + MTX | 1.11(0.19,8.08) | 1.09(0.23,4.48) | 0.01(‐0.18,0.40) | |
| LD GOLI IV | 0.56(0.13,2.42) | 0.60(0.16,2.10) | ‐0.06(‐0.22,0.11) | |
| LD RITUX IV + MTX | 0.38(0.11,1.33) | 0.42(0.13,1.28) | ‐0.09(‐0.24,0.03) | |
| LD ETN SC + MTX | 0.75(0.19,2.67) | 0.78(0.24,2.27) | ‐0.03(‐0.19,0.14) | |
| LD GOLI IV + MTX | 0.34(0.07,1.51) | 0.38(0.09,1.43) | ‐0.09(‐0.24,0.04) | |
| HD TOCI IV | 1.74(0.35,8.80) | 1.55(0.41,4.85) | 0.08(‐0.14,0.41) | |
| HD GOLI SC | 1.16(0.23,5.75) | 1.13(0.27,3.86) | 0.02(‐0.18,0.30) | |
| HD TOCI IV + MTX | 3.19(0.76,14.64) | 2.36(0.81,6.31) | 0.21(‐0.04,0.53) | |
| HD GOLI SC + MTX | 2.36(0.61,8.95) | 1.93(0.68,5.10) | 0.14(‐0.08,0.40) | |
| HD INF IV + MTX | 0.89(0.31,2.44) | 0.90(0.36,2.08) | ‐0.01(‐0.15,0.13) | |
| HD TOFA PO + MTX | 2.78(0.50,19.03) | 2.15(0.56,6.62) | 0.18(‐0.10,0.59) | |
| SD GOLI IV + MTX | SD RITUX IV + MTX | 1.66(0.42,6.80) | 1.56(0.47,5.23) | 0.05(‐0.09,0.24) |
| SD CERTO + MTX | 1.41(0.37,5.49) | 1.36(0.42,4.41) | 0.03(‐0.10,0.19) | |
| SD TOFA PO + MTX | 1.95(0.31,14.95) | 1.78(0.35,8.03) | 0.07(‐0.10,0.45) | |
| LD GOLI IV | 0.99(0.22,4.71) | 0.99(0.25,3.87) | 0.00(‐0.13,0.17) | |
| LD RITUX IV + MTX | 0.67(0.27,1.65) | 0.69(0.31,1.57) | ‐0.03(‐0.12,0.04) | |
| LD ETN SC + MTX | 1.31(0.32,5.33) | 1.27(0.36,4.26) | 0.02(‐0.11,0.19) | |
| LD GOLI IV + MTX | 0.59(0.12,2.88) | 0.62(0.14,2.59) | ‐0.03(‐0.16,0.10) | |
| HD TOCI IV | 3.08(0.58,17.34) | 2.55(0.62,9.19) | 0.14(‐0.06,0.47) | |
| HD GOLI SC | 2.01(0.37,11.18) | 1.82(0.42,7.17) | 0.08(‐0.09,0.37) | |
| HD TOCI IV + MTX | 5.62(1.26,29.31) | 3.84(1.21,12.06) | 0.27(0.03,0.59) | |
| HD GOLI SC + MTX | 4.11(1.00,17.68) | 3.14(1.00,9.76) | 0.20(0.00,0.46) | |
| HD INF IV + MTX | 1.56(0.39,6.21) | 1.48(0.43,4.88) | 0.04(‐0.10,0.22) | |
| HD TOFA PO + MTX | 4.96(0.82,35.53) | 3.52(0.85,12.24) | 0.24(‐0.02,0.65) | |
| SD CERTO + MTX | SD GOLI IV + MTX | 0.85(0.21,3.44) | 0.87(0.26,2.87) | ‐0.02(‐0.21,0.16) |
| SD TOFA PO + MTX | 1.18(0.19,9.19) | 1.15(0.23,5.14) | 0.02(‐0.20,0.40) | |
| LD GOLI IV | 0.60(0.19,1.85) | 0.64(0.23,1.68) | ‐0.05(‐0.20,0.08) | |
| LD RITUX IV + MTX | 0.40(0.10,1.58) | 0.44(0.13,1.50) | ‐0.08(‐0.26,0.04) | |
| LD ETN SC + MTX | 0.79(0.18,3.32) | 0.82(0.23,2.80) | ‐0.03(‐0.22,0.15) | |
| LD GOLI IV + MTX | 0.36(0.10,1.17) | 0.40(0.13,1.15) | ‐0.08(‐0.24,0.02) | |
| HD TOCI IV | 1.84(0.33,10.57) | 1.63(0.40,5.76) | 0.09(‐0.15,0.42) | |
| HD GOLI SC | 1.22(0.21,6.51) | 1.18(0.26,4.42) | 0.03(‐0.20,0.31) | |
| HD TOCI IV + MTX | 3.37(0.71,17.26) | 2.46(0.77,7.61) | 0.22(‐0.06,0.54) | |
| HD GOLI SC + MTX | 2.47(0.57,10.76) | 2.01(0.65,6.17) | 0.15(‐0.10,0.42) | |
| HD INF IV + MTX | 0.93(0.22,3.86) | 0.94(0.28,3.12) | ‐0.01(‐0.20,0.18) | |
| HD TOFA PO + MTX | 2.95(0.47,22.24) | 2.25(0.54,7.71) | 0.18(‐0.11,0.60) | |
| SD TOFA PO + MTX | SD CERTO + MTX | 1.39(0.22,10.48) | 1.32(0.26,5.76) | 0.04(‐0.16,0.42) |
| LD GOLI IV | 0.70(0.15,3.29) | 0.73(0.19,2.78) | ‐0.03(‐0.20,0.14) | |
| LD RITUX IV + MTX | 0.47(0.12,1.82) | 0.51(0.15,1.71) | ‐0.06(‐0.22,0.05) | |
| LD ETN SC + MTX | 0.93(0.22,3.77) | 0.94(0.27,3.11) | ‐0.01(‐0.18,0.17) | |
| LD GOLI IV + MTX | 0.42(0.08,2.06) | 0.45(0.11,1.88) | ‐0.07(‐0.22,0.07) | |
| HD TOCI IV | 2.19(0.42,11.58) | 1.89(0.48,6.34) | 0.11(‐0.12,0.44) | |
| HD GOLI SC | 1.44(0.25,7.80) | 1.36(0.30,5.12) | 0.04(‐0.16,0.33) | |
| HD TOCI IV + MTX | 4.02(0.87,19.52) | 2.85(0.90,8.47) | 0.24(‐0.02,0.55) | |
| HD GOLI SC + MTX | 2.93(0.69,12.45) | 2.33(0.75,7.03) | 0.17(‐0.06,0.43) | |
| HD INF IV + MTX | 1.11(0.27,4.48) | 1.09(0.32,3.56) | 0.01(‐0.16,0.20) | |
| HD TOFA PO + MTX | 3.50(0.57,25.92) | 2.61(0.63,8.77) | 0.20(‐0.08,0.62) | |
| LD GOLI IV | SD TOFA PO + MTX | 0.51(0.06,3.59) | 0.56(0.11,3.10) | ‐0.07(‐0.45,0.13) |
| LD RITUX IV + MTX | 0.34(0.04,2.14) | 0.38(0.08,2.01) | ‐0.10(‐0.48,0.06) | |
| LD ETN SC + MTX | 0.67(0.08,4.23) | 0.71(0.15,3.54) | ‐0.05(‐0.43,0.16) | |
| LD GOLI IV + MTX | 0.30(0.04,2.17) | 0.35(0.06,2.01) | ‐0.11(‐0.48,0.06) | |
| HD TOCI IV | 1.57(0.17,12.59) | 1.42(0.27,7.37) | 0.07(‐0.34,0.41) | |
| HD GOLI SC | 1.01(0.11,8.36) | 1.01(0.19,5.78) | 0.00(‐0.39,0.31) | |
| HD TOCI IV + MTX | 2.87(0.34,21.54) | 2.14(0.50,10.18) | 0.19(‐0.23,0.54) | |
| HD GOLI SC + MTX | 2.13(0.27,14.17) | 1.77(0.42,8.28) | 0.12(‐0.28,0.42) | |
| HD INF IV + MTX | 0.80(0.10,5.01) | 0.83(0.18,4.09) | ‐0.03(‐0.41,0.19) | |
| HD TOFA PO + MTX | 2.51(0.78,7.97) | 1.91(0.84,5.02) | 0.15(‐0.04,0.40) | |
| LD RITUX IV + MTX | LD GOLI IV | 0.67(0.14,3.16) | 0.69(0.17,2.91) | ‐0.03(‐0.19,0.08) |
| LD ETN SC + MTX | 1.33(0.27,6.27) | 1.29(0.31,5.14) | 0.03(‐0.15,0.19) | |
| LD GOLI IV + MTX | 0.60(0.17,2.13) | 0.62(0.19,1.99) | ‐0.03(‐0.17,0.06) | |
| HD TOCI IV | 3.09(0.51,19.56) | 2.56(0.56,10.74) | 0.14(‐0.08,0.47) | |
| HD GOLI SC | 2.08(0.31,12.45) | 1.87(0.37,8.26) | 0.08(‐0.13,0.36) | |
| HD TOCI IV + MTX | 5.69(1.07,33.26) | 3.88(1.05,14.48) | 0.27(0.01,0.58) | |
| HD GOLI SC + MTX | 4.19(0.83,20.60) | 3.20(0.86,11.72) | 0.20(‐0.03,0.46) | |
| HD INF IV + MTX | 1.57(0.32,7.49) | 1.49(0.37,5.88) | 0.04(‐0.13,0.23) | |
| HD TOFA PO + MTX | 4.98(0.72,41.12) | 3.54(0.76,14.75) | 0.24(‐0.04,0.65) | |
| LD ETN SC + MTX | LD RITUX IV + MTX | 1.99(0.47,8.10) | 1.86(0.50,6.51) | 0.05(‐0.06,0.21) |
| LD GOLI IV + MTX | 0.89(0.18,4.47) | 0.90(0.20,3.94) | ‐0.01(‐0.10,0.12) | |
| HD TOCI IV | 4.64(0.88,26.29) | 3.70(0.89,13.62) | 0.17(‐0.01,0.49) | |
| HD GOLI SC | 3.04(0.55,17.31) | 2.66(0.58,10.88) | 0.11(‐0.05,0.39) | |
| HD TOCI IV + MTX | 8.48(1.87,44.14) | 5.60(1.69,18.05) | 0.30(0.07,0.61) | |
| HD GOLI SC + MTX | 6.21(1.48,27.00) | 4.58(1.39,14.77) | 0.23(0.04,0.48) | |
| HD INF IV + MTX | 2.34(0.57,9.51) | 2.14(0.60,7.37) | 0.07(‐0.05,0.25) | |
| HD TOFA PO + MTX | 7.45(1.20,54.85) | 5.13(1.18,18.55) | 0.27(0.02,0.68) | |
| LD GOLI IV + MTX | LD ETN SC + MTX | 0.45(0.09,2.36) | 0.48(0.11,2.15) | ‐0.06(‐0.22,0.08) |
| HD TOCI IV | 2.34(0.43,13.32) | 1.99(0.49,7.41) | 0.12(‐0.11,0.44) | |
| HD GOLI SC | 1.54(0.28,8.83) | 1.44(0.33,5.85) | 0.05(‐0.15,0.34) | |
| HD TOCI IV + MTX | 4.26(0.92,23.05) | 3.01(0.93,9.99) | 0.24(‐0.01,0.56) | |
| HD GOLI SC + MTX | 3.14(0.72,13.83) | 2.47(0.78,7.96) | 0.17(‐0.05,0.43) | |
| HD INF IV + MTX | 1.18(0.28,5.15) | 1.16(0.34,4.06) | 0.02(‐0.16,0.20) | |
| HD TOFA PO + MTX | 3.72(0.61,28.41) | 2.75(0.67,10.26) | 0.21(‐0.07,0.62) | |
| HD TOCI IV | LD GOLI IV + MTX | 5.18(0.80,34.35) | 4.10(0.83,18.72) | 0.18(‐0.02,0.50) |
| HD GOLI SC | 3.45(0.51,22.27) | 2.98(0.55,14.47) | 0.11(‐0.06,0.39) | |
| HD TOCI IV + MTX | 9.49(1.71,57.08) | 6.21(1.55,25.67) | 0.30(0.07,0.61) | |
| HD GOLI SC + MTX | 6.98(1.34,36.74) | 5.09(1.27,20.68) | 0.24(0.04,0.48) | |
| HD INF IV + MTX | 2.63(0.51,13.20) | 2.39(0.56,10.09) | 0.08(‐0.06,0.26) | |
| HD TOFA PO + MTX | 8.33(1.18,70.80) | 5.66(1.15,26.06) | 0.27(0.02,0.68) | |
| HD GOLI SC | HD TOCI IV | 0.66(0.09,4.65) | 0.73(0.16,3.30) | ‐0.06(‐0.41,0.26) |
| HD TOCI IV + MTX | 1.83(0.81,4.49) | 1.49(0.88,3.09) | 0.12(‐0.04,0.30) | |
| HD GOLI SC + MTX | 1.34(0.24,7.54) | 1.23(0.38,4.56) | 0.05(‐0.30,0.36) | |
| HD INF IV + MTX | 0.51(0.09,2.83) | 0.58(0.16,2.36) | ‐0.10(‐0.43,0.14) | |
| HD TOFA PO + MTX | 1.61(0.20,14.77) | 1.39(0.32,5.74) | 0.09(‐0.31,0.54) | |
| HD TOCI IV + MTX | HD GOLI SC | 2.79(0.45,18.52) | 2.09(0.57,8.62) | 0.19(‐0.16,0.53) |
| HD GOLI SC + MTX | 2.04(0.62,6.84) | 1.70(0.72,4.85) | 0.12(‐0.10,0.32) | |
| HD INF IV + MTX | 0.76(0.14,4.27) | 0.80(0.20,3.48) | ‐0.03(‐0.32,0.18) | |
| HD TOFA PO + MTX | 2.47(0.31,22.14) | 1.92(0.41,8.54) | 0.16(‐0.21,0.59) | |
| HD GOLI SC + MTX | HD TOCI IV + MTX | 0.73(0.14,3.66) | 0.81(0.29,2.43) | ‐0.07(‐0.43,0.27) |
| HD INF IV + MTX | 0.28(0.05,1.32) | 0.38(0.12,1.24) | ‐0.22(‐0.55,0.05) | |
| HD TOFA PO + MTX | 0.88(0.12,7.15) | 0.93(0.24,3.06) | ‐0.03(‐0.43,0.44) | |
| HD INF IV + MTX | HD GOLI SC + MTX | 0.38(0.08,1.63) | 0.47(0.15,1.45) | ‐0.16(‐0.42,0.08) |
| HD TOFA PO + MTX | 1.19(0.19,9.27) | 1.13(0.29,3.57) | 0.04(‐0.32,0.49) | |
| HD TOFA PO + MTX | HD INF IV + MTX | 3.15(0.51,24.06) | 2.38(0.58,8.44) | 0.19(‐0.10,0.61) |
| Random‐effects model | Residual deviance | 77.83 vs 76 data points | ||
| Deviance information criteria | 494.211 | |||
| Fixed‐effect model | Residual deviance | 114.7 vs 76 data points | ||
| Deviance information criteria | 519.067 | |||
| Note | ||||
| Total participants | 14,125 | |||
| Total studies | 30 | |||
| 2‐arm | 17 | |||
| 3‐arm | 11 | |||
| 4‐arm | 1 | |||
| 5‐arm | 1 | |||
Appendix 12. Remission: subgroup ‐ established RA (2‐10 years)
| Remission established: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX + DMARD | MTX + PL | 0.70(0.22,2.23) | 0.71(0.22,2.11) | ‐0.01(‐0.04,0.05) |
| PL | 1.02(0.12,8.51) | 1.02(0.13,6.35) | 0.00(‐0.05,0.25) | |
| SD ETN SC | 1.79(0.76,4.33) | 1.73(0.77,3.73) | 0.04(‐0.01,0.13) | |
| SD ADA SC | 1.22(0.20,8.20) | 1.21(0.21,6.15) | 0.01(‐0.04,0.24) | |
| SD GOLI IV | 1.42(0.41,5.02) | 1.39(0.42,4.22) | 0.02(‐0.03,0.15) | |
| SD GOLI SC | 3.62(0.36,35.55) | 3.21(0.38,13.57) | 0.11(‐0.03,0.59) | |
| SD ETN SC + MTX | 3.21(1.48,7.01) | 2.89(1.44,5.42) | 0.09(0.02,0.22) | |
| SD ABA IV + MTX | 4.73(2.39,9.83) | 3.99(2.23,6.95) | 0.15(0.06,0.28) | |
| SD ABA SC + MTX | 3.50(1.34,8.74) | 3.12(1.32,6.43) | 0.10(0.02,0.26) | |
| SD GOLI SC + MTX | 10.54(3.79,32.51) | 7.16(3.30,13.55) | 0.30(0.12,0.56) | |
| SD ADA SC + MTX | 3.94(1.73,9.61) | 3.44(1.67,6.81) | 0.12(0.03,0.28) | |
| SD INF IV + MTX | 2.26(0.88,6.08) | 2.13(0.88,4.89) | 0.06(‐0.01,0.19) | |
| SD RITUX IV + MTX | 3.63(1.35,10.50) | 3.21(1.33,7.25) | 0.11(0.02,0.30) | |
| SD GOLI IV + MTX | 3.27(1.24,8.88) | 2.94(1.22,6.48) | 0.09(0.01,0.26) | |
| SD CERTO + MTX | 10.74(1.18,283.80) | 7.24(1.17,21.74) | 0.31(0.01,0.88) | |
| SD TOFA PO + MTX | 4.30(0.91,25.42) | 3.69(0.92,11.98) | 0.13(0.00,0.51) | |
| LD GOLI IV | 2.21(0.65,7.72) | 2.09(0.66,5.86) | 0.05(‐0.02,0.23) | |
| LD RITUX IV + MTX | 1.51(0.58,4.16) | 1.48(0.59,3.61) | 0.02(‐0.02,0.13) | |
| LD ETN SC + MTX | 2.96(1.03,8.69) | 2.70(1.03,6.35) | 0.08(0.00,0.26) | |
| LD GOLI IV + MTX | 1.31(0.37,4.63) | 1.29(0.38,3.96) | 0.01(‐0.03,0.14) | |
| HD TOCI IV | 7.03(1.84,31.06) | 5.42(1.76,13.25) | 0.22(0.04,0.55) | |
| HD GOLI SC | 4.69(1.16,20.27) | 3.97(1.15,10.81) | 0.15(0.01,0.45) | |
| HD TOCI IV + MTX | 12.92(4.14,49.77) | 8.11(3.56,15.88) | 0.35(0.13,0.66) | |
| HD GOLI SC + MTX | 9.48(3.37,28.37) | 6.67(2.99,12.84) | 0.28(0.10,0.53) | |
| HD INF IV + MTX | 3.49(1.22,10.51) | 3.11(1.21,7.20) | 0.10(0.01,0.30) | |
| HD TOFA PO + MTX | 10.91(2.39,64.71) | 7.33(2.23,16.48) | 0.31(0.06,0.71) | |
| PL | MTX + DMARD | 1.45(0.13,16.52) | 1.42(0.14,12.42) | 0.01(‐0.07,0.26) |
| SD ETN SC | 2.56(0.89,7.68) | 2.42(0.89,6.93) | 0.05(‐0.01,0.13) | |
| SD ADA SC | 1.76(0.21,16.15) | 1.71(0.22,12.41) | 0.02(‐0.06,0.25) | |
| SD GOLI IV | 2.04(0.37,11.34) | 1.96(0.40,9.70) | 0.03(‐0.05,0.17) | |
| SD GOLI SC | 5.22(0.39,68.59) | 4.45(0.40,30.13) | 0.12(‐0.04,0.61) | |
| SD ETN SC + MTX | 4.56(1.89,11.45) | 4.02(1.76,9.98) | 0.10(0.04,0.20) | |
| SD ABA IV + MTX | 6.74(1.80,27.16) | 5.57(1.67,20.56) | 0.16(0.05,0.30) | |
| SD ABA SC + MTX | 4.96(1.09,22.38) | 4.33(1.08,17.14) | 0.11(0.01,0.28) | |
| SD GOLI SC + MTX | 15.31(3.22,75.02) | 10.02(2.67,37.41) | 0.31(0.12,0.57) | |
| SD ADA SC + MTX | 5.62(1.39,25.28) | 4.81(1.35,18.90) | 0.13(0.03,0.29) | |
| SD INF IV + MTX | 3.25(0.73,15.40) | 2.99(0.75,12.72) | 0.07(‐0.02,0.20) | |
| SD RITUX IV + MTX | 5.18(1.15,25.60) | 4.48(1.13,19.01) | 0.12(0.01,0.31) | |
| SD GOLI IV + MTX | 4.67(1.04,22.15) | 4.11(1.04,16.92) | 0.11(0.00,0.28) | |
| SD CERTO + MTX | 15.62(1.25,484.40) | 9.93(1.23,54.76) | 0.32(0.01,0.89) | |
| SD TOFA PO + MTX | 6.20(0.89,51.49) | 5.14(0.90,27.65) | 0.14(‐0.01,0.52) | |
| LD GOLI IV | 3.16(0.59,17.69) | 2.92(0.61,13.92) | 0.06(‐0.03,0.25) | |
| LD RITUX IV + MTX | 2.15(0.48,10.46) | 2.06(0.50,9.20) | 0.04(‐0.04,0.14) | |
| LD ETN SC + MTX | 4.24(1.07,17.46) | 3.78(1.07,13.63) | 0.09(0.00,0.26) | |
| LD GOLI IV + MTX | 1.87(0.34,10.69) | 1.81(0.36,9.21) | 0.03(‐0.05,0.15) | |
| HD TOCI IV | 10.18(1.72,66.28) | 7.53(1.62,32.99) | 0.23(0.04,0.56) | |
| HD GOLI SC | 6.78(1.08,43.15) | 5.55(1.07,25.91) | 0.16(0.01,0.46) | |
| HD TOCI IV + MTX | 18.61(3.66,112.50) | 11.21(2.96,44.17) | 0.36(0.13,0.67) | |
| HD GOLI SC + MTX | 13.61(2.86,68.76) | 9.29(2.45,35.46) | 0.29(0.10,0.54) | |
| HD INF IV + MTX | 4.98(1.07,25.53) | 4.33(1.06,18.66) | 0.11(0.00,0.31) | |
| HD TOFA PO + MTX | 15.72(2.31,130.70) | 10.00(2.09,43.78) | 0.32(0.06,0.72) | |
| SD ETN SC | PL | 1.76(0.18,17.32) | 1.69(0.24,15.33) | 0.03(‐0.21,0.14) |
| SD ADA SC | 1.21(0.07,20.18) | 1.20(0.09,16.14) | 0.01(‐0.23,0.23) | |
| SD GOLI IV | 1.41(0.12,16.35) | 1.38(0.15,14.33) | 0.02(‐0.23,0.16) | |
| SD GOLI SC | 3.52(0.81,16.88) | 2.95(0.83,11.43) | 0.09(‐0.01,0.45) | |
| SD ETN SC + MTX | 3.14(0.34,30.37) | 2.82(0.41,24.64) | 0.08(‐0.16,0.23) | |
| SD ABA IV + MTX | 4.66(0.50,44.57) | 3.92(0.58,34.30) | 0.14(‐0.12,0.29) | |
| SD ABA SC + MTX | 3.40(0.34,34.84) | 3.01(0.42,27.46) | 0.09(‐0.15,0.27) | |
| SD GOLI SC + MTX | 10.48(1.43,79.41) | 6.91(1.28,49.53) | 0.29(0.06,0.52) | |
| SD ADA SC + MTX | 3.92(0.40,39.59) | 3.40(0.47,30.44) | 0.11(‐0.14,0.29) | |
| SD INF IV + MTX | 2.25(0.22,23.79) | 2.11(0.28,19.89) | 0.05(‐0.20,0.19) | |
| SD RITUX IV + MTX | 3.60(0.34,38.36) | 3.15(0.42,29.24) | 0.10(‐0.15,0.30) | |
| SD GOLI IV + MTX | 3.21(0.31,33.38) | 2.87(0.39,26.31) | 0.09(‐0.16,0.27) | |
| SD CERTO + MTX | 11.15(0.48,564.20) | 6.80(0.54,81.10) | 0.29(‐0.09,0.88) | |
| SD TOFA PO + MTX | 4.29(0.30,70.57) | 3.60(0.36,41.14) | 0.12(‐0.15,0.50) | |
| LD GOLI IV | 2.17(0.18,25.75) | 2.04(0.23,20.97) | 0.05(‐0.20,0.23) | |
| LD RITUX IV + MTX | 1.49(0.15,16.00) | 1.45(0.19,14.02) | 0.02(‐0.22,0.14) | |
| LD ETN SC + MTX | 2.92(0.27,31.42) | 2.64(0.33,24.82) | 0.08(‐0.17,0.26) | |
| LD GOLI IV + MTX | 1.29(0.11,15.14) | 1.27(0.14,13.32) | 0.01(‐0.23,0.15) | |
| HD TOCI IV | 7.04(0.55,89.56) | 5.25(0.62,50.27) | 0.20(‐0.09,0.54) | |
| HD GOLI SC | 4.55(1.02,24.12) | 3.76(1.01,19.15) | 0.13(0.00,0.35) | |
| HD TOCI IV + MTX | 12.86(1.15,155.00) | 7.82(1.11,70.11) | 0.33(0.03,0.66) | |
| HD GOLI SC + MTX | 9.38(1.32,73.10) | 6.43(1.21,45.84) | 0.26(0.05,0.50) | |
| HD INF IV + MTX | 3.46(0.32,37.71) | 3.04(0.39,28.79) | 0.09(‐0.16,0.30) | |
| HD TOFA PO + MTX | 10.89(0.78,168.40) | 6.93(0.82,67.45) | 0.29(‐0.04,0.70) | |
| SD ADA SC | SD ETN SC | 0.69(0.09,5.40) | 0.71(0.10,4.25) | ‐0.02(‐0.14,0.20) |
| SD GOLI IV | 0.80(0.17,3.58) | 0.81(0.19,3.12) | ‐0.01(‐0.12,0.12) | |
| SD GOLI SC | 2.02(0.17,22.98) | 1.85(0.19,9.98) | 0.07(‐0.10,0.55) | |
| SD ETN SC + MTX | 1.78(0.98,3.28) | 1.66(0.98,2.89) | 0.05(0.00,0.13) | |
| SD ABA IV + MTX | 2.64(0.86,8.24) | 2.31(0.88,6.23) | 0.11(‐0.02,0.25) | |
| SD ABA SC + MTX | 1.95(0.52,6.80) | 1.80(0.56,5.28) | 0.07(‐0.06,0.23) | |
| SD GOLI SC + MTX | 5.93(1.54,23.52) | 4.14(1.42,11.54) | 0.26(0.06,0.53) | |
| SD ADA SC + MTX | 2.19(0.66,7.51) | 1.98(0.70,5.75) | 0.08(‐0.04,0.25) | |
| SD INF IV + MTX | 1.26(0.35,4.76) | 1.23(0.39,4.03) | 0.02(‐0.09,0.16) | |
| SD RITUX IV + MTX | 2.03(0.55,7.94) | 1.86(0.59,5.85) | 0.07(‐0.06,0.26) | |
| SD GOLI IV + MTX | 1.83(0.49,6.84) | 1.70(0.53,5.28) | 0.06(‐0.07,0.23) | |
| SD CERTO + MTX | 6.05(0.54,173.40) | 4.14(0.58,17.25) | 0.27(‐0.05,0.85) | |
| SD TOFA PO + MTX | 2.40(0.41,17.30) | 2.13(0.45,8.97) | 0.09(‐0.07,0.47) | |
| LD GOLI IV | 1.24(0.27,5.59) | 1.21(0.30,4.48) | 0.02(‐0.10,0.20) | |
| LD RITUX IV + MTX | 0.84(0.23,3.24) | 0.85(0.26,2.91) | ‐0.01(‐0.12,0.10) | |
| LD ETN SC + MTX | 1.65(0.51,5.30) | 1.56(0.55,4.24) | 0.05(‐0.06,0.21) | |
| LD GOLI IV + MTX | 0.73(0.15,3.38) | 0.75(0.18,2.98) | ‐0.02(‐0.13,0.11) | |
| HD TOCI IV | 3.97(0.79,21.11) | 3.13(0.81,10.30) | 0.18(‐0.02,0.52) | |
| HD GOLI SC | 2.63(0.51,13.94) | 2.30(0.55,8.37) | 0.11(‐0.06,0.41) | |
| HD TOCI IV + MTX | 7.26(1.70,35.12) | 4.66(1.54,13.53) | 0.31(0.07,0.62) | |
| HD GOLI SC + MTX | 5.29(1.38,21.36) | 3.84(1.31,10.96) | 0.24(0.04,0.50) | |
| HD INF IV + MTX | 1.95(0.50,7.90) | 1.80(0.54,5.80) | 0.07(‐0.06,0.27) | |
| HD TOFA PO + MTX | 6.14(1.05,42.98) | 4.19(1.05,13.49) | 0.27(0.01,0.68) | |
| SD GOLI IV | SD ADA SC | 1.16(0.12,10.30) | 1.15(0.15,8.96) | 0.01(‐0.22,0.15) |
| SD GOLI SC | 2.93(0.15,54.59) | 2.56(0.19,26.46) | 0.09(‐0.17,0.57) | |
| SD ETN SC + MTX | 2.61(0.34,18.74) | 2.38(0.42,15.27) | 0.08(‐0.16,0.22) | |
| SD ABA IV + MTX | 3.86(0.53,27.42) | 3.29(0.61,20.65) | 0.13(‐0.10,0.29) | |
| SD ABA SC + MTX | 2.85(0.34,21.22) | 2.55(0.41,16.70) | 0.09(‐0.15,0.26) | |
| SD GOLI SC + MTX | 8.70(1.00,72.73) | 5.85(1.00,37.81) | 0.28(0.00,0.56) | |
| SD ADA SC + MTX | 3.21(0.42,24.69) | 2.81(0.50,19.01) | 0.10(‐0.13,0.28) | |
| SD INF IV + MTX | 1.85(0.23,14.89) | 1.75(0.28,12.48) | 0.04(‐0.19,0.19) | |
| SD RITUX IV + MTX | 2.95(0.36,24.01) | 2.63(0.43,18.22) | 0.09(‐0.14,0.29) | |
| SD GOLI IV + MTX | 2.65(0.31,21.24) | 2.41(0.38,16.56) | 0.08(‐0.16,0.26) | |
| SD CERTO + MTX | 9.30(0.48,342.30) | 5.75(0.54,50.05) | 0.28(‐0.08,0.87) | |
| SD TOFA PO + MTX | 3.54(0.30,45.36) | 3.02(0.36,26.00) | 0.11(‐0.14,0.50) | |
| LD GOLI IV | 1.78(0.20,16.52) | 1.69(0.25,13.47) | 0.04(‐0.19,0.23) | |
| LD RITUX IV + MTX | 1.22(0.15,9.80) | 1.21(0.19,8.76) | 0.01(‐0.21,0.13) | |
| LD ETN SC + MTX | 2.42(0.28,19.81) | 2.22(0.34,15.66) | 0.07(‐0.17,0.26) | |
| LD GOLI IV + MTX | 1.07(0.11,9.71) | 1.06(0.14,8.49) | 0.00(‐0.22,0.14) | |
| HD TOCI IV | 5.76(1.72,19.49) | 4.34(1.48,14.65) | 0.19(0.05,0.42) | |
| HD GOLI SC | 3.83(0.39,38.62) | 3.22(0.45,25.05) | 0.12(‐0.12,0.43) | |
| HD TOCI IV + MTX | 10.55(2.48,49.64) | 6.46(1.81,28.75) | 0.32(0.13,0.57) | |
| HD GOLI SC + MTX | 7.76(0.92,64.05) | 5.42(0.94,35.92) | 0.26(‐0.01,0.53) | |
| HD INF IV + MTX | 2.84(0.34,23.63) | 2.53(0.41,17.70) | 0.09(‐0.15,0.29) | |
| HD TOFA PO + MTX | 9.03(0.76,112.30) | 5.86(0.81,42.45) | 0.29(‐0.04,0.70) | |
| SD GOLI SC | SD GOLI IV | 2.54(0.19,35.63) | 2.26(0.21,15.81) | 0.08(‐0.11,0.57) |
| SD ETN SC + MTX | 2.25(0.52,9.72) | 2.06(0.57,7.98) | 0.07(‐0.08,0.20) | |
| SD ABA IV + MTX | 3.33(0.79,14.04) | 2.86(0.82,10.67) | 0.12(‐0.03,0.27) | |
| SD ABA SC + MTX | 2.45(0.50,11.43) | 2.22(0.55,8.97) | 0.08(‐0.08,0.25) | |
| SD GOLI SC + MTX | 7.47(1.48,40.23) | 5.10(1.36,19.75) | 0.28(0.06,0.55) | |
| SD ADA SC + MTX | 2.77(0.62,12.74) | 2.45(0.67,9.74) | 0.10(‐0.06,0.27) | |
| SD INF IV + MTX | 1.59(0.33,7.86) | 1.53(0.38,6.60) | 0.03(‐0.11,0.18) | |
| SD RITUX IV + MTX | 2.55(0.78,8.64) | 2.29(0.80,6.92) | 0.08(‐0.03,0.24) | |
| SD GOLI IV + MTX | 2.31(0.47,11.30) | 2.10(0.52,8.80) | 0.07(‐0.08,0.25) | |
| SD CERTO + MTX | 7.77(0.58,252.40) | 5.09(0.62,27.52) | 0.28(‐0.05,0.86) | |
| SD TOFA PO + MTX | 3.07(0.41,26.15) | 2.64(0.45,14.11) | 0.11(‐0.08,0.49) | |
| LD GOLI IV | 1.55(0.43,5.55) | 1.49(0.46,4.72) | 0.03(‐0.07,0.18) | |
| LD RITUX IV + MTX | 1.06(0.22,5.21) | 1.06(0.25,4.64) | 0.00(‐0.13,0.12) | |
| LD ETN SC + MTX | 2.09(0.40,10.76) | 1.93(0.44,8.34) | 0.06(‐0.09,0.24) | |
| LD GOLI IV + MTX | 0.92(0.25,3.40) | 0.92(0.27,3.10) | 0.00(‐0.11,0.10) | |
| HD TOCI IV | 5.02(0.80,33.52) | 3.86(0.83,17.14) | 0.19(‐0.02,0.53) | |
| HD GOLI SC | 3.28(0.50,22.95) | 2.80(0.55,13.84) | 0.12(‐0.07,0.43) | |
| HD TOCI IV + MTX | 9.19(1.68,56.26) | 5.76(1.51,22.84) | 0.32(0.07,0.64) | |
| HD GOLI SC + MTX | 6.66(1.27,35.02) | 4.72(1.22,18.47) | 0.25(0.03,0.51) | |
| HD INF IV + MTX | 2.44(0.48,13.07) | 2.21(0.53,9.75) | 0.08(‐0.08,0.29) | |
| HD TOFA PO + MTX | 7.78(1.07,64.92) | 5.12(1.06,22.12) | 0.28(0.01,0.69) | |
| SD ETN SC + MTX | SD GOLI SC | 0.89(0.08,10.10) | 0.90(0.18,8.44) | ‐0.01(‐0.50,0.18) |
| SD ABA IV + MTX | 1.31(0.12,14.37) | 1.24(0.26,11.15) | 0.04(‐0.45,0.25) | |
| SD ABA SC + MTX | 0.96(0.08,11.17) | 0.96(0.18,9.10) | ‐0.01(‐0.50,0.22) | |
| SD GOLI SC + MTX | 2.96(0.34,25.94) | 2.21(0.56,16.14) | 0.18(‐0.24,0.44) | |
| SD ADA SC + MTX | 1.10(0.10,12.89) | 1.08(0.21,10.13) | 0.01(‐0.48,0.24) | |
| SD INF IV + MTX | 0.63(0.05,7.62) | 0.67(0.12,6.55) | ‐0.05(‐0.53,0.15) | |
| SD RITUX IV + MTX | 1.01(0.08,12.47) | 1.01(0.18,9.79) | 0.00(‐0.49,0.24) | |
| SD GOLI IV + MTX | 0.91(0.08,11.45) | 0.93(0.17,9.11) | ‐0.01(‐0.49,0.22) | |
| SD CERTO + MTX | 3.11(0.13,171.40) | 2.18(0.22,26.61) | 0.18(‐0.38,0.82) | |
| SD TOFA PO + MTX | 1.21(0.08,21.40) | 1.16(0.15,13.28) | 0.02(‐0.47,0.42) | |
| LD GOLI IV | 0.61(0.05,8.20) | 0.66(0.10,6.84) | ‐0.05(‐0.54,0.18) | |
| LD RITUX IV + MTX | 0.42(0.03,5.11) | 0.46(0.08,4.64) | ‐0.08(‐0.57,0.10) | |
| LD ETN SC + MTX | 0.83(0.07,10.66) | 0.85(0.15,8.61) | ‐0.02(‐0.51,0.21) | |
| LD GOLI IV + MTX | 0.37(0.03,4.99) | 0.41(0.06,4.46) | ‐0.09(‐0.57,0.10) | |
| HD TOCI IV | 1.99(0.14,28.76) | 1.69(0.26,16.67) | 0.10(‐0.41,0.48) | |
| HD GOLI SC | 1.30(0.22,8.06) | 1.23(0.37,6.71) | 0.03(‐0.32,0.24) | |
| HD TOCI IV + MTX | 3.67(0.27,50.42) | 2.51(0.48,23.04) | 0.23(‐0.29,0.59) | |
| HD GOLI SC + MTX | 2.62(0.31,23.79) | 2.05(0.52,15.43) | 0.15(‐0.27,0.42) | |
| HD INF IV + MTX | 0.98(0.08,12.35) | 0.98(0.17,9.59) | 0.00(‐0.49,0.25) | |
| HD TOFA PO + MTX | 3.07(0.20,54.35) | 2.23(0.36,21.96) | 0.18(‐0.34,0.63) | |
| SD ABA IV + MTX | SD ETN SC + MTX | 1.48(0.53,4.24) | 1.38(0.59,3.35) | 0.05(‐0.09,0.21) |
| SD ABA SC + MTX | 1.09(0.31,3.61) | 1.08(0.37,2.92) | 0.01(‐0.14,0.18) | |
| SD GOLI SC + MTX | 3.32(0.91,12.57) | 2.48(0.93,6.26) | 0.21(‐0.01,0.48) | |
| SD ADA SC + MTX | 1.23(0.40,3.93) | 1.19(0.46,3.09) | 0.03(‐0.12,0.20) | |
| SD INF IV + MTX | 0.71(0.21,2.48) | 0.74(0.25,2.17) | ‐0.04(‐0.17,0.11) | |
| SD RITUX IV + MTX | 1.13(0.32,4.15) | 1.11(0.38,3.22) | 0.02(‐0.14,0.21) | |
| SD GOLI IV + MTX | 1.02(0.29,3.55) | 1.02(0.35,2.89) | 0.00(‐0.15,0.18) | |
| SD CERTO + MTX | 3.40(0.32,96.36) | 2.50(0.37,9.56) | 0.21(‐0.12,0.80) | |
| SD TOFA PO + MTX | 1.35(0.24,9.23) | 1.28(0.28,4.96) | 0.04(‐0.15,0.42) | |
| LD GOLI IV | 0.69(0.16,2.98) | 0.73(0.19,2.49) | ‐0.04(‐0.18,0.15) | |
| LD RITUX IV + MTX | 0.47(0.14,1.68) | 0.51(0.17,1.58) | ‐0.07(‐0.20,0.05) | |
| LD ETN SC + MTX | 0.92(0.32,2.70) | 0.94(0.37,2.26) | ‐0.01(‐0.13,0.15) | |
| LD GOLI IV + MTX | 0.41(0.09,1.76) | 0.45(0.11,1.64) | ‐0.07(‐0.21,0.06) | |
| HD TOCI IV | 2.21(0.46,11.41) | 1.88(0.52,5.73) | 0.12(‐0.10,0.47) | |
| HD GOLI SC | 1.47(0.30,7.52) | 1.38(0.35,4.55) | 0.05(‐0.14,0.36) | |
| HD TOCI IV + MTX | 4.06(1.01,18.90) | 2.80(1.01,7.22) | 0.25(0.00,0.57) | |
| HD GOLI SC + MTX | 2.97(0.82,11.42) | 2.30(0.85,6.00) | 0.18(‐0.03,0.45) | |
| HD INF IV + MTX | 1.09(0.30,4.14) | 1.08(0.35,3.17) | 0.01(‐0.14,0.22) | |
| HD TOFA PO + MTX | 3.44(0.61,23.13) | 2.52(0.66,7.40) | 0.22(‐0.06,0.62) | |
| SD ABA SC + MTX | SD ABA IV + MTX | 0.74(0.29,1.75) | 0.78(0.35,1.55) | ‐0.04(‐0.17,0.09) |
| SD GOLI SC + MTX | 2.25(0.64,8.15) | 1.80(0.71,4.15) | 0.15(‐0.08,0.44) | |
| SD ADA SC + MTX | 0.83(0.33,2.17) | 0.86(0.40,1.83) | ‐0.03(‐0.16,0.13) | |
| SD INF IV + MTX | 0.48(0.15,1.60) | 0.53(0.19,1.48) | ‐0.09(‐0.24,0.07) | |
| SD RITUX IV + MTX | 0.77(0.22,2.72) | 0.81(0.29,2.19) | ‐0.04(‐0.20,0.17) | |
| SD GOLI IV + MTX | 0.69(0.21,2.32) | 0.74(0.26,1.95) | ‐0.05(‐0.21,0.14) | |
| SD CERTO + MTX | 2.30(0.22,64.08) | 1.81(0.27,6.40) | 0.16(‐0.19,0.75) | |
| SD TOFA PO + MTX | 0.91(0.17,6.04) | 0.92(0.21,3.36) | ‐0.01(‐0.21,0.37) | |
| LD GOLI IV | 0.46(0.11,1.93) | 0.52(0.15,1.70) | ‐0.09(‐0.25,0.10) | |
| LD RITUX IV + MTX | 0.32(0.10,1.08) | 0.37(0.13,1.07) | ‐0.12(‐0.27,0.01) | |
| LD ETN SC + MTX | 0.63(0.17,2.23) | 0.68(0.22,1.89) | ‐0.06(‐0.22,0.13) | |
| LD GOLI IV + MTX | 0.27(0.06,1.16) | 0.32(0.09,1.14) | ‐0.13(‐0.27,0.02) | |
| HD TOCI IV | 1.49(0.32,7.39) | 1.36(0.39,3.84) | 0.07(‐0.16,0.42) | |
| HD GOLI SC | 0.99(0.21,4.87) | 0.99(0.26,3.09) | 0.00(‐0.20,0.31) | |
| HD TOCI IV + MTX | 2.75(0.71,11.99) | 2.03(0.77,4.78) | 0.20(‐0.06,0.53) | |
| HD GOLI SC + MTX | 2.02(0.55,7.41) | 1.67(0.63,4.00) | 0.13(‐0.10,0.41) | |
| HD INF IV + MTX | 0.74(0.22,2.50) | 0.78(0.28,2.02) | ‐0.04(‐0.20,0.16) | |
| HD TOFA PO + MTX | 2.31(0.43,15.08) | 1.82(0.50,4.87) | 0.16(‐0.12,0.57) | |
| SD GOLI SC + MTX | SD ABA SC + MTX | 3.08(0.76,13.00) | 2.32(0.81,6.60) | 0.20(‐0.05,0.48) |
| SD ADA SC + MTX | 1.13(0.36,3.92) | 1.10(0.43,3.12) | 0.02(‐0.15,0.19) | |
| SD INF IV + MTX | 0.65(0.18,2.58) | 0.69(0.22,2.27) | ‐0.05(‐0.22,0.11) | |
| SD RITUX IV + MTX | 1.04(0.27,4.32) | 1.03(0.33,3.37) | 0.01(‐0.18,0.21) | |
| SD GOLI IV + MTX | 0.93(0.25,3.73) | 0.94(0.31,3.04) | ‐0.01(‐0.19,0.18) | |
| SD CERTO + MTX | 3.14(0.27,91.33) | 2.32(0.33,9.80) | 0.20(‐0.15,0.79) | |
| SD TOFA PO + MTX | 1.24(0.21,9.08) | 1.19(0.26,5.02) | 0.03(‐0.18,0.41) | |
| LD GOLI IV | 0.63(0.14,3.03) | 0.67(0.18,2.55) | ‐0.05(‐0.22,0.15) | |
| LD RITUX IV + MTX | 0.43(0.12,1.76) | 0.47(0.15,1.65) | ‐0.08(‐0.24,0.06) | |
| LD ETN SC + MTX | 0.85(0.21,3.58) | 0.87(0.26,2.88) | ‐0.02(‐0.20,0.18) | |
| LD GOLI IV + MTX | 0.37(0.08,1.84) | 0.42(0.10,1.70) | ‐0.09(‐0.25,0.06) | |
| HD TOCI IV | 2.03(0.39,11.76) | 1.74(0.46,5.96) | 0.11(‐0.13,0.46) | |
| HD GOLI SC | 1.35(0.26,7.64) | 1.28(0.31,4.78) | 0.04(‐0.17,0.36) | |
| HD TOCI IV + MTX | 3.75(0.85,19.24) | 2.60(0.89,7.76) | 0.24(‐0.03,0.57) | |
| HD GOLI SC + MTX | 2.75(0.68,11.78) | 2.15(0.74,6.29) | 0.17(‐0.07,0.45) | |
| HD INF IV + MTX | 1.00(0.26,4.19) | 1.00(0.32,3.25) | 0.00(‐0.18,0.21) | |
| HD TOFA PO + MTX | 3.16(0.54,22.86) | 2.33(0.61,7.65) | 0.20(‐0.09,0.62) | |
| SD ADA SC + MTX | SD GOLI SC + MTX | 0.37(0.09,1.49) | 0.48(0.19,1.35) | ‐0.18(‐0.46,0.07) |
| SD INF IV + MTX | 0.21(0.05,0.90) | 0.30(0.10,0.92) | ‐0.24(‐0.52,‐0.02) | |
| SD RITUX IV + MTX | 0.34(0.08,1.49) | 0.45(0.15,1.34) | ‐0.19(‐0.47,0.07) | |
| SD GOLI IV + MTX | 0.31(0.07,1.31) | 0.41(0.14,1.22) | ‐0.20(‐0.48,0.05) | |
| SD CERTO + MTX | 1.03(0.08,31.79) | 1.02(0.15,3.86) | 0.01(‐0.43,0.64) | |
| SD TOFA PO + MTX | 0.41(0.06,3.16) | 0.52(0.11,2.04) | ‐0.16(‐0.48,0.26) | |
| LD GOLI IV | 0.21(0.04,1.04) | 0.29(0.08,1.03) | ‐0.24(‐0.52,0.01) | |
| LD RITUX IV + MTX | 0.14(0.03,0.61) | 0.21(0.07,0.67) | ‐0.27(‐0.54,‐0.07) | |
| LD ETN SC + MTX | 0.28(0.06,1.23) | 0.38(0.12,1.17) | ‐0.21(‐0.49,0.04) | |
| LD GOLI IV + MTX | 0.12(0.02,0.63) | 0.18(0.05,0.70) | ‐0.28(‐0.55,‐0.06) | |
| HD TOCI IV | 0.66(0.11,3.95) | 0.76(0.21,2.34) | ‐0.08(‐0.42,0.31) | |
| HD GOLI SC | 0.44(0.13,1.52) | 0.56(0.20,1.31) | ‐0.15(‐0.37,0.09) | |
| HD TOCI IV + MTX | 1.23(0.24,6.60) | 1.13(0.41,2.97) | 0.05(‐0.31,0.42) | |
| HD GOLI SC + MTX | 0.89(0.41,1.99) | 0.93(0.55,1.57) | ‐0.02(‐0.20,0.15) | |
| HD INF IV + MTX | 0.33(0.07,1.53) | 0.43(0.14,1.36) | ‐0.19(‐0.47,0.08) | |
| HD TOFA PO + MTX | 1.04(0.16,7.84) | 1.03(0.27,3.02) | 0.01(‐0.37,0.46) | |
| SD INF IV + MTX | SD ADA SC + MTX | 0.58(0.16,2.08) | 0.62(0.20,1.86) | ‐0.06(‐0.24,0.09) |
| SD RITUX IV + MTX | 0.92(0.24,3.53) | 0.94(0.31,2.77) | ‐0.01(‐0.20,0.19) | |
| SD GOLI IV + MTX | 0.83(0.22,3.06) | 0.85(0.28,2.51) | ‐0.02(‐0.21,0.16) | |
| SD CERTO + MTX | 2.75(0.25,80.90) | 2.09(0.30,8.25) | 0.18(‐0.17,0.78) | |
| SD TOFA PO + MTX | 1.09(0.18,7.62) | 1.08(0.23,4.23) | 0.01(‐0.21,0.40) | |
| LD GOLI IV | 0.56(0.12,2.44) | 0.61(0.16,2.09) | ‐0.06(‐0.24,0.13) | |
| LD RITUX IV + MTX | 0.38(0.10,1.41) | 0.43(0.14,1.35) | ‐0.09(‐0.26,0.04) | |
| LD ETN SC + MTX | 0.76(0.19,2.89) | 0.79(0.24,2.38) | ‐0.03(‐0.22,0.15) | |
| LD GOLI IV + MTX | 0.33(0.07,1.50) | 0.38(0.09,1.42) | ‐0.10(‐0.27,0.05) | |
| HD TOCI IV | 1.80(0.35,9.44) | 1.58(0.42,4.83) | 0.09(‐0.15,0.44) | |
| HD GOLI SC | 1.19(0.23,6.33) | 1.15(0.29,3.95) | 0.02(‐0.19,0.34) | |
| HD TOCI IV + MTX | 3.30(0.75,15.65) | 2.35(0.81,6.23) | 0.23(‐0.05,0.55) | |
| HD GOLI SC + MTX | 2.40(0.61,9.56) | 1.93(0.69,5.15) | 0.15(‐0.09,0.43) | |
| HD INF IV + MTX | 0.89(0.30,2.55) | 0.91(0.36,2.11) | ‐0.02(‐0.15,0.15) | |
| HD TOFA PO + MTX | 2.79(0.48,18.97) | 2.11(0.55,6.33) | 0.19(‐0.11,0.60) | |
| SD RITUX IV + MTX | SD INF IV + MTX | 1.61(0.39,6.53) | 1.51(0.44,4.92) | 0.05(‐0.11,0.25) |
| SD GOLI IV + MTX | 1.45(0.36,5.50) | 1.38(0.41,4.35) | 0.04(‐0.12,0.22) | |
| SD CERTO + MTX | 4.83(0.41,139.90) | 3.36(0.46,14.62) | 0.25(‐0.09,0.83) | |
| SD TOFA PO + MTX | 1.90(0.30,14.52) | 1.73(0.34,7.58) | 0.07(‐0.12,0.46) | |
| LD GOLI IV | 0.98(0.19,4.59) | 0.98(0.23,3.74) | 0.00(‐0.15,0.18) | |
| LD RITUX IV + MTX | 0.67(0.26,1.69) | 0.69(0.30,1.60) | ‐0.03(‐0.13,0.05) | |
| LD ETN SC + MTX | 1.31(0.30,5.36) | 1.27(0.35,4.26) | 0.03(‐0.13,0.21) | |
| LD GOLI IV + MTX | 0.58(0.11,2.82) | 0.60(0.13,2.53) | ‐0.04(‐0.18,0.10) | |
| HD TOCI IV | 3.11(0.58,17.79) | 2.52(0.63,8.80) | 0.16(‐0.07,0.50) | |
| HD GOLI SC | 2.07(0.38,11.71) | 1.84(0.43,7.08) | 0.09(‐0.10,0.40) | |
| HD TOCI IV + MTX | 5.76(1.23,29.64) | 3.78(1.18,11.45) | 0.29(0.03,0.61) | |
| HD GOLI SC + MTX | 4.20(0.99,17.74) | 3.10(0.99,9.28) | 0.22(0.00,0.48) | |
| HD INF IV + MTX | 1.55(0.37,6.58) | 1.46(0.42,4.93) | 0.05(‐0.11,0.25) | |
| HD TOFA PO + MTX | 4.86(0.78,36.18) | 3.38(0.81,11.54) | 0.25(‐0.03,0.66) | |
| SD GOLI IV + MTX | SD RITUX IV + MTX | 0.90(0.21,3.64) | 0.91(0.28,2.98) | ‐0.01(‐0.22,0.18) |
| SD CERTO + MTX | 3.00(0.26,85.82) | 2.23(0.32,9.56) | 0.19(‐0.17,0.79) | |
| SD TOFA PO + MTX | 1.19(0.17,9.07) | 1.15(0.22,5.06) | 0.02(‐0.21,0.41) | |
| LD GOLI IV | 0.61(0.19,1.95) | 0.65(0.23,1.76) | ‐0.05(‐0.21,0.09) | |
| LD RITUX IV + MTX | 0.42(0.10,1.77) | 0.46(0.13,1.66) | ‐0.08(‐0.28,0.06) | |
| LD ETN SC + MTX | 0.82(0.19,3.57) | 0.84(0.24,2.91) | ‐0.02(‐0.23,0.17) | |
| LD GOLI IV + MTX | 0.36(0.10,1.22) | 0.40(0.13,1.18) | ‐0.09(‐0.25,0.02) | |
| HD TOCI IV | 1.96(0.35,10.94) | 1.68(0.43,5.67) | 0.10(‐0.16,0.45) | |
| HD GOLI SC | 1.28(0.22,7.76) | 1.23(0.29,4.76) | 0.03(‐0.20,0.36) | |
| HD TOCI IV + MTX | 3.60(0.76,18.40) | 2.51(0.81,7.46) | 0.24(‐0.05,0.56) | |
| HD GOLI SC + MTX | 2.61(0.59,11.59) | 2.06(0.67,6.26) | 0.17(‐0.09,0.44) | |
| HD INF IV + MTX | 0.96(0.22,4.22) | 0.97(0.28,3.26) | 0.00(‐0.21,0.21) | |
| HD TOFA PO + MTX | 3.03(0.46,22.18) | 2.25(0.54,7.62) | 0.20(‐0.12,0.61) | |
| SD CERTO + MTX | SD GOLI IV + MTX | 3.38(0.30,95.03) | 2.47(0.35,10.37) | 0.21(‐0.15,0.80) |
| SD TOFA PO + MTX | 1.33(0.21,10.15) | 1.26(0.26,5.55) | 0.04(‐0.19,0.42) | |
| LD GOLI IV | 0.68(0.14,3.34) | 0.71(0.17,2.77) | ‐0.04(‐0.22,0.15) | |
| LD RITUX IV + MTX | 0.46(0.12,1.94) | 0.50(0.15,1.80) | ‐0.07(‐0.24,0.06) | |
| LD ETN SC + MTX | 0.91(0.21,3.88) | 0.92(0.26,3.14) | ‐0.01(‐0.20,0.18) | |
| LD GOLI IV + MTX | 0.40(0.08,2.00) | 0.44(0.10,1.85) | ‐0.08(‐0.25,0.07) | |
| HD TOCI IV | 2.18(0.40,12.48) | 1.84(0.48,6.34) | 0.12(‐0.13,0.47) | |
| HD GOLI SC | 1.43(0.25,8.39) | 1.34(0.32,5.14) | 0.05(‐0.17,0.36) | |
| HD TOCI IV + MTX | 3.99(0.88,20.79) | 2.74(0.91,8.32) | 0.25(‐0.02,0.58) | |
| HD GOLI SC + MTX | 2.92(0.68,12.70) | 2.27(0.74,6.77) | 0.18(‐0.06,0.45) | |
| HD INF IV + MTX | 1.07(0.25,4.68) | 1.06(0.31,3.59) | 0.01(‐0.18,0.22) | |
| HD TOFA PO + MTX | 3.37(0.53,25.33) | 2.47(0.60,8.31) | 0.21(‐0.09,0.63) | |
| SD TOFA PO + MTX | SD CERTO + MTX | 0.39(0.01,6.54) | 0.53(0.08,4.31) | ‐0.16(‐0.78,0.32) |
| LD GOLI IV | 0.20(0.01,2.58) | 0.29(0.06,2.25) | ‐0.25(‐0.83,0.10) | |
| LD RITUX IV + MTX | 0.14(0.00,1.63) | 0.21(0.04,1.55) | ‐0.28(‐0.86,0.04) | |
| LD ETN SC + MTX | 0.27(0.01,3.26) | 0.38(0.08,2.75) | ‐0.22(‐0.81,0.14) | |
| LD GOLI IV + MTX | 0.12(0.00,1.60) | 0.18(0.03,1.53) | ‐0.29(‐0.87,0.04) | |
| HD TOCI IV | 0.63(0.02,9.38) | 0.74(0.15,5.59) | ‐0.09(‐0.72,0.39) | |
| HD GOLI SC | 0.43(0.01,6.41) | 0.56(0.10,4.40) | ‐0.15(‐0.78,0.29) | |
| HD TOCI IV + MTX | 1.18(0.04,15.85) | 1.10(0.28,7.55) | 0.04(‐0.60,0.51) | |
| HD GOLI SC + MTX | 0.86(0.03,10.85) | 0.91(0.23,6.33) | ‐0.03(‐0.66,0.40) | |
| HD INF IV + MTX | 0.32(0.01,3.83) | 0.44(0.09,3.13) | ‐0.20(‐0.80,0.17) | |
| HD TOFA PO + MTX | 1.00(0.03,16.78) | 1.00(0.20,7.22) | 0.00(‐0.66,0.53) | |
| LD GOLI IV | SD TOFA PO + MTX | 0.51(0.06,3.84) | 0.57(0.11,3.26) | ‐0.07(‐0.46,0.15) |
| LD RITUX IV + MTX | 0.35(0.05,2.23) | 0.40(0.09,2.08) | ‐0.11(‐0.49,0.06) | |
| LD ETN SC + MTX | 0.69(0.09,4.57) | 0.73(0.16,3.73) | ‐0.05(‐0.43,0.18) | |
| LD GOLI IV + MTX | 0.30(0.03,2.31) | 0.35(0.06,2.12) | ‐0.11(‐0.49,0.07) | |
| HD TOCI IV | 1.63(0.17,14.23) | 1.45(0.29,7.68) | 0.08(‐0.34,0.46) | |
| HD GOLI SC | 1.08(0.12,9.33) | 1.06(0.20,6.10) | 0.01(‐0.38,0.35) | |
| HD TOCI IV + MTX | 3.03(0.35,24.24) | 2.17(0.52,10.32) | 0.21(‐0.23,0.57) | |
| HD GOLI SC + MTX | 2.18(0.29,14.76) | 1.78(0.45,8.32) | 0.14(‐0.27,0.45) | |
| HD INF IV + MTX | 0.81(0.10,5.60) | 0.84(0.19,4.34) | ‐0.03(‐0.41,0.22) | |
| HD TOFA PO + MTX | 2.54(0.77,8.35) | 1.90(0.84,4.96) | 0.16(‐0.05,0.42) | |
| LD RITUX IV + MTX | LD GOLI IV | 0.68(0.14,3.49) | 0.70(0.18,3.15) | ‐0.03(‐0.21,0.10) |
| LD ETN SC + MTX | 1.34(0.26,6.97) | 1.29(0.32,5.50) | 0.03(‐0.16,0.22) | |
| LD GOLI IV + MTX | 0.59(0.16,2.13) | 0.62(0.19,1.99) | ‐0.04(‐0.18,0.06) | |
| HD TOCI IV | 3.21(0.52,21.14) | 2.57(0.58,10.98) | 0.16(‐0.09,0.50) | |
| HD GOLI SC | 2.11(0.33,14.71) | 1.88(0.39,8.95) | 0.09(‐0.13,0.40) | |
| HD TOCI IV + MTX | 5.89(1.07,35.70) | 3.84(1.05,14.58) | 0.29(0.01,0.61) | |
| HD GOLI SC + MTX | 4.28(0.85,22.51) | 3.16(0.88,12.10) | 0.22(‐0.03,0.49) | |
| HD INF IV + MTX | 1.57(0.32,8.29) | 1.48(0.38,6.27) | 0.05(‐0.15,0.26) | |
| HD TOFA PO + MTX | 5.02(0.68,41.56) | 3.45(0.73,14.51) | 0.25(‐0.05,0.66) | |
| LD ETN SC + MTX | LD RITUX IV + MTX | 1.97(0.45,8.35) | 1.83(0.49,6.47) | 0.06(‐0.07,0.24) |
| LD GOLI IV + MTX | 0.87(0.17,4.33) | 0.87(0.19,3.78) | ‐0.01(‐0.12,0.12) | |
| HD TOCI IV | 4.73(0.84,27.17) | 3.68(0.86,13.18) | 0.19(‐0.02,0.53) | |
| HD GOLI SC | 3.09(0.56,17.99) | 2.66(0.59,10.63) | 0.12(‐0.05,0.42) | |
| HD TOCI IV + MTX | 8.66(1.83,45.28) | 5.47(1.63,17.09) | 0.32(0.08,0.64) | |
| HD GOLI SC + MTX | 6.35(1.46,27.01) | 4.52(1.36,13.87) | 0.25(0.05,0.51) | |
| HD INF IV + MTX | 2.32(0.54,9.92) | 2.11(0.57,7.28) | 0.08(‐0.06,0.28) | |
| HD TOFA PO + MTX | 7.28(1.16,54.51) | 4.88(1.13,17.36) | 0.28(0.02,0.69) | |
| LD GOLI IV + MTX | LD ETN SC + MTX | 0.44(0.08,2.25) | 0.48(0.11,2.06) | ‐0.07(‐0.25,0.08) |
| HD TOCI IV | 2.39(0.42,14.52) | 2.00(0.49,7.43) | 0.13(‐0.12,0.48) | |
| HD GOLI SC | 1.58(0.27,9.48) | 1.46(0.33,5.95) | 0.06(‐0.17,0.37) | |
| HD TOCI IV + MTX | 4.41(0.89,24.33) | 2.98(0.92,9.81) | 0.26(‐0.02,0.59) | |
| HD GOLI SC + MTX | 3.20(0.73,14.55) | 2.45(0.79,7.88) | 0.19(‐0.05,0.46) | |
| HD INF IV + MTX | 1.17(0.26,5.51) | 1.15(0.32,4.19) | 0.02(‐0.18,0.23) | |
| HD TOFA PO + MTX | 3.68(0.58,28.24) | 2.65(0.64,9.74) | 0.22(‐0.08,0.63) | |
| HD TOCI IV | LD GOLI IV + MTX | 5.42(0.85,36.93) | 4.15(0.87,18.80) | 0.20(‐0.02,0.54) |
| HD GOLI SC | 3.57(0.54,25.19) | 3.03(0.59,15.30) | 0.13(‐0.06,0.43) | |
| HD TOCI IV + MTX | 9.93(1.80,60.87) | 6.18(1.59,25.14) | 0.33(0.08,0.64) | |
| HD GOLI SC + MTX | 7.23(1.42,39.03) | 5.08(1.33,20.87) | 0.26(0.05,0.52) | |
| HD INF IV + MTX | 2.67(0.52,14.26) | 2.40(0.56,10.66) | 0.09(‐0.07,0.29) | |
| HD TOFA PO + MTX | 8.50(1.13,72.78) | 5.57(1.11,24.42) | 0.29(0.01,0.70) | |
| HD GOLI SC | HD TOCI IV | 0.66(0.09,4.91) | 0.73(0.17,3.28) | ‐0.07(‐0.44,0.29) |
| HD TOCI IV + MTX | 1.83(0.81,4.61) | 1.46(0.88,3.04) | 0.12(‐0.05,0.31) | |
| HD GOLI SC + MTX | 1.35(0.23,7.71) | 1.23(0.39,4.44) | 0.06(‐0.33,0.39) | |
| HD INF IV + MTX | 0.49(0.08,2.84) | 0.58(0.16,2.31) | ‐0.11(‐0.46,0.16) | |
| HD TOFA PO + MTX | 1.55(0.18,14.57) | 1.33(0.31,5.42) | 0.09(‐0.35,0.55) | |
| HD TOCI IV + MTX | HD GOLI SC | 2.78(0.43,18.85) | 2.03(0.57,8.00) | 0.20(‐0.18,0.55) |
| HD GOLI SC + MTX | 2.00(0.60,7.01) | 1.65(0.71,4.74) | 0.12(‐0.11,0.34) | |
| HD INF IV + MTX | 0.74(0.12,4.36) | 0.79(0.20,3.43) | ‐0.04(‐0.36,0.20) | |
| HD TOFA PO + MTX | 2.37(0.29,21.00) | 1.83(0.41,7.89) | 0.16(‐0.23,0.59) | |
| HD GOLI SC + MTX | HD TOCI IV + MTX | 0.73(0.13,3.62) | 0.82(0.30,2.30) | ‐0.07(‐0.44,0.28) |
| HD INF IV + MTX | 0.27(0.05,1.32) | 0.39(0.12,1.22) | ‐0.24(‐0.57,0.05) | |
| HD TOFA PO + MTX | 0.84(0.10,7.14) | 0.90(0.23,2.86) | ‐0.04(‐0.47,0.44) | |
| HD INF IV + MTX | HD GOLI SC + MTX | 0.37(0.08,1.66) | 0.47(0.15,1.46) | ‐0.17(‐0.45,0.09) |
| HD TOFA PO + MTX | 1.16(0.18,8.74) | 1.10(0.29,3.31) | 0.03(‐0.34,0.48) | |
| HD TOFA PO + MTX | HD INF IV + MTX | 3.12(0.48,24.05) | 2.31(0.56,8.31) | 0.20(‐0.11,0.62) |
| Random‐effects model | Residual deviance | 75.74 vs 74 data points | ||
| Deviance information criteria | 478.266 | |||
| Fixed‐effect model | Residual deviance | 113.5 vs 74 data points | ||
| Deviance information criteria | 504.534 | |||
| Note | ||||
| Total participants | 13,479 | |||
| Total studies | 29 | |||
| 2‐arm | 16 | |||
| 3‐arm | 11 | |||
| 4‐arm | 1 | |||
| 5‐arm | 1 | |||
Appendix 13. Remission: subgroup ‐ trial duration (<= 6 months) network 1
| Remission short, network 1: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| PL | MTX + PL | 1.02(0.13,7.23) | 1.02(0.14,5.92) | 0.00(‐0.04,0.17) |
| SD ADA SC | 1.30(0.23,7.29) | 1.29(0.24,5.96) | 0.01(‐0.03,0.17) | |
| SD GOLI IV | 1.43(0.46,4.54) | 1.40(0.47,4.03) | 0.02(‐0.02,0.11) | |
| SD GOLI SC | 3.56(0.42,30.78) | 3.25(0.43,15.03) | 0.09(‐0.02,0.50) | |
| SD ABA IV + MTX | 4.64(2.54,9.03) | 4.07(2.39,7.01) | 0.12(0.05,0.22) | |
| SD GOLI SC + MTX | 10.73(4.13,31.34) | 7.80(3.64,15.92) | 0.26(0.11,0.49) | |
| SD ABA SC + MTX | 3.62(1.47,8.24) | 3.29(1.44,6.52) | 0.09(0.02,0.21) | |
| SD INF IV + MTX | 3.76(1.87,8.65) | 3.40(1.81,6.79) | 0.09(0.03,0.22) | |
| SD GOLI IV + MTX | 3.64(1.48,9.89) | 3.31(1.45,7.52) | 0.09(0.02,0.24) | |
| SD CERTO + MTX | 3.21(1.36,7.93) | 2.96(1.34,6.33) | 0.07(0.01,0.20) | |
| SD ADA SC + MTX | 10.55(1.27,278.50) | 7.69(1.25,28.95) | 0.26(0.01,0.87) | |
| SD RITUX IV + MTX | 4.64(1.13,21.72) | 4.07(1.13,12.45) | 0.12(0.00,0.41) | |
| LD GOLI IV | 2.23(0.73,6.90) | 2.13(0.74,5.67) | 0.04(‐0.01,0.17) | |
| LD RITUX IV + MTX | 4.78(1.18,22.42) | 4.18(1.17,12.68) | 0.12(0.01,0.42) | |
| LD GOLI IV + MTX | 1.32(0.41,4.19) | 1.30(0.42,3.75) | 0.01(‐0.02,0.10) | |
| HD TOCI IV | 7.52(2.12,29.66) | 6.01(2.03,15.14) | 0.19(0.04,0.48) | |
| HD GOLI SC | 4.61(1.28,18.39) | 4.05(1.27,11.58) | 0.12(0.01,0.36) | |
| HD TOCI IV + MTX | 13.01(4.27,48.87) | 8.89(3.78,18.95) | 0.30(0.11,0.60) | |
| HD GOLI SC + MTX | 9.34(3.56,27.52) | 7.07(3.21,14.86) | 0.23(0.09,0.46) | |
| HD INF IV + MTX | 3.42(1.37,9.17) | 3.13(1.35,7.04) | 0.08(0.01,0.23) | |
| SD ADA SC | PL | 1.32(0.09,17.85) | 1.30(0.10,15.38) | 0.01(‐0.17,0.17) |
| SD GOLI IV | 1.41(0.14,14.45) | 1.39(0.17,13.08) | 0.01(‐0.16,0.11) | |
| SD GOLI SC | 3.53(0.89,15.52) | 3.10(0.90,11.21) | 0.08(‐0.01,0.40) | |
| SD ABA IV + MTX | 4.61(0.60,39.26) | 4.02(0.65,31.84) | 0.11(‐0.07,0.23) | |
| SD GOLI SC + MTX | 10.77(1.72,70.14) | 7.69(1.51,47.78) | 0.25(0.08,0.45) | |
| SD ABA SC + MTX | 3.55(0.40,31.45) | 3.22(0.45,26.18) | 0.08(‐0.10,0.21) | |
| SD INF IV + MTX | 3.74(0.48,33.61) | 3.37(0.53,27.59) | 0.09(‐0.09,0.22) | |
| SD GOLI IV + MTX | 3.65(0.43,33.50) | 3.29(0.48,27.39) | 0.08(‐0.10,0.24) | |
| SD CERTO + MTX | 3.19(0.37,28.06) | 2.92(0.43,23.81) | 0.07(‐0.11,0.20) | |
| SD ADA SC + MTX | 11.28(0.57,490.80) | 7.61(0.61,90.41) | 0.25(‐0.05,0.86) | |
| SD RITUX IV + MTX | 4.66(0.41,58.97) | 4.01(0.46,38.62) | 0.11(‐0.09,0.41) | |
| LD GOLI IV | 2.23(0.24,21.68) | 2.12(0.28,18.65) | 0.04(‐0.13,0.17) | |
| LD RITUX IV + MTX | 4.78(0.43,62.35) | 4.10(0.49,41.53) | 0.11(‐0.08,0.42) | |
| LD GOLI IV + MTX | 1.31(0.13,13.37) | 1.30(0.16,12.13) | 0.01(‐0.16,0.11) | |
| HD TOCI IV | 7.60(0.68,86.19) | 5.93(0.72,52.77) | 0.18(‐0.05,0.48) | |
| HD GOLI SC | 4.58(1.12,21.84) | 3.94(1.10,18.47) | 0.11(0.01,0.29) | |
| HD TOCI IV + MTX | 13.21(1.31,144.40) | 8.78(1.23,74.37) | 0.29(0.04,0.60) | |
| HD GOLI SC + MTX | 9.44(1.55,63.26) | 6.98(1.40,44.69) | 0.22(0.06,0.42) | |
| HD INF IV + MTX | 3.40(0.40,31.17) | 3.09(0.44,25.68) | 0.07(‐0.10,0.23) | |
| SD GOLI IV | SD ADA SC | 1.11(0.14,8.73) | 1.10(0.16,7.93) | 0.00(‐0.16,0.11) |
| SD GOLI SC | 2.71(0.19,47.64) | 2.47(0.21,25.90) | 0.07(‐0.12,0.49) | |
| SD ABA IV + MTX | 3.55(0.59,23.21) | 3.14(0.65,18.80) | 0.10(‐0.07,0.22) | |
| SD GOLI SC + MTX | 8.30(1.14,63.29) | 6.02(1.11,37.52) | 0.24(0.02,0.48) | |
| SD ABA SC + MTX | 2.75(0.41,19.04) | 2.52(0.46,15.52) | 0.07(‐0.10,0.20) | |
| SD INF IV + MTX | 2.90(0.47,20.44) | 2.64(0.53,16.67) | 0.08(‐0.09,0.21) | |
| SD GOLI IV + MTX | 2.82(0.40,20.17) | 2.58(0.45,16.28) | 0.07(‐0.10,0.23) | |
| SD CERTO + MTX | 2.48(0.36,17.55) | 2.31(0.42,14.61) | 0.06(‐0.11,0.20) | |
| SD ADA SC + MTX | 8.67(0.54,322.10) | 6.02(0.58,50.30) | 0.24(‐0.05,0.86) | |
| SD RITUX IV + MTX | 3.58(0.40,37.56) | 3.13(0.45,24.46) | 0.10(‐0.09,0.40) | |
| LD GOLI IV | 1.73(0.22,13.67) | 1.66(0.26,11.58) | 0.03(‐0.14,0.17) | |
| LD RITUX IV + MTX | 3.67(0.42,38.80) | 3.20(0.47,25.07) | 0.10(‐0.09,0.41) | |
| LD GOLI IV + MTX | 1.02(0.13,7.94) | 1.02(0.15,7.23) | 0.00(‐0.16,0.10) | |
| HD TOCI IV | 5.86(1.95,17.74) | 4.61(1.68,14.05) | 0.17(0.05,0.37) | |
| HD GOLI SC | 3.52(0.41,33.97) | 3.10(0.46,23.66) | 0.10(‐0.09,0.36) | |
| HD TOCI IV + MTX | 10.08(2.86,42.71) | 6.75(2.14,27.63) | 0.28(0.11,0.51) | |
| HD GOLI SC + MTX | 7.19(1.00,57.28) | 5.45(1.00,35.01) | 0.21(0.00,0.45) | |
| HD INF IV + MTX | 2.63(0.38,19.53) | 2.42(0.44,15.73) | 0.07(‐0.10,0.22) | |
| SD GOLI SC | SD GOLI IV | 2.50(0.22,29.37) | 2.30(0.24,15.68) | 0.07(‐0.08,0.48) |
| SD ABA IV + MTX | 3.25(0.91,12.19) | 2.89(0.92,9.88) | 0.10(‐0.01,0.21) | |
| SD GOLI SC + MTX | 7.64(1.73,36.50) | 5.56(1.58,20.65) | 0.24(0.07,0.47) | |
| SD ABA SC + MTX | 2.51(0.59,10.11) | 2.31(0.63,8.40) | 0.07(‐0.04,0.19) | |
| SD INF IV + MTX | 2.66(0.70,10.96) | 2.44(0.73,8.99) | 0.07(‐0.03,0.20) | |
| SD GOLI IV + MTX | 2.55(0.88,7.86) | 2.34(0.90,6.62) | 0.07(‐0.01,0.19) | |
| SD CERTO + MTX | 2.26(0.54,9.70) | 2.12(0.57,8.02) | 0.06(‐0.05,0.19) | |
| SD ADA SC + MTX | 7.71(0.64,222.50) | 5.48(0.67,31.74) | 0.24(‐0.03,0.85) | |
| SD RITUX IV + MTX | 3.29(0.53,22.27) | 2.91(0.56,14.12) | 0.10(‐0.05,0.40) | |
| LD GOLI IV | 1.56(0.50,4.98) | 1.51(0.53,4.43) | 0.03(‐0.05,0.13) | |
| LD RITUX IV + MTX | 3.40(0.55,23.16) | 2.99(0.58,14.60) | 0.10(‐0.04,0.41) | |
| LD GOLI IV + MTX | 0.92(0.28,3.05) | 0.93(0.30,2.87) | 0.00(‐0.08,0.07) | |
| HD TOCI IV | 5.29(0.90,31.93) | 4.24(0.92,18.03) | 0.17(‐0.01,0.47) | |
| HD GOLI SC | 3.25(0.58,19.52) | 2.88(0.61,13.26) | 0.10(‐0.04,0.35) | |
| HD TOCI IV + MTX | 9.18(1.86,52.28) | 6.28(1.67,24.03) | 0.28(0.07,0.59) | |
| HD GOLI SC + MTX | 6.61(1.47,31.64) | 5.04(1.39,19.09) | 0.21(0.04,0.44) | |
| HD INF IV + MTX | 2.41(0.56,10.60) | 2.23(0.59,8.62) | 0.06(‐0.05,0.21) | |
| SD ABA IV + MTX | SD GOLI SC | 1.31(0.14,12.45) | 1.26(0.25,10.16) | 0.03(‐0.39,0.19) |
| SD GOLI SC + MTX | 3.06(0.42,22.38) | 2.40(0.58,15.49) | 0.16(‐0.19,0.38) | |
| SD ABA SC + MTX | 1.01(0.10,10.03) | 1.01(0.18,8.47) | 0.00(‐0.42,0.17) | |
| SD INF IV + MTX | 1.07(0.11,10.50) | 1.06(0.20,8.78) | 0.01(‐0.41,0.18) | |
| SD GOLI IV + MTX | 1.03(0.10,10.66) | 1.02(0.18,8.85) | 0.00(‐0.41,0.19) | |
| SD CERTO + MTX | 0.90(0.09,9.21) | 0.92(0.16,7.91) | ‐0.01(‐0.42,0.16) | |
| SD ADA SC + MTX | 3.17(0.15,138.40) | 2.36(0.22,27.91) | 0.16(‐0.32,0.79) | |
| SD RITUX IV + MTX | 1.30(0.11,18.12) | 1.25(0.17,12.61) | 0.03(‐0.39,0.35) | |
| LD GOLI IV | 0.63(0.06,6.88) | 0.66(0.10,6.07) | ‐0.04(‐0.45,0.13) | |
| LD RITUX IV + MTX | 1.36(0.11,18.80) | 1.29(0.18,12.79) | 0.03(‐0.38,0.36) | |
| LD GOLI IV + MTX | 0.37(0.03,4.33) | 0.40(0.06,4.03) | ‐0.07(‐0.48,0.07) | |
| HD TOCI IV | 2.13(0.16,25.65) | 1.85(0.27,16.56) | 0.10(‐0.35,0.42) | |
| HD GOLI SC | 1.30(0.24,6.99) | 1.25(0.37,5.92) | 0.03(‐0.28,0.19) | |
| HD TOCI IV + MTX | 3.73(0.31,45.30) | 2.73(0.46,23.56) | 0.20(‐0.25,0.54) | |
| HD GOLI SC + MTX | 2.66(0.36,20.08) | 2.17(0.53,14.30) | 0.13(‐0.22,0.35) | |
| HD INF IV + MTX | 0.97(0.09,9.98) | 0.97(0.17,8.40) | 0.00(‐0.42,0.18) | |
| SD GOLI SC + MTX | SD ABA IV + MTX | 2.31(0.73,7.75) | 1.91(0.77,4.51) | 0.14(‐0.05,0.39) |
| SD ABA SC + MTX | 0.78(0.33,1.62) | 0.81(0.37,1.49) | ‐0.03(‐0.13,0.07) | |
| SD INF IV + MTX | 0.82(0.36,1.96) | 0.84(0.41,1.75) | ‐0.02(‐0.13,0.09) | |
| SD GOLI IV + MTX | 0.79(0.25,2.49) | 0.81(0.30,2.11) | ‐0.03(‐0.16,0.13) | |
| SD CERTO + MTX | 0.69(0.23,2.03) | 0.73(0.28,1.81) | ‐0.04(‐0.17,0.09) | |
| SD ADA SC + MTX | 2.28(0.24,61.63) | 1.89(0.29,7.79) | 0.14(‐0.15,0.77) | |
| SD RITUX IV + MTX | 1.00(0.21,4.99) | 1.00(0.25,3.30) | 0.00(‐0.16,0.30) | |
| LD GOLI IV | 0.48(0.13,1.70) | 0.52(0.16,1.57) | ‐0.07(‐0.19,0.07) | |
| LD RITUX IV + MTX | 1.04(0.22,5.26) | 1.03(0.26,3.41) | 0.00(‐0.16,0.31) | |
| LD GOLI IV + MTX | 0.28(0.07,1.05) | 0.32(0.09,1.04) | ‐0.10(‐0.22,0.00) | |
| HD TOCI IV | 1.63(0.38,7.24) | 1.48(0.44,4.18) | 0.07(‐0.12,0.38) | |
| HD GOLI SC | 0.99(0.24,4.38) | 0.99(0.28,3.13) | 0.00(‐0.16,0.26) | |
| HD TOCI IV + MTX | 2.80(0.77,11.87) | 2.18(0.81,5.35) | 0.18(‐0.04,0.50) | |
| HD GOLI SC + MTX | 2.01(0.63,6.82) | 1.74(0.69,4.15) | 0.11(‐0.07,0.35) | |
| HD INF IV + MTX | 0.74(0.25,2.18) | 0.77(0.30,1.90) | ‐0.03(‐0.15,0.11) | |
| SD ABA SC + MTX | SD GOLI SC + MTX | 0.33(0.08,1.20) | 0.42(0.14,1.16) | ‐0.17(‐0.41,0.03) |
| SD INF IV + MTX | 0.35(0.10,1.25) | 0.44(0.17,1.19) | ‐0.17(‐0.41,0.03) | |
| SD GOLI IV + MTX | 0.33(0.09,1.35) | 0.42(0.15,1.27) | ‐0.17(‐0.41,0.05) | |
| SD CERTO + MTX | 0.30(0.08,1.10) | 0.38(0.13,1.08) | ‐0.18(‐0.43,0.01) | |
| SD ADA SC + MTX | 1.02(0.09,26.57) | 1.01(0.14,4.24) | 0.00(‐0.38,0.64) | |
| SD RITUX IV + MTX | 0.43(0.08,2.62) | 0.52(0.13,1.96) | ‐0.14(‐0.40,0.19) | |
| LD GOLI IV | 0.20(0.05,0.91) | 0.27(0.08,0.92) | ‐0.21(‐0.45,‐0.01) | |
| LD RITUX IV + MTX | 0.44(0.08,2.70) | 0.54(0.13,1.99) | ‐0.13(‐0.40,0.20) | |
| LD GOLI IV + MTX | 0.12(0.03,0.56) | 0.17(0.04,0.61) | ‐0.25(‐0.48,‐0.07) | |
| HD TOCI IV | 0.69(0.13,3.71) | 0.77(0.21,2.43) | ‐0.07(‐0.36,0.27) | |
| HD GOLI SC | 0.42(0.14,1.33) | 0.52(0.20,1.22) | ‐0.14(‐0.32,0.06) | |
| HD TOCI IV + MTX | 1.21(0.26,6.11) | 1.14(0.39,3.14) | 0.04(‐0.28,0.39) | |
| HD GOLI SC + MTX | 0.87(0.43,1.82) | 0.91(0.55,1.53) | ‐0.03(‐0.17,0.12) | |
| HD INF IV + MTX | 0.32(0.08,1.22) | 0.40(0.14,1.17) | ‐0.18(‐0.42,0.03) | |
| SD INF IV + MTX | SD ABA SC + MTX | 1.04(0.40,3.38) | 1.04(0.45,2.89) | 0.00(‐0.11,0.14) |
| SD GOLI IV + MTX | 1.01(0.30,3.90) | 1.01(0.35,3.22) | 0.00(‐0.14,0.16) | |
| SD CERTO + MTX | 0.89(0.27,3.19) | 0.90(0.32,2.76) | ‐0.01(‐0.15,0.13) | |
| SD ADA SC + MTX | 3.03(0.29,84.52) | 2.40(0.34,11.34) | 0.17(‐0.12,0.79) | |
| SD RITUX IV + MTX | 1.30(0.26,7.55) | 1.25(0.30,4.94) | 0.03(‐0.13,0.33) | |
| LD GOLI IV | 0.62(0.16,2.62) | 0.65(0.19,2.31) | ‐0.04(‐0.17,0.10) | |
| LD RITUX IV + MTX | 1.34(0.27,7.82) | 1.28(0.31,5.03) | 0.03(‐0.13,0.34) | |
| LD GOLI IV + MTX | 0.37(0.09,1.59) | 0.40(0.11,1.52) | ‐0.07(‐0.20,0.04) | |
| HD TOCI IV | 2.10(0.46,10.73) | 1.84(0.51,6.23) | 0.10(‐0.09,0.41) | |
| HD GOLI SC | 1.29(0.29,6.69) | 1.24(0.33,4.64) | 0.03(‐0.13,0.29) | |
| HD TOCI IV + MTX | 3.64(0.92,17.80) | 2.72(0.94,8.17) | 0.21(‐0.01,0.53) | |
| HD GOLI SC + MTX | 2.63(0.74,10.50) | 2.18(0.78,6.45) | 0.14(‐0.04,0.39) | |
| HD INF IV + MTX | 0.95(0.29,3.51) | 0.95(0.34,2.97) | ‐0.01(‐0.13,0.15) | |
| SD GOLI IV + MTX | SD INF IV + MTX | 0.96(0.28,3.24) | 0.97(0.33,2.69) | 0.00(‐0.15,0.15) |
| SD CERTO + MTX | 0.85(0.25,2.66) | 0.87(0.30,2.31) | ‐0.02(‐0.15,0.12) | |
| SD ADA SC + MTX | 2.79(0.27,77.24) | 2.24(0.32,9.97) | 0.16(‐0.13,0.78) | |
| SD RITUX IV + MTX | 1.23(0.23,6.51) | 1.19(0.27,4.22) | 0.02(‐0.15,0.32) | |
| LD GOLI IV | 0.59(0.14,2.20) | 0.62(0.17,1.97) | ‐0.05(‐0.18,0.09) | |
| LD RITUX IV + MTX | 1.26(0.24,6.78) | 1.22(0.29,4.30) | 0.03(‐0.15,0.33) | |
| LD GOLI IV + MTX | 0.35(0.08,1.32) | 0.38(0.10,1.28) | ‐0.08(‐0.21,0.03) | |
| HD TOCI IV | 2.00(0.42,9.02) | 1.76(0.48,5.20) | 0.10(‐0.11,0.40) | |
| HD GOLI SC | 1.22(0.26,5.62) | 1.18(0.31,3.95) | 0.02(‐0.15,0.28) | |
| HD TOCI IV + MTX | 3.44(0.86,15.09) | 2.59(0.89,6.83) | 0.21(‐0.02,0.52) | |
| HD GOLI SC + MTX | 2.47(0.70,8.84) | 2.06(0.74,5.39) | 0.14(‐0.05,0.38) | |
| HD INF IV + MTX | 0.91(0.35,2.26) | 0.92(0.40,1.98) | ‐0.01(‐0.12,0.11) | |
| SD CERTO + MTX | SD GOLI IV + MTX | 0.88(0.23,3.24) | 0.89(0.29,2.80) | ‐0.01(‐0.18,0.13) |
| SD ADA SC + MTX | 2.98(0.27,81.52) | 2.34(0.32,11.07) | 0.17(‐0.14,0.79) | |
| SD RITUX IV + MTX | 1.27(0.23,7.74) | 1.23(0.27,4.98) | 0.03(‐0.16,0.33) | |
| LD GOLI IV | 0.61(0.21,1.74) | 0.64(0.24,1.62) | ‐0.04(‐0.16,0.06) | |
| LD RITUX IV + MTX | 1.31(0.23,7.91) | 1.26(0.28,5.06) | 0.03(‐0.16,0.34) | |
| LD GOLI IV + MTX | 0.36(0.12,1.06) | 0.40(0.14,1.05) | ‐0.07(‐0.20,0.00) | |
| HD TOCI IV | 2.07(0.41,10.99) | 1.80(0.47,6.31) | 0.10(‐0.11,0.41) | |
| HD GOLI SC | 1.27(0.25,6.53) | 1.23(0.30,4.60) | 0.03(‐0.16,0.29) | |
| HD TOCI IV + MTX | 3.57(0.82,18.21) | 2.66(0.86,8.18) | 0.21(‐0.03,0.53) | |
| HD GOLI SC + MTX | 2.61(0.65,10.30) | 2.15(0.71,6.30) | 0.14(‐0.07,0.38) | |
| HD INF IV + MTX | 0.94(0.24,3.52) | 0.95(0.30,2.97) | ‐0.01(‐0.17,0.15) | |
| SD ADA SC + MTX | SD CERTO + MTX | 3.34(0.33,97.49) | 2.61(0.37,12.59) | 0.18(‐0.11,0.80) |
| SD RITUX IV + MTX | 1.45(0.28,8.31) | 1.38(0.32,5.29) | 0.04(‐0.12,0.34) | |
| LD GOLI IV | 0.70(0.16,2.87) | 0.72(0.19,2.53) | ‐0.03(‐0.17,0.11) | |
| LD RITUX IV + MTX | 1.49(0.29,8.70) | 1.41(0.33,5.49) | 0.04(‐0.12,0.35) | |
| LD GOLI IV + MTX | 0.41(0.10,1.71) | 0.44(0.11,1.62) | ‐0.06(‐0.19,0.05) | |
| HD TOCI IV | 2.34(0.49,11.91) | 2.02(0.54,6.76) | 0.11(‐0.09,0.42) | |
| HD GOLI SC | 1.42(0.30,7.41) | 1.36(0.35,5.11) | 0.04(‐0.13,0.30) | |
| HD TOCI IV + MTX | 4.05(0.97,19.75) | 2.98(0.98,9.09) | 0.22(0.00,0.54) | |
| HD GOLI SC + MTX | 2.93(0.79,11.69) | 2.39(0.83,6.97) | 0.15(‐0.03,0.39) | |
| HD INF IV + MTX | 1.07(0.29,3.90) | 1.06(0.34,3.26) | 0.01(‐0.13,0.16) | |
| SD RITUX IV + MTX | SD ADA SC + MTX | 0.43(0.01,5.91) | 0.53(0.08,4.32) | ‐0.13(‐0.77,0.26) |
| LD GOLI IV | 0.20(0.01,2.39) | 0.27(0.05,2.18) | ‐0.21(‐0.83,0.08) | |
| LD RITUX IV + MTX | 0.44(0.01,6.24) | 0.54(0.09,4.41) | ‐0.13(‐0.77,0.26) | |
| LD GOLI IV + MTX | 0.12(0.00,1.42) | 0.17(0.03,1.38) | ‐0.24(‐0.85,0.02) | |
| HD TOCI IV | 0.69(0.02,8.56) | 0.77(0.14,5.61) | ‐0.07(‐0.72,0.33) | |
| HD GOLI SC | 0.42(0.01,5.69) | 0.52(0.09,4.24) | ‐0.14(‐0.77,0.24) | |
| HD TOCI IV + MTX | 1.23(0.04,14.53) | 1.14(0.24,7.79) | 0.04(‐0.64,0.46) | |
| HD GOLI SC + MTX | 0.87(0.03,9.72) | 0.90(0.21,6.37) | ‐0.03(‐0.67,0.35) | |
| HD INF IV + MTX | 0.32(0.01,3.55) | 0.40(0.08,3.05) | ‐0.17(‐0.80,0.13) | |
| LD GOLI IV | SD RITUX IV + MTX | 0.48(0.07,2.91) | 0.53(0.11,2.59) | ‐0.07(‐0.37,0.10) |
| LD RITUX IV + MTX | 1.03(0.32,3.38) | 1.03(0.39,2.72) | 0.00(‐0.18,0.19) | |
| LD GOLI IV + MTX | 0.28(0.04,1.72) | 0.32(0.07,1.64) | ‐0.10(‐0.40,0.04) | |
| HD TOCI IV | 1.64(0.21,10.95) | 1.48(0.30,6.69) | 0.07(‐0.28,0.39) | |
| HD GOLI SC | 1.00(0.13,6.82) | 1.00(0.20,4.94) | 0.00(‐0.32,0.27) | |
| HD TOCI IV + MTX | 2.84(0.41,18.48) | 2.18(0.54,9.28) | 0.18(‐0.17,0.51) | |
| HD GOLI SC + MTX | 2.04(0.33,11.71) | 1.74(0.46,7.51) | 0.11(‐0.22,0.37) | |
| HD INF IV + MTX | 0.74(0.12,4.15) | 0.77(0.19,3.51) | ‐0.03(‐0.34,0.15) | |
| LD RITUX IV + MTX | LD GOLI IV | 2.17(0.36,14.89) | 1.97(0.40,9.39) | 0.08(‐0.10,0.38) |
| LD GOLI IV + MTX | 0.59(0.19,1.89) | 0.62(0.21,1.80) | ‐0.03(‐0.14,0.04) | |
| HD TOCI IV | 3.40(0.59,19.68) | 2.83(0.64,11.27) | 0.14(‐0.06,0.44) | |
| HD GOLI SC | 2.10(0.38,11.85) | 1.91(0.42,8.22) | 0.07(‐0.10,0.32) | |
| HD TOCI IV + MTX | 5.89(1.23,32.83) | 4.17(1.18,15.06) | 0.25(0.03,0.56) | |
| HD GOLI SC + MTX | 4.29(0.96,19.28) | 3.36(0.97,11.80) | 0.19(‐0.01,0.42) | |
| HD INF IV + MTX | 1.54(0.36,6.75) | 1.47(0.41,5.54) | 0.04(‐0.11,0.19) | |
| LD GOLI IV + MTX | LD RITUX IV + MTX | 0.27(0.04,1.68) | 0.31(0.06,1.61) | ‐0.11(‐0.41,0.04) |
| HD TOCI IV | 1.58(0.20,10.50) | 1.44(0.29,6.43) | 0.07(‐0.28,0.38) | |
| HD GOLI SC | 0.96(0.13,6.78) | 0.97(0.20,4.90) | 0.00(‐0.32,0.27) | |
| HD TOCI IV + MTX | 2.76(0.39,17.69) | 2.13(0.53,8.73) | 0.17(‐0.19,0.51) | |
| HD GOLI SC + MTX | 1.97(0.33,11.42) | 1.70(0.45,7.20) | 0.11(‐0.22,0.37) | |
| HD INF IV + MTX | 0.72(0.12,4.00) | 0.75(0.18,3.37) | ‐0.04(‐0.35,0.15) | |
| HD TOCI IV | LD GOLI IV + MTX | 5.79(0.98,34.99) | 4.60(0.99,19.95) | 0.18(0.00,0.47) |
| HD GOLI SC | 3.51(0.62,21.01) | 3.10(0.65,14.48) | 0.10(‐0.04,0.35) | |
| HD TOCI IV + MTX | 9.97(2.01,58.65) | 6.76(1.79,26.50) | 0.28(0.08,0.59) | |
| HD GOLI SC + MTX | 7.14(1.56,34.84) | 5.40(1.46,20.76) | 0.22(0.05,0.45) | |
| HD INF IV + MTX | 2.60(0.60,11.86) | 2.39(0.63,9.67) | 0.07(‐0.04,0.22) | |
| HD GOLI SC | HD TOCI IV | 0.60(0.09,4.24) | 0.67(0.16,3.11) | ‐0.07(‐0.39,0.23) |
| HD TOCI IV + MTX | 1.71(0.85,4.09) | 1.45(0.90,2.96) | 0.10(‐0.03,0.27) | |
| HD GOLI SC + MTX | 1.24(0.24,6.87) | 1.17(0.37,4.39) | 0.04(‐0.29,0.33) | |
| HD INF IV + MTX | 0.45(0.09,2.37) | 0.52(0.15,2.08) | ‐0.11(‐0.41,0.11) | |
| HD TOCI IV + MTX | HD GOLI SC | 2.91(0.47,17.65) | 2.22(0.58,8.48) | 0.18(‐0.14,0.51) |
| HD GOLI SC + MTX | 2.05(0.67,6.28) | 1.74(0.75,4.57) | 0.11(‐0.07,0.29) | |
| HD INF IV + MTX | 0.74(0.14,3.71) | 0.77(0.20,3.14) | ‐0.03(‐0.29,0.14) | |
| HD GOLI SC + MTX | HD TOCI IV + MTX | 0.71(0.14,3.45) | 0.80(0.29,2.39) | ‐0.07(‐0.41,0.25) |
| HD INF IV + MTX | 0.26(0.05,1.15) | 0.35(0.12,1.12) | ‐0.22(‐0.52,0.02) | |
| HD INF IV + MTX | HD GOLI SC + MTX | 0.36(0.09,1.39) | 0.44(0.15,1.31) | ‐0.15(‐0.39,0.05) |
| Random‐effects model | Residual deviance | 54.1 vs 52 data points | ||
| Deviance information criteria | 326.692 | |||
| Fixed‐effect model | Residual deviance | 67.08 vs 52 data points | ||
| Deviance information criteria | 333.907 | |||
| Note | ||||
| Total participants | 9626 | |||
| Total studies | 20 | |||
| 2‐arm | 11 | |||
| 3‐arm | 7 | |||
| 4‐arm | 1 | |||
| 5‐arm | 1 | |||
Appendix 14. Remission: subgroup ‐ trial duration (<= 6 months) network 2
| Remission short, network 2: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| SD ETN SC | MTX + DMARD | 3.16(1.02,10.45) | 2.59(1.02,5.96) | 0.16(0.00,0.40) |
| SD ETN SC + MTX | 4.41(1.96,11.94) | 3.29(1.76,6.51) | 0.23(0.08,0.43) | |
| SD ETN SC + MTX | SD ETN SC | 1.39(0.71,3.08) | 1.26(0.81,2.38) | 0.07(‐0.08,0.20) |
| Random‐effects model | Residual deviance | 12.14 vs 10 data points | ||
| Deviance information criteria | 69.459 | |||
| Fixed‐effect model | Residual deviance | 18.44 vs 10 data points | ||
| Deviance information criteria | 73.457 | |||
| Note | ||||
| Total participants | 1392 | |||
| Total studies | 5 | |||
| 2‐arm | 5 | |||
Appendix 15. Withdrawals due to adverse events: main analysis
| Withdrawals: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX | PL | 3.10(1.12,5.73) | 2.98(1.12,5.25) | 0.04(0.00,0.09) |
| DMARD | 1.22(0.47,2.89) | 1.22(0.48,2.79) | 0.00(‐0.01,0.04) | |
| MTX + DMARD | 6.88(2.16,18.40) | 6.11(2.09,13.62) | 0.11(0.03,0.27) | |
| SD ETN SC | 2.60(0.98,4.77) | 2.51(0.98,4.46) | 0.03(0.00,0.07) | |
| SD ADA SC | 1.96(0.95,3.70) | 1.92(0.96,3.52) | 0.02(0.00,0.05) | |
| SD TOCI IV | 1.59(0.61,3.68) | 1.57(0.61,3.50) | 0.01(‐0.01,0.05) | |
| SD CERTO SC | 2.94(0.87,16.78) | 2.82(0.87,13.25) | 0.04(0.00,0.22) | |
| SD TOFA | 0.27(0.01,2.00) | 0.28(0.01,1.96) | ‐0.01(‐0.03,0.02) | |
| SD TOC SC + PL IV | 1.15(0.35,3.23) | 1.15(0.36,3.10) | 0.00(‐0.02,0.04) | |
| SD RITUX IV | 17.34(1.88,260.80) | 12.73(1.84,42.45) | 0.25(0.02,0.83) | |
| SD ANA | 1.31(0.38,5.06) | 1.30(0.39,4.69) | 0.01(‐0.01,0.08) | |
| SD ETN SC + MTX | 2.58(0.89,5.37) | 2.50(0.89,4.97) | 0.03(0.00,0.08) | |
| SD ADA SC + MTX | 4.52(1.45,9.52) | 4.21(1.43,8.17) | 0.07(0.01,0.16) | |
| SD INF IV + MTX | 5.75(1.89,13.05) | 5.22(1.84,10.50) | 0.09(0.02,0.21) | |
| SD ABA IV + MTX | 2.95(0.96,6.66) | 2.83(0.96,6.01) | 0.04(0.00,0.10) | |
| SD RITUX IV + MTX | 3.88(1.07,17.77) | 3.66(1.07,12.91) | 0.06(0.00,0.27) | |
| SD CERTO SC + MTX | 4.31(1.33,10.05) | 4.02(1.32,8.45) | 0.06(0.01,0.15) | |
| SD GOLI SC + MTX | 3.75(0.88,13.26) | 3.55(0.89,10.46) | 0.05(0.00,0.21) | |
| SD TOFA PO + MTX | 5.76(1.76,13.89) | 5.24(1.73,11.07) | 0.09(0.02,0.21) | |
| SD ABA SC + MTX | 1.56(0.47,4.05) | 1.54(0.48,3.83) | 0.01(‐0.01,0.06) | |
| SD TOCI IV + MTX | 3.04(0.88,9.39) | 2.92(0.88,8.03) | 0.04(0.00,0.15) | |
| SD ETN SC + DMARD | 1.28(0.51,2.82) | 1.27(0.52,2.72) | 0.01(‐0.01,0.03) | |
| SD CERTO + DMARD | 1.73(0.50,5.05) | 1.70(0.51,4.70) | 0.01(‐0.01,0.07) | |
| SD ABA IV + DMARD | 1.66(0.47,4.64) | 1.64(0.47,4.33) | 0.01(‐0.01,0.07) | |
| SD ADA SC + DMARD | 1.41(0.30,6.24) | 1.40(0.30,5.66) | 0.01(‐0.02,0.10) | |
| SD TOCI SC + DMARD | 2.99(0.53,32.55) | 2.87(0.54,19.83) | 0.04(‐0.01,0.39) | |
| LD ETN SC | 2.30(0.84,4.86) | 2.24(0.84,4.54) | 0.03(0.00,0.08) | |
| LD ADA SC | 0.68(0.23,1.93) | 0.69(0.23,1.89) | ‐0.01(‐0.02,0.02) | |
| LD ANA | 0.98(0.29,3.69) | 0.98(0.30,3.49) | 0.00(‐0.02,0.05) | |
| LD TOCI IV | 1.85(0.40,6.07) | 1.82(0.40,5.51) | 0.02(‐0.02,0.09) | |
| LD RITUX IV + MTX | 5.85(1.49,28.36) | 5.29(1.47,17.52) | 0.09(0.01,0.37) | |
| LD ABA IV + MTX | 3.83(0.87,12.23) | 3.61(0.88,10.03) | 0.05(0.00,0.19) | |
| LD CERTO SC + MTX | 3.49(0.40,13.84) | 3.31(0.41,11.15) | 0.05(‐0.01,0.21) | |
| LD ETN SC + MTX | 1.48(0.32,6.59) | 1.47(0.33,5.93) | 0.01(‐0.02,0.10) | |
| LD TOCI IV + MTX | 1.27(0.24,5.29) | 1.27(0.24,4.88) | 0.01(‐0.02,0.08) | |
| HD TOCI IV | 2.47(0.88,5.24) | 2.39(0.88,4.86) | 0.03(0.00,0.08) | |
| HD GOLI SC | 1.62(0.18,9.11) | 1.59(0.18,7.88) | 0.01(‐0.02,0.14) | |
| HD ADA SC | 0.71(0.23,1.91) | 0.72(0.23,1.87) | ‐0.01(‐0.02,0.02) | |
| HD TOFA | 2.08(0.51,9.04) | 2.03(0.52,7.87) | 0.02(‐0.01,0.13) | |
| HD ANA | 2.33(0.82,7.82) | 2.26(0.82,6.89) | 0.03(0.00,0.12) | |
| HD TOCI IV + MTX | 3.17(1.01,8.67) | 3.02(1.01,7.50) | 0.04(0.00,0.14) | |
| HD GOLI SC + MTX | 4.97(1.35,18.57) | 4.58(1.34,13.50) | 0.07(0.01,0.27) | |
| HD INF IV + MTX | 5.25(1.46,12.43) | 4.81(1.44,10.24) | 0.08(0.01,0.19) | |
| HD TOFA PO + MTX | 4.42(1.38,11.69) | 4.13(1.36,9.66) | 0.06(0.01,0.18) | |
| HD CERTO SC + MTX | 4.83(1.23,13.41) | 4.46(1.22,10.78) | 0.07(0.01,0.20) | |
| HD TOCI IV + DMARD | 2.40(0.75,6.94) | 2.33(0.76,6.20) | 0.03(‐0.01,0.11) | |
| DMARD | MTX | 0.41(0.21,0.87) | 0.43(0.22,0.88) | ‐0.03(‐0.08,0.00) |
| MTX + DMARD | 2.33(1.13,5.01) | 2.14(1.12,4.13) | 0.07(0.01,0.20) | |
| SD ETN SC | 0.85(0.59,1.28) | 0.86(0.61,1.26) | ‐0.01(‐0.03,0.01) | |
| SD ADA SC | 0.66(0.31,1.63) | 0.67(0.33,1.59) | ‐0.02(‐0.07,0.02) | |
| SD TOCI IV | 0.55(0.20,1.45) | 0.56(0.21,1.42) | ‐0.03(‐0.08,0.02) | |
| SD CERTO SC | 1.03(0.24,6.88) | 1.02(0.26,5.58) | 0.00(‐0.08,0.18) | |
| SD TOFA | 0.09(0.00,0.86) | 0.09(0.00,0.86) | ‐0.05(‐0.11,0.00) | |
| SD TOC SC + PL IV | 0.38(0.13,1.21) | 0.40(0.14,1.21) | ‐0.03(‐0.09,0.01) | |
| SD RITUX IV | 6.00(0.81,64.99) | 4.49(0.82,15.08) | 0.21(‐0.01,0.76) | |
| SD ANA | 0.46(0.10,2.27) | 0.48(0.11,2.15) | ‐0.03(‐0.09,0.05) | |
| SD ETN SC + MTX | 0.84(0.55,1.33) | 0.85(0.57,1.31) | ‐0.01(‐0.03,0.02) | |
| SD ADA SC + MTX | 1.47(0.91,2.40) | 1.43(0.91,2.22) | 0.02(0.00,0.08) | |
| SD INF IV + MTX | 1.90(1.14,3.12) | 1.80(1.13,2.78) | 0.05(0.01,0.13) | |
| SD ABA IV + MTX | 0.96(0.52,1.64) | 0.97(0.53,1.59) | 0.00(‐0.04,0.03) | |
| SD RITUX IV + MTX | 1.35(0.51,4.96) | 1.32(0.52,3.70) | 0.02(‐0.03,0.21) | |
| SD CERTO SC + MTX | 1.39(0.74,2.52) | 1.36(0.76,2.34) | 0.02(‐0.02,0.08) | |
| SD GOLI SC + MTX | 1.23(0.46,3.62) | 1.21(0.48,3.11) | 0.01(‐0.04,0.14) | |
| SD TOFA PO + MTX | 1.91(1.02,3.27) | 1.81(1.02,2.90) | 0.05(0.00,0.14) | |
| SD ABA SC + MTX | 0.52(0.26,1.05) | 0.54(0.27,1.05) | ‐0.03(‐0.07,0.00) | |
| SD TOCI IV + MTX | 1.04(0.35,3.03) | 1.04(0.37,2.77) | 0.00(‐0.05,0.09) | |
| SD ETN SC + DMARD | 0.44(0.20,0.94) | 0.45(0.21,0.94) | ‐0.03(‐0.08,0.00) | |
| SD CERTO + DMARD | 0.59(0.19,1.84) | 0.60(0.20,1.76) | ‐0.02(‐0.07,0.03) | |
| SD ABA IV + DMARD | 0.56(0.21,1.51) | 0.57(0.22,1.47) | ‐0.02(‐0.07,0.02) | |
| SD ADA SC + DMARD | 0.50(0.12,2.02) | 0.51(0.13,1.91) | ‐0.03(‐0.08,0.05) | |
| SD TOCI SC + DMARD | 1.03(0.19,9.50) | 1.03(0.21,6.14) | 0.00(‐0.07,0.33) | |
| LD ETN SC | 0.76(0.46,1.31) | 0.77(0.47,1.29) | ‐0.01(‐0.04,0.01) | |
| LD ADA SC | 0.23(0.07,0.89) | 0.24(0.07,0.89) | ‐0.04(‐0.10,0.00) | |
| LD ANA | 0.33(0.08,1.68) | 0.35(0.09,1.62) | ‐0.04(‐0.09,0.02) | |
| LD TOCI IV | 0.64(0.17,1.99) | 0.65(0.18,1.89) | ‐0.02(‐0.08,0.05) | |
| LD RITUX IV + MTX | 2.03(0.76,7.40) | 1.90(0.77,5.06) | 0.05(‐0.01,0.31) | |
| LD ABA IV + MTX | 1.28(0.44,3.32) | 1.26(0.45,2.92) | 0.01(‐0.04,0.12) | |
| LD CERTO SC + MTX | 1.13(0.20,4.27) | 1.12(0.21,3.55) | 0.01(‐0.05,0.15) | |
| LD ETN SC + MTX | 0.52(0.13,1.80) | 0.54(0.14,1.70) | ‐0.02(‐0.08,0.05) | |
| LD TOCI IV + MTX | 0.45(0.08,1.69) | 0.47(0.09,1.62) | ‐0.03(‐0.09,0.03) | |
| HD TOCI IV | 0.82(0.44,1.51) | 0.82(0.45,1.48) | ‐0.01(‐0.05,0.02) | |
| HD GOLI SC | 0.54(0.07,2.76) | 0.56(0.08,2.50) | ‐0.02(‐0.08,0.09) | |
| HD ADA SC | 0.25(0.06,0.83) | 0.26(0.07,0.84) | ‐0.04(‐0.10,‐0.01) | |
| HD TOFA | 0.72(0.12,3.83) | 0.73(0.13,3.47) | ‐0.01(‐0.09,0.10) | |
| HD ANA | 0.83(0.21,3.42) | 0.84(0.23,3.12) | ‐0.01(‐0.08,0.09) | |
| HD TOCI IV + MTX | 1.04(0.46,2.56) | 1.04(0.48,2.36) | 0.00(‐0.04,0.08) | |
| HD GOLI SC + MTX | 1.70(0.65,4.99) | 1.63(0.66,3.95) | 0.04(‐0.02,0.20) | |
| HD INF IV + MTX | 1.69(0.87,3.17) | 1.62(0.87,2.82) | 0.04(‐0.01,0.12) | |
| HD TOFA PO + MTX | 1.47(0.80,2.70) | 1.42(0.81,2.44) | 0.02(‐0.01,0.10) | |
| HD CERTO SC + MTX | 1.58(0.63,3.62) | 1.52(0.64,3.14) | 0.03(‐0.02,0.14) | |
| HD TOCI IV + DMARD | 0.81(0.33,2.21) | 0.82(0.34,2.09) | ‐0.01(‐0.06,0.06) | |
| MTX + DMARD | DMARD | 5.53(1.99,14.90) | 4.92(1.92,11.77) | 0.10(0.03,0.26) |
| SD ETN SC | 2.08(0.99,4.11) | 2.02(0.99,3.91) | 0.02(0.00,0.06) | |
| SD ADA SC | 1.60(0.69,4.02) | 1.58(0.70,3.85) | 0.01(‐0.01,0.05) | |
| SD TOCI IV | 1.31(0.48,3.47) | 1.30(0.49,3.33) | 0.01(‐0.02,0.04) | |
| SD CERTO SC | 2.52(0.49,16.43) | 2.43(0.50,13.02) | 0.03(‐0.03,0.21) | |
| SD TOFA | 0.21(0.00,2.23) | 0.21(0.00,2.19) | ‐0.02(‐0.06,0.02) | |
| SD TOC SC + PL IV | 0.93(0.29,2.88) | 0.93(0.30,2.79) | 0.00(‐0.03,0.04) | |
| SD RITUX IV | 14.16(1.88,174.10) | 10.24(1.84,40.02) | 0.25(0.02,0.82) | |
| SD ANA | 1.09(0.24,5.35) | 1.09(0.25,5.00) | 0.00(‐0.04,0.07) | |
| SD ETN SC + MTX | 2.05(0.89,4.39) | 2.00(0.90,4.13) | 0.02(0.00,0.07) | |
| SD ADA SC + MTX | 3.55(1.47,7.89) | 3.33(1.44,7.02) | 0.06(0.01,0.14) | |
| SD INF IV + MTX | 4.60(1.83,10.64) | 4.18(1.77,9.10) | 0.08(0.02,0.19) | |
| SD ABA IV + MTX | 2.30(0.87,5.54) | 2.22(0.88,5.14) | 0.03(0.00,0.09) | |
| SD RITUX IV + MTX | 3.21(0.97,14.89) | 3.03(0.97,10.94) | 0.05(0.00,0.26) | |
| SD CERTO SC + MTX | 3.30(1.40,8.27) | 3.10(1.38,7.41) | 0.05(0.01,0.14) | |
| SD GOLI SC + MTX | 2.96(0.88,10.47) | 2.81(0.88,8.73) | 0.05(0.00,0.20) | |
| SD TOFA PO + MTX | 4.57(1.69,10.85) | 4.16(1.65,9.21) | 0.08(0.02,0.20) | |
| SD ABA SC + MTX | 1.26(0.47,3.42) | 1.25(0.48,3.29) | 0.01(‐0.02,0.05) | |
| SD TOCI IV + MTX | 2.45(0.71,7.82) | 2.35(0.72,6.95) | 0.03(‐0.01,0.13) | |
| SD ETN SC + DMARD | 1.04(0.56,1.99) | 1.04(0.57,1.96) | 0.00(‐0.02,0.02) | |
| SD CERTO + DMARD | 1.42(0.49,3.66) | 1.41(0.50,3.49) | 0.01(‐0.02,0.06) | |
| SD ABA IV + DMARD | 1.34(0.69,2.64) | 1.33(0.69,2.54) | 0.01(‐0.01,0.05) | |
| SD ADA SC + DMARD | 1.18(0.32,3.95) | 1.17(0.33,3.66) | 0.00(‐0.02,0.08) | |
| SD TOCI SC + DMARD | 2.45(0.60,18.52) | 2.36(0.60,11.56) | 0.03(‐0.01,0.36) | |
| LD ETN SC | 1.83(0.80,4.24) | 1.79(0.80,4.01) | 0.02(‐0.01,0.06) | |
| LD ADA SC | 0.56(0.14,2.27) | 0.57(0.14,2.22) | ‐0.01(‐0.05,0.02) | |
| LD ANA | 0.82(0.20,3.74) | 0.82(0.20,3.57) | 0.00(‐0.04,0.05) | |
| LD TOCI IV | 1.50(0.36,5.38) | 1.48(0.37,4.95) | 0.01(‐0.03,0.08) | |
| LD RITUX IV + MTX | 4.94(1.42,22.86) | 4.43(1.40,15.30) | 0.09(0.01,0.36) | |
| LD ABA IV + MTX | 3.08(0.78,10.12) | 2.91(0.78,8.63) | 0.05(‐0.01,0.17) | |
| LD CERTO SC + MTX | 2.78(0.44,11.03) | 2.63(0.45,9.07) | 0.04(‐0.02,0.20) | |
| LD ETN SC + MTX | 1.26(0.28,4.65) | 1.25(0.28,4.29) | 0.01(‐0.03,0.09) | |
| LD TOCI IV + MTX | 1.09(0.19,4.45) | 1.09(0.19,4.11) | 0.00(‐0.03,0.07) | |
| HD TOCI IV | 1.99(0.93,3.88) | 1.93(0.93,3.70) | 0.02(0.00,0.06) | |
| HD GOLI SC | 1.35(0.15,8.10) | 1.34(0.15,7.20) | 0.01(‐0.04,0.14) | |
| HD ADA SC | 0.59(0.14,2.08) | 0.60(0.15,2.04) | ‐0.01(‐0.04,0.02) | |
| HD TOFA | 1.73(0.26,9.88) | 1.70(0.27,8.54) | 0.02(‐0.04,0.13) | |
| HD ANA | 1.97(0.49,8.48) | 1.92(0.50,7.59) | 0.02(‐0.02,0.12) | |
| HD TOCI IV + MTX | 2.58(0.94,6.70) | 2.47(0.95,6.01) | 0.04(0.00,0.12) | |
| HD GOLI SC + MTX | 4.10(1.18,15.88) | 3.78(1.17,12.18) | 0.07(0.01,0.25) | |
| HD INF IV + MTX | 4.14(1.45,9.85) | 3.80(1.43,8.51) | 0.07(0.01,0.18) | |
| HD TOFA PO + MTX | 3.54(1.33,8.88) | 3.30(1.31,7.67) | 0.06(0.01,0.16) | |
| HD CERTO SC + MTX | 3.85(1.19,10.54) | 3.55(1.18,8.78) | 0.06(0.00,0.19) | |
| HD TOCI IV + DMARD | 1.95(1.05,3.79) | 1.90(1.05,3.55) | 0.02(0.00,0.08) | |
| SD ETN SC | MTX + DMARD | 0.37(0.17,0.79) | 0.40(0.21,0.81) | ‐0.08(‐0.21,‐0.01) |
| SD ADA SC | 0.28(0.10,0.88) | 0.31(0.13,0.89) | ‐0.09(‐0.24,‐0.01) | |
| SD TOCI IV | 0.24(0.07,0.80) | 0.26(0.09,0.81) | ‐0.09(‐0.26,‐0.01) | |
| SD CERTO SC | 0.45(0.09,3.17) | 0.49(0.11,2.70) | ‐0.06(‐0.25,0.13) | |
| SD TOFA | 0.04(0.00,0.38) | 0.05(0.00,0.40) | ‐0.12(‐0.29,‐0.03) | |
| SD TOC SC + PL IV | 0.17(0.04,0.68) | 0.19(0.05,0.69) | ‐0.10(‐0.27,‐0.02) | |
| SD RITUX IV | 2.57(0.28,29.12) | 2.11(0.31,7.78) | 0.14(‐0.12,0.67) | |
| SD ANA | 0.20(0.03,1.19) | 0.22(0.04,1.18) | ‐0.10(‐0.27,0.01) | |
| SD ETN SC + MTX | 0.36(0.17,0.74) | 0.40(0.21,0.76) | ‐0.08(‐0.21,‐0.01) | |
| SD ADA SC + MTX | 0.63(0.26,1.50) | 0.66(0.31,1.44) | ‐0.04(‐0.17,0.03) | |
| SD INF IV + MTX | 0.83(0.41,1.53) | 0.85(0.46,1.46) | ‐0.02(‐0.12,0.04) | |
| SD ABA IV + MTX | 0.41(0.15,1.01) | 0.45(0.18,1.01) | ‐0.07(‐0.22,0.00) | |
| SD RITUX IV + MTX | 0.58(0.16,2.42) | 0.62(0.19,2.05) | ‐0.04(‐0.19,0.13) | |
| SD CERTO SC + MTX | 0.59(0.24,1.51) | 0.63(0.28,1.46) | ‐0.05(‐0.18,0.04) | |
| SD GOLI SC + MTX | 0.54(0.16,2.03) | 0.57(0.19,1.86) | ‐0.05(‐0.19,0.08) | |
| SD TOFA PO + MTX | 0.83(0.30,2.06) | 0.85(0.36,1.90) | ‐0.02(‐0.16,0.07) | |
| SD ABA SC + MTX | 0.22(0.08,0.61) | 0.25(0.09,0.63) | ‐0.09(‐0.25,‐0.02) | |
| SD TOCI IV + MTX | 0.44(0.12,1.66) | 0.48(0.15,1.58) | ‐0.06(‐0.22,0.05) | |
| SD ETN SC + DMARD | 0.19(0.06,0.52) | 0.21(0.08,0.54) | ‐0.10(‐0.26,‐0.02) | |
| SD CERTO + DMARD | 0.26(0.07,0.96) | 0.29(0.08,0.96) | ‐0.09(‐0.25,0.00) | |
| SD ABA IV + DMARD | 0.24(0.07,0.81) | 0.27(0.09,0.82) | ‐0.09(‐0.25,‐0.01) | |
| SD ADA SC + DMARD | 0.21(0.04,1.02) | 0.24(0.05,1.01) | ‐0.09(‐0.25,0.00) | |
| SD TOCI SC + DMARD | 0.44(0.08,5.05) | 0.47(0.09,3.48) | ‐0.06(‐0.23,0.26) | |
| LD ETN SC | 0.33(0.14,0.78) | 0.36(0.17,0.80) | ‐0.08(‐0.22,‐0.01) | |
| LD ADA SC | 0.10(0.02,0.43) | 0.12(0.03,0.45) | ‐0.11(‐0.27,‐0.03) | |
| LD ANA | 0.14(0.03,0.87) | 0.16(0.04,0.88) | ‐0.10(‐0.27,‐0.01) | |
| LD TOCI IV | 0.27(0.05,1.08) | 0.30(0.07,1.08) | ‐0.09(‐0.26,0.01) | |
| LD RITUX IV + MTX | 0.88(0.25,3.66) | 0.90(0.29,2.76) | ‐0.01(‐0.16,0.22) | |
| LD ABA IV + MTX | 0.54(0.16,1.87) | 0.58(0.18,1.73) | ‐0.05(‐0.19,0.06) | |
| LD CERTO SC + MTX | 0.48(0.07,2.19) | 0.52(0.08,1.97) | ‐0.06(‐0.21,0.09) | |
| LD ETN SC + MTX | 0.22(0.05,0.97) | 0.25(0.06,0.98) | ‐0.09(‐0.25,0.00) | |
| LD TOCI IV + MTX | 0.19(0.03,0.80) | 0.22(0.04,0.82) | ‐0.09(‐0.26,‐0.01) | |
| HD TOCI IV | 0.35(0.13,0.94) | 0.39(0.17,0.95) | ‐0.08(‐0.23,0.00) | |
| HD GOLI SC | 0.24(0.02,1.37) | 0.27(0.03,1.32) | ‐0.09(‐0.25,0.03) | |
| HD ADA SC | 0.10(0.02,0.44) | 0.12(0.03,0.46) | ‐0.11(‐0.28,‐0.03) | |
| HD TOFA | 0.31(0.05,2.02) | 0.34(0.06,1.89) | ‐0.08(‐0.26,0.06) | |
| HD ANA | 0.35(0.08,1.77) | 0.38(0.10,1.67) | ‐0.08(‐0.25,0.05) | |
| HD TOCI IV + MTX | 0.45(0.15,1.46) | 0.49(0.18,1.40) | ‐0.06(‐0.21,0.03) | |
| HD GOLI SC + MTX | 0.73(0.20,2.55) | 0.76(0.24,2.22) | ‐0.03(‐0.17,0.12) | |
| HD INF IV + MTX | 0.73(0.30,1.70) | 0.76(0.34,1.60) | ‐0.03(‐0.15,0.05) | |
| HD TOFA PO + MTX | 0.63(0.24,1.67) | 0.66(0.29,1.59) | ‐0.04(‐0.18,0.05) | |
| HD CERTO SC + MTX | 0.66(0.20,2.10) | 0.70(0.24,1.91) | ‐0.04(‐0.17,0.08) | |
| HD TOCI IV + DMARD | 0.35(0.11,1.20) | 0.39(0.13,1.18) | ‐0.07(‐0.24,0.01) | |
| SD ADA SC | SD ETN SC | 0.76(0.37,1.84) | 0.77(0.39,1.79) | ‐0.01(‐0.05,0.03) |
| SD TOCI IV | 0.64(0.24,1.60) | 0.66(0.26,1.57) | ‐0.02(‐0.06,0.02) | |
| SD CERTO SC | 1.20(0.29,7.82) | 1.18(0.31,6.28) | 0.01(‐0.06,0.19) | |
| SD TOFA | 0.10(0.00,0.98) | 0.11(0.00,0.98) | ‐0.04(‐0.09,0.00) | |
| SD TOC SC + PL IV | 0.45(0.15,1.39) | 0.47(0.16,1.37) | ‐0.03(‐0.07,0.01) | |
| SD RITUX IV | 7.02(0.94,80.12) | 5.23(0.94,17.44) | 0.22(0.00,0.78) | |
| SD ANA | 0.54(0.12,2.57) | 0.55(0.13,2.45) | ‐0.02(‐0.08,0.05) | |
| SD ETN SC + MTX | 0.99(0.63,1.51) | 0.99(0.64,1.48) | 0.00(‐0.02,0.03) | |
| SD ADA SC + MTX | 1.72(0.92,3.17) | 1.66(0.93,2.87) | 0.03(0.00,0.10) | |
| SD INF IV + MTX | 2.25(1.21,4.07) | 2.10(1.20,3.56) | 0.06(0.01,0.15) | |
| SD ABA IV + MTX | 1.14(0.55,2.13) | 1.13(0.56,2.02) | 0.01(‐0.03,0.05) | |
| SD RITUX IV + MTX | 1.56(0.57,6.29) | 1.51(0.58,4.73) | 0.03(‐0.02,0.22) | |
| SD CERTO SC + MTX | 1.62(0.80,3.28) | 1.57(0.81,2.98) | 0.03(‐0.01,0.10) | |
| SD GOLI SC + MTX | 1.45(0.47,4.57) | 1.42(0.49,3.88) | 0.02(‐0.03,0.16) | |
| SD TOFA PO + MTX | 2.22(1.08,4.41) | 2.08(1.07,3.77) | 0.05(0.00,0.16) | |
| SD ABA SC + MTX | 0.61(0.27,1.36) | 0.62(0.28,1.34) | ‐0.02(‐0.06,0.02) | |
| SD TOCI IV + MTX | 1.20(0.38,3.68) | 1.19(0.40,3.30) | 0.01(‐0.04,0.11) | |
| SD ETN SC + DMARD | 0.51(0.24,1.04) | 0.52(0.26,1.04) | ‐0.02(‐0.06,0.00) | |
| SD CERTO + DMARD | 0.69(0.21,2.15) | 0.70(0.23,2.06) | ‐0.01(‐0.06,0.04) | |
| SD ABA IV + DMARD | 0.65(0.25,1.78) | 0.67(0.26,1.72) | ‐0.02(‐0.06,0.03) | |
| SD ADA SC + DMARD | 0.57(0.13,2.40) | 0.59(0.14,2.25) | ‐0.02(‐0.06,0.06) | |
| SD TOCI SC + DMARD | 1.19(0.24,11.56) | 1.18(0.25,7.13) | 0.01(‐0.05,0.34) | |
| LD ETN SC | 0.90(0.54,1.49) | 0.90(0.55,1.46) | 0.00(‐0.03,0.02) | |
| LD ADA SC | 0.28(0.07,1.01) | 0.29(0.08,1.01) | ‐0.04(‐0.08,0.00) | |
| LD ANA | 0.39(0.10,1.84) | 0.41(0.11,1.78) | ‐0.03(‐0.08,0.03) | |
| LD TOCI IV | 0.74(0.19,2.39) | 0.75(0.20,2.25) | ‐0.01(‐0.06,0.06) | |
| LD RITUX IV + MTX | 2.37(0.84,9.50) | 2.20(0.85,6.26) | 0.06(‐0.01,0.32) | |
| LD ABA IV + MTX | 1.49(0.45,4.26) | 1.45(0.46,3.67) | 0.02(‐0.03,0.14) | |
| LD CERTO SC + MTX | 1.32(0.23,5.22) | 1.30(0.24,4.36) | 0.02(‐0.04,0.17) | |
| LD ETN SC + MTX | 0.62(0.15,2.09) | 0.63(0.16,1.97) | ‐0.02(‐0.06,0.05) | |
| LD TOCI IV + MTX | 0.53(0.10,2.17) | 0.54(0.10,2.05) | ‐0.02(‐0.07,0.05) | |
| HD TOCI IV | 0.96(0.48,1.84) | 0.96(0.50,1.78) | 0.00(‐0.04,0.03) | |
| HD GOLI SC | 0.64(0.08,3.42) | 0.65(0.08,3.06) | ‐0.02(‐0.07,0.10) | |
| HD ADA SC | 0.29(0.08,0.98) | 0.30(0.08,0.98) | ‐0.04(‐0.08,0.00) | |
| HD TOFA | 0.84(0.14,4.49) | 0.85(0.15,4.02) | ‐0.01(‐0.08,0.11) | |
| HD ANA | 0.98(0.26,3.87) | 0.98(0.27,3.51) | 0.00(‐0.06,0.09) | |
| HD TOCI IV + MTX | 1.24(0.52,3.08) | 1.23(0.54,2.82) | 0.01(‐0.03,0.09) | |
| HD GOLI SC + MTX | 2.01(0.69,6.29) | 1.91(0.70,4.95) | 0.04(‐0.02,0.22) | |
| HD INF IV + MTX | 1.99(0.92,3.94) | 1.88(0.92,3.46) | 0.05(0.00,0.14) | |
| HD TOFA PO + MTX | 1.71(0.83,3.55) | 1.65(0.84,3.14) | 0.03(‐0.01,0.13) | |
| HD CERTO SC + MTX | 1.86(0.68,4.63) | 1.77(0.69,3.98) | 0.04(‐0.02,0.15) | |
| HD TOCI IV + DMARD | 0.96(0.37,2.54) | 0.96(0.39,2.38) | 0.00(‐0.04,0.07) | |
| SD TOCI IV | SD ADA SC | 0.81(0.37,1.75) | 0.82(0.38,1.70) | ‐0.01(‐0.04,0.03) |
| SD CERTO SC | 1.52(0.37,9.81) | 1.49(0.38,7.90) | 0.02(‐0.04,0.20) | |
| SD TOFA | 0.14(0.00,1.12) | 0.14(0.00,1.11) | ‐0.03(‐0.07,0.00) | |
| SD TOC SC + PL IV | 0.58(0.21,1.56) | 0.59(0.21,1.54) | ‐0.02(‐0.05,0.02) | |
| SD RITUX IV | 9.13(1.02,124.00) | 6.71(1.01,23.65) | 0.23(0.00,0.80) | |
| SD ANA | 0.67(0.18,3.07) | 0.68(0.19,2.90) | ‐0.01(‐0.05,0.06) | |
| SD ETN SC + MTX | 1.28(0.48,3.00) | 1.26(0.49,2.82) | 0.01(‐0.03,0.06) | |
| SD ADA SC + MTX | 2.19(0.80,5.46) | 2.09(0.81,4.80) | 0.04(‐0.01,0.13) | |
| SD INF IV + MTX | 2.89(1.04,7.38) | 2.68(1.04,6.12) | 0.07(0.00,0.18) | |
| SD ABA IV + MTX | 1.46(0.49,3.64) | 1.43(0.51,3.38) | 0.02(‐0.03,0.08) | |
| SD RITUX IV + MTX | 2.04(0.54,10.36) | 1.95(0.55,7.84) | 0.04(‐0.02,0.25) | |
| SD CERTO SC + MTX | 2.14(0.71,5.54) | 2.04(0.72,4.87) | 0.04(‐0.01,0.13) | |
| SD GOLI SC + MTX | 1.90(0.47,6.64) | 1.83(0.48,5.52) | 0.03(‐0.03,0.18) | |
| SD TOFA PO + MTX | 2.87(0.97,7.71) | 2.65(0.98,6.36) | 0.07(0.00,0.19) | |
| SD ABA SC + MTX | 0.78(0.25,2.25) | 0.79(0.26,2.17) | ‐0.01(‐0.05,0.04) | |
| SD TOCI IV + MTX | 1.54(0.44,4.96) | 1.51(0.45,4.36) | 0.02(‐0.03,0.12) | |
| SD ETN SC + DMARD | 0.65(0.30,1.40) | 0.66(0.31,1.39) | ‐0.01(‐0.04,0.01) | |
| SD CERTO + DMARD | 0.89(0.24,2.86) | 0.89(0.25,2.70) | 0.00(‐0.05,0.05) | |
| SD ABA IV + DMARD | 0.86(0.27,2.42) | 0.86(0.28,2.30) | ‐0.01(‐0.04,0.05) | |
| SD ADA SC + DMARD | 0.74(0.16,3.18) | 0.75(0.17,2.94) | ‐0.01(‐0.05,0.07) | |
| SD TOCI SC + DMARD | 1.54(0.29,15.81) | 1.50(0.29,9.51) | 0.02(‐0.04,0.36) | |
| LD ETN SC | 1.16(0.44,2.74) | 1.16(0.46,2.59) | 0.01(‐0.03,0.05) | |
| LD ADA SC | 0.35(0.11,1.01) | 0.36(0.12,1.01) | ‐0.02(‐0.06,0.00) | |
| LD ANA | 0.49(0.14,2.28) | 0.50(0.15,2.19) | ‐0.02(‐0.05,0.04) | |
| LD TOCI IV | 0.96(0.21,3.13) | 0.96(0.22,2.90) | 0.00(‐0.05,0.07) | |
| LD RITUX IV + MTX | 3.08(0.78,16.12) | 2.84(0.79,10.43) | 0.07(‐0.01,0.35) | |
| LD ABA IV + MTX | 1.92(0.46,6.61) | 1.85(0.48,5.54) | 0.03(‐0.03,0.16) | |
| LD CERTO SC + MTX | 1.71(0.25,8.18) | 1.66(0.26,6.54) | 0.03(‐0.04,0.19) | |
| LD ETN SC + MTX | 0.78(0.16,3.34) | 0.79(0.17,3.07) | ‐0.01(‐0.05,0.08) | |
| LD TOCI IV + MTX | 0.68(0.13,2.88) | 0.69(0.14,2.69) | ‐0.01(‐0.05,0.06) | |
| HD TOCI IV | 1.26(0.47,2.57) | 1.24(0.48,2.44) | 0.01(‐0.03,0.05) | |
| HD GOLI SC | 0.80(0.09,5.09) | 0.80(0.10,4.48) | ‐0.01(‐0.05,0.12) | |
| HD ADA SC | 0.37(0.12,0.98) | 0.38(0.12,0.99) | ‐0.02(‐0.05,0.00) | |
| HD TOFA | 1.07(0.19,5.71) | 1.06(0.20,5.05) | 0.00(‐0.05,0.12) | |
| HD ANA | 1.20(0.37,4.77) | 1.19(0.38,4.27) | 0.01(‐0.04,0.10) | |
| HD TOCI IV + MTX | 1.63(0.56,4.30) | 1.59(0.58,3.85) | 0.02(‐0.02,0.11) | |
| HD GOLI SC + MTX | 2.60(0.71,9.46) | 2.43(0.72,7.29) | 0.06(‐0.01,0.24) | |
| HD INF IV + MTX | 2.64(0.81,6.77) | 2.47(0.81,5.71) | 0.06(‐0.01,0.17) | |
| HD TOFA PO + MTX | 2.21(0.76,6.31) | 2.10(0.77,5.40) | 0.04(‐0.01,0.15) | |
| HD CERTO SC + MTX | 2.45(0.65,7.02) | 2.31(0.66,5.90) | 0.05(‐0.02,0.17) | |
| HD TOCI IV + DMARD | 1.24(0.40,3.52) | 1.23(0.41,3.24) | 0.01(‐0.03,0.08) | |
| SD CERTO SC | SD TOCI IV | 1.94(0.39,12.65) | 1.88(0.41,10.21) | 0.03(‐0.04,0.21) |
| SD TOFA | 0.16(0.00,1.65) | 0.17(0.00,1.62) | ‐0.03(‐0.07,0.01) | |
| SD TOC SC + PL IV | 0.72(0.37,1.37) | 0.73(0.37,1.35) | ‐0.01(‐0.03,0.01) | |
| SD RITUX IV | 11.08(1.26,174.80) | 8.04(1.25,33.84) | 0.24(0.01,0.82) | |
| SD ANA | 0.83(0.21,4.13) | 0.84(0.22,3.87) | ‐0.01(‐0.05,0.07) | |
| SD ETN SC + MTX | 1.52(0.56,4.60) | 1.49(0.57,4.29) | 0.02(‐0.02,0.07) | |
| SD ADA SC + MTX | 2.68(0.92,7.69) | 2.53(0.93,6.71) | 0.05(0.00,0.14) | |
| SD INF IV + MTX | 3.45(1.19,10.63) | 3.17(1.18,9.08) | 0.07(0.01,0.19) | |
| SD ABA IV + MTX | 1.78(0.56,5.40) | 1.73(0.57,4.95) | 0.02(‐0.02,0.09) | |
| SD RITUX IV + MTX | 2.47(0.65,14.93) | 2.34(0.66,10.94) | 0.04(‐0.02,0.26) | |
| SD CERTO SC + MTX | 2.58(0.81,7.94) | 2.44(0.81,6.99) | 0.05(‐0.01,0.14) | |
| SD GOLI SC + MTX | 2.31(0.57,9.13) | 2.21(0.58,7.72) | 0.04(‐0.02,0.20) | |
| SD TOFA PO + MTX | 3.45(1.12,11.10) | 3.17(1.11,9.16) | 0.07(0.01,0.20) | |
| SD ABA SC + MTX | 0.95(0.29,3.09) | 0.95(0.30,2.96) | 0.00(‐0.04,0.05) | |
| SD TOCI IV + MTX | 1.92(0.60,5.94) | 1.86(0.61,5.30) | 0.03(‐0.02,0.12) | |
| SD ETN SC + DMARD | 0.79(0.32,2.13) | 0.80(0.34,2.08) | ‐0.01(‐0.04,0.02) | |
| SD CERTO + DMARD | 1.10(0.30,3.98) | 1.10(0.31,3.74) | 0.00(‐0.04,0.06) | |
| SD ABA IV + DMARD | 1.06(0.32,3.38) | 1.06(0.33,3.24) | 0.00(‐0.04,0.05) | |
| SD ADA SC + DMARD | 0.91(0.19,4.20) | 0.91(0.20,3.87) | 0.00(‐0.04,0.08) | |
| SD TOCI SC + DMARD | 1.91(0.34,21.36) | 1.85(0.36,12.70) | 0.03(‐0.03,0.37) | |
| LD ETN SC | 1.41(0.51,4.14) | 1.39(0.52,3.90) | 0.01(‐0.03,0.06) | |
| LD ADA SC | 0.44(0.10,1.65) | 0.44(0.11,1.63) | ‐0.02(‐0.06,0.01) | |
| LD ANA | 0.61(0.15,3.07) | 0.62(0.16,2.95) | ‐0.01(‐0.05,0.04) | |
| LD TOCI IV | 1.14(0.28,3.90) | 1.13(0.29,3.63) | 0.00(‐0.04,0.07) | |
| LD RITUX IV + MTX | 3.74(0.87,23.98) | 3.40(0.87,15.48) | 0.08(‐0.01,0.36) | |
| LD ABA IV + MTX | 2.32(0.60,9.07) | 2.21(0.61,7.69) | 0.04(‐0.02,0.17) | |
| LD CERTO SC + MTX | 2.11(0.32,10.24) | 2.02(0.33,8.47) | 0.03(‐0.03,0.19) | |
| LD ETN SC + MTX | 0.97(0.18,4.42) | 0.97(0.19,4.00) | 0.00(‐0.05,0.09) | |
| LD TOCI IV + MTX | 0.82(0.17,3.29) | 0.82(0.17,3.09) | ‐0.01(‐0.04,0.06) | |
| HD TOCI IV | 1.51(0.62,3.61) | 1.48(0.63,3.42) | 0.02(‐0.02,0.06) | |
| HD GOLI SC | 1.01(0.10,6.70) | 1.01(0.11,5.94) | 0.00(‐0.05,0.13) | |
| HD ADA SC | 0.46(0.11,1.57) | 0.47(0.12,1.55) | ‐0.02(‐0.06,0.01) | |
| HD TOFA | 1.34(0.23,7.74) | 1.32(0.25,6.81) | 0.01(‐0.05,0.12) | |
| HD ANA | 1.46(0.40,6.43) | 1.44(0.41,5.82) | 0.01(‐0.03,0.11) | |
| HD TOCI IV + MTX | 1.98(0.69,5.77) | 1.92(0.70,5.14) | 0.03(‐0.01,0.12) | |
| HD GOLI SC + MTX | 3.26(0.80,11.93) | 3.02(0.81,9.60) | 0.06(‐0.01,0.25) | |
| HD INF IV + MTX | 3.15(0.93,9.83) | 2.93(0.93,8.35) | 0.06(0.00,0.18) | |
| HD TOFA PO + MTX | 2.65(0.89,9.57) | 2.50(0.90,8.07) | 0.05(‐0.01,0.16) | |
| HD CERTO SC + MTX | 2.87(0.77,9.83) | 2.68(0.78,8.26) | 0.06(‐0.01,0.19) | |
| HD TOCI IV + DMARD | 1.52(0.48,4.67) | 1.49(0.49,4.29) | 0.02(‐0.03,0.09) | |
| SD TOFA | SD CERTO SC | 0.08(0.00,0.98) | 0.08(0.00,0.98) | ‐0.05(‐0.22,0.00) |
| SD TOC SC + PL IV | 0.36(0.05,2.04) | 0.38(0.06,1.98) | ‐0.04(‐0.21,0.03) | |
| SD RITUX IV | 5.72(0.33,138.30) | 4.19(0.38,26.23) | 0.20(‐0.10,0.81) | |
| SD ANA | 0.43(0.06,2.58) | 0.45(0.08,2.47) | ‐0.03(‐0.20,0.04) | |
| SD ETN SC + MTX | 0.83(0.12,3.49) | 0.84(0.14,3.31) | ‐0.01(‐0.19,0.06) | |
| SD ADA SC + MTX | 1.41(0.19,6.58) | 1.38(0.22,5.73) | 0.02(‐0.17,0.14) | |
| SD INF IV + MTX | 1.81(0.27,8.78) | 1.72(0.32,7.27) | 0.04(‐0.14,0.19) | |
| SD ABA IV + MTX | 0.92(0.13,3.90) | 0.92(0.16,3.62) | 0.00(‐0.18,0.08) | |
| SD RITUX IV + MTX | 1.23(0.15,9.69) | 1.21(0.19,7.46) | 0.01(‐0.17,0.25) | |
| SD CERTO SC + MTX | 1.33(0.20,5.69) | 1.30(0.23,5.05) | 0.02(‐0.16,0.12) | |
| SD GOLI SC + MTX | 1.16(0.15,8.47) | 1.15(0.18,6.94) | 0.01(‐0.17,0.19) | |
| SD TOFA PO + MTX | 1.85(0.25,8.74) | 1.75(0.30,7.31) | 0.04(‐0.15,0.18) | |
| SD ABA SC + MTX | 0.50(0.07,2.26) | 0.51(0.08,2.18) | ‐0.03(‐0.20,0.03) | |
| SD TOCI IV + MTX | 0.99(0.14,5.92) | 0.99(0.16,5.27) | 0.00(‐0.17,0.12) | |
| SD ETN SC + DMARD | 0.42(0.06,1.98) | 0.43(0.08,1.94) | ‐0.03(‐0.21,0.02) | |
| SD CERTO + DMARD | 0.58(0.08,2.97) | 0.59(0.09,2.81) | ‐0.02(‐0.20,0.05) | |
| SD ABA IV + DMARD | 0.53(0.07,3.06) | 0.55(0.09,2.90) | ‐0.03(‐0.20,0.05) | |
| SD ADA SC + DMARD | 0.46(0.05,3.98) | 0.48(0.06,3.65) | ‐0.03(‐0.20,0.08) | |
| SD TOCI SC + DMARD | 0.98(0.10,15.14) | 0.98(0.11,10.46) | 0.00(‐0.18,0.33) | |
| LD ETN SC | 0.74(0.11,3.25) | 0.75(0.14,3.08) | ‐0.01(‐0.20,0.06) | |
| LD ADA SC | 0.22(0.03,1.25) | 0.23(0.04,1.25) | ‐0.05(‐0.22,0.01) | |
| LD ANA | 0.32(0.04,1.89) | 0.34(0.05,1.85) | ‐0.04(‐0.21,0.03) | |
| LD TOCI IV | 0.57(0.07,3.46) | 0.59(0.09,3.23) | ‐0.02(‐0.20,0.07) | |
| LD RITUX IV + MTX | 1.89(0.26,15.75) | 1.78(0.30,10.34) | 0.05(‐0.14,0.35) | |
| LD ABA IV + MTX | 1.20(0.15,6.68) | 1.18(0.17,5.77) | 0.01(‐0.17,0.15) | |
| LD CERTO SC + MTX | 1.06(0.09,6.73) | 1.06(0.10,5.65) | 0.00(‐0.18,0.17) | |
| LD ETN SC + MTX | 0.48(0.06,3.74) | 0.50(0.07,3.45) | ‐0.03(‐0.20,0.08) | |
| LD TOCI IV + MTX | 0.45(0.04,3.12) | 0.47(0.04,2.93) | ‐0.03(‐0.21,0.06) | |
| HD TOCI IV | 0.79(0.12,3.45) | 0.80(0.14,3.26) | ‐0.01(‐0.19,0.06) | |
| HD GOLI SC | 0.52(0.04,4.22) | 0.54(0.05,3.81) | ‐0.02(‐0.20,0.10) | |
| HD ADA SC | 0.23(0.03,1.19) | 0.24(0.03,1.18) | ‐0.04(‐0.22,0.00) | |
| HD TOFA | 0.67(0.09,5.10) | 0.68(0.11,4.58) | ‐0.02(‐0.19,0.11) | |
| HD ANA | 0.76(0.11,4.16) | 0.77(0.14,3.80) | ‐0.01(‐0.19,0.09) | |
| HD TOCI IV + MTX | 1.02(0.14,6.37) | 1.02(0.17,5.62) | 0.00(‐0.19,0.12) | |
| HD GOLI SC + MTX | 1.58(0.21,10.64) | 1.52(0.25,8.37) | 0.03(‐0.15,0.24) | |
| HD INF IV + MTX | 1.65(0.21,8.03) | 1.58(0.26,6.70) | 0.03(‐0.16,0.17) | |
| HD TOFA PO + MTX | 1.41(0.20,7.04) | 1.38(0.24,6.02) | 0.02(‐0.16,0.15) | |
| HD CERTO SC + MTX | 1.51(0.19,7.72) | 1.46(0.22,6.53) | 0.03(‐0.16,0.17) | |
| HD TOCI IV + DMARD | 0.80(0.10,4.54) | 0.81(0.13,4.14) | ‐0.01(‐0.19,0.09) | |
| SD TOC SC + PL IV | SD TOFA | 4.37(0.39,237.10) | 4.27(0.40,230.40) | 0.02(‐0.02,0.06) |
| SD RITUX IV | 90.29(2.36,2738.00) | 51.22(2.27,1449.00) | 0.27(0.02,0.84) | |
| SD ANA | 5.12(0.51,202.90) | 4.96(0.52,188.50) | 0.02(‐0.01,0.09) | |
| SD ETN SC + MTX | 9.32(0.97,538.50) | 8.84(0.97,503.00) | 0.04(0.00,0.10) | |
| SD ADA SC + MTX | 17.06(1.57,1008.00) | 15.37(1.54,889.20) | 0.08(0.02,0.17) | |
| SD INF IV + MTX | 21.14(2.16,1164.00) | 18.66(2.07,1032.00) | 0.10(0.03,0.22) | |
| SD ABA IV + MTX | 11.22(1.08,671.50) | 10.51(1.07,616.10) | 0.05(0.00,0.12) | |
| SD RITUX IV + MTX | 16.10(1.40,919.80) | 14.67(1.38,803.50) | 0.07(0.01,0.28) | |
| SD CERTO SC + MTX | 15.61(1.50,871.80) | 14.25(1.46,783.10) | 0.07(0.01,0.17) | |
| SD GOLI SC + MTX | 12.69(1.27,961.90) | 11.72(1.26,881.00) | 0.06(0.01,0.23) | |
| SD TOFA PO + MTX | 21.37(2.07,1357.00) | 18.89(1.99,1173.00) | 0.10(0.02,0.23) | |
| SD ABA SC + MTX | 6.23(0.56,355.00) | 6.02(0.57,341.50) | 0.02(‐0.01,0.07) | |
| SD TOCI IV + MTX | 12.02(0.91,425.90) | 11.14(0.91,397.10) | 0.05(0.00,0.16) | |
| SD ETN SC + DMARD | 5.06(0.48,222.60) | 4.94(0.49,214.90) | 0.02(‐0.02,0.05) | |
| SD CERTO + DMARD | 6.71(0.63,291.80) | 6.47(0.64,278.50) | 0.03(‐0.01,0.09) | |
| SD ABA IV + DMARD | 6.65(0.56,390.70) | 6.40(0.57,369.70) | 0.03(‐0.01,0.09) | |
| SD ADA SC + DMARD | 5.92(0.39,309.10) | 5.74(0.39,294.20) | 0.02(‐0.02,0.11) | |
| SD TOCI SC + DMARD | 13.23(0.72,691.70) | 12.18(0.73,511.00) | 0.05(‐0.01,0.40) | |
| LD ETN SC | 8.60(0.88,483.30) | 8.20(0.89,457.00) | 0.04(0.00,0.09) | |
| LD ADA SC | 2.70(0.23,151.70) | 2.67(0.24,148.30) | 0.01(‐0.03,0.04) | |
| LD ANA | 3.58(0.38,160.00) | 3.52(0.39,156.70) | 0.01(‐0.02,0.06) | |
| LD TOCI IV | 6.87(0.54,406.80) | 6.62(0.55,385.60) | 0.03(‐0.01,0.11) | |
| LD RITUX IV + MTX | 25.15(1.89,1318.00) | 21.63(1.84,1104.00) | 0.11(0.02,0.38) | |
| LD ABA IV + MTX | 15.16(1.01,766.30) | 13.85(1.01,685.00) | 0.07(0.00,0.20) | |
| LD CERTO SC + MTX | 13.36(0.59,1200.00) | 12.17(0.60,1027.00) | 0.06(‐0.01,0.22) | |
| LD ETN SC + MTX | 6.03(0.42,326.80) | 5.84(0.43,313.40) | 0.02(‐0.02,0.12) | |
| LD TOCI IV + MTX | 4.95(0.31,384.40) | 4.82(0.32,362.00) | 0.02(‐0.02,0.10) | |
| HD TOCI IV | 9.13(0.93,494.60) | 8.68(0.93,464.70) | 0.04(0.00,0.10) | |
| HD GOLI SC | 5.91(0.32,670.90) | 5.69(0.32,609.00) | 0.02(‐0.02,0.16) | |
| HD ADA SC | 2.64(0.25,181.10) | 2.61(0.26,175.70) | 0.01(‐0.03,0.04) | |
| HD TOFA | 7.51(1.09,383.70) | 7.10(1.08,364.20) | 0.03(0.00,0.14) | |
| HD ANA | 8.79(0.87,362.20) | 8.31(0.87,334.70) | 0.04(0.00,0.13) | |
| HD TOCI IV + MTX | 12.29(1.07,538.20) | 11.41(1.07,498.40) | 0.05(0.00,0.16) | |
| HD GOLI SC + MTX | 18.81(1.79,1361.00) | 16.75(1.74,1194.00) | 0.09(0.02,0.29) | |
| HD INF IV + MTX | 19.27(1.70,1144.00) | 17.26(1.66,1022.00) | 0.09(0.02,0.21) | |
| HD TOFA PO + MTX | 16.49(1.52,1010.00) | 15.01(1.49,906.60) | 0.08(0.01,0.19) | |
| HD CERTO SC + MTX | 17.97(1.58,959.70) | 16.16(1.55,853.10) | 0.08(0.01,0.22) | |
| HD TOCI IV + DMARD | 9.42(0.82,558.60) | 8.94(0.83,522.00) | 0.04(‐0.01,0.13) | |
| SD RITUX IV | SD TOC SC + PL IV | 15.60(1.57,249.50) | 10.99(1.55,51.72) | 0.25(0.01,0.83) |
| SD ANA | 1.15(0.26,6.72) | 1.15(0.27,6.31) | 0.00(‐0.04,0.07) | |
| SD ETN SC + MTX | 2.15(0.66,7.39) | 2.09(0.67,6.93) | 0.02(‐0.02,0.08) | |
| SD ADA SC + MTX | 3.81(1.07,12.64) | 3.56(1.06,11.19) | 0.06(0.00,0.15) | |
| SD INF IV + MTX | 4.91(1.34,17.81) | 4.46(1.31,14.86) | 0.08(0.01,0.20) | |
| SD ABA IV + MTX | 2.48(0.66,8.85) | 2.39(0.68,8.11) | 0.03(‐0.02,0.10) | |
| SD RITUX IV + MTX | 3.47(0.78,21.79) | 3.27(0.79,16.32) | 0.05(‐0.01,0.27) | |
| SD CERTO SC + MTX | 3.62(0.97,13.08) | 3.39(0.97,11.55) | 0.06(0.00,0.15) | |
| SD GOLI SC + MTX | 3.24(0.68,14.40) | 3.07(0.69,12.21) | 0.05(‐0.01,0.20) | |
| SD TOFA PO + MTX | 4.81(1.33,18.40) | 4.38(1.31,15.04) | 0.08(0.01,0.21) | |
| SD ABA SC + MTX | 1.35(0.35,5.15) | 1.34(0.36,4.91) | 0.01(‐0.03,0.06) | |
| SD TOCI IV + MTX | 2.65(0.70,9.57) | 2.54(0.71,8.60) | 0.04(‐0.01,0.13) | |
| SD ETN SC + DMARD | 1.10(0.38,3.56) | 1.10(0.40,3.48) | 0.00(‐0.03,0.03) | |
| SD CERTO + DMARD | 1.51(0.35,6.42) | 1.49(0.36,5.99) | 0.01(‐0.03,0.07) | |
| SD ABA IV + DMARD | 1.45(0.39,5.58) | 1.43(0.40,5.26) | 0.01(‐0.03,0.06) | |
| SD ADA SC + DMARD | 1.28(0.25,6.49) | 1.27(0.26,5.95) | 0.01(‐0.03,0.09) | |
| SD TOCI SC + DMARD | 2.70(0.44,31.01) | 2.58(0.45,19.46) | 0.04(‐0.02,0.38) | |
| LD ETN SC | 1.98(0.59,6.66) | 1.93(0.60,6.27) | 0.02(‐0.02,0.07) | |
| LD ADA SC | 0.61(0.13,2.73) | 0.62(0.14,2.68) | ‐0.01(‐0.05,0.02) | |
| LD ANA | 0.86(0.19,4.86) | 0.86(0.20,4.64) | 0.00(‐0.04,0.05) | |
| LD TOCI IV | 1.60(0.34,6.66) | 1.58(0.36,6.18) | 0.01(‐0.03,0.09) | |
| LD RITUX IV + MTX | 5.29(1.06,35.09) | 4.75(1.06,22.36) | 0.09(0.00,0.37) | |
| LD ABA IV + MTX | 3.26(0.74,14.34) | 3.07(0.75,12.22) | 0.05(‐0.01,0.18) | |
| LD CERTO SC + MTX | 2.94(0.40,16.23) | 2.80(0.41,13.62) | 0.04(‐0.02,0.20) | |
| LD ETN SC + MTX | 1.37(0.24,6.62) | 1.36(0.25,6.06) | 0.01(‐0.04,0.10) | |
| LD TOCI IV + MTX | 1.15(0.21,5.27) | 1.14(0.22,4.93) | 0.00(‐0.04,0.08) | |
| HD TOCI IV | 2.13(0.72,6.03) | 2.06(0.73,5.69) | 0.02(‐0.01,0.07) | |
| HD GOLI SC | 1.42(0.14,10.92) | 1.41(0.14,9.53) | 0.01(‐0.04,0.14) | |
| HD ADA SC | 0.63(0.15,2.52) | 0.64(0.15,2.47) | ‐0.01(‐0.05,0.02) | |
| HD TOFA | 1.87(0.29,12.04) | 1.83(0.31,10.73) | 0.02(‐0.04,0.13) | |
| HD ANA | 2.04(0.49,10.56) | 1.98(0.50,9.53) | 0.02(‐0.02,0.12) | |
| HD TOCI IV + MTX | 2.79(0.80,8.98) | 2.66(0.81,8.07) | 0.04(‐0.01,0.13) | |
| HD GOLI SC + MTX | 4.52(0.97,18.85) | 4.12(0.97,15.15) | 0.07(0.00,0.26) | |
| HD INF IV + MTX | 4.45(1.14,15.67) | 4.08(1.13,13.41) | 0.07(0.01,0.19) | |
| HD TOFA PO + MTX | 3.74(1.05,15.53) | 3.49(1.05,13.29) | 0.06(0.00,0.17) | |
| HD CERTO SC + MTX | 4.05(0.93,16.67) | 3.75(0.94,14.04) | 0.07(0.00,0.20) | |
| HD TOCI IV + DMARD | 2.12(0.59,7.72) | 2.06(0.60,7.09) | 0.02(‐0.02,0.10) | |
| SD ANA | SD RITUX IV | 0.07(0.00,1.16) | 0.10(0.01,1.15) | ‐0.24(‐0.83,0.01) |
| SD ETN SC + MTX | 0.14(0.01,1.09) | 0.19(0.05,1.09) | ‐0.22(‐0.77,0.00) | |
| SD ADA SC + MTX | 0.24(0.02,1.91) | 0.31(0.09,1.82) | ‐0.19(‐0.72,0.04) | |
| SD INF IV + MTX | 0.32(0.03,2.44) | 0.40(0.11,2.26) | ‐0.16(‐0.68,0.07) | |
| SD ABA IV + MTX | 0.15(0.01,1.37) | 0.21(0.06,1.35) | ‐0.22(‐0.76,0.02) | |
| SD RITUX IV + MTX | 0.22(0.03,1.73) | 0.31(0.07,1.64) | ‐0.19(‐0.67,0.04) | |
| SD CERTO SC + MTX | 0.23(0.02,1.99) | 0.30(0.07,1.89) | ‐0.19(‐0.74,0.05) | |
| SD GOLI SC + MTX | 0.21(0.02,2.17) | 0.28(0.06,2.03) | ‐0.19(‐0.76,0.06) | |
| SD TOFA PO + MTX | 0.31(0.03,2.49) | 0.39(0.10,2.30) | ‐0.16(‐0.68,0.08) | |
| SD ABA SC + MTX | 0.09(0.01,0.78) | 0.12(0.03,0.79) | ‐0.24(‐0.80,‐0.01) | |
| SD TOCI IV + MTX | 0.18(0.01,1.59) | 0.24(0.05,1.54) | ‐0.20(‐0.78,0.03) | |
| SD ETN SC + DMARD | 0.07(0.01,0.58) | 0.10(0.03,0.60) | ‐0.25(‐0.82,‐0.02) | |
| SD CERTO + DMARD | 0.09(0.01,1.03) | 0.13(0.03,1.03) | ‐0.24(‐0.80,0.00) | |
| SD ABA IV + DMARD | 0.09(0.01,0.83) | 0.13(0.03,0.83) | ‐0.24(‐0.81,‐0.01) | |
| SD ADA SC + DMARD | 0.09(0.00,0.88) | 0.12(0.02,0.88) | ‐0.24(‐0.81,‐0.01) | |
| SD TOCI SC + DMARD | 0.19(0.01,2.74) | 0.26(0.03,2.32) | ‐0.19(‐0.77,0.10) | |
| LD ETN SC | 0.13(0.01,1.02) | 0.17(0.05,1.01) | ‐0.23(‐0.78,0.00) | |
| LD ADA SC | 0.04(0.00,0.39) | 0.06(0.01,0.41) | ‐0.26(‐0.84,‐0.03) | |
| LD ANA | 0.05(0.00,0.84) | 0.08(0.01,0.85) | ‐0.25(‐0.83,‐0.01) | |
| LD TOCI IV | 0.10(0.01,1.01) | 0.14(0.03,1.01) | ‐0.23(‐0.80,0.00) | |
| LD RITUX IV + MTX | 0.33(0.04,2.64) | 0.44(0.09,2.38) | ‐0.15(‐0.61,0.09) | |
| LD ABA IV + MTX | 0.21(0.02,2.01) | 0.27(0.06,1.89) | ‐0.19(‐0.73,0.06) | |
| LD CERTO SC + MTX | 0.17(0.01,2.03) | 0.24(0.03,1.89) | ‐0.20(‐0.76,0.06) | |
| LD ETN SC + MTX | 0.08(0.01,0.87) | 0.12(0.02,0.88) | ‐0.24(‐0.78,‐0.01) | |
| LD TOCI IV + MTX | 0.07(0.00,0.86) | 0.10(0.01,0.87) | ‐0.24(‐0.79,‐0.01) | |
| HD TOCI IV | 0.13(0.01,1.05) | 0.18(0.05,1.05) | ‐0.22(‐0.78,0.00) | |
| HD GOLI SC | 0.08(0.00,1.36) | 0.13(0.01,1.31) | ‐0.23(‐0.80,0.02) | |
| HD ADA SC | 0.04(0.00,0.40) | 0.06(0.01,0.42) | ‐0.26(‐0.84,‐0.02) | |
| HD TOFA | 0.12(0.01,2.02) | 0.17(0.02,1.90) | ‐0.22(‐0.81,0.05) | |
| HD ANA | 0.14(0.01,1.78) | 0.18(0.03,1.69) | ‐0.22(‐0.81,0.03) | |
| HD TOCI IV + MTX | 0.18(0.02,1.42) | 0.25(0.06,1.39) | ‐0.20(‐0.75,0.02) | |
| HD GOLI SC + MTX | 0.28(0.02,2.84) | 0.37(0.08,2.48) | ‐0.17(‐0.73,0.11) | |
| HD INF IV + MTX | 0.28(0.02,2.45) | 0.36(0.09,2.27) | ‐0.17(‐0.71,0.06) | |
| HD TOFA PO + MTX | 0.24(0.02,2.16) | 0.31(0.08,2.04) | ‐0.19(‐0.72,0.05) | |
| HD CERTO SC + MTX | 0.28(0.02,2.38) | 0.35(0.07,2.23) | ‐0.17(‐0.73,0.06) | |
| HD TOCI IV + DMARD | 0.13(0.01,1.21) | 0.18(0.04,1.19) | ‐0.22(‐0.79,0.01) | |
| SD ETN SC + MTX | SD ANA | 1.84(0.37,8.78) | 1.79(0.40,8.13) | 0.02(‐0.05,0.08) |
| SD ADA SC + MTX | 3.21(0.57,17.02) | 3.01(0.60,14.73) | 0.05(‐0.03,0.16) | |
| SD INF IV + MTX | 4.21(0.75,22.03) | 3.84(0.76,18.07) | 0.08(‐0.02,0.20) | |
| SD ABA IV + MTX | 2.06(0.39,10.94) | 1.99(0.41,9.90) | 0.03(‐0.05,0.10) | |
| SD RITUX IV + MTX | 2.88(0.43,27.56) | 2.72(0.45,21.34) | 0.05(‐0.04,0.27) | |
| SD CERTO SC + MTX | 3.16(0.54,14.38) | 2.97(0.56,12.58) | 0.05(‐0.04,0.15) | |
| SD GOLI SC + MTX | 2.79(0.43,16.71) | 2.65(0.45,14.36) | 0.04(‐0.04,0.21) | |
| SD TOFA PO + MTX | 4.13(0.73,23.47) | 3.78(0.74,19.15) | 0.08(‐0.02,0.21) | |
| SD ABA SC + MTX | 1.13(0.20,6.18) | 1.12(0.21,5.91) | 0.00(‐0.07,0.06) | |
| SD TOCI IV + MTX | 2.35(0.34,11.77) | 2.26(0.36,10.37) | 0.03(‐0.05,0.14) | |
| SD ETN SC + DMARD | 0.95(0.21,4.25) | 0.95(0.23,4.11) | 0.00(‐0.07,0.04) | |
| SD CERTO + DMARD | 1.31(0.22,7.06) | 1.30(0.23,6.66) | 0.01(‐0.07,0.07) | |
| SD ABA IV + DMARD | 1.24(0.21,6.35) | 1.23(0.23,6.03) | 0.01(‐0.07,0.07) | |
| SD ADA SC + DMARD | 1.11(0.15,6.45) | 1.11(0.16,6.00) | 0.00(‐0.07,0.09) | |
| SD TOCI SC + DMARD | 2.28(0.29,39.40) | 2.19(0.31,24.14) | 0.03(‐0.05,0.38) | |
| LD ETN SC | 1.68(0.34,7.96) | 1.65(0.36,7.44) | 0.02(‐0.06,0.08) | |
| LD ADA SC | 0.51(0.09,2.71) | 0.52(0.10,2.66) | ‐0.01(‐0.08,0.02) | |
| LD ANA | 0.76(0.23,2.51) | 0.77(0.24,2.44) | ‐0.01(‐0.06,0.03) | |
| LD TOCI IV | 1.36(0.20,7.81) | 1.34(0.21,7.22) | 0.01(‐0.07,0.09) | |
| LD RITUX IV + MTX | 4.38(0.68,43.49) | 3.97(0.70,29.32) | 0.08(‐0.02,0.37) | |
| LD ABA IV + MTX | 2.85(0.37,17.37) | 2.69(0.39,14.91) | 0.05(‐0.04,0.18) | |
| LD CERTO SC + MTX | 2.50(0.23,18.65) | 2.39(0.24,15.57) | 0.04(‐0.05,0.20) | |
| LD ETN SC + MTX | 1.15(0.14,7.59) | 1.15(0.15,6.96) | 0.00(‐0.07,0.10) | |
| LD TOCI IV + MTX | 0.95(0.11,7.17) | 0.95(0.12,6.63) | 0.00(‐0.08,0.08) | |
| HD TOCI IV | 1.81(0.34,8.14) | 1.76(0.36,7.62) | 0.02(‐0.06,0.08) | |
| HD GOLI SC | 1.21(0.09,11.22) | 1.21(0.09,10.00) | 0.00(‐0.07,0.14) | |
| HD ADA SC | 0.55(0.08,2.59) | 0.56(0.09,2.55) | ‐0.01(‐0.08,0.02) | |
| HD TOFA | 1.57(0.25,11.87) | 1.55(0.26,10.42) | 0.01(‐0.06,0.13) | |
| HD ANA | 1.76(0.63,5.69) | 1.71(0.65,5.33) | 0.02(‐0.02,0.08) | |
| HD TOCI IV + MTX | 2.44(0.41,11.47) | 2.34(0.43,10.27) | 0.03(‐0.05,0.13) | |
| HD GOLI SC + MTX | 3.95(0.58,24.60) | 3.63(0.60,19.54) | 0.07(‐0.03,0.27) | |
| HD INF IV + MTX | 3.65(0.64,20.36) | 3.39(0.66,17.05) | 0.07(‐0.03,0.19) | |
| HD TOFA PO + MTX | 3.23(0.59,19.19) | 3.03(0.61,16.12) | 0.05(‐0.03,0.18) | |
| HD CERTO SC + MTX | 3.40(0.54,18.21) | 3.16(0.56,15.23) | 0.06(‐0.03,0.19) | |
| HD TOCI IV + DMARD | 1.78(0.33,8.84) | 1.74(0.35,8.12) | 0.02(‐0.05,0.10) | |
| SD ADA SC + MTX | SD ETN SC + MTX | 1.75(0.91,3.37) | 1.68(0.92,3.09) | 0.03(0.00,0.10) |
| SD INF IV + MTX | 2.28(1.20,4.20) | 2.12(1.19,3.71) | 0.06(0.01,0.14) | |
| SD ABA IV + MTX | 1.15(0.53,2.20) | 1.14(0.54,2.10) | 0.01(‐0.03,0.05) | |
| SD RITUX IV + MTX | 1.60(0.56,6.34) | 1.55(0.57,4.96) | 0.03(‐0.03,0.22) | |
| SD CERTO SC + MTX | 1.65(0.77,3.49) | 1.59(0.78,3.20) | 0.03(‐0.01,0.10) | |
| SD GOLI SC + MTX | 1.47(0.50,4.84) | 1.43(0.52,4.13) | 0.02(‐0.03,0.16) | |
| SD TOFA PO + MTX | 2.28(1.05,4.54) | 2.13(1.04,3.99) | 0.05(0.00,0.15) | |
| SD ABA SC + MTX | 0.63(0.26,1.39) | 0.64(0.27,1.37) | ‐0.02(‐0.06,0.02) | |
| SD TOCI IV + MTX | 1.23(0.38,3.83) | 1.21(0.40,3.46) | 0.01(‐0.04,0.11) | |
| SD ETN SC + DMARD | 0.51(0.23,1.20) | 0.53(0.25,1.19) | ‐0.02(‐0.07,0.01) | |
| SD CERTO + DMARD | 0.70(0.20,2.33) | 0.71(0.21,2.23) | ‐0.01(‐0.07,0.04) | |
| SD ABA IV + DMARD | 0.67(0.24,1.93) | 0.68(0.25,1.86) | ‐0.02(‐0.06,0.03) | |
| SD ADA SC + DMARD | 0.58(0.14,2.59) | 0.59(0.15,2.43) | ‐0.02(‐0.07,0.06) | |
| SD TOCI SC + DMARD | 1.21(0.23,11.79) | 1.19(0.25,7.39) | 0.01(‐0.06,0.34) | |
| LD ETN SC | 0.91(0.49,1.73) | 0.91(0.51,1.68) | 0.00(‐0.04,0.03) | |
| LD ADA SC | 0.28(0.07,1.09) | 0.29(0.08,1.08) | ‐0.04(‐0.09,0.00) | |
| LD ANA | 0.40(0.09,1.94) | 0.41(0.10,1.87) | ‐0.03(‐0.09,0.03) | |
| LD TOCI IV | 0.76(0.18,2.56) | 0.77(0.20,2.40) | ‐0.01(‐0.07,0.06) | |
| LD RITUX IV + MTX | 2.43(0.78,9.60) | 2.25(0.79,6.75) | 0.06(‐0.01,0.32) | |
| LD ABA IV + MTX | 1.51(0.48,4.44) | 1.47(0.49,3.86) | 0.02(‐0.03,0.14) | |
| LD CERTO SC + MTX | 1.34(0.22,5.44) | 1.31(0.23,4.55) | 0.02(‐0.05,0.17) | |
| LD ETN SC + MTX | 0.62(0.16,2.15) | 0.64(0.17,2.02) | ‐0.02(‐0.07,0.05) | |
| LD TOCI IV + MTX | 0.54(0.09,2.11) | 0.55(0.10,2.02) | ‐0.02(‐0.08,0.05) | |
| HD TOCI IV | 0.98(0.46,2.03) | 0.98(0.48,1.96) | 0.00(‐0.04,0.04) | |
| HD GOLI SC | 0.64(0.08,3.35) | 0.66(0.09,3.02) | ‐0.02(‐0.07,0.10) | |
| HD ADA SC | 0.29(0.07,1.05) | 0.30(0.08,1.05) | ‐0.03(‐0.09,0.00) | |
| HD TOFA | 0.84(0.14,5.02) | 0.85(0.15,4.46) | ‐0.01(‐0.08,0.11) | |
| HD ANA | 0.99(0.23,4.25) | 0.99(0.25,3.85) | 0.00(‐0.07,0.10) | |
| HD TOCI IV + MTX | 1.25(0.49,3.39) | 1.24(0.51,3.09) | 0.01(‐0.04,0.09) | |
| HD GOLI SC + MTX | 2.01(0.73,6.45) | 1.90(0.74,5.11) | 0.04(‐0.02,0.22) | |
| HD INF IV + MTX | 2.04(0.93,4.21) | 1.92(0.94,3.71) | 0.05(0.00,0.14) | |
| HD TOFA PO + MTX | 1.75(0.80,3.67) | 1.68(0.81,3.27) | 0.03(‐0.01,0.12) | |
| HD CERTO SC + MTX | 1.92(0.63,4.93) | 1.83(0.64,4.24) | 0.04(‐0.02,0.15) | |
| HD TOCI IV + DMARD | 0.97(0.36,2.71) | 0.97(0.38,2.55) | 0.00(‐0.05,0.07) | |
| SD INF IV + MTX | SD ADA SC + MTX | 1.31(0.67,2.57) | 1.28(0.70,2.34) | 0.02(‐0.04,0.10) |
| SD ABA IV + MTX | 0.66(0.32,1.28) | 0.68(0.34,1.26) | ‐0.03(‐0.09,0.02) | |
| SD RITUX IV + MTX | 0.90(0.31,3.63) | 0.91(0.34,2.93) | ‐0.01(‐0.08,0.18) | |
| SD CERTO SC + MTX | 0.94(0.44,2.05) | 0.95(0.47,1.92) | 0.00(‐0.07,0.06) | |
| SD GOLI SC + MTX | 0.84(0.28,2.69) | 0.86(0.31,2.39) | ‐0.01(‐0.09,0.11) | |
| SD TOFA PO + MTX | 1.28(0.67,2.52) | 1.25(0.69,2.28) | 0.02(‐0.03,0.10) | |
| SD ABA SC + MTX | 0.36(0.18,0.70) | 0.38(0.19,0.72) | ‐0.05(‐0.12,‐0.01) | |
| SD TOCI IV + MTX | 0.71(0.21,2.35) | 0.73(0.23,2.17) | ‐0.02(‐0.11,0.07) | |
| SD ETN SC + DMARD | 0.30(0.13,0.74) | 0.32(0.14,0.75) | ‐0.06(‐0.14,‐0.01) | |
| SD CERTO + DMARD | 0.40(0.12,1.44) | 0.42(0.13,1.41) | ‐0.05(‐0.14,0.02) | |
| SD ABA IV + DMARD | 0.38(0.14,1.15) | 0.41(0.15,1.14) | ‐0.05(‐0.13,0.01) | |
| SD ADA SC + DMARD | 0.34(0.08,1.47) | 0.36(0.09,1.42) | ‐0.05(‐0.14,0.03) | |
| SD TOCI SC + DMARD | 0.70(0.13,6.98) | 0.72(0.14,4.72) | ‐0.02(‐0.12,0.31) | |
| LD ETN SC | 0.52(0.26,1.09) | 0.54(0.29,1.09) | ‐0.04(‐0.11,0.00) | |
| LD ADA SC | 0.16(0.04,0.70) | 0.17(0.05,0.72) | ‐0.07(‐0.17,‐0.01) | |
| LD ANA | 0.23(0.05,1.21) | 0.25(0.06,1.19) | ‐0.06(‐0.16,0.01) | |
| LD TOCI IV | 0.43(0.11,1.52) | 0.45(0.12,1.47) | ‐0.04(‐0.14,0.03) | |
| LD RITUX IV + MTX | 1.36(0.46,5.70) | 1.32(0.49,4.11) | 0.03(‐0.06,0.28) | |
| LD ABA IV + MTX | 0.87(0.26,2.47) | 0.88(0.28,2.23) | ‐0.01(‐0.09,0.10) | |
| LD CERTO SC + MTX | 0.77(0.13,3.02) | 0.79(0.14,2.65) | ‐0.02(‐0.11,0.12) | |
| LD ETN SC + MTX | 0.35(0.09,1.35) | 0.38(0.10,1.31) | ‐0.05(‐0.13,0.02) | |
| LD TOCI IV + MTX | 0.31(0.05,1.23) | 0.33(0.06,1.21) | ‐0.05(‐0.14,0.01) | |
| HD TOCI IV | 0.56(0.26,1.20) | 0.58(0.28,1.18) | ‐0.03(‐0.11,0.01) | |
| HD GOLI SC | 0.37(0.04,2.09) | 0.40(0.05,1.95) | ‐0.05(‐0.14,0.07) | |
| HD ADA SC | 0.16(0.04,0.67) | 0.18(0.05,0.68) | ‐0.07(‐0.16,‐0.01) | |
| HD TOFA | 0.49(0.09,2.90) | 0.51(0.10,2.66) | ‐0.04(‐0.15,0.08) | |
| HD ANA | 0.57(0.13,2.57) | 0.59(0.15,2.40) | ‐0.03(‐0.14,0.07) | |
| HD TOCI IV + MTX | 0.72(0.28,1.92) | 0.74(0.31,1.81) | ‐0.02(‐0.10,0.06) | |
| HD GOLI SC + MTX | 1.15(0.43,3.51) | 1.14(0.46,2.97) | 0.01(‐0.07,0.17) | |
| HD INF IV + MTX | 1.17(0.51,2.47) | 1.16(0.54,2.25) | 0.01(‐0.06,0.09) | |
| HD TOFA PO + MTX | 0.99(0.51,2.02) | 0.99(0.54,1.88) | 0.00(‐0.06,0.07) | |
| HD CERTO SC + MTX | 1.09(0.38,2.75) | 1.08(0.40,2.45) | 0.01(‐0.08,0.11) | |
| HD TOCI IV + DMARD | 0.55(0.20,1.69) | 0.58(0.22,1.62) | ‐0.03(‐0.12,0.04) | |
| SD ABA IV + MTX | SD INF IV + MTX | 0.50(0.23,1.06) | 0.54(0.26,1.05) | ‐0.05(‐0.14,0.00) |
| SD RITUX IV + MTX | 0.70(0.24,2.60) | 0.73(0.27,2.22) | ‐0.03(‐0.12,0.15) | |
| SD CERTO SC + MTX | 0.73(0.32,1.63) | 0.75(0.35,1.56) | ‐0.02(‐0.12,0.05) | |
| SD GOLI SC + MTX | 0.65(0.21,2.18) | 0.68(0.23,1.95) | ‐0.03(‐0.14,0.09) | |
| SD TOFA PO + MTX | 1.00(0.45,2.09) | 1.00(0.49,1.93) | 0.00(‐0.09,0.08) | |
| SD ABA SC + MTX | 0.27(0.12,0.66) | 0.30(0.13,0.68) | ‐0.07(‐0.18,‐0.02) | |
| SD TOCI IV + MTX | 0.55(0.15,1.85) | 0.58(0.18,1.74) | ‐0.04(‐0.16,0.05) | |
| SD ETN SC + DMARD | 0.23(0.09,0.56) | 0.25(0.11,0.58) | ‐0.08(‐0.19,‐0.02) | |
| SD CERTO + DMARD | 0.31(0.09,1.08) | 0.34(0.10,1.07) | ‐0.07(‐0.19,0.00) | |
| SD ABA IV + DMARD | 0.30(0.10,0.92) | 0.32(0.11,0.93) | ‐0.07(‐0.18,0.00) | |
| SD ADA SC + DMARD | 0.26(0.06,1.19) | 0.29(0.07,1.17) | ‐0.07(‐0.18,0.01) | |
| SD TOCI SC + DMARD | 0.53(0.09,5.68) | 0.56(0.11,3.78) | ‐0.04(‐0.17,0.28) | |
| LD ETN SC | 0.40(0.20,0.82) | 0.43(0.23,0.83) | ‐0.06(‐0.15,‐0.01) | |
| LD ADA SC | 0.12(0.03,0.51) | 0.14(0.04,0.53) | ‐0.09(‐0.21,‐0.02) | |
| LD ANA | 0.17(0.04,1.01) | 0.19(0.05,1.01) | ‐0.09(‐0.21,0.00) | |
| LD TOCI IV | 0.33(0.07,1.19) | 0.36(0.09,1.18) | ‐0.07(‐0.19,0.01) | |
| LD RITUX IV + MTX | 1.07(0.35,4.08) | 1.07(0.38,3.02) | 0.01(‐0.09,0.23) | |
| LD ABA IV + MTX | 0.67(0.21,1.93) | 0.70(0.23,1.79) | ‐0.03(‐0.12,0.07) | |
| LD CERTO SC + MTX | 0.59(0.09,2.46) | 0.62(0.10,2.16) | ‐0.04(‐0.15,0.11) | |
| LD ETN SC + MTX | 0.28(0.07,1.03) | 0.30(0.08,1.02) | ‐0.07(‐0.18,0.00) | |
| LD TOCI IV + MTX | 0.23(0.04,0.93) | 0.26(0.05,0.94) | ‐0.08(‐0.19,0.00) | |
| HD TOCI IV | 0.43(0.20,0.96) | 0.46(0.23,0.97) | ‐0.06(‐0.16,0.00) | |
| HD GOLI SC | 0.28(0.03,1.63) | 0.31(0.04,1.55) | ‐0.07(‐0.19,0.05) | |
| HD ADA SC | 0.13(0.03,0.49) | 0.14(0.04,0.50) | ‐0.09(‐0.21,‐0.02) | |
| HD TOFA | 0.38(0.06,2.16) | 0.41(0.07,2.01) | ‐0.06(‐0.20,0.07) | |
| HD ANA | 0.42(0.10,2.01) | 0.45(0.12,1.89) | ‐0.06(‐0.18,0.06) | |
| HD TOCI IV + MTX | 0.56(0.21,1.51) | 0.59(0.24,1.45) | ‐0.04(‐0.14,0.04) | |
| HD GOLI SC + MTX | 0.90(0.30,2.87) | 0.91(0.34,2.46) | ‐0.01(‐0.11,0.14) | |
| HD INF IV + MTX | 0.89(0.44,1.71) | 0.90(0.48,1.60) | ‐0.01(‐0.08,0.06) | |
| HD TOFA PO + MTX | 0.77(0.36,1.66) | 0.79(0.39,1.57) | ‐0.02(‐0.10,0.05) | |
| HD CERTO SC + MTX | 0.85(0.30,2.16) | 0.86(0.32,1.96) | ‐0.01(‐0.11,0.09) | |
| HD TOCI IV + DMARD | 0.43(0.15,1.34) | 0.46(0.17,1.31) | ‐0.05(‐0.17,0.02) | |
| SD RITUX IV + MTX | SD ABA IV + MTX | 1.41(0.46,5.59) | 1.37(0.48,4.44) | 0.02(‐0.04,0.21) |
| SD CERTO SC + MTX | 1.44(0.65,3.43) | 1.40(0.67,3.16) | 0.02(‐0.03,0.10) | |
| SD GOLI SC + MTX | 1.30(0.42,4.51) | 1.28(0.44,3.89) | 0.01(‐0.05,0.16) | |
| SD TOFA PO + MTX | 1.98(0.92,4.34) | 1.86(0.92,3.84) | 0.05(0.00,0.15) | |
| SD ABA SC + MTX | 0.54(0.29,1.06) | 0.56(0.31,1.05) | ‐0.02(‐0.07,0.00) | |
| SD TOCI IV + MTX | 1.08(0.33,3.72) | 1.08(0.35,3.35) | 0.00(‐0.06,0.10) | |
| SD ETN SC + DMARD | 0.45(0.18,1.23) | 0.47(0.19,1.22) | ‐0.03(‐0.09,0.01) | |
| SD CERTO + DMARD | 0.61(0.18,2.27) | 0.62(0.20,2.19) | ‐0.02(‐0.08,0.04) | |
| SD ABA IV + DMARD | 0.59(0.20,1.92) | 0.61(0.21,1.84) | ‐0.02(‐0.08,0.03) | |
| SD ADA SC + DMARD | 0.51(0.11,2.48) | 0.53(0.12,2.35) | ‐0.02(‐0.09,0.06) | |
| SD TOCI SC + DMARD | 1.07(0.18,11.24) | 1.07(0.20,6.98) | 0.00(‐0.07,0.34) | |
| LD ETN SC | 0.79(0.37,1.81) | 0.80(0.39,1.75) | ‐0.01(‐0.06,0.03) | |
| LD ADA SC | 0.24(0.06,1.08) | 0.26(0.07,1.08) | ‐0.04(‐0.11,0.00) | |
| LD ANA | 0.36(0.08,1.86) | 0.37(0.09,1.81) | ‐0.03(‐0.11,0.03) | |
| LD TOCI IV | 0.65(0.16,2.50) | 0.67(0.17,2.33) | ‐0.02(‐0.08,0.06) | |
| LD RITUX IV + MTX | 2.12(0.70,8.53) | 1.98(0.71,6.20) | 0.06(‐0.02,0.31) | |
| LD ABA IV + MTX | 1.34(0.47,3.63) | 1.31(0.48,3.21) | 0.02(‐0.04,0.13) | |
| LD CERTO SC + MTX | 1.19(0.20,5.06) | 1.18(0.21,4.32) | 0.01(‐0.06,0.16) | |
| LD ETN SC + MTX | 0.55(0.12,2.24) | 0.57(0.13,2.10) | ‐0.02(‐0.09,0.05) | |
| LD TOCI IV + MTX | 0.47(0.08,1.98) | 0.49(0.08,1.88) | ‐0.03(‐0.09,0.04) | |
| HD TOCI IV | 0.85(0.36,2.06) | 0.86(0.39,1.99) | ‐0.01(‐0.06,0.04) | |
| HD GOLI SC | 0.58(0.07,3.08) | 0.59(0.08,2.82) | ‐0.02(‐0.09,0.09) | |
| HD ADA SC | 0.26(0.06,1.02) | 0.27(0.07,1.02) | ‐0.04(‐0.11,0.00) | |
| HD TOFA | 0.75(0.15,4.54) | 0.76(0.16,4.05) | ‐0.01(‐0.09,0.10) | |
| HD ANA | 0.85(0.21,4.02) | 0.86(0.22,3.64) | ‐0.01(‐0.08,0.09) | |
| HD TOCI IV + MTX | 1.10(0.41,3.36) | 1.10(0.43,3.08) | 0.01(‐0.05,0.09) | |
| HD GOLI SC + MTX | 1.80(0.58,5.90) | 1.71(0.60,4.89) | 0.04(‐0.03,0.21) | |
| HD INF IV + MTX | 1.77(0.76,4.22) | 1.69(0.78,3.71) | 0.04(‐0.01,0.14) | |
| HD TOFA PO + MTX | 1.53(0.70,3.53) | 1.48(0.72,3.16) | 0.03(‐0.02,0.11) | |
| HD CERTO SC + MTX | 1.60(0.60,4.81) | 1.54(0.62,4.14) | 0.03(‐0.03,0.15) | |
| HD TOCI IV + DMARD | 0.85(0.30,2.69) | 0.86(0.32,2.53) | ‐0.01(‐0.07,0.06) | |
| SD CERTO SC + MTX | SD RITUX IV + MTX | 1.02(0.21,3.21) | 1.02(0.28,2.94) | 0.00(‐0.20,0.08) |
| SD GOLI SC + MTX | 0.95(0.16,4.08) | 0.95(0.21,3.61) | 0.00(‐0.20,0.12) | |
| SD TOFA PO + MTX | 1.40(0.37,4.09) | 1.36(0.42,3.69) | 0.02(‐0.14,0.12) | |
| SD ABA SC + MTX | 0.39(0.09,1.26) | 0.41(0.12,1.24) | ‐0.04(‐0.24,0.01) | |
| SD TOCI IV + MTX | 0.79(0.12,3.06) | 0.80(0.16,2.82) | ‐0.01(‐0.23,0.08) | |
| SD ETN SC + DMARD | 0.33(0.06,1.14) | 0.35(0.08,1.13) | ‐0.05(‐0.26,0.00) | |
| SD CERTO + DMARD | 0.44(0.08,2.02) | 0.46(0.11,1.95) | ‐0.04(‐0.25,0.03) | |
| SD ABA IV + DMARD | 0.42(0.09,1.66) | 0.44(0.11,1.63) | ‐0.04(‐0.25,0.02) | |
| SD ADA SC + DMARD | 0.37(0.05,2.23) | 0.39(0.06,2.11) | ‐0.04(‐0.26,0.04) | |
| SD TOCI SC + DMARD | 0.79(0.07,8.30) | 0.80(0.09,5.59) | ‐0.01(‐0.21,0.29) | |
| LD ETN SC | 0.57(0.14,1.71) | 0.59(0.18,1.67) | ‐0.03(‐0.23,0.02) | |
| LD ADA SC | 0.18(0.03,0.97) | 0.19(0.03,0.97) | ‐0.06(‐0.28,0.00) | |
| LD ANA | 0.25(0.04,1.64) | 0.27(0.05,1.59) | ‐0.05(‐0.26,0.02) | |
| LD TOCI IV | 0.46(0.07,2.17) | 0.48(0.09,2.08) | ‐0.04(‐0.24,0.04) | |
| LD RITUX IV + MTX | 1.49(0.65,3.70) | 1.41(0.67,3.26) | 0.03(‐0.04,0.15) | |
| LD ABA IV + MTX | 0.92(0.19,3.72) | 0.93(0.22,3.37) | 0.00(‐0.18,0.11) | |
| LD CERTO SC + MTX | 0.82(0.09,4.54) | 0.83(0.11,3.86) | ‐0.01(‐0.22,0.15) | |
| LD ETN SC + MTX | 0.39(0.05,1.91) | 0.42(0.07,1.84) | ‐0.04(‐0.24,0.04) | |
| LD TOCI IV + MTX | 0.33(0.04,1.68) | 0.35(0.05,1.63) | ‐0.04(‐0.25,0.03) | |
| HD TOCI IV | 0.61(0.15,1.88) | 0.63(0.20,1.83) | ‐0.03(‐0.22,0.03) | |
| HD GOLI SC | 0.39(0.04,2.46) | 0.41(0.05,2.29) | ‐0.04(‐0.25,0.07) | |
| HD ADA SC | 0.18(0.02,0.93) | 0.19(0.03,0.93) | ‐0.06(‐0.28,0.00) | |
| HD TOFA | 0.52(0.07,3.62) | 0.54(0.08,3.29) | ‐0.03(‐0.24,0.09) | |
| HD ANA | 0.61(0.09,3.43) | 0.63(0.12,3.14) | ‐0.03(‐0.24,0.08) | |
| HD TOCI IV + MTX | 0.80(0.16,2.84) | 0.81(0.20,2.65) | ‐0.01(‐0.22,0.07) | |
| HD GOLI SC + MTX | 1.28(0.23,5.07) | 1.25(0.29,4.26) | 0.02(‐0.19,0.19) | |
| HD INF IV + MTX | 1.29(0.30,4.10) | 1.25(0.37,3.69) | 0.02(‐0.17,0.12) | |
| HD TOFA PO + MTX | 1.09(0.28,3.25) | 1.09(0.33,3.00) | 0.01(‐0.16,0.09) | |
| HD CERTO SC + MTX | 1.16(0.24,4.11) | 1.15(0.30,3.68) | 0.01(‐0.18,0.12) | |
| HD TOCI IV + DMARD | 0.61(0.12,2.47) | 0.63(0.15,2.35) | ‐0.03(‐0.23,0.05) | |
| SD GOLI SC + MTX | SD CERTO SC + MTX | 0.89(0.28,3.10) | 0.90(0.31,2.73) | ‐0.01(‐0.09,0.13) |
| SD TOFA PO + MTX | 1.37(0.61,3.04) | 1.32(0.64,2.73) | 0.02(‐0.04,0.12) | |
| SD ABA SC + MTX | 0.37(0.15,0.95) | 0.40(0.16,0.95) | ‐0.05(‐0.13,0.00) | |
| SD TOCI IV + MTX | 0.74(0.22,2.59) | 0.76(0.24,2.39) | ‐0.02(‐0.11,0.08) | |
| SD ETN SC + DMARD | 0.31(0.12,0.79) | 0.33(0.14,0.80) | ‐0.05(‐0.14,‐0.01) | |
| SD CERTO + DMARD | 0.43(0.12,1.44) | 0.45(0.14,1.42) | ‐0.04(‐0.13,0.02) | |
| SD ABA IV + DMARD | 0.41(0.13,1.22) | 0.43(0.15,1.20) | ‐0.04(‐0.13,0.01) | |
| SD ADA SC + DMARD | 0.35(0.08,1.61) | 0.37(0.09,1.57) | ‐0.05(‐0.14,0.03) | |
| SD TOCI SC + DMARD | 0.76(0.13,6.94) | 0.77(0.14,4.68) | ‐0.02(‐0.12,0.31) | |
| LD ETN SC | 0.55(0.26,1.25) | 0.57(0.28,1.23) | ‐0.03(‐0.11,0.01) | |
| LD ADA SC | 0.17(0.04,0.71) | 0.18(0.05,0.72) | ‐0.07(‐0.16,‐0.01) | |
| LD ANA | 0.25(0.06,1.37) | 0.26(0.06,1.35) | ‐0.06(‐0.16,0.01) | |
| LD TOCI IV | 0.45(0.10,1.61) | 0.48(0.12,1.56) | ‐0.04(‐0.13,0.03) | |
| LD RITUX IV + MTX | 1.42(0.49,6.62) | 1.37(0.52,4.65) | 0.03(‐0.05,0.28) | |
| LD ABA IV + MTX | 0.94(0.25,2.71) | 0.95(0.28,2.47) | 0.00(‐0.09,0.10) | |
| LD CERTO SC + MTX | 0.84(0.14,2.91) | 0.86(0.15,2.55) | ‐0.01(‐0.10,0.12) | |
| LD ETN SC + MTX | 0.37(0.10,1.57) | 0.39(0.10,1.51) | ‐0.05(‐0.13,0.03) | |
| LD TOCI IV + MTX | 0.32(0.05,1.45) | 0.34(0.06,1.42) | ‐0.05(‐0.14,0.02) | |
| HD TOCI IV | 0.57(0.25,1.37) | 0.60(0.28,1.35) | ‐0.03(‐0.11,0.02) | |
| HD GOLI SC | 0.40(0.04,2.11) | 0.43(0.05,1.96) | ‐0.04(‐0.14,0.07) | |
| HD ADA SC | 0.17(0.04,0.68) | 0.19(0.05,0.69) | ‐0.07(‐0.16,‐0.01) | |
| HD TOFA | 0.52(0.10,3.16) | 0.54(0.11,2.89) | ‐0.04(‐0.14,0.09) | |
| HD ANA | 0.57(0.14,2.93) | 0.60(0.15,2.70) | ‐0.03(‐0.13,0.08) | |
| HD TOCI IV + MTX | 0.77(0.27,2.33) | 0.78(0.30,2.17) | ‐0.02(‐0.10,0.07) | |
| HD GOLI SC + MTX | 1.24(0.38,3.90) | 1.21(0.41,3.25) | 0.01(‐0.08,0.18) | |
| HD INF IV + MTX | 1.24(0.50,2.74) | 1.21(0.53,2.50) | 0.02(‐0.06,0.11) | |
| HD TOFA PO + MTX | 1.06(0.47,2.47) | 1.06(0.50,2.29) | 0.00(‐0.06,0.09) | |
| HD CERTO SC + MTX | 1.13(0.48,2.54) | 1.12(0.51,2.29) | 0.01(‐0.05,0.11) | |
| HD TOCI IV + DMARD | 0.59(0.20,1.82) | 0.61(0.23,1.73) | ‐0.03(‐0.11,0.04) | |
| SD TOFA PO + MTX | SD GOLI SC + MTX | 1.50(0.43,4.80) | 1.45(0.47,4.22) | 0.03(‐0.10,0.14) |
| SD ABA SC + MTX | 0.43(0.12,1.39) | 0.45(0.14,1.37) | ‐0.04(‐0.19,0.01) | |
| SD TOCI IV + MTX | 0.83(0.17,3.80) | 0.84(0.20,3.48) | ‐0.01(‐0.16,0.09) | |
| SD ETN SC + DMARD | 0.34(0.09,1.35) | 0.36(0.11,1.34) | ‐0.04(‐0.20,0.01) | |
| SD CERTO + DMARD | 0.48(0.10,2.21) | 0.50(0.12,2.13) | ‐0.03(‐0.19,0.03) | |
| SD ABA IV + DMARD | 0.45(0.11,1.84) | 0.47(0.13,1.79) | ‐0.04(‐0.19,0.03) | |
| SD ADA SC + DMARD | 0.38(0.07,2.34) | 0.40(0.08,2.21) | ‐0.04(‐0.18,0.05) | |
| SD TOCI SC + DMARD | 0.85(0.12,9.05) | 0.86(0.14,6.20) | ‐0.01(‐0.16,0.31) | |
| LD ETN SC | 0.61(0.20,1.97) | 0.63(0.23,1.92) | ‐0.02(‐0.16,0.03) | |
| LD ADA SC | 0.18(0.04,1.15) | 0.19(0.04,1.14) | ‐0.06(‐0.21,0.00) | |
| LD ANA | 0.26(0.05,1.85) | 0.27(0.06,1.79) | ‐0.05(‐0.21,0.02) | |
| LD TOCI IV | 0.49(0.09,2.41) | 0.51(0.11,2.29) | ‐0.03(‐0.19,0.05) | |
| LD RITUX IV + MTX | 1.59(0.39,8.09) | 1.52(0.43,6.02) | 0.03(‐0.10,0.29) | |
| LD ABA IV + MTX | 1.05(0.22,4.07) | 1.04(0.25,3.57) | 0.00(‐0.14,0.13) | |
| LD CERTO SC + MTX | 0.94(0.10,4.65) | 0.94(0.11,3.97) | 0.00(‐0.14,0.14) | |
| LD ETN SC + MTX | 0.42(0.07,2.04) | 0.44(0.09,1.94) | ‐0.04(‐0.19,0.05) | |
| LD TOCI IV + MTX | 0.34(0.05,2.00) | 0.36(0.07,1.92) | ‐0.04(‐0.20,0.03) | |
| HD TOCI IV | 0.66(0.19,2.12) | 0.67(0.22,2.05) | ‐0.02(‐0.17,0.03) | |
| HD GOLI SC | 0.44(0.06,2.47) | 0.46(0.06,2.28) | ‐0.03(‐0.18,0.07) | |
| HD ADA SC | 0.19(0.04,0.98) | 0.21(0.05,0.98) | ‐0.06(‐0.21,0.00) | |
| HD TOFA | 0.58(0.06,4.14) | 0.60(0.07,3.76) | ‐0.03(‐0.20,0.09) | |
| HD ANA | 0.64(0.13,3.81) | 0.66(0.16,3.49) | ‐0.02(‐0.19,0.08) | |
| HD TOCI IV + MTX | 0.86(0.21,3.26) | 0.87(0.25,3.04) | ‐0.01(‐0.15,0.08) | |
| HD GOLI SC + MTX | 1.36(0.52,3.68) | 1.32(0.56,3.27) | 0.02(‐0.06,0.14) | |
| HD INF IV + MTX | 1.36(0.39,4.39) | 1.32(0.43,3.98) | 0.02(‐0.10,0.12) | |
| HD TOFA PO + MTX | 1.15(0.35,3.84) | 1.14(0.39,3.43) | 0.01(‐0.12,0.11) | |
| HD CERTO SC + MTX | 1.24(0.32,4.81) | 1.22(0.36,4.24) | 0.01(‐0.11,0.14) | |
| HD TOCI IV + DMARD | 0.65(0.17,2.85) | 0.66(0.20,2.68) | ‐0.02(‐0.17,0.06) | |
| SD ABA SC + MTX | SD TOFA PO + MTX | 0.28(0.12,0.65) | 0.30(0.14,0.66) | ‐0.07(‐0.18,‐0.02) |
| SD TOCI IV + MTX | 0.55(0.15,1.91) | 0.58(0.18,1.79) | ‐0.04(‐0.17,0.05) | |
| SD ETN SC + DMARD | 0.23(0.09,0.63) | 0.25(0.11,0.65) | ‐0.08(‐0.20,‐0.02) | |
| SD CERTO + DMARD | 0.31(0.09,1.17) | 0.34(0.10,1.16) | ‐0.07(‐0.19,0.01) | |
| SD ABA IV + DMARD | 0.29(0.10,0.96) | 0.32(0.12,0.97) | ‐0.07(‐0.18,0.00) | |
| SD ADA SC + DMARD | 0.26(0.06,1.28) | 0.28(0.07,1.25) | ‐0.07(‐0.20,0.02) | |
| SD TOCI SC + DMARD | 0.55(0.10,5.34) | 0.58(0.11,3.62) | ‐0.04(‐0.17,0.28) | |
| LD ETN SC | 0.40(0.20,0.90) | 0.43(0.23,0.90) | ‐0.06(‐0.16,‐0.01) | |
| LD ADA SC | 0.12(0.03,0.52) | 0.14(0.04,0.54) | ‐0.09(‐0.22,‐0.02) | |
| LD ANA | 0.18(0.04,0.99) | 0.19(0.05,0.99) | ‐0.08(‐0.21,0.00) | |
| LD TOCI IV | 0.33(0.08,1.19) | 0.36(0.09,1.18) | ‐0.06(‐0.19,0.01) | |
| LD RITUX IV + MTX | 1.06(0.36,4.40) | 1.05(0.39,3.26) | 0.01(‐0.09,0.23) | |
| LD ABA IV + MTX | 0.67(0.20,2.18) | 0.70(0.23,1.99) | ‐0.03(‐0.13,0.08) | |
| LD CERTO SC + MTX | 0.61(0.09,2.40) | 0.64(0.11,2.13) | ‐0.03(‐0.15,0.10) | |
| LD ETN SC + MTX | 0.28(0.06,1.10) | 0.30(0.07,1.09) | ‐0.07(‐0.19,0.01) | |
| LD TOCI IV + MTX | 0.24(0.04,1.01) | 0.26(0.04,1.01) | ‐0.08(‐0.20,0.00) | |
| HD TOCI IV | 0.43(0.19,1.04) | 0.46(0.22,1.04) | ‐0.06(‐0.16,0.00) | |
| HD GOLI SC | 0.29(0.03,1.68) | 0.31(0.04,1.59) | ‐0.07(‐0.19,0.05) | |
| HD ADA SC | 0.13(0.03,0.53) | 0.14(0.04,0.54) | ‐0.09(‐0.22,‐0.02) | |
| HD TOFA | 0.37(0.07,2.34) | 0.40(0.09,2.17) | ‐0.06(‐0.19,0.07) | |
| HD ANA | 0.43(0.10,2.09) | 0.46(0.11,1.94) | ‐0.06(‐0.19,0.06) | |
| HD TOCI IV + MTX | 0.57(0.20,1.56) | 0.60(0.23,1.50) | ‐0.04(‐0.15,0.04) | |
| HD GOLI SC + MTX | 0.91(0.30,2.95) | 0.92(0.33,2.57) | ‐0.01(‐0.12,0.14) | |
| HD INF IV + MTX | 0.89(0.39,2.13) | 0.90(0.42,1.96) | ‐0.01(‐0.10,0.08) | |
| HD TOFA PO + MTX | 0.78(0.47,1.32) | 0.80(0.50,1.28) | ‐0.02(‐0.08,0.02) | |
| HD CERTO SC + MTX | 0.83(0.28,2.37) | 0.85(0.31,2.13) | ‐0.01(‐0.12,0.10) | |
| HD TOCI IV + DMARD | 0.43(0.15,1.42) | 0.46(0.17,1.38) | ‐0.06(‐0.17,0.02) | |
| SD TOCI IV + MTX | SD ABA SC + MTX | 1.98(0.54,7.25) | 1.92(0.55,6.45) | 0.03(‐0.02,0.13) |
| SD ETN SC + DMARD | 0.83(0.31,2.44) | 0.83(0.32,2.38) | ‐0.01(‐0.05,0.02) | |
| SD CERTO + DMARD | 1.10(0.30,4.32) | 1.09(0.31,4.09) | 0.00(‐0.04,0.06) | |
| SD ABA IV + DMARD | 1.07(0.33,3.53) | 1.07(0.34,3.37) | 0.00(‐0.04,0.05) | |
| SD ADA SC + DMARD | 0.94(0.18,4.61) | 0.94(0.19,4.27) | 0.00(‐0.05,0.08) | |
| SD TOCI SC + DMARD | 1.94(0.33,21.80) | 1.88(0.34,13.97) | 0.03(‐0.03,0.37) | |
| LD ETN SC | 1.45(0.62,3.58) | 1.43(0.63,3.42) | 0.01(‐0.02,0.06) | |
| LD ADA SC | 0.44(0.10,2.10) | 0.45(0.11,2.07) | ‐0.02(‐0.07,0.02) | |
| LD ANA | 0.66(0.14,3.58) | 0.67(0.15,3.45) | ‐0.01(‐0.06,0.04) | |
| LD TOCI IV | 1.19(0.28,4.91) | 1.18(0.29,4.51) | 0.01(‐0.04,0.08) | |
| LD RITUX IV + MTX | 3.86(1.18,17.07) | 3.50(1.17,11.65) | 0.08(0.01,0.35) | |
| LD ABA IV + MTX | 2.45(0.72,7.32) | 2.33(0.73,6.35) | 0.04(‐0.01,0.16) | |
| LD CERTO SC + MTX | 2.19(0.34,9.45) | 2.10(0.34,8.02) | 0.03(‐0.03,0.19) | |
| LD ETN SC + MTX | 1.00(0.23,4.25) | 1.00(0.24,3.96) | 0.00(‐0.04,0.08) | |
| LD TOCI IV + MTX | 0.87(0.13,3.80) | 0.87(0.13,3.54) | 0.00(‐0.05,0.07) | |
| HD TOCI IV | 1.55(0.59,4.07) | 1.52(0.60,3.87) | 0.02(‐0.02,0.06) | |
| HD GOLI SC | 1.07(0.12,5.91) | 1.07(0.13,5.34) | 0.00(‐0.05,0.12) | |
| HD ADA SC | 0.47(0.10,2.01) | 0.48(0.11,1.97) | ‐0.02(‐0.06,0.02) | |
| HD TOFA | 1.38(0.26,8.10) | 1.36(0.28,7.27) | 0.01(‐0.05,0.12) | |
| HD ANA | 1.60(0.35,7.74) | 1.57(0.37,6.99) | 0.02(‐0.04,0.11) | |
| HD TOCI IV + MTX | 2.03(0.67,6.58) | 1.96(0.68,5.95) | 0.03(‐0.02,0.12) | |
| HD GOLI SC + MTX | 3.20(1.01,11.32) | 2.97(1.01,9.37) | 0.06(0.00,0.24) | |
| HD INF IV + MTX | 3.26(1.23,8.35) | 3.02(1.21,7.28) | 0.06(0.01,0.17) | |
| HD TOFA PO + MTX | 2.82(1.18,7.00) | 2.65(1.17,6.19) | 0.05(0.01,0.14) | |
| HD CERTO SC + MTX | 2.99(0.95,9.37) | 2.80(0.95,7.92) | 0.06(0.00,0.18) | |
| HD TOCI IV + DMARD | 1.56(0.49,5.11) | 1.53(0.50,4.73) | 0.02(‐0.03,0.09) | |
| SD ETN SC + DMARD | SD TOCI IV + MTX | 0.42(0.13,1.48) | 0.44(0.15,1.46) | ‐0.03(‐0.14,0.01) |
| SD CERTO + DMARD | 0.57(0.13,2.75) | 0.58(0.15,2.63) | ‐0.02(‐0.12,0.04) | |
| SD ABA IV + DMARD | 0.55(0.14,2.19) | 0.56(0.16,2.10) | ‐0.02(‐0.12,0.03) | |
| SD ADA SC + DMARD | 0.47(0.09,2.47) | 0.49(0.10,2.36) | ‐0.03(‐0.12,0.05) | |
| SD TOCI SC + DMARD | 1.02(0.15,11.97) | 1.01(0.17,7.82) | 0.00(‐0.11,0.33) | |
| LD ETN SC | 0.75(0.23,2.33) | 0.76(0.26,2.25) | ‐0.01(‐0.11,0.04) | |
| LD ADA SC | 0.23(0.05,1.05) | 0.24(0.05,1.05) | ‐0.04(‐0.15,0.00) | |
| LD ANA | 0.32(0.07,2.09) | 0.33(0.08,2.03) | ‐0.04(‐0.14,0.03) | |
| LD TOCI IV | 0.61(0.13,2.31) | 0.63(0.15,2.19) | ‐0.02(‐0.12,0.04) | |
| LD RITUX IV + MTX | 1.93(0.47,13.68) | 1.82(0.50,8.72) | 0.05(‐0.06,0.33) | |
| LD ABA IV + MTX | 1.20(0.30,5.18) | 1.18(0.33,4.51) | 0.01(‐0.09,0.14) | |
| LD CERTO SC + MTX | 1.12(0.14,6.32) | 1.11(0.15,5.28) | 0.01(‐0.11,0.16) | |
| LD ETN SC + MTX | 0.48(0.10,2.96) | 0.50(0.11,2.76) | ‐0.03(‐0.13,0.07) | |
| LD TOCI IV + MTX | 0.44(0.07,1.86) | 0.46(0.08,1.81) | ‐0.03(‐0.12,0.03) | |
| HD TOCI IV | 0.78(0.28,2.44) | 0.79(0.31,2.34) | ‐0.01(‐0.10,0.04) | |
| HD GOLI SC | 0.51(0.06,3.80) | 0.53(0.06,3.42) | ‐0.02(‐0.13,0.10) | |
| HD ADA SC | 0.23(0.05,1.08) | 0.24(0.05,1.08) | ‐0.04(‐0.15,0.00) | |
| HD TOFA | 0.71(0.11,4.57) | 0.72(0.13,4.14) | ‐0.02(‐0.13,0.10) | |
| HD ANA | 0.79(0.16,4.42) | 0.80(0.18,4.00) | ‐0.01(‐0.12,0.09) | |
| HD TOCI IV + MTX | 1.06(0.34,3.10) | 1.05(0.36,2.90) | 0.00(‐0.08,0.08) | |
| HD GOLI SC + MTX | 1.68(0.38,8.14) | 1.61(0.41,6.45) | 0.03(‐0.07,0.22) | |
| HD INF IV + MTX | 1.64(0.46,6.02) | 1.57(0.49,5.25) | 0.03(‐0.06,0.15) | |
| HD TOFA PO + MTX | 1.39(0.41,5.38) | 1.36(0.44,4.71) | 0.02(‐0.07,0.14) | |
| HD CERTO SC + MTX | 1.57(0.34,6.02) | 1.52(0.37,5.28) | 0.03(‐0.08,0.15) | |
| HD TOCI IV + DMARD | 0.79(0.22,3.36) | 0.80(0.24,3.14) | ‐0.01(‐0.11,0.07) | |
| SD CERTO + DMARD | SD ETN SC + DMARD | 1.39(0.40,3.86) | 1.38(0.40,3.65) | 0.01(‐0.02,0.06) |
| SD ABA IV + DMARD | 1.30(0.50,3.23) | 1.29(0.51,3.07) | 0.01(‐0.02,0.05) | |
| SD ADA SC + DMARD | 1.13(0.26,4.48) | 1.13(0.27,4.12) | 0.00(‐0.03,0.08) | |
| SD TOCI SC + DMARD | 2.33(0.50,21.45) | 2.24(0.51,13.22) | 0.03(‐0.02,0.37) | |
| LD ETN SC | 1.75(0.78,4.17) | 1.71(0.79,3.93) | 0.02(‐0.01,0.06) | |
| LD ADA SC | 0.55(0.14,1.84) | 0.55(0.14,1.81) | ‐0.01(‐0.04,0.02) | |
| LD ANA | 0.79(0.19,3.58) | 0.80(0.20,3.43) | ‐0.01(‐0.04,0.05) | |
| LD TOCI IV | 1.43(0.34,5.30) | 1.42(0.35,4.89) | 0.01(‐0.03,0.08) | |
| LD RITUX IV + MTX | 4.68(1.26,23.89) | 4.24(1.25,16.44) | 0.09(0.01,0.36) | |
| LD ABA IV + MTX | 2.96(0.72,10.28) | 2.80(0.72,8.76) | 0.05(‐0.01,0.17) | |
| LD CERTO SC + MTX | 2.66(0.40,10.81) | 2.53(0.41,8.85) | 0.04(‐0.02,0.20) | |
| LD ETN SC + MTX | 1.21(0.25,4.70) | 1.20(0.26,4.32) | 0.00(‐0.03,0.09) | |
| LD TOCI IV + MTX | 1.05(0.18,4.30) | 1.05(0.18,4.00) | 0.00(‐0.04,0.08) | |
| HD TOCI IV | 1.89(0.81,4.21) | 1.85(0.81,3.98) | 0.02(‐0.01,0.06) | |
| HD GOLI SC | 1.24(0.14,7.96) | 1.23(0.14,6.96) | 0.01(‐0.04,0.13) | |
| HD ADA SC | 0.57(0.15,1.87) | 0.57(0.16,1.84) | ‐0.01(‐0.04,0.01) | |
| HD TOFA | 1.67(0.28,9.51) | 1.64(0.29,8.34) | 0.02(‐0.03,0.13) | |
| HD ANA | 1.87(0.46,7.61) | 1.83(0.48,6.80) | 0.02(‐0.02,0.12) | |
| HD TOCI IV + MTX | 2.46(0.87,6.60) | 2.36(0.88,5.87) | 0.04(0.00,0.12) | |
| HD GOLI SC + MTX | 3.92(1.14,14.50) | 3.62(1.13,11.20) | 0.07(0.00,0.26) | |
| HD INF IV + MTX | 3.92(1.37,10.22) | 3.61(1.35,8.57) | 0.07(0.01,0.18) | |
| HD TOFA PO + MTX | 3.39(1.22,8.78) | 3.19(1.21,7.60) | 0.06(0.01,0.16) | |
| HD CERTO SC + MTX | 3.67(1.10,11.01) | 3.40(1.09,9.12) | 0.06(0.00,0.19) | |
| HD TOCI IV + DMARD | 1.91(0.75,4.42) | 1.86(0.76,4.08) | 0.02(‐0.01,0.09) | |
| SD ABA IV + DMARD | SD CERTO + DMARD | 0.94(0.30,3.33) | 0.94(0.31,3.18) | 0.00(‐0.05,0.05) |
| SD ADA SC + DMARD | 0.83(0.15,4.32) | 0.83(0.16,4.04) | ‐0.01(‐0.07,0.08) | |
| SD TOCI SC + DMARD | 1.85(0.33,16.46) | 1.79(0.34,10.19) | 0.02(‐0.04,0.35) | |
| LD ETN SC | 1.31(0.40,4.34) | 1.29(0.42,4.12) | 0.01(‐0.05,0.06) | |
| LD ADA SC | 0.39(0.07,1.94) | 0.40(0.08,1.91) | ‐0.02(‐0.08,0.02) | |
| LD ANA | 0.58(0.11,3.43) | 0.59(0.12,3.29) | ‐0.01(‐0.08,0.04) | |
| LD TOCI IV | 1.04(0.21,4.88) | 1.03(0.22,4.56) | 0.00(‐0.06,0.08) | |
| LD RITUX IV + MTX | 3.60(0.71,18.43) | 3.26(0.73,13.17) | 0.08(‐0.02,0.35) | |
| LD ABA IV + MTX | 2.27(0.40,8.91) | 2.16(0.42,7.70) | 0.04(‐0.04,0.16) | |
| LD CERTO SC + MTX | 1.98(0.24,9.17) | 1.89(0.25,7.80) | 0.03(‐0.05,0.18) | |
| LD ETN SC + MTX | 0.86(0.17,4.71) | 0.87(0.17,4.31) | 0.00(‐0.07,0.09) | |
| LD TOCI IV + MTX | 0.74(0.12,4.29) | 0.75(0.13,4.01) | ‐0.01(‐0.07,0.07) | |
| HD TOCI IV | 1.39(0.42,4.44) | 1.37(0.43,4.20) | 0.01(‐0.04,0.06) | |
| HD GOLI SC | 0.91(0.09,7.34) | 0.92(0.09,6.43) | 0.00(‐0.07,0.13) | |
| HD ADA SC | 0.41(0.09,1.89) | 0.42(0.09,1.86) | ‐0.02(‐0.08,0.01) | |
| HD TOFA | 1.25(0.17,8.18) | 1.24(0.19,7.38) | 0.01(‐0.07,0.12) | |
| HD ANA | 1.39(0.30,7.33) | 1.37(0.31,6.54) | 0.01(‐0.06,0.11) | |
| HD TOCI IV + MTX | 1.85(0.48,6.83) | 1.78(0.50,6.20) | 0.03(‐0.04,0.11) | |
| HD GOLI SC + MTX | 2.94(0.60,15.08) | 2.73(0.62,11.65) | 0.06(‐0.03,0.25) | |
| HD INF IV + MTX | 2.88(0.75,10.33) | 2.69(0.76,8.90) | 0.06(‐0.01,0.18) | |
| HD TOFA PO + MTX | 2.52(0.67,9.17) | 2.38(0.69,7.95) | 0.05(‐0.02,0.16) | |
| HD CERTO SC + MTX | 2.69(0.67,9.81) | 2.53(0.69,8.44) | 0.05(‐0.02,0.18) | |
| HD TOCI IV + DMARD | 1.35(0.45,4.64) | 1.33(0.47,4.33) | 0.01(‐0.04,0.09) | |
| SD ADA SC + DMARD | SD ABA IV + DMARD | 0.88(0.21,3.50) | 0.89(0.22,3.29) | 0.00(‐0.05,0.06) |
| SD TOCI SC + DMARD | 1.84(0.40,15.36) | 1.78(0.41,10.07) | 0.02(‐0.03,0.35) | |
| LD ETN SC | 1.35(0.49,4.05) | 1.33(0.51,3.86) | 0.01(‐0.04,0.06) | |
| LD ADA SC | 0.41(0.09,1.97) | 0.42(0.10,1.93) | ‐0.02(‐0.08,0.02) | |
| LD ANA | 0.61(0.12,3.20) | 0.62(0.13,3.08) | ‐0.01(‐0.07,0.04) | |
| LD TOCI IV | 1.09(0.25,4.69) | 1.08(0.25,4.37) | 0.00(‐0.05,0.07) | |
| LD RITUX IV + MTX | 3.63(0.89,17.74) | 3.30(0.90,12.40) | 0.08(‐0.01,0.35) | |
| LD ABA IV + MTX | 2.29(0.50,9.18) | 2.18(0.52,7.94) | 0.04(‐0.03,0.17) | |
| LD CERTO SC + MTX | 2.03(0.28,9.64) | 1.95(0.29,8.03) | 0.03(‐0.04,0.19) | |
| LD ETN SC + MTX | 0.92(0.18,4.09) | 0.92(0.19,3.80) | 0.00(‐0.05,0.08) | |
| LD TOCI IV + MTX | 0.80(0.12,4.04) | 0.80(0.13,3.78) | ‐0.01(‐0.06,0.07) | |
| HD TOCI IV | 1.46(0.53,3.79) | 1.44(0.55,3.62) | 0.01(‐0.03,0.06) | |
| HD GOLI SC | 1.00(0.10,6.64) | 1.00(0.10,6.02) | 0.00(‐0.06,0.12) | |
| HD ADA SC | 0.43(0.09,1.89) | 0.44(0.10,1.86) | ‐0.02(‐0.07,0.01) | |
| HD TOFA | 1.27(0.19,8.28) | 1.25(0.20,7.30) | 0.01(‐0.06,0.12) | |
| HD ANA | 1.46(0.33,7.39) | 1.44(0.35,6.66) | 0.01(‐0.05,0.11) | |
| HD TOCI IV + MTX | 1.91(0.57,6.17) | 1.85(0.59,5.62) | 0.03(‐0.03,0.11) | |
| HD GOLI SC + MTX | 3.02(0.75,12.91) | 2.80(0.76,10.46) | 0.06(‐0.01,0.24) | |
| HD INF IV + MTX | 3.07(0.87,9.09) | 2.85(0.88,8.04) | 0.06(‐0.01,0.17) | |
| HD TOFA PO + MTX | 2.62(0.82,8.06) | 2.47(0.83,7.11) | 0.05(‐0.01,0.15) | |
| HD CERTO SC + MTX | 2.82(0.74,9.54) | 2.63(0.75,8.18) | 0.06(‐0.01,0.18) | |
| HD TOCI IV + DMARD | 1.45(0.60,3.77) | 1.43(0.62,3.55) | 0.01(‐0.02,0.07) | |
| SD TOCI SC + DMARD | SD ADA SC + DMARD | 2.07(0.34,27.25) | 1.98(0.35,17.22) | 0.03(‐0.05,0.37) |
| LD ETN SC | 1.53(0.35,6.97) | 1.51(0.37,6.62) | 0.01(‐0.07,0.07) | |
| LD ADA SC | 0.48(0.07,2.65) | 0.49(0.08,2.60) | ‐0.01(‐0.10,0.02) | |
| LD ANA | 0.68(0.12,4.95) | 0.69(0.13,4.72) | ‐0.01(‐0.09,0.05) | |
| LD TOCI IV | 1.24(0.19,7.93) | 1.23(0.21,7.38) | 0.01(‐0.07,0.08) | |
| LD RITUX IV + MTX | 4.13(0.69,31.08) | 3.74(0.71,21.92) | 0.08(‐0.02,0.35) | |
| LD ABA IV + MTX | 2.55(0.44,14.21) | 2.42(0.46,12.33) | 0.04(‐0.05,0.18) | |
| LD CERTO SC + MTX | 2.28(0.25,14.73) | 2.17(0.27,12.41) | 0.03(‐0.06,0.19) | |
| LD ETN SC + MTX | 1.08(0.17,6.01) | 1.07(0.18,5.62) | 0.00(‐0.08,0.09) | |
| LD TOCI IV + MTX | 0.90(0.11,5.76) | 0.90(0.12,5.41) | 0.00(‐0.09,0.07) | |
| HD TOCI IV | 1.62(0.41,7.14) | 1.59(0.43,6.69) | 0.02(‐0.06,0.07) | |
| HD GOLI SC | 1.11(0.08,9.24) | 1.11(0.08,8.34) | 0.00(‐0.09,0.12) | |
| HD ADA SC | 0.49(0.08,2.76) | 0.50(0.09,2.71) | ‐0.01(‐0.10,0.02) | |
| HD TOFA | 1.42(0.17,12.52) | 1.40(0.18,11.15) | 0.01(‐0.08,0.13) | |
| HD ANA | 1.69(0.28,10.54) | 1.65(0.31,9.64) | 0.02(‐0.07,0.11) | |
| HD TOCI IV + MTX | 2.17(0.47,10.43) | 2.09(0.49,9.60) | 0.03(‐0.04,0.12) | |
| HD GOLI SC + MTX | 3.52(0.61,20.06) | 3.21(0.64,16.36) | 0.06(‐0.03,0.24) | |
| HD INF IV + MTX | 3.47(0.71,15.60) | 3.20(0.73,13.54) | 0.06(‐0.02,0.17) | |
| HD TOFA PO + MTX | 2.93(0.64,15.08) | 2.75(0.66,12.86) | 0.05(‐0.03,0.16) | |
| HD CERTO SC + MTX | 3.26(0.58,15.34) | 3.02(0.60,13.30) | 0.06(‐0.03,0.18) | |
| HD TOCI IV + DMARD | 1.66(0.42,6.93) | 1.62(0.44,6.49) | 0.02(‐0.05,0.09) | |
| LD ETN SC | SD TOCI SC + DMARD | 0.74(0.07,3.88) | 0.75(0.12,3.70) | ‐0.01(‐0.35,0.05) |
| LD ADA SC | 0.24(0.01,1.58) | 0.25(0.02,1.56) | ‐0.04(‐0.39,0.01) | |
| LD ANA | 0.34(0.02,2.39) | 0.35(0.03,2.33) | ‐0.04(‐0.39,0.03) | |
| LD TOCI IV | 0.57(0.04,4.60) | 0.59(0.07,4.32) | ‐0.02(‐0.35,0.06) | |
| LD RITUX IV + MTX | 1.96(0.19,18.88) | 1.83(0.27,14.50) | 0.04(‐0.25,0.30) | |
| LD ABA IV + MTX | 1.18(0.10,9.75) | 1.16(0.15,8.54) | 0.01(‐0.33,0.15) | |
| LD CERTO SC + MTX | 0.99(0.09,9.20) | 0.99(0.11,7.69) | 0.00(‐0.32,0.17) | |
| LD ETN SC + MTX | 0.51(0.04,3.40) | 0.53(0.06,3.22) | ‐0.03(‐0.36,0.05) | |
| LD TOCI IV + MTX | 0.41(0.03,3.45) | 0.43(0.04,3.27) | ‐0.03(‐0.38,0.05) | |
| HD TOCI IV | 0.78(0.09,4.24) | 0.79(0.13,4.04) | ‐0.01(‐0.34,0.05) | |
| HD GOLI SC | 0.49(0.02,6.37) | 0.51(0.04,5.81) | ‐0.03(‐0.37,0.11) | |
| HD ADA SC | 0.24(0.02,1.69) | 0.25(0.03,1.67) | ‐0.04(‐0.39,0.01) | |
| HD TOFA | 0.69(0.03,7.36) | 0.70(0.04,6.68) | ‐0.02(‐0.38,0.11) | |
| HD ANA | 0.76(0.05,5.66) | 0.77(0.08,5.22) | ‐0.01(‐0.37,0.09) | |
| HD TOCI IV + MTX | 1.02(0.10,5.63) | 1.02(0.15,5.17) | 0.00(‐0.31,0.09) | |
| HD GOLI SC + MTX | 1.57(0.16,11.86) | 1.51(0.22,9.86) | 0.03(‐0.28,0.21) | |
| HD INF IV + MTX | 1.63(0.16,8.70) | 1.57(0.24,7.68) | 0.03(‐0.29,0.15) | |
| HD TOFA PO + MTX | 1.40(0.15,8.64) | 1.36(0.21,7.45) | 0.02(‐0.30,0.14) | |
| HD CERTO SC + MTX | 1.43(0.16,10.29) | 1.39(0.22,8.74) | 0.02(‐0.28,0.17) | |
| HD TOCI IV + DMARD | 0.79(0.10,3.53) | 0.81(0.15,3.36) | ‐0.01(‐0.32,0.06) | |
| LD ADA SC | LD ETN SC | 0.30(0.08,1.22) | 0.31(0.09,1.21) | ‐0.03(‐0.08,0.01) |
| LD ANA | 0.43(0.11,2.16) | 0.44(0.12,2.07) | ‐0.02(‐0.08,0.03) | |
| LD TOCI IV | 0.82(0.20,2.75) | 0.83(0.21,2.57) | ‐0.01(‐0.06,0.06) | |
| LD RITUX IV + MTX | 2.65(0.85,10.20) | 2.45(0.85,7.18) | 0.06(‐0.01,0.33) | |
| LD ABA IV + MTX | 1.66(0.50,5.08) | 1.61(0.51,4.41) | 0.03(‐0.03,0.15) | |
| LD CERTO SC + MTX | 1.47(0.24,6.01) | 1.44(0.25,5.04) | 0.02(‐0.04,0.17) | |
| LD ETN SC + MTX | 0.69(0.16,2.48) | 0.70(0.17,2.34) | ‐0.01(‐0.07,0.06) | |
| LD TOCI IV + MTX | 0.59(0.10,2.49) | 0.60(0.10,2.35) | ‐0.02(‐0.07,0.05) | |
| HD TOCI IV | 1.07(0.49,2.36) | 1.07(0.51,2.27) | 0.00(‐0.04,0.04) | |
| HD GOLI SC | 0.70(0.08,4.00) | 0.71(0.09,3.59) | ‐0.01(‐0.07,0.11) | |
| HD ADA SC | 0.32(0.09,1.19) | 0.33(0.09,1.18) | ‐0.03(‐0.08,0.00) | |
| HD TOFA | 0.96(0.17,5.29) | 0.97(0.18,4.74) | 0.00(‐0.07,0.11) | |
| HD ANA | 1.06(0.26,4.60) | 1.06(0.27,4.15) | 0.00(‐0.06,0.10) | |
| HD TOCI IV + MTX | 1.38(0.53,3.94) | 1.35(0.54,3.55) | 0.02(‐0.03,0.10) | |
| HD GOLI SC + MTX | 2.25(0.72,7.04) | 2.12(0.74,5.65) | 0.05(‐0.01,0.22) | |
| HD INF IV + MTX | 2.24(0.91,5.05) | 2.10(0.92,4.43) | 0.05(0.00,0.15) | |
| HD TOFA PO + MTX | 1.94(0.84,4.19) | 1.86(0.85,3.71) | 0.04(‐0.01,0.13) | |
| HD CERTO SC + MTX | 2.07(0.71,5.33) | 1.96(0.73,4.60) | 0.04(‐0.01,0.16) | |
| HD TOCI IV + DMARD | 1.07(0.37,3.06) | 1.07(0.39,2.86) | 0.00(‐0.05,0.07) | |
| LD ANA | LD ADA SC | 1.44(0.31,8.09) | 1.43(0.31,7.57) | 0.01(‐0.02,0.06) |
| LD TOCI IV | 2.66(0.40,14.95) | 2.59(0.41,13.66) | 0.02(‐0.02,0.10) | |
| LD RITUX IV + MTX | 8.62(1.37,57.32) | 7.68(1.35,40.36) | 0.10(0.01,0.38) | |
| LD ABA IV + MTX | 5.56(0.94,24.86) | 5.16(0.94,21.40) | 0.06(0.00,0.19) | |
| LD CERTO SC + MTX | 4.88(0.47,30.85) | 4.58(0.48,25.09) | 0.05(‐0.01,0.21) | |
| LD ETN SC + MTX | 2.20(0.37,13.74) | 2.15(0.38,12.44) | 0.02(‐0.02,0.11) | |
| LD TOCI IV + MTX | 1.92(0.29,12.66) | 1.90(0.29,11.49) | 0.01(‐0.02,0.09) | |
| HD TOCI IV | 3.45(0.85,14.87) | 3.32(0.85,13.75) | 0.03(0.00,0.09) | |
| HD GOLI SC | 2.36(0.20,18.20) | 2.30(0.20,16.26) | 0.02(‐0.03,0.14) | |
| HD ADA SC | 1.02(0.28,3.57) | 1.02(0.29,3.50) | 0.00(‐0.02,0.02) | |
| HD TOFA | 2.99(0.46,23.86) | 2.90(0.47,21.13) | 0.03(‐0.02,0.14) | |
| HD ANA | 3.54(0.81,18.38) | 3.41(0.81,16.47) | 0.03(‐0.01,0.13) | |
| HD TOCI IV + MTX | 4.59(1.12,25.04) | 4.33(1.11,21.54) | 0.05(0.00,0.15) | |
| HD GOLI SC + MTX | 7.41(1.26,35.91) | 6.72(1.25,28.23) | 0.08(0.01,0.27) | |
| HD INF IV + MTX | 7.39(1.53,30.49) | 6.71(1.50,25.84) | 0.08(0.01,0.20) | |
| HD TOFA PO + MTX | 6.24(1.50,26.17) | 5.79(1.48,22.53) | 0.07(0.01,0.18) | |
| HD CERTO SC + MTX | 6.85(1.31,32.18) | 6.25(1.29,26.32) | 0.08(0.01,0.21) | |
| HD TOCI IV + DMARD | 3.49(0.83,16.32) | 3.37(0.84,14.62) | 0.03(0.00,0.12) | |
| LD TOCI IV | LD ANA | 1.82(0.25,9.92) | 1.79(0.26,9.13) | 0.02(‐0.04,0.10) |
| LD RITUX IV + MTX | 6.14(0.88,38.40) | 5.47(0.89,27.35) | 0.09(‐0.01,0.37) | |
| LD ABA IV + MTX | 3.75(0.56,22.34) | 3.53(0.57,18.83) | 0.05(‐0.02,0.19) | |
| LD CERTO SC + MTX | 3.29(0.29,22.13) | 3.12(0.30,18.27) | 0.05(‐0.03,0.21) | |
| LD ETN SC + MTX | 1.57(0.19,9.74) | 1.55(0.20,8.84) | 0.01(‐0.05,0.10) | |
| LD TOCI IV + MTX | 1.28(0.15,9.16) | 1.27(0.16,8.47) | 0.01(‐0.05,0.09) | |
| HD TOCI IV | 2.43(0.48,9.80) | 2.36(0.50,9.15) | 0.03(‐0.03,0.08) | |
| HD GOLI SC | 1.62(0.11,13.13) | 1.60(0.12,11.58) | 0.01(‐0.05,0.14) | |
| HD ADA SC | 0.72(0.09,3.37) | 0.73(0.10,3.29) | ‐0.01(‐0.06,0.02) | |
| HD TOFA | 2.10(0.32,16.47) | 2.05(0.34,14.50) | 0.02(‐0.04,0.13) | |
| HD ANA | 2.32(0.81,7.38) | 2.25(0.82,6.87) | 0.03(‐0.01,0.10) | |
| HD TOCI IV + MTX | 3.20(0.54,15.11) | 3.04(0.56,13.35) | 0.04(‐0.03,0.14) | |
| HD GOLI SC + MTX | 5.38(0.80,27.56) | 4.89(0.81,21.65) | 0.07(‐0.01,0.27) | |
| HD INF IV + MTX | 5.09(0.89,23.21) | 4.66(0.90,19.49) | 0.07(0.00,0.19) | |
| HD TOFA PO + MTX | 4.37(0.81,22.35) | 4.06(0.82,18.77) | 0.06(‐0.01,0.18) | |
| HD CERTO SC + MTX | 4.57(0.79,22.13) | 4.21(0.80,18.75) | 0.07(‐0.01,0.20) | |
| HD TOCI IV + DMARD | 2.40(0.47,11.30) | 2.32(0.48,10.27) | 0.03(‐0.03,0.11) | |
| LD RITUX IV + MTX | LD TOCI IV | 3.28(0.72,21.10) | 2.98(0.73,15.12) | 0.07(‐0.02,0.35) |
| LD ABA IV + MTX | 2.10(0.37,10.21) | 2.01(0.40,8.71) | 0.03(‐0.05,0.16) | |
| LD CERTO SC + MTX | 1.78(0.23,11.92) | 1.72(0.24,9.97) | 0.03(‐0.05,0.19) | |
| LD ETN SC + MTX | 0.87(0.15,4.94) | 0.87(0.16,4.57) | 0.00(‐0.08,0.08) | |
| LD TOCI IV + MTX | 0.73(0.12,3.60) | 0.74(0.13,3.42) | ‐0.01(‐0.08,0.06) | |
| HD TOCI IV | 1.29(0.45,4.64) | 1.27(0.47,4.44) | 0.01(‐0.05,0.06) | |
| HD GOLI SC | 0.89(0.08,6.92) | 0.90(0.09,6.19) | 0.00(‐0.09,0.12) | |
| HD ADA SC | 0.39(0.08,2.25) | 0.40(0.08,2.22) | ‐0.02(‐0.10,0.02) | |
| HD TOFA | 1.16(0.15,9.94) | 1.15(0.16,8.89) | 0.01(‐0.09,0.12) | |
| HD ANA | 1.31(0.26,8.56) | 1.29(0.28,7.68) | 0.01(‐0.07,0.11) | |
| HD TOCI IV + MTX | 1.70(0.54,6.34) | 1.65(0.57,5.89) | 0.02(‐0.04,0.10) | |
| HD GOLI SC + MTX | 2.79(0.59,13.55) | 2.58(0.62,11.16) | 0.06(‐0.03,0.24) | |
| HD INF IV + MTX | 2.72(0.68,11.98) | 2.54(0.70,10.42) | 0.06(‐0.03,0.18) | |
| HD TOFA PO + MTX | 2.33(0.65,10.94) | 2.21(0.67,9.58) | 0.04(‐0.03,0.15) | |
| HD CERTO SC + MTX | 2.50(0.57,11.84) | 2.34(0.60,10.12) | 0.05(‐0.03,0.18) | |
| HD TOCI IV + DMARD | 1.30(0.33,6.43) | 1.29(0.35,5.99) | 0.01(‐0.06,0.09) | |
| LD ABA IV + MTX | LD RITUX IV + MTX | 0.62(0.13,2.39) | 0.66(0.16,2.22) | ‐0.04(‐0.27,0.08) |
| LD CERTO SC + MTX | 0.56(0.06,3.24) | 0.60(0.07,2.83) | ‐0.04(‐0.31,0.12) | |
| LD ETN SC + MTX | 0.26(0.04,1.20) | 0.29(0.05,1.19) | ‐0.08(‐0.35,0.01) | |
| LD TOCI IV + MTX | 0.22(0.03,1.15) | 0.24(0.04,1.14) | ‐0.08(‐0.35,0.01) | |
| HD TOCI IV | 0.40(0.10,1.34) | 0.43(0.15,1.32) | ‐0.06(‐0.33,0.01) | |
| HD GOLI SC | 0.27(0.03,1.63) | 0.30(0.03,1.56) | ‐0.07(‐0.35,0.04) | |
| HD ADA SC | 0.12(0.01,0.64) | 0.13(0.02,0.66) | ‐0.10(‐0.38,‐0.01) | |
| HD TOFA | 0.36(0.05,2.62) | 0.39(0.07,2.41) | ‐0.06(‐0.35,0.07) | |
| HD ANA | 0.40(0.06,2.30) | 0.43(0.09,2.15) | ‐0.06(‐0.34,0.06) | |
| HD TOCI IV + MTX | 0.54(0.11,1.99) | 0.57(0.15,1.89) | ‐0.05(‐0.32,0.05) | |
| HD GOLI SC + MTX | 0.83(0.14,3.38) | 0.85(0.21,2.93) | ‐0.01(‐0.29,0.15) | |
| HD INF IV + MTX | 0.82(0.20,2.59) | 0.84(0.27,2.38) | ‐0.02(‐0.26,0.09) | |
| HD TOFA PO + MTX | 0.75(0.18,2.27) | 0.77(0.24,2.13) | ‐0.02(‐0.25,0.06) | |
| HD CERTO SC + MTX | 0.77(0.17,2.79) | 0.79(0.23,2.51) | ‐0.02(‐0.28,0.10) | |
| HD TOCI IV + DMARD | 0.40(0.08,1.65) | 0.43(0.12,1.59) | ‐0.06(‐0.33,0.03) | |
| LD CERTO SC + MTX | LD ABA IV + MTX | 0.87(0.12,5.00) | 0.88(0.14,4.36) | ‐0.01(‐0.13,0.14) |
| LD ETN SC + MTX | 0.41(0.08,2.14) | 0.43(0.09,2.03) | ‐0.04(‐0.17,0.05) | |
| LD TOCI IV + MTX | 0.36(0.05,1.88) | 0.38(0.06,1.81) | ‐0.04(‐0.18,0.03) | |
| HD TOCI IV | 0.63(0.20,2.35) | 0.65(0.23,2.26) | ‐0.03(‐0.15,0.04) | |
| HD GOLI SC | 0.43(0.04,3.00) | 0.45(0.04,2.76) | ‐0.04(‐0.17,0.08) | |
| HD ADA SC | 0.19(0.04,1.04) | 0.21(0.04,1.04) | ‐0.06(‐0.19,0.00) | |
| HD TOFA | 0.58(0.09,3.96) | 0.60(0.11,3.63) | ‐0.03(‐0.17,0.09) | |
| HD ANA | 0.63(0.12,3.99) | 0.65(0.15,3.68) | ‐0.02(‐0.16,0.08) | |
| HD TOCI IV + MTX | 0.83(0.24,3.43) | 0.84(0.27,3.17) | ‐0.01(‐0.13,0.09) | |
| HD GOLI SC + MTX | 1.36(0.34,5.61) | 1.32(0.38,4.67) | 0.02(‐0.10,0.19) | |
| HD INF IV + MTX | 1.31(0.42,4.73) | 1.28(0.45,4.21) | 0.02(‐0.08,0.12) | |
| HD TOFA PO + MTX | 1.17(0.35,3.83) | 1.15(0.39,3.53) | 0.01(‐0.10,0.10) | |
| HD CERTO SC + MTX | 1.18(0.35,5.34) | 1.17(0.39,4.66) | 0.01(‐0.09,0.14) | |
| HD TOCI IV + DMARD | 0.64(0.16,2.81) | 0.66(0.19,2.67) | ‐0.02(‐0.15,0.06) | |
| LD ETN SC + MTX | LD CERTO SC + MTX | 0.46(0.07,3.96) | 0.48(0.08,3.68) | ‐0.03(‐0.19,0.06) |
| LD TOCI IV + MTX | 0.40(0.05,3.88) | 0.42(0.05,3.67) | ‐0.04(‐0.20,0.05) | |
| HD TOCI IV | 0.71(0.16,4.53) | 0.73(0.19,4.33) | ‐0.02(‐0.17,0.05) | |
| HD GOLI SC | 0.48(0.03,6.26) | 0.51(0.04,5.75) | ‐0.03(‐0.19,0.09) | |
| HD ADA SC | 0.21(0.04,2.13) | 0.22(0.05,2.10) | ‐0.05(‐0.21,0.01) | |
| HD TOFA | 0.67(0.08,8.97) | 0.68(0.09,8.20) | ‐0.02(‐0.19,0.11) | |
| HD ANA | 0.72(0.12,7.23) | 0.73(0.14,6.73) | ‐0.02(‐0.18,0.09) | |
| HD TOCI IV + MTX | 0.95(0.18,6.83) | 0.95(0.22,6.35) | 0.00(‐0.16,0.10) | |
| HD GOLI SC + MTX | 1.54(0.27,12.02) | 1.48(0.31,10.30) | 0.03(‐0.13,0.19) | |
| HD INF IV + MTX | 1.54(0.34,9.25) | 1.48(0.38,8.37) | 0.03(‐0.12,0.13) | |
| HD TOFA PO + MTX | 1.27(0.32,8.90) | 1.24(0.37,7.99) | 0.02(‐0.12,0.12) | |
| HD CERTO SC + MTX | 1.36(0.38,8.62) | 1.32(0.42,7.83) | 0.02(‐0.10,0.13) | |
| HD TOCI IV + DMARD | 0.71(0.17,4.89) | 0.73(0.19,4.59) | ‐0.02(‐0.17,0.07) | |
| LD TOCI IV + MTX | LD ETN SC + MTX | 0.87(0.12,5.40) | 0.88(0.13,5.11) | 0.00(‐0.09,0.06) |
| HD TOCI IV | 1.55(0.41,6.44) | 1.53(0.44,6.08) | 0.02(‐0.06,0.07) | |
| HD GOLI SC | 1.09(0.09,8.28) | 1.08(0.09,7.38) | 0.00(‐0.09,0.13) | |
| HD ADA SC | 0.47(0.08,2.82) | 0.48(0.09,2.77) | ‐0.02(‐0.11,0.02) | |
| HD TOFA | 1.30(0.19,11.98) | 1.29(0.20,10.81) | 0.01(‐0.09,0.13) | |
| HD ANA | 1.59(0.24,10.01) | 1.56(0.26,9.11) | 0.02(‐0.09,0.11) | |
| HD TOCI IV + MTX | 2.11(0.46,9.23) | 2.03(0.48,8.44) | 0.03(‐0.05,0.12) | |
| HD GOLI SC + MTX | 3.37(0.69,15.82) | 3.09(0.71,13.13) | 0.06(‐0.02,0.24) | |
| HD INF IV + MTX | 3.24(0.80,12.75) | 3.01(0.82,11.40) | 0.06(‐0.01,0.17) | |
| HD TOFA PO + MTX | 2.77(0.72,14.24) | 2.61(0.74,12.29) | 0.05(‐0.02,0.16) | |
| HD CERTO SC + MTX | 2.99(0.57,14.18) | 2.79(0.60,12.47) | 0.05(‐0.04,0.18) | |
| HD TOCI IV + DMARD | 1.57(0.37,8.18) | 1.54(0.39,7.65) | 0.02(‐0.06,0.09) | |
| HD TOCI IV | LD TOCI IV + MTX | 1.79(0.48,9.72) | 1.75(0.50,9.20) | 0.02(‐0.05,0.07) |
| HD GOLI SC | 1.15(0.14,13.22) | 1.15(0.14,11.88) | 0.00(‐0.06,0.13) | |
| HD ADA SC | 0.52(0.11,3.57) | 0.53(0.12,3.49) | ‐0.01(‐0.09,0.02) | |
| HD TOFA | 1.65(0.24,15.03) | 1.62(0.26,13.35) | 0.01(‐0.06,0.13) | |
| HD ANA | 1.91(0.27,14.13) | 1.86(0.29,12.88) | 0.02(‐0.07,0.12) | |
| HD TOCI IV + MTX | 2.34(0.61,13.07) | 2.24(0.63,11.72) | 0.03(‐0.03,0.12) | |
| HD GOLI SC + MTX | 3.87(0.70,28.06) | 3.56(0.72,23.65) | 0.06(‐0.02,0.25) | |
| HD INF IV + MTX | 3.82(0.87,22.47) | 3.52(0.88,19.76) | 0.07(‐0.01,0.19) | |
| HD TOFA PO + MTX | 3.29(0.75,19.51) | 3.08(0.77,17.42) | 0.05(‐0.02,0.16) | |
| HD CERTO SC + MTX | 3.57(0.68,22.55) | 3.30(0.70,19.56) | 0.06(‐0.02,0.19) | |
| HD TOCI IV + DMARD | 1.81(0.38,12.15) | 1.77(0.40,11.15) | 0.02(‐0.05,0.10) | |
| HD GOLI SC | HD TOCI IV | 0.67(0.08,3.76) | 0.68(0.08,3.37) | ‐0.01(‐0.07,0.11) |
| HD ADA SC | 0.30(0.08,1.10) | 0.31(0.08,1.10) | ‐0.03(‐0.09,0.00) | |
| HD TOFA | 0.90(0.14,5.15) | 0.90(0.15,4.61) | 0.00(‐0.08,0.11) | |
| HD ANA | 1.02(0.25,4.24) | 1.02(0.27,3.87) | 0.00(‐0.07,0.10) | |
| HD TOCI IV + MTX | 1.31(0.62,2.97) | 1.29(0.64,2.74) | 0.01(‐0.02,0.08) | |
| HD GOLI SC + MTX | 2.09(0.65,6.95) | 1.97(0.67,5.57) | 0.05(‐0.02,0.22) | |
| HD INF IV + MTX | 2.08(0.82,4.98) | 1.97(0.83,4.36) | 0.05(‐0.01,0.15) | |
| HD TOFA PO + MTX | 1.77(0.76,4.46) | 1.70(0.77,3.95) | 0.03(‐0.02,0.13) | |
| HD CERTO SC + MTX | 1.94(0.62,5.34) | 1.84(0.63,4.59) | 0.04(‐0.02,0.16) | |
| HD TOCI IV + DMARD | 0.98(0.41,2.63) | 0.98(0.42,2.47) | 0.00(‐0.04,0.06) | |
| HD ADA SC | HD GOLI SC | 0.43(0.06,4.25) | 0.43(0.07,4.15) | ‐0.02(‐0.15,0.02) |
| HD TOFA | 1.33(0.16,16.40) | 1.31(0.18,14.89) | 0.01(‐0.12,0.12) | |
| HD ANA | 1.48(0.19,18.42) | 1.45(0.21,16.51) | 0.01(‐0.12,0.12) | |
| HD TOCI IV + MTX | 1.93(0.28,17.16) | 1.86(0.31,15.78) | 0.03(‐0.10,0.13) | |
| HD GOLI SC + MTX | 3.12(0.64,21.46) | 2.88(0.68,18.85) | 0.06(‐0.03,0.22) | |
| HD INF IV + MTX | 3.12(0.53,27.43) | 2.88(0.56,23.72) | 0.06(‐0.05,0.17) | |
| HD TOFA PO + MTX | 2.69(0.45,23.24) | 2.53(0.49,20.88) | 0.05(‐0.07,0.15) | |
| HD CERTO SC + MTX | 2.81(0.43,27.49) | 2.62(0.46,24.09) | 0.05(‐0.07,0.18) | |
| HD TOCI IV + DMARD | 1.43(0.23,14.99) | 1.41(0.25,13.84) | 0.01(‐0.11,0.10) | |
| HD TOFA | HD ADA SC | 3.13(0.49,18.47) | 3.02(0.50,16.34) | 0.03(‐0.01,0.14) |
| HD ANA | 3.24(0.79,19.98) | 3.12(0.79,17.83) | 0.03(‐0.01,0.13) | |
| HD TOCI IV + MTX | 4.33(1.13,18.72) | 4.10(1.12,16.72) | 0.05(0.00,0.15) | |
| HD GOLI SC + MTX | 7.26(1.58,35.84) | 6.56(1.55,28.74) | 0.08(0.01,0.27) | |
| HD INF IV + MTX | 7.15(1.65,30.74) | 6.49(1.62,26.12) | 0.08(0.01,0.20) | |
| HD TOFA PO + MTX | 6.05(1.50,26.47) | 5.57(1.47,22.99) | 0.07(0.01,0.18) | |
| HD CERTO SC + MTX | 6.70(1.34,28.73) | 6.11(1.33,24.30) | 0.08(0.01,0.21) | |
| HD TOCI IV + DMARD | 3.33(0.83,15.41) | 3.21(0.83,14.08) | 0.03(0.00,0.11) | |
| HD ANA | HD TOFA | 1.11(0.17,6.20) | 1.10(0.19,5.65) | 0.00(‐0.11,0.10) |
| HD TOCI IV + MTX | 1.46(0.22,10.93) | 1.43(0.25,9.74) | 0.02(‐0.10,0.13) | |
| HD GOLI SC + MTX | 2.32(0.32,19.22) | 2.18(0.35,14.99) | 0.05(‐0.08,0.25) | |
| HD INF IV + MTX | 2.32(0.37,16.42) | 2.19(0.40,13.67) | 0.05(‐0.08,0.19) | |
| HD TOFA PO + MTX | 2.09(0.33,10.76) | 1.99(0.36,9.37) | 0.04(‐0.08,0.16) | |
| HD CERTO SC + MTX | 2.17(0.31,18.28) | 2.06(0.34,14.85) | 0.05(‐0.08,0.20) | |
| HD TOCI IV + DMARD | 1.18(0.17,8.33) | 1.17(0.19,7.64) | 0.01(‐0.11,0.10) | |
| HD TOCI IV + MTX | HD ANA | 1.32(0.27,6.07) | 1.30(0.29,5.38) | 0.01(‐0.09,0.12) |
| HD GOLI SC + MTX | 2.12(0.40,11.43) | 2.00(0.43,8.78) | 0.04(‐0.07,0.24) | |
| HD INF IV + MTX | 2.04(0.41,9.42) | 1.93(0.44,7.93) | 0.04(‐0.07,0.17) | |
| HD TOFA PO + MTX | 1.82(0.39,8.12) | 1.74(0.42,7.03) | 0.03(‐0.07,0.15) | |
| HD CERTO SC + MTX | 1.97(0.34,8.66) | 1.87(0.37,7.38) | 0.04(‐0.07,0.18) | |
| HD TOCI IV + DMARD | 1.02(0.21,4.29) | 1.02(0.23,3.97) | 0.00(‐0.10,0.08) | |
| HD GOLI SC + MTX | HD TOCI IV + MTX | 1.54(0.43,7.13) | 1.49(0.45,5.59) | 0.03(‐0.06,0.22) |
| HD INF IV + MTX | 1.59(0.53,4.84) | 1.53(0.56,4.20) | 0.03(‐0.05,0.14) | |
| HD TOFA PO + MTX | 1.36(0.48,4.33) | 1.33(0.51,3.81) | 0.02(‐0.06,0.12) | |
| HD CERTO SC + MTX | 1.52(0.39,4.84) | 1.47(0.42,4.24) | 0.03(‐0.07,0.14) | |
| HD TOCI IV + DMARD | 0.75(0.25,2.48) | 0.76(0.27,2.33) | ‐0.01(‐0.10,0.06) | |
| HD INF IV + MTX | HD GOLI SC + MTX | 0.99(0.29,3.09) | 0.99(0.34,2.81) | 0.00(‐0.15,0.10) |
| HD TOFA PO + MTX | 0.84(0.27,2.75) | 0.85(0.32,2.52) | ‐0.01(‐0.16,0.09) | |
| HD CERTO SC + MTX | 0.91(0.23,3.61) | 0.92(0.27,3.18) | ‐0.01(‐0.17,0.11) | |
| HD TOCI IV + DMARD | 0.47(0.12,2.10) | 0.49(0.14,2.00) | ‐0.05(‐0.22,0.04) | |
| HD TOFA PO + MTX | HD INF IV + MTX | 0.86(0.37,2.15) | 0.87(0.41,2.00) | ‐0.01(‐0.10,0.07) |
| HD CERTO SC + MTX | 0.94(0.30,2.74) | 0.95(0.33,2.49) | 0.00(‐0.11,0.10) | |
| HD TOCI IV + DMARD | 0.48(0.16,1.67) | 0.51(0.19,1.61) | ‐0.05(‐0.16,0.03) | |
| HD CERTO SC + MTX | HD TOFA PO + MTX | 1.08(0.36,3.03) | 1.07(0.39,2.68) | 0.00(‐0.09,0.12) |
| HD TOCI IV + DMARD | 0.55(0.18,1.81) | 0.57(0.20,1.73) | ‐0.03(‐0.14,0.04) | |
| HD TOCI IV + DMARD | HD CERTO SC + MTX | 0.52(0.16,2.00) | 0.54(0.18,1.92) | ‐0.04(‐0.16,0.04) |
| Random‐effects model | Residual deviance | 181.1 vs 179 data points | ||
| Deviance information criteria | 904.308 | |||
| Fixed‐effect model | Residual deviance | vs data points | ||
| Deviance information criteria | ||||
| Note | ||||
| Total participants | ||||
| Total studies | ||||
| 2‐arm | ||||
Appendix 16. Withdrawals due to adverse events: subgroup ‐ established RA (2 to 10 years)
| Withdrawals established: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX | PL | 4.16(1.40,14.34) | 3.82(1.39,11.43) | 0.07(0.01,0.21) |
| DMARD | 1.15(0.35,3.27) | 1.15(0.35,3.11) | 0.00(‐0.02,0.05) | |
| MTX + DMARD | 12.33(3.59,52.86) | 9.51(3.35,26.49) | 0.22(0.05,0.52) | |
| SD ETN SC | 4.38(1.53,13.94) | 4.02(1.51,11.03) | 0.07(0.01,0.23) | |
| SD ADA SC | 1.88(0.74,4.66) | 1.83(0.74,4.34) | 0.02(‐0.01,0.07) | |
| SD TOCI IV | 1.10(0.28,4.22) | 1.09(0.28,3.94) | 0.00(‐0.02,0.06) | |
| SD CERTO SC | 2.79(0.85,13.90) | 2.67(0.86,11.36) | 0.04(0.00,0.19) | |
| SD TOC SC + PL IV | 0.74(0.16,3.46) | 0.74(0.16,3.29) | ‐0.01(‐0.03,0.05) | |
| SD ANA | 1.33(0.43,5.50) | 1.31(0.44,4.98) | 0.01(‐0.02,0.10) | |
| SD ETN SC + MTX | 3.99(1.26,13.55) | 3.71(1.26,10.84) | 0.07(0.01,0.22) | |
| SD INF IV + MTX | 10.77(3.24,41.96) | 8.52(3.04,23.16) | 0.19(0.05,0.47) | |
| SD ABA IV + MTX | 4.10(1.10,17.02) | 3.79(1.10,12.95) | 0.07(0.00,0.25) | |
| SD CERTO SC + MTX | 5.89(1.67,21.44) | 5.22(1.64,14.98) | 0.10(0.02,0.31) | |
| SD ADA SC + MTX | 5.65(1.51,22.53) | 5.05(1.48,15.90) | 0.10(0.01,0.32) | |
| SD GOLI SC + MTX | 6.12(1.21,34.77) | 5.38(1.20,20.95) | 0.11(0.00,0.42) | |
| SD TOFA PO + MTX | 7.66(2.03,28.75) | 6.48(1.98,18.76) | 0.14(0.02,0.37) | |
| SD ABA SC + MTX | 2.35(0.48,10.73) | 2.28(0.49,8.91) | 0.03(‐0.01,0.18) | |
| SD ETN SC + DMARD | 2.14(0.72,6.14) | 2.08(0.73,5.55) | 0.03(‐0.01,0.11) | |
| SD CERTO SC + DMARD | 1.56(0.44,5.61) | 1.54(0.45,5.07) | 0.01(‐0.02,0.10) | |
| SD ADA SC + DMARD | 1.38(0.24,7.00) | 1.37(0.25,6.12) | 0.01(‐0.02,0.12) | |
| LD ETN SC | 4.75(1.40,18.66) | 4.33(1.38,13.86) | 0.08(0.01,0.29) | |
| LD ADA SC | 0.67(0.18,2.27) | 0.67(0.19,2.20) | ‐0.01(‐0.03,0.03) | |
| LD ANA | 1.01(0.30,3.95) | 1.01(0.30,3.68) | 0.00(‐0.02,0.07) | |
| LD ABA IV + MTX | 4.98(1.18,25.38) | 4.52(1.18,17.01) | 0.09(0.00,0.35) | |
| LD CERTO SC + MTX | 4.16(0.64,22.14) | 3.85(0.65,14.79) | 0.07(‐0.01,0.34) | |
| LD ETN SC + MTX | 2.59(0.50,12.69) | 2.50(0.51,10.09) | 0.04(‐0.01,0.21) | |
| HD TOCI IV | 2.73(0.85,8.26) | 2.61(0.86,7.25) | 0.04(0.00,0.13) | |
| HD ADA SC | 0.68(0.18,2.20) | 0.68(0.19,2.14) | ‐0.01(‐0.03,0.02) | |
| HD ANA | 2.47(0.84,8.49) | 2.39(0.84,7.29) | 0.03(0.00,0.15) | |
| HD TOCI IV + MTX | 3.65(0.83,15.79) | 3.42(0.83,12.09) | 0.06(0.00,0.25) | |
| HD GOLI SC + MTX | 8.63(1.73,51.09) | 7.22(1.69,25.93) | 0.15(0.02,0.50) | |
| HD TOFA PO + MTX | 5.91(1.60,21.68) | 5.21(1.57,15.42) | 0.11(0.01,0.31) | |
| HD CERTO SC + MTX | 6.36(1.50,25.92) | 5.57(1.48,17.21) | 0.11(0.01,0.36) | |
| HD INF IV + MTX | 11.49(2.97,47.79) | 9.00(2.82,24.75) | 0.20(0.04,0.51) | |
| HD TOCI IV + DMARD | 2.26(0.57,8.05) | 2.19(0.58,6.96) | 0.03(‐0.01,0.14) | |
| DMARD | MTX | 0.27(0.10,0.74) | 0.30(0.12,0.75) | ‐0.06(‐0.19,‐0.01) |
| MTX + DMARD | 3.04(1.41,6.63) | 2.48(1.34,4.54) | 0.14(0.03,0.35) | |
| SD ETN SC | 1.06(0.67,1.79) | 1.05(0.70,1.68) | 0.00(‐0.04,0.06) | |
| SD ADA SC | 0.44(0.14,1.36) | 0.47(0.17,1.33) | ‐0.05(‐0.18,0.02) | |
| SD TOCI IV | 0.27(0.05,1.13) | 0.29(0.06,1.13) | ‐0.07(‐0.20,0.01) | |
| SD CERTO SC | 0.69(0.13,4.72) | 0.71(0.16,4.09) | ‐0.03(‐0.18,0.13) | |
| SD TOC SC + PL IV | 0.18(0.03,0.90) | 0.20(0.04,0.91) | ‐0.07(‐0.21,0.00) | |
| SD ANA | 0.32(0.06,1.80) | 0.35(0.07,1.71) | ‐0.06(‐0.21,0.04) | |
| SD ETN SC + MTX | 0.97(0.59,1.57) | 0.97(0.62,1.50) | 0.00(‐0.05,0.05) | |
| SD INF IV + MTX | 2.64(1.44,4.87) | 2.24(1.37,3.66) | 0.12(0.03,0.29) | |
| SD ABA IV + MTX | 0.98(0.49,1.91) | 0.98(0.51,1.75) | 0.00(‐0.05,0.09) | |
| SD CERTO SC + MTX | 1.38(0.78,2.67) | 1.32(0.80,2.34) | 0.03(‐0.02,0.14) | |
| SD ADA SC + MTX | 1.36(0.65,3.10) | 1.31(0.67,2.57) | 0.03(‐0.04,0.17) | |
| SD GOLI SC + MTX | 1.52(0.39,5.54) | 1.43(0.42,3.94) | 0.04(‐0.07,0.29) | |
| SD TOFA PO + MTX | 1.82(0.96,3.36) | 1.67(0.97,2.74) | 0.06(0.00,0.20) | |
| SD ABA SC + MTX | 0.55(0.19,1.57) | 0.58(0.21,1.47) | ‐0.03(‐0.12,0.05) | |
| SD ETN SC + DMARD | 0.52(0.19,1.31) | 0.54(0.22,1.29) | ‐0.04(‐0.15,0.02) | |
| SD CERTO SC + DMARD | 0.37(0.09,1.52) | 0.39(0.11,1.48) | ‐0.05(‐0.19,0.03) | |
| SD ADA SC + DMARD | 0.32(0.07,1.58) | 0.35(0.08,1.51) | ‐0.06(‐0.19,0.04) | |
| LD ETN SC | 1.18(0.55,2.68) | 1.15(0.58,2.33) | 0.01(‐0.05,0.14) | |
| LD ADA SC | 0.16(0.04,0.70) | 0.17(0.04,0.72) | ‐0.08(‐0.22,‐0.01) | |
| LD ANA | 0.24(0.04,1.36) | 0.26(0.05,1.33) | ‐0.07(‐0.21,0.02) | |
| LD ABA IV + MTX | 1.24(0.45,3.45) | 1.20(0.47,2.83) | 0.02(‐0.06,0.19) | |
| LD CERTO SC + MTX | 0.97(0.21,4.35) | 0.97(0.23,3.42) | 0.00(‐0.11,0.22) | |
| LD ETN SC + MTX | 0.61(0.17,2.10) | 0.64(0.18,1.92) | ‐0.03(‐0.13,0.09) | |
| HD TOCI IV | 0.66(0.29,1.33) | 0.68(0.32,1.30) | ‐0.03(‐0.12,0.02) | |
| HD ADA SC | 0.17(0.03,0.74) | 0.18(0.03,0.75) | ‐0.08(‐0.22,‐0.01) | |
| HD ANA | 0.59(0.11,2.75) | 0.62(0.14,2.51) | ‐0.03(‐0.19,0.09) | |
| HD TOCI IV + MTX | 0.87(0.26,2.62) | 0.89(0.28,2.30) | ‐0.01(‐0.11,0.12) | |
| HD GOLI SC + MTX | 2.06(0.61,7.76) | 1.84(0.63,4.84) | 0.08(‐0.04,0.37) | |
| HD TOFA PO + MTX | 1.40(0.76,2.63) | 1.34(0.77,2.28) | 0.03(‐0.02,0.14) | |
| HD CERTO SC + MTX | 1.49(0.61,3.96) | 1.41(0.64,3.12) | 0.04(‐0.04,0.22) | |
| HD INF IV + MTX | 2.84(1.22,6.43) | 2.35(1.19,4.46) | 0.13(0.01,0.34) | |
| HD TOCI IV + DMARD | 0.53(0.17,1.74) | 0.56(0.20,1.66) | ‐0.04(‐0.15,0.05) | |
| MTX + DMARD | DMARD | 11.40(3.26,38.36) | 8.53(2.95,22.99) | 0.21(0.06,0.50) |
| SD ETN SC | 3.98(1.50,10.12) | 3.64(1.45,8.55) | 0.07(0.02,0.21) | |
| SD ADA SC | 1.66(0.50,5.14) | 1.63(0.51,4.88) | 0.02(‐0.03,0.06) | |
| SD TOCI IV | 0.95(0.21,3.89) | 0.95(0.22,3.69) | 0.00(‐0.04,0.06) | |
| SD CERTO SC | 2.53(0.46,16.45) | 2.41(0.47,13.75) | 0.04(‐0.03,0.19) | |
| SD TOC SC + PL IV | 0.65(0.12,3.28) | 0.65(0.13,3.12) | ‐0.01(‐0.05,0.04) | |
| SD ANA | 1.20(0.24,7.26) | 1.19(0.25,6.54) | 0.00(‐0.05,0.10) | |
| SD ETN SC + MTX | 3.57(1.22,9.72) | 3.31(1.20,8.18) | 0.06(0.01,0.20) | |
| SD INF IV + MTX | 9.77(3.01,30.69) | 7.62(2.76,20.19) | 0.19(0.05,0.45) | |
| SD ABA IV + MTX | 3.60(1.05,12.86) | 3.33(1.05,10.27) | 0.06(0.00,0.24) | |
| SD CERTO SC + MTX | 5.09(1.64,16.53) | 4.53(1.60,12.70) | 0.10(0.02,0.29) | |
| SD ADA SC + MTX | 5.10(1.47,17.33) | 4.53(1.43,12.98) | 0.09(0.01,0.30) | |
| SD GOLI SC + MTX | 5.49(1.09,29.09) | 4.79(1.09,18.35) | 0.10(0.00,0.42) | |
| SD TOFA PO + MTX | 6.59(1.93,21.27) | 5.60(1.84,15.33) | 0.13(0.03,0.35) | |
| SD ABA SC + MTX | 1.98(0.46,8.73) | 1.92(0.47,7.49) | 0.02(‐0.02,0.17) | |
| SD ETN SC + DMARD | 1.88(0.59,5.45) | 1.83(0.60,5.06) | 0.02(‐0.02,0.09) | |
| SD CERTO SC + DMARD | 1.38(0.47,4.20) | 1.36(0.48,3.94) | 0.01(‐0.03,0.07) | |
| SD ADA SC + DMARD | 1.20(0.35,4.15) | 1.19(0.36,3.76) | 0.00(‐0.03,0.10) | |
| LD ETN SC | 4.42(1.34,14.67) | 3.99(1.33,11.28) | 0.08(0.01,0.26) | |
| LD ADA SC | 0.59(0.11,2.75) | 0.60(0.12,2.68) | ‐0.01(‐0.06,0.02) | |
| LD ANA | 0.85(0.16,5.46) | 0.86(0.17,5.11) | 0.00(‐0.05,0.07) | |
| LD ABA IV + MTX | 4.52(1.07,20.02) | 4.06(1.06,14.38) | 0.08(0.00,0.33) | |
| LD CERTO SC + MTX | 3.68(0.56,19.15) | 3.39(0.57,13.89) | 0.06(‐0.02,0.32) | |
| LD ETN SC + MTX | 2.34(0.46,10.32) | 2.25(0.47,8.67) | 0.03(‐0.02,0.19) | |
| HD TOCI IV | 2.36(0.98,5.77) | 2.27(0.98,5.24) | 0.03(0.00,0.11) | |
| HD ADA SC | 0.59(0.12,2.80) | 0.60(0.12,2.74) | ‐0.01(‐0.05,0.03) | |
| HD ANA | 2.16(0.46,11.61) | 2.09(0.47,9.96) | 0.03(‐0.03,0.15) | |
| HD TOCI IV + MTX | 3.16(0.85,10.58) | 2.95(0.86,8.87) | 0.05(0.00,0.22) | |
| HD GOLI SC + MTX | 7.85(1.73,35.07) | 6.42(1.68,20.82) | 0.15(0.02,0.49) | |
| HD TOFA PO + MTX | 5.16(1.56,15.90) | 4.55(1.52,12.28) | 0.10(0.02,0.29) | |
| HD CERTO SC + MTX | 5.60(1.40,19.90) | 4.86(1.38,14.30) | 0.11(0.01,0.34) | |
| HD INF IV + MTX | 10.45(2.75,36.46) | 8.01(2.55,22.09) | 0.20(0.05,0.49) | |
| HD TOCI IV + DMARD | 1.96(1.04,3.88) | 1.90(1.04,3.58) | 0.02(0.00,0.10) | |
| SD ETN SC | MTX + DMARD | 0.35(0.15,0.82) | 0.43(0.22,0.84) | ‐0.14(‐0.35,‐0.02) |
| SD ADA SC | 0.15(0.04,0.56) | 0.19(0.07,0.59) | ‐0.20(‐0.48,‐0.04) | |
| SD TOCI IV | 0.09(0.01,0.47) | 0.11(0.02,0.51) | ‐0.21(‐0.51,‐0.05) | |
| SD CERTO SC | 0.23(0.04,1.66) | 0.29(0.07,1.56) | ‐0.17(‐0.47,0.05) | |
| SD TOC SC + PL IV | 0.06(0.01,0.37) | 0.08(0.01,0.41) | ‐0.22(‐0.52,‐0.05) | |
| SD ANA | 0.11(0.02,0.68) | 0.14(0.03,0.71) | ‐0.20(‐0.51,‐0.03) | |
| SD ETN SC + MTX | 0.32(0.15,0.67) | 0.39(0.21,0.71) | ‐0.14(‐0.35,‐0.03) | |
| SD INF IV + MTX | 0.86(0.43,1.81) | 0.90(0.52,1.59) | ‐0.02(‐0.17,0.10) | |
| SD ABA IV + MTX | 0.32(0.12,0.92) | 0.40(0.17,0.93) | ‐0.14(‐0.36,‐0.01) | |
| SD CERTO SC + MTX | 0.45(0.18,1.31) | 0.53(0.25,1.25) | ‐0.11(‐0.31,0.03) | |
| SD ADA SC + MTX | 0.45(0.15,1.34) | 0.53(0.21,1.27) | ‐0.11(‐0.33,0.04) | |
| SD GOLI SC + MTX | 0.50(0.11,2.13) | 0.58(0.15,1.75) | ‐0.09(‐0.34,0.13) | |
| SD TOFA PO + MTX | 0.60(0.21,1.60) | 0.67(0.30,1.46) | ‐0.08(‐0.28,0.07) | |
| SD ABA SC + MTX | 0.18(0.05,0.73) | 0.23(0.07,0.77) | ‐0.18(‐0.43,‐0.03) | |
| SD ETN SC + DMARD | 0.17(0.05,0.54) | 0.22(0.08,0.58) | ‐0.19(‐0.46,‐0.04) | |
| SD CERTO SC + DMARD | 0.12(0.03,0.60) | 0.16(0.05,0.63) | ‐0.20(‐0.49,‐0.03) | |
| SD ADA SC + DMARD | 0.10(0.02,0.65) | 0.14(0.03,0.69) | ‐0.20(‐0.48,‐0.03) | |
| LD ETN SC | 0.38(0.14,1.16) | 0.47(0.19,1.13) | ‐0.13(‐0.34,0.02) | |
| LD ADA SC | 0.05(0.01,0.27) | 0.07(0.02,0.30) | ‐0.22(‐0.52,‐0.06) | |
| LD ANA | 0.08(0.01,0.49) | 0.10(0.02,0.53) | ‐0.21(‐0.52,‐0.04) | |
| LD ABA IV + MTX | 0.41(0.11,1.50) | 0.48(0.15,1.36) | ‐0.12(‐0.35,0.06) | |
| LD CERTO SC + MTX | 0.32(0.06,1.72) | 0.39(0.09,1.52) | ‐0.14(‐0.39,0.09) | |
| LD ETN SC + MTX | 0.20(0.05,0.81) | 0.26(0.07,0.85) | ‐0.17(‐0.43,‐0.02) | |
| HD TOCI IV | 0.21(0.07,0.60) | 0.27(0.11,0.64) | ‐0.17(‐0.44,‐0.03) | |
| HD ADA SC | 0.05(0.01,0.28) | 0.07(0.01,0.31) | ‐0.22(‐0.52,‐0.06) | |
| HD ANA | 0.20(0.03,1.08) | 0.25(0.06,1.07) | ‐0.17(‐0.49,0.01) | |
| HD TOCI IV + MTX | 0.28(0.07,1.02) | 0.35(0.11,1.02) | ‐0.15(‐0.42,0.00) | |
| HD GOLI SC + MTX | 0.69(0.16,3.23) | 0.75(0.22,2.35) | ‐0.05(‐0.29,0.23) | |
| HD TOFA PO + MTX | 0.47(0.17,1.21) | 0.55(0.24,1.17) | ‐0.10(‐0.31,0.03) | |
| HD CERTO SC + MTX | 0.49(0.15,1.77) | 0.57(0.22,1.56) | ‐0.10(‐0.32,0.09) | |
| HD INF IV + MTX | 0.92(0.34,2.53) | 0.94(0.43,2.00) | ‐0.01(‐0.20,0.18) | |
| HD TOCI IV + DMARD | 0.17(0.05,0.69) | 0.22(0.07,0.72) | ‐0.18(‐0.46,‐0.03) | |
| SD ADA SC | SD ETN SC | 0.42(0.14,1.21) | 0.45(0.17,1.19) | ‐0.05(‐0.19,0.01) |
| SD TOCI IV | 0.25(0.05,0.97) | 0.27(0.06,0.97) | ‐0.07(‐0.22,0.00) | |
| SD CERTO SC | 0.64(0.13,4.25) | 0.67(0.15,3.71) | ‐0.03(‐0.19,0.13) | |
| SD TOC SC + PL IV | 0.17(0.03,0.80) | 0.19(0.04,0.81) | ‐0.08(‐0.23,‐0.01) | |
| SD ANA | 0.30(0.06,1.67) | 0.33(0.07,1.59) | ‐0.06(‐0.22,0.04) | |
| SD ETN SC + MTX | 0.91(0.54,1.45) | 0.92(0.57,1.39) | ‐0.01(‐0.06,0.04) | |
| SD INF IV + MTX | 2.48(1.15,5.38) | 2.12(1.12,3.88) | 0.11(0.01,0.30) | |
| SD ABA IV + MTX | 0.92(0.38,2.10) | 0.93(0.41,1.89) | ‐0.01(‐0.09,0.10) | |
| SD CERTO SC + MTX | 1.32(0.59,2.84) | 1.27(0.62,2.47) | 0.03(‐0.05,0.15) | |
| SD ADA SC + MTX | 1.29(0.52,3.11) | 1.25(0.56,2.61) | 0.02(‐0.06,0.17) | |
| SD GOLI SC + MTX | 1.39(0.33,5.60) | 1.33(0.36,4.02) | 0.03(‐0.08,0.29) | |
| SD TOFA PO + MTX | 1.70(0.76,3.63) | 1.58(0.79,2.93) | 0.06(‐0.03,0.20) | |
| SD ABA SC + MTX | 0.52(0.15,1.66) | 0.55(0.17,1.55) | ‐0.04(‐0.14,0.06) | |
| SD ETN SC + DMARD | 0.49(0.20,1.09) | 0.52(0.23,1.08) | ‐0.05(‐0.16,0.01) | |
| SD CERTO SC + DMARD | 0.34(0.09,1.40) | 0.37(0.11,1.36) | ‐0.06(‐0.20,0.02) | |
| SD ADA SC + DMARD | 0.30(0.07,1.42) | 0.32(0.08,1.38) | ‐0.06(‐0.20,0.03) | |
| LD ETN SC | 1.11(0.54,2.35) | 1.10(0.56,2.08) | 0.01(‐0.06,0.12) | |
| LD ADA SC | 0.15(0.03,0.64) | 0.17(0.04,0.66) | ‐0.08(‐0.23,‐0.02) | |
| LD ANA | 0.23(0.04,1.22) | 0.25(0.05,1.20) | ‐0.07(‐0.23,0.01) | |
| LD ABA IV + MTX | 1.17(0.37,3.52) | 1.15(0.40,2.86) | 0.01(‐0.08,0.19) | |
| LD CERTO SC + MTX | 0.92(0.18,4.15) | 0.93(0.20,3.21) | ‐0.01(‐0.13,0.21) | |
| LD ETN SC + MTX | 0.58(0.15,2.02) | 0.61(0.17,1.83) | ‐0.03(‐0.15,0.08) | |
| HD TOCI IV | 0.61(0.26,1.33) | 0.64(0.30,1.30) | ‐0.03(‐0.14,0.02) | |
| HD ADA SC | 0.16(0.03,0.64) | 0.17(0.03,0.65) | ‐0.08(‐0.23,‐0.01) | |
| HD ANA | 0.56(0.11,2.56) | 0.59(0.13,2.34) | ‐0.04(‐0.20,0.09) | |
| HD TOCI IV + MTX | 0.82(0.23,2.51) | 0.84(0.26,2.20) | ‐0.01(‐0.13,0.12) | |
| HD GOLI SC + MTX | 1.94(0.52,7.83) | 1.74(0.55,4.94) | 0.07(‐0.05,0.37) | |
| HD TOFA PO + MTX | 1.33(0.60,2.88) | 1.28(0.63,2.46) | 0.03(‐0.05,0.15) | |
| HD CERTO SC + MTX | 1.42(0.51,3.99) | 1.35(0.55,3.15) | 0.03(‐0.06,0.22) | |
| HD INF IV + MTX | 2.69(1.00,6.71) | 2.23(1.00,4.53) | 0.12(0.00,0.35) | |
| HD TOCI IV + DMARD | 0.49(0.17,1.59) | 0.52(0.19,1.52) | ‐0.04(‐0.17,0.04) | |
| SD TOCI IV | SD ADA SC | 0.59(0.18,1.65) | 0.60(0.19,1.60) | ‐0.02(‐0.06,0.03) |
| SD CERTO SC | 1.52(0.35,8.50) | 1.49(0.37,7.21) | 0.02(‐0.05,0.17) | |
| SD TOC SC + PL IV | 0.40(0.11,1.39) | 0.41(0.11,1.37) | ‐0.02(‐0.07,0.02) | |
| SD ANA | 0.71(0.16,4.21) | 0.72(0.18,3.82) | ‐0.01(‐0.07,0.09) | |
| SD ETN SC + MTX | 2.20(0.67,6.68) | 2.08(0.69,5.74) | 0.05(‐0.02,0.18) | |
| SD INF IV + MTX | 6.02(1.69,21.72) | 4.84(1.61,13.66) | 0.17(0.03,0.44) | |
| SD ABA IV + MTX | 2.22(0.60,8.65) | 2.09(0.61,7.04) | 0.05(‐0.02,0.22) | |
| SD CERTO SC + MTX | 3.17(0.87,11.36) | 2.86(0.87,8.58) | 0.08(‐0.01,0.28) | |
| SD ADA SC + MTX | 3.09(0.85,11.78) | 2.80(0.86,8.86) | 0.08(‐0.01,0.29) | |
| SD GOLI SC + MTX | 3.34(0.63,19.92) | 3.01(0.65,12.39) | 0.09(‐0.02,0.40) | |
| SD TOFA PO + MTX | 4.10(1.07,14.42) | 3.56(1.07,10.15) | 0.12(0.00,0.34) | |
| SD ABA SC + MTX | 1.25(0.24,6.01) | 1.24(0.25,5.06) | 0.01(‐0.05,0.16) | |
| SD ETN SC + DMARD | 1.16(0.47,2.78) | 1.15(0.49,2.60) | 0.01(‐0.03,0.07) | |
| SD CERTO SC + DMARD | 0.83(0.22,3.65) | 0.83(0.23,3.37) | ‐0.01(‐0.06,0.08) | |
| SD ADA SC + DMARD | 0.72(0.14,4.11) | 0.73(0.14,3.72) | ‐0.01(‐0.06,0.10) | |
| LD ETN SC | 2.67(0.77,9.32) | 2.48(0.78,7.28) | 0.06(‐0.01,0.25) | |
| LD ADA SC | 0.36(0.11,1.10) | 0.37(0.11,1.09) | ‐0.03(‐0.07,0.00) | |
| LD ANA | 0.53(0.11,2.91) | 0.54(0.12,2.75) | ‐0.02(‐0.08,0.05) | |
| LD ABA IV + MTX | 2.76(0.59,13.23) | 2.54(0.60,9.67) | 0.07(‐0.02,0.32) | |
| LD CERTO SC + MTX | 2.21(0.30,12.79) | 2.09(0.32,8.93) | 0.05(‐0.04,0.31) | |
| LD ETN SC + MTX | 1.42(0.24,6.86) | 1.40(0.25,5.62) | 0.02(‐0.05,0.18) | |
| HD TOCI IV | 1.43(0.49,4.51) | 1.40(0.50,4.08) | 0.02(‐0.03,0.11) | |
| HD ADA SC | 0.36(0.10,1.12) | 0.37(0.11,1.11) | ‐0.03(‐0.07,0.00) | |
| HD ANA | 1.32(0.32,5.93) | 1.30(0.34,5.23) | 0.01(‐0.05,0.13) | |
| HD TOCI IV + MTX | 1.91(0.47,8.16) | 1.82(0.49,6.50) | 0.04(‐0.03,0.21) | |
| HD GOLI SC + MTX | 4.72(0.87,25.90) | 3.98(0.88,14.16) | 0.13(‐0.01,0.48) | |
| HD TOFA PO + MTX | 3.18(0.88,11.05) | 2.87(0.88,8.41) | 0.08(‐0.01,0.27) | |
| HD CERTO SC + MTX | 3.37(0.79,13.32) | 3.01(0.80,9.47) | 0.09(‐0.01,0.33) | |
| HD INF IV + MTX | 6.51(1.52,25.77) | 5.11(1.47,14.75) | 0.18(0.03,0.47) | |
| HD TOCI IV + DMARD | 1.20(0.33,4.67) | 1.19(0.34,4.23) | 0.01(‐0.04,0.11) | |
| SD CERTO SC | SD TOCI IV | 2.68(0.41,19.00) | 2.55(0.43,16.33) | 0.04(‐0.04,0.19) |
| SD TOC SC + PL IV | 0.68(0.34,1.37) | 0.69(0.35,1.35) | ‐0.01(‐0.03,0.01) | |
| SD ANA | 1.23(0.20,9.09) | 1.22(0.21,8.32) | 0.01(‐0.06,0.10) | |
| SD ETN SC + MTX | 3.66(0.80,19.86) | 3.40(0.81,16.57) | 0.06(‐0.01,0.20) | |
| SD INF IV + MTX | 10.03(1.96,59.04) | 7.87(1.86,38.07) | 0.19(0.04,0.46) | |
| SD ABA IV + MTX | 3.73(0.70,22.24) | 3.44(0.72,17.77) | 0.06(‐0.02,0.24) | |
| SD CERTO SC + MTX | 5.29(0.99,31.10) | 4.68(0.99,23.45) | 0.10(0.00,0.30) | |
| SD ADA SC + MTX | 5.06(1.19,30.49) | 4.50(1.18,22.84) | 0.09(0.01,0.31) | |
| SD GOLI SC + MTX | 5.65(0.91,43.68) | 4.95(0.92,28.00) | 0.10(0.00,0.42) | |
| SD TOFA PO + MTX | 6.78(1.52,38.03) | 5.78(1.46,27.53) | 0.13(0.02,0.36) | |
| SD ABA SC + MTX | 2.18(0.29,14.06) | 2.10(0.31,11.88) | 0.03(‐0.04,0.18) | |
| SD ETN SC + DMARD | 1.98(0.52,8.46) | 1.92(0.54,7.84) | 0.02(‐0.03,0.10) | |
| SD CERTO SC + DMARD | 1.47(0.25,7.41) | 1.45(0.26,6.83) | 0.01(‐0.05,0.09) | |
| SD ADA SC + DMARD | 1.23(0.17,9.90) | 1.22(0.19,8.87) | 0.01(‐0.05,0.11) | |
| LD ETN SC | 4.44(1.09,25.96) | 4.03(1.08,19.92) | 0.08(0.00,0.27) | |
| LD ADA SC | 0.61(0.13,3.05) | 0.62(0.14,2.98) | ‐0.01(‐0.07,0.02) | |
| LD ANA | 0.90(0.16,5.80) | 0.91(0.17,5.45) | 0.00(‐0.07,0.07) | |
| LD ABA IV + MTX | 4.67(0.74,33.52) | 4.18(0.75,24.35) | 0.08(‐0.01,0.34) | |
| LD CERTO SC + MTX | 3.87(0.38,28.37) | 3.55(0.39,20.57) | 0.06(‐0.03,0.33) | |
| LD ETN SC + MTX | 2.36(0.35,17.59) | 2.26(0.36,14.29) | 0.03(‐0.03,0.20) | |
| HD TOCI IV | 2.50(0.63,10.96) | 2.39(0.65,10.03) | 0.04(‐0.02,0.12) | |
| HD ADA SC | 0.63(0.13,2.99) | 0.64(0.14,2.92) | ‐0.01(‐0.07,0.02) | |
| HD ANA | 2.28(0.38,14.45) | 2.20(0.40,12.67) | 0.03(‐0.05,0.15) | |
| HD TOCI IV + MTX | 3.28(0.68,20.69) | 3.06(0.70,17.13) | 0.05(‐0.02,0.23) | |
| HD GOLI SC + MTX | 8.12(1.32,66.92) | 6.67(1.30,36.81) | 0.15(0.01,0.49) | |
| HD TOFA PO + MTX | 5.31(1.17,30.10) | 4.69(1.15,23.16) | 0.10(0.01,0.30) | |
| HD CERTO SC + MTX | 5.80(1.02,35.17) | 5.03(1.02,24.92) | 0.11(0.00,0.35) | |
| HD INF IV + MTX | 10.98(1.76,71.90) | 8.40(1.68,41.28) | 0.20(0.03,0.50) | |
| HD TOCI IV + DMARD | 2.09(0.46,10.33) | 2.02(0.48,9.30) | 0.03(‐0.03,0.13) | |
| SD TOC SC + PL IV | SD CERTO SC | 0.25(0.03,1.97) | 0.27(0.04,1.92) | ‐0.05(‐0.19,0.03) |
| SD ANA | 0.46(0.07,2.99) | 0.48(0.09,2.79) | ‐0.03(‐0.18,0.07) | |
| SD ETN SC + MTX | 1.40(0.20,7.14) | 1.36(0.23,5.99) | 0.02(‐0.13,0.18) | |
| SD INF IV + MTX | 3.85(0.51,21.76) | 3.18(0.56,13.11) | 0.15(‐0.07,0.43) | |
| SD ABA IV + MTX | 1.41(0.17,8.32) | 1.37(0.20,6.72) | 0.02(‐0.13,0.21) | |
| SD CERTO SC + MTX | 2.04(0.28,11.93) | 1.89(0.32,8.85) | 0.06(‐0.11,0.28) | |
| SD ADA SC + MTX | 2.03(0.26,11.15) | 1.88(0.29,8.30) | 0.06(‐0.11,0.28) | |
| SD GOLI SC + MTX | 2.17(0.23,16.64) | 1.98(0.26,10.56) | 0.06(‐0.11,0.38) | |
| SD TOFA PO + MTX | 2.72(0.34,13.73) | 2.42(0.38,9.93) | 0.09(‐0.10,0.32) | |
| SD ABA SC + MTX | 0.79(0.09,5.50) | 0.80(0.10,4.78) | ‐0.01(‐0.16,0.15) | |
| SD ETN SC + DMARD | 0.74(0.12,3.87) | 0.75(0.14,3.57) | ‐0.02(‐0.17,0.08) | |
| SD CERTO SC + DMARD | 0.51(0.08,3.54) | 0.53(0.09,3.29) | ‐0.03(‐0.17,0.08) | |
| SD ADA SC + DMARD | 0.48(0.04,3.96) | 0.50(0.05,3.58) | ‐0.03(‐0.18,0.09) | |
| LD ETN SC | 1.72(0.23,10.93) | 1.63(0.27,8.27) | 0.04(‐0.13,0.25) | |
| LD ADA SC | 0.23(0.03,1.32) | 0.25(0.04,1.31) | ‐0.05(‐0.19,0.01) | |
| LD ANA | 0.35(0.05,2.17) | 0.37(0.06,2.09) | ‐0.04(‐0.19,0.04) | |
| LD ABA IV + MTX | 1.78(0.21,12.49) | 1.68(0.24,8.89) | 0.04(‐0.13,0.30) | |
| LD CERTO SC + MTX | 1.43(0.14,11.25) | 1.39(0.17,7.97) | 0.02(‐0.14,0.30) | |
| LD ETN SC + MTX | 0.91(0.09,6.45) | 0.92(0.11,5.41) | 0.00(‐0.15,0.17) | |
| HD TOCI IV | 0.95(0.13,4.84) | 0.96(0.16,4.35) | 0.00(‐0.16,0.11) | |
| HD ADA SC | 0.24(0.03,1.25) | 0.26(0.03,1.24) | ‐0.05(‐0.19,0.01) | |
| HD ANA | 0.86(0.13,4.89) | 0.87(0.15,4.35) | ‐0.01(‐0.16,0.12) | |
| HD TOCI IV + MTX | 1.24(0.15,8.44) | 1.21(0.17,6.67) | 0.01(‐0.14,0.21) | |
| HD GOLI SC + MTX | 3.00(0.33,23.62) | 2.60(0.37,13.39) | 0.10(‐0.09,0.46) | |
| HD TOFA PO + MTX | 2.12(0.27,10.88) | 1.95(0.30,8.36) | 0.06(‐0.11,0.26) | |
| HD CERTO SC + MTX | 2.14(0.27,14.72) | 1.98(0.31,10.09) | 0.06(‐0.11,0.33) | |
| HD INF IV + MTX | 4.07(0.51,24.65) | 3.31(0.55,14.20) | 0.16(‐0.07,0.47) | |
| HD TOCI IV + DMARD | 0.76(0.10,4.67) | 0.78(0.11,4.20) | ‐0.01(‐0.16,0.11) | |
| SD ANA | SD TOC SC + PL IV | 1.80(0.27,14.61) | 1.77(0.28,13.22) | 0.01(‐0.05,0.11) |
| SD ETN SC + MTX | 5.49(1.00,31.67) | 5.00(1.00,26.65) | 0.07(0.00,0.22) | |
| SD INF IV + MTX | 14.95(2.51,95.09) | 11.53(2.31,61.42) | 0.20(0.05,0.47) | |
| SD ABA IV + MTX | 5.54(0.91,35.38) | 5.04(0.92,28.47) | 0.07(0.00,0.25) | |
| SD CERTO SC + MTX | 7.83(1.28,49.12) | 6.86(1.25,37.88) | 0.11(0.01,0.31) | |
| SD ADA SC + MTX | 7.49(1.44,50.57) | 6.60(1.40,37.92) | 0.10(0.01,0.32) | |
| SD GOLI SC + MTX | 8.23(1.19,69.88) | 7.17(1.17,46.33) | 0.11(0.01,0.43) | |
| SD TOFA PO + MTX | 9.99(1.84,62.80) | 8.42(1.75,45.86) | 0.14(0.03,0.37) | |
| SD ABA SC + MTX | 3.21(0.38,22.77) | 3.07(0.40,19.26) | 0.04(‐0.03,0.19) | |
| SD ETN SC + DMARD | 2.94(0.63,14.61) | 2.83(0.64,13.47) | 0.03(‐0.02,0.11) | |
| SD CERTO SC + DMARD | 2.17(0.31,12.32) | 2.11(0.32,11.32) | 0.02(‐0.04,0.10) | |
| SD ADA SC + DMARD | 1.82(0.23,15.61) | 1.78(0.24,13.89) | 0.01(‐0.04,0.12) | |
| LD ETN SC | 6.63(1.32,42.11) | 5.95(1.30,32.66) | 0.09(0.01,0.28) | |
| LD ADA SC | 0.90(0.17,5.28) | 0.90(0.18,5.14) | 0.00(‐0.05,0.03) | |
| LD ANA | 1.34(0.19,9.24) | 1.33(0.20,8.68) | 0.01(‐0.05,0.07) | |
| LD ABA IV + MTX | 6.84(0.99,52.99) | 6.10(0.99,38.94) | 0.09(0.00,0.35) | |
| LD CERTO SC + MTX | 5.60(0.50,46.64) | 5.08(0.52,34.66) | 0.07(‐0.02,0.33) | |
| LD ETN SC + MTX | 3.44(0.46,28.88) | 3.27(0.47,24.09) | 0.04(‐0.02,0.21) | |
| HD TOCI IV | 3.67(0.78,19.07) | 3.48(0.79,17.25) | 0.04(‐0.01,0.13) | |
| HD ADA SC | 0.91(0.16,4.99) | 0.91(0.17,4.81) | 0.00(‐0.06,0.03) | |
| HD ANA | 3.37(0.50,23.43) | 3.23(0.51,20.50) | 0.04(‐0.03,0.16) | |
| HD TOCI IV + MTX | 4.87(0.80,34.83) | 4.49(0.81,27.96) | 0.06(‐0.01,0.24) | |
| HD GOLI SC + MTX | 11.77(1.71,109.60) | 9.59(1.64,62.61) | 0.16(0.02,0.50) | |
| HD TOFA PO + MTX | 7.86(1.40,49.76) | 6.88(1.37,38.21) | 0.11(0.01,0.31) | |
| HD CERTO SC + MTX | 8.37(1.33,55.91) | 7.24(1.30,40.16) | 0.12(0.01,0.36) | |
| HD INF IV + MTX | 16.24(2.30,110.50) | 12.33(2.14,66.29) | 0.21(0.04,0.50) | |
| HD TOCI IV + DMARD | 3.05(0.56,16.80) | 2.92(0.57,15.06) | 0.03(‐0.02,0.14) | |
| SD ETN SC + MTX | SD ANA | 2.94(0.51,16.94) | 2.75(0.54,13.83) | 0.05(‐0.04,0.21) |
| SD INF IV + MTX | 7.78(1.37,51.01) | 6.27(1.31,30.15) | 0.18(0.02,0.46) | |
| SD ABA IV + MTX | 3.03(0.47,19.87) | 2.83(0.50,15.70) | 0.06(‐0.04,0.25) | |
| SD CERTO SC + MTX | 4.42(0.67,25.87) | 3.94(0.70,19.35) | 0.09(‐0.03,0.31) | |
| SD ADA SC + MTX | 4.28(0.61,25.46) | 3.82(0.63,18.80) | 0.09(‐0.03,0.31) | |
| SD GOLI SC + MTX | 4.72(0.42,39.83) | 4.18(0.45,24.37) | 0.10(‐0.05,0.42) | |
| SD TOFA PO + MTX | 5.57(0.87,33.21) | 4.79(0.88,22.98) | 0.12(‐0.01,0.36) | |
| SD ABA SC + MTX | 1.71(0.23,12.07) | 1.67(0.24,10.10) | 0.02(‐0.07,0.18) | |
| SD ETN SC + DMARD | 1.59(0.26,7.75) | 1.55(0.29,7.09) | 0.02(‐0.08,0.10) | |
| SD CERTO SC + DMARD | 1.19(0.17,7.10) | 1.18(0.18,6.46) | 0.01(‐0.09,0.09) | |
| SD ADA SC + DMARD | 1.05(0.11,7.48) | 1.05(0.12,6.66) | 0.00(‐0.10,0.11) | |
| LD ETN SC | 3.64(0.56,21.91) | 3.34(0.59,16.88) | 0.07(‐0.04,0.28) | |
| LD ADA SC | 0.48(0.08,2.79) | 0.49(0.09,2.72) | ‐0.02(‐0.11,0.03) | |
| LD ANA | 0.75(0.21,2.44) | 0.75(0.22,2.36) | ‐0.01(‐0.07,0.03) | |
| LD ABA IV + MTX | 3.63(0.53,31.01) | 3.32(0.56,21.28) | 0.07(‐0.04,0.34) | |
| LD CERTO SC + MTX | 3.10(0.29,23.29) | 2.88(0.31,16.91) | 0.06(‐0.06,0.32) | |
| LD ETN SC + MTX | 1.90(0.22,14.40) | 1.84(0.23,11.78) | 0.03(‐0.07,0.20) | |
| HD TOCI IV | 2.01(0.35,10.73) | 1.94(0.37,9.47) | 0.03(‐0.07,0.13) | |
| HD ADA SC | 0.50(0.07,2.65) | 0.51(0.07,2.59) | ‐0.01(‐0.11,0.03) | |
| HD ANA | 1.80(0.62,5.47) | 1.74(0.63,5.05) | 0.02(‐0.03,0.10) | |
| HD TOCI IV + MTX | 2.65(0.31,18.29) | 2.51(0.33,14.37) | 0.05(‐0.07,0.24) | |
| HD GOLI SC + MTX | 6.47(0.74,53.84) | 5.39(0.75,30.22) | 0.14(‐0.02,0.50) | |
| HD TOFA PO + MTX | 4.32(0.65,25.79) | 3.86(0.68,19.21) | 0.09(‐0.03,0.30) | |
| HD CERTO SC + MTX | 4.72(0.62,30.94) | 4.17(0.65,21.43) | 0.10(‐0.03,0.36) | |
| HD INF IV + MTX | 8.30(1.37,56.91) | 6.57(1.32,32.12) | 0.19(0.02,0.50) | |
| HD TOCI IV + DMARD | 1.62(0.25,9.74) | 1.58(0.27,8.41) | 0.02(‐0.08,0.13) | |
| SD INF IV + MTX | SD ETN SC + MTX | 2.73(1.34,5.75) | 2.30(1.29,4.24) | 0.12(0.02,0.31) |
| SD ABA IV + MTX | 1.01(0.43,2.41) | 1.01(0.46,2.15) | 0.00(‐0.07,0.11) | |
| SD CERTO SC + MTX | 1.43(0.68,3.28) | 1.37(0.71,2.82) | 0.03(‐0.04,0.16) | |
| SD ADA SC + MTX | 1.43(0.57,3.65) | 1.37(0.61,3.00) | 0.03(‐0.05,0.18) | |
| SD GOLI SC + MTX | 1.55(0.36,6.33) | 1.47(0.38,4.54) | 0.04(‐0.07,0.30) | |
| SD TOFA PO + MTX | 1.89(0.83,4.04) | 1.73(0.85,3.31) | 0.06(‐0.02,0.21) | |
| SD ABA SC + MTX | 0.57(0.17,1.90) | 0.60(0.19,1.76) | ‐0.03(‐0.13,0.07) | |
| SD ETN SC + DMARD | 0.53(0.20,1.41) | 0.56(0.23,1.37) | ‐0.04(‐0.16,0.02) | |
| SD CERTO SC + DMARD | 0.38(0.10,1.69) | 0.41(0.11,1.62) | ‐0.05(‐0.19,0.04) | |
| SD ADA SC + DMARD | 0.33(0.07,1.71) | 0.35(0.08,1.62) | ‐0.05(‐0.19,0.04) | |
| LD ETN SC | 1.22(0.53,2.87) | 1.20(0.56,2.53) | 0.02(‐0.06,0.14) | |
| LD ADA SC | 0.16(0.04,0.75) | 0.18(0.04,0.76) | ‐0.07(‐0.22,‐0.01) | |
| LD ANA | 0.25(0.04,1.41) | 0.27(0.05,1.38) | ‐0.06(‐0.22,0.02) | |
| LD ABA IV + MTX | 1.28(0.42,4.02) | 1.24(0.44,3.22) | 0.02(‐0.07,0.20) | |
| LD CERTO SC + MTX | 1.00(0.20,4.70) | 1.00(0.22,3.67) | 0.00(‐0.12,0.22) | |
| LD ETN SC + MTX | 0.63(0.18,2.13) | 0.66(0.19,1.93) | ‐0.03(‐0.13,0.09) | |
| HD TOCI IV | 0.67(0.28,1.60) | 0.69(0.31,1.53) | ‐0.03(‐0.13,0.03) | |
| HD ADA SC | 0.17(0.03,0.80) | 0.19(0.03,0.81) | ‐0.07(‐0.22,‐0.01) | |
| HD ANA | 0.62(0.11,2.93) | 0.64(0.14,2.69) | ‐0.03(‐0.19,0.09) | |
| HD TOCI IV + MTX | 0.90(0.25,2.94) | 0.91(0.28,2.56) | ‐0.01(‐0.12,0.13) | |
| HD GOLI SC + MTX | 2.12(0.58,8.85) | 1.89(0.61,5.57) | 0.08(‐0.04,0.38) | |
| HD TOFA PO + MTX | 1.47(0.64,3.21) | 1.40(0.67,2.74) | 0.03(‐0.04,0.15) | |
| HD CERTO SC + MTX | 1.54(0.55,4.66) | 1.46(0.58,3.63) | 0.04(‐0.05,0.23) | |
| HD INF IV + MTX | 2.93(1.15,7.44) | 2.43(1.13,5.14) | 0.13(0.01,0.36) | |
| HD TOCI IV + DMARD | 0.54(0.18,1.92) | 0.57(0.20,1.81) | ‐0.04(‐0.16,0.05) | |
| SD ABA IV + MTX | SD INF IV + MTX | 0.37(0.16,0.85) | 0.44(0.20,0.88) | ‐0.12(‐0.30,‐0.02) |
| SD CERTO SC + MTX | 0.52(0.23,1.35) | 0.59(0.30,1.28) | ‐0.08(‐0.25,0.04) | |
| SD ADA SC + MTX | 0.51(0.19,1.47) | 0.58(0.25,1.37) | ‐0.08(‐0.28,0.05) | |
| SD GOLI SC + MTX | 0.57(0.13,2.29) | 0.64(0.17,1.87) | ‐0.07(‐0.29,0.15) | |
| SD TOFA PO + MTX | 0.68(0.28,1.61) | 0.74(0.36,1.47) | ‐0.05(‐0.23,0.07) | |
| SD ABA SC + MTX | 0.21(0.07,0.67) | 0.26(0.09,0.72) | ‐0.15(‐0.37,‐0.03) | |
| SD ETN SC + DMARD | 0.20(0.06,0.59) | 0.24(0.09,0.62) | ‐0.16(‐0.41,‐0.03) | |
| SD CERTO SC + DMARD | 0.14(0.03,0.65) | 0.18(0.05,0.68) | ‐0.17(‐0.44,‐0.03) | |
| SD ADA SC + DMARD | 0.12(0.02,0.67) | 0.15(0.03,0.71) | ‐0.18(‐0.43,‐0.03) | |
| LD ETN SC | 0.44(0.17,1.29) | 0.51(0.22,1.24) | ‐0.10(‐0.29,0.03) | |
| LD ADA SC | 0.06(0.01,0.30) | 0.08(0.02,0.32) | ‐0.20(‐0.47,‐0.05) | |
| LD ANA | 0.09(0.01,0.57) | 0.12(0.02,0.60) | ‐0.19(‐0.47,‐0.03) | |
| LD ABA IV + MTX | 0.46(0.14,1.52) | 0.53(0.18,1.39) | ‐0.09(‐0.29,0.07) | |
| LD CERTO SC + MTX | 0.36(0.07,1.88) | 0.43(0.10,1.62) | ‐0.11(‐0.34,0.10) | |
| LD ETN SC + MTX | 0.23(0.06,0.94) | 0.29(0.08,0.95) | ‐0.15(‐0.38,‐0.01) | |
| HD TOCI IV | 0.25(0.09,0.62) | 0.30(0.13,0.66) | ‐0.15(‐0.38,‐0.03) | |
| HD ADA SC | 0.06(0.01,0.30) | 0.08(0.02,0.33) | ‐0.20(‐0.48,‐0.05) | |
| HD ANA | 0.23(0.04,1.16) | 0.28(0.06,1.14) | ‐0.15(‐0.44,0.01) | |
| HD TOCI IV + MTX | 0.33(0.09,1.15) | 0.39(0.12,1.12) | ‐0.12(‐0.35,0.02) | |
| HD GOLI SC + MTX | 0.77(0.19,3.72) | 0.82(0.25,2.53) | ‐0.04(‐0.25,0.26) | |
| HD TOFA PO + MTX | 0.53(0.23,1.24) | 0.60(0.29,1.19) | ‐0.08(‐0.26,0.03) | |
| HD CERTO SC + MTX | 0.57(0.19,1.91) | 0.64(0.24,1.63) | ‐0.07(‐0.28,0.11) | |
| HD INF IV + MTX | 1.07(0.49,2.28) | 1.06(0.56,1.85) | 0.01(‐0.12,0.16) | |
| HD TOCI IV + DMARD | 0.20(0.06,0.79) | 0.25(0.08,0.81) | ‐0.16(‐0.40,‐0.02) | |
| SD CERTO SC + MTX | SD ABA IV + MTX | 1.41(0.56,3.91) | 1.35(0.60,3.37) | 0.03(‐0.07,0.16) |
| SD ADA SC + MTX | 1.38(0.50,4.02) | 1.33(0.55,3.37) | 0.03(‐0.08,0.18) | |
| SD GOLI SC + MTX | 1.53(0.30,7.38) | 1.44(0.33,5.22) | 0.04(‐0.11,0.30) | |
| SD TOFA PO + MTX | 1.83(0.73,4.69) | 1.67(0.76,3.88) | 0.06(‐0.04,0.22) | |
| SD ABA SC + MTX | 0.56(0.25,1.25) | 0.59(0.27,1.21) | ‐0.03(‐0.13,0.02) | |
| SD ETN SC + DMARD | 0.53(0.14,1.61) | 0.56(0.18,1.56) | ‐0.04(‐0.20,0.02) | |
| SD CERTO SC + DMARD | 0.39(0.08,1.90) | 0.42(0.09,1.82) | ‐0.05(‐0.23,0.04) | |
| SD ADA SC + DMARD | 0.33(0.06,1.92) | 0.36(0.07,1.80) | ‐0.05(‐0.22,0.05) | |
| LD ETN SC | 1.19(0.44,3.64) | 1.17(0.49,3.18) | 0.01(‐0.09,0.15) | |
| LD ADA SC | 0.17(0.03,0.82) | 0.18(0.04,0.83) | ‐0.08(‐0.25,‐0.01) | |
| LD ANA | 0.25(0.04,1.69) | 0.27(0.05,1.64) | ‐0.07(‐0.25,0.03) | |
| LD ABA IV + MTX | 1.25(0.43,3.75) | 1.22(0.46,3.10) | 0.02(‐0.07,0.19) | |
| LD CERTO SC + MTX | 0.96(0.19,5.92) | 0.96(0.21,4.52) | 0.00(‐0.14,0.23) | |
| LD ETN SC + MTX | 0.62(0.15,2.72) | 0.64(0.17,2.44) | ‐0.03(‐0.17,0.10) | |
| HD TOCI IV | 0.67(0.21,1.82) | 0.69(0.25,1.74) | ‐0.03(‐0.17,0.04) | |
| HD ADA SC | 0.17(0.02,0.86) | 0.18(0.03,0.86) | ‐0.08(‐0.26,0.00) | |
| HD ANA | 0.62(0.10,3.49) | 0.64(0.12,3.15) | ‐0.03(‐0.22,0.09) | |
| HD TOCI IV + MTX | 0.90(0.20,3.21) | 0.91(0.23,2.82) | ‐0.01(‐0.15,0.13) | |
| HD GOLI SC + MTX | 2.13(0.48,10.08) | 1.89(0.52,6.28) | 0.08(‐0.07,0.38) | |
| HD TOFA PO + MTX | 1.43(0.57,3.62) | 1.37(0.61,3.11) | 0.03(‐0.06,0.16) | |
| HD CERTO SC + MTX | 1.53(0.50,5.03) | 1.45(0.54,4.12) | 0.04(‐0.07,0.22) | |
| HD INF IV + MTX | 2.87(1.05,8.09) | 2.39(1.04,5.83) | 0.13(0.01,0.35) | |
| HD TOCI IV + DMARD | 0.54(0.14,2.26) | 0.57(0.17,2.12) | ‐0.04(‐0.20,0.06) | |
| SD ADA SC + MTX | SD CERTO SC + MTX | 0.98(0.37,2.66) | 0.98(0.42,2.30) | 0.00(‐0.13,0.14) |
| SD GOLI SC + MTX | 1.07(0.28,4.14) | 1.06(0.32,3.12) | 0.01(‐0.14,0.24) | |
| SD TOFA PO + MTX | 1.30(0.52,3.03) | 1.24(0.58,2.53) | 0.03(‐0.09,0.16) | |
| SD ABA SC + MTX | 0.40(0.11,1.27) | 0.44(0.13,1.23) | ‐0.07(‐0.22,0.02) | |
| SD ETN SC + DMARD | 0.37(0.11,1.09) | 0.41(0.15,1.08) | ‐0.07(‐0.25,0.01) | |
| SD CERTO SC + DMARD | 0.26(0.06,1.16) | 0.30(0.08,1.15) | ‐0.08(‐0.29,0.01) | |
| SD ADA SC + DMARD | 0.23(0.04,1.19) | 0.26(0.05,1.18) | ‐0.09(‐0.28,0.01) | |
| LD ETN SC | 0.85(0.32,2.34) | 0.87(0.37,2.07) | ‐0.02(‐0.14,0.11) | |
| LD ADA SC | 0.11(0.02,0.54) | 0.13(0.03,0.56) | ‐0.11(‐0.32,‐0.02) | |
| LD ANA | 0.17(0.03,1.09) | 0.20(0.04,1.09) | ‐0.10(‐0.31,0.00) | |
| LD ABA IV + MTX | 0.88(0.26,2.89) | 0.90(0.30,2.46) | ‐0.01(‐0.15,0.16) | |
| LD CERTO SC + MTX | 0.72(0.15,2.75) | 0.75(0.18,2.28) | ‐0.03(‐0.17,0.15) | |
| LD ETN SC + MTX | 0.44(0.11,1.73) | 0.48(0.12,1.61) | ‐0.06(‐0.23,0.06) | |
| HD TOCI IV | 0.47(0.16,1.14) | 0.51(0.20,1.13) | ‐0.06(‐0.23,0.01) | |
| HD ADA SC | 0.12(0.02,0.60) | 0.14(0.03,0.62) | ‐0.11(‐0.32,‐0.02) | |
| HD ANA | 0.42(0.07,2.30) | 0.46(0.10,2.12) | ‐0.07(‐0.29,0.07) | |
| HD TOCI IV + MTX | 0.62(0.16,2.16) | 0.66(0.19,1.94) | ‐0.04(‐0.21,0.09) | |
| HD GOLI SC + MTX | 1.47(0.42,6.21) | 1.37(0.46,4.06) | 0.04(‐0.10,0.33) | |
| HD TOFA PO + MTX | 1.01(0.41,2.38) | 1.01(0.46,2.10) | 0.00(‐0.12,0.11) | |
| HD CERTO SC + MTX | 1.09(0.45,2.50) | 1.08(0.50,2.12) | 0.01(‐0.10,0.15) | |
| HD INF IV + MTX | 2.06(0.68,5.54) | 1.77(0.72,3.94) | 0.10(‐0.05,0.30) | |
| HD TOCI IV + DMARD | 0.38(0.11,1.41) | 0.42(0.13,1.36) | ‐0.07(‐0.26,0.03) | |
| SD GOLI SC + MTX | SD ADA SC + MTX | 1.11(0.21,5.08) | 1.09(0.25,3.71) | 0.01(‐0.17,0.27) |
| SD TOFA PO + MTX | 1.30(0.61,3.02) | 1.24(0.66,2.57) | 0.03(‐0.07,0.16) | |
| SD ABA SC + MTX | 0.40(0.11,1.44) | 0.44(0.13,1.38) | ‐0.06(‐0.23,0.04) | |
| SD ETN SC + DMARD | 0.37(0.11,1.22) | 0.41(0.14,1.20) | ‐0.07(‐0.27,0.01) | |
| SD CERTO SC + DMARD | 0.27(0.06,1.35) | 0.30(0.08,1.32) | ‐0.08(‐0.29,0.02) | |
| SD ADA SC + DMARD | 0.24(0.04,1.32) | 0.27(0.05,1.29) | ‐0.08(‐0.29,0.02) | |
| LD ETN SC | 0.87(0.30,2.59) | 0.89(0.35,2.27) | ‐0.01(‐0.16,0.12) | |
| LD ADA SC | 0.11(0.02,0.62) | 0.13(0.03,0.64) | ‐0.11(‐0.32,‐0.02) | |
| LD ANA | 0.18(0.03,1.17) | 0.20(0.04,1.16) | ‐0.10(‐0.32,0.01) | |
| LD ABA IV + MTX | 0.92(0.24,2.98) | 0.93(0.28,2.52) | ‐0.01(‐0.17,0.16) | |
| LD CERTO SC + MTX | 0.72(0.13,3.46) | 0.75(0.16,2.86) | ‐0.03(‐0.21,0.18) | |
| LD ETN SC + MTX | 0.45(0.09,1.92) | 0.49(0.12,1.76) | ‐0.06(‐0.24,0.07) | |
| HD TOCI IV | 0.48(0.15,1.33) | 0.51(0.19,1.31) | ‐0.06(‐0.24,0.02) | |
| HD ADA SC | 0.12(0.02,0.67) | 0.13(0.03,0.68) | ‐0.11(‐0.32,‐0.01) | |
| HD ANA | 0.44(0.07,2.46) | 0.47(0.10,2.29) | ‐0.06(‐0.29,0.08) | |
| HD TOCI IV + MTX | 0.63(0.15,2.43) | 0.66(0.18,2.15) | ‐0.04(‐0.22,0.10) | |
| HD GOLI SC + MTX | 1.53(0.34,6.42) | 1.41(0.40,4.41) | 0.05(‐0.13,0.32) | |
| HD TOFA PO + MTX | 1.01(0.46,2.37) | 1.01(0.52,2.12) | 0.00(‐0.11,0.11) | |
| HD CERTO SC + MTX | 1.07(0.34,3.87) | 1.06(0.38,3.09) | 0.01(‐0.14,0.20) | |
| HD INF IV + MTX | 2.10(0.61,6.08) | 1.80(0.67,4.32) | 0.10(‐0.06,0.31) | |
| HD TOCI IV + DMARD | 0.39(0.10,1.58) | 0.43(0.12,1.51) | ‐0.07(‐0.26,0.03) | |
| SD TOFA PO + MTX | SD GOLI SC + MTX | 1.18(0.26,5.22) | 1.15(0.35,4.32) | 0.02(‐0.24,0.19) |
| SD ABA SC + MTX | 0.37(0.06,2.32) | 0.41(0.08,2.17) | ‐0.07(‐0.35,0.06) | |
| SD ETN SC + DMARD | 0.35(0.06,1.73) | 0.39(0.10,1.68) | ‐0.08(‐0.38,0.03) | |
| SD CERTO SC + DMARD | 0.26(0.04,1.50) | 0.29(0.05,1.46) | ‐0.09(‐0.41,0.02) | |
| SD ADA SC + DMARD | 0.23(0.02,1.66) | 0.26(0.03,1.59) | ‐0.09(‐0.41,0.03) | |
| LD ETN SC | 0.80(0.17,3.36) | 0.82(0.24,3.02) | ‐0.02(‐0.28,0.12) | |
| LD ADA SC | 0.10(0.02,0.69) | 0.12(0.02,0.70) | ‐0.12(‐0.43,‐0.01) | |
| LD ANA | 0.16(0.02,1.65) | 0.18(0.03,1.61) | ‐0.11(‐0.43,0.02) | |
| LD ABA IV + MTX | 0.83(0.15,4.66) | 0.85(0.20,3.97) | ‐0.02(‐0.27,0.18) | |
| LD CERTO SC + MTX | 0.64(0.10,4.03) | 0.68(0.13,3.34) | ‐0.04(‐0.30,0.18) | |
| LD ETN SC + MTX | 0.41(0.07,2.34) | 0.45(0.09,2.16) | ‐0.07(‐0.34,0.07) | |
| HD TOCI IV | 0.43(0.09,1.94) | 0.48(0.13,1.86) | ‐0.07(‐0.37,0.04) | |
| HD ADA SC | 0.11(0.01,0.79) | 0.13(0.02,0.79) | ‐0.12(‐0.43,‐0.01) | |
| HD ANA | 0.40(0.05,3.78) | 0.43(0.07,3.42) | ‐0.07(‐0.39,0.10) | |
| HD TOCI IV + MTX | 0.57(0.10,2.97) | 0.61(0.15,2.64) | ‐0.05(‐0.33,0.11) | |
| HD GOLI SC + MTX | 1.40(0.43,4.95) | 1.31(0.50,3.80) | 0.04(‐0.13,0.25) | |
| HD TOFA PO + MTX | 0.93(0.20,4.03) | 0.94(0.27,3.49) | ‐0.01(‐0.27,0.15) | |
| HD CERTO SC + MTX | 1.02(0.23,4.37) | 1.02(0.29,3.72) | 0.00(‐0.24,0.19) | |
| HD INF IV + MTX | 1.87(0.39,9.22) | 1.64(0.48,6.66) | 0.08(‐0.16,0.33) | |
| HD TOCI IV + DMARD | 0.36(0.06,2.02) | 0.40(0.09,1.92) | ‐0.08(‐0.38,0.04) | |
| SD ABA SC + MTX | SD TOFA PO + MTX | 0.31(0.09,1.05) | 0.35(0.11,1.04) | ‐0.10(‐0.28,0.01) |
| SD ETN SC + DMARD | 0.28(0.09,0.92) | 0.32(0.12,0.93) | ‐0.11(‐0.31,0.00) | |
| SD CERTO SC + DMARD | 0.20(0.05,1.00) | 0.24(0.07,1.00) | ‐0.12(‐0.34,0.00) | |
| SD ADA SC + DMARD | 0.18(0.03,1.04) | 0.21(0.04,1.04) | ‐0.12(‐0.34,0.00) | |
| LD ETN SC | 0.66(0.24,1.88) | 0.70(0.29,1.72) | ‐0.04(‐0.20,0.08) | |
| LD ADA SC | 0.09(0.02,0.45) | 0.10(0.03,0.47) | ‐0.14(‐0.37,‐0.03) | |
| LD ANA | 0.13(0.02,0.88) | 0.16(0.03,0.89) | ‐0.13(‐0.37,‐0.01) | |
| LD ABA IV + MTX | 0.68(0.21,2.22) | 0.73(0.25,1.91) | ‐0.04(‐0.19,0.13) | |
| LD CERTO SC + MTX | 0.54(0.10,2.69) | 0.59(0.13,2.24) | ‐0.06(‐0.24,0.15) | |
| LD ETN SC + MTX | 0.34(0.08,1.40) | 0.39(0.10,1.34) | ‐0.09(‐0.28,0.04) | |
| HD TOCI IV | 0.36(0.13,0.93) | 0.41(0.17,0.94) | ‐0.09(‐0.28,0.00) | |
| HD ADA SC | 0.09(0.01,0.47) | 0.11(0.02,0.49) | ‐0.14(‐0.37,‐0.03) | |
| HD ANA | 0.32(0.06,1.76) | 0.37(0.08,1.66) | ‐0.10(‐0.34,0.05) | |
| HD TOCI IV + MTX | 0.48(0.12,1.68) | 0.53(0.15,1.56) | ‐0.07(‐0.26,0.06) | |
| HD GOLI SC + MTX | 1.17(0.30,4.64) | 1.13(0.35,3.13) | 0.02(‐0.15,0.28) | |
| HD TOFA PO + MTX | 0.78(0.46,1.36) | 0.81(0.51,1.29) | ‐0.03(‐0.12,0.04) | |
| HD CERTO SC + MTX | 0.82(0.28,2.66) | 0.85(0.34,2.19) | ‐0.02(‐0.18,0.15) | |
| HD INF IV + MTX | 1.57(0.56,4.36) | 1.42(0.62,3.24) | 0.06(‐0.08,0.27) | |
| HD TOCI IV + DMARD | 0.30(0.08,1.17) | 0.34(0.11,1.15) | ‐0.10(‐0.31,0.01) | |
| SD ETN SC + DMARD | SD ABA SC + MTX | 0.93(0.22,3.79) | 0.94(0.25,3.63) | 0.00(‐0.14,0.06) |
| SD CERTO SC + DMARD | 0.69(0.12,4.29) | 0.71(0.14,4.01) | ‐0.01(‐0.16,0.07) | |
| SD ADA SC + DMARD | 0.59(0.09,4.03) | 0.60(0.10,3.73) | ‐0.02(‐0.16,0.08) | |
| LD ETN SC | 2.13(0.60,8.40) | 1.99(0.64,7.20) | 0.05(‐0.05,0.21) | |
| LD ADA SC | 0.30(0.05,1.87) | 0.31(0.06,1.85) | ‐0.04(‐0.19,0.01) | |
| LD ANA | 0.46(0.05,3.64) | 0.47(0.06,3.46) | ‐0.03(‐0.19,0.05) | |
| LD ABA IV + MTX | 2.26(0.59,8.74) | 2.08(0.62,7.19) | 0.05(‐0.04,0.25) | |
| LD CERTO SC + MTX | 1.71(0.28,12.60) | 1.63(0.30,9.56) | 0.03(‐0.09,0.27) | |
| LD ETN SC + MTX | 1.09(0.22,6.05) | 1.08(0.24,5.23) | 0.00(‐0.12,0.15) | |
| HD TOCI IV | 1.20(0.30,4.59) | 1.18(0.33,4.31) | 0.01(‐0.12,0.08) | |
| HD ADA SC | 0.30(0.04,2.03) | 0.31(0.05,2.00) | ‐0.04(‐0.19,0.02) | |
| HD ANA | 1.09(0.16,8.11) | 1.09(0.18,7.29) | 0.00(‐0.16,0.12) | |
| HD TOCI IV + MTX | 1.62(0.31,7.06) | 1.55(0.34,6.04) | 0.02(‐0.10,0.18) | |
| HD GOLI SC + MTX | 3.78(0.73,21.88) | 3.19(0.76,14.15) | 0.11(‐0.02,0.44) | |
| HD TOFA PO + MTX | 2.54(0.77,8.87) | 2.30(0.80,7.40) | 0.07(‐0.03,0.22) | |
| HD CERTO SC + MTX | 2.71(0.71,11.35) | 2.43(0.74,9.16) | 0.07(‐0.03,0.27) | |
| HD INF IV + MTX | 5.13(1.43,18.96) | 4.03(1.33,13.25) | 0.17(0.03,0.42) | |
| HD TOCI IV + DMARD | 0.98(0.20,4.88) | 0.98(0.23,4.49) | 0.00(‐0.13,0.10) | |
| SD CERTO SC + DMARD | SD ETN SC + DMARD | 0.73(0.19,3.11) | 0.74(0.21,2.90) | ‐0.01(‐0.09,0.07) |
| SD ADA SC + DMARD | 0.63(0.13,3.47) | 0.64(0.14,3.15) | ‐0.02(‐0.09,0.08) | |
| LD ETN SC | 2.32(0.79,7.27) | 2.16(0.80,5.78) | 0.06(‐0.01,0.23) | |
| LD ADA SC | 0.32(0.07,1.21) | 0.33(0.08,1.20) | ‐0.03(‐0.11,0.01) | |
| LD ANA | 0.47(0.09,2.82) | 0.48(0.10,2.69) | ‐0.02(‐0.11,0.05) | |
| LD ABA IV + MTX | 2.43(0.59,10.18) | 2.24(0.60,7.61) | 0.06(‐0.03,0.29) | |
| LD CERTO SC + MTX | 1.95(0.32,10.32) | 1.85(0.34,7.67) | 0.04(‐0.05,0.29) | |
| LD ETN SC + MTX | 1.21(0.25,5.31) | 1.20(0.26,4.49) | 0.01(‐0.06,0.16) | |
| HD TOCI IV | 1.26(0.47,3.72) | 1.24(0.49,3.40) | 0.01(‐0.05,0.09) | |
| HD ADA SC | 0.32(0.06,1.26) | 0.33(0.07,1.25) | ‐0.03(‐0.11,0.01) | |
| HD ANA | 1.15(0.24,5.74) | 1.14(0.26,5.06) | 0.01(‐0.08,0.13) | |
| HD TOCI IV + MTX | 1.70(0.43,6.49) | 1.64(0.45,5.33) | 0.03(‐0.05,0.19) | |
| HD GOLI SC + MTX | 4.11(0.85,22.42) | 3.48(0.86,12.51) | 0.12(‐0.01,0.46) | |
| HD TOFA PO + MTX | 2.75(0.88,8.37) | 2.50(0.88,6.62) | 0.07(‐0.01,0.25) | |
| HD CERTO SC + MTX | 2.90(0.80,11.04) | 2.62(0.81,8.10) | 0.08(‐0.01,0.31) | |
| HD INF IV + MTX | 5.53(1.54,19.06) | 4.37(1.47,11.80) | 0.18(0.03,0.45) | |
| HD TOCI IV + DMARD | 1.06(0.31,3.76) | 1.05(0.33,3.46) | 0.00(‐0.06,0.09) | |
| SD ADA SC + DMARD | SD CERTO SC + DMARD | 0.87(0.17,4.47) | 0.87(0.18,4.08) | 0.00(‐0.08,0.10) |
| LD ETN SC | 3.26(0.68,14.59) | 2.98(0.70,11.42) | 0.07(‐0.02,0.26) | |
| LD ADA SC | 0.43(0.06,2.38) | 0.44(0.06,2.34) | ‐0.02(‐0.11,0.02) | |
| LD ANA | 0.64(0.11,4.35) | 0.64(0.12,4.07) | ‐0.01(‐0.10,0.06) | |
| LD ABA IV + MTX | 3.24(0.58,19.34) | 2.95(0.60,13.98) | 0.07(‐0.03,0.33) | |
| LD CERTO SC + MTX | 2.61(0.34,17.40) | 2.43(0.35,12.75) | 0.05(‐0.05,0.32) | |
| LD ETN SC + MTX | 1.66(0.24,9.45) | 1.61(0.25,7.83) | 0.02(‐0.07,0.19) | |
| HD TOCI IV | 1.75(0.47,5.92) | 1.70(0.50,5.38) | 0.02(‐0.05,0.11) | |
| HD ADA SC | 0.42(0.08,2.44) | 0.43(0.08,2.38) | ‐0.02(‐0.10,0.02) | |
| HD ANA | 1.54(0.29,10.14) | 1.51(0.32,8.63) | 0.02(‐0.07,0.15) | |
| HD TOCI IV + MTX | 2.30(0.47,11.24) | 2.18(0.50,9.15) | 0.04(‐0.04,0.22) | |
| HD GOLI SC + MTX | 5.61(0.92,35.60) | 4.71(0.93,21.37) | 0.13(‐0.01,0.48) | |
| HD TOFA PO + MTX | 3.85(0.77,16.28) | 3.44(0.79,12.54) | 0.09(‐0.02,0.28) | |
| HD CERTO SC + MTX | 4.01(0.77,19.98) | 3.55(0.78,14.41) | 0.09(‐0.01,0.34) | |
| HD INF IV + MTX | 7.55(1.54,36.27) | 5.86(1.48,21.72) | 0.19(0.03,0.48) | |
| HD TOCI IV + DMARD | 1.42(0.40,5.17) | 1.39(0.42,4.71) | 0.01(‐0.05,0.11) | |
| LD ETN SC | SD ADA SC + DMARD | 3.71(0.67,19.35) | 3.36(0.70,16.02) | 0.07(‐0.03,0.26) |
| LD ADA SC | 0.50(0.07,3.64) | 0.51(0.08,3.57) | ‐0.02(‐0.13,0.02) | |
| LD ANA | 0.71(0.09,6.60) | 0.71(0.10,6.20) | ‐0.01(‐0.12,0.07) | |
| LD ABA IV + MTX | 3.82(0.62,22.35) | 3.44(0.65,17.55) | 0.07(‐0.03,0.32) | |
| LD CERTO SC + MTX | 2.97(0.33,24.44) | 2.75(0.36,18.94) | 0.06(‐0.06,0.30) | |
| LD ETN SC + MTX | 1.92(0.24,13.82) | 1.85(0.27,11.72) | 0.02(‐0.08,0.18) | |
| HD TOCI IV | 2.00(0.44,8.92) | 1.92(0.47,8.26) | 0.03(‐0.06,0.11) | |
| HD ADA SC | 0.50(0.07,3.63) | 0.51(0.08,3.53) | ‐0.02(‐0.13,0.02) | |
| HD ANA | 1.77(0.25,14.77) | 1.72(0.28,13.03) | 0.02(‐0.09,0.15) | |
| HD TOCI IV + MTX | 2.69(0.44,14.78) | 2.52(0.47,12.76) | 0.04(‐0.05,0.21) | |
| HD GOLI SC + MTX | 6.44(0.90,47.97) | 5.29(0.91,31.43) | 0.14(‐0.01,0.48) | |
| HD TOFA PO + MTX | 4.45(0.76,22.61) | 3.92(0.77,18.48) | 0.09(‐0.02,0.28) | |
| HD CERTO SC + MTX | 4.70(0.78,26.70) | 4.09(0.80,20.69) | 0.10(‐0.02,0.33) | |
| HD INF IV + MTX | 8.93(1.42,51.00) | 6.82(1.36,33.32) | 0.19(0.03,0.47) | |
| HD TOCI IV + DMARD | 1.64(0.42,6.67) | 1.60(0.45,6.23) | 0.02(‐0.06,0.11) | |
| LD ADA SC | LD ETN SC | 0.13(0.03,0.64) | 0.15(0.04,0.66) | ‐0.09(‐0.29,‐0.01) |
| LD ANA | 0.20(0.03,1.31) | 0.23(0.04,1.29) | ‐0.08(‐0.29,0.02) | |
| LD ABA IV + MTX | 1.06(0.28,3.66) | 1.05(0.32,3.03) | 0.00(‐0.14,0.18) | |
| LD CERTO SC + MTX | 0.82(0.15,4.12) | 0.84(0.17,3.30) | ‐0.02(‐0.19,0.20) | |
| LD ETN SC + MTX | 0.52(0.11,2.06) | 0.55(0.13,1.88) | ‐0.04(‐0.21,0.08) | |
| HD TOCI IV | 0.55(0.19,1.45) | 0.58(0.23,1.40) | ‐0.04(‐0.21,0.02) | |
| HD ADA SC | 0.14(0.02,0.68) | 0.15(0.03,0.68) | ‐0.09(‐0.29,‐0.01) | |
| HD ANA | 0.51(0.08,2.69) | 0.54(0.11,2.47) | ‐0.05(‐0.26,0.09) | |
| HD TOCI IV + MTX | 0.72(0.18,2.65) | 0.75(0.21,2.34) | ‐0.02(‐0.19,0.11) | |
| HD GOLI SC + MTX | 1.75(0.40,8.10) | 1.60(0.45,5.29) | 0.06(‐0.10,0.35) | |
| HD TOFA PO + MTX | 1.18(0.42,3.21) | 1.15(0.47,2.76) | 0.02(‐0.11,0.15) | |
| HD CERTO SC + MTX | 1.27(0.39,4.03) | 1.23(0.44,3.36) | 0.02(‐0.12,0.20) | |
| HD INF IV + MTX | 2.41(0.70,7.54) | 2.05(0.75,5.18) | 0.11(‐0.04,0.34) | |
| HD TOCI IV + DMARD | 0.45(0.13,1.70) | 0.48(0.15,1.63) | ‐0.05(‐0.22,0.04) | |
| LD ANA | LD ADA SC | 1.54(0.27,9.03) | 1.53(0.28,8.47) | 0.01(‐0.03,0.08) |
| LD ABA IV + MTX | 7.75(1.31,43.87) | 6.86(1.30,32.11) | 0.10(0.01,0.35) | |
| LD CERTO SC + MTX | 6.18(0.79,46.45) | 5.60(0.79,33.25) | 0.08(‐0.01,0.34) | |
| LD ETN SC + MTX | 3.94(0.57,25.49) | 3.73(0.58,20.90) | 0.04(‐0.01,0.21) | |
| HD TOCI IV | 4.00(0.90,19.67) | 3.78(0.91,17.85) | 0.05(0.00,0.14) | |
| HD ADA SC | 1.01(0.24,4.75) | 1.01(0.24,4.65) | 0.00(‐0.03,0.03) | |
| HD ANA | 3.84(0.71,17.97) | 3.65(0.72,15.84) | 0.04(‐0.01,0.16) | |
| HD TOCI IV + MTX | 5.36(0.87,36.14) | 4.96(0.88,29.48) | 0.07(0.00,0.25) | |
| HD GOLI SC + MTX | 13.44(1.89,96.52) | 10.86(1.83,53.58) | 0.16(0.02,0.51) | |
| HD TOFA PO + MTX | 8.95(1.82,41.65) | 7.76(1.76,31.67) | 0.11(0.02,0.31) | |
| HD CERTO SC + MTX | 9.49(1.74,51.76) | 8.16(1.69,38.07) | 0.12(0.02,0.36) | |
| HD INF IV + MTX | 18.00(3.26,96.45) | 13.61(3.01,58.71) | 0.21(0.05,0.51) | |
| HD TOCI IV + DMARD | 3.38(0.62,18.86) | 3.24(0.63,16.78) | 0.03(‐0.01,0.14) | |
| LD ABA IV + MTX | LD ANA | 4.88(0.72,43.50) | 4.41(0.73,30.76) | 0.08(‐0.02,0.35) |
| LD CERTO SC + MTX | 4.08(0.43,36.38) | 3.74(0.45,25.78) | 0.07(‐0.03,0.34) | |
| LD ETN SC + MTX | 2.55(0.29,21.37) | 2.44(0.30,17.43) | 0.03(‐0.04,0.21) | |
| HD TOCI IV | 2.70(0.45,15.69) | 2.59(0.47,13.98) | 0.04(‐0.04,0.14) | |
| HD ADA SC | 0.67(0.10,3.83) | 0.68(0.10,3.69) | ‐0.01(‐0.08,0.03) | |
| HD ANA | 2.43(0.83,7.61) | 2.33(0.84,6.98) | 0.03(‐0.01,0.12) | |
| HD TOCI IV + MTX | 3.64(0.39,24.25) | 3.40(0.41,19.48) | 0.06(‐0.04,0.24) | |
| HD GOLI SC + MTX | 8.39(0.98,80.29) | 6.96(0.98,44.53) | 0.15(0.00,0.51) | |
| HD TOFA PO + MTX | 5.99(0.89,36.38) | 5.26(0.90,27.40) | 0.10(‐0.01,0.31) | |
| HD CERTO SC + MTX | 6.21(0.90,42.89) | 5.44(0.91,30.30) | 0.11(0.00,0.36) | |
| HD INF IV + MTX | 11.36(1.66,82.92) | 8.85(1.59,46.36) | 0.20(0.03,0.51) | |
| HD TOCI IV + DMARD | 2.28(0.31,13.22) | 2.20(0.33,11.80) | 0.03(‐0.05,0.14) | |
| LD CERTO SC + MTX | LD ABA IV + MTX | 0.77(0.12,4.94) | 0.80(0.15,3.92) | ‐0.02(‐0.24,0.20) |
| LD ETN SC + MTX | 0.49(0.10,2.67) | 0.53(0.12,2.41) | ‐0.05(‐0.26,0.09) | |
| HD TOCI IV | 0.52(0.14,1.86) | 0.56(0.19,1.79) | ‐0.05(‐0.27,0.04) | |
| HD ADA SC | 0.13(0.02,0.82) | 0.15(0.02,0.82) | ‐0.09(‐0.35,‐0.01) | |
| HD ANA | 0.51(0.06,3.18) | 0.54(0.09,2.92) | ‐0.05(‐0.32,0.08) | |
| HD TOCI IV + MTX | 0.71(0.14,3.06) | 0.74(0.18,2.72) | ‐0.03(‐0.24,0.11) | |
| HD GOLI SC + MTX | 1.68(0.33,9.35) | 1.53(0.38,6.24) | 0.06(‐0.14,0.36) | |
| HD TOFA PO + MTX | 1.12(0.37,3.82) | 1.10(0.43,3.33) | 0.01(‐0.16,0.14) | |
| HD CERTO SC + MTX | 1.22(0.30,4.91) | 1.19(0.36,4.04) | 0.02(‐0.16,0.20) | |
| HD INF IV + MTX | 2.30(0.60,8.38) | 1.95(0.66,6.14) | 0.10(‐0.07,0.33) | |
| HD TOCI IV + DMARD | 0.44(0.09,2.16) | 0.47(0.12,2.05) | ‐0.05(‐0.29,0.05) | |
| LD ETN SC + MTX | LD CERTO SC + MTX | 0.63(0.09,4.48) | 0.66(0.11,3.95) | ‐0.03(‐0.25,0.12) |
| HD TOCI IV | 0.64(0.13,3.64) | 0.67(0.17,3.40) | ‐0.03(‐0.27,0.07) | |
| HD ADA SC | 0.17(0.02,1.36) | 0.18(0.03,1.35) | ‐0.08(‐0.34,0.01) | |
| HD ANA | 0.60(0.07,6.05) | 0.63(0.11,5.35) | ‐0.03(‐0.31,0.12) | |
| HD TOCI IV + MTX | 0.87(0.14,5.80) | 0.88(0.18,5.02) | ‐0.01(‐0.25,0.15) | |
| HD GOLI SC + MTX | 2.13(0.36,16.41) | 1.86(0.42,10.89) | 0.08(‐0.13,0.39) | |
| HD TOFA PO + MTX | 1.46(0.29,7.82) | 1.39(0.35,6.63) | 0.03(‐0.18,0.19) | |
| HD CERTO SC + MTX | 1.53(0.38,7.09) | 1.44(0.45,5.81) | 0.04(‐0.14,0.21) | |
| HD INF IV + MTX | 2.99(0.50,16.18) | 2.45(0.58,11.51) | 0.13(‐0.10,0.38) | |
| HD TOCI IV + DMARD | 0.53(0.10,3.94) | 0.56(0.13,3.66) | ‐0.04(‐0.28,0.08) | |
| HD TOCI IV | LD ETN SC + MTX | 1.04(0.27,4.60) | 1.04(0.31,4.33) | 0.00(‐0.14,0.08) |
| HD ADA SC | 0.25(0.04,1.96) | 0.27(0.04,1.93) | ‐0.04(‐0.21,0.01) | |
| HD ANA | 0.96(0.13,7.30) | 0.97(0.16,6.58) | 0.00(‐0.18,0.12) | |
| HD TOCI IV + MTX | 1.41(0.26,7.53) | 1.36(0.30,6.43) | 0.02(‐0.12,0.17) | |
| HD GOLI SC + MTX | 3.42(0.63,19.26) | 2.89(0.67,13.47) | 0.11(‐0.04,0.41) | |
| HD TOFA PO + MTX | 2.30(0.57,9.28) | 2.11(0.61,7.87) | 0.06(‐0.06,0.22) | |
| HD CERTO SC + MTX | 2.41(0.55,12.18) | 2.18(0.60,9.63) | 0.07(‐0.06,0.28) | |
| HD INF IV + MTX | 4.68(1.01,21.09) | 3.70(1.01,14.81) | 0.16(0.00,0.42) | |
| HD TOCI IV + DMARD | 0.87(0.17,4.86) | 0.88(0.20,4.50) | ‐0.01(‐0.16,0.09) | |
| HD ADA SC | HD TOCI IV | 0.26(0.05,1.10) | 0.27(0.05,1.10) | ‐0.05(‐0.14,0.00) |
| HD ANA | 0.94(0.19,4.46) | 0.94(0.22,3.96) | 0.00(‐0.11,0.12) | |
| HD TOCI IV + MTX | 1.34(0.48,3.67) | 1.31(0.50,3.12) | 0.02(‐0.04,0.16) | |
| HD GOLI SC + MTX | 3.26(0.80,14.57) | 2.80(0.81,8.80) | 0.11(‐0.01,0.43) | |
| HD TOFA PO + MTX | 2.14(0.84,5.92) | 1.97(0.86,4.84) | 0.06(‐0.01,0.22) | |
| HD CERTO SC + MTX | 2.33(0.74,7.94) | 2.12(0.76,5.94) | 0.07(‐0.02,0.29) | |
| HD INF IV + MTX | 4.35(1.45,14.16) | 3.47(1.39,9.01) | 0.16(0.02,0.42) | |
| HD TOCI IV + DMARD | 0.84(0.29,2.43) | 0.85(0.31,2.28) | ‐0.01(‐0.08,0.07) | |
| HD ANA | HD ADA SC | 3.67(0.72,21.32) | 3.51(0.73,18.39) | 0.04(‐0.01,0.16) |
| HD TOCI IV + MTX | 5.15(0.96,35.80) | 4.76(0.96,28.99) | 0.07(0.00,0.25) | |
| HD GOLI SC + MTX | 12.95(1.77,115.10) | 10.61(1.72,64.66) | 0.16(0.02,0.51) | |
| HD TOFA PO + MTX | 8.79(1.73,50.82) | 7.66(1.68,39.38) | 0.11(0.02,0.31) | |
| HD CERTO SC + MTX | 9.24(1.63,61.35) | 7.95(1.59,42.40) | 0.12(0.02,0.37) | |
| HD INF IV + MTX | 17.57(3.18,112.80) | 13.18(2.95,66.15) | 0.21(0.05,0.51) | |
| HD TOCI IV + DMARD | 3.31(0.61,19.74) | 3.16(0.62,17.49) | 0.04(‐0.01,0.14) | |
| HD TOCI IV + MTX | HD ANA | 1.47(0.20,9.19) | 1.42(0.22,7.27) | 0.02(‐0.12,0.22) |
| HD GOLI SC + MTX | 3.36(0.42,29.91) | 2.91(0.46,16.31) | 0.11(‐0.06,0.48) | |
| HD TOFA PO + MTX | 2.39(0.42,13.63) | 2.20(0.46,10.07) | 0.07(‐0.07,0.28) | |
| HD CERTO SC + MTX | 2.53(0.41,16.39) | 2.30(0.44,11.42) | 0.07(‐0.07,0.33) | |
| HD INF IV + MTX | 4.64(0.83,29.95) | 3.77(0.85,16.58) | 0.16(‐0.02,0.48) | |
| HD TOCI IV + DMARD | 0.90(0.15,5.07) | 0.91(0.16,4.53) | 0.00(‐0.13,0.11) | |
| HD GOLI SC + MTX | HD TOCI IV + MTX | 2.48(0.44,12.93) | 2.17(0.49,8.68) | 0.09(‐0.08,0.40) |
| HD TOFA PO + MTX | 1.63(0.46,6.29) | 1.53(0.51,5.27) | 0.04(‐0.09,0.21) | |
| HD CERTO SC + MTX | 1.72(0.43,7.79) | 1.60(0.48,6.01) | 0.05(‐0.09,0.27) | |
| HD INF IV + MTX | 3.25(0.77,13.96) | 2.66(0.81,9.43) | 0.14(‐0.03,0.40) | |
| HD TOCI IV + DMARD | 0.62(0.16,2.73) | 0.64(0.19,2.54) | ‐0.03(‐0.19,0.07) | |
| HD TOFA PO + MTX | HD GOLI SC + MTX | 0.68(0.16,2.60) | 0.73(0.24,2.32) | ‐0.04(‐0.32,0.11) |
| HD CERTO SC + MTX | 0.71(0.15,3.14) | 0.76(0.22,2.66) | ‐0.04(‐0.33,0.15) | |
| HD INF IV + MTX | 1.38(0.25,6.03) | 1.28(0.36,4.39) | 0.04(‐0.26,0.30) | |
| HD TOCI IV + DMARD | 0.25(0.05,1.36) | 0.30(0.08,1.32) | ‐0.12(‐0.44,0.02) | |
| HD CERTO SC + MTX | HD TOFA PO + MTX | 1.05(0.36,3.44) | 1.05(0.41,2.82) | 0.01(‐0.12,0.18) |
| HD INF IV + MTX | 2.03(0.72,5.44) | 1.75(0.76,3.98) | 0.10(‐0.04,0.30) | |
| HD TOCI IV + DMARD | 0.38(0.11,1.44) | 0.42(0.13,1.40) | ‐0.07(‐0.25,0.03) | |
| HD INF IV + MTX | HD CERTO SC + MTX | 1.88(0.50,6.44) | 1.65(0.58,4.56) | 0.08(‐0.10,0.31) |
| HD TOCI IV + DMARD | 0.35(0.09,1.60) | 0.39(0.12,1.54) | ‐0.08(‐0.30,0.04) | |
| HD TOCI IV + DMARD | HD INF IV + MTX | 0.19(0.04,0.85) | 0.24(0.07,0.86) | ‐0.17(‐0.45,‐0.01) |
| Random‐effects model | Residual deviance | 119.1 vs 119 data points | ||
| Deviance information criteria | 622.675 | |||
| Fixed‐effect model | Residual deviance | 123.8 vs 119 data points | ||
| Deviance information criteria | 622.968 | |||
| Note | ||||
| Total participants | 20,301 | |||
| Total studies | 48 | |||
| 2‐arm | 30 | |||
| 3‐arm | 13 | |||
| 4‐arm | 5 | |||
Appendix 17. Withdrawals due to adverse events: subgroup ‐ late RA (> 10 years)
| Withdrawals late: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX + PL | PL | 2.70(0.42,18.18) | 2.63(0.43,15.53) | 0.02(‐0.01,0.16) |
| SD ETN SC | 1.24(0.22,7.53) | 1.24(0.23,7.13) | 0.00(‐0.02,0.06) | |
| SD ADA SC | 5.91(0.86,132.50) | 5.50(0.86,89.14) | 0.06(0.00,0.35) | |
| SD RITUX IV | 36.20(1.14,1221.00) | 22.61(1.14,115.20) | 0.31(0.00,0.93) | |
| SD ADA SC + MTX | 3.94(0.51,30.99) | 3.75(0.52,24.30) | 0.04(‐0.01,0.26) | |
| SD RITUX IV + MTX | 9.81(0.76,167.10) | 8.62(0.77,64.71) | 0.10(0.00,0.69) | |
| SD ETN SC + MTX | 3.63(0.09,276.70) | 3.50(0.10,61.27) | 0.03(‐0.02,0.80) | |
| SD INF IV + MTX | 1.84(0.16,18.50) | 1.82(0.16,15.68) | 0.01(‐0.02,0.17) | |
| LD ETN SC | 1.27(0.24,7.42) | 1.27(0.24,6.95) | 0.00(‐0.02,0.06) | |
| LD RITUX IV + MTX | 6.93(0.45,113.20) | 6.30(0.46,52.49) | 0.07(‐0.01,0.60) | |
| HD INF IV + MTX | 1.37(0.12,15.94) | 1.36(0.12,13.75) | 0.00(‐0.02,0.14) | |
| SD ETN SC | MTX + PL | 0.47(0.16,1.27) | 0.48(0.18,1.26) | ‐0.02(‐0.12,0.00) |
| SD ADA SC | 2.26(0.15,83.91) | 2.15(0.17,57.17) | 0.04(‐0.14,0.35) | |
| SD RITUX IV | 12.49(0.87,298.80) | 7.50(0.88,46.18) | 0.27(0.00,0.87) | |
| SD ADA SC + MTX | 1.47(0.56,3.45) | 1.43(0.58,3.11) | 0.01(‐0.02,0.13) | |
| SD RITUX IV + MTX | 3.42(0.63,35.37) | 3.02(0.64,16.33) | 0.07(‐0.01,0.61) | |
| SD ETN SC + MTX | 1.23(0.07,71.41) | 1.21(0.07,19.33) | 0.01(‐0.07,0.73) | |
| SD INF IV + MTX | 0.64(0.14,2.92) | 0.65(0.15,2.64) | ‐0.01(‐0.08,0.08) | |
| LD ETN SC | 0.47(0.17,1.37) | 0.48(0.19,1.36) | ‐0.02(‐0.12,0.01) | |
| LD RITUX IV + MTX | 2.53(0.35,25.06) | 2.34(0.36,13.34) | 0.04(‐0.04,0.52) | |
| HD INF IV + MTX | 0.51(0.10,2.39) | 0.52(0.10,2.22) | ‐0.01(‐0.10,0.06) | |
| SD ADA SC | SD ETN SC | 4.96(0.35,179.90) | 4.62(0.37,117.30) | 0.06(‐0.04,0.35) |
| SD RITUX IV | 26.58(1.53,769.90) | 15.92(1.50,105.40) | 0.30(0.01,0.91) | |
| SD ADA SC + MTX | 3.15(0.81,12.13) | 2.99(0.81,10.21) | 0.03(0.00,0.22) | |
| SD RITUX IV + MTX | 7.41(1.02,95.24) | 6.48(1.01,42.96) | 0.09(0.00,0.67) | |
| SD ETN SC + MTX | 2.70(0.11,176.40) | 2.58(0.11,45.07) | 0.02(‐0.03,0.78) | |
| SD INF IV + MTX | 1.39(0.24,9.02) | 1.38(0.24,7.91) | 0.01(‐0.03,0.14) | |
| LD ETN SC | 0.99(0.40,2.86) | 0.99(0.41,2.79) | 0.00(‐0.03,0.03) | |
| LD RITUX IV + MTX | 5.47(0.56,68.87) | 4.93(0.57,34.34) | 0.07(‐0.01,0.58) | |
| HD INF IV + MTX | 1.09(0.16,6.93) | 1.08(0.16,6.27) | 0.00(‐0.04,0.12) | |
| SD RITUX IV | SD ADA SC | 5.66(0.06,320.10) | 3.86(0.08,31.65) | 0.23(‐0.27,0.88) |
| SD ADA SC + MTX | 0.63(0.01,11.32) | 0.65(0.02,8.64) | ‐0.03(‐0.34,0.23) | |
| SD RITUX IV + MTX | 1.51(0.03,55.04) | 1.45(0.04,19.78) | 0.03(‐0.32,0.65) | |
| SD ETN SC + MTX | 0.51(0.01,87.27) | 0.54(0.01,19.52) | ‐0.03(‐0.33,0.75) | |
| SD INF IV + MTX | 0.27(0.01,5.93) | 0.29(0.01,5.05) | ‐0.05(‐0.35,0.13) | |
| LD ETN SC | 0.20(0.01,3.10) | 0.22(0.01,2.93) | ‐0.06(‐0.35,0.05) | |
| LD RITUX IV + MTX | 1.11(0.02,39.98) | 1.10(0.03,17.39) | 0.01(‐0.32,0.57) | |
| HD INF IV + MTX | 0.21(0.00,5.18) | 0.23(0.01,4.48) | ‐0.06(‐0.35,0.11) | |
| SD ADA SC + MTX | SD RITUX IV | 0.12(0.00,2.00) | 0.19(0.03,1.88) | ‐0.25(‐0.85,0.03) |
| SD RITUX IV + MTX | 0.31(0.01,3.19) | 0.48(0.05,2.70) | ‐0.15(‐0.71,0.12) | |
| SD ETN SC + MTX | 0.11(0.00,13.37) | 0.17(0.01,5.47) | ‐0.20(‐0.88,0.42) | |
| SD INF IV + MTX | 0.05(0.00,1.16) | 0.09(0.01,1.14) | ‐0.28(‐0.90,0.00) | |
| LD ETN SC | 0.04(0.00,0.70) | 0.06(0.01,0.71) | ‐0.30(‐0.91,‐0.01) | |
| LD RITUX IV + MTX | 0.21(0.01,2.60) | 0.35(0.03,2.22) | ‐0.18(‐0.74,0.09) | |
| HD INF IV + MTX | 0.04(0.00,0.87) | 0.07(0.01,0.88) | ‐0.29(‐0.90,0.00) | |
| SD RITUX IV + MTX | SD ADA SC + MTX | 2.41(0.35,26.99) | 2.17(0.38,13.90) | 0.05(‐0.07,0.58) |
| SD ETN SC + MTX | 0.84(0.04,57.07) | 0.85(0.04,15.50) | 0.00(‐0.15,0.70) | |
| SD INF IV + MTX | 0.45(0.08,2.68) | 0.47(0.09,2.48) | ‐0.02(‐0.18,0.06) | |
| LD ETN SC | 0.31(0.09,1.38) | 0.33(0.10,1.36) | ‐0.03(‐0.22,0.01) | |
| LD RITUX IV + MTX | 1.75(0.20,20.27) | 1.65(0.22,11.34) | 0.03(‐0.11,0.49) | |
| HD INF IV + MTX | 0.34(0.05,2.21) | 0.36(0.06,2.08) | ‐0.03(‐0.19,0.04) | |
| SD ETN SC + MTX | SD RITUX IV + MTX | 0.38(0.01,27.97) | 0.42(0.01,8.97) | ‐0.04(‐0.61,0.58) |
| SD INF IV + MTX | 0.18(0.01,1.71) | 0.21(0.02,1.63) | ‐0.08(‐0.63,0.02) | |
| LD ETN SC | 0.13(0.01,1.12) | 0.15(0.02,1.12) | ‐0.09(‐0.67,0.00) | |
| LD RITUX IV + MTX | 0.71(0.14,3.24) | 0.77(0.17,2.70) | ‐0.02(‐0.28,0.16) | |
| HD INF IV + MTX | 0.14(0.01,1.39) | 0.17(0.02,1.35) | ‐0.09(‐0.65,0.01) | |
| SD INF IV + MTX | SD ETN SC + MTX | 0.50(0.01,12.90) | 0.52(0.02,12.19) | ‐0.02(‐0.75,0.10) |
| LD ETN SC | 0.38(0.01,8.85) | 0.40(0.02,8.64) | ‐0.02(‐0.78,0.03) | |
| LD RITUX IV + MTX | 1.85(0.03,106.20) | 1.73(0.08,65.42) | 0.02(‐0.63,0.52) | |
| HD INF IV + MTX | 0.40(0.01,11.23) | 0.42(0.02,10.54) | ‐0.02(‐0.76,0.07) | |
| LD ETN SC | SD INF IV + MTX | 0.73(0.11,4.60) | 0.74(0.13,4.48) | 0.00(‐0.14,0.03) |
| LD RITUX IV + MTX | 4.05(0.35,59.56) | 3.61(0.38,35.42) | 0.05(‐0.05,0.55) | |
| HD INF IV + MTX | 0.77(0.14,3.87) | 0.78(0.15,3.66) | 0.00(‐0.10,0.06) | |
| LD RITUX IV + MTX | LD ETN SC | 5.43(0.55,68.53) | 4.90(0.55,34.17) | 0.07(‐0.01,0.58) |
| HD INF IV + MTX | 1.10(0.15,6.61) | 1.10(0.15,5.80) | 0.00(‐0.04,0.12) | |
| HD INF IV + MTX | LD RITUX IV + MTX | 0.19(0.01,2.60) | 0.22(0.02,2.46) | ‐0.06(‐0.56,0.04) |
| Random‐effects model | Residual deviance | 26.96 vs 24 data points | ||
| Deviance information criteria | 122.322 | |||
| Fixed‐effect model | Residual deviance | 27.51 vs 24 data points | ||
| Deviance information criteria | 122.485 | |||
| Note | ||||
| Total participants | 3276 | |||
| Total studies | 9 | |||
| 2‐arm | 4 | |||
| 3‐arm | 4 | |||
| 4‐arm | 1 | |||
Appendix 18. Withdrawals due to adverse events: subgroup ‐ trial duration (<= 6 months)
| Withdrawals short: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX | PL | 1.11(0.30,3.75) | 1.11(0.31,3.58) | 0.00(‐0.02,0.05) |
| DMARD + PL | 3.39(0.98,11.24) | 3.23(0.98,9.44) | 0.05(0.00,0.17) | |
| MTX + DMARD | 3.08(0.54,14.28) | 2.95(0.55,11.47) | 0.04(‐0.01,0.20) | |
| SD ETN SC | 1.27(0.34,4.27) | 1.26(0.35,4.03) | 0.01(‐0.02,0.06) | |
| SD ADA SC | 2.00(1.00,4.48) | 1.95(1.00,4.24) | 0.02(0.00,0.06) | |
| SD TOCI IV | 0.98(0.37,2.60) | 0.98(0.38,2.53) | 0.00(‐0.02,0.03) | |
| SD CERTO SC | 2.92(0.85,12.52) | 2.81(0.85,10.59) | 0.04(0.00,0.16) | |
| SD TOC SC + PL IV | 0.70(0.20,2.23) | 0.70(0.20,2.18) | ‐0.01(‐0.02,0.02) | |
| SD RITUX IV | 7.58(0.55,151.10) | 6.69(0.56,38.26) | 0.11(‐0.01,0.74) | |
| SD ETN SC + MTX | 1.01(0.22,3.98) | 1.01(0.23,3.81) | 0.00(‐0.02,0.05) | |
| SD ADA SC + MTX | 1.44(0.31,6.62) | 1.43(0.32,5.97) | 0.01(‐0.02,0.09) | |
| SD INF IV + MTX | 2.98(0.68,11.68) | 2.86(0.68,9.66) | 0.04(‐0.01,0.18) | |
| SD ABA IV + MTX | 1.09(0.22,3.96) | 1.09(0.22,3.76) | 0.00(‐0.02,0.05) | |
| SD CERTO SC + MTX | 1.50(0.35,6.04) | 1.49(0.36,5.52) | 0.01(‐0.02,0.09) | |
| SD RITUX IV + MTX | 2.15(0.38,14.47) | 2.10(0.38,11.41) | 0.02(‐0.01,0.20) | |
| SD GOLI SC + MTX | 1.16(0.22,6.22) | 1.16(0.23,5.69) | 0.00(‐0.02,0.09) | |
| SD TOFA PO + MTX | 1.97(0.39,10.08) | 1.93(0.39,8.63) | 0.02(‐0.01,0.14) | |
| SD ABA SC + MTX | 0.61(0.10,2.67) | 0.61(0.10,2.59) | ‐0.01(‐0.02,0.03) | |
| SD TOCI IV + MTX | 1.24(0.27,5.65) | 1.24(0.28,5.18) | 0.00(‐0.02,0.08) | |
| SD ETN SC + DMARD | 2.41(0.83,7.47) | 2.34(0.83,6.75) | 0.03(0.00,0.11) | |
| SD CERTO SC + DMARD | 3.17(0.85,12.73) | 3.03(0.85,10.52) | 0.04(0.00,0.18) | |
| SD ADA SC + DMARD | 4.17(0.70,22.23) | 3.90(0.70,15.74) | 0.06(‐0.01,0.29) | |
| SD TOCI SC + DMARD | 9.78(1.20,77.69) | 8.22(1.20,33.00) | 0.15(0.00,0.59) | |
| LD ADA SC | 0.71(0.17,2.12) | 0.72(0.17,2.08) | ‐0.01(‐0.02,0.02) | |
| LD ETN SC | 2.45(0.54,11.59) | 2.38(0.55,9.66) | 0.03(‐0.01,0.16) | |
| LD TOCI IV | 0.75(0.14,3.61) | 0.76(0.14,3.44) | 0.00(‐0.02,0.04) | |
| LD RITUX IV + MTX | 1.98(0.34,14.46) | 1.94(0.35,11.35) | 0.02(‐0.02,0.21) | |
| LD ABA IV + MTX | 1.36(0.21,6.99) | 1.35(0.21,6.27) | 0.01(‐0.02,0.10) | |
| LD CERTO SC + MTX | 0.98(0.12,6.19) | 0.98(0.12,5.64) | 0.00(‐0.02,0.09) | |
| LD TOCI IV + MTX | 0.53(0.09,2.70) | 0.54(0.09,2.63) | ‐0.01(‐0.02,0.03) | |
| HD TOCI IV | 0.89(0.26,3.16) | 0.90(0.27,3.03) | 0.00(‐0.02,0.04) | |
| HD ADA SC | 0.74(0.20,2.32) | 0.74(0.20,2.26) | ‐0.01(‐0.02,0.02) | |
| HD GOLI SC | 0.59(0.05,4.89) | 0.59(0.05,4.53) | ‐0.01(‐0.03,0.07) | |
| HD TOCI IV + MTX | 1.24(0.34,4.88) | 1.24(0.35,4.57) | 0.00(‐0.02,0.06) | |
| HD GOLI SC + MTX | 1.72(0.31,8.68) | 1.69(0.32,7.58) | 0.01(‐0.02,0.12) | |
| HD TOFA PO + MTX | 1.68(0.35,9.23) | 1.66(0.35,8.00) | 0.01(‐0.02,0.13) | |
| HD CERTO SC + MTX | 1.56(0.33,7.71) | 1.54(0.34,6.83) | 0.01(‐0.02,0.11) | |
| HD INF IV + MTX | 3.17(0.64,13.94) | 3.03(0.64,11.19) | 0.04(‐0.01,0.20) | |
| HD TOCI IV + DMARD | 6.54(1.64,26.27) | 5.85(1.62,17.84) | 0.10(0.01,0.34) | |
| DMARD + PL | MTX | 3.06(0.54,23.08) | 2.91(0.55,19.70) | 0.04(‐0.02,0.17) |
| MTX + DMARD | 2.92(0.45,13.15) | 2.78(0.46,11.30) | 0.04(‐0.03,0.19) | |
| SD ETN SC | 1.20(0.25,4.31) | 1.19(0.27,4.13) | 0.00(‐0.04,0.05) | |
| SD ADA SC | 1.81(0.50,8.47) | 1.77(0.52,8.10) | 0.02(‐0.03,0.06) | |
| SD TOCI IV | 0.89(0.32,2.89) | 0.89(0.33,2.85) | 0.00(‐0.04,0.02) | |
| SD CERTO SC | 2.69(0.45,21.20) | 2.58(0.46,18.20) | 0.03(‐0.03,0.16) | |
| SD TOC SC + PL IV | 0.62(0.18,2.43) | 0.63(0.19,2.40) | ‐0.01(‐0.05,0.01) | |
| SD RITUX IV | 6.81(0.71,93.71) | 5.84(0.72,33.71) | 0.11(‐0.01,0.72) | |
| SD ETN SC + MTX | 0.92(0.20,3.52) | 0.92(0.21,3.39) | 0.00(‐0.05,0.04) | |
| SD ADA SC + MTX | 1.28(0.64,2.91) | 1.27(0.64,2.80) | 0.01(‐0.01,0.06) | |
| SD INF IV + MTX | 2.69(1.30,5.51) | 2.58(1.29,4.92) | 0.03(0.00,0.14) | |
| SD ABA IV + MTX | 0.95(0.49,1.87) | 0.96(0.50,1.83) | 0.00(‐0.02,0.02) | |
| SD CERTO SC + MTX | 1.35(0.72,2.59) | 1.33(0.72,2.47) | 0.01(‐0.01,0.05) | |
| SD RITUX IV + MTX | 1.96(0.65,7.23) | 1.91(0.66,6.14) | 0.02(‐0.01,0.17) | |
| SD GOLI SC + MTX | 1.07(0.39,3.04) | 1.07(0.40,2.87) | 0.00(‐0.02,0.06) | |
| SD TOFA PO + MTX | 1.75(0.75,4.46) | 1.71(0.75,4.11) | 0.02(‐0.01,0.10) | |
| SD ABA SC + MTX | 0.52(0.19,1.56) | 0.53(0.19,1.54) | ‐0.01(‐0.04,0.01) | |
| SD TOCI IV + MTX | 1.18(0.34,3.72) | 1.17(0.34,3.55) | 0.00(‐0.02,0.06) | |
| SD ETN SC + DMARD | 2.20(0.44,13.50) | 2.14(0.45,12.30) | 0.02(‐0.03,0.11) | |
| SD CERTO SC + DMARD | 2.71(0.52,26.30) | 2.60(0.54,21.79) | 0.04(‐0.02,0.19) | |
| SD ADA SC + DMARD | 3.89(0.39,40.36) | 3.64(0.41,28.92) | 0.06(‐0.03,0.29) | |
| SD TOCI SC + DMARD | 9.51(0.77,96.91) | 7.80(0.78,47.08) | 0.15(‐0.01,0.58) | |
| LD ADA SC | 0.63(0.10,3.03) | 0.64(0.10,2.96) | ‐0.01(‐0.06,0.02) | |
| LD ETN SC | 2.24(0.34,13.33) | 2.17(0.35,11.70) | 0.02(‐0.03,0.16) | |
| LD TOCI IV | 0.70(0.16,2.25) | 0.70(0.17,2.21) | ‐0.01(‐0.04,0.02) | |
| LD RITUX IV + MTX | 1.83(0.55,7.25) | 1.79(0.56,6.33) | 0.02(‐0.01,0.16) | |
| LD ABA IV + MTX | 1.19(0.40,3.43) | 1.19(0.41,3.25) | 0.00(‐0.02,0.07) | |
| LD CERTO SC + MTX | 0.93(0.17,3.71) | 0.93(0.17,3.51) | 0.00(‐0.03,0.07) | |
| LD TOCI IV + MTX | 0.49(0.08,2.06) | 0.50(0.09,2.03) | ‐0.01(‐0.05,0.02) | |
| HD TOCI IV | 0.81(0.40,1.70) | 0.82(0.41,1.67) | 0.00(‐0.03,0.01) | |
| HD ADA SC | 0.66(0.12,3.48) | 0.67(0.13,3.42) | ‐0.01(‐0.06,0.02) | |
| HD GOLI SC | 0.56(0.05,2.97) | 0.57(0.06,2.83) | ‐0.01(‐0.04,0.05) | |
| HD TOCI IV + MTX | 1.12(0.48,2.77) | 1.12(0.49,2.70) | 0.00(‐0.02,0.04) | |
| HD GOLI SC + MTX | 1.50(0.62,4.60) | 1.48(0.63,4.19) | 0.01(‐0.01,0.10) | |
| HD TOFA PO + MTX | 1.57(0.67,4.11) | 1.54(0.68,3.83) | 0.01(‐0.01,0.09) | |
| HD CERTO SC + MTX | 1.46(0.62,3.50) | 1.44(0.62,3.29) | 0.01(‐0.01,0.08) | |
| HD INF IV + MTX | 2.87(1.22,7.01) | 2.73(1.21,6.14) | 0.04(0.00,0.16) | |
| HD TOCI IV + DMARD | 5.90(0.99,49.48) | 5.26(0.99,34.87) | 0.09(0.00,0.34) | |
| MTX + DMARD | DMARD + PL | 0.90(0.10,6.94) | 0.91(0.12,5.89) | ‐0.01(‐0.15,0.17) |
| SD ETN SC | 0.38(0.05,2.53) | 0.40(0.07,2.43) | ‐0.04(‐0.17,0.04) | |
| SD ADA SC | 0.60(0.19,1.93) | 0.62(0.21,1.89) | ‐0.02(‐0.14,0.02) | |
| SD TOCI IV | 0.29(0.06,1.44) | 0.30(0.07,1.42) | ‐0.05(‐0.17,0.01) | |
| SD CERTO SC | 0.88(0.14,5.75) | 0.88(0.17,5.10) | ‐0.01(‐0.14,0.12) | |
| SD TOC SC + PL IV | 0.20(0.04,1.13) | 0.21(0.04,1.12) | ‐0.05(‐0.18,0.00) | |
| SD RITUX IV | 2.22(0.10,67.50) | 2.03(0.12,19.44) | 0.06(‐0.13,0.70) | |
| SD ETN SC + MTX | 0.30(0.03,1.88) | 0.31(0.04,1.83) | ‐0.04(‐0.17,0.02) | |
| SD ADA SC + MTX | 0.42(0.05,3.03) | 0.44(0.06,2.81) | ‐0.03(‐0.17,0.07) | |
| SD INF IV + MTX | 0.89(0.10,6.25) | 0.90(0.12,5.16) | ‐0.01(‐0.15,0.14) | |
| SD ABA IV + MTX | 0.31(0.03,2.03) | 0.33(0.04,1.96) | ‐0.04(‐0.17,0.03) | |
| SD CERTO SC + MTX | 0.44(0.06,3.07) | 0.46(0.06,2.87) | ‐0.03(‐0.17,0.06) | |
| SD RITUX IV + MTX | 0.61(0.07,6.67) | 0.63(0.08,5.53) | ‐0.02(‐0.16,0.18) | |
| SD GOLI SC + MTX | 0.34(0.04,2.89) | 0.36(0.04,2.69) | ‐0.04(‐0.17,0.05) | |
| SD TOFA PO + MTX | 0.57(0.06,4.36) | 0.59(0.07,3.86) | ‐0.02(‐0.16,0.11) | |
| SD ABA SC + MTX | 0.18(0.02,1.27) | 0.19(0.02,1.26) | ‐0.05(‐0.18,0.01) | |
| SD TOCI IV + MTX | 0.36(0.05,2.45) | 0.38(0.06,2.34) | ‐0.04(‐0.17,0.05) | |
| SD ETN SC + DMARD | 0.71(0.32,1.70) | 0.73(0.34,1.65) | ‐0.02(‐0.10,0.03) | |
| SD CERTO SC + DMARD | 0.93(0.30,3.16) | 0.93(0.32,2.90) | 0.00(‐0.09,0.10) | |
| SD ADA SC + DMARD | 1.27(0.35,4.05) | 1.24(0.37,3.33) | 0.01(‐0.06,0.19) | |
| SD TOCI SC + DMARD | 2.74(0.57,17.79) | 2.39(0.59,9.33) | 0.09(‐0.03,0.50) | |
| LD ADA SC | 0.20(0.04,1.08) | 0.21(0.04,1.07) | ‐0.05(‐0.17,0.00) | |
| LD ETN SC | 0.71(0.10,6.19) | 0.73(0.11,5.42) | ‐0.02(‐0.15,0.12) | |
| LD TOCI IV | 0.22(0.03,1.87) | 0.23(0.03,1.82) | ‐0.05(‐0.18,0.02) | |
| LD RITUX IV + MTX | 0.55(0.06,5.59) | 0.57(0.07,4.57) | ‐0.02(‐0.16,0.17) | |
| LD ABA IV + MTX | 0.39(0.04,3.22) | 0.41(0.04,2.99) | ‐0.04(‐0.17,0.06) | |
| LD CERTO SC + MTX | 0.29(0.02,2.74) | 0.31(0.03,2.56) | ‐0.04(‐0.17,0.06) | |
| LD TOCI IV + MTX | 0.15(0.02,1.12) | 0.16(0.02,1.12) | ‐0.05(‐0.18,0.00) | |
| HD TOCI IV | 0.26(0.04,1.77) | 0.27(0.05,1.73) | ‐0.05(‐0.17,0.02) | |
| HD ADA SC | 0.21(0.05,1.08) | 0.22(0.05,1.08) | ‐0.05(‐0.17,0.00) | |
| HD GOLI SC | 0.18(0.01,1.90) | 0.19(0.01,1.83) | ‐0.05(‐0.18,0.03) | |
| HD TOCI IV + MTX | 0.36(0.06,2.49) | 0.38(0.07,2.39) | ‐0.04(‐0.17,0.04) | |
| HD GOLI SC + MTX | 0.48(0.06,4.25) | 0.50(0.06,3.81) | ‐0.03(‐0.16,0.09) | |
| HD TOFA PO + MTX | 0.50(0.06,3.97) | 0.52(0.07,3.54) | ‐0.03(‐0.16,0.09) | |
| HD CERTO SC + MTX | 0.46(0.05,3.44) | 0.47(0.06,3.17) | ‐0.03(‐0.16,0.08) | |
| HD INF IV + MTX | 0.94(0.09,6.85) | 0.95(0.11,5.77) | 0.00(‐0.15,0.16) | |
| HD TOCI IV + DMARD | 1.91(1.01,3.79) | 1.78(1.01,3.21) | 0.05(0.00,0.20) | |
| SD ETN SC | MTX + DMARD | 0.43(0.12,1.35) | 0.45(0.14,1.34) | ‐0.03(‐0.18,0.01) |
| SD ADA SC | 0.66(0.13,4.13) | 0.67(0.15,3.95) | ‐0.02(‐0.18,0.04) | |
| SD TOCI IV | 0.33(0.06,2.20) | 0.35(0.07,2.16) | ‐0.04(‐0.21,0.02) | |
| SD CERTO SC | 0.99(0.13,9.94) | 0.99(0.15,8.63) | 0.00(‐0.18,0.14) | |
| SD TOC SC + PL IV | 0.24(0.03,1.70) | 0.25(0.04,1.67) | ‐0.04(‐0.21,0.01) | |
| SD RITUX IV | 2.52(0.15,60.44) | 2.26(0.17,22.31) | 0.07(‐0.11,0.69) | |
| SD ETN SC + MTX | 0.34(0.12,0.84) | 0.36(0.14,0.84) | ‐0.04(‐0.17,0.00) | |
| SD ADA SC + MTX | 0.45(0.09,3.49) | 0.47(0.10,3.22) | ‐0.03(‐0.18,0.06) | |
| SD INF IV + MTX | 0.93(0.18,6.70) | 0.93(0.21,5.86) | 0.00(‐0.15,0.13) | |
| SD ABA IV + MTX | 0.33(0.06,2.27) | 0.34(0.07,2.21) | ‐0.04(‐0.19,0.03) | |
| SD CERTO SC + MTX | 0.47(0.09,3.17) | 0.48(0.11,3.03) | ‐0.03(‐0.18,0.05) | |
| SD RITUX IV + MTX | 0.66(0.11,8.71) | 0.68(0.12,7.23) | ‐0.02(‐0.16,0.17) | |
| SD GOLI SC + MTX | 0.37(0.06,3.20) | 0.39(0.07,3.04) | ‐0.03(‐0.19,0.05) | |
| SD TOFA PO + MTX | 0.62(0.11,4.75) | 0.64(0.13,4.21) | ‐0.02(‐0.17,0.09) | |
| SD ABA SC + MTX | 0.18(0.03,1.49) | 0.19(0.03,1.47) | ‐0.05(‐0.20,0.01) | |
| SD TOCI IV + MTX | 0.39(0.06,3.43) | 0.41(0.08,3.25) | ‐0.03(‐0.19,0.06) | |
| SD ETN SC + DMARD | 0.79(0.12,5.95) | 0.80(0.14,5.53) | ‐0.01(‐0.18,0.09) | |
| SD CERTO SC + DMARD | 1.03(0.14,10.75) | 1.03(0.17,9.18) | 0.00(‐0.17,0.16) | |
| SD ADA SC + DMARD | 1.40(0.12,16.85) | 1.36(0.14,12.84) | 0.02(‐0.16,0.26) | |
| SD TOCI SC + DMARD | 3.35(0.27,42.87) | 2.86(0.30,23.36) | 0.10(‐0.10,0.55) | |
| LD ADA SC | 0.23(0.03,1.63) | 0.24(0.04,1.61) | ‐0.04(‐0.21,0.01) | |
| LD ETN SC | 0.82(0.12,5.84) | 0.83(0.14,5.26) | ‐0.01(‐0.16,0.11) | |
| LD TOCI IV | 0.24(0.03,2.22) | 0.26(0.04,2.15) | ‐0.04(‐0.20,0.03) | |
| LD RITUX IV + MTX | 0.61(0.10,7.69) | 0.63(0.11,6.64) | ‐0.02(‐0.17,0.16) | |
| LD ABA IV + MTX | 0.42(0.06,3.37) | 0.44(0.07,3.17) | ‐0.03(‐0.18,0.06) | |
| LD CERTO SC + MTX | 0.32(0.03,3.06) | 0.34(0.04,2.85) | ‐0.03(‐0.19,0.05) | |
| LD TOCI IV + MTX | 0.18(0.02,1.40) | 0.19(0.02,1.39) | ‐0.05(‐0.21,0.01) | |
| HD TOCI IV | 0.29(0.06,2.22) | 0.30(0.07,2.16) | ‐0.04(‐0.20,0.02) | |
| HD ADA SC | 0.24(0.03,1.87) | 0.25(0.04,1.84) | ‐0.04(‐0.21,0.01) | |
| HD GOLI SC | 0.20(0.01,2.18) | 0.21(0.01,2.12) | ‐0.04(‐0.21,0.03) | |
| HD TOCI IV + MTX | 0.40(0.08,3.22) | 0.41(0.09,3.10) | ‐0.03(‐0.19,0.04) | |
| HD GOLI SC + MTX | 0.55(0.08,4.15) | 0.57(0.10,3.79) | ‐0.02(‐0.18,0.08) | |
| HD TOFA PO + MTX | 0.56(0.09,4.34) | 0.58(0.11,3.95) | ‐0.02(‐0.18,0.08) | |
| HD CERTO SC + MTX | 0.51(0.09,3.71) | 0.53(0.10,3.48) | ‐0.02(‐0.18,0.07) | |
| HD INF IV + MTX | 0.99(0.17,7.26) | 0.99(0.20,6.40) | 0.00(‐0.15,0.16) | |
| HD TOCI IV + DMARD | 2.16(0.24,21.17) | 2.00(0.28,15.79) | 0.05(‐0.13,0.30) | |
| SD ADA SC | SD ETN SC | 1.62(0.37,7.02) | 1.60(0.38,6.65) | 0.01(‐0.05,0.06) |
| SD TOCI IV | 0.79(0.19,3.40) | 0.79(0.20,3.30) | ‐0.01(‐0.06,0.03) | |
| SD CERTO SC | 2.32(0.38,17.04) | 2.24(0.40,14.61) | 0.03(‐0.04,0.15) | |
| SD TOC SC + PL IV | 0.55(0.11,2.67) | 0.56(0.11,2.61) | ‐0.01(‐0.06,0.02) | |
| SD RITUX IV | 6.17(0.39,134.40) | 5.35(0.40,39.89) | 0.11(‐0.02,0.74) | |
| SD ETN SC + MTX | 0.78(0.37,1.73) | 0.79(0.38,1.70) | 0.00(‐0.03,0.02) | |
| SD ADA SC + MTX | 1.10(0.26,6.30) | 1.09(0.28,5.77) | 0.00(‐0.05,0.09) | |
| SD INF IV + MTX | 2.30(0.52,10.85) | 2.22(0.53,9.35) | 0.03(‐0.02,0.17) | |
| SD ABA IV + MTX | 0.81(0.19,3.95) | 0.81(0.20,3.78) | 0.00(‐0.05,0.05) | |
| SD CERTO SC + MTX | 1.11(0.28,6.13) | 1.11(0.29,5.61) | 0.00(‐0.04,0.08) | |
| SD RITUX IV + MTX | 1.64(0.32,16.45) | 1.61(0.33,13.21) | 0.01(‐0.03,0.20) | |
| SD GOLI SC + MTX | 0.90(0.18,5.88) | 0.90(0.19,5.40) | 0.00(‐0.06,0.08) | |
| SD TOFA PO + MTX | 1.49(0.32,9.16) | 1.47(0.33,8.08) | 0.01(‐0.04,0.13) | |
| SD ABA SC + MTX | 0.44(0.09,2.63) | 0.45(0.09,2.56) | ‐0.01(‐0.06,0.03) | |
| SD TOCI IV + MTX | 0.96(0.20,6.07) | 0.96(0.21,5.69) | 0.00(‐0.05,0.08) | |
| SD ETN SC + DMARD | 1.90(0.34,11.43) | 1.86(0.36,10.27) | 0.02(‐0.04,0.11) | |
| SD CERTO SC + DMARD | 2.44(0.41,19.48) | 2.33(0.43,16.34) | 0.03(‐0.04,0.19) | |
| SD ADA SC + DMARD | 3.25(0.31,31.78) | 3.07(0.32,23.73) | 0.05(‐0.04,0.29) | |
| SD TOCI SC + DMARD | 7.75(0.69,93.28) | 6.45(0.70,45.67) | 0.14(‐0.01,0.58) | |
| LD ADA SC | 0.56(0.08,2.79) | 0.57(0.09,2.73) | ‐0.01(‐0.07,0.02) | |
| LD ETN SC | 1.93(0.41,9.68) | 1.88(0.43,8.58) | 0.02(‐0.03,0.14) | |
| LD TOCI IV | 0.58(0.09,3.58) | 0.59(0.09,3.44) | ‐0.01(‐0.06,0.04) | |
| LD RITUX IV + MTX | 1.48(0.29,15.74) | 1.46(0.30,12.57) | 0.01(‐0.04,0.20) | |
| LD ABA IV + MTX | 0.99(0.19,6.57) | 0.99(0.19,6.03) | 0.00(‐0.05,0.09) | |
| LD CERTO SC + MTX | 0.79(0.09,5.77) | 0.79(0.10,5.33) | 0.00(‐0.05,0.08) | |
| LD TOCI IV + MTX | 0.43(0.05,2.85) | 0.44(0.06,2.77) | ‐0.01(‐0.07,0.03) | |
| HD TOCI IV | 0.69(0.18,3.35) | 0.69(0.19,3.23) | ‐0.01(‐0.06,0.03) | |
| HD ADA SC | 0.58(0.09,3.10) | 0.59(0.10,3.02) | ‐0.01(‐0.07,0.02) | |
| HD GOLI SC | 0.48(0.03,4.58) | 0.49(0.03,4.33) | ‐0.01(‐0.06,0.06) | |
| HD TOCI IV + MTX | 0.94(0.24,4.81) | 0.95(0.25,4.59) | 0.00(‐0.05,0.06) | |
| HD GOLI SC + MTX | 1.30(0.26,8.54) | 1.29(0.27,7.57) | 0.01(‐0.04,0.12) | |
| HD TOFA PO + MTX | 1.34(0.27,8.65) | 1.33(0.28,7.71) | 0.01(‐0.04,0.11) | |
| HD CERTO SC + MTX | 1.21(0.26,7.19) | 1.20(0.27,6.53) | 0.00(‐0.04,0.10) | |
| HD INF IV + MTX | 2.43(0.52,12.82) | 2.33(0.54,10.65) | 0.03(‐0.02,0.19) | |
| HD TOCI IV + DMARD | 4.96(0.65,42.82) | 4.46(0.67,29.86) | 0.09(‐0.02,0.34) | |
| SD TOCI IV | SD ADA SC | 0.48(0.19,1.31) | 0.49(0.20,1.30) | ‐0.02(‐0.05,0.01) |
| SD CERTO SC | 1.43(0.32,7.10) | 1.41(0.33,6.07) | 0.02(‐0.04,0.14) | |
| SD TOC SC + PL IV | 0.34(0.10,1.17) | 0.35(0.11,1.16) | ‐0.03(‐0.06,0.00) | |
| SD RITUX IV | 3.65(0.28,85.75) | 3.29(0.30,22.52) | 0.09(‐0.04,0.72) | |
| SD ETN SC + MTX | 0.48(0.10,2.30) | 0.49(0.10,2.22) | ‐0.02(‐0.06,0.03) | |
| SD ADA SC + MTX | 0.70(0.14,3.36) | 0.71(0.15,3.11) | ‐0.01(‐0.05,0.07) | |
| SD INF IV + MTX | 1.47(0.30,6.43) | 1.44(0.31,5.46) | 0.02(‐0.04,0.15) | |
| SD ABA IV + MTX | 0.54(0.10,2.13) | 0.55(0.10,2.05) | ‐0.02(‐0.06,0.03) | |
| SD CERTO SC + MTX | 0.74(0.15,3.28) | 0.75(0.16,3.05) | ‐0.01(‐0.05,0.07) | |
| SD RITUX IV + MTX | 1.06(0.17,7.31) | 1.05(0.18,5.98) | 0.00(‐0.05,0.18) | |
| SD GOLI SC + MTX | 0.59(0.11,3.24) | 0.60(0.11,3.03) | ‐0.02(‐0.05,0.07) | |
| SD TOFA PO + MTX | 0.96(0.16,4.85) | 0.96(0.17,4.25) | 0.00(‐0.05,0.12) | |
| SD ABA SC + MTX | 0.30(0.04,1.36) | 0.31(0.05,1.35) | ‐0.03(‐0.07,0.01) | |
| SD TOCI IV + MTX | 0.62(0.13,3.12) | 0.63(0.13,2.91) | ‐0.01(‐0.05,0.06) | |
| SD ETN SC + DMARD | 1.20(0.46,3.11) | 1.19(0.47,2.88) | 0.01(‐0.03,0.08) | |
| SD CERTO SC + DMARD | 1.55(0.43,6.48) | 1.51(0.44,5.53) | 0.02(‐0.03,0.16) | |
| SD ADA SC + DMARD | 2.06(0.35,11.30) | 1.97(0.37,8.29) | 0.04(‐0.03,0.27) | |
| SD TOCI SC + DMARD | 4.83(0.61,35.37) | 4.13(0.62,15.62) | 0.13(‐0.02,0.56) | |
| LD ADA SC | 0.34(0.09,0.97) | 0.35(0.10,0.97) | ‐0.03(‐0.06,0.00) | |
| LD ETN SC | 1.21(0.22,7.27) | 1.20(0.23,6.17) | 0.01(‐0.05,0.15) | |
| LD TOCI IV | 0.36(0.07,1.79) | 0.37(0.07,1.74) | ‐0.02(‐0.06,0.03) | |
| LD RITUX IV + MTX | 0.97(0.16,7.03) | 0.97(0.17,5.65) | 0.00(‐0.05,0.19) | |
| LD ABA IV + MTX | 0.66(0.10,3.49) | 0.67(0.10,3.21) | ‐0.01(‐0.05,0.08) | |
| LD CERTO SC + MTX | 0.50(0.05,3.20) | 0.51(0.06,2.95) | ‐0.02(‐0.06,0.07) | |
| LD TOCI IV + MTX | 0.26(0.04,1.33) | 0.27(0.04,1.31) | ‐0.03(‐0.07,0.01) | |
| HD TOCI IV | 0.44(0.12,1.79) | 0.45(0.12,1.75) | ‐0.02(‐0.06,0.02) | |
| HD ADA SC | 0.36(0.11,1.05) | 0.37(0.12,1.05) | ‐0.02(‐0.06,0.00) | |
| HD GOLI SC | 0.29(0.02,2.64) | 0.30(0.02,2.49) | ‐0.03(‐0.06,0.05) | |
| HD TOCI IV + MTX | 0.60(0.16,2.47) | 0.61(0.16,2.37) | ‐0.01(‐0.05,0.04) | |
| HD GOLI SC + MTX | 0.83(0.14,4.49) | 0.84(0.15,4.05) | ‐0.01(‐0.05,0.10) | |
| HD TOFA PO + MTX | 0.87(0.15,4.22) | 0.87(0.16,3.79) | 0.00(‐0.05,0.10) | |
| HD CERTO SC + MTX | 0.79(0.15,4.15) | 0.79(0.16,3.78) | ‐0.01(‐0.05,0.09) | |
| HD INF IV + MTX | 1.59(0.28,7.28) | 1.55(0.29,5.97) | 0.02(‐0.04,0.17) | |
| HD TOCI IV + DMARD | 3.24(0.86,12.32) | 2.96(0.87,8.70) | 0.08(‐0.01,0.31) | |
| SD CERTO SC | SD TOCI IV | 3.02(0.55,15.80) | 2.89(0.56,13.66) | 0.04(‐0.02,0.16) |
| SD TOC SC + PL IV | 0.69(0.34,1.40) | 0.70(0.34,1.39) | ‐0.01(‐0.02,0.01) | |
| SD RITUX IV | 7.31(0.68,131.90) | 6.42(0.69,38.38) | 0.11(‐0.01,0.74) | |
| SD ETN SC + MTX | 0.96(0.21,5.03) | 0.96(0.22,4.78) | 0.00(‐0.03,0.05) | |
| SD ADA SC + MTX | 1.46(0.37,5.37) | 1.44(0.37,4.94) | 0.01(‐0.02,0.09) | |
| SD INF IV + MTX | 2.99(0.80,10.91) | 2.86(0.81,9.27) | 0.04(0.00,0.17) | |
| SD ABA IV + MTX | 1.09(0.26,3.56) | 1.09(0.26,3.43) | 0.00(‐0.02,0.04) | |
| SD CERTO SC + MTX | 1.50(0.41,5.06) | 1.48(0.41,4.72) | 0.01(‐0.02,0.08) | |
| SD RITUX IV + MTX | 2.24(0.45,11.73) | 2.18(0.46,9.67) | 0.02(‐0.01,0.19) | |
| SD GOLI SC + MTX | 1.17(0.28,5.58) | 1.16(0.29,5.11) | 0.00(‐0.02,0.08) | |
| SD TOFA PO + MTX | 1.99(0.44,8.07) | 1.95(0.44,7.06) | 0.02(‐0.02,0.13) | |
| SD ABA SC + MTX | 0.60(0.11,2.59) | 0.61(0.11,2.52) | ‐0.01(‐0.03,0.03) | |
| SD TOCI IV + MTX | 1.28(0.33,4.58) | 1.27(0.33,4.30) | 0.01(‐0.02,0.07) | |
| SD ETN SC + DMARD | 2.45(0.65,9.83) | 2.38(0.66,8.88) | 0.03(‐0.01,0.11) | |
| SD CERTO SC + DMARD | 3.15(0.70,17.46) | 3.02(0.71,14.55) | 0.04(‐0.01,0.18) | |
| SD ADA SC + DMARD | 4.44(0.56,28.99) | 4.15(0.57,21.07) | 0.06(‐0.01,0.29) | |
| SD TOCI SC + DMARD | 10.45(0.99,89.45) | 8.62(0.99,41.13) | 0.15(0.00,0.59) | |
| LD ADA SC | 0.71(0.13,2.55) | 0.71(0.13,2.51) | ‐0.01(‐0.03,0.02) | |
| LD ETN SC | 2.47(0.45,13.58) | 2.39(0.46,11.51) | 0.03(‐0.02,0.16) | |
| LD TOCI IV | 0.75(0.17,2.99) | 0.75(0.17,2.90) | 0.00(‐0.03,0.04) | |
| LD RITUX IV + MTX | 1.97(0.40,11.32) | 1.93(0.41,9.46) | 0.02(‐0.02,0.20) | |
| LD ABA IV + MTX | 1.35(0.25,5.66) | 1.34(0.26,5.20) | 0.01(‐0.02,0.09) | |
| LD CERTO SC + MTX | 1.01(0.13,5.92) | 1.01(0.14,5.40) | 0.00(‐0.03,0.09) | |
| LD TOCI IV + MTX | 0.53(0.10,2.50) | 0.53(0.10,2.44) | ‐0.01(‐0.03,0.03) | |
| HD TOCI IV | 0.89(0.34,2.41) | 0.89(0.34,2.35) | 0.00(‐0.02,0.02) | |
| HD ADA SC | 0.72(0.18,2.83) | 0.73(0.18,2.75) | ‐0.01(‐0.03,0.02) | |
| HD GOLI SC | 0.61(0.05,4.55) | 0.62(0.05,4.23) | ‐0.01(‐0.03,0.07) | |
| HD TOCI IV + MTX | 1.24(0.42,3.68) | 1.23(0.43,3.51) | 0.00(‐0.02,0.05) | |
| HD GOLI SC + MTX | 1.66(0.37,7.62) | 1.64(0.38,6.67) | 0.01(‐0.02,0.12) | |
| HD TOFA PO + MTX | 1.74(0.42,7.29) | 1.71(0.42,6.43) | 0.01(‐0.02,0.12) | |
| HD CERTO SC + MTX | 1.60(0.39,6.87) | 1.58(0.40,6.15) | 0.01(‐0.02,0.10) | |
| HD INF IV + MTX | 3.18(0.76,12.25) | 3.03(0.76,10.30) | 0.04(0.00,0.18) | |
| HD TOCI IV + DMARD | 6.64(1.26,36.78) | 5.89(1.25,25.18) | 0.10(0.01,0.34) | |
| SD TOC SC + PL IV | SD CERTO SC | 0.23(0.04,1.44) | 0.24(0.04,1.43) | ‐0.04(‐0.16,0.01) |
| SD RITUX IV | 2.44(0.14,76.28) | 2.22(0.16,21.26) | 0.07(‐0.10,0.71) | |
| SD ETN SC + MTX | 0.34(0.04,2.10) | 0.35(0.05,2.04) | ‐0.04(‐0.16,0.03) | |
| SD ADA SC + MTX | 0.48(0.06,3.27) | 0.49(0.07,3.07) | ‐0.03(‐0.15,0.06) | |
| SD INF IV + MTX | 0.98(0.11,7.46) | 0.98(0.12,6.43) | 0.00(‐0.13,0.15) | |
| SD ABA IV + MTX | 0.36(0.04,2.42) | 0.38(0.04,2.34) | ‐0.03(‐0.16,0.03) | |
| SD CERTO SC + MTX | 0.50(0.06,3.74) | 0.52(0.07,3.48) | ‐0.03(‐0.15,0.07) | |
| SD RITUX IV + MTX | 0.72(0.09,6.72) | 0.73(0.10,5.65) | ‐0.01(‐0.14,0.16) | |
| SD GOLI SC + MTX | 0.39(0.04,3.32) | 0.41(0.05,3.05) | ‐0.03(‐0.16,0.06) | |
| SD TOFA PO + MTX | 0.65(0.08,5.01) | 0.66(0.09,4.45) | ‐0.02(‐0.15,0.11) | |
| SD ABA SC + MTX | 0.21(0.02,1.54) | 0.22(0.02,1.51) | ‐0.04(‐0.17,0.01) | |
| SD TOCI IV + MTX | 0.45(0.05,2.95) | 0.46(0.06,2.76) | ‐0.03(‐0.16,0.05) | |
| SD ETN SC + DMARD | 0.83(0.15,4.44) | 0.84(0.17,4.10) | ‐0.01(‐0.13,0.09) | |
| SD CERTO SC + DMARD | 1.09(0.16,7.46) | 1.09(0.18,6.30) | 0.00(‐0.13,0.15) | |
| SD ADA SC + DMARD | 1.40(0.16,12.37) | 1.36(0.18,9.47) | 0.02(‐0.11,0.26) | |
| SD TOCI SC + DMARD | 3.30(0.29,36.82) | 2.86(0.32,17.86) | 0.11(‐0.08,0.55) | |
| LD ADA SC | 0.23(0.03,1.33) | 0.24(0.04,1.32) | ‐0.04(‐0.17,0.01) | |
| LD ETN SC | 0.83(0.10,6.50) | 0.84(0.11,5.51) | ‐0.01(‐0.14,0.14) | |
| LD TOCI IV | 0.24(0.03,1.92) | 0.25(0.04,1.86) | ‐0.04(‐0.16,0.02) | |
| LD RITUX IV + MTX | 0.70(0.08,5.92) | 0.71(0.09,5.04) | ‐0.01(‐0.14,0.16) | |
| LD ABA IV + MTX | 0.45(0.04,3.83) | 0.46(0.05,3.55) | ‐0.03(‐0.15,0.07) | |
| LD CERTO SC + MTX | 0.33(0.02,3.24) | 0.35(0.03,3.02) | ‐0.03(‐0.16,0.06) | |
| LD TOCI IV + MTX | 0.18(0.02,1.28) | 0.19(0.02,1.27) | ‐0.04(‐0.17,0.01) | |
| HD TOCI IV | 0.31(0.05,1.88) | 0.32(0.05,1.84) | ‐0.04(‐0.16,0.02) | |
| HD ADA SC | 0.25(0.03,1.38) | 0.26(0.04,1.37) | ‐0.04(‐0.16,0.01) | |
| HD GOLI SC | 0.19(0.01,2.56) | 0.21(0.01,2.46) | ‐0.04(‐0.17,0.04) | |
| HD TOCI IV + MTX | 0.41(0.06,2.64) | 0.43(0.07,2.53) | ‐0.03(‐0.15,0.04) | |
| HD GOLI SC + MTX | 0.57(0.06,4.86) | 0.59(0.07,4.36) | ‐0.02(‐0.15,0.10) | |
| HD TOFA PO + MTX | 0.59(0.07,4.29) | 0.60(0.08,3.94) | ‐0.02(‐0.15,0.10) | |
| HD CERTO SC + MTX | 0.55(0.06,4.54) | 0.57(0.07,4.12) | ‐0.02(‐0.15,0.09) | |
| HD INF IV + MTX | 1.05(0.11,8.22) | 1.04(0.13,6.95) | 0.00(‐0.13,0.17) | |
| HD TOCI IV + DMARD | 2.17(0.30,15.51) | 2.02(0.33,11.21) | 0.06(‐0.09,0.30) | |
| SD RITUX IV | SD TOC SC + PL IV | 10.51(0.89,207.80) | 9.09(0.89,65.09) | 0.12(0.00,0.74) |
| SD ETN SC + MTX | 1.39(0.27,8.22) | 1.38(0.28,7.82) | 0.00(‐0.03,0.06) | |
| SD ADA SC + MTX | 2.09(0.45,9.00) | 2.05(0.45,8.36) | 0.01(‐0.01,0.09) | |
| SD INF IV + MTX | 4.26(0.98,18.60) | 4.05(0.98,16.17) | 0.04(0.00,0.18) | |
| SD ABA IV + MTX | 1.56(0.31,6.10) | 1.55(0.32,5.83) | 0.01(‐0.02,0.05) | |
| SD CERTO SC + MTX | 2.15(0.51,8.92) | 2.11(0.52,8.35) | 0.01(‐0.01,0.09) | |
| SD RITUX IV + MTX | 3.24(0.57,18.99) | 3.12(0.57,15.36) | 0.03(‐0.01,0.20) | |
| SD GOLI SC + MTX | 1.69(0.35,9.56) | 1.67(0.36,8.67) | 0.01(‐0.02,0.09) | |
| SD TOFA PO + MTX | 2.90(0.57,13.65) | 2.81(0.58,12.22) | 0.02(‐0.01,0.14) | |
| SD ABA SC + MTX | 0.86(0.14,4.47) | 0.86(0.15,4.31) | 0.00(‐0.03,0.03) | |
| SD TOCI IV + MTX | 1.88(0.39,7.68) | 1.85(0.40,7.21) | 0.01(‐0.01,0.08) | |
| SD ETN SC + DMARD | 3.50(0.79,16.67) | 3.37(0.80,15.21) | 0.03(‐0.01,0.12) | |
| SD CERTO SC + DMARD | 4.58(0.91,28.39) | 4.34(0.91,23.91) | 0.05(0.00,0.19) | |
| SD ADA SC + DMARD | 6.27(0.70,48.05) | 5.77(0.70,35.39) | 0.06(‐0.01,0.30) | |
| SD TOCI SC + DMARD | 14.73(1.30,149.20) | 12.08(1.29,70.17) | 0.15(0.01,0.59) | |
| LD ADA SC | 1.00(0.16,4.56) | 1.00(0.17,4.44) | 0.00(‐0.03,0.03) | |
| LD ETN SC | 3.54(0.57,22.62) | 3.39(0.58,19.49) | 0.03(‐0.01,0.17) | |
| LD TOCI IV | 1.07(0.21,5.14) | 1.07(0.22,4.96) | 0.00(‐0.02,0.05) | |
| LD RITUX IV + MTX | 2.86(0.49,18.72) | 2.77(0.49,15.58) | 0.02(‐0.01,0.21) | |
| LD ABA IV + MTX | 1.91(0.31,10.00) | 1.88(0.32,9.23) | 0.01(‐0.02,0.09) | |
| LD CERTO SC + MTX | 1.45(0.17,9.86) | 1.44(0.17,8.96) | 0.01(‐0.02,0.09) | |
| LD TOCI IV + MTX | 0.76(0.13,4.19) | 0.76(0.13,4.05) | 0.00(‐0.03,0.03) | |
| HD TOCI IV | 1.29(0.39,4.35) | 1.28(0.40,4.25) | 0.00(‐0.02,0.03) | |
| HD ADA SC | 1.03(0.23,4.93) | 1.03(0.23,4.79) | 0.00(‐0.03,0.03) | |
| HD GOLI SC | 0.87(0.07,7.33) | 0.87(0.07,6.80) | 0.00(‐0.03,0.07) | |
| HD TOCI IV + MTX | 1.79(0.50,6.47) | 1.77(0.50,6.14) | 0.01(‐0.01,0.06) | |
| HD GOLI SC + MTX | 2.42(0.48,13.41) | 2.36(0.48,11.96) | 0.02(‐0.01,0.12) | |
| HD TOFA PO + MTX | 2.50(0.51,12.15) | 2.44(0.52,11.00) | 0.02(‐0.01,0.13) | |
| HD CERTO SC + MTX | 2.34(0.49,11.62) | 2.29(0.49,10.60) | 0.02(‐0.01,0.11) | |
| HD INF IV + MTX | 4.61(0.93,20.76) | 4.35(0.93,17.43) | 0.05(0.00,0.19) | |
| HD TOCI IV + DMARD | 9.62(1.52,58.01) | 8.47(1.50,42.43) | 0.10(0.01,0.34) | |
| SD ETN SC + MTX | SD RITUX IV | 0.13(0.01,2.02) | 0.15(0.02,1.98) | ‐0.11(‐0.74,0.01) |
| SD ADA SC + MTX | 0.18(0.01,2.01) | 0.22(0.04,1.97) | ‐0.10(‐0.70,0.02) | |
| SD INF IV + MTX | 0.39(0.03,4.05) | 0.44(0.07,3.82) | ‐0.07(‐0.66,0.06) | |
| SD ABA IV + MTX | 0.14(0.01,1.59) | 0.16(0.02,1.57) | ‐0.11(‐0.72,0.01) | |
| SD CERTO SC + MTX | 0.19(0.01,2.30) | 0.22(0.04,2.26) | ‐0.10(‐0.70,0.02) | |
| SD RITUX IV + MTX | 0.29(0.02,2.48) | 0.33(0.06,2.36) | ‐0.08(‐0.66,0.04) | |
| SD GOLI SC + MTX | 0.16(0.01,1.84) | 0.19(0.02,1.81) | ‐0.10(‐0.72,0.01) | |
| SD TOFA PO + MTX | 0.25(0.02,3.22) | 0.29(0.04,3.10) | ‐0.09(‐0.68,0.04) | |
| SD ABA SC + MTX | 0.08(0.00,1.02) | 0.09(0.01,1.02) | ‐0.12(‐0.74,0.00) | |
| SD TOCI IV + MTX | 0.17(0.01,1.79) | 0.19(0.03,1.75) | ‐0.10(‐0.72,0.01) | |
| SD ETN SC + DMARD | 0.33(0.01,6.01) | 0.36(0.04,5.45) | ‐0.08(‐0.72,0.07) | |
| SD CERTO SC + DMARD | 0.46(0.01,8.38) | 0.50(0.05,7.37) | ‐0.06(‐0.71,0.13) | |
| SD ADA SC + DMARD | 0.58(0.01,13.09) | 0.63(0.04,10.38) | ‐0.04(‐0.70,0.22) | |
| SD TOCI SC + DMARD | 1.28(0.03,35.73) | 1.22(0.09,20.39) | 0.02(‐0.64,0.48) | |
| LD ADA SC | 0.10(0.00,1.35) | 0.11(0.01,1.34) | ‐0.12(‐0.75,0.00) | |
| LD ETN SC | 0.34(0.01,6.22) | 0.38(0.03,5.53) | ‐0.08(‐0.72,0.10) | |
| LD TOCI IV | 0.10(0.00,1.21) | 0.12(0.01,1.20) | ‐0.11(‐0.74,0.00) | |
| LD RITUX IV + MTX | 0.26(0.02,2.38) | 0.30(0.06,2.28) | ‐0.09(‐0.65,0.03) | |
| LD ABA IV + MTX | 0.18(0.01,2.30) | 0.21(0.02,2.23) | ‐0.10(‐0.72,0.02) | |
| LD CERTO SC + MTX | 0.13(0.01,1.81) | 0.16(0.02,1.75) | ‐0.10(‐0.72,0.01) | |
| LD TOCI IV + MTX | 0.07(0.00,0.93) | 0.09(0.01,0.93) | ‐0.12(‐0.74,0.00) | |
| HD TOCI IV | 0.12(0.01,1.27) | 0.14(0.02,1.26) | ‐0.11(‐0.73,0.00) | |
| HD ADA SC | 0.10(0.00,1.35) | 0.11(0.01,1.34) | ‐0.11(‐0.75,0.00) | |
| HD GOLI SC | 0.08(0.00,1.34) | 0.09(0.01,1.33) | ‐0.11(‐0.74,0.01) | |
| HD TOCI IV + MTX | 0.16(0.01,1.74) | 0.19(0.03,1.72) | ‐0.10(‐0.72,0.01) | |
| HD GOLI SC + MTX | 0.23(0.01,2.71) | 0.26(0.03,2.60) | ‐0.09(‐0.70,0.03) | |
| HD TOFA PO + MTX | 0.22(0.01,2.86) | 0.26(0.04,2.80) | ‐0.09(‐0.69,0.03) | |
| HD CERTO SC + MTX | 0.21(0.01,2.41) | 0.24(0.04,2.34) | ‐0.10(‐0.70,0.03) | |
| HD INF IV + MTX | 0.41(0.03,4.56) | 0.45(0.07,4.27) | ‐0.06(‐0.65,0.07) | |
| HD TOCI IV + DMARD | 0.87(0.03,19.65) | 0.89(0.09,14.68) | ‐0.01(‐0.65,0.27) | |
| SD ADA SC + MTX | SD ETN SC + MTX | 1.45(0.32,8.40) | 1.44(0.33,7.73) | 0.01(‐0.04,0.09) |
| SD INF IV + MTX | 2.91(0.65,14.89) | 2.80(0.66,12.53) | 0.03(‐0.02,0.17) | |
| SD ABA IV + MTX | 1.03(0.25,5.18) | 1.03(0.25,4.95) | 0.00(‐0.04,0.05) | |
| SD CERTO SC + MTX | 1.48(0.36,7.67) | 1.46(0.37,7.09) | 0.01(‐0.04,0.08) | |
| SD RITUX IV + MTX | 2.12(0.39,19.71) | 2.06(0.40,16.29) | 0.02(‐0.03,0.20) | |
| SD GOLI SC + MTX | 1.16(0.24,7.64) | 1.16(0.25,7.09) | 0.00(‐0.04,0.08) | |
| SD TOFA PO + MTX | 1.96(0.39,10.92) | 1.92(0.40,9.63) | 0.02(‐0.03,0.14) | |
| SD ABA SC + MTX | 0.57(0.12,3.64) | 0.57(0.12,3.53) | ‐0.01(‐0.05,0.03) | |
| SD TOCI IV + MTX | 1.25(0.23,7.97) | 1.24(0.24,7.49) | 0.00(‐0.04,0.08) | |
| SD ETN SC + DMARD | 2.41(0.41,17.16) | 2.35(0.42,15.45) | 0.03(‐0.03,0.11) | |
| SD CERTO SC + DMARD | 3.14(0.50,28.53) | 2.99(0.52,23.65) | 0.04(‐0.02,0.19) | |
| SD ADA SC + DMARD | 4.12(0.40,44.83) | 3.85(0.41,33.49) | 0.06(‐0.03,0.29) | |
| SD TOCI SC + DMARD | 9.94(0.85,118.40) | 8.15(0.85,60.89) | 0.15(‐0.01,0.59) | |
| LD ADA SC | 0.73(0.11,3.98) | 0.73(0.11,3.89) | ‐0.01(‐0.05,0.02) | |
| LD ETN SC | 2.48(0.45,14.38) | 2.40(0.46,12.84) | 0.03(‐0.02,0.15) | |
| LD TOCI IV | 0.75(0.10,5.00) | 0.75(0.11,4.75) | 0.00(‐0.05,0.04) | |
| LD RITUX IV + MTX | 1.89(0.34,18.95) | 1.85(0.35,15.39) | 0.02(‐0.03,0.20) | |
| LD ABA IV + MTX | 1.29(0.23,8.26) | 1.28(0.24,7.52) | 0.01(‐0.04,0.09) | |
| LD CERTO SC + MTX | 1.02(0.11,7.45) | 1.02(0.11,6.81) | 0.00(‐0.05,0.08) | |
| LD TOCI IV + MTX | 0.55(0.06,3.54) | 0.56(0.06,3.43) | ‐0.01(‐0.06,0.03) | |
| HD TOCI IV | 0.89(0.22,4.38) | 0.89(0.23,4.24) | 0.00(‐0.05,0.04) | |
| HD ADA SC | 0.74(0.11,4.66) | 0.75(0.11,4.55) | 0.00(‐0.06,0.03) | |
| HD GOLI SC | 0.62(0.04,5.74) | 0.62(0.04,5.46) | ‐0.01(‐0.06,0.07) | |
| HD TOCI IV + MTX | 1.21(0.28,6.42) | 1.21(0.29,6.10) | 0.00(‐0.04,0.06) | |
| HD GOLI SC + MTX | 1.68(0.29,10.64) | 1.65(0.30,9.52) | 0.01(‐0.04,0.12) | |
| HD TOFA PO + MTX | 1.75(0.31,10.93) | 1.72(0.32,9.88) | 0.01(‐0.04,0.12) | |
| HD CERTO SC + MTX | 1.59(0.32,8.88) | 1.57(0.33,8.04) | 0.01(‐0.04,0.10) | |
| HD INF IV + MTX | 3.15(0.58,16.51) | 3.01(0.59,13.91) | 0.04(‐0.02,0.19) | |
| HD TOCI IV + DMARD | 6.42(0.89,65.47) | 5.72(0.89,44.98) | 0.10(0.00,0.34) | |
| SD INF IV + MTX | SD ADA SC + MTX | 2.10(0.70,5.68) | 2.02(0.71,5.25) | 0.03(‐0.02,0.13) |
| SD ABA IV + MTX | 0.74(0.25,1.97) | 0.75(0.26,1.94) | ‐0.01(‐0.06,0.02) | |
| SD CERTO SC + MTX | 1.03(0.38,2.80) | 1.03(0.40,2.71) | 0.00(‐0.04,0.04) | |
| SD RITUX IV + MTX | 1.51(0.42,6.65) | 1.48(0.44,5.93) | 0.01(‐0.03,0.14) | |
| SD GOLI SC + MTX | 0.81(0.22,3.21) | 0.82(0.23,3.03) | 0.00(‐0.06,0.06) | |
| SD TOFA PO + MTX | 1.35(0.58,3.33) | 1.33(0.59,3.16) | 0.01(‐0.02,0.08) | |
| SD ABA SC + MTX | 0.41(0.11,1.49) | 0.42(0.11,1.48) | ‐0.01(‐0.08,0.01) | |
| SD TOCI IV + MTX | 0.88(0.21,3.51) | 0.89(0.22,3.38) | 0.00(‐0.06,0.05) | |
| SD ETN SC + DMARD | 1.70(0.27,12.24) | 1.67(0.29,11.07) | 0.02(‐0.07,0.11) | |
| SD CERTO SC + DMARD | 2.20(0.32,20.20) | 2.12(0.34,16.83) | 0.03(‐0.07,0.18) | |
| SD ADA SC + DMARD | 2.99(0.26,30.76) | 2.82(0.28,22.84) | 0.05(‐0.06,0.29) | |
| SD TOCI SC + DMARD | 7.15(0.47,76.37) | 5.94(0.50,39.68) | 0.14(‐0.04,0.58) | |
| LD ADA SC | 0.50(0.07,2.67) | 0.51(0.07,2.62) | ‐0.01(‐0.10,0.02) | |
| LD ETN SC | 1.73(0.22,12.01) | 1.69(0.23,10.59) | 0.02(‐0.07,0.15) | |
| LD TOCI IV | 0.53(0.10,2.15) | 0.54(0.11,2.11) | ‐0.01(‐0.09,0.02) | |
| LD RITUX IV + MTX | 1.40(0.34,6.80) | 1.37(0.35,6.07) | 0.01(‐0.03,0.13) | |
| LD ABA IV + MTX | 0.92(0.25,3.29) | 0.92(0.26,3.12) | 0.00(‐0.05,0.06) | |
| LD CERTO SC + MTX | 0.71(0.11,3.53) | 0.71(0.11,3.34) | ‐0.01(‐0.07,0.06) | |
| LD TOCI IV + MTX | 0.37(0.06,1.87) | 0.38(0.06,1.85) | ‐0.02(‐0.09,0.01) | |
| HD TOCI IV | 0.63(0.22,1.77) | 0.64(0.24,1.75) | ‐0.01(‐0.08,0.01) | |
| HD ADA SC | 0.51(0.07,2.96) | 0.52(0.08,2.90) | ‐0.01(‐0.10,0.02) | |
| HD GOLI SC | 0.42(0.04,2.90) | 0.43(0.04,2.74) | ‐0.01(‐0.08,0.05) | |
| HD TOCI IV + MTX | 0.86(0.27,2.83) | 0.86(0.29,2.75) | 0.00(‐0.07,0.03) | |
| HD GOLI SC + MTX | 1.16(0.36,4.50) | 1.16(0.37,4.11) | 0.00(‐0.04,0.09) | |
| HD TOFA PO + MTX | 1.20(0.52,3.16) | 1.19(0.53,3.01) | 0.00(‐0.02,0.07) | |
| HD CERTO SC + MTX | 1.12(0.36,3.67) | 1.11(0.37,3.43) | 0.00(‐0.04,0.07) | |
| HD INF IV + MTX | 2.20(0.66,7.04) | 2.11(0.67,6.33) | 0.03(‐0.02,0.15) | |
| HD TOCI IV + DMARD | 4.49(0.61,41.34) | 4.04(0.63,29.17) | 0.09(‐0.03,0.33) | |
| SD ABA IV + MTX | SD INF IV + MTX | 0.35(0.14,0.85) | 0.37(0.16,0.86) | ‐0.03(‐0.14,0.00) |
| SD CERTO SC + MTX | 0.50(0.18,1.36) | 0.52(0.20,1.34) | ‐0.03(‐0.13,0.01) | |
| SD RITUX IV + MTX | 0.71(0.19,3.30) | 0.73(0.21,2.91) | ‐0.01(‐0.11,0.12) | |
| SD GOLI SC + MTX | 0.39(0.12,1.47) | 0.41(0.13,1.43) | ‐0.03(‐0.14,0.02) | |
| SD TOFA PO + MTX | 0.65(0.21,2.03) | 0.66(0.23,1.93) | ‐0.02(‐0.11,0.05) | |
| SD ABA SC + MTX | 0.20(0.06,0.64) | 0.21(0.07,0.65) | ‐0.04(‐0.16,‐0.01) | |
| SD TOCI IV + MTX | 0.43(0.10,1.71) | 0.45(0.11,1.66) | ‐0.03(‐0.15,0.02) | |
| SD ETN SC + DMARD | 0.80(0.14,5.44) | 0.81(0.16,4.95) | ‐0.01(‐0.15,0.09) | |
| SD CERTO SC + DMARD | 1.01(0.16,11.39) | 1.01(0.19,9.71) | 0.00(‐0.14,0.16) | |
| SD ADA SC + DMARD | 1.43(0.13,16.55) | 1.39(0.15,12.63) | 0.02(‐0.14,0.26) | |
| SD TOCI SC + DMARD | 3.44(0.27,40.63) | 2.93(0.30,19.51) | 0.11(‐0.10,0.54) | |
| LD ADA SC | 0.24(0.03,1.37) | 0.25(0.04,1.36) | ‐0.04(‐0.18,0.01) | |
| LD ETN SC | 0.81(0.13,5.80) | 0.82(0.15,4.92) | ‐0.01(‐0.14,0.13) | |
| LD TOCI IV | 0.26(0.05,1.03) | 0.27(0.06,1.03) | ‐0.04(‐0.16,0.00) | |
| LD RITUX IV + MTX | 0.68(0.15,3.26) | 0.69(0.17,2.87) | ‐0.02(‐0.11,0.12) | |
| LD ABA IV + MTX | 0.44(0.13,1.51) | 0.46(0.14,1.48) | ‐0.03(‐0.13,0.02) | |
| LD CERTO SC + MTX | 0.33(0.06,1.63) | 0.35(0.06,1.57) | ‐0.03(‐0.14,0.03) | |
| LD TOCI IV + MTX | 0.18(0.03,0.95) | 0.19(0.03,0.95) | ‐0.05(‐0.17,0.00) | |
| HD TOCI IV | 0.30(0.11,0.84) | 0.32(0.12,0.84) | ‐0.04(‐0.16,0.00) | |
| HD ADA SC | 0.24(0.04,1.50) | 0.26(0.05,1.48) | ‐0.04(‐0.18,0.01) | |
| HD GOLI SC | 0.20(0.02,1.34) | 0.22(0.02,1.30) | ‐0.04(‐0.16,0.02) | |
| HD TOCI IV + MTX | 0.41(0.13,1.38) | 0.43(0.14,1.36) | ‐0.03(‐0.15,0.01) | |
| HD GOLI SC + MTX | 0.56(0.17,2.17) | 0.58(0.19,2.02) | ‐0.02(‐0.12,0.05) | |
| HD TOFA PO + MTX | 0.58(0.19,1.92) | 0.60(0.21,1.83) | ‐0.02(‐0.11,0.04) | |
| HD CERTO SC + MTX | 0.54(0.17,1.71) | 0.55(0.19,1.65) | ‐0.02(‐0.12,0.03) | |
| HD INF IV + MTX | 1.08(0.49,2.25) | 1.07(0.51,2.11) | 0.00(‐0.05,0.07) | |
| HD TOCI IV + DMARD | 2.19(0.29,22.07) | 2.04(0.32,15.50) | 0.06(‐0.11,0.31) | |
| SD CERTO SC + MTX | SD ABA IV + MTX | 1.40(0.57,3.57) | 1.39(0.57,3.42) | 0.01(‐0.02,0.06) |
| SD RITUX IV + MTX | 1.99(0.55,9.38) | 1.94(0.56,8.14) | 0.02(‐0.02,0.18) | |
| SD GOLI SC + MTX | 1.14(0.32,4.03) | 1.13(0.33,3.79) | 0.00(‐0.03,0.07) | |
| SD TOFA PO + MTX | 1.84(0.64,5.70) | 1.80(0.65,5.35) | 0.02(‐0.01,0.10) | |
| SD ABA SC + MTX | 0.55(0.24,1.27) | 0.56(0.25,1.26) | ‐0.01(‐0.04,0.01) | |
| SD TOCI IV + MTX | 1.22(0.31,4.69) | 1.21(0.32,4.49) | 0.00(‐0.03,0.06) | |
| SD ETN SC + DMARD | 2.25(0.43,16.91) | 2.18(0.45,15.36) | 0.02(‐0.03,0.11) | |
| SD CERTO SC + DMARD | 2.90(0.51,33.96) | 2.77(0.53,28.74) | 0.04(‐0.02,0.19) | |
| SD ADA SC + DMARD | 4.01(0.36,50.25) | 3.74(0.38,37.99) | 0.06(‐0.03,0.29) | |
| SD TOCI SC + DMARD | 9.66(0.78,109.60) | 7.90(0.79,58.74) | 0.15(‐0.01,0.58) | |
| LD ADA SC | 0.67(0.09,4.03) | 0.67(0.09,3.94) | ‐0.01(‐0.06,0.02) | |
| LD ETN SC | 2.30(0.36,17.41) | 2.23(0.38,14.95) | 0.02(‐0.03,0.16) | |
| LD TOCI IV | 0.73(0.14,2.85) | 0.73(0.14,2.78) | ‐0.01(‐0.05,0.03) | |
| LD RITUX IV + MTX | 1.90(0.46,9.12) | 1.85(0.47,8.10) | 0.02(‐0.02,0.17) | |
| LD ABA IV + MTX | 1.23(0.45,3.65) | 1.23(0.45,3.49) | 0.00(‐0.02,0.07) | |
| LD CERTO SC + MTX | 0.95(0.15,4.55) | 0.95(0.16,4.29) | 0.00(‐0.04,0.07) | |
| LD TOCI IV + MTX | 0.51(0.08,2.66) | 0.52(0.08,2.62) | ‐0.01(‐0.05,0.02) | |
| HD TOCI IV | 0.84(0.32,2.34) | 0.84(0.34,2.31) | 0.00(‐0.04,0.02) | |
| HD ADA SC | 0.68(0.12,4.34) | 0.69(0.13,4.24) | ‐0.01(‐0.06,0.02) | |
| HD GOLI SC | 0.57(0.05,3.42) | 0.58(0.05,3.20) | ‐0.01(‐0.05,0.06) | |
| HD TOCI IV + MTX | 1.16(0.41,3.87) | 1.15(0.42,3.77) | 0.00(‐0.03,0.04) | |
| HD GOLI SC + MTX | 1.56(0.52,5.99) | 1.54(0.53,5.36) | 0.01(‐0.02,0.10) | |
| HD TOFA PO + MTX | 1.62(0.57,5.30) | 1.59(0.58,4.92) | 0.01(‐0.01,0.09) | |
| HD CERTO SC + MTX | 1.53(0.50,4.70) | 1.51(0.51,4.38) | 0.01(‐0.02,0.08) | |
| HD INF IV + MTX | 3.03(1.06,8.79) | 2.87(1.06,7.86) | 0.04(0.00,0.16) | |
| HD TOCI IV + DMARD | 6.08(0.88,65.01) | 5.42(0.88,47.28) | 0.09(0.00,0.34) | |
| SD RITUX IV + MTX | SD CERTO SC + MTX | 1.44(0.39,6.06) | 1.42(0.40,5.29) | 0.01(‐0.03,0.15) |
| SD GOLI SC + MTX | 0.81(0.24,2.77) | 0.82(0.25,2.60) | 0.00(‐0.05,0.05) | |
| SD TOFA PO + MTX | 1.30(0.45,3.97) | 1.28(0.46,3.72) | 0.01(‐0.03,0.09) | |
| SD ABA SC + MTX | 0.39(0.11,1.39) | 0.40(0.12,1.37) | ‐0.02(‐0.08,0.01) | |
| SD TOCI IV + MTX | 0.86(0.20,3.23) | 0.87(0.21,3.11) | 0.00(‐0.06,0.05) | |
| SD ETN SC + DMARD | 1.63(0.27,10.75) | 1.60(0.30,9.88) | 0.02(‐0.07,0.10) | |
| SD CERTO SC + DMARD | 2.00(0.34,20.65) | 1.93(0.36,17.12) | 0.03(‐0.06,0.18) | |
| SD ADA SC + DMARD | 2.91(0.24,31.58) | 2.73(0.26,23.67) | 0.05(‐0.06,0.28) | |
| SD TOCI SC + DMARD | 6.97(0.49,74.76) | 5.73(0.52,39.56) | 0.14(‐0.04,0.57) | |
| LD ADA SC | 0.48(0.06,2.60) | 0.48(0.07,2.56) | ‐0.01(‐0.09,0.02) | |
| LD ETN SC | 1.66(0.22,10.92) | 1.63(0.23,9.61) | 0.02(‐0.07,0.15) | |
| LD TOCI IV | 0.51(0.10,1.96) | 0.52(0.11,1.92) | ‐0.01(‐0.08,0.02) | |
| LD RITUX IV + MTX | 1.33(0.35,5.87) | 1.31(0.36,5.31) | 0.01(‐0.03,0.15) | |
| LD ABA IV + MTX | 0.88(0.25,2.99) | 0.89(0.26,2.87) | 0.00(‐0.05,0.05) | |
| LD CERTO SC + MTX | 0.68(0.13,2.60) | 0.69(0.13,2.46) | ‐0.01(‐0.06,0.05) | |
| LD TOCI IV + MTX | 0.36(0.05,1.75) | 0.37(0.06,1.73) | ‐0.02(‐0.09,0.01) | |
| HD TOCI IV | 0.60(0.23,1.57) | 0.61(0.24,1.55) | ‐0.01(‐0.07,0.01) | |
| HD ADA SC | 0.49(0.08,2.82) | 0.50(0.09,2.77) | ‐0.01(‐0.09,0.02) | |
| HD GOLI SC | 0.40(0.04,2.39) | 0.41(0.04,2.27) | ‐0.01(‐0.08,0.04) | |
| HD TOCI IV + MTX | 0.84(0.29,2.45) | 0.84(0.30,2.40) | 0.00(‐0.06,0.03) | |
| HD GOLI SC + MTX | 1.13(0.36,3.85) | 1.12(0.38,3.52) | 0.00(‐0.04,0.08) | |
| HD TOFA PO + MTX | 1.17(0.39,3.71) | 1.16(0.40,3.46) | 0.00(‐0.03,0.07) | |
| HD CERTO SC + MTX | 1.08(0.48,2.41) | 1.07(0.49,2.30) | 0.00(‐0.03,0.05) | |
| HD INF IV + MTX | 2.13(0.70,6.78) | 2.05(0.71,6.14) | 0.03(‐0.01,0.15) | |
| HD TOCI IV + DMARD | 4.33(0.60,39.11) | 3.90(0.62,28.12) | 0.08(‐0.03,0.33) | |
| SD GOLI SC + MTX | SD RITUX IV + MTX | 0.54(0.10,2.49) | 0.55(0.12,2.40) | ‐0.02(‐0.16,0.04) |
| SD TOFA PO + MTX | 0.89(0.21,3.52) | 0.90(0.23,3.36) | 0.00(‐0.13,0.06) | |
| SD ABA SC + MTX | 0.27(0.05,1.32) | 0.28(0.06,1.31) | ‐0.03(‐0.20,0.00) | |
| SD TOCI IV + MTX | 0.60(0.10,2.89) | 0.62(0.11,2.78) | ‐0.01(‐0.16,0.03) | |
| SD ETN SC + DMARD | 1.15(0.13,9.29) | 1.14(0.15,8.49) | 0.01(‐0.18,0.10) | |
| SD CERTO SC + DMARD | 1.42(0.14,15.13) | 1.39(0.17,12.81) | 0.02(‐0.17,0.17) | |
| SD ADA SC + DMARD | 2.07(0.11,22.08) | 1.97(0.14,17.07) | 0.04(‐0.17,0.27) | |
| SD TOCI SC + DMARD | 4.77(0.27,60.57) | 3.99(0.30,30.37) | 0.12(‐0.13,0.56) | |
| LD ADA SC | 0.33(0.03,2.14) | 0.35(0.04,2.10) | ‐0.03(‐0.21,0.01) | |
| LD ETN SC | 1.11(0.11,9.72) | 1.10(0.13,8.32) | 0.00(‐0.17,0.14) | |
| LD TOCI IV | 0.35(0.05,1.74) | 0.36(0.05,1.72) | ‐0.03(‐0.19,0.01) | |
| LD RITUX IV + MTX | 0.91(0.28,2.83) | 0.91(0.29,2.67) | 0.00(‐0.08,0.07) | |
| LD ABA IV + MTX | 0.61(0.11,2.71) | 0.62(0.12,2.60) | ‐0.01(‐0.17,0.04) | |
| LD CERTO SC + MTX | 0.46(0.05,2.78) | 0.48(0.05,2.65) | ‐0.02(‐0.18,0.04) | |
| LD TOCI IV + MTX | 0.25(0.03,1.44) | 0.26(0.03,1.43) | ‐0.03(‐0.20,0.01) | |
| HD TOCI IV | 0.42(0.09,1.47) | 0.43(0.11,1.46) | ‐0.02(‐0.19,0.01) | |
| HD ADA SC | 0.35(0.03,2.26) | 0.36(0.04,2.22) | ‐0.03(‐0.21,0.01) | |
| HD GOLI SC | 0.27(0.02,2.29) | 0.28(0.02,2.20) | ‐0.03(‐0.19,0.03) | |
| HD TOCI IV + MTX | 0.57(0.12,2.26) | 0.58(0.14,2.22) | ‐0.02(‐0.17,0.02) | |
| HD GOLI SC + MTX | 0.77(0.15,3.75) | 0.78(0.17,3.46) | ‐0.01(‐0.15,0.07) | |
| HD TOFA PO + MTX | 0.80(0.18,3.17) | 0.81(0.20,3.01) | ‐0.01(‐0.13,0.05) | |
| HD CERTO SC + MTX | 0.74(0.16,3.09) | 0.75(0.18,2.96) | ‐0.01(‐0.14,0.05) | |
| HD INF IV + MTX | 1.48(0.30,5.91) | 1.44(0.34,5.38) | 0.01(‐0.11,0.13) | |
| HD TOCI IV + DMARD | 3.10(0.27,32.15) | 2.83(0.32,23.28) | 0.07(‐0.14,0.32) | |
| SD TOFA PO + MTX | SD GOLI SC + MTX | 1.68(0.36,6.34) | 1.65(0.37,5.96) | 0.01(‐0.05,0.10) |
| SD ABA SC + MTX | 0.49(0.11,2.38) | 0.50(0.12,2.33) | ‐0.01(‐0.08,0.02) | |
| SD TOCI IV + MTX | 1.11(0.22,4.32) | 1.10(0.24,4.17) | 0.00(‐0.07,0.05) | |
| SD ETN SC + DMARD | 2.09(0.29,14.85) | 2.03(0.31,13.63) | 0.02(‐0.06,0.11) | |
| SD CERTO SC + DMARD | 2.64(0.34,25.59) | 2.54(0.36,21.85) | 0.03(‐0.06,0.18) | |
| SD ADA SC + DMARD | 3.57(0.28,41.74) | 3.31(0.30,31.20) | 0.05(‐0.05,0.29) | |
| SD TOCI SC + DMARD | 8.39(0.61,111.10) | 6.85(0.62,56.25) | 0.14(‐0.02,0.58) | |
| LD ADA SC | 0.59(0.07,3.79) | 0.59(0.08,3.73) | ‐0.01(‐0.09,0.02) | |
| LD ETN SC | 2.15(0.24,16.00) | 2.08(0.26,13.92) | 0.02(‐0.07,0.15) | |
| LD TOCI IV | 0.64(0.10,2.90) | 0.65(0.11,2.82) | ‐0.01(‐0.08,0.03) | |
| LD RITUX IV + MTX | 1.71(0.34,8.96) | 1.68(0.36,8.05) | 0.01(‐0.04,0.15) | |
| LD ABA IV + MTX | 1.11(0.24,4.67) | 1.11(0.25,4.45) | 0.00(‐0.06,0.07) | |
| LD CERTO SC + MTX | 0.85(0.11,4.67) | 0.85(0.11,4.44) | 0.00(‐0.07,0.06) | |
| LD TOCI IV + MTX | 0.47(0.05,2.56) | 0.48(0.05,2.51) | ‐0.01(‐0.09,0.02) | |
| HD TOCI IV | 0.77(0.21,2.59) | 0.78(0.23,2.54) | 0.00(‐0.08,0.02) | |
| HD ADA SC | 0.62(0.09,3.84) | 0.63(0.10,3.75) | ‐0.01(‐0.09,0.02) | |
| HD GOLI SC | 0.50(0.06,2.96) | 0.51(0.06,2.84) | ‐0.01(‐0.07,0.04) | |
| HD TOCI IV + MTX | 1.07(0.26,3.67) | 1.07(0.28,3.56) | 0.00(‐0.07,0.04) | |
| HD GOLI SC + MTX | 1.40(0.52,4.07) | 1.38(0.54,3.84) | 0.01(‐0.02,0.07) | |
| HD TOFA PO + MTX | 1.45(0.34,6.13) | 1.42(0.36,5.71) | 0.01(‐0.05,0.09) | |
| HD CERTO SC + MTX | 1.33(0.35,5.21) | 1.32(0.36,4.90) | 0.01(‐0.04,0.08) | |
| HD INF IV + MTX | 2.71(0.65,10.12) | 2.58(0.66,8.95) | 0.03(‐0.02,0.16) | |
| HD TOCI IV + DMARD | 5.45(0.62,54.43) | 4.88(0.65,39.70) | 0.09(‐0.03,0.33) | |
| SD ABA SC + MTX | SD TOFA PO + MTX | 0.30(0.08,1.17) | 0.31(0.08,1.16) | ‐0.02(‐0.13,0.00) |
| SD TOCI IV + MTX | 0.65(0.15,2.73) | 0.66(0.16,2.64) | ‐0.01(‐0.11,0.04) | |
| SD ETN SC + DMARD | 1.28(0.19,9.68) | 1.26(0.21,8.84) | 0.01(‐0.12,0.10) | |
| SD CERTO SC + DMARD | 1.57(0.24,16.86) | 1.54(0.27,14.15) | 0.02(‐0.10,0.17) | |
| SD ADA SC + DMARD | 2.23(0.15,22.92) | 2.12(0.17,17.33) | 0.04(‐0.11,0.28) | |
| SD TOCI SC + DMARD | 5.24(0.35,61.42) | 4.38(0.38,31.90) | 0.13(‐0.07,0.57) | |
| LD ADA SC | 0.37(0.04,2.20) | 0.38(0.05,2.16) | ‐0.02(‐0.15,0.01) | |
| LD ETN SC | 1.28(0.15,10.16) | 1.26(0.16,8.97) | 0.01(‐0.11,0.14) | |
| LD TOCI IV | 0.39(0.07,1.74) | 0.40(0.08,1.72) | ‐0.02(‐0.13,0.01) | |
| LD RITUX IV + MTX | 1.05(0.23,5.10) | 1.04(0.24,4.65) | 0.00(‐0.06,0.11) | |
| LD ABA IV + MTX | 0.68(0.18,2.52) | 0.69(0.19,2.44) | ‐0.01(‐0.09,0.04) | |
| LD CERTO SC + MTX | 0.51(0.07,2.95) | 0.52(0.08,2.77) | ‐0.02(‐0.11,0.05) | |
| LD TOCI IV + MTX | 0.29(0.04,1.42) | 0.29(0.04,1.40) | ‐0.02(‐0.14,0.01) | |
| HD TOCI IV | 0.46(0.15,1.44) | 0.47(0.16,1.43) | ‐0.02(‐0.12,0.01) | |
| HD ADA SC | 0.38(0.05,2.35) | 0.39(0.06,2.31) | ‐0.02(‐0.14,0.02) | |
| HD GOLI SC | 0.31(0.03,2.23) | 0.32(0.03,2.12) | ‐0.02(‐0.12,0.04) | |
| HD TOCI IV + MTX | 0.64(0.18,2.24) | 0.65(0.20,2.19) | ‐0.01(‐0.11,0.02) | |
| HD GOLI SC + MTX | 0.86(0.25,3.53) | 0.86(0.27,3.30) | 0.00(‐0.08,0.07) | |
| HD TOFA PO + MTX | 0.90(0.40,2.02) | 0.90(0.42,1.97) | 0.00(‐0.05,0.04) | |
| HD CERTO SC + MTX | 0.82(0.24,2.95) | 0.83(0.26,2.81) | ‐0.01(‐0.08,0.05) | |
| HD INF IV + MTX | 1.62(0.48,5.69) | 1.57(0.50,5.11) | 0.02(‐0.04,0.13) | |
| HD TOCI IV + DMARD | 3.31(0.40,34.04) | 3.01(0.44,25.25) | 0.08(‐0.08,0.32) | |
| SD TOCI IV + MTX | SD ABA SC + MTX | 2.19(0.39,10.76) | 2.16(0.40,10.28) | 0.01(‐0.02,0.08) |
| SD ETN SC + DMARD | 3.97(0.68,37.58) | 3.82(0.70,34.13) | 0.03(‐0.01,0.12) | |
| SD CERTO SC + DMARD | 5.08(0.76,70.23) | 4.79(0.77,59.89) | 0.05(‐0.01,0.19) | |
| SD ADA SC + DMARD | 7.25(0.61,104.80) | 6.67(0.62,80.67) | 0.06(‐0.01,0.30) | |
| SD TOCI SC + DMARD | 16.82(1.33,239.10) | 13.58(1.32,133.60) | 0.15(0.01,0.59) | |
| LD ADA SC | 1.19(0.15,8.61) | 1.18(0.16,8.39) | 0.00(‐0.04,0.03) | |
| LD ETN SC | 4.03(0.55,35.89) | 3.87(0.57,31.34) | 0.03(‐0.01,0.17) | |
| LD TOCI IV | 1.32(0.20,6.33) | 1.31(0.21,6.16) | 0.00(‐0.03,0.04) | |
| LD RITUX IV + MTX | 3.43(0.62,20.07) | 3.30(0.63,18.11) | 0.03(‐0.01,0.19) | |
| LD ABA IV + MTX | 2.23(0.62,9.10) | 2.18(0.62,8.61) | 0.01(‐0.01,0.09) | |
| LD CERTO SC + MTX | 1.75(0.21,10.16) | 1.74(0.21,9.45) | 0.01(‐0.02,0.09) | |
| LD TOCI IV + MTX | 0.91(0.12,5.85) | 0.91(0.12,5.72) | 0.00(‐0.03,0.03) | |
| HD TOCI IV | 1.54(0.41,5.70) | 1.52(0.42,5.59) | 0.01(‐0.02,0.03) | |
| HD ADA SC | 1.23(0.20,9.65) | 1.23(0.21,9.42) | 0.00(‐0.03,0.03) | |
| HD GOLI SC | 1.02(0.08,6.93) | 1.02(0.08,6.54) | 0.00(‐0.03,0.07) | |
| HD TOCI IV + MTX | 2.09(0.52,8.73) | 2.06(0.53,8.45) | 0.01(‐0.02,0.06) | |
| HD GOLI SC + MTX | 2.86(0.71,13.35) | 2.78(0.72,12.02) | 0.02(‐0.01,0.12) | |
| HD TOFA PO + MTX | 2.91(0.78,11.82) | 2.83(0.78,11.04) | 0.02(0.00,0.12) | |
| HD CERTO SC + MTX | 2.76(0.70,10.72) | 2.68(0.71,9.99) | 0.02(‐0.01,0.10) | |
| HD INF IV + MTX | 5.40(1.47,20.63) | 5.05(1.44,18.46) | 0.05(0.01,0.19) | |
| HD TOCI IV + DMARD | 10.91(1.42,138.90) | 9.56(1.40,101.60) | 0.10(0.01,0.35) | |
| SD ETN SC + DMARD | SD TOCI IV + MTX | 1.97(0.32,12.41) | 1.92(0.34,11.26) | 0.02(‐0.06,0.10) |
| SD CERTO SC + DMARD | 2.53(0.36,21.24) | 2.43(0.39,17.95) | 0.03(‐0.05,0.18) | |
| SD ADA SC + DMARD | 3.49(0.31,33.03) | 3.24(0.33,24.56) | 0.05(‐0.05,0.29) | |
| SD TOCI SC + DMARD | 8.22(0.61,101.50) | 6.77(0.62,49.38) | 0.14(‐0.02,0.58) | |
| LD ADA SC | 0.56(0.07,2.99) | 0.57(0.08,2.94) | ‐0.01(‐0.09,0.02) | |
| LD ETN SC | 1.99(0.24,13.21) | 1.94(0.26,11.45) | 0.02(‐0.06,0.16) | |
| LD TOCI IV | 0.58(0.12,2.56) | 0.59(0.12,2.51) | ‐0.01(‐0.07,0.02) | |
| LD RITUX IV + MTX | 1.57(0.30,9.88) | 1.54(0.31,8.59) | 0.01(‐0.04,0.16) | |
| LD ABA IV + MTX | 1.03(0.21,5.12) | 1.03(0.21,4.81) | 0.00(‐0.06,0.07) | |
| LD CERTO SC + MTX | 0.78(0.10,5.14) | 0.79(0.11,4.82) | 0.00(‐0.06,0.07) | |
| LD TOCI IV + MTX | 0.43(0.07,1.94) | 0.43(0.07,1.91) | ‐0.01(‐0.08,0.01) | |
| HD TOCI IV | 0.71(0.23,2.39) | 0.71(0.24,2.36) | ‐0.01(‐0.06,0.02) | |
| HD ADA SC | 0.59(0.08,3.31) | 0.60(0.09,3.27) | ‐0.01(‐0.09,0.02) | |
| HD GOLI SC | 0.46(0.04,3.78) | 0.47(0.04,3.58) | ‐0.01(‐0.07,0.05) | |
| HD TOCI IV + MTX | 0.97(0.31,3.59) | 0.97(0.32,3.47) | 0.00(‐0.05,0.03) | |
| HD GOLI SC + MTX | 1.31(0.31,6.31) | 1.30(0.32,5.73) | 0.01(‐0.04,0.10) | |
| HD TOFA PO + MTX | 1.36(0.32,6.42) | 1.35(0.33,6.00) | 0.01(‐0.04,0.10) | |
| HD CERTO SC + MTX | 1.25(0.29,5.96) | 1.24(0.30,5.59) | 0.01(‐0.04,0.09) | |
| HD INF IV + MTX | 2.46(0.57,11.59) | 2.35(0.59,10.26) | 0.03(‐0.02,0.17) | |
| HD TOCI IV + DMARD | 5.23(0.72,42.60) | 4.67(0.74,31.27) | 0.09(‐0.02,0.33) | |
| SD CERTO SC + DMARD | SD ETN SC + DMARD | 1.29(0.37,5.39) | 1.27(0.39,4.66) | 0.01(‐0.05,0.13) |
| SD ADA SC + DMARD | 1.74(0.37,7.43) | 1.67(0.38,5.74) | 0.03(‐0.04,0.24) | |
| SD TOCI SC + DMARD | 3.92(0.61,26.92) | 3.35(0.62,13.27) | 0.12(‐0.02,0.54) | |
| LD ADA SC | 0.28(0.06,1.21) | 0.29(0.06,1.20) | ‐0.03(‐0.11,0.00) | |
| LD ETN SC | 1.00(0.14,7.23) | 1.00(0.15,6.28) | 0.00(‐0.09,0.14) | |
| LD TOCI IV | 0.30(0.04,2.21) | 0.31(0.05,2.15) | ‐0.03(‐0.12,0.03) | |
| LD RITUX IV + MTX | 0.80(0.09,7.31) | 0.81(0.10,6.03) | ‐0.01(‐0.10,0.18) | |
| LD ABA IV + MTX | 0.54(0.06,3.59) | 0.55(0.07,3.34) | ‐0.02(‐0.11,0.07) | |
| LD CERTO SC + MTX | 0.40(0.04,3.56) | 0.42(0.05,3.26) | ‐0.03(‐0.11,0.07) | |
| LD TOCI IV + MTX | 0.21(0.03,1.44) | 0.22(0.03,1.42) | ‐0.03(‐0.12,0.01) | |
| HD TOCI IV | 0.36(0.07,1.92) | 0.37(0.08,1.87) | ‐0.03(‐0.11,0.02) | |
| HD ADA SC | 0.30(0.07,1.24) | 0.31(0.08,1.23) | ‐0.03(‐0.11,0.01) | |
| HD GOLI SC | 0.25(0.01,2.71) | 0.26(0.02,2.56) | ‐0.03(‐0.12,0.05) | |
| HD TOCI IV + MTX | 0.50(0.10,2.74) | 0.52(0.11,2.62) | ‐0.02(‐0.11,0.04) | |
| HD GOLI SC + MTX | 0.68(0.09,4.95) | 0.69(0.10,4.48) | ‐0.01(‐0.10,0.10) | |
| HD TOFA PO + MTX | 0.70(0.10,4.95) | 0.71(0.11,4.42) | ‐0.01(‐0.10,0.10) | |
| HD CERTO SC + MTX | 0.65(0.09,4.34) | 0.66(0.10,3.96) | ‐0.01(‐0.10,0.09) | |
| HD INF IV + MTX | 1.33(0.17,7.96) | 1.31(0.19,6.75) | 0.01(‐0.08,0.17) | |
| HD TOCI IV + DMARD | 2.66(0.92,7.61) | 2.44(0.92,5.92) | 0.07(0.00,0.27) | |
| SD ADA SC + DMARD | SD CERTO SC + DMARD | 1.37(0.21,6.53) | 1.34(0.23,5.15) | 0.02(‐0.10,0.22) |
| SD TOCI SC + DMARD | 3.06(0.38,24.04) | 2.65(0.41,12.27) | 0.10(‐0.06,0.52) | |
| LD ADA SC | 0.22(0.03,1.17) | 0.24(0.04,1.16) | ‐0.05(‐0.19,0.00) | |
| LD ETN SC | 0.79(0.09,6.25) | 0.80(0.10,5.42) | ‐0.01(‐0.16,0.13) | |
| LD TOCI IV | 0.24(0.03,1.83) | 0.25(0.03,1.79) | ‐0.04(‐0.19,0.02) | |
| LD RITUX IV + MTX | 0.65(0.06,6.01) | 0.67(0.07,5.07) | ‐0.02(‐0.17,0.17) | |
| LD ABA IV + MTX | 0.44(0.03,2.82) | 0.45(0.04,2.66) | ‐0.03(‐0.18,0.05) | |
| LD CERTO SC + MTX | 0.32(0.02,2.84) | 0.34(0.02,2.66) | ‐0.04(‐0.18,0.06) | |
| LD TOCI IV + MTX | 0.16(0.02,1.27) | 0.17(0.02,1.26) | ‐0.05(‐0.19,0.01) | |
| HD TOCI IV | 0.29(0.04,1.48) | 0.30(0.05,1.46) | ‐0.04(‐0.19,0.01) | |
| HD ADA SC | 0.23(0.04,1.26) | 0.24(0.05,1.25) | ‐0.05(‐0.19,0.01) | |
| HD GOLI SC | 0.19(0.01,2.45) | 0.20(0.01,2.34) | ‐0.04(‐0.19,0.04) | |
| HD TOCI IV + MTX | 0.40(0.05,2.30) | 0.42(0.06,2.21) | ‐0.03(‐0.18,0.03) | |
| HD GOLI SC + MTX | 0.54(0.05,4.20) | 0.56(0.06,3.80) | ‐0.02(‐0.17,0.09) | |
| HD TOFA PO + MTX | 0.55(0.05,3.76) | 0.57(0.07,3.37) | ‐0.02(‐0.17,0.09) | |
| HD CERTO SC + MTX | 0.53(0.05,3.72) | 0.55(0.06,3.39) | ‐0.02(‐0.18,0.08) | |
| HD INF IV + MTX | 1.04(0.09,6.44) | 1.04(0.10,5.55) | 0.00(‐0.16,0.15) | |
| HD TOCI IV + DMARD | 2.08(0.52,7.65) | 1.93(0.55,6.07) | 0.05(‐0.06,0.25) | |
| SD TOCI SC + DMARD | SD ADA SC + DMARD | 2.19(0.34,21.65) | 1.94(0.38,13.85) | 0.07(‐0.12,0.48) |
| LD ADA SC | 0.16(0.02,1.32) | 0.17(0.03,1.30) | ‐0.06(‐0.30,0.01) | |
| LD ETN SC | 0.58(0.06,7.71) | 0.61(0.08,6.71) | ‐0.03(‐0.26,0.12) | |
| LD TOCI IV | 0.17(0.02,2.21) | 0.18(0.02,2.15) | ‐0.06(‐0.30,0.03) | |
| LD RITUX IV + MTX | 0.44(0.04,8.02) | 0.47(0.05,6.54) | ‐0.04(‐0.27,0.16) | |
| LD ABA IV + MTX | 0.30(0.02,4.07) | 0.32(0.03,3.76) | ‐0.05(‐0.29,0.07) | |
| LD CERTO SC + MTX | 0.22(0.01,3.43) | 0.24(0.02,3.20) | ‐0.06(‐0.29,0.05) | |
| LD TOCI IV + MTX | 0.12(0.01,1.49) | 0.13(0.01,1.48) | ‐0.07(‐0.30,0.01) | |
| HD TOCI IV | 0.20(0.03,2.11) | 0.22(0.03,2.07) | ‐0.06(‐0.29,0.02) | |
| HD ADA SC | 0.17(0.03,1.29) | 0.18(0.03,1.28) | ‐0.06(‐0.30,0.01) | |
| HD GOLI SC | 0.13(0.01,2.51) | 0.15(0.01,2.36) | ‐0.06(‐0.30,0.03) | |
| HD TOCI IV + MTX | 0.30(0.03,2.85) | 0.32(0.05,2.73) | ‐0.05(‐0.29,0.04) | |
| HD GOLI SC + MTX | 0.38(0.03,5.33) | 0.40(0.04,4.69) | ‐0.04(‐0.28,0.09) | |
| HD TOFA PO + MTX | 0.40(0.04,5.84) | 0.42(0.05,5.16) | ‐0.04(‐0.28,0.09) | |
| HD CERTO SC + MTX | 0.36(0.03,4.47) | 0.38(0.04,4.15) | ‐0.05(‐0.28,0.07) | |
| HD INF IV + MTX | 0.74(0.06,8.95) | 0.76(0.08,7.46) | ‐0.02(‐0.26,0.16) | |
| HD TOCI IV + DMARD | 1.54(0.40,6.56) | 1.46(0.47,5.47) | 0.03(‐0.13,0.20) | |
| LD ADA SC | SD TOCI SC + DMARD | 0.07(0.01,0.80) | 0.08(0.01,0.81) | ‐0.15(‐0.59,‐0.01) |
| LD ETN SC | 0.25(0.02,3.29) | 0.29(0.04,2.99) | ‐0.11(‐0.57,0.09) | |
| LD TOCI IV | 0.07(0.01,1.06) | 0.09(0.01,1.06) | ‐0.15(‐0.59,0.00) | |
| LD RITUX IV + MTX | 0.20(0.01,3.64) | 0.24(0.03,3.22) | ‐0.12(‐0.57,0.11) | |
| LD ABA IV + MTX | 0.13(0.01,2.02) | 0.16(0.02,1.92) | ‐0.14(‐0.58,0.04) | |
| LD CERTO SC + MTX | 0.09(0.01,1.81) | 0.12(0.01,1.73) | ‐0.14(‐0.58,0.03) | |
| LD TOCI IV + MTX | 0.05(0.00,0.82) | 0.06(0.01,0.83) | ‐0.16(‐0.60,‐0.01) | |
| HD TOCI IV | 0.08(0.01,1.05) | 0.10(0.02,1.04) | ‐0.15(‐0.59,0.00) | |
| HD ADA SC | 0.07(0.01,0.74) | 0.09(0.02,0.75) | ‐0.15(‐0.59,‐0.01) | |
| HD GOLI SC | 0.06(0.00,1.19) | 0.08(0.00,1.18) | ‐0.15(‐0.59,0.01) | |
| HD TOCI IV + MTX | 0.12(0.01,1.52) | 0.15(0.02,1.48) | ‐0.14(‐0.58,0.02) | |
| HD GOLI SC + MTX | 0.17(0.01,2.41) | 0.20(0.03,2.28) | ‐0.13(‐0.57,0.05) | |
| HD TOFA PO + MTX | 0.17(0.02,2.64) | 0.20(0.03,2.42) | ‐0.13(‐0.56,0.06) | |
| HD CERTO SC + MTX | 0.16(0.01,2.27) | 0.19(0.03,2.13) | ‐0.13(‐0.57,0.05) | |
| HD INF IV + MTX | 0.31(0.03,4.12) | 0.36(0.05,3.63) | ‐0.10(‐0.54,0.12) | |
| HD TOCI IV + DMARD | 0.69(0.10,3.93) | 0.73(0.17,3.47) | ‐0.04(‐0.43,0.14) | |
| LD ETN SC | LD ADA SC | 3.55(0.54,22.64) | 3.41(0.55,19.87) | 0.03(‐0.01,0.17) |
| LD TOCI IV | 1.09(0.15,7.77) | 1.09(0.16,7.44) | 0.00(‐0.03,0.05) | |
| LD RITUX IV + MTX | 2.66(0.43,29.58) | 2.59(0.44,24.04) | 0.02(‐0.02,0.22) | |
| LD ABA IV + MTX | 1.90(0.25,16.00) | 1.87(0.25,14.73) | 0.01(‐0.02,0.10) | |
| LD CERTO SC + MTX | 1.41(0.15,13.12) | 1.40(0.15,12.07) | 0.01(‐0.02,0.10) | |
| LD TOCI IV + MTX | 0.73(0.10,6.56) | 0.73(0.10,6.29) | 0.00(‐0.03,0.04) | |
| HD TOCI IV | 1.23(0.29,8.12) | 1.22(0.29,7.76) | 0.00(‐0.02,0.04) | |
| HD ADA SC | 1.04(0.28,4.33) | 1.04(0.28,4.24) | 0.00(‐0.02,0.03) | |
| HD GOLI SC | 0.83(0.06,12.86) | 0.83(0.06,12.01) | 0.00(‐0.03,0.08) | |
| HD TOCI IV + MTX | 1.69(0.38,11.29) | 1.67(0.39,10.64) | 0.01(‐0.02,0.07) | |
| HD GOLI SC + MTX | 2.41(0.35,20.58) | 2.36(0.35,18.19) | 0.02(‐0.02,0.13) | |
| HD TOFA PO + MTX | 2.37(0.42,25.52) | 2.33(0.43,22.58) | 0.02(‐0.01,0.14) | |
| HD CERTO SC + MTX | 2.19(0.38,19.66) | 2.15(0.39,17.88) | 0.02(‐0.02,0.12) | |
| HD INF IV + MTX | 4.40(0.73,36.52) | 4.16(0.74,30.80) | 0.05(‐0.01,0.20) | |
| HD TOCI IV + DMARD | 9.65(1.66,55.55) | 8.50(1.63,41.19) | 0.10(0.01,0.34) | |
| LD TOCI IV | LD ETN SC | 0.31(0.03,2.07) | 0.32(0.04,2.02) | ‐0.03(‐0.17,0.02) |
| LD RITUX IV + MTX | 0.79(0.10,8.70) | 0.80(0.11,7.21) | ‐0.01(‐0.14,0.18) | |
| LD ABA IV + MTX | 0.54(0.06,4.59) | 0.55(0.07,4.33) | ‐0.02(‐0.15,0.07) | |
| LD CERTO SC + MTX | 0.41(0.04,3.60) | 0.43(0.04,3.32) | ‐0.02(‐0.15,0.06) | |
| LD TOCI IV + MTX | 0.21(0.02,2.05) | 0.22(0.03,2.01) | ‐0.04(‐0.17,0.02) | |
| HD TOCI IV | 0.36(0.06,2.20) | 0.38(0.07,2.17) | ‐0.03(‐0.16,0.02) | |
| HD ADA SC | 0.30(0.04,2.09) | 0.31(0.05,2.05) | ‐0.03(‐0.17,0.01) | |
| HD GOLI SC | 0.24(0.01,2.81) | 0.26(0.02,2.68) | ‐0.03(‐0.16,0.04) | |
| HD TOCI IV + MTX | 0.52(0.08,3.07) | 0.53(0.09,2.95) | ‐0.02(‐0.16,0.04) | |
| HD GOLI SC + MTX | 0.67(0.09,6.12) | 0.68(0.10,5.53) | ‐0.01(‐0.14,0.10) | |
| HD TOFA PO + MTX | 0.71(0.09,6.08) | 0.72(0.11,5.57) | ‐0.01(‐0.14,0.10) | |
| HD CERTO SC + MTX | 0.64(0.10,5.01) | 0.65(0.11,4.62) | ‐0.01(‐0.14,0.09) | |
| HD INF IV + MTX | 1.28(0.18,8.98) | 1.26(0.21,7.63) | 0.01(‐0.12,0.16) | |
| HD TOCI IV + DMARD | 2.58(0.27,22.63) | 2.38(0.30,16.75) | 0.06(‐0.10,0.31) | |
| LD RITUX IV + MTX | LD TOCI IV | 2.54(0.49,21.10) | 2.46(0.50,18.63) | 0.02(‐0.02,0.19) |
| LD ABA IV + MTX | 1.75(0.34,10.05) | 1.72(0.35,9.37) | 0.01(‐0.02,0.08) | |
| LD CERTO SC + MTX | 1.30(0.18,9.93) | 1.30(0.19,9.41) | 0.00(‐0.03,0.08) | |
| LD TOCI IV + MTX | 0.71(0.11,3.93) | 0.72(0.11,3.86) | 0.00(‐0.04,0.03) | |
| HD TOCI IV | 1.18(0.38,4.93) | 1.18(0.39,4.86) | 0.00(‐0.03,0.03) | |
| HD ADA SC | 0.99(0.15,6.59) | 0.99(0.15,6.46) | 0.00(‐0.05,0.03) | |
| HD GOLI SC | 0.80(0.07,6.92) | 0.80(0.07,6.65) | 0.00(‐0.04,0.06) | |
| HD TOCI IV + MTX | 1.66(0.50,6.99) | 1.64(0.51,6.77) | 0.01(‐0.02,0.05) | |
| HD GOLI SC + MTX | 2.23(0.51,12.84) | 2.17(0.52,11.56) | 0.02(‐0.01,0.11) | |
| HD TOFA PO + MTX | 2.26(0.52,13.28) | 2.21(0.53,11.95) | 0.02(‐0.02,0.12) | |
| HD CERTO SC + MTX | 2.13(0.48,11.19) | 2.08(0.49,10.39) | 0.01(‐0.02,0.10) | |
| HD INF IV + MTX | 4.12(0.94,22.44) | 3.90(0.94,20.02) | 0.04(0.00,0.18) | |
| HD TOCI IV + DMARD | 9.02(0.98,83.30) | 7.89(0.98,60.86) | 0.10(0.00,0.34) | |
| LD ABA IV + MTX | LD RITUX IV + MTX | 0.67(0.11,3.36) | 0.68(0.12,3.21) | ‐0.01(‐0.15,0.05) |
| LD CERTO SC + MTX | 0.50(0.05,3.42) | 0.52(0.06,3.28) | ‐0.02(‐0.17,0.05) | |
| LD TOCI IV + MTX | 0.27(0.03,1.61) | 0.28(0.04,1.60) | ‐0.03(‐0.19,0.01) | |
| HD TOCI IV | 0.45(0.09,1.82) | 0.46(0.11,1.80) | ‐0.02(‐0.18,0.01) | |
| HD ADA SC | 0.38(0.04,2.46) | 0.39(0.05,2.42) | ‐0.02(‐0.21,0.02) | |
| HD GOLI SC | 0.31(0.02,2.34) | 0.32(0.03,2.23) | ‐0.02(‐0.19,0.03) | |
| HD TOCI IV + MTX | 0.61(0.13,2.72) | 0.63(0.14,2.66) | ‐0.01(‐0.17,0.03) | |
| HD GOLI SC + MTX | 0.85(0.15,4.06) | 0.86(0.17,3.81) | 0.00(‐0.14,0.07) | |
| HD TOFA PO + MTX | 0.85(0.17,4.17) | 0.86(0.19,3.94) | 0.00(‐0.12,0.06) | |
| HD CERTO SC + MTX | 0.81(0.16,3.57) | 0.82(0.18,3.39) | ‐0.01(‐0.14,0.06) | |
| HD INF IV + MTX | 1.58(0.31,7.33) | 1.54(0.35,6.63) | 0.02(‐0.10,0.13) | |
| HD TOCI IV + DMARD | 3.45(0.31,36.59) | 3.11(0.36,26.63) | 0.07(‐0.12,0.32) | |
| LD CERTO SC + MTX | LD ABA IV + MTX | 0.77(0.09,4.51) | 0.78(0.10,4.25) | 0.00(‐0.08,0.06) |
| LD TOCI IV + MTX | 0.41(0.05,2.61) | 0.42(0.06,2.56) | ‐0.01(‐0.09,0.02) | |
| HD TOCI IV | 0.68(0.20,2.62) | 0.69(0.21,2.60) | ‐0.01(‐0.08,0.02) | |
| HD ADA SC | 0.54(0.08,4.28) | 0.55(0.09,4.16) | ‐0.01(‐0.10,0.02) | |
| HD GOLI SC | 0.46(0.04,3.35) | 0.47(0.04,3.17) | ‐0.01(‐0.09,0.05) | |
| HD TOCI IV + MTX | 0.93(0.25,3.85) | 0.93(0.27,3.73) | 0.00(‐0.07,0.04) | |
| HD GOLI SC + MTX | 1.27(0.32,5.68) | 1.26(0.34,5.22) | 0.01(‐0.05,0.09) | |
| HD TOFA PO + MTX | 1.33(0.35,5.24) | 1.31(0.36,4.90) | 0.01(‐0.05,0.09) | |
| HD CERTO SC + MTX | 1.22(0.31,4.90) | 1.21(0.33,4.62) | 0.00(‐0.05,0.08) | |
| HD INF IV + MTX | 2.40(0.63,8.96) | 2.29(0.65,8.15) | 0.03(‐0.02,0.15) | |
| HD TOCI IV + DMARD | 4.92(0.56,58.39) | 4.40(0.58,42.34) | 0.09(‐0.03,0.33) | |
| LD TOCI IV + MTX | LD CERTO SC + MTX | 0.54(0.06,4.77) | 0.55(0.07,4.66) | ‐0.01(‐0.09,0.03) |
| HD TOCI IV | 0.91(0.18,5.50) | 0.91(0.19,5.39) | 0.00(‐0.08,0.02) | |
| HD ADA SC | 0.74(0.08,6.79) | 0.75(0.09,6.66) | 0.00(‐0.10,0.03) | |
| HD GOLI SC | 0.62(0.04,5.52) | 0.63(0.04,5.25) | ‐0.01(‐0.08,0.05) | |
| HD TOCI IV + MTX | 1.24(0.23,8.46) | 1.23(0.25,8.19) | 0.00(‐0.07,0.04) | |
| HD GOLI SC + MTX | 1.66(0.31,13.02) | 1.63(0.33,12.31) | 0.01(‐0.05,0.10) | |
| HD TOFA PO + MTX | 1.71(0.32,13.32) | 1.68(0.34,11.98) | 0.01(‐0.05,0.10) | |
| HD CERTO SC + MTX | 1.57(0.38,8.66) | 1.55(0.39,8.27) | 0.01(‐0.04,0.08) | |
| HD INF IV + MTX | 3.24(0.61,21.17) | 3.06(0.63,19.24) | 0.04(‐0.02,0.17) | |
| HD TOCI IV + DMARD | 6.84(0.65,88.72) | 6.04(0.67,65.43) | 0.09(‐0.03,0.34) | |
| HD TOCI IV | LD TOCI IV + MTX | 1.64(0.43,8.55) | 1.62(0.44,8.34) | 0.01(‐0.02,0.03) |
| HD ADA SC | 1.35(0.21,10.50) | 1.34(0.22,10.18) | 0.00(‐0.04,0.03) | |
| HD GOLI SC | 1.11(0.09,12.12) | 1.11(0.09,11.47) | 0.00(‐0.03,0.07) | |
| HD TOCI IV + MTX | 2.29(0.57,13.30) | 2.26(0.58,12.88) | 0.01(‐0.01,0.06) | |
| HD GOLI SC + MTX | 3.20(0.52,25.25) | 3.10(0.53,22.96) | 0.02(‐0.01,0.12) | |
| HD TOFA PO + MTX | 3.19(0.55,22.26) | 3.09(0.56,20.61) | 0.02(‐0.01,0.13) | |
| HD CERTO SC + MTX | 2.98(0.54,23.00) | 2.91(0.55,21.48) | 0.02(‐0.01,0.11) | |
| HD INF IV + MTX | 5.91(1.03,40.58) | 5.53(1.03,35.84) | 0.05(0.00,0.19) | |
| HD TOCI IV + DMARD | 12.37(1.61,104.90) | 10.84(1.58,78.96) | 0.10(0.01,0.35) | |
| HD ADA SC | HD TOCI IV | 0.83(0.17,3.61) | 0.83(0.17,3.53) | 0.00(‐0.04,0.03) |
| HD GOLI SC | 0.66(0.07,4.19) | 0.66(0.07,3.90) | ‐0.01(‐0.03,0.06) | |
| HD TOCI IV + MTX | 1.39(0.64,2.92) | 1.37(0.65,2.86) | 0.01(‐0.01,0.04) | |
| HD GOLI SC + MTX | 1.86(0.60,6.64) | 1.83(0.61,5.79) | 0.01(‐0.01,0.11) | |
| HD TOFA PO + MTX | 1.96(0.62,6.46) | 1.92(0.63,5.86) | 0.02(‐0.01,0.11) | |
| HD CERTO SC + MTX | 1.77(0.58,5.60) | 1.74(0.59,5.16) | 0.01(‐0.01,0.09) | |
| HD INF IV + MTX | 3.51(1.17,10.94) | 3.33(1.17,9.37) | 0.04(0.00,0.18) | |
| HD TOCI IV + DMARD | 7.28(1.06,52.01) | 6.47(1.06,36.95) | 0.10(0.00,0.34) | |
| HD GOLI SC | HD ADA SC | 0.79(0.05,8.97) | 0.79(0.06,8.35) | 0.00(‐0.03,0.08) |
| HD TOCI IV + MTX | 1.66(0.34,8.86) | 1.64(0.35,8.37) | 0.01(‐0.02,0.06) | |
| HD GOLI SC + MTX | 2.37(0.35,15.50) | 2.31(0.35,13.80) | 0.02(‐0.02,0.13) | |
| HD TOFA PO + MTX | 2.33(0.38,17.76) | 2.28(0.39,15.68) | 0.02(‐0.02,0.13) | |
| HD CERTO SC + MTX | 2.14(0.35,14.86) | 2.10(0.35,13.44) | 0.01(‐0.02,0.11) | |
| HD INF IV + MTX | 4.42(0.67,26.42) | 4.17(0.68,22.23) | 0.05(‐0.01,0.20) | |
| HD TOCI IV + DMARD | 9.33(1.63,49.48) | 8.25(1.60,35.54) | 0.10(0.01,0.34) | |
| HD TOCI IV + MTX | HD GOLI SC | 2.12(0.32,21.15) | 2.09(0.34,20.51) | 0.01(‐0.05,0.05) |
| HD GOLI SC + MTX | 2.69(0.59,24.71) | 2.60(0.60,23.79) | 0.02(‐0.02,0.10) | |
| HD TOFA PO + MTX | 2.94(0.38,37.19) | 2.85(0.41,34.95) | 0.02(‐0.04,0.11) | |
| HD CERTO SC + MTX | 2.63(0.43,27.76) | 2.57(0.45,26.47) | 0.02(‐0.03,0.09) | |
| HD INF IV + MTX | 5.22(0.76,61.62) | 4.89(0.77,56.54) | 0.04(‐0.01,0.18) | |
| HD TOCI IV + DMARD | 10.78(0.86,228.60) | 9.41(0.87,171.10) | 0.10(‐0.01,0.34) | |
| HD GOLI SC + MTX | HD TOCI IV + MTX | 1.38(0.39,5.21) | 1.37(0.40,4.67) | 0.01(‐0.03,0.10) |
| HD TOFA PO + MTX | 1.39(0.40,5.14) | 1.38(0.41,4.60) | 0.01(‐0.03,0.10) | |
| HD CERTO SC + MTX | 1.30(0.35,4.44) | 1.29(0.36,4.08) | 0.01(‐0.03,0.08) | |
| HD INF IV + MTX | 2.60(0.72,8.87) | 2.49(0.73,7.77) | 0.04(‐0.01,0.17) | |
| HD TOCI IV + DMARD | 5.27(0.75,37.47) | 4.71(0.76,26.81) | 0.09(‐0.02,0.33) | |
| HD TOFA PO + MTX | HD GOLI SC + MTX | 1.04(0.26,3.64) | 1.04(0.28,3.43) | 0.00(‐0.08,0.07) |
| HD CERTO SC + MTX | 0.97(0.24,3.38) | 0.97(0.26,3.22) | 0.00(‐0.08,0.06) | |
| HD INF IV + MTX | 1.90(0.44,6.86) | 1.84(0.47,6.16) | 0.02(‐0.05,0.14) | |
| HD TOCI IV + DMARD | 3.96(0.40,39.07) | 3.58(0.44,28.51) | 0.08(‐0.06,0.32) | |
| HD CERTO SC + MTX | HD TOFA PO + MTX | 0.91(0.26,3.43) | 0.92(0.27,3.24) | 0.00(‐0.07,0.06) |
| HD INF IV + MTX | 1.82(0.52,6.26) | 1.76(0.54,5.62) | 0.02(‐0.04,0.14) | |
| HD TOCI IV + DMARD | 3.85(0.42,36.87) | 3.47(0.46,26.58) | 0.08(‐0.07,0.32) | |
| HD INF IV + MTX | HD CERTO SC + MTX | 2.00(0.55,6.87) | 1.92(0.56,6.22) | 0.03(‐0.03,0.14) |
| HD TOCI IV + DMARD | 4.22(0.52,38.97) | 3.79(0.54,28.18) | 0.08(‐0.05,0.33) | |
| HD TOCI IV + DMARD | HD INF IV + MTX | 2.01(0.26,22.03) | 1.88(0.30,16.07) | 0.05(‐0.13,0.30) |
| Random‐effects model | Residual deviance | 128 vs 132 data points | ||
| Deviance information criteria | 641.601 | |||
| Fixed‐effect model | Residual deviance | 131 vs 132 data points | ||
| Deviance information criteria | 641.171 | |||
| Note | ||||
| Total participants | 20,850 | |||
| Total studies | 52 | |||
| 2‐arm | 34 | |||
| 3‐arm | 11 | |||
| 4‐arm | 6 | |||
| 7‐arm | 1 | |||
Appendix 19. Withdrawals due to adverse events: subgroup ‐ trial duration (6 to 12 months)
| Withdrawals intermediate: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD ETN SC | MTX + PL | 1.99(0.58,6.33) | 1.91(0.59,5.20) | 0.04(‐0.02,0.18) |
| SD ETN SC + MTX | 1.43(0.34,6.31) | 1.41(0.35,5.26) | 0.02(‐0.03,0.17) | |
| SD ADA SC + MTX | 1.63(0.54,5.06) | 1.59(0.55,4.32) | 0.03(‐0.02,0.14) | |
| SD INF IV + MTX | 0.64(0.14,2.88) | 0.65(0.15,2.68) | ‐0.02(‐0.04,0.07) | |
| SD RITUX IV + MTX | 0.25(0.01,2.63) | 0.26(0.01,2.49) | ‐0.03(‐0.05,0.06) | |
| SD TOFA PO + MTX | 1.74(0.56,5.52) | 1.69(0.57,4.65) | 0.03(‐0.02,0.16) | |
| LD ETN SC | 1.78(0.58,6.22) | 1.72(0.59,5.12) | 0.03(‐0.02,0.17) | |
| LD RITUX IV + MTX | 1.89(0.36,12.55) | 1.82(0.37,8.63) | 0.04(‐0.03,0.29) | |
| LD ETN SC + MTX | 0.76(0.13,3.84) | 0.77(0.14,3.46) | ‐0.01(‐0.04,0.10) | |
| HD INF IV + MTX | 0.51(0.10,2.39) | 0.52(0.10,2.26) | ‐0.02(‐0.05,0.05) | |
| HD TOFA PO + MTX | 1.23(0.38,3.95) | 1.22(0.39,3.52) | 0.01(‐0.03,0.11) | |
| SD ETN SC + MTX | SD ETN SC | 0.73(0.12,4.66) | 0.75(0.14,4.02) | ‐0.02(‐0.17,0.13) |
| SD ADA SC + MTX | 0.81(0.18,4.57) | 0.82(0.21,3.97) | ‐0.01(‐0.15,0.12) | |
| SD INF IV + MTX | 0.32(0.05,2.28) | 0.34(0.06,2.14) | ‐0.05(‐0.19,0.05) | |
| SD RITUX IV + MTX | 0.13(0.00,1.87) | 0.14(0.00,1.79) | ‐0.07(‐0.21,0.03) | |
| SD TOFA PO + MTX | 0.87(0.18,4.77) | 0.88(0.21,4.08) | ‐0.01(‐0.15,0.13) | |
| LD ETN SC | 0.90(0.37,2.59) | 0.91(0.41,2.36) | ‐0.01(‐0.09,0.08) | |
| LD RITUX IV + MTX | 0.95(0.12,8.78) | 0.96(0.15,6.44) | 0.00(‐0.16,0.25) | |
| LD ETN SC + MTX | 0.38(0.05,2.81) | 0.40(0.06,2.58) | ‐0.05(‐0.19,0.07) | |
| HD INF IV + MTX | 0.25(0.04,1.89) | 0.27(0.04,1.81) | ‐0.06(‐0.20,0.03) | |
| HD TOFA PO + MTX | 0.61(0.12,3.45) | 0.63(0.15,3.12) | ‐0.03(‐0.17,0.08) | |
| SD ADA SC + MTX | SD ETN SC + MTX | 1.14(0.18,7.31) | 1.13(0.21,6.24) | 0.01(‐0.15,0.13) |
| SD INF IV + MTX | 0.45(0.06,3.66) | 0.47(0.07,3.37) | ‐0.03(‐0.18,0.06) | |
| SD RITUX IV + MTX | 0.17(0.00,2.77) | 0.18(0.00,2.60) | ‐0.05(‐0.19,0.05) | |
| SD TOFA PO + MTX | 1.23(0.19,7.83) | 1.22(0.22,6.65) | 0.01(‐0.14,0.14) | |
| LD ETN SC | 1.25(0.21,8.21) | 1.23(0.24,6.99) | 0.01(‐0.14,0.16) | |
| LD RITUX IV + MTX | 1.33(0.14,14.20) | 1.30(0.16,10.48) | 0.02(‐0.14,0.27) | |
| LD ETN SC + MTX | 0.53(0.10,2.49) | 0.55(0.12,2.37) | ‐0.03(‐0.14,0.05) | |
| HD INF IV + MTX | 0.36(0.04,2.95) | 0.37(0.05,2.81) | ‐0.04(‐0.18,0.04) | |
| HD TOFA PO + MTX | 0.88(0.13,5.64) | 0.88(0.15,5.03) | ‐0.01(‐0.16,0.10) | |
| SD INF IV + MTX | SD ADA SC + MTX | 0.39(0.06,2.49) | 0.41(0.07,2.33) | ‐0.04(‐0.16,0.05) |
| SD RITUX IV + MTX | 0.15(0.00,2.02) | 0.16(0.00,1.92) | ‐0.06(‐0.17,0.04) | |
| SD TOFA PO + MTX | 1.08(0.21,5.10) | 1.07(0.24,4.39) | 0.00(‐0.12,0.13) | |
| LD ETN SC | 1.10(0.22,5.67) | 1.09(0.26,4.78) | 0.01(‐0.12,0.15) | |
| LD RITUX IV + MTX | 1.17(0.16,10.34) | 1.15(0.18,7.56) | 0.01(‐0.12,0.27) | |
| LD ETN SC + MTX | 0.46(0.06,3.13) | 0.48(0.07,2.86) | ‐0.03(‐0.15,0.08) | |
| HD INF IV + MTX | 0.31(0.04,1.93) | 0.33(0.05,1.85) | ‐0.04(‐0.16,0.03) | |
| HD TOFA PO + MTX | 0.76(0.15,3.56) | 0.77(0.17,3.22) | ‐0.02(‐0.14,0.09) | |
| SD RITUX IV + MTX | SD INF IV + MTX | 0.38(0.01,6.14) | 0.39(0.01,5.73) | ‐0.02(‐0.10,0.07) |
| SD TOFA PO + MTX | 2.74(0.41,17.55) | 2.59(0.43,15.01) | 0.04(‐0.05,0.17) | |
| LD ETN SC | 2.78(0.45,19.95) | 2.64(0.47,16.66) | 0.04(‐0.05,0.19) | |
| LD RITUX IV + MTX | 2.92(0.32,32.83) | 2.74(0.34,24.34) | 0.05(‐0.05,0.30) | |
| LD ETN SC + MTX | 1.20(0.12,10.87) | 1.19(0.13,9.61) | 0.00(‐0.08,0.11) | |
| HD INF IV + MTX | 0.79(0.14,3.96) | 0.80(0.15,3.80) | ‐0.01(‐0.07,0.05) | |
| HD TOFA PO + MTX | 1.94(0.28,12.38) | 1.88(0.30,11.03) | 0.02(‐0.07,0.12) | |
| SD TOFA PO + MTX | SD RITUX IV + MTX | 7.15(0.48,331.20) | 6.62(0.51,287.70) | 0.06(‐0.04,0.19) |
| LD ETN SC | 7.24(0.50,284.80) | 6.67(0.53,240.60) | 0.06(‐0.04,0.20) | |
| LD RITUX IV + MTX | 7.53(0.85,282.10) | 6.80(0.86,238.80) | 0.06(‐0.01,0.28) | |
| LD ETN SC + MTX | 3.23(0.15,137.40) | 3.13(0.16,122.50) | 0.02(‐0.07,0.13) | |
| HD INF IV + MTX | 2.10(0.12,91.78) | 2.07(0.13,86.53) | 0.01(‐0.08,0.08) | |
| HD TOFA PO + MTX | 4.97(0.34,226.00) | 4.73(0.36,203.00) | 0.04(‐0.05,0.14) | |
| LD ETN SC | SD TOFA PO + MTX | 1.03(0.21,5.39) | 1.03(0.24,4.59) | 0.00(‐0.13,0.15) |
| LD RITUX IV + MTX | 1.08(0.14,10.04) | 1.08(0.16,7.20) | 0.01(‐0.14,0.27) | |
| LD ETN SC + MTX | 0.43(0.06,3.17) | 0.45(0.07,2.90) | ‐0.04(‐0.17,0.08) | |
| HD INF IV + MTX | 0.29(0.04,1.99) | 0.30(0.04,1.91) | ‐0.05(‐0.18,0.04) | |
| HD TOFA PO + MTX | 0.71(0.24,1.98) | 0.72(0.27,1.87) | ‐0.02(‐0.11,0.04) | |
| LD RITUX IV + MTX | LD ETN SC | 1.04(0.13,9.29) | 1.03(0.15,6.80) | 0.00(‐0.15,0.26) |
| LD ETN SC + MTX | 0.42(0.05,3.01) | 0.44(0.06,2.74) | ‐0.04(‐0.18,0.07) | |
| HD INF IV + MTX | 0.28(0.04,1.94) | 0.30(0.04,1.86) | ‐0.05(‐0.19,0.03) | |
| HD TOFA PO + MTX | 0.69(0.12,3.47) | 0.71(0.15,3.16) | ‐0.02(‐0.17,0.08) | |
| LD ETN SC + MTX | LD RITUX IV + MTX | 0.40(0.03,4.13) | 0.43(0.04,3.79) | ‐0.04(‐0.30,0.08) |
| HD INF IV + MTX | 0.27(0.02,2.52) | 0.29(0.03,2.40) | ‐0.05(‐0.31,0.04) | |
| HD TOFA PO + MTX | 0.65(0.07,5.02) | 0.67(0.09,4.56) | ‐0.03(‐0.28,0.09) | |
| HD INF IV + MTX | LD ETN SC + MTX | 0.68(0.07,6.41) | 0.69(0.08,5.95) | ‐0.01(‐0.12,0.06) |
| HD TOFA PO + MTX | 1.63(0.22,12.55) | 1.59(0.24,11.11) | 0.02(‐0.09,0.12) | |
| HD TOFA PO + MTX | HD INF IV + MTX | 2.48(0.35,17.87) | 2.39(0.37,15.96) | 0.03(‐0.05,0.13) |
| Random‐effects model | Residual deviance | 19.23 vs 19 data points | ||
| Deviance information criteria | 109.73 | |||
| Fixed‐effect model | Residual deviance | 19.57 vs 19 data points | ||
| Deviance information criteria | 109.933 | |||
| Note | ||||
| Total participants | 3279 | |||
| Total studies | 7 | |||
| 2‐arm | 2 | |||
| 3‐arm | 5 | |||
Appendix 20. Serious adverse events: main analysis
| SAE: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX | PL | 1.32(0.38,6.19) | 1.30(0.39,5.23) | 0.01(‐0.03,0.15) |
| DMARD | 0.63(0.20,2.49) | 0.63(0.21,2.37) | ‐0.01(‐0.04,0.05) | |
| MTX + DMARD | 0.74(0.14,4.06) | 0.75(0.14,3.67) | ‐0.01(‐0.04,0.09) | |
| SD ETN SC | 1.55(0.50,6.08) | 1.52(0.51,5.18) | 0.02(‐0.02,0.14) | |
| SD ADA SC | 1.08(0.66,1.94) | 1.08(0.67,1.88) | 0.00(‐0.01,0.03) | |
| SD TOCI IV | 1.22(0.47,3.38) | 1.21(0.48,3.10) | 0.01(‐0.02,0.08) | |
| SD TOFA PO | 0.38(0.15,0.93) | 0.39(0.15,0.94) | ‐0.02(‐0.04,0.00) | |
| SD TOCI SC | 1.07(0.33,3.70) | 1.07(0.34,3.39) | 0.00(‐0.03,0.09) | |
| SD CERTO SC | 4.67(1.33,19.91) | 4.11(1.31,12.87) | 0.11(0.01,0.35) | |
| SD GOLI IV | 1.46(0.17,14.63) | 1.43(0.18,9.91) | 0.01(‐0.03,0.32) | |
| SD RITUX IV | 0.55(0.07,5.11) | 0.56(0.07,4.50) | ‐0.01(‐0.04,0.13) | |
| SD INF IV + MTX | 1.16(0.31,5.32) | 1.15(0.32,4.67) | 0.01(‐0.03,0.13) | |
| SD ETN SC + MTX | 1.28(0.34,5.50) | 1.27(0.35,4.80) | 0.01(‐0.03,0.14) | |
| SD ADA SC + MTX | 1.20(0.34,5.99) | 1.19(0.35,5.12) | 0.01(‐0.03,0.14) | |
| SD ABA IV + MTX | 1.07(0.30,4.66) | 1.06(0.30,4.17) | 0.00(‐0.03,0.11) | |
| SD RITUX IV + MTX | 1.43(0.37,7.39) | 1.40(0.38,6.09) | 0.01(‐0.03,0.17) | |
| SD ABA SC + MTX | 0.89(0.24,4.28) | 0.89(0.25,3.87) | 0.00(‐0.03,0.10) | |
| SD GOLI SC + MTX | 2.75(0.52,20.39) | 2.58(0.53,12.10) | 0.06(‐0.02,0.39) | |
| SD CERTO SC + MTX | 2.02(0.54,11.76) | 1.94(0.55,8.55) | 0.03(‐0.02,0.26) | |
| SD TOFA PO + MTX | 2.59(0.63,14.30) | 2.44(0.64,9.80) | 0.05(‐0.01,0.31) | |
| SD GOLI IV + MTX | 4.39(0.59,34.27) | 3.89(0.60,16.03) | 0.10(‐0.01,0.53) | |
| SD ANA SC + MTX | 1.80(0.35,12.98) | 1.75(0.36,9.03) | 0.03(‐0.02,0.28) | |
| SD ETN SC + DMARD | 1.28(0.44,4.62) | 1.26(0.45,4.11) | 0.01(‐0.02,0.10) | |
| SD ABA IV + DMARD | 0.67(0.18,2.94) | 0.68(0.19,2.77) | ‐0.01(‐0.04,0.06) | |
| SD ADA SC + DMARD | 0.45(0.10,2.35) | 0.46(0.11,2.25) | ‐0.02(‐0.04,0.04) | |
| SD ANA + DMARD | 0.64(0.17,2.85) | 0.65(0.17,2.67) | ‐0.01(‐0.04,0.06) | |
| SD CERTO SC + DMARD | 0.44(0.08,2.73) | 0.45(0.08,2.57) | ‐0.02(‐0.04,0.06) | |
| SD TOCI SC + DMARD | 0.81(0.18,4.36) | 0.81(0.19,3.89) | ‐0.01(‐0.04,0.10) | |
| LD ADA SC | 0.64(0.30,1.38) | 0.65(0.30,1.36) | ‐0.01(‐0.03,0.01) | |
| LD ETN SC | 0.99(0.21,5.85) | 0.99(0.22,5.04) | 0.00(‐0.04,0.14) | |
| LD GOLI IV | 6.90(1.23,55.27) | 5.64(1.22,19.92) | 0.17(0.01,0.64) | |
| LD RITUX IV + MTX | 1.23(0.31,6.12) | 1.22(0.31,5.22) | 0.01(‐0.03,0.15) | |
| LD ABA IV + MTX | 1.67(0.38,8.47) | 1.63(0.39,6.78) | 0.02(‐0.02,0.20) | |
| LD CERTO SC + MTX | 2.27(0.26,18.03) | 2.16(0.26,11.59) | 0.04(‐0.03,0.36) | |
| LD ETN SC + MTX | 0.64(0.13,3.60) | 0.65(0.13,3.31) | ‐0.01(‐0.04,0.08) | |
| LD GOLI IV + MTX | 3.95(0.66,32.35) | 3.55(0.67,15.74) | 0.09(‐0.01,0.51) | |
| HD TOCI IV | 1.24(0.34,5.83) | 1.23(0.35,5.01) | 0.01(‐0.03,0.14) | |
| HD TOFA PO | 0.52(0.23,1.24) | 0.53(0.24,1.23) | ‐0.02(‐0.04,0.01) | |
| HD GOLI SC | 1.78(0.34,12.98) | 1.73(0.35,9.30) | 0.03(‐0.03,0.28) | |
| HD ADA SC | 0.96(0.48,2.09) | 0.96(0.49,2.02) | 0.00(‐0.02,0.03) | |
| HD GOLI SC + MTX | 3.85(0.63,25.39) | 3.49(0.64,14.17) | 0.09(‐0.01,0.44) | |
| HD TOCI IV + MTX | 1.44(0.34,7.89) | 1.42(0.35,6.47) | 0.01(‐0.03,0.19) | |
| HD TOFA PO + MTX | 2.11(0.52,12.09) | 2.02(0.53,8.78) | 0.04(‐0.02,0.27) | |
| HD INF IV + MTX | 1.37(0.35,6.87) | 1.36(0.35,5.76) | 0.01(‐0.03,0.17) | |
| HD CERTO SC + MTX | 2.54(0.59,16.81) | 2.40(0.60,10.92) | 0.05(‐0.02,0.34) | |
| HD TOCI IV + DMARD | 0.95(0.27,3.95) | 0.96(0.28,3.57) | 0.00(‐0.03,0.09) | |
| DMARD | MTX | 0.46(0.20,1.02) | 0.47(0.22,1.02) | ‐0.02(‐0.12,0.00) |
| MTX + DMARD | 0.55(0.14,1.81) | 0.57(0.15,1.76) | ‐0.02(‐0.12,0.03) | |
| SD ETN SC | 1.14(0.58,2.31) | 1.13(0.60,2.23) | 0.01(‐0.05,0.05) | |
| SD ADA SC | 0.82(0.19,2.78) | 0.82(0.22,2.69) | ‐0.01(‐0.14,0.03) | |
| SD TOCI IV | 0.88(0.19,4.16) | 0.88(0.21,3.92) | ‐0.01(‐0.13,0.06) | |
| SD TOFA PO | 0.29(0.05,1.22) | 0.30(0.06,1.22) | ‐0.03(‐0.17,0.00) | |
| SD TOCI SC | 0.77(0.14,4.64) | 0.78(0.16,4.27) | ‐0.01(‐0.13,0.08) | |
| SD CERTO SC | 3.34(0.45,28.48) | 2.98(0.49,19.53) | 0.09(‐0.07,0.34) | |
| SD GOLI IV | 1.04(0.13,7.94) | 1.04(0.14,6.09) | 0.00(‐0.09,0.25) | |
| SD RITUX IV | 0.42(0.07,1.90) | 0.44(0.08,1.80) | ‐0.02(‐0.11,0.05) | |
| SD INF IV + MTX | 0.89(0.55,1.34) | 0.89(0.57,1.31) | 0.00(‐0.04,0.02) | |
| SD ETN SC + MTX | 0.97(0.43,1.95) | 0.97(0.46,1.86) | 0.00(‐0.06,0.05) | |
| SD ADA SC + MTX | 0.92(0.48,1.67) | 0.92(0.50,1.61) | 0.00(‐0.05,0.04) | |
| SD ABA IV + MTX | 0.80(0.51,1.20) | 0.81(0.53,1.19) | ‐0.01(‐0.05,0.01) | |
| SD RITUX IV + MTX | 1.05(0.65,1.79) | 1.05(0.66,1.70) | 0.00(‐0.03,0.05) | |
| SD ABA SC + MTX | 0.68(0.36,1.20) | 0.69(0.37,1.18) | ‐0.01(‐0.07,0.01) | |
| SD GOLI SC + MTX | 1.99(0.68,6.54) | 1.87(0.69,5.14) | 0.04(‐0.02,0.28) | |
| SD CERTO SC + MTX | 1.55(0.91,2.73) | 1.50(0.91,2.47) | 0.02(0.00,0.13) | |
| SD TOFA PO + MTX | 1.93(0.88,4.43) | 1.83(0.89,3.79) | 0.04(‐0.01,0.20) | |
| SD GOLI IV + MTX | 3.06(0.54,19.59) | 2.68(0.55,12.28) | 0.08(‐0.03,0.45) | |
| SD ANA SC + MTX | 1.32(0.45,4.19) | 1.30(0.46,3.53) | 0.01(‐0.04,0.18) | |
| SD ETN SC + DMARD | 0.93(0.39,2.13) | 0.94(0.42,2.07) | 0.00(‐0.08,0.04) | |
| SD ABA IV + DMARD | 0.49(0.18,1.33) | 0.51(0.19,1.31) | ‐0.02(‐0.12,0.01) | |
| SD ADA SC + DMARD | 0.33(0.09,1.06) | 0.34(0.10,1.06) | ‐0.03(‐0.13,0.00) | |
| SD ANA + DMARD | 0.47(0.15,1.31) | 0.48(0.16,1.29) | ‐0.02(‐0.12,0.01) | |
| SD CERTO SC + DMARD | 0.32(0.06,1.43) | 0.33(0.07,1.40) | ‐0.03(‐0.14,0.02) | |
| SD TOCI SC + DMARD | 0.61(0.16,2.08) | 0.62(0.17,1.99) | ‐0.02(‐0.11,0.05) | |
| LD ADA SC | 0.46(0.09,2.07) | 0.48(0.11,2.04) | ‐0.02(‐0.16,0.02) | |
| LD ETN SC | 0.75(0.28,2.04) | 0.76(0.30,1.93) | ‐0.01(‐0.08,0.05) | |
| LD GOLI IV | 5.07(0.99,30.48) | 3.97(0.99,15.67) | 0.15(0.00,0.57) | |
| LD RITUX IV + MTX | 0.90(0.55,1.57) | 0.91(0.56,1.52) | 0.00(‐0.04,0.04) | |
| LD ABA IV + MTX | 1.23(0.56,2.58) | 1.21(0.58,2.38) | 0.01(‐0.03,0.10) | |
| LD CERTO SC + MTX | 1.57(0.36,6.28) | 1.51(0.37,4.91) | 0.02(‐0.05,0.27) | |
| LD ETN SC + MTX | 0.48(0.16,1.34) | 0.49(0.17,1.31) | ‐0.02(‐0.10,0.01) | |
| LD GOLI IV + MTX | 2.88(0.52,16.55) | 2.56(0.54,11.00) | 0.07(‐0.03,0.43) | |
| HD TOCI IV | 0.91(0.44,1.90) | 0.91(0.46,1.82) | 0.00(‐0.06,0.05) | |
| HD TOFA PO | 0.39(0.07,1.82) | 0.41(0.08,1.80) | ‐0.03(‐0.17,0.01) | |
| HD GOLI SC | 1.30(0.36,4.60) | 1.28(0.37,3.89) | 0.01(‐0.05,0.19) | |
| HD ADA SC | 0.73(0.16,2.78) | 0.74(0.18,2.69) | ‐0.01(‐0.14,0.03) | |
| HD GOLI SC + MTX | 2.77(0.98,8.62) | 2.48(0.99,6.04) | 0.07(0.00,0.34) | |
| HD TOCI IV + MTX | 1.04(0.41,2.80) | 1.04(0.43,2.56) | 0.00(‐0.05,0.10) | |
| HD TOFA PO + MTX | 1.62(0.71,3.71) | 1.56(0.73,3.23) | 0.02(‐0.02,0.16) | |
| HD INF IV + MTX | 1.03(0.59,1.77) | 1.03(0.60,1.68) | 0.00(‐0.03,0.05) | |
| HD CERTO SC + MTX | 1.90(0.89,4.37) | 1.80(0.90,3.55) | 0.04(0.00,0.22) | |
| HD TOCI IV + DMARD | 0.69(0.26,1.84) | 0.71(0.28,1.79) | ‐0.01(‐0.10,0.03) | |
| MTX + DMARD | DMARD | 1.23(0.26,4.52) | 1.23(0.27,4.20) | 0.00(‐0.03,0.08) |
| SD ETN SC | 2.47(1.21,5.34) | 2.38(1.20,4.94) | 0.03(0.01,0.11) | |
| SD ADA SC | 1.75(0.48,5.24) | 1.72(0.50,5.03) | 0.02(‐0.04,0.05) | |
| SD TOCI IV | 1.88(0.43,7.81) | 1.83(0.45,7.34) | 0.02(‐0.04,0.09) | |
| SD TOFA PO | 0.61(0.11,2.37) | 0.62(0.12,2.34) | ‐0.01(‐0.07,0.01) | |
| SD TOCI SC | 1.67(0.34,8.83) | 1.64(0.35,8.08) | 0.01(‐0.04,0.10) | |
| SD CERTO SC | 7.36(1.10,47.68) | 6.36(1.09,33.14) | 0.12(0.00,0.36) | |
| SD GOLI IV | 2.34(0.26,17.59) | 2.25(0.27,13.34) | 0.03(‐0.03,0.31) | |
| SD RITUX IV | 0.93(0.13,5.38) | 0.93(0.13,4.80) | 0.00(‐0.04,0.12) | |
| SD INF IV + MTX | 1.91(0.78,4.86) | 1.87(0.79,4.43) | 0.02(‐0.01,0.11) | |
| SD ETN SC + MTX | 2.10(0.75,5.64) | 2.04(0.76,5.14) | 0.02(‐0.01,0.12) | |
| SD ADA SC + MTX | 1.97(0.74,5.38) | 1.92(0.75,4.85) | 0.02(‐0.01,0.12) | |
| SD ABA IV + MTX | 1.73(0.72,4.31) | 1.69(0.73,4.00) | 0.01(‐0.01,0.09) | |
| SD RITUX IV + MTX | 2.27(0.89,6.25) | 2.19(0.90,5.56) | 0.03(0.00,0.15) | |
| SD ABA SC + MTX | 1.47(0.55,3.88) | 1.45(0.56,3.61) | 0.01(‐0.02,0.08) | |
| SD GOLI SC + MTX | 4.31(1.18,18.62) | 3.93(1.17,13.56) | 0.07(0.00,0.37) | |
| SD CERTO SC + MTX | 3.40(1.24,9.31) | 3.18(1.23,7.77) | 0.05(0.00,0.23) | |
| SD TOFA PO + MTX | 4.19(1.43,12.67) | 3.83(1.41,10.16) | 0.06(0.01,0.29) | |
| SD GOLI IV + MTX | 6.65(1.04,48.72) | 5.71(1.04,29.61) | 0.11(0.00,0.52) | |
| SD ANA SC + MTX | 2.83(0.75,12.17) | 2.70(0.76,9.57) | 0.04(‐0.01,0.27) | |
| SD ETN SC + DMARD | 2.01(1.07,3.92) | 1.95(1.07,3.73) | 0.02(0.00,0.08) | |
| SD ABA IV + DMARD | 1.06(0.58,1.94) | 1.06(0.59,1.88) | 0.00(‐0.02,0.03) | |
| SD ADA SC + DMARD | 0.70(0.30,1.67) | 0.70(0.31,1.64) | ‐0.01(‐0.03,0.02) | |
| SD ANA + DMARD | 1.00(0.50,2.08) | 1.00(0.50,2.00) | 0.00(‐0.02,0.03) | |
| SD CERTO SC + DMARD | 0.69(0.18,2.56) | 0.69(0.18,2.44) | ‐0.01(‐0.04,0.04) | |
| SD TOCI SC + DMARD | 1.28(0.48,3.49) | 1.27(0.49,3.26) | 0.01(‐0.02,0.08) | |
| LD ADA SC | 1.00(0.22,3.79) | 1.00(0.24,3.68) | 0.00(‐0.06,0.03) | |
| LD ETN SC | 1.61(0.52,5.00) | 1.58(0.53,4.49) | 0.01(‐0.02,0.12) | |
| LD GOLI IV | 10.93(1.79,72.89) | 8.52(1.74,36.66) | 0.18(0.02,0.63) | |
| LD RITUX IV + MTX | 1.93(0.77,5.40) | 1.88(0.77,4.86) | 0.02(‐0.01,0.12) | |
| LD ABA IV + MTX | 2.66(0.90,8.38) | 2.54(0.90,7.24) | 0.03(0.00,0.18) | |
| LD CERTO SC + MTX | 3.33(0.61,18.14) | 3.11(0.61,12.90) | 0.05(‐0.01,0.34) | |
| LD ETN SC + MTX | 1.05(0.27,3.72) | 1.05(0.28,3.53) | 0.00(‐0.03,0.07) | |
| LD GOLI IV + MTX | 6.26(0.97,42.72) | 5.46(0.97,25.22) | 0.10(0.00,0.50) | |
| HD TOCI IV | 1.95(1.00,4.21) | 1.90(1.00,3.89) | 0.02(0.00,0.11) | |
| HD TOFA PO | 0.83(0.18,3.68) | 0.83(0.19,3.60) | 0.00(‐0.06,0.02) | |
| HD GOLI SC | 2.76(0.71,12.48) | 2.62(0.72,9.84) | 0.04(‐0.01,0.26) | |
| HD ADA SC | 1.56(0.38,5.47) | 1.54(0.40,5.21) | 0.01(‐0.04,0.05) | |
| HD GOLI SC + MTX | 6.03(1.61,24.27) | 5.27(1.58,16.49) | 0.10(0.01,0.42) | |
| HD TOCI IV + MTX | 2.25(0.85,6.67) | 2.18(0.85,5.70) | 0.03(0.00,0.16) | |
| HD TOFA PO + MTX | 3.49(1.15,10.74) | 3.26(1.14,8.78) | 0.05(0.00,0.25) | |
| HD INF IV + MTX | 2.21(0.84,6.17) | 2.14(0.84,5.57) | 0.02(0.00,0.14) | |
| HD CERTO SC + MTX | 4.14(1.31,13.83) | 3.79(1.30,10.42) | 0.06(0.01,0.32) | |
| HD TOCI IV + DMARD | 1.51(0.87,2.64) | 1.49(0.88,2.52) | 0.01(0.00,0.06) | |
| SD ETN SC | MTX + DMARD | 2.07(0.61,8.51) | 1.99(0.63,7.91) | 0.02(‐0.03,0.11) |
| SD ADA SC | 1.45(0.29,7.77) | 1.44(0.32,7.46) | 0.01(‐0.09,0.05) | |
| SD TOCI IV | 1.62(0.28,9.88) | 1.59(0.30,9.28) | 0.01(‐0.08,0.08) | |
| SD TOFA PO | 0.51(0.07,3.22) | 0.52(0.08,3.17) | ‐0.01(‐0.12,0.02) | |
| SD TOCI SC | 1.41(0.22,10.26) | 1.39(0.23,9.55) | 0.01(‐0.09,0.09) | |
| SD CERTO SC | 6.03(0.71,62.12) | 5.22(0.74,44.98) | 0.11(‐0.03,0.35) | |
| SD GOLI IV | 1.88(0.17,22.71) | 1.82(0.18,17.86) | 0.02(‐0.06,0.30) | |
| SD RITUX IV | 0.77(0.09,5.73) | 0.78(0.10,5.25) | 0.00(‐0.08,0.11) | |
| SD INF IV + MTX | 1.59(0.48,6.58) | 1.56(0.50,6.12) | 0.01(‐0.04,0.10) | |
| SD ETN SC + MTX | 1.72(0.66,5.48) | 1.68(0.67,5.18) | 0.02(‐0.02,0.09) | |
| SD ADA SC + MTX | 1.64(0.46,7.91) | 1.61(0.48,7.20) | 0.01(‐0.04,0.12) | |
| SD ABA IV + MTX | 1.44(0.41,6.00) | 1.41(0.42,5.69) | 0.01(‐0.05,0.09) | |
| SD RITUX IV + MTX | 1.89(0.55,8.74) | 1.83(0.57,8.00) | 0.02(‐0.03,0.14) | |
| SD ABA SC + MTX | 1.21(0.32,5.57) | 1.20(0.34,5.24) | 0.00(‐0.06,0.08) | |
| SD GOLI SC + MTX | 3.67(0.71,22.21) | 3.33(0.73,17.24) | 0.06(‐0.01,0.35) | |
| SD CERTO SC + MTX | 2.81(0.73,13.04) | 2.64(0.76,11.29) | 0.04(‐0.01,0.23) | |
| SD TOFA PO + MTX | 3.53(0.79,17.73) | 3.23(0.80,14.86) | 0.06(‐0.01,0.28) | |
| SD GOLI IV + MTX | 5.66(0.71,56.08) | 4.81(0.73,34.07) | 0.10(‐0.02,0.51) | |
| SD ANA SC + MTX | 2.41(0.48,13.72) | 2.29(0.50,11.11) | 0.03(‐0.03,0.24) | |
| SD ETN SC + DMARD | 1.65(0.44,7.67) | 1.62(0.46,7.31) | 0.01(‐0.05,0.08) | |
| SD ABA IV + DMARD | 0.87(0.20,4.57) | 0.87(0.21,4.41) | 0.00(‐0.08,0.05) | |
| SD ADA SC + DMARD | 0.59(0.11,3.41) | 0.60(0.12,3.35) | ‐0.01(‐0.10,0.03) | |
| SD ANA + DMARD | 0.82(0.19,4.49) | 0.83(0.20,4.36) | 0.00(‐0.08,0.05) | |
| SD CERTO SC + DMARD | 0.59(0.08,4.47) | 0.60(0.09,4.23) | ‐0.01(‐0.10,0.05) | |
| SD TOCI SC + DMARD | 1.08(0.20,6.42) | 1.08(0.21,5.99) | 0.00(‐0.08,0.08) | |
| LD ADA SC | 0.85(0.14,5.65) | 0.85(0.16,5.47) | 0.00(‐0.10,0.03) | |
| LD ETN SC | 1.39(0.28,6.71) | 1.36(0.30,6.18) | 0.01(‐0.06,0.11) | |
| LD GOLI IV | 8.93(1.27,83.42) | 6.96(1.25,44.05) | 0.17(0.01,0.62) | |
| LD RITUX IV + MTX | 1.63(0.44,7.33) | 1.59(0.46,6.82) | 0.01(‐0.04,0.12) | |
| LD ABA IV + MTX | 2.25(0.55,10.90) | 2.16(0.57,9.69) | 0.03(‐0.03,0.17) | |
| LD CERTO SC + MTX | 2.90(0.38,20.52) | 2.72(0.39,15.39) | 0.04(‐0.03,0.34) | |
| LD ETN SC + MTX | 0.86(0.20,4.02) | 0.87(0.21,3.83) | 0.00(‐0.07,0.06) | |
| LD GOLI IV + MTX | 5.16(0.64,51.52) | 4.50(0.66,31.65) | 0.09(‐0.02,0.49) | |
| HD TOCI IV | 1.62(0.43,7.95) | 1.59(0.45,7.35) | 0.01(‐0.05,0.11) | |
| HD TOFA PO | 0.71(0.11,4.62) | 0.72(0.12,4.56) | ‐0.01(‐0.11,0.03) | |
| HD GOLI SC | 2.32(0.42,14.31) | 2.22(0.44,11.65) | 0.03(‐0.04,0.25) | |
| HD ADA SC | 1.27(0.23,7.35) | 1.26(0.25,7.04) | 0.01(‐0.09,0.05) | |
| HD GOLI SC + MTX | 5.02(1.02,28.62) | 4.36(1.02,20.17) | 0.09(0.00,0.40) | |
| HD TOCI IV + MTX | 1.89(0.46,10.81) | 1.83(0.48,9.52) | 0.02(‐0.04,0.16) | |
| HD TOFA PO + MTX | 2.94(0.63,15.21) | 2.76(0.65,12.87) | 0.04(‐0.02,0.24) | |
| HD INF IV + MTX | 1.84(0.52,8.32) | 1.79(0.54,7.66) | 0.02(‐0.03,0.13) | |
| HD CERTO SC + MTX | 3.39(0.85,17.96) | 3.11(0.86,14.44) | 0.05(‐0.01,0.31) | |
| HD TOCI IV + DMARD | 1.26(0.29,6.68) | 1.25(0.31,6.34) | 0.01(‐0.07,0.07) | |
| SD ADA SC | SD ETN SC | 0.70(0.20,2.02) | 0.71(0.24,1.98) | ‐0.02(‐0.13,0.02) |
| SD TOCI IV | 0.77(0.19,2.97) | 0.78(0.21,2.82) | ‐0.01(‐0.12,0.06) | |
| SD TOFA PO | 0.25(0.05,0.90) | 0.26(0.06,0.90) | ‐0.04(‐0.16,0.00) | |
| SD TOCI SC | 0.68(0.14,3.30) | 0.69(0.16,3.04) | ‐0.02(‐0.13,0.07) | |
| SD CERTO SC | 3.00(0.44,17.80) | 2.69(0.49,12.42) | 0.09(‐0.07,0.33) | |
| SD GOLI IV | 0.95(0.11,6.84) | 0.96(0.12,5.27) | 0.00(‐0.09,0.25) | |
| SD RITUX IV | 0.37(0.05,2.05) | 0.39(0.06,1.91) | ‐0.03(‐0.11,0.06) | |
| SD INF IV + MTX | 0.77(0.34,1.74) | 0.78(0.35,1.66) | ‐0.01(‐0.07,0.04) | |
| SD ETN SC + MTX | 0.84(0.35,1.88) | 0.85(0.37,1.77) | ‐0.01(‐0.06,0.05) | |
| SD ADA SC + MTX | 0.79(0.33,1.98) | 0.80(0.35,1.86) | ‐0.01(‐0.06,0.06) | |
| SD ABA IV + MTX | 0.69(0.32,1.55) | 0.70(0.33,1.50) | ‐0.01(‐0.07,0.03) | |
| SD RITUX IV + MTX | 0.92(0.39,2.26) | 0.93(0.40,2.09) | 0.00(‐0.05,0.08) | |
| SD ABA SC + MTX | 0.58(0.25,1.43) | 0.60(0.26,1.40) | ‐0.02(‐0.08,0.02) | |
| SD GOLI SC + MTX | 1.73(0.50,6.33) | 1.64(0.51,4.73) | 0.03(‐0.03,0.29) | |
| SD CERTO SC + MTX | 1.36(0.57,3.20) | 1.33(0.58,2.78) | 0.02(‐0.03,0.15) | |
| SD TOFA PO + MTX | 1.66(0.63,4.87) | 1.59(0.64,4.06) | 0.03(‐0.03,0.22) | |
| SD GOLI IV + MTX | 2.73(0.45,18.38) | 2.42(0.46,10.85) | 0.08(‐0.04,0.46) | |
| SD ANA SC + MTX | 1.15(0.32,4.39) | 1.14(0.34,3.61) | 0.01(‐0.06,0.20) | |
| SD ETN SC + DMARD | 0.80(0.41,1.58) | 0.81(0.43,1.54) | ‐0.01(‐0.07,0.03) | |
| SD ABA IV + DMARD | 0.43(0.16,1.06) | 0.44(0.18,1.06) | ‐0.03(‐0.11,0.00) | |
| SD ADA SC + DMARD | 0.28(0.09,0.87) | 0.30(0.09,0.88) | ‐0.04(‐0.13,0.00) | |
| SD ANA + DMARD | 0.41(0.14,1.06) | 0.42(0.15,1.06) | ‐0.03(‐0.12,0.00) | |
| SD CERTO SC + DMARD | 0.28(0.06,1.17) | 0.30(0.06,1.15) | ‐0.03(‐0.13,0.01) | |
| SD TOCI SC + DMARD | 0.51(0.15,1.80) | 0.53(0.16,1.71) | ‐0.02(‐0.11,0.04) | |
| LD ADA SC | 0.41(0.10,1.42) | 0.42(0.11,1.41) | ‐0.03(‐0.15,0.01) | |
| LD ETN SC | 0.65(0.24,1.75) | 0.67(0.25,1.66) | ‐0.02(‐0.07,0.05) | |
| LD GOLI IV | 4.37(0.83,26.03) | 3.51(0.84,13.41) | 0.14(‐0.01,0.56) | |
| LD RITUX IV + MTX | 0.79(0.32,1.93) | 0.80(0.34,1.82) | ‐0.01(‐0.06,0.06) | |
| LD ABA IV + MTX | 1.07(0.38,2.98) | 1.06(0.40,2.63) | 0.00(‐0.05,0.12) | |
| LD CERTO SC + MTX | 1.36(0.26,6.57) | 1.33(0.27,4.86) | 0.02(‐0.06,0.27) | |
| LD ETN SC + MTX | 0.42(0.12,1.33) | 0.44(0.13,1.30) | ‐0.03(‐0.10,0.02) | |
| LD GOLI IV + MTX | 2.56(0.41,15.02) | 2.32(0.43,9.33) | 0.07(‐0.04,0.44) | |
| HD TOCI IV | 0.79(0.34,1.92) | 0.80(0.35,1.82) | ‐0.01(‐0.07,0.05) | |
| HD TOFA PO | 0.33(0.07,1.28) | 0.35(0.09,1.27) | ‐0.03(‐0.16,0.01) | |
| HD GOLI SC | 1.13(0.28,4.72) | 1.12(0.30,3.82) | 0.01(‐0.06,0.19) | |
| HD ADA SC | 0.61(0.16,2.11) | 0.63(0.18,2.06) | ‐0.02(‐0.14,0.03) | |
| HD GOLI SC + MTX | 2.49(0.69,8.84) | 2.26(0.70,6.11) | 0.06(‐0.02,0.35) | |
| HD TOCI IV + MTX | 0.91(0.31,2.82) | 0.92(0.33,2.53) | 0.00(‐0.06,0.11) | |
| HD TOFA PO + MTX | 1.36(0.50,4.12) | 1.33(0.52,3.53) | 0.02(‐0.04,0.18) | |
| HD INF IV + MTX | 0.89(0.36,2.23) | 0.89(0.37,2.07) | ‐0.01(‐0.06,0.08) | |
| HD CERTO SC + MTX | 1.65(0.59,4.87) | 1.58(0.60,3.85) | 0.03(‐0.02,0.24) | |
| HD TOCI IV + DMARD | 0.62(0.24,1.47) | 0.63(0.25,1.43) | ‐0.02(‐0.09,0.02) | |
| SD TOCI IV | SD ADA SC | 1.11(0.50,2.57) | 1.11(0.51,2.40) | 0.00(‐0.02,0.06) |
| SD TOFA PO | 0.35(0.12,0.97) | 0.36(0.12,0.97) | ‐0.02(‐0.06,0.00) | |
| SD TOCI SC | 0.98(0.34,2.96) | 0.98(0.35,2.75) | 0.00(‐0.03,0.07) | |
| SD CERTO SC | 4.27(1.05,18.66) | 3.78(1.05,12.53) | 0.11(0.00,0.34) | |
| SD GOLI IV | 1.32(0.15,13.23) | 1.30(0.16,9.17) | 0.01(‐0.04,0.31) | |
| SD RITUX IV | 0.51(0.06,4.56) | 0.52(0.07,4.00) | ‐0.02(‐0.05,0.12) | |
| SD INF IV + MTX | 1.09(0.29,4.61) | 1.08(0.30,4.07) | 0.00(‐0.03,0.12) | |
| SD ETN SC + MTX | 1.18(0.32,4.97) | 1.17(0.33,4.34) | 0.01(‐0.03,0.13) | |
| SD ADA SC + MTX | 1.12(0.31,5.13) | 1.12(0.32,4.44) | 0.00(‐0.04,0.14) | |
| SD ABA IV + MTX | 0.98(0.27,3.98) | 0.98(0.28,3.60) | 0.00(‐0.04,0.10) | |
| SD RITUX IV + MTX | 1.33(0.34,6.06) | 1.31(0.35,5.04) | 0.01(‐0.03,0.16) | |
| SD ABA SC + MTX | 0.83(0.22,3.65) | 0.84(0.23,3.33) | ‐0.01(‐0.04,0.09) | |
| SD GOLI SC + MTX | 2.57(0.47,17.20) | 2.42(0.48,10.44) | 0.05(‐0.02,0.38) | |
| SD CERTO SC + MTX | 1.89(0.50,9.64) | 1.82(0.51,7.22) | 0.03(‐0.02,0.25) | |
| SD TOFA PO + MTX | 2.38(0.62,11.91) | 2.25(0.64,8.45) | 0.05(‐0.02,0.30) | |
| SD GOLI IV + MTX | 4.04(0.52,33.18) | 3.59(0.54,15.66) | 0.10(‐0.02,0.53) | |
| SD ANA SC + MTX | 1.65(0.33,10.63) | 1.61(0.34,7.73) | 0.02(‐0.03,0.27) | |
| SD ETN SC + DMARD | 1.17(0.41,3.76) | 1.16(0.42,3.42) | 0.01(‐0.03,0.10) | |
| SD ABA IV + DMARD | 0.61(0.17,2.53) | 0.62(0.18,2.40) | ‐0.01(‐0.05,0.05) | |
| SD ADA SC + DMARD | 0.41(0.10,2.04) | 0.42(0.10,1.96) | ‐0.02(‐0.05,0.04) | |
| SD ANA + DMARD | 0.59(0.15,2.47) | 0.60(0.16,2.33) | ‐0.01(‐0.05,0.05) | |
| SD CERTO SC + DMARD | 0.40(0.07,2.51) | 0.41(0.07,2.36) | ‐0.02(‐0.05,0.05) | |
| SD TOCI SC + DMARD | 0.73(0.17,3.86) | 0.74(0.18,3.45) | ‐0.01(‐0.04,0.10) | |
| LD ADA SC | 0.59(0.26,1.29) | 0.60(0.27,1.28) | ‐0.01(‐0.04,0.01) | |
| LD ETN SC | 0.93(0.20,4.96) | 0.93(0.20,4.30) | 0.00(‐0.04,0.13) | |
| LD GOLI IV | 6.29(1.07,49.60) | 5.15(1.07,18.65) | 0.16(0.00,0.64) | |
| LD RITUX IV + MTX | 1.14(0.28,5.13) | 1.14(0.29,4.36) | 0.01(‐0.03,0.14) | |
| LD ABA IV + MTX | 1.54(0.36,7.36) | 1.51(0.37,6.00) | 0.02(‐0.03,0.19) | |
| LD CERTO SC + MTX | 2.06(0.25,15.74) | 1.97(0.25,10.23) | 0.04(‐0.04,0.35) | |
| LD ETN SC + MTX | 0.59(0.12,3.21) | 0.60(0.12,2.95) | ‐0.01(‐0.05,0.08) | |
| LD GOLI IV + MTX | 3.65(0.56,29.09) | 3.29(0.57,14.53) | 0.09(‐0.02,0.50) | |
| HD TOCI IV | 1.13(0.31,4.81) | 1.13(0.32,4.20) | 0.00(‐0.03,0.13) | |
| HD TOFA PO | 0.48(0.18,1.33) | 0.49(0.18,1.32) | ‐0.02(‐0.05,0.01) | |
| HD GOLI SC | 1.68(0.32,10.68) | 1.63(0.33,7.71) | 0.02(‐0.03,0.27) | |
| HD ADA SC | 0.89(0.45,1.82) | 0.90(0.46,1.77) | 0.00(‐0.03,0.03) | |
| HD GOLI SC + MTX | 3.54(0.62,20.74) | 3.20(0.64,11.83) | 0.08(‐0.01,0.43) | |
| HD TOCI IV + MTX | 1.30(0.31,6.77) | 1.28(0.32,5.57) | 0.01(‐0.03,0.18) | |
| HD TOFA PO + MTX | 1.98(0.50,10.20) | 1.90(0.51,7.58) | 0.03(‐0.02,0.26) | |
| HD INF IV + MTX | 1.27(0.33,5.82) | 1.26(0.34,4.91) | 0.01(‐0.03,0.16) | |
| HD CERTO SC + MTX | 2.34(0.56,13.33) | 2.22(0.57,9.02) | 0.05(‐0.02,0.33) | |
| HD TOCI IV + DMARD | 0.87(0.25,3.30) | 0.88(0.26,3.04) | 0.00(‐0.04,0.08) | |
| SD TOFA PO | SD TOCI IV | 0.31(0.08,1.15) | 0.32(0.08,1.15) | ‐0.03(‐0.10,0.00) |
| SD TOCI SC | 0.88(0.44,1.81) | 0.89(0.45,1.73) | 0.00(‐0.04,0.04) | |
| SD CERTO SC | 3.92(0.73,21.61) | 3.45(0.75,15.00) | 0.10(‐0.02,0.34) | |
| SD GOLI IV | 1.16(0.11,13.04) | 1.15(0.12,9.53) | 0.01(‐0.08,0.30) | |
| SD RITUX IV | 0.45(0.05,4.54) | 0.46(0.06,4.04) | ‐0.02(‐0.09,0.11) | |
| SD INF IV + MTX | 1.01(0.21,4.72) | 1.01(0.22,4.24) | 0.00(‐0.07,0.11) | |
| SD ETN SC + MTX | 1.07(0.24,5.27) | 1.06(0.25,4.66) | 0.00(‐0.07,0.12) | |
| SD ADA SC + MTX | 1.05(0.22,5.40) | 1.05(0.23,4.74) | 0.00(‐0.07,0.13) | |
| SD ABA IV + MTX | 0.92(0.19,4.16) | 0.93(0.20,3.80) | 0.00(‐0.07,0.09) | |
| SD RITUX IV + MTX | 1.21(0.24,6.23) | 1.19(0.26,5.32) | 0.01(‐0.06,0.15) | |
| SD ABA SC + MTX | 0.78(0.15,3.75) | 0.79(0.16,3.46) | ‐0.01(‐0.08,0.08) | |
| SD GOLI SC + MTX | 2.31(0.36,17.01) | 2.18(0.38,11.04) | 0.05(‐0.05,0.37) | |
| SD CERTO SC + MTX | 1.72(0.34,9.55) | 1.67(0.36,7.47) | 0.03(‐0.05,0.24) | |
| SD TOFA PO + MTX | 2.21(0.45,11.93) | 2.09(0.47,8.99) | 0.04(‐0.04,0.29) | |
| SD GOLI IV + MTX | 3.63(0.36,32.71) | 3.20(0.38,17.27) | 0.09(‐0.05,0.52) | |
| SD ANA SC + MTX | 1.50(0.25,10.21) | 1.46(0.26,7.55) | 0.02(‐0.06,0.27) | |
| SD ETN SC + DMARD | 1.05(0.28,4.15) | 1.05(0.30,3.82) | 0.00(‐0.06,0.09) | |
| SD ABA IV + DMARD | 0.56(0.12,2.74) | 0.57(0.13,2.62) | ‐0.02(‐0.09,0.05) | |
| SD ADA SC + DMARD | 0.38(0.07,2.10) | 0.39(0.08,2.01) | ‐0.02(‐0.09,0.03) | |
| SD ANA + DMARD | 0.53(0.11,2.65) | 0.54(0.12,2.53) | ‐0.02(‐0.09,0.05) | |
| SD CERTO SC + DMARD | 0.36(0.05,2.78) | 0.37(0.06,2.65) | ‐0.02(‐0.09,0.05) | |
| SD TOCI SC + DMARD | 0.66(0.12,4.24) | 0.67(0.13,3.84) | ‐0.01(‐0.08,0.09) | |
| LD ADA SC | 0.53(0.16,1.61) | 0.55(0.18,1.59) | ‐0.02(‐0.09,0.01) | |
| LD ETN SC | 0.84(0.15,5.15) | 0.84(0.16,4.48) | ‐0.01(‐0.08,0.12) | |
| LD GOLI IV | 5.66(0.78,51.04) | 4.61(0.79,21.30) | 0.16(‐0.01,0.63) | |
| LD RITUX IV + MTX | 1.04(0.20,5.24) | 1.04(0.21,4.63) | 0.00(‐0.07,0.13) | |
| LD ABA IV + MTX | 1.42(0.25,7.65) | 1.39(0.27,6.38) | 0.02(‐0.06,0.18) | |
| LD CERTO SC + MTX | 1.84(0.19,15.72) | 1.76(0.20,10.42) | 0.03(‐0.06,0.34) | |
| LD ETN SC + MTX | 0.55(0.08,3.39) | 0.56(0.09,3.15) | ‐0.02(‐0.09,0.07) | |
| LD GOLI IV + MTX | 3.26(0.40,30.45) | 2.92(0.42,16.40) | 0.08(‐0.04,0.50) | |
| HD TOCI IV | 1.04(0.22,5.24) | 1.03(0.24,4.64) | 0.00(‐0.07,0.12) | |
| HD TOFA PO | 0.43(0.12,1.55) | 0.44(0.13,1.53) | ‐0.02(‐0.10,0.01) | |
| HD GOLI SC | 1.49(0.21,10.95) | 1.46(0.22,8.15) | 0.02(‐0.06,0.26) | |
| HD ADA SC | 0.80(0.27,2.38) | 0.81(0.29,2.31) | ‐0.01(‐0.07,0.03) | |
| HD GOLI SC + MTX | 3.20(0.46,21.06) | 2.89(0.48,13.02) | 0.08(‐0.03,0.42) | |
| HD TOCI IV + MTX | 1.18(0.22,7.12) | 1.17(0.24,5.82) | 0.01(‐0.07,0.17) | |
| HD TOFA PO + MTX | 1.84(0.37,10.27) | 1.77(0.39,7.89) | 0.03(‐0.05,0.26) | |
| HD INF IV + MTX | 1.19(0.23,5.88) | 1.18(0.24,5.10) | 0.01(‐0.06,0.15) | |
| HD CERTO SC + MTX | 2.09(0.37,13.28) | 1.99(0.39,9.35) | 0.04(‐0.05,0.32) | |
| HD TOCI IV + DMARD | 0.80(0.17,3.74) | 0.81(0.18,3.44) | ‐0.01(‐0.08,0.08) | |
| SD TOCI SC | SD TOFA PO | 2.84(0.63,13.82) | 2.76(0.64,12.44) | 0.02(‐0.01,0.11) |
| SD CERTO SC | 12.27(2.90,70.20) | 10.49(2.78,46.77) | 0.13(0.03,0.37) | |
| SD GOLI IV | 3.97(0.39,46.38) | 3.80(0.40,31.97) | 0.04(‐0.01,0.34) | |
| SD RITUX IV | 1.45(0.16,15.81) | 1.44(0.16,13.70) | 0.01(‐0.02,0.15) | |
| SD INF IV + MTX | 3.08(0.68,19.11) | 2.98(0.68,16.68) | 0.03(‐0.01,0.15) | |
| SD ETN SC + MTX | 3.40(0.73,20.80) | 3.29(0.73,18.03) | 0.03(‐0.01,0.16) | |
| SD ADA SC + MTX | 3.16(0.73,20.78) | 3.06(0.74,17.66) | 0.03(‐0.01,0.17) | |
| SD ABA IV + MTX | 2.77(0.64,16.88) | 2.69(0.65,14.98) | 0.02(‐0.01,0.13) | |
| SD RITUX IV + MTX | 3.78(0.83,24.29) | 3.63(0.83,20.20) | 0.04(0.00,0.20) | |
| SD ABA SC + MTX | 2.36(0.54,14.79) | 2.31(0.55,13.28) | 0.02(‐0.01,0.12) | |
| SD GOLI SC + MTX | 7.05(1.17,68.25) | 6.49(1.16,41.07) | 0.08(0.00,0.41) | |
| SD CERTO SC + MTX | 5.42(1.18,37.02) | 5.09(1.17,27.85) | 0.06(0.00,0.28) | |
| SD TOFA PO + MTX | 6.80(1.55,46.08) | 6.25(1.53,32.52) | 0.07(0.01,0.33) | |
| SD GOLI IV + MTX | 11.17(1.38,111.20) | 9.61(1.37,56.64) | 0.13(0.01,0.55) | |
| SD ANA SC + MTX | 4.71(0.79,41.17) | 4.45(0.79,29.17) | 0.05(0.00,0.31) | |
| SD ETN SC + DMARD | 3.33(0.93,16.14) | 3.21(0.94,14.62) | 0.03(0.00,0.13) | |
| SD ABA IV + DMARD | 1.70(0.40,10.47) | 1.68(0.40,9.72) | 0.01(‐0.01,0.08) | |
| SD ADA SC + DMARD | 1.18(0.24,7.51) | 1.17(0.24,7.06) | 0.00(‐0.02,0.06) | |
| SD ANA + DMARD | 1.64(0.35,9.45) | 1.62(0.36,8.73) | 0.01(‐0.02,0.08) | |
| SD CERTO SC + DMARD | 1.11(0.18,9.34) | 1.11(0.19,8.48) | 0.00(‐0.02,0.08) | |
| SD TOCI SC + DMARD | 2.10(0.39,13.79) | 2.06(0.40,12.27) | 0.01(‐0.01,0.13) | |
| LD ADA SC | 1.69(0.51,6.16) | 1.67(0.52,5.95) | 0.01(‐0.01,0.04) | |
| LD ETN SC | 2.60(0.51,19.38) | 2.53(0.52,16.63) | 0.02(‐0.01,0.16) | |
| LD GOLI IV | 18.17(2.62,186.60) | 14.36(2.54,74.34) | 0.19(0.02,0.66) | |
| LD RITUX IV + MTX | 3.20(0.70,21.37) | 3.10(0.71,18.13) | 0.03(‐0.01,0.17) | |
| LD ABA IV + MTX | 4.31(0.87,29.92) | 4.11(0.88,24.05) | 0.04(0.00,0.22) | |
| LD CERTO SC + MTX | 5.77(0.69,54.24) | 5.35(0.70,35.20) | 0.06(‐0.01,0.38) | |
| LD ETN SC + MTX | 1.71(0.28,12.36) | 1.69(0.28,11.15) | 0.01(‐0.02,0.11) | |
| LD GOLI IV + MTX | 10.45(1.43,104.60) | 9.13(1.42,55.26) | 0.11(0.01,0.53) | |
| HD TOCI IV | 3.24(0.76,20.29) | 3.12(0.76,17.30) | 0.03(0.00,0.16) | |
| HD TOFA PO | 1.38(0.54,3.62) | 1.37(0.54,3.55) | 0.00(‐0.01,0.03) | |
| HD GOLI SC | 4.68(0.74,38.28) | 4.40(0.75,28.30) | 0.05(0.00,0.30) | |
| HD ADA SC | 2.56(0.81,8.50) | 2.51(0.81,8.09) | 0.02(‐0.01,0.06) | |
| HD GOLI SC + MTX | 9.72(1.53,81.82) | 8.60(1.52,47.54) | 0.11(0.01,0.46) | |
| HD TOCI IV + MTX | 3.74(0.74,27.08) | 3.59(0.74,22.00) | 0.04(‐0.01,0.21) | |
| HD TOFA PO + MTX | 5.59(1.34,40.53) | 5.22(1.33,29.59) | 0.06(0.01,0.30) | |
| HD INF IV + MTX | 3.67(0.80,23.77) | 3.53(0.80,19.77) | 0.03(0.00,0.19) | |
| HD CERTO SC + MTX | 6.58(1.28,50.90) | 6.04(1.27,34.89) | 0.07(0.01,0.36) | |
| HD TOCI IV + DMARD | 2.51(0.55,13.87) | 2.45(0.55,12.66) | 0.02(‐0.01,0.11) | |
| SD CERTO SC | SD TOCI SC | 4.45(0.71,28.16) | 3.90(0.73,19.68) | 0.11(‐0.03,0.35) |
| SD GOLI IV | 1.30(0.11,16.36) | 1.28(0.12,11.99) | 0.01(‐0.08,0.31) | |
| SD RITUX IV | 0.51(0.05,5.93) | 0.53(0.05,5.21) | ‐0.01(‐0.10,0.12) | |
| SD INF IV + MTX | 1.15(0.19,6.36) | 1.14(0.20,5.67) | 0.00(‐0.08,0.12) | |
| SD ETN SC + MTX | 1.23(0.21,7.03) | 1.22(0.23,6.16) | 0.01(‐0.08,0.13) | |
| SD ADA SC + MTX | 1.20(0.20,6.90) | 1.19(0.22,6.10) | 0.01(‐0.08,0.14) | |
| SD ABA IV + MTX | 1.04(0.17,5.48) | 1.04(0.18,5.01) | 0.00(‐0.08,0.10) | |
| SD RITUX IV + MTX | 1.38(0.21,8.05) | 1.35(0.23,6.98) | 0.01(‐0.08,0.16) | |
| SD ABA SC + MTX | 0.89(0.14,4.93) | 0.89(0.15,4.54) | 0.00(‐0.09,0.09) | |
| SD GOLI SC + MTX | 2.63(0.34,21.44) | 2.46(0.36,14.39) | 0.05(‐0.06,0.38) | |
| SD CERTO SC + MTX | 1.96(0.33,12.48) | 1.88(0.35,9.94) | 0.03(‐0.06,0.24) | |
| SD TOFA PO + MTX | 2.54(0.41,15.93) | 2.39(0.43,11.97) | 0.05(‐0.05,0.30) | |
| SD GOLI IV + MTX | 4.02(0.36,43.09) | 3.52(0.38,23.51) | 0.10(‐0.05,0.52) | |
| SD ANA SC + MTX | 1.72(0.22,13.22) | 1.67(0.24,9.98) | 0.02(‐0.07,0.27) | |
| SD ETN SC + DMARD | 1.19(0.25,5.55) | 1.18(0.27,5.08) | 0.01(‐0.07,0.10) | |
| SD ABA IV + DMARD | 0.64(0.11,3.62) | 0.65(0.12,3.43) | ‐0.01(‐0.10,0.06) | |
| SD ADA SC + DMARD | 0.43(0.07,2.68) | 0.44(0.07,2.56) | ‐0.02(‐0.10,0.04) | |
| SD ANA + DMARD | 0.60(0.10,3.41) | 0.61(0.11,3.21) | ‐0.01(‐0.10,0.05) | |
| SD CERTO SC + DMARD | 0.41(0.05,3.40) | 0.42(0.06,3.22) | ‐0.02(‐0.10,0.06) | |
| SD TOCI SC + DMARD | 0.76(0.12,5.40) | 0.76(0.13,4.91) | ‐0.01(‐0.09,0.10) | |
| LD ADA SC | 0.60(0.15,2.23) | 0.61(0.17,2.19) | ‐0.01(‐0.10,0.02) | |
| LD ETN SC | 0.96(0.13,6.45) | 0.96(0.15,5.69) | 0.00(‐0.09,0.13) | |
| LD GOLI IV | 6.55(0.75,67.05) | 5.21(0.77,28.89) | 0.16(‐0.02,0.63) | |
| LD RITUX IV + MTX | 1.17(0.18,6.85) | 1.16(0.20,6.08) | 0.01(‐0.08,0.13) | |
| LD ABA IV + MTX | 1.63(0.23,10.03) | 1.59(0.25,8.48) | 0.02(‐0.07,0.19) | |
| LD CERTO SC + MTX | 2.08(0.18,19.56) | 1.97(0.20,13.31) | 0.04(‐0.07,0.35) | |
| LD ETN SC + MTX | 0.61(0.08,4.40) | 0.62(0.09,4.02) | ‐0.01(‐0.10,0.08) | |
| LD GOLI IV + MTX | 3.63(0.39,39.12) | 3.24(0.41,21.84) | 0.08(‐0.05,0.50) | |
| HD TOCI IV | 1.17(0.21,6.70) | 1.17(0.22,5.87) | 0.01(‐0.08,0.13) | |
| HD TOFA PO | 0.49(0.11,2.09) | 0.50(0.12,2.05) | ‐0.02(‐0.10,0.02) | |
| HD GOLI SC | 1.65(0.20,14.59) | 1.60(0.21,10.90) | 0.02(‐0.07,0.27) | |
| HD ADA SC | 0.92(0.25,3.19) | 0.92(0.28,3.07) | 0.00(‐0.08,0.04) | |
| HD GOLI SC + MTX | 3.62(0.45,27.61) | 3.23(0.48,17.42) | 0.08(‐0.04,0.42) | |
| HD TOCI IV + MTX | 1.34(0.21,9.16) | 1.33(0.23,7.69) | 0.01(‐0.08,0.17) | |
| HD TOFA PO + MTX | 2.06(0.34,13.42) | 1.98(0.37,10.48) | 0.03(‐0.06,0.26) | |
| HD INF IV + MTX | 1.35(0.21,7.75) | 1.33(0.23,6.77) | 0.01(‐0.08,0.16) | |
| HD CERTO SC + MTX | 2.41(0.34,16.62) | 2.27(0.37,12.03) | 0.04(‐0.06,0.33) | |
| HD TOCI IV + DMARD | 0.91(0.16,4.82) | 0.92(0.17,4.42) | 0.00(‐0.09,0.09) | |
| SD GOLI IV | SD CERTO SC | 0.32(0.02,4.48) | 0.36(0.03,3.45) | ‐0.08(‐0.34,0.22) |
| SD RITUX IV | 0.12(0.01,1.83) | 0.14(0.01,1.72) | ‐0.12(‐0.36,0.06) | |
| SD INF IV + MTX | 0.27(0.03,2.00) | 0.31(0.04,1.84) | ‐0.10(‐0.34,0.06) | |
| SD ETN SC + MTX | 0.28(0.03,2.10) | 0.31(0.05,1.92) | ‐0.10(‐0.34,0.07) | |
| SD ADA SC + MTX | 0.27(0.04,2.22) | 0.30(0.05,2.00) | ‐0.10(‐0.34,0.08) | |
| SD ABA IV + MTX | 0.24(0.03,1.75) | 0.28(0.04,1.66) | ‐0.10(‐0.35,0.05) | |
| SD RITUX IV + MTX | 0.32(0.03,2.58) | 0.36(0.05,2.28) | ‐0.09(‐0.34,0.10) | |
| SD ABA SC + MTX | 0.20(0.03,1.53) | 0.23(0.04,1.48) | ‐0.11(‐0.35,0.03) | |
| SD GOLI SC + MTX | 0.59(0.05,7.42) | 0.63(0.08,4.77) | ‐0.05(‐0.32,0.33) | |
| SD CERTO SC + MTX | 0.45(0.05,4.23) | 0.49(0.07,3.38) | ‐0.07(‐0.33,0.19) | |
| SD TOFA PO + MTX | 0.57(0.07,5.23) | 0.61(0.10,3.92) | ‐0.05(‐0.32,0.24) | |
| SD GOLI IV + MTX | 0.91(0.07,10.37) | 0.92(0.09,5.76) | ‐0.01(‐0.29,0.43) | |
| SD ANA SC + MTX | 0.38(0.04,4.46) | 0.42(0.06,3.50) | ‐0.08(‐0.33,0.20) | |
| SD ETN SC + DMARD | 0.27(0.05,1.73) | 0.30(0.07,1.62) | ‐0.10(‐0.34,0.04) | |
| SD ABA IV + DMARD | 0.14(0.02,1.07) | 0.17(0.03,1.06) | ‐0.12(‐0.36,0.00) | |
| SD ADA SC + DMARD | 0.09(0.01,0.83) | 0.11(0.02,0.84) | ‐0.13(‐0.36,‐0.01) | |
| SD ANA + DMARD | 0.14(0.02,1.04) | 0.16(0.03,1.03) | ‐0.12(‐0.36,0.00) | |
| SD CERTO SC + DMARD | 0.09(0.01,0.93) | 0.10(0.01,0.94) | ‐0.13(‐0.36,0.00) | |
| SD TOCI SC + DMARD | 0.17(0.02,1.47) | 0.20(0.03,1.42) | ‐0.11(‐0.35,0.03) | |
| LD ADA SC | 0.14(0.03,0.65) | 0.16(0.04,0.67) | ‐0.12(‐0.36,‐0.02) | |
| LD ETN SC | 0.21(0.03,2.01) | 0.24(0.04,1.85) | ‐0.11(‐0.35,0.07) | |
| LD GOLI IV | 1.51(0.12,17.57) | 1.38(0.17,7.40) | 0.05(‐0.26,0.55) | |
| LD RITUX IV + MTX | 0.27(0.03,2.17) | 0.30(0.04,1.99) | ‐0.10(‐0.34,0.08) | |
| LD ABA IV + MTX | 0.36(0.04,3.05) | 0.40(0.06,2.63) | ‐0.08(‐0.33,0.13) | |
| LD CERTO SC + MTX | 0.46(0.04,6.19) | 0.51(0.05,4.20) | ‐0.07(‐0.32,0.28) | |
| LD ETN SC + MTX | 0.14(0.01,1.31) | 0.16(0.02,1.28) | ‐0.12(‐0.36,0.02) | |
| LD GOLI IV + MTX | 0.84(0.08,9.26) | 0.86(0.10,5.38) | ‐0.02(‐0.29,0.40) | |
| HD TOCI IV | 0.27(0.03,2.08) | 0.30(0.05,1.92) | ‐0.10(‐0.34,0.07) | |
| HD TOFA PO | 0.11(0.02,0.51) | 0.13(0.03,0.53) | ‐0.13(‐0.36,‐0.03) | |
| HD GOLI SC | 0.38(0.03,4.22) | 0.42(0.05,3.28) | ‐0.08(‐0.34,0.20) | |
| HD ADA SC | 0.21(0.05,0.93) | 0.24(0.07,0.94) | ‐0.11(‐0.35,0.00) | |
| HD GOLI SC + MTX | 0.81(0.06,9.63) | 0.83(0.09,5.72) | ‐0.02(‐0.31,0.37) | |
| HD TOCI IV + MTX | 0.30(0.04,2.71) | 0.34(0.06,2.39) | ‐0.09(‐0.34,0.11) | |
| HD TOFA PO + MTX | 0.44(0.06,4.61) | 0.49(0.09,3.62) | ‐0.07(‐0.32,0.20) | |
| HD INF IV + MTX | 0.31(0.03,2.44) | 0.35(0.04,2.17) | ‐0.09(‐0.34,0.09) | |
| HD CERTO SC + MTX | 0.56(0.05,5.92) | 0.60(0.08,4.22) | ‐0.06(‐0.32,0.27) | |
| HD TOCI IV + DMARD | 0.20(0.03,1.43) | 0.23(0.04,1.38) | ‐0.11(‐0.35,0.03) | |
| SD RITUX IV | SD GOLI IV | 0.38(0.03,5.73) | 0.40(0.03,5.39) | ‐0.03(‐0.29,0.08) |
| SD INF IV + MTX | 0.84(0.10,6.86) | 0.85(0.13,6.52) | ‐0.01(‐0.26,0.08) | |
| SD ETN SC + MTX | 0.91(0.12,8.29) | 0.92(0.15,7.71) | 0.00(‐0.26,0.09) | |
| SD ADA SC + MTX | 0.82(0.11,7.87) | 0.83(0.14,7.37) | ‐0.01(‐0.25,0.09) | |
| SD ABA IV + MTX | 0.76(0.09,6.22) | 0.77(0.12,5.85) | ‐0.01(‐0.27,0.07) | |
| SD RITUX IV + MTX | 1.00(0.13,8.42) | 1.00(0.17,7.81) | 0.00(‐0.24,0.11) | |
| SD ABA SC + MTX | 0.63(0.08,5.56) | 0.64(0.10,5.34) | ‐0.02(‐0.28,0.06) | |
| SD GOLI SC + MTX | 1.98(0.19,22.32) | 1.85(0.23,17.70) | 0.03(‐0.20,0.29) | |
| SD CERTO SC + MTX | 1.51(0.18,13.58) | 1.46(0.23,11.67) | 0.02(‐0.21,0.18) | |
| SD TOFA PO + MTX | 1.81(0.23,17.33) | 1.71(0.29,14.57) | 0.03(‐0.20,0.24) | |
| SD GOLI IV + MTX | 2.83(0.50,21.68) | 2.45(0.54,16.80) | 0.07(‐0.08,0.37) | |
| SD ANA SC + MTX | 1.25(0.12,11.97) | 1.23(0.16,10.38) | 0.01(‐0.23,0.21) | |
| SD ETN SC + DMARD | 0.85(0.12,7.56) | 0.86(0.16,7.17) | ‐0.01(‐0.27,0.07) | |
| SD ABA IV + DMARD | 0.46(0.06,4.38) | 0.47(0.07,4.25) | ‐0.02(‐0.30,0.04) | |
| SD ADA SC + DMARD | 0.30(0.03,3.25) | 0.32(0.04,3.17) | ‐0.03(‐0.32,0.02) | |
| SD ANA + DMARD | 0.43(0.05,4.27) | 0.44(0.07,4.18) | ‐0.03(‐0.30,0.04) | |
| SD CERTO SC + DMARD | 0.30(0.03,3.86) | 0.32(0.03,3.67) | ‐0.03(‐0.32,0.04) | |
| SD TOCI SC + DMARD | 0.57(0.06,5.87) | 0.58(0.08,5.48) | ‐0.02(‐0.29,0.07) | |
| LD ADA SC | 0.48(0.04,4.31) | 0.49(0.05,4.21) | ‐0.03(‐0.33,0.03) | |
| LD ETN SC | 0.70(0.08,7.60) | 0.71(0.10,7.20) | ‐0.01(‐0.27,0.10) | |
| LD GOLI IV | 4.58(1.04,30.01) | 3.62(1.03,21.69) | 0.13(0.00,0.48) | |
| LD RITUX IV + MTX | 0.83(0.11,7.49) | 0.84(0.14,7.01) | ‐0.01(‐0.25,0.09) | |
| LD ABA IV + MTX | 1.14(0.13,10.94) | 1.13(0.17,9.94) | 0.01(‐0.24,0.14) | |
| LD CERTO SC + MTX | 1.46(0.11,22.72) | 1.41(0.13,17.78) | 0.02(‐0.24,0.30) | |
| LD ETN SC + MTX | 0.46(0.05,4.79) | 0.48(0.06,4.49) | ‐0.02(‐0.30,0.05) | |
| LD GOLI IV + MTX | 2.69(0.51,18.96) | 2.35(0.56,14.97) | 0.06(‐0.07,0.36) | |
| HD TOCI IV | 0.83(0.11,7.70) | 0.84(0.15,7.24) | ‐0.01(‐0.26,0.09) | |
| HD TOFA PO | 0.36(0.03,3.75) | 0.38(0.04,3.67) | ‐0.03(‐0.34,0.02) | |
| HD GOLI SC | 1.20(0.12,15.08) | 1.19(0.15,12.76) | 0.01(‐0.23,0.21) | |
| HD ADA SC | 0.68(0.06,6.47) | 0.70(0.09,6.25) | ‐0.02(‐0.32,0.04) | |
| HD GOLI SC + MTX | 2.78(0.28,30.13) | 2.49(0.34,22.16) | 0.06(‐0.16,0.37) | |
| HD TOCI IV + MTX | 0.92(0.12,10.84) | 0.93(0.15,9.73) | 0.00(‐0.24,0.14) | |
| HD TOFA PO + MTX | 1.46(0.19,14.57) | 1.41(0.24,12.41) | 0.02(‐0.21,0.20) | |
| HD INF IV + MTX | 0.97(0.12,8.78) | 0.98(0.15,8.09) | 0.00(‐0.25,0.11) | |
| HD CERTO SC + MTX | 1.83(0.19,18.85) | 1.73(0.24,15.58) | 0.03(‐0.20,0.27) | |
| HD TOCI IV + DMARD | 0.63(0.08,6.18) | 0.65(0.11,5.85) | ‐0.02(‐0.28,0.06) | |
| SD INF IV + MTX | SD RITUX IV | 2.12(0.42,12.74) | 2.05(0.45,11.91) | 0.02(‐0.06,0.10) |
| SD ETN SC + MTX | 2.27(0.41,15.08) | 2.20(0.44,14.09) | 0.02(‐0.07,0.12) | |
| SD ADA SC + MTX | 2.16(0.41,13.79) | 2.09(0.43,13.07) | 0.02(‐0.07,0.12) | |
| SD ABA IV + MTX | 1.88(0.39,11.60) | 1.84(0.42,11.02) | 0.01(‐0.07,0.09) | |
| SD RITUX IV + MTX | 2.49(0.57,15.78) | 2.39(0.60,14.65) | 0.02(‐0.04,0.13) | |
| SD ABA SC + MTX | 1.59(0.30,9.80) | 1.56(0.33,9.43) | 0.01(‐0.09,0.07) | |
| SD GOLI SC + MTX | 4.90(0.68,36.64) | 4.39(0.70,30.32) | 0.06(‐0.02,0.35) | |
| SD CERTO SC + MTX | 3.82(0.70,22.45) | 3.53(0.73,19.95) | 0.04(‐0.03,0.22) | |
| SD TOFA PO + MTX | 4.55(0.79,32.27) | 4.15(0.81,27.50) | 0.06(‐0.02,0.28) | |
| SD GOLI IV + MTX | 7.54(0.65,97.23) | 6.30(0.67,65.26) | 0.11(‐0.02,0.51) | |
| SD ANA SC + MTX | 3.15(0.43,22.82) | 2.95(0.46,20.15) | 0.03(‐0.05,0.24) | |
| SD ETN SC + DMARD | 2.24(0.38,16.18) | 2.16(0.42,15.52) | 0.02(‐0.08,0.09) | |
| SD ABA IV + DMARD | 1.16(0.18,8.50) | 1.15(0.20,8.21) | 0.00(‐0.12,0.05) | |
| SD ADA SC + DMARD | 0.76(0.11,6.61) | 0.77(0.12,6.44) | 0.00(‐0.13,0.04) | |
| SD ANA + DMARD | 1.10(0.16,8.53) | 1.10(0.18,8.27) | 0.00(‐0.12,0.05) | |
| SD CERTO SC + DMARD | 0.75(0.08,8.38) | 0.76(0.09,8.13) | 0.00(‐0.13,0.05) | |
| SD TOCI SC + DMARD | 1.44(0.18,12.21) | 1.42(0.20,11.52) | 0.01(‐0.11,0.09) | |
| LD ADA SC | 1.13(0.11,10.42) | 1.13(0.12,10.16) | 0.00(‐0.14,0.04) | |
| LD ETN SC | 1.80(0.29,12.98) | 1.76(0.32,12.29) | 0.01(‐0.08,0.11) | |
| LD GOLI IV | 12.36(1.19,152.20) | 9.52(1.18,85.34) | 0.17(0.01,0.61) | |
| LD RITUX IV + MTX | 2.10(0.49,12.69) | 2.04(0.52,11.93) | 0.02(‐0.05,0.11) | |
| LD ABA IV + MTX | 2.90(0.50,19.26) | 2.75(0.53,17.83) | 0.03(‐0.05,0.17) | |
| LD CERTO SC + MTX | 3.72(0.44,32.20) | 3.43(0.46,25.64) | 0.04(‐0.05,0.34) | |
| LD ETN SC + MTX | 1.14(0.18,8.36) | 1.14(0.20,8.08) | 0.00(‐0.11,0.07) | |
| LD GOLI IV + MTX | 7.10(0.57,85.63) | 6.03(0.60,61.31) | 0.10(‐0.03,0.48) | |
| HD TOCI IV | 2.13(0.39,15.30) | 2.07(0.42,14.36) | 0.02(‐0.07,0.11) | |
| HD TOFA PO | 0.96(0.09,8.01) | 0.96(0.10,7.79) | 0.00(‐0.15,0.03) | |
| HD GOLI SC | 3.17(0.41,27.83) | 2.97(0.43,23.50) | 0.03(‐0.06,0.25) | |
| HD ADA SC | 1.73(0.19,16.10) | 1.71(0.22,15.40) | 0.01(‐0.12,0.06) | |
| HD GOLI SC + MTX | 6.60(0.99,50.10) | 5.68(0.99,37.38) | 0.09(0.00,0.40) | |
| HD TOCI IV + MTX | 2.41(0.43,20.11) | 2.32(0.46,18.37) | 0.02(‐0.06,0.16) | |
| HD TOFA PO + MTX | 3.77(0.62,26.53) | 3.52(0.65,23.64) | 0.05(‐0.03,0.24) | |
| HD INF IV + MTX | 2.48(0.48,15.41) | 2.39(0.50,14.33) | 0.02(‐0.06,0.13) | |
| HD CERTO SC + MTX | 4.61(0.78,29.98) | 4.19(0.80,25.76) | 0.06(‐0.02,0.29) | |
| HD TOCI IV + DMARD | 1.63(0.27,13.23) | 1.60(0.30,12.58) | 0.01(‐0.10,0.08) | |
| SD ETN SC + MTX | SD INF IV + MTX | 1.09(0.46,2.51) | 1.09(0.48,2.39) | 0.00(‐0.05,0.07) |
| SD ADA SC + MTX | 1.05(0.49,2.21) | 1.04(0.50,2.10) | 0.00(‐0.04,0.06) | |
| SD ABA IV + MTX | 0.90(0.52,1.58) | 0.91(0.54,1.54) | 0.00(‐0.05,0.02) | |
| SD RITUX IV + MTX | 1.19(0.64,2.42) | 1.18(0.65,2.27) | 0.01(‐0.03,0.07) | |
| SD ABA SC + MTX | 0.76(0.36,1.54) | 0.77(0.38,1.51) | ‐0.01(‐0.06,0.02) | |
| SD GOLI SC + MTX | 2.26(0.69,7.83) | 2.11(0.70,6.17) | 0.05(‐0.01,0.30) | |
| SD CERTO SC + MTX | 1.76(0.88,3.73) | 1.69(0.88,3.31) | 0.03(‐0.01,0.15) | |
| SD TOFA PO + MTX | 2.18(0.91,5.69) | 2.04(0.91,4.73) | 0.04(0.00,0.22) | |
| SD GOLI IV + MTX | 3.52(0.58,24.65) | 3.04(0.60,15.51) | 0.09(‐0.02,0.47) | |
| SD ANA SC + MTX | 1.51(0.47,4.87) | 1.47(0.49,4.08) | 0.02(‐0.04,0.19) | |
| SD ETN SC + DMARD | 1.05(0.41,2.72) | 1.05(0.43,2.62) | 0.00(‐0.07,0.05) | |
| SD ABA IV + DMARD | 0.56(0.19,1.65) | 0.57(0.20,1.62) | ‐0.02(‐0.10,0.02) | |
| SD ADA SC + DMARD | 0.37(0.10,1.33) | 0.38(0.11,1.31) | ‐0.02(‐0.12,0.01) | |
| SD ANA + DMARD | 0.53(0.16,1.61) | 0.54(0.17,1.58) | ‐0.02(‐0.11,0.02) | |
| SD CERTO SC + DMARD | 0.37(0.07,1.78) | 0.38(0.07,1.72) | ‐0.02(‐0.13,0.02) | |
| SD TOCI SC + DMARD | 0.69(0.18,2.53) | 0.70(0.19,2.39) | ‐0.01(‐0.10,0.05) | |
| LD ADA SC | 0.52(0.10,2.43) | 0.54(0.12,2.38) | ‐0.02(‐0.14,0.02) | |
| LD ETN SC | 0.85(0.28,2.61) | 0.86(0.30,2.47) | 0.00(‐0.07,0.07) | |
| LD GOLI IV | 5.64(1.13,36.21) | 4.42(1.11,18.80) | 0.15(0.01,0.58) | |
| LD RITUX IV + MTX | 1.02(0.54,2.09) | 1.02(0.56,1.98) | 0.00(‐0.04,0.05) | |
| LD ABA IV + MTX | 1.39(0.60,3.29) | 1.36(0.62,2.99) | 0.01(‐0.03,0.12) | |
| LD CERTO SC + MTX | 1.75(0.40,7.77) | 1.68(0.41,5.96) | 0.03(‐0.04,0.29) | |
| LD ETN SC + MTX | 0.54(0.17,1.69) | 0.56(0.18,1.66) | ‐0.02(‐0.09,0.03) | |
| LD GOLI IV + MTX | 3.27(0.57,20.03) | 2.88(0.59,12.96) | 0.08(‐0.02,0.45) | |
| HD TOCI IV | 1.02(0.44,2.46) | 1.02(0.46,2.33) | 0.00(‐0.05,0.06) | |
| HD TOFA PO | 0.45(0.08,2.13) | 0.46(0.09,2.10) | ‐0.02(‐0.15,0.02) | |
| HD GOLI SC | 1.46(0.37,5.86) | 1.43(0.39,4.80) | 0.02(‐0.05,0.21) | |
| HD ADA SC | 0.83(0.18,3.35) | 0.84(0.21,3.24) | ‐0.01(‐0.12,0.04) | |
| HD GOLI SC + MTX | 3.15(1.02,10.20) | 2.80(1.02,7.42) | 0.08(0.00,0.36) | |
| HD TOCI IV + MTX | 1.17(0.43,3.54) | 1.16(0.45,3.20) | 0.01(‐0.05,0.11) | |
| HD TOFA PO + MTX | 1.84(0.77,4.74) | 1.76(0.78,4.14) | 0.03(‐0.01,0.18) | |
| HD INF IV + MTX | 1.16(0.67,2.08) | 1.15(0.68,1.96) | 0.01(‐0.02,0.06) | |
| HD CERTO SC + MTX | 2.16(0.89,5.72) | 2.02(0.89,4.69) | 0.04(0.00,0.25) | |
| HD TOCI IV + DMARD | 0.79(0.27,2.28) | 0.80(0.29,2.19) | ‐0.01(‐0.09,0.04) | |
| SD ADA SC + MTX | SD ETN SC + MTX | 0.94(0.37,2.65) | 0.94(0.39,2.48) | 0.00(‐0.07,0.07) |
| SD ABA IV + MTX | 0.82(0.35,2.07) | 0.83(0.38,1.98) | ‐0.01(‐0.08,0.04) | |
| SD RITUX IV + MTX | 1.09(0.46,3.00) | 1.09(0.48,2.73) | 0.00(‐0.05,0.09) | |
| SD ABA SC + MTX | 0.70(0.27,1.95) | 0.71(0.29,1.87) | ‐0.01(‐0.09,0.04) | |
| SD GOLI SC + MTX | 2.06(0.57,8.59) | 1.94(0.59,6.64) | 0.04(‐0.03,0.30) | |
| SD CERTO SC + MTX | 1.63(0.66,4.15) | 1.57(0.68,3.61) | 0.02(‐0.02,0.16) | |
| SD TOFA PO + MTX | 2.01(0.73,6.26) | 1.90(0.74,5.24) | 0.04(‐0.02,0.22) | |
| SD GOLI IV + MTX | 3.25(0.48,21.79) | 2.85(0.50,13.68) | 0.08(‐0.04,0.47) | |
| SD ANA SC + MTX | 1.39(0.36,5.36) | 1.36(0.38,4.47) | 0.01(‐0.05,0.20) | |
| SD ETN SC + DMARD | 0.95(0.37,2.65) | 0.96(0.40,2.55) | 0.00(‐0.08,0.05) | |
| SD ABA IV + DMARD | 0.50(0.16,1.65) | 0.52(0.18,1.61) | ‐0.02(‐0.12,0.02) | |
| SD ADA SC + DMARD | 0.34(0.09,1.28) | 0.35(0.10,1.27) | ‐0.03(‐0.13,0.01) | |
| SD ANA + DMARD | 0.49(0.14,1.67) | 0.50(0.16,1.64) | ‐0.02(‐0.12,0.02) | |
| SD CERTO SC + DMARD | 0.34(0.06,1.67) | 0.35(0.06,1.63) | ‐0.03(‐0.13,0.02) | |
| SD TOCI SC + DMARD | 0.62(0.15,2.46) | 0.64(0.17,2.31) | ‐0.01(‐0.11,0.05) | |
| LD ADA SC | 0.49(0.09,2.25) | 0.50(0.11,2.21) | ‐0.02(‐0.15,0.02) | |
| LD ETN SC | 0.79(0.24,2.43) | 0.80(0.25,2.28) | ‐0.01(‐0.09,0.06) | |
| LD GOLI IV | 5.29(0.89,34.38) | 4.18(0.90,17.42) | 0.15(‐0.01,0.58) | |
| LD RITUX IV + MTX | 0.93(0.40,2.53) | 0.93(0.42,2.34) | 0.00(‐0.06,0.07) | |
| LD ABA IV + MTX | 1.27(0.43,3.97) | 1.25(0.46,3.53) | 0.01(‐0.06,0.13) | |
| LD CERTO SC + MTX | 1.66(0.31,7.96) | 1.59(0.33,5.90) | 0.02(‐0.05,0.28) | |
| LD ETN SC + MTX | 0.51(0.16,1.39) | 0.52(0.16,1.35) | ‐0.02(‐0.10,0.02) | |
| LD GOLI IV + MTX | 3.13(0.45,19.11) | 2.75(0.47,12.09) | 0.08(‐0.04,0.44) | |
| HD TOCI IV | 0.94(0.36,2.72) | 0.95(0.38,2.56) | 0.00(‐0.07,0.07) | |
| HD TOFA PO | 0.41(0.08,1.95) | 0.42(0.09,1.91) | ‐0.03(‐0.15,0.02) | |
| HD GOLI SC | 1.39(0.31,5.82) | 1.36(0.33,4.69) | 0.01(‐0.07,0.20) | |
| HD ADA SC | 0.75(0.16,2.90) | 0.76(0.18,2.80) | ‐0.01(‐0.14,0.03) | |
| HD GOLI SC + MTX | 2.89(0.80,11.15) | 2.59(0.82,7.80) | 0.07(‐0.01,0.36) | |
| HD TOCI IV + MTX | 1.08(0.34,3.80) | 1.08(0.36,3.37) | 0.00(‐0.06,0.12) | |
| HD TOFA PO + MTX | 1.68(0.57,5.29) | 1.61(0.59,4.55) | 0.02(‐0.03,0.19) | |
| HD INF IV + MTX | 1.07(0.45,2.78) | 1.06(0.47,2.57) | 0.00(‐0.06,0.08) | |
| HD CERTO SC + MTX | 1.95(0.73,6.04) | 1.85(0.75,4.92) | 0.04(‐0.02,0.25) | |
| HD TOCI IV + DMARD | 0.73(0.23,2.33) | 0.74(0.25,2.24) | ‐0.01(‐0.10,0.04) | |
| SD ABA IV + MTX | SD ADA SC + MTX | 0.87(0.45,1.69) | 0.88(0.47,1.65) | 0.00(‐0.06,0.03) |
| SD RITUX IV + MTX | 1.16(0.53,2.65) | 1.15(0.55,2.51) | 0.01(‐0.04,0.07) | |
| SD ABA SC + MTX | 0.74(0.41,1.29) | 0.75(0.43,1.27) | ‐0.01(‐0.07,0.01) | |
| SD GOLI SC + MTX | 2.20(0.65,8.78) | 2.05(0.66,6.93) | 0.04(‐0.02,0.30) | |
| SD CERTO SC + MTX | 1.69(0.78,4.13) | 1.62(0.79,3.72) | 0.03(‐0.01,0.15) | |
| SD TOFA PO + MTX | 2.12(0.93,5.06) | 1.98(0.93,4.34) | 0.04(0.00,0.21) | |
| SD GOLI IV + MTX | 3.45(0.53,22.58) | 3.03(0.55,14.59) | 0.09(‐0.03,0.47) | |
| SD ANA SC + MTX | 1.45(0.39,5.40) | 1.41(0.41,4.60) | 0.02(‐0.05,0.19) | |
| SD ETN SC + DMARD | 1.02(0.37,2.72) | 1.02(0.40,2.62) | 0.00(‐0.09,0.05) | |
| SD ABA IV + DMARD | 0.54(0.17,1.69) | 0.55(0.19,1.66) | ‐0.02(‐0.12,0.02) | |
| SD ADA SC + DMARD | 0.36(0.09,1.30) | 0.37(0.10,1.30) | ‐0.02(‐0.14,0.01) | |
| SD ANA + DMARD | 0.51(0.14,1.68) | 0.52(0.16,1.65) | ‐0.02(‐0.13,0.02) | |
| SD CERTO SC + DMARD | 0.35(0.06,1.74) | 0.36(0.07,1.69) | ‐0.02(‐0.14,0.02) | |
| SD TOCI SC + DMARD | 0.66(0.16,2.68) | 0.67(0.18,2.50) | ‐0.01(‐0.11,0.05) | |
| LD ADA SC | 0.52(0.09,2.35) | 0.53(0.11,2.30) | ‐0.02(‐0.16,0.02) | |
| LD ETN SC | 0.82(0.26,2.61) | 0.83(0.29,2.47) | ‐0.01(‐0.09,0.07) | |
| LD GOLI IV | 5.68(1.01,36.39) | 4.44(1.01,18.67) | 0.15(0.00,0.57) | |
| LD RITUX IV + MTX | 0.99(0.44,2.29) | 0.99(0.46,2.18) | 0.00(‐0.06,0.06) | |
| LD ABA IV + MTX | 1.35(0.51,3.37) | 1.33(0.53,3.08) | 0.01(‐0.04,0.11) | |
| LD CERTO SC + MTX | 1.69(0.34,8.53) | 1.62(0.36,6.60) | 0.03(‐0.05,0.28) | |
| LD ETN SC + MTX | 0.52(0.15,1.74) | 0.54(0.17,1.69) | ‐0.02(‐0.11,0.03) | |
| LD GOLI IV + MTX | 3.22(0.51,20.51) | 2.86(0.54,13.14) | 0.08(‐0.04,0.45) | |
| HD TOCI IV | 0.98(0.40,2.65) | 0.98(0.43,2.51) | 0.00(‐0.07,0.06) | |
| HD TOFA PO | 0.42(0.07,1.97) | 0.43(0.08,1.94) | ‐0.02(‐0.16,0.01) | |
| HD GOLI SC | 1.42(0.34,5.82) | 1.39(0.36,4.85) | 0.02(‐0.06,0.20) | |
| HD ADA SC | 0.80(0.15,3.29) | 0.80(0.18,3.17) | ‐0.01(‐0.14,0.04) | |
| HD GOLI SC + MTX | 3.01(0.90,11.42) | 2.69(0.91,8.50) | 0.07(0.00,0.35) | |
| HD TOCI IV + MTX | 1.13(0.39,3.69) | 1.12(0.41,3.32) | 0.00(‐0.06,0.11) | |
| HD TOFA PO + MTX | 1.76(0.77,4.21) | 1.69(0.78,3.70) | 0.03(‐0.01,0.16) | |
| HD INF IV + MTX | 1.12(0.49,2.57) | 1.11(0.51,2.41) | 0.00(‐0.05,0.07) | |
| HD CERTO SC + MTX | 2.06(0.79,6.21) | 1.93(0.81,5.24) | 0.04(‐0.01,0.24) | |
| HD TOCI IV + DMARD | 0.76(0.25,2.35) | 0.77(0.27,2.26) | ‐0.01(‐0.10,0.04) | |
| SD RITUX IV + MTX | SD ABA IV + MTX | 1.33(0.69,2.68) | 1.31(0.71,2.50) | 0.01(‐0.02,0.09) |
| SD ABA SC + MTX | 0.84(0.47,1.48) | 0.85(0.49,1.45) | 0.00(‐0.04,0.02) | |
| SD GOLI SC + MTX | 2.48(0.78,9.26) | 2.31(0.79,6.89) | 0.05(‐0.01,0.31) | |
| SD CERTO SC + MTX | 1.94(1.00,4.06) | 1.85(1.00,3.58) | 0.03(0.00,0.16) | |
| SD TOFA PO + MTX | 2.43(1.05,5.95) | 2.26(1.05,5.08) | 0.05(0.00,0.23) | |
| SD GOLI IV + MTX | 3.89(0.67,26.04) | 3.35(0.68,16.14) | 0.09(‐0.02,0.48) | |
| SD ANA SC + MTX | 1.66(0.51,5.57) | 1.60(0.53,4.63) | 0.02(‐0.03,0.21) | |
| SD ETN SC + DMARD | 1.18(0.47,2.92) | 1.17(0.49,2.81) | 0.01(‐0.05,0.05) | |
| SD ABA IV + DMARD | 0.61(0.21,1.79) | 0.62(0.22,1.74) | ‐0.01(‐0.09,0.02) | |
| SD ADA SC + DMARD | 0.40(0.12,1.43) | 0.42(0.13,1.41) | ‐0.02(‐0.11,0.01) | |
| SD ANA + DMARD | 0.59(0.18,1.80) | 0.60(0.19,1.75) | ‐0.01(‐0.09,0.02) | |
| SD CERTO SC + DMARD | 0.40(0.07,1.92) | 0.41(0.08,1.84) | ‐0.02(‐0.11,0.03) | |
| SD TOCI SC + DMARD | 0.76(0.20,2.90) | 0.77(0.21,2.70) | ‐0.01(‐0.08,0.06) | |
| LD ADA SC | 0.58(0.12,2.61) | 0.59(0.13,2.55) | ‐0.01(‐0.12,0.02) | |
| LD ETN SC | 0.93(0.32,2.84) | 0.94(0.34,2.66) | 0.00(‐0.06,0.08) | |
| LD GOLI IV | 6.30(1.24,40.25) | 4.95(1.22,19.94) | 0.16(0.01,0.58) | |
| LD RITUX IV + MTX | 1.13(0.60,2.34) | 1.12(0.62,2.20) | 0.00(‐0.03,0.07) | |
| LD ABA IV + MTX | 1.53(0.72,3.35) | 1.49(0.73,3.06) | 0.02(‐0.01,0.12) | |
| LD CERTO SC + MTX | 1.94(0.43,8.74) | 1.86(0.45,6.53) | 0.03(‐0.03,0.30) | |
| LD ETN SC + MTX | 0.60(0.18,1.86) | 0.61(0.19,1.81) | ‐0.01(‐0.08,0.03) | |
| LD GOLI IV + MTX | 3.58(0.63,22.53) | 3.16(0.65,14.45) | 0.08(‐0.02,0.46) | |
| HD TOCI IV | 1.13(0.50,2.76) | 1.12(0.53,2.58) | 0.00(‐0.04,0.07) | |
| HD TOFA PO | 0.49(0.09,2.31) | 0.50(0.10,2.27) | ‐0.02(‐0.13,0.02) | |
| HD GOLI SC | 1.63(0.41,6.48) | 1.58(0.42,5.26) | 0.02(‐0.04,0.22) | |
| HD ADA SC | 0.90(0.20,3.69) | 0.91(0.22,3.52) | 0.00(‐0.11,0.04) | |
| HD GOLI SC + MTX | 3.46(1.09,12.03) | 3.05(1.09,8.52) | 0.08(0.00,0.36) | |
| HD TOCI IV + MTX | 1.30(0.49,3.82) | 1.28(0.50,3.47) | 0.01(‐0.03,0.12) | |
| HD TOFA PO + MTX | 2.03(0.85,5.12) | 1.94(0.86,4.38) | 0.03(‐0.01,0.19) | |
| HD INF IV + MTX | 1.29(0.67,2.56) | 1.27(0.68,2.38) | 0.01(‐0.02,0.08) | |
| HD CERTO SC + MTX | 2.36(0.99,6.39) | 2.20(0.99,5.15) | 0.05(0.00,0.26) | |
| HD TOCI IV + DMARD | 0.87(0.31,2.49) | 0.88(0.33,2.39) | 0.00(‐0.07,0.05) | |
| SD ABA SC + MTX | SD RITUX IV + MTX | 0.64(0.28,1.37) | 0.65(0.30,1.35) | ‐0.02(‐0.10,0.01) |
| SD GOLI SC + MTX | 1.86(0.56,6.73) | 1.76(0.58,5.32) | 0.04(‐0.03,0.27) | |
| SD CERTO SC + MTX | 1.48(0.70,3.10) | 1.43(0.72,2.81) | 0.02(‐0.02,0.13) | |
| SD TOFA PO + MTX | 1.84(0.70,4.82) | 1.75(0.73,4.19) | 0.03(‐0.02,0.20) | |
| SD GOLI IV + MTX | 2.92(0.46,20.20) | 2.57(0.48,12.96) | 0.08(‐0.04,0.45) | |
| SD ANA SC + MTX | 1.25(0.37,4.20) | 1.24(0.39,3.58) | 0.01(‐0.06,0.17) | |
| SD ETN SC + DMARD | 0.88(0.31,2.27) | 0.88(0.34,2.20) | ‐0.01(‐0.11,0.04) | |
| SD ABA IV + DMARD | 0.47(0.14,1.36) | 0.48(0.16,1.34) | ‐0.02(‐0.15,0.01) | |
| SD ADA SC + DMARD | 0.31(0.08,1.09) | 0.33(0.09,1.08) | ‐0.03(‐0.16,0.00) | |
| SD ANA + DMARD | 0.45(0.13,1.39) | 0.47(0.14,1.37) | ‐0.03(‐0.15,0.01) | |
| SD CERTO SC + DMARD | 0.30(0.05,1.46) | 0.32(0.06,1.44) | ‐0.03(‐0.16,0.02) | |
| SD TOCI SC + DMARD | 0.58(0.13,2.10) | 0.59(0.15,2.00) | ‐0.02(‐0.14,0.04) | |
| LD ADA SC | 0.43(0.08,2.19) | 0.45(0.09,2.16) | ‐0.03(‐0.18,0.02) | |
| LD ETN SC | 0.71(0.24,2.06) | 0.72(0.26,1.97) | ‐0.01(‐0.10,0.05) | |
| LD GOLI IV | 4.74(0.90,29.07) | 3.81(0.91,16.09) | 0.14(‐0.01,0.56) | |
| LD RITUX IV + MTX | 0.85(0.51,1.45) | 0.86(0.54,1.41) | ‐0.01(‐0.05,0.02) | |
| LD ABA IV + MTX | 1.16(0.45,2.80) | 1.15(0.48,2.59) | 0.01(‐0.06,0.10) | |
| LD CERTO SC + MTX | 1.48(0.31,6.46) | 1.44(0.33,4.91) | 0.02(‐0.07,0.26) | |
| LD ETN SC + MTX | 0.45(0.13,1.40) | 0.47(0.14,1.37) | ‐0.02(‐0.13,0.02) | |
| LD GOLI IV + MTX | 2.73(0.43,16.96) | 2.44(0.46,11.26) | 0.07(‐0.04,0.43) | |
| HD TOCI IV | 0.86(0.34,2.04) | 0.87(0.37,1.95) | ‐0.01(‐0.09,0.05) | |
| HD TOFA PO | 0.37(0.06,1.82) | 0.38(0.07,1.80) | ‐0.03(‐0.19,0.01) | |
| HD GOLI SC | 1.22(0.31,4.73) | 1.21(0.33,3.88) | 0.01(‐0.07,0.19) | |
| HD ADA SC | 0.68(0.14,2.96) | 0.69(0.16,2.85) | ‐0.01(‐0.17,0.03) | |
| HD GOLI SC + MTX | 2.59(0.83,9.14) | 2.33(0.84,6.53) | 0.07(‐0.01,0.33) | |
| HD TOCI IV + MTX | 0.98(0.35,2.96) | 0.98(0.37,2.72) | 0.00(‐0.08,0.09) | |
| HD TOFA PO + MTX | 1.53(0.60,3.96) | 1.47(0.62,3.50) | 0.02(‐0.04,0.16) | |
| HD INF IV + MTX | 0.98(0.45,2.01) | 0.98(0.47,1.92) | 0.00(‐0.06,0.05) | |
| HD CERTO SC + MTX | 1.81(0.73,4.73) | 1.72(0.74,3.87) | 0.03(‐0.02,0.21) | |
| HD TOCI IV + DMARD | 0.67(0.22,1.93) | 0.68(0.24,1.86) | ‐0.01(‐0.12,0.03) | |
| SD GOLI SC + MTX | SD ABA SC + MTX | 2.95(0.88,11.72) | 2.71(0.89,8.91) | 0.06(0.00,0.33) |
| SD CERTO SC + MTX | 2.28(1.07,5.45) | 2.15(1.07,4.78) | 0.04(0.00,0.18) | |
| SD TOFA PO + MTX | 2.86(1.22,7.48) | 2.65(1.21,6.30) | 0.05(0.01,0.24) | |
| SD GOLI IV + MTX | 4.71(0.76,32.59) | 4.00(0.77,19.95) | 0.10(‐0.01,0.49) | |
| SD ANA SC + MTX | 1.95(0.57,7.11) | 1.88(0.58,5.89) | 0.03(‐0.02,0.22) | |
| SD ETN SC + DMARD | 1.39(0.50,3.77) | 1.36(0.53,3.59) | 0.01(‐0.04,0.06) | |
| SD ABA IV + DMARD | 0.72(0.23,2.28) | 0.73(0.25,2.20) | ‐0.01(‐0.08,0.03) | |
| SD ADA SC + DMARD | 0.49(0.13,1.81) | 0.50(0.14,1.78) | ‐0.01(‐0.09,0.02) | |
| SD ANA + DMARD | 0.70(0.20,2.30) | 0.71(0.21,2.22) | ‐0.01(‐0.08,0.03) | |
| SD CERTO SC + DMARD | 0.48(0.09,2.32) | 0.49(0.09,2.25) | ‐0.01(‐0.09,0.03) | |
| SD TOCI SC + DMARD | 0.88(0.22,3.64) | 0.89(0.24,3.41) | 0.00(‐0.07,0.07) | |
| LD ADA SC | 0.69(0.13,3.15) | 0.70(0.14,3.08) | ‐0.01(‐0.11,0.03) | |
| LD ETN SC | 1.11(0.36,3.59) | 1.10(0.37,3.35) | 0.00(‐0.05,0.09) | |
| LD GOLI IV | 7.54(1.41,50.69) | 5.85(1.37,26.19) | 0.16(0.01,0.60) | |
| LD RITUX IV + MTX | 1.33(0.61,3.19) | 1.31(0.63,3.02) | 0.01(‐0.02,0.08) | |
| LD ABA IV + MTX | 1.82(0.73,4.57) | 1.76(0.75,4.10) | 0.02(‐0.01,0.14) | |
| LD CERTO SC + MTX | 2.28(0.49,10.87) | 2.16(0.50,8.46) | 0.04(‐0.02,0.31) | |
| LD ETN SC + MTX | 0.71(0.21,2.36) | 0.72(0.22,2.28) | ‐0.01(‐0.07,0.04) | |
| LD GOLI IV + MTX | 4.26(0.70,28.12) | 3.73(0.71,18.64) | 0.09(‐0.01,0.47) | |
| HD TOCI IV | 1.33(0.55,3.61) | 1.31(0.57,3.37) | 0.01(‐0.03,0.08) | |
| HD TOFA PO | 0.58(0.10,2.72) | 0.59(0.12,2.66) | ‐0.01(‐0.12,0.02) | |
| HD GOLI SC | 1.97(0.46,7.91) | 1.89(0.47,6.46) | 0.03(‐0.03,0.23) | |
| HD ADA SC | 1.07(0.22,4.64) | 1.07(0.24,4.44) | 0.00(‐0.09,0.05) | |
| HD GOLI SC + MTX | 4.09(1.26,15.06) | 3.59(1.24,10.89) | 0.09(0.01,0.38) | |
| HD TOCI IV + MTX | 1.54(0.53,5.07) | 1.51(0.54,4.49) | 0.01(‐0.03,0.14) | |
| HD TOFA PO + MTX | 2.39(0.98,6.30) | 2.26(0.98,5.41) | 0.04(0.00,0.20) | |
| HD INF IV + MTX | 1.52(0.70,3.53) | 1.48(0.71,3.26) | 0.01(‐0.02,0.10) | |
| HD CERTO SC + MTX | 2.81(1.07,8.50) | 2.59(1.07,6.85) | 0.05(0.00,0.27) | |
| HD TOCI IV + DMARD | 1.03(0.34,3.18) | 1.03(0.35,3.03) | 0.00(‐0.06,0.06) | |
| SD CERTO SC + MTX | SD GOLI SC + MTX | 0.78(0.22,2.53) | 0.80(0.27,2.31) | ‐0.02(‐0.23,0.09) |
| SD TOFA PO + MTX | 0.97(0.22,3.91) | 0.97(0.28,3.46) | 0.00(‐0.22,0.15) | |
| SD GOLI IV + MTX | 1.55(0.18,12.61) | 1.44(0.21,8.27) | 0.04(‐0.19,0.39) | |
| SD ANA SC + MTX | 0.66(0.14,3.21) | 0.69(0.17,2.82) | ‐0.02(‐0.25,0.11) | |
| SD ETN SC + DMARD | 0.47(0.11,1.80) | 0.50(0.15,1.74) | ‐0.04(‐0.33,0.02) | |
| SD ABA IV + DMARD | 0.24(0.05,1.02) | 0.27(0.07,1.02) | ‐0.06(‐0.37,0.00) | |
| SD ADA SC + DMARD | 0.16(0.03,0.78) | 0.18(0.04,0.79) | ‐0.07(‐0.39,0.00) | |
| SD ANA + DMARD | 0.23(0.05,1.04) | 0.25(0.06,1.04) | ‐0.07(‐0.37,0.00) | |
| SD CERTO SC + DMARD | 0.16(0.02,1.09) | 0.18(0.02,1.09) | ‐0.07(‐0.39,0.00) | |
| SD TOCI SC + DMARD | 0.30(0.05,1.50) | 0.33(0.07,1.46) | ‐0.06(‐0.35,0.02) | |
| LD ADA SC | 0.22(0.03,1.44) | 0.24(0.05,1.43) | ‐0.07(‐0.40,0.01) | |
| LD ETN SC | 0.36(0.09,1.68) | 0.39(0.11,1.62) | ‐0.05(‐0.31,0.03) | |
| LD GOLI IV | 2.62(0.35,18.37) | 2.17(0.41,10.49) | 0.09(‐0.13,0.50) | |
| LD RITUX IV + MTX | 0.46(0.12,1.54) | 0.49(0.15,1.51) | ‐0.04(‐0.30,0.02) | |
| LD ABA IV + MTX | 0.62(0.14,2.30) | 0.65(0.17,2.15) | ‐0.03(‐0.27,0.06) | |
| LD CERTO SC + MTX | 0.75(0.12,4.20) | 0.78(0.15,3.47) | ‐0.02(‐0.23,0.20) | |
| LD ETN SC + MTX | 0.24(0.05,1.02) | 0.26(0.06,1.02) | ‐0.06(‐0.35,0.00) | |
| LD GOLI IV + MTX | 1.51(0.17,11.67) | 1.42(0.20,7.80) | 0.03(‐0.19,0.37) | |
| HD TOCI IV | 0.46(0.11,1.63) | 0.49(0.15,1.59) | ‐0.04(‐0.31,0.02) | |
| HD TOFA PO | 0.19(0.02,1.22) | 0.20(0.04,1.21) | ‐0.07(‐0.41,0.01) | |
| HD GOLI SC | 0.62(0.18,2.32) | 0.66(0.21,2.14) | ‐0.03(‐0.22,0.08) | |
| HD ADA SC | 0.35(0.05,2.18) | 0.37(0.08,2.11) | ‐0.06(‐0.39,0.02) | |
| HD GOLI SC + MTX | 1.36(0.53,3.57) | 1.30(0.58,2.98) | 0.02(‐0.09,0.20) | |
| HD TOCI IV + MTX | 0.53(0.11,2.19) | 0.56(0.14,2.08) | ‐0.04(‐0.29,0.05) | |
| HD TOFA PO + MTX | 0.82(0.18,3.20) | 0.84(0.22,2.90) | ‐0.01(‐0.23,0.11) | |
| HD INF IV + MTX | 0.52(0.14,1.76) | 0.55(0.18,1.70) | ‐0.04(‐0.29,0.03) | |
| HD CERTO SC + MTX | 0.93(0.23,3.46) | 0.94(0.29,3.02) | 0.00(‐0.20,0.15) | |
| HD TOCI IV + DMARD | 0.35(0.07,1.39) | 0.38(0.09,1.37) | ‐0.05(‐0.34,0.01) | |
| SD TOFA PO + MTX | SD CERTO SC + MTX | 1.24(0.47,3.28) | 1.21(0.51,2.93) | 0.01(‐0.07,0.14) |
| SD GOLI IV + MTX | 1.97(0.32,14.28) | 1.79(0.36,8.69) | 0.06(‐0.10,0.42) | |
| SD ANA SC + MTX | 0.85(0.25,3.00) | 0.86(0.28,2.58) | ‐0.01(‐0.12,0.12) | |
| SD ETN SC + DMARD | 0.59(0.21,1.59) | 0.61(0.25,1.55) | ‐0.03(‐0.18,0.02) | |
| SD ABA IV + DMARD | 0.31(0.10,0.99) | 0.33(0.12,0.99) | ‐0.05(‐0.23,0.00) | |
| SD ADA SC + DMARD | 0.21(0.05,0.78) | 0.23(0.07,0.79) | ‐0.05(‐0.24,‐0.01) | |
| SD ANA + DMARD | 0.30(0.08,0.99) | 0.32(0.10,0.99) | ‐0.05(‐0.23,0.00) | |
| SD CERTO SC + DMARD | 0.20(0.04,1.03) | 0.22(0.04,1.02) | ‐0.05(‐0.25,0.00) | |
| SD TOCI SC + DMARD | 0.39(0.09,1.49) | 0.41(0.11,1.46) | ‐0.04(‐0.22,0.02) | |
| LD ADA SC | 0.31(0.05,1.46) | 0.32(0.07,1.45) | ‐0.05(‐0.27,0.01) | |
| LD ETN SC | 0.48(0.15,1.51) | 0.51(0.17,1.47) | ‐0.03(‐0.18,0.03) | |
| LD GOLI IV | 3.16(0.59,22.08) | 2.63(0.63,11.15) | 0.11(‐0.04,0.53) | |
| LD RITUX IV + MTX | 0.58(0.27,1.25) | 0.60(0.30,1.23) | ‐0.03(‐0.15,0.01) | |
| LD ABA IV + MTX | 0.78(0.30,1.96) | 0.80(0.33,1.85) | ‐0.01(‐0.13,0.06) | |
| LD CERTO SC + MTX | 1.02(0.22,3.73) | 1.02(0.24,3.07) | 0.00(‐0.11,0.20) | |
| LD ETN SC + MTX | 0.31(0.09,0.96) | 0.33(0.10,0.96) | ‐0.04(‐0.21,0.00) | |
| LD GOLI IV + MTX | 1.80(0.30,12.15) | 1.67(0.34,7.95) | 0.05(‐0.10,0.40) | |
| HD TOCI IV | 0.58(0.23,1.47) | 0.60(0.26,1.43) | ‐0.03(‐0.16,0.02) | |
| HD TOFA PO | 0.26(0.04,1.29) | 0.27(0.05,1.28) | ‐0.05(‐0.28,0.01) | |
| HD GOLI SC | 0.84(0.20,3.36) | 0.86(0.22,2.83) | ‐0.01(‐0.14,0.15) | |
| HD ADA SC | 0.46(0.09,1.99) | 0.48(0.12,1.94) | ‐0.04(‐0.26,0.02) | |
| HD GOLI SC + MTX | 1.76(0.53,6.62) | 1.63(0.57,4.72) | 0.04(‐0.05,0.29) | |
| HD TOCI IV + MTX | 0.65(0.23,2.10) | 0.68(0.26,1.97) | ‐0.02(‐0.15,0.06) | |
| HD TOFA PO + MTX | 1.04(0.38,2.78) | 1.03(0.41,2.53) | 0.00(‐0.09,0.11) | |
| HD INF IV + MTX | 0.66(0.30,1.40) | 0.68(0.34,1.35) | ‐0.02(‐0.13,0.02) | |
| HD CERTO SC + MTX | 1.22(0.61,2.45) | 1.19(0.63,2.19) | 0.01(‐0.04,0.13) | |
| HD TOCI IV + DMARD | 0.44(0.14,1.42) | 0.47(0.17,1.40) | ‐0.04(‐0.21,0.02) | |
| SD GOLI IV + MTX | SD TOFA PO + MTX | 1.63(0.26,10.42) | 1.50(0.29,6.85) | 0.04(‐0.14,0.38) |
| SD ANA SC + MTX | 0.68(0.17,2.72) | 0.71(0.20,2.41) | ‐0.02(‐0.18,0.11) | |
| SD ETN SC + DMARD | 0.49(0.15,1.37) | 0.51(0.19,1.35) | ‐0.04(‐0.24,0.02) | |
| SD ABA IV + DMARD | 0.26(0.07,0.85) | 0.28(0.09,0.86) | ‐0.06(‐0.28,‐0.01) | |
| SD ADA SC + DMARD | 0.17(0.04,0.64) | 0.19(0.05,0.65) | ‐0.07(‐0.30,‐0.01) | |
| SD ANA + DMARD | 0.24(0.06,0.85) | 0.27(0.08,0.86) | ‐0.06(‐0.29,‐0.01) | |
| SD CERTO SC + DMARD | 0.17(0.03,0.85) | 0.18(0.03,0.86) | ‐0.07(‐0.30,‐0.01) | |
| SD TOCI SC + DMARD | 0.31(0.07,1.34) | 0.33(0.08,1.31) | ‐0.06(‐0.27,0.02) | |
| LD ADA SC | 0.25(0.04,1.17) | 0.26(0.06,1.16) | ‐0.06(‐0.32,0.00) | |
| LD ETN SC | 0.39(0.10,1.26) | 0.42(0.12,1.24) | ‐0.05(‐0.24,0.01) | |
| LD GOLI IV | 2.70(0.43,16.94) | 2.26(0.49,9.26) | 0.10(‐0.09,0.50) | |
| LD RITUX IV + MTX | 0.47(0.18,1.21) | 0.50(0.21,1.19) | ‐0.04(‐0.21,0.01) | |
| LD ABA IV + MTX | 0.63(0.20,1.86) | 0.66(0.23,1.77) | ‐0.03(‐0.19,0.05) | |
| LD CERTO SC + MTX | 0.80(0.14,4.11) | 0.82(0.16,3.27) | ‐0.01(‐0.19,0.20) | |
| LD ETN SC + MTX | 0.24(0.06,0.93) | 0.27(0.07,0.93) | ‐0.06(‐0.27,0.00) | |
| LD GOLI IV + MTX | 1.53(0.23,9.91) | 1.43(0.26,6.41) | 0.03(‐0.15,0.36) | |
| HD TOCI IV | 0.46(0.17,1.36) | 0.49(0.20,1.33) | ‐0.04(‐0.22,0.02) | |
| HD TOFA PO | 0.20(0.03,0.97) | 0.22(0.04,0.97) | ‐0.07(‐0.33,0.00) | |
| HD GOLI SC | 0.66(0.15,3.17) | 0.69(0.18,2.72) | ‐0.02(‐0.21,0.13) | |
| HD ADA SC | 0.38(0.07,1.52) | 0.40(0.09,1.49) | ‐0.05(‐0.31,0.02) | |
| HD GOLI SC + MTX | 1.44(0.37,5.51) | 1.36(0.41,4.24) | 0.03(‐0.11,0.26) | |
| HD TOCI IV + MTX | 0.54(0.17,1.89) | 0.57(0.19,1.77) | ‐0.03(‐0.20,0.05) | |
| HD TOFA PO + MTX | 0.83(0.41,1.71) | 0.85(0.45,1.60) | ‐0.01(‐0.11,0.05) | |
| HD INF IV + MTX | 0.53(0.20,1.36) | 0.56(0.23,1.33) | ‐0.03(‐0.20,0.02) | |
| HD CERTO SC + MTX | 0.97(0.32,3.10) | 0.98(0.35,2.68) | 0.00(‐0.13,0.14) | |
| HD TOCI IV + DMARD | 0.36(0.10,1.20) | 0.39(0.13,1.18) | ‐0.05(‐0.26,0.01) | |
| SD ANA SC + MTX | SD GOLI IV + MTX | 0.43(0.05,3.71) | 0.48(0.08,3.16) | ‐0.06(‐0.43,0.13) |
| SD ETN SC + DMARD | 0.30(0.04,1.95) | 0.33(0.07,1.88) | ‐0.09(‐0.48,0.03) | |
| SD ABA IV + DMARD | 0.16(0.02,1.13) | 0.19(0.03,1.13) | ‐0.11(‐0.52,0.00) | |
| SD ADA SC + DMARD | 0.10(0.01,0.80) | 0.12(0.02,0.81) | ‐0.12(‐0.53,0.00) | |
| SD ANA + DMARD | 0.15(0.02,1.06) | 0.18(0.03,1.06) | ‐0.11(‐0.51,0.00) | |
| SD CERTO SC + DMARD | 0.10(0.01,1.04) | 0.12(0.02,1.04) | ‐0.12(‐0.52,0.00) | |
| SD TOCI SC + DMARD | 0.20(0.02,1.52) | 0.23(0.03,1.46) | ‐0.10(‐0.51,0.02) | |
| LD ADA SC | 0.15(0.02,1.22) | 0.17(0.03,1.21) | ‐0.12(‐0.54,0.00) | |
| LD ETN SC | 0.24(0.03,1.76) | 0.28(0.05,1.70) | ‐0.09(‐0.48,0.03) | |
| LD GOLI IV | 1.66(0.47,6.30) | 1.46(0.55,4.85) | 0.06(‐0.12,0.31) | |
| LD RITUX IV + MTX | 0.29(0.04,1.86) | 0.34(0.07,1.80) | ‐0.09(‐0.46,0.03) | |
| LD ABA IV + MTX | 0.40(0.05,2.91) | 0.45(0.09,2.66) | ‐0.07(‐0.45,0.07) | |
| LD CERTO SC + MTX | 0.51(0.05,5.40) | 0.56(0.07,4.23) | ‐0.05(‐0.42,0.19) | |
| LD ETN SC + MTX | 0.16(0.02,1.06) | 0.19(0.03,1.05) | ‐0.11(‐0.51,0.00) | |
| LD GOLI IV + MTX | 0.93(0.25,3.96) | 0.94(0.31,3.35) | ‐0.01(‐0.22,0.20) | |
| HD TOCI IV | 0.29(0.04,1.99) | 0.34(0.07,1.92) | ‐0.09(‐0.47,0.03) | |
| HD TOFA PO | 0.12(0.01,1.05) | 0.14(0.03,1.05) | ‐0.12(‐0.55,0.00) | |
| HD GOLI SC | 0.41(0.05,3.42) | 0.46(0.07,3.01) | ‐0.07(‐0.43,0.13) | |
| HD ADA SC | 0.23(0.02,1.84) | 0.25(0.05,1.80) | ‐0.10(‐0.53,0.02) | |
| HD GOLI SC + MTX | 0.91(0.12,7.69) | 0.92(0.17,5.80) | ‐0.01(‐0.35,0.26) | |
| HD TOCI IV + MTX | 0.34(0.04,2.45) | 0.38(0.07,2.26) | ‐0.08(‐0.45,0.06) | |
| HD TOFA PO + MTX | 0.51(0.08,3.53) | 0.56(0.13,3.18) | ‐0.05(‐0.40,0.12) | |
| HD INF IV + MTX | 0.34(0.05,2.09) | 0.38(0.07,2.00) | ‐0.08(‐0.45,0.04) | |
| HD CERTO SC + MTX | 0.62(0.08,4.49) | 0.66(0.12,3.83) | ‐0.04(‐0.39,0.16) | |
| HD TOCI IV + DMARD | 0.23(0.03,1.53) | 0.26(0.05,1.50) | ‐0.10(‐0.49,0.02) | |
| SD ETN SC + DMARD | SD ANA SC + MTX | 0.70(0.17,2.81) | 0.72(0.22,2.69) | ‐0.02(‐0.22,0.04) |
| SD ABA IV + DMARD | 0.37(0.08,1.65) | 0.39(0.10,1.61) | ‐0.04(‐0.26,0.01) | |
| SD ADA SC + DMARD | 0.25(0.05,1.26) | 0.26(0.06,1.25) | ‐0.04(‐0.27,0.01) | |
| SD ANA + DMARD | 0.35(0.07,1.57) | 0.37(0.09,1.53) | ‐0.04(‐0.26,0.01) | |
| SD CERTO SC + DMARD | 0.25(0.03,1.62) | 0.26(0.04,1.57) | ‐0.04(‐0.27,0.02) | |
| SD TOCI SC + DMARD | 0.46(0.08,2.37) | 0.48(0.10,2.25) | ‐0.03(‐0.25,0.04) | |
| LD ADA SC | 0.36(0.04,2.25) | 0.37(0.06,2.21) | ‐0.04(‐0.30,0.02) | |
| LD ETN SC | 0.56(0.12,2.51) | 0.58(0.14,2.35) | ‐0.02(‐0.22,0.05) | |
| LD GOLI IV | 3.83(0.55,31.58) | 3.09(0.61,17.01) | 0.12(‐0.06,0.55) | |
| LD RITUX IV + MTX | 0.68(0.18,2.40) | 0.70(0.22,2.30) | ‐0.02(‐0.19,0.05) | |
| LD ABA IV + MTX | 0.93(0.23,3.40) | 0.93(0.26,3.15) | 0.00(‐0.16,0.09) | |
| LD CERTO SC + MTX | 1.19(0.19,6.81) | 1.17(0.22,5.50) | 0.01(‐0.14,0.24) | |
| LD ETN SC + MTX | 0.36(0.08,1.61) | 0.38(0.09,1.58) | ‐0.04(‐0.24,0.02) | |
| LD GOLI IV + MTX | 2.20(0.28,17.70) | 1.99(0.33,11.53) | 0.06(‐0.13,0.42) | |
| HD TOCI IV | 0.68(0.18,2.73) | 0.70(0.21,2.61) | ‐0.02(‐0.20,0.05) | |
| HD TOFA PO | 0.28(0.04,1.92) | 0.30(0.05,1.89) | ‐0.04(‐0.30,0.01) | |
| HD GOLI SC | 0.99(0.18,5.06) | 1.00(0.20,4.43) | 0.00(‐0.16,0.16) | |
| HD ADA SC | 0.55(0.08,2.91) | 0.56(0.11,2.82) | ‐0.03(‐0.28,0.03) | |
| HD GOLI SC + MTX | 2.07(0.47,9.26) | 1.88(0.52,7.19) | 0.05(‐0.07,0.31) | |
| HD TOCI IV + MTX | 0.80(0.18,3.42) | 0.81(0.21,3.13) | ‐0.01(‐0.18,0.09) | |
| HD TOFA PO + MTX | 1.22(0.30,4.91) | 1.20(0.34,4.34) | 0.01(‐0.13,0.15) | |
| HD INF IV + MTX | 0.78(0.22,2.66) | 0.79(0.26,2.52) | ‐0.01(‐0.18,0.06) | |
| HD CERTO SC + MTX | 1.42(0.35,5.88) | 1.37(0.41,5.02) | 0.02(‐0.11,0.20) | |
| HD TOCI IV + DMARD | 0.53(0.11,2.29) | 0.55(0.14,2.22) | ‐0.03(‐0.24,0.03) | |
| SD ABA IV + DMARD | SD ETN SC + DMARD | 0.53(0.22,1.24) | 0.54(0.23,1.22) | ‐0.02(‐0.08,0.01) |
| SD ADA SC + DMARD | 0.35(0.12,0.99) | 0.36(0.13,0.99) | ‐0.03(‐0.10,0.00) | |
| SD ANA + DMARD | 0.50(0.19,1.28) | 0.51(0.20,1.26) | ‐0.02(‐0.08,0.01) | |
| SD CERTO SC + DMARD | 0.35(0.08,1.42) | 0.36(0.08,1.37) | ‐0.03(‐0.10,0.02) | |
| SD TOCI SC + DMARD | 0.63(0.20,2.22) | 0.64(0.21,2.11) | ‐0.01(‐0.07,0.05) | |
| LD ADA SC | 0.50(0.12,1.77) | 0.51(0.14,1.74) | ‐0.02(‐0.12,0.02) | |
| LD ETN SC | 0.81(0.26,2.48) | 0.82(0.27,2.31) | ‐0.01(‐0.06,0.08) | |
| LD GOLI IV | 5.45(0.94,33.63) | 4.39(0.95,16.67) | 0.15(0.00,0.59) | |
| LD RITUX IV + MTX | 0.97(0.36,2.72) | 0.97(0.37,2.49) | 0.00(‐0.05,0.08) | |
| LD ABA IV + MTX | 1.30(0.43,4.19) | 1.28(0.45,3.57) | 0.01(‐0.04,0.14) | |
| LD CERTO SC + MTX | 1.68(0.29,9.16) | 1.62(0.31,6.62) | 0.03(‐0.05,0.30) | |
| LD ETN SC + MTX | 0.53(0.13,1.80) | 0.54(0.14,1.73) | ‐0.02(‐0.08,0.04) | |
| LD GOLI IV + MTX | 3.12(0.47,20.12) | 2.80(0.49,12.01) | 0.08(‐0.03,0.47) | |
| HD TOCI IV | 0.97(0.41,2.40) | 0.97(0.43,2.24) | 0.00(‐0.04,0.07) | |
| HD TOFA PO | 0.42(0.09,1.53) | 0.43(0.11,1.52) | ‐0.02(‐0.12,0.01) | |
| HD GOLI SC | 1.40(0.32,6.48) | 1.37(0.34,5.09) | 0.02(‐0.05,0.22) | |
| HD ADA SC | 0.77(0.21,2.41) | 0.78(0.23,2.33) | ‐0.01(‐0.10,0.03) | |
| HD GOLI SC + MTX | 3.00(0.79,11.92) | 2.70(0.80,8.13) | 0.07(‐0.01,0.38) | |
| HD TOCI IV + MTX | 1.13(0.37,3.53) | 1.12(0.38,3.09) | 0.00(‐0.05,0.13) | |
| HD TOFA PO + MTX | 1.72(0.59,5.47) | 1.66(0.60,4.62) | 0.03(‐0.03,0.20) | |
| HD INF IV + MTX | 1.11(0.40,3.12) | 1.10(0.41,2.83) | 0.00(‐0.04,0.10) | |
| HD CERTO SC + MTX | 2.05(0.66,6.90) | 1.94(0.68,5.29) | 0.04(‐0.02,0.27) | |
| HD TOCI IV + DMARD | 0.76(0.32,1.69) | 0.77(0.33,1.65) | ‐0.01(‐0.06,0.03) | |
| SD ADA SC + DMARD | SD ABA IV + DMARD | 0.66(0.23,1.89) | 0.67(0.24,1.85) | ‐0.01(‐0.05,0.02) |
| SD ANA + DMARD | 0.95(0.37,2.40) | 0.95(0.39,2.31) | 0.00(‐0.04,0.03) | |
| SD CERTO SC + DMARD | 0.66(0.15,2.70) | 0.66(0.16,2.59) | ‐0.01(‐0.05,0.04) | |
| SD TOCI SC + DMARD | 1.21(0.39,3.91) | 1.20(0.40,3.66) | 0.00(‐0.03,0.08) | |
| LD ADA SC | 0.94(0.19,4.08) | 0.94(0.20,3.95) | 0.00(‐0.07,0.03) | |
| LD ETN SC | 1.51(0.43,5.52) | 1.49(0.45,5.09) | 0.01(‐0.03,0.12) | |
| LD GOLI IV | 10.09(1.53,75.14) | 7.91(1.50,38.29) | 0.17(0.02,0.62) | |
| LD RITUX IV + MTX | 1.82(0.61,6.07) | 1.78(0.63,5.55) | 0.02(‐0.02,0.12) | |
| LD ABA IV + MTX | 2.51(0.70,9.02) | 2.40(0.72,7.73) | 0.03(‐0.01,0.18) | |
| LD CERTO SC + MTX | 3.14(0.52,18.76) | 2.93(0.53,13.87) | 0.05(‐0.02,0.34) | |
| LD ETN SC + MTX | 0.98(0.22,4.02) | 0.98(0.23,3.80) | 0.00(‐0.05,0.07) | |
| LD GOLI IV + MTX | 5.91(0.83,45.07) | 5.13(0.84,27.29) | 0.10(‐0.01,0.49) | |
| HD TOCI IV | 1.82(0.77,5.12) | 1.78(0.78,4.68) | 0.02(‐0.01,0.10) | |
| HD TOFA PO | 0.78(0.15,3.82) | 0.79(0.16,3.74) | 0.00(‐0.08,0.03) | |
| HD GOLI SC | 2.62(0.58,12.98) | 2.49(0.59,10.41) | 0.03(‐0.02,0.26) | |
| HD ADA SC | 1.47(0.32,5.79) | 1.45(0.34,5.55) | 0.01(‐0.06,0.05) | |
| HD GOLI SC + MTX | 5.69(1.34,26.59) | 4.95(1.32,17.60) | 0.10(0.01,0.42) | |
| HD TOCI IV + MTX | 2.13(0.68,7.44) | 2.05(0.69,6.54) | 0.02(‐0.01,0.16) | |
| HD TOFA PO + MTX | 3.29(0.97,11.66) | 3.07(0.97,9.70) | 0.05(0.00,0.24) | |
| HD INF IV + MTX | 2.09(0.69,6.86) | 2.02(0.70,6.22) | 0.02(‐0.01,0.14) | |
| HD CERTO SC + MTX | 3.91(1.09,15.15) | 3.58(1.08,11.68) | 0.06(0.00,0.31) | |
| HD TOCI IV + DMARD | 1.44(0.63,3.23) | 1.42(0.65,3.10) | 0.01(‐0.02,0.06) | |
| SD ANA + DMARD | SD ADA SC + DMARD | 1.43(0.46,4.34) | 1.42(0.48,4.20) | 0.01(‐0.02,0.05) |
| SD CERTO SC + DMARD | 0.98(0.20,4.76) | 0.98(0.20,4.51) | 0.00(‐0.04,0.05) | |
| SD TOCI SC + DMARD | 1.81(0.48,6.66) | 1.78(0.49,6.24) | 0.01(‐0.02,0.09) | |
| LD ADA SC | 1.44(0.24,7.20) | 1.43(0.25,6.94) | 0.01(‐0.06,0.04) | |
| LD ETN SC | 2.25(0.55,9.63) | 2.20(0.56,8.79) | 0.02(‐0.02,0.13) | |
| LD GOLI IV | 16.15(1.98,122.00) | 12.22(1.91,62.43) | 0.18(0.02,0.64) | |
| LD RITUX IV + MTX | 2.75(0.78,10.76) | 2.65(0.79,9.78) | 0.03(‐0.01,0.14) | |
| LD ABA IV + MTX | 3.77(0.94,15.63) | 3.58(0.94,13.76) | 0.04(0.00,0.19) | |
| LD CERTO SC + MTX | 4.77(0.70,32.76) | 4.40(0.71,23.85) | 0.06(‐0.01,0.36) | |
| LD ETN SC + MTX | 1.47(0.29,6.93) | 1.46(0.30,6.51) | 0.01(‐0.03,0.08) | |
| LD GOLI IV + MTX | 9.17(1.06,72.09) | 7.80(1.06,45.57) | 0.11(0.00,0.51) | |
| HD TOCI IV | 2.75(0.97,9.19) | 2.66(0.97,8.40) | 0.03(0.00,0.12) | |
| HD TOFA PO | 1.18(0.19,6.10) | 1.17(0.20,5.97) | 0.00(‐0.06,0.03) | |
| HD GOLI SC | 3.93(0.76,23.07) | 3.67(0.77,18.71) | 0.04(‐0.01,0.27) | |
| HD ADA SC | 2.20(0.41,9.67) | 2.16(0.43,9.22) | 0.02(‐0.04,0.06) | |
| HD GOLI SC + MTX | 8.53(1.73,46.07) | 7.31(1.68,31.81) | 0.10(0.01,0.43) | |
| HD TOCI IV + MTX | 3.19(0.88,12.82) | 3.05(0.89,11.09) | 0.03(0.00,0.18) | |
| HD TOFA PO + MTX | 4.88(1.33,21.39) | 4.52(1.31,17.87) | 0.05(0.01,0.26) | |
| HD INF IV + MTX | 3.18(0.84,12.23) | 3.03(0.85,11.01) | 0.03(0.00,0.16) | |
| HD CERTO SC + MTX | 5.81(1.42,26.15) | 5.28(1.39,20.12) | 0.07(0.01,0.33) | |
| HD TOCI IV + DMARD | 2.16(0.76,5.90) | 2.11(0.76,5.65) | 0.02(‐0.01,0.08) | |
| SD CERTO SC + DMARD | SD ANA + DMARD | 0.70(0.15,3.00) | 0.71(0.15,2.89) | ‐0.01(‐0.05,0.04) |
| SD TOCI SC + DMARD | 1.25(0.39,4.40) | 1.25(0.40,4.08) | 0.00(‐0.03,0.08) | |
| LD ADA SC | 1.01(0.20,4.45) | 1.01(0.21,4.33) | 0.00(‐0.07,0.03) | |
| LD ETN SC | 1.57(0.45,6.44) | 1.55(0.46,5.94) | 0.01(‐0.03,0.12) | |
| LD GOLI IV | 11.02(1.58,82.43) | 8.43(1.54,41.91) | 0.18(0.02,0.62) | |
| LD RITUX IV + MTX | 1.92(0.61,6.90) | 1.86(0.62,6.33) | 0.02(‐0.02,0.13) | |
| LD ABA IV + MTX | 2.64(0.73,10.38) | 2.52(0.74,8.95) | 0.03(‐0.01,0.18) | |
| LD CERTO SC + MTX | 3.37(0.52,21.60) | 3.14(0.53,15.79) | 0.05(‐0.02,0.34) | |
| LD ETN SC + MTX | 1.04(0.22,4.60) | 1.04(0.23,4.33) | 0.00(‐0.04,0.07) | |
| LD GOLI IV + MTX | 6.34(0.82,49.57) | 5.47(0.84,29.87) | 0.10(‐0.01,0.50) | |
| HD TOCI IV | 1.95(0.72,5.47) | 1.90(0.73,5.06) | 0.02(‐0.01,0.11) | |
| HD TOFA PO | 0.82(0.15,4.15) | 0.83(0.17,4.04) | 0.00(‐0.08,0.03) | |
| HD GOLI SC | 2.80(0.59,14.12) | 2.66(0.61,11.41) | 0.04(‐0.02,0.26) | |
| HD ADA SC | 1.54(0.32,6.46) | 1.52(0.34,6.24) | 0.01(‐0.06,0.05) | |
| HD GOLI SC + MTX | 6.05(1.41,29.32) | 5.25(1.38,19.59) | 0.10(0.01,0.42) | |
| HD TOCI IV + MTX | 2.23(0.66,8.36) | 2.16(0.67,7.30) | 0.02(‐0.01,0.16) | |
| HD TOFA PO + MTX | 3.46(0.97,13.39) | 3.21(0.97,11.04) | 0.05(0.00,0.25) | |
| HD INF IV + MTX | 2.19(0.66,7.82) | 2.12(0.68,7.05) | 0.02(‐0.01,0.15) | |
| HD CERTO SC + MTX | 4.07(1.07,16.84) | 3.73(1.06,13.00) | 0.06(0.00,0.32) | |
| HD TOCI IV + DMARD | 1.51(0.60,3.67) | 1.49(0.61,3.51) | 0.01(‐0.02,0.06) | |
| SD TOCI SC + DMARD | SD CERTO SC + DMARD | 1.84(0.36,10.22) | 1.81(0.37,9.67) | 0.01(‐0.04,0.10) |
| LD ADA SC | 1.45(0.21,10.21) | 1.44(0.22,9.85) | 0.01(‐0.07,0.04) | |
| LD ETN SC | 2.35(0.40,13.39) | 2.29(0.42,12.27) | 0.02(‐0.03,0.13) | |
| LD GOLI IV | 16.49(1.62,145.80) | 12.41(1.56,80.73) | 0.18(0.02,0.64) | |
| LD RITUX IV + MTX | 2.81(0.58,15.17) | 2.71(0.60,13.86) | 0.02(‐0.02,0.14) | |
| LD ABA IV + MTX | 3.91(0.69,22.50) | 3.69(0.71,19.30) | 0.04(‐0.01,0.19) | |
| LD CERTO SC + MTX | 4.84(0.51,48.28) | 4.41(0.53,35.63) | 0.05(‐0.02,0.36) | |
| LD ETN SC + MTX | 1.46(0.23,9.21) | 1.45(0.25,8.69) | 0.01(‐0.05,0.09) | |
| LD GOLI IV + MTX | 9.44(0.88,90.20) | 7.94(0.88,56.94) | 0.11(0.00,0.50) | |
| HD TOCI IV | 2.88(0.64,13.40) | 2.77(0.66,12.30) | 0.02(‐0.02,0.13) | |
| HD TOFA PO | 1.21(0.16,8.49) | 1.21(0.17,8.27) | 0.00(‐0.08,0.03) | |
| HD GOLI SC | 3.93(0.55,34.46) | 3.71(0.57,27.35) | 0.04(‐0.02,0.28) | |
| HD ADA SC | 2.22(0.34,14.61) | 2.17(0.36,13.97) | 0.02(‐0.06,0.06) | |
| HD GOLI SC + MTX | 8.51(1.28,71.10) | 7.35(1.25,48.69) | 0.10(0.01,0.44) | |
| HD TOCI IV + MTX | 3.25(0.63,19.14) | 3.10(0.65,16.82) | 0.03(‐0.02,0.18) | |
| HD TOFA PO + MTX | 5.08(0.98,28.44) | 4.67(0.98,24.43) | 0.05(0.00,0.26) | |
| HD INF IV + MTX | 3.24(0.65,18.74) | 3.09(0.67,16.57) | 0.03(‐0.02,0.16) | |
| HD CERTO SC + MTX | 5.91(1.05,37.13) | 5.38(1.04,28.90) | 0.07(0.00,0.33) | |
| HD TOCI IV + DMARD | 2.18(0.52,9.76) | 2.13(0.54,9.11) | 0.02(‐0.03,0.08) | |
| LD ADA SC | SD TOCI SC + DMARD | 0.80(0.13,4.09) | 0.80(0.14,3.96) | ‐0.01(‐0.12,0.03) |
| LD ETN SC | 1.25(0.27,5.83) | 1.24(0.30,5.30) | 0.01(‐0.07,0.11) | |
| LD GOLI IV | 8.47(1.16,73.25) | 6.58(1.15,38.20) | 0.17(0.01,0.61) | |
| LD RITUX IV + MTX | 1.50(0.41,6.39) | 1.48(0.43,5.83) | 0.01(‐0.05,0.11) | |
| LD ABA IV + MTX | 2.02(0.49,9.52) | 1.95(0.51,8.30) | 0.02(‐0.04,0.17) | |
| LD CERTO SC + MTX | 2.62(0.37,19.05) | 2.46(0.39,13.89) | 0.04(‐0.04,0.33) | |
| LD ETN SC + MTX | 0.81(0.16,4.16) | 0.82(0.17,3.96) | 0.00(‐0.08,0.06) | |
| LD GOLI IV + MTX | 4.74(0.59,42.79) | 4.18(0.61,26.98) | 0.09(‐0.02,0.48) | |
| HD TOCI IV | 1.51(0.47,5.54) | 1.48(0.49,5.16) | 0.01(‐0.05,0.10) | |
| HD TOFA PO | 0.65(0.10,3.67) | 0.66(0.11,3.62) | ‐0.01(‐0.12,0.02) | |
| HD GOLI SC | 2.17(0.39,12.49) | 2.08(0.41,10.37) | 0.03(‐0.05,0.25) | |
| HD ADA SC | 1.22(0.22,5.82) | 1.21(0.24,5.60) | 0.01(‐0.10,0.05) | |
| HD GOLI SC + MTX | 4.65(0.93,26.84) | 4.06(0.94,18.35) | 0.09(0.00,0.41) | |
| HD TOCI IV + MTX | 1.76(0.44,7.85) | 1.71(0.45,7.03) | 0.02(‐0.04,0.15) | |
| HD TOFA PO + MTX | 2.76(0.60,12.01) | 2.58(0.62,10.29) | 0.04(‐0.03,0.23) | |
| HD INF IV + MTX | 1.70(0.46,7.43) | 1.66(0.48,6.67) | 0.02(‐0.05,0.13) | |
| HD CERTO SC + MTX | 3.15(0.73,15.95) | 2.90(0.75,12.41) | 0.05(‐0.02,0.30) | |
| HD TOCI IV + DMARD | 1.19(0.39,3.55) | 1.18(0.41,3.42) | 0.00(‐0.06,0.05) | |
| LD ETN SC | LD ADA SC | 1.59(0.28,9.81) | 1.57(0.29,8.54) | 0.01(‐0.03,0.15) |
| LD GOLI IV | 10.84(1.75,102.40) | 8.64(1.71,38.74) | 0.18(0.02,0.65) | |
| LD RITUX IV + MTX | 1.96(0.39,10.77) | 1.92(0.41,9.33) | 0.02(‐0.02,0.16) | |
| LD ABA IV + MTX | 2.71(0.51,16.21) | 2.61(0.52,13.13) | 0.03(‐0.02,0.21) | |
| LD CERTO SC + MTX | 3.47(0.36,31.74) | 3.24(0.37,20.74) | 0.05(‐0.02,0.37) | |
| LD ETN SC + MTX | 1.00(0.17,6.54) | 1.00(0.18,5.97) | 0.00(‐0.03,0.10) | |
| LD GOLI IV + MTX | 6.27(0.89,56.60) | 5.54(0.90,29.64) | 0.10(0.00,0.52) | |
| HD TOCI IV | 1.94(0.44,10.37) | 1.89(0.45,9.01) | 0.02(‐0.02,0.15) | |
| HD TOFA PO | 0.81(0.25,2.64) | 0.81(0.26,2.59) | 0.00(‐0.04,0.02) | |
| HD GOLI SC | 2.75(0.43,22.86) | 2.63(0.44,16.38) | 0.04(‐0.02,0.29) | |
| HD ADA SC | 1.53(0.64,3.69) | 1.51(0.64,3.55) | 0.01(‐0.02,0.04) | |
| HD GOLI SC + MTX | 5.87(0.92,45.19) | 5.19(0.92,26.11) | 0.10(0.00,0.46) | |
| HD TOCI IV + MTX | 2.28(0.40,14.43) | 2.21(0.41,11.61) | 0.03(‐0.03,0.20) | |
| HD TOFA PO + MTX | 3.38(0.66,22.14) | 3.20(0.67,16.02) | 0.05(‐0.01,0.29) | |
| HD INF IV + MTX | 2.24(0.46,12.53) | 2.18(0.47,10.32) | 0.03(‐0.02,0.18) | |
| HD CERTO SC + MTX | 3.96(0.72,27.13) | 3.69(0.73,18.22) | 0.06(‐0.01,0.35) | |
| HD TOCI IV + DMARD | 1.51(0.32,7.27) | 1.49(0.33,6.63) | 0.01(‐0.03,0.10) | |
| LD GOLI IV | LD ETN SC | 6.83(1.04,49.43) | 5.29(1.03,27.62) | 0.16(0.00,0.59) |
| LD RITUX IV + MTX | 1.21(0.41,3.66) | 1.20(0.44,3.44) | 0.01(‐0.06,0.08) | |
| LD ABA IV + MTX | 1.63(0.46,5.83) | 1.59(0.49,5.26) | 0.02(‐0.05,0.14) | |
| LD CERTO SC + MTX | 2.07(0.34,11.64) | 1.97(0.36,8.95) | 0.03(‐0.05,0.30) | |
| LD ETN SC + MTX | 0.63(0.14,2.73) | 0.65(0.15,2.64) | ‐0.01(‐0.11,0.05) | |
| LD GOLI IV + MTX | 3.93(0.50,27.79) | 3.41(0.52,19.30) | 0.08(‐0.03,0.46) | |
| HD TOCI IV | 1.22(0.38,4.00) | 1.21(0.41,3.73) | 0.01(‐0.07,0.08) | |
| HD TOFA PO | 0.51(0.08,2.75) | 0.52(0.09,2.69) | ‐0.02(‐0.15,0.02) | |
| HD GOLI SC | 1.76(0.37,7.99) | 1.68(0.38,6.77) | 0.02(‐0.06,0.21) | |
| HD ADA SC | 0.96(0.17,4.65) | 0.96(0.19,4.47) | 0.00(‐0.14,0.04) | |
| HD GOLI SC + MTX | 3.83(0.85,15.86) | 3.35(0.86,11.52) | 0.08(‐0.01,0.37) | |
| HD TOCI IV + MTX | 1.41(0.37,5.43) | 1.39(0.39,4.85) | 0.01(‐0.06,0.14) | |
| HD TOFA PO + MTX | 2.14(0.66,7.89) | 2.03(0.68,6.92) | 0.03(‐0.03,0.20) | |
| HD INF IV + MTX | 1.38(0.42,4.39) | 1.36(0.45,4.10) | 0.01(‐0.06,0.10) | |
| HD CERTO SC + MTX | 2.55(0.72,9.23) | 2.35(0.74,7.73) | 0.05(‐0.02,0.26) | |
| HD TOCI IV + DMARD | 0.95(0.26,3.27) | 0.95(0.29,3.11) | 0.00(‐0.10,0.05) | |
| LD RITUX IV + MTX | LD GOLI IV | 0.17(0.03,1.00) | 0.22(0.06,1.00) | ‐0.15(‐0.57,0.00) |
| LD ABA IV + MTX | 0.24(0.03,1.45) | 0.30(0.07,1.39) | ‐0.13(‐0.56,0.03) | |
| LD CERTO SC + MTX | 0.30(0.03,2.89) | 0.37(0.05,2.40) | ‐0.11(‐0.54,0.13) | |
| LD ETN SC + MTX | 0.09(0.01,0.61) | 0.12(0.02,0.64) | ‐0.17(‐0.62,‐0.02) | |
| LD GOLI IV + MTX | 0.56(0.17,2.02) | 0.64(0.22,1.76) | ‐0.06(‐0.32,0.11) | |
| HD TOCI IV | 0.17(0.03,1.09) | 0.22(0.05,1.08) | ‐0.15(‐0.58,0.00) | |
| HD TOFA PO | 0.08(0.01,0.54) | 0.10(0.02,0.55) | ‐0.18(‐0.66,‐0.02) | |
| HD GOLI SC | 0.25(0.03,2.00) | 0.31(0.06,1.80) | ‐0.13(‐0.55,0.07) | |
| HD ADA SC | 0.14(0.02,0.86) | 0.18(0.04,0.86) | ‐0.17(‐0.64,‐0.01) | |
| HD GOLI SC + MTX | 0.54(0.08,4.00) | 0.61(0.13,3.18) | ‐0.06(‐0.46,0.21) | |
| HD TOCI IV + MTX | 0.20(0.03,1.35) | 0.26(0.05,1.31) | ‐0.14(‐0.56,0.02) | |
| HD TOFA PO + MTX | 0.31(0.05,1.96) | 0.38(0.09,1.79) | ‐0.12(‐0.52,0.06) | |
| HD INF IV + MTX | 0.20(0.03,1.12) | 0.26(0.06,1.11) | ‐0.14(‐0.56,0.01) | |
| HD CERTO SC + MTX | 0.38(0.05,2.33) | 0.45(0.10,2.05) | ‐0.10(‐0.51,0.10) | |
| HD TOCI IV + DMARD | 0.14(0.02,0.88) | 0.17(0.04,0.89) | ‐0.16(‐0.60,‐0.01) | |
| LD ABA IV + MTX | LD RITUX IV + MTX | 1.36(0.52,3.30) | 1.33(0.54,3.04) | 0.01(‐0.04,0.11) |
| LD CERTO SC + MTX | 1.71(0.36,7.85) | 1.64(0.38,6.18) | 0.03(‐0.05,0.28) | |
| LD ETN SC + MTX | 0.52(0.16,1.67) | 0.53(0.17,1.62) | ‐0.02(‐0.11,0.02) | |
| LD GOLI IV + MTX | 3.25(0.50,19.21) | 2.87(0.51,12.56) | 0.08(‐0.03,0.44) | |
| HD TOCI IV | 1.03(0.39,2.39) | 1.02(0.42,2.28) | 0.00(‐0.07,0.06) | |
| HD TOFA PO | 0.43(0.07,2.03) | 0.45(0.09,2.00) | ‐0.02(‐0.16,0.02) | |
| HD GOLI SC | 1.42(0.35,5.66) | 1.38(0.37,4.70) | 0.01(‐0.06,0.21) | |
| HD ADA SC | 0.79(0.16,3.43) | 0.80(0.19,3.31) | ‐0.01(‐0.14,0.04) | |
| HD GOLI SC + MTX | 3.03(0.94,11.06) | 2.71(0.94,8.04) | 0.07(0.00,0.35) | |
| HD TOCI IV + MTX | 1.15(0.39,3.49) | 1.15(0.41,3.18) | 0.01(‐0.06,0.11) | |
| HD TOFA PO + MTX | 1.78(0.69,4.56) | 1.70(0.71,4.01) | 0.03(‐0.02,0.18) | |
| HD INF IV + MTX | 1.15(0.53,2.34) | 1.14(0.55,2.20) | 0.00(‐0.04,0.07) | |
| HD CERTO SC + MTX | 2.10(0.84,5.76) | 1.97(0.85,4.67) | 0.04(‐0.01,0.24) | |
| HD TOCI IV + DMARD | 0.77(0.26,2.20) | 0.78(0.28,2.12) | ‐0.01(‐0.10,0.04) | |
| LD CERTO SC + MTX | LD ABA IV + MTX | 1.26(0.24,6.61) | 1.23(0.26,5.30) | 0.01(‐0.10,0.25) |
| LD ETN SC + MTX | 0.39(0.10,1.49) | 0.41(0.11,1.46) | ‐0.03(‐0.17,0.02) | |
| LD GOLI IV + MTX | 2.37(0.35,16.71) | 2.14(0.39,10.92) | 0.06(‐0.07,0.42) | |
| HD TOCI IV | 0.74(0.26,2.18) | 0.75(0.30,2.09) | ‐0.01(‐0.12,0.05) | |
| HD TOFA PO | 0.31(0.05,1.76) | 0.32(0.07,1.73) | ‐0.04(‐0.22,0.01) | |
| HD GOLI SC | 1.05(0.23,4.85) | 1.05(0.25,3.97) | 0.00(‐0.11,0.18) | |
| HD ADA SC | 0.58(0.11,2.69) | 0.60(0.13,2.61) | ‐0.02(‐0.20,0.03) | |
| HD GOLI SC + MTX | 2.22(0.61,9.17) | 2.02(0.64,6.89) | 0.06(‐0.04,0.33) | |
| HD TOCI IV + MTX | 0.83(0.27,2.90) | 0.85(0.29,2.68) | ‐0.01(‐0.11,0.09) | |
| HD TOFA PO + MTX | 1.32(0.46,4.03) | 1.28(0.49,3.58) | 0.01(‐0.07,0.16) | |
| HD INF IV + MTX | 0.84(0.33,2.15) | 0.85(0.36,2.03) | ‐0.01(‐0.10,0.05) | |
| HD CERTO SC + MTX | 1.55(0.52,4.90) | 1.49(0.54,4.11) | 0.03(‐0.05,0.20) | |
| HD TOCI IV + DMARD | 0.56(0.16,1.93) | 0.58(0.19,1.89) | ‐0.02(‐0.16,0.03) | |
| LD ETN SC + MTX | LD CERTO SC + MTX | 0.30(0.05,1.92) | 0.32(0.07,1.86) | ‐0.05(‐0.33,0.02) |
| LD GOLI IV + MTX | 1.88(0.19,18.68) | 1.71(0.24,12.62) | 0.05(‐0.20,0.41) | |
| HD TOCI IV | 0.59(0.11,3.13) | 0.61(0.15,2.96) | ‐0.03(‐0.28,0.05) | |
| HD TOFA PO | 0.23(0.03,1.92) | 0.25(0.04,1.90) | ‐0.06(‐0.37,0.01) | |
| HD GOLI SC | 0.83(0.11,5.66) | 0.84(0.14,4.82) | ‐0.01(‐0.26,0.16) | |
| HD ADA SC | 0.44(0.06,3.66) | 0.46(0.09,3.55) | ‐0.04(‐0.35,0.03) | |
| HD GOLI SC + MTX | 1.78(0.32,10.84) | 1.64(0.39,8.10) | 0.04(‐0.15,0.31) | |
| HD TOCI IV + MTX | 0.68(0.11,4.01) | 0.70(0.15,3.74) | ‐0.02(‐0.27,0.09) | |
| HD TOFA PO + MTX | 1.04(0.19,6.11) | 1.03(0.24,5.45) | 0.00(‐0.22,0.15) | |
| HD INF IV + MTX | 0.66(0.15,3.06) | 0.69(0.19,2.93) | ‐0.02(‐0.26,0.06) | |
| HD CERTO SC + MTX | 1.20(0.31,5.73) | 1.17(0.37,5.12) | 0.01(‐0.16,0.17) | |
| HD TOCI IV + DMARD | 0.46(0.07,2.65) | 0.48(0.10,2.57) | ‐0.04(‐0.32,0.03) | |
| LD GOLI IV + MTX | LD ETN SC + MTX | 6.13(0.83,43.62) | 5.25(0.84,29.87) | 0.10(‐0.01,0.48) |
| HD TOCI IV | 1.88(0.56,7.62) | 1.83(0.58,7.10) | 0.02(‐0.03,0.11) | |
| HD TOFA PO | 0.82(0.12,5.16) | 0.83(0.13,5.03) | 0.00(‐0.10,0.03) | |
| HD GOLI SC | 2.74(0.49,14.78) | 2.60(0.51,12.17) | 0.03(‐0.03,0.25) | |
| HD ADA SC | 1.46(0.26,8.32) | 1.44(0.28,7.97) | 0.01(‐0.08,0.05) | |
| HD GOLI SC + MTX | 5.83(1.36,27.75) | 5.02(1.32,20.70) | 0.09(0.01,0.41) | |
| HD TOCI IV + MTX | 2.19(0.52,10.32) | 2.11(0.54,9.41) | 0.02(‐0.03,0.16) | |
| HD TOFA PO + MTX | 3.42(0.87,13.28) | 3.18(0.88,11.55) | 0.05(‐0.01,0.23) | |
| HD INF IV + MTX | 2.17(0.65,7.50) | 2.09(0.67,6.91) | 0.02(‐0.02,0.13) | |
| HD CERTO SC + MTX | 3.95(1.14,15.46) | 3.60(1.13,12.95) | 0.06(0.00,0.29) | |
| HD TOCI IV + DMARD | 1.46(0.35,6.28) | 1.44(0.37,5.99) | 0.01(‐0.05,0.07) | |
| HD TOCI IV | LD GOLI IV + MTX | 0.30(0.05,2.05) | 0.34(0.08,1.97) | ‐0.08(‐0.45,0.03) |
| HD TOFA PO | 0.14(0.01,1.02) | 0.15(0.03,1.02) | ‐0.11(‐0.53,0.00) | |
| HD GOLI SC | 0.44(0.05,3.88) | 0.48(0.08,3.35) | ‐0.06(‐0.42,0.14) | |
| HD ADA SC | 0.24(0.03,1.75) | 0.27(0.06,1.71) | ‐0.09(‐0.50,0.02) | |
| HD GOLI SC + MTX | 0.94(0.12,8.65) | 0.94(0.17,6.55) | ‐0.01(‐0.33,0.27) | |
| HD TOCI IV + MTX | 0.34(0.05,2.58) | 0.39(0.08,2.40) | ‐0.07(‐0.43,0.06) | |
| HD TOFA PO + MTX | 0.54(0.09,3.74) | 0.59(0.13,3.25) | ‐0.05(‐0.38,0.13) | |
| HD INF IV + MTX | 0.36(0.06,2.22) | 0.40(0.09,2.10) | ‐0.07(‐0.43,0.04) | |
| HD CERTO SC + MTX | 0.67(0.09,4.60) | 0.71(0.14,3.79) | ‐0.03(‐0.37,0.16) | |
| HD TOCI IV + DMARD | 0.24(0.03,1.69) | 0.27(0.06,1.63) | ‐0.09(‐0.47,0.02) | |
| HD TOFA PO | HD TOCI IV | 0.43(0.08,1.99) | 0.44(0.09,1.96) | ‐0.02(‐0.16,0.01) |
| HD GOLI SC | 1.39(0.35,6.05) | 1.36(0.37,4.99) | 0.01(‐0.06,0.21) | |
| HD ADA SC | 0.80(0.17,3.09) | 0.81(0.19,2.99) | ‐0.01(‐0.13,0.04) | |
| HD GOLI SC + MTX | 3.05(0.89,11.48) | 2.72(0.89,8.07) | 0.07(‐0.01,0.36) | |
| HD TOCI IV + MTX | 1.15(0.53,2.56) | 1.14(0.55,2.36) | 0.01(‐0.04,0.09) | |
| HD TOFA PO + MTX | 1.80(0.61,4.93) | 1.72(0.63,4.32) | 0.03(‐0.03,0.18) | |
| HD INF IV + MTX | 1.14(0.45,2.80) | 1.13(0.47,2.64) | 0.00(‐0.05,0.08) | |
| HD CERTO SC + MTX | 2.11(0.73,6.38) | 1.98(0.75,5.17) | 0.04(‐0.02,0.25) | |
| HD TOCI IV + DMARD | 0.77(0.31,1.88) | 0.78(0.33,1.81) | ‐0.01(‐0.08,0.03) | |
| HD GOLI SC | HD TOFA PO | 3.40(0.52,26.74) | 3.23(0.53,18.87) | 0.04(‐0.01,0.30) |
| HD ADA SC | 1.83(0.61,5.97) | 1.80(0.62,5.68) | 0.01(‐0.01,0.06) | |
| HD GOLI SC + MTX | 7.54(1.02,53.03) | 6.65(1.02,30.60) | 0.10(0.00,0.46) | |
| HD TOCI IV + MTX | 2.71(0.52,18.48) | 2.62(0.53,14.87) | 0.03(‐0.01,0.21) | |
| HD TOFA PO + MTX | 4.18(0.88,27.29) | 3.94(0.88,20.32) | 0.05(0.00,0.29) | |
| HD INF IV + MTX | 2.59(0.53,15.27) | 2.51(0.54,12.69) | 0.03(‐0.01,0.18) | |
| HD CERTO SC + MTX | 4.75(0.85,34.40) | 4.42(0.85,23.12) | 0.06(0.00,0.36) | |
| HD TOCI IV + DMARD | 1.83(0.38,9.43) | 1.80(0.39,8.52) | 0.01(‐0.02,0.11) | |
| HD ADA SC | HD GOLI SC | 0.53(0.08,3.39) | 0.54(0.11,3.27) | ‐0.03(‐0.28,0.04) |
| HD GOLI SC + MTX | 2.14(0.65,7.60) | 1.95(0.69,6.20) | 0.06(‐0.04,0.28) | |
| HD TOCI IV + MTX | 0.81(0.16,4.00) | 0.82(0.19,3.64) | ‐0.01(‐0.20,0.11) | |
| HD TOFA PO + MTX | 1.26(0.27,5.74) | 1.24(0.32,4.99) | 0.01(‐0.15,0.17) | |
| HD INF IV + MTX | 0.79(0.20,3.25) | 0.80(0.24,3.05) | ‐0.01(‐0.19,0.07) | |
| HD CERTO SC + MTX | 1.44(0.34,7.29) | 1.39(0.39,6.22) | 0.02(‐0.13,0.22) | |
| HD TOCI IV + DMARD | 0.55(0.11,2.33) | 0.57(0.14,2.26) | ‐0.02(‐0.24,0.04) | |
| HD GOLI SC + MTX | HD ADA SC | 3.96(0.66,25.40) | 3.58(0.67,14.63) | 0.09(‐0.01,0.43) |
| HD TOCI IV + MTX | 1.43(0.31,8.45) | 1.41(0.32,6.87) | 0.01(‐0.04,0.19) | |
| HD TOFA PO + MTX | 2.20(0.53,12.89) | 2.11(0.55,9.58) | 0.04(‐0.02,0.27) | |
| HD INF IV + MTX | 1.42(0.32,7.34) | 1.40(0.34,6.12) | 0.01(‐0.04,0.16) | |
| HD CERTO SC + MTX | 2.62(0.57,15.86) | 2.47(0.58,10.84) | 0.05(‐0.02,0.34) | |
| HD TOCI IV + DMARD | 0.97(0.25,4.31) | 0.97(0.26,3.94) | 0.00(‐0.04,0.09) | |
| HD TOCI IV + MTX | HD GOLI SC + MTX | 0.37(0.09,1.50) | 0.42(0.12,1.45) | ‐0.06(‐0.35,0.03) |
| HD TOFA PO + MTX | 0.59(0.14,2.27) | 0.64(0.18,2.10) | ‐0.04(‐0.28,0.08) | |
| HD INF IV + MTX | 0.38(0.11,1.22) | 0.42(0.15,1.20) | ‐0.07(‐0.33,0.01) | |
| HD CERTO SC + MTX | 0.69(0.17,2.72) | 0.73(0.23,2.42) | ‐0.03(‐0.27,0.10) | |
| HD TOCI IV + DMARD | 0.25(0.06,1.03) | 0.28(0.08,1.03) | ‐0.08(‐0.40,0.00) | |
| HD TOFA PO + MTX | HD TOCI IV + MTX | 1.54(0.46,5.11) | 1.48(0.49,4.51) | 0.02(‐0.06,0.17) |
| HD INF IV + MTX | 1.00(0.31,2.85) | 1.00(0.34,2.69) | 0.00(‐0.10,0.07) | |
| HD CERTO SC + MTX | 1.83(0.51,6.30) | 1.74(0.54,5.27) | 0.03(‐0.05,0.23) | |
| HD TOCI IV + DMARD | 0.67(0.21,2.15) | 0.68(0.23,2.06) | ‐0.01(‐0.14,0.03) | |
| HD INF IV + MTX | HD TOFA PO + MTX | 0.63(0.24,1.64) | 0.66(0.27,1.60) | ‐0.02(‐0.17,0.03) |
| HD CERTO SC + MTX | 1.15(0.37,3.77) | 1.13(0.41,3.25) | 0.01(‐0.10,0.17) | |
| HD TOCI IV + DMARD | 0.43(0.12,1.46) | 0.46(0.15,1.44) | ‐0.04(‐0.22,0.02) | |
| HD CERTO SC + MTX | HD INF IV + MTX | 1.85(0.72,5.14) | 1.75(0.74,4.24) | 0.03(‐0.02,0.22) |
| HD TOCI IV + DMARD | 0.67(0.21,2.04) | 0.69(0.24,1.98) | ‐0.01(‐0.12,0.03) | |
| HD TOCI IV + DMARD | HD CERTO SC + MTX | 0.37(0.10,1.33) | 0.40(0.13,1.31) | ‐0.05(‐0.29,0.01) |
| Random‐effects model | Residual deviance | 152 vs 153 data points | ||
| Deviance information criteria | 843.894 | |||
| Fixed‐effect model | Residual deviance | 161.1 vs 153 data points | ||
| Deviance information criteria | 845.774 | |||
| Note | ||||
| Total participants | 28,661 | |||
| Total studies | 61 | |||
| 2‐arm | 38 | |||
| 3‐arm | 16 | |||
| 4‐arm | 6 | |||
| 5‐arm | 1 | |||
Appendix 21. Serious adverse events: subgroup ‐ established RA (2 to 10 years)
| SAE established: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| MTX | PL | 1.96(0.39,5.90) | 1.90(0.39,5.24) | 0.02(‐0.02,0.12) |
| DMARD | 0.76(0.20,2.86) | 0.76(0.20,2.73) | ‐0.01(‐0.03,0.05) | |
| MTX + DMARD | 1.08(0.19,4.61) | 1.08(0.20,4.15) | 0.00(‐0.03,0.09) | |
| SD ETN SC | 2.30(0.66,6.73) | 2.22(0.67,5.90) | 0.04(‐0.01,0.14) | |
| SD ADA SC | 1.52(0.73,3.04) | 1.49(0.73,2.90) | 0.01(‐0.01,0.05) | |
| SD TOCI IV | 1.69(0.57,4.79) | 1.65(0.58,4.33) | 0.02(‐0.01,0.10) | |
| SD TOFA PO | 0.37(0.15,0.95) | 0.38(0.16,0.95) | ‐0.02(‐0.04,0.00) | |
| SD CERTO SC | 4.55(1.35,24.41) | 4.09(1.34,16.75) | 0.09(0.01,0.31) | |
| SD TOC SC + PL IV | 1.46(0.40,5.21) | 1.44(0.41,4.65) | 0.01(‐0.02,0.11) | |
| SD GOLI IV | 1.88(0.12,52.25) | 1.83(0.12,24.92) | 0.02(‐0.03,0.51) | |
| SD INF IV + MTX | 1.89(0.45,6.27) | 1.84(0.46,5.47) | 0.02(‐0.02,0.13) | |
| SD ETN SC + MTX | 1.85(0.37,6.22) | 1.81(0.38,5.44) | 0.02(‐0.02,0.13) | |
| SD ABA IV + MTX | 1.52(0.30,5.17) | 1.50(0.31,4.64) | 0.01(‐0.02,0.11) | |
| SD CERTO SC + MTX | 2.78(0.59,10.08) | 2.64(0.60,8.00) | 0.05(‐0.01,0.21) | |
| SD ADA SC + MTX | 2.30(0.36,7.68) | 2.22(0.37,6.52) | 0.03(‐0.02,0.16) | |
| SD ABA SC + MTX | 1.10(0.21,4.40) | 1.09(0.22,4.02) | 0.00(‐0.03,0.09) | |
| SD GOLI SC + MTX | 4.26(0.71,17.63) | 3.89(0.71,12.29) | 0.08(‐0.01,0.33) | |
| SD RITUX IV + MTX | 1.59(0.31,5.87) | 1.56(0.31,5.16) | 0.02(‐0.02,0.12) | |
| SD TOFA PO + MTX | 4.59(0.80,17.14) | 4.14(0.81,11.97) | 0.09(‐0.01,0.31) | |
| SD GOLI IV + MTX | 5.40(0.45,107.10) | 4.77(0.46,32.58) | 0.11(‐0.02,0.71) | |
| SD ETN SC + DMARD | 2.12(0.67,6.42) | 2.05(0.68,5.62) | 0.03(‐0.01,0.13) | |
| SD ADA SC + DMARD | 0.54(0.11,2.58) | 0.55(0.12,2.47) | ‐0.01(‐0.04,0.04) | |
| SD CERTO SC + DMARD | 0.52(0.09,3.17) | 0.53(0.09,2.99) | ‐0.01(‐0.04,0.05) | |
| LD ADA SC | 0.77(0.30,1.68) | 0.78(0.31,1.65) | ‐0.01(‐0.03,0.02) | |
| LD ETN SC | 1.51(0.33,6.09) | 1.48(0.34,5.28) | 0.01(‐0.02,0.13) | |
| LD GOLI IV | 9.67(0.64,176.00) | 7.62(0.65,38.84) | 0.20(‐0.01,0.77) | |
| LD RITUX IV + MTX | 1.03(0.19,3.98) | 1.03(0.20,3.67) | 0.00(‐0.03,0.08) | |
| LD ABA IV + MTX | 2.31(0.39,9.43) | 2.23(0.40,7.69) | 0.03(‐0.02,0.20) | |
| LD CERTO SC + MTX | 2.65(0.32,13.80) | 2.52(0.33,9.96) | 0.04(‐0.02,0.28) | |
| LD ETN SC + MTX | 0.94(0.18,4.22) | 0.94(0.19,3.86) | 0.00(‐0.03,0.09) | |
| LD GOLI IV + MTX | 5.28(0.35,98.46) | 4.68(0.36,33.02) | 0.11(‐0.02,0.67) | |
| HD TOCI IV | 1.62(0.39,6.09) | 1.59(0.40,5.38) | 0.02(‐0.02,0.13) | |
| HD TOFA PO | 0.49(0.20,1.18) | 0.50(0.21,1.17) | ‐0.01(‐0.03,0.00) | |
| HD ADA SC | 1.17(0.51,2.71) | 1.16(0.52,2.61) | 0.00(‐0.02,0.04) | |
| HD GOLI SC | 2.50(0.38,12.40) | 2.39(0.39,9.42) | 0.04(‐0.02,0.25) | |
| HD GOLI SC + MTX | 5.84(0.85,23.62) | 5.10(0.86,14.31) | 0.12(0.00,0.40) | |
| HD TOCI IV + MTX | 1.98(0.41,8.14) | 1.92(0.42,6.85) | 0.03(‐0.02,0.17) | |
| HD TOFA PO + MTX | 3.77(0.70,14.44) | 3.47(0.71,10.70) | 0.07(‐0.01,0.28) | |
| HD CERTO SC + MTX | 3.56(0.84,13.69) | 3.31(0.85,9.97) | 0.07(‐0.01,0.27) | |
| HD INF IV + MTX | 1.84(0.36,6.84) | 1.79(0.37,5.88) | 0.02(‐0.02,0.14) | |
| HD TOCI IV + DMARD | 1.16(0.27,5.05) | 1.15(0.27,4.52) | 0.00(‐0.03,0.10) | |
| DMARD | MTX | 0.41(0.16,0.98) | 0.42(0.17,0.98) | ‐0.03(‐0.10,0.00) |
| MTX + DMARD | 0.57(0.18,1.64) | 0.58(0.19,1.59) | ‐0.02(‐0.09,0.03) | |
| SD ETN SC | 1.23(0.58,2.42) | 1.21(0.60,2.32) | 0.01(‐0.04,0.06) | |
| SD ADA SC | 0.82(0.22,3.48) | 0.83(0.25,3.36) | ‐0.01(‐0.11,0.04) | |
| SD TOCI IV | 0.89(0.21,4.69) | 0.90(0.23,4.41) | ‐0.01(‐0.11,0.08) | |
| SD TOFA PO | 0.19(0.05,1.01) | 0.20(0.06,1.01) | ‐0.04(‐0.15,0.00) | |
| SD CERTO SC | 2.31(0.42,19.65) | 2.15(0.46,14.43) | 0.06(‐0.07,0.30) | |
| SD TOC SC + PL IV | 0.78(0.15,4.75) | 0.79(0.17,4.40) | ‐0.01(‐0.11,0.08) | |
| SD GOLI IV | 0.93(0.07,23.30) | 0.94(0.07,11.95) | 0.00(‐0.10,0.49) | |
| SD INF IV + MTX | 1.00(0.62,1.57) | 1.00(0.64,1.54) | 0.00(‐0.03,0.04) | |
| SD ETN SC + MTX | 0.95(0.47,1.96) | 0.95(0.49,1.87) | 0.00(‐0.05,0.05) | |
| SD ABA IV + MTX | 0.80(0.49,1.19) | 0.81(0.51,1.18) | ‐0.01(‐0.05,0.01) | |
| SD CERTO SC + MTX | 1.51(0.92,2.49) | 1.46(0.92,2.29) | 0.02(0.00,0.11) | |
| SD ADA SC + MTX | 1.11(0.49,2.42) | 1.11(0.51,2.25) | 0.00(‐0.04,0.08) | |
| SD ABA SC + MTX | 0.59(0.27,1.18) | 0.60(0.28,1.17) | ‐0.02(‐0.07,0.01) | |
| SD GOLI SC + MTX | 2.22(0.64,6.56) | 2.06(0.66,5.32) | 0.05(‐0.02,0.26) | |
| SD RITUX IV + MTX | 0.85(0.46,1.57) | 0.86(0.48,1.52) | ‐0.01(‐0.05,0.04) | |
| SD TOFA PO + MTX | 2.23(0.97,5.52) | 2.06(0.98,4.48) | 0.06(0.00,0.22) | |
| SD GOLI IV + MTX | 2.67(0.43,47.82) | 2.40(0.45,16.29) | 0.08(‐0.03,0.67) | |
| SD ETN SC + DMARD | 1.14(0.43,2.79) | 1.13(0.45,2.67) | 0.01(‐0.06,0.07) | |
| SD ADA SC + DMARD | 0.29(0.09,0.96) | 0.31(0.09,0.96) | ‐0.03(‐0.12,0.00) | |
| SD CERTO SC + DMARD | 0.28(0.06,1.45) | 0.29(0.06,1.43) | ‐0.03(‐0.12,0.01) | |
| LD ADA SC | 0.42(0.09,1.60) | 0.43(0.11,1.59) | ‐0.03(‐0.14,0.01) | |
| LD ETN SC | 0.80(0.30,1.90) | 0.81(0.31,1.81) | ‐0.01(‐0.07,0.05) | |
| LD GOLI IV | 4.77(0.85,81.13) | 3.72(0.86,19.33) | 0.17(‐0.01,0.73) | |
| LD RITUX IV + MTX | 0.56(0.29,1.06) | 0.57(0.30,1.06) | ‐0.02(‐0.07,0.00) | |
| LD ABA IV + MTX | 1.19(0.56,2.57) | 1.18(0.57,2.33) | 0.01(‐0.03,0.10) | |
| LD CERTO SC + MTX | 1.45(0.24,5.28) | 1.41(0.25,4.30) | 0.02(‐0.05,0.21) | |
| LD ETN SC + MTX | 0.50(0.17,1.32) | 0.52(0.18,1.29) | ‐0.02(‐0.09,0.02) | |
| LD GOLI IV + MTX | 2.68(0.49,45.71) | 2.42(0.51,16.27) | 0.08(‐0.03,0.62) | |
| HD TOCI IV | 0.87(0.41,1.83) | 0.88(0.43,1.75) | ‐0.01(‐0.06,0.05) | |
| HD TOFA PO | 0.26(0.07,1.26) | 0.27(0.07,1.25) | ‐0.04(‐0.14,0.00) | |
| HD ADA SC | 0.61(0.16,2.93) | 0.63(0.18,2.83) | ‐0.02(‐0.12,0.03) | |
| HD GOLI SC | 1.32(0.35,4.40) | 1.29(0.36,3.74) | 0.01(‐0.05,0.17) | |
| HD GOLI SC + MTX | 3.00(1.10,8.04) | 2.64(1.09,5.79) | 0.09(0.00,0.33) | |
| HD TOCI IV + MTX | 1.05(0.42,2.61) | 1.04(0.44,2.41) | 0.00(‐0.05,0.09) | |
| HD TOFA PO + MTX | 1.88(0.73,4.58) | 1.77(0.74,3.90) | 0.04(‐0.01,0.19) | |
| HD CERTO SC + MTX | 1.88(0.89,3.98) | 1.78(0.90,3.50) | 0.04(‐0.01,0.18) | |
| HD INF IV + MTX | 0.97(0.49,1.89) | 0.97(0.51,1.79) | 0.00(‐0.04,0.05) | |
| HD TOCI IV + DMARD | 0.62(0.21,1.71) | 0.64(0.23,1.64) | ‐0.02(‐0.09,0.03) | |
| MTX + DMARD | DMARD | 1.36(0.35,4.84) | 1.35(0.36,4.47) | 0.01(‐0.03,0.08) |
| SD ETN SC | 2.95(1.26,7.79) | 2.80(1.24,7.26) | 0.04(0.01,0.12) | |
| SD ADA SC | 1.98(0.52,7.97) | 1.93(0.54,7.59) | 0.02(‐0.03,0.06) | |
| SD TOCI IV | 2.15(0.48,10.49) | 2.09(0.50,9.63) | 0.02(‐0.03,0.10) | |
| SD TOFA PO | 0.47(0.11,2.81) | 0.48(0.12,2.76) | ‐0.01(‐0.07,0.01) | |
| SD CERTO SC | 6.23(0.92,44.44) | 5.53(0.92,32.46) | 0.10(0.00,0.31) | |
| SD TOC SC + PL IV | 1.94(0.36,10.55) | 1.89(0.37,9.48) | 0.02(‐0.04,0.11) | |
| SD GOLI IV | 2.27(0.18,57.03) | 2.17(0.18,27.77) | 0.03(‐0.04,0.51) | |
| SD INF IV + MTX | 2.45(0.90,6.95) | 2.35(0.91,6.35) | 0.03(0.00,0.12) | |
| SD ETN SC + MTX | 2.34(0.86,6.83) | 2.25(0.86,6.27) | 0.03(‐0.01,0.11) | |
| SD ABA IV + MTX | 1.90(0.71,5.44) | 1.86(0.72,5.06) | 0.02(‐0.01,0.09) | |
| SD CERTO SC + MTX | 3.70(1.33,10.74) | 3.46(1.31,9.24) | 0.05(0.01,0.19) | |
| SD ADA SC + MTX | 2.77(0.81,8.47) | 2.64(0.82,7.66) | 0.04(‐0.01,0.15) | |
| SD ABA SC + MTX | 1.41(0.44,4.63) | 1.40(0.45,4.36) | 0.01(‐0.03,0.08) | |
| SD GOLI SC + MTX | 5.36(1.32,21.74) | 4.75(1.31,16.88) | 0.09(0.01,0.32) | |
| SD RITUX IV + MTX | 2.07(0.65,6.43) | 2.01(0.66,5.91) | 0.02(‐0.01,0.11) | |
| SD TOFA PO + MTX | 5.58(1.73,18.92) | 4.94(1.67,14.94) | 0.09(0.01,0.29) | |
| SD GOLI IV + MTX | 6.73(0.82,121.50) | 5.74(0.82,37.64) | 0.11(0.00,0.71) | |
| SD ETN SC + DMARD | 2.72(1.02,7.85) | 2.61(1.02,7.26) | 0.03(0.00,0.11) | |
| SD ADA SC + DMARD | 0.74(0.31,1.65) | 0.74(0.31,1.62) | 0.00(‐0.03,0.02) | |
| SD CERTO SC + DMARD | 0.70(0.18,2.38) | 0.71(0.18,2.29) | ‐0.01(‐0.04,0.04) | |
| LD ADA SC | 1.03(0.21,4.28) | 1.03(0.22,4.17) | 0.00(‐0.06,0.03) | |
| LD ETN SC | 1.88(0.61,6.75) | 1.84(0.62,6.19) | 0.02(‐0.02,0.11) | |
| LD GOLI IV | 11.82(1.38,182.20) | 8.82(1.37,46.95) | 0.20(0.01,0.77) | |
| LD RITUX IV + MTX | 1.38(0.43,4.39) | 1.37(0.44,4.15) | 0.01(‐0.03,0.07) | |
| LD ABA IV + MTX | 2.92(0.88,10.07) | 2.78(0.88,8.61) | 0.04(0.00,0.18) | |
| LD CERTO SC + MTX | 3.43(0.45,16.59) | 3.22(0.46,13.21) | 0.05(‐0.02,0.27) | |
| LD ETN SC + MTX | 1.20(0.33,4.69) | 1.19(0.34,4.41) | 0.00(‐0.04,0.08) | |
| LD GOLI IV + MTX | 6.52(0.76,107.20) | 5.63(0.77,38.47) | 0.11(0.00,0.67) | |
| HD TOCI IV | 2.12(1.07,4.54) | 2.06(1.06,4.29) | 0.02(0.00,0.10) | |
| HD TOFA PO | 0.63(0.14,3.48) | 0.64(0.16,3.42) | ‐0.01(‐0.06,0.02) | |
| HD ADA SC | 1.56(0.34,6.43) | 1.54(0.35,6.19) | 0.01(‐0.05,0.05) | |
| HD GOLI SC | 3.21(0.60,16.83) | 3.02(0.61,13.75) | 0.04(‐0.01,0.24) | |
| HD GOLI SC + MTX | 7.20(1.84,31.16) | 6.09(1.78,22.25) | 0.12(0.01,0.39) | |
| HD TOCI IV + MTX | 2.52(0.93,7.29) | 2.43(0.93,6.54) | 0.03(0.00,0.15) | |
| HD TOFA PO + MTX | 4.63(1.38,16.09) | 4.20(1.36,12.91) | 0.07(0.01,0.26) | |
| HD CERTO SC + MTX | 4.71(1.42,14.36) | 4.29(1.39,11.75) | 0.07(0.01,0.26) | |
| HD INF IV + MTX | 2.36(0.75,7.70) | 2.27(0.76,7.03) | 0.03(‐0.01,0.13) | |
| HD TOCI IV + DMARD | 1.51(0.90,2.62) | 1.49(0.90,2.52) | 0.01(0.00,0.06) | |
| SD ETN SC | MTX + DMARD | 2.14(0.69,7.09) | 2.05(0.71,6.66) | 0.03(‐0.02,0.10) |
| SD ADA SC | 1.45(0.30,7.18) | 1.43(0.32,6.81) | 0.01(‐0.08,0.06) | |
| SD TOCI IV | 1.60(0.28,9.19) | 1.57(0.30,8.53) | 0.02(‐0.07,0.10) | |
| SD TOFA PO | 0.35(0.07,2.21) | 0.36(0.07,2.18) | ‐0.02(‐0.11,0.01) | |
| SD CERTO SC | 4.18(0.54,46.06) | 3.77(0.57,33.19) | 0.09(‐0.05,0.31) | |
| SD TOC SC + PL IV | 1.42(0.22,9.70) | 1.40(0.24,8.97) | 0.01(‐0.08,0.10) | |
| SD GOLI IV | 1.69(0.10,61.18) | 1.65(0.11,31.36) | 0.02(‐0.08,0.51) | |
| SD INF IV + MTX | 1.78(0.57,5.86) | 1.72(0.59,5.43) | 0.02(‐0.03,0.10) | |
| SD ETN SC + MTX | 1.71(0.64,4.59) | 1.66(0.67,4.35) | 0.02(‐0.03,0.08) | |
| SD ABA IV + MTX | 1.41(0.43,4.65) | 1.39(0.45,4.41) | 0.01(‐0.05,0.07) | |
| SD CERTO SC + MTX | 2.69(0.83,9.40) | 2.52(0.84,8.55) | 0.04(‐0.01,0.17) | |
| SD ADA SC + MTX | 2.00(0.52,8.04) | 1.92(0.54,7.30) | 0.03(‐0.03,0.13) | |
| SD ABA SC + MTX | 1.07(0.28,3.91) | 1.07(0.30,3.72) | 0.00(‐0.07,0.06) | |
| SD GOLI SC + MTX | 3.87(0.80,22.09) | 3.46(0.81,17.69) | 0.07(‐0.01,0.31) | |
| SD RITUX IV + MTX | 1.50(0.44,5.59) | 1.47(0.46,5.23) | 0.01(‐0.05,0.10) | |
| SD TOFA PO + MTX | 4.05(1.05,17.25) | 3.66(1.04,14.00) | 0.08(0.00,0.28) | |
| SD GOLI IV + MTX | 4.85(0.64,118.10) | 4.14(0.66,42.92) | 0.10(‐0.01,0.71) | |
| SD ETN SC + DMARD | 2.00(0.54,7.48) | 1.93(0.57,7.01) | 0.02(‐0.04,0.10) | |
| SD ADA SC + DMARD | 0.52(0.12,2.69) | 0.53(0.12,2.63) | ‐0.01(‐0.09,0.03) | |
| SD CERTO SC + DMARD | 0.50(0.09,3.53) | 0.51(0.09,3.37) | ‐0.01(‐0.10,0.04) | |
| LD ADA SC | 0.75(0.13,3.80) | 0.75(0.14,3.72) | ‐0.01(‐0.10,0.03) | |
| LD ETN SC | 1.42(0.36,5.64) | 1.39(0.38,5.33) | 0.01(‐0.05,0.09) | |
| LD GOLI IV | 8.77(1.13,208.10) | 6.47(1.13,53.45) | 0.19(0.00,0.76) | |
| LD RITUX IV + MTX | 0.99(0.29,3.92) | 0.99(0.31,3.74) | 0.00(‐0.07,0.06) | |
| LD ABA IV + MTX | 2.12(0.56,8.51) | 2.02(0.58,7.49) | 0.03(‐0.03,0.16) | |
| LD CERTO SC + MTX | 2.65(0.32,14.88) | 2.49(0.33,12.20) | 0.04(‐0.04,0.25) | |
| LD ETN SC + MTX | 0.89(0.22,3.61) | 0.89(0.23,3.47) | 0.00(‐0.08,0.06) | |
| LD GOLI IV + MTX | 4.84(0.71,118.60) | 4.13(0.72,42.49) | 0.10(‐0.01,0.65) | |
| HD TOCI IV | 1.58(0.46,5.65) | 1.55(0.48,5.24) | 0.01(‐0.04,0.10) | |
| HD TOFA PO | 0.48(0.09,2.82) | 0.49(0.09,2.77) | ‐0.02(‐0.11,0.02) | |
| HD ADA SC | 1.11(0.22,6.26) | 1.11(0.24,6.00) | 0.00(‐0.09,0.05) | |
| HD GOLI SC | 2.28(0.40,14.03) | 2.17(0.42,11.53) | 0.03(‐0.04,0.22) | |
| HD GOLI SC + MTX | 5.21(1.22,28.19) | 4.44(1.20,20.46) | 0.11(0.01,0.38) | |
| HD TOCI IV + MTX | 1.84(0.45,7.48) | 1.78(0.47,6.76) | 0.02(‐0.05,0.14) | |
| HD TOFA PO + MTX | 3.36(0.85,14.74) | 3.08(0.86,12.33) | 0.06(‐0.01,0.25) | |
| HD CERTO SC + MTX | 3.33(0.94,13.50) | 3.05(0.95,11.55) | 0.06(0.00,0.23) | |
| HD INF IV + MTX | 1.72(0.50,6.42) | 1.67(0.53,5.91) | 0.02(‐0.04,0.11) | |
| HD TOCI IV + DMARD | 1.11(0.29,4.52) | 1.10(0.31,4.32) | 0.00(‐0.07,0.07) | |
| SD ADA SC | SD ETN SC | 0.68(0.21,2.00) | 0.69(0.24,1.94) | ‐0.02(‐0.12,0.03) |
| SD TOCI IV | 0.72(0.19,2.97) | 0.73(0.21,2.78) | ‐0.02(‐0.12,0.07) | |
| SD TOFA PO | 0.16(0.04,0.74) | 0.17(0.05,0.75) | ‐0.05(‐0.16,‐0.01) | |
| SD CERTO SC | 2.02(0.37,13.99) | 1.88(0.40,10.33) | 0.06(‐0.09,0.29) | |
| SD TOC SC + PL IV | 0.64(0.14,3.14) | 0.66(0.15,2.91) | ‐0.02(‐0.13,0.08) | |
| SD GOLI IV | 0.79(0.05,19.56) | 0.81(0.06,9.33) | ‐0.01(‐0.12,0.48) | |
| SD INF IV + MTX | 0.82(0.36,1.94) | 0.83(0.37,1.84) | ‐0.01(‐0.07,0.06) | |
| SD ETN SC + MTX | 0.78(0.38,1.69) | 0.79(0.40,1.61) | ‐0.01(‐0.06,0.04) | |
| SD ABA IV + MTX | 0.65(0.28,1.59) | 0.67(0.30,1.52) | ‐0.02(‐0.08,0.03) | |
| SD CERTO SC + MTX | 1.24(0.53,3.02) | 1.22(0.55,2.69) | 0.01(‐0.04,0.12) | |
| SD ADA SC + MTX | 0.92(0.32,2.57) | 0.93(0.33,2.38) | 0.00(‐0.06,0.08) | |
| SD ABA SC + MTX | 0.48(0.17,1.37) | 0.50(0.19,1.34) | ‐0.03(‐0.10,0.02) | |
| SD GOLI SC + MTX | 1.80(0.45,6.53) | 1.70(0.47,4.91) | 0.04(‐0.04,0.26) | |
| SD RITUX IV + MTX | 0.69(0.28,1.85) | 0.71(0.29,1.76) | ‐0.02(‐0.08,0.05) | |
| SD TOFA PO + MTX | 1.88(0.64,5.53) | 1.75(0.66,4.39) | 0.05(‐0.02,0.23) | |
| SD GOLI IV + MTX | 2.24(0.31,43.59) | 2.03(0.33,13.85) | 0.07(‐0.05,0.66) | |
| SD ETN SC + DMARD | 0.92(0.45,1.90) | 0.93(0.47,1.82) | 0.00(‐0.06,0.05) | |
| SD ADA SC + DMARD | 0.24(0.07,0.79) | 0.26(0.08,0.81) | ‐0.05(‐0.13,‐0.01) | |
| SD CERTO SC + DMARD | 0.23(0.05,1.09) | 0.25(0.05,1.09) | ‐0.04(‐0.14,0.00) | |
| LD ADA SC | 0.35(0.09,1.16) | 0.36(0.10,1.15) | ‐0.04(‐0.15,0.00) | |
| LD ETN SC | 0.65(0.25,1.65) | 0.67(0.27,1.58) | ‐0.02(‐0.08,0.04) | |
| LD GOLI IV | 3.94(0.51,64.81) | 3.19(0.52,15.77) | 0.15(‐0.03,0.73) | |
| LD RITUX IV + MTX | 0.46(0.18,1.25) | 0.48(0.19,1.22) | ‐0.03(‐0.10,0.01) | |
| LD ABA IV + MTX | 1.00(0.34,2.96) | 1.00(0.36,2.64) | 0.00(‐0.06,0.11) | |
| LD CERTO SC + MTX | 1.22(0.17,4.95) | 1.20(0.18,3.97) | 0.01(‐0.08,0.21) | |
| LD ETN SC + MTX | 0.41(0.13,1.36) | 0.43(0.14,1.33) | ‐0.03(‐0.11,0.02) | |
| LD GOLI IV + MTX | 2.20(0.28,34.53) | 2.02(0.29,13.51) | 0.06(‐0.05,0.62) | |
| HD TOCI IV | 0.72(0.29,1.74) | 0.73(0.31,1.66) | ‐0.01(‐0.07,0.04) | |
| HD TOFA PO | 0.21(0.06,0.92) | 0.22(0.07,0.93) | ‐0.05(‐0.15,0.00) | |
| HD ADA SC | 0.51(0.14,1.82) | 0.53(0.16,1.78) | ‐0.03(‐0.14,0.02) | |
| HD GOLI SC | 1.09(0.23,4.28) | 1.08(0.25,3.57) | 0.00(‐0.08,0.17) | |
| HD GOLI SC + MTX | 2.40(0.73,8.31) | 2.17(0.75,5.84) | 0.07(‐0.02,0.33) | |
| HD TOCI IV + MTX | 0.86(0.28,2.55) | 0.87(0.30,2.34) | ‐0.01(‐0.08,0.08) | |
| HD TOFA PO + MTX | 1.56(0.47,4.79) | 1.50(0.49,3.89) | 0.03(‐0.04,0.20) | |
| HD CERTO SC + MTX | 1.53(0.59,4.30) | 1.47(0.61,3.63) | 0.03(‐0.03,0.19) | |
| HD INF IV + MTX | 0.79(0.30,2.16) | 0.81(0.32,2.02) | ‐0.01(‐0.07,0.07) | |
| HD TOCI IV + DMARD | 0.52(0.18,1.43) | 0.53(0.19,1.39) | ‐0.03(‐0.10,0.02) | |
| SD TOCI IV | SD ADA SC | 1.09(0.50,2.49) | 1.08(0.52,2.33) | 0.00(‐0.02,0.07) |
| SD TOFA PO | 0.24(0.08,0.76) | 0.25(0.09,0.77) | ‐0.03(‐0.08,‐0.01) | |
| SD CERTO SC | 3.06(0.75,17.88) | 2.79(0.76,12.62) | 0.08(‐0.02,0.30) | |
| SD TOC SC + PL IV | 0.97(0.34,2.76) | 0.97(0.35,2.54) | 0.00(‐0.04,0.08) | |
| SD GOLI IV | 1.27(0.07,27.30) | 1.25(0.08,12.99) | 0.01(‐0.06,0.50) | |
| SD INF IV + MTX | 1.20(0.33,4.77) | 1.19(0.34,4.25) | 0.01(‐0.04,0.12) | |
| SD ETN SC + MTX | 1.14(0.29,4.42) | 1.14(0.30,3.95) | 0.01(‐0.04,0.11) | |
| SD ABA IV + MTX | 0.96(0.23,3.86) | 0.96(0.24,3.51) | 0.00(‐0.05,0.09) | |
| SD CERTO SC + MTX | 1.80(0.45,7.39) | 1.74(0.46,6.04) | 0.03(‐0.03,0.19) | |
| SD ADA SC + MTX | 1.42(0.26,5.81) | 1.39(0.27,4.99) | 0.02(‐0.04,0.14) | |
| SD ABA SC + MTX | 0.70(0.16,3.29) | 0.71(0.17,3.03) | ‐0.01(‐0.06,0.07) | |
| SD GOLI SC + MTX | 2.82(0.51,12.81) | 2.59(0.52,8.93) | 0.07(‐0.03,0.32) | |
| SD RITUX IV + MTX | 1.04(0.23,4.37) | 1.04(0.24,3.93) | 0.00(‐0.05,0.11) | |
| SD TOFA PO + MTX | 2.96(0.57,11.61) | 2.71(0.59,8.51) | 0.07(‐0.02,0.29) | |
| SD GOLI IV + MTX | 3.68(0.31,60.18) | 3.28(0.32,18.17) | 0.10(‐0.04,0.69) | |
| SD ETN SC + DMARD | 1.37(0.52,3.89) | 1.35(0.54,3.51) | 0.01(‐0.03,0.10) | |
| SD ADA SC + DMARD | 0.37(0.08,1.81) | 0.38(0.08,1.76) | ‐0.03(‐0.07,0.03) | |
| SD CERTO SC + DMARD | 0.36(0.06,2.04) | 0.37(0.06,1.95) | ‐0.03(‐0.07,0.04) | |
| LD ADA SC | 0.50(0.22,1.07) | 0.51(0.23,1.06) | ‐0.02(‐0.06,0.00) | |
| LD ETN SC | 0.97(0.22,4.50) | 0.97(0.23,4.00) | 0.00(‐0.05,0.11) | |
| LD GOLI IV | 6.59(0.46,83.79) | 5.19(0.47,21.73) | 0.18(‐0.02,0.75) | |
| LD RITUX IV + MTX | 0.68(0.15,3.18) | 0.69(0.15,2.96) | ‐0.01(‐0.06,0.07) | |
| LD ABA IV + MTX | 1.47(0.27,6.54) | 1.44(0.28,5.50) | 0.02(‐0.04,0.18) | |
| LD CERTO SC + MTX | 1.74(0.20,10.56) | 1.68(0.21,7.95) | 0.03(‐0.05,0.26) | |
| LD ETN SC + MTX | 0.60(0.12,2.94) | 0.61(0.13,2.72) | ‐0.02(‐0.06,0.07) | |
| LD GOLI IV + MTX | 3.63(0.24,51.00) | 3.22(0.25,18.00) | 0.09(‐0.04,0.65) | |
| HD TOCI IV | 1.07(0.28,4.37) | 1.07(0.29,3.89) | 0.00(‐0.04,0.11) | |
| HD TOFA PO | 0.32(0.11,0.99) | 0.33(0.12,0.99) | ‐0.03(‐0.07,0.00) | |
| HD ADA SC | 0.78(0.37,1.59) | 0.79(0.38,1.57) | ‐0.01(‐0.04,0.02) | |
| HD GOLI SC | 1.64(0.26,8.47) | 1.59(0.27,6.60) | 0.02(‐0.04,0.23) | |
| HD GOLI SC + MTX | 3.70(0.65,16.83) | 3.30(0.66,10.82) | 0.10(‐0.02,0.38) | |
| HD TOCI IV + MTX | 1.28(0.27,6.06) | 1.26(0.28,5.17) | 0.01(‐0.04,0.15) | |
| HD TOFA PO + MTX | 2.42(0.47,10.13) | 2.26(0.48,7.76) | 0.06(‐0.03,0.26) | |
| HD CERTO SC + MTX | 2.28(0.57,10.24) | 2.14(0.58,7.74) | 0.05(‐0.02,0.26) | |
| HD INF IV + MTX | 1.20(0.25,5.10) | 1.18(0.26,4.46) | 0.01(‐0.04,0.13) | |
| HD TOCI IV + DMARD | 0.78(0.17,3.23) | 0.79(0.18,2.99) | ‐0.01(‐0.05,0.08) | |
| SD TOFA PO | SD TOCI IV | 0.22(0.05,0.91) | 0.23(0.06,0.91) | ‐0.04(‐0.12,0.00) |
| SD CERTO SC | 2.75(0.54,20.04) | 2.52(0.57,14.46) | 0.07(‐0.05,0.30) | |
| SD TOC SC + PL IV | 0.88(0.43,1.74) | 0.88(0.45,1.67) | 0.00(‐0.04,0.04) | |
| SD GOLI IV | 1.16(0.06,27.62) | 1.15(0.07,13.48) | 0.01(‐0.09,0.49) | |
| SD INF IV + MTX | 1.12(0.24,5.05) | 1.11(0.25,4.53) | 0.00(‐0.08,0.12) | |
| SD ETN SC + MTX | 1.06(0.22,4.62) | 1.06(0.23,4.14) | 0.00(‐0.08,0.11) | |
| SD ABA IV + MTX | 0.89(0.17,4.18) | 0.90(0.18,3.81) | 0.00(‐0.09,0.09) | |
| SD CERTO SC + MTX | 1.67(0.34,7.87) | 1.61(0.36,6.57) | 0.03(‐0.06,0.19) | |
| SD ADA SC + MTX | 1.28(0.20,6.39) | 1.26(0.21,5.59) | 0.01(‐0.07,0.14) | |
| SD ABA SC + MTX | 0.65(0.12,3.39) | 0.66(0.13,3.14) | ‐0.01(‐0.10,0.08) | |
| SD GOLI SC + MTX | 2.56(0.40,13.46) | 2.35(0.42,9.78) | 0.06(‐0.05,0.31) | |
| SD RITUX IV + MTX | 0.97(0.18,4.75) | 0.97(0.19,4.30) | 0.00(‐0.08,0.11) | |
| SD TOFA PO + MTX | 2.64(0.42,12.84) | 2.41(0.44,9.51) | 0.07(‐0.05,0.28) | |
| SD GOLI IV + MTX | 3.41(0.22,61.85) | 3.02(0.24,19.34) | 0.09(‐0.06,0.69) | |
| SD ETN SC + DMARD | 1.27(0.34,4.44) | 1.26(0.36,4.01) | 0.01(‐0.06,0.10) | |
| SD ADA SC + DMARD | 0.34(0.06,1.91) | 0.35(0.06,1.86) | ‐0.03(‐0.11,0.03) | |
| SD CERTO SC + DMARD | 0.32(0.04,2.17) | 0.33(0.05,2.07) | ‐0.03(‐0.11,0.03) | |
| LD ADA SC | 0.46(0.15,1.35) | 0.48(0.16,1.34) | ‐0.02(‐0.10,0.01) | |
| LD ETN SC | 0.89(0.16,4.48) | 0.90(0.18,4.08) | 0.00(‐0.09,0.10) | |
| LD GOLI IV | 5.99(0.36,88.57) | 4.66(0.38,23.50) | 0.18(‐0.04,0.74) | |
| LD RITUX IV + MTX | 0.63(0.11,3.31) | 0.65(0.12,3.11) | ‐0.01(‐0.10,0.07) | |
| LD ABA IV + MTX | 1.35(0.20,7.19) | 1.33(0.21,6.07) | 0.01(‐0.07,0.18) | |
| LD CERTO SC + MTX | 1.61(0.15,10.72) | 1.55(0.16,8.10) | 0.03(‐0.07,0.25) | |
| LD ETN SC + MTX | 0.55(0.09,3.13) | 0.57(0.10,2.94) | ‐0.02(‐0.10,0.07) | |
| LD GOLI IV + MTX | 3.24(0.19,51.29) | 2.87(0.20,18.93) | 0.09(‐0.06,0.64) | |
| HD TOCI IV | 1.00(0.21,4.73) | 1.00(0.22,4.29) | 0.00(‐0.08,0.11) | |
| HD TOFA PO | 0.29(0.08,1.15) | 0.30(0.08,1.15) | ‐0.03(‐0.12,0.00) | |
| HD ADA SC | 0.71(0.24,2.05) | 0.72(0.26,2.00) | ‐0.01(‐0.09,0.03) | |
| HD GOLI SC | 1.49(0.20,8.95) | 1.46(0.21,7.38) | 0.02(‐0.08,0.22) | |
| HD GOLI SC + MTX | 3.39(0.47,18.48) | 3.00(0.50,12.23) | 0.09(‐0.04,0.37) | |
| HD TOCI IV + MTX | 1.18(0.22,6.35) | 1.17(0.23,5.49) | 0.01(‐0.08,0.15) | |
| HD TOFA PO + MTX | 2.17(0.35,10.99) | 2.03(0.37,8.57) | 0.05(‐0.06,0.25) | |
| HD CERTO SC + MTX | 2.09(0.45,10.78) | 1.97(0.47,8.32) | 0.05(‐0.05,0.25) | |
| HD INF IV + MTX | 1.10(0.18,5.34) | 1.09(0.20,4.74) | 0.00(‐0.08,0.13) | |
| HD TOCI IV + DMARD | 0.72(0.13,3.49) | 0.73(0.14,3.22) | ‐0.01(‐0.09,0.07) | |
| SD CERTO SC | SD TOFA PO | 12.44(2.55,73.20) | 10.94(2.45,52.33) | 0.11(0.03,0.32) |
| SD TOC SC + PL IV | 3.99(0.81,18.05) | 3.85(0.81,16.08) | 0.03(0.00,0.13) | |
| SD GOLI IV | 5.00(0.25,137.40) | 4.75(0.25,67.34) | 0.04(‐0.01,0.53) | |
| SD INF IV + MTX | 5.05(0.92,20.77) | 4.83(0.92,18.27) | 0.04(0.00,0.15) | |
| SD ETN SC + MTX | 4.93(0.93,20.71) | 4.71(0.94,18.23) | 0.04(0.00,0.15) | |
| SD ABA IV + MTX | 4.04(0.73,16.71) | 3.90(0.74,15.08) | 0.03(0.00,0.13) | |
| SD CERTO SC + MTX | 7.49(1.44,33.76) | 6.94(1.43,27.00) | 0.07(0.01,0.23) | |
| SD ADA SC + MTX | 5.98(0.93,25.95) | 5.63(0.93,21.85) | 0.05(0.00,0.18) | |
| SD ABA SC + MTX | 2.96(0.49,15.03) | 2.89(0.50,13.55) | 0.02(‐0.01,0.11) | |
| SD GOLI SC + MTX | 11.33(1.54,60.51) | 10.03(1.53,42.27) | 0.10(0.01,0.35) | |
| SD RITUX IV + MTX | 4.23(0.77,19.73) | 4.07(0.77,17.37) | 0.03(0.00,0.14) | |
| SD TOFA PO + MTX | 12.35(1.88,52.11) | 10.85(1.85,37.92) | 0.11(0.01,0.33) | |
| SD GOLI IV + MTX | 14.11(1.10,325.50) | 12.12(1.09,104.00) | 0.13(0.00,0.73) | |
| SD ETN SC + DMARD | 5.66(1.30,21.61) | 5.35(1.30,18.91) | 0.05(0.01,0.15) | |
| SD ADA SC + DMARD | 1.51(0.24,7.91) | 1.50(0.24,7.46) | 0.01(‐0.02,0.06) | |
| SD CERTO SC + DMARD | 1.44(0.18,9.45) | 1.44(0.19,8.88) | 0.00(‐0.02,0.07) | |
| LD ADA SC | 2.05(0.59,6.36) | 2.03(0.60,6.19) | 0.01(‐0.01,0.04) | |
| LD ETN SC | 4.04(0.69,18.56) | 3.90(0.70,16.21) | 0.03(‐0.01,0.14) | |
| LD GOLI IV | 24.13(1.44,460.60) | 18.77(1.43,115.20) | 0.21(0.01,0.78) | |
| LD RITUX IV + MTX | 2.78(0.50,13.35) | 2.73(0.50,12.22) | 0.02(‐0.01,0.10) | |
| LD ABA IV + MTX | 6.20(0.89,30.14) | 5.85(0.89,24.31) | 0.05(0.00,0.22) | |
| LD CERTO SC + MTX | 7.22(0.69,46.10) | 6.70(0.69,33.71) | 0.06(0.00,0.30) | |
| LD ETN SC + MTX | 2.49(0.39,14.93) | 2.45(0.40,13.39) | 0.02(‐0.01,0.11) | |
| LD GOLI IV + MTX | 13.82(0.71,270.00) | 11.89(0.72,95.32) | 0.13(0.00,0.69) | |
| HD TOCI IV | 4.39(0.80,20.33) | 4.22(0.81,17.98) | 0.04(0.00,0.15) | |
| HD TOFA PO | 1.31(0.54,3.37) | 1.31(0.54,3.31) | 0.00(‐0.01,0.02) | |
| HD ADA SC | 3.22(0.94,9.73) | 3.14(0.94,9.28) | 0.02(0.00,0.06) | |
| HD GOLI SC | 6.55(0.89,38.98) | 6.14(0.89,30.39) | 0.06(0.00,0.27) | |
| HD GOLI SC + MTX | 15.78(2.00,79.86) | 13.36(1.96,50.15) | 0.13(0.01,0.42) | |
| HD TOCI IV + MTX | 5.32(0.84,26.88) | 5.05(0.84,22.38) | 0.04(0.00,0.19) | |
| HD TOFA PO + MTX | 10.06(1.46,44.56) | 9.05(1.45,33.23) | 0.09(0.01,0.30) | |
| HD CERTO SC + MTX | 9.49(1.66,44.50) | 8.60(1.64,33.59) | 0.09(0.01,0.30) | |
| HD INF IV + MTX | 4.87(0.82,21.86) | 4.66(0.82,18.99) | 0.04(0.00,0.17) | |
| HD TOCI IV + DMARD | 3.25(0.54,16.14) | 3.16(0.54,14.37) | 0.02(‐0.01,0.12) | |
| SD TOC SC + PL IV | SD CERTO SC | 0.32(0.04,1.88) | 0.35(0.05,1.77) | ‐0.08(‐0.30,0.05) |
| SD GOLI IV | 0.39(0.02,7.16) | 0.43(0.02,4.77) | ‐0.06(‐0.28,0.34) | |
| SD INF IV + MTX | 0.43(0.05,2.44) | 0.46(0.07,2.23) | ‐0.06(‐0.30,0.08) | |
| SD ETN SC + MTX | 0.41(0.05,2.40) | 0.44(0.06,2.19) | ‐0.07(‐0.30,0.08) | |
| SD ABA IV + MTX | 0.34(0.04,1.98) | 0.37(0.05,1.87) | ‐0.07(‐0.30,0.05) | |
| SD CERTO SC + MTX | 0.65(0.07,4.07) | 0.68(0.10,3.40) | ‐0.04(‐0.28,0.16) | |
| SD ADA SC + MTX | 0.45(0.05,3.02) | 0.49(0.07,2.67) | ‐0.06(‐0.29,0.11) | |
| SD ABA SC + MTX | 0.25(0.03,1.71) | 0.27(0.04,1.64) | ‐0.08(‐0.31,0.04) | |
| SD GOLI SC + MTX | 0.88(0.08,6.96) | 0.89(0.11,5.01) | ‐0.01(‐0.25,0.27) | |
| SD RITUX IV + MTX | 0.36(0.04,2.25) | 0.40(0.05,2.09) | ‐0.07(‐0.30,0.07) | |
| SD TOFA PO + MTX | 0.97(0.10,6.22) | 0.97(0.13,4.70) | 0.00(‐0.26,0.24) | |
| SD GOLI IV + MTX | 1.22(0.07,21.66) | 1.19(0.08,8.54) | 0.02(‐0.24,0.58) | |
| SD ETN SC + DMARD | 0.46(0.07,2.53) | 0.49(0.09,2.30) | ‐0.06(‐0.29,0.08) | |
| SD ADA SC + DMARD | 0.11(0.01,0.92) | 0.13(0.02,0.93) | ‐0.10(‐0.32,‐0.01) | |
| SD CERTO SC + DMARD | 0.11(0.01,0.96) | 0.13(0.01,0.96) | ‐0.10(‐0.31,0.00) | |
| LD ADA SC | 0.16(0.03,0.75) | 0.18(0.04,0.76) | ‐0.10(‐0.32,‐0.01) | |
| LD ETN SC | 0.33(0.04,2.29) | 0.36(0.05,2.10) | ‐0.07(‐0.30,0.07) | |
| LD GOLI IV | 2.16(0.09,35.08) | 1.87(0.11,10.26) | 0.10(‐0.22,0.66) | |
| LD RITUX IV + MTX | 0.24(0.03,1.49) | 0.27(0.03,1.44) | ‐0.09(‐0.31,0.03) | |
| LD ABA IV + MTX | 0.51(0.05,3.43) | 0.54(0.07,2.96) | ‐0.05(‐0.29,0.13) | |
| LD CERTO SC + MTX | 0.58(0.04,5.23) | 0.61(0.05,4.03) | ‐0.04(‐0.29,0.21) | |
| LD ETN SC + MTX | 0.21(0.02,1.44) | 0.24(0.03,1.39) | ‐0.09(‐0.31,0.03) | |
| LD GOLI IV + MTX | 1.20(0.05,21.01) | 1.17(0.06,8.42) | 0.02(‐0.25,0.57) | |
| HD TOCI IV | 0.36(0.05,2.32) | 0.39(0.06,2.13) | ‐0.07(‐0.30,0.07) | |
| HD TOFA PO | 0.11(0.02,0.50) | 0.12(0.03,0.51) | ‐0.11(‐0.32,‐0.02) | |
| HD ADA SC | 0.25(0.04,1.10) | 0.28(0.06,1.09) | ‐0.09(‐0.30,0.00) | |
| HD GOLI SC | 0.51(0.05,4.48) | 0.55(0.06,3.58) | ‐0.05(‐0.29,0.18) | |
| HD GOLI SC + MTX | 1.26(0.12,9.71) | 1.22(0.16,6.04) | 0.02(‐0.24,0.35) | |
| HD TOCI IV + MTX | 0.42(0.05,3.00) | 0.46(0.07,2.63) | ‐0.06(‐0.29,0.11) | |
| HD TOFA PO + MTX | 0.79(0.08,5.26) | 0.81(0.10,4.15) | ‐0.02(‐0.27,0.21) | |
| HD CERTO SC + MTX | 0.78(0.09,5.39) | 0.81(0.12,4.17) | ‐0.02(‐0.28,0.22) | |
| HD INF IV + MTX | 0.41(0.05,2.60) | 0.45(0.06,2.36) | ‐0.06(‐0.30,0.09) | |
| HD TOCI IV + DMARD | 0.25(0.03,1.71) | 0.27(0.04,1.63) | ‐0.08(‐0.31,0.04) | |
| SD GOLI IV | SD TOC SC + PL IV | 1.31(0.06,35.13) | 1.29(0.07,17.60) | 0.01(‐0.09,0.50) |
| SD INF IV + MTX | 1.28(0.23,6.92) | 1.26(0.25,6.17) | 0.01(‐0.09,0.12) | |
| SD ETN SC + MTX | 1.20(0.20,6.39) | 1.19(0.22,5.75) | 0.01(‐0.08,0.11) | |
| SD ABA IV + MTX | 1.02(0.16,5.64) | 1.02(0.17,5.09) | 0.00(‐0.09,0.10) | |
| SD CERTO SC + MTX | 1.93(0.33,10.52) | 1.85(0.35,8.85) | 0.03(‐0.07,0.20) | |
| SD ADA SC + MTX | 1.45(0.20,8.80) | 1.42(0.21,7.63) | 0.02(‐0.08,0.15) | |
| SD ABA SC + MTX | 0.75(0.11,4.55) | 0.76(0.12,4.20) | ‐0.01(‐0.11,0.08) | |
| SD GOLI SC + MTX | 2.87(0.40,18.47) | 2.63(0.42,13.74) | 0.07(‐0.05,0.32) | |
| SD RITUX IV + MTX | 1.10(0.16,6.25) | 1.10(0.18,5.60) | 0.00(‐0.09,0.11) | |
| SD TOFA PO + MTX | 3.00(0.41,17.48) | 2.73(0.43,13.40) | 0.07(‐0.05,0.29) | |
| SD GOLI IV + MTX | 3.87(0.23,79.95) | 3.35(0.25,25.62) | 0.09(‐0.06,0.70) | |
| SD ETN SC + DMARD | 1.43(0.33,6.22) | 1.40(0.36,5.65) | 0.02(‐0.07,0.11) | |
| SD ADA SC + DMARD | 0.37(0.06,2.54) | 0.38(0.06,2.46) | ‐0.02(‐0.12,0.03) | |
| SD CERTO SC + DMARD | 0.36(0.05,2.86) | 0.37(0.05,2.73) | ‐0.02(‐0.12,0.04) | |
| LD ADA SC | 0.52(0.14,1.88) | 0.53(0.15,1.86) | ‐0.02(‐0.11,0.01) | |
| LD ETN SC | 1.02(0.16,6.15) | 1.02(0.17,5.56) | 0.00(‐0.09,0.11) | |
| LD GOLI IV | 6.71(0.39,114.40) | 5.16(0.41,31.45) | 0.18(‐0.04,0.75) | |
| LD RITUX IV + MTX | 0.73(0.11,4.41) | 0.74(0.11,4.07) | ‐0.01(‐0.11,0.07) | |
| LD ABA IV + MTX | 1.56(0.20,9.63) | 1.52(0.21,8.15) | 0.02(‐0.08,0.18) | |
| LD CERTO SC + MTX | 1.80(0.16,13.73) | 1.73(0.17,10.47) | 0.03(‐0.08,0.26) | |
| LD ETN SC + MTX | 0.63(0.09,4.02) | 0.64(0.10,3.74) | ‐0.01(‐0.11,0.07) | |
| LD GOLI IV + MTX | 3.69(0.22,64.74) | 3.23(0.23,25.19) | 0.09(‐0.06,0.65) | |
| HD TOCI IV | 1.11(0.19,6.52) | 1.10(0.21,5.79) | 0.00(‐0.09,0.12) | |
| HD TOFA PO | 0.33(0.08,1.57) | 0.34(0.08,1.55) | ‐0.03(‐0.12,0.01) | |
| HD ADA SC | 0.79(0.22,2.79) | 0.80(0.24,2.71) | ‐0.01(‐0.10,0.03) | |
| HD GOLI SC | 1.71(0.20,12.11) | 1.65(0.22,9.83) | 0.02(‐0.08,0.22) | |
| HD GOLI SC + MTX | 3.84(0.46,24.30) | 3.38(0.48,16.34) | 0.10(‐0.04,0.38) | |
| HD TOCI IV + MTX | 1.31(0.20,8.60) | 1.29(0.22,7.37) | 0.01(‐0.08,0.15) | |
| HD TOFA PO + MTX | 2.48(0.34,14.84) | 2.29(0.36,11.67) | 0.05(‐0.06,0.26) | |
| HD CERTO SC + MTX | 2.37(0.42,14.34) | 2.21(0.45,11.46) | 0.05(‐0.05,0.26) | |
| HD INF IV + MTX | 1.24(0.18,7.29) | 1.23(0.20,6.48) | 0.01(‐0.09,0.13) | |
| HD TOCI IV + DMARD | 0.79(0.14,4.68) | 0.80(0.15,4.35) | ‐0.01(‐0.10,0.08) | |
| SD INF IV + MTX | SD GOLI IV | 1.06(0.04,14.72) | 1.06(0.08,13.26) | 0.00(‐0.49,0.11) |
| SD ETN SC + MTX | 1.00(0.04,15.05) | 1.00(0.07,13.60) | 0.00(‐0.49,0.10) | |
| SD ABA IV + MTX | 0.84(0.03,13.09) | 0.85(0.07,11.96) | ‐0.01(‐0.49,0.09) | |
| SD CERTO SC + MTX | 1.61(0.05,25.92) | 1.55(0.10,22.04) | 0.02(‐0.47,0.18) | |
| SD ADA SC + MTX | 1.14(0.05,16.99) | 1.13(0.10,15.00) | 0.00(‐0.47,0.14) | |
| SD ABA SC + MTX | 0.64(0.02,9.88) | 0.65(0.04,9.23) | ‐0.02(‐0.50,0.07) | |
| SD GOLI SC + MTX | 2.20(0.14,25.21) | 2.03(0.24,21.07) | 0.04(‐0.39,0.28) | |
| SD RITUX IV + MTX | 0.92(0.03,12.15) | 0.93(0.05,11.13) | 0.00(‐0.49,0.09) | |
| SD TOFA PO + MTX | 2.29(0.08,34.30) | 2.11(0.16,27.82) | 0.04(‐0.43,0.27) | |
| SD GOLI IV + MTX | 2.89(0.49,28.72) | 2.37(0.53,22.84) | 0.07(‐0.07,0.44) | |
| SD ETN SC + DMARD | 1.16(0.05,16.68) | 1.15(0.10,15.28) | 0.01(‐0.48,0.11) | |
| SD ADA SC + DMARD | 0.32(0.01,5.03) | 0.33(0.02,4.87) | ‐0.03(‐0.52,0.03) | |
| SD CERTO SC + DMARD | 0.29(0.01,4.92) | 0.30(0.02,4.77) | ‐0.03(‐0.51,0.03) | |
| LD ADA SC | 0.39(0.02,6.60) | 0.41(0.04,6.44) | ‐0.03(‐0.51,0.03) | |
| LD ETN SC | 0.85(0.03,14.28) | 0.86(0.06,13.00) | ‐0.01(‐0.49,0.10) | |
| LD GOLI IV | 4.52(1.07,55.75) | 3.34(1.05,37.84) | 0.14(0.00,0.53) | |
| LD RITUX IV + MTX | 0.62(0.02,8.93) | 0.63(0.04,8.43) | ‐0.02(‐0.50,0.06) | |
| LD ABA IV + MTX | 1.29(0.06,18.60) | 1.27(0.11,16.42) | 0.01(‐0.47,0.16) | |
| LD CERTO SC + MTX | 1.51(0.03,30.51) | 1.46(0.05,25.29) | 0.02(‐0.48,0.24) | |
| LD ETN SC + MTX | 0.53(0.02,7.96) | 0.55(0.03,7.55) | ‐0.02(‐0.51,0.06) | |
| LD GOLI IV + MTX | 2.67(0.51,27.32) | 2.29(0.56,21.59) | 0.06(‐0.08,0.45) | |
| HD TOCI IV | 0.93(0.04,12.50) | 0.94(0.07,11.45) | 0.00(‐0.49,0.10) | |
| HD TOFA PO | 0.26(0.01,5.24) | 0.27(0.02,5.12) | ‐0.04(‐0.52,0.02) | |
| HD ADA SC | 0.61(0.03,10.74) | 0.62(0.06,10.32) | ‐0.02(‐0.50,0.05) | |
| HD GOLI SC | 1.40(0.05,17.22) | 1.36(0.10,15.33) | 0.01(‐0.45,0.19) | |
| HD GOLI SC + MTX | 3.15(0.16,34.11) | 2.76(0.27,27.90) | 0.07(‐0.37,0.34) | |
| HD TOCI IV + MTX | 1.11(0.04,16.32) | 1.10(0.08,14.56) | 0.00(‐0.48,0.14) | |
| HD TOFA PO + MTX | 1.91(0.07,28.08) | 1.80(0.13,23.61) | 0.03(‐0.44,0.24) | |
| HD CERTO SC + MTX | 2.04(0.05,31.07) | 1.91(0.11,25.09) | 0.03(‐0.46,0.22) | |
| HD INF IV + MTX | 1.05(0.04,13.99) | 1.04(0.07,12.82) | 0.00(‐0.49,0.11) | |
| HD TOCI IV + DMARD | 0.68(0.03,8.51) | 0.70(0.05,7.99) | ‐0.01(‐0.50,0.07) | |
| SD ETN SC + MTX | SD INF IV + MTX | 0.95(0.42,2.16) | 0.95(0.44,2.06) | 0.00(‐0.06,0.05) |
| SD ABA IV + MTX | 0.80(0.45,1.39) | 0.81(0.47,1.36) | ‐0.01(‐0.06,0.02) | |
| SD CERTO SC + MTX | 1.50(0.75,3.07) | 1.46(0.77,2.81) | 0.02(‐0.02,0.11) | |
| SD ADA SC + MTX | 1.10(0.45,2.72) | 1.09(0.47,2.52) | 0.00(‐0.05,0.09) | |
| SD ABA SC + MTX | 0.59(0.25,1.32) | 0.61(0.26,1.29) | ‐0.02(‐0.08,0.01) | |
| SD GOLI SC + MTX | 2.16(0.66,7.28) | 2.00(0.68,5.93) | 0.05(‐0.02,0.26) | |
| SD RITUX IV + MTX | 0.84(0.40,1.87) | 0.85(0.42,1.79) | ‐0.01(‐0.07,0.04) | |
| SD TOFA PO + MTX | 2.21(0.87,6.63) | 2.04(0.87,5.27) | 0.06(‐0.01,0.23) | |
| SD GOLI IV + MTX | 2.74(0.41,48.63) | 2.44(0.42,17.20) | 0.08(‐0.04,0.67) | |
| SD ETN SC + DMARD | 1.14(0.40,3.16) | 1.13(0.43,2.96) | 0.01(‐0.07,0.07) | |
| SD ADA SC + DMARD | 0.30(0.08,1.09) | 0.31(0.09,1.09) | ‐0.03(‐0.13,0.00) | |
| SD CERTO SC + DMARD | 0.28(0.06,1.46) | 0.29(0.06,1.44) | ‐0.03(‐0.13,0.02) | |
| LD ADA SC | 0.42(0.09,1.74) | 0.43(0.10,1.71) | ‐0.03(‐0.15,0.01) | |
| LD ETN SC | 0.79(0.28,2.14) | 0.80(0.30,2.04) | ‐0.01(‐0.08,0.05) | |
| LD GOLI IV | 4.85(0.72,82.94) | 3.81(0.73,20.70) | 0.16(‐0.01,0.73) | |
| LD RITUX IV + MTX | 0.55(0.26,1.27) | 0.57(0.27,1.25) | ‐0.02(‐0.09,0.01) | |
| LD ABA IV + MTX | 1.21(0.50,2.89) | 1.19(0.52,2.62) | 0.01(‐0.04,0.11) | |
| LD CERTO SC + MTX | 1.45(0.24,5.89) | 1.41(0.25,4.84) | 0.02(‐0.06,0.21) | |
| LD ETN SC + MTX | 0.50(0.16,1.42) | 0.51(0.17,1.39) | ‐0.02(‐0.10,0.02) | |
| LD GOLI IV + MTX | 2.69(0.43,50.10) | 2.43(0.45,17.39) | 0.08(‐0.04,0.62) | |
| HD TOCI IV | 0.88(0.36,2.18) | 0.89(0.38,2.08) | 0.00(‐0.07,0.05) | |
| HD TOFA PO | 0.26(0.06,1.33) | 0.27(0.07,1.33) | ‐0.04(‐0.15,0.01) | |
| HD ADA SC | 0.62(0.15,2.63) | 0.63(0.17,2.56) | ‐0.02(‐0.13,0.03) | |
| HD GOLI SC | 1.29(0.33,4.74) | 1.27(0.35,4.04) | 0.01(‐0.06,0.18) | |
| HD GOLI SC + MTX | 2.93(1.03,8.58) | 2.59(1.03,6.38) | 0.09(0.00,0.33) | |
| HD TOCI IV + MTX | 1.03(0.37,3.07) | 1.03(0.39,2.81) | 0.00(‐0.07,0.09) | |
| HD TOFA PO + MTX | 1.86(0.68,5.16) | 1.76(0.68,4.36) | 0.04(‐0.02,0.20) | |
| HD CERTO SC + MTX | 1.87(0.80,4.58) | 1.77(0.81,3.97) | 0.04(‐0.01,0.18) | |
| HD INF IV + MTX | 0.97(0.50,1.92) | 0.97(0.51,1.83) | 0.00(‐0.04,0.05) | |
| HD TOCI IV + DMARD | 0.62(0.20,1.93) | 0.64(0.22,1.86) | ‐0.02(‐0.10,0.04) | |
| SD ABA IV + MTX | SD ETN SC + MTX | 0.84(0.35,1.84) | 0.85(0.37,1.78) | ‐0.01(‐0.07,0.04) |
| SD CERTO SC + MTX | 1.57(0.68,3.73) | 1.52(0.70,3.40) | 0.02(‐0.03,0.13) | |
| SD ADA SC + MTX | 1.17(0.41,3.58) | 1.16(0.42,3.22) | 0.01(‐0.06,0.10) | |
| SD ABA SC + MTX | 0.63(0.21,1.64) | 0.65(0.23,1.60) | ‐0.02(‐0.09,0.03) | |
| SD GOLI SC + MTX | 2.28(0.56,8.90) | 2.12(0.59,6.95) | 0.05(‐0.03,0.28) | |
| SD RITUX IV + MTX | 0.87(0.36,2.32) | 0.88(0.38,2.18) | 0.00(‐0.07,0.06) | |
| SD TOFA PO + MTX | 2.37(0.78,7.41) | 2.20(0.80,6.04) | 0.06(‐0.01,0.24) | |
| SD GOLI IV + MTX | 2.72(0.45,58.61) | 2.45(0.46,20.08) | 0.08(‐0.04,0.68) | |
| SD ETN SC + DMARD | 1.18(0.45,3.04) | 1.17(0.47,2.86) | 0.01(‐0.06,0.07) | |
| SD ADA SC + DMARD | 0.31(0.08,1.11) | 0.32(0.09,1.10) | ‐0.03(‐0.12,0.00) | |
| SD CERTO SC + DMARD | 0.30(0.06,1.55) | 0.31(0.06,1.53) | ‐0.03(‐0.13,0.02) | |
| LD ADA SC | 0.44(0.09,1.71) | 0.45(0.11,1.68) | ‐0.03(‐0.14,0.01) | |
| LD ETN SC | 0.84(0.28,2.41) | 0.85(0.30,2.29) | ‐0.01(‐0.08,0.06) | |
| LD GOLI IV | 5.01(0.75,96.66) | 3.88(0.76,22.99) | 0.17(‐0.01,0.74) | |
| LD RITUX IV + MTX | 0.58(0.23,1.56) | 0.60(0.25,1.53) | ‐0.02(‐0.09,0.02) | |
| LD ABA IV + MTX | 1.27(0.43,3.63) | 1.24(0.45,3.25) | 0.01(‐0.05,0.12) | |
| LD CERTO SC + MTX | 1.51(0.21,6.24) | 1.46(0.23,5.18) | 0.02(‐0.06,0.21) | |
| LD ETN SC + MTX | 0.52(0.18,1.40) | 0.54(0.19,1.37) | ‐0.02(‐0.09,0.02) | |
| LD GOLI IV + MTX | 2.83(0.44,53.74) | 2.53(0.45,20.04) | 0.08(‐0.04,0.63) | |
| HD TOCI IV | 0.92(0.36,2.38) | 0.93(0.38,2.26) | 0.00(‐0.07,0.06) | |
| HD TOFA PO | 0.28(0.06,1.33) | 0.29(0.07,1.32) | ‐0.04(‐0.15,0.01) | |
| HD ADA SC | 0.65(0.16,3.13) | 0.66(0.18,3.03) | ‐0.02(‐0.13,0.03) | |
| HD GOLI SC | 1.37(0.29,5.77) | 1.35(0.30,4.81) | 0.01(‐0.07,0.19) | |
| HD GOLI SC + MTX | 3.07(0.90,11.35) | 2.71(0.91,8.03) | 0.09(‐0.01,0.34) | |
| HD TOCI IV + MTX | 1.08(0.36,3.51) | 1.07(0.38,3.18) | 0.00(‐0.06,0.10) | |
| HD TOFA PO + MTX | 2.01(0.60,6.31) | 1.88(0.62,5.17) | 0.04(‐0.03,0.21) | |
| HD CERTO SC + MTX | 1.98(0.74,5.48) | 1.85(0.76,4.67) | 0.04(‐0.02,0.19) | |
| HD INF IV + MTX | 1.01(0.40,2.69) | 1.01(0.42,2.52) | 0.00(‐0.06,0.07) | |
| HD TOCI IV + DMARD | 0.65(0.21,2.04) | 0.67(0.22,1.95) | ‐0.01(‐0.10,0.04) | |
| SD CERTO SC + MTX | SD ABA IV + MTX | 1.90(1.00,3.75) | 1.81(1.00,3.43) | 0.03(0.00,0.13) |
| SD ADA SC + MTX | 1.38(0.57,3.64) | 1.36(0.59,3.28) | 0.01(‐0.03,0.10) | |
| SD ABA SC + MTX | 0.74(0.39,1.36) | 0.75(0.41,1.34) | ‐0.01(‐0.05,0.02) | |
| SD GOLI SC + MTX | 2.74(0.82,9.31) | 2.52(0.83,7.34) | 0.06(‐0.01,0.28) | |
| SD RITUX IV + MTX | 1.08(0.50,2.33) | 1.07(0.52,2.22) | 0.00(‐0.04,0.06) | |
| SD TOFA PO + MTX | 2.83(1.12,7.91) | 2.58(1.12,6.37) | 0.07(0.00,0.25) | |
| SD GOLI IV + MTX | 3.47(0.51,60.68) | 3.05(0.52,20.36) | 0.09(‐0.02,0.69) | |
| SD ETN SC + DMARD | 1.44(0.49,3.89) | 1.41(0.52,3.64) | 0.02(‐0.05,0.09) | |
| SD ADA SC + DMARD | 0.38(0.10,1.31) | 0.39(0.11,1.30) | ‐0.02(‐0.10,0.01) | |
| SD CERTO SC + DMARD | 0.35(0.07,1.90) | 0.36(0.08,1.85) | ‐0.02(‐0.11,0.02) | |
| LD ADA SC | 0.53(0.11,2.17) | 0.54(0.12,2.15) | ‐0.02(‐0.12,0.02) | |
| LD ETN SC | 1.01(0.35,2.66) | 1.00(0.37,2.52) | 0.00(‐0.05,0.07) | |
| LD GOLI IV | 6.15(1.03,98.16) | 4.73(1.02,24.52) | 0.18(0.00,0.74) | |
| LD RITUX IV + MTX | 0.70(0.33,1.60) | 0.71(0.35,1.55) | ‐0.01(‐0.06,0.02) | |
| LD ABA IV + MTX | 1.51(0.72,3.34) | 1.47(0.73,3.01) | 0.02(‐0.01,0.12) | |
| LD CERTO SC + MTX | 1.86(0.30,7.15) | 1.78(0.31,5.90) | 0.03(‐0.04,0.22) | |
| LD ETN SC + MTX | 0.63(0.21,1.82) | 0.65(0.22,1.76) | ‐0.01(‐0.08,0.03) | |
| LD GOLI IV + MTX | 3.47(0.60,57.15) | 3.08(0.61,20.44) | 0.09(‐0.02,0.64) | |
| HD TOCI IV | 1.12(0.44,2.77) | 1.11(0.46,2.62) | 0.00(‐0.05,0.07) | |
| HD TOFA PO | 0.33(0.07,1.69) | 0.34(0.08,1.67) | ‐0.03(‐0.12,0.01) | |
| HD ADA SC | 0.78(0.18,3.81) | 0.79(0.20,3.66) | ‐0.01(‐0.10,0.04) | |
| HD GOLI SC | 1.62(0.42,6.28) | 1.57(0.43,5.32) | 0.02(‐0.04,0.19) | |
| HD GOLI SC + MTX | 3.65(1.36,11.85) | 3.20(1.32,8.55) | 0.09(0.01,0.35) | |
| HD TOCI IV + MTX | 1.31(0.49,3.78) | 1.29(0.50,3.44) | 0.01(‐0.04,0.11) | |
| HD TOFA PO + MTX | 2.34(0.85,6.64) | 2.19(0.86,5.59) | 0.05(‐0.01,0.21) | |
| HD CERTO SC + MTX | 2.37(1.05,5.68) | 2.20(1.05,4.92) | 0.05(0.00,0.20) | |
| HD INF IV + MTX | 1.22(0.57,2.71) | 1.21(0.59,2.54) | 0.01(‐0.03,0.08) | |
| HD TOCI IV + DMARD | 0.80(0.26,2.46) | 0.81(0.28,2.32) | ‐0.01(‐0.08,0.05) | |
| SD ADA SC + MTX | SD CERTO SC + MTX | 0.73(0.28,1.92) | 0.75(0.31,1.82) | ‐0.02(‐0.11,0.05) |
| SD ABA SC + MTX | 0.39(0.15,0.93) | 0.42(0.17,0.94) | ‐0.04(‐0.15,0.00) | |
| SD GOLI SC + MTX | 1.45(0.41,4.99) | 1.39(0.44,3.99) | 0.03(‐0.08,0.23) | |
| SD RITUX IV + MTX | 0.56(0.26,1.24) | 0.58(0.29,1.22) | ‐0.03(‐0.14,0.02) | |
| SD TOFA PO + MTX | 1.48(0.54,4.28) | 1.42(0.57,3.55) | 0.03(‐0.05,0.19) | |
| SD GOLI IV + MTX | 1.78(0.27,40.10) | 1.66(0.29,13.19) | 0.05(‐0.09,0.65) | |
| SD ETN SC + DMARD | 0.76(0.26,1.99) | 0.78(0.29,1.90) | ‐0.02(‐0.14,0.05) | |
| SD ADA SC + DMARD | 0.20(0.05,0.71) | 0.21(0.06,0.73) | ‐0.06(‐0.21,‐0.01) | |
| SD CERTO SC + DMARD | 0.19(0.04,0.96) | 0.20(0.04,0.96) | ‐0.06(‐0.21,0.00) | |
| LD ADA SC | 0.28(0.05,1.11) | 0.30(0.07,1.11) | ‐0.05(‐0.22,0.00) | |
| LD ETN SC | 0.53(0.18,1.50) | 0.56(0.20,1.45) | ‐0.03(‐0.15,0.03) | |
| LD GOLI IV | 3.11(0.53,62.39) | 2.57(0.54,15.29) | 0.13(‐0.04,0.72) | |
| LD RITUX IV + MTX | 0.36(0.16,0.85) | 0.39(0.18,0.86) | ‐0.04(‐0.16,‐0.01) | |
| LD ABA IV + MTX | 0.80(0.32,1.99) | 0.82(0.34,1.86) | ‐0.01(‐0.10,0.07) | |
| LD CERTO SC + MTX | 0.97(0.17,3.36) | 0.97(0.19,2.87) | 0.00(‐0.10,0.15) | |
| LD ETN SC + MTX | 0.33(0.10,1.03) | 0.35(0.11,1.03) | ‐0.05(‐0.18,0.00) | |
| LD GOLI IV + MTX | 1.78(0.30,34.81) | 1.67(0.31,12.62) | 0.05(‐0.08,0.60) | |
| HD TOCI IV | 0.59(0.23,1.40) | 0.62(0.26,1.36) | ‐0.03(‐0.14,0.02) | |
| HD TOFA PO | 0.17(0.04,0.88) | 0.18(0.05,0.88) | ‐0.06(‐0.23,0.00) | |
| HD ADA SC | 0.41(0.09,1.95) | 0.43(0.12,1.90) | ‐0.04(‐0.21,0.02) | |
| HD GOLI SC | 0.88(0.20,3.24) | 0.89(0.23,2.78) | ‐0.01(‐0.13,0.14) | |
| HD GOLI SC + MTX | 1.99(0.63,6.11) | 1.81(0.66,4.57) | 0.06(‐0.04,0.29) | |
| HD TOCI IV + MTX | 0.69(0.24,1.93) | 0.71(0.27,1.80) | ‐0.02(‐0.13,0.06) | |
| HD TOFA PO + MTX | 1.25(0.43,3.53) | 1.22(0.46,3.02) | 0.02(‐0.06,0.16) | |
| HD CERTO SC + MTX | 1.26(0.62,2.45) | 1.23(0.65,2.20) | 0.02(‐0.04,0.12) | |
| HD INF IV + MTX | 0.65(0.27,1.47) | 0.67(0.30,1.42) | ‐0.02(‐0.12,0.03) | |
| HD TOCI IV + DMARD | 0.42(0.13,1.31) | 0.44(0.15,1.28) | ‐0.04(‐0.17,0.01) | |
| SD ABA SC + MTX | SD ADA SC + MTX | 0.53(0.17,1.57) | 0.55(0.19,1.54) | ‐0.02(‐0.12,0.02) |
| SD GOLI SC + MTX | 2.01(0.43,7.61) | 1.86(0.45,6.26) | 0.05(‐0.05,0.25) | |
| SD RITUX IV + MTX | 0.76(0.28,2.16) | 0.77(0.31,2.07) | ‐0.01(‐0.10,0.05) | |
| SD TOFA PO + MTX | 2.03(0.84,5.26) | 1.89(0.86,4.45) | 0.05(‐0.01,0.21) | |
| SD GOLI IV + MTX | 2.55(0.29,45.08) | 2.29(0.31,15.26) | 0.07(‐0.07,0.66) | |
| SD ETN SC + DMARD | 1.00(0.30,3.39) | 1.00(0.33,3.24) | 0.00(‐0.10,0.07) | |
| SD ADA SC + DMARD | 0.26(0.07,1.10) | 0.28(0.07,1.10) | ‐0.04(‐0.16,0.00) | |
| SD CERTO SC + DMARD | 0.25(0.05,1.58) | 0.27(0.05,1.55) | ‐0.04(‐0.16,0.01) | |
| LD ADA SC | 0.36(0.07,1.97) | 0.38(0.09,1.94) | ‐0.04(‐0.17,0.02) | |
| LD ETN SC | 0.72(0.20,2.36) | 0.73(0.22,2.26) | ‐0.01(‐0.11,0.05) | |
| LD GOLI IV | 4.47(0.59,68.73) | 3.51(0.61,18.38) | 0.16(‐0.04,0.72) | |
| LD RITUX IV + MTX | 0.51(0.18,1.44) | 0.53(0.20,1.42) | ‐0.03(‐0.12,0.01) | |
| LD ABA IV + MTX | 1.08(0.35,3.32) | 1.08(0.38,3.03) | 0.00(‐0.08,0.11) | |
| LD CERTO SC + MTX | 1.31(0.21,5.45) | 1.28(0.23,4.55) | 0.01(‐0.09,0.20) | |
| LD ETN SC + MTX | 0.44(0.11,1.54) | 0.46(0.13,1.50) | ‐0.03(‐0.14,0.02) | |
| LD GOLI IV + MTX | 2.49(0.38,38.28) | 2.23(0.40,15.17) | 0.07(‐0.06,0.61) | |
| HD TOCI IV | 0.79(0.28,2.40) | 0.80(0.30,2.27) | ‐0.01(‐0.10,0.05) | |
| HD TOFA PO | 0.22(0.05,1.42) | 0.24(0.06,1.41) | ‐0.05(‐0.18,0.01) | |
| HD ADA SC | 0.54(0.12,3.30) | 0.55(0.14,3.17) | ‐0.03(‐0.16,0.04) | |
| HD GOLI SC | 1.19(0.24,5.36) | 1.17(0.26,4.56) | 0.01(‐0.09,0.17) | |
| HD GOLI SC + MTX | 2.65(0.74,10.32) | 2.34(0.76,7.75) | 0.08(‐0.02,0.33) | |
| HD TOCI IV + MTX | 0.93(0.28,3.19) | 0.93(0.30,2.92) | 0.00(‐0.09,0.09) | |
| HD TOFA PO + MTX | 1.68(0.67,4.64) | 1.60(0.68,3.99) | 0.03(‐0.03,0.18) | |
| HD CERTO SC + MTX | 1.70(0.57,5.21) | 1.61(0.59,4.53) | 0.03(‐0.04,0.17) | |
| HD INF IV + MTX | 0.87(0.31,2.44) | 0.88(0.34,2.33) | ‐0.01(‐0.09,0.06) | |
| HD TOCI IV + DMARD | 0.55(0.16,2.05) | 0.57(0.17,1.96) | ‐0.02(‐0.13,0.04) | |
| SD GOLI SC + MTX | SD ABA SC + MTX | 3.69(0.99,15.15) | 3.31(0.99,12.09) | 0.07(0.00,0.30) |
| SD RITUX IV + MTX | 1.42(0.57,4.03) | 1.40(0.59,3.76) | 0.01(‐0.03,0.08) | |
| SD TOFA PO + MTX | 3.83(1.26,12.32) | 3.44(1.24,10.14) | 0.08(0.01,0.26) | |
| SD GOLI IV + MTX | 4.73(0.63,90.95) | 4.07(0.64,32.54) | 0.10(‐0.01,0.70) | |
| SD ETN SC + DMARD | 1.92(0.57,6.26) | 1.86(0.60,5.76) | 0.02(‐0.04,0.10) | |
| SD ADA SC + DMARD | 0.51(0.13,2.07) | 0.52(0.14,2.03) | ‐0.01(‐0.09,0.02) | |
| SD CERTO SC + DMARD | 0.47(0.09,2.76) | 0.48(0.10,2.68) | ‐0.01(‐0.09,0.04) | |
| LD ADA SC | 0.72(0.13,3.27) | 0.73(0.14,3.20) | ‐0.01(‐0.10,0.02) | |
| LD ETN SC | 1.36(0.44,4.27) | 1.34(0.46,4.00) | 0.01(‐0.04,0.09) | |
| LD GOLI IV | 8.24(1.28,164.20) | 6.26(1.26,40.30) | 0.19(0.00,0.76) | |
| LD RITUX IV + MTX | 0.92(0.37,2.60) | 0.93(0.39,2.51) | 0.00(‐0.05,0.04) | |
| LD ABA IV + MTX | 2.05(0.78,5.69) | 1.97(0.79,5.18) | 0.03(‐0.01,0.15) | |
| LD CERTO SC + MTX | 2.49(0.38,10.82) | 2.32(0.39,9.07) | 0.04(‐0.03,0.24) | |
| LD ETN SC + MTX | 0.85(0.25,2.92) | 0.85(0.26,2.79) | 0.00(‐0.06,0.05) | |
| LD GOLI IV + MTX | 4.69(0.74,95.89) | 4.05(0.74,33.23) | 0.10(‐0.01,0.65) | |
| HD TOCI IV | 1.49(0.50,4.41) | 1.47(0.53,4.14) | 0.01(‐0.04,0.09) | |
| HD TOFA PO | 0.45(0.08,2.61) | 0.45(0.09,2.58) | ‐0.02(‐0.11,0.01) | |
| HD ADA SC | 1.06(0.21,5.46) | 1.06(0.23,5.26) | 0.00(‐0.09,0.05) | |
| HD GOLI SC | 2.18(0.50,9.75) | 2.08(0.51,8.02) | 0.03(‐0.03,0.21) | |
| HD GOLI SC + MTX | 4.91(1.55,18.50) | 4.24(1.48,13.49) | 0.11(0.01,0.37) | |
| HD TOCI IV + MTX | 1.76(0.57,5.91) | 1.71(0.58,5.43) | 0.02(‐0.03,0.13) | |
| HD TOFA PO + MTX | 3.23(0.98,10.47) | 2.97(0.98,8.68) | 0.06(0.00,0.23) | |
| HD CERTO SC + MTX | 3.19(1.18,9.28) | 2.92(1.17,7.96) | 0.06(0.01,0.22) | |
| HD INF IV + MTX | 1.61(0.65,4.64) | 1.57(0.67,4.33) | 0.02(‐0.02,0.10) | |
| HD TOCI IV + DMARD | 1.07(0.30,3.84) | 1.07(0.32,3.58) | 0.00(‐0.06,0.07) | |
| SD RITUX IV + MTX | SD GOLI SC + MTX | 0.38(0.10,1.47) | 0.42(0.12,1.44) | ‐0.06(‐0.27,0.02) |
| SD TOFA PO + MTX | 1.00(0.27,6.16) | 1.00(0.32,4.94) | 0.00(‐0.17,0.19) | |
| SD GOLI IV + MTX | 1.36(0.16,17.59) | 1.30(0.19,6.69) | 0.03(‐0.20,0.58) | |
| SD ETN SC + DMARD | 0.51(0.13,2.10) | 0.54(0.17,2.02) | ‐0.05(‐0.28,0.04) | |
| SD ADA SC + DMARD | 0.14(0.03,0.64) | 0.16(0.03,0.65) | ‐0.09(‐0.34,‐0.01) | |
| SD CERTO SC + DMARD | 0.13(0.02,0.86) | 0.14(0.02,0.88) | ‐0.09(‐0.33,0.00) | |
| LD ADA SC | 0.18(0.03,1.02) | 0.20(0.05,1.02) | ‐0.09(‐0.34,0.00) | |
| LD ETN SC | 0.37(0.08,1.52) | 0.40(0.11,1.48) | ‐0.06(‐0.28,0.02) | |
| LD GOLI IV | 2.28(0.32,25.66) | 1.93(0.34,8.10) | 0.10(‐0.14,0.65) | |
| LD RITUX IV + MTX | 0.26(0.06,0.91) | 0.29(0.08,0.92) | ‐0.08(‐0.30,0.00) | |
| LD ABA IV + MTX | 0.55(0.15,2.13) | 0.59(0.18,2.00) | ‐0.04(‐0.25,0.06) | |
| LD CERTO SC + MTX | 0.67(0.08,3.57) | 0.70(0.09,3.12) | ‐0.03(‐0.24,0.15) | |
| LD ETN SC + MTX | 0.23(0.05,1.05) | 0.25(0.06,1.04) | ‐0.08(‐0.32,0.00) | |
| LD GOLI IV + MTX | 1.33(0.16,15.12) | 1.28(0.18,6.26) | 0.02(‐0.20,0.54) | |
| HD TOCI IV | 0.40(0.11,1.47) | 0.44(0.14,1.44) | ‐0.06(‐0.27,0.02) | |
| HD TOFA PO | 0.12(0.02,0.79) | 0.13(0.03,0.79) | ‐0.10(‐0.35,0.00) | |
| HD ADA SC | 0.27(0.06,1.64) | 0.30(0.08,1.62) | ‐0.08(‐0.33,0.02) | |
| HD GOLI SC | 0.60(0.14,2.04) | 0.64(0.17,1.88) | ‐0.03(‐0.21,0.08) | |
| HD GOLI SC + MTX | 1.36(0.55,3.67) | 1.29(0.60,3.09) | 0.03(‐0.08,0.19) | |
| HD TOCI IV + MTX | 0.48(0.12,2.02) | 0.51(0.14,1.93) | ‐0.05(‐0.27,0.05) | |
| HD TOFA PO + MTX | 0.83(0.21,4.16) | 0.85(0.25,3.65) | ‐0.01(‐0.19,0.14) | |
| HD CERTO SC + MTX | 0.87(0.21,3.58) | 0.89(0.26,3.19) | ‐0.01(‐0.21,0.13) | |
| HD INF IV + MTX | 0.44(0.12,1.70) | 0.48(0.14,1.64) | ‐0.05(‐0.26,0.03) | |
| HD TOCI IV + DMARD | 0.29(0.06,1.27) | 0.32(0.08,1.25) | ‐0.07(‐0.30,0.01) | |
| SD TOFA PO + MTX | SD RITUX IV + MTX | 2.72(0.89,7.80) | 2.47(0.90,6.36) | 0.07(‐0.01,0.24) |
| SD GOLI IV + MTX | 3.12(0.48,76.53) | 2.79(0.49,25.89) | 0.08(‐0.03,0.68) | |
| SD ETN SC + DMARD | 1.33(0.42,3.98) | 1.31(0.45,3.75) | 0.01(‐0.07,0.08) | |
| SD ADA SC + DMARD | 0.35(0.09,1.52) | 0.36(0.10,1.49) | ‐0.03(‐0.12,0.01) | |
| SD CERTO SC + DMARD | 0.32(0.06,2.05) | 0.34(0.07,2.00) | ‐0.03(‐0.12,0.03) | |
| LD ADA SC | 0.49(0.10,2.03) | 0.50(0.11,2.00) | ‐0.02(‐0.13,0.02) | |
| LD ETN SC | 0.96(0.29,2.70) | 0.96(0.31,2.55) | 0.00(‐0.08,0.06) | |
| LD GOLI IV | 5.72(0.93,126.70) | 4.39(0.94,32.30) | 0.17(0.00,0.75) | |
| LD RITUX IV + MTX | 0.66(0.33,1.27) | 0.67(0.35,1.25) | ‐0.01(‐0.07,0.01) | |
| LD ABA IV + MTX | 1.42(0.51,3.91) | 1.39(0.54,3.60) | 0.02(‐0.04,0.13) | |
| LD CERTO SC + MTX | 1.70(0.25,6.95) | 1.64(0.27,5.60) | 0.02(‐0.06,0.23) | |
| LD ETN SC + MTX | 0.61(0.17,1.78) | 0.62(0.18,1.73) | ‐0.02(‐0.10,0.03) | |
| LD GOLI IV + MTX | 3.15(0.53,72.16) | 2.81(0.54,27.02) | 0.08(‐0.02,0.64) | |
| HD TOCI IV | 1.03(0.39,2.94) | 1.02(0.42,2.78) | 0.00(‐0.06,0.06) | |
| HD TOFA PO | 0.31(0.07,1.63) | 0.32(0.08,1.61) | ‐0.03(‐0.14,0.01) | |
| HD ADA SC | 0.71(0.17,3.74) | 0.72(0.19,3.62) | ‐0.01(‐0.12,0.04) | |
| HD GOLI SC | 1.54(0.36,6.06) | 1.50(0.38,5.04) | 0.02(‐0.05,0.19) | |
| HD GOLI SC + MTX | 3.45(1.07,11.28) | 3.02(1.06,8.47) | 0.09(0.00,0.34) | |
| HD TOCI IV + MTX | 1.23(0.41,3.76) | 1.21(0.43,3.45) | 0.01(‐0.05,0.10) | |
| HD TOFA PO + MTX | 2.32(0.68,6.53) | 2.15(0.69,5.46) | 0.05(‐0.02,0.21) | |
| HD CERTO SC + MTX | 2.25(0.83,5.74) | 2.11(0.84,4.92) | 0.05(‐0.01,0.20) | |
| HD INF IV + MTX | 1.14(0.46,2.79) | 1.13(0.48,2.61) | 0.00(‐0.05,0.08) | |
| HD TOCI IV + DMARD | 0.73(0.21,2.45) | 0.74(0.23,2.36) | ‐0.01(‐0.09,0.05) | |
| SD GOLI IV + MTX | SD TOFA PO + MTX | 1.24(0.14,25.44) | 1.19(0.17,9.33) | 0.02(‐0.18,0.60) |
| SD ETN SC + DMARD | 0.50(0.14,1.67) | 0.54(0.17,1.62) | ‐0.05(‐0.25,0.03) | |
| SD ADA SC + DMARD | 0.13(0.03,0.53) | 0.15(0.04,0.56) | ‐0.10(‐0.30,‐0.01) | |
| SD CERTO SC + DMARD | 0.12(0.02,0.73) | 0.14(0.02,0.75) | ‐0.10(‐0.30,‐0.01) | |
| LD ADA SC | 0.17(0.04,0.97) | 0.19(0.05,0.97) | ‐0.09(‐0.32,0.00) | |
| LD ETN SC | 0.36(0.09,1.23) | 0.39(0.11,1.22) | ‐0.07(‐0.26,0.01) | |
| LD GOLI IV | 2.22(0.23,37.58) | 1.88(0.27,10.55) | 0.10(‐0.16,0.68) | |
| LD RITUX IV + MTX | 0.25(0.08,0.73) | 0.28(0.10,0.75) | ‐0.08(‐0.27,‐0.01) | |
| LD ABA IV + MTX | 0.54(0.17,1.69) | 0.58(0.20,1.62) | ‐0.04(‐0.22,0.04) | |
| LD CERTO SC + MTX | 0.62(0.09,3.08) | 0.66(0.11,2.64) | ‐0.03(‐0.23,0.14) | |
| LD ETN SC + MTX | 0.22(0.05,0.77) | 0.25(0.06,0.79) | ‐0.08(‐0.28,‐0.01) | |
| LD GOLI IV + MTX | 1.20(0.17,22.16) | 1.17(0.19,8.91) | 0.02(‐0.19,0.57) | |
| HD TOCI IV | 0.39(0.13,1.19) | 0.42(0.16,1.17) | ‐0.06(‐0.24,0.01) | |
| HD TOFA PO | 0.11(0.02,0.71) | 0.12(0.03,0.71) | ‐0.10(‐0.33,‐0.01) | |
| HD ADA SC | 0.26(0.06,1.51) | 0.28(0.08,1.49) | ‐0.08(‐0.30,0.01) | |
| HD GOLI SC | 0.58(0.09,2.55) | 0.62(0.12,2.31) | ‐0.04(‐0.23,0.10) | |
| HD GOLI SC + MTX | 1.32(0.31,4.99) | 1.27(0.36,3.95) | 0.03(‐0.15,0.25) | |
| HD TOCI IV + MTX | 0.45(0.13,1.68) | 0.49(0.16,1.59) | ‐0.05(‐0.23,0.04) | |
| HD TOFA PO + MTX | 0.83(0.42,1.64) | 0.85(0.46,1.53) | ‐0.01(‐0.11,0.06) | |
| HD CERTO SC + MTX | 0.84(0.27,2.51) | 0.86(0.32,2.28) | ‐0.01(‐0.17,0.10) | |
| HD INF IV + MTX | 0.42(0.14,1.25) | 0.46(0.17,1.23) | ‐0.06(‐0.23,0.01) | |
| HD TOCI IV + DMARD | 0.27(0.07,0.98) | 0.31(0.09,0.98) | ‐0.08(‐0.27,0.00) | |
| SD ETN SC + DMARD | SD GOLI IV + MTX | 0.41(0.02,3.36) | 0.45(0.07,3.18) | ‐0.07(‐0.67,0.06) |
| SD ADA SC + DMARD | 0.11(0.01,1.01) | 0.13(0.02,1.01) | ‐0.12(‐0.72,0.00) | |
| SD CERTO SC + DMARD | 0.09(0.01,1.10) | 0.11(0.01,1.09) | ‐0.12(‐0.72,0.00) | |
| LD ADA SC | 0.13(0.01,1.67) | 0.16(0.03,1.65) | ‐0.12(‐0.71,0.01) | |
| LD ETN SC | 0.30(0.01,2.23) | 0.34(0.04,2.16) | ‐0.08(‐0.69,0.04) | |
| LD GOLI IV | 1.62(0.50,6.95) | 1.39(0.57,5.18) | 0.05(‐0.12,0.33) | |
| LD RITUX IV + MTX | 0.21(0.01,1.46) | 0.24(0.03,1.44) | ‐0.10(‐0.69,0.01) | |
| LD ABA IV + MTX | 0.44(0.02,3.24) | 0.48(0.07,3.03) | ‐0.06(‐0.66,0.08) | |
| LD CERTO SC + MTX | 0.50(0.01,5.23) | 0.55(0.03,4.67) | ‐0.05(‐0.67,0.15) | |
| LD ETN SC + MTX | 0.18(0.01,1.35) | 0.21(0.02,1.33) | ‐0.11(‐0.70,0.01) | |
| LD GOLI IV + MTX | 0.93(0.23,4.35) | 0.95(0.28,3.54) | ‐0.01(‐0.26,0.22) | |
| HD TOCI IV | 0.33(0.02,2.36) | 0.37(0.05,2.28) | ‐0.08(‐0.68,0.03) | |
| HD TOFA PO | 0.09(0.00,1.15) | 0.10(0.01,1.14) | ‐0.12(‐0.73,0.00) | |
| HD ADA SC | 0.20(0.01,2.59) | 0.23(0.04,2.52) | ‐0.11(‐0.70,0.03) | |
| HD GOLI SC | 0.46(0.02,4.11) | 0.51(0.06,3.64) | ‐0.06(‐0.65,0.12) | |
| HD GOLI SC + MTX | 1.07(0.06,8.37) | 1.06(0.17,6.75) | 0.00(‐0.56,0.26) | |
| HD TOCI IV + MTX | 0.38(0.02,3.04) | 0.43(0.05,2.86) | ‐0.07(‐0.68,0.06) | |
| HD TOFA PO + MTX | 0.66(0.04,6.57) | 0.71(0.09,5.59) | ‐0.04(‐0.61,0.16) | |
| HD CERTO SC + MTX | 0.72(0.03,4.74) | 0.76(0.08,4.30) | ‐0.03(‐0.64,0.13) | |
| HD INF IV + MTX | 0.36(0.02,2.66) | 0.40(0.05,2.55) | ‐0.08(‐0.67,0.04) | |
| HD TOCI IV + DMARD | 0.23(0.01,2.02) | 0.26(0.04,1.96) | ‐0.10(‐0.70,0.03) | |
| SD ADA SC + DMARD | SD ETN SC + DMARD | 0.27(0.07,0.92) | 0.28(0.08,0.92) | ‐0.04(‐0.12,0.00) |
| SD CERTO SC + DMARD | 0.26(0.05,1.22) | 0.27(0.05,1.20) | ‐0.04(‐0.13,0.01) | |
| LD ADA SC | 0.37(0.10,1.16) | 0.39(0.11,1.15) | ‐0.04(‐0.14,0.00) | |
| LD ETN SC | 0.69(0.22,2.35) | 0.71(0.24,2.20) | ‐0.01(‐0.09,0.06) | |
| LD GOLI IV | 4.34(0.47,70.46) | 3.48(0.49,17.47) | 0.16(‐0.02,0.73) | |
| LD RITUX IV + MTX | 0.49(0.16,1.62) | 0.51(0.17,1.57) | ‐0.03(‐0.10,0.03) | |
| LD ABA IV + MTX | 1.06(0.31,3.65) | 1.06(0.32,3.22) | 0.00(‐0.07,0.13) | |
| LD CERTO SC + MTX | 1.27(0.16,6.01) | 1.25(0.17,4.79) | 0.01(‐0.08,0.22) | |
| LD ETN SC + MTX | 0.44(0.12,1.66) | 0.46(0.13,1.60) | ‐0.03(‐0.11,0.03) | |
| LD GOLI IV + MTX | 2.40(0.27,37.95) | 2.18(0.29,14.36) | 0.07(‐0.04,0.62) | |
| HD TOCI IV | 0.78(0.28,2.22) | 0.79(0.30,2.09) | ‐0.01(‐0.08,0.06) | |
| HD TOFA PO | 0.23(0.06,0.95) | 0.24(0.07,0.95) | ‐0.04(‐0.15,0.00) | |
| HD ADA SC | 0.56(0.16,1.80) | 0.58(0.18,1.76) | ‐0.02(‐0.12,0.02) | |
| HD GOLI SC | 1.20(0.23,5.00) | 1.18(0.24,4.19) | 0.01(‐0.08,0.18) | |
| HD GOLI SC + MTX | 2.59(0.65,10.42) | 2.33(0.66,7.23) | 0.08(‐0.02,0.34) | |
| HD TOCI IV + MTX | 0.90(0.28,3.12) | 0.91(0.29,2.81) | 0.00(‐0.07,0.10) | |
| HD TOFA PO + MTX | 1.68(0.46,6.35) | 1.60(0.47,5.13) | 0.03(‐0.04,0.21) | |
| HD CERTO SC + MTX | 1.67(0.56,5.34) | 1.59(0.58,4.41) | 0.03(‐0.04,0.20) | |
| HD INF IV + MTX | 0.86(0.27,2.78) | 0.86(0.29,2.57) | ‐0.01(‐0.08,0.09) | |
| HD TOCI IV + DMARD | 0.56(0.17,1.71) | 0.58(0.18,1.64) | ‐0.02(‐0.09,0.04) | |
| SD CERTO SC + DMARD | SD ADA SC + DMARD | 0.96(0.21,4.43) | 0.96(0.22,4.25) | 0.00(‐0.04,0.05) |
| LD ADA SC | 1.42(0.23,7.43) | 1.41(0.24,7.19) | 0.01(‐0.05,0.04) | |
| LD ETN SC | 2.62(0.66,11.84) | 2.53(0.67,10.82) | 0.02(‐0.01,0.12) | |
| LD GOLI IV | 16.18(1.71,259.20) | 12.00(1.68,79.82) | 0.21(0.01,0.77) | |
| LD RITUX IV + MTX | 1.90(0.46,7.60) | 1.86(0.47,7.17) | 0.01(‐0.02,0.08) | |
| LD ABA IV + MTX | 4.02(1.00,17.26) | 3.79(1.00,15.13) | 0.04(0.00,0.19) | |
| LD CERTO SC + MTX | 4.78(0.53,27.51) | 4.41(0.54,22.26) | 0.05(‐0.01,0.28) | |
| LD ETN SC + MTX | 1.66(0.37,8.11) | 1.64(0.37,7.66) | 0.01(‐0.03,0.09) | |
| LD GOLI IV + MTX | 9.11(0.93,166.80) | 7.76(0.94,66.04) | 0.12(0.00,0.68) | |
| HD TOCI IV | 2.93(1.03,9.02) | 2.82(1.03,8.43) | 0.03(0.00,0.11) | |
| HD TOFA PO | 0.90(0.16,5.31) | 0.91(0.17,5.21) | 0.00(‐0.06,0.02) | |
| HD ADA SC | 2.14(0.38,10.97) | 2.09(0.40,10.50) | 0.02(‐0.04,0.06) | |
| HD GOLI SC | 4.36(0.71,27.18) | 4.07(0.72,21.91) | 0.05(‐0.01,0.25) | |
| HD GOLI SC + MTX | 9.74(2.04,52.03) | 8.24(1.95,37.68) | 0.12(0.02,0.40) | |
| HD TOCI IV + MTX | 3.47(0.97,13.17) | 3.28(0.97,11.99) | 0.04(0.00,0.16) | |
| HD TOFA PO + MTX | 6.38(1.50,28.50) | 5.71(1.47,22.87) | 0.08(0.01,0.27) | |
| HD CERTO SC + MTX | 6.48(1.48,26.19) | 5.82(1.45,21.42) | 0.08(0.01,0.27) | |
| HD INF IV + MTX | 3.28(0.81,13.81) | 3.14(0.81,12.75) | 0.03(‐0.01,0.14) | |
| HD TOCI IV + DMARD | 2.08(0.79,5.83) | 2.04(0.80,5.57) | 0.02(‐0.01,0.08) | |
| LD ADA SC | SD CERTO SC + DMARD | 1.43(0.20,9.17) | 1.42(0.21,8.89) | 0.01(‐0.06,0.04) |
| LD ETN SC | 2.83(0.50,17.09) | 2.73(0.51,15.83) | 0.02(‐0.03,0.13) | |
| LD GOLI IV | 17.55(1.27,287.30) | 12.83(1.26,94.88) | 0.20(0.00,0.77) | |
| LD RITUX IV + MTX | 2.03(0.33,10.35) | 1.99(0.34,9.84) | 0.01(‐0.04,0.08) | |
| LD ABA IV + MTX | 4.36(0.63,25.11) | 4.09(0.64,21.71) | 0.04(‐0.01,0.20) | |
| LD CERTO SC + MTX | 4.87(0.42,40.97) | 4.50(0.43,32.29) | 0.05(‐0.02,0.29) | |
| LD ETN SC + MTX | 1.74(0.28,11.44) | 1.72(0.29,10.66) | 0.01(‐0.04,0.09) | |
| LD GOLI IV + MTX | 10.24(0.72,172.80) | 8.78(0.73,73.72) | 0.12(‐0.01,0.67) | |
| HD TOCI IV | 3.11(0.74,13.65) | 2.98(0.75,12.82) | 0.03(‐0.01,0.12) | |
| HD TOFA PO | 0.89(0.14,6.81) | 0.90(0.15,6.69) | 0.00(‐0.07,0.02) | |
| HD ADA SC | 2.20(0.35,13.64) | 2.16(0.36,13.11) | 0.02(‐0.05,0.06) | |
| HD GOLI SC | 4.77(0.54,33.58) | 4.46(0.55,28.50) | 0.05(‐0.02,0.25) | |
| HD GOLI SC + MTX | 10.91(1.43,69.85) | 9.17(1.39,51.80) | 0.12(0.01,0.40) | |
| HD TOCI IV + MTX | 3.60(0.73,19.77) | 3.42(0.74,17.76) | 0.04(‐0.01,0.16) | |
| HD TOFA PO + MTX | 6.65(1.16,39.61) | 5.97(1.15,33.50) | 0.08(0.00,0.27) | |
| HD CERTO SC + MTX | 6.65(1.12,35.45) | 6.00(1.11,29.35) | 0.08(0.00,0.27) | |
| HD INF IV + MTX | 3.54(0.55,18.29) | 3.37(0.56,16.76) | 0.03(‐0.02,0.14) | |
| HD TOCI IV + DMARD | 2.20(0.57,9.58) | 2.14(0.58,9.14) | 0.02(‐0.02,0.08) | |
| LD ETN SC | LD ADA SC | 1.89(0.42,10.33) | 1.85(0.43,9.07) | 0.02(‐0.02,0.13) |
| LD GOLI IV | 13.34(0.97,180.00) | 10.13(0.97,49.19) | 0.20(0.00,0.77) | |
| LD RITUX IV + MTX | 1.35(0.30,7.16) | 1.34(0.31,6.55) | 0.01(‐0.03,0.09) | |
| LD ABA IV + MTX | 2.89(0.58,15.87) | 2.76(0.59,13.02) | 0.04(‐0.01,0.20) | |
| LD CERTO SC + MTX | 3.42(0.37,24.54) | 3.21(0.38,17.98) | 0.05(‐0.02,0.29) | |
| LD ETN SC + MTX | 1.16(0.23,6.78) | 1.16(0.23,6.22) | 0.00(‐0.03,0.09) | |
| LD GOLI IV + MTX | 7.43(0.45,113.80) | 6.40(0.46,40.22) | 0.12(‐0.01,0.67) | |
| HD TOCI IV | 2.10(0.51,10.85) | 2.05(0.52,9.53) | 0.02(‐0.02,0.14) | |
| HD TOFA PO | 0.64(0.21,2.12) | 0.64(0.21,2.08) | ‐0.01(‐0.04,0.01) | |
| HD ADA SC | 1.53(0.68,3.54) | 1.51(0.69,3.40) | 0.01(‐0.01,0.04) | |
| HD GOLI SC | 3.25(0.50,19.74) | 3.07(0.51,15.16) | 0.05(‐0.02,0.25) | |
| HD GOLI SC + MTX | 7.31(1.33,41.87) | 6.35(1.32,26.06) | 0.12(0.01,0.41) | |
| HD TOCI IV + MTX | 2.46(0.52,14.10) | 2.38(0.53,11.88) | 0.03(‐0.01,0.18) | |
| HD TOFA PO + MTX | 4.64(0.90,24.96) | 4.24(0.90,18.78) | 0.08(0.00,0.28) | |
| HD CERTO SC + MTX | 4.57(1.08,25.10) | 4.20(1.08,18.91) | 0.07(0.00,0.28) | |
| HD INF IV + MTX | 2.34(0.52,12.01) | 2.27(0.53,10.29) | 0.03(‐0.01,0.16) | |
| HD TOCI IV + DMARD | 1.49(0.32,8.08) | 1.48(0.33,7.24) | 0.01(‐0.02,0.11) | |
| LD GOLI IV | LD ETN SC | 5.85(0.87,122.00) | 4.57(0.87,31.29) | 0.17(0.00,0.75) |
| LD RITUX IV + MTX | 0.68(0.24,2.34) | 0.69(0.26,2.23) | ‐0.01(‐0.09,0.04) | |
| LD ABA IV + MTX | 1.49(0.47,5.17) | 1.45(0.49,4.57) | 0.02(‐0.05,0.14) | |
| LD CERTO SC + MTX | 1.85(0.25,8.58) | 1.77(0.26,7.16) | 0.03(‐0.06,0.23) | |
| LD ETN SC + MTX | 0.62(0.16,2.50) | 0.63(0.18,2.40) | ‐0.01(‐0.10,0.05) | |
| LD GOLI IV + MTX | 3.32(0.45,69.20) | 2.95(0.47,25.84) | 0.08(‐0.03,0.64) | |
| HD TOCI IV | 1.11(0.36,3.54) | 1.10(0.38,3.31) | 0.00(‐0.07,0.08) | |
| HD TOFA PO | 0.33(0.07,1.76) | 0.34(0.08,1.73) | ‐0.03(‐0.14,0.01) | |
| HD ADA SC | 0.80(0.15,3.82) | 0.80(0.17,3.69) | ‐0.01(‐0.12,0.04) | |
| HD GOLI SC | 1.59(0.33,7.69) | 1.54(0.35,6.42) | 0.02(‐0.06,0.20) | |
| HD GOLI SC + MTX | 3.67(0.94,15.33) | 3.20(0.95,11.05) | 0.09(0.00,0.35) | |
| HD TOCI IV + MTX | 1.29(0.37,4.83) | 1.27(0.39,4.39) | 0.01(‐0.06,0.12) | |
| HD TOFA PO + MTX | 2.34(0.64,8.99) | 2.19(0.66,7.42) | 0.05(‐0.02,0.23) | |
| HD CERTO SC + MTX | 2.38(0.72,7.52) | 2.22(0.75,6.48) | 0.05(‐0.02,0.21) | |
| HD INF IV + MTX | 1.20(0.41,3.91) | 1.19(0.44,3.64) | 0.01(‐0.06,0.09) | |
| HD TOCI IV + DMARD | 0.81(0.21,2.75) | 0.82(0.23,2.61) | ‐0.01(‐0.09,0.05) | |
| LD RITUX IV + MTX | LD GOLI IV | 0.12(0.01,0.67) | 0.16(0.02,0.68) | ‐0.19(‐0.76,‐0.01) |
| LD ABA IV + MTX | 0.25(0.02,1.57) | 0.31(0.06,1.51) | ‐0.15(‐0.72,0.03) | |
| LD CERTO SC + MTX | 0.29(0.01,2.81) | 0.37(0.03,2.66) | ‐0.13(‐0.74,0.10) | |
| LD ETN SC + MTX | 0.10(0.00,0.76) | 0.14(0.02,0.77) | ‐0.19(‐0.77,0.00) | |
| LD GOLI IV + MTX | 0.59(0.15,1.96) | 0.69(0.22,1.66) | ‐0.06(‐0.34,0.11) | |
| HD TOCI IV | 0.19(0.01,1.30) | 0.24(0.04,1.29) | ‐0.17(‐0.74,0.01) | |
| HD TOFA PO | 0.05(0.00,0.85) | 0.07(0.01,0.85) | ‐0.21(‐0.78,0.00) | |
| HD ADA SC | 0.11(0.01,1.72) | 0.15(0.04,1.69) | ‐0.19(‐0.75,0.02) | |
| HD GOLI SC | 0.27(0.02,1.97) | 0.34(0.04,1.83) | ‐0.14(‐0.71,0.06) | |
| HD GOLI SC + MTX | 0.61(0.04,3.92) | 0.69(0.15,3.19) | ‐0.06(‐0.63,0.19) | |
| HD TOCI IV + MTX | 0.22(0.01,1.51) | 0.28(0.04,1.48) | ‐0.16(‐0.74,0.02) | |
| HD TOFA PO + MTX | 0.38(0.02,3.10) | 0.47(0.08,2.83) | ‐0.12(‐0.70,0.10) | |
| HD CERTO SC + MTX | 0.40(0.02,2.81) | 0.48(0.07,2.58) | ‐0.11(‐0.71,0.08) | |
| HD INF IV + MTX | 0.20(0.01,1.24) | 0.26(0.04,1.22) | ‐0.17(‐0.74,0.01) | |
| HD TOCI IV + DMARD | 0.13(0.01,1.13) | 0.17(0.03,1.13) | ‐0.18(‐0.75,0.00) | |
| LD ABA IV + MTX | LD RITUX IV + MTX | 2.17(0.77,6.04) | 2.08(0.78,5.48) | 0.03(‐0.01,0.15) |
| LD CERTO SC + MTX | 2.60(0.36,10.41) | 2.45(0.37,8.54) | 0.04(‐0.03,0.24) | |
| LD ETN SC + MTX | 0.91(0.25,2.83) | 0.92(0.26,2.71) | 0.00(‐0.06,0.05) | |
| LD GOLI IV + MTX | 4.82(0.79,95.19) | 4.16(0.80,34.24) | 0.10(0.00,0.66) | |
| HD TOCI IV | 1.58(0.58,4.42) | 1.54(0.60,4.17) | 0.01(‐0.03,0.09) | |
| HD TOFA PO | 0.47(0.10,2.50) | 0.47(0.11,2.47) | ‐0.01(‐0.10,0.01) | |
| HD ADA SC | 1.12(0.23,5.97) | 1.11(0.25,5.74) | 0.00(‐0.08,0.05) | |
| HD GOLI SC | 2.36(0.53,9.25) | 2.24(0.54,7.73) | 0.03(‐0.02,0.21) | |
| HD GOLI SC + MTX | 5.23(1.59,18.35) | 4.50(1.54,13.09) | 0.11(0.01,0.37) | |
| HD TOCI IV + MTX | 1.86(0.62,5.73) | 1.80(0.63,5.25) | 0.02(‐0.02,0.13) | |
| HD TOFA PO + MTX | 3.43(1.05,10.42) | 3.14(1.04,8.72) | 0.07(0.00,0.24) | |
| HD CERTO SC + MTX | 3.44(1.27,9.01) | 3.15(1.25,7.74) | 0.06(0.01,0.23) | |
| HD INF IV + MTX | 1.75(0.67,4.42) | 1.70(0.68,4.11) | 0.02(‐0.02,0.10) | |
| HD TOCI IV + DMARD | 1.12(0.31,3.79) | 1.11(0.32,3.58) | 0.00(‐0.05,0.07) | |
| LD CERTO SC + MTX | LD ABA IV + MTX | 1.20(0.17,5.21) | 1.18(0.18,4.38) | 0.01(‐0.11,0.19) |
| LD ETN SC + MTX | 0.41(0.11,1.43) | 0.43(0.13,1.40) | ‐0.03(‐0.16,0.02) | |
| LD GOLI IV + MTX | 2.28(0.37,32.76) | 2.08(0.40,12.94) | 0.06(‐0.08,0.61) | |
| HD TOCI IV | 0.73(0.24,2.17) | 0.75(0.27,2.08) | ‐0.01(‐0.13,0.05) | |
| HD TOFA PO | 0.21(0.04,1.39) | 0.22(0.05,1.39) | ‐0.05(‐0.21,0.01) | |
| HD ADA SC | 0.52(0.10,3.23) | 0.54(0.12,3.11) | ‐0.03(‐0.19,0.03) | |
| HD GOLI SC | 1.08(0.24,4.61) | 1.08(0.27,3.93) | 0.00(‐0.11,0.16) | |
| HD GOLI SC + MTX | 2.42(0.71,8.77) | 2.17(0.74,6.58) | 0.07(‐0.03,0.32) | |
| HD TOCI IV + MTX | 0.86(0.26,2.93) | 0.87(0.28,2.71) | ‐0.01(‐0.12,0.08) | |
| HD TOFA PO + MTX | 1.58(0.46,5.21) | 1.50(0.49,4.41) | 0.03(‐0.06,0.18) | |
| HD CERTO SC + MTX | 1.56(0.55,4.52) | 1.49(0.58,3.98) | 0.03(‐0.06,0.17) | |
| HD INF IV + MTX | 0.81(0.29,2.28) | 0.82(0.32,2.16) | ‐0.01(‐0.11,0.05) | |
| HD TOCI IV + DMARD | 0.52(0.13,1.90) | 0.54(0.15,1.84) | ‐0.03(‐0.16,0.03) | |
| LD ETN SC + MTX | LD CERTO SC + MTX | 0.34(0.07,2.73) | 0.36(0.09,2.64) | ‐0.04(‐0.25,0.03) |
| LD GOLI IV + MTX | 1.95(0.20,68.80) | 1.79(0.23,28.25) | 0.05(‐0.16,0.63) | |
| HD TOCI IV | 0.61(0.14,4.32) | 0.63(0.17,4.11) | ‐0.02(‐0.23,0.07) | |
| HD TOFA PO | 0.19(0.03,1.86) | 0.20(0.03,1.84) | ‐0.06(‐0.30,0.01) | |
| HD ADA SC | 0.44(0.07,4.81) | 0.46(0.09,4.54) | ‐0.04(‐0.28,0.04) | |
| HD GOLI SC | 0.94(0.14,8.93) | 0.94(0.16,7.66) | 0.00(‐0.20,0.16) | |
| HD GOLI SC + MTX | 2.09(0.37,17.72) | 1.88(0.42,13.69) | 0.06(‐0.12,0.31) | |
| HD TOCI IV + MTX | 0.72(0.15,4.92) | 0.74(0.18,4.57) | ‐0.02(‐0.22,0.09) | |
| HD TOFA PO + MTX | 1.33(0.26,9.72) | 1.29(0.30,8.11) | 0.02(‐0.16,0.20) | |
| HD CERTO SC + MTX | 1.29(0.38,6.96) | 1.26(0.43,6.26) | 0.02(‐0.12,0.15) | |
| HD INF IV + MTX | 0.67(0.16,4.26) | 0.70(0.19,3.98) | ‐0.02(‐0.21,0.07) | |
| HD TOCI IV + DMARD | 0.44(0.09,3.58) | 0.46(0.11,3.45) | ‐0.04(‐0.25,0.04) | |
| LD GOLI IV + MTX | LD ETN SC + MTX | 5.52(0.74,109.30) | 4.70(0.74,40.75) | 0.10(‐0.01,0.66) |
| HD TOCI IV | 1.79(0.49,6.20) | 1.74(0.51,5.76) | 0.02(‐0.04,0.10) | |
| HD TOFA PO | 0.55(0.08,3.44) | 0.55(0.09,3.39) | ‐0.01(‐0.10,0.02) | |
| HD ADA SC | 1.28(0.24,6.59) | 1.27(0.26,6.37) | 0.01(‐0.08,0.05) | |
| HD GOLI SC | 2.57(0.48,14.56) | 2.44(0.50,12.02) | 0.04(‐0.03,0.23) | |
| HD GOLI SC + MTX | 5.95(1.41,26.39) | 5.10(1.38,19.11) | 0.11(0.01,0.38) | |
| HD TOCI IV + MTX | 2.11(0.52,8.39) | 2.03(0.54,7.44) | 0.02(‐0.03,0.14) | |
| HD TOFA PO + MTX | 3.80(1.00,16.97) | 3.45(1.00,13.75) | 0.07(0.00,0.25) | |
| HD CERTO SC + MTX | 3.74(1.16,14.09) | 3.42(1.15,12.04) | 0.06(0.01,0.24) | |
| HD INF IV + MTX | 1.90(0.62,6.79) | 1.85(0.63,6.26) | 0.02(‐0.02,0.11) | |
| HD TOCI IV + DMARD | 1.27(0.30,5.18) | 1.26(0.32,4.84) | 0.01(‐0.06,0.08) | |
| HD TOCI IV | LD GOLI IV + MTX | 0.33(0.02,2.33) | 0.37(0.05,2.28) | ‐0.08(‐0.64,0.03) |
| HD TOFA PO | 0.09(0.01,1.73) | 0.10(0.01,1.72) | ‐0.12(‐0.69,0.01) | |
| HD ADA SC | 0.21(0.02,3.37) | 0.24(0.04,3.27) | ‐0.10(‐0.66,0.03) | |
| HD GOLI SC | 0.48(0.03,3.51) | 0.52(0.06,3.22) | ‐0.05(‐0.61,0.11) | |
| HD GOLI SC + MTX | 1.11(0.08,7.30) | 1.09(0.18,5.87) | 0.01(‐0.52,0.26) | |
| HD TOCI IV + MTX | 0.39(0.02,2.70) | 0.43(0.05,2.60) | ‐0.07(‐0.64,0.05) | |
| HD TOFA PO + MTX | 0.67(0.03,5.31) | 0.71(0.09,4.94) | ‐0.03(‐0.59,0.15) | |
| HD CERTO SC + MTX | 0.69(0.03,5.01) | 0.73(0.08,4.55) | ‐0.03(‐0.60,0.13) | |
| HD INF IV + MTX | 0.36(0.02,2.11) | 0.40(0.05,2.03) | ‐0.08(‐0.62,0.04) | |
| HD TOCI IV + DMARD | 0.23(0.01,2.04) | 0.27(0.04,2.00) | ‐0.10(‐0.66,0.02) | |
| HD TOFA PO | HD TOCI IV | 0.29(0.07,1.56) | 0.30(0.08,1.55) | ‐0.03(‐0.14,0.01) |
| HD ADA SC | 0.72(0.16,3.15) | 0.73(0.18,3.03) | ‐0.01(‐0.12,0.04) | |
| HD GOLI SC | 1.49(0.31,6.74) | 1.45(0.32,5.68) | 0.02(‐0.06,0.19) | |
| HD GOLI SC + MTX | 3.31(0.97,12.50) | 2.91(0.98,8.99) | 0.09(0.00,0.35) | |
| HD TOCI IV + MTX | 1.16(0.55,2.52) | 1.15(0.57,2.34) | 0.01(‐0.04,0.08) | |
| HD TOFA PO + MTX | 2.16(0.68,6.69) | 2.02(0.70,5.58) | 0.05(‐0.02,0.22) | |
| HD CERTO SC + MTX | 2.19(0.73,6.02) | 2.06(0.74,5.12) | 0.04(‐0.02,0.21) | |
| HD INF IV + MTX | 1.10(0.39,3.12) | 1.10(0.41,2.85) | 0.00(‐0.06,0.09) | |
| HD TOCI IV + DMARD | 0.72(0.28,1.73) | 0.73(0.30,1.67) | ‐0.01(‐0.08,0.03) | |
| HD ADA SC | HD TOFA PO | 2.36(0.77,7.53) | 2.32(0.77,7.13) | 0.02(‐0.01,0.06) |
| HD GOLI SC | 5.11(0.67,28.98) | 4.80(0.68,22.31) | 0.05(‐0.01,0.26) | |
| HD GOLI SC + MTX | 11.88(1.52,62.49) | 10.12(1.50,40.49) | 0.13(0.01,0.42) | |
| HD TOCI IV + MTX | 4.05(0.67,19.24) | 3.85(0.68,16.06) | 0.04(‐0.01,0.18) | |
| HD TOFA PO + MTX | 7.48(1.14,35.73) | 6.75(1.14,27.02) | 0.09(0.00,0.29) | |
| HD CERTO SC + MTX | 7.27(1.36,33.78) | 6.61(1.35,25.82) | 0.08(0.01,0.29) | |
| HD INF IV + MTX | 3.73(0.64,18.72) | 3.58(0.65,16.11) | 0.04(‐0.01,0.16) | |
| HD TOCI IV + DMARD | 2.47(0.42,11.88) | 2.41(0.43,10.69) | 0.02(‐0.01,0.11) | |
| HD GOLI SC | HD ADA SC | 2.15(0.30,12.14) | 2.07(0.31,9.45) | 0.03(‐0.03,0.24) |
| HD GOLI SC + MTX | 4.89(0.75,23.04) | 4.28(0.75,15.01) | 0.11(‐0.01,0.40) | |
| HD TOCI IV + MTX | 1.66(0.32,8.66) | 1.63(0.33,7.37) | 0.02(‐0.03,0.17) | |
| HD TOFA PO + MTX | 3.17(0.57,14.30) | 2.92(0.58,10.85) | 0.07(‐0.02,0.27) | |
| HD CERTO SC + MTX | 3.05(0.68,14.59) | 2.82(0.69,10.97) | 0.06(‐0.01,0.27) | |
| HD INF IV + MTX | 1.57(0.30,7.33) | 1.54(0.31,6.34) | 0.02(‐0.04,0.14) | |
| HD TOCI IV + DMARD | 0.99(0.22,4.96) | 0.99(0.23,4.47) | 0.00(‐0.04,0.09) | |
| HD GOLI SC + MTX | HD GOLI SC | 2.28(0.71,8.29) | 2.04(0.75,6.87) | 0.07(‐0.03,0.28) |
| HD TOCI IV + MTX | 0.80(0.16,4.19) | 0.81(0.19,3.84) | ‐0.01(‐0.18,0.10) | |
| HD TOFA PO + MTX | 1.47(0.31,7.45) | 1.40(0.35,6.40) | 0.02(‐0.12,0.19) | |
| HD CERTO SC + MTX | 1.44(0.34,6.72) | 1.38(0.38,5.78) | 0.02(‐0.12,0.18) | |
| HD INF IV + MTX | 0.74(0.19,3.34) | 0.76(0.22,3.13) | ‐0.01(‐0.18,0.07) | |
| HD TOCI IV + DMARD | 0.47(0.09,2.69) | 0.49(0.10,2.57) | ‐0.03(‐0.22,0.04) | |
| HD TOCI IV + MTX | HD GOLI SC + MTX | 0.36(0.08,1.32) | 0.40(0.12,1.28) | ‐0.08(‐0.34,0.02) |
| HD TOFA PO + MTX | 0.62(0.16,2.68) | 0.67(0.20,2.37) | ‐0.04(‐0.26,0.12) | |
| HD CERTO SC + MTX | 0.63(0.18,2.17) | 0.67(0.23,1.99) | ‐0.04(‐0.27,0.09) | |
| HD INF IV + MTX | 0.33(0.10,1.06) | 0.38(0.13,1.06) | ‐0.09(‐0.33,0.00) | |
| HD TOCI IV + DMARD | 0.21(0.05,0.91) | 0.25(0.06,0.91) | ‐0.10(‐0.37,0.00) | |
| HD TOFA PO + MTX | HD TOCI IV + MTX | 1.88(0.49,6.42) | 1.77(0.51,5.44) | 0.04(‐0.05,0.21) |
| HD CERTO SC + MTX | 1.84(0.57,5.76) | 1.74(0.60,4.89) | 0.04(‐0.04,0.19) | |
| HD INF IV + MTX | 0.93(0.30,2.85) | 0.93(0.32,2.68) | 0.00(‐0.10,0.08) | |
| HD TOCI IV + DMARD | 0.61(0.19,1.90) | 0.62(0.21,1.83) | ‐0.02(‐0.12,0.03) | |
| HD CERTO SC + MTX | HD TOFA PO + MTX | 1.00(0.31,3.23) | 1.00(0.37,2.90) | 0.00(‐0.14,0.12) |
| HD INF IV + MTX | 0.51(0.17,1.59) | 0.54(0.21,1.54) | ‐0.04(‐0.20,0.02) | |
| HD TOCI IV + DMARD | 0.33(0.09,1.24) | 0.36(0.11,1.23) | ‐0.06(‐0.24,0.01) | |
| HD INF IV + MTX | HD CERTO SC + MTX | 0.51(0.19,1.40) | 0.55(0.22,1.36) | ‐0.04(‐0.19,0.02) |
| HD TOCI IV + DMARD | 0.33(0.09,1.13) | 0.35(0.11,1.12) | ‐0.06(‐0.24,0.01) | |
| HD TOCI IV + DMARD | HD INF IV + MTX | 0.65(0.18,2.20) | 0.67(0.20,2.11) | ‐0.01(‐0.11,0.04) |
| Random‐effect model | Residual deviance | 125.1 vs 127 data points | ||
| Deviance information criteria | 688.58 | |||
| Fixed‐effect model | Residual deviance | 130.2 vs 127 data points | ||
| Deviance information criteria | 689.019 | |||
| Note | ||||
| Total participants | 22,022 | |||
| Total studies | 50 | |||
| 2‐arm | 30 | |||
| 3‐arm | 14 | |||
| 4‐arm | 5 | |||
| 5‐arm | 1 | |||
Appendix 22. Serious adverse events: subgroup ‐ late RA (> 10 years)
| SAE late: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD RITUX IV | MTX + PL | 0.79(0.09,4.27) | 0.80(0.09,3.70) | ‐0.01(‐0.06,0.13) |
| SD RITUX IV + MTX | 2.02(0.71,5.91) | 1.90(0.72,4.90) | 0.05(‐0.02,0.17) | |
| SD INF IV + MTX | 0.48(0.16,1.42) | 0.50(0.17,1.39) | ‐0.03(‐0.06,0.02) | |
| SD ANA SC + MTX | 1.26(0.39,4.26) | 1.24(0.41,3.65) | 0.01(‐0.04,0.14) | |
| LD RITUX IV + MTX | 2.67(0.96,7.84) | 2.43(0.96,6.09) | 0.08(0.00,0.22) | |
| HD INF IV + MTX | 0.94(0.35,2.57) | 0.94(0.36,2.37) | 0.00(‐0.04,0.07) | |
| SD RITUX IV + MTX | SD RITUX IV | 2.56(0.50,21.54) | 2.38(0.55,18.75) | 0.06(‐0.07,0.17) |
| SD INF IV + MTX | 0.61(0.08,6.91) | 0.62(0.10,6.58) | ‐0.02(‐0.15,0.05) | |
| SD ANA SC + MTX | 1.61(0.20,19.67) | 1.56(0.23,17.05) | 0.02(‐0.12,0.16) | |
| LD RITUX IV + MTX | 3.39(0.68,28.39) | 3.03(0.72,23.75) | 0.09(‐0.04,0.22) | |
| HD INF IV + MTX | 1.20(0.17,12.80) | 1.19(0.19,11.66) | 0.01(‐0.13,0.10) | |
| SD INF IV + MTX | SD RITUX IV + MTX | 0.24(0.05,1.10) | 0.26(0.06,1.09) | ‐0.08(‐0.19,0.01) |
| SD ANA SC + MTX | 0.63(0.13,3.18) | 0.65(0.15,2.79) | ‐0.04(‐0.17,0.11) | |
| LD RITUX IV + MTX | 1.32(0.54,3.31) | 1.27(0.58,2.84) | 0.03(‐0.07,0.14) | |
| HD INF IV + MTX | 0.47(0.11,1.98) | 0.50(0.13,1.87) | ‐0.05(‐0.18,0.05) | |
| SD ANA SC + MTX | SD INF IV + MTX | 2.61(0.54,13.70) | 2.49(0.56,11.58) | 0.04(‐0.03,0.17) |
| LD RITUX IV + MTX | 5.58(1.23,25.49) | 4.91(1.21,19.87) | 0.11(0.01,0.25) | |
| HD INF IV + MTX | 1.95(0.65,5.91) | 1.89(0.67,5.46) | 0.02(‐0.02,0.09) | |
| LD RITUX IV + MTX | SD ANA SC + MTX | 2.13(0.43,10.31) | 1.97(0.48,8.18) | 0.07(‐0.09,0.22) |
| HD INF IV + MTX | 0.74(0.15,3.47) | 0.76(0.18,3.20) | ‐0.02(‐0.15,0.08) | |
| HD INF IV + MTX | LD RITUX IV + MTX | 0.35(0.08,1.48) | 0.39(0.10,1.42) | ‐0.08(‐0.23,0.03) |
| Random‐effects model | Residual deviance | 11.23 vs 12 data points | ||
| Deviance information criteria | 65.874 | |||
| Fixed‐effect model | Residual deviance | 11.24 vs 12 data points | ||
| Deviance information criteria | 65.611 | |||
| Note | ||||
| Total participants | 1390 | |||
| Total studies | 4 | |||
| 2‐arm | 1 | |||
| 3‐arm | 2 | |||
| 4‐arm | 1 | |||
Appendix 23. Serious adverse events: subgroup ‐ trial duration (<= 6 months) network 1
| SAE short, network 1: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| DMARD + PL | PL | 0.96(0.14,6.18) | 0.96(0.15,5.17) | 0.00(‐0.04,0.15) |
| MTX + DMARD | 0.93(0.06,13.23) | 0.93(0.06,9.40) | 0.00(‐0.04,0.28) | |
| SD ADA SC | 1.11(0.59,2.11) | 1.11(0.60,2.04) | 0.00(‐0.02,0.04) | |
| SD ETN SC | 1.62(0.21,13.99) | 1.58(0.22,9.90) | 0.02(‐0.03,0.29) | |
| SD TOC IV + PL SC | 1.27(0.41,3.80) | 1.26(0.42,3.48) | 0.01(‐0.02,0.09) | |
| SD TOFA PO | 0.39(0.14,1.05) | 0.40(0.14,1.05) | ‐0.02(‐0.04,0.00) | |
| SD CERTO SC | 4.43(1.10,21.91) | 3.94(1.10,13.92) | 0.10(0.00,0.37) | |
| SD TOC SC + PL IV | 1.10(0.26,4.60) | 1.09(0.27,4.06) | 0.00(‐0.03,0.11) | |
| SD ETN SC + MTX | 1.66(0.15,21.12) | 1.62(0.16,13.16) | 0.02(‐0.04,0.38) | |
| SD ETN SC + DMARD | 1.45(0.29,6.57) | 1.42(0.30,5.47) | 0.01(‐0.03,0.16) | |
| SD ADA SC + DMARD | 0.67(0.08,5.30) | 0.68(0.08,4.61) | ‐0.01(‐0.04,0.13) | |
| SD ANA + DMARD | 0.95(0.12,7.22) | 0.95(0.12,5.96) | 0.00(‐0.04,0.18) | |
| SD CERTO SC + DMARD | 0.66(0.06,6.85) | 0.67(0.06,5.67) | ‐0.01(‐0.04,0.17) | |
| SD TOCI SC + DMARD | 1.25(0.14,10.79) | 1.23(0.14,8.01) | 0.01(‐0.04,0.25) | |
| LD ADA SC | 0.65(0.25,1.49) | 0.66(0.26,1.47) | ‐0.01(‐0.03,0.02) | |
| HD TOFA PO | 0.53(0.22,1.37) | 0.54(0.22,1.35) | ‐0.02(‐0.04,0.01) | |
| HD ADA SC | 1.00(0.45,2.30) | 1.00(0.46,2.21) | 0.00(‐0.02,0.04) | |
| HD TOCI IV + DMARD | 1.47(0.20,10.44) | 1.45(0.21,7.81) | 0.02(‐0.03,0.25) | |
| MTX + DMARD | DMARD + PL | 0.91(0.04,25.54) | 0.91(0.04,19.57) | 0.00(‐0.15,0.27) |
| SD ADA SC | 1.18(0.20,7.16) | 1.18(0.24,6.85) | 0.01(‐0.14,0.05) | |
| SD ETN SC | 1.63(0.11,29.72) | 1.59(0.13,22.57) | 0.02(‐0.13,0.28) | |
| SD TOC IV + PL SC | 1.34(0.18,10.39) | 1.33(0.21,9.65) | 0.01(‐0.13,0.09) | |
| SD TOFA PO | 0.40(0.04,3.31) | 0.41(0.05,3.25) | ‐0.02(‐0.18,0.02) | |
| SD CERTO SC | 4.76(0.43,57.12) | 4.15(0.49,40.20) | 0.10(‐0.08,0.37) | |
| SD TOC SC + PL IV | 1.18(0.14,10.56) | 1.17(0.16,9.81) | 0.00(‐0.14,0.10) | |
| SD ETN SC + MTX | 1.71(0.09,40.13) | 1.65(0.10,28.01) | 0.02(‐0.12,0.37) | |
| SD ETN SC + DMARD | 1.52(0.57,4.02) | 1.48(0.60,3.82) | 0.01(‐0.04,0.08) | |
| SD ADA SC + DMARD | 0.70(0.25,1.88) | 0.71(0.26,1.80) | ‐0.01(‐0.07,0.04) | |
| SD ANA + DMARD | 1.00(0.42,2.36) | 1.00(0.44,2.21) | 0.00(‐0.04,0.07) | |
| SD CERTO SC + DMARD | 0.69(0.15,2.76) | 0.71(0.16,2.55) | ‐0.01(‐0.08,0.08) | |
| SD TOCI SC + DMARD | 1.29(0.46,4.02) | 1.28(0.47,3.50) | 0.01(‐0.03,0.15) | |
| LD ADA SC | 0.68(0.09,5.06) | 0.69(0.11,4.90) | ‐0.01(‐0.16,0.03) | |
| HD TOFA PO | 0.56(0.06,4.78) | 0.57(0.08,4.64) | ‐0.01(‐0.17,0.03) | |
| HD ADA SC | 1.04(0.16,7.57) | 1.04(0.19,7.26) | 0.00(‐0.15,0.05) | |
| HD TOCI IV + DMARD | 1.52(0.81,2.99) | 1.48(0.82,2.76) | 0.01(‐0.01,0.12) | |
| SD ADA SC | MTX + DMARD | 1.22(0.08,20.81) | 1.21(0.11,19.91) | 0.01(‐0.27,0.06) |
| SD ETN SC | 1.76(0.38,9.71) | 1.68(0.44,9.08) | 0.02(‐0.11,0.15) | |
| SD TOC IV + PL SC | 1.39(0.08,26.66) | 1.37(0.11,24.75) | 0.01(‐0.26,0.10) | |
| SD TOFA PO | 0.42(0.02,8.11) | 0.43(0.03,7.96) | ‐0.02(‐0.30,0.02) | |
| SD CERTO SC | 4.76(0.23,123.50) | 4.17(0.30,86.98) | 0.10(‐0.19,0.37) | |
| SD TOC SC + PL IV | 1.22(0.06,26.45) | 1.21(0.08,24.20) | 0.01(‐0.26,0.11) | |
| SD ETN SC + MTX | 1.81(0.63,6.63) | 1.73(0.66,6.05) | 0.02(‐0.04,0.18) | |
| SD ETN SC + DMARD | 1.64(0.07,34.32) | 1.60(0.10,30.75) | 0.02(‐0.25,0.16) | |
| SD ADA SC + DMARD | 0.74(0.02,20.69) | 0.75(0.03,18.63) | ‐0.01(‐0.28,0.13) | |
| SD ANA + DMARD | 1.12(0.04,27.80) | 1.12(0.05,24.55) | 0.00(‐0.27,0.17) | |
| SD CERTO SC + DMARD | 0.74(0.02,25.08) | 0.75(0.02,21.69) | ‐0.01(‐0.28,0.17) | |
| SD TOCI SC + DMARD | 1.44(0.04,39.90) | 1.41(0.05,33.84) | 0.01(‐0.26,0.24) | |
| LD ADA SC | 0.69(0.04,12.56) | 0.70(0.06,12.17) | ‐0.01(‐0.29,0.04) | |
| HD TOFA PO | 0.58(0.03,10.77) | 0.59(0.05,10.42) | ‐0.01(‐0.29,0.03) | |
| HD ADA SC | 1.09(0.07,21.03) | 1.08(0.09,19.95) | 0.00(‐0.28,0.06) | |
| HD TOCI IV + DMARD | 1.68(0.06,42.31) | 1.64(0.08,35.79) | 0.02(‐0.25,0.24) | |
| SD ETN SC | SD ADA SC | 1.47(0.17,13.61) | 1.44(0.17,9.75) | 0.02(‐0.05,0.28) |
| SD TOC IV + PL SC | 1.14(0.45,2.86) | 1.13(0.46,2.66) | 0.00(‐0.02,0.07) | |
| SD TOFA PO | 0.35(0.10,1.12) | 0.36(0.11,1.12) | ‐0.02(‐0.06,0.00) | |
| SD CERTO SC | 3.98(0.83,23.16) | 3.55(0.84,14.95) | 0.10(‐0.01,0.37) | |
| SD TOC SC + PL IV | 0.99(0.28,3.51) | 1.00(0.28,3.18) | 0.00(‐0.04,0.09) | |
| SD ETN SC + MTX | 1.50(0.12,19.86) | 1.47(0.13,12.19) | 0.02(‐0.05,0.38) | |
| SD ETN SC + DMARD | 1.31(0.30,5.28) | 1.29(0.31,4.51) | 0.01(‐0.03,0.15) | |
| SD ADA SC + DMARD | 0.60(0.08,4.43) | 0.61(0.08,3.83) | ‐0.01(‐0.05,0.12) | |
| SD ANA + DMARD | 0.85(0.12,6.02) | 0.85(0.12,4.95) | ‐0.01(‐0.05,0.17) | |
| SD CERTO SC + DMARD | 0.58(0.06,5.65) | 0.59(0.06,4.77) | ‐0.01(‐0.05,0.16) | |
| SD TOCI SC + DMARD | 1.11(0.14,8.73) | 1.10(0.14,6.65) | 0.00(‐0.04,0.23) | |
| LD ADA SC | 0.58(0.23,1.32) | 0.59(0.24,1.30) | ‐0.02(‐0.05,0.01) | |
| HD TOFA PO | 0.47(0.16,1.47) | 0.49(0.16,1.44) | ‐0.02(‐0.06,0.01) | |
| HD ADA SC | 0.90(0.41,1.99) | 0.90(0.42,1.93) | 0.00(‐0.03,0.03) | |
| HD TOCI IV + DMARD | 1.31(0.20,8.63) | 1.29(0.20,6.50) | 0.01(‐0.04,0.24) | |
| SD TOC IV + PL SC | SD ETN SC | 0.76(0.07,7.99) | 0.77(0.10,7.32) | ‐0.01(‐0.28,0.09) |
| SD TOFA PO | 0.23(0.02,2.47) | 0.25(0.03,2.43) | ‐0.04(‐0.31,0.01) | |
| SD CERTO SC | 2.71(0.21,39.52) | 2.44(0.27,27.00) | 0.07(‐0.21,0.36) | |
| SD TOC SC + PL IV | 0.66(0.05,7.95) | 0.67(0.07,7.18) | ‐0.02(‐0.28,0.10) | |
| SD ETN SC + MTX | 1.04(0.33,3.10) | 1.03(0.35,2.65) | 0.00(‐0.07,0.16) | |
| SD ETN SC + DMARD | 0.90(0.06,11.09) | 0.91(0.09,9.54) | 0.00(‐0.27,0.15) | |
| SD ADA SC + DMARD | 0.42(0.02,7.51) | 0.44(0.03,6.63) | ‐0.03(‐0.29,0.11) | |
| SD ANA + DMARD | 0.60(0.03,9.77) | 0.62(0.04,8.48) | ‐0.02(‐0.28,0.15) | |
| SD CERTO SC + DMARD | 0.41(0.02,9.20) | 0.42(0.02,7.82) | ‐0.03(‐0.29,0.15) | |
| SD TOCI SC + DMARD | 0.78(0.04,14.46) | 0.79(0.04,11.43) | ‐0.01(‐0.27,0.22) | |
| LD ADA SC | 0.39(0.04,3.55) | 0.41(0.05,3.45) | ‐0.03(‐0.30,0.03) | |
| HD TOFA PO | 0.32(0.03,3.15) | 0.33(0.05,3.09) | ‐0.04(‐0.30,0.02) | |
| HD ADA SC | 0.60(0.06,5.72) | 0.62(0.09,5.48) | ‐0.02(‐0.29,0.05) | |
| HD TOCI IV + DMARD | 0.94(0.05,14.51) | 0.94(0.06,11.74) | 0.00(‐0.27,0.21) | |
| SD TOFA PO | SD TOC IV + PL SC | 0.31(0.07,1.32) | 0.32(0.07,1.31) | ‐0.03(‐0.11,0.01) |
| SD CERTO SC | 3.51(0.60,25.56) | 3.13(0.62,17.15) | 0.09(‐0.03,0.36) | |
| SD TOC SC + PL IV | 0.87(0.37,2.09) | 0.88(0.38,1.98) | 0.00(‐0.04,0.05) | |
| SD ETN SC + MTX | 1.35(0.10,19.89) | 1.33(0.10,12.73) | 0.01(‐0.09,0.36) | |
| SD ETN SC + DMARD | 1.14(0.20,6.39) | 1.14(0.21,5.47) | 0.01(‐0.07,0.15) | |
| SD ADA SC + DMARD | 0.53(0.05,4.81) | 0.54(0.06,4.23) | ‐0.02(‐0.10,0.11) | |
| SD ANA + DMARD | 0.75(0.08,6.39) | 0.76(0.09,5.39) | ‐0.01(‐0.09,0.16) | |
| SD CERTO SC + DMARD | 0.51(0.04,5.99) | 0.53(0.05,5.09) | ‐0.02(‐0.10,0.15) | |
| SD TOCI SC + DMARD | 0.97(0.10,9.56) | 0.98(0.11,7.46) | 0.00(‐0.08,0.23) | |
| LD ADA SC | 0.51(0.14,1.74) | 0.52(0.15,1.71) | ‐0.02(‐0.10,0.01) | |
| HD TOFA PO | 0.42(0.10,1.83) | 0.43(0.11,1.81) | ‐0.02(‐0.11,0.01) | |
| HD ADA SC | 0.79(0.24,2.69) | 0.80(0.26,2.60) | ‐0.01(‐0.08,0.04) | |
| HD TOCI IV + DMARD | 1.15(0.14,8.99) | 1.14(0.15,7.16) | 0.01(‐0.08,0.23) | |
| SD CERTO SC | SD TOFA PO | 11.21(2.11,79.76) | 9.71(2.05,51.52) | 0.12(0.02,0.39) |
| SD TOC SC + PL IV | 2.80(0.52,16.83) | 2.72(0.52,14.73) | 0.02(‐0.01,0.13) | |
| SD ETN SC + MTX | 4.42(0.32,64.65) | 4.20(0.33,40.39) | 0.04(‐0.02,0.40) | |
| SD ETN SC + DMARD | 3.74(0.58,23.89) | 3.59(0.58,19.88) | 0.04(‐0.01,0.19) | |
| SD ADA SC + DMARD | 1.74(0.17,18.47) | 1.72(0.17,15.85) | 0.01(‐0.02,0.15) | |
| SD ANA + DMARD | 2.46(0.25,25.78) | 2.40(0.26,20.60) | 0.02(‐0.02,0.21) | |
| SD CERTO SC + DMARD | 1.69(0.12,22.75) | 1.67(0.12,18.34) | 0.01(‐0.02,0.19) | |
| SD TOCI SC + DMARD | 3.20(0.29,36.23) | 3.09(0.30,26.52) | 0.03(‐0.02,0.27) | |
| LD ADA SC | 1.65(0.45,6.49) | 1.64(0.46,6.22) | 0.01(‐0.02,0.04) | |
| HD TOFA PO | 1.36(0.51,3.82) | 1.35(0.52,3.74) | 0.00(‐0.01,0.03) | |
| HD ADA SC | 2.53(0.75,9.86) | 2.47(0.75,9.32) | 0.02(‐0.01,0.07) | |
| HD TOCI IV + DMARD | 3.79(0.42,38.62) | 3.63(0.42,28.27) | 0.04(‐0.01,0.27) | |
| SD TOC SC + PL IV | SD CERTO SC | 0.25(0.03,1.75) | 0.28(0.04,1.65) | ‐0.10(‐0.36,0.04) |
| SD ETN SC + MTX | 0.38(0.02,6.87) | 0.42(0.03,4.60) | ‐0.07(‐0.35,0.30) | |
| SD ETN SC + DMARD | 0.32(0.03,2.65) | 0.36(0.05,2.36) | ‐0.08(‐0.35,0.09) | |
| SD ADA SC + DMARD | 0.15(0.01,1.89) | 0.17(0.01,1.76) | ‐0.11(‐0.37,0.06) | |
| SD ANA + DMARD | 0.21(0.01,2.69) | 0.24(0.02,2.33) | ‐0.10(‐0.37,0.10) | |
| SD CERTO SC + DMARD | 0.15(0.01,2.31) | 0.17(0.01,2.09) | ‐0.11(‐0.37,0.09) | |
| SD TOCI SC + DMARD | 0.28(0.02,3.62) | 0.32(0.03,2.96) | ‐0.09(‐0.36,0.16) | |
| LD ADA SC | 0.14(0.02,0.73) | 0.17(0.03,0.74) | ‐0.12(‐0.38,‐0.01) | |
| HD TOFA PO | 0.12(0.02,0.68) | 0.14(0.03,0.69) | ‐0.12(‐0.38,‐0.01) | |
| HD ADA SC | 0.22(0.03,1.18) | 0.25(0.05,1.17) | ‐0.10(‐0.37,0.01) | |
| HD TOCI IV + DMARD | 0.32(0.02,3.90) | 0.36(0.03,3.14) | ‐0.08(‐0.35,0.17) | |
| SD ETN SC + MTX | SD TOC SC + PL IV | 1.57(0.10,26.25) | 1.53(0.11,17.17) | 0.02(‐0.10,0.37) |
| SD ETN SC + DMARD | 1.31(0.19,8.95) | 1.29(0.21,7.69) | 0.01(‐0.09,0.15) | |
| SD ADA SC + DMARD | 0.61(0.05,6.35) | 0.62(0.06,5.57) | ‐0.01(‐0.11,0.11) | |
| SD ANA + DMARD | 0.86(0.08,8.52) | 0.87(0.09,7.35) | 0.00(‐0.10,0.17) | |
| SD CERTO SC + DMARD | 0.59(0.04,8.07) | 0.60(0.05,6.79) | ‐0.01(‐0.11,0.16) | |
| SD TOCI SC + DMARD | 1.11(0.10,12.81) | 1.10(0.11,10.24) | 0.00(‐0.10,0.23) | |
| LD ADA SC | 0.58(0.12,2.68) | 0.59(0.14,2.61) | ‐0.01(‐0.12,0.02) | |
| HD TOFA PO | 0.48(0.09,2.65) | 0.49(0.10,2.59) | ‐0.02(‐0.13,0.02) | |
| HD ADA SC | 0.91(0.21,4.07) | 0.91(0.23,3.91) | 0.00(‐0.10,0.04) | |
| HD TOCI IV + DMARD | 1.30(0.14,12.44) | 1.28(0.15,9.98) | 0.01(‐0.09,0.23) | |
| SD ETN SC + DMARD | SD ETN SC + MTX | 0.87(0.05,14.52) | 0.88(0.07,12.70) | ‐0.01(‐0.36,0.14) |
| SD ADA SC + DMARD | 0.40(0.02,8.85) | 0.42(0.02,8.05) | ‐0.03(‐0.38,0.11) | |
| SD ANA + DMARD | 0.58(0.02,11.97) | 0.60(0.03,10.31) | ‐0.02(‐0.37,0.15) | |
| SD CERTO SC + DMARD | 0.40(0.01,10.37) | 0.42(0.02,8.96) | ‐0.03(‐0.38,0.14) | |
| SD TOCI SC + DMARD | 0.75(0.03,17.16) | 0.76(0.04,13.90) | ‐0.01(‐0.36,0.21) | |
| LD ADA SC | 0.37(0.03,4.99) | 0.39(0.04,4.85) | ‐0.03(‐0.39,0.03) | |
| HD TOFA PO | 0.31(0.02,4.21) | 0.33(0.04,4.10) | ‐0.04(‐0.39,0.02) | |
| HD ADA SC | 0.60(0.04,7.95) | 0.61(0.07,7.59) | ‐0.02(‐0.38,0.05) | |
| HD TOCI IV + DMARD | 0.90(0.04,17.66) | 0.91(0.05,14.64) | 0.00(‐0.36,0.21) | |
| SD ADA SC + DMARD | SD ETN SC + DMARD | 0.47(0.11,1.82) | 0.48(0.12,1.72) | ‐0.02(‐0.11,0.04) |
| SD ANA + DMARD | 0.66(0.18,2.43) | 0.67(0.19,2.21) | ‐0.01(‐0.09,0.08) | |
| SD CERTO SC + DMARD | 0.46(0.08,2.47) | 0.48(0.08,2.22) | ‐0.02(‐0.12,0.08) | |
| SD TOCI SC + DMARD | 0.85(0.21,3.82) | 0.86(0.22,3.21) | 0.00(‐0.08,0.15) | |
| LD ADA SC | 0.44(0.08,2.38) | 0.46(0.10,2.34) | ‐0.03(‐0.18,0.02) | |
| HD TOFA PO | 0.37(0.06,2.42) | 0.38(0.07,2.38) | ‐0.03(‐0.18,0.02) | |
| HD ADA SC | 0.68(0.14,3.82) | 0.70(0.17,3.67) | ‐0.01(‐0.16,0.04) | |
| HD TOCI IV + DMARD | 1.01(0.32,3.26) | 1.01(0.33,2.86) | 0.00(‐0.06,0.14) | |
| SD ANA + DMARD | SD ADA SC + DMARD | 1.43(0.38,5.47) | 1.40(0.40,5.10) | 0.01(‐0.05,0.11) |
| SD CERTO SC + DMARD | 1.00(0.16,5.64) | 1.00(0.17,5.15) | 0.00(‐0.08,0.11) | |
| SD TOCI SC + DMARD | 1.87(0.43,8.46) | 1.81(0.45,7.40) | 0.02(‐0.04,0.18) | |
| LD ADA SC | 0.95(0.11,9.15) | 0.95(0.12,8.93) | 0.00(‐0.14,0.04) | |
| HD TOFA PO | 0.80(0.08,8.40) | 0.80(0.09,8.19) | 0.00(‐0.15,0.03) | |
| HD ADA SC | 1.46(0.18,14.45) | 1.44(0.21,13.87) | 0.01(‐0.13,0.06) | |
| HD TOCI IV + DMARD | 2.18(0.68,7.44) | 2.09(0.70,6.80) | 0.02(‐0.02,0.16) | |
| SD CERTO SC + DMARD | SD ANA + DMARD | 0.68(0.12,3.59) | 0.70(0.13,3.29) | ‐0.01(‐0.11,0.08) |
| SD TOCI SC + DMARD | 1.30(0.33,5.29) | 1.28(0.35,4.65) | 0.01(‐0.07,0.15) | |
| LD ADA SC | 0.68(0.08,5.77) | 0.69(0.10,5.61) | ‐0.01(‐0.19,0.03) | |
| HD TOFA PO | 0.56(0.05,5.63) | 0.57(0.07,5.47) | ‐0.01(‐0.20,0.03) | |
| HD ADA SC | 1.05(0.13,8.86) | 1.05(0.16,8.49) | 0.00(‐0.17,0.05) | |
| HD TOCI IV + DMARD | 1.53(0.54,4.55) | 1.49(0.56,4.16) | 0.01(‐0.04,0.13) | |
| SD TOCI SC + DMARD | SD CERTO SC + DMARD | 1.90(0.33,11.57) | 1.83(0.36,10.40) | 0.01(‐0.07,0.18) |
| LD ADA SC | 0.98(0.08,12.31) | 0.98(0.10,11.89) | 0.00(‐0.18,0.04) | |
| HD TOFA PO | 0.81(0.07,12.06) | 0.81(0.08,11.72) | 0.00(‐0.19,0.03) | |
| HD ADA SC | 1.51(0.14,18.93) | 1.49(0.17,18.07) | 0.01(‐0.16,0.06) | |
| HD TOCI IV + DMARD | 2.21(0.47,11.44) | 2.10(0.51,10.48) | 0.02(‐0.05,0.17) | |
| LD ADA SC | SD TOCI SC + DMARD | 0.52(0.05,4.94) | 0.53(0.07,4.78) | ‐0.02(‐0.26,0.03) |
| HD TOFA PO | 0.43(0.04,4.68) | 0.44(0.06,4.56) | ‐0.02(‐0.26,0.03) | |
| HD ADA SC | 0.81(0.09,7.72) | 0.82(0.12,7.37) | ‐0.01(‐0.24,0.05) | |
| HD TOCI IV + DMARD | 1.17(0.33,4.05) | 1.16(0.37,3.75) | 0.00(‐0.11,0.12) | |
| HD TOFA PO | LD ADA SC | 0.82(0.24,2.89) | 0.82(0.25,2.82) | 0.00(‐0.04,0.03) |
| HD ADA SC | 1.54(0.64,4.18) | 1.52(0.65,4.01) | 0.01(‐0.01,0.05) | |
| HD TOCI IV + DMARD | 2.27(0.27,18.38) | 2.20(0.28,13.99) | 0.03(‐0.03,0.26) | |
| HD ADA SC | HD TOFA PO | 1.90(0.55,6.60) | 1.86(0.56,6.22) | 0.02(‐0.02,0.06) |
| HD TOCI IV + DMARD | 2.71(0.30,26.42) | 2.61(0.30,19.47) | 0.03(‐0.02,0.27) | |
| HD TOCI IV + DMARD | HD ADA SC | 1.47(0.18,10.69) | 1.45(0.19,8.12) | 0.01(‐0.05,0.24) |
| Random‐effects model | Residual deviance | 54.1 vs 52 data points | ||
| Deviance information criteria | 294.538 | |||
| Fixed‐effect model | Residual deviance | 56.54 vs 52 data points | ||
| Deviance information criteria | 294.2 | |||
| Note | ||||
| Total participants | 11,146 | |||
| Total studies | 23 | |||
| 2‐arm | 19 | |||
| 3‐arm | 2 | |||
| 4‐arm | 2 | |||
Appendix 24. Serious adverse events: subgroup ‐ trial duration (<= 6 months) network 2
| SAE short, network 2: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD GOLI IV | MTX | 0.95(0.08,10.49) | 0.96(0.09,7.69) | 0.00(‐0.04,0.26) |
| SD RITUX IV | 0.49(0.06,2.35) | 0.50(0.07,2.23) | ‐0.02(‐0.04,0.05) | |
| SD CERTO SC + MTX | 1.49(0.88,2.73) | 1.46(0.88,2.55) | 0.02(0.00,0.06) | |
| SD INF IV + MTX | 1.08(0.60,1.86) | 1.08(0.61,1.80) | 0.00(‐0.02,0.03) | |
| SD ADA SC + MTX | 1.10(0.46,2.50) | 1.09(0.47,2.36) | 0.00(‐0.02,0.05) | |
| SD ABA SC + MTX | 0.61(0.21,1.34) | 0.62(0.22,1.32) | ‐0.02(‐0.03,0.01) | |
| SD ABA IV + MTX | 0.80(0.40,1.36) | 0.81(0.41,1.34) | ‐0.01(‐0.02,0.01) | |
| SD RITUX IV + MTX | 1.36(0.69,2.65) | 1.34(0.70,2.49) | 0.01(‐0.01,0.06) | |
| SD GOLI SC + MTX | 2.15(0.71,7.89) | 2.06(0.72,6.26) | 0.04(‐0.01,0.20) | |
| SD TOFA PO + MTX | 2.15(0.88,5.43) | 2.05(0.89,4.64) | 0.04(0.00,0.14) | |
| SD GOLI IV + MTX | 2.91(0.54,24.54) | 2.70(0.55,12.82) | 0.07(‐0.02,0.46) | |
| SD ANA SC + MTX | 1.28(0.43,4.20) | 1.26(0.44,3.72) | 0.01(‐0.02,0.11) | |
| LD GOLI IV | 4.76(0.99,38.40) | 4.12(0.99,15.69) | 0.13(0.00,0.57) | |
| LD RITUX IV + MTX | 1.08(0.55,2.28) | 1.07(0.56,2.18) | 0.00(‐0.02,0.05) | |
| LD CERTO SC + MTX | 1.58(0.27,8.35) | 1.55(0.28,6.47) | 0.02(‐0.03,0.21) | |
| LD GOLI IV + MTX | 2.81(0.53,22.70) | 2.62(0.54,12.34) | 0.07(‐0.02,0.44) | |
| HD TOCI IV | 1.39(0.54,3.71) | 1.36(0.55,3.34) | 0.01(‐0.02,0.09) | |
| HD GOLI SC | 1.30(0.32,5.56) | 1.28(0.33,4.73) | 0.01(‐0.03,0.14) | |
| HD GOLI SC + MTX | 2.90(0.99,9.95) | 2.69(0.99,7.48) | 0.07(0.00,0.24) | |
| HD TOCI IV + MTX | 1.48(0.50,4.45) | 1.45(0.52,3.91) | 0.02(‐0.02,0.12) | |
| HD TOFA PO + MTX | 1.83(0.73,4.62) | 1.77(0.74,4.07) | 0.03(‐0.01,0.12) | |
| HD INF IV + MTX | 1.03(0.46,2.17) | 1.03(0.47,2.07) | 0.00(‐0.02,0.04) | |
| HD CERTO SC + MTX | 2.33(0.59,11.61) | 2.21(0.60,8.17) | 0.05(‐0.02,0.28) | |
| HD CERTO + MTX | 1.70(0.67,4.47) | 1.65(0.68,3.93) | 0.03(‐0.01,0.12) | |
| SD RITUX IV | SD GOLI IV | 0.50(0.02,9.39) | 0.51(0.03,8.89) | ‐0.02(‐0.28,0.06) |
| SD CERTO SC + MTX | 1.57(0.15,20.71) | 1.54(0.19,19.14) | 0.02(‐0.23,0.08) | |
| SD INF IV + MTX | 1.14(0.10,13.44) | 1.13(0.13,12.80) | 0.00(‐0.25,0.05) | |
| SD ADA SC + MTX | 1.16(0.09,14.40) | 1.15(0.12,13.64) | 0.01(‐0.26,0.07) | |
| SD ABA SC + MTX | 0.62(0.05,8.33) | 0.63(0.06,8.03) | ‐0.01(‐0.27,0.03) | |
| SD ABA IV + MTX | 0.83(0.07,10.06) | 0.84(0.10,9.73) | ‐0.01(‐0.26,0.04) | |
| SD RITUX IV + MTX | 1.46(0.12,17.67) | 1.43(0.17,16.53) | 0.02(‐0.24,0.08) | |
| SD GOLI SC + MTX | 2.40(0.16,36.31) | 2.26(0.21,32.04) | 0.04(‐0.22,0.20) | |
| SD TOFA PO + MTX | 2.33(0.17,30.02) | 2.21(0.23,26.61) | 0.04(‐0.22,0.15) | |
| SD GOLI IV + MTX | 3.05(0.52,39.86) | 2.71(0.55,30.57) | 0.06(‐0.05,0.34) | |
| SD ANA SC + MTX | 1.36(0.10,21.91) | 1.34(0.13,19.64) | 0.01(‐0.25,0.12) | |
| LD GOLI IV | 5.03(1.01,54.83) | 4.10(1.01,38.98) | 0.12(0.00,0.44) | |
| LD RITUX IV + MTX | 1.17(0.10,14.55) | 1.16(0.14,13.83) | 0.01(‐0.25,0.06) | |
| LD CERTO SC + MTX | 1.70(0.10,31.87) | 1.65(0.12,26.33) | 0.02(‐0.23,0.21) | |
| LD GOLI IV + MTX | 3.01(0.49,33.93) | 2.66(0.52,27.76) | 0.06(‐0.05,0.31) | |
| HD TOCI IV | 1.48(0.11,20.90) | 1.45(0.14,19.03) | 0.02(‐0.24,0.11) | |
| HD GOLI SC | 1.41(0.09,27.43) | 1.39(0.12,24.34) | 0.01(‐0.24,0.15) | |
| HD GOLI SC + MTX | 3.13(0.22,54.92) | 2.87(0.28,44.48) | 0.07(‐0.20,0.24) | |
| HD TOCI IV + MTX | 1.62(0.12,22.86) | 1.57(0.15,20.53) | 0.02(‐0.23,0.13) | |
| HD TOFA PO + MTX | 1.96(0.14,26.74) | 1.88(0.19,23.80) | 0.03(‐0.23,0.13) | |
| HD INF IV + MTX | 1.09(0.09,13.72) | 1.08(0.12,13.02) | 0.00(‐0.26,0.06) | |
| HD CERTO SC + MTX | 2.53(0.16,48.64) | 2.36(0.20,37.83) | 0.05(‐0.21,0.28) | |
| HD CERTO + MTX | 1.84(0.16,27.40) | 1.78(0.20,24.59) | 0.03(‐0.22,0.12) | |
| SD CERTO SC + MTX | SD RITUX IV | 3.08(0.59,24.72) | 2.96(0.61,23.13) | 0.04(‐0.03,0.09) |
| SD INF IV + MTX | 2.24(0.40,18.26) | 2.19(0.42,17.40) | 0.02(‐0.05,0.06) | |
| SD ADA SC + MTX | 2.29(0.36,22.59) | 2.23(0.38,21.25) | 0.02(‐0.05,0.08) | |
| SD ABA SC + MTX | 1.26(0.18,10.83) | 1.25(0.20,10.47) | 0.00(‐0.07,0.04) | |
| SD ABA IV + MTX | 1.65(0.29,13.43) | 1.63(0.31,12.97) | 0.01(‐0.06,0.04) | |
| SD RITUX IV + MTX | 2.76(0.58,22.50) | 2.66(0.60,21.05) | 0.03(‐0.03,0.08) | |
| SD GOLI SC + MTX | 4.58(0.69,45.04) | 4.25(0.70,38.73) | 0.06(‐0.02,0.21) | |
| SD TOFA PO + MTX | 4.53(0.71,43.46) | 4.21(0.73,38.18) | 0.06(‐0.02,0.16) | |
| SD GOLI IV + MTX | 6.47(0.54,111.50) | 5.73(0.56,67.91) | 0.09(‐0.03,0.48) | |
| SD ANA SC + MTX | 2.76(0.39,26.18) | 2.66(0.41,23.71) | 0.03(‐0.04,0.13) | |
| LD GOLI IV | 10.40(1.11,164.90) | 8.52(1.10,89.52) | 0.14(0.00,0.59) | |
| LD RITUX IV + MTX | 2.19(0.47,17.80) | 2.14(0.49,16.85) | 0.02(‐0.04,0.07) | |
| LD CERTO SC + MTX | 3.40(0.31,44.12) | 3.21(0.32,36.77) | 0.04(‐0.05,0.23) | |
| LD GOLI IV + MTX | 6.24(0.58,104.50) | 5.58(0.59,63.30) | 0.08(‐0.02,0.46) | |
| HD TOCI IV | 2.88(0.47,26.87) | 2.77(0.49,24.52) | 0.03(‐0.04,0.12) | |
| HD GOLI SC | 2.73(0.36,30.48) | 2.63(0.38,26.94) | 0.03(‐0.04,0.16) | |
| HD GOLI SC + MTX | 6.22(0.87,59.87) | 5.57(0.87,48.16) | 0.09(‐0.01,0.26) | |
| HD TOCI IV + MTX | 3.10(0.46,30.30) | 2.96(0.48,27.39) | 0.04(‐0.04,0.14) | |
| HD TOFA PO + MTX | 3.87(0.56,36.71) | 3.65(0.58,32.83) | 0.05(‐0.03,0.14) | |
| HD INF IV + MTX | 2.13(0.35,19.07) | 2.08(0.37,18.11) | 0.02(‐0.05,0.07) | |
| HD CERTO SC + MTX | 4.95(0.60,66.80) | 4.53(0.61,51.60) | 0.07(‐0.02,0.30) | |
| HD CERTO + MTX | 3.50(0.56,32.87) | 3.32(0.58,29.51) | 0.04(‐0.03,0.14) | |
| SD INF IV + MTX | SD CERTO SC + MTX | 0.72(0.30,1.54) | 0.74(0.32,1.50) | ‐0.02(‐0.06,0.02) |
| SD ADA SC + MTX | 0.72(0.26,1.96) | 0.74(0.27,1.88) | ‐0.02(‐0.07,0.04) | |
| SD ABA SC + MTX | 0.40(0.11,1.05) | 0.42(0.12,1.05) | ‐0.03(‐0.08,0.00) | |
| SD ABA IV + MTX | 0.53(0.21,1.14) | 0.55(0.22,1.13) | ‐0.03(‐0.07,0.01) | |
| SD RITUX IV + MTX | 0.92(0.36,2.10) | 0.92(0.38,2.00) | 0.00(‐0.06,0.05) | |
| SD GOLI SC + MTX | 1.45(0.42,5.66) | 1.41(0.45,4.63) | 0.02(‐0.05,0.18) | |
| SD TOFA PO + MTX | 1.44(0.49,4.19) | 1.40(0.51,3.65) | 0.02(‐0.04,0.12) | |
| SD GOLI IV + MTX | 1.97(0.32,16.73) | 1.86(0.34,9.14) | 0.05(‐0.05,0.44) | |
| SD ANA SC + MTX | 0.86(0.24,3.11) | 0.87(0.26,2.81) | ‐0.01(‐0.06,0.09) | |
| LD GOLI IV | 3.21(0.57,27.22) | 2.83(0.59,11.63) | 0.11(‐0.03,0.55) | |
| LD RITUX IV + MTX | 0.72(0.30,1.77) | 0.74(0.32,1.71) | ‐0.02(‐0.06,0.03) | |
| LD CERTO SC + MTX | 1.07(0.18,5.18) | 1.06(0.19,4.18) | 0.00(‐0.06,0.19) | |
| LD GOLI IV + MTX | 1.91(0.32,15.94) | 1.81(0.33,8.87) | 0.05(‐0.05,0.42) | |
| HD TOCI IV | 0.92(0.30,2.82) | 0.92(0.32,2.59) | 0.00(‐0.06,0.08) | |
| HD GOLI SC | 0.87(0.19,4.04) | 0.88(0.21,3.51) | ‐0.01(‐0.07,0.13) | |
| HD GOLI SC + MTX | 1.97(0.57,7.23) | 1.86(0.59,5.59) | 0.05(‐0.03,0.22) | |
| HD TOCI IV + MTX | 0.98(0.29,3.33) | 0.98(0.30,2.98) | 0.00(‐0.06,0.10) | |
| HD TOFA PO + MTX | 1.23(0.40,3.56) | 1.21(0.42,3.19) | 0.01(‐0.05,0.10) | |
| HD INF IV + MTX | 0.69(0.25,1.68) | 0.70(0.27,1.63) | ‐0.02(‐0.07,0.03) | |
| HD CERTO SC + MTX | 1.57(0.39,7.23) | 1.51(0.41,5.32) | 0.03(‐0.04,0.25) | |
| HD CERTO + MTX | 1.14(0.48,2.71) | 1.13(0.50,2.48) | 0.01(‐0.04,0.09) | |
| SD ADA SC + MTX | SD INF IV + MTX | 1.01(0.37,2.81) | 1.01(0.39,2.67) | 0.00(‐0.04,0.05) |
| SD ABA SC + MTX | 0.56(0.19,1.41) | 0.57(0.19,1.39) | ‐0.02(‐0.05,0.01) | |
| SD ABA IV + MTX | 0.74(0.34,1.47) | 0.74(0.36,1.45) | ‐0.01(‐0.04,0.01) | |
| SD RITUX IV + MTX | 1.25(0.53,3.11) | 1.24(0.54,2.92) | 0.01(‐0.03,0.06) | |
| SD GOLI SC + MTX | 1.99(0.63,8.32) | 1.91(0.64,6.65) | 0.04(‐0.02,0.20) | |
| SD TOFA PO + MTX | 2.00(0.72,5.98) | 1.92(0.73,5.19) | 0.04(‐0.02,0.14) | |
| SD GOLI IV + MTX | 2.72(0.45,24.78) | 2.52(0.47,13.37) | 0.07(‐0.03,0.46) | |
| SD ANA SC + MTX | 1.19(0.35,4.60) | 1.18(0.37,4.10) | 0.01(‐0.04,0.11) | |
| LD GOLI IV | 4.46(0.85,40.18) | 3.86(0.85,16.61) | 0.12(‐0.01,0.57) | |
| LD RITUX IV + MTX | 1.00(0.43,2.65) | 1.00(0.44,2.53) | 0.00(‐0.04,0.05) | |
| LD CERTO SC + MTX | 1.46(0.24,8.65) | 1.43(0.24,6.78) | 0.02(‐0.04,0.21) | |
| LD GOLI IV + MTX | 2.61(0.45,23.29) | 2.44(0.47,12.83) | 0.06(‐0.03,0.44) | |
| HD TOCI IV | 1.27(0.43,4.06) | 1.26(0.45,3.68) | 0.01(‐0.03,0.09) | |
| HD GOLI SC | 1.21(0.27,5.82) | 1.20(0.28,4.99) | 0.01(‐0.04,0.14) | |
| HD GOLI SC + MTX | 2.70(0.84,10.95) | 2.51(0.85,8.27) | 0.07(‐0.01,0.24) | |
| HD TOCI IV + MTX | 1.36(0.41,4.85) | 1.34(0.43,4.27) | 0.01(‐0.03,0.12) | |
| HD TOFA PO + MTX | 1.70(0.59,5.03) | 1.65(0.61,4.47) | 0.03(‐0.02,0.12) | |
| HD INF IV + MTX | 0.95(0.44,2.07) | 0.95(0.45,1.99) | 0.00(‐0.03,0.04) | |
| HD CERTO SC + MTX | 2.17(0.49,11.88) | 2.06(0.50,8.58) | 0.05(‐0.03,0.28) | |
| HD CERTO + MTX | 1.57(0.54,4.97) | 1.53(0.56,4.41) | 0.02(‐0.03,0.12) | |
| SD ABA SC + MTX | SD ADA SC + MTX | 0.54(0.15,1.76) | 0.55(0.16,1.73) | ‐0.02(‐0.07,0.02) |
| SD ABA IV + MTX | 0.72(0.25,1.98) | 0.73(0.26,1.94) | ‐0.01(‐0.06,0.02) | |
| SD RITUX IV + MTX | 1.25(0.43,3.71) | 1.23(0.45,3.49) | 0.01(‐0.05,0.06) | |
| SD GOLI SC + MTX | 1.99(0.50,9.13) | 1.90(0.52,7.48) | 0.04(‐0.04,0.19) | |
| SD TOFA PO + MTX | 1.98(0.77,5.34) | 1.90(0.78,4.73) | 0.04(‐0.01,0.13) | |
| SD GOLI IV + MTX | 2.70(0.42,27.86) | 2.50(0.44,15.01) | 0.07(‐0.04,0.45) | |
| SD ANA SC + MTX | 1.18(0.29,5.25) | 1.17(0.30,4.70) | 0.01(‐0.05,0.11) | |
| LD GOLI IV | 4.41(0.74,40.46) | 3.79(0.75,18.28) | 0.12(‐0.02,0.56) | |
| LD RITUX IV + MTX | 1.00(0.34,3.09) | 1.00(0.36,2.93) | 0.00(‐0.05,0.05) | |
| LD CERTO SC + MTX | 1.49(0.21,9.09) | 1.46(0.22,7.21) | 0.02(‐0.06,0.21) | |
| LD GOLI IV + MTX | 2.61(0.40,24.70) | 2.42(0.42,14.06) | 0.06(‐0.04,0.44) | |
| HD TOCI IV | 1.26(0.36,4.73) | 1.24(0.38,4.30) | 0.01(‐0.05,0.09) | |
| HD GOLI SC | 1.19(0.25,6.36) | 1.18(0.26,5.46) | 0.01(‐0.06,0.14) | |
| HD GOLI SC + MTX | 2.67(0.70,12.09) | 2.48(0.71,9.27) | 0.06(‐0.02,0.24) | |
| HD TOCI IV + MTX | 1.36(0.34,5.65) | 1.33(0.36,4.99) | 0.01(‐0.05,0.12) | |
| HD TOFA PO + MTX | 1.69(0.64,4.55) | 1.63(0.66,4.12) | 0.03(‐0.02,0.11) | |
| HD INF IV + MTX | 0.94(0.30,2.93) | 0.94(0.32,2.79) | 0.00(‐0.05,0.05) | |
| HD CERTO SC + MTX | 2.16(0.44,12.68) | 2.05(0.46,9.32) | 0.04(‐0.04,0.27) | |
| HD CERTO + MTX | 1.58(0.44,5.72) | 1.54(0.46,5.05) | 0.02(‐0.04,0.12) | |
| SD ABA IV + MTX | SD ABA SC + MTX | 1.32(0.67,2.91) | 1.31(0.68,2.85) | 0.01(‐0.01,0.03) |
| SD RITUX IV + MTX | 2.27(0.79,7.79) | 2.20(0.80,7.27) | 0.03(‐0.01,0.08) | |
| SD GOLI SC + MTX | 3.67(0.94,17.64) | 3.43(0.94,14.25) | 0.06(0.00,0.21) | |
| SD TOFA PO + MTX | 3.61(1.11,14.60) | 3.38(1.11,12.47) | 0.06(0.00,0.16) | |
| SD GOLI IV + MTX | 4.91(0.78,51.18) | 4.44(0.79,28.37) | 0.08(‐0.01,0.48) | |
| SD ANA SC + MTX | 2.19(0.54,10.29) | 2.12(0.55,9.13) | 0.03(‐0.02,0.13) | |
| LD GOLI IV | 8.06(1.38,80.92) | 6.82(1.36,35.50) | 0.14(0.01,0.59) | |
| LD RITUX IV + MTX | 1.79(0.64,6.57) | 1.76(0.65,6.22) | 0.02(‐0.02,0.07) | |
| LD CERTO SC + MTX | 2.65(0.39,19.16) | 2.54(0.40,15.15) | 0.04(‐0.02,0.23) | |
| LD GOLI IV + MTX | 4.78(0.76,50.17) | 4.34(0.77,27.75) | 0.08(‐0.01,0.46) | |
| HD TOCI IV | 2.30(0.68,9.67) | 2.23(0.69,8.73) | 0.03(‐0.01,0.11) | |
| HD GOLI SC | 2.21(0.45,12.33) | 2.14(0.46,10.59) | 0.03(‐0.02,0.16) | |
| HD GOLI SC + MTX | 4.94(1.27,24.28) | 4.49(1.25,18.21) | 0.08(0.01,0.26) | |
| HD TOCI IV + MTX | 2.47(0.65,11.42) | 2.38(0.66,10.08) | 0.03(‐0.01,0.13) | |
| HD TOFA PO + MTX | 3.07(0.88,12.42) | 2.92(0.88,10.92) | 0.05(‐0.01,0.14) | |
| HD INF IV + MTX | 1.70(0.59,6.08) | 1.67(0.60,5.73) | 0.02(‐0.02,0.06) | |
| HD CERTO SC + MTX | 3.99(0.81,25.92) | 3.70(0.82,18.92) | 0.06(‐0.01,0.30) | |
| HD CERTO + MTX | 2.82(0.84,12.46) | 2.69(0.85,10.93) | 0.04(‐0.01,0.14) | |
| SD RITUX IV + MTX | SD ABA IV + MTX | 1.70(0.73,4.42) | 1.67(0.74,4.14) | 0.02(‐0.01,0.07) |
| SD GOLI SC + MTX | 2.73(0.82,11.35) | 2.58(0.83,9.11) | 0.05(‐0.01,0.21) | |
| SD TOFA PO + MTX | 2.71(0.98,8.73) | 2.56(0.99,7.48) | 0.05(0.00,0.15) | |
| SD GOLI IV + MTX | 3.71(0.65,33.56) | 3.41(0.66,17.95) | 0.08(‐0.01,0.47) | |
| SD ANA SC + MTX | 1.63(0.48,6.36) | 1.60(0.49,5.62) | 0.02(‐0.02,0.12) | |
| LD GOLI IV | 6.05(1.16,54.64) | 5.18(1.15,22.43) | 0.14(0.01,0.58) | |
| LD RITUX IV + MTX | 1.37(0.57,3.86) | 1.35(0.59,3.63) | 0.01(‐0.02,0.06) | |
| LD CERTO SC + MTX | 2.01(0.32,12.28) | 1.94(0.32,9.59) | 0.03(‐0.03,0.22) | |
| LD GOLI IV + MTX | 3.58(0.62,32.54) | 3.31(0.63,17.38) | 0.07(‐0.01,0.45) | |
| HD TOCI IV | 1.74(0.59,5.78) | 1.70(0.60,5.22) | 0.02(‐0.02,0.11) | |
| HD GOLI SC | 1.66(0.38,8.06) | 1.62(0.39,6.83) | 0.02(‐0.03,0.15) | |
| HD GOLI SC + MTX | 3.69(1.11,14.81) | 3.38(1.10,11.22) | 0.08(0.00,0.25) | |
| HD TOCI IV + MTX | 1.85(0.56,6.95) | 1.80(0.57,6.08) | 0.03(‐0.02,0.13) | |
| HD TOFA PO + MTX | 2.31(0.78,7.33) | 2.22(0.79,6.48) | 0.04(‐0.01,0.13) | |
| HD INF IV + MTX | 1.28(0.52,3.46) | 1.27(0.53,3.28) | 0.01(‐0.02,0.05) | |
| HD CERTO SC + MTX | 2.98(0.68,16.76) | 2.80(0.69,11.93) | 0.06(‐0.01,0.29) | |
| HD CERTO + MTX | 2.13(0.75,7.20) | 2.05(0.76,6.37) | 0.03(‐0.01,0.13) | |
| SD GOLI SC + MTX | SD RITUX IV + MTX | 1.60(0.44,6.74) | 1.55(0.46,5.48) | 0.03(‐0.04,0.19) |
| SD TOFA PO + MTX | 1.58(0.53,5.03) | 1.53(0.56,4.37) | 0.03(‐0.04,0.13) | |
| SD GOLI IV + MTX | 2.16(0.35,19.22) | 2.02(0.37,10.50) | 0.05(‐0.05,0.45) | |
| SD ANA SC + MTX | 0.94(0.26,3.76) | 0.95(0.27,3.38) | 0.00(‐0.06,0.10) | |
| LD GOLI IV | 3.53(0.66,29.62) | 3.09(0.68,13.17) | 0.11(‐0.02,0.55) | |
| LD RITUX IV + MTX | 0.80(0.41,1.62) | 0.81(0.43,1.58) | ‐0.01(‐0.05,0.02) | |
| LD CERTO SC + MTX | 1.17(0.18,7.05) | 1.16(0.19,5.62) | 0.01(‐0.06,0.20) | |
| LD GOLI IV + MTX | 2.06(0.35,18.28) | 1.94(0.37,10.36) | 0.05(‐0.05,0.43) | |
| HD TOCI IV | 1.02(0.32,3.32) | 1.02(0.34,3.06) | 0.00(‐0.06,0.09) | |
| HD GOLI SC | 0.96(0.20,4.79) | 0.97(0.22,4.17) | 0.00(‐0.06,0.13) | |
| HD GOLI SC + MTX | 2.15(0.59,9.11) | 2.02(0.61,6.97) | 0.05(‐0.03,0.23) | |
| HD TOCI IV + MTX | 1.09(0.30,3.97) | 1.09(0.32,3.54) | 0.00(‐0.06,0.11) | |
| HD TOFA PO + MTX | 1.35(0.43,4.24) | 1.32(0.46,3.79) | 0.02(‐0.05,0.11) | |
| HD INF IV + MTX | 0.75(0.27,2.08) | 0.76(0.29,2.00) | ‐0.01(‐0.06,0.04) | |
| HD CERTO SC + MTX | 1.73(0.37,9.58) | 1.66(0.39,7.09) | 0.04(‐0.05,0.27) | |
| HD CERTO + MTX | 1.24(0.41,4.12) | 1.23(0.43,3.70) | 0.01(‐0.05,0.11) | |
| SD TOFA PO + MTX | SD GOLI SC + MTX | 0.98(0.21,4.23) | 0.99(0.24,3.76) | 0.00(‐0.16,0.11) |
| SD GOLI IV + MTX | 1.32(0.16,14.51) | 1.28(0.19,8.33) | 0.02(‐0.15,0.42) | |
| SD ANA SC + MTX | 0.59(0.11,3.10) | 0.61(0.14,2.83) | ‐0.03(‐0.19,0.08) | |
| LD GOLI IV | 2.20(0.30,25.05) | 1.99(0.34,11.21) | 0.08(‐0.13,0.53) | |
| LD RITUX IV + MTX | 0.51(0.11,1.86) | 0.53(0.14,1.80) | ‐0.04(‐0.20,0.03) | |
| LD CERTO SC + MTX | 0.70(0.09,5.67) | 0.72(0.10,4.66) | ‐0.02(‐0.18,0.18) | |
| LD GOLI IV + MTX | 1.29(0.16,14.85) | 1.25(0.19,8.50) | 0.02(‐0.16,0.41) | |
| HD TOCI IV | 0.63(0.13,2.77) | 0.65(0.16,2.58) | ‐0.03(‐0.19,0.07) | |
| HD GOLI SC | 0.59(0.15,2.18) | 0.62(0.17,2.03) | ‐0.03(‐0.14,0.06) | |
| HD GOLI SC + MTX | 1.35(0.50,3.55) | 1.31(0.53,3.15) | 0.02(‐0.07,0.14) | |
| HD TOCI IV + MTX | 0.67(0.13,3.09) | 0.69(0.16,2.82) | ‐0.02(‐0.18,0.09) | |
| HD TOFA PO + MTX | 0.84(0.16,3.56) | 0.85(0.20,3.23) | ‐0.01(‐0.17,0.09) | |
| HD INF IV + MTX | 0.47(0.11,1.70) | 0.49(0.13,1.65) | ‐0.04(‐0.20,0.03) | |
| HD CERTO SC + MTX | 1.09(0.16,7.45) | 1.08(0.19,5.64) | 0.01(‐0.16,0.25) | |
| HD CERTO + MTX | 0.77(0.17,3.41) | 0.79(0.20,3.11) | ‐0.02(‐0.17,0.09) | |
| SD GOLI IV + MTX | SD TOFA PO + MTX | 1.35(0.19,13.94) | 1.31(0.22,7.95) | 0.03(‐0.11,0.42) |
| SD ANA SC + MTX | 0.60(0.14,2.62) | 0.62(0.16,2.42) | ‐0.03(‐0.13,0.08) | |
| LD GOLI IV | 2.21(0.35,20.86) | 1.99(0.38,9.63) | 0.08(‐0.08,0.53) | |
| LD RITUX IV + MTX | 0.50(0.16,1.58) | 0.52(0.19,1.54) | ‐0.04(‐0.14,0.02) | |
| LD CERTO SC + MTX | 0.75(0.10,4.70) | 0.77(0.11,3.88) | ‐0.02(‐0.13,0.17) | |
| LD GOLI IV + MTX | 1.28(0.20,12.91) | 1.25(0.22,7.62) | 0.02(‐0.11,0.40) | |
| HD TOCI IV | 0.64(0.17,2.42) | 0.66(0.19,2.27) | ‐0.03(‐0.13,0.06) | |
| HD GOLI SC | 0.59(0.12,3.36) | 0.62(0.13,2.99) | ‐0.03(‐0.14,0.11) | |
| HD GOLI SC + MTX | 1.36(0.34,6.29) | 1.32(0.37,5.01) | 0.03(‐0.09,0.21) | |
| HD TOCI IV + MTX | 0.68(0.16,2.87) | 0.70(0.18,2.61) | ‐0.02(‐0.13,0.09) | |
| HD TOFA PO + MTX | 0.85(0.40,1.75) | 0.86(0.43,1.68) | ‐0.01(‐0.08,0.04) | |
| HD INF IV + MTX | 0.47(0.14,1.53) | 0.50(0.16,1.49) | ‐0.04(‐0.14,0.02) | |
| HD CERTO SC + MTX | 1.09(0.21,6.80) | 1.08(0.23,5.12) | 0.01(‐0.11,0.24) | |
| HD CERTO + MTX | 0.80(0.21,2.92) | 0.81(0.24,2.67) | ‐0.02(‐0.12,0.09) | |
| SD ANA SC + MTX | SD GOLI IV + MTX | 0.44(0.04,3.50) | 0.47(0.07,3.22) | ‐0.06(‐0.45,0.08) |
| LD GOLI IV | 1.62(0.46,6.80) | 1.48(0.53,5.24) | 0.05(‐0.11,0.29) | |
| LD RITUX IV + MTX | 0.37(0.04,2.39) | 0.40(0.08,2.30) | ‐0.06(‐0.45,0.03) | |
| LD CERTO SC + MTX | 0.54(0.04,5.87) | 0.58(0.06,4.88) | ‐0.04(‐0.43,0.16) | |
| LD GOLI IV + MTX | 0.97(0.21,4.31) | 0.98(0.25,3.62) | 0.00(‐0.20,0.18) | |
| HD TOCI IV | 0.47(0.05,3.34) | 0.50(0.08,3.11) | ‐0.05(‐0.44,0.07) | |
| HD GOLI SC | 0.45(0.03,4.21) | 0.48(0.06,3.77) | ‐0.05(‐0.45,0.10) | |
| HD GOLI SC + MTX | 1.03(0.09,8.26) | 1.02(0.16,6.68) | 0.00(‐0.40,0.20) | |
| HD TOCI IV + MTX | 0.49(0.05,3.86) | 0.53(0.09,3.54) | ‐0.05(‐0.43,0.09) | |
| HD TOFA PO + MTX | 0.62(0.06,4.38) | 0.65(0.11,3.99) | ‐0.04(‐0.43,0.09) | |
| HD INF IV + MTX | 0.35(0.04,2.22) | 0.38(0.07,2.15) | ‐0.07(‐0.46,0.03) | |
| HD CERTO SC + MTX | 0.80(0.07,8.10) | 0.82(0.11,6.35) | ‐0.02(‐0.40,0.23) | |
| HD CERTO + MTX | 0.58(0.06,4.16) | 0.61(0.11,3.77) | ‐0.04(‐0.43,0.09) | |
| LD GOLI IV | SD ANA SC + MTX | 3.84(0.51,38.84) | 3.30(0.54,17.85) | 0.11(‐0.05,0.56) |
| LD RITUX IV + MTX | 0.83(0.22,3.22) | 0.84(0.25,3.06) | ‐0.01(‐0.11,0.05) | |
| LD CERTO SC + MTX | 1.21(0.16,9.34) | 1.19(0.17,7.59) | 0.01(‐0.10,0.20) | |
| LD GOLI IV + MTX | 2.22(0.28,23.97) | 2.07(0.31,13.81) | 0.05(‐0.08,0.43) | |
| HD TOCI IV | 1.08(0.23,4.68) | 1.07(0.26,4.32) | 0.00(‐0.10,0.09) | |
| HD GOLI SC | 1.01(0.15,6.05) | 1.01(0.17,5.29) | 0.00(‐0.11,0.13) | |
| HD GOLI SC + MTX | 2.27(0.48,11.71) | 2.12(0.51,9.10) | 0.06(‐0.06,0.23) | |
| HD TOCI IV + MTX | 1.15(0.23,5.51) | 1.14(0.25,4.89) | 0.01(‐0.10,0.11) | |
| HD TOFA PO + MTX | 1.43(0.31,5.87) | 1.40(0.35,5.25) | 0.02(‐0.09,0.11) | |
| HD INF IV + MTX | 0.79(0.20,2.97) | 0.80(0.22,2.84) | ‐0.01(‐0.11,0.04) | |
| HD CERTO SC + MTX | 1.84(0.29,13.10) | 1.75(0.32,9.85) | 0.04(‐0.08,0.27) | |
| HD CERTO + MTX | 1.32(0.30,5.81) | 1.30(0.33,5.22) | 0.01(‐0.09,0.11) | |
| LD RITUX IV + MTX | LD GOLI IV | 0.23(0.03,1.27) | 0.26(0.06,1.26) | ‐0.12(‐0.56,0.01) |
| LD CERTO SC + MTX | 0.32(0.02,3.22) | 0.37(0.04,2.78) | ‐0.10(‐0.54,0.12) | |
| LD GOLI IV + MTX | 0.59(0.14,2.18) | 0.65(0.19,1.89) | ‐0.05(‐0.29,0.11) | |
| HD TOCI IV | 0.28(0.03,1.90) | 0.33(0.06,1.81) | ‐0.11(‐0.55,0.04) | |
| HD GOLI SC | 0.27(0.02,2.17) | 0.31(0.05,2.02) | ‐0.11(‐0.56,0.07) | |
| HD GOLI SC + MTX | 0.62(0.06,4.45) | 0.66(0.13,3.69) | ‐0.05(‐0.51,0.17) | |
| HD TOCI IV + MTX | 0.31(0.03,2.13) | 0.35(0.07,1.99) | ‐0.10(‐0.55,0.06) | |
| HD TOFA PO + MTX | 0.38(0.04,2.45) | 0.43(0.09,2.27) | ‐0.09(‐0.54,0.06) | |
| HD INF IV + MTX | 0.21(0.02,1.21) | 0.24(0.05,1.20) | ‐0.13(‐0.57,0.01) | |
| HD CERTO SC + MTX | 0.48(0.04,4.63) | 0.53(0.09,3.70) | ‐0.07(‐0.52,0.19) | |
| HD CERTO + MTX | 0.35(0.04,2.39) | 0.40(0.08,2.22) | ‐0.10(‐0.54,0.06) | |
| LD CERTO SC + MTX | LD RITUX IV + MTX | 1.46(0.22,8.69) | 1.43(0.24,6.92) | 0.02(‐0.05,0.21) |
| LD GOLI IV + MTX | 2.59(0.42,23.11) | 2.41(0.44,12.92) | 0.06(‐0.03,0.44) | |
| HD TOCI IV | 1.28(0.37,4.36) | 1.26(0.39,3.94) | 0.01(‐0.04,0.09) | |
| HD GOLI SC | 1.20(0.25,6.18) | 1.19(0.27,5.29) | 0.01(‐0.05,0.14) | |
| HD GOLI SC + MTX | 2.68(0.74,11.68) | 2.49(0.76,8.92) | 0.06(‐0.02,0.24) | |
| HD TOCI IV + MTX | 1.37(0.35,5.10) | 1.34(0.37,4.52) | 0.01(‐0.05,0.12) | |
| HD TOFA PO + MTX | 1.70(0.52,5.30) | 1.65(0.54,4.68) | 0.03(‐0.03,0.12) | |
| HD INF IV + MTX | 0.95(0.31,2.62) | 0.95(0.33,2.49) | 0.00(‐0.05,0.04) | |
| HD CERTO SC + MTX | 2.16(0.45,11.99) | 2.04(0.47,8.72) | 0.05(‐0.03,0.28) | |
| HD CERTO + MTX | 1.57(0.48,5.00) | 1.53(0.50,4.41) | 0.02(‐0.04,0.11) | |
| LD GOLI IV + MTX | LD CERTO SC + MTX | 1.82(0.17,25.58) | 1.72(0.21,16.06) | 0.04(‐0.16,0.41) |
| HD TOCI IV | 0.86(0.13,6.63) | 0.87(0.17,6.13) | ‐0.01(‐0.20,0.09) | |
| HD GOLI SC | 0.84(0.09,7.69) | 0.85(0.12,6.82) | ‐0.01(‐0.20,0.13) | |
| HD GOLI SC + MTX | 1.93(0.24,15.70) | 1.81(0.29,12.44) | 0.05(‐0.16,0.22) | |
| HD TOCI IV + MTX | 0.93(0.13,7.66) | 0.93(0.16,6.90) | 0.00(‐0.20,0.11) | |
| HD TOFA PO + MTX | 1.13(0.18,8.34) | 1.12(0.22,7.53) | 0.01(‐0.18,0.11) | |
| HD INF IV + MTX | 0.65(0.10,4.22) | 0.67(0.13,4.04) | ‐0.02(‐0.21,0.05) | |
| HD CERTO SC + MTX | 1.52(0.32,8.76) | 1.46(0.35,7.48) | 0.03(‐0.11,0.20) | |
| HD CERTO + MTX | 1.07(0.18,7.47) | 1.06(0.22,6.82) | 0.00(‐0.18,0.10) | |
| HD TOCI IV | LD GOLI IV + MTX | 0.49(0.05,3.43) | 0.52(0.09,3.16) | ‐0.05(‐0.42,0.07) |
| HD GOLI SC | 0.47(0.04,4.33) | 0.51(0.06,3.84) | ‐0.05(‐0.43,0.11) | |
| HD GOLI SC + MTX | 1.05(0.10,8.70) | 1.05(0.16,6.87) | 0.00(‐0.38,0.20) | |
| HD TOCI IV + MTX | 0.52(0.05,3.97) | 0.55(0.09,3.62) | ‐0.05(‐0.41,0.09) | |
| HD TOFA PO + MTX | 0.67(0.07,4.37) | 0.70(0.11,4.00) | ‐0.03(‐0.41,0.09) | |
| HD INF IV + MTX | 0.36(0.04,2.29) | 0.39(0.07,2.21) | ‐0.06(‐0.44,0.03) | |
| HD CERTO SC + MTX | 0.83(0.07,8.30) | 0.85(0.12,6.57) | ‐0.01(‐0.39,0.23) | |
| HD CERTO + MTX | 0.59(0.06,4.34) | 0.62(0.11,3.97) | ‐0.04(‐0.41,0.09) | |
| HD GOLI SC | HD TOCI IV | 0.95(0.16,5.40) | 0.96(0.18,4.70) | 0.00(‐0.09,0.13) |
| HD GOLI SC + MTX | 2.14(0.50,10.16) | 2.00(0.53,7.91) | 0.05(‐0.05,0.23) | |
| HD TOCI IV + MTX | 1.07(0.46,2.52) | 1.07(0.48,2.35) | 0.00(‐0.05,0.07) | |
| HD TOFA PO + MTX | 1.34(0.34,5.09) | 1.31(0.37,4.53) | 0.02(‐0.07,0.11) | |
| HD INF IV + MTX | 0.74(0.21,2.49) | 0.76(0.23,2.39) | ‐0.01(‐0.10,0.04) | |
| HD CERTO SC + MTX | 1.71(0.30,10.93) | 1.64(0.33,8.02) | 0.03(‐0.07,0.27) | |
| HD CERTO + MTX | 1.24(0.31,4.81) | 1.23(0.34,4.34) | 0.01(‐0.08,0.11) | |
| HD GOLI SC + MTX | HD GOLI SC | 2.23(0.65,8.53) | 2.08(0.68,7.39) | 0.05(‐0.04,0.19) |
| HD TOCI IV + MTX | 1.12(0.19,7.26) | 1.11(0.22,6.47) | 0.01(‐0.13,0.12) | |
| HD TOFA PO + MTX | 1.42(0.25,7.47) | 1.39(0.28,6.68) | 0.02(‐0.12,0.12) | |
| HD INF IV + MTX | 0.78(0.15,3.89) | 0.79(0.17,3.71) | ‐0.01(‐0.14,0.05) | |
| HD CERTO SC + MTX | 1.82(0.25,15.28) | 1.74(0.27,11.49) | 0.04(‐0.11,0.27) | |
| HD CERTO + MTX | 1.30(0.23,7.11) | 1.28(0.27,6.33) | 0.01(‐0.12,0.11) | |
| HD TOCI IV + MTX | HD GOLI SC + MTX | 0.50(0.10,2.26) | 0.53(0.13,2.09) | ‐0.05(‐0.23,0.07) |
| HD TOFA PO + MTX | 0.63(0.12,2.48) | 0.66(0.16,2.31) | ‐0.04(‐0.22,0.07) | |
| HD INF IV + MTX | 0.35(0.08,1.27) | 0.38(0.10,1.25) | ‐0.07(‐0.24,0.01) | |
| HD CERTO SC + MTX | 0.80(0.13,5.61) | 0.82(0.16,4.30) | ‐0.02(‐0.21,0.22) | |
| HD CERTO + MTX | 0.57(0.13,2.54) | 0.60(0.16,2.34) | ‐0.04(‐0.22,0.08) | |
| HD TOFA PO + MTX | HD TOCI IV + MTX | 1.25(0.29,5.36) | 1.23(0.32,4.82) | 0.01(‐0.10,0.11) |
| HD INF IV + MTX | 0.70(0.18,2.55) | 0.71(0.20,2.46) | ‐0.02(‐0.12,0.04) | |
| HD CERTO SC + MTX | 1.58(0.26,10.73) | 1.52(0.29,8.08) | 0.03(‐0.09,0.26) | |
| HD CERTO + MTX | 1.15(0.27,4.95) | 1.14(0.30,4.47) | 0.01(‐0.10,0.11) | |
| HD INF IV + MTX | HD TOFA PO + MTX | 0.56(0.17,1.89) | 0.58(0.19,1.83) | ‐0.03(‐0.12,0.03) |
| HD CERTO SC + MTX | 1.28(0.25,8.06) | 1.25(0.27,6.01) | 0.02(‐0.09,0.25) | |
| HD CERTO + MTX | 0.94(0.24,3.46) | 0.94(0.27,3.14) | 0.00(‐0.10,0.09) | |
| HD CERTO SC + MTX | HD INF IV + MTX | 2.28(0.48,13.55) | 2.15(0.49,9.88) | 0.05(‐0.03,0.28) |
| HD CERTO + MTX | 1.66(0.51,5.89) | 1.61(0.53,5.23) | 0.02(‐0.03,0.12) | |
| HD CERTO + MTX | HD CERTO SC + MTX | 0.72(0.13,3.65) | 0.74(0.17,3.35) | ‐0.02(‐0.25,0.08) |
| Random‐effects model | Residual deviance | 70 vs 71 data points | ||
| Deviance information criteria | 380.174 | |||
| Fixed‐effect model | Residual deviance | 75.17 vs 71 data points | ||
| Deviance information criteria | 381.124 | |||
| Note | ||||
| Total participants | 12,263 | |||
| Total studies | 26 | |||
| 2‐arm | 13 | |||
| 3‐arm | 8 | |||
| 4‐arm | 4 | |||
| 5‐arm | 1 | |||
Appendix 25. Serious adverse events: subgroup ‐ trial duration (6 to 12 months)
| SAE intermediate: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| SD ETN SC + PL | MTX + PL | 1.06(0.34,3.38) | 1.06(0.37,2.68) | 0.01(‐0.08,0.19) |
| SD INF IV + MTX | 0.52(0.22,1.19) | 0.55(0.25,1.16) | ‐0.05(‐0.10,0.02) | |
| SD ETN SC + MTX | 0.77(0.27,2.20) | 0.79(0.30,1.94) | ‐0.02(‐0.09,0.11) | |
| SD ABA IV + MTX | 0.73(0.26,1.99) | 0.76(0.29,1.78) | ‐0.03(‐0.09,0.09) | |
| SD RITUX IV + MTX | 0.74(0.27,1.96) | 0.76(0.30,1.76) | ‐0.03(‐0.09,0.09) | |
| LD ETN SC + PL | 0.72(0.22,2.50) | 0.75(0.24,2.13) | ‐0.03(‐0.10,0.13) | |
| LD RITUX IV + MTX | 0.70(0.25,1.86) | 0.73(0.28,1.69) | ‐0.03(‐0.09,0.08) | |
| LD ABA IV + MTX | 1.16(0.44,3.19) | 1.14(0.47,2.55) | 0.02(‐0.07,0.18) | |
| LD ETN SC + MTX | 0.42(0.12,1.34) | 0.46(0.14,1.29) | ‐0.06(‐0.11,0.03) | |
| HD INF IV + MTX | 0.96(0.37,2.51) | 0.96(0.40,2.14) | 0.00(‐0.08,0.13) | |
| SD INF IV + MTX | SD ETN SC + PL | 0.49(0.12,1.98) | 0.52(0.15,1.87) | ‐0.06(‐0.24,0.05) |
| SD ETN SC + MTX | 0.74(0.15,3.24) | 0.76(0.20,2.84) | ‐0.03(‐0.21,0.12) | |
| SD ABA IV + MTX | 0.68(0.15,3.17) | 0.72(0.20,2.78) | ‐0.04(‐0.22,0.11) | |
| SD RITUX IV + MTX | 0.69(0.15,3.08) | 0.72(0.20,2.72) | ‐0.03(‐0.22,0.11) | |
| LD ETN SC + PL | 0.69(0.20,2.19) | 0.72(0.24,1.98) | ‐0.03(‐0.18,0.08) | |
| LD RITUX IV + MTX | 0.65(0.14,2.89) | 0.68(0.19,2.56) | ‐0.04(‐0.22,0.10) | |
| LD ABA IV + MTX | 1.10(0.25,4.94) | 1.08(0.31,4.01) | 0.01(‐0.18,0.19) | |
| LD ETN SC + MTX | 0.40(0.08,2.05) | 0.43(0.10,1.91) | ‐0.07(‐0.25,0.05) | |
| HD INF IV + MTX | 0.90(0.20,4.07) | 0.91(0.25,3.43) | ‐0.01(‐0.20,0.15) | |
| SD ETN SC + MTX | SD INF IV + MTX | 1.46(0.40,5.88) | 1.42(0.42,4.88) | 0.03(‐0.06,0.17) |
| SD ABA IV + MTX | 1.42(0.38,5.13) | 1.38(0.41,4.38) | 0.02(‐0.06,0.15) | |
| SD RITUX IV + MTX | 1.42(0.39,5.12) | 1.38(0.42,4.36) | 0.02(‐0.06,0.15) | |
| LD ETN SC + PL | 1.40(0.31,6.27) | 1.36(0.34,5.13) | 0.02(‐0.07,0.18) | |
| LD RITUX IV + MTX | 1.36(0.37,4.84) | 1.33(0.40,4.16) | 0.02(‐0.07,0.14) | |
| LD ABA IV + MTX | 2.26(0.63,8.37) | 2.09(0.66,6.45) | 0.07(‐0.03,0.23) | |
| LD ETN SC + MTX | 0.82(0.19,3.39) | 0.83(0.21,3.09) | ‐0.01(‐0.09,0.09) | |
| HD INF IV + MTX | 1.86(0.65,5.30) | 1.75(0.68,4.44) | 0.05(‐0.03,0.17) | |
| SD ABA IV + MTX | SD ETN SC + MTX | 0.94(0.22,4.00) | 0.94(0.26,3.47) | ‐0.01(‐0.14,0.13) |
| SD RITUX IV + MTX | 0.94(0.22,3.95) | 0.95(0.26,3.44) | 0.00(‐0.14,0.13) | |
| LD ETN SC + PL | 0.93(0.20,4.50) | 0.94(0.23,3.79) | ‐0.01(‐0.15,0.16) | |
| LD RITUX IV + MTX | 0.92(0.22,3.75) | 0.92(0.25,3.28) | ‐0.01(‐0.15,0.12) | |
| LD ABA IV + MTX | 1.51(0.36,6.41) | 1.43(0.41,5.12) | 0.04(‐0.11,0.21) | |
| LD ETN SC + MTX | 0.55(0.16,1.81) | 0.58(0.18,1.72) | ‐0.04(‐0.15,0.04) | |
| HD INF IV + MTX | 1.25(0.30,5.12) | 1.22(0.34,4.29) | 0.02(‐0.13,0.16) | |
| SD RITUX IV + MTX | SD ABA IV + MTX | 0.99(0.25,4.19) | 0.99(0.29,3.63) | 0.00(‐0.13,0.13) |
| LD ETN SC + PL | 1.00(0.21,4.82) | 1.00(0.24,3.99) | 0.00(‐0.14,0.16) | |
| LD RITUX IV + MTX | 0.94(0.24,4.00) | 0.95(0.28,3.49) | 0.00(‐0.13,0.12) | |
| LD ABA IV + MTX | 1.61(0.60,4.49) | 1.52(0.64,3.74) | 0.05(‐0.05,0.18) | |
| LD ETN SC + MTX | 0.58(0.12,2.77) | 0.60(0.14,2.54) | ‐0.03(‐0.16,0.08) | |
| HD INF IV + MTX | 1.30(0.33,5.25) | 1.26(0.37,4.39) | 0.02(‐0.11,0.17) | |
| LD ETN SC + PL | SD RITUX IV + MTX | 0.98(0.21,4.73) | 0.99(0.24,3.95) | 0.00(‐0.13,0.16) |
| LD RITUX IV + MTX | 0.95(0.35,2.71) | 0.96(0.39,2.46) | 0.00(‐0.09,0.09) | |
| LD ABA IV + MTX | 1.61(0.41,6.48) | 1.52(0.45,5.08) | 0.05(‐0.09,0.22) | |
| LD ETN SC + MTX | 0.58(0.12,2.63) | 0.60(0.14,2.42) | ‐0.03(‐0.16,0.07) | |
| HD INF IV + MTX | 1.30(0.34,5.23) | 1.26(0.38,4.30) | 0.02(‐0.11,0.17) | |
| LD RITUX IV + MTX | LD ETN SC + PL | 0.98(0.19,4.42) | 0.98(0.24,3.88) | 0.00(‐0.17,0.12) |
| LD ABA IV + MTX | 1.61(0.34,7.65) | 1.52(0.40,6.07) | 0.04(‐0.12,0.22) | |
| LD ETN SC + MTX | 0.60(0.12,3.00) | 0.62(0.14,2.76) | ‐0.03(‐0.19,0.08) | |
| HD INF IV + MTX | 1.33(0.28,6.29) | 1.29(0.33,5.20) | 0.03(‐0.14,0.17) | |
| LD ABA IV + MTX | LD RITUX IV + MTX | 1.67(0.42,6.88) | 1.58(0.47,5.38) | 0.05(‐0.09,0.22) |
| LD ETN SC + MTX | 0.60(0.13,2.82) | 0.62(0.15,2.58) | ‐0.03(‐0.15,0.08) | |
| HD INF IV + MTX | 1.35(0.35,5.49) | 1.31(0.39,4.57) | 0.03(‐0.10,0.17) | |
| LD ETN SC + MTX | LD ABA IV + MTX | 0.36(0.07,1.68) | 0.40(0.10,1.59) | ‐0.08(‐0.25,0.04) |
| HD INF IV + MTX | 0.82(0.21,3.17) | 0.84(0.26,2.71) | ‐0.02(‐0.19,0.13) | |
| HD INF IV + MTX | LD ETN SC + MTX | 2.26(0.52,10.49) | 2.11(0.56,8.68) | 0.06(‐0.06,0.20) |
| Random‐effects model | Residual deviance | 16.48 vs 17 data points | ||
| Deviance information criteria | 105.18 | |||
| Fixed‐effect model | Residual deviance | 16.25 vs 17 data points | ||
| Deviance information criteria | 104.718 | |||
| Note | ||||
| Total participants | 2277 | |||
| Total studies | 6 | |||
| 2‐arm | 1 | |||
| 5‐arm | 5 | |||
Appendix 26. Cancer: main analysis
| Cancer: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| DMARD | MTX | 0.11(0.01,1.07) | 0.11(0.01,1.07) | ‐0.01(‐0.01,0.00) |
| SD ETN SC | 1.44(0.54,4.04) | 1.44(0.54,3.96) | 0.00(0.00,0.02) | |
| SD ADA SC | 0.19(0.01,3.31) | 0.19(0.01,3.25) | ‐0.01(‐0.01,0.02) | |
| SD ABA IV + MTX | 0.69(0.14,3.11) | 0.69(0.14,3.07) | 0.00(‐0.01,0.01) | |
| SD ABA SC + MTX | 0.47(0.07,2.70) | 0.48(0.07,2.67) | 0.00(‐0.01,0.01) | |
| SD ADA SC + MTX | 0.51(0.06,3.76) | 0.51(0.06,3.69) | 0.00(‐0.01,0.02) | |
| SD ETN SC + MTX | 1.99(0.59,7.18) | 1.97(0.59,6.87) | 0.01(0.00,0.05) | |
| SD INF IV + MTX | 0.80(0.13,5.22) | 0.80(0.13,5.08) | 0.00(‐0.01,0.03) | |
| SD RITUX IV + MTX | 0.92(0.15,5.66) | 0.92(0.15,5.47) | 0.00(‐0.01,0.03) | |
| SD ETN SC + DMARD | 0.09(0.00,1.04) | 0.09(0.00,1.04) | ‐0.01(‐0.01,0.00) | |
| SD ABA IV + DMARD | 0.11(0.00,1.33) | 0.11(0.00,1.32) | ‐0.01(‐0.01,0.00) | |
| LD ETN SC | 0.60(0.11,2.67) | 0.60(0.12,2.63) | 0.00(‐0.01,0.01) | |
| LD RITUX IV + MTX | 0.59(0.06,4.03) | 0.59(0.06,3.95) | 0.00(‐0.01,0.02) | |
| LD ETN SC + MTX | 4.34(0.58,31.67) | 4.23(0.58,25.72) | 0.03(0.00,0.19) | |
| HD TOCI IV | 0.39(0.03,2.63) | 0.39(0.04,2.60) | 0.00(‐0.01,0.01) | |
| SD ETN SC | DMARD | 13.86(1.28,256.80) | 13.69(1.28,252.60) | 0.01(0.00,0.03) |
| SD ADA SC | 1.78(0.12,35.45) | 1.78(0.12,34.93) | 0.00(0.00,0.02) | |
| SD ABA IV + MTX | 6.72(0.33,176.20) | 6.68(0.33,174.30) | 0.00(0.00,0.02) | |
| SD ABA SC + MTX | 4.59(0.18,131.60) | 4.57(0.18,130.50) | 0.00(‐0.01,0.02) | |
| SD ADA SC + MTX | 4.98(0.17,173.70) | 4.95(0.17,170.90) | 0.00(‐0.01,0.02) | |
| SD ETN SC + MTX | 18.62(1.52,383.20) | 18.30(1.52,370.80) | 0.01(0.00,0.05) | |
| SD INF IV + MTX | 7.56(0.44,241.20) | 7.51(0.44,236.90) | 0.01(0.00,0.03) | |
| SD RITUX IV + MTX | 8.97(0.40,259.70) | 8.89(0.40,253.70) | 0.01(0.00,0.04) | |
| SD ETN SC + DMARD | 0.90(0.14,6.08) | 0.90(0.14,6.06) | 0.00(0.00,0.00) | |
| SD ABA IV + DMARD | 1.00(0.36,2.93) | 1.00(0.36,2.92) | 0.00(0.00,0.00) | |
| LD ETN SC | 5.56(0.35,127.80) | 5.53(0.35,126.40) | 0.00(0.00,0.02) | |
| LD RITUX IV + MTX | 5.23(0.24,189.60) | 5.21(0.24,185.20) | 0.00(‐0.01,0.03) | |
| LD ETN SC + MTX | 40.81(1.88,1326.00) | 38.78(1.88,1162.00) | 0.03(0.00,0.20) | |
| HD TOCI IV | 3.43(0.51,37.98) | 3.41(0.51,37.66) | 0.00(0.00,0.02) | |
| SD ADA SC | SD ETN SC | 0.13(0.00,2.48) | 0.13(0.00,2.44) | ‐0.01(‐0.03,0.01) |
| SD ABA IV + MTX | 0.48(0.07,2.75) | 0.48(0.07,2.73) | ‐0.01(‐0.03,0.01) | |
| SD ABA SC + MTX | 0.33(0.04,2.37) | 0.34(0.04,2.35) | ‐0.01(‐0.03,0.01) | |
| SD ADA SC + MTX | 0.36(0.03,3.36) | 0.36(0.03,3.31) | ‐0.01(‐0.03,0.02) | |
| SD ETN SC + MTX | 1.37(0.39,4.94) | 1.36(0.40,4.78) | 0.00(‐0.01,0.04) | |
| SD INF IV + MTX | 0.56(0.06,4.28) | 0.56(0.06,4.18) | 0.00(‐0.03,0.02) | |
| SD RITUX IV + MTX | 0.64(0.07,5.43) | 0.64(0.07,5.24) | 0.00(‐0.03,0.03) | |
| SD ETN SC + DMARD | 0.06(0.00,0.74) | 0.06(0.00,0.74) | ‐0.01(‐0.03,0.00) | |
| SD ABA IV + DMARD | 0.07(0.00,0.97) | 0.07(0.00,0.97) | ‐0.01(‐0.03,0.00) | |
| LD ETN SC | 0.41(0.08,1.68) | 0.42(0.09,1.67) | ‐0.01(‐0.02,0.01) | |
| LD RITUX IV + MTX | 0.41(0.03,3.46) | 0.42(0.03,3.39) | ‐0.01(‐0.03,0.02) | |
| LD ETN SC + MTX | 2.99(0.36,22.54) | 2.91(0.37,18.66) | 0.02(‐0.01,0.19) | |
| HD TOCI IV | 0.26(0.02,2.07) | 0.26(0.02,2.05) | ‐0.01(‐0.03,0.01) | |
| SD ABA IV + MTX | SD ADA SC | 3.64(0.12,133.50) | 3.62(0.12,132.00) | 0.00(‐0.02,0.02) |
| SD ABA SC + MTX | 2.53(0.07,111.90) | 2.52(0.07,110.80) | 0.00(‐0.02,0.02) | |
| SD ADA SC + MTX | 2.75(0.07,141.30) | 2.74(0.08,139.30) | 0.00(‐0.02,0.02) | |
| SD ETN SC + MTX | 10.74(0.47,343.40) | 10.53(0.47,333.70) | 0.01(‐0.01,0.05) | |
| SD INF IV + MTX | 4.07(0.14,175.40) | 4.04(0.14,171.80) | 0.00(‐0.02,0.03) | |
| SD RITUX IV + MTX | 4.95(0.16,210.00) | 4.92(0.16,205.60) | 0.00(‐0.02,0.04) | |
| SD ETN SC + DMARD | 0.54(0.03,6.33) | 0.54(0.03,6.32) | 0.00(‐0.02,0.00) | |
| SD ABA IV + DMARD | 0.58(0.03,10.26) | 0.58(0.03,10.22) | 0.00(‐0.02,0.01) | |
| LD ETN SC | 3.22(0.12,111.50) | 3.21(0.12,110.40) | 0.00(‐0.02,0.02) | |
| LD RITUX IV + MTX | 3.06(0.08,161.40) | 3.04(0.08,158.90) | 0.00(‐0.02,0.03) | |
| LD ETN SC + MTX | 22.80(0.79,1116.00) | 21.68(0.80,992.50) | 0.03(0.00,0.20) | |
| HD TOCI IV | 2.00(0.15,27.53) | 2.00(0.15,27.33) | 0.00(‐0.02,0.02) | |
| SD ABA SC + MTX | SD ABA IV + MTX | 0.69(0.15,3.16) | 0.69(0.15,3.13) | 0.00(‐0.01,0.01) |
| SD ADA SC + MTX | 0.74(0.12,5.36) | 0.74(0.12,5.30) | 0.00(‐0.01,0.02) | |
| SD ETN SC + MTX | 2.97(0.41,22.99) | 2.93(0.41,22.11) | 0.01(‐0.01,0.05) | |
| SD INF IV + MTX | 1.17(0.16,9.26) | 1.16(0.16,9.06) | 0.00(‐0.01,0.03) | |
| SD RITUX IV + MTX | 1.33(0.13,14.46) | 1.33(0.13,13.96) | 0.00(‐0.02,0.04) | |
| SD ETN SC + DMARD | 0.14(0.00,2.83) | 0.14(0.00,2.82) | 0.00(‐0.02,0.00) | |
| SD ABA IV + DMARD | 0.15(0.00,3.67) | 0.15(0.00,3.64) | 0.00(‐0.02,0.01) | |
| LD ETN SC | 0.86(0.09,7.50) | 0.86(0.10,7.39) | 0.00(‐0.02,0.02) | |
| LD RITUX IV + MTX | 0.85(0.06,10.44) | 0.85(0.06,10.16) | 0.00(‐0.02,0.02) | |
| LD ETN SC + MTX | 6.30(0.56,94.02) | 6.08(0.57,77.80) | 0.03(‐0.01,0.20) | |
| HD TOCI IV | 0.55(0.03,7.57) | 0.55(0.03,7.43) | 0.00(‐0.02,0.02) | |
| SD ADA SC + MTX | SD ABA SC + MTX | 1.08(0.31,4.13) | 1.08(0.32,4.08) | 0.00(‐0.01,0.01) |
| SD ETN SC + MTX | 4.19(0.51,46.24) | 4.13(0.51,44.65) | 0.01(‐0.01,0.05) | |
| SD INF IV + MTX | 1.70(0.17,18.51) | 1.69(0.17,18.06) | 0.00(‐0.01,0.03) | |
| SD RITUX IV + MTX | 1.93(0.16,25.05) | 1.92(0.16,24.22) | 0.00(‐0.01,0.04) | |
| SD ETN SC + DMARD | 0.20(0.01,4.89) | 0.20(0.01,4.85) | 0.00(‐0.02,0.01) | |
| SD ABA IV + DMARD | 0.23(0.01,6.55) | 0.23(0.01,6.51) | 0.00(‐0.02,0.01) | |
| LD ETN SC | 1.22(0.12,15.79) | 1.22(0.12,15.59) | 0.00(‐0.01,0.02) | |
| LD RITUX IV + MTX | 1.26(0.08,17.13) | 1.26(0.08,16.78) | 0.00(‐0.01,0.03) | |
| LD ETN SC + MTX | 8.93(0.69,159.80) | 8.61(0.70,134.80) | 0.03(0.00,0.20) | |
| HD TOCI IV | 0.79(0.04,13.43) | 0.79(0.04,13.21) | 0.00(‐0.01,0.02) | |
| SD ETN SC + MTX | SD ADA SC + MTX | 3.93(0.38,49.01) | 3.88(0.38,47.02) | 0.01(‐0.01,0.05) |
| SD INF IV + MTX | 1.63(0.12,17.80) | 1.62(0.12,17.48) | 0.00(‐0.02,0.03) | |
| SD RITUX IV + MTX | 1.78(0.12,24.81) | 1.77(0.13,24.14) | 0.00(‐0.02,0.04) | |
| SD ETN SC + DMARD | 0.18(0.00,4.97) | 0.18(0.00,4.94) | 0.00(‐0.02,0.01) | |
| SD ABA IV + DMARD | 0.20(0.00,6.76) | 0.21(0.01,6.71) | 0.00(‐0.02,0.01) | |
| LD ETN SC | 1.11(0.09,15.89) | 1.11(0.09,15.63) | 0.00(‐0.02,0.02) | |
| LD RITUX IV + MTX | 1.15(0.06,16.48) | 1.15(0.06,16.09) | 0.00(‐0.02,0.03) | |
| LD ETN SC + MTX | 8.53(0.46,164.50) | 8.21(0.47,140.20) | 0.03(‐0.01,0.20) | |
| HD TOCI IV | 0.73(0.03,14.83) | 0.73(0.03,14.60) | 0.00(‐0.02,0.02) | |
| SD INF IV + MTX | SD ETN SC + MTX | 0.39(0.04,3.52) | 0.40(0.05,3.45) | ‐0.01(‐0.05,0.02) |
| SD RITUX IV + MTX | 0.46(0.05,4.10) | 0.46(0.05,4.00) | ‐0.01(‐0.05,0.03) | |
| SD ETN SC + DMARD | 0.05(0.00,0.65) | 0.05(0.00,0.66) | ‐0.01(‐0.05,0.00) | |
| SD ABA IV + DMARD | 0.05(0.00,0.83) | 0.05(0.00,0.83) | ‐0.01(‐0.05,0.00) | |
| LD ETN SC | 0.30(0.04,1.76) | 0.30(0.05,1.75) | ‐0.01(‐0.05,0.01) | |
| LD RITUX IV + MTX | 0.29(0.02,2.63) | 0.30(0.02,2.59) | ‐0.01(‐0.05,0.02) | |
| LD ETN SC + MTX | 2.18(0.36,13.13) | 2.13(0.37,11.26) | 0.02(‐0.02,0.17) | |
| HD TOCI IV | 0.19(0.01,1.78) | 0.19(0.01,1.77) | ‐0.01(‐0.05,0.01) | |
| SD RITUX IV + MTX | SD INF IV + MTX | 1.13(0.08,15.99) | 1.13(0.08,15.50) | 0.00(‐0.03,0.04) |
| SD ETN SC + DMARD | 0.12(0.00,2.35) | 0.12(0.00,2.34) | ‐0.01(‐0.03,0.00) | |
| SD ABA IV + DMARD | 0.13(0.00,2.83) | 0.13(0.00,2.81) | ‐0.01(‐0.03,0.01) | |
| LD ETN SC | 0.73(0.07,8.35) | 0.73(0.07,8.24) | 0.00(‐0.03,0.02) | |
| LD RITUX IV + MTX | 0.72(0.04,9.82) | 0.72(0.04,9.64) | 0.00(‐0.03,0.02) | |
| LD ETN SC + MTX | 5.44(0.41,75.23) | 5.26(0.41,63.70) | 0.03(‐0.01,0.20) | |
| HD TOCI IV | 0.49(0.02,6.73) | 0.49(0.02,6.63) | 0.00(‐0.03,0.02) | |
| SD ETN SC + DMARD | SD RITUX IV + MTX | 0.10(0.00,2.43) | 0.10(0.00,2.42) | ‐0.01(‐0.04,0.00) |
| SD ABA IV + DMARD | 0.11(0.00,2.96) | 0.11(0.00,2.94) | ‐0.01(‐0.04,0.01) | |
| LD ETN SC | 0.65(0.05,7.28) | 0.66(0.06,7.18) | 0.00(‐0.04,0.02) | |
| LD RITUX IV + MTX | 0.63(0.06,4.55) | 0.63(0.06,4.50) | 0.00(‐0.03,0.01) | |
| LD ETN SC + MTX | 4.74(0.31,76.08) | 4.58(0.32,63.38) | 0.02(‐0.02,0.19) | |
| HD TOCI IV | 0.41(0.02,6.31) | 0.41(0.02,6.23) | 0.00(‐0.04,0.01) | |
| SD ABA IV + DMARD | SD ETN SC + DMARD | 1.14(0.13,9.36) | 1.14(0.13,9.33) | 0.00(0.00,0.01) |
| LD ETN SC | 6.66(0.37,163.90) | 6.63(0.37,162.00) | 0.00(0.00,0.02) | |
| LD RITUX IV + MTX | 6.29(0.22,240.90) | 6.26(0.22,237.30) | 0.00(0.00,0.03) | |
| LD ETN SC + MTX | 47.44(2.15,1487.00) | 45.16(2.14,1309.00) | 0.03(0.00,0.20) | |
| HD TOCI IV | 3.98(0.41,52.17) | 3.97(0.41,51.60) | 0.00(0.00,0.02) | |
| LD ETN SC | SD ABA IV + DMARD | 5.70(0.29,150.80) | 5.67(0.30,149.00) | 0.00(‐0.01,0.02) |
| LD RITUX IV + MTX | 5.12(0.20,213.20) | 5.10(0.20,210.50) | 0.00(‐0.01,0.03) | |
| LD ETN SC + MTX | 40.87(1.75,1502.00) | 38.93(1.74,1347.00) | 0.03(0.00,0.20) | |
| HD TOCI IV | 3.49(0.38,46.06) | 3.47(0.38,45.72) | 0.00(0.00,0.02) | |
| LD RITUX IV + MTX | LD ETN SC | 1.00(0.06,12.70) | 1.00(0.06,12.38) | 0.00(‐0.02,0.03) |
| LD ETN SC + MTX | 7.24(0.63,85.94) | 6.98(0.63,72.53) | 0.03(0.00,0.20) | |
| HD TOCI IV | 0.63(0.04,8.20) | 0.63(0.04,8.05) | 0.00(‐0.02,0.02) | |
| LD ETN SC + MTX | LD RITUX IV + MTX | 7.45(0.46,147.40) | 7.16(0.47,125.70) | 0.03(‐0.01,0.20) |
| HD TOCI IV | 0.67(0.03,12.35) | 0.67(0.03,12.16) | 0.00(‐0.03,0.02) | |
| HD TOCI IV | LD ETN SC + MTX | 0.09(0.00,1.55) | 0.09(0.00,1.54) | ‐0.03(‐0.20,0.00) |
| Random‐effects model | Residual deviance | 43.47 vs 56 data point | ||
| Deviance information criteria | 213.751 | |||
| Fixed‐effect model | Residual deviance | 43.15 vs 56 data point | ||
| Deviance information criteria | 212.255 | |||
| Total participants | 10,843 | |||
| Total Studies | 24 | |||
| 2‐arm | 16 | |||
| 3‐arm | 8 | |||
Appendix 27. Cancer: subgroup ‐ established RA (2‐10 years)
| Cancer established RA: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD ETN SC | MTX | 2.33(0.46,14.33) | 2.31(0.47,13.27) | 0.01(0.00,0.08) |
| SD ABA IV + MTX | 0.64(0.11,3.33) | 0.65(0.11,3.29) | 0.00(‐0.01,0.01) | |
| SD ETN SC + MTX | 2.74(0.69,15.56) | 2.70(0.69,14.38) | 0.01(0.00,0.08) | |
| SD INF IV + MTX | 0.86(0.15,5.23) | 0.86(0.15,5.13) | 0.00(‐0.01,0.02) | |
| SD ABA SC + MTX | 0.40(0.04,3.16) | 0.40(0.04,3.12) | 0.00(‐0.01,0.01) | |
| SD RITUX IV + MTX | 0.98(0.16,6.79) | 0.98(0.16,6.57) | 0.00(‐0.01,0.03) | |
| LD RITUX IV + MTX | 0.63(0.06,4.29) | 0.64(0.06,4.21) | 0.00(‐0.01,0.02) | |
| LD ETN SC + MTX | 5.55(0.81,53.48) | 5.37(0.81,41.14) | 0.03(0.00,0.24) | |
| HD TOCI IV | 0.24(0.01,2.58) | 0.25(0.01,2.56) | 0.00(‐0.01,0.01) | |
| SD ABA IV + MTX | SD ETN SC | 0.27(0.02,2.86) | 0.27(0.02,2.83) | ‐0.01(‐0.08,0.01) |
| SD ETN SC + MTX | 1.18(0.34,4.40) | 1.18(0.35,4.27) | 0.00(‐0.03,0.04) | |
| SD INF IV + MTX | 0.37(0.03,4.06) | 0.37(0.03,4.01) | ‐0.01(‐0.08,0.02) | |
| SD ABA SC + MTX | 0.17(0.01,2.36) | 0.17(0.01,2.34) | ‐0.01(‐0.08,0.01) | |
| SD RITUX IV + MTX | 0.42(0.03,5.21) | 0.42(0.03,5.08) | ‐0.01(‐0.08,0.03) | |
| LD RITUX IV + MTX | 0.26(0.01,3.20) | 0.27(0.01,3.16) | ‐0.01(‐0.08,0.01) | |
| LD ETN SC + MTX | 2.38(0.30,22.42) | 2.32(0.30,18.84) | 0.02(‐0.03,0.20) | |
| HD TOCI IV | 0.10(0.00,1.88) | 0.10(0.00,1.87) | ‐0.01(‐0.08,0.01) | |
| SD ETN SC + MTX | SD ABA IV + MTX | 4.45(0.50,46.49) | 4.37(0.50,43.50) | 0.01(‐0.01,0.08) |
| SD INF IV + MTX | 1.34(0.16,12.75) | 1.34(0.17,12.51) | 0.00(‐0.01,0.02) | |
| SD ABA SC + MTX | 0.62(0.11,2.82) | 0.62(0.11,2.80) | 0.00(‐0.01,0.01) | |
| SD RITUX IV + MTX | 1.54(0.13,20.39) | 1.54(0.13,19.65) | 0.00(‐0.01,0.04) | |
| LD RITUX IV + MTX | 0.98(0.06,12.64) | 0.98(0.06,12.41) | 0.00(‐0.01,0.02) | |
| LD ETN SC + MTX | 9.00(0.69,131.50) | 8.66(0.70,105.40) | 0.03(0.00,0.24) | |
| HD TOCI IV | 0.36(0.01,6.96) | 0.36(0.01,6.88) | 0.00(‐0.02,0.01) | |
| SD INF IV + MTX | SD ETN SC + MTX | 0.31(0.03,2.90) | 0.32(0.03,2.87) | ‐0.01(‐0.08,0.01) |
| SD ABA SC + MTX | 0.14(0.01,1.79) | 0.14(0.01,1.78) | ‐0.02(‐0.08,0.01) | |
| SD RITUX IV + MTX | 0.35(0.03,3.80) | 0.35(0.03,3.70) | ‐0.01(‐0.08,0.02) | |
| LD RITUX IV + MTX | 0.22(0.01,2.42) | 0.22(0.01,2.39) | ‐0.01(‐0.08,0.01) | |
| LD ETN SC + MTX | 1.99(0.33,13.37) | 1.94(0.34,11.30) | 0.02(‐0.03,0.19) | |
| HD TOCI IV | 0.09(0.00,1.37) | 0.09(0.00,1.37) | ‐0.02(‐0.08,0.00) | |
| SD ABA SC + MTX | SD INF IV + MTX | 0.45(0.03,5.71) | 0.45(0.03,5.63) | 0.00(‐0.02,0.01) |
| SD RITUX IV + MTX | 1.13(0.09,14.61) | 1.13(0.09,14.22) | 0.00(‐0.02,0.03) | |
| LD RITUX IV + MTX | 0.71(0.04,9.81) | 0.71(0.04,9.60) | 0.00(‐0.02,0.02) | |
| LD ETN SC + MTX | 6.32(0.50,104.40) | 6.09(0.51,84.16) | 0.03(‐0.01,0.24) | |
| HD TOCI IV | 0.26(0.01,5.97) | 0.27(0.01,5.90) | 0.00(‐0.02,0.01) | |
| SD RITUX IV + MTX | SD ABA SC + MTX | 2.49(0.15,53.39) | 2.48(0.16,51.97) | 0.00(‐0.01,0.04) |
| LD RITUX IV + MTX | 1.60(0.07,32.68) | 1.59(0.07,32.08) | 0.00(‐0.01,0.02) | |
| LD ETN SC + MTX | 14.80(0.86,336.80) | 14.14(0.86,276.00) | 0.03(0.00,0.24) | |
| HD TOCI IV | 0.60(0.01,16.38) | 0.60(0.01,16.17) | 0.00(‐0.02,0.01) | |
| LD RITUX IV + MTX | SD RITUX IV + MTX | 0.63(0.06,4.34) | 0.64(0.06,4.30) | 0.00(‐0.03,0.01) |
| LD ETN SC + MTX | 5.70(0.38,104.80) | 5.49(0.39,84.29) | 0.03(‐0.02,0.23) | |
| HD TOCI IV | 0.24(0.00,5.04) | 0.24(0.00,4.99) | 0.00(‐0.04,0.01) | |
| LD ETN SC + MTX | LD RITUX IV + MTX | 9.11(0.58,216.70) | 8.73(0.58,178.10) | 0.03(‐0.01,0.24) |
| HD TOCI IV | 0.39(0.01,9.91) | 0.39(0.01,9.78) | 0.00(‐0.02,0.01) | |
| HD TOCI IV | LD ETN SC + MTX | 0.04(0.00,0.97) | 0.04(0.00,0.98) | ‐0.03(‐0.24,0.00) |
| Random‐effects model | Residual deviance | 23.95 vs data points 31 | ||
| Deviance information criteria | 115.121 | |||
| Fixed‐effect model | Residual deviance | 23.65 vs 31 data points | ||
| Deviance information criteria | 114.266 | |||
| Note | ||||
| Total studies | 13 | |||
| 2‐arm | 8 | |||
| 3‐arm | 5 | |||
Appendix 28. Cancer: subgroup ‐ trial duration (<= 6 months)
| Cancer short: odds ratios, risk ratios and risk difference for all treatment comparisons ‐ random‐effects model | ||||
| Treatment | Reference | OR (95% CrI) | RR (95% CrI) | RD % (95% CrI) |
| SD ABA IV + MTX | MTX | 0.72(0.11,4.57) | 0.73(0.11,4.52) | 0.00(‐0.01,0.01) |
| SD ABA SC + MTX | 0.44(0.04,3.99) | 0.44(0.04,3.95) | 0.00(‐0.01,0.01) | |
| SD INF IV + MTX | 1.45(0.16,16.43) | 1.44(0.16,15.69) | 0.00(‐0.01,0.05) | |
| SD RITUX IV + MTX | 2.39(0.19,69.59) | 2.37(0.19,53.42) | 0.01(‐0.01,0.22) | |
| LD RITUX IV + MTX | 0.94(0.03,30.30) | 0.94(0.03,26.84) | 0.00(‐0.01,0.12) | |
| HD TOCI IV | 0.25(0.01,2.66) | 0.26(0.01,2.64) | 0.00(‐0.01,0.01) | |
| SD ABA SC + MTX | SD ABA IV + MTX | 0.61(0.11,2.89) | 0.61(0.11,2.86) | 0.00(‐0.01,0.01) |
| SD INF IV + MTX | 2.02(0.21,24.23) | 2.01(0.21,23.28) | 0.00(‐0.01,0.05) | |
| SD RITUX IV + MTX | 3.45(0.13,139.90) | 3.41(0.13,110.00) | 0.01(‐0.01,0.22) | |
| LD RITUX IV + MTX | 1.35(0.02,67.15) | 1.35(0.02,59.70) | 0.00(‐0.01,0.12) | |
| HD TOCI IV | 0.34(0.01,6.62) | 0.34(0.01,6.53) | 0.00(‐0.01,0.01) | |
| SD INF IV + MTX | SD ABA SC + MTX | 3.40(0.23,58.33) | 3.38(0.23,56.39) | 0.00(‐0.01,0.05) |
| SD RITUX IV + MTX | 5.71(0.18,315.00) | 5.62(0.19,251.50) | 0.01(‐0.01,0.22) | |
| LD RITUX IV + MTX | 2.25(0.03,143.80) | 2.24(0.03,126.20) | 0.00(‐0.01,0.12) | |
| HD TOCI IV | 0.57(0.01,16.97) | 0.57(0.01,16.74) | 0.00(‐0.01,0.01) | |
| SD RITUX IV + MTX | SD INF IV + MTX | 1.67(0.05,92.96) | 1.66(0.05,73.20) | 0.00(‐0.04,0.22) |
| LD RITUX IV + MTX | 0.64(0.01,43.56) | 0.64(0.01,38.58) | 0.00(‐0.05,0.12) | |
| HD TOCI IV | 0.16(0.00,4.88) | 0.16(0.00,4.83) | ‐0.01(‐0.05,0.01) | |
| LD RITUX IV + MTX | SD RITUX IV + MTX | 0.40(0.01,5.52) | 0.41(0.02,5.32) | ‐0.01(‐0.15,0.04) |
| HD TOCI IV | 0.10(0.00,3.61) | 0.10(0.00,3.57) | ‐0.01(‐0.22,0.01) | |
| HD TOCI IV | LD RITUX IV + MTX | 0.26(0.00,15.60) | 0.26(0.00,15.50) | 0.00(‐0.12,0.01) |
| Random‐effects model | Residual deviance | 13.3 vs 18 data points | ||
| Deviance information criteria | 64.955 | |||
| Fixed‐Effect Model | Residual deviance | 13.33 vs 18 data points | ||
| Deviance information criteria | 65.149 | |||
| Note | ||||
| Total participants | 3895 | |||
| Total studies | 8 | |||
| 2‐arm | 6 | |||
| 3‐arm | 2 | |||
Contributions of authors
JS, GW ‐ study concept JS, GW ‐ protocol development JS, PT, GW, ETG ‐ protocol editing JS, GW, ETG, AM ‐ data extraction AH, AM, GW, JS ‐ data analysis JS ‐ first draft of the review and NMA
All authors ‐ revision of the manuscript, and approval of the final version
Sources of support
Internal sources
-
The Oak Foundation, Switzerland.
Provide support for The Parker Institute: Musculoskeletal Statistics Unit.
-
Birmingham VA Medical Center, Other.
JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.
External sources
-
Jasvinder Singh, USA.
This work was supported in part by resources provided to the UAB Cochrane NMA Satellite by the Rheumatology Division at University of Alabama at Birmingham (UAB). JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, and research contract CE‐1304‐6631 from the Patient Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.
Declarations of interest
JS ‐ JS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Iroko, Merz, Bioiberica, Crealta and Allergan pharmaceuticals, WebMD, Medscape, the American College of Rheumatology and UBM, LLC. JS serves as the principal investigator for an investigator‐initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501c3 entity. JS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms‐length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. AH ‐ none ETG ‐ none RC ‐ research grant and consultant fee (paid to his institution) from Abbott/Abbvie, MSD, Norpharma/Mundipharma, Roche AM ‐ none PT ‐ grants/honoraria from Bristol Myers, Chiltern International, and UCB GW ‐ research grant and consultant fee from Bristol‐Myers Squibb
Joint senior author
Joint senior author
New
References
References to included reviews
Boyle 2015
- Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1‐STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015;74:1311‐6. [DOI] [PMC free article] [PubMed] [Google Scholar]
Bresnihan 1998
- Bresnihan B, Alvaro‐Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist. Arthritis Rheum 1998;41:2196‐204. [DOI] [PubMed] [Google Scholar]
Burmester 2014
- Burmester GR, Rubbert‐Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double‐blind, parallel‐group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease‐modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69‐74. [DOI] [PMC free article] [PubMed] [Google Scholar]
Combe 2009
- Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient‐reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double‐blind randomised 2‐year study. Ann Rheum Dis 2009;68:1146‐52. [DOI] [PMC free article] [PubMed] [Google Scholar]
Coombs 2010
- Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP‐690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double‐blind, placebo‐controlled trial. Ann Rheum Dis 2010;69:413‐6. [DOI] [PubMed] [Google Scholar]
Dougados 2013
- Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24‐week symptomatic and structural results of a 2‐year randomised controlled strategy trial in rheumatoid arthritis (ACT‐RAY). Ann Rheum Dis 2013;72:43‐50. [DOI] [PMC free article] [PubMed] [Google Scholar]
Doyle 2013
- Doyle MK, Rahman MU, Frederick B, Birbara CA, Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open‐label trial. Rheumatology (Oxford) 2013;52:1214‐9. [DOI] [PubMed] [Google Scholar]
Edwards 2004
- Edwards JC, Szczepanski L, Szechinski J, Filipowicz‐Sosnowska A, Emery P, Close DR, et al. Efficacy of B‐cell‐targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572‐81. [DOI] [PubMed] [Google Scholar]
Fleischmann 2012a
- Fleischmann R, Kremer J, Cush J, Schulze‐Koops H, Connell CA, Bradley JD, et al. Placebo‐controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495‐507. [DOI] [PubMed] [Google Scholar]
Fleischmann 2012b
- Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs. Arthritis Rheum 2012;64:617‐29. [DOI] [PubMed] [Google Scholar]
Gabay 2013b
- Gabay C, Emery P, Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double‐blind, controlled phase 4 trial. Lancet 2013;381:1541‐50. [DOI] [PubMed] [Google Scholar]
Genovese 2002
- Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two‐year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443‐50. [DOI] [PubMed] [Google Scholar]
Hobbs 2015
- Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J, et al. Randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. Springerplus 2015;4:113. [DOI] [PMC free article] [PubMed] [Google Scholar]
Huizinga 2015
- Huizinga TW, Conaghan PG, Martin‐Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT‐RAY study. Ann Rheum Dis 2015;74:35‐43. [DOI] [PMC free article] [PubMed] [Google Scholar]
Jobanputra 2012
- Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non‐inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2012;2(6):e001395. [DOI] [PMC free article] [PubMed] [Google Scholar]
Johnsen 2006
- Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006;33:659‐64. [PubMed] [Google Scholar]
Jones 2010
- Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez‐Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88‐96. [DOI] [PMC free article] [PubMed] [Google Scholar]
Kameda 2010
- Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol 2010;20:531‐8. [DOI] [PubMed] [Google Scholar]
Keystone 2009
- Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO‐FORWARD Study. Ann Rheum Dis 2009;68:789‐96. [DOI] [PMC free article] [PubMed] [Google Scholar]
Kremer 2009
- Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo. Arthritis Rheum 2009;60:1895‐905. [DOI] [PubMed] [Google Scholar]
Kremer 2010
- Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti‐tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty‐eight‐week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled study. Arthritis Rheum 2010;62:917‐28. [DOI] [PubMed] [Google Scholar]
Kremer 2013
- Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin‐Mola E, et al. Tofacitinib in combination with nonbiologic disease‐modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253‐61. [DOI] [PubMed] [Google Scholar]
MacIsaac 2014
- MacIsaac KD, Baumgartner R, Kang J, Loboda A, Peterfy C, DiCarlo J, et al. Pre‐treatment whole blood gene expression is associated with 14‐week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab‐treated rheumatoid arthritis patients. PloS One 2014;9(12):e113937. [DOI] [PMC free article] [PubMed] [Google Scholar]
Maini 2006
- Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817‐29. [DOI] [PubMed] [Google Scholar]
Mathias 2000
- Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health‐related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128‐39. [DOI] [PubMed] [Google Scholar]
Miyasaka 2008
- Miyasaka N, Investigators CS. Clinical investigation in highly disease‐affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008;18:252‐62. [DOI] [PMC free article] [PubMed] [Google Scholar]
Moreland 1999
- Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478‐86. [DOI] [PubMed] [Google Scholar]
Moreland 2012
- Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis and Rheumatism 2012;64(9):2824‐35. [DOI] [PMC free article] [PubMed] [Google Scholar]
Nishimoto 2004
- Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti‐interleukin‐6 receptor antibody: a multicenter, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism 2004;50(6):1761‐9. [DOI] [PubMed] [Google Scholar]
Nishimoto 2007
- Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL‐6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X‐ray reader‐blinded randomised controlled trial of tocilizumab. Annals of the Rheumatic Diseases 2007;66(9):1162‐7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Ohta 2014
- Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, et al. Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). Journal of Clinical Pharmacology 2014 Jan;54(1):109‐19. [DOI] [PMC free article] [PubMed] [Google Scholar]
Pavelka 2009
- Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Annals of the Rheumatic Diseases 2009;68(8):1285‐9. [DOI] [PubMed] [Google Scholar]
Pope 2014
- Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin‐Costello M, Keystone EC. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis 2014;73:2144‐51. [DOI] [PMC free article] [PubMed] [Google Scholar]
Strand 2006
- Strand V, Balbir‐Gurman A, Pavelka K, Emery P, Li N, Yin M, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford) 2006;45:1505‐13. [DOI] [PubMed] [Google Scholar]
Tada 2012
- Tada M, Koike T, Okano T, Sugioka Y, Wakitani S, Fukushima K, et al. Comparison of joint destruction between standard‐ and low‐dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. Rheumatology (Oxford) 2012;51:2164‐9. [DOI] [PubMed] [Google Scholar]
Takeuchi 2013a
- Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S, et al. Phase II dose‐response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol 2013;23:226‐35. [DOI] [PubMed] [Google Scholar]
Takeuchi 2013b
- Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, et al. A phase 3 randomized, double‐blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol 2013;23:623‐33. [DOI] [PubMed] [Google Scholar]
Takeuchi 2013c
- Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease‐modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double‐blind, placebo‐controlled GO‐MONO study through 24 weeks. Ann Rheum Dis 2013;72:1488‐95. [DOI] [PMC free article] [PubMed] [Google Scholar]
Van de Putte 2003
- Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, Riel PL, et al. Efficacy and safety of the fully human anti‐tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003;62:1168‐77. [DOI] [PMC free article] [PubMed] [Google Scholar]
Van de Putte 2004
- Putte LB, Atkins C, Malaise M, Sany J, Russell AS, Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508‐16. [DOI] [PMC free article] [PubMed] [Google Scholar]
Van der Heidje 2006
- Heijde D, Klareskog L, Rodriguez‐Valverde V, Codreanu C, Bolosiu H, Melo‐Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two‐year clinical and radiographic results from the TEMPO study, a double‐blind, randomized trial. Arthritis and Rheumatism 2006;54:1063‐74. [DOI] [PubMed] [Google Scholar]
Van der Heijde 2007
- Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928‐39. [DOI] [PubMed] [Google Scholar]
Van Riel 2006
- Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478‐83. [DOI] [PMC free article] [PubMed] [Google Scholar]
Van Riel 2008
- Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A. Patient‐reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Annals of the Rheumatic Diseases 2008;67(8):1104‐10. [DOI] [PubMed] [Google Scholar]
Yamamoto 2014a
- Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J‐RAPID randomized, placebo‐controlled trial. Mod Rheumatol 2014;24:715‐24. [DOI] [PubMed] [Google Scholar]
Østergaard 2015
- Østergaard M, Jacobsson LT, Schaufelberger C, Hansen MS, Bijlsma JW, Dudek A, et al. MRI assessment of early response to certolizumabpegol in rheumatoid arthritis: a randomised,double‐blind, placebo‐controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Annals of the Rheumatic Diseases 2015;74:1156–63. [DOI] [DOI] [PMC free article] [PubMed] [Google Scholar]
References to excluded reviews
Abe 2006
- Abe T, Takeuchi T, Miyasaka N. Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double‐blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. The Journal of Rheumatology 2006;33:37‐44. [PubMed] [Google Scholar]
Axelsen 2015
- Axelsen MB, Eshed I, Hørslev‐Petersen K, Stengaard‐Pedersen K, Hetland ML, Møller J, et al. A treat‐to‐target strategy with methotrexate and intra‐articular triamcinolone with or without adalimumab effectively reduces MRI synovitis,osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Annals of the Rheumatic Diseases 2015;74:867–75. [DOI] [PubMed] [Google Scholar]
Bae 2013
- Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorders 2013;14:13. [DOI] [PMC free article] [PubMed] [Google Scholar]
Bathon 2000
- Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine 2000;343(22):1586‐93. [DOI] [PubMed] [Google Scholar]
Bejarano 2008
- Bejarano V, Quinn MA, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis and Rheumatism 2008;59(10):1467‐74. [DOI] [PubMed] [Google Scholar]
Bingham 2015
- Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Annals of the Rheumatic Diseases 2015;74(5):818‐22. [DOI] [PMC free article] [PubMed] [Google Scholar]
Bonafede 2015
- Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. Etanercept‐methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis. Arthritis Care and Research (Hoboken) 2015;67(12):1656‐63. [DOI] [PMC free article] [PubMed] [Google Scholar]
Breedveld 2006
- Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism 2006;54:26‐37. [DOI] [PubMed] [Google Scholar]
Burmester 2013
- Burmester GR, Blanco R, Charles‐Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP‐690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381(9865):451‐60. [DOI] [PubMed] [Google Scholar]
Burmester 2015
- Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Annals of the Rheumatic Diseases 2015;74(6):1037‐44. [DOI] [PMC free article] [PubMed] [Google Scholar]
Chen 2009
- Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. Randomized, double‐blind, placebo‐controlled, comparative study of human anti‐TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. Journal of the Formosan Medical Association 2009;108:310‐9. [DOI] [PubMed] [Google Scholar]
Cheng 2014
- Cheng T, Wang M, Chen Z, Eisenberg RA, Zhang Y, Zou Y, et al. Tartrate‐resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese. Chinese Medical Journal 2014;127(16):2894‐9. [PubMed] [Google Scholar]
Choy 2012
- Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 2012;51:1226‐34. [DOI] [PubMed] [Google Scholar]
Cohen 2002
- Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: results of a twenty‐four‐week, multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatology 2002;46:614‐24. [DOI] [PubMed] [Google Scholar]
Cohen 2003
- Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology 2003;30(3):523‐8. [PubMed] [Google Scholar]
Cohen 2004
- Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Annals of the Rheumatic Diseases 2004;63:1062‐8. [DOI] [PMC free article] [PubMed] [Google Scholar]
Cohen 2006
- Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti‐tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis and Rheumatism 2006;54(9):2793‐806. [DOI] [PubMed] [Google Scholar]
Combe 2006
- Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double‐blind comparison. Annals of the Rheumatic Diseases 2006;65:1357‐62. [DOI] [PMC free article] [PubMed] [Google Scholar]
Conaghan 2013
- Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Annals of the Rheumatic Diseases 2013;72:1287‐94. [DOI] [PMC free article] [PubMed] [Google Scholar]
Conaghan 2014
- Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, DiCarlo J, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT‐RAY MRI substudy. Annals of the Rheumatic Diseases 2014;73(5):810‐6. [DOI] [PMC free article] [PubMed] [Google Scholar]
Detert 2013
- Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD‐naïve patients with early rheumatoid arthritis: HIT HARD, an investigator‐initiated study. Annals of the Rheumatic Diseases 2013;72:844–50. [DOI] [PubMed] [Google Scholar]
Dougados 2014
- Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab‐based treatment strategies in rheumatoid arthritis: the ACT‐RAY study. Annals of the Rheumatic Diseases 2014;73(5):803‐9. [DOI] [PMC free article] [PubMed] [Google Scholar]
Durez 2004
- Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis and Rheumatism 2004;63:1069‐74. [DOI] [PMC free article] [PubMed] [Google Scholar]
Durez 2007
- Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis. A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis and Rheumatism 2007;56(12):3919–27. [DOI] [PubMed] [Google Scholar]
Emery 2006
- Emery P, Fleischmann R, Filipowicz‐Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis and Rheumatology 2006;54:1390‐400. [DOI] [PubMed] [Google Scholar]
Emery 2008
- Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. Lancet 2008;372:375‐82. [DOI] [PubMed] [Google Scholar]
Emery 2010
- Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo‐controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Annals of the Rheumatic Diseases 2010;69:1629‐35. [DOI] [PMC free article] [PubMed] [Google Scholar]
Emery 2014a
- Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin‐Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. New England Journal of Medicine 2014;371(19):1781‐92. [DOI] [PubMed] [Google Scholar]
Emery 2014b
- Emery P, Fleischmann RM, Hsia EC, Xu S, Zhou Y, Baker D. Efficacy of golimumab plus methotrexate in methotrexate‐naïve patients with severe active rheumatoid arthritis. Clinical Rheumatology 2014;33(9):1239‐46. [DOI] [PubMed] [Google Scholar]
Eriksson 2015
- Eriksson JK, Karlsson JA, Bratt J, Petersson IF, Vollenhoven RF, Ernestam S, et al. Cost‐effectiveness of infliximab versus conventional combination treatment in methotrexate‐refractory early rheumatoid arthritis: 2‐year results of the register‐enriched randomised controlled SWEFOT trial. Annals of the Rheumatic Disease 2015;74(6):1094‐101. [DOI] [PMC free article] [PubMed] [Google Scholar]
Fleischmann 2003
- Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo‐controlled trial. Arthritis and Rheumatology 2003;48:927‐34. [DOI] [PubMed] [Google Scholar]
Fleischmann 2009
- Fleischmann R, Vencovsky J, Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease‐modifying antirheumatic therapy: the FAST4WARD study. Annals of the Rheumatic Diseases 2009;68:805‐11. [DOI] [PMC free article] [PubMed] [Google Scholar]
Fleischmann 2013
- Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, et al. 2‐year results from the Ample (Abatacept versus adalimumab comparison in biologic‐naïve RA patients with background Methotrexate) trial: changes in patient‐reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis. Arthritis and Rheumatism 2013;65(Suppl 10):S577. [Google Scholar]
Fleischmann 2014
- Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A. 2‐year results from the Ample (abatacept versus adalimumab comparison in biologic‐naïve RA patients with background methotrexate) trial: changes in patient‐reported outcomes in response to subcutaneous abatacept or adalimumab In rheumatoid arthritis.. Arthritis and Rheumatism 2014;65(Suppl 10):424. [Google Scholar]
Furst 2003
- Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor‐alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Journal of Rheumatology 2003;30:2563‐71. [PubMed] [Google Scholar]
Furst 2007
- Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open‐label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases 2007;66(7):893‐9. [DOI] [PMC free article] [PubMed] [Google Scholar]
Furst 2015
- Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijtens K, et al. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. Arthritis Care and Research (Hoboken) 2015;67(2):151‐60. [DOI] [DOI] [PMC free article] [PubMed] [Google Scholar]
Gashi 2014
- Gashi AA, Rexhepi S, Berisha I, Kryeziu A, Ismaili J, Krasniqi G. Treatment of rheumatoid arthritis with biologic DMARDS (rituximab and etanercept). Medical Archives 2014;68(1):51‐3. [DOI] [PMC free article] [PubMed] [Google Scholar]
Genovese 2004
- Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis and Rheumatology 2004;50:1412‐9. [DOI] [PubMed] [Google Scholar]
Genovese 2005
- Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New England Journal of Medicine 2005;353(11):1114‐23. [DOI] [PubMed] [Google Scholar]
Genovese 2008
- Genovese MC, McKay JD, Nasonov EL, Mysler EF, Silva NA, Alecock E, et al. Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: the tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study. Arthritis and Rheumatology 2008;58:2968‐80. [DOI] [PubMed] [Google Scholar]
Genovese 2011
- Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb non‐inferiority study in patients with an inadequate response to methotrexate. Arthritis and Rheumatology 2011;63:2854‐64. [DOI] [PMC free article] [PubMed] [Google Scholar]
Genovese 2014
- Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases 2014;73(9):1607‐15. [DOI] [PMC free article] [PubMed] [Google Scholar]
Gherge 2014
- Gherge AM, Ramiro S, Landewé R, Mihai C, Heidje D. THU0229 association of radiographic damage with physical function in patients with rheumatoid arthritis – results from the RAPID1 Trial. Annals of the Rheumatic Diseases 2014;73(Suppl 2):261. [Google Scholar]
Goekoop‐Ruiterman 2007
- Goekoop‐Ruiterman YP, Vries‐Bouwstra JK, Allaart CF, Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2007;146:406‐15. [DOI] [PubMed] [Google Scholar]
Haraoui 2014
- Haraoui B, Thorne JC, Keystone EC, Poulin‐Costello M, Trottier E, Vieira A, et al. Clinical and radiographic outcomes with etanercept and etanercept and methotrexate in patients with rheumatoid arthritis: two‐year results from the Canadian Methotrexate And Etanercept Outcome Study (CAMEO). Arthritis and Rheumatism 2014;65(Suppl 10):1464. [Google Scholar]
Heimans 2014
- Heimans L, Wevers‐de Boer KV, Visser K, Goekoop RJ, Oosterhout M, Harbers JB, et al. A two‐step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Annals of the Rheumatic Diseases 2014;73(7):1356‐61. [DOI] [PubMed] [Google Scholar]
Hørslev‐Petersen 2014
- Hørslev‐Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, et al. Adalimumab added to a treat‐to‐target strategy with methotrexate and intra‐articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator‐initiated, randomised, double‐blind, parallel‐group, placebo‐controlled trial. Annals of the Rheumatic Diseases 2014;73(4):654‐61. [DOI] [PubMed] [Google Scholar]
Iannone 2014
- Iannone F, Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. Journal of Rheumatology 2014;41(2):286‐92. [DOI] [PubMed] [Google Scholar]
Kaine 2011
- Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Annals of the Rheumatic Diseases 2012;71:38‐44. [DOI] [PMC free article] [PubMed] [Google Scholar]
Kameda 2011
- Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52‐week results from the JESMR study. Journal of Rheumatology 2011;38(8):1585‐92. [DOI] [PubMed] [Google Scholar]
Kavanaugh 2013
- Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26‐week results from the randomised, controlled OPTIMA study. Annals of the Rheumatic Diseases 2013;72(1):64‐71. [DOI] [PMC free article] [PubMed] [Google Scholar]
Kavanaugh 2014
- Kavanaugh A, Mease PJ, Strand V, Purcaru O, Curtis JR. Effect of certolizumab pegol on workplace and household productivity in US patients with rheumatoid arthritis with or without prior anti‐tumor necrosis factor exposure: results from the predict study. Annals of the Rheumatic Diseases 2014;73(Suppl 2):927‐8. [Google Scholar]
Kay 2008
- Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double‐blind, placebo‐controlled, dose‐ranging study. Arthritis and Rheumatism 2008;58(4):964‐75. [DOI] [PubMed] [Google Scholar]
Kennedy 2014
- Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, et al. Efficacy and safety of pateclizumab (anti‐lymphotoxin‐alpha) compared to adalimumab in rheumatoid arthritis: a head‐to‐head phase 2 randomized controlled study (The ALTARA Study). Arthritis Research and Therapy 2014;16(5):467. [DOI] [PMC free article] [PubMed] [Google Scholar]
Keystone 2004a
- Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo‐controlled, 52‐week trial. Arthritis Rheum 2004;50(5):1400‐11. [DOI] [PubMed] [Google Scholar]
Keystone 2004b
- Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatology 2004;50:353‐63. [DOI] [PubMed] [Google Scholar]
Keystone 2008
- Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy. Arthritis and Rheumatism 2008;59(6):785–93. [DOI] [PubMed] [Google Scholar]
Keystone 2014
- Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR. Continued benefit of tocilizumab plus disease‐modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment. Journal of Rheumatology 2014;41(2):216‐26. [DOI] [PubMed] [Google Scholar]
Kim 2007
- Kim HY, Lee SK, Song YW, Yoo DH, Koh EM, Yoo B, et al. A randomized, double‐blind, placebo‐controlled, phase III study of the human anti‐tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology 2007;10:9‐16. [Google Scholar]
Kim 2012
- Kim HY, Hsu PN, Barba M, Sulaiman W, Robertson D, Vlahos B, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. International Journal of Rheumatic Diseases 2012;15(2):188‐96. [DOI] [PubMed] [Google Scholar]
Kim 2013
- Kim J, Ryu H, Yoo DH, Park SH, Song GG, Park W, et al. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. Journal of Korean Medical Science 2013;28:1716‐22. [DOI] [PMC free article] [PubMed] [Google Scholar]
Kivitz 2014
- Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro‐Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease‐modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care and Research 2014;66:1653‐61. [DOI] [PMC free article] [PubMed] [Google Scholar]
Koroleva 2014a
- Koroleva MV, Raskina TA. Effect of rituximab therapy on life quality with rheumatoid arthritis patients. Osteoporosis International 2014;25:S365‐6. [Google Scholar]
Koroleva 2014b
- Koroleva MV, Raskina TA. The effect of rituximab therapy on bone mineral density with rheumatoid arthritis patients. Osteoporosis International 2014;25:S374. [Google Scholar]
Kremer 2003
- Kremer JM, Westhovens R, Leon M, Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T‐cell activation with fusion protein CTLA4Ig. New England Journal of Medicine 2003;349:1907‐15. [DOI] [PubMed] [Google Scholar]
Kremer 2005
- Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trial. Arthritis and Rheumatology 2005;52:2263‐71. [DOI] [PubMed] [Google Scholar]
Kremer 2006
- Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud‐Mendoza C, et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2006;144:865‐76. [DOI] [PubMed] [Google Scholar]
Kremer 2011
- Kremer JM, Blanco R, Brzosko M, Burgos‐Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double‐blind treatment phase of a randomized placebo‐controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis and Rheumatology 2011;63(3):609‐21. [DOI] [PubMed] [Google Scholar]
Kremer 2012
- Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez‐Reino J, et al. A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis and Rheumatology 2012;64:970‐81. [DOI] [PubMed] [Google Scholar]
Kremer 2015
- Kremer JM, Kivitz AJ, Simon‐Campos JA, Nasonov EL, Tony HP, Lee SK, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Research & Therapy 2015;17(95):1‐11. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lan 2004
- Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12‐week, double‐blind, randomized, placebo‐controlled study. Journal of the Formosan Medical Association 2004;103:618‐23. [PubMed] [Google Scholar]
Landewé 2015
- Landewé R, Smolen JS, Florentinus S, Chen S, Guérette B, Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Research and Therapy 2015;17:133. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lipsky 2000
- Lipsky PE, Heijde DM, Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343(22):1594‐602. [DOI] [PubMed] [Google Scholar]
Lisbona 2008
- Lisbona MP, Maymo J, Perich J, Almirall M, Pérez‐García C, Carbonell J. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. Journal of Rheumatology 2008;35(3):394‐7. [PubMed] [Google Scholar]
Lisbona 2010
- Lisbona MP, Maymo J, Perich J, Almirall M, Carbonell J. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. Annals of the Rheumatic Diseases 2010;69:1117‐22. [DOI] [PubMed] [Google Scholar]
Machado 2014
- Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, et al. Open‐label observation of addition of etanercept versus a conventional disease‐modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. Journal of Clinical Rheumatology 2014;20:25‐33. [DOI] [PubMed] [Google Scholar]
Maini 1999
- Maini R, Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354(9194):1932‐9. [DOI] [PubMed] [Google Scholar]
Manders 2015
- Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, et al. Cost‐effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi‐centre randomised trial. Arthritis Research and Therapy 2015;17(1):134. [DOI] [PMC free article] [PubMed] [Google Scholar]
Mathias 2000a
- Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health‐related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clinical Therapeutics 2000;22(1):128‐39. [DOI] [PubMed] [Google Scholar]
McInnes 2015
- McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin‐6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo‐controlled study. Annals of the Rheumatic Diseases 2015;74(4):694‐702. [DOI] [PMC free article] [PubMed] [Google Scholar]
Moreland 2002
- Moreland LW, Alten R, Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion. Arthritis and Rheumatism 2002;46(6):1470‐9. [DOI] [PubMed] [Google Scholar]
Nam 2014a
- Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high‐dose intravenous steroid, followed by treat‐to‐target: a double‐blind, randomised, controlled trial in new‐onset, treatment‐naive, rheumatoid arthritis (the IDEA study). Annals of the Rheumatic Diseases 2014;73(1):75‐85. [DOI] [PubMed] [Google Scholar]
Nam 2014b
- Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Annals of the Rheumatic Diseases 2014;73(6):1027‐36. [DOI] [PubMed] [Google Scholar]
Navarro 2014
- Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, et al. The ‘Switch’ study protocol: a randomised controlled trial of switching to an alternative tumour‐necrosis factor (TNF)‐inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF‐inhibitor drug. BMC Musculoskeletal Disorders 2014;15:452. [DOI] [PMC free article] [PubMed] [Google Scholar]
Nishimoto 2009
- Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL‐6 receptor inhibition therapy. Modern Rheumatology 2009;19:12‐9. [DOI] [PMC free article] [PubMed] [Google Scholar]
O'Dell 2013
- O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. New England Journal of Medicine 2013;369:307‐18. [DOI] [PubMed] [Google Scholar]
Oakley 2014
- Oakley S, Esmaili N, Major G, Mathers D, Ratnarajah S, Kallen J, et al. A randomised controlled trial evaluating the effect of humira upon endothelial function in ACPA positive rheumatoid arthritis: an interim analysis. Arthritis and Rheumatology 2014;66:S211. [Google Scholar]
Pavelka 2013
- Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, et al. Induction of response with etanercept‐methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clinical Rheumatology 2013;32(9):1275‐81. [DOI] [PubMed] [Google Scholar]
Quinn 2005
- Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve‐month randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism 2005;52(1):27‐35. [DOI] [PubMed] [Google Scholar]
Rantalaiho 2014
- Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen‐Seppanen O, Mottonen T, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long‐term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5‐year follow‐up results of a randomised clinical trial, the NEO‐RACo trial. Annals of the Rheumatic Diseases 2014;73(11):1954‐61. [DOI] [PubMed] [Google Scholar]
Rau 2004
- Rau R, Simianer S, Riel PL, Putte LB, Krüger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scandinavian Journal of Rheumatology 2004;33(3):145‐53. [DOI] [PubMed] [Google Scholar]
Rigby 2011
- Rigby W, Ferraccioli G, Greenwald M, Zazueta‐Montiel B, Fleischmann R, Wassenberg S, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care and Research (Hoboken) 2011;63(5):711‐20. [DOI] [PubMed] [Google Scholar]
Rubbert‐Roth 2010
- Rubbert‐Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010;49(9):1683‐93. [DOI] [PMC free article] [PubMed] [Google Scholar]
Schiff 2004
- Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al. The safety of anakinra in high‐risk patients with active rheumatoid arthritis: six‐month observations of patients with comorbid conditions. Arthritis and Rheumatism 2004;50(6):1752‐60. [DOI] [PubMed] [Google Scholar]
Smolen 2008
- Smolen JS, Beaulieu A, Rubbert‐Roth A, Ramos‐Remus C, Rovensky J, Alecock E, et al. Effect of interleukin‐6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double‐blind, placebo‐controlled, randomised trial. Lancet 2008;371:987‐97. [DOI] [PubMed] [Google Scholar]
Smolen 2009
- Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the Rheumatic Diseases 2009;68:797‐804. [DOI] [PMC free article] [PubMed] [Google Scholar]
Smolen 2013a
- Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque‐Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918‐29. [DOI] [PubMed] [Google Scholar]
Smolen 2013b
- Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque‐Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918‐29. [DOI] [PubMed] [Google Scholar]
Smolen 2014b
- Smolen JS, Emery P, Fleischmann R, Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383(9914):321‐32. [DOI] [PubMed] [Google Scholar]
Smolen 2015
- Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double‐blind, randomised, placebo‐controlled trial. Annals of the Rheumatic Diseases 2015;74:843‐50. [DOI] [PMC free article] [PubMed] [Google Scholar]
Sonomoto 2014
- Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology (Oxford) 2014;53(5):914‐8. [DOI] [PubMed] [Google Scholar]
Soubrier 2009
- Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 2009;49:1429–34. [DOI] [PubMed] [Google Scholar]
St Clair 2004
- Clair EW, Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism 2004;50(11):3432‐43. [DOI] [PubMed] [Google Scholar]
Strand 2012
- Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health‐related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. Journal of Rheumatology 2012;39(1):63‐72. [DOI] [PubMed] [Google Scholar]
Tak 2011
- Tak PP, Rigby W, Rubbert‐Roth A, Peterfy C, Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Annals of the Rheumatic Diseases 2011;71(3):351‐7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Tak 2012
- Tak PP, Rigby W, Rubbert‐Roth A, Peterfy C, Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2‐year results from the randomised controlled trial IMAGE. Annals of the Rheumatic Diseases 2012;71:351–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Takeuchi 2014
- Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti‐TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Annals of the Rheumatic Diseases 2014;73(3):536‐43. [DOI] [PMC free article] [PubMed] [Google Scholar]
Tam 2012
- Tam L‐S, Shang Q, Li EK, Wang S, Li R‐J, Lee K‐L, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis ‐ a randomized trial. The Journal of Rheumatology 2012;39:2267‐75. [DOI] [PubMed] [Google Scholar]
Tanaka 2011
- Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care and Research (Hoboken) 2011;63(8):1150‐8. [DOI] [PubMed] [Google Scholar]
Tanaka 2012
- Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO‐FORTH study. Annals of the Rheumatic Diseases 2012;71:817‐24. [DOI] [PMC free article] [PubMed] [Google Scholar]
Taylor 2004
- Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo‐controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis and Rheumatism 2004;50(4):1107‐16. [DOI] [PubMed] [Google Scholar]
Taylor 2006
- Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, et al. Ultrasonographic and radiographic results from a two‐year controlled trial of immediate or one‐year‐delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis and Rheumatism 2006;54(1):47‐53. [DOI] [PubMed] [Google Scholar]
Van der Heidje 2013
- Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four‐month phase III randomized radiographic study. Arthritis and Rheumatism 2013;65(3):559‐70. [DOI] [PubMed] [Google Scholar]
Van der Kooij 2009
- Kooij SM, Cessie S, Goekoop‐Ruiterman YP, Vries‐Bouwstra JK, Zeben D, Kerstens PJ, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases 2009;68(7):1153‐8. [DOI] [PubMed] [Google Scholar]
Van Vollenhoven 2009
- Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1‐year results of a randomised trial. Lancet 2009;374(9688):459‐66. [DOI] [PubMed] [Google Scholar]
Van Vollenhoven 2012a
- Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. New England Journal of Medicine 2012;367:508‐19. [DOI] [PubMed] [Google Scholar]
Van Vollenhoven 2012b
- Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate‐refractory early rheumatoid arthritis: 2 year follow‐up of the randomised, non‐blinded, parallel‐group Swefot trial. Lancet 2012;379:1712‐20. [DOI] [PubMed] [Google Scholar]
Vital 2015
- Vital EM, Dass S, Buch MH, Rawstron AC, Emery P. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Annals of the Rheumatic Diseases 2015;74:1195–201. [DOI] [PubMed] [Google Scholar]
Weinblatt 1999
- Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 1999;340:253‐9. [DOI] [PubMed] [Google Scholar]
Weinblatt 2003
- Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatology 2003;48:35‐45. [DOI] [PubMed] [Google Scholar]
Weinblatt 2006
- Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: a one‐year randomized, placebo‐controlled study. Arthritis and Rheumatology 2006;54:2807‐16. [DOI] [PubMed] [Google Scholar]
Weinblatt 2007
- Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Annals of the Rheumatic Diseases 2007;66:228–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
Weinblatt 2008
- Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double‐blind, active drug‐controlled study. Arthritis and Rheumatism 2008;58(7):1921‐30. [DOI] [PubMed] [Google Scholar]
Weinblatt 2012
- Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 2012;51:2204‐14. [DOI] [PubMed] [Google Scholar]
Weinblatt 2013a
- Weinblatt ME, Schiff M, Valente R, Heijde D, Citera G, Zhao C, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65(1):28‐38. [DOI] [PMC free article] [PubMed] [Google Scholar]
Weinblatt 2013b
- Weinblatt ME, Schiff M, Valente R, Heijde D, Citera G, Zhao C, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis and Rheumatism 2013;65(1):28‐38. [DOI] [PMC free article] [PubMed] [Google Scholar]
Weinblatt 2014
- Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO‐FURTHER trial. Annals of the Rheumatic Diseases 2014;73(12):2152‐9. [DOI] [PMC free article] [PubMed] [Google Scholar]
Weisman 2003
- Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti‐tumor necrosis factor‐alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clinical Therapeutics 2003;25:1700‐21. [DOI] [PubMed] [Google Scholar]
Weisman 2007
- Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo‐controlled, randomized, double‐blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 2007;46:1122‐5. [DOI] [PubMed] [Google Scholar]
Westhovens 2006
- Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo‐controlled trial. Arthritis and Rheumatology 2006;54:1075‐86. [DOI] [PubMed] [Google Scholar]
Westhovens 2009
- Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate‐naive patients with early rheumatoid arthritis and poor prognostic factors. Annals of the Rheumatic Diseases 2009;68:1870–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Westhovens 2014
- Westhovens R, Weinblatt ME, Han C, Kim L, Mack M, Lu J, et al. Health‐related quality of life of patients with rheumatoid arthritis achieving DAS28 remission, improvement in physical function and no radiographic progression. Annals of the Rheumatic Diseases 2014;73:479‐80. [Google Scholar]
Yamamoto 2014b
- Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol without methotrexate co‐administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo‐controlled trial. Modern Rheumatology 2014;24(4):552‐60. [DOI] [PubMed] [Google Scholar]
Yamanaka 2014
- Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate‐treated Japanese patients with early rheumatoid arthritis: 52‐week results of the HOPEFUL‐1 trial. Rheumatology (Oxford) 2014;53(5):904‐13. [DOI] [PMC free article] [PubMed] [Google Scholar]
Yazici 2012
- Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease‐modifying antirheumatic drugs: the ROSE study. Annals of the Rheumatic Diseases 2012;71:198‐205. [DOI] [PubMed] [Google Scholar]
Zhang 2006
- Zhang F, Hou Y, Huang F, Wu D, Bao C, Ni L, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR Journal of Rheumatology 2006;9:127‐30. [Google Scholar]
Additional references
Aletaha 2010
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569‐81. [DOI] [PubMed] [Google Scholar]
Alonso‐Ruiz 2008
- Alonso‐Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta analysis of efficacy and safety. BMC Musculoskeletal Disorders 2008;9:52. [DOI] [PMC free article] [PubMed] [Google Scholar]
Arnett 1988
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31(3):315‐24. [DOI] [PubMed] [Google Scholar]
Barlow 1999
- Barlow JH, Cullen LA, Rowe IF. Comparison of knowledge and psychological well‐being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration). Patient Education and Counseling 1999;38:195‐203. [DOI] [PubMed] [Google Scholar]
Becker 2011
- Becker LA, Oxman AD. Chapter 22: Overviews of Reviews. In: Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Blumenauer 2002
- Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785] [DOI] [PMC free article] [PubMed] [Google Scholar]
Boers 2001
- Boers M. Treatment of early disease. Rheumatic Diseases Clinics of North America 2001;27:405‐14, x. [DOI] [PubMed] [Google Scholar]
Bongartz 2006
- Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti‐TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta‐analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275‐85. [DOI] [PubMed] [Google Scholar]
Bongartz 2009
- Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta‐analysis of randomised controlled trials. Annals of the Rheumatic Diseases 2009;68(7):1177‐83. [DOI] [PubMed] [Google Scholar]
Bradburn 2007
- Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events. Statistics in Medicine 2007;26:53‐77. [DOI] [PubMed] [Google Scholar]
Brennan 2008
- Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. Journal of Clinical Investigation 2008;118(11):3537‐45. [DOI] [PMC free article] [PubMed] [Google Scholar]
Cash 1994
- Cash JM, Klippel JH. Second‐line drug therapy for rheumatoid arthritis. New England Journal of Medicine 1994;330(19):1368‐75. [DOI] [PubMed] [Google Scholar]
Cates 2009 [Computer program]
- Dr Chris Cates' EBM web site. Available from www.Nntonline.Net/visualrx/. Visual Rx NNT Calculator version 3. Dr Chris Cates' EBM web site. Available from www.Nntonline.Net/visualrx/, Accessed 13 February 2009.
Choy 2001
- Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 2001;344(12):907‐16. [DOI] [PubMed] [Google Scholar]
Chung 2006
- Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta‐analysis of discriminant capacities. Annals of the Rheumatic Diseases 2006;65(12):1602‐7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Connell 2006
- Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Practice and Research Clinical Rheumatology 2006;20(5):865‐78. [DOI] [PubMed] [Google Scholar]
Cope 2008
- Cope AP. T cells in rheumatoid arthritis. Arthritis Research and Therapy 2008;10 Suppl 1:S1. [DOI] [PMC free article] [PubMed] [Google Scholar]
Deeks 2011
- Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
DerSimonian 2007
- DerSimonian R, Kacker R. Random‐effects model for meta‐analysis of clinical trials: an update. Contemporary Clinical Trials 2007;28(2):105‐14. [DOI] [PubMed] [Google Scholar]
Desai 2012
- Desai RJ, Hansen RA, Rao JK, Wilkins TM, Harden EA, Yuen A, et al. Mixed treatment comparison of the treatment discontinuations of biologic disease‐modifying antirheumatic drugs in adults with rheumatoid arthritis. Ann Pharmacother 2012;46(11):1491‐505. [DOI] [PubMed] [Google Scholar]
Dias 2011
- Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 1–39 (2011). Available at www.nicedsu.org.uk. [PubMed]
Donahue 2008
- Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease‐modifying medications for rheumatoid arthritis. Annals of Internal Medicine 2008;148(2):124‐34. [DOI] [PubMed] [Google Scholar]
Drugs 2006
- Drug Information Online. Drugs.com. FDA Approves First Rheumatoid Arthritis Indication for Rituxan. www.drugs.com/news/fda‐approves‐first‐rheumatoid‐arthritis‐indication‐rituxan‐1745.html 03/01/2006.
EMA 2001
- European Medicines Agency (EMA). EMA Public Statement on Infliximab (Remicade): Increased incidence of mortality and hospitalization for worsening Congestive Heart Failure. www.emea.europa.eu/pdfs/human/press/pus/325701en.pdf.
EMA 2003
- European Medicines Agency (EMA). EMA public statement: Increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept). www.emea.europa.eu/humandocs/PDFs/EPAR/kineret/3163102en.pdf.
EMA 2004
- European Medicines Agency (EMA). EPARs for authorized medicinal products for human use: Anakinra: European Public Assessment Report. www.emea.europa.eu/humandocs/Humans/EPAR/kineret/kineret.htm Revision 11, published 27/01/09.
EMA 2009a
- European Medicines Agency (EMA). Remicade (inflixmab). www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H‐240‐PI‐en.pdf.
EMA 2009b
- European Medicines Agency (EMA). EPARs for authorized medicinal products for human use: Humira: European Public Assessment Report. www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm Revision 15, Published 11/05/09.
FDA 2004
- Food, Drug Administration. Safety information. October 2004. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166515.pdf.
FDA 1998
- Food, Drug Administration. Etanercept Product Approval Information‐ Licensing Action 12/2/1998. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm 1998.
FDA 1999
- Food, Drug Administration. Remicade® (infliximab) for IV Injection. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107722.pdf 1999.
FDA 2001
- Food, Drug Administration. Kineret® (anakinra) Physician packet insert: Kineret® (anakinra) prescribing information. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080650.htm 2001.
FDA 2002
- Food, Drug Administration. Package Insert. HUMIRA® (adalimumab). Abbott Laboratories. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080610.htm 2002.
FDA 2005
- Food, Drug Administration. Patient Information Sheet. Abatacept (marketed as Orencia®). www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/FastTrackApprovalReports/ucm082380.htm 2005.
FDA 2006
- Food, Drug Administration. Rituxan® (rituximab). www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150747.htm.
FDA 2007
- Food, Drug Administration. Drug details: Orencia. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
FDA 2008a
- Food, Drug Administration. Humira (adalimumab): Highlights of prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf.
FDA 2008b
- Food, Drug Administration. FDA: Manufacturers of TNF‐blocker drugs must highlight risk of fungal infections. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116942.htm.
FDA 2008c
- Food, Drug Administration. Medication Guide: Enbrel® (etanercept). www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf.
FDA 2008d
- Food, Drug Administration. CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008. CDER report. Application number:125160. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM081805.pdf December 31, 2008.
FDA 2009
- Food, Drug Administration. Remicade® (infliximab) for IV Injection. www.accessdata.fda.gov/drugsatfda_docs/label/2009/103772s5234lbl.pdf.
FDA 2009a
- Food, Drug Administration. Safety information. Rituxan (Ritiximab). www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM187792.pdf 2009.
FDA 2010
- Food, Drug Administration. CDER report. Application number: L 125276/0.0, December 31, 2010. CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals. As of December 31, 2010. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM242677.pdf 2010.
FDA 2012
- Food, Drug Administration. CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals As of December 31, 2012. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM342733.pdf 2012.
FDA 2015
- Food, Drug Administration. Risk Evaluation and Mitigation Strategy (REMS). NDA 203,214 XELJANZ® (TOFACITINIB). www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM330290.pdf.
Felson 1995
- Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995;38(6):727‐35. [DOI] [PubMed] [Google Scholar]
Finckh 2006
- Finckh A, Liang MH, Herckenrode CM, Pablo P. Long‐term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta‐analysis. Arthritis and Rheumatism 2006;55(6):86‐72. [DOI] [PubMed] [Google Scholar]
Fransen 2005
- Fransen J, Riel PL. The Disease Activity Score and the EULAR response criteria. Clinical and Experimental Rheumatology 2005;23(5 Suppl 39):S93‐9. [PubMed] [Google Scholar]
Fries 1980
- Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism 1980;23(2):137‐45. [DOI] [PubMed] [Google Scholar]
Furst 2008
- Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Annals of the Rheumatic Diseases 2008;67 Suppl 3(Suppl 3):iii2‐25. [DOI] [PubMed] [Google Scholar]
Furst 2010
- Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2009. Annals of the rheumatic diseases 2010;69:Suppl 1:i2‐29. [DOI] [PubMed] [Google Scholar]
Furst 2012
- Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011. Annals of the rheumatic diseases 2012;71(Suppl 2):i2‐45. [DOI] [PubMed] [Google Scholar]
Gabay 2013a
- Gabay C, Emery P, Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double‐blind, controlled phase 4 trial. Lancet 2013;381(9877):1541‐50. [DOI] [PubMed] [Google Scholar]
Gartlehner 2006
- Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. The Journal of Rheumatology 2006;33(12):2398‐408. [PubMed] [Google Scholar]
Ghogomu 2014
- Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo Pardo J, Johnston RV, et al. Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and meta‐analyses. The Journal of Rheumatology 2014;41(2):194‐205. [DOI] [PubMed] [Google Scholar]
Ghoreschi 2009
- Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273‐87. [DOI] [PMC free article] [PubMed] [Google Scholar]
Guyatt 2008
- Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians?. BMJ May 3, 2008;336(7651):995‐8. [DOI] [PMC free article] [PubMed] [Google Scholar]
Health Canada 2006
- Health Canada. Important Safety Information on anti‐TNFα Therapy: Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) ‐ for health professionals. www.hc‐sc.gc.ca/dhp‐mps/medeff/advisories‐avis/prof/_2006/anti‐tnf_therap_hpc‐cps‐eng.php.
Health Canada 2006b
- Health Canada. Possible association of Remicade (infliximab) with hepatosplenic T‐cell lymphoma in pediatric and young adult patients with Crohn's disease ‐ for health professionals. www.hc‐sc.gc.ca/dhp‐mps/medeff/advisories‐avis/prof/_2006/remicade_3_hpc‐cps‐eng.php.
Health Canada 2009
- Health Canada. Association of Enbrel (etanercept) with histoplasmosis and other invasive fungal infections ‐ for health professionals. www.hc‐sc.gc.ca/dhp‐mps/medeff/advisories‐avis/prof/_2009/enbrel_hpc‐cps‐eng.php.
Higgins 2002
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21:1539‐58. [DOI] [PubMed] [Google Scholar]
Higgins 2003
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. [DOI] [PMC free article] [PubMed] [Google Scholar]
Higgins 2011
- Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Ioannidis 2004
- Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781‐8. [DOI] [PubMed] [Google Scholar]
Kristensen 2011
- Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, et al. The number needed to treat for second‐generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scandinavian Journal of Rheumatology 2011;40(1):1‐7. [DOI] [PubMed] [Google Scholar]
Kristensen 2007
- Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold‐Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scandinavian Journal of Rheumatology 2007;36:411‐7. [DOI] [PubMed] [Google Scholar]
Kvien 2004
- Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(2 Suppl 1):1‐12. [DOI] [PubMed] [Google Scholar]
Kvien 2005
- Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. Scandinavian Journal of Rheumatology 2005;34(5):333‐41. [DOI] [PubMed] [Google Scholar]
Larsen 1977
- Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica: Diagnosis (Stockholm) 1977;4:481‐91. [DOI] [PubMed] [Google Scholar]
Lee 2001
- Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358(9285):903‐11. [DOI] [PubMed] [Google Scholar]
Lee 2008
- Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta‐analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatology International 2008;28(6):553‐9. [DOI] [PubMed] [Google Scholar]
Leombruno 2008
- Leombruno JP, Einarson TR, Keystone EC. The safety of anti‐tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure‐adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68(7):1136‐45. [DOI] [PubMed] [Google Scholar]
Lethaby 2013
- Lethaby A, Lopez‐Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD004525.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
Liberati 2009
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lopez‐Olivo 2012
- Lopez‐Olivo MA, Tayar JH, Martinez‐Lopez JA, Pollono EN, Cueto JP, Gonzales‐Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta‐analysis. JAMA 2012;308(9):898‐908. [DOI] [PubMed] [Google Scholar]
Lopez‐Olivo 2013
- Lopez‐Olivo A, Bavineni M, Suarez‐Almazor ME. Tofacitinib for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD010476] [DOI] [Google Scholar]
Lopez‐Olivo 2015
- Lopez‐Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez‐Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD007356.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
Lubeck 2004
- Lubeck DP. Patient‐reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004;22(2 Suppl 1):27‐38. [DOI] [PubMed] [Google Scholar]
Maxwell 2009
- Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007277.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
Mertens 2009
- Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005121.pub3] [DOI] [PMC free article] [PubMed] [Google Scholar]
Mustafa 2013
- Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology 2013;66(7):736‐42. [DOI] [PubMed] [Google Scholar]
Nam 2010
- Nam JL, Winthrop KL, Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease‐modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69(6):976‐86. [DOI] [PubMed] [Google Scholar]
Navarro‐Sarabia 2005
- Navarro‐Sarabia F, Ariza‐Ariza R, Hernandez‐Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
Nixon 2007
- Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine 2007;26(6):1237‐54. [DOI] [PubMed] [Google Scholar]
Odegard 2005
- Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7‐year study from the Oslo RA register. Scandinavian Journal of Rheumatology 2005;34(6):441‐7. [DOI] [PubMed] [Google Scholar]
Orme 2012
- Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta‐analysis of combination and monotherapy treatments in disease‐modifying antirheumatic drug‐experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics : targets & therapy 2012;6:429‐64. [DOI] [PMC free article] [PubMed] [Google Scholar]
Osiri 2003
- Osiri M, Suarez‐Almazor ME, Wells GA, Robinson V, Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. Annals of the Rheumatic Diseases 2003;62:316‐21. [DOI] [PMC free article] [PubMed] [Google Scholar]
O’Sullivan 2007
- O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak‐Stat‐Socs pathway in disease. Mol Immunol 2007;44(10):2497‐506. [DOI] [PubMed] [Google Scholar]
Pincus 1983
- Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis and Rheumatism 1983;26(11):1346‐53. [DOI] [PubMed] [Google Scholar]
Pincus 2002
- Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long‐term observational studies that disease‐modifying anti‐rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002;41(12):1346‐56. [DOI] [PubMed] [Google Scholar]
Prevoo 1996
- Prevoo ML, Gestel AM, T Hoff MA, Rijswijk MH, Putte LB, Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology 1996;35(11):1101‐5. [DOI] [PubMed] [Google Scholar]
Puhan 2014
- Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello‐Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta‐analysis. BMJ 2014;349:g5630. [DOI] [PubMed] [Google Scholar]
Revman 2014 [Computer program]
- Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ruiz Garcia 2014
- Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Vela Casasempere P, Bort‐Marti S, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD007649.pub3] [DOI] [PubMed] [Google Scholar]
Saag 2008
- Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59(6):762‐84. [DOI] [PubMed] [Google Scholar]
Salanti 2008
- Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008;17(3):279‐301. [DOI] [PubMed] [Google Scholar]
Schiff 2008
- Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi‐centre, randomised, double‐blind, placebo‐controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases 2008;8:1096‐103. [DOI] [PMC free article] [PubMed] [Google Scholar]
Schünemann 2011
- Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Scott 2006
- Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. New England Journal of Medicine 2006;355(7):704‐12. [DOI] [PubMed] [Google Scholar]
Sharp 1971
- Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism 1971;14(6):706‐20. [DOI] [PubMed] [Google Scholar]
Shea 2007
- Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. [DOI] [PMC free article] [PubMed] [Google Scholar]
Singh 2010a
- Singh JA, Beg S, Lopez‐Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD008331.pub2] [DOI] [PubMed] [Google Scholar]
Singh 2010b
- Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008341] [DOI] [PMC free article] [PubMed] [Google Scholar]
Singh 2012
- Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625‐39. [DOI] [PMC free article] [PubMed] [Google Scholar]
Singh 2016
- Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD012183] [DOI] [PMC free article] [PubMed] [Google Scholar]
Singh 2016a
- Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis and Rheumatology 2016;Epub(68):1‐26. [DOI: 10.1002/acr.22783] [DOI] [PubMed] [Google Scholar]
Smolen 2014a
- Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492‐509. [DOI] [PMC free article] [PubMed] [Google Scholar]
Song 2003
- Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. BMJ 2003;326:472. [DOI] [PMC free article] [PubMed] [Google Scholar]
Spiegelhalter 2003
- Spiegelhalter D, Thomas A, Best N. WinBUGS user manual. Version 1.4, January 2003.. MRC Biostat. Unit 2. faculty.washington.edu/jmiyamot/p548/spiegelhalter%20winbugs%20user%20manual.pdf. 2003.
Strand 2008
- Strand V, Singh JA. Improved health‐related quality of life with effective disease‐modifying antirheumatic drugs: evidence from randomized controlled trials. American Journal of Managed Care 2008;14(4)(4):234‐54. [PubMed] [Google Scholar]
Sweeting 2004
- Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine 2004;23:1351‐75. [DOI] [PubMed] [Google Scholar]
Szekanecz 2007
- Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Current Opinion in Rheumatology 2007;19(3):289‐95. [DOI] [PubMed] [Google Scholar]
Thompson 1999
- Thompson SG, Sharp SJ. Explaining heterogeneity in meta‐analysis: a comparison of methods. Statistics in Medicine 1999;18(20):2693‐708. [DOI] [PubMed] [Google Scholar]
Thompson 2011
- Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta‐analysis of randomized controlled trials. Arthritis Rheum 2011;63(6):1479‐85. [DOI] [PubMed] [Google Scholar]
Tugwell 2000
- Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, et al. “Stepping‐up” from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis. N Engl J Med 2000;343(21):1520–8. [Google Scholar]
Turner 2012
- Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta‐analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818‐27. [DOI] [PMC free article] [PubMed] [Google Scholar]
Van der Heijde 1989
- Heijde DM, Riel PL, Nuver‐Zwart IH, Gribnau FW, Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1(8646):1036‐8. [DOI] [PubMed] [Google Scholar]
Wells 1993
- Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. The Journal of Rheumatology 1993;20(3):557‐60. [PubMed] [Google Scholar]
Woolley 2003
- Woolley DE. The mast cell in inflammatory arthritis. New England Journal of Medicine 2003;348(17):1709‐11. [DOI] [PubMed] [Google Scholar]
Yelin 2007
- Yelin E. Work disability in rheumatic diseases. Current Opinion in Rheumatology 2007;19(2):91‐6. [DOI] [PubMed] [Google Scholar]
Zhang 2016
- Zhang J, Xie F, Yun H, Chen L, Muntner P, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75(10):1813‐18. [DOI] [PubMed] [Google Scholar]